Aao Final Program2014 PDF

Where all of ophthalmology meets
AAO 2014
October 1821
Subspecialty Day
October 1718
AAOE Program
October 1821
www.aao.org/2014
FINAL
PROGRAM
#aao2014
The American Academy of Ophthalmology is accredited by the Accreditation Council for

Continuing Medical Education to provide continuing medical education for physicians.
TABLE OF CONTENTS
AAO 2014 Highlights...................................................................... ix
2014 Board of Trustees ................................................................. xv
2014 Committe of Secretaries .................................................... xvii
The Council................................................................................. xxiii
AAO 2014 Overview ...................................................................xxvii
Meeting Directory ......................................................................xxxv
Shuttle Schedule .......................................................................xxxix
Awards
Laureate Recognition Award ..........................................................1
Special Awards ...............................................................................4
Secretariat Award .........................................................................16
Achievement Award Program .......................................................18
International Awards ....................................................................30
Visionary Society, Corporate and Organizational Donors .............31
Courses and Breakfasts

Selection Committees ...................................................................33
Programs-by-Day ...........................................................................35
Breakfast With the Experts ...........................................................51
Instruction Course Progam ............................................................58
Skills Transfer Program

Skills Transfer Program General Information..............................101
Skills Transfer Course Contributors ............................................102
Skills Transfer Programs-by-Day .................................................103
Skills Transfer Program ...............................................................106
Papers / Posters, Videos

Original Papers ............................................................................145
Scientific Posters.........................................................................164
Video Program .............................................................................241
Special Meetings and Events

Special Meetings & Events.........................................................249
Learning Lounge ..........................................................................253
Technology Pavilion.....................................................................258
Informational Posters ..................................................................262
AAOE Program / Practice Management

AAOE Program.............................................................................265
AAOE Coding Sessions ...............................................................266
AAOE Instruction Courses ...........................................................267
Practice Management Master Classes.......................................280
Exhibition, Indexes
Exhibitors.....................................................................................281
Product Index...............................................................................285
Participant Index .........................................................................296
Participant Financial Disclosure Index ........................................307
CME & CE Credit .........................................................................325
Future Meeting Dates & Locations .............................................328
Sessions and Symposia

Opening Session .........................................................................121
Academy Caf .............................................................................122
Spotlight Sessions & Symposia ..................................................123
P.O. Box 7424, San Francisco, CA 94120-7424 | Tel: 415-561-8500 Fax: 415-561-8533
2014 American Academy of Ophthalmology. All rights reserved.
No portion may be reproduced without express consent of the American Academy of Ophthalmology.
A Little Curious?
Come see whats inside at Booth #2834
www.alimerasciences.com
2014 Alimera Sciences
US-NONE-MMM-0001
PIONEERED
BY ALCON
POWERED BY YOU
A COMPLETE
SURGICAL
PROCESS. PRE-OP
TO POST-OP.
THE CATARACT
Visit the Alcon

booth to experience the
REFRACTIVE
VERION Image
Guided
System, part of the first
SUITE
BY ALCON
and only complete cataract refractive suite.
THE CATARACT
REFRACTIVE THE CATARACT
SUITE BY ALCON
REFRACTIVE
2014 Novartis 8/14 VRN14105JAD
For important product information, please see the back of tab 2.
SUITE BY ALCON
Bacitracin
Ophthalmic
Ointment USP
STERILE
Rx Only
DESCRIPTION: Each gram of ointment contains 500 units of Bacitracin in a low melting special
base containing White Petrolatum and Mineral Oil.
CLINICAL PHARMACOLOGY: The antibiotic, Bacitracin, exerts a profound action against many
gram-positive pathogens, including the common Streptococci and Staphylococci. It is also
destructive for certain gram-negative organisms. It is ineffective against fungi.
INDICATIONS AND USAGE: For the treatment of superficial ocular infections involving the
conjunctiva and/or cornea caused by Bacitracin susceptible organisms.
CONTRAINDICATIONS: This product should not be used in patients with a history of
hypersensitivity to Bacitracin.
PRECAUTIONS: Bacitracin ophthalmic ointment should not be used in deep-seated ocular
infections or in those that are likely to become systemic. The prolonged use of antibiotic
containing preparations may result in overgrowth of nonsusceptible organisms particularly
fungi. If new infections develop during treatment appropriate antibiotic or chemotherapy should
be instituted.
ADVERSE REACTIONS: Bacitracin has such a low incidence of allergenicity that for all practical
purposes side reactions are practically non-existent. However, if such reaction should occur,
therapy should be discontinued.
To report SUSPECTED ADVERSE REACTIONS, contact Perrigo at 1-866-634-9120 or FDA at
1-800-FDA-1088 or www.fda.gov/medwatch.
DOSAGE AND ADMINISTRATION: The ointment should be applied directly into the conjunctival
sac 1 to 3 times daily. In blepharitis all scales and crusts should be carefully removed and the
ointment then spread uniformly over the lid margins. Patients should be instructed to take
appropriate measures to avoid gross contamination of the ointment when applying the ointment
directly to the infected eye.
HOW SUPPLIED:
NDC 0574-4022-13 3 - 1 g sterile tamper evident tubes with ophthalmic tip.
NDC 0574-4022-35 3.5 g (1/8 oz.) sterile tamper evident tubes with ophthalmic tip.
Store at 20-25C (68-77F) [see USP Controlled Room Temperature].
Manufactured For
Minneapolis, MN 55427
0S400 RC J1 Rev 08-13 A
R0813
Ini0813
Her eye disease.
Our motivation.
Image is designed to represent nondescript visual impairment and is not

intended to be medically accurate. For illustrative purposes only.
At Santen, our single focus in ophthalmology enables

To learn how Santen is
advancing the ophthalmic field,
research of novel therapies in uveitis, glaucoma, and
scan this code with your mobile
dry eye/corneal disorderstherapies determined to
device or visit www.santeninc.com.
challenge eye disease, one patient at a time.
Inspiring ophthalmic medicines
2013 Santen Pharmaceutical Co., Ltd. All rights reserved. SAN-269.00 07/12
PIONEERED
BY ALCON
POWERED BY YOU
A STREAMLINED
SURGICAL
EXPERIENCE.
VERION
TM
Image Guided System
LenSx
Laser
LuxOR LX3
TM
Ophthalmic Microscope
CENTURION
Vision System
AcrySof
Family of IOLs
THE CATARACT
REFRACTIVE
SUITE
BY ALCON
SEE THE FIRST AND
ONLY
COMPLETE
CATARACT SUITE AT THE ALCON BOOTH.
THE CATARACT
SUITE BY ALCON REFRACTIVE
2014 Novartis 8/14 CRS14029JAD
SUITE BY ALCON
AAO 2014
HIGHLIGHTS
Join Us at the Opening Session
Sunday, Oct. 19, 8:30 - 10 AM
North, Hall B
Officially launch AAO 2014, in conjunction with the European Society of Ophthalmology (SOE).
Congratulate award winners including the recipient of the 2014 Laureate Award: Jerry A. Shields, MD.
Hear the 2014 Jackson Memorial Lecture, Retinoblastoma: 50 Years of Progress, by Hans E. Grossniklau,s MD, director
of the L.F. Montgomery Laboratory and the founding director of the Ocular Oncology and Pathology service of Emory Eye
Center. Dr. Grossniklaus is also Professor of Ophthalmology and Pathology, Oculo-Pathology, at the Emory University
School of Medicine.
Listen to a distinguished panel discuss: Can We Better Prepare the Residents of 2015 for the Practice of 2020? moderated by Thomas A. Oetting, MD. Panelists include: Nicholas J. Volpe, MD, Tara A. Uhler, MD, Paul Sternberg, Jr., MD
and Anthony C. Arnold, MD.
AAO
Virtual Meeting
The AAO Virtual Meeting allows you to
see live-streaming presentations or click
on recorded content throughout the meeting. You can also share comments with
colleagues.
There will be approximately 20 hours
of content streamed live.
Find details at
www.aao.org/virtual-meeting.
Three AAO-SOE Joint Sessions

Dont miss the three AAO-SOE joint View Across the Pond symposia examining
differences between the United States and Europe in the areas of IOLs, cornea
and retina.
A View Across the Pond: Current Cataract and

IOL Practices in Europe and the United States
SYM04; Sunday, Oct. 19, 2:00 - 3:30 PM
North, Hall B
A View Across the Pond: Retina

SYM44; Monday, Oct. 20, 8:30 - 10:00 AM
Grand Ballroom S100ab
A View Across the Pond: Cornea Enigmas

SYM20; Tuesday, Oct. 21, 10:45 AM - 12:15 PM
Academy staff are available at the Academy Resource Center, Booth 508, to answer any questions you may have.
ix
AAO 2014
HIGHLIGHTS
Engage Your Mind at Named Lectures
Michael F Marmor MD Lecture in
Ophthalmology and the Arts
NEW! Jones/Smolin Lecture
SYM09; Sunday, Oct. 19, 12:45 to 1:45PM

S406a
Architecture, Ophthalmology and the Seeing of Space will be
given by Mark Foster Gage, a recognized innovator in the fields of
architecture and design. In addition to being the principal of Mark
Foster Gage Architects (MFGA llc), in New York City, he also holds
the positions of Assistant Dean and tenured professor at the Yale
School of Architecture, where he has been on the faculty since
2001. His pioneering designs have received numerous awards,
been exhibited in museums and featured in the press.
SYM26; Monday, Oct. 20, 10:15 - 11:45 AM

Changing Times in the Diagnosis and Management of Ocular
Infectious Diseases, will be given by Russell N. Van Gelder, MD,
PhD, the Boyd K. Bucey Memorial Endowed Chair in Ophthalmology and Professor in the Department of Ophthalmology at the
University of Washington. The lecture will take place during the
Clinical Pearls in the Diagnosis of Masquerades in Infectious and
Inflammatory Disease of the Eye symposium.
Combined meeting with the Ocular Microbiology and Immunology
Group (OMIG)
The Bruce E. Spivey, MD Lecture in Risk

Management and Patient Safety
NEW! Dr. Allan Jensen and Claire Jensen

Lecture in Professionalism and Ethics
SPE15; Sunday, Oct. 19, 2:00 - 4:00 PM

S406b
Come hear Ajit K. Sachdeva, MD, FRSC, FACS, founding director
of the Division of Education at the American College of Surgeons,
lecture on education and training programs that enhance patient
safety and minimize risk of adverse outcomes. The lecture is followed by the OMIC Forum.
SYM33; Monday, Oct. 20, 12:45 - 1:45 PM

S406a
Promoting Ethics and Professionalism, will be given by Gerald
B. Hickson, MD, Senior Vice President for Quality, Safety and
Risk Prevention, Assistant Vice Chancellor for Health Affairs, and
Joseph C. Ross Chair in Medical Education and Administration, at
Vanderbilt University Medical Center.
More Interactive Sessions

Dynamic experts lead discussions in informal settings throughout AAO 2014:
Learning Lounge
Scientific Poster Tours
Saturday - Tuesday, Oct. 18 - 21

Booth 107
Float among the lounges theaters new topics begin every 15
minutes.
Sunday, Oct. 19 and Monday, Oct. 20, 12:30-1:30 PM

The Meeting Point near Scientific Posters Online/
Videos on Demand, Booth 65.
Explore posters with your peers led by subject matter experts.
Breakfast With the Experts
Ophthalmic Premier League:

A Team Video Competition on Managing
Cataract Complications
Sunday Tuesday, Oct. 19 21, 7:30 - 8:30 AM

South, Hall A
Start your day off right with an energetic conversation over
breakfast. Separate tickets must be purchased to attend.
SYM60; Tuesday, Oct. 21, 8:30 - 10:00 AM

North Hall B
Check out this exciting session where four teams will compete for the AAO-OPL trophy, awarded based on audience
votes.
JOIN US!
Understanding JETREA (ocriplasmin)
Intravitreal Injection, 2.5 mg/mL
Key Safety Topics
An overview of visual function and macular adverse events,
and OCT and ERG changes, as presented by leaders in the field.
October 18 20, 2014 | AAO Booth 1174 | McCormick Place
Saturday, Oct 18
Sunday, Oct 19
Monday, Oct 20
11:00 am 11:30 am
Pravin Dugel, MD
1:00 pm 1:30 pm
Baruch Kuppermann, MD
3:00 pm 3:30 pm
11:00 am 11:30 am
Jay Duker, MD
1:00 pm 1:30 pm
Jay Duker, MD
3:00 pm 3:30 pm
Carl Regillo, MD
11:00 am 11:30 am
Pravin Dugel, MD
1:00 pm 1:30 pm
Peter Kaiser, MD
3:00 pm 3:30 pm
Peter Kaiser, MD
Pravin Dugel, MD
Jay Duker, MD
Peter Kaiser, MD
Carl Regillo, MD
These presentations are not affiliated with the official program of AAO 2014.
Indication
JETREA (ocriplasmin) Intravitreal Injection, 2.5 mg/mL, is a proteolytic enzyme indicated for the treatment of symptomatic
vitreomacular adhesion (VMA).
Important Safety Information

Warnings and Precautions
A decrease of 3 lines of best-corrected visual acuity (BCVA) was experienced by 5.6% of patients treated with JETREA and 3.2%
of patients treated with vehicle in the controlled trials. The majority of these decreases in vision were due to progression of the
condition with traction and many required surgical intervention. Patients should be monitored appropriately.
Intravitreal injections are associated with intraocular inflammation/infection, intraocular hemorrhage and increased intraocular
pressure (IOP). Patients should be monitored and instructed to report any symptoms without delay. In the controlled trials,
intraocular inflammation occurred in 7.1% of patients injected with JETREA vs 3.7% of patients injected with vehicle. Most of the
post-injection intraocular inflammation events were mild and transient. If the contralateral eye requires treatment with JETREA,
it is not recommended within 7 days of the initial injection in order to monitor the post-injection course in the injected eye.
Potential for lens subluxation.
In the controlled trials, the incidence of retinal detachment was 0.9% in the JETREA group and 1.6% in the vehicle group, while
the incidence of retinal tear (without detachment) was 1.1% in the JETREA group and 2.7% in the vehicle group. Most of these
events occurred during or after vitrectomy in both groups.
Dyschromatopsia (generally described as yellowish vision) was reported in 2% of all patients injected with JETREA. In
approximately half of these dyschromatopsia cases there were also electroretinographic (ERG) changes reported (a- and b-wave
amplitude decrease).
Adverse Reactions
The most commonly reported reactions ( 5%) in patients treated with JETREA were vitreous floaters, conjunctival hemorrhage,
eye pain, photopsia, blurred vision, macular hole, reduced visual acuity, visual impairment, and retinal edema.
Please see Brief Summary of full Prescribing Information on adjacent page.
2014 ThromboGenics, Inc. All rights reserved. ThromboGenics, Inc., 101 Wood Avenue South,
Suite 610, Iselin, NJ 08830 USA. JETREA and the JETREA logo and THROMBOGENICS
and the THROMBOGENICS logo are trademarks or registered trademarks of ThromboGenics NV.
10/14 OCRVMA0223
BRIEF SUMMARY OF FULL PRESCRIBING

INFORMATION
Please see the JETREA package insert for full
Prescribing Information.
5 WARNINGS AND PRECAUTIONS

5.1 Decreased Vision
A decrease of 3 line of best corrected visual acuity (BCVA)
was experienced by 5.6% of patients treated with JETREA
and 3.2% of patients treated with vehicle in the controlled
trials [see Clinical Studies].
The majority of these decreases in vision were due to
progression of the condition with traction and many
required surgical intervention. Patients should be
monitored appropriately [see Dosage and Administration].
5.2 Intravitreal Injection Procedure Associated

1 INDICATIONS AND USAGE
JETREA is a proteolytic enzyme indicated for the treatment Effects
Intravitreal injections are associated with intraocular
of symptomatic vitreomacular adhesion.
inflammation / infection, intraocular hemorrhage and increased
2 DOSAGE AND ADMINISTRATION
intraocular pressure (IOP). In the controlled trials, intraocular
2.1 General Dosing Information
inflammation occurred in 7.1% of patients injected with
Must be diluted before use. For single-use ophthalmic JETREA vs. 3.7% of patients injected with vehicle. Most of
intravitreal injection only. JETREA must only be the post-injection intraocular inflammation events were
administered by a qualified physician.
mild and transient. Intraocular hemorrhage occurred in
2.4% vs. 3.7% of patients injected with JETREA vs. vehicle,
2.2 Dosing
The recommended dose is 0.125 mg (0.1 mL of the diluted respectively. Increased intraocular pressure occurred in
solution) administered by intravitreal injection to the 4.1% vs. 5.3% of patients injected with JETREA vs. vehicle,
respectively.
affected eye once as a single dose.
5.3 Potential for Lens Subluxation
2.3 Preparation for Administration
Remove the vial (2.5 mg/mL corresponding to 0.5 mg One case of lens subluxation was reported in a patient who
ocriplasmin) from the freezer and allow to thaw at room received an intravitreal injection of 0.175 mg (1.4 times
temperature (within a few minutes). Once completely higher than the recommended dose). Lens subluxation was
thawed, remove the protective polypropylene flip-off cap observed in three animal species (monkey, rabbit, minipig)
from the vial. The top of the vial should be disinfected with following a single intravitreal injection that achieved
an alcohol wipe. Using aseptic technique, add 0.2 mL of vitreous concentrations of ocriplasmin 1.4 times higher
0.9% w/v Sodium Chloride Injection, USP (sterile, than achieved with the recommended treatment dose.
preservative-free) into the JETREA vial and gently swirl the Administration of a second intravitreal dose in monkeys,
28 days apart, produced lens subluxation in 100% of the
vial until the solutions are mixed.
treated eyes [see Nonclinical Toxicology].
Visually inspect the vial for particulate matter. Only a clear,
colorless solution without visible particles should be used. 5.4 Retinal Breaks
Using aseptic technique, withdraw all of the diluted solution In the controlled trials, the incidence of retinal detachment
using a sterile #19 gauge needle (slightly tilt the vial to ease was 0.9% in the JETREA group and 1.6% in the vehicle
withdrawal) and discard the needle after withdrawal of group, while the incidence of retinal tear (without
the vial contents. Do not use this needle for the intravitreal detachment) was 1.1% in the JETREA group and 2.7% in
the vehicle group. Most of these events occurred during
injection.
or after vitrectomy in both groups. The incidence of retinal
Replace the needle with a sterile #30 gauge needle, detachment that occurred pre-vitrectomy was 0.4% in
carefully expel the air bubbles and excess drug from the the JETREA group and none in the vehicle group, while
syringe and adjust the dose to the 0.1 mL mark on the the incidence of retinal tear (without detachment) that
syringe (corresponding to 0.125 mg ocriplasmin). THE occurred pre-vitrectomy was none in the JETREA group and
SOLUTION SHOULD BE USED IMMEDIATELY AS IT CONTAINS 0.5% in the vehicle group.
NO PRESERVATIVES. Discard the vial and any unused
5.5 Dyschromatopsia
portion of the diluted solution after single use.
Dyschromatopsia (generally described as yellowish vision)
2.4 Administration and Monitoring
was reported in 2% of all patients injected with JETREA. In
The intravitreal injection procedure should be carried out approximately half of these dyschromatopsia cases there
under controlled aseptic conditions, which include the use were also electroretinographic (ERG) changes reported
of sterile gloves, a sterile drape and a sterile eyelid speculum (a- and b-wave amplitude decrease).
(or equivalent). Adequate anesthesia and a broad spectrum
microbiocide should be administered according to standard 6 ADVERSE REACTIONS
The following adverse reactions are described below and
medical practice.
elsewhere in the labeling:
The injection needle should be inserted 3.5 - 4.0 mm
posterior to the limbus aiming towards the Decreased Vision [see Warnings and Precautions]
center of the vitreous cavity, avoiding the Intravitreal Injection Procedure Associated Effects
horizontal meridian. The injection volume of
[see Warnings and Precautions and Dosage and
0.1 mL is then delivered into the mid-vitreous.
Administration]
Immediately following the intravitreal injection, patients Potential for Lens Subluxation [see Warnings
should be monitored for elevation in intraocular pressure.
and Precautions]
Appropriate monitoring may consist of a check for
perfusion of the optic nerve head or tonometry. If required, Retinal Breaks [see Warnings and Precautions and
Dosage and Administration]
a sterile paracentesis needle should be available.
Following intravitreal injection, patients should be
instructed to report any symptoms suggestive of
endophthalmitis or retinal detachment (e.g., eye pain,
redness of the eye, photophobia, blurred or decreased
vision) without delay [see Patient Counseling Information].
6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying
conditions, adverse reaction rates in one clinical trial of a
drug cannot be directly compared with rates in the clinical
trials of the same or another drug and may not reflect the
Each vial should only be used to provide a single injection rates observed in practice.
for the treatment of a single eye. If the contralateral eye Approximately 800 patients have been treated with an
requires treatment, a new vial should be used and the intravitreal injection of JETREA. Of these, 465 patients
sterile field, syringe, gloves, drapes, eyelid speculum, and received an intravitreal injection of ocriplasmin 0.125 mg
injection needles should be changed before JETREA is (187 patients received vehicle) in the 2 vehicle-controlled
administered to the other eye, however, treatment with studies (Study 1 and Study 2).
JETREA in the other eye is not recommended within 7 days
of the initial injection in order to monitor the post-injection The most common adverse reactions (incidence 5% - 20%
course including the potential for decreased vision in the listed in descending order of frequency) in the vehiclecontrolled clinical studies were: vitreous floaters,
injected eye.
conjunctival hemorrhage, eye pain, photopsia, blurred
Repeated administration of JETREA in the same eye is not vision, macular hole, reduced visual acuity, visual
recommended [see Nonclinical Toxicology].
impairment, and retinal edema.
After injection, any unused product must be discarded.
Less common adverse reactions observed in the studies at
frequency of 2% - < 5% in patients treated with JETREA
No special dosage modification is required for any of the aincluded
macular edema, increased intraocular pressure,
populations that have been studied (e.g. gender, elderly). anterior chamber
cell, photophobia, vitreous detachment,
ocular discomfort, iritis, cataract, dry eye, metamorphopsia,
3 DOSAGE FORMS AND STRENGTHS
conjunctival
hyperemia,
and retinal degeneration.
Single-use glass vial containing JETREA 0.5 mg in 0.2 mL
solution for intravitreal injection (2.5 mg/mL).
Dyschromatopsia was reported in 2% of patients injected
with JETREA, with the majority of cases reported from
4 CONTRAINDICATIONS
two uncontrolled clinical studies. In approximately
None
half of these dyschromatopsia cases there were also The number of patients with at least 3 lines increase in
electroretinographic (ERG) changes reported (a- and visual acuity was numerically higher in the ocriplasmin
b-wave amplitude decrease).
group compared to vehicle in both trials, however, the
number of patients with at least a 3 lines decrease in visual
6.2 Immunogenicity
acuity was also higher in the ocriplasmin group in one of the
As with all therapeutic proteins, there is potential for studies (Table 1 and Figure 1).
immunogenicity. Immunogenicity for this product has not
been evaluated.
Table 1: Categorical Change from Baseline in
BCVA at Month 6, Irrespective of Vitrectomy
8 USE IN SPECIFIC POPULATIONS
(Study 1 and Study 2)
8.1 Pregnancy: Teratogenic Effects
Pregnancy Category C. Animal reproduction studies
Study 1
have not been conducted with ocriplasmin. There are no
adequate and well-controlled studies of ocriplasmin in
JETREA
Vehicle
Difference
pregnant women. It is not known whether ocriplasmin
can cause fetal harm when administered to a pregnant
N=219
N=107
(95% CI)
woman or can affect reproduction capacity. The systemic
3
line
Improvement
in
BCVA
exposure to ocriplasmin is expected to be low after
intravitreal injection of a single 0.125 mg dose. Assuming
Month 6
28 (12.8%)
9 (8.4%)
4.4 (-2.5, 11.2)
100% systemic absorption (and a plasma volume
of 2700 mL), the estimated plasma concentration is
> 3 line Worsening in BCVA
46 ng/mL. JETREA should be given to a pregnant woman
Month 6
16 (7.3%)
2 (1.9%)
5.4 (1.1, 9.7)
only if clearly needed.
8.3 Nursing Mothers
It is not known whether ocriplasmin is excreted in human
milk. Because many drugs are excreted in human milk,
and because the potential for absorption and harm to
infant growth and development exists, caution should
be exercised when JETREA is administered to a nursing
woman.
8.4 Pediatric Use
Safety and effectiveness in pediatric patients have not been
established.
Study 2
JETREA
Vehicle
Difference
N=245
N=81
(95% CI)
3 line Improvement in BCVA

Month 6
29 (11.8%)
3 (3.8%)
8.1 (2.3, 13.9)
> 3 line Worsening in BCVA
Month 6
10 (4.1%)
4 (5.0%)
-0.9 (-6.3, 4.5)
8.5 Geriatric Use
In the clinical studies, 384 and 145 patients were 65 years
and of these 192 and 73 patients were 75 years in the
JETREA and vehicle groups respectively. No significant Figure 1: Percentage of Patients with Gain or
differences in efficacy or safety were seen with increasing Loss of 3 Lines of BCVA at Protocol-Specified
Visits
age in these studies.
10 OVERDOSAGE
The clinical data on the effects of JETREA overdose are
limited. One case of accidental overdose of 0.250 mg
ocriplasmin (twice the recommended dose) was reported
to be associated with inflammation and a decrease in visual
acuity.
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment
of Fertility
No carcinogenicity, mutagenicity or reproductive and
developmental toxicity studies were conducted with
ocriplasmin.
13.2 Animal Toxicology and/or Pharmacology
The ocular toxicity of ocriplasmin after a single
intravitreal dose has been evaluated in rabbits,
monkeys and minipigs. Ocriplasmin induced an
inflammatory response and transient ERG changes in
rabbits and monkeys, which tended to resolve over
time. Lens subluxation was observed in the 3 species at
ocriplasmin concentrations in the vitreous at or above
41 mcg/mL, a concentration 1.4-fold above the intended
clinical concentration in the vitreous of 29 mcg/mL.
Intraocular hemorrhage was observed in rabbits and
monkeys.
A second intravitreal administration of ocriplasmin
(28 days apart) in monkeys at doses of 75 mcg/eye
(41 mcg/mL vitreous) or 125 mcg/eye (68 mcg/mL
vitreous) was associated with lens subluxation in all
ocriplasmin treated eyes. Sustained increases in IOP
occurred in two animals with lens subluxation.
Microscopic findings in the eye included vitreous
liquefaction, degeneration/disruption of the hyaloideocapsular ligament (with loss of ciliary zonular fibers), lens
degeneration, mononuclear cell infiltration of the vitreous,
and vacuolation of the retinal inner nuclear cell layer.
These doses are 1.4-fold and 2.3-fold the intended clinical
concentration in the vitreous of 29 mcg/mL, respectively.
14 CLINICAL STUDIES
The efficacy and safety of JETREA was demonstrated
in two multicenter, randomized, double masked,
vehicle-controlled, 6 month studies in patients
with
symptomatic
vitreomacular
adhesion
(VMA). A total of 652 patients (JETREA 464,
vehicle 188) were randomized in these 2 studies.
Randomization was 2:1 (JETREA:vehicle) in Study 1 and
3:1 in Study 2.
15%
10%
5%
0%
-5%
-10%
-15%
14
28
90
180
Days
Study 1
JETREA
Study 1
Vehicle
Study 2
JETREA
Study 2
Vehicle
16 HOW SUPPLIED/STORAGE AND HANDLING

Each vial of JETREA contains 0.5 mg ocriplasmin in 0.2 mL
citric-buffered solution (2.5 mg/mL). JETREA is supplied in
a 2 mL glass vial with a latex free rubber stopper. Vials are
for single use only.
Storage
Store frozen at or below -4F ( -20C). Protect the vials
from light by storing in the original package until time of
use.
17 PATIENT COUNSELING INFORMATION
In the days following JETREA administration, patients
are at risk of developing intraocular inflammation/
infection. Advise patients to seek immediate care from an
ophthalmologist if the eye becomes red, sensitive to light,
painful, or develops a change in vision [see Warnings and
Precautions].
Patients may experience temporary visual impairment after
receiving an intravitreal injection of JETREA [see Warnings
and Precautions]. Advise patients to not drive or operate
heavy machinery until this visual impairment has resolved.
If visual impairment persists or decreases further, advise
patients to seek care from an ophthalmologist.
Manufactured for:
ThromboGenics, Inc.
101 Wood Avenue South, 6th Floor
Iselin, NJ 08830
U.S. License Number: 1866

2013, ThromboGenics, Inc. All rights reserved.
Version 1.0
Initial U.S. Approval: 2012
Patients were treated with a single injection of JETREA or ThromboGenics U.S. patents: 7,445,775; 7,547,435; 7,914,783
vehicle. In both of the studies, the proportion of patients and other pending patents.
who achieved VMA resolution at Day 28 (i.e., achieved
success on the primary endpoint) was significantly higher JETREA and the JETREA logo are trademarks or registered
in the ocriplasmin group compared with the vehicle group trademarks of ThromboGenics NV in the United States,
European Union, Japan, and other countries.
through Month 6.
05/13 OCRVMA0072 PI G
The Solution to Every Case.

Follow the clues and find the worlds finest surgical
microscope designed for ophthalmic surgeons. Our
key piece of evidence: our new C.Red that emits an
even brighter, redder and more stable red reflex.
Add extreme depth perception. Super stable, surgeon
friendly mechanics. Precise optics. And thats our case.
Now prove it to yourself. Call 800-787-5426 for demo.
800.787.5426
haag-streit-usa.com
2014 Haag-Streit USA. All Rights Reserved.
AAO 2014
BOARD OF TRUSTEES
Gregory L Skuta MD
Russell N Van Gelder MD PhD
David W Parke II MD
Paul Sternberg Jr MD
George B Bartley MD
Cynthia A Bradford MD
Louis B Cantor MD
Jane C Edmond MD
Alaa ElDanasoury MD
Paul B Ginsburg MD
Mathew W MacCumber MD PhD
Frank J Martin MD
Christie L Morse MD
Thomas A Oetting MD
Mildred M G Olivier MD
Jonathan B Rubenstein MD
John R Stechschulte MD
Humphrey J F Taylor
Linda M Tsai MD
Ann A Warn MD MBA
Robert E Wiggins Jr MD MHA
Charles M Zacks MD
President
President-Elect
Executive Vice President/CEO
Past President
Editor, Ophthalmology
Senior Secretary for Advocacy
Senior Secretary for Clinical Education
Trustee-at-Large
International Trustee-at-Large
Public Trustee
Vice Chair, The Council
International Trustee-at-Large
Chair, FAAO Advisory Board
Trustee-at-Large
Trustee-at-Large
Secretary for Annual Meeting
Trustee-at-Large
Public Trustee
Trustee-at-Large
Chair, The Council
Senior Secretary for Ophthalmic Practice
Trustee-at-Large
xv
SEE YOU IN VIENNA!

www.soe2015.org
AAO 2014
COMMITTEE
OF SECRETARIES
The Committee of Secretaries is directly involved in the development and management of program activities and services. This committee
plays an important role in program planning as well as providing recommendations to the board on the relative priority of major programs
within the Academy.
David W Parke II MD*
Richard L Abbott MD
George B Bartley MD*
Cynthia A Bradford MD*
Daniel J Briceland MD
Louis B Cantor MD*
Anne L Coleman MD PhD
Tamara R Fountain MD
Robert F Melendez MD MBA
Richard P Mills MD MPH
Jeffrey A Nerad MD
Christopher J Rapuano MD
Michael X Repka MD
William L Rich III MD
Philip R Rizzuto MD
Jonathan B Rubenstein MD*
Robert E Wiggins Jr MD MHA*
George A Williams MD
Chair
Secretary for Global Alliances
Editor, Ophthalmology
Senior Secretary for Advocacy
Secretary for State Affairs
Senior Secretary for Clinical Education
Secretary for Quality of Care
Secretary for Member Services
Editor-in-Chief, the ONE Network
Secretary for Online Education/eLearning
Chief Medical Editor, EyeNet Magazine
Secretary for Knowledge Base Development
Secretary for Ophthalmic Knowledge
Academy Medical Director for Governmental Affairs
Academy Medical Director of Health Policy
Secretary for Communications
Senior Secretary for Ophthalmic Practice
Secretary for Federal Affairs
*Members of the Board of Trustees
xvii
International Society of Refractive Surgery

A Partner of the American Academy of Ophthalmology
ISRS Chicago Schedule

REFRACTIVE SURGERY
SUBSPECIALTY DAY 2014: MISSION 20/20
The ISRS Annual Meeting
Friday, 17 October | 08:00 to 17:30
Saturday, 18 October | 08:00 to 17:30
Arie Crown Theater
Dont miss the ISRS Award presentation
at 10:15 AM on Friday!
ISRS Member Lunch
Friday, 17 October | 12:30 to 13:30
E354, Lakeside Center
ISRS SPECIAL SESSIONS
Introduction to Corneal and Lens-Based
Refractive Surgery for Residents (SYM02)
Sunday, 19 October | 08:00 to 11:00
E450
Best of the Anterior Segment Specialty
Meetings 2014 (SYM41)
Monday, 20 October | 10:15 to 11:30
S406A
Decision Making in Contemporary Refractive
Surgery (SYM48)
Tuesday, 21 October | 10:15 to 11:45
S406A
ISRS ROUNTABLES*
Sunday, 19 October through Tuesday, 21 October
07:30 to 08:30
Hall A
ISRS INSTRUCTION COURSES*
Surgical Management of Astigmatism in
Cataract and Refractive Surgery (198)
Sunday, 19 October | 14:00 to 15:00
S103BC
Danger Zone: Refractive Surgery Nightmares
and Worst-Case Scenarios: A Video-Based
Course (314)
Monday, 20, October | 09:00 to 11:15
N140
ISRS Laser Refractive Surgery Course (131)
N138
Laser Refractive Surgery (LAB131A)
Monday | 15:30 to 17:30 | N227B
Laser Refractive Surgery (LAB131B)
Tuesday | 08:00 to 10:00 | N227B
A Step-by-Step Primer to Starting LASIK in
2014 (380)
S103BC
Advanced Corneal Topographic Analysis (598)
Tuesday, 21 October | 14:00 to 16:15
S104A
For more information on ISRS or to become a member, visit Member Services booth
in the Academy Resource Center (Booth 508) or visit www.isrs.org.
*onsite fee applies
AAO Final Program
Cover more ground

in less time.
Leaping over 50 times its own length,

the rocket frog can accelerate up to twice
the speed of gravity.
The Integrated WaveLight Refractive Suite

The fastest refractive platform in the US features:
Unrivaled 500 Hz Excimer Laser ablation times at just 1.4 seconds per diopter*
Precise 200 kHz Femtosecond Laser custom flap creation in 6 seconds*
A 1050 Hz-type Eye Tracker, synchronized at 500 Hz, with 2 millisecond latency time
A broad range of customized, patient-specific treatments available
Ask your Alcon Sales Representative for more information.

*Based on typical treatment parameters for myopia.
For important safety information about this product, please refer to the adjacent page.
2013 Novartis
9/13
ALL13174JAD
WaveLight FS200
Femtosecond Laser
WaveLight EX500
Excimer Laser
taking the medication sumatriptan succinate (Imitrex*);

corneal, lens and/or vitreous opacities including, but not limited
to cataract;
Important Safety Information about the WaveLight Excimer
Laser Systems
This information pertains to all WaveLight Excimer Laser Systems,
including the WaveLight ALLEGRETTO WAVE, the ALLEGRETTO WAVE
Eye-Q , and the WaveLight EX500.
Caution: Federal (U.S.) law restricts the WaveLight Excimer Laser
Systems to sale by or on the order of a physician. Only practitioners who
are experienced in the medical mangement and surgical treatment of the
cornea, who have been trained in laser refractive surgery (including laser
calibration and operation) should use a WaveLight Excimer Laser System.
Indications: FDA has approved the WaveLight Excimer Laser for use in
laser-assisted in situ keratomileusis (LASIK) treatments for:
iris problems including , but not limited to, coloboma and previous
iris surgery compromising proper eye tracking; or
taking medications likely to affect wound healing including (but not
limited to) antimetabolites.
In addition, safety and effectiveness of the WaveLight Excimer Laser
Systems have not been established for:
treatments with an optical zone < 6.0 mm or > 6.5 mm in diameter,
or an ablation zone > 9.0 mm in diameter; or
wavefront-guided treatment targets different from emmetropia
(plano) in which the wavefront calculated defocus (spherical term)
has been adjusted;
the reduction or elimination of myopia of up to - 12.0 DS and up to

6.0 D of astigmatism at the spectacle plane;
In the WaveLight Excimer Laser System clinical studies, there were few
subjects with cylinder amounts > 4 D and 6 D. Not all complications,
adverse events, and levels of effectiveness may have been determined for
this population.
the reduction or elimination of hyperopia up to + 6.0 DS with and

without astigmatic refractive errors up to 5.0 D at the spectacle plane,
with a maximum manifest refraction spherical equivalent of + 6.0 D;
Pupil sizes should be evaluated under mesopic illumination conditions.

Effects of treatment on vision under poor illumination cannot be predicted
prior to surgery.
the reduction or elimination of naturally occurring mixed astigmatism

of up to 6.0 D at the spectacle plane; and
Adverse Events and Complications
the wavefront-guided reduction or elimination of myopia of up to

-7.0 DS and up to 3.0 D of astigmatism at the spectacle plane.
In addition, FDA has approved the WaveLight ALLEGRETTO WAVE Eye-Q
Excimer Laser System, when used with the WaveLight ALLEGRO Topolyzer
and topography-guided treatment planning software for topographyguided LASIK treatments for the reduction or elimination of up to -9.00 D
of myopia, or for the reduction or elimination of myopia with astigmatism,
with up to -8.00 D of myopia and up to 3.00 D of astigmatism.
The WaveLight Excimer Laser Systems are only indicated for use in
patients who are 18 years of age or older (21 years of age or older for mixed
astigmatism) with documentation of a stable manifest refraction defined
as 0.50 D of preoperative spherical equivalent shift over one year prior to
surgery, exclusive of changes due to unmasking latent hyperopia.
Contraindications: The WaveLight Excimer Laser Systems are
contraindicated for use with patients who:
are pregnant or nursing;
have a diagnosed collagen vascular, autoimmune or
immunodeficiency disease;
have been diagnosed keratoconus or if there are any clinical pictures
suggestive of keratoconus; or
are taking isotretinoin (Accutane*) and/or amiodarone hydrochloride
(Cordarone*).
Warnings: The WaveLight Excimer Laser Systems are not recommended
for use with patients who have:
systemic diseases likely to affect wound healing, such as connective
tissue disease, insulin dependent diabetes, severe atopic disease or an
immunocompromised status;
a history of Herpes simplex or Herpes zoster keratitis;
significant dry eye that is unresponsive to treatment;
severe allergies; or
an unreliable preoperative wavefront examination that precludes
wavefront-guided treatment.
a poor quality preoperative topography map that precludes
topography-guided LASIK treatment.
The wavefront-guided LASIK procedure requires accurate and reliable
data from the wavefront examination. Every step of every wavefront
measurement that may be used as the basis for a wavefront-guided LASIK
procedure must be validated by the user. Inaccurate or unreliable data from
the wavefront examination will lead to an inaccurate treatment.
Topography-guided LASIK requires preoperative topography maps
of sufficient quality to use for planning a topography-guided LASIK
treatment. Poor quality topography maps may affect the accuracy of the
topography-guided LASIK treatment and may result in poor vision after
topography-guided LASIK.
Precautions: The safety and effectiveness of the WaveLight Excimer Laser
Systems have not been established for patients with:
progressive myopia, hyperopia, astigmatism and/or mixed
astigmatism, ocular disease, previous corneal or intraocular surgery,
or trauma in the ablation zone;
corneal abnormalities including, but not limited to, scars, irregular
astigmatism and corneal warpage;
residual corneal thickness after ablation of less than 250 microns due
to the increased risk for corneal ectasia;
pupil size below 7.0 mm after mydriatics where applied for
wavefront-guided ablation planning;
history of glaucoma or ocular hypertension of > 23 mmHg;
Myopia: In the myopia clinical study, 0.2% (2/876) of the eyes had a lost,
misplaced, or misaligned flap reported at the 1 month examination.
The following complications were reported 6 months after LASIK: 0.9%
(7/818) had ghosting or double images in the operative eye; 0.1% (1/818)
of the eyes had a corneal epithelial defect.
Hyperopia: In the hyperopia clinical study, 0.4% (1/276) of the eyes had
a retinal detachment or retinal vascular accident reported at the 3 month
examination.
(2/262) of the eyes had a corneal epithelial defect and 0.8% (2/262) had
any epithelium in the interface.
Mixed Astigmatism: In the mixed astigmatism clinical study, two
adverse events were reported. The first event involved a patient who
postoperatively was subject to blunt trauma to the treatment eye 6 days
after surgery. The patient was found to have an intact globe with no
rupture, inflammation or any dislodgement of the flap. UCVA was decreased
due to this event. The second event involved the treatment of an incorrect
axis of astigmatism. The axis was treated at 60 degrees instead of 160
degrees.
(2/111) of the eyes had ghosting or double images in the operative eye.
Wavefront-Guided Myopia: No adverse events occurred during the
postoperative period of the wavefront-guided LASIK procedures. In the
Control Cohort (traditional LASIK treatment) one subject undergoing
traditional LASIK had the axis of astigmatism programmed as 115 degrees
instead of the actual 155 degree axis. This led to cylinder in the left eye.
The following complications were reported 6 months after wavefrontguided LASIK in the Study Cohort: 1.2% (2/166) of the eyes had a corneal
epithelial defect; 1.2% (2/166) had foreign body sensation; and 0.6%
(1/166) had pain. No complications were reported in the Control Cohort.
Topography-Guided Myopia: There were six adverse events reported in the
topography-guided myopia study. Four of the eyes experienced transient
or temporary decreases in vision prior to the final 12 month follow-up visit,
all of which were resolved by the final follow-up visit. One subject suffered
from decreased vision in the treated eye, following blunt force trauma 4
days after surgery. One subject experienced retinal detachment, which was
concluded to be unrelated to the surgical procedure.
Clinical Data
Myopia: The myopia clinical study included 901 eyes treated, of which
813 of 866 eligible eyes were followed for 12 months. Accountability at 3
months was 93.8%, at 6 months was 91.9%, and at 12 months was 93.9%.
Of the 782 eyes eligible for the uncorrected visual acuity (UCVA) analysis of
effectiveness at the 6-month stability time point, 98.3% were corrected to
20/40 or better, and 87.7% were corrected to 20/20 or better. Subjects who
responded to a patient satisfaction questionnaire before and after LASIK
reported the following visual symptoms at a moderate or severe level
at least 1% higher at 3 months post-treatment than at baseline: visual
fluctuations (28.6% vs. 12.8% at baseline).
Long term risks of LASIK for hyperopia with and without astigmatism have
not been studied beyond 12 months.
Mixed Astigmatism: The mixed astigmatism clinical study included 162
eyes treated, of which 111 were eligible to be followed for 6 months.
Accountability at 1 month was 99.4%, at 3 months was 96.0%, and at
6 months was 100.0%. Of the 142 eyes eligible for the UCVA analysis of
effectiveness at the 6-month stability time point, 97.3% achieved acuity
of 20/40 or better, and 69.4% achieved acuity of 20/20 or better. Subjects
who responded to a patient satisfaction questionnaire before and after
LASIK reported the following visual symptoms at a moderate or severe
level at least 1% higher at 3 months post-treatment than at baseline:
sensitivity to light (52.9% vs. 43.3% at baseline); visual fluctuations (43.0%
vs. 32.1% at baseline); and halos (42.3% vs. 37.0% at baseline).
Long term risks of LASIK for mixed astigmatism have not been studied
beyond 6 months.
Wavefront-Guided Myopia: The wavefront-guided myopia clinical study
included 374 eyes treated; 188 with wavefront-guided LASIK (Study Cohort)
and 186 with Wavefront Optimized LASIK (Control Cohort). 166 of the
Study Cohort and 166 of the Control Cohort were eligible to be followed at
6 months. In the Study Cohort, accountability at 1 month was 96.8%, at
3 months was 96.8%, and at 6 months was 93.3%. In the Control Cohort,
accountability at 1 month was 94.6%, at 3 months was 94.6%, and at 6
months was 92.2%.
Of the 166 eyes in the Study Cohort that were eligible for the UCVA analysis
of effectiveness at the 6-month stability time point, 99.4% were corrected
to 20/40 or better, and 93.4% were corrected to 20/20 or better. Of the 166
eyes in the Control Cohort eligible for the UCVA analysis of effectiveness at
the 6-month stability time point, 99.4% were corrected to 20/40 or better,
and 92.8% were corrected to 20/20.
In the Study Cohort, subjects who responded to a patient satisfaction
questionnaire before and after LASIK reported the following visual
symptoms at a moderate or severe level at least 1% higher at 3 months
post-treatment than at baseline: light sensitivity (47.8% vs. 37.2%
at baseline) and visual fluctuations (20.0% vs. 13.8% at baseline). In
the Control Cohort, the following visual symptoms were reported at a
moderate or severe level at least 1% higher at 3 months post-treatment
than at baseline: halos (45.4% vs. 36.6% at baseline) and visual
fluctuations (21.9% vs. 18.3% at baseline).
Long term risks of wavefront-guided LASIK for myopia with and without
astigmatism have not been studied beyond 6 months.
Topography-Guided Myopia: The topography-guided myopia clinical
study included 249 eyes treated, of which 230 eyes were followed for 12
months. Accountability at 3 months was 99.2%, at 6 months was 98.0%,
and at 12 months was 92.4%. Of the 247 eyes that were eligible for the
UCVA analysis at the 3-month stability time point, 99.2% were corrected
to 20/40 or better, and 92.7% were corrected to 20/20 or better. Subjects
who responded to a patient satisfaction questionnaire before and after
LASIK reported the following visual symptoms as marked or severe at an
incidence greater than 5% at 1 month after surgery: dryness (7% vs. 4%
at baseline) and light sensitivity (7% vs. 5% at baseline). Visual symptoms
continued to improve with time, and none of the visual symptoms were
rated as being marked or severe with an incidence of at least 5% at 3
months or later after surgery.
Long term risks of topography-guided LASIK for myopia with and without
astigmatism have not been studied beyond 12 months.
Information for Patients: Prior to undergoing LASIK surgery with a
WaveLight Excimer Laser System, prospective patients must receive a
copy of the relevant Patient Information Booklet, and must be informed
of the alternatives for correcting their vision, including (but not limited
to) eyeglasses, contact lenses, photorefractive keratectomy, and other
refractive surgeries.
Attention: Please refer to a current WaveLight Excimer Laser System
Procedure Manual for a complete listing of the indications, complications,
warnings, precautions, and side effects.
* Trademarks are property of their respective owners.
Long term risks of LASIK for myopia with and without astigmatism have not
been studied beyond 12 months.
Hyperopia: The hyperopia clinical study included 290 eyes treated, of which
100 of 290 eligible eyes were followed for 12 months. Accountability at
3 months was 95.2%, at 6 months was 93.9%, and at 12 months was
69.9%. Of the 212 eyes eligible for the UCVA analysis of effectiveness at
the 6-month stability time point, 95.3% were corrected to 20/40 or better,
and 69.4% were corrected to 20/20 or better. Subjects who responded to
a patient satisfaction questionnaire before and after LASIK reported the
following visual symptoms as much worse at 6 months post-treatment:
halos (6.4%); visual fluctuations (6.1%); light sensitivity (4.9%); night
driving glare (4.2%); and glare from bright lights (3.0%).
2014 Novartis 2/14 ALL13174JADUS-PI
LOOK WHOS DROPPING

INTO CHICAGO
VISIT US AT ALLERGAN BOOTH #1408
2014 Allergan, Inc., Irvine, CA 92612 marks owned by Allergan, Inc. www.Combigan.com www.AlphaganP.com APC05FF14 142474
Save the Date!

Theres strength in numbers. Lobby on Capitol Hill for
ophthalmologys top legislative issues including advocating
for fair Medicare physician payment, reducing regulatory
burdens and vision research. Meet face-to-face with your
Members of Congress and show the might of our members at
this important event. Its the most effective way to protect the
interests of our profession and our patients.
CONGRESSIONAL
ADVOCACY DAy
April 15 16, 2015
Washington, DC
Be an advocate for our patients and our
profession! Participate in Congressional
Advocacy Day and play a vital role
in communicating with our national
legislators about issues of importance
to ophthalmology during these critical
times. Join hundreds of your colleagues
and me in Washington, DC in 2015!

Gregory L. Skuta, MD
Academy President
Registration opens in January 2015.

Congressional Advocacy Day is open to all
Academy members and registration is free.
www.aao.org/myf
The Council
The Council serves as the advisory body to the Board of Trustees. It was established in accordance with section 7.01 of the Bylaws of the
American Academy of Ophthalmology.
Mathew W MacCumber MD PhD Vice

Chair
Councilors representing State Societies

Alabama Academy of Ophthalmology
Stephen J Kelly MD
Alaska Society of Eye Physicians and Surgeons
Scott A Limstrom MD
Arizona Ophthalmological Society
Thomas J McPhee MD
Arkansas Ophthalmological Society
Justine W Charton MD
California Academy of Eye Physicians and
Surgeons
JoAnn A Giaconi MD
Lynn K Gordon MD PhD
Asa Dan Morton III MD
Frank A Scotti MD
Colorado Society of Eye Physicians and
Surgeons
Alan E Kimura MD MPH
Connecticut Society of Eye Physicians
Jeffrey R Sandler MD
Delaware Academy of Ophthalmology
Edward S A Jaoude MD
Florida Society of Ophthalmology
David B Cano MD
Stephen G Schwartz MD MBA
Charles B Slonim MD FACS
Kansas Society of Eye Physicians and Surgeons

William S Clifford MD
Kentucky Academy of Eye Physicians and
Surgeons
David E Jones MD
Louisiana Ophthalmology Association
George S Ellis Jr MD FAAO FACS
Maine Society of Eye Physicians and Surgeons
Cynthia A Self MD
Maryland Society of Eye Physicians and
Surgeons
Sanjay D Goel MD
John T Thompson MD
Massachusetts Society of Eye Physicians and
Surgeons
Michael H Goldstein MD
Michael J Price MD
Michigan Society of Eye Physicians and
Surgeons
Arezo Amirikia MD
Anne M Nachazel MD
Minnesota Academy of Ophthalmology
Geoffrey G Emerson MD PhD
Mississippi Academy of Eye Physicians and
Surgeons
Curtis D Whittington Jr MD
Missouri Society of Eye Physicians and
Surgeons
P Kumar Rao MD
New York State Ophthalmological Society

Gary S Hirshfield MD
James A Kinsey MD
Martin E Lederman MD
Stephen G Spitzer MD
North Carolina Society of Eye Physicians and
Surgeons
J Stuart McCracken MD
North Dakota Society of Eye Physicians and
Surgeons
Lance K Bergstrom MD
Ohio Ophthalmological Society
Anita Dash-Modi MD
Bernard D Perla MD
Oklahoma Academy of Ophthalmology
Amalia Miranda MD
Oregon Academy of Ophthalmology
Mary P DeFrank MD
Pennsylvania Academy of Ophthalmology
James B Dickey MD
Joanna M Fisher MD
Karl R Olsen MD
Puerto Rican Society of Ophthalmology
Emilio A Arce-Lpez MD
Rhode Island Society of Eye Physicians and
Surgeons
Robert H Janigian Jr MD
South Carolina Society of Ophthalmology
Todd D Gwin MD
Montana Academy of Ophthalmology

Brian D Sippy MD PhD
South Dakota Academy of Ophthalmology

Dustin L Dierks MD
Hawaii Ophthalmological Society

George Nardin MD
Nebraska Academy of Eye Physicians and

Surgeons
David D Ingvoldstad MD
Tennessee Academy of Ophthalmology

Ben B Mahan MD
Idaho Society of Ophthalmology

Adam C Reynolds MD
Nevada Academy of Ophthalmology

Steve M Friedlander MD FACS
Illinois Society of Eye Physicians and Surgeons

Sohail J Hasan MD PhD
David K Yoo MD
New Hampshire Society of Eye Physicians and

Surgeons
John J Dagianis MD
Indiana Academy of Ophthalmology

Derek T Sprunger MD
New Jersey Academy of Ophthalmology

Cecily A Lesko MD FACS
John R Stabile MD
Georgia Society of Ophthalmology

James Gerard Brooks Jr MD
Iowa Academy of Ophthalmology

Brandt M Riley DO
New Mexico Academy of Ophthalmology

Kamalesh J Ramaiya MD
The Council
Ann A Warn MD MBA Chair
Texas Ophthalmological Association

John R Fish MD
Richard Galen Kemp MD
Aaron M Miller MD MBA
Utah Ophthalmology Society
James G Howard MD
Vermont Ophthalmological Society
Brian Y Kim MD
Virginia Society of Eye Physicians and Surgeons
Anthony J Viti MD
xxiii
The Council
The Council
Washington Academy of Eye Physicians and
Surgeons
Brian E Bowe MD
American Society of Retina Specialists

Peter K Kaiser MD
Judy E Kim MD
Washington DC Metropolitan Ophthalmological

Society
Reshma Katira MD
American Uveitis Society

Justine R Smith MD
West Virginia Academy of Eye Physicians and

Surgeons
Mark D Mayle MD
Wisconsin Academy of Ophthalmology
Deborah W Bernstein MD
Association for Research in Vision and

Ophthalmology
Emily Y Chew MD
Association of University Professors of
Ophthalmology
Joel S Schuman MD
Wyoming Ophthalmological Society

Anne Elizabeth Miller MD
Association of Veterans Affairs

Ophthalmologists
Mary Gilbert Lawrence MD MPH
Councilors representing Subspecialty

and Specialized Interest Societies
Canadian Ophthalmological Society

Paul E Rafuse MD PhD
American Academy of Pediatrics, Section on

Ophthalmology
Gregg T Lueder MD
Contact Lens Association of Ophthalmologists

Bennie H Jeng MD
American Association for Pediatric

Ophthalmology and Strabismus
David A Plager MD
Cornea Society
Shahzad I Mian MD
Eye Bank Association of America
Woodford S Van Meter MD FACS
American Association of Ophthalmic

Oncologists and Pathologists
George Harocopos MD
Macula Society
Michael J Elman MD
American Board of Ophthalmology

John E Sutphin MD
National Medical Association, Ophthalmology

Section
Chasidy D Singleton MD
American College of Surgeons, Advisory Council

for Ophthalmic Surgery
Vikram D Durairaj MD
Sarwat Salim MD
American Glaucoma Society
Thomas W Samuelson MD
American Ophthalmological Society
Thomas J Liesegang MD
American Osteopathic College of
Ophthalmology
Kristin E Reidy DO
American Society of Cataract and Refractie
Surgery
David A Goldman MD
Thomas M Harvey MD
American Society of Ocular Trauma
Michael P Grant MD PhD
North American Neuro-Ophthalmology Society

Matthew Dean Kay MD
Ocular Microbiology and Immunology Group
Bradley Dean Fouraker MD
Outpatient Ophthalmic Surgery Society
Y Ralph Chu MD
Pan-American Association of Ophthalmology
Stephanie Jones Marioneaux MD
Retina Society
Jennifer I Lim MD
Society of Military Ophthalmologists
Jonathan S Collins MD
Women in Ophthalmology
Laura J King MD MMM
American Society of Ophthalmic Plastic and

Reconstructive Surgery
Louise A Mawn MD
xxiv
AAO 2014 Overview

Thursday, Oct. 16
Registration
Time
Attendees - onsite
4:00 - 6:00 pm
Attendees - satellite location
2:00 - 6:00 pm
Exhibitors
Ticket Sales
AAO 2014 Overview
Event
7:30 am - 6:00 pm
4:00 - 6:00 pm
Friday, Oct. 17
Event
Time
Alumni & Related Group Functions
All Day
Registration
Attendees - onsite
7:00 am - 5:00 pm
Attendees - satellite location
7:00 am - 5:00 pm
Exhibitors
7:00 am - 6:00 pm
Special Meetings & Events
7:30 am - 3:00 pm
Subspecialty Day Meetings
Refractive Surgery
8:00 am - 5:15 pm
Refractive Surgery E-posters
7:00 am - 5:30 pm
Retina
8:00 am - 5:15 pm
Retina Exhibits
9:30 am - 5:30 pm
Ticket Sales
7:00 am - 5:00 pm
Saturday, Oct. 18
Event
Time
AAOE/Practice Management: Introduction to Ophthalmic Coding and ICD-10-CM
8:00 - 11:00 am
AAOE/Practice Management: Coding Camp and Advanced ICD-10-CM
12:30 - 3:30 pm
AAOE/Practice Management Master Classes
8:00 am - 4:30 pm
Academy Caf
1:15 - 4:30 pm
before 8:00 am &

after 5:30 pm
Exhibition
9:00 am - 5:00 pm
Learning Lounge
12:00 - 5:00 pm
Registration
Attendees
7:00 am - 5:00 pm
Exhibitors
7:00 am - 5:00 pm
Scientific Posters
9:00 am - 5:00 pm
Scientific Posters Online/Videos on Demand Booth 65
9:00 am - 5:00 pm
9:00 am - 4:00 pm
xxvii
AAO 2014 Overview

AAO 2014 Overview
Saturday, Oct. 18 (cont.)

Event
Subspecialty Day Meetings
Time
Cornea
8:00 am - 5:30 pm
Glaucoma
8:00 am - 5:00 pm
Ocular Oncology and Pathology
8:00 am - 5:15 pm
Oculofacial Plastic Surgery
8:00 am - 5:00 pm
Pediatric Ophthalmology
8:00 am - 5:00 pm
Refractive Surgery
8:00 am - 5:30 pm
Refractive Surgery E-posters
7:00 am - 5:00 pm
Retina
8:00 am - 5:30 pm
Uveitus
7:30 am - 5:30 pm
Symposia
2:00 - 5:30 pm
Technology Pavilion
9:30 am - 5:00 pm
Ticket Sales
7:00 am - 5:00 pm
Sunday, Oct. 19
Event
Time
AAO 2014 Opening Session
8:30 - 10:00 am
AAO-SOE Joint Session, A View Across the Pond: Current Cataract and IOL Practices in Europe and the United States
2:00 - 3:30 pm
AAOE/Practice Management Courses
2:00 pm - 5:30 pm
AAOE/Practice Management General Session
10:00 am - 12:00 pm
Academy Business Meeting
10:00 - 10:30 am
Academy Caf
10:30 am - 3:45 pm
before 8:00 am &

after 5:30 pm
7:30 - 8:30 am
Exhibition
9:00 am - 5:00 pm
Fall Council Meeting
11:30 am - 5:00 pm
Instruction Courses
9:00 am - 5:30 pm
Learning Lounge
10:30 am - 5:00 pm
Orbital Gala
6:00 - 10:00 pm
Original Paper Sessions
10:30 am - 5:30 pm
Registration
Attendees
7:00 am - 5:00 pm
Exhibitors
7:00 am - 5:00 pm
Scientific Posters
7:00 am - 5:00 pm
Scientific Posters Online/Videos on Demand - Booth 65
7:00 am - 5:00 pm
Scientific Posters Online/Videos on Demand - Lakeside Center
8:00 am - 5:00 pm
12:30 - 1:30 pm
8:00 am - 5:30 pm
6:30 am - 4:00 pm
Symposia and Spotlight Sessions
8:00 am - 5:15 pm
xxviii
AAO 2014 Overview

Sunday, Oct. 19 (cont.)
AAO 2014 Overview
Event
Time
Technology Pavilion
9:30 am - 5:00 pm
Ticket Sales
7:00 am - 5:00 pm
Young Ophthalmologist (YO) Program
10:00 am - 2:00 pm
Monday, Oct. 20
Event
Time
AAO-SOE Joint Session, A View Across the Pond: Retina
8:30 - 10:00 am
9:00 am - 5:30 pm
Academy Caf
8:30 - 11:45 am
before 8:30 am &

after 5:30 pm
7:30 - 8:30 am
Exhibition
9:00 am - 5:00 pm
Instruction Courses
9:00 am - 5:30 pm
Learning Lounge
9:00 am - 5:00 pm
8:30 am - 5:30 pm
Registration
Attendees
7:00 am - 5:00 pm
Exhibitors
7:00 am - 5:00 pm
Scientific Posters
7:00 am - 5:00 pm
7:00 am - 5:00 pm
8:00 am - 5:00 pm
12:30 - 1:30 pm
Senior Ophthalmologist (SO) Program
2:30 - 5:00 pm
7:30 am - 4:30 pm
12:30 - 5:00 pm
Symposia and Spotlight Sessions
8:15 am - 5:15 pm
Technology Pavilion
9:30 am - 5:00 pm
Ticket Sales
7:00 am - 5:00 pm
Tuesday, Oct. 21
Event
AAO-SOE Joint Session, A View Across the Pond: Cornea Enigmas
Time
10:45 am - 12:15 pm
9:00 am - 1:45 pm
Academy Caf
10:30 - 11:45 am
before 8:30 am &

after 1:00 pm
7:30 - 8:30 am
Exhibition
9:00 am - 1:00 pm
Instruction Courses
9:00 am - 5:30 pm
Learning Lounge
9:00 am - 12:00 pm
xxix
AAO 2014 Overview

Tuesday, Oct. 21 (cont.)
AAO 2014 Overview
Event
Time
8:30 am - 12:45 pm
Registration
Attendees
7:00 am - 1:00 pm
Exhibitors
7:00 am - 1:00 pm
Scientific Posters
7:00 am - 1:00 pm
7:00 am - 1:00 pm
8:00 am - 5:00 pm
8:00 am - 4:00 pm
Symposia
8:30 am - 12:15 pm
Technology Pavilion
9:30 am - 12:30 pm
Ticket Sales
7:00 am - 1:00 pm
Wednesday, Oct. 22
Event
28 Lo Mejor de la Academia en Espaol 2014 (The Best of the Academy in Spanish 2014)
xxx
Time
8:00 am - 5:30 pm
UNLOCK TREATMENT POSSIBILITIES
10/1/14
SIMBRINZA Suspension provided additional

1-3 mm Hg IOP lowering compared to
the individual components1
IOP measured at 8 AM, 10 AM, 3 PM, and 5 PM
was reduced by 21-35% at Month 32-4
Efficacy proven in two pivotal Phase 3 randomized,
multicenter, double-masked, parallel-group, 3-month,
3-arm, contribution-of-elements studies2,3
The most frequently reported adverse reactions (3-7%)
in a six month clinical trial were eye irritation, eye allergy,
conjunctivitis, blurred vision, dysgeusia (bad taste),
conjunctivitis allergic, eye pruritus, and dry mouth5
Only available beta-blocker-free fixed combination2,3
INDICATIONS AND USAGE
SIMBRINZA (brinzolamide/brimonidine tartrate ophthalmic suspension)
1%/0.2% is a fixed combination indicated in the reduction of elevated
intraocular pressure (IOP) in patients with open-angle glaucoma or
ocular hypertension.
Dosage and Administration
The recommended dose is one drop of SIMBRINZA Suspension
in the affected eye(s) three times daily. Shake well before use.
SIMBRINZA Suspension may be used concomitantly with other topical
ophthalmic drug products to lower intraocular pressure. If more than one
topical ophthalmic drug is being used, the drugs should be administered
at least five (5) minutes apart.
IMPORTANT SAFETY INFORMATION
Contraindications
SIMBRINZA Suspension is contraindicated in patients who are
hypersensitive to any component of this product and neonates and
infants under the age of 2 years.
Warnings and Precautions
Sulfonamide Hypersensitivity Reactions Brinzolamide is a sulfonamide,
and although administered topically, is absorbed systemically. Sulfonamide
attributable adverse reactions may occur. Fatalities have occurred due
to severe reactions to sulfonamides. Sensitization may recur when a
sulfonamide is readministered irrespective of the route of administration.
If signs of serious reactions or hypersensitivity occur, discontinue the use
of this preparation.
Corneal EndotheliumThere is an increased potential for developing
corneal edema in patients with low endothelial cell counts.
References: 1. SIMBRINZA Suspension Package Insert. 2. Katz G, DuBiner H,
Samples J, et al. Three-month randomized trial of fixed-combination brinzolamide, 1%,
and brimonidine, 0.2% [published online ahead of print April 11, 2013]. JAMA Ophthalmol.
doi:10.1001/jamaophthalmol.2013.188. 3. Nguyen QH, McMenemy MG, Realini T,
et al. Phase 3 randomized 3-month trial with an ongoing 3-month safety extension
of fixed-combination brinzolamide 1%/brimonidine 0.2%. J Ocul Pharmacol Ther.
2013;29(3):
290-297. 4. Data on file, 2013. 5. Whitson JT, Realini T, Nguyen QH, McMenemy MG,
Goode SM. Six-month results from a Phase III randomized trial of fixed-combination
brinzolamide 1% + brimonidine 0.2% versus brinzolamide or brimonidine monotherapy in
glaucoma or ocular hypertension. Clin Ophthalmol. 2013;7:1053-1060.
Severe Hepatic or Renal Impairment (CrCl <30 mL/min)SIMBRINZA

Suspension has not been specifically studied in these patients and
is not recommended.
Adverse Reactions
In two clinical trials of 3 months duration with SIMBRINZA Suspension,
the most frequent reactions associated with its use occurring in
approximately 3-5% of patients in descending order of incidence included:
blurred vision, eye irritation, dysgeusia (bad taste), dry mouth, and eye allergy.
Adverse reaction rates with SIMBRINZA Suspension were comparable to
those of the individual components. Treatment discontinuation, mainly due to
adverse reactions, was reported in 11% of SIMBRINZA Suspension patients.
Drug InteractionsConsider the following when prescribing
SIMBRINZA Suspension:
Concomitant administration with oral carbonic anhydrase inhibitors is not
recommended due to the potential additive effect. Use with high-dose
salicylate may result in acid-base and electrolyte alterations. Use with
CNS depressants may result in an additive or potentiating effect. Use with
antihypertensives/cardiac glycosides may result in additive or potentiating
effect on lowering blood pressure. Use with tricyclic antidepressants may
blunt the hypotensive effect of systemic clonidine and it is unknown if use
with this class of drugs interferes with IOP lowering. Use with monoamine
oxidase inhibitors may result in increased hypotension.
For additional information about SIMBRINZA Suspension,
please see Brief Summary of full Prescribing Information on
adjacent page.
Learn more at myalcon.com/simbrinza

TM
(brinzolamide/brimonidine
tartrate ophthalmic suspension)
1%/0.2%
ONE BOTTLE. MANY POSSIBILITIES.
2013 Novartis 9/13 SMB13064JAD
AAO Final Program
For the treatment of elevated IOP
BRIEF SUMMARY OF PRESCRIBING INFORMATION

INDICATIONS AND USAGE
SIMBRINZA (brinzolamide/brimonidine tartrate ophthalmic
suspension) 1%/0.2% is a fixed combination of a carbonic anhydrase
inhibitor and an alpha 2 adrenergic receptor agonist indicated for
the reduction of elevated intraocular pressure (IOP) in patients with
open-angle glaucoma or ocular hypertension.
DOSAGE AND ADMINISTRATION
The recommended dose is one drop of SIMBRINZA Suspension
in the affected eye(s) three times daily. Shake well before use. SIMBRINZA Suspension may be used concomitantly with other topical
ophthalmic drug products to lower intraocular pressure. If more
than one topical ophthalmic drug is being used, the drugs should be
administered at least five (5) minutes apart.
DOSAGE FORMS AND STRENGTHS
Suspension containing 10 mg/mL brinzolamide and 2 mg/mL
brimonidine tartrate.
CONTRAINDICATIONS
Hypersensitivity - SIMBRINZA Suspension is contraindicated in
patients who are hypersensitive to any component of this product.
Neonates and Infants (under the age of 2 years) - SIMBRINZA
Suspension is contraindicated in neonates and infants (under the age
of 2 years) see Use in Specific Populations
WARNINGS AND PRECAUTIONS
Sulfonamide Hypersensitivity Reactions - SIMBRINZA
Suspension contains brinzolamide, a sulfonamide, and although
administered topically is absorbed systemically. Therefore, the same
types of adverse reactions that are attributable to sulfonamides
may occur with topical administration of SIMBRINZA Suspension.
Fatalities have occurred due to severe reactions to sulfonamides
including Stevens-Johnson syndrome, toxic epidermal necrolysis,
fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and
other blood dyscrasias. Sensitization may recur when a sulfonamide
is re-administered irrespective of the route of administration. If signs
of serious reactions or hypersensitivity occur, discontinue the use of
this preparation [see Patient Counseling Information]
Corneal Endothelium - Carbonic anhydrase activity has been
observed in both the cytoplasm and around the plasma membranes
of the corneal endothelium. There is an increased potential for developing corneal edema in patients with low endothelial cell counts.
Caution should be used when prescribing SIMBRINZA Suspension
to this group of patients.
Severe Renal Impairment - SIMBRINZA Suspension has not been
specifically studied in patients with severe renal impairment (CrCl
< 30 mL/min). Since brinzolamide and its metabolite are excreted
predominantly by the kidney, SIMBRINZA Suspension is not recommended in such patients.
Acute Angle-Closure Glaucoma - The management of patients with
acute angle-closure glaucoma requires therapeutic interventions in
addition to ocular hypotensive agents. SIMBRINZA Suspension has
not been studied in patients with acute angle-closure glaucoma.
Contact Lens Wear - The preservative in SIMBRINZA, benzalkonium chloride, may be absorbed by soft contact lenses. Contact lenses
should be removed during instillation of SIMBRINZA Suspension
but may be reinserted 15 minutes after instillation [see Patient
Counseling Information].
Severe Cardiovascular Disease - Brimonidine tartrate, a component
of SIMBRINZATM Suspension, has a less than 5% mean decrease in
blood pressure 2 hours after dosing in clinical studies; caution should
be exercised in treating patients with severe cardiovascular disease.
Severe Hepatic Impairment - Because brimonidine tartrate, a
component of SIMBRINZA Suspension, has not been studied in
patients with hepatic impairment, caution should be exercised in
such patients.
Potentiation of Vascular Insufficiency - Brimonidine tartrate, a
component of SIMBRINZATM Suspension, may potentiate syndromes
associated with vascular insufficiency. SIMBRINZA Suspension
should be used with caution in patients with depression, cerebral or
coronary insufficiency, Raynauds phenomenon, orthostatic hypotension, or thromboangitis obliterans.
Contamination of Topical Ophthalmic Products After Use - There
have been reports of bacterial keratitis associated with the use
of multiple-dose containers of topical ophthalmic products. These
containers have been inadvertently contaminated by patients who, in
most cases, had a concurrent corneal disease or a disruption of the
ocular epithelial surface [see Patient Counseling Information].
ADVERSE REACTIONS
Clinical Studies Experience - Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed
in the clinical studies of a drug cannot be directly compared to the
rates in the clinical studies of another drug and may not reflect the
rates observed in practice.
SIMBRINZA Suspension - In two clinical trials of 3 months
duration 435 patients were treated with SIMBRINZA Suspension,
and 915 were treated with the two individual components. The most
frequently reported adverse reactions in patients treated with SIMBRINZA Suspension occurring in approximately 3 to 5% of patients
in descending order of incidence were blurred vision, eye irritation,
dysgeusia (bad taste), dry mouth, and eye allergy. Rates of adverse
reactions reported with the individual components were comparable.
Treatment discontinuation, mainly due to adverse reactions, was
reported in 11% of SIMBRINZA Suspension patients.
Other adverse reactions that have been reported with the individual
components during clinical trials are listed below.
Brinzolamide 1% - In clinical studies of brinzolamide ophthalmic

suspension 1%, the most frequently reported adverse reactions
reported in 5 to 10% of patients were blurred vision and bitter,
sour or unusual taste. Adverse reactions occurring in 1 to 5% of
patients were blepharitis, dermatitis, dry eye, foreign body sensation,
headache, hyperemia, ocular discharge, ocular discomfort, ocular
keratitis, ocular pain, ocular pruritus and rhinitis.
The following adverse reactions were reported at an incidence
below 1%: allergic reactions, alopecia, chest pain, conjunctivitis,
diarrhea, diplopia, dizziness, dry mouth, dyspnea, dyspepsia, eye
fatigue, hypertonia, keratoconjunctivitis, keratopathy, kidney pain,
lid margin crusting or sticky sensation, nausea, pharyngitis, tearing
and urticaria.
Brimonidine Tartrate 0.2% - In clinical studies of brimonidine
tartrate 0.2%, adverse reactions occurring in approximately 10 to
30% of the subjects, in descending order of incidence, included oral
dryness, ocular hyperemia, burning and stinging, headache, blurring,
foreign body sensation, fatigue/drowsiness, conjunctival follicles,
ocular allergic reactions, and ocular pruritus.
Reactions occurring in approximately 3 to 9% of the subjects, in
descending order included corneal staining/erosion, photophobia,
eyelid erythema, ocular ache/pain, ocular dryness, tearing, upper
respiratory symptoms, eyelid edema, conjunctival edema, dizziness,
blepharitis, ocular irritation, gastrointestinal symptoms, asthenia,
conjunctival blanching, abnormal vision and muscular pain.
The following adverse reactions were reported in less than 3% of
the patients: lid crusting, conjunctival hemorrhage, abnormal taste,
insomnia, conjunctival discharge, depression, hypertension, anxiety,
palpitations/arrhythmias, nasal dryness and syncope.
Postmarketing Experience - The following reactions have
been identified during postmarketing use of brimonidine tartrate
ophthalmic solutions in clinical practice. Because they are reported
voluntarily from a population of unknown size, estimates of frequency
cannot be made. The reactions, which have been chosen for
inclusion due to either their seriousness, frequency of reporting,
possible causal connection to brimonidine tartrate ophthalmic
solutions, or a combination of these factors, include: bradycardia,
hypersensitivity, iritis, keratoconjunctivitis sicca, miosis, nausea, skin
reactions (including erythema, eyelid pruritus, rash, and vasodilation),
and tachycardia.
Apnea, bradycardia, coma, hypotension, hypothermia, hypotonia,
lethargy, pallor, respiratory depression, and somnolence have
been reported in infants receiving brimonidine tartrate ophthalmic
solutions [see Contraindications].
DRUG INTERACTIONS
Oral Carbonic Anhydrase Inhibitors - There is a potential for an
additive effect on the known systemic effects of carbonic anhydrase
inhibition in patients receiving an oral carbonic anhydrase inhibitor
and brinzolamide ophthalmic suspension 1%, a component of
SIMBRINZA Suspension. The concomitant administration of
SIMBRINZA Suspension and oral carbonic anhydrase inhibitors is
not recommended.
High-Dose Salicylate Therapy - Carbonic anhydrase inhibitors
may produce acid-base and electrolyte alterations. These alterations
were not reported in the clinical trials with brinzolamide ophthalmic
suspension 1%. However, in patients treated with oral carbonic
anhydrase inhibitors, rare instances of acid-base alterations have
occurred with high-dose salicylate therapy. Therefore, the potential
for such drug interactions should be considered in patients receiving
SIMBRINZA Suspension.
CNS Depressants - Although specific drug interaction studies have
not been conducted with SIMBRINZA, the possibility of an additive
or potentiating effect with CNS depressants (alcohol, opiates, barbiturates, sedatives, or anesthetics) should be considered.
Antihypertensives/Cardiac Glycosides - Because brimonidine tartrate, a component of SIMBRINZA Suspension, may reduce blood
pressure, caution in using drugs such as antihypertensives and/or
cardiac glycosides with SIMBRINZA Suspension is advised.
Tricyclic Antidepressants - Tricyclic antidepressants have been
reported to blunt the hypotensive effect of systemic clonidine. It is not
known whether the concurrent use of these agents with SIMBRINZA
Suspension in humans can lead to resulting interference with the
IOP lowering effect. Caution is advised in patients taking tricyclic
antidepressants which can affect the metabolism and uptake of
circulating amines.
Monoamine Oxidase Inhibitors - Monoamine oxidase (MAO) inhibitors may theoretically interfere with the metabolism of brimonidine
tartrate and potentially result in an increased systemic side-effect
such as hypotension. Caution is advised in patients taking MAO
inhibitors which can affect the metabolism and uptake of circulating
amines.
USE IN SPECIFIC POPULATIONS
Pregnancy - Pregnancy Category C: Developmental toxicity
studies with brinzolamide in rabbits at oral doses of 1, 3, and 6 mg/
kg/day (20, 60, and 120 times the recommended human ophthalmic
dose) produced maternal toxicity at 6 mg/kg/day and a significant
increase in the number of fetal variations, such as accessory skull
bones, which was only slightly higher than the historic value at 1 and
6 mg/kg. In rats, statistically decreased body weights of fetuses from
dams receiving oral doses of 18 mg/kg/day (180 times the recommended human ophthalmic dose) during gestation were proportional
to the reduced maternal weight gain, with no statistically significant
effects on organ or tissue development. Increases in unossified
sternebrae, reduced ossification of the skull, and unossified hyoid
that occurred at 6 and 18 mg/kg were not statistically significant. No
treatment-related malformations were seen. Following oral adminis-
tration of 14C-brinzolamide to pregnant rats, radioactivity was found

to cross the placenta and was present in the fetal tissues and blood.
Developmental toxicity studies performed in rats with oral doses of
0.66 mg brimonidine base/kg revealed no evidence of harm to the
fetus. Dosing at this level resulted in a plasma drug concentration
approximately 100 times higher than that seen in humans at the
recommended human ophthalmic dose. In animal studies, brimonidine crossed the placenta and entered into the fetal circulation to a
limited extent.
There are no adequate and well-controlled studies in pregnant women. SIMBRINZA Suspension should be used during pregnancy
only if the potential benefit justifies the potential risk to the fetus.
Nursing Mothers - In a study of brinzolamide in lactating rats,
decreases in body weight gain in offspring at an oral dose of 15 mg/
kg/day (150 times the recommended human ophthalmic dose) were
observed during lactation. No other effects were observed. However,
following oral administration of 14C-brinzolamide to lactating rats,
radioactivity was found in milk at concentrations below those in the
blood and plasma. In animal studies, brimonidine was excreted in
breast milk.
It is not known whether brinzolamide and brimonidine tartrate are
excreted in human milk following topical ocular administration.
Because many drugs are excreted in human milk and because of the
potential for serious adverse reactions in nursing infants from SIMBRINZA (brinzolamide/brimonidine tartrate ophthalmic suspension)
1%/0.2%, a decision should be made whether to discontinue nursing
or to discontinue the drug, taking into account the importance of the
drug to the mother.
Pediatric Use - The individual component, brinzolamide, has been
studied in pediatric glaucoma patients 4 weeks to 5 years of age. The
individual component, brimonidine tartrate, has been studied in pediatric patients 2 to 7 years old. Somnolence (50-83%) and decreased
alertness was seen in patients 2 to 6 years old. SIMBRINZA
Suspension is contraindicated in children under the age of 2 years
[see Contraindications].
Geriatric Use - No overall differences in safety or effectiveness have
been observed between elderly and adult patients.
OVERDOSAGE
Although no human data are available, electrolyte imbalance,
development of an acidotic state, and possible nervous system
effects may occur following an oral overdose of brinzolamide. Serum
electrolyte levels (particularly potassium) and blood pH levels should
be monitored.
Very limited information exists on accidental ingestion of brimonidine
in adults; the only adverse event reported to date has been hypotension. Symptoms of brimonidine overdose have been reported in
neonates, infants, and children receiving brimonidine as part of medical treatment of congenital glaucoma or by accidental oral ingestion.
Treatment of an oral overdose includes supportive and symptomatic
therapy; a patent airway should be maintained.
PATIENT COUNSELING INFORMATION
Sulfonamide Reactions - Advise patients that if serious or unusual
ocular or systemic reactions or signs of hypersensitivity occur, they
should discontinue the use of the product and consult their physician.
Temporary Blurred Vision - Vision may be temporarily blurred
following dosing with SIMBRINZA Suspension. Care should be
exercised in operating machinery or driving a motor vehicle.
Effect on Ability to Drive and Use Machinery - As with other drugs
in this class, SIMBRINZA Suspension may cause fatigue and/or
drowsiness in some patients. Caution patients who engage in hazardous activities of the potential for a decrease in mental alertness.
Avoiding Contamination of the Product - Instruct patients that
ocular solutions, if handled improperly or if the tip of the dispensing
container contacts the eye or surrounding structures, can become
contaminated by common bacteria known to cause ocular infections.
Serious damage to the eye and subsequent loss of vision may result
from using contaminated solutions [see Warnings and Precautions ]. Always replace the cap after using. If solution changes color
or becomes cloudy, do not use. Do not use the product after the
expiration date marked on the bottle.
Intercurrent Ocular Conditions - Advise patients that if they have
ocular surgery or develop an intercurrent ocular condition (e.g., trauma or infection), they should immediately seek their physicians advice concerning the continued use of the present multidose container.
Concomitant Topical Ocular Therapy - If more than one topical
ophthalmic drug is being used, the drugs should be administered at
least five minutes apart.
Contact Lens Wear - The preservative in SIMBRINZA, benzalkonium chloride, may be absorbed by soft contact lenses. Contact lenses
should be removed during instillation of SIMBRINZA Suspension,
but may be reinserted 15 minutes after instillation.
2013 Novartis
U.S. Patent No:
6,316,441
ALCON LABORATORIES, INC.
Fort Worth, Texas 76134 USA
1-800-757-9195
alcon.medinfo@alcon.com
2013 Novartis 8/13
SMB13064JAD
New Innovation in Lipid Technology for
DRY EYE RELIEF

An advanced clear emollient nanotechnology tear solution
of lipid particles ranging in size from 5 to 50 nanometers
Upon instillation into the eye, solution provides extended, soothing comfort
to the ocular surface with minimal haze
Designed to repair and restore the lipid layer of the tear film, NanoTears has been shown to:
Increase Tear Break-Up Time
Reduce Corneal Staining
Support Aqueous Layer Function
Re-establish Normal Osmolality
NanoTears is a clear solution that does not cause the blurriness/haze
that may be associated with opaque emollient tear drops.
*NanoTears is a solution that gels upon introduction into the eyes, which eases administration.
**NanoTears is the ONLY clear emollient on the market.
***NanoTears Lipid Particle size is demonstrably smaller than that of traditional emollient tear drops,
when comparison is made based upon average Gaussian distribution of particles.
Data on File - Altaire Pharmaceuticals, Inc.
Use only as directed - See product labeling for details
Visit us at www.NanoTearsEyeDrops.com
Meeting Directory
All rooms are in McCormick Place: North Building (N), South Building (S), Lakeside Center (E), unless otherwise indicated. Exhibition and Registration is located in South Building, Level 3, Hall A.
Meeting Directory
AAO Meetings On Demand (Subspecialty Day and AAO 2014

content)
AAOE Coding Sessions (Saturday)
AAOE Practice Management and Coding Center,
ICD-10-CM, Conversations With the Experts
AAOE Member Lounge
AAOE Program
Academy Caf
Academy Resource Center
Bags and Programs
Bistro AAO Caf
Business Center
CME Reporting/Proof-of-Attendance
Coat and Bag Check
Electronic Office, The (IHE)
European Society of Ophthalmology (SOE)
Evaluation Help Desk
Executive Offices
Exhibitor Locator Booth
Exhibitor Lounge (Wi-Fi available)
Exhibitor Registration
Exhibitor Service Center/Exhibitions Office
First Aid
Foundation of the American Academy of Ophthalmology (FAAO)
Global Alliance Office
Hotel Assistance
Informational Exhibits
Informational Posters
International Center
International Society of Refractive Surgery (ISRS)
Internet Access and Email
Las Vegas 2015
Learning Lounge
Lost and Found
Meditation/Prayer Room
Meeting Information
Meetings Office
Mobile Device Charging
Mobile Meeting Guide Assistance
Mobile Meeting Guide Download
Museum of Vision
Newsroom
OMIC - Ophthalmic Mutual Insurance Company
Ophthalmology Job Center
OPHTHPAC/Surgical Scope
Proof-of-Attendance/CME Reporting
Resource Center, Booth 508; Grand Concourse, Level 3; Retina Exhibits, Booth 56
(Friday only)
S105
Academy Resource Center, Booth 508
South, Level 5
South, Level 5
S404
Booth 508
South, Hall A
Booth 2781
South, Hall A
South, Level 2.5
Academy Resource Center, Booth 508 and South, Level 2.5
South, Level 1, Lobby and South, Level 1 near Hyatt
Booth 114
S400c and Booth 1200
Ticket Sales, Hall A
S401
Booth 3500
Booth 2485
South, Hall A
South, Hall A
South, Level 2.5
N426c
South, Level 2.5
South, Hall A
Booth 2480
Grand Concourse, Level 3, Lobby
Rest Stop, Booth 780
South, Level 2.5
Booth 107
Meetings Office, S402
SA1a
Grand Concourse, Level 3 and South, Level 1, Lobby
S402
Tech Bar at Rest Stop, Booth 780
www.aao.org/mobile
Booth 704
N426ab
Booth 1004
Booth 67
Grand Concourse, Level 3
xxxv
Meeting Directory
Meeting Directory
Publishers Row
Registration
Rest Stop
South, Hall A
South, Hall A
Booth 780
Restaurant Reservations
Ribbons
Scientific Posters
Scientific Posters Online/Videos on Demand
Seated Massage Stations
Senior Ophthalmologist (SO) Lounge
Shuttle Bus Drop-off and Pick-up
Routes 1 - 7
Routes 8 - 10
Speaker Ready Room
Subspecialty Day
South, Level 2.5

Bags & Programs, South, Hall A
South, Hall A
Meeting Point, South, Hall A
Booth 65 and Lakeside Center
Internet Access and Email

Mobile Device Charging
Seated Massage
Tech Bar
Wi-Fi Access
South, Level 1, Lobby

North, Level 1, Gates 26 and 27
Tech Bar
Technology Pavilion
E354
Grand Ballroom, S100ab
E350
Grand Ballroom, S100c
Vista Room, S406a
Arie Crown Theater (Lakeside Center)
Lakeside Center, Level 3, Lobby
North, Hall B
North, Hall B
E450
Booth 165
Ticket Sales
Tour Departures
Videos on Demand/Scientific Posters Online
Volunteer Lounge
Wi-Fi Access
Young Ophthalmologist (YO) Lounge
South, Hall A
South, Level 1, Lobby
Cornea
Glaucoma
Ocular Oncology and Pathology
Oculofacial Plastic Surgery
Refractive Surgery
Refractive Surgery E-Posters
Retina
Retina Exhibits (Friday Only)
Uveitis
xxxvi
PIONEERED
BY ALCON
POWERED BY YOU
SUPERIOR
VISUALIZATION.
THE CATARACT
Visit the Alcon booth to experience the

REFRACTIVE
LuxOR LX3 Microscope,
part ALCON
of the first
SUITE BY
and only complete cataract refractive suite.
THE CATARACT
2014 Novartis 8/14 LUX14023JAD

1. Alcon data on file.
SUITE BY ALCON
W H E R E A L L O F O P H T H A L M O LO GY M E E T S
LAS VEGAS
Products
Networking
Technology
Trends
Techniques
Ideas
SAVE THE DATE!

Master new skills in hands-on labs.
Get inspired by the latest research
and techniques. Immerse yourself
in thought-provoking presentations.
Connect in face-to-face conversations.
Discover! Only at AAO 2015.
www.aao.org/2015
#aao2015
The American Academy of Ophthalmology is accredited by the
Accreditation Council for Continuing Medical Education to provide
continuing medical education for physicians.
AAO 2015
November 1417
Subspecialty Day
November 1314
AAOE Program
November 1417
Shuttle Schedule
6:30 PM
6:00 PM
5:30 PM
5:00 PM
4:30 PM
4:00 PM
3:30 PM
3:00 PM
2:30 PM
2:00 PM
1:30 PM
1:00 PM
12:30 PM
12:00 PM
11:30 AM
11:00 AM
10:30 AM
10:00 AM
9:30 AM
9:00 AM
8:30 AM
8:00 AM
7:30 AM
7:00 AM
6:30 AM
Friday, Oct. 17
Saturday, Oct. 18
Sunday, Oct. 19
Monday, Oct. 20
Tuesday, Oct. 21
During peak hours shuttles will run every 10 to 15 minutes.
During non-peak hours shuttles will run every 20 to 25 minutes.
McCormick Place Drop Off & Pick Up Locations

Routes 1-7
Route 8
Routes 9 & 10
South, Level 1, Transportation Lobby

North, Level 1, Gate 27
North, Level 1, Gate 26
Hotel
Address in Chicago
Phone
Route
Boarding Location
ACME Hotel Company
15 East Ohio Street
+1 312.894.0800
Embassy Suites Chicago Downtown
Best Western Grant Park
1100 South Michigan Avenue
+1 312.922.2900
Curbside on 11th Street
Chicago Marriott Downtown Mag Mile
540 North Michigan Avenue
+1 312.836.0100
Corner of Ohio & Rush Streets
Chicagos Essex Inn
+1 312.939.2800
Hilton Chicago
Conrad Chicago
521 North Rush Street
+1 312.645.1500
Courtyard Chicago Mag Mile
165 East Ontario Street
+1 312.573.0800
Fairfield Inn & Suites Chicago Mag Mile
Courtyard Chicago River North
30 East Hubbard Street
+1 312.329.2500
CTA stop SE corner Dearborn before Hubbard
dana hotel & spa
660 North State Street
+1 312.202.6000
Doubletree Hotel Chicago Mag Mile
300 East Ohio Street
+1 312.787.6100
Curbside on Fairbanks Court
Drake Hotel
140 East Walton Place
+1 312.787.2200
Curbside on Oak Street
+1 312.943.3800
Front Entrance
Embassy Suites Chicago Lakefront
511 North Columbus Drive
+1 312.836.5900
Curbside on Columbus Drive
+1 312.787.3777
Front Entrance
Fairmont Chicago, Millennium Park
+1 312.565.8000
10
Four Points by Sheraton Chicago Mag Mile
630 North Rush Street
+1 312.981.6600
Four Seasons Hotel Chicago
120 East Delaware Place
+1 312.280.8800
Westin Michigan Avenue Chicago
Godfrey Hotel Chicago
127 West Huron Street
+1 312.649.2000
Hampton Inn Chicago Downtown/Mag Mile
160 East Huron Street
+1 312.706.0888
Warwick Allerton Hotel
Hampton Inn Majestic
22 West Monroe Street
+1 312.332.5052
Palmer House Hilton
Hard Rock Hotel Chicago
+1 312.345.1000
Curbside on Wacker Place
Hilton Chicago
+1 312.922.4400
Curbside on 8th Street
Hilton Garden Inn Chicago
10 East Grand Avenue
+1 312.595.0000
Hilton Suites Chicago Mag Mile
198 East Delaware Place
+1 312.664.1100
Homewood Suites Chicago Downtown
40 East Grand Avenue
+1 312.644.2222
Corner & Ohio & Rush Streets
Homewood Suites Chicago Mag Mile
152 East Huron Street
+1 312.585.9333
Hotel Cass A Holiday Inn Express
640 North Wabash Avenue
+1 312.787.4030
xxxix
Shuttle Schedule
Continuous shuttle bus service will operate during AAO 2014 according to the schedule below. Times of operation and boarding locations are subject to
change. Additional shuttle information and updates will be available at your hotel and McCormick Place. Please note: Hotel rates include $8 to partially
defray shuttle costs.
Shuttle Schedule
Shuttle Scgedule
Hotel
xl
Address in Chicago
Phone
Route
Boarding Location
Hotel Chicago
333 North Dearborn Street
+1 312.245.0333
Hotel Felix Chicago
111 West Huron Street
+1 312.447.3440
Hyatt Chicago Mag Mile
633 North Saint Clair Street
+1 312.787.1234
Hyatt Regency Chicago
151 East Wacker Drive
+1 312.565.1234
10
Curbside on Wacker Drive
Hyatt Regency McCormick Place
2233 South Martin L King Dr
+1 312.567.1234
walk
Inn of Chicago Mag Mile
162 East Ohio Street
+1 312.787.3100
InterContinental Chicago Mag Mile
+1 312.944.4100
Side Entrance on Upper Illinois Street
James Chicago
+1 312.337.1000
JW Marriott Chicago
151 West Adams Street
+1 312.660.8200
W Chicago City Center
Kinzie Hotel Chicago
20 West Kinzie Street
+1 312.395.9000
Langham, Chicago
+1 312.923 9988
Millennium Knickerbocker Hotel Chicago
+1 312.751.8100
Omni Chicago Hotel
+1 312.944.6664
Palmer House Hilton
17 East Monroe Street
+1 312.726.7500
Curbside on Wabash Avenue
Park Hyatt
+1 312.335.1234
Peninsula Chicago
108 East Superior Street
+1 312.337.2888
Radisson Blu Aqua Chicago Hotel
+1 312.565.5258
10
Fairmont Chicago, Millennium Park
Renaissance Blackstone Chicago Hotel
+1 312.447.0955
Hilton Chicago
Renaissance Chicago Downtown Hotel
1 West Wacker Drive
+1 312.372.7200
Curbside on Wacker Drive
Residence Inn Chicago Mag Mile
+1 312.943.9800
Residence Inn Chicago River North
+1 312.494.9301
Ritz-Carlton Chicago (A Four Seasons Hotel)
160 East Pearson Street
+1 312.266.1000
Sheraton Chicago Hotel & Towers
301 East North Water Street
+1 312.464.1000
Silversmith Hotel & Suites
10 South Wabash Avenue
+1 312.372.7696
Palmer House Hilton
Sofitel Chicago Water Tower
20 East Chestnut Street
+1 312.324.4000
SpringHill Suites Chicago River North
+1 312.644.4071
Swisstel Chicago
+1 312.565.0565
10
Hyatt Regency Chicago
Thompson Chicago
21 East Bellevue Place
+1 312.266.2100
Drake Hotel
Trump International Hotel & Tower Chicago
+1 312.588.8000
W Chicago City Center
172 West Adams Street
+1 312.332.1200
Curbside on Adams Street
W Chicago Lakeshore
644 North Lake Shore Drive
+1 312.943.9200
Curbside on Inner Lake Shore Drive
+1 312.440.1500
Front Entrance on Huron Street
Westin Chicago River North
+1 312.744.1900
Curbside on Clark Street, across street
+1 312.943.7200
Front Entrance, Across St on Delaware Place
theWit A DoubleTree by HiIlton
+1 312.467.0200
Renaissance Chicago Downtown Hotel
Wyndham Grand Chicago Riverfront
+1 312.346.7100
N/A
LOOK WHOS DROPPING

INTO CHICAGO
VISIT US AT ALLERGAN BOOTH #1408
2014 Allergan, Inc., Irvine, CA 92612 marks owned by Allergan, Inc. www.Combigan.com www.AlphaganP.com APC05FF14 142474
Mobile Meeting Guide

Access the 2014 Mobile Meeting Guide at www.aao.org/mobile.
Get the most out of the Mobile Meeting Guide when you:
Sign-in with your Academy credentials and import the calendar created during
registration.
Add courses, sessions and exhibitors to the My Planner feature by selecting the
icon. This allows you to plan in advance your meeting experience. Restaurants and
hotels can also be added.
Use the Map feature to locate a course room or exhibitors booth.
Use the Happening Now feature to see courses and sessions taking place at that
moment.
Use the Program Search filters to locate a course or session. Filter by day, meeting,
format, topic and more.
To view handouts or access course evaluations, filter to the course description
page where these buttons will appear.
New! Start or join an interactive
networking community to share meeting
insights with your colleagues.
View the #aao2014 Twitter feed for
updates and program discussions.
Watch a video tutorial how to use all the
Where all of ophthalmology meets
features of this dynamic Mobile Meeting Guide.
See a demonstration of these features when
you attend Get the Most Out of Your Mobile
Meeting Guide session at the Technology
Pavilion, Booth 165:
Saturday, Oct. 18 at 11:30 a.m.
Sunday, Oct. 19 at 11:30 a.m.
For assistance or questions, visit the Tech Bar,
Booth 780.
Supported by ZEISS
Supported by:
Booth 3808
MOBILE
MEETING
GUIDE
OCTOBER 18-21
Scan this code to learn more and

access the Mobile Meeting Guide.
LAUREATE RECOGNITION
AWARD
In September 2002, the Board of Trustees approved an award program to induct individuals as Academy Laureatesoutstanding ophthalmologists whose significant scientific contribution to the field has shaped the way modern ophthalmology is practiced. The Laureate award
program recognizes individuals from around the world who have made exceptional scientific contributions to the betterment of eye care,
leading to the prevention of blindness and the restoration of sight worldwide.
The Laureate Recognition Award may be given to individuals who have:
Developed new techniques now accepted worldwide
Designed a seminal invention or an adaptation of previous technology
Developed a new treatment modality
Discovered the etiology of a disease state
Reassessed previous findings resulting in a significant shift in treatment
Established new standards of quality care in ophthalmology
Made a breakthrough in genetic understanding
Led primary research in new pharmacological products
Focused on eye care for people worldwide
On behalf of the Board of Trustees, we are pleased to announce the 2014 Academy Laureate.
Laureate Recognition Awardees

Laureate Awards
2014 Laureate Award

Jerry A Shields MD
Dr. Jerry A. Shields was born in a small southwestern Kentucky town. In his own words Dr. Shields has
written that he never thought he would go to college or become a physician much less an ophthalmologist. He attended Sturgis High School where he was an All-Star football and basketball player. Following his graduation Dr. Shields attended Murray State University where he had a football scholarship.
Dr. Shields went on to the University of Michigan Medical School. He then interned in Denver thinking
that he might want to go into psychiatry, but changed his mind. In the meantime, he was called up for
duty in Vietnam. He requested the Navy and was assigned as a battalion surgeon to a Marine unit in the
highlands of Vietnam. There Dr. Shields decided on ophthalmology and was accepted at The Wills Eye
Hospital in Philadelphia.
After residency Dr. Shields jumped at the opportunity to serve as a Wills retina fellow and subsequently
studied ophthalmic pathology with Dr. Lorenz Zimmerman at the Armed Forces Institute of Pathology.
He soon began to establish a reputation in Oncology by doing P32 tests on individuals with pigmented
lesions in the fundus, and next became one of the first pioneers in the use of radioactive plaques for the
treatment of intraocular tumors.
Today the Wills Eye Hospital Oncology Service is run by Dr. Jerry Shields and his partner and wife,
Dr. Carol Shields. He cares deeply about his patients, his teaching and has trained approximately 100
fellows from all parts of the world in ocular oncology. He has authored or co-authored 1314 articles and
550 textbook chapters for a total of 1872 scientific publications. He has also authored or co-authored
13 textbooks. Furthermore, he is well-recognized for his teaching by lectureships, and has given
1560 talks and 76 prestigious named lectures, again, throughout the world.
Dr. Shields awards number over 40 and in 2012 the Asia Pacific Academy of Ophthalmology established
the Jerry A. Shields, MD Lecture to be presented annually at their Congress. In March of 2013
Dr. Shields was awarded the National Physician of the Year Award for Clinical Excellence (top doctor in
America) by Castle Connelly Medical, Ltd., New York, N.Y.
Dr. Shields has served on Editorial Boards in the United States, Great Britain, Germany, and Denmark.
He has been President of the Macula Society and was the first President of the International Society of
Ocular Oncology.
Dr. Shields is often described as humble, generous, loyal and dedicated. The Academy is pleased to
present its highest honor, the Laureate Award, to Dr. Jerry A. Shields.
Laureate Recognition Awardees

2013
2006
Lorenz E Zimmerman MD
Recognized for his seminal contributions to ophthalmology including those in patient care, education, research,
ophthalmic history, medical ethics, journal editing and
administration.
Widely recognized for his many contributions to our

understanding of a broad spectrum of diseases of
the eye and for his ability to clearly communicate his
cogent observations to ophthalmologists in clinical
practice through a series of seminal publications and
lucid lectures.
2012
Stephen J Ryan MD
Recognized for his valuable and innumerable contributions to the field of vitreoretinal disease and ocular
trauma. Dr. Ryans key leadership in major national and
international organizations reshaped not only ophthalmology but the entire field of medicine.
2011
2005
Arnall Patz MD
A gifted teacher and clinician who saved the sight of
an untold number of newborns when he suspected
oxygen had a role in the alarming number of retrolental fibroplasia cases among premature infants.
2004
Alfred Sommer MD MHS
Danile S Aron Rosa MD PhD
Recognized for his remarkable career and lasting contributions to ophthalmology, epidemiology and public
health worldwide through his discovery of the link
between vitamin A deficiency and childhood blindness
and mortality.
Honorary Professor and Chair of Ophthalmology, Park

University and Chair of Ophthalmology at Hospital
Robert Debr and Foundation Rothschild in Paris and
inventor of the YAG Laser for the treatment of posterior capsule opacity (secondary cataract).
2010
Bradley R Straatsma MD JD
Recognized for his unique contributions to the science of ophthalmology through innovative research
in posterior segment pathology and his leadership
in enhancing ophthalmic education institutions and
organizations worldwide.
2009
Bernard Becker MD
Recognized as a pioneer in ophthalmic research,
clinical care, education and leadership. He was
widely accepted as a world expert on the treatment of
intraocular pressure regulation and neuroprotection of
the optic nerve.
2008
Professor Alan C Bird MD
Recognized as a pioneer in ophthalmic research,
teaching and clinical medicine. He is one of the
worlds experts on the treatment of retinal vascular
disease and genetic and degenerative retinal disorder.
2007
Claes H Dohlman MD
Recognized as the founder of modern corneal science
and for his years of teaching and educating young
ophthalmologists in the field of cornea.
Laureate Awards
Daniel M Albert MD MS
J Donald M Gass MD
Professor at both the University of Miami School of
Medicine and Vanderbilt University in Nashville, he
was well known for his research on diseases of the
retina, macula and uvea, much of which was done in
Miami.
Marshall M Parks MD
Almost single-handedly created the subspecialty
field of pediatric ophthalmology and world-renowned
for his contributions to understanding and treating
amblyopia and strabismus.
2003
Charles D Kelman MD
New York Medical College clinical professor of ophthalmology and attending surgeon at the New York
Eye and Ear Infirmary and the Manhattan Eye, Ear and
Throat Hospital, pioneered phacoemulsification and
invented the cryoprobe.
Robert Machemer MD
Former chairman of the Department of Ophthalmology,
Duke University, Durham, N.C., invented the vitreous
infusion suction cutter, which allowed surgeons to
more safely remove vitreous from the eye.
Charles L Schepens MD
Harvard Medical School clinical professor emeritus,
and president of the Eye Research Institute of the
Retina Foundation, is the father of modern retinal
surgery.
SPECIAL AWARDS
Recipients of the following awards attend the Academys annual meeting as guests of the president. The Academy formally presents them
with an award during the opening ceremonies. Descriptions of each award bestowed by the Academy are below; however, not all awards
are presented each year.
Guests of Honor
Each president has the privilege of selecting individuals as Guests of Honor at the annual meeting. Individuals are selected in recognition
of their significant contribution to ophthalmology and to the Academy.
Distinguished Service Award

The Distinguished Service Award honors an individual or organization for ongoing notable service to ophthalmology and to the Academy.
The president has the honor of selecting the recipient of this award, with approval of the Board of Trustees.
Special Recognition Award

First awarded in 1991, the Special Recognition Award is presented to an individual or organization for outstanding service in a specific effort or cause that improves the quality of eye care. The recipient need not be an ophthalmologist. The president has the honor of selecting
the recipient of this award, with approval of the Board of Trustees.
Outstanding Humanitarian Service Award

First awarded in 1992, the Outstanding Humanitarian Service Award recognizes the contributions of Academy Fellows and Members
in selflessly providing medical eye care. Each year this award is presented to individuals for their participation in charitable activities,
indigent care, community service, or other humanitarian activities. The Academys Awards Committee reviews nominations and selects
awardees, with final approval by the Board of Trustees.
International Blindness Prevention Award

Established in 1992, the International Blindness Prevention Award honors individuals who have made significant contributions to the
prevention of blindness or the restoration of sight around the world.
Outstanding Advocate Award

The Outstanding Advocate Award, established in 2008, recognizes Academy members participation in advocacy-related efforts at either
the state and/or federal levels. The Academys Awards Committee reviews nominations and selects awardees, with final approval by the
Board of Trustees.
Straatsma Award for Excellence in Resident Education

Established through the Academy, the Association of University Professors of Ophthalmology (AUPO), and private funds, the Straatsma
Award for Excellence in Resident Education is given to a program director dedicated to the principles and significance of residency education.
Special Awards
Guest of Honor
Special Awards
Richard K Parrish II MD
It is a very special privilege for the American Academy of Ophthalmology to recognize Richard K. Parrish II, MD
as a Guest of Honor at AAO 2014 in Chicago. He is being acknowledged for his outstanding leadership and
accomplishments and for his distinguished contributions to the understanding and treatment of glaucoma.
A native of Indiana and the son of an ophthalmologist, Dr. Parrish earned his undergraduate (Phi Beta Kappa)
and medical (Alpha Omega Alpha Honor Medical Society) degrees from Indiana University. He completed his
internship at the University of Alabama - Birmingham and his residency in ophthalmology at the Wills Eye Hospital in Philadelphia, where he also served as chief resident. He completed clinical and research fellowships in
glaucoma at the Bascom Palmer Institute/University of Miami Miller School of Medicine.
Dr. Parrish joined the faculty at the University of Miami in 1982 as an Assistant Professor and was promoted to
Associate Professor in 1989 and to Professor in 1994. He served as Chair of the Department of Ophthalmology
from 1996 to 1999. As a member of the faculty at the Bascom Palmer Eye Institute, Dr. Parrish has trained and
mentored many of the countrys most prominent ophthalmologists, including many national and international
leaders in the glaucoma community. His passion for education and teaching was reflected in the Outstanding
Professor Teaching Award in 1985 and his tenure as the Bascom Palmer Eye Institutes Residency Program
Director from 1993 to 1999. Since 2000, he has served as the Associate Dean for Graduate Medical Education
and as Chair of the Graduate Medical Education Committee at the University of Miami. He is also currently the
Accreditation Council for Graduate Medical Educations Designated Institutional Official for the Jackson Health
System.
Dr. Parrish is a highly respected international authority on glaucoma clinical trials and the pharmacologic
modulation of wound healing in glaucoma filtering surgery. He served as the project chair for the landmark
multi-center Fluorouracil Filtering Surgery Study, which was funded by the National Eye Institute. He also has
been deeply engaged in evaluating the role of glaucoma drainage implant surgery through such studies as the
Tube versus Trabeculectomy Study. Dr. Parrish played a vital role in the Ocular Hypertension Treatment Study
(OHTS), for which he served as a Vice Chair and the Principal Investigator for the OHTS Optic Disc Reading
Center. He also has furthered our understanding of the comparative effects of the major prostaglandin analogs
in the medical treatment of glaucoma, quality of life issues in patients with glaucoma, and surgical trends
among members of the American Glaucoma Society over an at least 12-year period (1996-2008).
The author or co-author of scores of publications, Dr. Parrish has been actively engaged in a number of editorial boards, has served as an invited speaker at countless meetings throughout the world, and has delivered
many named lectures, including the Irving H. Leopold Lecture, the Doheny Lecture, the Edward W. D. Norton
Lecture, the Shaffer-Hetherington-Hoskins Lecture, the H. Saul Sugar Lecture, the Robert N. Shaffer Lecture,
and the American Glaucoma Society Lecture.
Dr. Parrish recently served as President of the American Ophthalmological Society and also has served as
the American Glaucoma Societys Councilor to the American Academy of Ophthalmology. He received the
Academys Life Achievement Honor Award in 2009 and the John R. Brayton, Jr., M.D., Leadership Award from
the Florida Society of Ophthalmology in 2014.
He and his wife Marianne have three children.
For his outstanding achievements and inspirational mentorship and leadership, it is with great pleasure that
the American Academy of Ophthalmology recognizes Dr. Richard K. Parrish II as a 2014 Guest of Honor.
Special Awards
Special Awards
Guest of Honor
M Bruce Shields MD
It is with great pleasure that the American Academy of Ophthalmology welcomes gifted educator, revered
author, and beloved leader, M. Bruce Shields, MD, as a Guest of Honor at AAO 2014 in Chicago. He is well
known for his extraordinary professional contributions and has been described on countless occasions as one
of the kindest persons in ophthalmology.
Dr. Shields received his bachelors degree from Phillips University in Enid, Oklahoma, where he also grew up.
After earning his medical degree from the University of Oklahoma College of Medicine (Alpha Omega Alpha
Honor Medical Society) in 1966, he interned at the Philadelphia US Naval Hospital and began his career in
ophthalmology as a resident at Duke University. Following a glaucoma fellowship at the Massachusetts Eye
and Ear Infirmary of Harvard University, he returned to Duke University in 1974 to join the faculty as Director of
the Glaucoma Service and Assistant Professor. He rose to the rank of Professor of Ophthalmology in 1984. In
1996, he was appointed as the Marvin L. Sears Professor and Chair of the Department of Ophthalmology and
Visual Science at the Yale University School of Medicine, served in this role for 10 years, and remained on the
full-time faculty until his retirement in 2011.
Dr. Shields has published over 180 scientific papers in refereed journals, 10 books, and 36 chapters in other
books. His Textbook of Glaucoma is now in its sixth edition and was cited in the year 2000 as one of the 100
important ophthalmology books of the twentieth century. His research interests have included secondary
glaucomas (including Axenfeld-Rieger syndrome), evaluation of the optic nerve head in glaucoma, and laser
and incisional surgeries for glaucoma.
He was consistently listed among the Best Doctors in America, served on numerous editorial boards, and participated in the training of over 130 residents and 50 glaucoma fellows at Duke and Yale Universities. At Duke,
he received the Davison Council Award for Excellence in Teaching from the School of Medicine in 1983 and
the Golden Globe Honoring Outstanding Attending of the Year at Duke Eye Center in 1988. During his tenure
at Yale University, Dr. Shields received the 2010 Excellence in Teaching Award, which now bears his name. He
has delivered 44 named lectures, including some of the most prestigious in the profession. In 2007, the Shields
Glaucoma Lectureship was established by Yale University in his honor. Dr. Shields has also served as visiting
professor at over 50 universities and has been a guest speaker at more than 150 major meetings in the United
States and 34 outside the US.
Dr. Shields has served as President of the American Glaucoma Society, the North Carolina Ophthalmology
Society, and the Chandler-Grant Glaucoma Society. He has been Chair of the Board of Directors of the American Board of Ophthalmology, the Glaucoma Committee of the National Society to Prevent Blindness, and the
Glaucoma Program Committee of the Association for Research in Vision and Ophthalmology. He has served on
several committees of the Residency Review Committee for Ophthalmology, the American Board of Medical Specialties, and the American Academy of Ophthalmology, from which he received the Life Achievement
Honor Award in 2007. In 2008, he was recognized as the Guest of Honor of the American Glaucoma Society.
In retirement, he has completed and published a book entitled Gifts and Sight, which tells the stories of
patients he cared for at Duke and Yale and the lessons he learned from them. He continues to teach residents
as a volunteer at Duke University and started a free eye clinic in Burlington, North Carolina, where he and his
wife Sharon now live. They have two children and two grandchildren.
The American Academy of Ophthalmology is delighted to recognize Dr. M. Bruce Shields as a 2014 Guest of
Honor.
Special Awards
Guest of Honor
Special Awards
Richard A Zorab MSc

It is with great pride that the American Academy of Ophthalmology welcomes Richard A. Zorab, MSc as a
Guest of Honor in recognition of his 12 years of exceptional leadership as the Academys Vice President for
Ophthalmic Knowledge.
Mr. Zorab, whose father and paternal grandfather were ophthalmologists, was born and privately educated
in the United Kingdom. He attended medical school for two years at Guys Hospital Medical School in London
before transferring to the University of Aberdeen (Scotland), where he earned a Master of Science degree in
Physiology in 1970.
He joined Churchill Livingstone, a venerable British medical publishing house, in 1973 in Edinburgh, Scotland, worked there for seven years, and rose to the role of Senior Publisher. From 1980 to 1983, he served as
Editorial Director for Blackwell Science in Edinburgh and then moved from the United Kingdom to Boston to
establish a new United States office for Blackwell Science, which he supervised from 1983 to 1988. He joined
W. B. Saunders, the largest US medical publisher, in Philadelphia in 1988 as a Senior Medical Editor and
was responsible for the management of publications in 12 medical specialties and subspecialties. A series
of editorial positions and consolidations within the medical publishing industry culminated in Mr. Zorab s
appointment as Editor-in-Chief of Medicine and Publishing Director of General and Internal Medicine for W.B.
Saunders/ Mosby/ Churchill Livingstone, which became Harcourt Health Sciences in 1999 before the purchase
of the company by the Reed Elsevier publishing group in 2001. In his leadership roles for Harcourt Health Sciences, Mr. Zorab developed vital initiatives in the transition to electronic and online publishing
In 2002, Mr. Zorab joined the American Academy of Ophthalmology and brought his vast experience in medical
publishing to the role of Vice President for Clinical Education (now Vice President for Ophthalmic Knowledge).
During his eventful tenure at the Academy, Mr. Zorab played key leadership roles in the development of the
Ophthalmic News and Education (ONE) Network, which was launched in 2007. He also was instrumental
in the success of the Academys journal Ophthalmology and in the development and implementation of The
Resident Hub, EyeWiki, OKAP International, the electronic versions of the Basic and Clinical Science Course,
Maintenance of Certification (MOC) Essentials, the Hoskins Center for Quality Eye Care, the IRIS Registry, and
numerous other programs and products.
He has two sons, who live in the United Kingdom and Dubai, United Arab Emirates respectively.
Given Richard A. Zorab s deep transformational impact on the Academys educational programs, which
will continue far into the future, it is an immense privilege for the American Academy of Ophthalmology to
acknowledge him as a very special Guest of Honor for 2014.
Special Awards
Special Awards

Societas Ophthalmologica Europa
The Academy is pleased to honor the Societas Ophthalmologica Europa (SOE), the European Society of
Ophthalmology, with the Distinguished Service Award.
SOE is being honored for its rich tradition as an ophthalmic leader and for its long-standing relationship as a
key Academy partner. As Europes supranational ophthalmological society, the SOE consists of representatives
from 40 member societies.
Over the years, the SOE and the Academy have jointly sponsored numerous meetings both in the United States
and abroad. Together, our efforts foster strong relationships and advance ophthalmic education, central goals
of both organizations.
It is fitting that the SOE is honored with the Distinguished Service Award this year, as the Society again partners with the Academy at AAO 2014 in Chicago. It is equally appropriate that Stefan Seregard, MD, president
of the SOE, is accepting this award for the organization, since he was one of the first international trustees on
the Academy Board of Trustees.
Special Awards
Special Awards

It is with great respect that the American Academy of Ophthalmology recognizes Richard P. Mills, MD, MPH with
this years Special Recognition Award.
Born in Evanston, Illinois, where his father was an argumentation and debate professor at Northwestern University, Dr. Mills completed his undergraduate (Phi Beta Kappa) and medical (Alpha Omega Alpha Honor Medical
Society) degrees at Yale University. He served as a resident in ophthalmology at the University of Washington in
Seattle and later pursued neuro-ophthalmology fellowships at the University of Utah and University of California, San Francisco and a glaucoma fellowship at the University of British Columbia in Vancouver. Initially in
private practice in Olympia, Washington, Dr. Mills joined the full-time faculty at the University of Washington
in 1984, rose to the rank of Professor of Ophthalmology in 1987, and served as Acting Chair from 1997 to 1998.
He earned his Master of Public Health (MPH) degree from the University of Washington in 1999. From 1999 to
2003, he chaired the Department of Ophthalmology at the University of Kentucky in Lexington before returning to
private practice in his beloved Seattle, where he is also Clinical Professor of Ophthalmology at the University of
Washington.
In his more than 160 scientific publications, book chapters, and books, Dr. Mills has furthered our understanding
of numerous topics but particularly automated perimetry and glaucoma surgery. He served as National Study Vice
Chair for the National Eye Institute-sponsored Collaborative Initial Glaucoma Treatment Study (CIGTS). In addition, he is a member of the Editorial Board for the Journal of Glaucoma and has delivered countless national and
international invited lectures and several named lectures.
Dr. Mills has been an integral part of the American Academy of Ophthalmology leadership for the past three
decades, from serving on the Board of Trustees in the early 1990s as Secretary for Public and Professional Information to being elected the Academys President in 1995. In his current role as the Chief Medical Editor of EyeNet
Magazine, he has written a monthly editorial for the past 12 years, in which his eloquence, keen intelligence,
striking insight, and wonderful and often self-effacing sense of humor are readily evident. As a leader in the
American Ophthalmological Society (AOS), Dr. Mills has served as Chair of the Program Committee and Chair of
the AOS Council and is currently the President of the Society. He has been President of the Washington Academy
of Eye Physicians and Surgeons, Secretary of the American Glaucoma Society, a Director of the American Board
of Ophthalmology, and a delegate to the American Medical Association. In addition, he has served as Vice Chair
for the Residency Review Committee for Ophthalmology and as a delegate to the American Board of Medical
Specialties.
A principal public service activity has been with Eye Care America, the largest and longest running such project in
American medicine, operated under the auspices of the Foundation of the American Academy of Ophthalmology.
Dr. Mills retired as chair of the project at the end of 2013. For his extensive Academy service, he received its Life
Achievement Honor Award in 2007. He has also twice served as a board member of Prevent Blindness America
and is a Community Action Board member for the University of Washington Eye Institute.
Beyond his professional commitments, Dr. Mills is a devoted husband, father, and grandfather to his wife Karen,
three daughters, and seven grandchildren.
It is with deep admiration and appreciation for his remarkable influence on our profession that we honor Dr.
Richard P. Mills with the 2014 Special Recognition Award.
Special Awards
Special Awards

Donald L Budenz MD MPH
Donald L Budenz, MD, MPH, was nominated by the American Glaucoma Society to receive this years Outstanding Humanitarian Service Award.
Since 1995 Dr. Budenz, Chair of Ophthalmology at the University of North Carolina, has passionately devoted
his life to spending weeks to months each year abroad at his own expense. He has sacrificed his family, his
work, and his free time making several journeys per year to Ghana, West Africa. Each trip has lasted between
one to three weeks. His time in Ghana has been spent providing clinical care, teaching local ophthalmologists
and other health care providers, and conducting research.
It was during these trips that Dr. Budenz developed a keen interest in Ophthalmic Epidemiology and International Health, which prompted him to pursue a Masters of Public Health degree at the prestigious John
Hopkins School of Public Medicine focusing his studies on these two disciplines. He conducted the first welldesigned epidemiology study of glaucoma prevalence in West Africa. Instead of an academic exercise, his
study focused on assessing the types and severity of diseases so that he could develop approaches to attack
and minimize blindness. He has developed research protocols to answer the question of how to better detect
and treat diseases in Ghana.
Dr. Budenzs countless trips to Ghana have been spent setting up the infrastructure and conducting clinical
evaluations of subjects who failed ocular screenings in the field. He outlined the responsibilities of the clinical
evaluators to ensure that the research was conducted in an ethical and professional manner. The success of
his projects were directly related to the high regard that Dr. Budenz was held by the team of people conducting
the screenings from the van drivers to the physicians in the clinic.
Dr. Budenz has devoted countless hours serving patients in West Africa. In 2009 he established the Christian
Eye Ministry, which supports two clinics in Ghana. He works under the philosophy that it is far more effective
to impact an underserved area of the world by developing an infrastructure for sustained care rather than
performing single interventions. He is presently creating a Glaucoma Center of Excellence in Ghana.
Dr. Budenz is currently serving as the principal investigator in two large, prospective studies in Africa. One
study is investigating the incidence and outcomes of glaucoma in an urban West Africa setting. The other is a
randomized clinical trial comparing glaucoma tube implant surgery and trabeculectomy with mitomycin C as an
initial surgical treatment for glaucoma. These studies will provide important information to elevate the quality
of patient care in underserved areas of the world.
Dr. Budenz embodies the highest ideals of our specialty. His impeccable service, tireless efforts to teach and
to serve, and his devotion to healing is nurtured by his generous heart of compassion. He has made enormous
contributions toward overcoming world blindness. The Academy is proud to honor Dr. Donald Budenz with this
years Outstanding Humanitarian Service Award.
10
Special Awards
Special Awards
Alan S Crandall MD
Alan S. Crandall, MD was nominated by the American Society of Cataract and Refractive Surgery to receive
this years Outstanding Humanitarian Service Award.
For more than 18 years Dr. Crandall has dedicated his skills, his time, and his personal financial support to
curing preventable blindness in the developing world. He has also identified and educated up-and-coming
ophthalmic leaders in countries that lack adequate opportunities for advanced training.
Dr. Crandalls first eye care mission began almost 20 years ago in Ghana when an acquaintance who was
working there asked him to hold a surgical camp. Dr. Crandall used his copious skills as a surgeon to try and
make a dent in the backlog of needless blindness. An enthusiastic teacher, he quickly realized that helping
developing countries to create or expand their own ophthalmology residency program would be the key to
long-term success. He began working with local authorities and medical professionals, bringing promising
young ophthalmologists to the Moran Eye Center for advanced training, and providing equipment and supplies to their home hospitals. Dr. Crandall continued to expand the scope of his work. He formed strategic
partnerships with other physicians, especially with Geoff Tabin, MD, throughout the U.S. and abroad to ensure
quality training for as many young ophthalmologists as possible. He has conducted numerous outreach trips to
Tanzania, Ethiopia, Kenya, Nepal, India, and China.
It is because of Dr. Crandalls boundless determination and energy that the Komfo Anokye Teach Hospital (KATH), in Kumasi, Ghana was able to open its first eye hospital. He was one of the earliest and most
consistent supporters of this project and through his tireless work is credited with elevating the level of care
provided by KATH physicians and staff members.
Another example of Dr. Crandalls amazing passion for improving international eye care is the work that he
has done in South Sudan. Dr. Crandall promised to spearhead a medical mission to Sudan after meeting John
Dau, a former refugee who has dedicated his life to providing health care and fostering peace in his homeland.
Sudan was in the grips of a decades-long civil war. It took years of planning and luck before Dr. Crandall could
make good on his promise but in 2011 he brought one of the first ophthalmic teams to the country and operated a highly successful eye camp out of John Daus clinic. Travel was difficult. The mission was dangerous
and the operating conditions were physically and mentally challenging. Despite this, after seeing the positive
end results, Dr. Crandall has returned numerous times.
When not traveling to remote areas of the world to help the blind see or to train surgeons, Dr. Crandall spends
his free-time courting potential donors to support his work. Nearly every moment of every day Dr. Crandall
is devoted to helping others. He has never once asked for anything in return. Because of his tireless energy,
skill, personal sacrifice, and strong belief in humanitarian service, the Academy is privileged to honor Dr. Alan
Crandall with this years Outstanding Humanitarian Service Award.
11
Special Awards
Special Awards

Kenneth D Tuck MD
Kenneth D. Tuck, MD was nominated by the Virginia Society of Eye Physicians and Surgeons to receive this
years Outstanding Advocate Award.
Dr. Tuck is one of Roanoke Valleys most active physicians in political advocacy and policy development. He
has been a long standing resource for information and a vigorous advocate for issues important to both physicians and patients. He has created strong relationships with nearly every elected official in his region which
has made him an effective advocate on legislative and regulatory issues.
During his term as President of the Virginia Society of Eye Physicians and Surgeons (VSEPS), Dr. Tuck instituted
his states EyePAC. He most recently assisted VSEPS with state and federal advocacy related to the access
of compound medications. He is Virginias Go-To Man for advice and assistance on challenging state and
national issues.
As President of the Medical Society of Virginia, Dr. Tucks many duties and obligations required him to
frequently travel from his home and practice in Roanoke. With all the associated demands as a leader of ophthalmology in the Commonwealth of Virginia, he sustained the passion and joy he received in serving those
who seek his care.
As a valued member of the American Medical Political Action Committee (AMPAC) Board from 2000-2006,
Dr. Tuck was very active in fund raising. He was always willing to stand up and make the case even when the
audience was at least a bit skeptical and occasionally a bit hostile. Dr. Tuck always made the case artfully and
with grace.
Dr. Tuck has been a model, not only in patient care, but in political leadership and policy development. He has
been a mentor to many other physicians. Using his seemingly limitless energy, Dr. Tuck has inspired many
young doctors to get involved in politics through bi-partisan relationships, always keeping quality patient care
in the forefront of any debate. The candidates he has helped over the years continue to turn to him for guidance as elected officials. Many have risen to high positions in Virginia and in Congress.
Dr. Tuck has been recognized countless times by his peers, community, fellow Rotarians and members of the
Virginia General Assembly for his dedication and selfless work to improving his community and advocating for
the profession of ophthalmology.
Dr. Tuck has held virtually every leadership role in Virginias medical and ophthalmological organizations. He
has also been a leader at the national level. He is a tireless volunteer advocate for patients and his profession
as well as for countless other causes. He has been encouraging and supportive, and a true inspiration to those
around him. The Academy is proud to honor Dr. Kenneth Tuck with this years Outstanding Advocate Award.
12
Special Awards
Special Awards
Cynthia Mattox MD
Cynthia Mattox, MD was nominated by the American Glaucoma Society and Women in Ophthalmology to
receive this years Outstanding Advocate Award.
Over the past 21 years, Dr. Mattox has energetically advocated on behalf of all patients for safety initiatives,
better access, and better care at both the state and national levels. She has led important initiatives that
have profoundly affected all ophthalmologists, clearly impacting and improving day-to-day clinical care and
the welfare of their patients. She has a local, national and international reputation as not only an outstanding
glaucoma and cataract diagnostician and surgeon, but a true advocate in every sense of the word.
As a member of the Academys Health Policy committee since 2004, Dr. Mattox has successfully leveraged her
insight of the various federal governmental agencies that control patient care. Her leadership paved the way
for many projects that improved the clinical care and vision of countless patients. Her grasp of the manner in
which federal agencies view health care in general, and ophthalmology patients specifically, has allowed her
to be highly successful in dealing with government initiatives. Among her best successes was her leadership
in the effort to relax the refill rules in Medicare Part D drug plans. She also defended the system of color
coding on ophthalmic eye drops bottles, improved formulary access to ophthalmics in pharmacy plans and
assisted access to glaucoma surgical implants for patients with severe glaucoma.
Additionally, Dr. Mattox has worked on behalf of her fellow ophthalmologists for fair payment and review
policies. She has been an invaluable resource to all ophthalmologists through her input on Academy efforts
at the Relative Value Update Committee that determines the value of subspecialty services for the Medicare
fee schedule. Her efforts have been deeply appreciated by the American Glaucoma Society (AGS) membership, which recognized the need for subspecialty society involvement in advocacy, by recently nominating and
electing her to be the next AGS vice president in line for the presidency. Dr. Mattox has also held leadership
positions in other organizations such as the Chandler Grant Glaucoma Society and the New England Ophthalmological Society.
Dr. Mattox has also embarked on exciting work for the Academys IRISTM Registry (Intelligent Research in
Sight), the nations first comprehensive eye disease clinical registry which will play a critical role in the continual improvement in the delivery of eye care. She has contributed to the development of quality measures
which ultimately will raise the standard of care and improve the delivery of ophthalmic care in the U.S. In
addition to the clinical activities of her practice, her teaching responsibilities, and her volunteer activities, Dr.
Mattox continues to tackle important issues to ensure better care for all patients with eye diseases in the
United States.
Dr. Mattox is a leader who inspires the best from her colleagues, is a constant force of good will, and an
ambassador for all of ophthalmology and patients. The Academy is honored to announce Dr. Cynthia Mattox as
a recipient of the 2014 Outstanding Advocate Award.
13
Special Awards
Special Awards

Rubens Belfort Jr MD PhD MBA
Rubens Belfort Jr., MD, PhD, MBA currently serves as the Head Professor of Ophthalmology at the Federal
University of Sao Paulo in Brazil, a position he has held since 1990. Dr. Belfort also directs the Philanthropic
Vision Institute and is president of the Brazilian Academy of Ophthalmology. He is a CNPq (Brasil) 1-A Level
scientist and current member of the National Academy of Medicine, Academia Ophthalmologica Internationalis, Brazilian Academy of Sciences and Brazilian Academy of Pharmacy.
After residency in Brazil, Dr. Belfort did his fellowship at the Proctor Foundation. This reconfirmed his interest
and desire to work in international eye health and began his work with isolated populations in the Amazon.
To date, Dr. Belfort has played a major role in surveys to investigate the prevalence and causes of blindness
in Parintins, Brazil and has been involved in diagnostic and therapeutic multimodal internet-based projects in
Rondonia, Brazil and in the development of the first Ocular Oncology Center in the Amazon.
In 1990, he joined the National Eye Institute of the National Institutes of Health with a commitment to study
uveitis, ocular AIDS, prevention of blindness and restoration of sight.
Knowing that problems in ocular health can be solved only through new technologies, Dr. Belfort has been
intensely involved in the innovative deconstruction of education and eye care delivery systems. He has
focused on the redefinition, reeducation and reorganization of health care professional teams to work together
in mutually beneficial ways.
Dr. Belfort has held a number of prominent international positions within ophthalmology and vision research.
He has been on the board of trustees of many international groups, including the International Council of Ophthalmology Foundation. Dr. Belfort has also served as chair of the Pan-American Association of Ophthalmology
Foundation and president of the Pan-American Association of Ophthalmology, World Congress of Ophthalmology and Pan-American Congress of Ophthalmology. He was editor of the Brazilian Archives of Ophthalmology
for over 20 years.
His scientific contributions include conferences in 31 countries, more than 390 peer-reviewed scientific publications, hundreds of review articles and book chapters. Dr. Belfort has also edited 11 ophthalmological books
in Portuguese, English and Spanish.
Dr. Belfort has delivered a number of named lectures that include the Jackson Memorial Lecture, American
Journal of Ophthalmology Lecture, Pan-American Association of Ophthalmology Lecture, Mourad Khalil
Lecture, Gradle Lecture and Moacyr Alvaro Lecture.
His awards include the President of Brazil Brazilian Medal of Scientific Merit, Senior Achievement Award of
the American Academy of Ophthalmology, OConnor/Schlaegel Gold Medal, Pan-American Medal for Distinguished Services, Gradle Medal for Teaching and Societ Oftalmologica Italiana Honorary Award.
14
Special Awards
Special Awards
Laura L Wayman MD
Laura L. Wayman, MD is currently an Associate Professor and Vice Chair for Education, and Director of Resident Education at the Vanderbilt Eye Institute. Dr. Wayman completed her medical education at Mayo Medical
School and her ophthalmology residency at Mayo Clinic in Rochester, Minnesota. She was in private practice
as a comprehensive ophthalmologist in central Florida before joining the faculty at Vanderbilt Eye Institute in
2005.
Dr. Wayman completed her medical education at Mayo Medical School and her ophthalmology residency at
Mayo Clinic in Rochester, Minnesota. She was in private practice as a comprehensive ophthalmologist in
central Florida before joining the faculty at Vanderbilt Eye Institute in 2005. Her interest in teaching developed during residency through observation of her own program directors dedication. The hands-on practical
instruction used in residency inspired her to develop curricula that involved one-on-one clinical and surgical
instruction.
Her goal to improve the quality of surgical instruction led to the development of a ten week stepwise cataract
surgical curriculum designed to take PGY-2 residents from wet lab to operating room. This systematic
surgical exercise allows Vanderbilt Eye Institute to introduce surgical instruction earlier without compromising the quality of patient care. Another important benefit, from her perspective as a residency director, is the
opportunity to develop a relationship with each resident very early in their training.
Early in her tenure at Vanderbilt Eye Institute she partnered with the Chairman, Paul Sternberg, Jr., M.D.
to implement quality improvement strategies in the training program. Dr. Wayman modified the Ishikawa
Fishbone Diagram, a well-known quality improvement tool developed by Kaoru Ishikawa in the 1960s, to
evaluate patient care by using the ACGME core competencies while considering the Institute of Medicine
Aims. Incorporating the improvement component with the competency-based analysis led to a change in how
Vanderbilt Eye Institute approaches system issues whether they involve medical error or resident training policies. It allows Vanderbilt Eye Institutes staff, faculty and trainees to learn from each others experiences in a
non-threatening environment while building a strong foundation for the future of ophthalmic practice through
our residents.
In an effort to establish a well-rounded educational program and with the help of the faculty from the ethics
division at Vanderbilt University Medical Center, Dr. Wayman developed an interactive quarterly ethics conference. Much like case presentations used for teaching differential diagnosis or clinical management, this
method puts responsibility on the resident to select an appropriate case and identify the relevant ethical issue.
This type of participation encourages residents and faculty to expose their ethical decision-making capacity,
and therefore the educational process becomes less passive. The goal of this process is that, by exposing
residents to these cases and the differing opinions of the group, they will develop reflective decision making
skills that will help them succeed in their careers as ophthalmologists.
Dr. Wayman was recently awarded the Women in Ophthalmology 2014 Educator Award. She is a member of
the American Academy of Ophthalmologys Committee on Resident Education, the Association of University
Professors of Ophthalmology Program Directors Council, member of the ACGMEs Resident Review Committee, and Chair of the Vanderbilt Eye Institutes Education Committee. She believes that building a strong
educational program is accomplished through team work and a commitment to excellence.
15
SECRETARIAT AWARD
The Secretariat Award recognizes ophthalmologists and non-ophthalmologists for special contributions to the Academy and the field of
ophthalmology. Senior secretaries and secretaries in their respective areas select award recipients with the approval from the Board of
Trustees.
This annual award was developed to increase opportunities for individuals to be recognized for contributions that are outside the scope of
the current Achievement Awards program.
16
Secretariat Awards
Dimitri T Azar MD
Joseph N Caprioli MD
Allan M Eisenbaum MD
Laura K Green MD
Richard J Grostern MD
Malik Y Kahook MD
Lawrence M Levine
Shan C Lin MD
Gregg T Lueder MD
Ramana S Moorthy MD
Thomas A Oetting MD
Eric P Purdy MD
Kuldev Singh MD MPH
Roger F Steinert MD
J Timothy Stout MD PhD
Jonathan D Trobe MD
Rohit Varma MD
Chicago, IL
Los Angeles, CA
Lubbock, TX
Boston, MA
Baltimore, MD
Chicago, IL
Denver, CO
Orange Park, FL
San Francisco, CA
St. Louis, MO
Indianapolis, IN
Iowa City, IA
Fort Wayne, IN
Palo Alto, CA
Irvine, CA
Houston, TX
Ann Arbor, MI
Los Angeles, CA
Robert E Wiggins, MD, Senior Secretary for Ophthalmic

Practice honors:
Michael F Chiang MD
William L Rich MD
Portland, OR
Falls Church, VA
Daniel J Briceland, MD, Secretary for State Affairs, George

A Williams, MD, Secretary for Federal Affairs, William L Rich
III MD, AAO Medical Directory of Health Policy, Cynthia Ann
Bradford, MD, Senior Secretary for Advocacy honor:
Ramesh S Ayyala MD
Alan E Kimura MD
James Jorkasky
Jay M Lustbader MD
C Blake Myers MD
Millicent Palmer MD
John T Thompson MD
Byron N Wilkes MD
Ruth D Williams MD
New Orleans, LA
Denver, CO
Rockville, MD
Washington, DC
Greenville, SC
Omaha, NE
Baltimore, MD
Germantown, TN
Wheaton, IL
Phillip R. Rizzuto, MD, Secretary for Communications honors:

Devin A Harrison MD
Robert H Janigian Jr MD
Raj K Maturi MD
Anne Sumers MD
Richland, WA
Providence, RI
Indianapolis, IN
Ridgewood, NJ
Secretariat Awards
Ann Louise Coleman, MD PhD, Secretary for Quality

Care, Jeffrey A Nerad MD, Secretary for Knowledge
Base Development, Christopher J Rapuano, Secretary for
Ophthalmic Knowledge, Jeffrey S Heier, MD, Secretary for
Online Education/eLearning, Robert F Melendez, MD, Editor-inChief, the ONE Network, Louis B Cantor, MD, Senior Secretary
for Clinical Education honor:
Jonathan B. Rubenstein, MD, Secretary for Annual Meeting

honors:
William J Fishkind MD
John T Thompson MD
Carla J Siegfried MD
Tucson, AZ
Baltimore, MD
St Louis, MO
George B. Bartley, MD, Ophthalmology Editor honors:

Stephen D Klyce PhD
Richard Alan Lewis MD
Curtis Margo MD
Richard A Stone MD
David T Tse MD
Port Washington, NY
Houston, TX
Lakeland, FL
Philadelphia, PA
Weston, FL
Tamara R Fountain, MD, Secretary for Member Services

honors:
Eliza Hoskins MD
Rene Ostertag DPT MPT COMT
Purnima S Patel MD
Martin Wand MD
Orinda, CA
Denver, CO
Atlanta, GA
Farmington, CT
Richard P Mills, MD MPH, Chief Medical Editor, EyeNet

honors:
Douglas J Rhee MD
Cleveland, OH
Richard L. Abbott, MD, Secretary for Global Alliance honors:

Amar Agarwal MD
R V Paul Chan MD
David S Friedman MD MPH PhD
Alfred Sommer MD
Chennai, India
New York, NY
Baltimore, MD
Baltimore, MD
17
ACHIEVEMENT AWARD
PROGRAM
The Achievement Award program recognizes individuals for their
contributions to the Academy, its scientific and educational programs, and to ophthalmology.
Categories of contribution for participation in the Academys annual
meeting include:
Instruction Course, Skills, or Breakfast With the Experts
Scientific E-Poster presentation
Film or Video Production
Scientific Exhibitor
Scientific Paper Presentation
Symposia
Scientific Poster Presentation
Subspecialty Day
Informational Posters and Exhibits are not awarded points toward
the Achievement Award programs.
Other categories of contribution for Academy service include:
Committee Members
Trustees
State Society Presidents
Participants in the Academys Leadership Development Program
Representatives
Authors, Co-Authors, and Reviewers of Academy Educational
Material
Councilors
Support of Advocacy Efforts
The program is based on a cumulative point system; one point is

awarded per category of contribution. An individual can earn
a maximum of three points per year. For example, an individual
serving on a committee and presenting two scientific papers, one
instruction course, and one scientific poster during the Academys
annual meeting would receive one point for committee participation, one point for the instruction course, and one point for the paper. The individual would not receive a fourth point for the poster
or the additional paper.
Individuals who earn 10 points receive the Achievement Award.
Individuals who earn 30 points receive the Senior Achievement
Award. Individuals who earn 60 points are eligible to receive the
Life Achievement Honor Award. The Awards Committee reviews
all nominees and submits their recommendations to the Board of
Trustees for final approval.
On behalf of the Board of Trustees, we are pleased to announce the
recipients of the 2014 Achievement Award, Senior Achievement
Award, and Life Achievement Honor Award.
Members of the 2014 Awards Committee of the American Academy
of Ophthalmology:
Jane C Edmond MD - Chair
Cynthia Ann Bradford MD
James G Brooks Jr MD
Louis B Cantor MD
Lynn K Gordon MD
Louise A Mawn MD
18
Life Achievement Honor Awards

Life Achievement
Honor Awards
Eduardo C Alfonso MD
Miami, FL
Neil M Bressler MD
Baltimore, MD
Devron H Char MD
San Francisco, CA
Anne Louise Coleman MD PhD

Los Angeles, CA
Donald J DAmico MD
New York, NY
Davie Durfee MD
Portland, OR
David R Hardten MD
Minneapolis, MN
Richard A Lewis MD
Sacramento, CA
James P McCulley MD FACS FRCOphth

Dallas, TX
Dale R Meyer MD FACS

Slingerlands, NY
Stephen A Obstbaum MD
New York, NY
Andrew J Packer MD
Hartford, CT
Jose S Pulido MD MS
Rochester, MN
19
Senior Achievement
Awards
Senior Achievement Awards
20
Natalie A Afshari MD
San Diego, CA
Esen K Akpek MD
Baltimore, MD
Deborah M Alcorn MD
Palo Alto, CA
Anthony J Aldave MD
Los Angeles, CA
Richard C Angrist MD
Point Pleasant, NJ
Lisa Brothers Arbisser MD

Bettendorf, IA
Kerry K Assil MD
Beverly Hills, CA
Tin Aung FRCS PhD

Singapore, Singapore
Edward H Bedrossian Jr MD FACS

Drexel Hill, PA
Abdhish R Bhavsar MD
Medina, MN
Mark H Blecher MD
Philadelphia, PA
David M Brown MD
Houston, TX
Susan R Carter MD
Chatham, NJ
Tom S Chang MD
Arcadia, CA
Francois Codere MD
Montreal, Canada
Vital Paulino Costa MD

Sao Paulo, Brazil
Arlene V Drack MD
Iowa City, IA
Alaa M Eldanasoury MD
Jeddah, Saudi Arabia
Sharon Fekrat MD
Durham, NC
David S Friedman MD MPH PhD

Baltimore, MD
Damien Gatinel MD
Paris, France
Dan S Gombos MD
Houston, TX

Los Angeles, CA
Mike P Holzer MD
Heidelberg, Germany
Mohamad S Jaafar MD FACS

Washington, DC
Maurice B Landers MD
Chapel Hill, NC
Linda M Lawrence MD
Salina, KS
Thomas C Lee MD
Los Angeles, CA
Shan C Lin MD
San Francisco, CA
Gregg T Lueder MD
Saint Louis, MO
Mary Gerard Lynch MD

Atlanta, GA
Richard J Mackool MD
Astoria, NY
Francis S Mah MD
La Jolla, CA
Edward E Manche MD
Palo Alto, CA
Steven L Mansberger MD MPH

Portland, OR
Antonio A P Marinho MD PhD

Porto, Portugal
Arman Mashayekhi MD
Philadelphia, PA
Ramana S Moorthy MD
Indianapolis, IN
Asa Dan Morton III MD

San Diego, CA
Jonathan S Myers MD
Philadelphia, PA
Thomas A Oetting MD
Iowa City, IA
Dante Pieramici MD
Santa Barbara, CA
Roberto Pineda II MD
Waltham, MA
Rajesh K Rajpal MD
Mc Lean, VA
J Bradley Randleman MD
Atlanta, GA
Russell W Read MD PhD

Birmingham, AL
Shimon Rumelt MD MPA

Holon, Israel
Virender S Sangwan MBBS

Hyderabad, India
Robert L Schultze MD
Delmar, NY
Senior Achievement
Awards
Gregg T Kokame MD
Aiea, HI
21
Senior Achievement
Awards
Victoria M Sheffield
Kensington, MD
Scott R Sneed MD
Traverse City, MI
Jason E Stahl MD
Kansas City, MO
Timothy J Sullivan MBBS

Brisbane, Australia
Sonia H Yoo MD
Miami, FL
22
Theodore P Werblin MD PhD

Princeton, WV
Achievement Awards
Arezo Amirikia MD
Bloomfield Hills, MI
Anas A Anbari MD PhD FACS

East Grinstead, United Kingdom
James T Banta MD
Miami Beach, FL
Peter T Beaudette MD
Albuquerque, NM
Rachel Benator MD
Salt Lake City, UT
Jenny E Benjamin MA
San Francisco, CA
Daniel M Bernick JD
Plymouth Meeting, PA
Deborah W Bernstein MD
Waukesha, WI
Robert B Bhisitkul MD PhD

San Francisco, CA
Alan B Brackup MD
Langhorne, PA
Jens Buehren MD
Frankfurt am Main, Germany
Matthew C Caldwell MD
Helotes, TX
Emilio C Campos MD
Bologna, Italy
Kristin Carter MD
Tucson, AZ
Petros Carvounis MD FRCSC

Houston, TX
Usha Chakravarthy MBBS PhD

Belfast, Northern Ireland
Tat-Keong Chan FRCS FRCOphth

Singapore, Singapore
David Chaokai Chang MD MPH PhD

Taipei, Taiwan
Sunita Chaurasia MD
Hyderabad, India
Hunter Cherwek MD
Fredericksburg, VA
Amy S Chomsky MD
Nashville, TN
Craig N Czyz DO
Columbus, OH
John K G Dart MD
London, England
Daniel G Dawson MD
Gainesville, FL
Achievement Awards
Elena Albe MD
Legnano, Italy
23
Achievement Awards
Achievement Awards
24
Mangat R Dogra MBBS

Chandigarh, India
Denise F Dudley MD
Bellingham, WA
Justis P Ehlers MD
Shaker Heights, OH
Geoffrey Emerick MD
Farmington, CT
Uzeyir Erdem MD
Ankara, Turkey
Ayad A Farjo MD
Brighton, MI
Amani Fawzi MD
Chicago, IL
Alistair R Fielder FRCS

London, United Kingdom
Laura C Fine MD
Boston, MA
Kevin Thomas Flaherty MD

Wausau, WI
Luigi Fontana MD PhD

Reggio Emilia, Italy
Bruno M Fontes MD PhD

Rio de Janeiro, Brazil
Pierre R Fournie MD
Toulouse, France
Pamela B Fritz
Clinton, CT
Joseph Frucht-Pery MD
Jerusalem, Israel
Salvador Garcia-Delpech MD
Betera Valencia, Spain
Ioannis P Glavas MD FACS

Boston, MA
David A Goldman MD
Palm Beach Gardens, FL
Scott M Goldstein MD
Southampton, PA
Darren G Gregory MD
Denver, CO
Leon Grupenmacher MD
Curitiba, Brazil
Omesh P Gupta MD
Philadelphia, PA
Gregory S Hageman PhD

Salt Lake City, UT
Paul J Harasymowycz MD
Westmount, Canada
Devin A Harrison MD
Richland, WA
Achievement Awards
Marko Hawlina MD PhD

Ljubljana, Slovenia
Mingguang He MD PhD
Guangzhou, China
Catherine J Hwang MD
Los Angeles, CA
Raymond Iezzi MD
Rochester, MN
Tomohiro Iida MD
Tokyo, Japan
Soosan Jacob MBBS MS FRCS

Chennai, India
Mohammad A Javadi MD
Tehran, Iran
James V Jester PhD

Orange, CA
Sharon L Jick MD
St Louis, MO
Sonia Rani John DNB

Trivandrum, Kerala, India
Daniel A Johnson MD
San Antonio, TX
Choun-ki Joo MD
Seoul, Korea
Swathi Kaliki MD
Hyderabad, India
William R Katowitz MD
Wynnewood, PA
Ahmad Kheirkhah MD
Boston, MA
Stephen J Kim MD
Nashville, TN
Szilard Kiss MD
New York, NY
Richard C Koval MPA CMPE

Reno, NV
Igor Kozak MD
Riyadh, Saudia Arabia
David B Krebs MD
Saginaw, MI
Ronald W Kristan MD
Long Branch, NJ
Alvin K H Kwok MD PhD

Hong Kong, Hong Kong
Gabriele E Lang MD
Ulm, Germany
Elise Levine MAG CRC OCS

Mission Hills, CA
Achievement Awards
Adam S Hassan MD
Ada, MI
25
Achievement Awards
Achievement Awards
26
Helen Lew MD PhD

Seongnam, Korea
Jennifer Y Li MD
Sacramento, CA
Linda S Lippa MD
Irvine, CA
James C Loden MD
Goodlettsville, TN
Ronald Mancini MD
Dallas, TX
Raj K Maturi MD
Indianapolis, IN
Mark D Mayle MD
Morgantown, WV
Jim Mazzo
Irvine, CA
Tony McClellan
Herefordshire, United Kingdom
Thomas J McPhee MD
Scottsdale, AZ
Amel Meddeb-Ouertani MD
Tunis, Tunisia
Daniel Matthew Miller MD PhD

Cincinnati, OH
Amalia Miranda MD
Oklahoma City, OK
James Mitchell MD
Edina, MN
Santanu Mitra MBBS

Howrah, India
David G Morrison MD
Brentwood, TN
Charles Munnerlyn PhD

San Jose, CA
Somasheila I Murthy MD
Hyderabad, India
Jerzy Nawrocki MD PhD

Lodz, Poland
Arvind Neelakantan MD
Dallas, TX
Kouros Nouri-Mahdavi MD MSc

Los Angeles, CA
Sawsan R Nowilaty MD
Riyadh, Saudia Arabia
Michael OKeeffe MD
Dublin, Ireland
Ihab S Othman MD
Dokki, Egypt
Cynthia Owsley MSPH PhD

Birmingham, AL
Achievement Awards
Leon G Partamian MD
Northridge, CA
Jacob Peer MD
Jerusalem, Israel
Sushil K Premchand
Zurich, Switzerland
Michael J Price MD
Malden, MA
Gabriel G Quentel MD
Paris, France
Nathan M Radcliffe MD
New York, NY
Sunita Radhakrishnan MD
San Mateo, CA
Usha K Raina MD FRCS FRCOphth

New Delhi, India
Muralidhar Ramappa MBBS

Hyderabad, India
Tito Ramirez-Luquin MD
Mexico City, Mexico
Arturo J Ramirez-Miranda MD
Mexico City, Mexico
Kristin E Reidy DO
Santa Fe, NM
Kourous Rezaei MD
Harvey, IL
David M Ringel DO
Sewell, NJ
Eduardo B Rodrigues MD
Florianopolis, Brazil
Prin Rojanapongpun MD
Bangkok, Thailand
Mark I Rosenblatt MD PhD

New York, NY
Paul Joseph Rychwalski MD

Abu Dhabi, United Arab Emirates
Daniel J Salchow MD
Berlin, Germany
David Salom MD
Valencia, Spain
Gary B Schemmer MD
Winter Haven, FL
Stephen V Scoper MD
Norfolk, VA
Cynthia A Self MD
Bangor, ME
Anand K Shah MD
Athens, GA
Achievement Awards
Richard B Packard MD
London, England
27
Achievement Awards
Achievement Awards
28
Howard Shapiro PhD

Denver, CO
Kenneth S Shindler MD PhD

Philadelphia, PA
Michael A Singer MD
San Antonio, TX
Rishi P Singh MD
Cleveland, OH
Jennifer A Sivak-Callcott MD
Morgantown, WV
Clark L Springs MD
Plainfield, IN
Miguel Srur MD
Santiago, Chile
Donald Stone MD
Oklahoma City, OK
Michael D Straiko MD
Portland, OR
Mehryar Taban MD FACS

Beverly Hills, CA
Homayoun Tabandeh MD
Los Angeles, CA
Jeremiah P Tao MD
Irvine, CA
Manoj M Thakker MD
Holmdel, NJ
Martin Lee Thomley MD

Birmingham, AL
Minoru Tomita MD PhD

Tokyo, Japan
David Touboul MD PhD

Bordeaux, France
Akitaka Tsujikawa MD PhD

Kyoto, Japan
Patricia Udaondo MD
Valencia, Spain
Steven M Verity MD
Dallas, TX
Ning Li Wang MD
Beijing, China
Michael S Wiedman MD FACS

Malden, MA
Agnes M Wong MD
Toronto, Canada
Kyung In Woo MD
Seoul, Korea
Shahin Yazdani MD
Tehran, Iran
Elizabeth Yeu MD
Norfolk, VA
Achievement Awards
Achievement Awards
Jin S Yoon MD
Seoul, Korea
David W Zauel MD
Danville, IN
29
International Awards
International Awards
International Ophthalmologist Education Award

The International Ophthalmologist Education Award was developed to recognize international Academy members who pursue lifelong
education in ophthalmology. To qualify, international members need to earn 90 Continuing Medical Education (CME) credits over a period
of three years. Half of these credits (45) must be from Academy-sponsored CME activities. After applying for the award, members are
responsible for recording their Academy and non-Academy credits on their online CME transcript.
2014 Recipients
Ahmed Ibrahim FRCS (Saudi Arabia)
Margarita I Estribi MD (Venezuela)
Airton L. Kronbauer MD PHD (Brazil)
Mariana E Palavecino MD (Argentina)
Alexandre A Ventura MD (Brazil)
Mohamad Houri MBBCH PhD (Lebanon)
Azzam Abdul-Kader Ahmed FICO FRCS (Iraq)
Mohammad Rifaat FRCS(ED) (United Kingdom)
Carmen Barra MD (Chile)
Mustafa Y Mehyar MD (Jordan)
David Diaz-Valle MD PhD (Spain)
Nadia M G Hwessa MBBCh (Libya)
Francisco E Salazar-Marrugo MD (Colombia)
Narendra Dhingra MBBS (United Kingdom)
Giovanni Cuozzo MD (Italy)
Nikolaos T Chontos MD (Greece)
Guillermo Fernandez Sanz MD (Australia)
Patricio O Jara MD (Chile)
John Helal MD (Brazil)
Renato Ambrosio Jr MD (Brazil)
Joshua F A Owoeye MD (Nigeria)
Rodrigo Donato Costa MD (Brazil)
Julian Castro-Velilla MD (Spain)
Salem A Abualghanam MBBS (Jordan)
Klemens Ueberbacher MD (Italy)
Sarmad H Jassim MBChB (Iraq)
Krzysztof Muskalski MD PhD (Poland)
Valentin Huerva MD (Spain)
Luis Arias MD (Spain)
Vishal Jhanji MBBS (Hong Kong)
Luiz F Hagemann MD (Brazil)
Ziauddin A Shaikh MBBS (United Kingdom)
Mamdouh S El Shafei MD PhD (Egypt)
International Scholar Award Recipients

The International Scholar Award honors international Academy members who have demonstrated their dedication to lifelong education in
ophthalmology. To qualify, international members must have already received the International Ophthalmologist Education Award. They need to
earn 60 Continuing Medical Education (CME) credits within two years of applying and half of the credits (30) must be from Academy-sponsored
CME activities. They must also successfully complete a timed, online self-assessment test.
2014 Recipients
Ashok Sharma MD (India)
Pavel Rozsival MD PhD (Czech Republic)
Emma Teresa Villasenor Fierro MD (Mexico)
Ramesh Kekunnaya MBBS MD (India)
Gian P Giuliari MD (Venezuela)
Roberto Gallego-Pinazo MD (Spain)
Ibrahim M Ali MD (Lebanon)
Roberto Murillo Limongi S Carvalho MD (Brazil)
Ivan M Tavares MD (Brazil)
Rosario Tapia-Ramirez MD (Mexico)
Javier Aguirre Moreno MD (Ecuador)
Satinder Pal Singh Grewal MD MBBS (India)
Jorge E Valdez-Garcia MD (Mexico)
Sawsan R Nowilaty MD (Saudi Arabia)
Mike P Holzer MD (Germany)
Shivanand J Sheth MS DOMS FICO (India)
Paul E Tesha MBChB (United Kingdom)
30
Visionary Society, Corporate

and Organizational Donors
The Academy greatly appreciates the generous support provided by the following corporations, organizations and individuals.
The Visionary Society recognizes donors who have contributed
$1 million or more to the Academy Foundation.
Platinum Members
(One-time contributions of $1 million or more in two or more
calendar years)
Alcon, Inc.
Pfizer Ophthalmics
Gold Members
(One-time contributions of $1 million or more in any one
calendar year)
Alice R. McPherson, MD
Dr. Charles R. and Judith G. Munnerlyn
Stanley M. Truhlsen, MD
Knights Templar Eye Foundation, Inc.
Allergan, Inc.
Members
(Cumulative giving of $1 million or more)
Abbott Medical Optics, Inc.
Eli Lilly and Company
Genentech, Inc.
Merck & Co., Inc.
Industry Support
The Academy would like to thank the following companies for
their generous support of AAO 2014 and Subspecialty Day.
AAO 2014 Gold Support Level
Genentech, Inc.
Regeneron Pharmaceuticals, Inc.
Retina Subspecialty Day
Regeneron Pharmaceuticals, Inc.
2013 Corporate and Organizational Donors
Visionary Society, Corporate

and Organizational Donors
The Visionary Society
The Academy and its Foundation greatly appreciate the support*

provided by the following corporations and organizations.
$500,000 to $999,999
Abbott Medical Optics, Inc. ................................................. $762,500
The Allergan Foundation ...................................................... $500,000
$250,000 to $499,999
Regeneron Pharmaceuticals, Inc. ........................................ $360,000
Genentech, Inc. ..................................................................... $333,500
Alcon, Inc. ............................................................................. $327,500
Allergan, Inc.......................................................................... $300,000
Knights Templar Eye Foundation, Inc. .................................. $250,000
$50,000 to $99,999
Bausch + Lomb ........................................................................$87,500
HOYA Surgical Optics ..............................................................$50,000
Retina Research Foundation ...................................................$50,000
$25,000 to $49,999
Merck & Co., Inc. .....................................................................$40,000
$10,000 to $24,999
AcuFocus, Inc. ..........................................................................$17,500
Oceanic Heritage Foundation..................................................$15,000
Up to $10,000
Roanoke Rotary Club .................................................................$8,000
Freeman .....................................................................................$7,500
Oculus Optikgeraete GMBH ......................................................$7,500
Horncrest Foundation, Inc. ........................................................$5,000
Morgantown Rotary Club ..........................................................$4,000
San Clemente Rotary Club ........................................................$4,000
Tri-Cities Rotary Club .................................................................$4,000
Retina Society............................................................................$1,000
Wills Eye Hospital .....................................................................$1,000
Wills Eye Hospital Society ........................................................$1,000
*This list recognizes gifts and pledges made from January 1
December 31, 2013, with cumulative support of $1,000 or greater.
Cataract Monday
Alcon, Inc.
Bausch + Lomb
Abbott Medical Optics, Inc.
31
Who benefits from Academy Foundation funding?

a. Ophthalmologists
b. An infant with retinopathy of prematurity
c. Residents in Nairobi
d. A grandmother in Warner, Oklahoma
e. All of the above
For more than 30 years, the Foundation has supported the Academys education, quality of care and
service programs, which benefit ophthalmologists and their patients worldwide.
The ONE Network gives us cutting-edge knowledge to provide better patient care. The Hoskins
Center for Quality Eye Care ensures best practices and accurate benchmarking. The International
Outreach Program helps educate our colleagues in the developing world. EyeCare America changes
the lives of the medically underserved across the U.S. And the Museum of Vision shares the history
of ophthalmology with the world.
Your tax-deductible contributions make these and many other innovative programs possible.
Help us continue to impact your continuing education, improve patient care and prevent avoidable
blindness.
Make a gift today! www.faao.org

Questions? Contact Karen Duke at kduke@aao.org or 415.447.0356
PIONEERED
BY ALCON
POWERED BY YOU
PRECISION
OPTIMIZED FOR
THE CORNEA,
CAPSULE & LENS.
THE CATARACT
REFRACTIVE
Visit the Alcon booth to experience the LenSx Laser,
SUITE BY ALCON
part of the first and only complete cataract refractive suite.
THE CATARACT
2014 Novartis 8/14 LSX14076SOV
SUITE BY ALCON
VERION REFERENCE UNIT AND VERION DIGITAL MARKER

IMPORTANT PRODUCT INFORMATION
CAUTION: Federal (USA) law restricts this device to sale by, or on the order
of, a physician.
INTENDED USES: The VERION Reference Unit is a preoperative
measurement device that captures and utilizes a high-resolution reference
image of a patients eye in order to determine the radii and corneal curvature
of steep and flat axes, limbal position and diameter, pupil position and
diameter, and corneal reflex position. In addition, the VERION Reference
Unit provides preoperative surgical planning functions that utilize the
reference image and preoperative measurements to assist with planning
cataract surgical procedures, including the number and location of incisions
and the appropriate intraocular lens using existing formulas. The VERION
Reference Unit also supports the export of the high-resolution reference
image, preoperative measurement data, and surgical plans for use with the
VERION Digital Marker and other compatible devices through the use of a
USB memory stick.
The VERION Digital Marker links to compatible surgical microscopes to
display concurrently the reference and microscope images, allowing the
surgeon to account for lateral and rotational eye movements. In addition,
the planned capsulorhexis position and radius, IOL positioning, and
implantation axis from the VERION Reference Unit surgical plan can be
overlaid on a computer screen or the physicians microscope view.
CONTRAINDICATIONS: The following conditions may affect the
accuracy of surgical plans prepared with the VERION Reference Unit:
a pseudophakic eye, eye fixation problems, a non-intact cornea, or an
irregular cornea. In addition, patients should refrain from wearing contact
lenses during the reference measurement as this may interfere with the
accuracy of the measurements.
Only trained personnel familiar with the process of IOL power calculation and
astigmatism correction planning should use the VERION Reference Unit.
Poor quality or inadequate biometer measurements will affect the accuracy
of surgical plans prepared with the VERION Reference Unit.
The following contraindications may affect the proper functioning of the
VERION Digital Marker: changes in a patients eye between preoperative
measurement and surgery, an irregular elliptic limbus (e.g., due to eye
fixation during surgery, and bleeding or bloated conjunctiva due to
anesthesia). In addition, the use of eye drops that constrict sclera vessels
before or during surgery should be avoided.
WARNINGS: Only properly trained personnel should operate the VERION
Reference Unit and VERION Digital Marker.
Only use the provided medical power supplies and data communication
cable. The power supplies for the VERION Reference Unit and the VERION
Digital Marker must be uninterruptible. Do not use these devices in
combination with an extension cord. Do not cover any of the component
devices while turned on.
Only use a VERION USB stick to transfer data. The VERION USB stick should
only be connected to the VERION Reference Unit, the VERION Digital
Marker, and other compatible devices. Do not disconnect the VERION USB
stick from the VERION Reference Unit during shutdown of the system.
The VERION Reference Unit uses infrared light. Unless necessary, medical
personnel and patients should avoid direct eye exposure to the emitted
or reflected beam.
PRECAUTIONS: To ensure the accuracy of VERION Reference Unit
measurements, device calibration and the reference measurement should
be conducted in dimmed ambient light conditions. Only use the VERION
Digital Marker in conjunction with compatible surgical microscopes.
ATTENTION: Refer to the user manuals for the VERION Reference Unit and
the VERION Digital Marker for a complete description of proper use and
maintenance of these devices, as well as a complete list of contraindications,
warnings and precautions.
LENSX LASER IMPORTANT PRODUCT INFORMATION
CAUTION: United States Federal Law restricts this device to sale and use by
or on the order of a physician or licensed eye care practitioner.
INDICATION: The LenSx Laser is indicated for use in patients undergoing
cataract surgery for removal of the crystalline lens. Intended uses in
cataract surgery include anterior capsulotomy, phacofragmentation,
and the creation of single plane and multi-plane arc cuts/incisions in
the cornea, each of which may be performed either individually or
consecutively during the same procedure.
RESTRICTIONS: Patients must be able to lie flat and motionless in a
supine position. Patient must be able to understand and give an informed
consent. Patients must be able to tolerate local or topical anesthesia.
Patients with elevated IOP should use topical steroids only under close
medical supervision.
CONTRAINDICATIONS: Corneal disease that precludes applanation of the
cornea or transmission of laser light at 1030 nm wavelength. Descemetocele
with impending corneal rupture. Presence of blood or other material in the
anterior chamber. Poorly dilating pupil, such that the iris is not peripheral to
the intended diameter for the capsulotomy. Conditions which would cause
inadequate clearance between the intended capsulotomy depth and the
endothelium (applicable to capsulotomy only). Previous corneal incisions
that might provide a potential space into which the gas produced by the
procedure can escape. Corneal thickness requirements that are beyond the
range of the system. Corneal opacity that would interfere with the laser
beam. Hypotony or the presence of a corneal implant. Residual, recurrent,
active ocular or eyelid disease, including any corneal abnormality (for
example, recurrent corneal erosion, severe basement membrane disease).

History of lens or zonular instability. Any contraindication to cataract or
keratoplasty. This device is not intended for use in pediatric surgery.
WARNINGS: The LenSx Laser System should only be operated by a
physician trained in its use.
The LenSx Laser delivery system employs one sterile disposable LenSx
Laser Patient Interface consisting of an applanation lens and suction ring.
The Patient Interface is intended for single use only. The disposables used in
conjunction with ALCON instrument products constitute a complete surgical
system. Use of disposables other than those manufactured by Alcon may
affect system performance and create potential hazards.
The physician should base patient selection criteria on professional
experience, published literature, and educational courses. Adult patients
should be scheduled to undergo cataract extraction.
PRECAUTIONS: Do not use cell phones or pagers of any kind in the same
room as the LenSx Laser. Discard used Patient Interfaces as medical waste.
AEs/COMPLICATIONS: Capsulotomy, phacofragmentation, or cut or incision
decentration. Incomplete or interrupted capsulotomy, fragmentation, or
corneal incision procedure. Capsular tear. Corneal abrasion or defect. Pain.
Infection. Bleeding. Damage to intraocular structures. Anterior chamber fluid
leakage, anterior chamber collapse. Elevated pressure to the eye.
ATTENTION: Refer to the LenSx Laser Operators Manual for a complete
listing of indications, warnings and precautions.
CENTURION VISION SYSTEM IMPORTANT
PRODUCT INFORMATION
CAUTION: Federal (USA) law restricts this device to sale by, or on the order
of, a physician.
As part of a properly maintained surgical environment, it is recommended
that a backup IOL Injector be made available in the event the AutoSert IOL
Injector Handpiece does not perform as expected.
INDICATION: The CENTURION Vision System is indicated for emulsification,
separation, irrigation, and aspiration of cataracts, residual cortical material
and lens epithelial cells, vitreous aspiration and cutting associated with
anterior vitrectomy, bipolar coagulation, and intraocular lens injection. The
AutoSert IOL Injector Handpiece is intended to deliver qualified AcrySof
intraocular lenses into the eye following cataract removal.
The AutoSert IOL Injector Handpiece achieves the functionality of injection
of intraocular lenses. The AutoSert IOL Injector Handpiece is indicated for
use with the AcrySof lenses SN6OWF, SN6AD1, SN6AT3 through SN6AT9, as
well as approved AcrySof lenses that are specifically indicated for use with
this inserter, as indicated in the approved labeling of those lenses.
WARNINGS: Appropriate use of CENTURION Vision System parameters and
accessories is important for successful procedures. Use of low vacuum limits,
low flow rates, low bottle heights, high power settings, extended power
usage, power usage during occlusion conditions (beeping tones), failure
to sufficiently aspirate viscoelastic prior to using power, excessively tight
incisions, and combinations of the above actions may result in significant
temperature increases at incision site and inside the eye, and lead to severe
thermal eye tissue damage.
Good clinical practice dictates the testing for adequate irrigation and
aspiration flow prior to entering the eye. Ensure that tubings are not
occluded or pinched during any phase of operation.
The consumables used in conjunction with ALCON instrument products
constitute a complete surgical system. Use of consumables and handpieces
other than those manufactured by Alcon may affect system performance
and create potential hazards.
AEs/COMPLICATIONS: Inadvertent actuation of Prime or Tune while a
handpiece is in the eye can create a hazardous condition that may result in
patient injury.During any ultrasonic procedure, metal particles may result
from inadvertent touching of the ultrasonic tip with a second instrument.
Another potential source of metal particles resulting from any ultrasonic
handpiece may be the result of ultrasonic energy causing micro abrasion of
the ultrasonic tip.
ATTENTION: Refer to the Directions for Use and Operators Manual for a
complete listing of indications, warnings, cautions and notes.
ACRYSOF IQ INTRAOCULAR LENSES IMPORTANT
PRODUCT INFORMATION
CAUTION: Federal (USA) law restricts this device to the sale by or on the
order of a physician.
INDICATIONS: The AcrySof IQ posterior chamber intraocular lens is
intended for the replacement of the human lens to achieve visual correction
of aphakia in adult patients following cataract surgery. This lens is intended
for placement in the capsular bag.
WARNING/PRECAUTION: Careful preoperative evaluation and sound
clinical judgment should be used by the surgeon to decide the risk/benefit
ratio before implanting a lens in a patient with any of the conditions
described in the Directions for Use labeling. Caution should be used prior
to lens encapsulation to avoid lens decentrations or dislocations.
Studies have shown that color vision discrimination is not adversely affected
in individuals with the AcrySof Natural IOL and normal color vision. The
effect on vision of the AcrySof Natural IOL in subjects with hereditary color
vision defects and acquired color vision defects secondary to ocular disease
(e.g., glaucoma, diabetic retinopathy, chronic uveitis, and other retinal or
optic nerve diseases) has not been studied. Do not resterilize; do not store
over 45 C; use only sterile irrigating solutions such as BSS or BSS PLUS
Sterile Intraocular Irrigating Solutions.
ATTENTION: Reference the Directions for Use labeling for a complete listing
of indications, warnings and precautions.
ACRYSOF IQ RESTOR INTRAOCULAR LENSES IMPORTANT
PRODUCT INFORMATION
INDICATIONS: The AcrySof IQ ReSTOR Posterior Chamber Intraocular
Lens (IOL) is intended for primary implantation for the visual correction
of aphakia secondary to removal of a cataractous lens in adult patients
with and without presbyopia, who desire near, intermediate and
distance vision with increased spectacle independence. The lens is
intended to be placed in the capsular bag.
clinical judgment should be used by the surgeon to decide the risk/
benefit ratio before implanting a lens in a patient with any of the
conditions described in the Directions for Use labeling. Physicians
should target emmetropia, and ensure that IOL centration is achieved.
Care should be taken to remove viscoelastic from the eye at the close
of surgery.
Some patients may experience visual disturbances and/or discomfort
due to multifocality, especially under dim light conditions. Clinical
studies with the AcrySof ReSTOR lens indicated that posterior capsule
opacification (PCO), when present, developed earlier into clinically
significant PCO. Prior to surgery, physicians should provide prospective
patients with a copy of the Patient Information Brochure available from
Alcon for this product informing them of possible risks and benefits
associated with the AcrySof IQ ReSTOR IOLs.
Studies have shown that color vision discrimination is not adversely
affected in individuals with the AcrySof Natural IOL and normal color
vision. The effect on vision of the AcrySof Natural IOL in subjects
with hereditary color vision defects and acquired color vision defects
secondary to ocular disease (e.g., glaucoma, diabetic retinopathy,
chronic uveitis, and other retinal or optic nerve diseases) has not been
studied. Do not resterilize; do not store over 45 C; use only sterile
irrigating solutions such as BSS or BSS PLUS Sterile Intraocular
Irrigating Solutions.
ATTENTION: Reference the Directions for Use labeling for a complete
ACRYSOF IQ TORIC INTRAOCULAR LENSES IMPORTANT
PRODUCT INFORMATION
INDICATIONS: The AcrySof IQ Toric posterior chamber intraocular
lenses are intended for primary implantation in the capsular bag
of the eye for visual correction of aphakia and pre-existing corneal
astigmatism secondary to removal of a cataractous lens in adult
patients with or without presbyopia, who desire improved uncorrected
distance vision, reduction of residual refractive cylinder and increased
spectacle independence for distance vision.
clinical judgment should be used by the surgeon to decide the risk/
benefit ratio before implanting a lens in a patient with any of the
conditions described in the Directions for Use labeling. Toric IOLs should
not be implanted if the posterior capsule is ruptured, if the zonules are
damaged, or if a primary posterior capsulotomy is planned. Rotation
can reduce astigmatic correction; if necessary lens repositioning should
occur as early as possible prior to lens encapsulation. All viscoelastics
should be removed from both the anterior and posterior sides of the
lens; residual viscoelastics may allow the lens to rotate.
Optical theory suggests that high astigmatic patients (i.e., > 2.5 D)
may experience spatial distortions. Possible toric IOL related factors
may include residual cylindrical error or axis misalignments. Prior to
surgery, physicians should provide prospective patients with a copy of
the Patient Information Brochure available from Alcon for this product
informing them of possible risks and benefits associated with the
AcrySof IQ Toric Cylinder Power IOLs.
Studies have shown that color vision discrimination is not adversely
affected in individuals with the AcrySof Natural IOL and normal color
vision. The effect on vision of the AcrySof Natural IOL in subjects
with hereditary color vision defects and acquired color vision defects
secondary to ocular disease (e.g., glaucoma, diabetic retinopathy,
chronic uveitis, and other retinal or optic nerve diseases) has not been
studied. Do not resterilize; do not store over 45 C; use only sterile
irrigating solutions such as BSS or BSS PLUS Sterile Intraocular
Irrigating Solutions.
ATTENTION: Reference the Directions for Use labeling for a complete
2014 Novartis 8/14 CRS14007JAD-PI
Selection Committees
Each subcommittee has five-ten reviewers who grade the instruction
courses and paper/poster abstracts, and three subcommittee members
who review the grades and select the courses and abstracts for presentation. The chair of the subcommittee represents the group on the Annual
Meeting Program Committee. This peer-review selection process ensures
the quality and integrity of Academy educational programs and allows
broader input from Academy Members.
The Annual Meeting Program Committee monitors the scientific program
by reviewing evaluation data, the post-annual meeting survey and reports
from independent course/symposium monitors.
Volunteer to be a reviewer by visiting Member Services on the Academys
website and completing the online volunteer form. Volunteer to be a
course/symposium monitor by e-mailing the Meetings Division at
meetings@aao.org.
Associate Secretary for the Annual Meeting Program
Cynthia Mattox MD FACS*
Annual Meeting Program Committee

Kathryn A Colby MD PhD*
Janet Louise Davis MD*
William J Fishkind MD FACS*
Don O Kikkawa MD *
Jacqueline A Leavitt MD
Molly Walsh MD MPH*
Sonia H Yoo MD*
Terri L Young MD*
Subcommittee for: Cataract

Chair: William J Fishkind MD FACS*
Subcommittee Members
Nicole R Fram MD*
Mitchell P Weikert MD*
Subcommittee Reviewers
George Beiko MD*
Gary J Foster MD*
Colleen P Halfpenny MD
Stephen H Johnson MD
Kevin M Miller MD*
Subcommittee for: Cornea, External Disease

Chair: Kathryn A Colby MD PhD*
Bennie H Jeng MD*
Shahzad I Mian MD*
Jessica B Ciralsky MD*
Darren G Gregory MD
Christina R Prescott MD
Vincenzo Sarnicola MD
Sonal S Tuli MD
Subcommittee for: Glaucoma

Chair: Molly Walsh MD MPH*
Steven J Gedde MD*
Malik Y Kahook MD*
Husam Ansari MD PhD*
Martha Motuz Leen MD*
Steven L Mansberger MD MPH*
Brian C Samuels MD PhD
Thasarat S Vajaranant MD*
The Annual Meeting Program Committee is responsible for the Academys

annual meeting Scientific Program, including Breakfast With the Experts,
Instruction Courses, Symposia, and Scientific Papers, Posters and Videos.
Subcommittee for: Neuro-Ophthalmology, Computers/

Information Technology, Ethics, General Medical Care,
Global Ophthalmology, Electronic Health Records,
Medical Education, Ophthalmic History and Vision
Rehabilitation
Chair: Jacqueline A Leavitt MD
Sophia Mihe Chung MD*
Michael S Lee MD*
Madhu R Agarwal MD
John B Kerrison MD*
Howard D Pomeranz MD PhD
Prem S Subramanian MD PhD*
Subcommittee for: Ocular Tumors, Pathology and Orbit,

Lacrimal Plastic Surgery
Chair: Don O Kikkawa MD*
Julian D Perry MD*
Matthew W Wilson MD
Jonathan W Kim MD
Bobby S Korn MD PhD FACS*
Jill S Melicher Larson MD
Pete Setabutr MD
Erin M Shriver MD
Subcommittee for: Pediatric Ophthalmology,

Strabismus
Chair: Terri L Young MD*
Hilda Capo MD
Martha P Schatz MD
Arlene V Drack MD*
Judith E Gurland MD
Anthony Pruett Johnson MD FACS
Natalie C Kerr MD
Scott R Lambert MD*
33
Subcommittee for: Refractive Surgery and Optics,

Refraction Contact Lenses
Chair: Sonia H Yoo MD*
William B Trattler MD*
John Allan Vukich MD*
David A Goldman MD*
Daniel F Goodman MD FACS
George D Kymionis MD PhD
Rajesh K Rajpal MD*
Elizabeth Yeu MD*
Subcommittee for: Retina, Vitreous and Intraocular

Inflammation, Uveitis
Chair: Janet Louise Davis MD*
Srinivas R Sadda MD*
Sharon D Solomon MD
Ron Afshari Adelman MD MPH
J Fernando Arevalo MD*
Alay S Banker MD
Sharon Fekrat MD*
Christina J Flaxel MD
Colin A McCannel MD*
Andrew A Moshfeghi MD MBA*
Dante Pieramici MD*
Shlomit Schaal MD PhD*
Homayoun Tabandeh MD MS FRCP FRCOphth*
Special Projects Committee

The Special Projects Committee is responsible for developing programs
and formats that cross subspecialities as well as complement those that
are submitted by members or societies.
Associate Secretary: Maria M Aaron MD
Committee Members
Jill S Melicher Larson MD
Scott C Oliver MD*
Florentino E Palmon MD
Douglas J Rhee MD*
Nicholas J Volpe MD
Tammy L Yanovitch MD
AAOE Program
The AAOE Program Committee, with the AAOE Board of Directors, are
responsible for selecting the AAOE Program and Practice Management
Breakfast With the Experts roundtables.
Chair: Sandra Dixon Curd MBA COE COA OCS
Board Members
Nancy Baker
Mary Becka
Nan Eversgerd
Ravi D Goel MD
Elise Levine MA CRC OCS
Bonnie Callahan Parker
Rajiv R Rathod MD MBA
Andrew Wang COE FACHE MHSA MBA
Robert E Wiggins Jr MD MHA*
Annual Meeting Program Committee Members
Albert Castillo*
Tim D Couch
Heather Hambrick Dunn COA
Traci Fritz COE OCS
Barbara Krzeszowski LPN COT
Julia Lee JD OCS*
Susan M Loen OCS
Rosa M Montes COA OCS
Paula Vaughn OCS
Academy Staff
Julia Fennell
Sangeeta Fernandes
Brandi Garrigus
Susan Oslar
Melanie Rafaty
Michael Rhea*
Debra Rosencrance
Elizabeth Washburn
European Society of Ophthalmology (SOE) Planning

Committee
Chair: Stefan Seregard MD
Committee Members
Jan-Tjeerd H N de Faber MD
Thomas F Fenech MBBS
Skills Transfer Advisory Committee

The Skills Transfer Advisory Committee is responsible for selecting the
Skills Transfer courses and labs.
Associate Secretary: Thomas W Samuelson MD*
Advisory Committee
Susan R Carter MD
Jack A Cohen MD FACS
William Barry Lee MD*
Kevin M Miller MD*
Nathan M Radcliffe MD*
David D Verdier MD
34
Programs-By-Day
All rooms are in McCormick Place: North Building (N), South Building (S), Lakeside Center (E), unless otherwise indicated.
Courses designated with a plus (+) sign are part of the Academy Plus course pass. Courses designated with a dollar ($) sign are not included in the
course pass and must be purchased separately. Sessions and events that are left blank are free. Content from courses and sessions with a diamond
will be captured and available to purchase through AAO Meetings On Demand; courses are not sold individually. Disclaimer: Some content may not
be available, or may be audio only, due to extent of recording permission granted by presenter.
MEDED - Medical Education

NEURO - Neuro-Ophthalmology
NON - General Non-Medical
OPTIC - Optics, Refraction, Contact Lenses
PATH - Ocular Tumors, Pathology
PEDS - Pediatric Ophthalmology, Strabismus
PLAST - Orbit, Lacrimal, Plastic Surgery
REF - Refractive Surgery
RET - Retina, Vitreous
VIS - Vision Rehabilitation
Programs-By-Day
Topic Key
CAT - Cataract
COM - Computers, Information Technology
COR - Cornea, External Disease
EHR - Elecgtronic Health Records
ETH - Ethics
GEN - General Medical Care
GLA - Glaucoma
GO - Global Ophthalmology
HIST - Ophthalmic History
INTRA - Intraocular Inflammation, Uveitis
PRACTICE MANAGEMENT/AAOE
PM-ASC - Ambulatory Surgery Centers
PM-BUS - Business Operations & Finance
PM-EHR - Electronic Health Records
PM-HMR - Human Resources
PM-IMT - Information Technology
PM-MKT - Marketing & Business Development
PM-OPT - Optical Dispensing
PM-PROF - Professional Growth
PM-REMB - Coding & Reimbursement
PM-RISK - Compliance & Risk Management
Type Key
AAOEIC - AAOE Instruction Course
AAOESP - AAOE Special Meeting
ACADCAFE - Academy Caf
BWE - Breakfast with the Experts
IC - Instruction Course
LL - Learning Lounge
OP - Original Paper Session
OPSESS - Opening Session
PT - Poster Tour
SKILLS - Skills Transfer Course
SPE - Special Meeting
SPOTLIT - Spotlight Session
SUB - Subspecialty Day Meeting

SYM - Symposium
TP - Technology Pavilion
Friday, Oct. 17
Time
Type
No.
Title
Topic
7:30 AM - 3:00 PM
SPE
SPE01
8:00 AM - 5:23 PM
SUB
Refractive Surgery 2014: Mission 20/20
REF
8:00 AM - 5:38 PM
SUB
Retina 2014: Reaching New Heights
RET
DICOM Working Group 9 - Eye Care
Room
Page
Hyatt Regency
McCormick
Place
$ Arie Crown
Theater (E)
$ North, Hall B
250
Page

Time
Type
7:50 AM - 5:30 PM
8:00 - 11:00 AM
8:00 AM - 12:00 PM
8:00 AM - 5:00 PM
SUB
CODE1
AAOESP
SUB
8:00 AM - 5:05 PM
SUB
8:00 AM - 5:15 PM
SUB
8:00 AM - 5:21 PM
SUB
8:00 AM - 5:25 PM
SUB
8:00 AM - 5:32 PM
8:00 AM - 5:35 PM
SUB
SUB
9:00 - 11:00 AM
9:00 AM - 1:00 PM
SPE
AAOESP
No.
SPE03
SPE04
SPE05
Title
Topic
Room
Uveitis 2014: Extinguishing the Great Fire

INTRA $
E450
Introduction to Ophthalmic Coding and ICD-10-CM
PM-REMB $
S105
The Profitable Practice: Managing Your Billing Operations
PM-BUS $
S502ab
Glaucoma 2014: Integrating New Technologies and Approaches
GLA
$ Grand Ballroom
Into Your Daily Practice
S100ab
Oculofacial Plastic Surgery 2014: A Global Summit
PLAST $ Grand Ballroom
S100c
Ocular Oncology and Pathology 2014: Saving Eyes and Saving
PATH
$
E350
Lives
Refractive Surgery 2014: Mission 20/20
REF
$ Arie Crown
Theater (E)
Cornea 2014: Restocking the Toolbox: Concepts and Techniques
COR
$
E354
for the Toughest Jobs
Retina 2014: Reaching New Heights
RET
$ North, Hall B
Pediatric Ophthalmology 2014: A Magnificent Mile of
PEDS
$ Vista Room
Innovations
S406a
Brain Health and Longevity for SOs in the Digital Age
GEN
N427bc
Keeping Your Practice Out of Legal Hot Water: An HR and
PM-ASC $
S503ab
Compliance Workshop
During AAO 2014 visit www.aao.org/mobile to access course handouts and evaluations. After the meeting visit www.aao.org/aao-archives.
266
280
250
280
35
Programs-By-Day
Programs-By-Day
Time
Type
No.
9:30 AM - 5:00 PM
12:00 - 4:00 PM
TP
AAOESP
SPE24
12:00 - 5:00 PM
12:30 - 3:30 PM
12:30 - 4:30 PM
1:00 - 4:00 PM
LL
CODE2
AAOESP
AAOESP
SPE
SPE02
SPE06
SPE07
1:15 - 2:30 PM
2:00 - 3:30 PM
ACADCAFE
SYM
SYM50
SYM01
2:00 - 5:30 PM
SYM
SYM58
3:15 - 4:30 PM
ACADCAFE
SYM51
Title
Technology Pavilion
The Entrepreneurial ASC: Embracing Policy, People, Possibilities
and Planning
Learning Lounge
Coding Camp and Advanced ICD-10-CM
Scott Demings Emotional Brand Building Workshop
The Optical Dispensing Boot Camp
Use Blogging & Social Networking to Super Charge Your
Website & Internet Marketing
Academy Caf: IRIS Registry
Global Symposium: Low Vision Rehabilitation and New
Technologies for the Developing World
Conference for Ophthalmic Educators: Improving Teaching
Effectiveness
Academy Caf: Cataract
Topic
Room
Page
Booth 165
S505ab
258
280
Booth 107
S105
S501abc
S504bc
N227a
254
266
280
280
250
S404
S405
122
124
S104ab
124
S404
122
Room
Page
Hall A
E450
250
51
124
N226
North Hall B
S102d
114
121
125
E352
114
E351
N230
N231
S105bc
110
106
114
111
S103bc
N427a
S102abc
Booth 165
North Hall B
S406b
N227a
S101ab
S102d
S104a
109
110
106
258
250
265
109
250
118
83
S104b
E353c
66
74
E352
106
S106a
115
N427bc
107
PM-ASC
PM-REMB $
PM-PROF $
PM-OPT $
COM
EHR
GO
MEDED
CAT
Sunday, Oct.19 (cont.)

Type
No.
6:30 - 7:30 AM
7:30 - 8:30 AM
8:00 - 11:00 AM
Time
SPE
BWE
SYM
SPE23
SYM02
8:30 - 10:00 AM
9:00 - 10:00 AM
SKILLS
OPSESS
SYM
LAB100
SYM61
SYM03
SKILLS
LEC106
SKILLS
SKILLS
SKILLS
SKILLS
LEC107
LAB108
LAB105
LEC101
SKILLS
SKILLS
SKILLS
TP
SPE
AAOESP
SKILLS
SPE
SKILLS
IC
LEC102
LEC103
LEC104
SPE22
SPE09
LAB109
SPE08
LEC111
150
IC
IC
166
167
SKILLS
LEC110
SKILLS
LEC112
SKILLS
LEC113
9:00 - 10:30 AM
9:00 - 11:00 AM
9:00 - 11:15 AM
9:30 AM - 5:00 PM
10:00 - 10:30 AM
10:00 AM - 12:00 PM
10:00 AM - 2:00 PM
10:15 - 11:15 AM
10:15 AM - 12:30 PM
36
Title
Topic
29th Annual Run for Vision

NON
$
$
Introduction to Corneal and Lens-Based Refractive Surgery for
REF
Residents
Orbitofacial Fracture Repair: Plating Workshop
PLAST $
Opening Session
NON
Free and Easy for Low Vision: Help and Resources for the
VIS
Visually Impaired
Periocular Rejuvenation With Fillers and BOTOX With 2-D
PLAST +
Videos and Video-Assisted Teaching
Crosslinking
COR
+
Cataract Femtosecond Laser Surgery
CAT
$
Neuroimaging in Ophthalmology
NEURO $
Computerized Scanning Imaging of the Optic Nerve and Retinal
GLA
+
Nerve Fiber Layer
Endothelial Keratoplasty Techniques
COR
+
Anterior Lamellar Keratoplasty: Principles and Practice
COR
+
Management of the Vitreous for the Anterior Segment Surgeon
CAT
+
Technology Pavilion
Annual Business Meeting
NON
AAOE General Session: Powered by Purpose
PM-PROF
The iPhone and iPad for Ophthalmologists (Basic)
COM
$
2014 YO Program - Its YO World, Jumpstart Your Career!
NON
+
New Techniques for Strabismus Surgery
PEDS
+
Diagnosis and Management of Essential Blepharospasm and
PLAST +
Hemifacial Spasm
Surgical Management of Infectious Keratitis: Make It Simple
COR
+
Selective Laser Trabeculoplasty: Basic Principles and Pearls for
GLA
+
Practice
Advanced Refractive Cataract Surgery and Anterior Segment
CAT
+
Reconstruction
Cosmetic Botulinum Toxin and Facial Fillers: An Introductory
PLAST +
Course
Phacoemulsification and Advanced Techniques: The Core
CAT
+
Curriculum
Programs-By-Day
Type
No.
Title
Topic
Room
Page
10:15 AM - 12:30 PM
SKILLS
SKILLS
LEC114
LEC115
RET
PLAST
+
+
E351
S106b
120
115
IC
151
GLA
E353b
74
IC
IC
IC
152
153
154
COR
PLAST
PLAST
+
+
+
S103d
S403a
N135
66
84
84
IC
IC
IC
IC
IC
IC
155
156
157
158
159
160
+
+
+
+
+
+
N427d
E451a
E353a
E451b
N140
S103a
89
59
59
91
91
91
IC
161
NEURO
S105d
80
IC
IC
162
163
RET
PLAST
+
+
N138
S403b
92
84
IC
164
RET
N139
92
IC
165
Macular OCT: Mastering the Basics

Introduction to Aesthetic Facial Surgery by Fractional Lasers,
Intense Pulsed Light, Radiofrequency, and Ultrasound Devices
Examining the Optic Nerve and Evaluating the Visual Field: The
5 Rs
Top 10 Hot Corneal Surgical Tips for 2014
Complete Guide to the Evaluation and Management of Ptosis
Management of Orbital Tumors: Case Presentation and
Discussion
Solving the High Myopia Problem With Phakic IOLs
Best of the Best: An Update in Cataract Surgery
Cataract Surgery Crisis Management 101
OCT: Interpretation and Clinical Applications
Retinoblastoma 2014: They Live and See!
State-of-the-Art Techniques and Technologies for Microincision
Vitrectomy Surgery to Treat Complex Vitreoretinal Diseases
What You Need to Know About Headache: A Pain for the
Patient and a Pain for the Doctor
Surgery of Retinal Detachment
Optimizing Outcomes and Minimizing Complications in
Oculofacial Plastic Procedures: A Case-Based Approach
Advances in Intraocular Endoscopic Surgery: Anterior and
Posterior Segment Techniques
White Dots, Spots, and Plaques: Making Sense of the
Inflammatory Retinal Lesions: A Case-Based Approach
ABC in Effective Ophthalmic Publishing
Academy Caf: Glaucoma
Update on Molecular Analysis in Ophthalmic Disease
Treatment for Wet and Dry AMD: Where We Are and Where
We Are Going
Update 2014: Infectious Keratitis
RET
S105a
92
MEDED
GLA
PATH
RET
N136
S404
E350
S406a
80
122
126
126
IC
10:30 - 11:45 AM
ACADCAFE
10:30 AM - 12:00 PM
SYM
SYM
SYM
SYM07
SPOTLIT
SPO1
10:30 AM - 12:00 PM
10:30 AM - 12:30 PM
OP
SKILLS
10:30 AM - 5:00 PM
11:00 AM - 12:00 PM
11:00 AM - 12:30 PM
11:30 AM - 12:30 PM
LL
SKILLS
SKILLS
IC
IC
IC
IC
IC
IC
IC
SYM
11:30 AM - 1:00 PM
215
SYM52
SYM05
SYM06
SKILLS
Spotlight on Pediatric Ophthalmology: Front Line and First

StepsManagement of Strabismus for the Comprehensive
Ophthalmologist
OP01
Cataract Original Paper Session
LAB106A Periocular Rejuvenation With Fillers and BOTOX on Silicone
Head Simulators
Learning Lounge
LAB107A Crosslinking
LAB116 Cataract Femtosecond Laser Surgery
169
Oculoplastic Procedures for the General Ophthalmologist
170
International (Dis)Agreement on Infectious Uveitis
171
Better Surgery Through Chemicals
172
Oculoplastic Office Procedures: Video Clips
173
Peering to the Periphery: Applications of Wide-Angle Retinal
Imaging
174
Endothelial Keratoplasty: Descemet-Stripping EK / Descemet
Membrane EK / Pre-Descemet EKA Video-Based Course
175
Useful Things to Do With Your New EHR
SYM59 The Food and Drug Administration/National Eye Institute/
Department of Defense LASIK Quality of Life Project
LAB104A Management of the Vitreous for the Anterior Segment Surgeon
REF
CAT
CAT
RET
RET
RET
OPTIC
Programs-By-Day
Time
Grand Ballroom 126

S100c
Grand Ballroom 125
S100ab
PEDS
CAT
PLAST
COR
CAT
PLAST
INTRA
CAT
PLAST
RET
$
$
+
+
+
+
+
COR
EHR
REF
CAT
S405
N229
146
106
Booth 107
N227b
N230
S103bc
E353c
S105bc
S102abc
S104a
253
110
106
84
79
59
84
92
N427a
66
S102d
E450
72
127
N228
106
37
Programs-By-Day
Time
Programs-By-Day
11:30 AM - 5:00 PM
Type
No.
SPE
SPE10
12:00 - 2:00 PM
SKILLS
12:00 - 2:30 PM
12:15 - 1:45 PM
SKILLS
SYM
SPE
12:30-1:30 PM
PT
12:30 - 2:30 PM
12:45 - 1:45 PM
1:00 - 2:15 PM
1:00 - 3:00 PM
1:30 - 2:00 PM
1:30 - 3:00 PM
2:00 - 3:00 PM
2:00 - 3:15 PM
LAB101A Computerized Scanning Imaging of the Optic Nerve and Retinal

Nerve Fiber Layer
LAB117 Surgical Anatomy of the Eyelids: Cadaver Demonstration
SYM08 Cataract Surgery: The Cutting Edge
SPE11 2015 Medicare Update
SKILLS
LAB103A Anterior Lamellar Keratoplasty: Principles and Practice
SYM
SYM09 Michael F Marmor MD Lecture in Ophthalmology and the Arts
SYM
SYM10 EHRs: Improve Quality, Cost-Effectiveness and Your Headaches
SPE
SPE13 Q&A with FDA
ACADCAFE SYM53 Academy Caf: Cornea, External Disease
SKILLS
LAB111A New Techniques for Strabismus Surgery
SPE
SPE14 OMIC Annual Members Meeting
SKILLS
LAB112A Cosmetic Botulinum Toxin and Facial Fillers: An Introductory
Course
SKILLS
LAB113A Phacoemulsification and Advanced Techniques
AAOEIC
178
Social Media Liability in Your Office
AAOEIC
179
Defending the Ophthalmologist in a Medical Malpractice
Lawsuit
AAOEIC
180
Improving Workflow With EHR
AAOEIC
181
Managing Practice Performance
AAOEIC
182
Practice Mergers and Division or Care Center Based Mega
Groups
AAOEIC
183
What Every Administrator (and Optician) Needs to Know About
the Retail Selling Process
IC
187
Comprehensive Strategy for Unplanned Vitrectomy Technique
for the Anterior Segment Surgeon
IC
188
Controversies in the Management of Open-Globe Injuries
Involving the Posterior Segment
IC
196
Pearls for Evaluating Corneal Topography in Patients Scheduled
for Cataract Surgery
IC
197
Drug-Related Adverse Effects of Clinical Importance to the
Ophthalmologist
IC
198
Surgical Management of Astigmatism in Cataract and
Refractive Surgery
IC
200
Electronic Media and Patient Care: Ethical Considerations,
Confidentiality, HIPAA, and Encryption
IC
201
Optimizing Deep Anterior Lamellar Keratoplasty: The Small
Bubble Technique
IC
202
Pediatric Eye Emergencies You Dont Want to Miss!
IC
203
All White Dots Are Not the Same! Imaging Techniques in the
Diagnosis and Management of Posterior Uveitis
IC
207
Surgical Management of Complicated Retinal Detachments
AAOEIC
550
ASC Nuts and Bolts of Transitioning ASC Ownership
IC
607
Presentation Skills: How to Improve the Effectiveness of
Lectures
OP
OP02
Intraocular Inflammation, Uveitis Original Paper Session
SYM
SYM12 Grand Rounds: Cases and Experts From Across the Nation
SYM
38
Title
SYM47
The Great Debate: Retina
Topic
PLAST
CAT
HP
Meeting
PT
COR
NON
EHR
NON
COR
PEDS
NON
PLAST
Page
250
Fairmont
Chicago,
Millennium Park
N231
111
GEN
GLA
Room
N226
North Hall B
Grand Ballroom
S100c
Hall A
164
N227b
S406a
S406b
N427d
S404
N230
S403b
N229
110
127
127
250
122
118
251
115
CAT
PM-RISK
PM-RISK
$
+
+
N228
S504bc
S504d
107
272
272
PM-EHR
PM-BUS
PM-BUS
+
+
+
S502ab
S504a
S505ab
274
267
267
PM-OPT
S503ab
277
CAT
E451a
59
RET
E352
92
CAT
S102abc
60
GEN
N136
74
CAT
S103bc
60
ETH
N427d
73
COR
S105d
66
PEDS
INTRA
+
+
S403a
S102d
87
79
RET
PM-ASC
MEDED
+
+
+
S103a
S501d
N427a
93
267
80
INTRA
GEN
RET
115
127
250
S405
155
Grand Ballroom 128
S100ab
E450
128
Programs-By-Day
Time
2:00 - 3:30 PM
2:00 - 4:15 PM
2:30 - 3:45 PM
2:30 - 5:00 PM
3:00 - 5:00 PM
3:15 - 4:15 PM
3:15 - 5:30 PM
No.
SYM
SYM04
Title
A View Across the Pond: Current Cataract and IOL Practices in

Europe and the United States
SYM
SYM13 Making a Bad Situation Better: Retinoblastoma and the
Anophthalmic Socket
SYM
SYM14 Hot Topics 2014
SYM
SYM15 Contemporary Management of Orbital Fractures: An
International Perspective
SPE
SPE15 The Bruce E Spivey MD Lecture in Risk Management and
Patient Safety and OMIC Forum
SKILLS
LEC118 Ab-Interno Approach to Schlemms Canal
AAOEIC
176
Audits: Its Not a Matter of If, but When
IC
184
Angle Closure and Angle-Closure Glaucoma
IC
185
Management of Malpositioned IOLs
IC
186
Combined Cataract Surgery With Glaucoma Surgery:
Guidelines, Indications, Methods, Techniques, and
Postoperative Management
IC
189
A Video Symposium of Challenging Cases and the Management
of Intraoperative Complications During Cataract Surgery
IC
190
Decoding the Uveitis Workup: Why, When, and What to Order
IC
191
Ophthalmoscopic Evaluation of the Optic Disc and Retinal
Nerve Fiber Layer
IC
192
Practical Ocular Oncology for the Comprehensive
Ophthalmologist: What You Should Know
IC
193
Multifocal and Accommodative IOLs: Face the Challenge
IC
194
Practical Considerations for Telemedicine Diabetic Retinopathy
Screening
IC
195
Complications and Growing Applications in Collagen
Crosslinking: Diagnosis, Management, and Prevention
IC
199
Advances in Treatment of Severe Ocular Surface Disease:
Views From Experts on the Front Lines
IC
204
Seeing Is Believing: Spectral Domain OCT and Clinicopathologic
Correlation in Macular Diseases
IC
205
Descemet Membrane Endothelial Keratoplasty
IC
206
Pediatric Corneal Disorders: A Comprehensive Overview
ACADCAFE SYM54 Academy Caf: Retina
SKILLS
LAB119 Soft Contact Lens Fitting for the Practicing Ophthalmologist
SKILLS
LAB114A Macular OCT: Small Group Instruction
IC
168
Vision and the Artist
AAOEIC
211
Predictive Analytics: The New Face of Quality
AAOEIC
212
Fundamentals of Creating an Ophthalmic / Optometric Vision
Plan
IC
216
How to Handle Pediatric Traumatic Cataract
IC
217
Ocular Parasitoses: Diagnosis and Treatment
AAOEIC
219
How to Create a Professional Development Program for Your
Staff
AAOEIC
220
Compliance and Quality of Care
IC
543
Case Studies on the Use of Optical Coherence Tomography
(OCT) for Diagnosis of Unknown Causes of Visual Loss: Is it
the Retina, Anterior Visual Pathway, or Misinterpretation of
Normal?
SKILLS
LEC120 Implantation of Glaucoma Drainage Devices
SKILLS
LEC121 Diabetes 2014: Course on Diabetic Retinopathy
SKILLS
LEC122 Microsurgical Suturing Techniques
SKILLS
LEC123 Endoscopic Forehead and Eyebrow Elevation
Topic
Room
Page
CAT
North Hall B
128
PATH
Grand Ballroom 129

S100c
S406a
129
E350
129
GEN
PLAST
PM-RISK
S406b
251
GLA
PM-REMB
GLA
CAT
GLA
+
+
+
+
+
S103d
S501abc
S105bc
E353b
S403b
111
271
75
59
75
CAT
E451b
59
INTRA
GLA
+
+
E351
N139
79
75
PATH
S105a
82
CAT
RET
+
+
E353a
N427bc
59
92
COR
N140
66
COR
S106a
66
RET
E353c
93
COR
PEDS
RET
OPTIC
RET
HIST
PM-BUS
PM-MKT
+
+
$
$
+
+
+
S106b
N138
S404
N227a
N231
S105d
S502ab
S504d
67
87
122
114
120
83
267
276
PEDS
+
GO
+
PM-PROF +
N136
S103a
S504bc
87
78
278
PM-RISK
NEURO
+
+
S503ab
E352
273
81
+
+
+
+
S101ab
S102abc
S103bc
N427a
112
120
107
115
GLA
RET
CAT
PLAST
Programs-By-Day
2:00 - 4:00 PM
Type
39
Programs-By-Day
Time
3:15 - 5:30 PM
Type
No.
SKILLS
LEC124
Programs-By-Day
SKILLS
AAOEIC
AAOEIC
AAOEIC
IC
IC
IC
IC
3:30 - 5:30 PM
OP
SKILLS
SKILLS
SKILLS
SKILLS
SYM
3:45 - 5:15 PM
3:45 - 5:20 PM
4:00 - 5:30 PM
4:30 - 5:30 PM
40
SYM
Title
Endothelial Keratoplasty Surgery: Comprehensive Overview and

Surgical Pearls
LEC125 Phakic IOLs
208
A Practical Guide to Understanding and Negotiating Your First
Employment Agreement
209
Surgery Billing Made Easy for All Specialties
210
Human Resources and Your Practice: A Consultants Guide to
Improved Performance
213
Advanced Techniques With Laser Cataract Surgery
214
Atypical Keratitis
218
Femtosecond Cataract Surgery: Exploring the Limits
326
Pediatric Vitreoretinal Disorders: Current and Future
Management
OP03
Cornea, External Disease Original Paper Session
LAB102A Endothelial Keratoplasty Techniques
LAB110A Advanced Refractive Cataract Surgery and Anterior Segment
Reconstruction
LAB115A Introduction to Aesthetic Facial Surgery by Fractional Lasers,
Intense Pulsed Light, Radiofrequency, and Ultrasound Devices
LAB126 Workshop in Flap Techniques in Oculoplastic Surgery
SYM16 Tumors of the Brain and Orbits: Neuro-Ophthalmic
Considerations
SYM17 Adult Strabismus: Techniques to Alleviate Visual Discomfort
SYM
SYM18
SYM
SPOTLIT
SYM19
SPO2
OP
SKILLS
SKILLS
AAOEIC
AAOEIC
AAOEIC
AAOEIC
AAOEIC
OP04
LAB127
LEC128
221
222
223
224
225
IC
IC
IC
226
227
228
IC
IC
229
230
IC
231
IC
IC
IC
IC
IC
IC
IC
232
233
234
235
236
237
238
Structuring a Part-time Practice in the Evolving Medical

Environment: How to Make It Work
Ocular Drug and Gene Delivery to the Posterior Segment
Spotlight on Glaucoma: Medical and Surgical Management for
the Comprehensive Ophthalmologist
Cataract Original Paper Session
Workshop in Techniques of Lacrimal Intubation
Endoscopic Transnasal Lacrimal Surgery: Principles and Practice
ICD-10-CM: Simplifying the Complex
Managing Generation Y Employees
Business Strategies for the New Era
Identifying and Developing Trainers
Better Results from Bad Complications: Risk Management to
Avoid Lawsuits and Licence Investigations
Pediatric Uveitis: What You Need to Know
Pediatric Ocular Tumors
Top 10 Essentials of Gonioscopy: 3-D Viewing and
Interpretation
Intraocular Foreign Body Injuries: An Update
Ocular Surface Diseases in Cancer Patients: Update on Clinical
Spectrum and Treatment
Swollen Disks, Headache, and Vision Loss: A Case-Based
Approach to Pseudotumor Cerebri
Gonioscopy and Angle Imaging
Conjunctival Autografting in Pterygium Surgery, Simplified
Toxic Anterior Segment Syndrome Following Cataract Surgery
EHR and Meaningful Use for the Small Practice: Is It Worth It?
Allergic Eye Disease: An Enigma for Physicians
Identifying and Managing Unhappy Patients
From Front to Back: Managing Posterior Segment Sequelae of
Anterior Segment Surgery
Topic
Room
Page
COR
S104b
110
REF
+
PM-PROF +
N427d
S504a
119
278
PM-REMB +
PM-HMR +
S505ab
S501d
271
275
CAT
COR
CAT
RET
+
+
+
+
E451a
S102d
S104a
S403a
60
67
60
93
COR
COR
CAT
$
$
S405
N227b
N228
149
109
106
PLAST
N230
115
PLAST
NEURO
GEN
N226
Grand Ballroom
S100ab
Grand Ballroom
S100c
S406a
RET
GLA
E450
North Hall B
131
130
PEDS
116
130
131
131
CAT
PLAST
PLAST
PM-REMB
PM-HMR
PM-BUS
PM-HMR
PM-RISK
$
+
+
+
+
+
+
E350
N229
N427bc
S406b
S502ab
S504d
S501abc
S503ab
147
116
116
271
275
267
275
273
PEDS
PATH
GLA
+
+
+
N140
N139
S105bc
87
82
75
RET
COR
+
+
E351
E353c
93
67
NEURO
E352
81
GLA
COR
CAT
EHR
COR
GEN
CAT
+
+
+
+
+
+
+
S403b
S105a
E451b
E353a
S106a
S106b
N138
75
67
60
73
67
74
60
Programs-By-Day
Time
4:30 - 5:30 PM
No.
IC
IC
IC
239
240
241
IC
242
IC
243
AAOEIC
244
Title
Topic
Evaluation and Treatment of Facial Nerve Palsy

PLAST
Open Sesame: Dealing With the Small Pupil
CAT
Optimizing the Aesthetic Appearance of the Anophthalmic
PLAST
Socket
Improving Outcomes in Refractive Cataract Surgery With
CAT
Intraoperative Aberrometry Utilizing Streaming Refractive Data
Glued IOL: Scleral Fixation of Posterior Chamber IOL Without
CAT
Sutures in Absence of Capsular Support
Meaningful Use Stage 2, and How to Survive a Meaningful Use PM-EHR
Audit
Room
Page
+
+
+
S105d
N136
S103a
84
61
84
E353b
61
S103d
61
S504bc
274
Programs-By-Day
Type
Monday, Oct. 20 (cont.)

Time
7:30 - 8:30 AM
7:30 - 9:30 AM
7:30 - 10:00 AM
8:00 - 9:30 AM
Type
No.
8:00 - 10:00 AM
BWE
SKILLS
SKILLS
SKILLS
SKILLS
SKILLS
LAB122A
LAB123A
LAB113B
LAB118A
LAB129
8:00 - 10:30 AM
8:15 AM - 12:15 PM
SKILLS
SPOTLIT
LAB121A
SPO3
8:30 - 9:30 AM
SYM
SYM24
8:30 - 9:45 AM
8:30 - 10:00 AM
ACADCAFE
SYM
SYM55
SYM21
SYM
SYM22
SYM
SYM
SYM23
SYM44
SKILLS
SYM
AAOEIC
LAB130
SYM25
300
AAOEIC
AAOEIC
AAOEIC
IC
IC
IC
IC
IC
302
303
305
313
320
321
323
324
IC
325
AAOEIC
SKILLS
328
LEC131
SKILLS
LEC132
8:30 - 10:30 AM
8:30 - 11:00 AM
9:00 - 10:00 AM
9:00 - 11:15 AM
Title
Breakfast With the Experts Roundtables

Microsurgical Suturing Techniques
Endoscopic Forehead and Eyebrow Elevation
Phacoemulsification and Advanced Techniques
Ab Interno Approach to Schlemms Canal
Oculoplastic Surgery: Anatomic Foundations, Surgical
Techniques, and Enhanced Results
Diabetes 2014: Workshop on Diabetic Retinopathy
Spotlight on Cataracts: Clinical Decision-making With Cataract
Complications
Best of NANOS 2014: Featuring Best Papers from the North
American Neuro-Ophthalmology Society
Academy Caf: Uveitis
Leveraging Technology and the Educational Team
The Affordable Care Act: Present and Future Prospects for
Ophthalmology
Oculoplastics Oncology Update
A View Across the Pond: Retina
The iPhone and iPad for Ophthalmologists (Advanced)
Global Forum: Global Research
Income Division for Group Practices: Structuring Appropriate
Physician Compensation Arrangements
Three Areas of Succession Planning for Senior Physicians
ASC Administration, Operations, and Procedures
Health Law From the Patient Perspective
Glaucoma Filtration Device Mini-shunt: Friend or Foe?
Protecting Your Online Image
Scleral Buckling Surgery: A Forgotten Art!
Google Hangouts for Free Videoconferencing
Managing White Cataracts: Conventional and Femto-Assisted
Phacoemulsification
Nano-Ophthalmology: State of the Art, Practical Applications
and Perspectives
Financial Management of Your Practice
International Society of Refractive Surgery Laser Refractive
Surgery Course
Manual Extracapsular Cataract Extraction Surgery: Indications
and Techniques
Topic
CAT
PLAST
CAT
GLA
PLAST
$
$
$
$
$
$
Room
Page
Hall A
N227b
N229
N228
N230
N226
51
107
116
107
112
116
N231
North Hall B
120
132
NEURO
S405
133
INTRA
MEDED
S404
122
Grand Ballroom 133
S100c
S406a
133
RET
CAT
HP
PLAST
RET
134
134
COM
GO
PM-BUS
E350
Grand Ballroom
S100ab
$
N227a
S101ab
+
S501abc
PM-PROF
PM-ASC
PM-RISK
GLA
COM
RET
COM
CAT
+
+
+
+
+
+
+
+
S501d
S504d
S504a
S105bc
N427a
S106a
N427d
E352
278
267
273
76
65
94
65
61
CAT
S103a
61
PM-BUS
REF
+
+
S503ab
N138
268
119
CAT
S102d
108
109
134
267
41
Programs-By-Day
Time
9:00 - 11:15 AM
Type
No.
SKILLS
AAOESP
LEC133
SPE16
Programs-By-Day
AAOEIC
AAOEIC
IC
IC
IC
IC
IC
IC
IC
IC
IC
IC
IC
IC
IC
IC
9:00 AM - 5:00 PM
9:30 AM - 5:00 PM
10:00 - 11:30 AM
10:15 - 11:15 AM
10:15 - 11:30 AM
10:15 - 11:45 AM
IC
LL
TP
SKILLS
SKILLS
AAOEIC
AAOEIC
AAOEIC
IC
AAOEIC
SYM
SYM
SYM
10:15 AM - 12:30 PM
SKILLS
SKILLS
AAOEIC
IC
IC
42
Title
The Surgical Correction of Astigmatism

PQRS, Value Based Modifier, Meaningful Use and
Sequestration: Bonus and Penalties for 2014 and Beyond
301
Steps for Successful Retina Coding
304
Our Biller Is Leaving! How Do I Handle This Situation and Come
Out Ahead?
306
Medical and Surgical Therapy and Diagnosis of Uveitis
307
Systemic Therapeutic Agents and Retinal Toxicity
308
Ocular Surface Disease Management: Moving From Adequate
to Expert
309
Review of Clinical Optics
310
Glaucoma Postop Care in the Office: A Video Compendium of
TechniquesWhen and How to Intervene
311
Whats New and Important in Pediatric Ophthalmology and
Strabismus for 2014
312
Update on Treatments for Diabetic Retinopathy: Clinically
Relevant Results From the Diabetic Retinopathy Clinical
Research Network
314
Danger Zone: Refractive Surgery Nightmares and Worst-Case
Scenarios: A Video-Based Course
315
Tackling Weak Zonules and Using Capsular Tension Devices
316
Canal-Based Glaucoma Surgery: Canaloplasty vs. Microstent
ImplantationEverything You Want to Know
317
Help! A Corneal Ulcer Just Walked In! What Do I Do Next?
318
Diagnosis and Treatment of Polypoidal Choroidal Vasculopathy
319
Spectral Domain OCT Interpretation for the General
Ophthalmologist
322
Diagnosis and Management of Ocular Surface Disease due to
Systemic Conditions
327
Critical Issues in Management of Ocular Trauma
Learning Lounge
Technology Pavilion
LAB118B Ab Interno Approach to the Schlemm Canal
LEC136 Fat Grafting and Volume Restoration
329
Managing Up!
332
Simplifying EHR Security Audits
333
Red 80! Set! Lead! Leadership Lessons From a Football Coach
338
Vitreoretinal Tips for the Comprehensive Ophthalmologist:
When to Watch, Treat, or Refer
339
Incorporating the Four Agreements Into Your Practice
SYM41 Best of Anterior Segment Specialty Meetings 2014
SYM26 Clinical Pearls in the Diagnosis of Masquerades in Infectious
and Inflammatory Disease of the Eye
SYM28 New Frontiers of the Vitreoretinal Interface: Where Worlds
Collide
LEC134 Computerized Perimetry Lecture: Visual Field Testing and
Interpretation, Emphasizing Glaucoma
LEC135 Schlemm Canal Surgery: From the Outside In
331
Do You Know Your Cornea From Your Retina? Ocular Anatomy
and Physiology for Beginners
334
Current Topics in Cornea / External Disease: Highlights of the
Basic and Clinical Science Course 8
335
Retinal and Choroidal Manifestations of Selected Systemic
Diseases 2014
Topic
Room
Page
REF
+
PM-REMB
N427bc
S505ab
119
280
PM-REMB +
PM-BUS +
S504bc
S502ab
271
268
INTRA
RET
COR
+
+
+
S103d
S106b
E351
79
93
67
OPTIC
GLA
+
+
N140
S104a
83
75
PEDS
S403a
87
RET
S102abc
93
REF
S105d
89
CAT
GLA
+
+
E451b
S105a
61
76
COR
RET
RET
+
+
+
N136
S406b
E451a
68
94
94
COR
S104b
68
GEN
GLA
PLAST
PM-HMR
PM-EHR
PM-PROF
RET
$
+
+
+
+
+
N139
Booth 107
Booth 165
N230
S103a
S501abc
S503ab
S504d
N427a
74
253
258
112
117
275
274
278
94
PM-PROF +
S504a
GEN
S406a
Grand Ballroom
INTRA
S100ab
Grand Ballroom
RET
S100c
GLA
+
S105bc
275
135
135
112
GLA
PM-PROF +
N427d
S501d
113
278
136
COR
E352
68
RET
S106a
94
Programs-By-Day
Type
No.
Title
Topic
10:15 AM - 12:30 PM
IC
336
Lotions, Potions, Botulinum Toxin, and Fillers: Nonlaser

Rejuvenation for the Ophthalmologist
IOL Implantation in the Absence of Capsular Support
Academy Caf: Oculoplastics
Phakic IOLs
Surgical Pearls
Adjusting to the Changing Demographic: Valuing the Patient in
Determining Options for Treatment
Pediatric Ophthalmology, Strabismus Original Paper Session
Basic Oculoplastic Surgery
How to Use Free Technology to Add Interactivity to Face-to-Face
Lectures and Presentations
Advanced Techniques in Orbital Decompression and Expansion
Budgeting for the Ophthalmology Practice
Ophthalmology Practice Buy-Ins and Payouts
Lean Interactive Workshop for Clinic Process Improvement
Battling Information Overload: What Reports Do Owners and
Administrators Need?
E&M vs. Eye Codes: Who Is the Winner?
Strategies for Patient Access in a Consolidating World
Asian Blepharoplasty and the Eyelid Crease: Challenges and
Solutions: A Video-Complemented Course
Evolutions Witness: How Eyes Evolved
Simplifying Treatment of Diabetic Retinopathy for the
Comprehensive Ophthalmologist: What You Really Need to
Know in 2014
Retinal OCT Interpretation 101
Diplopia After Cataract and Refractive Surgery
Contact Lens in Ophthalmology Practice
Visual Fields in Neuro-Ophthalmology
Refractive Lensectomy: Indications, Lenses, Formulas,
Outcomes
Update on Intrastromal Corneal Ring Segments
Approach to Genetic Eye Diseases for the Comprehensive
Ophthalmologist
Ocular Surface Disease and Glaucoma
Genetics of AMD: Concepts and Controversy
Phototherapeutic Keratectomy for the Treatment of Anterior
Corneal Pathology
An Introduction to Error Disclosure for Ophthalmologists
Corneal Edema, Opacification and Ectasia: Diagnostic and
Treatment Strategies From the Preferred Practice Pattern
Guidelines
Third World Cataracts in the First World Setting
Meaningful Use Stage 2: Qualifying for Payment
Mycotic Keratitis: Novel Strategies Against Emerging
Pathogens
Hanging a Shingle in the 21st Century: Is a Start-up Solo
Practice Possible in 2015?
Is It Time to Replace Gonioscopy by Anterior Segment Imaging
in the Diagnosis and Management of Angle-Closure Glaucoma?
Innovation in Ophthalmology: From Theory to Therapy
PLAST
CAT
PLAST
REF
COR
IC
337
10:30 - 11:45 AM
ACADCAFE SYM56
10:30 AM - 12:00 PM SKILLS
LAB125A
10:30 AM - 12:30 PM SKILLS
LAB124A
10:45 - 11:45 AM
11:00 AM -12:00 PM
11:00 AM - 1:30 PM
11:30 AM - 12:30 PM
11:30 AM - 1:30 PM
12:15 - 1:45 PM
SYM
SYM29
OP
SKILLS
SKILLS
SKILLS
OP05
LAB128A
LAB137
LAB138
SKILLS
AAOEIC
AAOEIC
AAOEIC
AAOEIC
LEC139
330
340
341
342
AAOEIC
AAOEIC
IC
343
344
345
IC
IC
346
347
IC
IC
IC
IC
IC
348
349
350
351
352
IC
IC
353
354
IC
IC
IC
355
356
357
IC
IC
358
359
IC
IC
IC
360
361
362
AAOEIC
363
SKILLS
LAB140
SYM
SYM30
Room
Page
S403b
85
S103bc
S404
N228
N227b
61
122
119
111
E350
136
$
$
GEN
PEDS
PLAST
PLAST
MEDED
$
$
$
S405
N229
N226
N227a
157
116
117
109
PLAST
PM-BUS
PM-BUS
PM-BUS
PM-BUS
+
+
+
+
+
N138
S504d
S504a
S502ab
S504bc
117
268
268
268
268
S503ab
S501abc
S104a
271
276
85
+
+
S103d
S102abc
83
94
RET
PEDS
COR
NEURO
REF
+
+
+
+
+
E451b
N427bc
S105a
E351
S403a
95
88
68
81
89
COR
PEDS
+
+
S105d
E451a
68
88
GLA
RET
REF
+
+
+
S104b
N427a
N136
76
95
90
ETH
COR
+
+
S106b
S102d
73
68
CAT
EHR
COR
+
+
+
N140
N139
S103a
62
73
69
PM-BUS
S505ab
268
GLA
N231
113
PM-REMB +
PM-MKT +
PLAST +
HIST
RET
MEDED
Programs-By-Day
Time
Grand Ballroom 136

S100c
43
Programs-By-Day
Time
Type
No.
SYM31
SYM32
12:30 - 1:30 PM
SYM
SYM
PT
Telehealth is in Your Future

Beyond Ophthalmology
12:30 - 1:30 PM
SPE
SPE17
12:30 - 2:30 PM
12:45 - 1:45 PM
SKILLS
SPE
SPE
SYM
LAB120A
SPE12
SPE18
SYM33
SYM
SYM34
SYM
SYM35
1:00 - 2:30 PM
SKILLS
LAB132A
1:30 - 2:30 PM
SKILLS
LAB141
1:30 - 3:00 PM
2:00 - 3:00 PM
SKILLS
SYM
AAOEIC
AAOEIC
AAOEIC
LAB133A
SYM27
364
365
366
AAOEIC
367
AAOEIC
AAOEIC
AAOEIC
IC
IC
368
369
370
375
376
IC
IC
377
385
IC
IC
389
390
IC
391
IC
395
AAOEIC
SYM
SPOTLIT
396
SYM40
SPO4
SYM
SYM43
OP
SYM
OP06
SYM39
Welcome to the Real World: Reality 101 for Residents and

Fellows
Implantation of Glaucoma Drainage Devices
Ergonomics/Musculoskeletal Disorders in Ophthalmologists
Visual Impact of Traumatic Brain Injury: Lessons Learned
Dr. Allan Jensen and Claire Jensen Lecture in Professionalism
and Ethics
Why Take the Risk? How to Create an Effective Risk
Management Strategy With Patient Education and Informed
Consent Documents
Management of Retinal Breaks and Idiopathic Macular Holes:
Latest Diagnostic and Treatment Strategies from the New
Preferred Practice Pattern Guidelines
and Techniques
An Innovative Approach to Iris Fixation of an IOL Without
Capsular Support: Hands-on and Practical
Ethics and Professionalism: Why Should I Care?
CodeFest
Practice Valuations: Whats a Practice Worth Today?
Seven Key Differences Between Thriving Practices ... and
Average Practices
Physician Provider Cooperatives a New Concept in Health Care
Delivery
The Urge to Merge: When Two or More EHRs Collide
Management and Dashboard Reporting for the Retina Practice
How to Build and Manage a Dispensarys Frame Inventory
Artificial Iris Implantation
Visual Electrophysiology Testing: Principles and Clinical
Applications
Tips for Cosmetic Eyelid Surgery in Asian Patients
Anterior Segment Imaging: A Practical Guide for
Ophthalmologists
Genetic Testing in Ophthalmology
Adult Uveal Tumors: A Systematic Approach for the General
Ophthalmologist
Ocular Chronic Graft vs. Host Disease: Update and Case Studies
for Clinicians
Inadequate Capsular Support and IOL Fixation: Techniques From
the Vitreoretinal Surgeons Toolbox
Negotiating Payer Contracts in Todays Health-care Environment
Pediatric Vision Rehabilitation
Spotlight on Neuro-Ophthalmology: Things You Dont Want to
Miss
Lessons Learned from Recent Clinical Trials on Diabetic
Retinopathy
Cornea, External Disease Original Paper Session
Challenges in Cataract Surgery: Gems to Take Home and
Treasure
Programs-By-Day
12:15 - 1:45 PM
2:00 - 3:30 PM
2:00 - 4:00 PM
44
Title
Topic
COM
HIST
Meeting
PT
GEN
GLA
GEN
GEN
ETH
Room
Page
S405
S406b
Hall A
137
137
164
S101ab
251
N230
N427bc
S102abc
S406a
112
251
251
137
S403b
137
E350
138
GEN
RET
CAT
N228
108
CAT
N227a
108
REF
ETH
PM-REMB
PM-BUS
PM-MKT
$
+
+
+
N227b
S406a
S505ab
S501d
S501abc
120
138
271
269
276
PM-BUS
S503ab
269
PM-EHR
PM-BUS
PM-OPT
CAT
RET
+
+
+
+
+
S504a
S504bc
S504d
N427d
N138
274
269
277
62
95
PLAST
COR
+
+
N427bc
S104a
85
69
GEN
PATH
+
+
N136
S106a
74
82
COR
S104b
69
CAT
E352
62
PM-RISK
VIS
NEURO
RET
COR
CAT
S502ab
E350
Grand Ballroom
S100ab
Grand Ballroom
S100c
S405
North Hall B
273
138
138
139
151
139
Programs-By-Day
Time
2:00 - 4:15 PM
2:30 - 5:00 PM
3:00 - 5:00 PM
3:15 - 4:15 PM
3:15 - 5:30 PM
No.
Title
Topic
Room
Page
IC
371
RET
IC
IC
IC
IC
IC
372
373
374
378
379
IC
IC
380
381
IC
382
IC
383
IC
IC
IC
384
386
387
IC
388
IC
OP
SKILLS
393
OP07
LAB134A
SKILLS
SKILLS
SPE
SKILLS
AAOEIC
LAB139A
LAB142
SPE19
LAB135A
397
AAOEIC
398
AAOEIC
AAOEIC
AAOEIC
AAOEIC
IC
400
401
402
403
407
IC
IC
SKILLS
SKILLS
408
409
LEC143
LEC144
SKILLS
SKILLS
AAOEIC
LEC145
LEC146
399
IC
IC
404
405
IC
406
AAOEIC
410
Principles of Pediatric Retinal Surgery in Pediatric Retinal

Diseases Other Than ROP
Conquering Capsule Complications: A Video Primer
Periocular Tumors and Techniques of Eyelid Reconstruction
Advanced Evidence-Based Management of Diabetic Retinopathy
Diagnostic and Therapeutic Dilemmas in Neuro-Ophthalmology
Stereo Anatomy of the Orbit, Eyelid, and Lacrimal System: A
Surgeons Perspective
A Step-by-Step Primer to Starting LASIK in 2014
ROP Screening and Treatment: What You Wanted to Know but
Were Afraid to Ask (Intermediate/Advanced)
Understanding Nystagmus: A Practical Approach for the
Clinician
The Boston Keratoprosthesis: Case-Based Presentations
Highlighting the Essentials for Beginning and Experienced
Surgeons
The ABCs of AMD for Comprehensive Ophthalmologists
Fundamentals of Anterior Segment Reconstruction
Managing Angle-Closure Glaucoma With Crystalline Lens
Removal and Adjunctive Procedures
Posterior Segment Complications of Anterior Segment Surgery:
Prevention and Management
Surgical Management of Pediatric Glaucoma
Glaucoma Original Paper Session
Computerized Perimetry Lab: Visual Field Interpretation,
Emphasizing Glaucoma
Enucleation and Evisceration: Hands-On Practical Pearls
SO Special Program and Reception
Schlemm Canal Surgery: From the Outside In
American Academy of Ophthalmic Executives Book Club:
Professional Growth and Development
Employee Discipline for the Smaller Practice: The New
Manager, the Seasoned Manager, and the Doctor
How Do You Know Your Revenue Cycle Really Is Efficient?
Flow and Efficiency With the Femtosecond Laser
Space Planning: A Guide to the Effective Ophthalmic Facility
How to Survive the Endless Money Pit of EHR
Surgical Education: Improving Upon and Going Beyond the
Apprentice Model
Diagnosis and Management of Corneal Endothelial Diseases
Controversies in the Management of Corneal Infections
Toric Alignment Imaging and Astigmatism Surgery
Glaucoma Laser Therapy: Innovations and Advice From the
Experts
Glaucoma Filtration Surgery
Fundamental Facelifting Techniques
Compliance FAQs and NSFAQs (Not So Frequently Asked
Questions)
How to Evaluate a Patient With Uveitis
Mystery Retina 2014: Interactive Discussion of Challenging
Cases
Code Red: Mastering Phaco Nightmares and Worst-Case
Retina-Specific Panel Discussion: Ask Your Peers
N139
95
+
+
+
+
+
E451b
S103a
S105bc
E351
S102d
62
85
95
81
85
REF
PEDS
+
+
S103bc
N140
90
88
NEURO
S105d
81
COR
S103d
69
RET
CAT
GLA
+
+
+
E451a
S403a
S403b
95
62
76
CAT
S105a
62
PEDS
GLA
GLA
S106b
S404
N231
88
152
112
PLAST
PLAST
NON
GLA
PM-PROF
$
$
$
+
N229
N226
S101ab
N230
S504bc
117
117
251
113
278
PM-HMR +
S503ab
275
PM-BUS
PM-OPT
PM-BUS
PM-EHR
MEDED
+
+
+
+
+
S501d
S504a
S505ab
S504d
N136
269
267
269
274
80
COR
COR
CAT
GLA
+
+
+
+
S104a
N427a
N427bc
S106a
69
69
108
113
GLA
PLAST
PM-RISK
+
+
+
S104b
N427d
S502ab
113
118
273
RET
+
+
E352
S406b
79
96
CAT
S102abc
63
S501abc
269
CAT
PLAST
RET
NEURO
PLAST
PM-BUS
Programs-By-Day
2:00 - 5:30 PM
2:30 - 4:30 PM
Type
45
Programs-By-Day
Programs-By-Day
Time
46
Type
No.
Title
3:30 - 4:30 PM
SKILLS
LAB147
3:30 - 5:30 PM
SKILLS
3:45 - 5:00 PM
SKILLS
SYM
3:45 - 5:00 PM
3:45 - 5:15 PM
SYM
OP
SYM
SYM36
OP08
SYM37
Best of the Posterior Segment Specialty Meetings 2014

Oculoplastics Original Paper Session
Pediatric Orbital Disease
4:30 - 5:30 PM
SYM
AAOEIC
SYM38
411
AAOEIC
AAOEIC
AAOEIC
AAOEIC
AAOEIC
IC
412
413
414
415
416
417
IC
418
IC
419
IC
420
IC
IC
IC
421
422
423
IC
IC
IC
IC
424
425
426
427
IC
429
IC
IC
IC
IC
IC
430
431
432
433
606
Funding Our Future: Making Investments in Ophthalmology

Smile Even If It Kills You: Training for Excellent Customer
Service
Financial Decision Making in the Eye Care Practice
Coding for Ophthalmic Testing Services
Managing Your Online Reputation
What Happens After an EMR Implementation?
How to Hire, Train, and Manage your Staff
Complex Endothelial Keratoplasty: Current Strategies to
Improve Results and Avoid Complications
Intraoperative Floppy Iris Syndrome: Pearls for Management
and Prevention
Cell Biology, Genetics, and Outflow in Glaucoma in 2014: Impact
on Practice
Femtolaser: Diagnosis and Management of Intraoperative and
Postoperative Complications With the Use of a Femtosecond
Laser for LASIK Surgery
Normal-Tension Glaucoma: Evaluation and Treatment
Basic Browlift: Principles and Techniques
Follow the Cornea: Do You Know Where Your Corneal
Transplant Tissue Comes From?
Diagnosis and Management of Corneal Perforation
Cut, Lift and Fill: Three-Way Path to a 3-D Rejuvenation
Scleritis: What to Order and How to Treat It!
IOL Implantation and Repositioning Techniques for the
Vitreoretinal Surgeon
Less Than Perfect Outcomes After Uneventful Cataract Surgery:
What Are We Missing?
Enhancement and Retreatment After Refractive Surgery
Refining the Refractive Error After Premium IOLs
Diagnosis and Management of Acanthamoeba Keratitis
Congenital Ptosis Simplified
Resident, Faculty and Program Assessment: Principles & Best
Practices

Capsular Tension Support
LAB110B Advanced Refractive Cataract Surgery and Anterior Segment
Reconstruction
LAB131A Laser Refractive Surgery
SYM11 The Great Debate: Cornea
Topic
Room
Page
CAT
N227a
108
CAT
N228
107
REF
COR
140
156
141
HP
PM-MKT
N227b
Grand Ballroom
S100ab
S406a
S405
Grand Ballroom
S100c
E350
+
S505ab
PM-BUS
PM-REMB
PM-MKT
PM-EHR
PM-HMR
COR
+
+
+
+
+
+
S501d
S504bc
S503ab
S504d
S504a
S105d
269
272
277
274
276
70
CAT
E451a
63
GLA
S103a
76
REF
S103bc
90
GLA
PLAST
COR
+
+
+
E451b
E351
N139
76
85
70
COR
PLAST
COR
RET
+
+
+
+
S106b
S103d
S102d
N427a
70
85
70
96
CAT
S403a
63
REF
CAT
COR
PLAST
MEDED
+
+
+
+
+
S105a
N136
S403b
S104a
N140
90
63
70
86
80
RET
PLA
PEDS
119
139
141
277
Programs-By-Day
Time
Type
No.
BWE
SKILLS
LAB132B
8:00 - 10:00 AM
SKILLS
SKILLS
SKILLS
LAB136A
LAB131B
LAB144A
8:30 - 10:00 AM
SYM
SYM42
SYM
SYM45
SYM
SYM60
OP
SYM
OP09
SYM46
OP
AAOEIC
AAOEIC
AAOEIC
AAOEIC
IC
IC
IC
IC
IC
IC
IC
IC
AAOEIC
AAOEIC
OP10
501
503
504
505
506
513
514
517
518
519
522
524
525
526
AAOEIC
530
AAOEIC
IC
500
507
IC
IC
IC
508
509
510
IC
511
IC
IC
IC
512
515
516
IC
IC
IC
IC
LL
520
521
523
605
8:30 - 10:15 AM
8:30 - 10:30 AM
8:30 AM - 12:45 PM
9:00 - 10:00 AM
9:00 - 11:15 AM
9:00 AM - 12:00 PM
Title
Breakfast With the Experts Roundtables

and Techniques
Fat Grafting and Volume Restoration
Laser Refractive Surgery
Glaucoma Laser Therapy: Innovations and Advice From the
Experts
Focus on Practice Efficiency: How to Deal Effectively with
Increasing Patient Volume of the Aging Population
The Battle of Glaucoma: How to Diagnose, Assess, and
Manage Glaucoma That is Getting Worse
Ophthalmic Premier League: A Team Video Competition on
Managing Cataract Complications
Refractive Surgery Original Paper Session
Advanced Treatment of Ocular Surface Inflammatory Diseases
Retina, Vitreous Original Paper Session
Practice Problems: Practical Solutions
Work/Life Balance: Unrealistic Expectation or Achievable Goal?
Top 20 Tips for Optimal Billing
Is Cloud Computing the Future of EHR?
Management of Strabismus in Thyroid Eye Disease
Controversies and Advances in Pediatric Oculoplastic Surgery
Argon Laser Peripheral Iridoplasty: All You Need to Know
Global Trends in Retina: Learning From Each Other
Refractive Surgical Complications and Solutions
Intraocular Tumor Biopsy: The How, Why, and Why Not?
Reading, Dyslexia, and Vision Therapy
Keratoconus: The 2014 Protocol
Deciphering Financial Reports
A Review of Facility Regulatory Requirements for CMS
Accreditation
X,Y, Boom!: Supercharge Your Management of Employees and
Patients Through Awareness of Generational Differences
Comprehensive Cataract Coding
How to Successfully Accomplish Endothelial Keratoplasty in the
Presence of Significant Ocular Comorbidities
Low Vision Rehabilitation for Ophthalmologists
Emergency Neuro-Ophthalmology: Diagnosis and Management
Tubes, Ties, and Videotape: Surgical Video of Baerveldt
Glaucoma Implants and Managing Complications
Herpes Simplex Keratitis: When Herpes Isnt a Dendrite, and
Vice Versa
Advanced Vitreoretinal Surgical Techniques
Curbside Consults in Neuro-Ophthalmology
A Genetic Approach to Inherited Retinal Dystrophies: Clinical
Classification of Common Retinal Dystrophies, Genotyping, and
Gene Therapy
Complex Corneal Clinics: Logical Solutions
Update on Lacrimal Surgery
Controversies in Ocular Oncology
Evidence-Based Guidelines in the Management of Glaucoma
Learning Lounge
Topic
Room
Page
CAT
$
$
Hall A
N228
51
108
PLAST
REF
GLA
$
$
$
N229
N227b
N230
117
119
113
HP
GLA
Grand Ballroom 141

S100c
S406a
142
CAT
REF
COR
S404
Grand Ballroom
S100ab
S405
S504a
S504bc
S502ab
S504d
S103bc
S103d
S105bc
N427a
S102d
N136
S104a
S103a
S501abc
S501d
RET
PM-BUS
PM-PROF
PM-BUS
PM-EHR
PEDS
PLAST
GLA
GO
REF
PATH
PEDS
COR
PM-BUS
PM-BUS
+
+
+
+
+
+
+
+
+
+
+
+
+
+
North Hall B
142
158
143
160
270
279
270
275
88
86
76
79
90
83
88
71
270
270
PM-HMR +
S505ab
276
PM-REMB +
COR
+
S503ab
S106a
272
70
VIS
NEURO
GLA
+
+
+
S101ab
S406b
S403a
97
81
76
COR
N138
71
E451a
N427bc
S105d
96
82
96
S403b
S106b
S104b
N139
Booth 107
71
86
83
77
253
RET
NEURO
RET
+
+
+
COR
PLAST
PATH
GLA
+
+
+
+
Programs-By-Day
7:30 - 8:30 AM
8:00 - 9:30 AM
47
Programs-By-Day
Time
No.
TP
AAOEIC
AAOEIC
AAOEIC
AAOEIC
AAOEIC
AAOEIC
IC
IC
IC
IC
IC
502
527
528
529
531
532
535
536
540
541
544
Title
Technology Pavilion
Revenue Cycle Reimbursement Strategies
Strategic Planning by Fact
Making the Most With Modifiers
EHR: Great Expectations
LED)
ANCE
Divorcing Medicare
Commercial
Insurance
(Cand
HIPAA Compliance - Now That There is HITECH
Evaluation and Management of Orbital Cellulitis
Case-Based Approach to Isolated Eye Pain
Myasthenia Gravis or Not?
Surgical Simulators: Tool or Toy?
OCT in Glaucoma: Whats Real Disease and Whats Red
Disease?
AAOEIC
545
How ObamaCare Taxes Affect You: New Taxes, Hikes, Breaks,
Credits, and Other Changes
10:15 - 11:45 AM
SYM
SYM48 Decision Making in Contemporary Refractive Surgery
10:15 AM - 12:30 PM SKILLS
LEC149 Blepharoplasty
SKILLS
LEC150 Surgery for Severe Corneal and Ocular Surface Disease
IC
533
Learning Phaco Chop: Pearls and Pitfalls
IC
534
Managing Your EHR After Implementation
IC
537
Corneal Topographic Analysis and Anterior Segment Imaging:
Pearls for Your Clinical Practice
IC
538
Retinal Pharmacotherapy
IC
539
A Video Bouquet of Phaco Complications That Should Never
Have Occurred, With Tips on Damage Control and Prevention to
Optimize Postoperative Outcome
IC
542
Personalized Cataract Surgery: Femtosecond, Advanced
Technology IOLs, and New Devices
10:30 - 11:45 AM
ACADCAFE SYM57 Academy Caf: Cataract
10:30 AM - 12:00 PM SKILLS
LAB113C Phacoemulsification and Advanced Techniques Lab
10:30 AM - 12:30 PM SKILLS
LAB143A Toric Alignment Imaging and Astigmatism Surgery
10:45 - 11:45 AM
SYM
SYM49 International Opportunities for Young Ophthalmologists
Programs-By-Day
9:30 AM - 12:30 PM
10:15 - 11:15 AM
Type
48
10:45 AM - 12:15 PM
SYM
SYM20
11:00 AM - 12:30 PM
11:00 AM - 1:00 PM
11:30 AM - 12:30 PM
SKILLS
SKILLS
AAOEIC
AAOEIC
AAOEIC
AAOEIC
AAOEIC
LAB145A
LAB146A
546
547
548
549
551
AAOEIC
AAOEIC
IC
IC
552
553
554
555
IC
556
IC
557
IC
558
A View Across the Pond: Cornea Enigmas

Glaucoma Filtration Surgery Lab
Employment Law Basics for the Small Ophthalmology Practice
Optical Shops: Sales Strategies for Todays Economy
Ophthalmic Coding Specialist Prep Course
Practice Management Perspectives: A Case Study
Handling Ancillary Businesses: ASC, Optical, Real Estate,
Equipment, and Management Services
Youve Hired a New EmployeeNow What?
Managing Clinical Trials in Small and Large Practices
Meibomian Gland Dysfunction and Chronic Blepharitis
3-D Optic Disc Viewing: Top 10 Pitfalls in Identifying Glaucoma
Damage and Progression
Diplopia Made Ridiculously Simple: Management of Diplopia
for the Comprehensive Ophthalmologist
Cliffhanger: Vitrectomy by the Anterior Segment Surgeon for
the Broken Posterior Capsule, the Sinking Nucleus, and the
Dangling IOL
Management of Ocular Chemical Injuries
Topic
PM-BUS
PM-MKT
PM-REMB
PM-EHR
PM-BUS
PM-RISK
PLAST
NEURO
NEURO
CAT
GLA
+
+
+
+
+
+
+
+
+
+
+
PM-BUS
REF
PLAST
COR
CAT
EHR
REF
+
+
+
+
+
RET
CAT
+
+
CAT
CAT
CAT
CAT
GO
$
$
Room
Page
Booth 165
S501d
S504bc
S505ab
S501abc
S504a
S502ab
S105bc
E351
S104a
S103bc
S103d
258
270
277
272
275
269
273
86
82
82
64
77
S504d
270
S406a
N140
N427a
E451b
S102d
E352
143
118
111
63
73
90
N136
S102abc
96
63
S105a
64
S404
N228
N227b
Grand Ballroom
S100c
Grand Ballroom
COR
S100ab
GLA
$
N230
PLAST $
N229
PM-RISK +
S501abc
PM-OPT +
S504d
PM-REMB +
S504bc
PM-PROF +
S503ab
PM-BUS +
S504a
122
107
108
144
144
114
118
273
277
272
279
270
PM-HMR
PM-BUS
COR
GLA
+
+
+
+
S501d
S502ab
S406b
S105bc
276
271
71
77
PEDS
S103bc
89
CAT
E351
64
COR
S403b
71
Programs-By-Day
Time
Type
No.
11:30 AM - 12:30 PM
IC
IC
559
560
IC
IC
12:45 - 1:45 PM
IC
SPE
AAOEIC
IC
IC
IC
IC
IC
IC
IC
IC
IC
IC
IC
IC
12:45 - 3:00 PM
AAOEIC
IC
IC
1:00 - 2:30 PM
1:30 - 3:30 PM
2:00 - 3:00 PM
2:00 - 4:00 PM
2:00 - 4:15 PM
IC
SKILLS
SKILLS
IC
SKILLS
IC
IC
IC
IC
Topic
Vitreoretinal Surgical Rounds, Unleashed!

RET
Whats Your Next Step? Case Studies in Glaucoma
GLA
Management
561
Inflammatory Orbital Disorders and Their Differential Diagnoses PLAST
562
Failed Graft: Never Say Die!
COR
563
Pediatric Refractive Surgery
PEDS
564
Subjective Refraction and Prescribing Glasses 102
OPTIC
565
New Treatments for Retinal Vein Occlusion: Results from Phase
RET
3 Clinical Trials
566
Continuous 24-Hour IOP Monitoring: Ready for Prime Time?
GLA
567
Preventing Postoperative Endophthalmitis: What We Know,
CAT
What We Do Not Know, and Where We Should Go From Here
569
Pearls and Pitfalls of OCT in Glaucoma
GLA
D)
SPE20 The Resident Hub User
Session
ANCELE
(CGroup
570
Live Website Analysis: Critique Your Website
PM-MKT
GLA
572
Medical Therapy for Open-Angle Glaucoma: A Complete
Review of the Pharmacodynamics, Pharmacokinetics, and
Toxicity of All Potentially Useful Drugs
573
Understanding Ophthalmic Viscosurgical Devices to Optimize
CAT
Their Use in Cataract Surgery and Complications
575
Presbyopia, the Corneal Approach: State of the Art
REF
577
Evaluation and Treatment of Lower Lid Ectropion, Entropion,
PLAST
and Retraction
578
The Vertical Diplopia Dilemma, Made Simple
NEURO
579
Diabetic Vitrectomy
RET
580
Achieving Proper Centration and Alignment for Vision
CAT
Correction in Keratorefractive and Intraocular Surgery
581
Cataract Surgery and Uveitis: Controlling Inflammation, Difficult INTRA
Pupils, and Distorted Anatomy
582
Nightmares in Pediatric Cataract Surgery
PEDS
583
Intraoperative Biometry for High-fidelity Phaco Surgery
CAT
COR
584
Descemet Membrane Endothelial Keratoplasty: A Simplified
Technique to Shorten the Learning Curve and Avoid
Complications
585
Phacoemulsification in Eyes with Coexisting Vitreoretinal
CAT
Pathologies
586
Reimbursement in 2024
PM-PROF
571
Pterygium: The Outcome Measure Is Now Cosmesis, Not
COR
Recurrence
574
Update Your Anterior Chamber Angle Skills: How to Best
GLA
Examine, Grade, and Treat
576
Innovative Uses of Adhesives in Anterior Segment Surgery
COR
LAB104B Management of the Vitreous for the Anterior Segment Surgeon
CAT
LAB150A Surgery for Severe Corneal Ocular Surface Disease
COR
592
Top 10 Pitfalls, Problem Solving, and Interpretive Strategy for
GLA
Automated Threshold Perimetry
LAB149A Blepharoplasty
PLAST
587
EHR: Compliance and Medicolegal Issues
EHR
588
Difficult Strabismus Problems: Diagnosis and Management
PEDS
2014
589
Management of High-risk ROP in the 21st Century: ThermalRET
Destructive vs. Pharmacologic Treatment
590
Advanced IOL Power Calculations for the Cataract and
CAT
Refractive Surgeon
Room
Page
+
+
S104a
S105d
96
77
+
+
+
+
+
S103d
S403a
S103a
N427bc
N139
86
71
89
83
97
+
+
S106a
N138
77
64
+
+
+
E451a
N427a
S501d
S104b
77
251
277
78
S106a
64
+
+
S105a
S103bc
91
86
+
+
+
N427bc
S406b
S103a
82
97
64
E451b
80
+
+
+
S106b
S105d
S102d
89
64
72
S102abc
65
+
+
S504a
S403a
271
71
E352
78
+
$
$
+
S101ab
N228
N227b
S105bc
72
106
111
78
$
+
+
N229
S103a
S105d
118
73
89
S106b
97
E351
65
Programs-By-Day
IC
IC
IC
IC
IC
Title
49
Programs-By-Day
Time
Programs-By-Day
2:00 - 4:15 PM
3:15 - 5:30 PM
Type
No.
Title
Topic
Room
Page
IC
591
GLA
IC
593
CAT
IC
IC
594
595
IC
596
IC
597
IC
IC
598
599
IC
IC
IC
IC
IC
600
601
602
603
604
Complications Following Glaucoma Filtering Surgery: Face

Them Boldly, Manage Them Efficiently
Cataract Surgery in the Setting of Ocular Comorbidities
and High-risk Features for Intraoperative and Postoperative
Complications
Thyroid Eye Disease
How to Interpret Fundus Fluorescein Angiography and
Autofluorescence
Recent Developments in the Diagnosis and Management of
Conjunctival Tumors
The Art and Science of Glaucoma Drainage Devices: How to
Optimize Your Surgical Results
Advanced Corneal Topographic Analysis
Improving Success in Filtration Surgery: Intraoperative Surgical
Techniques and Postoperative Management of the Failing Filter
Should My Visually Impaired Patient Be Driving?
Femtosecond Laser for Cornea Surgery: The Actual Options
Complex Cataract and IOL Complications
Basic Deep Anterior Lamellar Keratoplasty
Next-Generation Technologies for the Diagnosis and Treatment
of Dry Eye and Meibomian Gland Dysfunction
N140
78
N427bc
65
+
+
S103bc
E451a
87
87
COR
S103d
72
GLA
S106a
78
REF
GLA
+
+
S104a
S105a
91
78
VIS
REF
CAT
COR
COR
+
+
+
+
+
S104b
S102d
S403b
N427a
S101ab
97
91
65
72
72
Topic
Room
Page
GEN
PLAST
RET
Wednesday, Oct. 22
Time
8:00 AM - 5:30 PM
50
Type
No.
SPE
SPE21
Title
28 Lo Mejor de la Academia en Espaol / 28th Best of the

Academy in Spanish
252
Westin
Michigan
Avenue Chicago
BREAKFAST
WITH THE EXPERTS
Sunday Tuesday, Oct. 19 - 21
7:30 - 8:30 AM
South, Hall A
Roundtable discussions are moderated by leading experts in the field. Attendees are encouraged to bring their individual questions and
cases for discussion.
Onsite Fee: $40
Breakfast With the Experts roundtables are not part of the Academy Plus course pass. Separate tickets must be purchased.
Members in Training automatically receive a 50% discount on all roundtables.
Fee includes a buffet breakfast.
After breakfast, feel free to use the roundtables area to meet-up with colleagues and network.
Selection Committee
Practice Management roundtables were selected by the AAOE Program Committee.The Annual Meeting Program Committee selected all
other roundtables. See page 33 for committee details.
51

Sunday, Oct. 19
Glaucoma
Cataract
Jointly sponsored by the Academys Annual Meeting Program Committee
and the American Society of Cataract and Refractive Surgery (ASCRS)
Roundtable B100
Successfully Incorporate Minimally Invasive Glaucoma Surgery Into

Your Practice
Moderator: John P Berdahl MD*
Roundtable B110
Managing Cataract in Angle Closure Surgery

Moderator: Pratap Challa MD*
Roundtable B111
Judging Glaucomatous Progression

Moderator: Gustavo De Moraes MD
Roundtable B112
Roundtable B101
Limbal Relaxing Incisions/Presbyopia IOLs
Breakfast With
the Experts

and the American Glaucoma Society (AGS)
Moderator: R Bruce Wallace MD**
Roundtable B102
Managing Complications of Tube Shunts, Including Tube Failure

Moderator: Herbert P Fechter MD
Global Ophthalmology
Femto Cataract Surgery

and the Global Education and Outreach Committee
Moderator: Bradley C Black MD**
Roundtable B103
Fuchs Endothelial Dystrophy: Preoperative Considerations for

Cataract Surgery
Roundtable B113
Moderator: Clara C Chan MD*
Moderator: Grace Sun MD
Roundtable B104
Global Ophthalmology: How to Start Volunteering Now!
Intraocular Inflammation, Uveitis
Intraoperative Aberrometry
Moderator: Sumit Garg MD*
Roundtable B105

and the American Uveitis Society (AUS)
Moderator: Kevin M Miller MD*
Roundtable B114
Maximizing Patient Outcomes With Multifocal IOLs
Approach to Patients With Uveitis: Back to Basics
Cornea, External Disease

and the Cornea Society
Roundtable B106
Moderator: John J Huang MD*
Roundtable B115
Optimizing Workflow and Outcomes in Uveitis Care

Moderator: Paul A Latkany MD
Neuro-Ophthalmology
Boston Keratoprosthesis
Moderator: Peter Zloty MD
Roundtable B107

and the North American Neuro- Ophthalmology Society (NANOS)
Moderator: Erich Bryan Groos MD
Roundtable B117
Herpes Simplex Keratitis
Ischemic Optic Neuropathy and Giant Cell Arteritis
Ethics
and the Ethics Committee
Roundtable B108
The Ethical Dimensions of Global Ophthalmology

Moderator: Hardeep S Dhindsa MD
Roundtable B109
Ethical Relationships Between Physicians and Industry

Moderator: Anthony J Aldave MD*
Moderator: Melissa W Ko MD
Roundtable B118
Glaucomatous Versus Nonglaucomatous Visual Loss: A Neuroophthalmic Perspective

Moderator: Lanning B Kline MD
Ocular Tumors and Pathology

and Women in Ophthalmology (WIO)
Roundtable B119
Clinical Pearls for Management of Eyelid and Conjunctival Tumors

Moderator: Bita Esmaeli MD FACS
52
* The presenter has a financial interest.

** The presenter has not submitted financial interest disclosure information as of press date. No asterisk indicates that the presenter has no financial interest.

Orbit, Lacrimal, Plastic Surgery
and the American Society of Ophthalmic Plastic and Reconstructive
Surgery (ASOPRS)

and the Senior Ophthalmologist Committee (SO)
Roundtable B130
Transitions in Practice: Slowing Down and Its Implications

Moderator: Paul N Orloff MD
Refractive Surgery
Roundtable B120
Ptosis Repair: How to Achieve the Best Results

Moderator: Jeremiah P Tao MD
Roundtable B121

and the International Society of Refractive Surgery (ISRS) Executive
Committee
How to Diagnose Brow Ptosis and Browplasty and Techniques to

Correct
Roundtable B131
Moderator: John Joseph Martin MD*
Moderator: Damien Gatinel MD*
Eyelid Neoplasms: From Mundane to Malignant

Moderator: Hakan Demirci MD
Roundtable B132
Customized Corneal Laser Refractive Surgery in Special Situations

Moderator: Raymond Stein MD
Pediatric Ophthalmology, Strabismus
Retina, Vitreous

and the American Association for Pediatric Ophthalmology and
Strabismus (AAPOS)

and the American Society of Retina Specialists (ASRS)
Roundtable B124
The Role of Genetic Testing in the Treatment of Patients with AMD
Amblyopia Best Practices: Pearls from the PEDIG Studies

Moderator: David K Wallace MD MPH
Practice Management / AAOE

Sponsored by the American Academy of Ophthalmic Executives (AAOE)
Ambulatory Surgery Centers
Roundtable B125
ASC Numbers for Nurses

Moderator: Albert Castillo*
Business Operations & Finance
Roundtable B133
Moderator: David S Boyer MD*
Roundtable B134
Treatment Algorithms for Refractory Macula Edema From Diabetes

and Venous Occlusive Disease
Moderator: Judy E Kim MD*
and the Macula Society
Roundtable B135
Dietary Supplements and Monitoring Patients at High Risk for

Neovascular AMD
Moderator: Emily Y Chew MD
Roundtable B126

and The Retina Society
Moderator: Daniel M Bernick JD*
Roundtable B136
Roundtable B127
Moderator: Howard F Fine MD MHS*
Negotiating Your Buy-In: the New Partner Perspective
Partnership Pitfalls: Preparing for the Unexpected
Management of Retinal Vein Occlusions and Macular Edema
Moderator: Robert J Landau JD
Compliance and Risk Management
Roundtable B128
MD/OD Relationships: Business and Compliance Concerns

Moderator: Robert A Wade JD
Professional Growth
Breakfast With
the Experts
Roundtable B122
Risk Factors for Post-LASIK Ectasia
Vision Rehabilitation
and the Vision Rehabilitation Committee
Roundtable B137
The Kickoff: Initiating Low Vision Services in Your Practice

Moderator: Joseph L Fontenot MD
Roundtable B129
Savvy Social Security, Medicare, and Retirement Planning for Baby

Boomer Physicians
Moderator: Donna W Howell JD

53

Monday, Oct. 20
Cataract
Roundtable B146
Ethical Research: A Need-to-Know Basis for You and Your

Patients
Moderator: Carla J Siegfried MD*

Roundtable B138
Cataract Surgery Pearls: Special Techniques That Every Cataract

Surgeon Should Know
Moderator: Bonnie A Henderson MD*
Roundtable B139
Breakfast With
the Experts

Roundtable B147
Conversations Around Ethical Challenges

Moderator: George L Spaeth MD FACS*
Complex IOL Calculations

Moderator: Mitchell P Weikert MD*
Roundtable B140
Roundtable B148
Reducing Trabeculectomy Complications

Moderator: Jody R Piltz-Seymour MD*
Management of the Broken Capsule and Advanced Vitrectomy

Technique
Roundtable B149
Moderator: Louis D Skip Nichamin MD*
Moderator: Leon W Herndon JR MD*
Roundtable B141
Improving Operating Room Efficiency

Moderator: Gary J Foster MD**
Insights Into Glaucoma and Emerging Corneal Procedures

Roundtable B150
Roundtable B176
Integrating Microinvasive Glaucoma Surgery Into Clinical Practice
Dysphotopsia
Moderator: Steven D Vold MD*
Moderator: Samuel Masket MD*
Roundtable B151
Roundtable B177
Treatment of Astigmatism in Cataract Surgery

Moderator: Jonathan B Rubenstein MD*

Roundtable B142
Deep Anterior Lamellar Keratoplasty

Moderator: Vincenzo Sarnicola MD
Roundtable B143
Endothelial Keratoplasty
Techniques to Prevent Scarring with Glaucoma Filtration Surgery

Moderator: Steven R Sarkisian MD*
and the Global Education and Outreach Committee
Roundtable B152
How to Develop a Partnership with an Institution in a Developing

Country
Moderator: David S Friedman MD MPH PhD*
Moderator: Natalie A Afshari MD*
Roundtable B181

Moderator: Vincent P De Luise MD FACS
Roundtable B153

Committee
Moderator: C Stephen Foster MD*
Herpes Simplex Keratitis
Preparing for and Performing Cataract Surgery in Patients with

Uveitis
Roundtable B154
Roundtable B144
Corneal Collagen Crosslinking Advances

Moderator: Arthur B Cummings MD*
Ethics
Roundtable B145
Digital Media and Ethical Patient Care

Moderator: Keith D Carter MD FACS
54
Glaucoma
A Rational Approach to the Use of Laboratory Testing in the

Diagnosis of the Uveitides
Moderator: Douglas A Jabs MD MBA*
Neuro-Ophthalmology
Roundtable B155
How to Use OCT in Neuro-ophthalmology

Moderator: Robert C Sergott MD*


Roundtable B156
Roundtable B165
Assessing Practice Profitability

Moderator: Ron Rosenberg PA MPH*
Professional Growth
An Inflamed Orbit: What Should I Do First? and Next?

Moderator: Louise A Mawn MD*
Roundtable B157
Neuroimaging for the Comprehensive Ophthalmologist

Moderator: Michael S Vaphiades DO*
Roundtable B158
Seeking Shelter Under the Hospital Umbrella: From Employment

Agreements to Professional Service Agreements
Moderator: Lawrence Geller MBA*
Roundtable B167
Neuro-ophthalmology for Fun and Profit

Moderator: Thomas C Spoor MD
and the Senior Ophthalmologist Committee (SO)
Results and Complications of Ocriplasmin for Vitreomacular Traction

and Macular Holes
Roundtable B168
Moderator: Mark W Johnson MD*
Moderator: Harry Zink MD*
Stopping Surgery: When, Why, and What It Means to Your Practice
Refractive Surgery

Surgery (ASOPRS)

Committee
Roundtable B159
Roundtable B169
New Evaluations of and Treatments for Orbital Inflammations

Moderator: Steven M Couch MD
Breakfast With
the Experts

Roundtable B166
Topography-Guided Excimer Treatments

Moderator: David Lin MD
Roundtable B160
Management of Congenital Tearing Patient

Moderator: Parag D Gandhi MD

Strabismus (AAPOS)
Roundtable B123
Pediatric Cataract
Moderator: Scott R Lambert MD*
Roundtable B161
Pediatric Glaucoma
Moderator: Sharon F Freedman MD
Retina, Vitreous
Roundtable B170
Use of OCT and Autofluorescence Imaging for Diagnosis of

Choroidal and Retinal Tumors
Moderator: Carol L Shields MD
Roundtable B171
Current Management of Diabetic Macular Edema

Moderator: Susan B Bressler MD*
Roundtable B162

Moderator: Sean P Donahue MD PhD*
Roundtable B172
Vision Screening: Whats New in 2014
Practice Management /AAOE

Roundtable B163
Ophthalmology Practice Valuation

Moderator: Mark E Kropiewnicki JD LLM*
Roundtable B164
Making Practice Mergers Work

Moderator: Debra L Phairas
Update on the Mangement of Diabetic Retinopathy and Diabetic

Macular Edema
Moderator: Tamer H Mahmoud MD*
Roundtable B173
Management of Dry and Wet AMD: 2014 Update

Moderator: K Bailey Freund MD*
and Women in Ophthalmology (WIO)
Roundtable B174
Update on Screening for Plaquenil Toxicity

Susanna S Park MD Ph

55

and the Vision Rehabilitation Committee
Roundtable B175
Understanding the Newer Non-trab, Non-tube Glaucoma Surgeries

Moderator: Malik Y Kahook MD*

The Practical Use of Low Vision Referrals in Your Practice: The

When, Why, and How of This Critical Tool for Patient Satisfaction
Roundtable B186
Moderator: Kirk H Packo MD*
Moderator: R Christopher Walton MD
Uveitis in the Elderly Patient
Roundtable B187
Tuesday, Oct. 21
Breakfast With
the Experts
Roundtable B185
Chronic Anterior Uveitis: Whats the Next Step?

Moderator: Wendy M Smith MD
Cataract
Roundtable B178
Adding Microinvasive Glaucoma Surgery (iStent and Trabectome) to

Your Cataract Surgery
Moderator: Reay Brown MD*
Neuro-Ophthalmology
Roundtable B116
What To Do With a Patient Who Presents with Anisocoria

Moderator: Sophia Mihe Chung MD*
Roundtable B188
Roundtable B179
Psuedophakic Monovision Pearls, Pitfalls, and Contraindications

Moderator: Fuxiang Zhang MD
Committee
Roundtable B180
Femtosecond-Assisted Lens Surgery
CANCELED
Moderator: Jonathan D Solomon MD

Roundtable B182
Idiopathic Intracranial Hypertension for the Comprehensive

Ophthalmologist
Moderator: Beau Benjamin Bruce MD PHD*
Roundtable B189
Nystagmus in a Child: When to Image

Moderator: Paul H Phillips MD

Surgery (ASOPRS)
Roundtable B190
Pediatric Considerations in Oculoplastic Surgery

Moderator: Cat Burkat MD
Pterygium Surgery
Moderator: Stephen C Kaufman MD PhD*
Ethics
Roundtable B183
Ethical Dilemmas in Emergency Ophthalmic Care

Moderator: R V Paul Chan MD
Roundtable B191
Fillers and Neurotoxins for Facial Rejuvenation

Moderator: Wendy W Lee MD*

Strabismus (AAPOS)
Roundtable B192
Glaucoma
Drug Treatment for ROP: Ready for Prime Time?

Moderator: Graham E Quinn MD*

Roundtable B184
Management of the Leaking Blebs, Dyesthesia, and Blebitis

Moderator: Mark B Sherwood MD*
56


Practice Management / AAOE
Roundtable B193
The Nuts and Bolts of Transitioning ASC Ownership

Moderator: Albert Castillo*
Breakfast With
the Experts
Roundtable B194
Negotiating Your Buy-In

Moderator: Mark D Abruzzo JD
Roundtable B195
A Physicians Guide to Avoiding Embezzlement

Moderator: Robert J Wade JD
Professional Growth
Roundtable B196
Employee Physician Contract Review

Moderator: Michael D Brown*
Roundtable B197
Mid-Career Planning: Its Not Too Early to Plan for the Next 20 or 50
Years
Moderator: Frank J Weinstock MD
Refractive Surgery
Committee
Roundtable B198
Innovations in Femtosecond Corneal Refractive Surgery

Moderator: Osama I Ibrahim MD PhD*
Retina, Vitreous
Roundtable B199
CANCELED
Choice of Anti-VEGF Treatment for Diabetic Macula Edema

Moderator: Jeffrey S Heier MD*
Roundtable B200
Which Biologic to Use to Treat Neovascular AMD

Moderator: Daniel F Martin MD
Roundtable B201
Imaging of the Retina and Vitreomacular Interface

Moderator: Amani Fawzi MD

57
INSTRUCTION COURSE
PROGRAM
H
Course received an overall course grade within the top 10% of its subject area based on 2013 attendee evaluation data.
SOE
Sponsored by the European Society of Ophthalmology.
NEW New course

SA
Designated as self-assessment credit and is pre-approved by the ABO for the Maintenance of Certification (MOC) Part II CME
requirements.
Eligible for Pain Management credit
EHR
Electronic Health Records
GO
SO
Endorsed by Senior Ophthalmalogist Committee
YO
Endorsed by Young Ophthalmalogist Committee
Academy Plus Course Pass

All Instruction Courses are part of the Academy Plus course pass.
Academy Plus offers maximum convenience, with unlimited access to all Academy and AAOE instruction courses. Individual tickets for
Academy and AAOE instruction courses are not sold.
Note: Due to Fire Marshal regulations, seating capacities are limited. Seating is available on a first-come basis, so please plan accordingly.
Selection Committee
The Annual Meeting Program Committee selected all instruction courses in this section. See page 33 for committee details.
58
Instruction Courses
H Management of Malpositioned IOLs
Cataract
H YO Best of the Best: An Update in Cataract Surgery
Course: 156
Room: E451a
Education Level: INT
Sunday
10:15 AM - 12:30 PM
Target Audience: COMPSUB
YO Cataract Surgery Crisis Management 101

Course: 157
Room: E353a
Education Level: ADV
Sunday
10:15 AM - 12:30 PM
Synopsis: Present-day cataract management requires that surgeons not only incorporate newer technologies but also update their skills in managing complications.
This course aims to identify complicated situations that every surgeon may encounter
during or after cataract surgery and to provide pearls to effectively manage such crises. It will illustrate critical management issues such as posterior capsule rupture,
phacoemulsification in challenging ocular environments, and dissatisfied premium IOL
patients.
Objective: To provide trouble shooting pearls for successful management of different intraoperative and postoperative complications during cataract surgery. The
attendees shall learn from the instructors video case demonstration and interactive
discussion.
Senior Instructor(s): Abhay Raghukant Vasavada MBBS FRCS*
Instructor(s): Robert H Osher MD*, Alan S Crandall MD*, Nick Mamalis MD*, Kevin M
Miller MD*, Samuel Masket MD*, Gerd U Auffarth MD*
Better Surgery Through Chemicals

Course: 171
Room: S105bc
Sunday
11:30 AM - 12:30 PM
Synopsis: This course will review the relevant pharmacology and physiology of
intracamerally and intravitreally applied agents that include mydriatics, anesthetics,
stains, ophthalmic viscosurgical devices, antioxidants, gas, steroids, antibiotics, and
anti-VEGF agents. Potential risks of these agents and compounding as well as regulatory issues will be discussed. A panel discussion and questions from the audience will
conclude the presentation.
Objective: Attendees will learn current options for intraocular administration of intraocular medications and other agents for prophylaxis of intraoperative floppy iris
syndrome and endophthalmitis and management of intraocular complications in intraocular surgery.
Senior Instructor(s): William G Myers MD*
Instructor(s): Minas T Coroneo MD MS*, David B Glasser MD, Steve A Arshinoff MD*,
William F Mieler MD*, Charles Leiter*, Hiroyuki Nakashizuka MD, Daniel G Dawson
MD, Neal H Shorstein MD*, John Wittpenn Jr MD*, Jeffrey Todd Liegner MD*,
Ramon Lorente MD
Sunday
2:00 - 4:15 PM
Synopsis: Early and late decentration / dislocation of IOLs represent significant

complications of current cataract surgery. This instruction course will consider the
etiology, possible prevention, and, primarily, the surgical management of malpositioned IOLs.
Objective: To (1) recognize the causes of IOL dislocation / decentration, (2) consider
prevention of malpositioned IOLs, and (3) through use of video presentations, demonstrate various surgical techniques for correction of IOL decentration / dislocation.
Senior Instructor(s): Samuel Masket MD*
Instructor(s): Amar Agarwal MD*, Nicole R Fram MD*, Sadeer B Hannush MD,
Thomas A Oetting MD
YO Comprehensive Strategy for Unplanned Vitrectomy

Technique for the Anterior Segment Surgeon
Course: 187
Room: E451a
Sunday
2:00 - 3:00 PM
Synopsis: This course will propose a strategy for prevention, early recognition, damage control, and specific plans for action to achieve an optimal outcome in cataract
surgery complicated by vitreous presentation. Anterior and pars plana approaches
will be detailed with ample video. The panel includes a retina-vitreous subspecialist.
Objective: By the conclusion of this course, cataract surgeons of all levels of expertise will be able to describe a strategy for choosing the method and the timing for
removal of residual lens material and for undertaking appropriate vitreous management, incision, and choice of IOL to achieve optimal outcomes in cataract surgery
involving vitreous presentation.
Senior Instructor(s): Lisa B Arbisser MD*
Instructor(s): Michael J Howcroft MD*
H A Video Symposium of Challenging Cases and the
Management of Intraoperative Complications During

Cataract Surgery
Course: 189
Room: E451b
Sunday
2:00 - 4:15 PM
Synopsis: This course will cover a spectrum of difficult cataract cases as well as a
potpourri of intraoperative complications. The video content is updated yearly.
Objective: This course will expose the surgeon to principles and techniques useful in operating difficult cases and in managing serious intraoperative complications.
Senior Instructor(s): Robert H Osher MD*
Multifocal and Accommodative IOLs: Face the Challenge

Course: 193
Room: E353a
Sunday
2:00 - 4:15 PM
Synopsis: We will review the state-of-the-art knowledge on presently available

multifocal and accommodative IOLs (MAIs). Their features, indications and contraindications, matching possibilities, and clinical results, pursuing highly satisfactory
uncorrected distance, intermediate, and near vision, will be examined. New multifocal
IOLs (ie, torics) will be discussed.
Objective: Attendees will receive information on how to use MAIs. A structured approach on patient and IOL selection based on accurate matching of IOL features with
patient needs will be provided. Discussion will include IOL performance in terms of
contrast sensitivity, light distribution and loss, and management of complications and
visual complaints, with available solutions. The importance of achieving plano results
will be well supported. At the end of this course, the attendee will be able to improve
Electronic Health Records. GO Global Ophthalmology. P Eligible for Pain Management credit. SA Designated as self-assessment credit. SO Endorsed by Senior
Ophthalmologist Committee. SOE Sponsored by SOE. YO Endorsed by Young Ophthalmologists committee. * The presenter has a financial interest.
EHR
59
Instruction Courses
Synopsis: This course will discuss how advances in technology, IOLs, phaco machines, femtolasers, hydrogel bandages, and indications are making cataract surgery
extremely similar to refractive surgery. The cataract surgeon must not only provide
restoration of vision but also optimal vision quality; the ideal, and increasingly demanded, result of cataract surgery is plano correction. This requires accurate customization of IOL choice, obsessively accurate biometry, adoption of new technologies
(microincision and premium IOLs: multifocal, toric, multifocal + toric, aspheric).
Objective: This course is designed to provide attendees with key information in
applying a refractive surgery approach to exploiting recent technological, surgical,
organizational, and patient management advances.
Senior Instructor(s): Matteo Piovella MD*
Instructor(s): David F Chang MD*, Steven J Dell MD**, Eric D Donnenfeld MD*,
Richard L Lindstrom MD**, Roger F Steinert MD*, Steven C Schallhorn MD*, Fabrizio I
Camesasca MD, Burkhard Dick MD*
Course: 185
Room: E353b
Instruction Courses
surgical center organization, choose the best IOLs for each specific patient, and manage possible postop complications.
Instructor(s): Jorge L Alio MD PhD*, Claudio Carbonara MD, David F Chang MD*, Jack
T Holladay MD MSEE FACS*, Barbara Kusa MD, Richard L Lindstrom MD**, Richard
Tipperman MD*
YO Pearls for Evaluating Corneal Topography in Patients
Scheduled for Cataract Surgery

Course: 196
Room: S102abc
Sunday
2:00 - 3:00 PM
Instruction Courses
Synopsis: Patients scheduled for cataract surgery can have surprisingly abnormal
corneal topography. This course will be led by a team of topography experts who will
help attendees identify and interpret corneal topographies in patients scheduled for
cataract surgery, and demonstrate how this information can help them optimize their
treatment plans. Both virgin corneas, as well as corneas with previous PRK, LASIK,
and radial keratotomy, will be discussed and analyzed by the faculty.
Objective: At the conclusion of the course, attendees will be able to analyze and
identify normal vs. abnormal corneal topographies in patients scheduled for cataract
surgery, and will be able to determine whether patients are eligible for toric or presbyopic IOLs, or for limbal relaxing incisions. Attendees will also be able to determine
whether their patients would be eligible for PRK or LASIK following cataract surgery,
or would potentially benefit from crosslinking.
Senior Instructor(s): William B Trattler MD*
Instructor(s): George O Waring MD*, Karolinne M Rocha MD, Renato Ambrosio Jr
MD*, Jodi Luchs MD*, Quentin B Allen MD*, David A Goldman MD*
Surgical Management of Astigmatism in Cataract and

Refractive Surgery
Jointly Sponsored by the Academys Annual Meeting Program Committee and
the International Society of Refractive Surgery (ISRS)
Course: 198
Room: S103bc
Sunday
2:00 - 3:00 PM
Synopsis: This course will teach strategies for minimizing surgically induced astigmatism, discuss surgical options for treating astigmatism during cataract and refractive surgery (including wound construction approaches, limbal relaxing incisions, toric
IOLs, and corneal refractive surgical techniques), and demonstrate methods to treat
postoperative astigmatism occurring after cataract and refractive surgery.
Objective: By the conclusion of this course, the participants will be able to (1) identify regular and irregular astigmatism, (2) understand surgical strategies to minimize
surgically induced astigmatism and determine treatment strategies for astigmatism,
including complex refractive errors and eyes not amenable to surgical treatment, and
(3) employ practical strategies for determining patient goals and desires for astigmatism correction.
Senior Instructor(s): J Bradley Randleman MD
Instructor(s): David T Vroman MD*
Advanced Techniques With Laser Cataract Surgery

Course: 213
Room: E451a
Sunday
3:15 - 5:30 PM
Synopsis: Basic certification in the use of a particular femtosecond laser confers

only a degree of facility with the technology. This course will provide a wide range
of real-world, experience-driven pearls and tips to enhance efficiency, safety, and efficacy when using the femtosecond laser.
Objective: At the conclusion of the course, the surgeon will have a better understanding of optimal patient selection, preoperative preparation, surgical planning,
60
surgical execution, and unexpected event management than prior to this educational
event.
Senior Instructor(s): Mark H Blecher MD*
Instructor(s): William W Culbertson MD*, William Wiley MD*, Kathryn Masselam
Hatch MD*, Burkhard Dick MD
NEW Femtosecond Cataract Surgery: Exploring the Limits

Course: 218
Room: S104a
Sunday
3:15 - 5:30 PM
Target Audience: COMP
Synopsis: This course will show video footage of challenging cases and provide
a systematic approach to managing them. The use of the femtosecond laser in advanced cataracts, pediatric cataracts, zonular instability, small pupil, eyes with corneal / media opacity, and for posterior capsulorrhexis will be demonstrated.
Objective: Attendees will learn to make laser and technique-related adjustments
to facilitate use of the femtosecond laser for challenging cataract surgery situations.
Senior Instructor(s): Surendra Basti MBBS*
Instructor(s): David M Lubeck MD*, Mitchell P Weikert MD*, Burkhard Dick MD*
NEW Toxic Anterior Segment Syndrome Following Cataract

Surgery
Course: 234
Room: E451b
Sunday
4:30 - 5:30 PM
Synopsis: Toxic anterior segment syndrome (TASS) is a sterile postoperative anterior

segment inflammation following cataract surgery. Common signs include immediate
onset (within 12-48 hours of surgery), blurred vision, diffuse corneal edema, marked
anterior segment inflammation, and iris / trabecular meshwork damage. The potential
causes include irrigating solutions, medications, problems with instrument cleaning
/ sterilization, contaminants, and IOL-related problems. Differentiating TASS from infectious endophthalmitis is critical. Treatment requires intense topical corticosteroids
with close follow-up.
Objective: At the conclusion of this course, the attendee will be able to identify the
signs and symptoms, causes, and treatment of TASS, as well as to differentiate this
entity from infectious postoperative endophthalmitis.
Senior Instructor(s): Nick Mamalis MD*
Instructor(s): Randall J Olson MD, Alan S Crandall MD*, Tat-Keong Chan MD FRCS
FRCOphth*
NEW From Front to Back: Managing Posterior Segment

Sequelae of Anterior Segment Surgery
Course: 238
Room: N138
Education Level: BAS
Sunday
4:30 - 5:30 PM
Synopsis: Posterior segment sequelae frequently arise after anterior segment surgeries, including cataract surgery and refractive procedures. Some of these changes
include retained lens fragments, endophthalmitis, retinal detachments, cystoid
macular edema, progression of diabetic macular edema, and onset of neovascular
AMD. Ongoing advances in current surgical techniques, diagnostic modalities, and
evidence-based standards of treatment have altered the way these sequelae should
be managed.
Objective: The objective of this course is to educate the ophthalmology community
regarding current strategies of preventing and managing these posterior segment sequelae through case presentations and discussion by an interactive panel of anterior
segment and posterior segment surgeons. At the end of the course, attendees will be
able to better manage their own posterior segment complications, know when to appropriately refer, and understand fundamental principles of vitreoretinal approaches
to these sequelae.
Senior Instructor(s): Paul Hahn MD PhD
Instructor(s): Christopher S Boehlke MD, Netan Choudhry MD*, Jessica B Ciralsky
MD*, Derek W Del Monte MD, Preeya K Gupta MD*, Anton Orlin MD, Lejla Vajzovic
MD
H Top 10% in subject area. NEW New Course. Education Level Key: BAS = Basic, INT = Intermediate, ADV = Advanced
Target Audience: COMP = Comprehensive Ophthalmologist, SUB = Subspecialist, COMPSUB = Comprehensive & Subspecialist, ADMIN = Administrators
Instruction Courses
NEW Open Sesame: Dealing With the Small Pupil
Course: 240
Room: N136
Sunday
4:30 - 5:30 PM
NEW Improving Outcomes in Refractive Cataract Surgery

With Intraoperative Aberrometry Utilizing Streaming
Refractive Data
Course: 242
Room: E353b
Sunday
4:30 - 5:30 PM
Synopsis: This course will review the impact of intraoperative aberrometry with
streaming refractive data on refractive cataract surgery. Faculty will present personal
and multicenter study results, cases, and clinical pearls and best practices for the use
of this technology in IOL power selection, toric IOL axis selection and positioning, and
placement of astigmatic incisions, in both manual and femtosecond laser cataract
surgery.
Objective: Attendees will learn how to use intraoperative aberrometry with streaming refractive data to improve outcomes in refractive cataract surgery.
Senior Instructor(s): Samuel Masket MD*
Instructor(s): Nicole R Fram MD*, Tal Raviv MD*, Steven D Vold MD*
NEW Glued IOL: Scleral Fixation of Posterior Chamber IOL

Without Sutures in Absence of Capsular Support
Course: 243
Room: S103d
Sunday
4:30 - 5:30 PM
Synopsis: Management of aphakia in the absence of capsular support remains a

challenge for the ophthalmic surgeon. Historical options have included anterior chamber IOLs and iris or scleral suture-fixated IOLs. This course introduces a relatively novel approach for sutureless scleral fixation of a foldable posterior chamber IOL (PC-IOL)
by the creation of intrascleral tunnels and the use of fibrin sealant. The procedure may
be offered through a small corneal incision, decreasing intraoperative complications
and allowing for quicker visual rehabilitation. It compartmentalizes the eye nicely into
anterior and posterior segments.
Objective: To describe the surgical technique of implanting a foldable PC-IOL in the
absence of capsular support with scleral fixation without sutures.
Senior Instructor(s): Sadeer B Hannush MD
Instructor(s): Amar Agarwal MD*, Iqbal K Ahmed MD*, Thomas A Oetting MD
H Tackling Weak Zonules and Using Capsular Tension

Devices
Course: 315
Room: E451b
Monday
9:00 - 11:15 AM
NEW Managing White Cataracts: Conventional and FemtoAssisted Phacoemulsification

Course: 324
Room: E352
Monday
9:00 - 10:00 AM
Synopsis: This instruction course aims to teach attendees pitfalls and tips to manage white cataract using conventional and femtosecond-assisted phacoemulsification. Problems associated with white cataract, such as hard, soft, and floating nuclei
and hypermature or intumescent-type, will be shown. Complications during capsulorrhexis, nuclear emulsification, irrigation-aspiration, and lens implantation such as zonular dehiscence, rrhexis problems, posterior capsule rent, and nucleus drop will be illustrated. Further challenges during phacoemulsification in white cataract associated
with small pupil and subluxated cataract will also be shown. These will be discussed
in relation to both the conventional and femtosecond platforms.
Objective: At the end of the course, the attendees will be well versed in the challenges faced in managing a white cataract using both the conventional and femtosecond-assisted phacoemulsification techniques.
Senior Instructor(s): Jeewan S Titiyal MD
Instructor(s): Namrata Sharma MD MBBS, Abhay Raghukant Vasavada MBBS FRCS*,
Rajesh Sinha, Tarun Arora
NEW SOE Nano-Ophthalmology: State of the Art, Practical

Applications and Perspectives
Course: 325
Room: S103a
Monday
9:00 - 10:00 AM
Synopsis: This course will describe in detail the existing applications of nanotechnology and nano-sized medications in the treatment of glaucoma, dry eye, diabetic
macular edema, uveitis, and pre-and post-phaco anti-inflammatory prophylaxis and
treatment, as well as novel and even more effective nano-approaches to the treatment of these diseases.
Objective: At the conclusion of this course, the attendees will be able to make informed decisions on the use of nano-sized medications or devices in their practices to
achieve improved clinical outcomes.
Instructor(s): Jorge L Alio MD PhD*, Dimitri Dementiev MD**, Anselm Kampik MD*,
John Marshall PhD*, Tatiana Naoumidi MD**
NEW IOL Implantation in the Absence of Capsular Support

Course: 337
Room: S103bc
Monday
10:15 AM - 12:30 PM
Synopsis: This course will cover various techniques of IOL implantation in the absence of proper capsular support. This includes anterior chamber IOLs, iris claw IOLs,
posterior iris claw IOLs, sulcus fixation IOLs, scleral fixation IOLs, Hoffman technique,
glued IOLs, etc. The course will go through the details of each and every technique
mentioned above.
Synopsis: This course will cover techniques, indications, and pitfalls for the use of
capsular tension devices (rings and segments), capsular retractors, and other surgical
EHR
61
Instruction Courses
Synopsis: This course will provide comprehensive instructions on strategies, devices, and techniques to tackle preoperative and intraoperative small pupil in phacoemulsification. Topics will include fluidics, viscomydriasis, iris hooks, pupil expansion rings
(Malyugin), and new pupil expansion rings (Bhattacharjee) for Biaxial MICS, 0.9-mm
incisions and shallow chambers. Stepwise instructions for each of these devices will
be provided. Anticipation, recognition, and management of intraoperative floppy iris
syndrome (IFIS) will be specially emphasized.
Objective: At the conclusion of this course, the attendee will be able to distinguish
the elastic small pupil of IFIS from the nonelastic small pupil due to other causes and
also develop a clear strategy to deal with a nondilating or constricting pupil with or
without a floppy and prolapsing iris, with judicious use of fluidics, viscoelastics, and
devices like iris hooks and rings.
Senior Instructor(s): Suven Bhattacharjee MS*
Instructor(s): Robert H Osher MD*, David F Chang MD*, Boris Malyugin MD PhD*,
Arup Chakrabarti MBBS
techniques in patients with capsular-zonular complex pathology. A strategy for preoperative evaluation and intraoperative clues to unstable or potentially unstable zonules
will be presented, and surgical approach and selection of capsular device(s) and techniques for implantation will be discussed. Strategies for avoidance and management
of complications will also be presented.
Objective: Participants will gain an understanding of the premise of and indications
for capsular tension devices, the use of adjunctive devices, specific techniques in
implantation, and potential complications.
Senior Instructor(s): Iqbal K Ahmed MD*
Instructor(s): Robert J Cionni MD*, Alan S Crandall MD*, Samuel Masket MD*,
Robert H Osher MD*, Kenneth J Rosenthal MD FACS**
Instruction Courses
Objective: Attendees will adapt to different techniques of IOL implantation in the
presence of posterior capsular rupture.
Senior Instructor(s): Mohan Rajan MD MBBS
Instructor(s): Sujatha Mohan MBBS, Amar Agarwal MD*, Richard S Hoffman MD*,
Robert H Osher MD*
affect the choice of implant to be used. They will also be able to describe common
intraoperative problems and their solutions.
Senior Instructor(s): Kevin M Miller MD*
Instructor(s): Samuel Masket MD*, Michael E Snyder MD*, Sathish Srinivasan
MBBS*
NEW Third World Cataracts in the First World Setting
Fundamentals of Anterior Segment Reconstruction
Course: 360
Room: N140
Course: 386
Room: S403a
Monday
11:30 AM - 12:30 PM
Instruction Courses
Synopsis: Although cataract surgery is the most common surgery performed in the
United States, there still exists a large portion of the U.S. population with mature
and even hypermature cataracts. This course will provide pearls from panelists experienced at handling the most difficult cases-from the rock-hard nucleus to the white
intumescent cataract. A range of experiences will be presented, along with tips on
when to attempt phacoemulsification vs. when to perform extracapsular cataract
extraction (ECCE), how to convert from phaco to ECCE, IOL management and repositioning, capsular tension rings, and management of complications. Additionally, focus
will be placed on postop management of intraoperative complications-including input
from a retina faculty member-when faced with loss of capsular support and nuclear
fragments slipping toward the retina.
Objective: At the end of the course, the attendee will be able to successfully manage patients with mature and hypermature cataracts efficiently and optimize challenging cases where complications occur.
Senior Instructor(s): Jennifer M Loh MD
Instructor(s): Amar Agarwal MD*, William B Trattler MD*, Geoffrey C Tabin MD,
Benjamin J Thomas MD, Andrew M Schimel MD**, Ashvin Agarwal MBBS
H Conquering Capsule Complications: A Video Primer

Course: 372
Room: E451b
Monday
2:00 - 4:15 PM
Synopsis: Video cases will illustrate a spectrum of techniques for anterior and posterior capsule complications: trypan blue dye, vitreous tap for crowded anterior chamber, torn continuous curvilinear capsulorrhexis (CCC) options, secondary CCC enlargement, flap tear-out rescue technique, posterior CCC, rrhexis capture of the optic, early
recognition of posterior chamber rupture, conversion from top/clear corneal incision
to extracapsular cataract extraction, posterior polar cataracts, IOL fixation with torn
anterior or posterior capsule, capsular tension ring and capsule hooks for weak zonules, small pupil / floppy iris strategies (hooks, Malyugin and other expansion rings,
epinephrine, Healon 5), pars plana bimanual anterior vitrectomy ( triamcinolone), and
ophthalmic viscosurgical device (OVD) posterior-assisted levitation (PAL) + trap for
descending nuclei.
Objective: To use video cases to systematically review techniques of preventing,
recognizing, and handling complications with either the capsulorrhexis or posterior
capsule.
Senior Instructor(s): David F Chang MD*
Instructor(s): Robert H Osher MD*
Artificial Iris Implantation

Course: 375
Room: N427d
Monday
2:00 - 3:00 PM
Target Audience: SUB
Synopsis: This course will provide an overview of artificial iris devices available
from Morcher, Ophtec, and HumanOptics. Indications, device availability in different
markets, preoperative planning, implantation tips, and outcomes will be discussed.
The effect of ocular comorbidities on the decision-making process will be reviewed.
The didactic discussion will be supplemented by surgical video. Devices to be discussed include modified capsule tension rings, iris reconstruction lenses, and foldable
silicone wafers.
Objective: At the conclusion of the course, attendees will be able to describe the
artificial irises available commercially and understand their directions for use. They
will know which devices are suitable for capsular bag implantation and which devices
are suitable for the sulcus. They will be able to discuss how ocular comorbidities
62
Monday
2:00 - 4:15 PM
Synopsis: This course will consist of didactic lecture, surgical video, and panel discussion highlighting various current topics in anterior segment surgery. Topics will
include iris repair, IOL exchange, sutured IOLs, anterior vitrectomy, use of iris and
capsule support devices, and complex cataract surgery. Instructive surgical video intertwined with didactic slides will be used as the building blocks for this instructional
course. Each case will focus on a common anterior segment situation and a technique
or techniques for proper management and/or repair of that scenario.
Objective: Attendees will learn several surgical techniques for the repair of the
anterior segment and how to apply these techniques in their own clinical practices,
thereby improving patient care.
Senior Instructor(s): Brandon Ayres MD*
Instructor(s): William Barry Lee MD*, George O Waring MD*, Elizabeth Yeu MD*,
John P Berdahl MD*, Jeremy Z Kieval MD*
NEW Posterior Segment Complications of Anterior

Segment Surgery: Prevention and Management
Course: 388
Room: S105a
Monday
2:00 - 4:15 PM
Synopsis: This course will include lectures, images, and panel and interactive discussions of risk factors, early recognition, and management of posterior segment
complications of anterior segment surgery. A panel of anterior segment and vitreoretinal surgeons will discuss their perspectives. Topics include dislocated lens fragments,
dislocated IOL, cystoid macular edema, exacerbation of diabetic macular edema, microscope toxicity, choroidal hemorrhage, and endophthalmitis.
Objective: Attendees will be able to recognize risk factors, preventive steps, and
issues involved in the management of posterior segment complications of anterior
segment surgery.
Senior Instructor(s): David S Boyer MD*
Instructor(s): Homayoun Tabandeh MD MS FRCP FRCOphth*, Kourous Rezaei MD*,
Harry W Flynn MD, John D Hofbauer MD*, Afshin J Khodabakhsh MD*
NEW Inadequate Capsular Support and IOL Fixation:

Techniques From the Vitreoretinal Surgeons Toolbox
Course: 395
Room: E352
Monday
2:00 - 3:00 PM
Synopsis: This course will address surgical strategies for IOL fixation in the absence
of capsular support. We will review the techniques, outcomes, and complications
of scleral- and iris-sutured IOLs and anterior chamber IOLs. Contemporary methods,
including sutureless scleral fixation, transconjunctival scleral pocket fixation, and a
microincisional technique for capsular rescue, will be illustrated in detail with surgical video.
Objective: Attendees will develop an approach to IOL fixation in the absence of
capsular support using new methods, including sutureless scleral fixation, transconjunctival scleral pocket fixation, and microincisional capsular rescue. Evidence-based
recommendations will guide attendees in appropriate case selection.
Senior Instructor(s): Yannek I Leiderman MD PhD
Instructor(s): Jonathan Prenner MD*, Matthew Wheatley MD
Instruction Courses
H Code Red: Mastering Phaco Nightmares and Worst-Case
IOLs
Course: 406
Room: S102abc
Course: 431
Room: N136
Monday
3:15 - 5:30 PM
NEW SOE Refining the Refractive Error After Premium

Monday
4:30 - 5:30 PM
Synopsis: This course will first discuss the guidelines for managing refractive errors
after premium IOLs, such as avoidance, causes, diagnosis, and timing of management. Second, different methods of improving the refractive errors will be discussed.
This includes corneal solutions (femto astigmatic keratotomy, limbal relaxing incision,
LASIK, PRK) and intraocular solutions (IOL exchange, redialing, capsule manipulations,
etc.). The course will give a plan for each individual case.
Objective: At the conclusion of the course, attendees will be able to plan the best
procedure of refining the refractive error following premium IOL according to each
case.
Senior Instructor(s): Mounir A Khalifa MD
Instructor(s): David R Hardten MD*, Scott M MacRae MD*, Matteo Piovella MD*
H YO Intraoperative Floppy Iris Syndrome: Pearls for
Synopsis: Phaco chop minimizes ultrasound time and zonular stress. Pearls and
strategies for learning this technique will be presented, based upon the instructors
experience in teaching residents. Using a special projection system, the audience will
don stereo glasses to view 3-D high-definition videos that uniquely illustrate the angle
and depth of the instrument tips for both horizontal (Nagahara) and vertical (quick
chop) methods of chopping. A stepwise game plan for converting to phaco chop will
be presented, along with phacodynamics principles for selecting machine parameters
and instrumentation.
Objective: This course will present both variations of the phaco chop technique,
their advantages in complicated cases, the instrumentation, machine parameters, and
transition steps involved, and common mistakes.
Instructor(s): Randall J Olson MD, Louis D Skip Nichamin MD*, Barry S Seibel MD**
Management and Prevention

Course: 418
Room: E451a
Monday
4:30 - 5:30 PM
Synopsis: Intraoperative floppy iris syndrome (IFIS) continues to challenge cataract

surgeons. In this course multiple different surgical methods will be discussed in detail, with the goal of arming surgeons with a range of complimentary strategies. These
include intracameral alpha agonists, ophthalmic viscosurgical device strategies, phaco techniques, iris retractors, and pupil expansion devices, including the Malyugin
ring. This course will also review what is known about the pharmacologic basis and
mechanism of IFIS.
Objective: To update anterior segment surgeons on the latest clinical information
about benign hyperstatic hypertrophy pharmacology and the preoperative and intraoperative management of IFIS.
Instructor(s): Steve A Arshinoff MD*
NEW Less Than Perfect Outcomes After Uneventful
Cataract Surgery: What Are We Missing?

Course: 429
Room: S403a
Monday
4:30 - 5:30 PM
Synopsis: This course will deal with causes of less than perfect outcomes after uneventful cataract surgery. A definite game plan for dealing with these disgruntled
postoperative patients is presented. Topics covered will be a brief overview of the
common causes of poor visual outcome after uncomplicated cataract surgery, such
as ocular surface disease, keratitis medicamentosa, undetected preoperative astigmatism, problems with multifocal IOL implants, early posterior capsular opacification,
dysphotopsia, IOL decentration due to buttonholing, capsular bag decentration, unexpected postoperative ametropia, and subtle macular pathologies. The importance
of a thorough evaluation to rule out the entities responsible, as well as preoperative
counseling, will be emphasized.
Objective: At the end of the course the attendee will become competent in managing their dissatisfied patients who have less than perfect outcomes after uneventful
and uncomplicated cataract surgery.
Senior Instructor(s): Meena Chakrabarti MBBS
Instructor(s): Arup Chakrabarti MBBS, Samuel Masket MD*, Kevin M Miller MD*,
Thomas A Oetting MD, Parag A Majmudar MD*, Anthony J Aldave MD*
H YO Learning Phaco Chop: Pearls and Pitfalls

Course: 533
Room: E451b
Tuesday
10:15 AM - 12:30 PM
H A Video Bouquet of Phaco Complications That Should

Never Have Occurred, With Tips on Damage Control and
Prevention to Optimize Postoperative Outcome
Course: 539
Room: S102abc
Tuesday
10:15 AM - 12:30 PM
Synopsis: This video course deals with the genesis, management, and prevention
of unexpected surgeon- or technique-related complications in phacoemulsification
in uncomplicated cataracts. The course will demonstrate complications that may be
encountered during all steps of phaco (both uncomplicated and difficult cataracts)
and will offer a stepwise strategy to prevent and manage them. Complications and
remedial measures demonstrated include wound burns, wound length anomalies,
capsulorrhexis extension and retrieval, two-stage rrhexis, use of microrrhexis forceps
/ scissors in tricky cases, incomplete / difficult hydrodissection, hurdles in phaco chop,
misplaced capsular tension ring, inappropriately used iris hook, how to convert to a
safer nonphaco technique in problem situations, and more.
Objective: At the end of the course, the attendee will have learned how to avoid and
successfully manage certain intraoperative phaco complications that can not only mar
the postoperative outcome but can also lead to sight-threatening sequelae.
Senior Instructor(s): Arup Chakrabarti MBBS
Instructor(s): Thomas A Oetting MD, Amar Agarwal MD*, Kevin M Miller MD*, Abhay
Raghukant Vasavada MBBS FRCS*, Samuel Masket MD*, Khiun F Tjia MD*, Jeewan
S Titiyal MD, Arulmozhi Varman MBBS DO MS
EHR
63
Instruction Courses
Synopsis: Code red signifies danger, and its best to be prepared for such cases.
Endocapsular rings for subluxated cataracts, prosthetic irides, and pupil expanders
are secrets for mastering phaco surgerys worst-case scenarios. Intraoperative floppy
iris syndrome, IOL implantation in eyes with deficient capsules, and glued IOLs will
all be explained in this course. Vitreous loss, torn rrhexis management, and other
complication management will also be covered. Management of dropped lenses, hard
cataracts, posterior capsular ruptures, and the like will all be explained with excellent
videos. From basic complications to nightmare situations, all will be covered in this
course. Questions from the audience will be discussed so that attendees will be able
go back to their practices and manage any situation.
Objective: At the conclusion of this course, the attendee will be able to master
difficult phaco cases and manage various complications without developing a heart
attack.
Senior Instructor(s): Amar Agarwal MD*
Instructor(s): David F Chang MD*, Robert H Osher MD*, Athiya Agarwal MD, Iqbal K
Ahmed MD*, Brian C Little MD*
Instruction Courses
NEW SOE Surgical Simulators: Tool or Toy?
Course: 541
Room: S103bc
Tuesday
10:15 - 11:15 AM
Instruction Courses
Synopsis: Many tools are available to simulate cataract surgery, from traditional
wet lab experience to virtual reality computer simulation. Effective surgery simulation is essential for training; however, the time and cost of establishing a surgical
simulation program is significant. This course will discuss the spectrum of phacoemulsification simulation tools and their respective strengths and weaknesses. Three
distinct examples of surgical training through integration of surgical simulation from
the Flaum, Wilmer, and Moran Eye Institutes will be presented. Simulation systems
discussed will include the Kitaro wet and dry lab system, the EYESi VR Magic simulator, and the ImmersiveTouch MicroVis simulator.
Objective: At the conclusion of this course, the attendee will (1) know the spectrum of surgical simulation tools available, (2) understand the respective strengths
and weaknesses of available tools, and (3) know how to implement a systematic,
structured, surgical simulation curriculum for training.
Senior Instructor(s): Jeff H Pettey MD
Instructor(s): Yousuf M Khalifa MD, Shameema Sikder MD*
NEW SOE Personalized Cataract Surgery: Femtosecond,

Advanced Technology IOLs, and New Devices
Course: 542
Room: S105a
Tuesday
10:15 AM - 12:30 PM
Synopsis: Several new technological advancements are progressively transforming

cataract surgery into a personalized procedure. Femtosecond laser provides customized incisions and anterior and posterior capsulorrhexis, advanced technology IOLs
solve several refractive problems (ie, astigmatism, distance and near vision), and new
phaco technology and instruments facilitate complex cases and reduce occurrence
of complications. This course will discuss the targets of final plano refraction, reduction of surgical time, and intraoperative and postoperative (ie, better incision sealing)
complications.
Objective: This course will provide an update on the possibilities of customizing
cataract surgery to patient characteristics and needs through the use of new technological advancements.
Instructor(s): Jorge L Alio MD PhD*, Steve A Arshinoff MD*, Jack T Holladay MD
MSEE FACS*, Barbara Kusa MD, Richard L Lindstrom MD**, Zoltan Nagy MD*,
Stephen S Lane MD*
H Cliffhanger: Vitrectomy by the Anterior Segment Surgeon
for the Broken Posterior Capsule, the Sinking Nucleus, and

the Dangling IOL
Course: 557
Room: E351
Tuesday
11:30 AM - 12:30 PM
Synopsis: Every anterior segment surgeon faces the problem of a broken posterior
capsule at some time or another and should know how to perform vitrectomy. One
should also know how to manage a dropped nucleus or sinking fragments. In this
course, various techniques like the posterior-assisted levitation technique (PAL) and
others will be taught, including how to perform bimanual vitrectomy. The dangling
IOL and fixation of a posterior chamber IOL in eyes without capsule support using the
glued IOL technique will also be taught. The management of these various challenges
will be explained through videos.
Objective: At the end of the course, the attendee will be able to fix an IOL in eyes
without capsules, retrieve sinking lens fragments, and also do a thorough vitrectomy
when required.
Instructor(s): David F Chang MD*, William F Mieler MD*
64
NEW SOE Preventing Postoperative Endophthalmitis:

What We Know, What We Do Not Know, and Where We
Should Go From Here
Course: 567
Room: N138
Tuesday
11:30 AM - 12:30 PM
Synopsis: Presenting scientific findings from an evidence-based perspective as a

foundation, we will consider current clinical practices and outcomes from around the
world with an eye toward future research.
Objective: (1) To define the proven prophylaxis of postoperative endophthalmitis, (2)
To describe the problem of resistance, (3) To describe host and surgical risk factors for
endophthalmitis, (4) To describe current standard of care in the United States, (5) To
describe current standard of care in the European Union, and (6) To describe current
standard of care in Asia.
Senior Instructor(s): Andrzej Grzybowski MD*
Instructor(s): Mark Packer MD*, George Beiko MD*, Soosan Jacob FRCS
Understanding Ophthalmic Viscosurgical Devices to

Optimize Their Use in Cataract Surgery and Complications
Course: 573
Room: S106a
Tuesday
12:45 - 1:45 PM
Synopsis: This course will consist of a slide and video presentation of rheologic
properties, classification, and varied utilization techniques for different ophthalmic
viscosurgical device (OVD) types. New OVDs, recent discoveries, and principles and
techniques to prevent and manage complications and postoperative IOP spikes will be
covered. Ample opportunity for discussion will be available.
Objective: At the conclusion of this course, attendees will have gained (1) insight
into the rheologic properties and surgical behavior of different OVDs and (2) understanding about choice and optimal use of OVDs. This will enhance attendees skills in
surgery and complication management.
Senior Instructor(s): Steve A Arshinoff MD*
Achieving Proper Centration and Alignment for Vision

Correction in Keratorefractive and Intraocular Surgery
Course: 580
Room: S103a
Tuesday
12:45 - 1:45 PM
Synopsis: This lecture and video-based course will demonstrate how to center and
align keratorefractive and intraocular devices and procedures for vision correction.
Pearls on interpreting diagnostic testing, including corneal topography and pupil
imaging, will be presented. Techniques for achieving good alignment and centration
of diffractive multifocal and toric IOLs, limbal relaxing incisions, and corneal inlaysincluding the importance of angle kappa-will be demonstrated and discussed.
Objective: At the conclusion of this course, attendees will be able to apply practical
techniques, including the use of common imaging studies, to achieve good centration
and alignment in keratorefractive and intraocular surgery.
Senior Instructor(s): Daniel H Chang MD*
Instructor(s): George O Waring MD*, John P Berdahl MD*
NEW Intraoperative Biometry for High-fidelity Phaco

Surgery
Course: 583
Room: S105d
Tuesday
12:45 - 1:45 PM
Synopsis: The course will present the latest advances in intraoperative diagnostics
and imaging for phaco cataract surgery, with a focus on intraoperative aberrometry.
The faculty will discuss key aspects of the technology and how it can improve surgical
outcomes in both standard and challenging cases.
Instruction Courses
Objective: The is to provide a concise and practical primer of intraoperative refractive biometry for the cataract surgeon.
Senior Instructor(s): Tsontcho Ianchulev MD*
Instructor(s): Kenneth J Hoffer MD FACS*, Mark Packer MD*, David F Chang MD*,
Farrell Tyson II MD**, P Dee G Stephenson MD FACS*
NEW Phacoemulsification in Eyes with Coexisting

Vitreoretinal Pathologies
Course: 585
Room: S102abc
Tuesday
12:45 - 1:45 PM
H Advanced IOL Power Calculations for the Cataract and

Refractive Surgeon
Course: 590
Room: E351
Tuesday
2:00 - 4:15 PM
Synopsis: The indications for an IOL implantation following cataract or clear lensectomy have significantly increased. Techniques for determining the proper IOL and
power will be presented.
Objective: This course will provide clear methods and techniques for determining
the proper IOL and power for complicated cases and will familiarize the clinician with
indications and limitations of specialty lenses, such as multifocal and toric IOLs.
Senior Instructor(s): Jack T Holladay MD MSEE FACS*
H Cataract Surgery in the Setting of Ocular Comorbidities

and High-risk Features for Intraoperative and Postoperative
Complications
Course: 593
Room: N427bc
Tuesday
2:00 - 4:15 PM
Synopsis: Ocular comorbidities and high-risk characteristics for intraoperative and

postoperative complications occur with surprising regularity in cataract surgery patients. Ocular comorbidities often reduce visual potential. Systemic comorbidities
and other characteristics of the eye or patient are often associated with a high risk
of intraoperative and postoperative complications. In this course, a faculty of internationally recognized experts in cataract surgery will discuss a variety of common
comorbidities and high-risk characteristics, the unique problems they present, and
strategies for achieving successful visual and surgical outcomes.
Objective: At the conclusion of this course, the attendee will be able to identify a
variety of ocular comorbidities and high-risk eye and patient characteristics for surgi-
NEW Complex Cataract and IOL Complications

Course: 602
Room: S403b
Tuesday
2:00 - 4:15 PM
Synopsis: This course has two major areas of focus: the first is the complex cataract,
and the second is implant complications. The course will be primarily video based, but
some didactic lecture will also be presented. Lively discussion between the panelists
and attendees will also be encouraged. Topics to be covered include the white and
brunescent lens, traumatic cataracts, zonular instability, innovative use of intraoperative aberrometry, and anterior vitrectomy. Implant complications will also be covered,
including management of dislocated IOLs, techniques for scleral and iris fixation of
implants, and IOL exchange.
Objective: At the conclusion of the course attendees will learn both the fundamental concepts and surgical techniques to deal with complex cataracts and implant
dysfunction. Attendees should be able to directly apply what is learned to their own
clinical practice improving patient care.
Senior Instructor(s): Brandon Ayres MD*
Instructor(s): Elizabeth Yeu MD*, Jai G Parekh MD MBA, Jessica B Ciralsky MD*,
David A Goldman MD*, Nicole R Fram MD*, Preeya K Gupta MD*, Jimmy K Lee
MD**, William Wiley MD*
Computers, Information Technology

NEW YO Protecting Your Online Image
Course: 320
Room: N427a
Monday
9:00 - 10:00 AM
Synopsis: Currently, physicians are not doing a good job, or in many cases, any job of
monitoring their online reviews and reputation. This workshop will help the attendee
to understand how online media can help build their practice and reputation, and how
to protect against bad reviews or negative comments.
Objective: Many doctors and practices have a website, but few are actively managing their online persona and presence. Services like Yelp, Health Grades, Angies List,
Health Tap, Facebook, Twitter, and many more can either help your practice or hurt it.
Participants will be taught how to edit their personas on the websites most commonly
used by parents and patients. Strategies for protecting the participants online identity
will be given. Ethical considerations with regard to self-promotion and advertising will
also be addressed.
Senior Instructor(s): K David Epley MD
Instructor(s): Andrew P Doan MD PhD*
NEW Google Hangouts for Free Videoconferencing

Course: 323
Room: N427d
Monday
9:00 - 10:00 AM
Synopsis: This course shows how to use Google Hangouts for free videoconferencing. We will go through a step by step power point presentation. Attendees can follow
along with their smartphones if they have 4GS or 4GLTE capability or they can use the
power point to replicate the same at home with their laptop or mobile device. We will
show the audience how to get an gmail account, log onto Google Calendar, create a
meeting with videoconference and chat.
Objective: At the conclusion of this course, the attendee will be able to set up a
videoconference call among satellite offices via a computer or smart phone device.
Senior Instructor(s): Gloria Wu MD*
EHR
65
Instruction Courses
Synopsis: This course will deal with all issues pertaining to phacoemulsification (PE)
in the presence of posterior segment pathologies. Topics covered: a brief overview of
common vitreoretinal pathologies coexisting with cataract (diabetic retinopathy, vitrectomized eyes, high myopia retinal detachment, etc.), how these eyes are different
from the routine, intraoperative risks involved, preoperative assessment and surgical
planning, intraoperative management of distorted anatomy (small pupil, subluxation,
nuclear brunescence, pre-existing posterior capsular rent), combined single-stage
phaco vitrectomy, PE in vitrectomized eyes, IOL power calculation in silicone oil filled
eyes, IOL options, techniques of silicone oil removal after PE, pars plana vitrectomy for
the cataract surgeon, and postoperative management.
Objective: At the end of the course, the attendees will become familiar with current strategies in the management of eyes with cataract and coexisting vitreoretinal
pathologies.
Senior Instructor(s): Arup Chakrabarti MBBS
Instructor(s): Kevin M Miller MD*, Abhay Raghukant Vasavada MBBS FRCS*, Warren
E Hill MD*, Samuel Masket MD*, Jeewan S Titiyal MD, Meena Chakrabarti MBBS
cal complications at the time of cataract surgery. The attendee will also be able to
describe strategies for obtaining optimal outcomes under these conditions.
Instructor(s): Arup Chakrabarti MBBS, Michael Colvard MD*, Alan S Crandall MD*,
Bonnie A Henderson MD*, Terry Kim MD*, Nick Mamalis MD*, Samuel Masket MD*,
Thomas A Oetting MD, Randall J Olson MD, Robert H Osher MD*, Mark Packer MD*,
Abhay Raghukant Vasavada MBBS FRCS*
Instruction Courses
YO Top 10 Hot Corneal Surgical Tips for 2014
Course: 152
Room: S103d
Sunday
10:15 AM - 12:30 PM
Instruction Courses
Synopsis: An expert panel of experienced corneal surgeons will present their annual survey of the hottest corneal surgical tips for 2014. Each surgical tip has been
carefully selected for novelty and maximum potential impact on clinical practice.
Annually updated topics include time-saving office techniques (eg, rebubbling, amniotic membrane grafting), refinements of common operations (eg, Descemet-stripping
automated endothelial keratoplasty, pterygium), and pearls for cutting-edge surgical
procedures (eg, Descemet membrane endothelial keratoplasty, deep anterior lamellar
keratoplasty, femtosecond keratoplasty, keratoprosthesis, stem cell grafts). A rapidfire format with expert panel commentary and audience Q&A will promote lively discussion, and annual refreshing of topics and a rotating faculty ensure that material is
fresh and of interest to repeat attendees.
Objective: Through step-by-step instructions, surgical video, and detailed handouts,
the practitioner will gain practical, specific, and immediately applicable knowledge of
improved techniques and approaches for common and challenging corneal surgical
problems.
Senior Instructor(s): David G Hwang MD
Instructor(s): Eduardo C Alfonso MD*, Sadeer B Hannush MD, Allan Slomovic MD*,
Geoffrey C Tabin MD, Mark A Terry MD*
NEW Surgical Management of Infectious Keratitis: Make It

Simple
Course: 166
Room: S104b
Sunday
10:15 - 11:15 AM
Synopsis: The management of microbial keratitis is challenging. Many cases require

surgical treatment for eradication of infection and salvaging the eye. This course will
provide an overview of the indications, preoperative planning, surgical techniques,
and postoperative management of various surgical procedures, including the recent
ones used in the management of active microbial keratitis.
Objective: The course is aimed at improving the participants understanding of various aspects of surgical management of microbial keratitis so as to achieve preservation of the vision and globe, even under otherwise difficult-to-manage situations. At
the conclusion of this course, participants will be able to do manage these conditions
with significantly efficient preoperative planning and better postoperative care.
Senior Instructor(s): Bhupesh Bagga MD FRCS MBBS
Instructor(s): Prashant Garg MD*, Donald Tan MD FRCS FRCOphth*, Namrata Sharma
MD MBBS, Vishal Jhanji MBBS
NEW Endothelial Keratoplasty: Descemet-Stripping EK /

Descemet Membrane EK / Pre-Descemet EKA VideoBased Course
Course: 174
Room: N427a
Sunday
11:30 AM - 12:30 PM
Synopsis: Endothelial keratoplasty (EK), including Descemet-stripping EK (DSEK),

Descemet membrane EK (DMEK), and the latest, pre-Descemet EK (PDEK), will be
taught through videos in this course. The methods by which the graft can be prepared,
the injection of the graft into the anterior chamber, and the unrolling of the graft will
all be explained through videos. OCT images to explain the postoperative results will
also be shown. The technique of endoilluminator-assisted DMEK (E-DMEK), in which
an endoilluminator is used to help in identifying the position of the graft, will also
be shown. The advantages of PDEK, in that it can be done on any aged donor eye,
among others, will be explained. Finally, anterior segment reconstruction including
pupilloplasty and glued IOL to help create a barrier for the air to tamponade the graft
will also be taught.
66
Objective: At the conclusion of this course the attendee will be able to perform
endothelial keratoplasty and also master the challenges and complications of the
technique.
Instructor(s): Soosan Jacob FRCS, Massimo Busin MD*, Yuri F McKee MD*, Anthony
J Aldave MD*
Complications and Growing Applications in Collagen

Crosslinking: Diagnosis, Management, and Prevention
Course: 195
Room: N140
Sunday
2:00 - 4:15 PM
Synopsis: This course will present a didactic approach to the clinical experience
of complications encountered with several collagen crosslinking (CXL) treatments for
indications such as (1) keratoconus and (2) ectasia following refractive surgery. Several surgical treatment modalities utilized in the U.S. clinical trials and internationally
will be presented. Long-term clinical results will be presented.(3) Prophylactic CXL in
LASIK and PRK (4) CXL in bullous keratopathy, cornea scarring, infectious keratitis,
delayed epithelial healing, regression, and endothelial decompensation.Medical and
surgical and treatment techniques for the above will be presented and discussed in
detail.
Objective: The participants will share their vast experience in CXL and the potential
complications encountered in managing progressive keratoconus, post-LASIK ectasia,
bullous keratopathy, prophylactic CXL in LASIK and PRK and lamellar grafts in order to
obtain stabilization and potentially visual rehabilitation.
Senior Instructor(s): A John Kanellopoulos MD*
Instructor(s): Gregory Pamel MD**, Henry D Perry MD*, R Doyle Stulting MD PhD*,
Eric D Donnenfeld MD*, Soosan Jacob FRCS
H Advances in Treatment of Severe Ocular Surface

Disease: Views From Experts on the Front Lines
Course: 199
Room: S106a
Sunday
2:00 - 4:15 PM
Synopsis: Exciting new treatment approaches to severe ocular surface diseases

(Stevens-Johnson syndrome, graft vs. host disease, chemical injuries, and others)
have emerged in the past few years. In this course, leading experts in the field will
present their own innovations as well as their perspectives on the latest developments. In Stevens-Johnson syndrome, for example, interventions in the acute disease phase, including topical and systemic medications, specialty contact lenses, and
amniotic membrane application, have shown great promise in limiting devastating
long-term ocular sequelae. For patients with chronic ocular findings, treatment with
mucous membrane grafts, specialty devices such as prosthetic replacement of the
ocular surface ecosystem (PROSE), and keratoprostheses constitute potential sightrestoring interventions.
Objective: This course is designed to update general and subspecialty ophthalmologists on sophisticated novel treatment approaches to severe ocular surface disease.
Senior Instructor(s): Jessica B Ciralsky MD*
Instructor(s): C Stephen Foster MD*, Darren G Gregory MD, Deborah S Jacobs MD*,
Stella K Kim MD*, Gary J Lelli MD, Virender S Sangwan MBBS, Kimberly C Sippel
MD*
NEW Optimizing Deep Anterior Lamellar Keratoplasty: The

Small Bubble Technique
Course: 201
Room: S105d
Sunday
2:00 - 3:00 PM
Synopsis: The advantages of deep anterior lamellar keratoplasty (DALK) for the
patient with stromal disease and healthy endothelium are well established. Uptake
of this procedure has been poor, due to the high degree of difficulty and the often
frequent need to convert cases to penetrating keratoplasty (PK). In this course, the
instructors will use video and case presentations to explain several technique modifications that result in improved predictability and success of DALK surgery. In particular, the use of a deep measured trephination and a small-diameter big bubble and
Instruction Courses
reduced-diameter stromal dissection will be explained. Visual outcomes and complications will also be discussed in detail.
Objective: At the conclusion of this course, attendees will be able to improve the
success rate of their DALK surgery and reduce their rate of conversion to penetrating
keratoplasty.
Senior Instructor(s): Massimo Busin MD*
Instructor(s): Jacqueline E Beltz MBBS, Vincenzo Scorcia MD
NEW Descemet Membrane Endothelial Keratoplasty

Course: 205
Room: S106b
Sunday
2:00 - 4:15 PM
Atypical Keratitis
Course: 214
Room: S102d
Sunday
3:15 - 5:30 PM
Synopsis: Since many patients with corneal ulcer are managed empirically based
on clinical features, it is important to be familiar with not only the classical but also
the atypical clinical features. This course will present atypical features of common
pathogens as well as clinical features of uncommon pathogens using representative
cases. The course will also provide pearls for establishing diagnosis of such atypical
cases, including the role of newer diagnostic modalities such as confocal microscopy
and molecular methods.
Objective: To make participants familiar with atypical keratitis cases and provide
pearls for early diagnosis.
Senior Instructor(s): Prashant Garg MD*
Instructor(s): Yoshitsugu Inoue MD PhD*, Terrence P OBrien MD**, Elmer Tu MD,
Francis S Mah MD*
Ocular Surface Diseases in Cancer Patients: Update on

Clinical Spectrum and Treatment
Course: 230
Room: E353c
Sunday
4:30 - 5:30 PM
Synopsis: In this course the clinical spectrum and management of ocular surface
diseases due to cancer treatment will be summarized. Update of new cancer treatments and their ocular side effects will be covered. Special surgical considerations in
cancer patients will be discussed in an interactive format.
Objective: This course is designed to provide an overview and update of ocular surface diseases that result from modern cancer treatments. At the conclusion of the
course, the attendees will be able to recognize and treat the spectrum of the ocular
surface diseases in cancer patients.
Senior Instructor(s): Stella K Kim MD*
Instructor(s): Kimberly C Sippel MD*
Course: 233
Room: S105a
Sunday
4:30 - 5:30 PM
Synopsis: The primary goals of pterygium surgery should ideally be to have a very
low recurrence with minimal complications, and to be cosmetically acceptable. This
video-assisted course will describe the basics of different conjunctival autografting
techniques, which are the gold standard of any pterygium surgery, primary or recurrent. The course will demonstrate the different types of graft fixation: with sutures,
with fibrin tissue glue, and finally with autologous blood. It will also describe the complications, amniotic membrane grafting in difficult situations, and adjunctive medical
treatments to reduce recurrences.
Objective: At the conclusion of this course, the comprehensive ophthalmologist
will able to learn (1) the basics of surgical excision of the pterygium with autologous
conjunctival graft, (2) various types of graft fixation, and (3) how to deal with the
complications of pterygium surgery and tackle the difficult pterygium.
Senior Instructor(s): Santanu Mitra MBBS
Instructor(s): Anthony J Aldave MD*, Samar K Basak MD DNB MBBS*
NEW Allergic Eye Disease: An Enigma for Physicians

Course: 236
Room: S106a
Sunday
4:30 - 5:30 PM
Synopsis: Ocular allergy is a common disorder, affecting up to 20% of the population. Allergic eye diseases are important due to their chronic nature and refractory
behavior to most therapies. They affect overall quality of life. They are often missed
and may mimic other ocular surface pathologies and sometimes infection. This may
delay their diagnosis and management. In this course we will present a series of
cases depicting common and uncommon manifestations of allergic eye diseases. Topics will include seasonal, perennial, vernal, atopic, and toxic keratoconjunctivitis and
their complications and sequelae. A stepwise algorithm approach will describe management for each, including the role of steroidal and nonsteroidal drops, cyclosporine,
mast cell stabilizers and antihistamines, topical and oral anti-inflammatory and immunosuppressive drugs, and prevention and management of complications.
Objective: Attendees will be able to differentiate various forms of ocular allergies
and formulate a logical stepwise treatment plan for them.
Senior Instructor(s): Somasheila I Murthy MD
Instructor(s): Jatin Naresh Ashar MD, Victor L Perez MD*, Neal P Barney MD*, Anurag
Mathur MS
H Ocular Surface Disease Management: Moving From

Adequate to Expert
Course: 308
Room: E351
Monday
9:00 - 11:15 AM
Synopsis: Ocular surface disease encompasses several entities, including keratoconjunctivitis sicca and meibomian gland dysfunction, that share a common denominator: an inflamed and desiccated ocular surface. In this course, the pathogenesis,
signs and symptoms, and diagnosis of specific ocular surface disease entities will be
discussed. Case presentations will be used to help guide discussion of management
and treatment options.
Objective: This course will help the clinician understand the pathophysiology and
management of ocular surface disease. Attendees will (1) improve the diagnostic
skills and therapeutic techniques used with keratoconjunctivitis sicca, blepharitis /
meibomian gland dysfunction, and atypical conjunctival diseases, (2) understand the
pathophysiology of ocular surface disease, (3) increase their knowledge of drugs available to treat ocular surface disease, and (4) have a working differential diagnosis of
the irritated and red eye.
Senior Instructor(s): Joseph Tauber MD*
EHR
67
Instruction Courses
Synopsis: This course intends to provide a full description of the Descemet membrane endothelial keratoplasty (DMEK) surgical technique, emphasizing the key steps
necessary to make DMEK feasible in various conditions. The course will entail the
results and the lessons learned after more than 700 DMEK surgeries with a maximum
follow-up of 7 years. Descemet membrane graft harvesting and preparation will be
shown, indications and limitations of DMEK will be discussed, the standardized surgical technique will be explained, and additional alternative techniques and surgical
considerations for challenging cases will be presented.
Objective: At the conclusion of this course, the attendee will be able to recognize
the special characteristics of this lamellar keratoplasty technique, appreciate its advantages, and distinguish its limitations. The course intends to offer a stepwise approach to novice DMEK surgeons and useful surgical pearls to the more experienced.
Senior Instructor(s): Gerrit RJ Melles MD PhD*
Instructor(s): Vasilios S Liarakos MD, Isabel Dapena, Lamis Baydoun MD, Fook Chang
Lam MBChB, John Steven Parker MD, Maria Satue MD, Martin Dirisamer MD
NEW Conjunctival Autografting in Pterygium Surgery,

Simplified
Instruction Courses
H Help! A Corneal Ulcer Just Walked In! What Do I Do
Next?
Course: 317
Room: N136
Monday
9:00 - 11:15 AM
Instruction Courses
Synopsis: Ophthalmologists invariably encounter corneal ulcers in practice. The

knee-jerk response is to treat with fourth-generation fluoroquinolones. However, this
may be ineffective and could actually be detrimental in autoimmune or noninfectious
keratitis. Features to identify in diagnosing and differentiating between the various
types of corneal ulceration (infectious and noninfectious) will be presented in this
course. The various established and experimental medical and surgical therapies to
treat corneal ulceration will be described, along with an explanation of which therapies may be useful for which types of ulcers. A flow chart for formulating a therapy
plan for corneal ulceration will also be presented.
Objective: At the conclusion of this course, the attendees will be able to (1) differentiate the various types of corneal ulceration, (2) determine which ulcers need
emergent, urgent, or routine therapy, and (3) formulate a logical and stepwise treatment plan and decide when referral to a tertiary center is necessary.
Senior Instructor(s): Sonal S Tuli MD
NEW Diagnosis and Management of Ocular Surface

Disease due to Systemic Conditions
Course: 322
Room: S104b
Monday
9:00 - 11:15 AM
Synopsis: This course will cover the latest developments in the diagnosis and
treatment of ocular surface disease caused by systemic disease including Sjogren
syndrome (SS), graft vs. host disease (GVHD), and Stevens-Johnson syndrome (SJS).
Objective: At the end of this course, attendees will be familiar with systemic causes
of ocular surface disease including SS, GVHD, and SJS. An overview of etiopathogenesis, clinical manifestations, and current medical and surgical treatment options
for active disease states, as well as various vision rehabilitation options in chronic
stages, will be discussed.
Senior Instructor(s): Vatinee Y Bunya MD*
Instructor(s): Mina Massaro-Giordano MD*, Esen K Akpek MD*, Deborah S Jacobs
MD*, Kimberly C Sippel MD*, Frederick B Vivino MD**, Victor L Perez MD*
H SA Current Topics in Cornea / External Disease:

Highlights of the Basic and Clinical Science Course 8
Course: 334
Room: E352
Monday
10:15 AM - 12:30 PM
Synopsis: This course is designed to provide the latest in diagnosis and treatment in
the rapidly changing field of cornea and external disease.
Objective: At the conclusion of this course, participants should understand the difference between tear insufficiency and evaporative eye disease, as well as the role
of the new therapeutic interventions. They should be able to recognize common infectious, neoplastic, and immune-related diseases and prescribe appropriate treatment.
They should be able to differentiate the common corneal dystrophies. They should understand the role of collagen crosslinking, Descemet-stripping automated endothelial
keratoplasty, Descemet membrane endothelial keratoplasty, deep anterior lamellar
keratoplasty, and penetrating keratoplasty for the treatment of corneal disease.
Senior Instructor(s): Robert W Weisenthal MD
Instructor(s): Stephen E Orlin MD, Kathryn A Colby MD PhD*, Elmer Tu MD, Natalie A
Afshari MD*, Denise de Freitas MD, Woodford S Van Meter MD FACS
68
Contact Lens in Ophthalmology Practice

the Contact Lens Association of Ophthalmologists (CLAO)
Course: 350
Room: S105a
Monday
11:30 AM - 12:30 PM
Synopsis: In this course, the incentives, scope-of-practice options, and resource

requirements for contact lens practice will be presented. Practitioners from various
practice settings, including comprehensive solo practice, academic practice, cornea
practice, and multispecialty practice, will present their experiences in offering contact
lens services to their patients. Both private and institutional practices will be represented. Useful resources will be reviewed.
Objective: At the completion of this program, the participant will understand (1) the
incentives for offering contact lens as part of comprehensive eye care, (2) options for
offering a limited scope or full range of contact lens services, (3) resource requirements for a range of contact lens services and practice models, and (4) availability of
resources for reference.
Senior Instructor(s): Warren R Fagadau MD*
Instructor(s): Deborah S Jacobs MD*, S Lance Forstot MD FACS*, Bruce Koffler MD*,
Thomas L Steinemann MD
Update on Intrastromal Corneal Ring Segments

Course: 353
Room: S105d
Monday
11:30 AM - 12:30 PM
Synopsis: Intrastromal corneal ring segments are more than just a solution for low
myopia; they can also correct keratoconus, corneal ectasia, and high astigmatism.
With the aid of femtosecond lasers, the surgical technique is easier to perform and
the use of intracorneal rings is increasing. Nowadays, the principles of its use, the
indications, the surgical technique, and the management of complications must be
known by all ophthalmologists since it is becoming a frequently used technique for
refractive and corneal specialists.
Objective: By the conclusion of this course, attendees will be able to learn the principles, when to indicate the technique, and how to diagnose and solve complications
in patients with intracorneal rings.
Senior Instructor(s): Salvador Garcia-Delpech MD
Instructor(s): Paulo Ferrara MD**, Maria T Iradier MD PhD, Rafael I Barraquer Compte
MD*, Angel L Cisneros MD**, Patricia Udaondo MD, David Salom MD, Ana Hervas
MD, Leonardo Torquetti MD*
NEW Corneal Edema, Opacification and Ectasia: Diagnostic

and Treatment Strategies From the Preferred Practice
Pattern Guidelines
Course: 359
Room: S102d
Monday
11:30 AM - 12:30 PM
Synopsis: Corneal edema, opacification, and ectasia is the focus of 2 new Preferred
Practice Pattern (PPP) guidelines. The authors, PPP Cornea and External Disease panel
members, will use the evidence-based recommendations from these PPPs to provide
the comprehensive ophthalmologist with a good understanding of how the latest diagnostic equipment and surgical techniques are used to best care for an affected
patient. The utility of advanced corneal topography instrumentation and anterior segment OCT will be discussed. The emphasis will be on teaching the comprehensive eye
physician the basic indications and techniques and the advantages and disadvantages
of Descemet-stripping endothelial keratoplasty, Descemet membrane endothelial keratoplasty, deep anterior lamellar keratoplasty, anterior lamellar surgery, intrastromal
ring segment insertion, and collagen crosslinking.
Objective: Through didactic lecture and case presentation the attendees will not
only understand the terminology, but will leave with management pearls and takehome points that can be implemented in their clinical practices.
Senior Instructor(s): Robert S Feder MD
Instructor(s): Francis S Mah MD*, Audrey R Talley-Rostov MD*, Steven P Dunn MD
Instruction Courses
NEW Mycotic Keratitis: Novel Strategies Against Emerging
Pathogens
NEW Ocular Chronic Graft vs. Host Disease: Update and

Case Studies for Clinicians
Course: 362
Room: S103a
Course: 391
Room: S104b
Monday
11:30 AM - 12:30 PM
H The Boston Keratoprosthesis: Case-Based Presentations
Highlighting the Essentials for Beginning and Experienced

Surgeons
Course: 383
Room: S103d
Monday
2:00 - 4:15 PM
Synopsis: While traditionally considered a procedure of last resort, keratoprosthesis

(KPro) implantation is being performed with increasing frequency for an expanding
variety of indications, including repeat corneal graft failure and corneal opacification
combined with limbal stem cell failure. In this course the indications and contraindications, surgical technique, and postoperative management of the Boston KPro will be
presented along with illustrative case presentations.
Objective: Attendees will learn to recognize patients in their practices who are
good candidates for KPro implantation. Presentation of surgical videos and a detailed
discussion of the postoperative management will familiarize attendees with KPro
implantation, as well as with avoidance and management of postoperative complications.
Senior Instructor(s): Kathryn A Colby MD PhD*
Instructor(s): Anthony J Aldave MD*, Esen K Akpek MD*, James Aquavella MD*,
James Chodosh MD MPH*, Claes H Dohlman MD PhD*, Sadeer B Hannush MD ,
Andrea C Cruzat MD
Synopsis: The pathogenesis, presentation, and treatment strategy for ocular chronic
graft vs. host disease (cGVHD) will be presented by clinicians with substantial experience treating patients living with this disease. Exemplary cases will be presented for
panel and audience polling, review, and questions.
Objective: At the completion of this course, the participant will (1) appreciate the
presentation of ocular cGVHD, (2) become familiar with stepwise treatment per task
force recommendations, (3) understand management of surgical cataract in patients
with cGVHD, and (4) learn from the review of exemplary cases, including considerations regarding cataract surgery and innovative approaches to treatment.
Senior Instructor(s): Deborah S Jacobs MD*
Instructor(s): Stella K Kim MD*, Roni M Shtein MD, Michael C Wu MD
NEW Diagnosis and Management of Corneal Endothelial

Diseases
Course: 408
Room: S104a
Monday
3:15 - 4:15 PM
Synopsis: In order to properly diagnose and manage various corneal endothelial diseases, including Fuchs corneal dystrophy and CMV corneal endotheliitis, it is vital to
understand disease pathogenesis and the proper selection of surgical treatment. In
this course, attendees will learn how to properly diagnosis corneal endothelial diseases and perform current surgical techniques, such as Descemet-stripping automated
endothelial keratoplasty (DSAEK) and Descemet membrane endothelial keratoplasty
(DMEK). This course will also provide a review of endothelial remodeling and the
safety of using internationally shipped precut donor corneas for DSAEK, as well as
discussion on possible future treatments such as using Rho-associated kinase (ROCK)
inhibitors and cell-injection therapy.
Objective: At the conclusion of this course, attendees will have a broader understanding of the pathogenesis and clinical management of corneal endothelial diseases, including keys for diagnosis and surgical managements, including DSAEK and
DMEK.
Senior Instructor(s): Shigeru Kinoshita MD*
Instructor(s): Ula Jurkunas MD*, Jodhbir S Mehta MBBS PhD*, Tsutomu Inatomi MD
PhD, Friedrich Kruse MD
NEW Controversies in the Management of Corneal

Infections
Anterior Segment Imaging: A Practical Guide for

Ophthalmologists
Course: 409
Room: N427a
Course: 385
Room: S104a
Synopsis: In recent years there have been several issues that have either provoked
controversies or generated new dilemmas regarding various aspects of the management of corneal infections. Some of these controversial issues are empirical vs. microbiology-based management, the use of in vivo corneal imaging in diagnosis, and the
use of corticosteroids and lamellar keratoplasty.During this course we will present to
the audience the evidence, for and against, involved in these controversial issues. In
addition, the audience will also be able to know the opinions of the panel of experts
participating in the course.
Objective: The course will help participants make an informed decision on various
issues presented during the course.
Senior Instructor(s): Prashant Garg MD*
Instructor(s): Francis S Mah MD*, Donald Tan MD FRCS FRCOphth*, Bennie H Jeng
MD*
Monday
2:00 - 3:00 PM
Synopsis: This course will provide a comprehensive review of established and newer anterior segment imaging instruments and their practical clinical uses for evaluation of pathology of the cornea and angle. Instructors will cover anterior segment OCT,
ultrasound biomicroscopy, in vivo confocal microscopy, and corneal topography. The
course will emphasize a case-based approach to choosing from among the various imaging modalities, what each adds to clinical practice, and how to interpret the images.
Objective: This course will provide a practical and comprehensive review of anterior segment imaging techniques for comprehensive ophthalmologists and anterior
segment specialists. At the end of the course, attendees will be able to choose the
appropriate imaging modality to use for individual patients in the clinical setting.
Senior Instructor(s): Roni M Shtein MD
Instructor(s): Shahzad I Mian MD*, Sayoko E Moroi MD PhD*, Maria A Woodward
MD*
Monday
3:15 - 4:15 PM
EHR
69
Instruction Courses
Synopsis: Mycotic keratitis is an important cause of corneal blindness. Fungal keratitis is challenging from both a diagnostic and a therapeutic standpoint. Patients with
fungal keratitis are often misdiagnosed and incorrectly treated. Furthermore, organisms are often difficult to isolate on microbiological testing. Newer diagnostic modalities, including confocal microscopy, are being used to aid in the earlier detection of
mycotic keratitis. The treatments for these infectious disorders are equally challenging, requiring the use of multiple topical and systemic antifungal medications and
surgeries. In this course, leading experts will present updates on the medical management of these conditions, including the novel use of liposomal amphotericin B, along
with the surgical options and pre- and postoperative considerations.
Objective: To update general and subspecialty ophthalmologists on the novel treatment modalities and approaches to mycotic keratitis.
Senior Instructor(s): Ana G Alzaga Fernandez MD
Instructor(s): Jessica B Ciralsky MD*, Kimberly C Sippel MD*, Priyanka Sood MD,
Thomas J Walsh MD**
Monday
2:00 - 3:00 PM
Instruction Courses
Complex Endothelial Keratoplasty: Current Strategies to
Improve Results and Avoid Complications
Course: 417
Room: S105d
Monday
4:30 - 5:30 PM
Instruction Courses
Synopsis: This course will feature a video and slide presentation of the current
surgical technique, instrumentation, and complications of Descemet-stripping automated endothelial keratoplasty (DSAEK) in complex situations such as failed penetrating keratoplasty, aphakia, aniridia, filtering tubes, and retained anterior chamber IOL.
Easier, faster, and safer DSAEK techniques will be emphasized. Current modifications
of EK that avoid complications will be stressed. Various techniques for DSAEK insertion (forceps, Busin glide, pull through injectors) will be shown and correlated with
their induced endothelial damage. EK combined with vitrectomy, secondary IOL, and
cataract surgery will be presented. The course will emphasize an ethical, prospective
approach to complex DSAEK surgery and methods on how to avoid common surgical
and postoperative pitfalls.
Objective: At the conclusion of the course, the attendees will recognize the challenges and solutions of complex DSAEK in special circumstances that produce low
complications and excellent vision.
Senior Instructor(s): Mark A Terry MD*
Instructor(s): Michael D Straiko MD*, Paul M Phillips MD
Monday
4:30 - 5:30 PM
Synopsis: This course will review the epidemiology, diagnosis, and ophthalmic complications of anterior, necrotizing, and posterior scleritis. The wide array of systemic
diseases that may be associated with scleritis will be discussed. How to order an efficient and appropriate systemic workup will be emphasized. Treatment algorithms will
be presented, with particular attention to medication selection, proper dosing, safety
monitoring, and when to switch from one treatment modality to the other.
Objective: At the conclusion of this course, the attendee will be able to adequately
diagnose and classify patients with scleritis. The attendee will understand how to
elicit an appropriate history, undertake an appropriate physical examination, and order
a precise systemic workup for these patients. The attendee will also understand the
protocols used for different scleritis treatment modalities, such as NSAIDs, corticosteroids, immunomodulators, and antibiotics.
Senior Instructor(s): Armando L Oliver MD*
Instructor(s): Shree Kumar Kurup MD MB*
NEW Diagnosis and Management of Acanthamoeba

Keratitis
Follow the Cornea: Do You Know Where Your Corneal

Transplant Tissue Comes From?
Course: 432
Room: S403b
Course: 423
Room: N139
Synopsis: This course will review the epidemiology, diagnosis, and management of
Acanthamoeba keratitis, including the use of newer diagnostic tools such as confocal
microscopy and polymerase chain reaction (PCR) analysis.
Objective: At the conclusion of this course, the attendee will be able to (1) recognize the early and late clinical signs of Acanthamoeba keratitis, (2) understand the
strengths and limitations of confocal microscopy as a tool to diagnose and follow patients with Acanthamoeba keratitis, (3) understand the various microbiological tests
for diagnosing Acanthamoeba keratitis, including culture, smear, and PCR, (4) choose
the proper medication regimen for Acanthamoeba keratitis based on susceptibility
data, and (5) understand the potential beneficial and detrimental role of topical corticosteroids for Acanthamoeba keratitis.
Senior Instructor(s): Jeremy D Keenan MD MPH
Instructor(s): Elmer Tu MD, Jeena MARIA Mascarenhas MS, Lalitha Prajna MD,
Rajaraman Revathi MD
Monday
4:30 - 5:30 PM
Synopsis: The first steps of corneal transplant surgery take place in the eye bank.
Through a combination of brief talks and expert panel discussions, we will inform the
corneal surgeon about the process of eye tissue banking. We will (1) follow the path
of tissue through recovery to distribution for corneal transplantation, (2) provide the
evidence-based standards for surgical tissue selection, (3) discuss trends in eye banking, and (4) inform corneal surgeons on ways to get involved in the process.
Objective: At the conclusion of this course, the attendee will understand the intricacies of corneal donation and tissue processing, will know the results of the Cornea
Donor Study, will appreciate the complexity of the eye banks work, and will know
ways to become involved with eye banks. The goal is to educate corneal surgeons
in order to promote sustainability, to maintain availability of corneal tissue, and to
broaden the surgeons knowledge of the vital resource of eye banking.
Senior Instructor(s): Roni M Shtein MD
Instructor(s): Kristiana D Neff MD*, Maria A Woodward MD*, Bennie H Jeng MD*,
Mark J Mannis MD, Marian Sue Macsai-Kaplan MD*, David B Glasser MD, David E
Korroch CEBT**, Monty Montoya**, Kevin P Corcoran CAE*
Diagnosis and Management of Corneal Perforation

Course: 424
Room: S106b
Monday
4:30 - 5:30 PM
Synopsis: Corneal perforation is an ophthalmic emergency that requires prompt diagnosis and treatment. Although infectious keratitis is a common cause, other causes
such as corneal xerosis and collagen vascular diseases are also important differential
diagnoses, especially in cases that do not respond to conventional medical therapy.
Based on the size and location of the corneal perforation, various treatment options
are applicable that include medical therapy, corneal gluing, amniotic membrane transplantation, and corneal transplantation.
Objective: At the end of the course the attendee will have a clear understanding of
the concepts of stepwise management of corneal perforation.
Senior Instructor(s): Vishal Jhanji MBBS
Instructor(s): Rasik B Vajpayee MD, Sujata Das MBBS, Namrata Sharma MD MBBS,
Jodhbir S Mehta MBBS PhD*
70
NEW Scleritis: What to Order and How to Treat It!

Course: 426
Room: S102d
Monday
4:30 - 5:30 PM
How to Successfully Accomplish Endothelial Keratoplasty

in the Presence of Significant Ocular Comorbidities
Course: 507
Room: S106a
Tuesday
9:00 - 11:15 AM
Synopsis: This course will outline successful surgical strategies for accomplishing
endothelial keratoplasty (EK) in the presence of comorbidities that make successful
completion of surgery more challenging. The instructors will offer pearls for EK in
phakic eyes; in the presence of cataract, aphakia, iris coloboma or zonular dehiscence,
aniridia, anterior chamber IOLs, iris- or scleral-fixated posterior chamber IOLs; in unicameral eyes; and with failed penetrating or endothelial keratoplasty, trabeculectomy,
or tube shunt. Clinical examples will illustrate points where appropriate steps may
help avoid unwanted complications. Slides and videos of case studies will be shown,
emphasizing dangers and solutions.
Objective: This course is designed to enable participants to learn from our experience and avoid complications while shortening their learning curve for EK in the presence of ocular comorbidities.
Senior Instructor(s): Sadeer B Hannush MD
Instructor(s): Anthony J Aldave MD*, Henry D Perry MD*, George O D Rosenwasser
MD
Instruction Courses
H Herpes Simplex Keratitis: When Herpes Isnt a Dendrite,
and Vice Versa
Course: 511
Room: N138
Tuesday
9:00 - 11:15 AM
NEW Complex Corneal Clinics: Logical Solutions

Course: 520
Room: S403b
Tuesday
9:00 - 11:15 AM
Synopsis: Complex corneal cases may be treated by various surgical approaches. In

this course, options for pellucid marginal degeneration with or without keratoconus,
(tectonic patch graft, wedge resection and lamellar dissection, combined tissue excision and corneal tuck, diamond blade-assisted deep anterior lamellar keratoplasty),
keratoglobus (two-stage keratoplasty, tuck in keratoplasty, epikeratoplasty), Terrien
marginal degeneration (compressive keratoplasty), acute hydrops in ectasias (intracameral air/gas injection and intrastromal fluid drainage), severe chemical injuries
(stem cell transplant and large diameter lamellar keratoplasty), peripheral perforations (multilayered, patch and Tenon graft) and partial corneal opacities (optical iridectomy, autorotational keratoplasty) will be discussed in case-based demonstrations
by experienced surgeons.
Objective: At the end of the course the delegate will be able to master the principles
of surgical techniques in difficult corneal situations.
Senior Instructor(s): Rasik B Vajpayee MD
Instructor(s): Namrata Sharma MD MBBS, Vishal Jhanji MBBS, Jodhbir S Mehta
MBBS PhD*, Donald Tan MD FRCS FRCOphth*, Sheraz M Daya MD*, Massimo Busin
MD*
NEW Keratoconus: The 2014 Protocol

Course: 524
Room: S103a
Tuesday
9:00 - 10:00 AM
Synopsis: Over the past decade the management of keratoconus (KC) has undergone
a sea change. Previously KC management was limited only to rigid gas permeable
lenses or penetrating keratoplasty. However, in 2013, the aim of KC management is
not just management of ectasia but also to attain a BCVA of 20/20. Our course will
discuss a protocol-based approach that would help one customize the therapy based
on the severity of the disease. A panel of experts will debate their preferences of
therapies such as rigid gas permeable lenses, Rose K and scleral lenses, collagen
crosslinking (CXL) (standard and accelerated), Keraflex, intraocular ring segments,
combining CXL with PRK/Intacs, toric ICL, and deep anterior lamellar keratoplasty
(femtosecond assisted). Discussion of challenging cases, complications of various
managements, and wrong decisions will conclude the course.
Objective: At the end of the course, attendees will be familiar with the latest protocols and various treatment options for KC in 2014.
Senior Instructor(s): Vandana Jain MBBS
Instructor(s): Jatin Naresh Ashar MD, Rohit Shetty MD MBBS, Anurag Mathur MS
Course: 554
Room: S406b
Tuesday
11:30 AM - 12:30 PM
Synopsis: The role of meibomian gland dysfunction (MGD) in chronic blepharitis and
ocular surface disease is rapidly evolving. MGD is a form of chronic blepharitis and is
recognized as a cause of ocular surface disease. Subgroups of MGD will be discussed
in this course, along with pathophysiological mechanisms, including the role of bacteria and lipolytic exoenzyme, meibum changes, and tear evaporation. Acute and chronic
phase therapy will be presented. The role of topical therapies as well as systemic
therapies will be discussed as they relate to both lid and ocular surface abnormalities.
Objective: At the conclusion of this course, attendees will be able to diagnose and
treat MGD and associated ocular surface disease.
Senior Instructor(s): James P McCulley MD FACS FRCOphth*
Management of Ocular Chemical Injuries

Course: 558
Room: S403b
Tuesday
11:30 AM - 12:30 PM
Synopsis: Acute ocular chemical burn is an emergency and needs immediate management, which includes copious irrigation, topical steroids, autologous and cord
serum , amniotic membrane transplantation, and even tissue adhesives and tectonic
keratoplasty in severe cases. Regarding chronic chemical burns, this course will present a stepwise approach to the management of ocular surface reconstruction that
depends on the laterality and the severity of limbal stem cell deficiency, including the
limbal transplantation (direct and cultivated). Visual rehabilitative approaches that
include keratoplasty and keratoprosthesis will also be discussed.
Objective: At the end of the course, the attendee will be well versed in the acute
and emergency management of ocular chemical burns (as should be every ophthalmologist) and will be aware of ocular surface transplantation techniques. This course
will give a holistic overview of the management of ocular chemical burns.
Senior Instructor(s): Namrata Sharma MD MBBS
Instructor(s): Rasik B Vajpayee MD, Vishal Jhanji MBBS, Tushar Agarwal MD
Failed Graft: Never Say Die!

Course: 562
Room: S403a
Tuesday
11:30 AM - 12:30 PM
Synopsis: This course describes selection of appropriate surgical procedure for highrisk failed grafts, such as repeat penetrating keratoplasty (PK), Descemet-stripping
endothelial keratoplasty (DSEK), or keratoprosthesis. Even DSEK and deep anterior
lamellar keratoplasty (DALK) may fail over time, and repeat surgery may be required.
Keratoprosthesis is the answer to multiple failed grafts. Surgical techniques and
modifications required for performing DSEK for failed PK, repeat DSEK, repeat DALK,
postoperative immunosuppressive regimen, and outcomes of such surgeries will be
discussed. A panel discussion on expert consensus on controversial issues regarding
Descemet scoring, graft sizing for DSEK for failed PK, and multiple repeat PK / keratoprosthesis will conclude the course.
Objective: At the end of this course, attendees will be familiar with the indications
and patient selection for regrafts, surgical techniques and modifications, follow-up,
and risks of repeat graft (PK, DSEK, DALK, and keratoprosthesis).
Senior Instructor(s): Jatin Naresh Ashar MD
Instructor(s): Sonia H Yoo MD*, David S Rootman MD*, Anthony J Aldave MD*, Mark
A Terry MD*, Pravin Vaddavalli MD
H Pterygium: The Outcome Measure Is Now Cosmesis, Not

Recurrence
Course: 571
Room: S403a
Tuesday
12:45 - 3:00 PM
Synopsis: PERFECT for Pterygium (pterygium extended removal followed by extended conjunctival transplantation) not only results in minimal recurrences (1 recurrence
EHR
71
Instruction Courses
Synopsis: Herpes simplex keratitis (HSK) is the most common cause of corneal blindness in developed nations. Many cases are missed because ophthalmologists are unaware of the nondendritic manifestations of HSK, such as geographic, marginal, necrotizing, endotheliitis, and interstitial keratitis. Features and pathophysiology of the
different forms of HSK and clues to their diagnosis will be presented. A logical plan
for treatment will be presented, including when and how to use antivirals, steroids,
and surgery. Major literature on herpes simplex keratitis will also be briefly discussed.
Objective: At the conclusion of this course, attendees will be able to (1) diagnose
common as well as unusual forms of HSV keratitis, (2) formulate a logical treatment
plan based on their understanding of the pathophysiology of the different manifestations of herpes, and (3) get a general understanding of the newer treatment modalities
on the horizon.
Senior Instructor(s): Sonal S Tuli MD
Meibomian Gland Dysfunction and Chronic Blepharitis
Instruction Courses
in 1000 patients with 99% follow-up of more than 1 year) but also provides an excellent cosmetic result.
Objective: Attendees will understand the differences between the PERFECT for Pterygium surgical procedure and routine autoconjunctival surgery for pterygium. They
will be prepared to treat pterygium as a significant disease, with serious surgery
designed to achieve a low recurrence rate and a cosmetic appearance at 1 year, with
the site of the pterygium undetectable. Attendees will be able to incorporate into
their pterygium surgery any components of PERFECT for Pterygium that they do not
already use. They will understand the expected postoperative course and therapy and
the complications of this surgery. Above all else, they will learn a new respect for this
disease, which has so often been trivialized in the past.
Senior Instructor(s): Lawrence W Hirst MD MBBS MPH DO FRACO FRACS*
Instructor(s): Ivan R Schwab MD FACS, Linda Rose MD PhD*
Innovative Uses of Adhesives in Anterior Segment Surgery

Course: 576
Room: S101ab
Tuesday
12:45 - 3:00 PM
Instruction Courses
Synopsis: This course will present the use of cyanoacrylate, fibrin-based, and other
new adhesives for corneal wounds, cataract surgery, pterygium surgery, LASIK complications, dislocated IOLs, limbal stem cell transplants, and glaucoma surgery.
Objective: At the conclusion of this course, the attendee will be able to identify and
describe the use of various adhesives for corneal disorders, cataract / corneal procedures, dislocated IOL procedures, LASIK complications, and glaucoma procedures.
Senior Instructor(s): Terry Kim MD*
Instructor(s): Amar Agarwal MD*, Sadeer B Hannush MD, David R Hardten MD*,
Robert J Noecker MD*, Christopher Rapuano MD*, David C Ritterband MD*,
NEW Descemet Membrane Endothelial Keratoplasty: A

Simplified Technique to Shorten the Learning Curve and
Avoid Complications
Course: 584
Room: S102d
Tuesday
12:45 - 1:45 PM
Synopsis: This course will feature a video and slide presentation of a simplified
Descemet membrane endothelial keratoplasty (DMEK) technique that reduces the
learning curve. We have found it to be easier, faster, and safer than earlier published
techniques. Emphasis will be given to initial case selection, and specific surgical maneuvers that ensure correct orientation and unfolding of DMEK scrolls and that avoid
intraoperative mishaps. Important preoperative planning for DMEK combined with
cataract surgery as well as in special circumstances such as under failed penetrating
keratoplasty and prior refractive surgery will be presented. Postoperative complications and their management will also be presented.
Objective: At the conclusion of the course, the attendees will recognize the specific
steps of DMEK surgery that produce low complications and excellent vision.
Senior Instructor(s): Mark A Terry MD*
Instructor(s): Michael D Straiko MD*, Paul M Phillips MD
H Recent Developments in the Diagnosis and Management
of Conjunctival Tumors
Course: 596
Room: S103d
Tuesday
2:00 - 4:15 PM
Synopsis: Conjunctival tumors have a varied spectrum of clinical presentation.

These are often misdiagnosed as simulating conditions, resulting in inappropriate
management and tumor recurrence. The aim of this course is to provide a systematic
overview of clinical manifestations of conjunctival tumors and to discuss recent concepts in diagnosis, management, and prognosis. Clinical evaluation of a patient with
conjunctival tumor and typical and atypical manifestations will be demonstrated with
well-documented clinical cases. Systemic associations will be discussed. Advantages
of anterior segment imaging techniques will be highlighted. Evidence-based treatment protocols, and indications and outcome of newer treatment modalities such as
72
topical chemotherapy and plaque brachytherapy, will be discussed. Standard surgical

procedures will be demonstrated with video films.
Objective: This course is designed to enable participants to accurately diagnose and
appropriately manage common conjunctival tumors.
Senior Instructor(s): Santosh G Honavar MD
Instructor(s): Carol L Shields MD, Carol L Karp MD, Jerry A Shields MD
NEW SOE Basic Deep Anterior Lamellar Keratoplasty

Course: 603
Room: N427a
Tuesday
2:00 - 4:15 PM
Synopsis: This diagrams- and video-based course will analyze in detail indications
for surgery and various deep anterior lamellar keratoplasty (DALK) techniques (hydrodissection, manual dissection, needle big bubble, cannula big bubble, air-visco
bubble, and a new opening of bubble technique). The pros and cons of each technique,
complications, and penetrating keratoplasty (PK) conversion will also be discussed.
Based on 10 years follow-up study data, DALK advantages in terms of functional outcomes, endothelial cell count, and long-term survival will be reported.
Objective: At the conclusion of this course, the attendee will be able to move from
PK to DALK, acquiring the rupture management and PK conversion techniques.
Senior Instructor(s): Vincenzo Sarnicola MD
Instructor(s): Edward J Holland MD*, Sadeer B Hannush MD, Rajesh Fogla MD FRCS
H Next-Generation Technologies for the Diagnosis and

Treatment of Dry Eye and Meibomian Gland Dysfunction
Course: 604
Room: S101ab
Tuesday
3:15 - 5:30 PM
Synopsis: While diagnostics and treatments for dry eye are advancing, the majority of practitioners limit their interventions to giving out artificial tears. The panel of
experts in this course will engage members of the audience to share their experiences
with the presented technologies. The panel will discuss new diagnostic devices such
as the InflammaDry Detector, the LipiView Interferometer, and tear osmolarity measurement, as well as the use of existing devices such as high-resolution OCT and
topography to evaluate dry eye. Newer, as yet not widely used therapeutic strategies
will also be discussed, including LipiFlow, intense pulsed light lasers, and Maskin
Meibomian Probes. Finally, emerging therapeutics will be discussed.
Objective: Attendees will collaborate with faculty to both summarize and disseminate our growing intuitions about how to approach and successfully treat one of the
most common problems we see in the office every day.
Senior Instructor(s): Linda Rose MD PhD*
Instructor(s): William B Trattler MD*, Parag A Majmudar MD*, Marguerite B
McDonald MD*, Penny Asbell MD FACS*, Mina Massaro-Giordano MD*

NEW EHR Useful Things to Do With Your New EHR
the Medical Information Technology Committee
Course: 175
Room: S102d
Sunday
11:30 AM - 12:30 PM
Synopsis: Now that you have invested all of that time and money into your new EHR
system, what can you do to take advantage of it? The real benefits of EHR are only
manifest when you can use your data to improve the care you provide and enhance
your practice. To help you begin thinking about how your EHR can help you, we will
present stories (with data) showing how to make this happen. Examples presented
will include creation of a data mart to analyze clinical and operational data, leveraging participation in the Intelligent Research in Sight (IRIS) Registry to improve care,
development of forms to collect data on postoperative complications in glaucoma surgery, and integration of imaging devices to facilitate care.
Instruction Courses
Objective: At the conclusion of the course, attendees will be able to (1) describe
ways in which EHRs can be used to improve patient care and clinic operations and
(2) initiate discussions with their IT staff or EHR vendor regarding their own quality of
efficiency improvement initiatives.
Senior Instructor(s): Michael V Boland MD PhD*
Instructor(s): K David Epley MD, Rishi P Singh MD*, Linda L Wedemeyer MD
NEW EHR SO EHR and Meaningful Use for the Small

Practice: Is It Worth It?
Course: 235
Room: E353a
Sunday
4:30 - 5:30 PM
EHR EHR: Compliance and Medicolegal Issues

Jointly sponsored by the Academys Annual Meeting Program Committee and
Medical Information Technology Committee and the American Academy of
Ophthalmic Executives EHR Subcommittee
Course: 587
Room: S103a
Synopsis: This course will demonstrate how EHRs, while improving the quality of
medical records, can also create problems that can trigger serious medicolegal and
compliance issues. This course will explore how EHRs can be used wisely or foolishly.
Case studies will be presented to illustrate problems created by the use of EHRs.
Objective: By the conclusion of this course, attendees will be able to (1) describe
some strengths of EHR systems that can improve compliance with chart documentation requirements, (2) describe some tricks that could hurt documentation reliability
and compliance, (3) identify features in EHRs that pose the greatest threats, and (4)
modify EHR utilization to improve documentation reliability and compliance.
Senior Instructor(s): David E Silverstone MD
Instructor(s): Michele C Lim MD*, Kevin J Corcoran*
NEW EHR Meaningful Use Stage 2: Qualifying for Payment

Course: 361
Room: N139
Monday
11:30 AM - 12:30 PM
Synopsis: Health care is one of the last large industries to become computerized.
Although EHRs have been around for decades, adoption has only recently begun to
increase rapidly. EHRs create potential for improved access to patient data and clinical decision support tools as well as improved efficiency, but many have found the
transition difficult. The federal government is promoting an incentive program to propel a large majority of physicians to adopt EHRs. If physicians do not adopt EHRs by
2015, they will face payment penalties from the Centers for Medicare and Medicaid
Services. The final rule for Stage 2 of Meaningful Use will take effect in 2014. This
course will discuss everything ophthalmologists need to know about this topic.
Objective: At the end of this course, attendees will know what is needed to demonstrate Meaningful Use of their EHR system in 2014 by understanding the federal Stage
2 requirements, and what certified EHR technology is required.
Senior Instructor(s): Michael F Chiang MD*
Instructor(s): Michael V Boland MD PhD*, Julia Lee JD OCS*, Michael X Repka MD
MBA*
EHR Managing Your EHR After Implementation

Course: 534
Room: S102d
Tuesday
10:15 AM - 12:30 PM
Synopsis: Out-of-the-box EHR software doesnt work well for many physicians. Its
important to alter the EHR itself to make it work for each provider in your group and
for the practice as a whole. This timely session will reveal tips and tricks to help your
software work for you, whether you are a solo practice, a small group, or part of a
large organization.
Objective: Here are just a few things to expect from this dynamic session: You will
(1) discover tips and tricks for EHR optimization, (2) review lessons learned though
EHR implementation, (3) learn ways to customize the software to work for your chart-
Tuesday
2:00 - 4:15 PM
Ethics
NEW SO Electronic Media and Patient Care: Ethical
Considerations, Confidentiality, HIPAA, and Encryption

Course: 200
Room: N427d
Sunday
2:00 - 3:00 PM
Synopsis: This course will define federal privacy mandates and relevant ethical
practices: the HIPAA Privacy and Security Rules that protect the privacy of individually
identifiable health information. Also featured will be attendees responsibilities under
federal law, proper use of various mobile devices, encryption strategies, the multiple
password conundrum, email authorizations, patient use of social media for communication of health issues, and the relevant ethical issues.
Objective: At the conclusion of the course, attendees will be able to define federal
privacy mandates and relevant ethical practices by (1) identifying the key components
of secure electronic communication and data storage practices and (2) defining the
HIPAA Privacy and Security Rules, the HITECH Breach Notification Rule, safeguards
needed to ensure the protection of private health information, and the relevant ethical
dilemmas involved.
Senior Instructor(s): Christie L Morse MD*
Instructor(s): Anthony J Aldave MD*, Keith D Carter MD FACS, R V Paul Chan MD,
Nadia Martyn JD
NEW SO An Introduction to Error Disclosure for

Ophthalmologists
Course: 358
Room: S106b
Monday
11:30 AM - 12:30 PM
Synopsis: This course will present an introduction to error disclosure designed for
ophthalmologists. The didactic section will discuss current trends toward mandatory
error disclosure and summarize the experiences of providers who have adopted a
disclosure culture. Attendees will watch video of a sample disclosure conversation
and then break into small groups for ophthalmology-based case presentations with
role play. After the group members give each other feedback, the instructors will present a summary of best practices in error disclosure. The course will conclude with
a question and answer session and assessment of lessons learned from the cases.
EHR
73
Instruction Courses
Synopsis: EHR and Meaningful Use implementation are time consuming and expensive. This course will help the smaller practice decide whether or not it makes sense
for the practice to adopt these measures.
Objective: EHR systems and Meaningful Use program participation are large hurdles
for the small practice, given the time and expense necessary to implement them.
This course will address common concerns among practitioners in small practices and
debunk myths about adopting an EHR system and complying with Meaningful Use, so
attendees can decide whether or not it makes sense for their practices to invest in an
EHR and the process of Meaningful Use.
Instructor(s): Arvind Saini MD MBA
ing style, (4) learn how to deal with unanticipated problems, (5) discover how to maintain rapport with your patients despite the necessary computer use, (6) learn how
to stay efficient while complying with Stage 2 of the Meaningful Use requirements.
Anyone who has implemented an EHR system, or is in the beginning stages of implementation, should attend this course.
Instructor(s): Michele C Lim MD*, Michael V Boland MD PhD*
Instruction Courses
Objective: At the conclusion of this course, the attendee will be able to(1) explain
why error disclosure is relevant to ophthalmology,(2) describe the potential benefits
of error disclosure for the patient and physician,(3) conduct a basic error disclosure
conversation with a patient.
Senior Instructor(s): Bryan S Lee MD JD
Instructor(s): Gurunadh A Vemulakonda MD
General Medical Care

Drug-Related Adverse Effects of Clinical Importance to the
Ophthalmologist
Course: 197
Room: N136
Sunday
2:00 - 3:00 PM
Instruction Courses
Synopsis: This course will describe adverse ocular reactions from topical ocular and
systemic medications, with a focus on recently reported adverse events identified by
the National Registry of Drug-Induced Ocular Side Effects (Portland, Oregon) and applying the WHO classification system.
Objective: At the conclusion of this course, attendees will be able to recognize drugrelated adverse ocular and systemic side effects when they occur in association with
drugs commonly used by clinicians. Only those medications of clinical importance to
ophthalmologists will be discussed.
Senior Instructor(s): Rick W Fraunfelder MD
NEW Identifying and Managing Unhappy Patients

Course: 237
Room: S106b
Sunday
4:30 - 5:30 PM
Synopsis: Ophthalmologists report spending an increasing amount of time dealing

with difficult patients. Some of these patients are unhappy with the outcome of
their care, some have substance abuse (drug and alcohol) issues, some may have
mental health issues or dementia. At other times, eye surgeons are surprised to learn
that former, seemingly satisfied patients have filed a malpractice lawsuit against
them. In this course, actual calls to the Risk Management Hotline and closed malpractice cases will be used to identify patients who are unhappy, and to offer ways to
improve communication skills for dealing with patients once problems are apparent.
Objective: By the end of this course, participants will be able to (1) identify behaviors of patients who may be unhappy with their care, (2) develop approaches that
encourage patients to communicate their concerns, and (3) clarify when further communication will not be helpful.
Senior Instructor(s): Anne M Menke RN PhD
NEW Critical Issues in Management of Ocular Trauma

Course: 327
Room: N139
Monday
9:00 - 11:15 AM
Synopsis: Using video-assisted, case-based discussion, this course will investigate

critical issues in the management of adnexal and globe trauma and will critically review history, evaluation, timing, management principles, complications, prognosis,
outcome, and controversies involved. The course will highlight involving patients in
management of the injured eyes.
Objective: To provide attending ophthalmologists with evidence-based, videoassisted surgical skill transfer in optimal management of complex patients of ophthalmic trauma.
Senior Instructor(s): Rupesh Agrawal MBBS DMS FRCS
Instructor(s): Ferenc P Kuhn MD PhD, Michael P Grant MD PhD**, Gangadhara J K
Sundar MBBS, Rekha R Khandelwal MBBS FRCS
74
NEW SO Genetic Testing in Ophthalmology

the International Society for Genetic Eye Diseases and Retinoblastoma
Course: 389
Room: N136
Monday
2:00 - 3:00 PM
Synopsis: Genetic tests have become readily available for confirmation and refinement of the clinical diagnosis of inherited ocular diseases. While ophthalmologists
are adept at diagnostic feature recognition, many remain uncertain about the value
and process of obtaining and interpreting genetic tests. In this course, the panelists
will emphasize the importance of precise clinical diagnosis with the use of ancillary
testing modalities and available Web and book resources. The panelists will review
categories, definitions, and interpretation of genetic tests and address advantages
and difficulties in test interpretation for each. They will review the practical aspects
of ordering genetic tests and providing results to the patient / family in the context of
formal counseling. Selected cases will be used to illustrate teaching points.
Objective: At the conclusion of this course, the attendee will be able to explain the
current best-practice methodology for choosing, obtaining, and interpreting genetic
tests for inherited eye diseases.
Senior Instructor(s): Elias I Traboulsi MD*
Instructor(s): Alex V Levin MD, Terri L Young MD*
Glaucoma
YO Examining the Optic Nerve and Evaluating the Visual
Field: The 5 Rs
Course: 151
Room: E353b
Sunday
10:15 AM - 12:30 PM
Synopsis: This course will provide a standardized process and technique, using 5
rules, for examination and documentation of the optic disc and retinal nerve fiber layer
and for visual field evaluation to identify signs of glaucoma.
Objective: At the end of the course, participants will be better able to systematically perform optic nerve examination and interpret visual fields to diagnose glaucoma
earlier, correctly stage the disease, and detect glaucoma progression.
Senior Instructor(s): Ronald L Gross MD*
Instructor(s): Benjamin J Frankfort MD PhD*
NEW Selective Laser Trabeculoplasty: Basic Principles

and Pearls for Practice
Course: 167
Room: E353c
Sunday
10:15 - 11:15 AM
Synopsis: Laser trabeculoplasty (LT) is a commonly utilized technique for treating

glaucoma. Performing LT is now possible with several different approaches including
Argon Laser Trabeculoplasty (ALT), Selective Laser Trabeculoplasty (SLT), Diode Laser
Trabeculoplasty (DLT) and others. While LT has been utilized as primary therapy in
those newly diagnosed with glaucoma, it is more commonly used in patients who
have failed medical therapy or in patients with physical or economic limitations. This
session will cover the basics of performing LT with a focus on SLT as a tool for treating various types of glaucoma at various stages of the disease process. The basics of
patient consent, laser settings, preoperative drop therapy and postoperative care will
all be covered in detail. Case based learning will be used to emphasize key points
when appropriate.
Objective: At the conclusion of this course, the attendee will be able to explain
the current best-practice methodology for performing SLT including patient selection,
laser settings and the nuances of preoperative and postoperative care.
Senior Instructor(s): Malik Y Kahook MD*
Instructor(s): Leonard K Seibold MD*, Jeffrey R SooHoo MD, Mina B Pantcheva MD
Instruction Courses
Angle Closure and Angle-Closure Glaucoma
Course: 184
Room: S105bc
Sunday
2:00 - 4:15 PM
Combined Cataract Surgery With Glaucoma Surgery:

Guidelines, Indications, Methods, Techniques, and
Postoperative Management
Course: 186
Room: S403b
Sunday
2:00 - 4:15 PM
Synopsis: This course will provide a comprehensive review of guidelines and indications for combined cataract / glaucoma filtering surgery based on glaucoma severity, IOP control, extent of optic nerve damage, level of visual field loss, and type
of glaucoma. Preoperative considerations, from determination of surgical site and
antimetabolite use to poorly dilating pupil, shallow anterior chamber, and posterior
synechiae, will be discussed. Surgical methods, anesthesia, one- or two-site surgery,
and surgical techniques will be explained. Glaucoma filtering surgery methods from
conjunctival dissection and wound architecture to antimetabolite use will be stressed.
Anticipation, avoidance, and management of surgical and postsurgical complications,
and postoperative management of glaucoma will be explained.
Objective: At the conclusion of this course, attendees will be able to proceed with
combined cataract / glaucoma surgery, determine best surgical method, avoid complications, and manage postoperative glaucoma course.
Senior Instructor(s): Leon G Partamian MD*
Instructor(s): Eve J Higginbotham MD, Cynthia Mattox MD FACS*, David Lee MD*,
Anastasios P Costarides MD PhD*, Thomas W Samuelson MD*, Marlene R Moster
MD*
Ophthalmoscopic Evaluation of the Optic Disc and Retinal

Nerve Fiber Layer
Course: 191
Room: N139
Sunday
2:00 - 4:15 PM
Synopsis: This course covers the ophthalmoscopic evaluation of optic disc, cup,
neuroretinal rim, parapapillary atrophy, disc hemorrhages, retinal nerve fiber layer,
and retinal vessel width.
Objective: The course will help participants to (1) understand pseudoglaucomatous macrocupping and pseudonormal minicupping, (2) detect early glaucomatous
changes, (3) differentiate glaucoma types by disc morphology, (4) distinguish glaucomatous optic neuropathy from nonglaucomatous optic nerve atrophy, (5) consider
ethnic differences in the disc appearance, (6) discuss pathogenic implications of the
disc morphology for glaucoma, (7) perform the dynamic optic disc assessment using modified ophthalmodynamometry for estimation of central retinal artery and vein
pressure, orbital tissue pressure, and brain pressure, (8) understand the presence of
cerebrospinal fluid pressure, and (9) differentiate alpha, beta, gamma, and delta zone
of parapapillary atrophy by OCT and histology.
Senior Instructor(s): Jost B Jonas MD*
Course: 228
Room: S105bc
Sunday
4:30 - 5:30 PM
Synopsis: Participants will wear red-blue glasses to view 3-D PowerPoint projections of stereoscopic gonioscopy and slitlamp images. Identifying traditional gonioscopic anatomy may be confounded by a variety of anterior chamber angle pathologies. The use of different gonioprisms and indispensable gonioscopy techniques
(dynamic indentation and termination of the corneal light wedge) will be discussed.
Special emphasis will be placed on the evaluation of narrow angles, decision making
for laser iridotomy, and laser treatment of the angle and iris. Pathologic variations in
overly deep anterior chambers, angle blood vessels, increased trabecular meshwork
pigment, peripheral anterior synechiae due to anterior mechanisms with or without
membranes and posterior mechanisms with or without pupillary block, and anterior
chamber angle clefts will be presented.
Objective: While viewing stereoscopic images, the attendee will learn essential
gonioscopic anatomy, examination techniques, and categorization with variations in
pathology.
Senior Instructor(s): Alan H Zalta MD
Gonioscopy and Angle Imaging

Course: 232
Room: S403b
Sunday
4:30 - 5:30 PM
Synopsis: Gonioscopy, like any other skill in that it involves a learning curve. The
training here will concentrate on when and how best to hone this skill. This course will
educate the comprehensive ophthalmologist on different types of gonioscopy lenses
and techniques, correlating the information with imaging studies and the clinical implications of their findings. The different grading systems and methods of documentation will be covered, as well as advice on interpreting state-of-the-art imaging. The
course will utilize several high-resolution images of the angle.
Objective: At the conclusion of this course, the attendees will be able to incorporate
this valuable skill into their practices for the benefit of patients with various angle
abnormalities.
Senior Instructor(s): Shamira A Perera MBBS
Instructor(s): Tin Aung FRCS PhD
Glaucoma Postop Care in the Office: A Video Compendium

of TechniquesWhen and How to Intervene
Course: 310
Room: S104a
Monday
9:00 - 11:15 AM
Synopsis: This course will demonstrate strategies and techniques used during the
postoperative period of trabeculectomy and glaucoma drainage implant procedures to
increase surgical success.
Objective: At the conclusion of this course, the attendee will be able to identify
causes of surgical failure and early postoperative complications that require intervention. The strategies, timing, and techniques used to deal effectively with postoperative management of trabeculectomy and glaucoma implants will be discussed in
detail and demonstrated with the use of slitlamp video footage to allow attendees to
utilize these procedures in their own offices. The instructors, who have diverse training backgrounds, will show variations in technique that will allow even the seasoned
glaucoma surgeon an opportunity for learning.
Senior Instructor(s): Cynthia Mattox MD FACS*
Instructor(s): Chandrasekharan Krishnan MD**, Susan S Liang MD**, Alan E Lowinger
MD
EHR
75
Instruction Courses
Synopsis: Practically and logically, this course will define and classify these glaucomas, outline their prevalence and incidence, outline methods of assessment, and
discuss pathophysiological mechanisms before covering medical, laser, and surgical
strategies of prevention and treatment and current approaches to management of the
acute angle-closure crisis.
Objective: After the course, participants will have a deeper and broader understanding of the burden and current classification of angle closure and angle-closure
glaucoma, an awareness of pathophysiological principles underlying choices of new
treatment strategies, and a detailed update on how best to prevent and to manage
this spectrum of the glaucomas.
Senior Instructor(s): Tetsuya Yamamoto MD*
Instructor(s): Ivan Goldberg MBBS FRANZCO*, Clement C Y Tham MBBS*, Paul T K
Chew MD*, Tin Aung FRCS PhD*, Ki Ho Park MD*, Prin Rojanapongpun MD*, Ning Li
Wang MD, Ching Lin Ho FRCS MBBS*
H YO Top 10 Essentials of Gonioscopy: 3-D Viewing and

Interpretation
Instruction Courses
Glaucoma Filtration Device Mini-shunt: Friend or Foe?
Course: 313
Room: S105bc
Monday
9:00 - 10:00 AM
Synopsis: This course will provide practical tips in the use of Ex-Press shunts, including videos to demonstrate surgery to insert and remove the shunt if necessary.
The management pearls for treatment of complications will be highlighted with illustrative cases.
Objective: This course will review indications and contraindications for the use of
Ex-Press shunts and practical tips for insertion. The course will also discuss prevention of complications and management of these, if they should occur.
Senior Instructor(s): Annapurna Singh MD
Instructor(s): Richard A Lehrer MD*
Canal-Based Glaucoma Surgery: Canaloplasty vs.

Microstent ImplantationEverything You Want to Know
Instruction Courses
Course: 316
Room: S105a
Monday
9:00 - 11:15 AM
Synopsis: In this course the anatomy and pathophysiology of the Schlemm canal and
its role in glaucoma, ultrasound studies of the canal, canal surgery (canaloplasty and
microstent) indications, surgical techniques, outcomes, and management of complications will be discussed using surgical video footage and clinical pictures. Techniques
for performing combination cataract and canal surgery and variations in difficult cases
will be addressed. Future strategies for improving the surgical outcomes, including in
the design and antifibrosis agents, will be discussed.
Objective: At the conclusion of this course, the attendee will be able to understand
the basic anatomy, pathophysiology, indications, surgical techniques (including combination surgeries), and management of intra- and postoperative complications of
canal-based surgeries (canaloplasty and microstent implantation).
Senior Instructor(s): Ramesh S Ayyala MD FRCS*
Instructor(s): Thomas W Samuelson MD*
NEW Ocular Surface Disease and Glaucoma

Course: 355
Room: S104b
Monday
11:30 AM - 12:30 PM
Synopsis: Ocular surface disease and glaucoma are common conditions that affect
millions of individuals. Often the diagnosis and treatment options for patients with
both conditions can be confusing.
Objective: This course will present the current modalities of detecting and treating
ocular surface disease in individuals with glaucoma. Also, several clinical scenarios
will also be presented with audience participation to better illustrate clinical dilemmas. At the conclusion of this course, the attendee will be able to develop strategies
for the effective treatment of patients with both glaucoma and ocular surface disease.
Senior Instructor(s): Prithvi S Sankar MD
Instructor(s): Eydie G Miller MD*, Mina Massaro-Giordano MD*, Vatinee Y Bunya
MD*
Managing Angle-Closure Glaucoma With Crystalline Lens

Removal and Adjunctive Procedures
Course: 387
Room: S403b
Monday
2:00 - 4:15 PM
Synopsis: Preoperative diagnostics and ample surgical video will be used to demonstrate a unified approach and specific techniques to safely perform phacoemulsification as a definitive treatment for angle-closure glaucoma. In addition, adjunctive
procedures such as goniosynechialysis, endoscoplasty, pars plana vitreous tap, iridozonulo-hyaloidectomy, and pupilloplasty will be demonstrated. Tools such as capsular
tension rings, pupillary rings, iris hooks, and microinstrumentation to enhance surgical
success will be presented.
Objective: This course is designed to provide surgeons with an approach and tools
for safely performing phacoemulsification in the management of angle-closure glau76
coma and to introduce adjunctive procedures to further enhance outcomes in these

cases.
Senior Instructor(s): Devesh K Varma MD*
Instructor(s): Iqbal K Ahmed MD*, Garry P Condon MD*, Sebastien Gagne MD**,
Arsham Sheybani MD, Diamond Y Tam MD
Cell Biology, Genetics, and Outflow in Glaucoma in 2014:

Impact on Practice
Course: 419
Room: S103a
Monday
4:30 - 5:30 PM
Synopsis: An overview of biology-based theories relevant to clinical glaucoma will

be presented. A very brief summary of the discussions at the Trabecular Meshwork
Society meeting in December 2013 will be presented, along with other recent scientific advances pertaining to glaucoma. Uniquely, we emphasize the substantial relevance of these findings to diagnosis and therapy.
Objective: This course will discuss the pros and cons of future genetic testing. The
attendee will understand how specific concepts in cell biology impact clinical care of
the glaucoma patient. After the session, many attendees will engage in an ongoing
scientific dialog about specific aspects of glaucoma, conducted through email. Handouts will consist of numerous articles disseminated through a large file email service
and will serve as a partial basis for these ongoing and sometimes lengthy discussions
about the biology of the meshwork and its clinical relevance.
Senior Instructor(s): John R Samples MD*
Instructor(s): Murray A Johnstone MD*
H Normal-Tension Glaucoma: Evaluation and Treatment

Course: 421
Room: E451b
Monday
4:30 - 5:30 PM
Synopsis: A neuro-ophthalmologist will review neurologic conditions misdiagnosed

as normal-tension glaucoma (NTG) and present the appropriate diagnostic evaluation.
A glaucoma specialist will discuss the pathophysiology of NTG and appropriate medical and surgical therapies.
Objective: This course will enable participants to identify NTG patients who deserve
further neurologic evaluation and to become familiar with the appropriate treatment
of patients with glaucoma and normal IOP.
Senior Instructor(s): Mark L Moster MD*
Instructor(s): Marlene R Moster MD*
Tubes, Ties, and Videotape: Surgical Video of Baerveldt

Glaucoma Implants and Managing Complications
Course: 510
Room: S403a
Tuesday
9:00 - 11:15 AM
Synopsis: This course will present clinical photos, patient history, and edited surgical videos of several challenging glaucoma cases and will demonstrate efficient
techniques for tube insertion and how to manage postoperative complications. The
instructor will demonstrate how to reposition, extend, trim, cover, revise, and tie-off
problematic tubes and will discuss how tubes are used in conjunction with surgery for
cataracts, corneal failure, and retinal detachment.
Objective: At the conclusion of this course, the attendee will be able to formulate
an appropriate surgical plan for a glaucoma drainage implant and be better prepared
to avoid and manage potential complications.
Senior Instructor(s): Herbert P Fechter MD
Argon Laser Peripheral Iridoplasty: All You Need to Know

Course: 514
Room: S105bc
Tuesday
9:00 - 10:00 AM
Synopsis: This course covers all you need to know about argon laser peripheral iridoplasty (ALPI), from indications, contraindications, techniques, pearls, and results
to complications and their management. Slitlamp photographs and videos are exten-
Instruction Courses
sively used in the course, the handout, and the course website to illustrate the critical
techniques.
Objective: At the conclusion of this course, the attendee will be able to safely, effectively, and confidently perform ALPI in the appropriate patients.
Senior Instructor(s): Clement C Y Tham MBBS*
Instructor(s): Robert Ritch MD FACS*
including the evolution of rim notching, circumlinear vessel baring, laminar dot sign,
and vessel course changes.
Objective: While viewing stereoscopic optic disc images, physicians will learn to
identify (1) glaucomatous disc damage and progression and (2) the most common optic
disc anomalies and pathologies that may confound this assessment.
Evidence-Based Guidelines in the Management of

Glaucoma
Whats Your Next Step? Case Studies in Glaucoma

Management
Course: 605
Room: N139
Tuesday
9:00 - 11:15 AM
NEW OCT in Glaucoma: Whats Real Disease and Whats

Red Disease?
Course: 544
Room: S103d
Tuesday
10:15 - 11:15 AM
Synopsis: Optical Coherence Tomography has become an important tool for diagnosing glaucoma and detecting glaucoma progression. Using a combination of
didactic lecturing and case examples, interpretation of OCT for glaucoma diagnosis
and progression will be presented, primarily relying on the Cirrus (Zeiss) OCT platform. Examples of glaucoma detection and progression with Spectralis (Heidelberg)
and RTVue (Optovue) will also be presented. Case examples of false positives (red
disease) false negatives (green disease) and other diagnostic dilemmas will be
reviewed to help the participant sort out what is real vs. artifact in OCT interpretation
for glaucoma.
Objective: This course will improve the participants ability to diagnose glaucoma
and glaucoma progression and avoid diagnostic mistakes.
Senior Instructor(s): Donald L Budenz MD MPH*
3-D Optic Disc Viewing: Top 10 Pitfalls in Identifying

Glaucoma Damage and Progression
Course: 555
Room: S105bc
Tuesday
11:30 AM - 12:30 PM
Synopsis: Participants will wear red-blue glasses to view 3-D PowerPoint projections of stereoscopic optic disc images. The most common pitfalls in identifying glaucomatous disc damage (including optic disc anomalies, swelling, and atrophy) will be
viewed, discussed, and correlated with visual field loss. Characteristic glaucomatous
disc changes will be highlighted, including vertical elongation of cupping and pallor, cup-to-disc asymmetry, focal excavation, nerve fiber layer defects, and splinter
hemorrhages. Special emphasis will be placed on simultaneous viewing of serial stereoscopic images that demonstrate progressive glaucomatous disc damage over time,
Tuesday
11:30 AM - 12:30 PM
Synopsis: Both challenging and everyday glaucoma cases will be presented and
discussed in a panel format. Visual fields and OCT, among other ancillary tests, will
be used to demonstrate the case presentations. Audience participation will be encouraged.
Objective: At the conclusion of the course, the participants will have a better understanding of common glaucoma cases with diagnostic or interventional dilemmas.
Senior Instructor(s): Prithvi S Sankar MD
Instructor(s): Eydie G Miller MD*, Cynthia L Grosskreutz MD PhD*, Sarwat Salim MD*
NEW SOE Continuous 24-Hour IOP Monitoring: Ready for

Prime Time?
Course: 566
Room: S106a
Tuesday
11:30 AM - 12:30 PM
Synopsis: IOP, the only modifiable risk factor for glaucoma, is a dynamic parameter.
Peak IOPs occurring outside clinic hours remain undetected in many glaucoma patients. Recent availability of telemetric devices for continuous 24-hour IOP monitoring
has the potential to improve glaucoma care.
Objective: This course will present (1) the nature of 24-hour IOP and its clinical significanceand (2) the role of 24-hour IOP monitoring technologies in clinical practice.
At the conclusion of this course, the attendees will understand the complexities of
24-hour IOP patterns and how to integrate current technologies for monitoring IOP into
the clinical management of glaucoma patients.
Senior Instructor(s): Kaweh Mansouri MD*
Instructor(s): Malik Y Kahook MD*, Robert N Weinreb MD, Arthur J Sit MD, Syril
Dorairaj MD
NEW Pearls and Pitfalls of OCT in Glaucoma

Course: 569
Room: E451a
Tuesday
11:30 AM - 12:30 PM
Synopsis: This course will cover the following topics: (1) description of OCT testing
strategies for different machines and how to interpret the results, (2) how to use OCT
results for diagnosis and follow-up of glaucoma patients, (3) how to increase compliance with treatment using OCT, (4) frequency of OCT testing, (5) predicting visual
field findings from OCT results, (6) how to identify glaucoma masqueraders from OCT
results, (7) the rationale behind using macular thickness and ganglion cell complex
thickness, (8) pitfalls in results of OCT images, and (9) other nonglaucoma diagnoses
made with the help of OCT.
Objective: At the end of the course, the attendee will be able to utilize OCT for
the diagnosis and follow-up of different stages of glaucoma with confidence. The
attendee will be able to identify artifacts and differentiate glaucoma from other masqueraders and other neurological diseases.
Senior Instructor(s): Sanjay G Asrani MD*
Instructor(s): Masanori Hangai MD*, Michael P Kelly FOPS
EHR
77
Instruction Courses
Synopsis: Early detection and treatment of glaucoma are of paramount importance

to reduce the burden of blindness and its economic impact on society. Two important
questions often confront a glaucoma specialist when initiating therapy: Who needs
to be treated? And how should a patient be treated? This course will address the
evidence-based guidelines for treating glaucoma and review the invaluable information from major clinical trials (Glaucoma Laser Trial, Selective Laser Trabeculoplasty
vs. Medical Therapy study, Ocular Hypertension Treatment Study, European Glaucoma
Prevention Study, Early Manifest Glaucoma Trial, Collaborative Initial Glaucoma Treatment Study, Advanced Glaucoma Intervention Study, etc.) that have enhanced our
understanding of the risk factors and treatment strategies at various stages of the
disease.
Objective: At the conclusion of the course, the attendee will be knowledgeable
about when and how to treat glaucoma patients based on evidence, including many
of the major clinical trials that have guided clinical decision making in glaucoma practice.
Senior Instructor(s): Sarwat Salim MD*
Instructor(s): Malik Y Kahook MD*, Shan C Lin MD*, Raghu Mudumbai MD, Peter
Andreas Netland MD PhD**, Joel S Schuman MD*, Quang H Nguyen MD*, Carla J
Siegfried MD*
Course: 560
Room: S105d
Instruction Courses
Medical Therapy for Open-Angle Glaucoma: A Complete
Review of the Pharmacodynamics, Pharmacokinetics, and
Toxicity of All Potentially Useful Drugs
Course: 572
Room: S104b
Tuesday
12:45 - 1:45 PM
Synopsis: This course will present the pharmacodynamics, pharmacokinetics, and

toxicity of drugs potentially useful for open-angle glaucoma (OAG) treatment, including parasympathomimetics, sympathomimetics, sympatholytics, carbonic anhydrase
inhibitors, prostaglandin analogs, osmotics, neuroprotectors, blood flow enhancers,
marijuana, Ginkgo biloba, and other alternative therapies.
Objective: Participants will be able to treat OAG more effectively by enhancing compliance and risk-benefit ratios.
Senior Instructor(s): Allan J Flach MD
H SA Update Your Anterior Chamber Angle Skills: How to
Best Examine, Grade, and Treat

Instruction Courses
Course: 574
Room: E352
Tuesday
12:45 - 3:00 PM
Synopsis: Studies show we look at the chamber angle in less than half of all initial
glaucoma patient visits. Why? This course is about improving your chamber angle organizational skills to overcome chamber angle neglect. It will put everything together
for the comprehensive ophthalmologist: how to best look at the angle, distinguish normal from abnormal angles, indent crowded angles, record your findings, and treat the
iris and angle with laser therapy. In addition, important landmarks for up-and-coming
canal procedures will be emphasized.
Objective: At the conclusion of the course, attendees will be able to better view the
angle, improve their treatment of the angle, know when to perform and better record
their gonioscopic findings, and be updated on the risks and benefits of laser peripheral
iridotomy, selective laser trabeculoplasty, argon laser trabeculoplasty, and iridoplasty.
Senior Instructor(s): Ronald Leigh Fellman MD OCS*
Instructor(s): Ronald L Gross MD*, Silvia D Orengo-Nania MD*, Thomas W Samuelson
MD*, Mark B Sherwood MD*, Steven T Simmons MD*, George L Spaeth MD FACS*,
Arvind Neelakantan MD*
Complications Following Glaucoma Filtering Surgery: Face

Them Boldly, Manage Them Efficiently
Course: 591
Room: N140
Tuesday
2:00 - 4:15 PM
Synopsis: This course will review the early detection and prevention of and specific
management strategy for the common complications that may be associated with
glaucoma filtering surgery, such as hyphema, shallow to flat anterior chamber, early or
late leaking bleb, encapsulated blebs, hypotony, the wipeout phenomenon, blebitis,
bleb infection, and endophthalmitis.
Objective: At the conclusion of the course, attendees will be able to face complications following glaucoma filtering surgery more boldly and manage them more efficiently.
Senior Instructor(s): Anil K Mandal MD
Instructor(s): Peter Andreas Netland MD PhD**, Dale K Heuer MD*, Eve J
Higginbotham MD, Sriram Sonty MD FACS*
H Top 10 Pitfalls, Problem Solving, and Interpretive

Strategy for Automated Threshold Perimetry
Course: 592
Room: S105bc
Tuesday
2:00 - 3:00 PM
Synopsis: This course will present a step-by-step interpretive strategy for automated threshold perimetry. This course will also teach recognition of the most common
pitfalls encountered and problem solving to avoid misinterpretation, underdiagnosis,
and overdiagnosis.
78
Objective: Participants will learn to (1) systematically interpret central threshold

visual fields, (2) recognize common pitfalls, including testing legally blind eyes, low
reliability message, testing children, normal gray scale display in the presence of early
scotomas, isolated peripheral nasal steps, severe visual field loss, limitations of computerized interpretation, SITA variability, and pseudo-scotomas or pseudo-progression
due to artifact (miosis, ptosis, lens rim), and (3) problem solve using nonstandard parameters (eg, size V stimulus) or alternate strategies (eg, central 10-degree or peripheral 30/60 degree field). This course was designed to optimize automated perimetry
evaluation and monitoring and to eliminate common interpretational errors.
Instructor(s): John S Cohen MD*
The Art and Science of Glaucoma Drainage Devices: How to

Optimize Your Surgical Results
Course: 597
Room: S106a
Tuesday
2:00 - 4:15 PM
Synopsis: The basic differences among the different glaucoma drainage devices
(GDDs)-including design, size, biomaterial, the pathophysiology of the resulting blebs,
indications, surgical techniques, outcomes, and management of complications-will be
discussed using surgical video footage and clinical pictures. Techniques to perform
different surgeries such as Descemet-stripping automated endothelial keratoplasty,
penetrating keratoplasty, phaco / posterior chamber IOL, and pupilloplasty in the presence of or combined with GDD will be discussed. Future strategies for improving the
surgical outcomes, including in the design and antifibrosis agents, will be discussed.
Objective: At the conclusion of this course, the attendee will be able to understand
the basic differences among the different GDDs, the pathophysiology of the resulting blebs, the indications, surgical techniques (including combination surgeries), and
management of intra- and postoperative complications.
Senior Instructor(s): Ramesh S Ayyala MD FRCS*
Instructor(s): Steven Gedde MD*
H Improving Success in Filtration Surgery: Intraoperative

Surgical Techniques and Postoperative Management of the
Failing Filter
Course: 599
Room: S105a
Tuesday
2:00 - 4:15 PM
Synopsis: This course will describe techniques for successful performance of trabeculectomy and Ex-Press device implantation and will comprehensively review postoperative management of the failing glaucoma operation.
Objective: At the end of this course, attendees will understand the available techniques for enhancing glaucoma surgery success and will understand postoperative
adjuncts for dealing with failing filtration characterized by either high IOP or low IOP.
Senior Instructor(s): Husam Ansari MD PhD*
Instructor(s): Bradford J Shingleton MD*
NEW GO Ocular Parasitoses: Diagnosis and Treatment
Course: 217
Room: S103a
Sunday
3:15 - 4:15 PM
Synopsis: Parasitic infections of the eye are a major cause of ocular diseases in
many parts of the globe. Lesions in the eye can be due to direct invasion, indirect
damage by their toxic products, or the host immune response incited by them. Understanding the natural history of these parasitic diseases, their morphology, and the
symptoms and signs produced by them would help in timely diagnosis and prompt
intervention, saving vision and sometimes life. From basic anatomy and microbiology
to interactive case discussions and surgical videos, this course will give the attendee
a comprehensive, practical knowledge as well as presenting the latest trends in the
management of various parasitic infections of the eye.
Instruction Courses
Objective: At the conclusion of the course, the attendee will be able to gain ample
knowledge in the diagnosis and management of various parasitic infections of the
eye.
Senior Instructor(s): Tapas Ranjan Padhi MBBS MS
Instructor(s): Sujata Das MBBS, Savitri Sharma MD
NEW GO SOE Global Trends in Retina: Learning From
in a fashion that simplifies and optimizes the workup and reduces unnecessary testing. Clinical cases will highlight important features.
Objective: Upon completion of this course, participants will be able to (1) selectively
order appropriate diagnostic tests based on the clinical presentation of various uveitis
entities in a cost-effective fashion and (2) interpret the results of diagnostic tests.
Senior Instructor(s): Sarkis H Soukiasian MD
Instructor(s): Michael E Zegans MD*, Russell N Van Gelder MD PhD*
Course: 517
Room: N427a
NEW All White Dots Are Not the Same! Imaging

Techniques in the Diagnosis and Management of Posterior
Uveitis
Each Other
Tuesday
9:00 - 10:00 AM

International (Dis)Agreement on Infectious Uveitis
the American Uveitis Society (AUS)
Course: 170
Room: E353c
Sunday
11:30 AM - 12:30 PM
Synopsis: Infectious uveitis is estimated to be responsible for 10%-30% of all uveitis cases. In some parts of the world toxoplasmosis alone is responsible for up to
50% of all posterior uveitis. Infectious uveitis poses unique diagnostic and therapeutic
challenges. Uveitis resulting from infections can masquerade as noninfectious uveitis.
The diagnosis may require an anterior chamber or vitreous tap. While autoimmune
uveitis requires long-term immunosuppressive therapy, most infectious uveitides can
be treated with short-term antimicrobial therapy. It is therefore highly desirable to
identify possible infectious etiology in idiopathic uveitis. The instructors will present a variety of challenging cases from around the world, with interactive discussion
sessions.
Objective: At the end of this course, the audience will be able to develop a stepwise
approach to diagnosing and managing infectious uveitis entities.
Senior Instructor(s): Rubens Belfort Jr MD PhD*
Instructor(s): Hatice N Sen MD, Robert B Nussenblatt MD, Narsing A Rao MD, Khalid
F Tabbara MD*, Bahram Bodaghi MD PhD, Cristina Muccioli MD, Thomas A Albini
MD*, Heloisa Nascimento MD, Wendy M Smith MD
H Decoding the Uveitis Workup: Why, When, and What to

Order
Course: 190
Room: E351
Sunday
2:00 - 4:15 PM

Course: 203
Room: S102d
Sunday
2:00 - 3:00 PM
Synopsis: Advances in imaging technology have resulted in many modalities that

allow examination of posterior uveitis in new ways. Fluorescein angiography is often considered the gold standard for diagnosis, but indocyanine green with late
exposures may provide valuable information when inflammation arises primarily in
the choroid. The recent developments of spectral domain OCT (SD-OCT), enhanced
depth imaging OCT (EDI-OCT), and fundus autofluorescence (FAF) provide noninvasive
methods for examining inflammatory activity in the retina and choroid. Both OCT and
FAF can reveal early signs of recurrent disease activity and allow close monitoring of
treatment response. In this course the instructors will present a variety of posterior
uveitis cases to highlight the role of imaging in diagnosis and management.
Objective: The audience will understand how to utilize imaging techniques to diagnose posterior uveitis and monitor for recurrent or progressive inflammation.
Senior Instructor(s): Hatice N Sen MD
Instructor(s): Wendy M Smith MD, Debra A Goldstein MD*, Amani Fawzi MD, Thomas
A Albini MD*, Steven Yeh MD*, Sunil K Srivastava MD*, Emmett T Cunningham Jr
MD PhD MPH
Medical and Surgical Therapy and Diagnosis of Uveitis

Course: 306
Room: S103d
Monday
9:00 - 11:15 AM
Synopsis: Recent advances have increased our ability to identify a specific etiology for many cases of uveitis. Medical and surgical therapeutic advances have also
produced dramatic improvements in our ability to care for patients with uveitis. This
course will present our system.
Objective: This course will enable participants to recognize, investigate, and treat
patients with uveitis.
Senior Instructor(s): C Stephen Foster MD*
Instructor(s): Albert T Vitale MD, Emil Mitchel Opremcak MD
H SA How to Evaluate a Patient With Uveitis

Course: 404
Room: E352
Monday
3:15 - 5:30 PM
Synopsis: This course will focus on the step-by-step evaluation of patients with
uveitis by using case presentations to illustrate specific uveitis entities. Each course
instructor will present interesting cases as unknowns for discussion by the panel of
instructors. Course attendees will also be invited to present their own mystery cases
by submitting the cases in advance. The rationale for ordering laboratory evaluations
/ ancillary tests and for the treatment plan will be explained in detail.
Objective: Attendees will have ample opportunity to participate in this interactive
course and will experience how a uveitis specialist analyzes each patient. Presentations will include both infectious and noninfectious entities in patients with anterior,
intermediate, posterior, and pan-uveitis. Special emphasis will be given to the newest
Synopsis: This course will primarily focus on the stepwise, cost-effective uveitis
workup utilizing the history and clinical presentation. Uveitis entities will be classified
EHR
79
Instruction Courses
Synopsis: This course will outline the variations in current global trends in managing
vitreoretinal diseases. It will link various vitreoretinal societies from different parts of
the world in order to explore the huge potential to learn from their practice trends,
specifically where no level 1 evidence exists. The highlights of three comprehensive
surveys from three different countries (the United States, the United Kingdom, and
India) will be discussed, in addition to expert opinions from six continents. Specific
topics will include instrumentation, retinal detachment, macular surgery, perioperative management, AMD, and socioeconomics.
Objective: Upon completion of the course, attendees will have gained (1) greater
insight into a variety of options for managing a particular vitreoretinal disease, (2)
reasons for global variations in practice trends, and (3) the implications for their own
practices. This course will provide an opportunity for attendees to compare their own
preferences to the global retina practice trends.
Senior Instructor(s): Malhar Soni MD MS DNB FRCS
Instructor(s): Kirk H Packo MD*, Sundaram Natarajan MD, Ehab N El Rayes MD PHD*,
Martin Charles MD*, Virgilio Morales-Canton MD*
Instruction Courses
treatment modalities. At the completion of this course, the attendee will be able to
formulate a tailored laboratory evaluation for the entities presented.
Senior Instructor(s): Careen Yen Lowder MD PhD
Instructor(s): Janet Louise Davis MD*, Emilio M Dodds MD, James Philip Dunn Jr MD,
Sunil K Srivastava MD*, Debra A Goldstein MD*
design for a clear and organized presentation of content, summarize the communication skills needed for an engaging presentation, and add 3 strategies for increasing
interactivity during lectures.
Senior Instructor(s): Ana Gabriela Palis MD
Instructor(s): Peter A Quiros MD
H Cataract Surgery and Uveitis: Controlling Inflammation,

Difficult Pupils, and Distorted Anatomy
Surgical Education: Improving Upon and Going Beyond the

Apprentice Model
Course: 581
Room: E451b
Course: 407
Room: N136
Tuesday
12:45 - 1:45 PM
Instruction Courses
Synopsis: This course will teach the management of difficult and potentially complicated cataract surgery in uveitis using surgical videos (including 3-D videos) highlighting unique uveitic anatomy. The focus will be on preoperative immunosuppression
and patient selection, intraoperative management of distorted uveitic anatomy, and
postoperative considerations. Both surgical and medical guidelines for the ophthalmologist will be given, with an emphasis on immunosuppression.
Objective: At the conclusion of this course, attendees will understand preoperative planning and immunosuppression for cataract surgery in uveitis patients. They
will learn intraoperative management of uveitic anatomy via surgical videos and the
management of postoperative inflammation.
Senior Instructor(s): Michael Saidel MD*
Instructor(s): David M Hinkle MD, Donald Stone MD*, Debra A Goldstein MD*
Medical Education
NEW SOE ABC in Effective Ophthalmic Publishing
Course: 215
Room: N136
Sunday
10:15 AM - 12:30 PM
Synopsis: The fast development of computer technology and the Internet has
changed the publishing industry over the last decade. The need for speed and the
global availability of publications has become now at least as important as the prestige of a journal. In this workshop we will emphasize the basics of modern scientific
publishing, looking more closely at the manuscript traffic within the editorial office
and at manuscript selection. In this light we will indicate good author habits that
dramatically speed up the publication process. We also take a look at two other major
problems, namely, (1) plagiarism and understanding the role of citations and (2) journals impact factor on building up ones scientific career.
Objective: (1) To define the basis of a well-written article.(2) To describe how to
revise the paper.(3) To describe when the study is worthy of publishing.(4) To describe
the role and preparation of case reports.(5) To define the impact factor and its role as
a marker for journal ranking.(6) To define the ethical aspects of scientific publishing.
Senior Instructor(s): Andrzej Grzybowski MD*
Instructor(s): Andrew J Lotery MBCHB*, Jose G Cunha-Vaz MD PhD*, Thomas Kohnen
MD*, Thomas J Liesegang MD, Antonia M Joussen MD PhD
Presentation Skills: How to Improve the Effectiveness of

Lectures
the International Council of Ophthalmology
Course: 607
Room: N427a
Sunday
2:00 - 3:00 PM
Synopsis: This course intends to increase participants armamentarium for making

lectures more engaging, active, and effective. Participants will be able to: 1) consider
the need to apply the adult learning principles involved in creating meaningful presentations, 2) organize content logically, and 3) design slides adequately and clearly, and
4) present in an interesting, interactive way.
Objective: By the end of the course participants should be able to list the adult
learning principles applicable to the creation of presentations, provide a structure to
the lecture that allows a logical organization of knowledge. apply principles of slide
80
Monday
3:15 - 4:15 PM
Synopsis: Presenters will cover a wide variety of surgical education techniques,

including traditional surgery, wet lab, cognitive computer modeling, and simulation.
They will focus on how to improve traditional teaching techniques and how to incorporate new techniques and technologies. The course will include strategies to optimize
the use of existing resources and will give attendees a look at modalities to incorporate in the future.
Objective: To review and critique existing and new techniques in surgical education.
Senior Instructor(s): Andrew J Hendershot MD
Instructor(s): Andrew G Lee MD*, Karl C Golnik MD, Thomas A Oetting MD, Bonnie A
Henderson MD*
Resident, Faculty and Program Assessment: Principles &

Best Practices
the International Council of Ophthalmology
Course: 606
Room: N140
Monday
4:30 - 5:30 PM
Synopsis: Teaching does not equal learning and thus residents competence must be
assessed in a systematic, valid and reliable manner. Principles of good assessment
practices will be discussed. Specific, available assessment tools such as 360 degree
evaluation, surgical skill rubric and observed patient encounter will be demonstrated.
Effective faculty and program evaluation designed to improve teaching effectiveness
will also be discussed.
Objective: At the completion of this course, the attendee will be able to 1) list 5 principles of assessment, 2) describe several tools that can be used to teach and assess
residents, and 3) outline an approach to effective faculty and program assessment.
Senior Instructor(s): Karl C Golnik MD
Instructor(s): Ana Gabriela Palis MD, Eduardo P Mayorga MD*
Neuro-Ophthalmology
P H What You Need to Know About Headache: A Pain for
the Patient and a Pain for the Doctor
the North American Neuro-Ophthalmology Society (NANOS)
Course: 161
Room: S105d
Sunday
10:15 AM - 12:30 PM
Synopsis: Patients are often seen by or referred to the ophthalmologist because of

headache or eye pain. These patients present a diagnostic and therapeutic challenge,
as many will have no apparent ocular etiology for their pain. The purpose of this
course is to present a simplified framework for diagnosis and management of these
patients that will both streamline their evaluation and provide guidelines for potentially beneficial therapeutic interventions. This course will use a case-based approach
to discuss various headache syndromes with ocular manifestations.
Objective: At the conclusion of this course, the attendees will be able to identify the
major categories of underlying diagnoses for headache and eye pain, develop a suc-
Instruction Courses
cinct strategy for history and clinical examination to confirm the suspected diagnosis,
and develop treatment goals in order to help their patients.
Senior Instructor(s): Peter A Quiros MD
Instructor(s): Lynn K Gordon MD PhD*
NEW Case Studies on the Use of Optical Coherence

Tomography (OCT) for Diagnosis of Unknown Causes of
Visual Loss: Is it the Retina, Anterior Visual Pathway, or
Misinterpretation of Normal?
Course: 543
Room: E352
Sunday
3:15 - 4:15 PM
Swollen Disks, Headache, and Vision Loss: A Case-Based

Approach to Pseudotumor Cerebri
Course: 231
Room: E352
Sunday
4:30 - 5:30 PM
Synopsis: What do you do when a patient with bilateral disc swelling and headache
presents? How do you decide the urgency of evaluation and make the right diagnosis?
Using a case-based approach, we will emphasize the workup that this patient needs
and will show you how to use technology (CT, MRI/MR venography, spectral domain
OCT, visual fields) to help you recognize the warning signs of sight-threatening disease. We will discuss treatment outcomes including venous sinus stenting, and the
long-term consequences of pseudotumor cerebri.
features of optic disc swelling that suggest sight-threatening disease and will understand the evaluation and referral process. Attendees will be able to interpret the results of diagnostic imaging techniques and recognize critical findings of venous sinus
disease. They will be able to select appropriate medical, surgical, or interventional
treatments based on exam and test findings and predict patient outcomes.
Senior Instructor(s): Prem S Subramanian MD PhD*
Instructor(s): Vivek R Patel MD
H Visual Fields in Neuro-Ophthalmology

Course: 351
Room: E351
Monday
11:30 AM - 12:30 PM
H Diagnostic and Therapeutic Dilemmas in NeuroOphthalmology

Course: 378
Room: E351
Monday
2:00 - 4:15 PM
Synopsis: In this course, actual diagnostic and therapeutic clinical dilemmas will be
presented by a panel of university-based neuro-ophthalmologists, with members of
the audience participating in the generation of differential diagnoses and therapeutic
strategies.
Objective: At the conclusion of the course, the attendee will be able to address difficult problems in the diagnosis and management of neuro-ophthalmic cases.
Senior Instructor(s): Nancy J Newman MD
Instructor(s): Neil R Miller MD*, Valerie Biousse MD, Andrew G Lee MD*, Steven L
Galetta MD
H Understanding Nystagmus: A Practical Approach for the

Clinician
Course: 382
Room: S105d
Monday
2:00 - 4:15 PM
Synopsis: This course reviews the clinical features of different types of nystagmus.
By using a systematic pathophysiologic approach, clinicians will develop a rational
decision-making process in the diagnosis and management of nystagmus. Numerous
videos will be presented.
Objective: To impart an understanding of nystagmus using a practical approach. At
the conclusion of this course, the attendees will be able to identify the salient features of different types of nystagmus, including their etiology and pathophysiology, as
well as important diagnostic and treatment issues. This course will aid attendees in
improving their clinical management of nystagmus.
Senior Instructor(s): Agnes M Wong MD*
H Emergency Neuro-Ophthalmology: Diagnosis and

Management
Course: 509
Room: S406b
Tuesday
9:00 - 11:15 AM
Synopsis: This course will present a case-based review of the emergency management of acute and transient vision loss, optic nerve swelling, pupillary disorders, and
ocular motility defects.
Objective: To teach participants to identify and manage patients with true neuroophthalmic emergencies, and to review the differential diagnosis and management of
acute vision loss, anisocoria, and ophthalmoplegia.
Senior Instructor(s): Nicholas J Volpe MD
Instructor(s): Mark L Moster MD*
Synopsis: This course will provide an overview of visual fields, with an emphasis on
neuro-ophthalmic conditions. The role of visual fields in neuro-ophthalmology will be
put in perspective. Guidelines will be suggested for choosing the best field technique.
EHR
81
Instruction Courses
Synopsis: This will be a case-driven course with audience participation on the use
and interpretation of OCT for diagnosing causes of visual loss. Patients with unknown
diagnoses will be used as examples to provide a basis for the correct interpretation of
OCT results of the optic disc, retinal nerve fiber layer, retinal ganglion cell layer, and
outer retina with special reference to the probability plots, quantitative, and qualitative information on OCT reports. The cases will also relate fundus appearance, visual
field results and neuro-imaging results to the OCT test.
Objective: Attendees will understand how the OCT can be used to differentiate
retinopathies from optic neuropathies in patients with unknown causes of visual loss;
how to correctly interpret the optic nerve head analysis on OCT, including disc area,
rim diameter, and signs of optic nerve edema vs pseudo-papilledema; how to use
the retinal ganglion cell layer probability plot to differentiate optic neuropathy from
damage to the optic chiasm and optic tract; and become familiar with the pitfalls of
misinterpreting OCT scans with special reference to variations in normal and artifacts
that can cause a false positive diagnosis or a missed diagnosis.
Senior Instructor(s): Randy H Kardon MD PhD*
Instructor(s): Fiona E Costello MD*, John C Chen MD*
Some of the newest field techniques will be discussed. Anatomic correlations with
visual fields will be comprehensively detailed. Reliability and artifacts in visual fields
will be reviewed. Case examples of visual field defects will be presented, with audience participation.
Objective: At the end of this course, participants should be able to maximize their
use of visual fields as a component of the complete evaluation in assessment of
neuro-ophthalmology patients.
Senior Instructor(s): Susan M Pepin MD
Instructor(s): Jacqueline A Leavitt MD, Steven A Newman MD
Instruction Courses
H Curbside Consults in Neuro-Ophthalmology
Course: 515
Room: N427bc
Tuesday
9:00 - 11:15 AM
Synopsis: This course will engage the target audience in a participatory and interactive panel-led conversation about common neuro-ophthalmic conditions of interest to
general ophthalmologists.
Objective: By the conclusion of this course, participants should be able to define
specific distinguishing and differentiating symptoms and signs in neuro-ophthalmic
disorders; to list specific testing strategies for making an accurate diagnosis in lifethreatening neuro-ophthalmic conditions; and to describe the key clinical, laboratory,
diagnostic testing, or radiographic findings for specific neuro-ophthalmic diseases.
Senior Instructor(s): Andrew G Lee MD*
Instructor(s): Lanning B Kline MD
Instruction Courses
P H Case-Based Approach to Isolated Eye Pain

Course: 536
Room: E351
Tuesday
10:15 - 11:15 AM
Synopsis: Patients with eye pain and a normal ophthalmologic examination often
present to the ophthalmologist. In this course, differential diagnosis, pathophysiology, management, and cases of isolated eye pain will be discussed in an interactive
fashion.
Objective: The attendee will be able to identify common causes of isolated eye pain
and summarize current treatment options.
Senior Instructor(s): Michael S Lee MD*
Instructor(s): Gregory S Kosmorsky DO
NEW Myasthenia Gravis or Not?

Course: 540
Room: S104a
Tuesday
10:15 - 11:15 AM
Synopsis: This course will review the etiology of myasthenia gravis and discuss
the appropriate workup, associated diseases, and treatment principles. Case-based
examples of diagnostic dilemmas (eg, myasthenia gravis vs. another disease with a
similar complaint or exam) will be used to highlight the variable presenting symptoms
and exam findings.
Objective: Myasthenia gravis can be a challenging disease to diagnose, given the
varying manifestations and overlap in presentation with other conditions. This course
will allow the attendees to better evaluate and treat patients with myasthenia gravis.
At the conclusion of this course, the attendees will be able to (1) discuss the workup
for myasthenia gravis, (2) list treatment principles, and (3) discuss disease associations.
Senior Instructor(s): Courtney E Francis MD
Instructor(s): Peter A Quiros MD
H The Vertical Diplopia Dilemma, Made Simple

Course: 578
Room: N427bc
Tuesday
12:45 - 1:45 PM
Synopsis: In the majority of patients, the etiology of vertical diplopia can be established by careful history taking and clinical examination. In this course, illustrative
cases and discussion will identify specific features of common causes of vertical diplopia such as cranial nerve palsy, thyroid orbitopathy, myasthenia gravis, and orbital
and head trauma. A systematic approach toward evaluation and critical management
pathways will be presented.
Objective: At the conclusion of the course, the attendee will be able to diagnose
common causes of vertical diplopia. A systematic approach toward management will
82
aid the attendee in ordering appropriate tests, identifying patients requiring emergent
management, and making appropriate referrals to specialists.
Senior Instructor(s): Madhura A Tamhankar MD
Instructor(s): Kenneth S Shindler MD PhD, Nicholas J Volpe MD, Collin M McClelland
MD

Practical Ocular Oncology for the Comprehensive
Ophthalmologist: What You Should Know
Course: 192
Room: S105a
Sunday
2:00 - 4:15 PM
Synopsis: This course will consist of presentations and discussions of the topics
in ophthalmic oncology most important for comprehensive ophthalmologists. These
include classic but distinctive fundus lesions, including choroidal melanoma, retinoblastoma, metastatic carcinoma, intraocular lymphoma, and other neoplastic lesions,
both benign and malignant. The presenters will emphasize the clinical diagnosis and
current management as well as hot topics in ocular oncology. Current and future
management in cancer and how it can affect the eye will also be discussed (eg, target
therapy in systemic cancer has shown ocular side effects). Audience participation will
be encouraged with representative cases.
Objective: At the end of this course, attendees will be able to identify the most
common intraocular tumors as well as to understand current management and how
patients can present at a general ophthalmology practice. This course will help comprehensive ophthalmologist to counsel oncology patients.
Senior Instructor(s): Miguel A Materin MD
Instructor(s): James Augsburger MD, Zelia M Correa MD, Hakan Demirci MD, Dan S
Gombos MD*, J William Harbour MD*, Brian P Marr MD, Prithvi Mruthyunjaya MD*,
Jose S Pulido MD MS
Pediatric Ocular Tumors

Course: 227
Room: N139
Sunday
4:30 - 5:30 PM
Synopsis: This course will cover the important ocular tumors affecting children. An
organized presentation will be given on the recognition and management of tumors
of the eyelid, conjunctiva, intraocular structures, and orbit. Retinoblastoma management will be summarized. Various cases will be presented, along with discussion of
management.
Objective: At the conclusion of this course, the attendee should be able to identify
the most common ocular tumors of childhood and understand management strategies.
Senior Instructor(s): Carol L Shields MD
Instructor(s): Jerry A Shields MD
NEW Adult Uveal Tumors: A Systematic Approach for the

General Ophthalmologist
Course: 390
Room: S106a
Monday
2:00 - 3:00 PM
Synopsis: There are many different types of uveal tumor, each of which has a wide
variety of clinical features. Several are life threatening or associated with lethal disease. Most tumors can be diagnosed ophthalmoscopically. Imaging is often helpful
but can be highly misleading if the results are not interpreted correctly. The scope of
biopsy is increasing with advances in surgery and immunohistochemistry.
Objective: In this interactive course, a wide variety of cases will be presented to
illustrate essential diagnostic features as well as diagnostic pitfalls and clinicopathologic correlations.
Senior Instructor(s): Bertil E Damato MD PhD
Instructor(s): Arun D Singh MD
Instruction Courses
NEW Intraocular Tumor Biopsy: The How, Why, and Why
Not?
Course: 519
Room: N136
Tuesday
9:00 - 10:00 AM
NEW Controversies in Ocular Oncology

Course: 523
Room: S104b
Tuesday
9:00 - 11:15 AM
Synopsis: There has been a paradigm shift in the management of tumors of the
eye and adnexa in the recent past. Newer targeted therapies and multimodal protocols are gradually replacing the conventional gold standard management modalities.
Amidst this rapid revolution in evolution, controversies abound. This course aims to
compare conventional strategies with emerging modalities using available evidence
and create ground for common understanding.
Objective: At the end of the course, audience members will be able to categorize
their patients with common tumors of the eye and adnexa for conventional management vs. emerging modalities aimed at optimizing life, eye, and vision salvage with
minimum treatment-related morbidity.
Senior Instructor(s): Fairooz Puthiyapurayil Manjandavida MD
Instructor(s): Jerry A Shields MD, Carol L Shields MD, Brenda L Gallie MD*, Bertil E
Damato MD PhD, Ralph Eagle MD*, Carol L Karp MD, Santosh G Honavar MD, Arun D
Singh MD, Bita Esmaeli MD FACS, Hakan Demirci MD
Ophthalmic History
SO YO Vision and the Artist
Course: 168
Room: S105d
Sunday
3:15 - 4:15 PM
Synopsis: This course fuses ophthalmology and art. We will demonstrate how art
teaches ophthalmology - and how ophthalmology enhances the appreciation of art.
We will discuss how light, dark, and contrast underlie vision and make representation
in art possible. We will also discuss how art may reflect eye disease in the artist and
demonstrate the functional effects of failing vision. Art from all ages will be shown,
with special attention to the question of eye disease in Rembrandt, Cassatt, Degas,
Monet, and OKeeffe. Simulations of the artists own view of their work will illustrate
how different disabilities have affected different artists.
Objective: Attendees should gain understanding of how visual processes and eye
disease affect their patients and gain new appreciation of art.
Senior Instructor(s): Michael F Marmor MD*
Instructor(s): James G Ravin MD
Monday
11:30 AM - 12:30 PM
Synopsis: Although the journey to spatial vision actually began billions of years
ago, the Cambrian explosion (543-490 million years ago) saw the first known eye. The
Cambrian was a crucible of evolution and spawned nearly all ocular designs. This was
followed by descent over millions of years, providing an unimaginable variety of eyes
with at least 10 different models. Some eyes display spectacular creativity, with mirror, scanning, or telephoto optics. From initial photoreception 3.75 billion years ago to
early spatial recognition in the first cupped eyespot in Euglena to fully formed camerastyle eyes the size of beach balls in ichthyosaurs, animals have processed light to
compete and survive in their respective niches. Vision is evolutions greatest gift and
its greatest triumph. This course will present the story of the evolution of eyes.
Objective: To stimulate curiosity about the novelties and the triumphs of the evolution of the eye.
Senior Instructor(s): Ivan R Schwab MD FACS
Optics, Refraction, Contact Lenses

Review of Clinical Optics
Course: 309
Room: N140
Monday
9:00 - 11:15 AM
Synopsis: This review of clinical optics will prepare ophthalmology residents to take
the Ophthalmic Knowledge Assessment Program examination and graduates of residency training programs to take the written qualifying examination of the American
Board of Ophthalmology. It will also serve as a refresher course for those in practice.
The course will be taught in a question-and-answer format, focusing on problem solving. Content and illustrations will be drawn from the American Academy of Ophthalmologys Basic and Clinical Science Course book on clinical optics.
Objective: At the conclusion of the course, participants will be better prepared to
answer multiple-choice optics questions on written examinations.
NEW Subjective Refraction and Prescribing Glasses 102

Course: 564
Room: N427bc
Tuesday
11:30 AM - 12:30 PM
Synopsis: This course will present a discussion of subjective refraction and prescribing glasses, just beyond the basics, to enhance understanding and proficiency.
Objective: At the conclusion of this course, the attendee will be able to discuss
the role of the conoid of Sturm in the subjective refraction process, describe the order and reason for each step, explain why sphere power needs to be adjusted when
refining cylinder power, elucidate the reasons to avoid over-minusing, explain how to
determine if cylinder correction is needed, and discuss tips and strategies to manage
commonly encountered problems as we work to give the patient an optimal glasses
prescription.
Senior Instructor(s): Richard J Kolker MD

Diagnosis and Management of Essential Blepharospasm
and Hemifacial Spasm
Course: 150
Room: S104a
Sunday
10:15 - 11:15 AM
Synopsis: Patients with eyelid and facial spasms frequently present to ophthalmologists. The diagnosis and treatment of essential blepharospasm and hemifacial spasm
is straightforward and gratifying. Through lectures, video, and panel discussions, participants will learn to manage these patients confidently.
EHR
83
Instruction Courses
Synopsis: The management of intraocular lesions often requires accurate pathologic

diagnosis to direct future treatment. Whereas lesions can develop at various sites
including the iris, ciliary body, retina, and choroid, the approach and instrumentation
needs to address specific anatomic considerations. There are increasing indications
for tumor biopsy that utilize new instrumentation and approaches.
Objective: Using illustrative case examples and videos, this course will describe the
indications, techniques, pitfalls and potential complications of iris biopsy, iridocyclectomy, retino-choroidal biopsy, and choroidal lesion biopsy. A special emphasis will be
placed on tissue handling. At the conclusion of the course, the attendee will be able to
describe the indications for intraocular biopsy, dictate the instrumentation required for
successful biopsy, and understand the anatomic considerations relevant to prevention
of vision-threatening complications in retinal and choroidal biopsy.
Senior Instructor(s): Prithvi Mruthyunjaya MD*
Instructor(s): Tara A McCannel MD*, Miguel A Materin MD, Thomas M Aaberg Jr
MD*, Amy C Schefler MD
SO Evolutions Witness: How Eyes Evolved

Course: 346
Room: S103d
Instruction Courses
Objective: This course will familiarize participants with the diagnostic features and
current treatment options for blepharospasm, hemifacial spasm, and related facial
dystonias.
Senior Instructor(s): Richard L Anderson MD FACS*
Instructor(s): Michael T Yen MD*
Complete Guide to the Evaluation and Management of

Ptosis
and the American Society of Ophthalmic Plastic and Reconstructive Surgery
(ASOPRS)
Course: 153
Room: S403a
Sunday
10:15 AM - 12:30 PM
Instruction Courses
Synopsis: This course will provide a comprehensive understanding of ptosis syndromes and surgical treatments. Surgical techniques, including Mller muscle resection and levator and frontalis sling surgery, will be presented in detail.
Objective: Upon completion of this course, participants will gain a thorough understanding of ptosis syndromes and their evaluation and management. Participants will
evaluate, categorize, and surgically plan for the ptosis patient.
Senior Instructor(s): Morris E Hartstein MD
Instructor(s): Adam G Buchanan MD, Gabriela Espinoza MD, Steven M Couch MD
Management of Orbital Tumors: Case Presentation and

Discussion
(ASOPRS)
Course: 154
Room: N135
Sunday
10:15 AM - 12:30 PM
Synopsis: This course will focus on management of orbital tumors through representative cases from the instructors orbital practices. Emphasis will be on clinical
pictures showing initial presentation, imaging characteristics of orbital lesions, surgical approach, and the role of ancillary treatment options such as radiotherapy and/or
systemic chemotherapy.
Objective: This course is designed to enable the orbital and oculoplastic specialist to appropriately diagnose orbital tumors and become familiar with the multidisciplinary management of orbital tumors using illustrative cases and the collective
experience of the course instructors.
Senior Instructor(s): Bita Esmaeli MD FACS
Instructor(s): Geoffrey E Rose FRCOphth, Timothy J Sullivan MBBS, Dale R Meyer MD
FACS, Jonathan J Dutton MD PhD
Optimizing Outcomes and Minimizing Complications in

Oculofacial Plastic Procedures: A Case-Based Approach
Course: 163
Room: S403b
Sunday
10:15 AM - 12:30 PM
Synopsis: This course will present a practical, case-based guide for the evaluation,
planning, and surgical management of common oculofacial plastic procedures. The
course will feature high-definition surgical videos of selected cases, including blepharoplasty, eyelid and brow ptosis repair, and entropion and ectropion repair. Emphasis
will be placed on optimizing surgical outcomes and minimizing and managing complications, using case-based vignettes.
Objective: At the conclusion of this course, the attendee will be able to evaluate
and manage common outpatient oculofacial plastic procedures in an efficient manner
with optimal outcomes.
Senior Instructor(s): Bobby S Korn MD PhD FACS*
Instructor(s): Don Kikkawa MD*, Karim G Punja MD**, Nattawut Wanumkarng MD,
Richard L Scawn MBBS
84
YO Oculoplastic Procedures for the General

Ophthalmologist
Course: 169
Room: S103bc
Sunday
11:30 AM - 12:30 PM
Synopsis: This course will describe basic and effective procedures for the treatment
of involutional ectropion and entropion, tarsorrhaphy, marginal eyelid lesions, dermatochalasis, and aponeurogenic involutional ptosis.
Objective: At the conclusion of this course, the attendee will be able to select and
perform the appropriate surgical technique for the treatment of common eyelid problems encountered in a general ophthalmology practice.
Senior Instructor(s): Robert C Kersten MD
Instructor(s): Francesco P Bernardini MD, Carlo de Conciliis MD, Martin H Devoto MD,
Jose R Montes MD*
Oculoplastic Office Procedures: Video Clips

Course: 172
Room: S102abc
Sunday
11:30 AM - 12:30 PM
Synopsis: Detailed instruction with emphasis on pearls of office eyelid and lacrimal
surgeries will be presented with the use of video clips. The following procedures will
be discussed: incision and drainage of a chalazion, lesion biopsy, lesion excisions,
tarsorrhaphy (chemical and surgical), lacrimal probing and irrigation, punctoplasty,
punctal cauterization, canaliculotomy, entropion repair, ectropion repair, and upper
eyelid blepharoplasty.
Objective: Participants will be shown the relevant anatomy and surgical steps in
performing office eyelid and lacrimal procedures.
Senior Instructor(s): Susan M Tucker MD
Instructor(s): Nancy A Tucker MD
NEW Evaluation and Treatment of Facial Nerve Palsy

Course: 239
Room: S105d
Sunday
4:30 - 5:30 PM
Synopsis: Judicious treatment of patients with facial nerve palsy may be sight saving. Urgent situations often necessitate tarsorrhaphy procedures, while less urgent
situations address the lower eyelid / mid-face, upper eyelid, and brow.
Objective: At the conclusion of the course, the attendee will be able to list the indications and recite the procedures for urgent intervention in facial nerve palsy patients.
The attendee will also be able to recite the indications and procedural details for
addressing the less urgent lower eyelid / mid-face, upper eyelid, and brow conditions.
Senior Instructor(s): Erin Shriver MD
Instructor(s): Richard C Allen MD PhD, Alex W Cohen MD
NEW Optimizing the Aesthetic Appearance of the

Anophthalmic Socket
Course: 241
Room: S103a
Sunday
4:30 - 5:30 PM
Synopsis: Who gets an evisceration, and who gets an enucleation? How do we

choose an implant size and material? To peg, or not to peg? How do we address
the ill-fitting prosthesis? How can we work with ocularists to ensure an aesthetically
pleasing result? This course will discuss the management of the anophthalmic socket
from an aesthetic perspective, with surgical and nonsurgical techniques. At the end of
this course, the attendee will be able to assess the anophthalmic patient and formulate a plan to comprehensively address the appearance of the socket.
Objective: At the end of the course, participants will be familiar with surgical and
nonsurgical issues that arise in the anophthalmic socket, and how to work with ocularists to maximize cosmetic outcomes. Socket expansion and shrinkage techniques
Instruction Courses
will also be discussed, along with ocularistry and techniques to surgically address
upper and lower lid malpositions in the anophthalmic socket.
Senior Instructor(s): Victor M Elner Ph D MD*
Instructor(s): Cesar A Briceno MD, Christine C Nelson MD, Shivani Gupta MD, Hakan
Demirci MD, Fatemeh Rajaii MD, Allison N McCoy MD PhD**
sions, safely diagnose every suspicious periocular tumor, and master the most useful
techniques for upper and lower eyelid reconstruction.
Senior Instructor(s): Jeffrey A Nerad MD
Instructor(s): Francesco P Bernardini MD, Martin H Devoto MD, Robert C Kersten MD,
Carlo de Conciliis MD
Lotions, Potions, Botulinum Toxin, and Fillers: Nonlaser

Rejuvenation for the Ophthalmologist
Tips for Cosmetic Eyelid Surgery in Asian Patients

(ASOPRS)
Course: 336
Room: S403b
Monday
10:15 AM - 12:30 PM
Asian Blepharoplasty and the Eyelid Crease: Challenges

and Solutions: A Video-Complemented Course
Course: 345
Room: S104a
Monday
11:30 AM - 12:30 PM
Synopsis: This course will cover the basic surgical techniques used in creation of
an upper eyelid crease in Asians. The fundamental parameters, proper techniques,
pitfalls, and complications will be presented. Videos will be used to illustrate the
steps. A general handout will be available from each instructor. The senior instructor will present his views on the functional biodynamic of the lid crease, as well as
the Faden effect and consequences of placement of buried sutures used in some
techniques.
Objective: At the end of the course, the attendee will have an understanding of
anatomy, specific terminology, and issues relating to primary as well as revisional
cases and will take away a working knowledge of the steps involved in Asian blepharoplasty, as developed by the instructors.
Senior Instructor(s): William Pai-Dei Chen MD
Instructor(s): Don Liu MD
Periocular Tumors and Techniques of Eyelid Reconstruction

(ASOPRS)
Course: 373
Room: S103a
Monday
2:00 - 4:15 PM
Synopsis: This course will give an overview of the most common benign and malignant skin lesions that involve the periocular region, will highlight the general features
of malignancy, will provide a detailed description of the most common eyelid neoplasms, will describe the different biopsy techniques, and will provide the requisites
to reconstruct the upper and lower eyelid under any circumstance.
malignant and benign tumors, differentiate among the various types of malignant le-
Monday
2:00 - 3:00 PM
Synopsis: Asian people have different anatomic characteristics from non-Asian people, and different beauty standards as well. To obtain a satisfactory surgical outcome,
it is important to understand the distinct points in anatomy and surgical techniques.
This course will present detailed anatomic differences, as well as surgical pearls for
cosmetic eyelid surgery, such as double eyelid operation, upper lid blepharoplasty,
and epicanthoplasty for Asian patients.
Objective: At the conclusion of this course, the attendee will be familiar with different approaches and unique surgical techniques for performing various cosmetic eyelid
procedures in Asian patients.
Senior Instructor(s): Yoon-Duck Kim MD
Instructor(s): Don Kikkawa MD*, Randal Pham MD FACS, Kyung In Woo MD
Stereo Anatomy of the Orbit, Eyelid, and Lacrimal System: A

Surgeons Perspective
Course: 379
Room: S102d
Monday
2:00 - 4:15 PM
Synopsis: This course will provide a comprehensive review of orbital, eyelid, and
lacrimal system anatomy using projected stereo images of meticulous cadaveric dissections. Surgical approaches and complications will be emphasized.
Objective: This course will reacquaint participants with the anatomy of the orbit /
ocular adnexa and increase their confidence when operating in these areas.
Senior Instructor(s): Asa Dan Morton III MD
Instructor(s): Victor M Elner Ph D MD*, Kimberly Cockerham MD FACS*
H Basic Browlift: Principles and Techniques

Course: 422
Room: E351
Monday
4:30 - 5:30 PM
Synopsis: There are many brow elevation techniques, and in general the procedure
should be tailored to the specific patient. This course will review the anatomical foundations, evaluation, patient selection, and treatment of brow ptosis. The techniques
reviewed will include direct, mid-forehead, pretrichial, coronal, limited incision,
chemical, and browpexy.
Objective: At the conclusion of the course, the attendee will be able to describe the
anatomical foundations of brow ptosis, evaluate the patient with brow ptosis, list the
different techniques available for brow elevation, and select which procedure is most
appropriate for each particular patient.
Senior Instructor(s): Richard C Allen MD PhD
Instructor(s): Jill S Melicher Larson MD, Keith D Carter MD FACS
NEW SOE Cut, Lift and Fill: Three-Way Path to a 3-D

Rejuvenation
Course: 425
Room: S103d
Monday
4:30 - 5:30 PM
Synopsis: This course focuses on aesthetic rejuvenation of the periocular aesthetic

unit combining blepharoplasty (cut), endoscopic lifting (lift), and volume restoration
(fill). Three-D and HD videos will be used to demonstrate each technique proposed
during the course, including fat grafting, endoscopic lifting, and tissue-sparing blepharoplasty.
EHR
85
Instruction Courses
Synopsis: Cosmeceuticals, botulinum toxin, chemical peels, and facial fillers are all
nonlaser options for minimally invasive facial rejuvenation. This course will review
facial skin analysis and minimally invasive therapeutic options available to patients.
Assessment, indications, and techniques for use of botulinum toxin, chemical peels,
and facial fillers will be discussed.
Objective: At the end of this course, attendees will be familiar with skin assessment
techniques, cosmeceutical categories, and applications. The indications, techniques,
and complications (management and avoidance) for botulinum toxin, facial fillers, and
chemical peels will also be reviewed. Patient cases will be reviewed to emphasize the
integration of lotions, potions, and injectables to optimize outcomes.
Senior Instructor(s): Femida Kherani MD*
Instructor(s): Christopher M DeBacker MD, Jill Annette Foster MD FACS*, Scott M
Goldstein MD, Wendy W Lee MD*
Course: 377
Room: N427bc
Instruction Courses
Objective: The of the course is to provide the attendees with an alternative rejuvenative approach to the periocular aesthetic unit, based on tissue repositioning
and volume restoration, to traditional subtractive eyelid surgery, focusing on proper
patient selection for each specific technique and treatment combination. At the conclusion of this course attendees will be able to advance their skills in the field of
modern aesthetic practice and be able to recommend the best treatment option for
each individual patient.
Senior Instructor(s): Francesco P Bernardini MD
Instructor(s): Morris E Hartstein MD, Martin H Devoto MD, Jose R Montes MD*
Objective: At the conclusion of the course, the attendees will be able to make an
appropriate choice for management of the spectrum of lacrimal disorders and improve
their surgical techniques in lacrimal surgery.
Senior Instructor(s): Ashok K Grover MBBS
Instructor(s): Hunter Yuen MBBCHB MRCSED, Reynaldo M Javate MD**, Kelvin Kam
Lung Chong MD, Raoul D Henson MD*, Darmayanti Siswoy MD, Kyung In Woo MD,
Mohammad Javed Ali MD, Dongmei Li MD
NEW Congenital Ptosis Simplified
Course: 535
Room: S105bc
Course: 433
Room: S104a
Monday
4:30 - 5:30 PM
Instruction Courses
Synopsis: This course will present the approach to a patient with congenital ptosis.
Evaluation and nuances in the choice of appropriate surgical management will be discussed. Finer points in the surgical techniques for Mullers muscle surgery, Fasanella
Servat surgery, Levator resection and Sling procedures including fascia lata surgery
will be presented by video films. Management of Jaw winking syndrome and Blepharophimosis syndrome will be outlined.
Objective: At the conclusion of this course, the attendee will be able to choose
the appropriate management for a patient with congenital ptosis and understand the
surgical techniques for cases of simple and complicated ptosis.
Senior Instructor(s): Ashok K Grover MBBS
Instructor(s): Chai-Teck Choo**, Yoon-Duck Kim MD
Controversies and Advances in Pediatric Oculoplastic

Surgery
Course: 513
Room: S103d
Tuesday
9:00 - 10:00 AM
Synopsis: In this course a panel of experienced oculoplastic, pediatric, and pediatric oculoplastic surgeons will combine (1) short lectures on controversial topics,
presented by pediatric and oculoplastics for differing views and (2) interactive case
discussions. Topics include congenital ptosis with poor levator function, timing of surgery, unilateral vs. bilateral repair, technique (frontalis sling, levator / tarsal resection,
Mller muscle-conjunctival resection), fascia lata / gortex / silicone sling choices, and
whether bilateral surgery and levator extirpation are needed in Marcus-Gunn ptosis.
Other topics include congenital nasolacrimal duct obstruction, timing / order of repair,
Pediatric Eye Disease Investigator Group updates, balloon dacryoplasty and endoscopic dacryocystorhinostomy advanced techniques, anophthalmia management with
dermis fat, static and hydrogel expanders, and periorbital hemangioma treatment.
Objective: The attendee should be better equipped to make treatment recommendations that incorporate the expertise of both specialties for these difficult pediatric
oculoplastic issues.
Senior Instructor(s): Cat Burkat MD
Instructor(s): Francesco P Bernardini MD, Martin H Devoto MD, Morris E Hartstein
MD, Michael C Struck MD, Angela M Dolmetsch MD
NEW Update on Lacrimal Surgery

Course: 521
Room: S106b
Tuesday
9:00 - 11:15 AM
Synopsis: This course will present the current management practices for a wide
spectrum of lacrimal disorders. Choice of procedures will be discussed in the light of
currently available evidence and finer points of surgical techniques outlined by videos.
The course will discuss congenital nasolacrimal duct obstruction, proximal canalicular
obstructions, external and endonasal dacryocystorhinostomy (DCR), transcanalicular
recanalization, laser DCR, failed lacrimal surgery, and canalicular trauma.
86
Evaluation and Management of Orbital Cellulitis

Tuesday
10:15 - 11:15 AM
Synopsis: Orbital cellulitis is a condition that may be associated with vision- and
life-threatening complications. Despite numerous medical advances in antimicrobial
therapy, radiographic imaging, and surgical technique, the treatment of orbital cellulitis remains challenging. Successful management requires prompt diagnosis, aggressive medical therapy, and in some cases, timely surgical intervention. Through
lectures, video, and panel discussions, participants will learn to manage these patients confidently.
Objective: This course will familiarize participants with the clinical features, radiographic presentation, and current medical and surgical treatment options for orbital
cellulitis.
Senior Instructor(s): Michael T Yen MD*
Instructor(s): Thomas Edward Johnson MD
Inflammatory Orbital Disorders and Their Differential

Diagnoses
Course: 561
Room: S103d
Tuesday
11:30 AM - 12:30 PM
Synopsis: This course will cover the inflammatory orbital disorders and their differential diagnoses. The systemic manifestations of inflammatory disorders, including
infections, Graves eye disease, inflammatory pseudotumor and IgG-4 variant, Sjgren
disease, sarcoidosis, Wegener granulomatosis, adult xanthogranulomatous disease,
and fungal infections, will be discussed. The clinical and imaging characteristics, the
differential diagnosis from orbital malignancy, and current management options for
orbital inflammations will be reviewed. This will be an interactive course with case
presentations and discussions.
Objective: The attendee will learn how to evaluate, provide a differential diagnosis
for, and manage patients with inflammatory orbital diseases.
Senior Instructor(s): Hakan Demirci MD
Instructor(s): Victor M Elner Ph D MD*, Christine C Nelson MD, Alon Kahana MD PhD,
Raymond Douglas MD PhD*, Terry A Smith**, Cesar A Briceno MD
H Evaluation and Treatment of Lower Lid Ectropion,

Entropion, and Retraction
Course: 577
Room: S103bc
Tuesday
12:45 - 1:45 PM
Synopsis: Lower eyelid malpositions are common and include entropion, ectropion,
and retraction. Etiologies of entropion include involutional, cicatricial, and spastic;
etiologies of ectropion include involutional, cicatricial, paralytic, and mechanical; and
etiologies of retraction include involutional, cicatricial, and paralytic. Surgical management is based upon the underlying etiology.
Objective: At the conclusion of the course, the attendee will be able to identify and
classify each of the lower lid malpositions by their etiologies. In addition, the participant will be able to develop an appropriate surgical plan for each of the malpositions.
Senior Instructor(s): Richard C Allen MD PhD
Instructor(s): Erin Shriver MD, Jill S Melicher Larson MD
Instruction Courses
H Thyroid Eye Disease
the International Thyroid Eye Disease Society (ITEDS)
Course: 594
Room: S103bc
Tuesday
2:00 - 4:15 PM

NEW Pediatric Eye Emergencies You Dont Want to Miss!
Course: 202
Room: S403a
Sunday
2:00 - 3:00 PM
Synopsis: Pediatric eye emergencies that present to the comprehensive or pediatric

ophthalmologist can be vision- or life-threatening for the child. Appropriate and early
treatment of such eye conditions is critical in optimizing a successful outcome for the
patient. In this course diagnoses with typical clinical presentations such as retinoblastoma, acquired nystagmus, non-accidental trauma, orbital cellulitis, rhabdomyosarcoma, herpes simplex keratitis, neonatal dacryocystitis, infantile glaucoma, and
orbital vascular malformation will be presented. Illustrative photographs of clinical
findings will be used throughout the presentation. Critical collaborative medical care
will be discussed. Audience discussion and questions will be encouraged at the end
of the course.
Objective: At the conclusion of this course, the audience will be able to diagnose
and manage vision- and life-threatening pediatric eye conditions. The attendee will
be able to appropriately work up each diagnosis with relevant labs, neuroimaging,
and associated tests.
Senior Instructor(s): Yasmin Bradfield MD
Instructor(s): Laura B Enyedi MD, Megan E Collins MD, Shira L Robbins MD*
NEW Pediatric Corneal Disorders: A Comprehensive

Overview
Course: 206
Room: N138
Sunday
2:00 - 4:15 PM
Synopsis: Using didactic presentations and case scenarios, this course will explore
various aspects of pediatric corneal disorders. A comprehensive overview of typical
and atypical presentations of various corneal pathologies unique to the pediatric age
group, such as congenital corneal opacities, anterior segment dysgenesis, congenital
corneal anesthesia, corneal infections, ectatic disorders, and allergies will be presented. We will discuss the management protocols for these disorders and various
surgical challenges and modifications in techniques to perform pediatric penetrating,
rotational and lamellar keratoplasty (Descemet-stripping endothelial keratoplasty /
deep anterior lamellar keratoplasty), and keratoprosthesis.
NEW How to Handle Pediatric Traumatic Cataract

Course: 216
Room: N136
Sunday
3:15 - 4:15 PM
Synopsis: Ocular trauma is an important cause of cataract formation in the pediatric

age group. It may or may not be associated with corneal or uveal injury. The course
will discuss the various presentation patterns and the levels of involvement of the
lens and surrounding tissue. Emphasis will be placed on the need for thorough preoperative assessment and the evaluation parameters. The appropriate IOL designs and
power and the modifications needed in the surgical technique will also be highlighted.
The adjunctive and additional procedures needed for managing corneal and uveal
trauma will also be discussed. The need for parental counseling in order to prevent
ocular trauma to the child will be emphasized.
Objective: The course aims to provide an insight into the need for a careful assessment as well optimal management of pediatric traumatic cataract.
Senior Instructor(s): Rajesh Sinha
Instructor(s): Jeewan S Titiyal MD, Namrata Sharma MD MBBS, Tushar Agarwal MD,
Tarun Arora
H Pediatric Uveitis: What You Need to Know

the American Uveitis Society
Course: 226
Room: N140
Sunday
4:30 - 5:30 PM
Synopsis: This course will cover the challenging issue of pediatric uveitis through
case presentation and interactive discussion with the audience. More than 10% of
blindness due to uveitic conditions occurs in the pediatric population. Among etiologic
entities, juvenile idiopathic arthritis, infectious diseases, and pars planitis remain predominant.
Objective: At the conclusion of this course, the attendee will be able to diagnose
common intraocular inflammatory conditions in children, evaluate the severity of
disease, and propose a tailored workup. Therefore it will be possible to select the
best therapeutic strategy in each situation and propose systemic immunosuppressors,
when necessary.
Senior Instructor(s): Janet Louise Davis MD*
Instructor(s): Bahram Bodaghi MD PhD, Debra A Goldstein MD*
Whats New and Important in Pediatric Ophthalmology and

Strabismus for 2014
the American Association for Pediatric Ophthalmology and Strabismus (AAPOS)
Course: 311
Room: S403a
Monday
9:00 - 11:15 AM
Synopsis: This course will provide a stimulating overview of important publications

from a variety of peer-reviewed journals from 20013/2014 in the field of pediatric
ophthalmology and strabismus.
Objective: At the conclusion of this workshop, attendees will be able to (1) understand the latest research in retinopathy of prematurity prevention and treatment, (2)
understand the causes of various forms of strabismus, as elucidated by the most recent research, (3) be aware of the resources available for genetic testing and how
to more wisely implement genetic testing into their practices, (4) understand trends
in pediatric cataract and refractive surgery and implement this new information into
EHR
87
Instruction Courses
Synopsis: Thyroid eye disease (TED) can be challenging to manage. This course will
provide a practical update to help the ophthalmologist care for the patient with TED.
The International Thyroid Eye Disease Society (ITEDS) VISA standardized evaluation
form will be utilized in the discussion of the clinical evaluation and management of
this disorder. An overview of favored approaches for surgical management will also
be provided.
Objective: By the conclusion of this course, participants should understand (1) disease activity, progress, and severity, (2) the ITEDS-VISA classification, (3) the use of
the ITEDS-VISA classification for management, (4) management during the active
phase, including conservative therapy, medical therapy, radiotherapy, and urgent surgery, and (5) management during the quiescent phase, including conservative therapy
and surgical intervention.
Senior Instructor(s): Jennifer A Sivak MD
Instructor(s): Kenneth V Cahill MD FACS, Peter J Dolman MD, Raymond Douglas MD
PhD*, Jonathan J Dutton MD PhD, Victor M Elner Ph D MD*, Steven E Feldon MD*,
Michael Kazim MD, Don Kikkawa MD*, Mark J Lucarelli MD FACS, John Nguyen MD,
Jimmy M Uddin MD
Objective: By the conclusion of this course, attendees will be familiar with common
pediatric corneal pathologies, their typical and atypical features, overlapping features
and signs to differentiate one from other, and their medical and surgical management.
Senior Instructor(s): Vandana Jain MBBS
Instructor(s): Jatin Naresh Ashar MD, Muralidhar Ramappa MBBS, Kanwal K Nischal
MBBS*, Kathryn A Colby MD PhD*, Asim Ali MD
Instruction Courses
their practices, and (5) understand the latest information on therapeutic treatment
options for amblyopia.
Senior Instructor(s): Jitka L Zobal-Ratner MD
Instructor(s): Darron A Bacal MD*, Arlene V Drack MD*, Patrick J Droste MD, Majida
A Gaffar MD**, Ramesh Kekunnaya MBBS MD, Stacy L Pineles MD, Terri L Young
MD*, W Walker Motley MD
Diplopia After Cataract and Refractive Surgery

Course: 349
Room: N427bc
Monday
11:30 AM - 12:30 PM
Instruction Courses
Synopsis: Diplopia after cataract or refractive surgery is frustrating for the anterior segment surgeon and can be challenging for the strabismus specialist. We will
provide a case-based approach to the evaluation and management of patients with
diplopia after cataract or refractive surgery. Case presentations will illustrate how
some problems can be avoided prior to anterior segment surgery, and other cases
will illustrate how to manage the patient when problems occur. Specific topics to be
covered will include monocular vs. binocular diplopia, pre-existing strabismus, need
for a specific refractive state, need for a specific fixation pattern, long-standing optical blur, myotoxicity, and technical or optical problems. Audience participation and
discussion will be encouraged.
Objective: At the completion of this course, the attendee should have a greater
understanding of how to avoid diplopia after cataract and refractive surgery, and if
diplopia occurs, how to evaluate and manage the patient.
Senior Instructor(s): Jonathan M Holmes MD*
Instructor(s): Rosanne Superstein MD
Approach to Genetic Eye Diseases for the Comprehensive

Ophthalmologist
Course: 354
Room: E451a
Monday
11:30 AM - 12:30 PM
Synopsis: This course will focus on the comprehensive ophthalmologists role in the
treatment of genetic eye diseases. It will review the pertinent medical background
and the availability of diagnostic testing, and will discuss nondirective counseling.
Illustrative cases will be used to highlight important aspects of the management of
these patients.
Objective: By the end of this course, participants will be able to understand (1)
how to approach and evaluate a patient and family with a genetic disorder, (2) the
principles of inheritance patterns, (3) where to find reliable information and laboratory diagnostics, including the eyeGENE network on genetic disorders, (4) guidelines
on genetic counseling, and (5) complexities of the processes, including medicolegal
considerations.
Senior Instructor(s): Johnny Tang MD
Instructor(s): J Bronwyn Bateman MD, Wadih M Zein MD, Pamela C Sieving MA MS
AHIP
H ROP Screening and Treatment: What You Wanted to

Know but Were Afraid to Ask (Intermediate/Advanced)
Course: 381
Room: N140
Monday
2:00 - 4:15 PM
Synopsis: Retinopathy of prematurity (ROP) can be a difficult and challenging disease to manage. This course is for established screeners / treaters familiar with ROP
who want to enhance their proficiency. This course will provide advice on how to
effectively screen and treat with an emphasis on clinical pearls designed to improve
the approach to this condition. Topics include updated findings of the Early Treatment
for ROP study (ETROP), the accurate diagnosis of plus disease, pitfalls in managing
aggressive posterior ROP, the impact of oxygen on ROP, the appropriate time to refer
for vitreoretinal surgery, medicolegal issues, the role of telemedicine and photodocumentation, and the use of anti-VEGF therapy. This will be followed by a presentation
of challenging cases and how they were managed.
88
Objective: At the conclusion of this course, the attendee will be better able to recognize children progressing to treatment-requiring ROP and to more effectively deal
with the challenges of laser treatment.
Senior Instructor(s): Thomas Lee MD*
Instructor(s): Michael F Chiang MD*, William V Good MD**, Kenneth W Wright
MD*, G Baker Hubbard MD*, R V Paul Chan MD, Anne M Menke RN PhD, Maria Ana
Martinez-Castellanos MD, Audina Berrocal MD*
NEW Surgical Management of Pediatric Glaucoma

Course: 393
Room: S106b
Monday
2:00 - 4:15 PM
Synopsis: This two-hour course will give practical knowledge on when and how to
perform surgery for childhood glaucoma. A series of clinical cases will be presented
to the audience, and there will be a discussion of management between the audience
and the panel of experts. Videos of the surgical techniques will be presented, and
surgical pearls given by the panel of experts. The format will be interactive, with
participation of the audience encouraged in every section. All the surgical techniques
performed in pediatric glaucoma will be presented, including angle surgery (goniotomy and trabeculotomy), trabeculectomy, glaucoma drainage devices, and cyclodestructive procedures.
Objective: At the conclusion of this course, the attendees will be able to indicate
the optimal surgical procedure for different types of childhood glaucoma and will have
gained knowledge on how to perform the surgical techniques most frequently used.
The attendees will learn surgical pearls to apply on their procedures for childhood
glaucoma.
Senior Instructor(s): Alana Grajewski MD*
Instructor(s): Elena Bitrian MD*, Sharon F Freedman MD, Allen Dale Beck MD*,
James D Brandt MD*
Management of Strabismus in Thyroid Eye Disease

Course: 506
Room: S103bc
Tuesday
9:00 - 10:00 AM
Synopsis: Strabismus associated with thyroid eye disease (TED) is one of the more
challenging types of ocular misalignments to correct. A variety of techniques have
been described using adjustable as well as fixed sutures. This course will review the
steps in the preoperative examination of the patient in the office, the gathering of
necessary information to determine the muscles to be operated on, and the operative
technique used by the instructors. Video clips will be used to partly transfer the necessary skills. A summary of the literature on the topic will also be given.
Objective: Upon completion of the course, participants will be able to (1) list the
clinical data necessary for management of the patient with TED and strabismus, (2)
describe the operative steps involved in the surgical technique used to correct the
ocular misalignment, and (3) understand the differences between the different surgical techniques for the correction of strabismus in TED and the pros and cons for each.
Senior Instructor(s): Elias I Traboulsi MD*
Instructor(s): Paul Joseph Rychwalski MD, Natalie Kerr MD
NEW Reading, Dyslexia, and Vision Therapy

Course: 522
Room: S104a
Tuesday
9:00 - 10:00 AM
Synopsis: This course will give a comprehensive summary of the latest information
on reading, dyslexia, the eye functions necessary to read and how to test for them in
the ophthalmic examination, vision training, tinted lenses, and resources available
for our patients and their families. The role of the ophthalmologist will be stressed.
Objective: The attendees will achieve a full understanding of reading, dyslexia, and
the controversies involved. The participants will be better equipped to evaluate these
patients and discuss this subject with their patients and families.
Senior Instructor(s): Sheryl M Handler MD
Instructor(s): Walter M Fierson MD**, A Melinda Rainey MD
Instruction Courses
H YO Diplopia Made Ridiculously Simple: Management of
Diplopia for the Comprehensive Ophthalmologist
Course: 556
Room: S103bc
Tuesday
11:30 AM - 12:30 PM
NEW Pediatric Refractive Surgery

Course: 563
Room: S103a
Tuesday
11:30 AM - 12:30 PM
Synopsis: This course will cover many challenging aspects of pediatric refractive
surgery, including patient selection, surgical decision making, and postoperative expectations. Experts in the field will also present cases to reinforce the didactic topics.
Objective: At the completion of this course, the participant should be able to identify
pediatric patients who could benefit from refractive surgery. In addition, the participant should be able to differentiate between the goals and of adult refractive surgery
and those of pediatric refractive surgery.
Senior Instructor(s): Erin D Stahl MD*
Instructor(s): Evelyn A Paysse MD, Amy K Hutchinson MD
Nightmares in Pediatric Cataract Surgery

Course: 582
Room: S106b
Tuesday
12:45 - 1:45 PM
Synopsis: In this video- and case-based presentation, cataract surgery in children

with association of anterior segment trauma, anterior segment dysgenesis, microcornea, subluxation, posterior lenticonus, persistent fetal vasculature, coloboma, after
keratoplasty (penetrating / endothelial), after glaucoma filtering surgery, uveitis, and
extended anterior capsulorrhexis / other intraoperative disasters will be discussed.
These cases are prone to develop intraoperative complications. Modifications in standard surgical technique will be discussed.
Objective: At the end of this course, the attendee will be able to identify challenging
situations that arise in complicated pediatric cataract surgery, including the surgical
modifications required and the optimal outcomes of surgery.
Senior Instructor(s): Ramesh Kekunnaya MBBS MD
Instructor(s): Kanwal K Nischal MBBS*, Muralidhar Ramappa MBBS, Murali
Krishnamachary Aasuri
H Difficult Strabismus Problems: Diagnosis and

Management 2014
Course: 588
Room: S105d
Tuesday
2:00 - 4:15 PM
Synopsis: Case presentations of complex strabismus will form the basis for panel
discussion and audience participation in this course on proper diagnosis and management. Diagnostic techniques such as orbital imaging, forced ductions, saccadic
velocity, and active force generation testing will be discussed as they apply to specific cases. Reoperations, cranial nerve palsies, trauma, Duane syndrome, Brown syndrome, and thyroid ophthalmopathy are representative topics.
Refractive Surgery
Solving the High Myopia Problem With Phakic IOLs
Course: 155
Room: N427d
Sunday
10:15 AM - 12:30 PM
Synopsis: This course will present a review of state-of-the-art knowledge on anterior and posterior chamber phakic IOLs, with information on patient, eye, and IOL
selection, surgical techniques, and management of intra and postoperative complications. Special attention will be dedicated to diagnostic instruments for patient selection and follow-up.
Objective: Participants will be able to assess phakic IOLs as a valuable tool in refractive surgery. Experience, imaging, and long-term follow-up will provide a safer
approach to phakic IOLs. At the conclusion of this course, attendees will be able to
understand the phakic IOLs potential and possible weak points in order to decide
whether to add phakic IOLs advanced technology to their practices.
Senior Instructor(s): Dimitri Dementiev MD**
Instructor(s): Matteo Piovella MD*, Jorge L Alio MD PhD*, Georges D Baikoff MD*,
David R Hardten MD*, Gregory Parkhurst MD*, Luca Gualdi MD
H Danger Zone: Refractive Surgery Nightmares and WorstCase Scenarios: A Video-Based Course
Course: 314
Room: S105d
Monday
9:00 - 11:15 AM
Synopsis: Refractive surgery has its own danger zones. Various refractive surgery
techniques, from surface ablation to LASIK and phakic IOLs, can have disasters that
have to be handled with care. In this course, collagen crosslinking for ectasia and
other conditions will be taught. Viscocannula-assisted reinversion of an implantable
contact lens will be shown. Topics like flap complications, decentered ablations, and
iatrogenic ectasia will be explained in detail. Attendees will be taught how to manage
eyes with previous LASIK flaps and how to address problems with Kerarings and other
intrastromal ring segments.
Objective: At the conclusion of this course, the attendee will know how to manage
refractive surgery catastrophes, perform crosslinking, and treat iatrogenic keratectasia, flap complications, and femtosecond problems.
Instructor(s): Ronald R Krueger MD*, Athiya Agarwal MD, Alaa M Eldanasoury MD*,
Marguerite B McDonald MD*, Sonia H Yoo MD*, A John Kanellopoulos MD*, Soosan
Jacob FRCS, Ashvin Agarwal MBBS, J Bradley Randleman MD
Refractive Lensectomy: Indications, Lenses, Formulas,

Outcomes
Course: 352
Room: S403a
Monday
11:30 AM - 12:30 PM
Synopsis: This course will present different approaches using refractive lensectomy
as a refractive surgical procedure to achieve spectacle independence for far and near.
The indications, contraindications, IOL calculation and selection (monofocal, multifocal, accommodative), and patient selection criteria for successful outcomes will be
shown and discussed in a didactic format.
Objective: At the conclusion of this course, the attendee will be able to define the
best indications and most frequent contraindications of refractive lens exchange,
identify the best IOL calculation method, know how to manage astigmatism, select
EHR
89
Instruction Courses
Synopsis: This course will use diplopia case examples to illustrate important clinical management concerns, including when to consider medical workup, surgery, and
nonsurgical methods of alleviating diplopia. This course will demonstrate how presson (Fresnel) prisms, ground-in prisms, and occlusive methods can be used to treat
diplopia.
Objective: At the conclusion of this course, the attendee will be able to (1) identify
diplopic patients who need further evaluation for medical issues, (2) understand which
diplopic patients should be managed surgically vs. nonsurgically, (3) clinically evaluate
for and appropriately prescribe press-on and ground-in prisms, and (4) understand the
indications for occlusive devices (eg, spot patch, occlusive contact lens, and frosted
tape) for diplopia.
Senior Instructor(s): Laura B Enyedi MD
Instructor(s): Michelle J Cabrera MD, Andrew G Lee MD*
Objective: This course is intended to enhance participants ability to accurately diagnose and treat complicated strabismus patients. Surgical and nonsurgical options
will be elaborated.
Senior Instructor(s): Burton J Kushner MD
Instructor(s): Edward G Buckley MD, David G Hunter MD PhD*
Instruction Courses
the best choice for a multifocal IOL and the best cases for accommodative IOLs, and
understand practical tips to achieve a high patient satisfaction rate with refractive
lens exchange.
Senior Instructor(s): Jorge L Alio MD PhD*
Instructor(s): Andrzej Grzybowski MD*, Warren E Hill MD*, Mark Packer MD*, Eric D
Donnenfeld MD*
NEW Phototherapeutic Keratectomy for the Treatment of
Anterior Corneal Pathology

Course: 357
Room: N136
Monday
11:30 AM - 12:30 PM
Instruction Courses
Synopsis: This course will include an updated overview of phototherapeutic keratectomy (PTK) for the treatment of anterior corneal pathology.
Objective: At the conclusion of the course, the attendee will be able to (1) identify
the preoperative and patient selection criteria for PTK treatment, (2) select the surgical technique to improve PTK outcomes and minimize complications, and (3) recognize
the use of mitomycin C in PTK to prevent and treat corneal scarring.
Senior Instructor(s): Dimitri T Azar MD*
Instructor(s): Damien Gatinel MD*, Sandeep Jain MD*, Rajesh K Rajpal MD*,
Christopher Rapuano MD*, Walter J Stark MD*
H A Step-by-Step Primer to Starting LASIK in 2014

Course: 380
Room: S103bc
Monday
2:00 - 4:15 PM
Synopsis: This course will provide an overview of the principles underlying the safe,
modern practice of LASIK, as well as pearls of surgical technique to benefit the beginning LASIK surgeon. Technology overview will include wavefront sensing, excimer
laser, microkeratome, femtosecond, and modern topographic technologies. Prevention
and management of complications will also be covered.
Objective: The attendee will acquire a broad understanding of the scientific principles underlying the various technologies involved in the practice of LASIK. The course
will provide the foundations for patient selection, surgical planning, and operating
technique, as well as an overview of complication avoidance and management.
Senior Instructor(s): Dan Z Reinstein MD*
Instructor(s): Daniel S Durrie MD*, David R Hardten MD*, Jack T Holladay MD MSEE
FACS*, Cory M Lessner MD, Gustavo E Tamayo MD*
H Femtolaser: Diagnosis and Management of
Intraoperative and Postoperative Complications With the

Use of a Femtosecond Laser for LASIK Surgery
Course: 420
Room: S103bc
Monday
4:30 - 5:30 PM
Synopsis: We will discuss the surgical complications that occur with femtosecond
laser flap creation: data entry errors, centration difficulties, suction loss, interface
entry issues, vertical gas breakthrough, and flap tears. Also covered will be the diagnosis and management of postoperative complications: flap slippage, interface
inflammation, and how to distinguish these from diffuse lamellar keratitis, interface
haze, transient light sensitivity, rainbow glare, etc. This course is recommended for
those surgeons who have recently purchased or already use a femtosecond laser.
Objective: This course will educate users in the potential risks associated with femtoLASIK flap creation.
Senior Instructor(s): Christopher L Blanton MD*
Instructor(s): Edward E Manche MD*, Jonathan H Talamo MD*, Ronald R Krueger
MD*, Sonia H Yoo MD*
90
NEW SOE Enhancement and Retreatment After Refractive
Surgery
Course: 430
Room: S105a
Monday
4:30 - 5:30 PM
Synopsis: This course will be divided into four main sections: in the first part the authors will present how to diagnose regression and how to make differential diagnosis
from ectasia; moreover, the important role of corneal epithelium in regression will be
covered. The second part will illustrate the management of myopic, hyperopic, and
astigmatic regression. In the third section a new, multistep technique for the management of difficult cases will be presented (sequential custom therapeutic keratectomy
or SCTK). In the last section, how and when to retreat a small incision lenticule extraction (SMILE), an all-femto procedure, will be covered. Results and case reports will be
presented, as well as how to prepare a shot-file for a regression treatment.
Objective: Attendees will learn how to diagnose a regression after refractive surgery and to differentiate from ectasia. Moreover, they will learn how to treat a regression with advanced refractive therapeutic keratectomy.
Senior Instructor(s): Paolo Vinciguerra MD*
Instructor(s): Jorge L Alio MD PhD*, Jerry Tan MBBS*, Dan Z Reinstein MD*,
Leonardo Mastropasqua**, Fabrizio I Camesasca MD
NEW Refractive Surgical Complications and Solutions

Course: 518
Room: S102d
Tuesday
9:00 - 10:00 AM
Synopsis: This course is being offered by the editorial committee of the Basic and
Clinical Science Course, volume 13-Refractive Surgery, and will be directed toward
the general ophthalmologist who either performs some refractive surgery or cares for
patients who have undergone refractive surgery. Material to be covered will include
common (and some unusual) complications of refractive surgery and their management. Areas to be included range from preoperative screening issues to the intraoperative and postoperative surgical repair of patients with visual and structural complications resulting from a variety of refractive surgical procedures.
Objective: At the conclusion of this course, the attendee will have the intellectual
tools be able to recognize, prevent if possible, and manage a variety of complications
of refractive surgical procedures.
Senior Instructor(s): M Bowes Hamill MD*
Instructor(s): J Bradley Randleman MD, Richard S Davidson MD*, Neda Shamie MD*,
Gregg J Berdy MD*, Parag A Majmudar MD*, Bradley Dean Fouraker MD*, Renato
Ambrosio Jr MD*
SA Corneal Topographic Analysis and Anterior Segment

Imaging: Pearls for Your Clinical Practice
Course: 537
Room: E352
Tuesday
10:15 AM - 12:30 PM
Synopsis: This course will present a systematic approach to the interpretation of

corneal topographies and anterior segment imaging studies using didactic instruction
combined with numerous clinical examples. The course will highlight several imaging systems and technologies, including Placido-based topography, single and dual
Scheimpflug imaging, OCT, and scanning slit beam imaging.
Objective: At the conclusion of this course, the attendee will understand the different technologies used to image the anterior segment, be able to use the different
maps and displays available on multiple devices, know the advantages and disadvantages of the most common topographers and imaging devices, and use the study
results to manage common clinical situations in corneal, cataract, and refractive surgery.
Senior Instructor(s): Mitchell P Weikert MD*
Instructor(s): Douglas D Koch MD*, Thomas Kohnen MD*, Cynthia Roberts PhD*,
Surendra Basti MBBS*, William J Dupps MD PhD*
Instruction Courses
Presbyopia, the Corneal Approach: State of the Art
Course: 575
Room: S105a
Tuesday
12:45 - 1:45 PM
Synopsis: The course will discuss different corneal methods of correcting presbyopia, including Allegretto custom-Q, Visx presbyLASIK, Amaris PresbyMAX, Mel 80
laser blended vision, corneal inlays, and Femtec Intracor. Presbyopia and its adaptive
optics will be demonstrated.
Objective: Attendees will be able to design the best corneal treatment profile for
each presbyopic patient according to age, error of refraction, and corneal measurements.
Senior Instructor(s): Mounir A Khalifa MD
Instructor(s): Ronald R Krueger MD*, Gustavo E Tamayo MD*, Jorge L Alio MD PhD*,
Dan Z Reinstein MD*
Advanced Corneal Topographic Analysis

Course: 598
Room: S104a
Tuesday
2:00 - 4:15 PM
Synopsis: This course will discuss advanced topographic analysis in the patient
evaluation process for the comprehensive clinician and refractive surgeon, focusing
on understanding and recognizing normal and abnormal topographic patterns generated by multiple technologies, including standard Placido imaging, slitbeam-based
imaging (Orbscan II), Scheimpflug imaging (Pentacam), and wavefront imaging.
Objective: By the conclusion of this course, the participants will be able to (1) identify subtle abnormal topographic patterns that place patients at increased risk for
postoperative complications, including ectasia, (2) differentiate truly abnormal preoperative topographies from artifactual images, and (3) effectively utilize topographic
imaging techniques to demonstrate corneal pathology before keratorefractive refractive surgery.
Senior Instructor(s): J Bradley Randleman MD
Instructor(s): William J Dupps MD PhD*
Femtosecond Laser for Cornea Surgery: The Actual Options

Course: 601
Room: S102d
Tuesday
2:00 - 4:15 PM
Synopsis: The use of femtosecond laser for cornea and refractive surgery has rapidly
expanded, to the point that this technology is now the gold standard, state-of-the-art
procedure for cornea and refractive treatments. In this course instructors will use
video and case presentations to explain the five different femtosecond laser platforms
used for most techniques in routine cases such as flap creation, intrastromal ring
segment implantation, penetrating, anterior lamellar, and endothelial keratoplasties,
and refractive lenticule extraction. The panel members will discuss the benefits and
advantages of the different laser platforms. Clinical outcomes and complications will
also be discussed in detail.
Objective: Attendees will gain information about the similarities and differences
among the most popular femtosecond lasers and their use in all the cornea and refractive techniques.
Senior Instructor(s): Arturo J Ramirez-Miranda MD*
Instructor(s): Jose L Guell MD PhD*, Sheraz M Daya MD*, Jorge L Alio MD PhD*,
Arturo S Chayet MD*, Luis Izquierdo Jr MD, Mauricio Velez Fernandez MD, Alejandro
Navas MD*, Marco A Cantero MD**, Enrique O Graue Hernandez MD
H OCT: Interpretation and Clinical Applications

Course: 158
Room: E451b
Sunday
10:15 AM - 12:30 PM
Synopsis: Through a series of lectures and case presentations, participants will be

presented with a practical guide to reading OCT images. The OCT features of a large
variety of posterior pole pathologies will be reviewed, including vitreomacular traction, macular degeneration, macular edema, central serous retinopathy, hydroxychloroquine toxicity, and glaucoma. Instructive cases will be reviewed by the panel, with
audience participation.
Objective: At the conclusion of the course, the attendee will be able to interpret
OCT images for diagnosis and management of patients with posterior pole disorders.
Senior Instructor(s): Caroline R Baumal MD*
Instructor(s): Michael S Ip MD*, Joel S Schuman MD*, Carmen A Puliafito MD MBA*,
Brandon J Lujan MD*, Lejla Vajzovic MD
Retinoblastoma 2014: They Live and See!

Course: 159
Room: N140
Sunday
10:15 AM - 12:30 PM
Synopsis: Recent advances in the diagnosis and management of retinoblastoma

have contributed to improved outcome. The new staging and grouping systems are
now clinically validated. Modern diagnostic and management strategies such as
wide-field imaging, transpupillary thermotherapy, chemoreduction, and intravitreal
and periocular chemotherapy are effective in improving eye and vision salvage. Selective intra-arterial chemotherapy is an exciting new development. Minimal manipulation enucleation has been optimized. Adjuvant therapy for histopathologic risk factors identified following enucleation has reduced the risk of systemic metastasis. A
multimodal protocol is effective in orbital retinoblastoma. Genetic studies now help
in prenatal diagnosis and screening of siblings. This course will highlight the practical
aspects in the current standard of care for retinoblastoma.
Objective: To enable the participants to incorporate recent advances in the diagnosis and management of retinoblastoma into their practices.
Senior Instructor(s): Santosh G Honavar MD
Instructor(s): Ralph Eagle MD*, Brenda L Gallie MD*, Ashwin C Mallipatna MBBS,
Carol L Shields MD, Jerry A Shields MD, Arun D Singh MD
State-of-the-Art Techniques and Technologies for

Microincision Vitrectomy Surgery to Treat Complex
Vitreoretinal Diseases
Course: 160
Room: S103a
Sunday
10:15 AM - 12:30 PM
Synopsis: This course will highlight the current indications and state-of-theartsurgical techniques and technologies for 27-gauge sutureless vitrectomy to treat
a variety of vitreoretinal pathologies, including macular surgery, primary rhegmatogenous retinal detachment, diabetic traction retinal detachment, and massive subretinal
hemorrhage. With the video clips demonstration, the course will provide step-by-step
instruction on tips for transition to the 27-gauge system. The format will encourage
open interaction between the faculty and the audience.
Objective: By the end of this course, the attendees will not only be familiar with the
current indications and the state of the art in 27-gauge vitrectomy systems, but they
will also get a glimpse of future technological advances.
Senior Instructor(s): Yusuke Oshima MD*
Instructor(s): Maria H Berrocal MD*, Pravin U Dugel MD*, Marco Mura MD,
Sundaram Natarajan MD, Shunsuke Osawa MD*, Stanislao Rizzo MD
EHR
91
Instruction Courses

Retina, Vitreous
Instruction Courses
Surgery of Retinal Detachment
Course: 162
Room: N138
Sunday
10:15 AM - 12:30 PM
Instruction Courses
Synopsis: This course will review the principles involved in managing rhegmatogenous retinal detachment. We will provide a detailed, comprehensive, state-of-the-art
approach to techniques of scleral buckling, primary vitrectomy, and pneumatic retinopexy for the management of selected detachments. The principles of buckle placement, the selection of elements, drainage, and the use of gases and other adjutants
will be described.
Objective: At the conclusion of this course, the attendee will be able to (1) discuss
the advantages and disadvantages of scleral buckling, vitrectomy, and pneumatic retinopexy, (2) identify the indications and contraindications and technique of drainage
of subretinal fluid, (3) select the appropriate gas for intraocular injections, (4) discuss
postoperative management of retinal detachment patients, and (5) recognize alternate
techniques for the management of different types of retinal detachments.
Senior Instructor(s): Daniel P Joseph MD PhD
Instructor(s): Harry W Flynn MD, George A Williams MD*, Edwin Hurlbut Ryan MD*
Advances in Intraocular Endoscopic Surgery: Anterior and

Posterior Segment Techniques
Course: 164
Room: N139
Sunday
10:15 AM - 12:30 PM
Synopsis: This course will introduce the concept of endoscope-assisted intraocular

surgery and will showcase video-based presentations of a wide range of anterior and
posterior segment procedures. Pearls for rapid attainment of endoscopic proficiency
will be discussed. Anterior segment surgery will include cataract/IOL, trauma, and
glaucoma, including goniosynechialysis, cyclodialysis cleft repair, plateau iris treatment, and endoscopic cyclophotocoagulation. Posterior segment surgery will include
management of blunt and penetrating trauma, safe sutured IOL removal, sclerotomy
site pathology, cyclitic membranes, rhegmatogenous retinal detachment (RD) and
traction RD in ROP, familial exudative vitreoretinopathy, and persistent fetal vasculature syndrome. The presenters are experienced anterior and posterior segment surgeons familiar with endoscopy.
Objective: To educate anterior and posterior segment surgeons on how intraocular
endoscopy can assist them in complex surgical procedures.
Senior Instructor(s): S Chien Wong MBBS FRCS*
Instructor(s): Brian A Francis MD*, Robert J Noecker MD*, Thomas Lee MD*
NEW White Dots, Spots, and Plaques: Making Sense of the

Inflammatory Retinal Lesions: A Case-Based Approach
Course: 165
Room: S105a
Sunday
10:15 AM - 12:30 PM
Synopsis: Differentiating the white spot syndromes remains a challenging task

for ophthalmologists and subspecialists. Recent advances in retinal imaging have improved our understanding and expanded the spectrum of these entities. Great debate
still exists between the retina and the uveitis subspecialties regarding the classification and management of these entities. This course includes instructors from both
uveitis and retina subspecialties, which will allow dynamic and interesting discussions about controversies in the field. The instructors will present a variety of cases of
these entities, with a focus on an approach that differentiates them in an interactive
format.
Objective: At the end of this course, attendees will have an in-depth understanding
of the nuances of inflammatory spots of the retina, including finer points of differentiating and managing these entities in real life.
Senior Instructor(s): Amani Fawzi MD
Instructor(s): Janet Louise Davis MD*, K Bailey Freund MD*, Debra A Goldstein MD*,
Lee M Jampol MD*
92
Peering to the Periphery: Applications of Wide-Angle

Retinal Imaging
Course: 173
Room: S104a
Sunday
11:30 AM - 12:30 PM
Synopsis: Wide-angle retinal imaging platforms have gained increased popularity.

Numerous applications have been demonstrated, including disease documentation,
diagnosis, and targeted treatment of retinal diseases. Utilizing wide-angle angiography and autofluorescence provides insights into retinal and choroidal conditions such
as macular degeneration, diabetic retinopathy, retinal vascular disease, and ocular
tumors. Pitfalls with these technologies include artifact registration and false color
processing, which may result in inaccurate diagnosis. In this course, cases will be
presented to highlight the clinical applications of wide-angle imaging.
Objective: After completing this course, the attendee will be able to identify imaging options for retinal peripheral diseases, understand the role of wide-angle angiography in retinal vascular disease, identify critical imaging artifacts, and understand
applications of these technologies in pediatric and ocular oncology patients.
Senior Instructor(s): Prithvi Mruthyunjaya MD*
Instructor(s): Szilard Kiss MD*, Seenu M Hariprasad MD*, R V Paul Chan MD, Michael
P Kelly FOPS, Sunil K Srivastava MD*
Controversies in the Management of Open-Globe Injuries

Involving the Posterior Segment
Course: 188
Room: E352
Sunday
2:00 - 3:00 PM
Synopsis: Controversies in the management of open-globe injuries will be presented

and thoroughly discussed. An overview of the problem will be provided, followed by
a detailed breakdown of the controversies for which controlled clinical data regarding management are incomplete. These areas include the timing of surgery, use of
prophylactic antibiotics, placement of prophylactic cryotherapy and/or scleral buckle,
management of intraocular foreign bodies, use of silicone oil, concurrent placement
of primary IOLs, management of hypotony, and surgery on NLP eyes. Guidelines for
treatment will be provided based on clinical data and the experience of the presenters. Several videos will be presented, documenting select procedures and techniques.
Objective: This course is designed to provide an update on the clinical management
of controversial issues in the setting of open-globe injuries through the use of slide
presentations, videos, and interactive panel discussions. A comprehensive handout
will be provided.
Senior Instructor(s): William F Mieler MD*
Instructor(s): Ferenc P Kuhn MD PhD, Robert A Mittra MD
Practical Considerations for Telemedicine Diabetic

Retinopathy Screening
the American Telemedicine Association
Course: 194
Room: N427bc
Sunday
2:00 - 4:15 PM
Synopsis: Evidence-based recommendations for diabetes eye care are highly effective in reducing the risk for vision loss. However, poor compliance with recommendations for retinal examinations to ensure early detection of diabetic retinopathy
(DR) remains a major unresolved challenge in ophthalmology. Telemedicine programs
based on remote digital retinal imaging have demonstrated the potential to complement current DR surveillance methods and increase the rate of DR assessment. In this
course, clinical recommendations, technical requirements for hardware, software,
and personnel, and operational considerations will be discussed. Successful business
models and financial and reimbursement factors will be presented.
Objective: At the conclusion of this course, the attendee will understand the rationale for telemedicine DR assessment and have a framework for implementation of a
remote program for evaluation of DR.
Senior Instructor(s): Ingrid E Zimmer-Galler MD
Instructor(s): Mark B Horton MD, Paolo Antonio S Silva MD
Instruction Courses
NEW Seeing Is Believing: Spectral Domain OCT and
Clinicopathologic Correlation in Macular Diseases
Course: 204
Room: E353c
Sunday
2:00 - 4:15 PM
NEW Surgical Management of Complicated Retinal
Detachments
Course: 207
Room: S103a
Sunday
2:00 - 3:00 PM
Synopsis: This instruction course will discuss the management of complicated retinal detachments such as giant retinal tear, diabetic combined retinal detachments,
retinal detachments associated with coloboma, retinal detachments with severe proliferative vitreoretinopathy, and retinal detachments associated with microcornea /
microphthalmos. The course will include surgical video presentations, and speakers
will share their experience in managing such cases.
Objective: At end of the course, attendees will be able to improve surgical planning,
predict intraoperative difficulties, and understand the management of such cases.
Senior Instructor(s): Jay K Chhablani MD
Instructor(s): Alay S Banker MD, Manish Nagpal MD*, Sundaram Natarajan MD,
Yusuke Oshima MD*
NEW SOE Pediatric Vitreoretinal Disorders: Current and

Future Management
Course: 326
Room: S403a
Sunday
3:15 - 5:30 PM
Synopsis: This course will focus on advances in the management of a range of hereditary and nonhereditary pediatric vitreoretinal disorders. Management themes will
include the emerging role of intraoperative OCT, new surgical insights and techniques
including endoscopic vitrectomy, and a glimpse into the future of gene, stem cell,
and pharmacologic therapies for hereditary diseases. Disorders that will be discussed
will include (1) retinovascular diseases, including ROP, familial exudative vitreoretinopathy, Coats disease, incontinentia pigmenti, and persistent fetal vasculature syndrome, (2) vitreoretinal degeneration (eg, Stickler and X-linked retinoschisis), and (3)
childhood-onset retinal dystrophies.
Objective: At the conclusion of this course, the attendee will have a better understanding of the advances in the current and potential future management options for
a range of challenging hereditary and nonhereditary pediatric vitreoretinal disorders.
Senior Instructor(s): S Chien Wong MBBS FRCS*
Instructor(s): Cynthia A Toth MD*, Antonio Capone Jr MD*, Thomas Lee MD*, R V
Paul Chan MD

the American Society of Ocular Trauma and the International Society of Ocular
Trauma
Course: 229
Room: E351
Sunday
4:30 - 5:30 PM
Synopsis: Using intraoperative videotapes, this course will review all aspects of
managing patients with intraocular foreign bodies: history, epidemiology, pathophysiology, evaluation, instrumentation, timing, management principles and practice,
complications, prognosis and outcome, and controversies. A novel surgical method
(prophylactic chorioretinectomy) to prevent the development of proliferative vitreoretinopathy will also be discussed.
Objective: To provide ophthalmologists with the necessary information for optimal
treatment of patients with intraocular foreign body injuries.
Senior Instructor(s): Ferenc P Kuhn MD PhD
Instructor(s): Jose Dalma MD
Systemic Therapeutic Agents and Retinal Toxicity

Course: 307
Room: S106b
Monday
9:00 - 11:15 AM
Synopsis: This course will provide a thorough review of systemic (and select intravitreal) medications that are capable of causing various patterns of retinal toxicity.
Examples of all of these types and patterns of toxicity will be presented, including disruption of the retinal pigment epithelium, retinal vascular occlusion, cystoid macular
edema / retinal edema, crystalline deposition, uveitis, miscellaneous , and subjective
visual symptoms. The mechanism of action will be discussed. Numerous examples of
all conditions will be shown, and time will be allotted for questions and answers. A
comprehensive referenced handout will be provided to all attendees.
Objective: At the conclusion of the course, the attendee will be able to (1) recognize
the various patterns of toxicity induced by a variety of systemic, topical, and intravitreal medications, (2) recognize medications capable of causing subjective visual
symptoms, and (3) better understand the clinical setting in which toxicity is most likely
to occur.
Instructor(s): George A Williams MD*, David F Williams MD*, Scott R Sneed MD,
David Sarraf MD*
H Update on Treatments for Diabetic Retinopathy:

Clinically Relevant Results From the Diabetic Retinopathy
Clinical Research Network
Course: 312
Room: S102abc
Monday
9:00 - 11:15 AM
Synopsis: This course will present clinically relevant results of recently completed
Diabetic Retinopathy Clinical Research Network (DRCRnet) protocols, and through
case examples it will demonstrate implementation of these results into clinical practice.
Objective: At the conclusion of this course, the attendee will be able to describe the
results of recently completed DRCRnet protocols. Specifically, the attendee will learn
what role topical NSAIDs can play in the progression of noncentral diabetic macular
edema (DME) to center-involved DME. The course will also include a review of the
ongoing DRCRnet protocols, including the trial comparing ranibizumab, bevacizumab,
and aflibercept for DME and the ranibizumab for proliferative diabetic retinopathy trials. The assessment of wide-field imaging in the management of diabetic retinopathy
will also be discussed. Finally, the attendee will be able to apply the DRCRnet results
to clinically relevant situations in daily practice.
Senior Instructor(s): Carl W Baker MD*
Instructor(s): Lee M Jampol MD*, Neil M Bressler MD*, Susan B Bressler MD*, Scott
M Friedman MD*, Jennifer K Sun MD**, Andrew N Antoszyk MD*, Raj K Maturi
MD*, John A Wells III MD*
EHR
93
Instruction Courses
Synopsis: Although pathological biopsy has been the gold standard for our understanding of macular diseases for so many decades, the advent and continuing development of spectral domain OCT (SD-OCT) technology has enhanced our understanding of these conditions. Through case presentations and interactive discussions, this
course will correlate clinical scenarios through color fundus photography, fluorescein
angiography, SD-OCT, and fundus autofluorescence with the histopathology of various
macular diseases. This will include degenerative, inherited, inflammatory, vascular,
and toxic diseases of the macula.
Objective: At the conclusion of the course, the participants will have a better understanding of the normal macula and the conditions that can affect it. They will be able
to identify various conditions like macular degenerations and dystrophies, vascular
occlusions, diabetic retinopathy, and toxic maculopathies with the help of different
testing modalities with correlation of the pathophysiology of that condition.
Senior Instructor(s): Sandeep Grover MD
Instructor(s): Deepak Paul Edward MD, Vikram S Brar MD, Ralph Eagle MD*
Intraocular Foreign Body Injuries: An Update
Instruction Courses
H Diagnosis and Treatment of Polypoidal Choroidal
Vasculopathy
H Retinal and Choroidal Manifestations of Selected

Systemic Diseases 2014
Course: 318
Room: S406b

the Pan-American Retina and Vitreous Society
Monday
9:00 - 11:15 AM
Instruction Courses
Synopsis: Polypoidal choroidal vasculopathy (PCV) is a condition characterized by

multiple, recurrent, serosanguineous pigment epithelial detachment and neurosensory retinal detachment due to abnormal choroidal polypoidal, aneurysmal lesions.
PCV is particularly prevalent in Asians and occurs in up to 40% of cases presenting
as neovascular AMD; it may pose a diagnostic challenge to ophthalmologists. This
instruction course aims to provide a comprehensive overview of the diagnosis and
treatment of PCV through review of the currently available literature, illustrative case
examples, and interactive panel discussion.
Objective: By the completion of this course, participants will understand the epidemiology of PCV, the differences between PCV and AMD, the use of various diagnostic
tools for PCV, the available treatment options for PCV, and the overall management
strategy for PCV.
Senior Instructor(s): Timothy Y Lai MBBS*
Instructor(s): Fumi Gomi MD PhD*, Gregg T Kokame MD*, Adrian H Koh MD*, Won
Ki Lee MD*
H YO Spectral Domain OCT Interpretation for the General

Ophthalmologist
Course: 319
Room: E451a
Monday
9:00 - 11:15 AM
Synopsis: The purpose of this course is to provide general ophthalmologists with

basic knowledge for incorporating spectral domain OCT (SD-OCT) into clinical practice. Attendees will be given an overview of scanning protocols on various SD-OCT
systems on the market today. Lecturers will present an organized method for analysis
of images and identification of pathology in the anterior segment, optic nerve, vitreous, macula, and choroid. The course will have a special focus on use of SD-OCT in
patients with glaucoma and/or retinal disease.
Objective: At the conclusion of this course, the attendee will be able to select appropriate SD-OCT scanning protocols and analyze pathology in SD-OCTs of the anterior segment, optic nerve, and posterior segment, especially to detect preparametric
glaucoma, progression of glaucoma, and the most common retinal pathology.
Senior Instructor(s): Purnima S Patel MD
Instructor(s): Vikas Chopra MD*, Rajeev Kumar R Pappuru MBBS MD, Srinivas R
Sadda MD*, Alexander C Walsh MD*
NEW SOE Scleral Buckling Surgery: A Forgotten Art!

Course: 321
Room: S106a
Monday
9:00 - 10:00 AM
Synopsis: This course will provide a comprehensive, state-of-the-art approach to

techniques of scleral buckling (SB) surgery. A practical and interactive way to achieve
successful retinal detachment (RD) repair will be discussed with interesting videos.
Specific topics will include principles of buckle placement, selection of elements, segmental vs. circumferential, drainage vs. nondrainage, indications for and techniques
of drainage, and use of gases and other adjuvants. Advanced topics will include sutureless buckle, suprachoroidal buckling, macular buckling, management of complications and the goal of SB surgery in the 21st century. Audience participation will be
encouraged, and a detailed handout will be provided.
Objective: Upon completion of the course, the attendee will have gained a greater
insight into applying safe, efficient, and minimalist ways of performing SB surgery.
The course will provide beginners with a foundation for learning a forgotten art and
for understanding how to manage complications.
Senior Instructor(s): Malhar Soni MD MS DNB FRCS
Instructor(s): Ron Afshari Adelman MD MPH, Manish Nagpal MD*, Stanislao Rizzo
MD, Carlos Mateo MD*
94
Course: 335
Room: S106a
Monday
10:15 AM - 12:30 PM
Synopsis: This course will discuss the current state of retinal and choroidal manifestations of selected systemic diseases, including AIDS, gastrointestinal diseases, systemic syndromes with Coats disease, lupus, diffuse unilateral subacute neuroretinitis,
lymphoma, metastasis, tuberculosis, and retinal-choroidal toxicity of systemic drugs.
Experts from the United States, Asia, and South America will discuss the impact that
systemic diseases of the posterior pole of the eye have had worldwide. Topics are
rotated every year to cover a wide variety of diseases.
Objective: At the conclusion of this course, participants will understand the variety
of retinal and choroidal manifestations of selected systemic diseases both inside and
outside the United States.
Senior Instructor(s): J Fernando Arevalo MD FACS*
Instructor(s): Rubens Belfort Jr MD PhD*, Carol L Shields MD, Jerry A Shields MD,
William F Mieler MD*, Careen Yen Lowder MD PhD, Lihteh Wu MD*, Francisco J
Rodriguez MD*, Alay S Banker MD
NEW YO Vitreoretinal Tips for the Comprehensive

Ophthalmologist: When to Watch, Treat, or Refer
Course: 338
Room: N427a
Monday
10:15 - 11:15 AM
Synopsis: To aid the comprehensive ophthalmologist, ophthalmologist in training,

and other ophthalmologists without retina subspecialty training in planning a coherent strategy for managing or coordinating care with vitreoretinal specialists for those
patients with posterior segment disorders. The emphasis will be on clinical slides,
videos, and discussion between panel members and audience members, with an extensive handout for later reference.
Objective: This course will cover the relative indications for when to watch, treat,
or refer patients who have vitreoretinal disease and are followed in a comprehensive
practice. At the conclusion of the course, the attendees will be able to formulate an
effective treatment strategy based on their individual ophthalmological skills and the
resources available to them.
Senior Instructor(s): Richard M Feist MD
Instructor(s): Bradley T Smith MD, Thomas A Oetting MD, John O Mason MD, Martin
Lee Thomley MD, Michael A Albert MD
H Simplifying Treatment of Diabetic Retinopathy for the

Comprehensive Ophthalmologist: What You Really Need to
Know in 2014
Course: 347
Room: S102abc
Monday
11:30 AM - 12:30 PM
Synopsis: This course will provide a review of recent publications and clinical trials
involving diabetic retinopathy (DR), including the Diabetes Control and Complications
Trial, Early Treatment Diabetic Retinopathy Study, Diabetic Retinopathy Study, etc.
Indications / techniques of laser, control of systemic disease, anti-VEGF intravitreal
injections, and steroid treatment in the management of DR will be discussed. Actual
patient cases and management with panel discussion / audience participation will
include every DR scenario seen in clinical practice.
Objective: To present management and treatment approaches for DR, enabling
participants to understand (1) focal and panretinal photocoagulation, (2) anti-VEGF
intravitreal injections, and (3) other pharmacotherapy. At the conclusion of this course,
attendees will be confident about when and how to use laser based on current 2014
DR literature (DRCRnet articles on laser, ranibizumab, and steroids) and proficient in
Instruction Courses
determining when and how often to implement intravitreal injections as an adjunct
to laser.
Senior Instructor(s): John O Mason MD
Instructor(s): Richard M Feist MD, Michael A Albert MD, Thomas A Finley MD, Jacob
Yunker MD**
Advanced Evidence-Based Management of Diabetic

Retinopathy
H YO Retinal OCT Interpretation 101
Synopsis: This course assumes knowledge by the attendees of the Diabetic Retinopathy Study, Diabetic Retinopathy Vitrectomy Study, Early Treatment Diabetic
Retinopathy Study, Diabetes Control and Complications Trial, and the U.K. Prospective
Diabetes Study. From this base, a series of cases encountered by ophthalmologists
managing diabetic retinopathy will be presented, discussed by a course instructor
with extensive references to the pertinent literature, and then opened for a dialogue
with the ophthalmologists enrolled in the course. Therapies covered will include systemic and metabolic interventions, focal / grid and panretinal laser photocoagulation,
intravitreal pharmacology, and vitreoretinal surgery. Issues of timing, sequencing,
combination therapies, and modifying factors in choice of interventions will be covered.
Objective: At the conclusion of this course, the attendee will be able to successfully
integrate clinical presentations with evidence-based options for physician intervention, and will recognize the areas of controversy in management.
Senior Instructor(s): David J Browning MD PhD*
Instructor(s): Keye L Wong MD*, Scott E Pautler MD, Michael W Stewart MD*, David
G Telander MD*
Course: 348
Room: E451b
Monday
11:30 AM - 12:30 PM
NEW Genetics of AMD: Concepts and Controversy

Course: 356
Room: N427a
Monday
11:30 AM - 12:30 PM
Synopsis: In this course a summary of AMD genetics, commercially available genetic AMD tests, and the current state of knowledge regarding the pharmacogenetics
of AMD will be reviewed.
Objective: At the conclusion of this course, the attendee will be able to appreciate the relevant genetic polymorphisms that play a role in determining AMD risk, be
familiar with the currently available genetic AMD tests and the American Academy
of Ophthalmology guidelines on AMD genetic testing, and understand the potential
relationship of genetic AMD risk factors and response to vitamin supplementation and
antivascular endothelial growth factor therapy.
Senior Instructor(s): Jaclyn L Kovach MD
Instructor(s): Stephen G Schwartz MD MBA*, Milam A Brantley Jr MD
Principles of Pediatric Retinal Surgery in Pediatric Retinal

Diseases Other Than ROP
Course: 371
Room: N139
Monday
2:00 - 4:15 PM
Synopsis: This course will present the management of pediatric retinal diseases
other than retinopathy of prematurity, which are seen frequently in practices that are
focused on pediatric vitreoretinal surgery.
Objective: This course will deal with the surgical management of pediatric vitreous hemorrhage, Coats disease, familial exudative vitreoretinopathy, persistent fetal
vasculature syndrome, Norrie disease, and congenital retinoschisis. The material will
include timing of intervention as well as surgical intervention, utilization of genetic
testing, and analysis of angiographic data to aid in the management and prevention
of retinal detachment. Also covered will be the management of retinal detachment
in these diseases that are often accompanied by an exudative response. The use of
pharmacologic therapy as well as surgical techniques will be discussed. In addition,
instrumentation and timing of intervention will be emphasized.
Senior Instructor(s): Michael T Trese MD*
Instructor(s): Philip J Ferrone MD*, Antonio Capone Jr MD*, Kimberly A Drenser MD
PhD*
Monday
2:00 - 4:15 PM
H Visual Electrophysiology Testing: Principles and Clinical

Applications
Course: 376
Room: N138
Monday
2:00 - 3:00 PM
Synopsis: Visual electrophysiologic tests are diagnostic tools that are helpful or
essential in a variety of retinal and visual disorders. This course, approved by the International Society for Clinical Electrophysiology of Vision (ISCEV), provides a comprehensive overview of clinical electrophysiologic tests with a focus on basic principles
(including ISCEV standards) and clinical applications. A variety of clinical cases will
be presented to illustrate the appropriateness and utility of visual electrophysiology
testing.
Objective: At the conclusion of this course, the attendee will understand the basic
principles and clinical applications of full-field electroretinogram (ERG), multifocal
ERG, electro-oculogram, and pattern visual evoked potential, enabling the attendee
to incorporate these tests effectively in clinical practice.
Senior Instructor(s): Byron L Lam MD*
Instructor(s): Michael F Marmor MD*, Mitchell Brigell PhD*
The ABCs of AMD for Comprehensive Ophthalmologists

Course: 384
Room: E451a
Monday
2:00 - 4:15 PM
Synopsis: This course will present a review of major clinical trials and recent publications involving AMD. The pathogenesis of AMD, the progression of dry AMD to
wet AMD, and the indications and techniques of laser, pharmacologic, surgical, and
radiologic treatments for AMD, as well as nutritional supplementation recommendations, will be reviewed thoroughly. A panel of experts will present actual patient cases
and treatments for discussion.
Objective: To present an overview of the risk factors, pathogenesis, and management and treatment approaches for AMD. The indications for various treatment options and the potential complications associated with treatments will be discussed.
At the conclusion of this course, attendees will be familiar with the current and future
treatment options for managing this disease.
Senior Instructor(s): Michael A Albert MD
Instructor(s): John O Mason MD, Richard M Feist MD, Martin Lee Thomley MD, Dustin
Pomerleau MD
EHR
95
Instruction Courses
Synopsis: OCT is increasingly being used to diagnose and manage retinal diseases.
This is an introductory, basic-level course for those who are not retina specialists
and are interested in learning about OCT and interpretation of OCT images of retinal
conditions. In this course, we will review the fundamentals of OCT, with emphasis
on interpreting and recognizing OCT images obtained from various retinal conditions,
through examples, to become more proficient at differentiating normal from pathologic findings.
Objective: At the conclusion of this course, the participants will be able to (1) discuss how OCT works, (2) understand potential sources of artifacts, (3) recognize OCT
images of normal retina and common retinal diseases, and (4) learn to incorporate
OCT into a practice.
Senior Instructor(s): Judy E Kim MD*
Instructor(s): Jennifer Irene Lim MD*
Course: 374
Room: S105bc
Instruction Courses
H Mystery Retina 2014: Interactive Discussion of
Challenging Cases
Course: 405
Room: S406b
Monday
3:15 - 5:30 PM
Instruction Courses
Synopsis: The instructors will present 20 to 25 diagnostically challenging mystery

retina cases. The majority of the presentations will include interpretation of color
photographs, fluorescein angiograms, and OCT imaging studies. When indicated, indocyanine green angiography, echography, autofluorescence, enhanced depth imaging, infrared images, electrophysiologic studies, microperimetry, CT, MRI, cytology,
and/or histopathology will also be shown. The cases will be presented as unknowns,
and audience participation will be encouraged. At the completion of the case presentations, the attendees will receive a handout summarizing the cases, complete with
pertinent references and images.
Objective: At the conclusion of this course, attendees will be better able to assess
and evaluate a variety of diagnostically challenging mystery retina cases. They
should also be able to establish a more complete differential diagnosis and know how
to make the best use of ancillary diagnostic tests and formulate a definitive treatment
plan.
Instructor(s): Lee M Jampol MD*, Jerry A Shields MD, Richard F Spaide MD*,
Lawrence A Yannuzzi MD
NEW IOL Implantation and Repositioning Techniques for

the Vitreoretinal Surgeon
Course: 427
Room: N427a
Monday
4:30 - 5:30 PM
Synopsis: This interactive course will explore the latest IOL insertion and repositioning techniques for the vitreoretinal surgeon. Using cases and videos, a panel of
anterior segment and retina specialists will discuss specific surgical techniques, instrumentation, choice of IOLs, and potential pitfalls.
Objective: At the conclusion of this course, attendees will understand scleralfixated (sutureless and simplified sutured methods), iris-fixated, sulcus, and anterior
chamber IOL insertion techniques.
Senior Instructor(s): Jason Hsu MD*
Instructor(s): Allen C Ho MD*, Omesh P Gupta MD, Sunir J Garg MD*, Brandon Ayres
MD*
H Advanced Vitreoretinal Surgical Techniques

Course: 512
Room: E451a
Tuesday
9:00 - 11:15 AM
Synopsis: This interactive, case-based course will highlight the latest developments
in vitreoretinal surgery. The panel will make extensive use of videos to discuss the
most advanced approaches to vitreoretinal surgery.
Objective: By the end of this course, attendees will be familiar with the latest
advances in surgical techniques and instrumentation used to treatment macular
diseases, retinal detachment, dislocated IOLs, retained lens material, and diabetic
retinopathy.
Senior Instructor(s): Sunir J Garg MD*
Instructor(s): Julia A Haller MD*, Tarek S Hassan MD*, Allen C Ho MD*, Mark W
Johnson MD*, George A Williams MD*, Jason Hsu MD*
NEW A Genetic Approach to Inherited Retinal Dystrophies:

Clinical Classification of Common Retinal Dystrophies,
Genotyping, and Gene Therapy
Course: 516
Room: S105d
of international leaders in this field, several of whom are actively involved in gene
therapy trials. A version of this course was presented by some of the faculty at the
American Society of Retina Specialists meeting this past year in Toronto, and this was
very well attended and received.
Objective: To (1) provide an overview of common inherited retinal dystrophies,
reviewing clinical appearance / prevalence / natural history of these disorders,(2)
describe methodologies for characterizing these patients in the clinic (discuss imaging, including OCT and adaptive optics OCT, visual perimetry, electrophysiology),
(3) explain the logistics of genotyping patients at Clinical Laboratory Improvement
Amendments-certified genetic testing laboratories,4) provide an introduction to gene
therapy, explain the use of viral vectors (with a focus on both adeno-associated virus
and lentivirus), and (5) discuss previous and current clinical gene therapy trials.
Senior Instructor(s): Christine Nichols Kay MD*
Instructor(s): Jacque L Duncan MD, Elliott H Sohn MD, Isabelle Audo, Mark E Pennesi
MD PhD*, Michel Michaelides MD**, Byron L Lam MD*, Sandeep Grover MD
Retinal Pharmacotherapy
Course: 538
Room: N136
Tuesday
10:15 AM - 12:30 PM
Synopsis: The management of retinal diseases has changed in recent years, as the
focus has moved into pharmacologic treatments. Several currently existing and upcoming drugs are being used to treat various retinal diseases. This course will provide
an in-depth knowledge of the drugs in retinal pharmacotherapy.
Objective: This course will serve as an overview of how various drugs may work in
the retina. The session will present cutting-edge results of clinical trials, such as the
Comparison of AMD Treatment Trial (CATT), as well as an overview of the techniques
and complications in retinal pharmacotherapy. The most important drugs available
in clinical practice, ranibizumab (Lucentis), bevacizumab (Avastin), aflibercept (Eylea),
and dexamethasone intravitreal implant (Ozurdex), will be presented in detail. At the
conclusion, the attendee will be able to understand the indications, applications, and
status of drugs available in retinal pharmacotherapy.
Senior Instructor(s): Eduardo B Rodrigues MD*
Instructor(s): Andrew P Schachat MD*, Michel Eid Farah MD, Quan Dong Nguyen
MD*, Carsten H Meyer MD**, Philip J Rosenfeld MD PhD*, William F Mieler MD*,
Fernando M Penha MD**
Vitreoretinal Surgical Rounds, Unleashed!

Course: 559
Room: S104a
Tuesday
11:30 AM - 12:30 PM
Synopsis: This course will feature an interactive panel discussion, with debate
about different surgical approaches to a wide spectrum of vitreoretinal pathology and
management of complications during vitreoretinal surgery and in the postoperative
period. Challenging cases will be presented, with drawings, intraoperative photos,
and high-definition videos simulating the Saturday morning Duke vitreoretinal surgical rounds.
Objective: At the conclusion of this course, the attendee will be able to (1) determine the differences between and proper selection of 20-, 23-, 25-, and 27-gauge
vitrectomy instrumentation, (2) identify and manage complications associated with
different surgical approaches, (3) differentiate between the available light options
with a better selection of diffusion light pipes, lighted picks, and chandeliers, according to the selected approach, and (4) recognize the evolving value of intraoperative
OCT in vitreoretinal surgical techniques.
Senior Instructor(s): Tamer H Mahmoud MD*
Instructor(s): Carl C Awh MD*, Dean Eliott MD*, Sharon Fekrat MD*, Paul Hahn MD
PhD, Glenn J Jaffe MD*, Prithvi Mruthyunjaya MD*, Eric A Postel MD*, Cynthia A
Toth MD*, Lejla Vajzovic MD, Francisco A Folgar MD, Sumit Sharma MD
Tuesday
9:00 - 11:15 AM
Synopsis: In this course, we will discuss inherited retinal dystrophies and updates
in the field of gene therapy, providing both a lecture and Q&A session with a faculty
96
Instruction Courses
NEW New Treatments for Retinal Vein Occlusion: Results
from Phase 3 Clinical Trials
H How to Interpret Fundus Fluorescein Angiography and

Autofluorescence
Course: 565
Room: N139
Course: 595
Room: E451a
Tuesday
11:30 AM - 12:30 PM
Diabetic Vitrectomy
Course: 579
Room: S406b
Tuesday
12:45 - 1:45 PM
Synopsis: This course will use video and panel discussions, along with limited
didactic lecturing, to review the current indications, techniques, and results of vitrectomy for complications of proliferative diabetic retinopathy and diabetic macular
edema. The merit of preoperative and postoperative adjunctive treatments (such as
preoperative intravitreous bevacizumab or postoperative tamponade) will also be discussed. Emphasis will be placed on highlighting the advantages of each technique,
particularly in situations shown on the video presentations.
Objective: At the completion of the course, attendees will be familiar with several
intraoperative techniques and maneuvers that can be employed to increase anatomic
and visual success. Moreover, attendees will be able to judiciously employ preoperative, intraoperative, and postoperative adjunctive treatments that will benefit the
patient.
Senior Instructor(s): Petros Carvounis MD FRCSC
Instructor(s): Andrew J Barkmeier MD, Jorge A Fortun MD**, Annal D Meleth MD
H Management of High-risk ROP in the 21st Century:
Thermal-Destructive vs. Pharmacologic Treatment

Course: 589
Room: S106b
Tuesday
2:00 - 4:15 PM
Synopsis: This course will describe the identification of high-risk ROP eyes and will
present the rationale for both thermal and pharmacologic treatment.
Objective: By the conclusion of this course, attendees will be better able to (1) identify aggressive posterior ROP, (2) distinguish typical stage 3 ROP from flat stage 3 ROP,
(3) understand the rationale for both thermal (laser) and pharmacologic (anti-VEGF)
treatment, (4) be familiar with the technique of current thermal laser treatment for
posterior retinal disease, specifically dealing with flat neovascularization, and (5) be
familiar with the technique of off-label pharmacologic management using available
FDA-approved anti-VEGF drugs.
Senior Instructor(s): Michael T Trese MD*
Instructor(s): Antonio Capone Jr MD*, Kimberly A Drenser MD PhD*, Lois E H Smith
MD PhD*
Synopsis: This course will teach how to interpret fundus fluorescein angiography
(FA) and fundus autofluorescence (FAF) images. A step-by-step guide will be used,
supported by (1) targeted review of the retinochoroidal anatomy, (2) illustrations to
acquire a visual understanding of fluorescence patterns, and (3) numerous FA and
FAF images correlating these patterns with fundus findings. The majority of vascular,
degenerative, inflammatory, hereditary, and tumoral chorioretinal pathologies will be
reviewed, and the audience will be taught how to recognize these diseases based on
the imagery.
Objective: The attendee will be empowered with the know-how to recognize and interpret the angiographic and autofluorescent features of the majority of chorioretinal
pathologies and to recognize these disease entities based on the angiographic and
autofluorescence findings.
Senior Instructor(s): Sawsan R Nowilaty MD
Instructor(s): Emad Bishara Abboud MD, Hardeep S Dhindsa MD, Albert T Vitale MD
Low Vision Rehabilitation for Ophthalmologists
Course: 508
Room: S101ab
Tuesday
9:00 - 11:15 AM
Synopsis: Ophthalmologists already have the skills necessary to help low vision patients with vision rehabilitation. This course will offer basic, informative low vision
testing tools that will help your low vision patients achieve their visual potential.
Objective: After completion of this course, you will know how to use the necessary
tools, whether as a resident, comprehensive ophthalmologist, or retinal specialist, to
incorporate low vision rehabilitation into your practice.
Senior Instructor(s): Robert M Christiansen MD FACS
Instructor(s): Paul Homer MD, Gwen K Sterns MD
SO Should My Visually Impaired Patient Be Driving?

Course: 600
Room: S104b
Tuesday
2:00 - 4:15 PM
Synopsis: This course will cover the current evidence-based information on visual
risk factors for motor vehicle collision involvement and impaired driving performance,
ethical / legal issues for managing visually impaired patients who want to drive,
where ophthalmologists can refer patients for driving assessments, what these services are, case studies presented by specialists, and the increasingly common cases
of older drivers who are likely to have medical comorbidities in addition to visual
impairment. A nationally recognized expert panel will lead the course.
Objective: At the conclusion of this course, participants will be familiar with visual
characteristics that elevate crash risk, methods for managing and referring to driving assessment specialists those visually impaired patients who want to drive, the
ophthalmologists important role in having a dialogue about vision and driving with
visually impaired patients, and practical information from case studies that facilitate
clinical practice.
Senior Instructor(s): Cynthia Owsley MSPH PhD*
Instructor(s): David B Carr MD*, Lylas G Mogk MD*, Jennifer Elgin
EHR
97
Instruction Courses
Synopsis: This course will present results of relevant Phase 3 clinical trials for the
treatment of macular edema (ME) due to retinal vein occlusions.
Objective: At the conclusion of this course, the attendee will be able to describe
the results of relevant Phase 3 clinical trials for the treatment of ME due to retinal
vein occlusions. Specifically, the attendee will understand the results of the following
Phase 3 trials: Branch Retinal Vein Occlusion Study focal laser photocoagulation
for ME due to branch retinal vein occlusion (BRVO); BRAVO ranibizumab for ME due
to BRVO; CRUISE ranibizumab for ME due to central retinal vein occlusion (CRVO);
COPERNICUS and GALILEO aflibercept for ME due to CRVO; GENEVA dexamethasone implant for ME due to BRVO and CRVO; SCORE Study triamcinolone vs.
standard of care for ME due to BRVO and CRVO.
Senior Instructor(s): Scott M Friedman MD*
Instructor(s): David Brown MD FACS*, Michael A Singer MD*
Tuesday
2:00 - 4:15 PM
Notes
98
Notes
99
The
largest public service program in
American medicine
has helped more than
1.8 million people since 1985.

Visit the Foundation desk at the Academy Resource Center (Booth 508) to:
Pick up a special 30th anniversary volunteer gift and recognition certificate.
Enroll as a volunteer! www.eyecareamerica.org
Give MGD a Second Glance

normal meibomian gland structure
structural change (duct dilation,

gland atrophy and drop out)
structural change
(severe gland atrophy and drop out)
Meibomian Gland Dysfunction isnt always visible.

Identify, diagnose and treat MGD without all the dry eye complexity.
Visit us at Booth 3153 to learn more about the TearScience Solution
for MGD, featuring LipiView and LipiFlow.
tearscience.com
919-459-4880
sales@tearscience.com
O
nline & mobile viewing from your iPad,
iPhone and Android devices
More than 200 hours of synchronized
presentation slides with audio
AAO Meetings on Demand includes:

More than 150 hours of content from AAO 2014
A
AO 2014 Subspecialty Day content presented
in the following programs:
Cornea 2014:
Restocking the Toolbox: Concepts and Techniques for the Toughest Jobs
Glaucoma 2014:
Integrating New Technologies and Approaches Into Your Daily Practice
Ocular Oncology and Pathology 2014:

Saving Eyes and Saving Lives
Oculofacial Plastic Surgery 2014:

A Global Summit
Pediatric Ophthalmology 2014:

A Magnificent Mile of Innovations
Refractive Surgery 2014:

Mission 20/20
Retina 2014:
Reaching New Heights
Uveitis 2014:
Extinguishing the Great Fire
Dont miss out! Order onsite and save 10%

Grand Concourse Lobby (Friday Tuesday) credit card only
Academy Resource Center Booth #508 (Saturday Tuesday)
After the meeting, order online: www.aao.org/ondemand
Disclaimer: Some courses may not be available, or may be audio only, due to permissions not granted from the original presenter.
SKILLS TRANSFER
PROGRAM
NEW
New course
EQUIP
Participants are required to bring specific equipment to the course
Participants are required to sign an infectious disease transmission waiver/release form
YO
Endorsed by Young Ophthalmologist Committee
These hands-on courses offer intensive training in surgical and diagnostic techniques, with direct supervision and a low participant-toinstructor ratio. Attendance is limited to physicians only, except where noted in the course description. (The term physician refers to the
definition in the Federal Register: those individuals licensed to practice medicine and surgery or osteopathy.)
Registrants in Skills Transfer lab courses may be required to bring instruments and/or sign an infectious disease waiver form. Refer to
individual course listings for specific requirements.
Skills Transfer courses are intended to provide instruction leading to new knowledge and/or skills. The Academy does not certify competence upon completion of Academy courses. Academy courses are not intended to serve as a basis for requesting new or expanded
privileges.
Tickets and The Academy Plus Course Pass

Skills Transfer Labs are ticketed events - they are not included in the Academy Plus course pass and must be purchased separately.
New! Prerequisite lectures are recommended, NOT required.
Skills Transfer lectures are included in the Academy Plus course pass.
Due to Fire Marshal regulations, seating capacities in courses/lectures are limited. Seating is available on a first-come basis, so please
plan accordingly.
Members in Training automatically receive a 50% discount on all Skills Transfer labs, except where noted.
Tickets are non-transferable.
Selection Committee
The Skills Transfer Advisory Committee selected all Skills Transfer Courses and Labs.
Associate Secretary
Advisory Committee
Susan R Carter MD
Jack A Cohen MD FACS
William Barry Lee MD
Kevin M Miller MD
David D Verdier MD
101
Skills Transfer Course Contributors

The Academy gratefully acknowledges the following companies for their generous support of equipment and supplies used during
the Skills Transfer Course Program:
Medical Optics
Skills Transfer Course

Contributors
We would also like to thank the following companies for their contributions in the Cataract, Refractive Surgery/Cornea, Glaucoma,
Retina, and Plastics Skills Transfer Labs:
Durable Equipment / Instruments:

Abbott Medical Optics
Accurate Surgical & Scientific
Instruments Corporation
Accutome, Inc.
Alcon Laboratories, Inc.
Anodyne Surgical
Aurora Surgical
Bausch + Lomb
Black & Black Surgical
Buffalo Filter
Carl Zeiss Meditec
Crestpoint Management
Dutch Ophthalmic, USA
Ellman International Inc.
Endo Optiks, Inc
Epsilon Eye Care
Heidelberg Engineering
IOP Inc.
IRIDEX
JEDMED Instrument Company
Lensar Inc.
Lumenis, Inc.
Lutronic
Mastel Inc.
Microaire Surgical Instruments
MST (MicroSurgical Technology)
NeoMedix
New World Medical, Inc.
Rhein Medical
Rumex International Co
Sciton, Inc.
Stryker Medical
Surgistar
Disposables:
Beaver-Visitec International, Inc.
Ethicon, Inc.
FCI Ophthalmics
IOP, Inc.
STAAR Surgical Company
Tissue:
Bio-Tissue, Inc.
Vision Share Eyebank Network
102
Skills Transfer Programs-By-Day

All rooms are in McCormick Place: North Building (N), South Building (S), Lakeside Center (E), unless otherwise indicated.
The following schedule is organized by day and time. Courses designated with a plus (+) sign are part of the Academy Plus course pass.
Labs designated with a dollar ($) sign are not included in the course pass and must be purchased separately.
New! Prerequisite lectures are recommended, not required.
Topic Key
CAT - Cataract
COM - Computers, Information Technology
COR - Cornea, External Disease
GLA - Glaucoma
NEURO - Neuro-Ophthalmology
OPTIC - Optics, Refraction, Contact Lenses
PEDS - Pediatric Ophthalmology, Strabismus
PLAST - Orbit, Lacrimal, Plastic Surgery
REF - Refractive Surgery

RET - Retina, Vitreous

Time
No.
Topic
Room
Page
SKILLS
LAB100
Title
PLAST
N226
114
9:00 - 10:00 AM
SKILLS
LEC106
PLAST
E352
114
COR
E351
110
CAT
N230
106
NEURO
N231
114
SKILLS
LEC107
Periocular Rejuvenation With Fillers and BOTOX With 2-D Videos and
Video-Assisted Teaching
Crosslinking
9:00 - 10:30 AM
SKILLS
LAB108
9:00 - 11:00 AM
SKILLS
LAB105
9:00 - 11:15 AM
SKILLS
LEC101
GLA
S105bc
111
SKILLS
LEC102
Computerized Scanning Imaging of the Optic Nerve and Retinal

Nerve Fiber Layer
COR
S103bc
109
SKILLS
LEC103
COR
N427a
110
106
SKILLS
LEC104
Management of the Vitreous for the Anterior Segment Surgeon
CAT
S102abc
10:00 AM - 12:00 PM
SKILLS
LAB109
The iPhone and iPad for Ophthalmologists (Basic)
COM
N227a
109
10:15 - 11:15 AM
SKILLS
LEC111
PEDS
S102d
118
10:15 AM - 12:30 PM
SKILLS
LEC110
CAT
E352
106
PLAST
S106a
115
CAT
N427bc
107
SKILLS
LEC112
Advanced Refractive Cataract Surgery and Anterior Segment

Reconstruction
Cosmetic Botulinum Toxin and Facial Fillers: An Introductory Course
SKILLS
LEC113
Phacoemulsification and Advanced Techniques: The Core Curriculum
SKILLS
LEC114
SKILLS
LEC115
RET
E351
120
PLAST
S106b
115
PLAST
N229
115
COR
N227b
110
CAT
N230
106
10:30 AM - 12:30 PM
SKILLS
11:00 AM - 12:00 PM
SKILLS
Introduction to Aesthetic Facial Surgery by Fractional Lasers, Intense

Pulsed Light, Radiofrequency, and Ultrasound Devices
LAB106A Periocular Rejuvenation With Fillers and BOTOX on Silicone Head
Simulators
LAB107A Crosslinking
11:00 AM - 12:30 PM
SKILLS
LAB116
11:30 AM - 1:00 PM
SKILLS
LAB104A Management of the Vitreous for the Anterior Segment Surgeon
CAT
N228
106
12:00 - 2:00 PM
SKILLS
GLA
N231
111
PLAST
N226
115
COR
N227b
110
12:00 - 2:30 PM
SKILLS
LAB101A Computerized Scanning Imaging of the Optic Nerve and Retinal

Nerve Fiber Layer
LAB117 Surgical Anatomy of the Eyelids: Cadaver Demonstration
12:30 - 2:30 PM
SKILLS
LAB103A Anterior Lamellar Keratoplasty: Principles and Practice
1:00 - 3:00 PM
SKILLS
LAB111A New Techniques for Strabismus Surgery
PEDS
N230
118
1:30 - 3:00 PM
SKILLS
LAB112A Cosmetic Botulinum Toxin and Facial Fillers: An Introductory Course
PLAST
N229
115
SKILLS
LAB113A Phacoemulsification and Advanced Techniques
CAT
N228
107
2:00 - 4:15 PM
SKILLS
LEC118
Ab-Interno Approach to Schlemms Canal
2:30 - 5:00 PM
SKILLS
LAB119
Soft Contact Lens Fitting for the Practicing Ophthalmologist
3:00 - 5:00 PM
SKILLS
LAB114A Macular OCT: Small Group Instruction
GLA
S103d
111
OPTIC
N227a
114
RET
N231
120
Skills Transfer
Programs-By-Day
Type
8:00 - 11:00 AM
103

Time
3:15 - 5:30 PM
3:30 - 5:30 PM
Type
No.
SKILLS
LEC120
SKILLS
LEC121
SKILLS
Topic
GLA
Diabetes 2014: Course on Diabetic Retinopathy
RET
LEC122
SKILLS
LEC123
SKILLS
LEC124
SKILLS
LEC125

Surgical Pearls
Phakic IOLs
Room
Page
S101ab
112
S102abc
120
CAT
S103bc
107
PLAST
N427a
115
COR
S104b
110
REF
N427d
119
SKILLS
LAB102A Endothelial Keratoplasty Techniques
COR
N227b
109
SKILLS
CAT
N228
106
PLAST
N230
115
SKILLS
LAB110A Advanced Refractive Cataract Surgery and Anterior Segment

Reconstruction
LAB115A Introduction to Aesthetic Facial Surgery by Fractional Lasers, Intense
Pulsed Light, Radiofrequency, and Ultrasound Devices
LAB126 Workshop in Flap Techniques in Oculoplastic Surgery
PLAST
N226
116
4:00 - 5:30 PM
SKILLS
LAB127
PLAST
N229
116
4:30 - 5:30 PM
SKILLS
LEC128
PLAST
N427bc
116
SKILLS
Skills Transfer
Programs-By-Day
Title

Time
Type
No.
Title
Topic
Room
Page
8:00 - 10:00 AM
SKILLS
SKILLS
SKILLS
SKILLS
SKILLS
LAB122A
LAB123A
LAB113B
LAB118A
LAB129
CAT
PLAST
CAT
GLA
PLAST
$
$
$
$
$
N227b
N229
N228
N230
N226
107
116
107
112
116
8:00 - 10:30 AM
8:30 - 10:30 AM
9:00 - 11:15 AM
SKILLS
SKILLS
SKILLS
LAB121A
LAB130
LEC131
RET
COM
REF
$
$
+
N231
N227a
N138
120
109
119
SKILLS
LEC132
CAT
S102d
108
10:00 - 11:30 AM
10:15 - 11:15 AM
10:15 AM - 12:30 PM
SKILLS
SKILLS
SKILLS
SKILLS
LEC133
LAB118B
LEC136
LEC134
REF
GLA
PLAST
GLA
+
$
+
+
N427bc
N230
S103a
S105bc
119
112
117
112
10:30 AM - 12:00 PM
10:30 AM - 12:30 PM
SKILLS
SKILLS
SKILLS
LEC135
LAB125A
LAB124A
GLA
REF
COR
+
$
$
N427d
N228
N227b
113
119
111
11:30 AM - 12:30 PM
SKILLS
SKILLS
SKILLS
LAB128A
LAB137
LAB138
PLAST
PLAST
MEDED
$
$
$
N229
N226
N227a
116
117
109
11:30 AM - 1:30 PM
SKILLS
SKILLS
LEC139
LAB140
PLAST
GLA
+
$
N138
N231
117
113
12:30 - 2:30 PM
1:00 - 2:30 PM
SKILLS
SKILLS
LAB120A
LAB132A
GLA
CAT
$
$
N230
N228
112
108
1:30 - 2:30 PM
SKILLS
LAB141

Phacoemulsification and Advanced Techniques
Ab Interno Approach to Schlemms Canal
Oculoplastic Surgery: Anatomic Foundations, Surgical Techniques,
and Enhanced Results
Diabetes 2014: Workshop on Diabetic Retinopathy
The iPhone and iPad for Ophthalmologists (Advanced)
International Society of Refractive Surgery Laser Refractive Surgery
Course
Manual Extracapsular Cataract Extraction Surgery: Indications and
Techniques
Ab Interno Approach to the Schlemm Canal
Computerized Perimetry Lecture: Visual Field Testing and
Phakic IOLs
Surgical Pearls
How to Use Free Technology to Add Interactivity to Face-to-Face
Lectures and Presentations
Is It Time to Replace Gonioscopy by Anterior Segment Imaging in the
Diagnosis and Management of Angle-Closure Glaucoma?
Manual Extracapsular Cataract Extraction Surgery: Indications and
Techniques
An Innovative Approach to Iris Fixation of an IOL Without Capsular
Support: Hands-on and Practical
CAT
N227a
108
7:30 - 9:30 AM
7:30 - 10:00 AM
8:00 - 9:30 AM
11:00 AM - 1:30 PM
104

Time
Type
1:30 - 3:00 PM
2:30 - 4:30 PM
SKILLS
SKILLS
2:30 - 5:00 PM
3:30 - 4:30 PM
SKILLS
SKILLS
SKILLS
SKILLS
SKILLS
SKILLS
SKILLS
SKILLS
3:30 - 5:30 PM
SKILLS
3:00 - 5:00 PM
3:15 - 5:30 PM
SKILLS
No.
Title
LAB133A The Surgical Correction of Astigmatism

LAB134A Computerized Perimetry Lab: Visual Field Interpretation, Emphasizing
Glaucoma
LAB139A Advanced Techniques in Orbital Decompression and Expansion
LAB142 Enucleation and Evisceration: Hands-On Practical Pearls
LAB135A Schlemm Canal Surgery: From the Outside In
LEC143 Toric Alignment Imaging and Astigmatism Surgery
LEC144 Glaucoma Laser Therapy: Innovations and Advice From the Experts
LEC145 Glaucoma Filtration Surgery
LEC146 Fundamental Facelifting Techniques
LAB147 An Innovative Approach to Iris Fixation of an IOL Without Capsular
Tension Support
LAB110B Advanced Refractive Cataract Surgery and Anterior Segment
Reconstruction
LAB131A Laser Refractive Surgery
Topic
Room
Page
REF
GLA
$
$
N227b
N231
120
112
PLAST
PLAST
GLA
CAT
GLA
GLA
PLAST
CAT
$
$
$
+
+
+
+
$
N229
N226
N230
N427bc
S106a
S104b
N427d
N227a
117
117
113
108
113
113
118
108
CAT
N228
107
REF
N227b
119
Topic
Room
Page
CAT
N228
108
PLAST
REF
GLA
PLAST
COR
CAT
CAT
GLA
PLAST
CAT
COR
PLAST
$
$
$
+
+
$
$
$
$
$
$
$
N229
N227b
N230
N140
N427a
N228
N227b
N230
N229
N228
N227b
N229
117
119
113
118
111
107
108
114
118
106
111
118
Tuesday, Oct. 21
8:00 - 9:30 AM
8:00 - 10:00 AM
10:15 AM - 12:30 PM
10:30 AM - 12:00 PM
10:30 AM - 12:30 PM
11:00 AM - 12:30 PM
11:00 AM - 1:00 PM
1:00 - 2:30 PM
1:30 - 3:30 PM
2:00 - 4:00 PM
Type
SKILLS
SKILLS
SKILLS
SKILLS
SKILLS
SKILLS
SKILLS
SKILLS
SKILLS
SKILLS
SKILLS
SKILLS
SKILLS
No.
Title
LAB132B Manual Extracapsular Cataract Extraction Surgery: Indications and

Techniques
LAB136A Fat Grafting and Volume Restoration
LAB131B Laser Refractive Surgery
LAB144A Glaucoma Laser Therapy: Innovations and Advice From the Experts
LEC149 Blepharoplasty
LEC150 Surgery for Severe Corneal and Ocular Surface Disease
LAB113C Phacoemulsification and Advanced Techniques Lab
LAB143A Toric Alignment Imaging and Astigmatism Surgery
LAB145A Glaucoma Filtration Surgery Lab
LAB146A Fundamental Facelifting Techniques
LAB104B Management of the Vitreous for the Anterior Segment Surgeon
LAB150A Surgery for Severe Corneal Ocular Surface Disease
LAB149A Blepharoplasty
Skills Transfer
Programs-By-Day
Time
105

Cataract
Management of the Vitreous for the Anterior Segment

Surgeon
Course Director(s): Natalie A Afshari MD*
Recommended Didactic
Sunday, 9:00 - 11:15 AM
EduLevel: INT
Synopsis: This course will review the anatomy, physiology, and pathophysiology
of the vitreous and will present vitrectomy techniques for challenging anterior segment surgery scenarios. Topics will include management of vitreous loss from the
anterior and posterior approach, utilizing the vitrector for decompression in challenging cataract cases, and visualizing the vitreous with triamcinolone acetonide
(Kenalog).
Objective: This course is designed to enhance the anterior segment surgeons familiarity with anterior and posterior vitrectomy techniques for challenging anterior
segment cases.
Course: LEC104
Room: S102abc
Instructor(s): Iqbal K Ahmed MD*, Rosa Braga-Mele MD*, Ron Afshari Adelman
MD MPH, Keith A Warren MD*, Baseer U Khan MD*, Thomas A Oetting MD
Labs
Synopsis: This Skills Transfer course will present management of the vitreous
during complicated anterior segment surgery. A variety of vitrectomy techniques
will be discussed. Topics will include anterior vitrectomy, pars plana access to the
anterior vitreous, and effective use of small-gauge instrumentation.
Objective: This course is designed to enhance participants technical skills in handling vitreous during complicated anterior segment surgery.
Select one of the following
Course: LAB104A
Sunday, 11:30 AM - 1:00 PM
Room: N228
Fee: $255
EduLevel: INT
Instructor(s): Ron Afshari Adelman MD MPH, Sherleen Huang Chen MD, Baseer
U Khan MD*, Roberto Pineda II MD*, Jack A Cohen MD FACS, Ali R Djalilian MD,
Aryan Shayegani MD, Jerzy Nawrocki MD PhD, Francesco Boscia MD*, Shameema
Sikder MD*, Robert B Bhisitkul MD*, Thomas A Oetting MD, Shahzad I Mian MD*,
Joung Y Kim MD, William Barry Lee MD*
Course: LAB104B
Room: N228
Fee: $255
Tuesday, 1:00 - 2:30 PM

EduLevel: INT
Instructor(s): Ron Afshari Adelman MD MPH, Bonnie A Henderson MD*, Maria

Mendicino Aaron MD, Sherleen Huang Chen MD, Baseer U Khan MD*, Gary S
Schwartz MD, Ivan J Suner MD*, Roberto Pineda II MD*, Jack A Cohen MD FACS,
Neda Shamie MD*, Ali R Djalilian MD, Aryan Shayegani MD, Jerzy Nawrocki MD
PhD, Francesco Boscia MD*, Brad H Feldman MD, Shameema Sikder MD*, Robert
B Bhisitkul MD*, Kenneth M Goins MD**, Thomas A Oetting MD
NEW
Course Director(s): Robert P Rivera MD*
Synopsis: Femtosecond laser-assisted cataract surgery is performed in the United

States with 4 currently approved laser platforms. In this course each platform will
be described in detail and demonstrated in a wet lab format.
Objective: At the conclusion of this course, the attendee will understand the manner in which modern anterior segment imaging techniques are combined with femtosecond laser applications to successfully perform femtosecond laser-assisted
cataract surgery. The 4 major femtosecond lasers utilized for cataract surgical procedures in the United States will be demonstrated, and each attendee will be given
direct, hands-on exposure to these via a wet lab with each of the laser platforms.
Faculty will consist of surgeons widely experienced in the utilization of each of
106
the femtosecond cataract lasers, and will address the manner in which the lasers
perform advanced treatment of corneal astigmatism, the anterior capsulotomy, and
nuclear softening and fragmentation.
Note: Participants will be sharing equipment.
Course: LAB108
Room: N230
Fee: $255
Course: Course: LAB116
Room: Room: N230
Fee: $255

Sunday, 9:00 - 10:30 AM
EduLevel: ADV
Sunday, 11:00 AM - 12:30 PM
EduLevel: ADV
Instructor(s): Kevin M Miller MD*, Robert J Weinstock MD*, Carlos Buznego MD*
Advanced Refractive Cataract Surgery and Anterior

Segment Reconstruction
Course Director(s): Brock K Bakewell MD*
Sunday, 10:15 AM - 12:30 PM
EduLevel: INT
Synopsis: This course is designed for surgeons who (1) want to achieve a higher
level of emmetropic results by addressing toricity through the use of limbal relaxing
incisions, toric IOLs, and bioptics, and (2) want to expand their armamentarium for
dealing with difficult cataract cases, dislocated IOLs, and traumatized eyes.
Objective: This course will cover iris and scleral suture fixation techniques for
IOLs, chopping techniques, capsular tension rings, artificial iris vs. primary closure
for iris defects, pars plana vitrectomy, femtosecond cataract surgery on various
platforms, and strategies for dealing with challenging cases. These techniques
will be presented in the didactic course and many will be practiced in the Skills
Transfer lab.
Course: LEC110
Room: E352
Instructor(s): William J Fishkind MD FACS*, Samuel Masket MD*, Warren E Hill

MD*, Alan S Crandall MD*, Lisa B Arbisser MD*, Garry P Condon MD*, Richard S
Hoffman MD*, Louis D Skip Nichamin MD*, Mark K Walsh MD, Roger C Furlong
MD
Labs
Synopsis: This course is designed for surgeons who (1) want to achieve a higher
level of emmetropic results, and spectacle independence through the use of bioptics, limbal relaxing incisions, toric, multifocal, and accommodative IOLs and who
(2) want to expand their armamentarium for dealing with difficult cataract cases,
dislocated IOLs, and traumatized eyes.
Objective: This course will cover iris and scleral suture and sutureless fixation
techniques for IOLs, chopping techniques, capsular tension rings and stabilization
devices, pupil expanders, pupilloplasty and primary closure for iris defects, pars
plana vitrectomy, and strategies for dealing with challenging cases.
Course: LAB110A
Sunday, 3:30 - 5:30 PM
Room: N228
Fee: $290
EduLevel: INT
Senior Instructor(s): Robert P Liss MD
Instructor(s): Brock K Bakewell MD*, Louis D Skip Nichamin MD*, Warren E
Hill MD*, Bonnie A Henderson MD*, Ayman Naseri MD**, Garry P Condon MD*,
James A Bryan III MD, Michael G Orr MD, Richard S Hoffman MD*, Roger C
Furlong MD, Michele M Bloomer MD, Steven H Dewey MD*, Jeff S Maltzman MD,
Corey A Miller MD, Bruce David Nichols MD, Lynn Polonski MD, Kevin Lee Waltz
MD*, Christine S Ament MD, Cynthia S Chiu MD, Sumit Garg MD*, Mark Alan
DiPillo MD**, John J DeStafeno MD*


Course: LAB110B
Room: N228
Fee: $290
Monday, 3:30 - 5:30 PM

EduLevel: INT
Course: LAB113B
Room: N228
Fee: $255
Monday, 8:00 - 9:30 AM

EduLevel: INT
Senior Instructor(s): Roger C Furlong MD
Senior Instructor(s): Gerald Roper MD, Anita Nevyas-Wallace MD
Instructor(s): George Beiko MD*, Steven H Dewey MD*, William S Clifford MD*,
Kenneth J Rosenthal MD FACS**, Douglas Katsev MD*, Robert A Kaufer MD, Jeff
H Pettey MD, Richard S Davidson MD*, James T Banta MD, Brock K Bakewell
MD*, Pablo Miguel Arregui MD*, Charles S Ahn MD, Donald Stone MD*, Robert J
Weinstock MD*, Susan M MacDonald MD*, Sumit Garg MD*, Robert P Liss MD,
Daniel H Chang MD*, Jason J Jones MD*, Tal Raviv MD*, Anthony J Aldave MD*,
Jake P Bostrom MD, Balamurali K Ambati MD*, Lindsay Ong-Tone MD*
Instructor(s): David R Hardten MD*, Warren E Hill MD*, Alan N Carlson MD*,
Jeffrey Whitman MD OCS*, Bennett Chotiner MD*, Erik A Chotiner MD, Ricardo G
Glikin MD, Michael Hater MD, Herbert J Nevyas MD**, Florentino E Palmon MD,
Clark L Springs MD**, P Dee G Stephenson MD FACS*, Linda M Tsai MD, James
F Freeman MD, Kevin M Miller MD*, Asim R Piracha MD*, Maria Cirone Scott
MD*, Cathleen McCabe MD*, Tom Coffman MD**, James A Katz MD*, Dan B Tran
MD**
Senior Instructor(s): Maria Mendicino Aaron MD
Phacoemulsification and Advanced Techniques: The Core

Curriculum
Course Director(s): Steven H Dewey MD*
Instructor(s): Anita Nevyas-Wallace MD*, Ricardo G Glikin MD, Nick Mamalis

MD*, Helen K Wu MD*, Mark H Blecher MD*, Thomas A Oetting MD
Labs
Synopsis: In the past few years, noteworthy new phaco technologies have altered
the way surgeons execute and analyze this procedure. In this course, the latest
phaco techniques and technologies will be presented. The most topical techniques
will be taught, including wound construction, capsulorrhexis, capsular staining,
phaco chop techniques, techniques for operating the mature cataract, astigmatism management, capsular tension rings, and pupil expanders and hooks. New
machine principles, including micropulse phaco and torsional phaco, will be assessed. Training will be one on one, allowing for customization of the techniques
emphasized for each surgeon attendee.
Objective: By the conclusion of this course, the surgeon attendee should understand the concepts influencing the latest phaco machine technologies and phaco
techniques and attain the skills necessary for undertaking them.
Course: LAB113A
Sunday, 1:30 - 3:00 PM
Room: N228
Fee: $255
EduLevel: INT
Senior Instructor(s): Gerald Roper MD, Anita Nevyas-Wallace MD
Instructor(s): Boris Malyugin MD PhD*, Randall J Olson MD, Chi-Wah (Rudy) Yung
MD, Donald J Doughman MD, Linda M Tsai MD, Steven R Sarkisian MD*, Marc
A Michelson MD**, Audrey R Talley-Rostov MD*, Herbert J Ingraham MD, Nan
Wang MD PhD, Surendra Basti MBBS*, Frank W Bowden III MD FACS*, Stephen E
Orlin MD, Michael Sulewski MD, William Wiley MD*, Robert W Weisenthal MD,
Steven D Vold MD*, R Bruce Wallace MD**, Stephen V Scoper MD*, Deepinder K
Dhaliwal MD*, Luther Fry MD FACS*, Kristiana D Neff MD*
Tuesday, 10:30 AM - 12:00 PM

EduLevel: BAS
Instructor(s): Natalie A Afshari MD*, Ron Afshari Adelman MD MPH, David B Krebs
MD, Nina A Goyal MD, Raj K Goyal MD MPH*, Hilary A Beaver MD*, Robert S
Bailey MD, Chi-Wah (Rudy) Yung MD, C Diane Song MD, Thomas A Oetting MD,
Nan Wang MD PhD, Rahul T Pandit MD, Jill R Wells MD, Joung Y Kim MD, Amy
Grossman Coburn MD, Paul B Pruett MD, Maria A Woodward MD*, Clark L Springs
MD**, Preston H Blomquist MD, Daniel H Chang MD*, Purnima S Patel MD,
Jeremy K Jones MD

Course Director(s): Marian Sue Macsai-Kaplan MD*
Course: LEC122
Room: S103bc
Sunday, 3:15 - 5:30 PM

EduLevel: BAS
Synopsis: This course will cover basic microsurgical suturing techniques. In addition, principles, theories, and practical instruction in corneal-scleral laceration and
corneal wound repair, management of cataract wound problems, including wound
burns, and extension of clear corneal incisions will be offered.
Objective: This course offers basic microsurgical suturing training that is applicable in the management of penetrating keratoplasty suturing, corneal lacerations,
and cataract wound problems.
Instructor(s): Woodford S Van Meter MD FACS
Lab
Synopsis: This course will cover basic microsurgical suturing techniques. In addition, principles, theories, and practical instruction in corneal-scleral laceration and
corneal wound repair, management of cataract wound problems, including wound
burns, and extension of clear corneal incisions will be offered.
Objective: This course will offer basic microsurgical suturing training that is applicable in the management of penetrating keratoplasty suturing, corneal lacerations,
and cataract wound problems.
Course: LAB122A
Monday, 7:30 - 9:30 AM
Room: N227b
Fee: $180
EduLevel: BAS
Instructor(s): Marian Sue Macsai-Kaplan MD*, Woodford S Van Meter MD FACS,
Andrew J W Huang MD MPH*, Carol L Karp MD, Anthony J Lubniewski MD*, Joel
Sugar MD*, Andrea Kara-Jose MD, R Doyle Stulting MD PhD*, Anthony J Johnson
MD**, William Barry Lee MD*, Charles S Bouchard MD, David B Glasser MD,
Aaleya F Koreishi MD*, Ali R Djalilian MD, Anat Galor MD*, Michael Saidel MD*,
Satya Reddy MD, Jennifer Y Li MD, Robert S Feder MD, Denise de Freitas MD,
Wen-Hsiang Lee MD PhD*, Jeanine A Baqai MD**, Helen K Wu MD*, Julie H Tsai
MD, Paras R Shah MD, Tony N Pira MD, Luciene Sousa MD*
NEW New Course. YO Endorsed by Young Ophthalmologists committee. W Participants are required to sign an infectious disease transmission waiver/release form.
EQUIP Participants are required to bring specific equipment to the course. Education Level Key: BAS = Basic, INT = Intermediate, ADV = Advanced
107
Sunday, 10:15 AM - 12:30 PM
EduLevel: INT
Synopsis: In this course, a faculty of experienced surgeons will present the latest phaco techniques and technologies that are of interest to ophthalmologists
at every level of experience. This comprehensive course will cover the steps of
phacoemulsification, including incisions, capsulorrhexis, hydrodissection, and
phaco techniques with an emphasis chop. Safe cortex removal and IOL implantation will be demonstrated. Capsular tension rings, pupil expanders, hooks, capsular
staining, and related techniques will also be presented. This course will teach the
most up-to-date phacoemulsification techniques both to individuals with little or
no experience with the method and to those wishing to refine or update their technique or transitioning from other cataract surgery methods.
Objective: This course is designed to teach participants the principles and skills
necessary to understand and perform state-of-the-art phacoemulsification safely
and efficiently.
Course: LEC113
Room: N427bc
Course: LAB113C
Room: N228
Fee: $255

Manual Extracapsular Cataract Extraction Surgery:
Indications and Techniques

Capsular Support: Hands-on and Practical
Course Director(s): Jeff H Pettey MD
Course Director(s): Paul R Rosenberg MD FACS
Monday, 9:00 - 11:15 AM
EduLevel: BAS
Synopsis: Although extracapsular cataract extractions by large incision (ECCE)
and small incision (SICS), also known as sutureless extracapsular cataract surgery
(SECS), are still performed routinely throughout the world, phacoemulsification surgery has become the standard of care in many countries, and therefore ECCE / SICS
is no longer being taught. However, understanding how to perform this surgery
competently is still crucial when faced with complications during phacoemulsification surgery, or when a SECS approach may be a better choice for the patient.
Objective: By the conclusion of this course, the attendee will (1) have learned and
be able to practice primary ECCE and SECS surgery, (2) have learned and be able to
practice how to convert from a clear corneal phacoemulsification to either a ECCE
or a SECS approach, and (3) better understand how to deal with complications of
all forms of extracapsular cataract surgery.
Synopsis: This course will present an innovative variation of a McCannel / Siepser small-incision retrievable suture technique for peripheral iris fixation in the
absence of capsule support for secondary foldable IOLs and dislocated IOLs. This
technique will be demonstrated with video, animation, and hands-on practice with
a model.
Objective: Surgeons will learn the rationale for iris fixation of a foldable implant
and will add this technique to their arsenal of management options for IOL dislocation and aphakia. Their understanding of the practical method of suturing will be
cemented by a hands-on approach.
Course: LAB141
Monday, 1:30 - 2:30 PM
Room: N227a
Fee: $60
EduLevel: INT
Instructor(s): Bonnie A Henderson MD*, Geoffrey C Tabin MD, Maria Mendicino

Aaron MD
Instructor(s): Elana S Rosenberg MD**
Course: LEC132
Room: S102d
Labs
Synopsis: Although extracapsular cataract extractions by large incision (ECCE)
and small incision (SICS) are still performed routinely throughout the world, phacoemulsification surgery has become the standard of care in many countries, and
therefore ECCE / SICS is no longer being taught. However, understanding how to
perform this surgery competently is still crucial when faced with complications
during phacoemulsification surgery or when an ECCE approach may be a better
choice for the patient.
Objective: By the conclusion of this course, the attendee will (1) have learned and
be able to practice primary ECCE and SICS surgery, (2) have learned and be able to
practice how to convert from a clear corneal phacoemulsification to either a ECCE
or a SICS approach, and (3) better understand how to deal with complications of
ECCE surgery.
Course: LAB132A
Monday, 1:00 - 2:30 PM
Room: N228
Fee: $255
EduLevel: BAS
Senior Instructor(s): Bonnie A Henderson MD*
Instructor(s): Eduardo C Alfonso MD*, Maria Mendicino Aaron MD, Geoffrey C
Tabin MD, Preston H Blomquist MD, Abhay Raghukant Vasavada MBBS FRCS*,
Francisco J Gutierrez-Carmona MD PhD, Soosan Jacob FRCS, Amar Agarwal MD*,
Dianna L Bordewick MD, Neera N Kanjani MBBS, Surendra Basti MBBS*, Samar K
Basak MD DNB MBBS*, Arup Chakrabarti MBBS, Nilesh K Kanjani MBBS, Joung Y
Kim MD, Zaiba Malik MD, Jaime Tejedor MD
Course: LAB132B
Room: N228
Fee: $255
Tuesday, 8:00 - 9:30 AM

EduLevel: BAS
Senior Instructor(s): Bonnie A Henderson MD*,
Instructor(s): Elana S Rosenberg MD**
Course: Course: LAB147

Room: Room: N227a
Fee: $60
Monday, 3:30 - 4:30 PM

EduLevel: INT
Toric Alignment Imaging and Astigmatism Surgery

Course Director(s): Louis D Skip Nichamin MD*
Course: LEC143
Room: N427bc
Monday, 3:15 - 5:30 PM

EduLevel: INT
Synopsis: This course will cover management techniques for pre-existing astigmatism, specifically at the time of implant surgery, with focus upon intralimbal
relaxing incisions, toric IOLs, and laser (femto / excimer) treatment modalities.
Objective: At the conclusion of this course, participants will be able to plan and
perform the techniques necessary to control postcataract astigmatism.
Instructor(s): Jonathan B Rubenstein MD*
Lab
Synopsis: This course will cover management techniques for pre-existing astigmatism, specifically at the time of implant surgery, with focus upon intralimbal
relaxing incisions, toric IOLs, and laser (femto / excimer) treatment modalities.
Objective: At the conclusion of this course, participants will be able to plan and
perform the techniques necessary to control postcataract astigmatism.
Course: LAB143A
Tuesday, 10:30 AM - 12:30 PM
Room: N227b
Fee: $220
EduLevel: INT
Instructor(s): Brock K Bakewell MD*, Y Ralph Chu MD*, Jonathan Davidorf MD,
Steven J Dell MD**, Randy J Epstein MD*, Leslie Grosinger MD, James C Hays
MD*, Warren E Hill MD*, Richard S Hoffman MD*, Terry Kim MD*, Nick Mamalis
MD*, Kevin M Miller MD*, Parag D Parekh MD MPA**, Gerald Roper MD*, Kenneth J Rosenthal MD FACS**, Alan Victor Spigelman MD, David T Vroman MD*, R
Bruce Wallace MD**, Bonnie A Henderson MD*
Instructor(s): Eduardo C Alfonso MD*, Maria Mendicino Aaron MD, Geoffrey C

Tabin MD, Preston H Blomquist MD, Francisco J Gutierrez-Carmona MD PhD, Abhay Raghukant Vasavada MBBS FRCS*, Soosan Jacob FRCS, Amar Agarwal MD*,
Dianna L Bordewick MD, Neera N Kanjani MBBS, Surendra Basti MBBS*, Samar K
Basak MD DNB MBBS*, Nilesh K Kanjani MBBS, Arup Chakrabarti MBBS, Joung Y
Kim MD, Zaiba Malik MD, Craig J Chaya MD*, Michael R Feilmeier MD
108


Computer Courses are open to all registrants.
EQUIP YO
(Basic)
The iPhone and iPad for Ophthalmologists
Course Director(s): Vinay A Shah MD*
Note: Each participant is required to bring their iPhone or iPad to the course.
Instructor(s): Ron K Lord MD*, Hemang K Pandya MD, Rohit Krishna MD*, Michael
A Cassell MD**, Judith Lee**
EQUIP The iPhone and iPad for Ophthalmologists
(Advanced)
Course Director(s): Vinay A Shah MD*
Course: LAB130
Monday, 8:30 - 10:30 AM
Room: N22a
Fee: $80
EduLevel: INT
Synopsis: Eighty percent of physicians use smartphones, and this number is
expected to rise. The iPhone has covered about 50% of the smartphone market.
This course will introduce the user to intermediate to advanced applications of the
iPhone and iPad in following areas: (1) office management: calendar, ICD-9, schedules, (2) patient care tools: near vision card, Amsler grid, color plates, optokinetic
nystagmus drum, pupil gauge, patient consents, and external, slitlamp, and fundus
photos, (3) patient education material: diagrams / videos, (4) physician education
/ reference material: eye atlas, study guides, pharmacopoeia, and board review
material, (5) practice marketing through social media and a Personalized Doctor
app, and (6) use of the iPhone for personal use, from making a conference call to
using various handy apps.
Objective: After the course, attendees will have an advanced understanding of
and be able to use the iPhone for patient care, as a reference guide, for their education, and to be more efficient.
Note: Each participant is required to bring their iPhone or iPad to the course.
Instructor(s): Ron K Lord MD*, Hemang K Pandya MD, Rohit Krishna MD*, Michael
A Cassell MD**, Judith Lee**
How to Use Free Technology to Add

Interactivity to Face-to-Face Lectures and Presentations
NEW EQUIP
Jointly Sponsored by the Academys Skills Transfer Advisory Committee and the
nternational Council of Ophthalmology
Course Director(s): Eduardo P Mayorga MD*
Note: Each participant is required to bring their smartphone, iPad or laptop to the
course.
Instructor(s): Matthew D Gearinger MD, Ana Gabriela Palis MD

Course Director(s): Mark A Terry MD*
Course: LEC102
Room: S103bc
Sunday, 9:00 - 11:15 AM

EduLevel: INT
Synopsis: This course will explore the various surgical techniques used for endothelial keratoplasty (EK): Descemet-stripping EK, Descemet-stripping automated
EK, and Descemet membrane EK. Emphasis will be placed on basic techniques that
minimize complications and maximize donor endothelial survival. Methods of donor
tissue preparation, insertion, unfolding, and positioning will be discussed. Benefits
and problems with tissue injectors will be presented. Techniques to promote donor
tissue adhesion and to avoid primary graft failure will be emphasized. Detailed
videos and discussion of EK in complex and combined cases will be presented.
Objective: At the conclusion of the course, participants will understand the safest
methods of EK to avoid dislocation, primary graft failure, and pupillary block, and
how to enhance faster visual rehabilitation.
Instructor(s): Kenneth M Goins MD**, George O D Rosenwasser MD
Lab
Synopsis: This laboratory course will use pig eyes to allow participants to become
generally familiar with the instrumentation and surgical techniques involved with
Descemet-stripping endothelial keratoplasty (DSEK) and Descemet-stripping automated endothelial keratoplasty (DSAEK), but not Descemet membrane endothelial
keratoplasty (DMEK). Safe methods of donor insertion, unfolding, and positioning
will be stressed. Techniques of promoting donor adherence and avoiding primary
graft failure will be practiced.
Objective: At the conclusion of this course, the participants will understand the
complexity and required instrumentation for the most common technique of endothelial keratoplasty. Techniques to avoid complications and preserve donor endothelial cells will be understood.
Course: LAB102A
Room: N227b
Fee: $220
Sunday, 3:30 - 5:30 PM

EduLevel: INT
Instructor(s): Mark A Terry MD*, George O D Rosenwasser MD, Kenneth M Goins

MD**, Neda Shamie MD*, Anand K Shah MD, Irving M Raber MD*, Paul M Phillips MD, David D Verdier MD, Mark S Gorovoy MD, Edwin S Chen MD, Thomas
John MD**, Ann McColgin MD, Robert L Schultze MD*, Michael D Straiko MD*,
Mark Greiner MD, Jeffrey M Goshe MD, Julia C Talajic MD**, Peter B Veldman
109
Course: LAB109
Sunday, 10:00 AM - 12:00 PM
Room: N227a
Fee: $80
EduLevel: BAS
Synopsis: Eighty percent of physicians utilize smartphones, and this number is
expected to rise. Recently, the iPhone has covered about 50% of the smartphone
market. This course will introduce the user to more intermediate applications of
the iPhone and iPad in the following areas: (1) office management: calendar, ICD-9,
schedules, (2) patient care tools: near vision card, Amsler grid, color plates, optokinetic nystagmus drum, pupil gauge, patient consents, and external, slitlamp,
and fundus photos, (3) patient education material: diagrams / videos, (4) physician education / reference material: eye atlas, study guides, pharmacopoeia, and
board review material, (5) marketing of ones practice through social media and a
Personalized Doctor app, and (6) use of the iPhone for personal use, from making a
conference call to using various handy apps.
Objective: After the course, the attendees will understand and be able to use the
iPhone for patient care, as a reference guide, for their own education, and to be
more efficient.
Course: LAB138
Monday, 11:30 AM - 12:30 PM
Room: N227a
Fee: $45
EduLevel: BAS
Synopsis: This course will cover the principles, strategies, and techniques of lecture interactivity. The audience will actively participate during the entire course
using their smartphones, iPads, or laptops in the role of attendees. They will also
learn, as presenters, to set up different software (Socrative, Google Drive) and
use them effectively, working together with PowerPoint in the same presentation
screen.
Objective: At the end of the course, attendees will be able to apply different strategies of interaction, such as polling, multiple choice questions, hot spot questions,
brainstorming, and multiple column pro and con discussions, using free audience
interactive response software.

MD, Colleen C Grace MD, Jennifer Y Li MD, Rajesh Fogla MD FRCS, Luciene Sousa
MD*, Karen L Hoar MD**, Christopher S Sales MD
linking, and obtain hands-on experience with several UV light devices and corneal
ring segments.
Instructor(s): A John Kanellopoulos MD*, Theo Seiler MD PhD, Roy Scott Rubinfeld
MD**, Peter S Hersh MD*, William B Trattler MD*, Yaron S Rabinowitz MD
Course Director(s): Parag A Majmudar MD*
Course Director(s): Sheraz M Daya MD*, Sadeer B Hannush MD
Sunday, 9:00 - 11:15 AM
EduLevel: ADV
Synopsis: This course will cover current and evolving practice in anterior lamellar
keratoplasty. Topics include evolving lamellar techniques, including the big bubble, modified Melles, viscodissection, Ferrara, and automated and femtosecond
lamellar techniques. A series of didactic lectures will be provided, with technique
pearls (and complications), supported by video presentations and handouts. The
lecture portion is a prerequisite for the wet lab, where candidates will be guided
through many techniques.
Objective: The participant should leave the course with an understanding of various options for performing anterior lamellar keratoplasty. The participant will have
a thorough understanding of the indications, advantages, and disadvantages of
each of these techniques. Additional hands-on training on the use of some of these
procedures will be provided in the associated laboratory.
Course: LEC103
Room: N427a
Instructor(s): Luigi Fontana MD PhD, Shigeto Shimmura MD*, Donald Tan MD FRCS
FRCOphth*, Woodford S Van Meter MD FACS
Lab
Synopsis: This wet lab course will cover current and evolving practice in anterior
lamellar keratoplasty. An international faculty will cover different lamellar dissection techniques, including big bubble, viscodissection, modified Melles, and automated and femtosecond lamellar deep anterior lamellar keratoplasty. Avoiding
and managing complications will also be discussed. Candidates will be personally
guided through these techniques by expert and experienced faculty, and there will
be opportunity for in-depth discussion.
Objective: At the end of the course, the attendee will have a good understanding
of the indications for anterior lamellar keratoplasty, the techniques involved, and
how to avoid and manage complications.
Course: LAB103A
Sunday, 12:30 - 2:30 PM
Room: N227b
Fee: $220
EduLevel: ADV
Instructor(s): Luigi Fontana MD PhD, Shigeto Shimmura MD*, Donald Tan MD FRCS
FRCOphth*, Woodford S Van Meter MD FACS, Hamed Mofeez Anwar MD, Brandon
Ayres MD*, Federico Badala MD**, Deepinder K Dhaliwal MD*, Dasa Gangadhar
MD, Jose Gomes MD*, Samer Hamada MD, Alfonso Iovieno MD, Mayank A
Nanavaty MD, Irving M Raber MD*, Konstantinos Samaras MD, Vincenzo Sarnicola
MD, Elmer Tu MD
NEW
Crosslinking
Course Director(s): Parag A Majmudar MD*
Course: LEC107
Room: E351
Sunday, 9:00 - 10:00 AM

EduLevel: INT
Synopsis: Collagen crosslinking has emerged in the last several years as a frontline therapy in keratoconus and post-LASIK ectasia. This course will explore the
history and current uses of crosslinking, including epithelium-off and transepithelial crosslinking and concurrent crosslinking with corneal ring segments, as well as
examining future applications, including combined crosslinking with topographyguided excimer laser ablation.
Objective: At the conclusion of this course, participants will have a better understanding of patient selection criteria, be able to evaluate the merits of the various
treatment strategies, develop a protocol for postoperative management of cross110
Lab
Synopsis: Collagen crosslinking has emerged in the last several years as a frontline therapy in keratoconus and post-LASIK ectasia. This course will explore the
history and current uses of crosslinking, including epithelium-off, and transepithelial crosslinking, and concurrent crosslinking with corneal ring segments, as well as
examining future applications, including combined crosslinking with topographyguided excimer laser ablation.
Objective: At the conclusion of this course, participants will have a better understanding of patient selection criteria, be able to evaluate the merits of the various
treatment strategies, develop a protocol for postoperative management of crosslinking, and obtain hands-on experience with several UV light devices and corneal
ring segments.
Course: LAB107A
Room: N227b
Fee: $130
Sunday, 11:00 AM - 12:00 PM

EduLevel: INT
Instructor(s): A John Kanellopoulos MD*, Theo Seiler MD PhD, Roy Scott Rubinfeld
MD**, William B Trattler MD*, Peter S Hersh MD*, Yaron S Rabinowitz MD, Randy
J Epstein MD*, Jodi Luchs MD*, Jonathan H Talamo MD*, Kathryn Masselam
Hatch MD*, Sandy T Feldman MD**, Arthur B Cummings MD*, Michael Mrochen
PhD*, Antonio Leccisotti MD**, Paolo Vinciguerra MD*, Aleksandar Stojanovic
MD, R Doyle Stulting MD PhD*, Michael B Raizman MD*, Rajesh K Rajpal MD*,
Simon P Holland MD*, Raymond Stein MD
Endothelial Keratoplasty Surgery: Comprehensive

Overview and Surgical Pearls
Course Director(s): Edward J Holland MD*
Course: LEC124
Room: S104b
Sunday, 3:15 - 5:30 PM

EduLevel: INT
Synopsis: Endothelial keratoplasty (EK) has become the standard of care for the
surgical treatment of endothelial diseases of the cornea. This course will utilize international corneal experts to teach a comprehensive overview of a variety of surgical techniques for Descemet-stripping endothelial keratoplasty (DSEK) and Descemet membrane endothelial keratoplasty (DMEK). Participants will learn about
indications, surgical techniques, outcomes, and complications of both procedures
with specific pearls to enhance success from the experienced EK faculty. Updates
in donor tissue insertion for EK will be reviewed, including helpful tips for novice
and experienced surgeons for the various steps of DSEK and DMEK techniques.
Objective: At the conclusion of the course, the attendee will understand indications, surgical techniques, surgical pearls, and potential complications of DSEK
and DMEK.
Instructor(s): Francis W Price Jr MD*, Donald Tan MD FRCS FRCOphth*, Massimo
Busin MD*, Mark J Mannis MD, David T Vroman MD*, William Barry Lee MD*,
Keith A Walter MD*
Lab
Synopsis: Endothelial keratoplasty (EK) has become the standard of care for the
surgical treatment of endothelial diseases of the cornea. This course will utilize
international corneal experts to teach the various steps of Descemet-stripping endothelial keratoplasty (DSEK) and Descemet membrane endothelial keratoplasty
(DMEK). Participants will perform various steps of the EK procedure, with individual stations to practice various tissue insertion techniques. Surgical videos of
DSEK insertion techniques and surgical pearls will be reviewed during the course


to enhance performance of various steps. Attendees will receive hands-on experience with all steps of DSEK, including donor tissue preparation steps with DMEK.
Objective: At the end of this course, participants will understand all steps of
DSEK and have hands-on experience with donor tissue preparation and surgical
steps of DSEK and DMEK.
Course: LAB124A
Monday, 10:30 AM - 12:30 PM
Room: N227b
Fee: $220
EduLevel: INT
Maria S Cortina MD, Andrea Y Ang MBBS**, Guillermo Amescua MD, Leela V Raju
MD, Victor L Perez MD*, Joshua H Hou MD
Glaucoma
Computerized Scanning Imaging of the Optic Nerve and

Retinal Nerve Fiber Layer
Course Director(s): E Randy Craven MD*
Senior Instructor(s): Clara C Chan MD*, William Barry Lee MD*

Instructor(s): Francis W Price Jr MD*, Friedrich E Kruse MD*, Donald Tan MD FRCS
FRCOphth*, David B Glasser MD, Massimo Busin MD*, Mark J Mannis MD, David
T Vroman MD*, Keith A Walter MD*, David D Verdier MD, Richard S Davidson
MD*, Shahzad I Mian MD*, Andrea Y Ang MBBS**, Kristiana D Neff MD*,
Heather M Skeens MD**, Mahshad Darvish-Zargar MD, Jennifer Y Li MD, Kenneth
C Mathys MD**, Joseph S Tims MD, Florentino E Palmon MD, Michael J Taravella
MD**, Vipul C Shah MD, Charles L Thompson MD**
W
Surgery for Severe Corneal and Ocular Surface Disease
Course Director(s): Ali R Djalilian MD, Gunther Grabner MD*
Instructor(s): Edward J Holland MD*, Scheffer C G Tseng MD PhD*, James Chodosh

MD MPH*, Ahmad Kheirkhah MD, Maria S Cortina MD, Victor L Perez MD*, Darren
G Gregory MD
Lab
Synopsis: This course is intended for ophthalmologists who plan to expand their
surgical skills in the management of severe corneal and ocular surface disease.
The topics will include amniotic membrane transplantation, limbal stem cell transplantations, and keratoprosthesis.
Objective: At the conclusion of this wet lab course, the attendee will be able to (1)
apply the surgical techniques for amniotic membrane transplantation using sutures
and/or fibrin glue, (2) perform the various surgical techniques for limbal stem cell
transplantation including conjunctival limbal autograft / allograft and keratolimbal
allograft, and (3) assemble and surgically implant a Boston type I keratoprosthesis.
Attendees with all levels of experience (including no experience) are encouraged to
participate and take advantage of the opportunity to work one-on-one with faculty
with extensive experience in all of these techniques.
Note: Participants are required to sign an infectious disease transmission waiver /
release form.
Course: LAB150A
Room: N227b
Fee: $220
Tuesday, 1:30 - 3:30 PM

EduLevel: INT
Instructor(s): Andrew J W Huang MD MPH*, Jose Gomes MD*, Jose J de la Cruz

Napoli MD*, Joung Y Kim MD, David D Verdier MD, Daniel H Scorsetti MD, Julie
H Tsai MD, Pedram Hamrah MD*, Vadrevu K Raju MD FRCS FACS, Anthony J
Lubniewski MD*, Ahmad Kheirkhah MD, Kristiana D Neff MD*, Clara C Chan MD*,
Sunday, 9:00 - 11:15 AM

EduLevel: BAS
Synopsis: This lecture, required for the hands-on workshop, will deepen the participants understanding of OCT in glaucoma, with historical background of older
technologies as required to understand the OCT. This is a basic / intermediate
course featuring current technologies.
Objective: By the conclusion of this course, participants will be able to (1) understand the scientific basis for imaging, (2) understand how scanning imaging
may be used in clinical practice, (3) learn how imaging can be applied to the optic
nerve head, retinal nerve fiber layer, and macula, with emphasis on glaucoma, (4)
understand the relationship between structure and function, and (5) differentiate
normal from abnormal scans through appropriate clinical examples. A questionand-answer session will be held at the end of the presentations, during which time
questions will be entertained by the faculty.
Instructor(s): Neil T Choplin MD, Sanjay G Asrani MD*, Howard Barnebey MD*
Lab
Synopsis: This workshop will advance knowledge for participants in the clinical
uses of OCT for imaging the optic nerve, the nerve fiber layer, and the ganglion
cells of the macula. Historical review of older technologies will be briefly done as
needed for understanding OCT content. The main focus of the workshop will be
interpretation of representative printouts from clinical examples. Instructors will be
available to discuss imaging technologies for interested participants.
Objective: By the conclusion of this course, participants will be able to (1) understand image quality control and the indications for repeating images, (2) become
familiar with the analysis software, and (3) practice interpretation of representative cases.
Course: LAB101A
Sunday, 12:00 - 2:00 PM
Room: N231
Fee: $100
EduLevel: INT
Instructor(s): Howard Barnebey MD*, Arvind Neelakantan MD*
W
Ab-Interno Approach to Schlemms Canal
Course Director(s): Sameh Mosaed MD*
Course: LEC118
Room: S103d
Sunday, 2:00 - 4:15 PM

EduLevel: INT
Synopsis: Angle-based surgery for glaucoma via an internal approach will be
covered in this course. The Trabectome is an instrument used for ab-interno trabecular ablation for the treatment of adult and juvenile open-angle glaucoma. We
will review data from an ongoing case series exceeding 2000 eyes, including combined cataract and glaucoma surgery. Trabecular bypass stent (iStent) will also be
presented, including data from recent FDA trials comparing combined iStent and
cataract surgery with cataract extraction alone at 1 and 3 years postop. Indications,
surgical technique, IOP outcomes, and complications of these 2 procedures will be
described during a 2-hour didactic course. Other new and evolving ab-interno approaches to Schlemms Canal will be considered as well. This will be followed by a
hands-on lab session using inverted corneal donor rings for practice.
111
Tuesday, 10:15 AM - 12:30 PM
EduLevel: INT
Synopsis: This course is intended for ophthalmologists who plan to expand their
surgical skills in the management of severe corneal and ocular surface disease.
The topics will include amniotic membrane transplantation, limbal stem cell transplantations, and keratoprosthesis.
Objective: At the conclusion of this course, the attendee will be able to (1) describe the indications and apply the surgical techniques for amniotic membrane
transplantation, (2) recognize limbal stem cell deficiency and effectively apply the
various surgical techniques for limbal stem cell transplantation, (3) recognize and
successfully prevent / treat limbal allograft rejection using systemic immunosuppression, and (4) describe the patient selection, surgical techniques, and postoperative management of patients with keratoprosthesis.
Course: LEC150
Room: N427a
Course: LEC101
Room: S105bc

Objective: At the conclusion of the course, attendees will understand the indications, surgical technique, IOP outcomes, and complications associated with these
ab interno trabecular bypass procedures.
Instructor(s): Brian A Francis MD*, Nils A Loewen MD*, Nathan M Radcliffe MD*,
Steven R Sarkisian MD*
Labs
Synopsis: During this lab session, attendees will practice trabecular bypass procedures with a Trabectome console and handpiece, with adjustable power level
and foot-pedal control, and a tissue model consisting of an inverted human corneal
ring, including the trabecular meshwork. The corneal donor ring will be pin-fixated
to a rubber holding device. Practice surgery will be done via an operating microscope, enabling a realistic view of the instrument effects as the Schlemm canal is
unroofed by electroablation. Simultaneous video illustrating the gonioscopic view
and live surgeries will also be presented. A model of the iStent will be available
to gain comfort with the handling of a trabecular microbypass insertion device.
Objective: At the course conclusion, the attendees will have had a realistic exposure to the surgical technique and one-on-one discussion of the advantages and
disadvantages of these ab interno trabecular bypass procedures.

release form. Participants will be sharing equipment.
Course: LAB118A
Room: N230
Fee: $170

Monday, 8:00 - 9:30 AM
EduLevel: INT
Instructor(s): Nathan M Radcliffe MD*, Brian A Francis MD*, Donald S Minckler

MD*, Quang H Nguyen MD*, Douglas J Rhee MD*, Paul A Sidoti MD*, George
Baerveldt MD*, Arthur J Sit MD*, Michael C Stiles MD*, Steven D Vold MD*, Martha Motuz Leen MD*, Marina A Ramirez MD**, Troy M Tanji MD, Masahiro Maeda
MD, John P Berdahl MD*, Ilya M Rozenbaum MD*, Steven R Sarkisian MD*
Course: LAB118B
Room: N230
Fee: $170
Monday, 10:00 - 11:30 AM

EduLevel: INT
Instructor(s): Nathan M Radcliffe MD*, Brian A Francis MD*, George Baerveldt

MD*, Carla J Siegfried MD*, Douglas J Rhee MD*, Martha Motuz Leen MD*,
Donald S Minckler MD*, Paul A Sidoti MD*, Quang H Nguyen MD*, Arthur J Sit
MD*, Masahiro Maeda MD, John P Berdahl MD*, Ilya M Rozenbaum MD*

Course Director(s): Ronald Leigh Fellman MD OCS*
Course: LEC120
Room: S101ab
Sunday, 3:15 - 5:30 PM

EduLevel: INT
Synopsis: The first part of this course is didactic, covering the indications, pathophysiology, surgical technique, postoperative management, and complications of
drainage devices (from anterior chamber tube to extraocular reservoir). The second
part is hands-on, with implantation of Molteno, Krupin, Baerveldt, Ahmed, and
Schocket devices on porcine eyes. Ex-Press shunt, Trabectome, and canaloplasty
will not be covered.
Objective: At the conclusion of this course, the attendee will be aware of principles and techniques of glaucoma drainage device implantation.
Instructor(s): Richard P Mills MD MPH*, George Baerveldt MD*, Anne Louise Coleman MD PhD*, Frederick M Kapetansky MD, Donald L Budenz MD MPH*, Paul A
Sidoti MD*, Angelo P Tanna MD*
part is hands-on, with implantation of Molteno, Krupin, Baerveldt, Ahmed, and

Schocket devices on porcine eyes. Ex-Press shunt, Trabectome, and canaloplasty
will not be covered.
Objective: By the conclusion of this course, attendees will be able to complete a
drainage device implantation in a fresh tissue eye.
Course: LAB120A
Monday, 12:30 - 2:30 PM
Room: N230
Fee: $220
EduLevel: INT
Instructor(s): Richard P Mills MD MPH*, Paul A Sidoti MD*, Martha Motuz Leen
MD*, Alfred M Solish MD*, Keith Barton MD*, Frederick M Kapetansky MD, Howard Barnebey MD*, Eugenio J Maul MD, Margaret Sophia Spencer MD, Marianne
E Feitl MD, Simon K Law MD*, Joern B Soltau MD*, Steven Gedde MD*, Sameh
Mosaed MD*, JoAnn A Giaconi MD*
Computerized Perimetry: Visual Field Testing and

Jointly Sponsored by the Academys Skills Transfer Advisory Committee and The
Course Director(s): Julia Whiteside-de Vos MD MPH
Monday, 10:15 AM - 12:30 PM
EduLevel: BAS
Synopsis: This lecture reviews computerized perimetry, emphasizing glaucoma
and the Humphrey field analyzer. Topics will include the stepwise interpretation
of individual visual fields (VFs), the significance of each portion of the VF printout,
determining if the VF is reliable and if it is normal or abnormal, tips for obtaining
a more reliable VF and for selecting the appropriate test, SITA, SWAP, frequency
doubling perimetry, and the analysis of a series of VFs for progression. Numerous,
mostly glaucomatous, case examples will be used.
Objective: This course will provide participants with the background knowledge
necessary to be more comfortable with VF interpretation and to be prepared for the
separate laboratory session.
Course: LEC134
Room: S105bc
Note: Octopus perimetry will be covered in the lab. This is the lecture portion of a
Skills Transfer lab.
Instructor(s): Todd W Perkins MD*, Julia Whiteside-de Vos MD MPH
Lab
Synopsis: This lab will prepare clinicians to interpret computerized visual fields
(VFs) and use them more effectively in the diagnosis and management of glaucoma
patients. The first 30 minutes of the lab will be devoted to a lecture regarding Octopus perimetry. Subsequently, participants will practice interpreting Humphrey or
Octopus unknown VFs under the guidance of an experienced instructor. Examples
will include individual VFs and series of VFs for progression evaluation, using event
and trend progression analysis methods corresponding to the type of perimeter the
participant has chosen for concentration.
Objective: This course is designed to enable participants to master the skills necessary for interpreting automated VFs and for using them in the management of
glaucoma patients.
Course: LAB134A
Monday, 2:30 - 4:30 PM
Room: N231
Fee: $100
EduLevel: BAS
Senior Instructor(s): Todd W Perkins MD*
Instructor(s): Anand V Mantravadi MD**, E Randy Craven MD*, Jonathan S Myers
MD*, Jeffrey S Schultz MD**, David E Silverstone MD, Martha M Wright MD
Lab
Synopsis: The first part of this course is didactic, covering the indications, pathophysiology, surgical technique, postoperative management, and complications of
drainage devices (from anterior chamber tube to extraocular reservoir). The second
112


W
Course Director(s): Richard A Lehrer MD*
Course: LEC135
Monday, 10:15 AM - 12:30 PM
Room: N427d
EduLevel: INT
Synopsis: Canaloplasty, an ab externo glaucoma procedure, is an alternative approach in glaucoma filtering surgery and has shown results comparable to those
of other methods, with a reduction in overall complications. Yet this technique has
a learning curve, with its own set of unique challenges. This course will present a
systematic, multimedia, video-assisted review of the anatomy, rationale, explanation, and illustration of canaloplasty.
Objective: This course will explain (1) the procedures method of re-establishing
aqueous outflow, (2) the procedures advantages, disadvantages, risks, and benefits, and (3) the identification of glaucomas where the procedure would have highest probability of success. Recent clinical results and innovations to enhance the
procedure will also be discussed. New this year is added material on ab interno
goniotomy using the catheter.
Instructor(s): Iqbal K Ahmed MD*, Alan S Crandall MD*, Clive O Peckar MD, Howard
Barnebey MD*, John R Kearney MD, Davinder S Grover MD*, Robert Stegmann MD**
Note: Attendees should have experience with nonpenetrating glaucoma surgery. Participants are required to sign an infectious disease transmission waiver / release form.
Course: LAB135A
Room: N230
Fee: $220
Monday, 3:00 - 5:00 PM

EduLevel: INT
Instructor(s): Iqbal K Ahmed MD*, Alan S Crandall MD*, Clive O Peckar MD, Howard
Barnebey MD*, John R Kearney MD, Robert P Liss MD, Davinder S Grover MD*
Is It Time to Replace Gonioscopy by Anterior Segment

Imaging in the Diagnosis and Management of AngleClosure Glaucoma?
Course Director(s): Syril Dorairaj MD
Course: LAB140
Monday, 11:30 AM - 1:30 PM
Room: N231
Fee: $100
EduLevel: BAS
Synopsis: Angle-closure glaucomas (ACGs) are a group of disorders characterized by mechanical blockage of the trabecular meshwork by the peripheral iris,
resulting from interactions between the structures and hydrodynamics inside the
eye. Imaging of the anterior segment is an essential tool aiding the diagnosis and
understanding of the mechanism and management of ACG. Various imaging devices are now available, each one representing particular technical advantages /
disadvantages over the others. Anterior segment imaging cannot replace the direct
visualization of angle structures, but it can overcome some of the limitations of
gonioscopy by providing a more objective means of obtaining a qualitative and
quantitative evaluation of the angle. These imaging techniques are enlightening
clinicians and researchers about the importance of making an early diagnosis, establishing underlying causal mechanisms, and evaluating treatments.
Instructor(s): Christopher Kai-shun Leung MD MBChB*, Vishal Jhanji MBBS, Paul F
Palmberg MD PhD*, Clement C Y Tham MBBS*, Tin Aung FRCS PhD*
Course Director(s): Lisa S Gamell MD
Course: LEC144
Room: S106a
Monday, 3:15 - 5:30 PM

EduLevel: INT
Synopsis: This course will provide a comprehensive review of laser procedures
used to treat glaucoma. Topics discussed will include argon laser trabeculoplasty
(ALT), selective laser trabeculoplasty (SLT), micropulse laser trabeculoplasty (MLT),
cyclophotocoagulation (both endoscopic and trans-scleral), iridotomy (Nd:YAG,
argon, and diode), iridoplasty, and laser suture lysis. Indications, treatment techniques, and postoperative care will be discussed in detail during the didactic
portion of the course. During the laboratory section, participants will have the
opportunity to perform endoscopic cyclophotocoagulation, trans-scleral cyclophotocoagulation, SLT, ALT, MLT, and iridotomies under the supervision of the course
instructors.
Objective: At the conclusion of this course, attendees will be able to understand
the indications and techniques for the various laser therapies used in the treatment
of glaucoma. After the laboratory section, they will have hands-on experience using these modalities on animal eyes.
Instructor(s): Robert J Noecker MD*, Joel S Schuman MD*, Jorge A Alvarado MD,
Mark A Latina MD*, Malik Y Kahook MD*, Brian E Flowers MD*
Lab
Synopsis: This course will provide a comprehensive review of laser procedures
used in the treatment of glaucoma. Topics discussed will include argon laser
trabeculoplasty (ALT), selective laser trabeculoplasty (SLT), micropulse laser trabeculoplasty (MLT), cyclophotocoagulation (both endoscopic and trans-scleral),
iridotomy (Nd:YAG, argon, diode, and krypton), and iridoplasty. Laser enhancement
of filtering procedures will be covered as well, including laser suture lysis and bleb
revision. During the laboratory section, participants will have the opportunity to
perform endoscopic cyclophotocoagulation, trans-scleral cyclophotocoagulation,
SLT, ALT, MLT, and iridotomies under the supervision of the course instructors.
Objective: At the conclusion of this course, attendees will be able to understand
the indications and techniques for the various laser therapies used in the treatment
of glaucoma. After the laboratory section, they will have hands-on experience using these modalities on animal eyes.
Course: LAB144A
Room: N230
Fee: $220
Tuesday, 8:00 - 10:00 AM

EduLevel: INT
Instructor(s): Robert J Noecker MD*, Joel S Schuman MD*, Jorge A Alvarado MD,
Mark A Latina MD*, Malik Y Kahook MD*, Brian E Flowers MD*, Martin Uram
MD*
Glaucoma Filtration Surgery

Course Director(s): Steven L Mansberger MD*
Course: LEC145
Room: S104b
Monday, 3:15 - 5:30 PM

EduLevel: BAS
Synopsis: This course will provide a comprehensive review of the techniques and
complications of glaucoma filtration surgery. Glaucoma surgical technique will be
stressed in this update of filtration surgery, with a heavy emphasis on surgical
video presentations. The course will also discuss novel surgical techniques used in
filtration surgery, such as Ex-Press shunts, as compared to conventional surgery. A
panel discussion with questions and answers will conclude the session.
113
Lab
Synopsis: This course will demonstrate and train attendees in the procedure of
canaloplasty, an ab externo glaucoma procedure. Attendees will be mentored in
the procedure, with microscopic dissection and catheter, and then tension suture
placement in the Schlemm canal.
Objective: At the conclusion of this course, the attendees should have a good
understanding of and hands-on ability to perform this procedure, from the insertion
of the microcatheter through placement of the suture invaginating the trabecular
meshwork.
Glaucoma Laser Therapy: Innovations and Advice From

the Experts

Objective: This course will review surgical anatomy, basic trabeculectomy techniques, antimetabolites (including 5-fluorouracil and mitomycin C), and postoperative management and complications.
Instructor(s): George A Cioffi MD*, Jeffrey M Liebmann MD*, F Jane Durcan MD,
Robert D Fechtner MD FACS**, George A Cioffi MD*, Celso Tello MD**
Lab
Synopsis: This Skills Transfer course will offer hands-on instruction on glaucoma
filtration surgery, specifically for the general ophthalmologist and ophthalmology
resident. The lab session will provide experience with the techniques of trabeculectomy.
Objective: Using porcine eyes and dissection microscopes (one per student),
glaucoma surgical techniques will be performed. The attendees will learn surgical anatomy, scleral flap dissection, fistula creation with and without an Ex-Press
shunt, iridectomy, and releasable and standard flap closure techniques.
Course: LAB145A
Tuesday, 11:00 AM - 12:30 PM
Room: N230
Fee: $170
EduLevel: BAS
presentations, videos, and interactive computer simulations to demonstrate and

teach SCL fitting skills. The attendee will utilize computer simulation to fit and
evaluate multiple SCL fittings. Individual assistance will be available during the
computer simulation training.
Objective: This course will teach the practitioner (1) recognition of suitable candidates, (2) appropriate SCL selection, (3) soft spherical and toric lens fitting, and (4)
patient and practice management.
Note: Each participant is required to bring their own PC laptop or MAC computer to
the course, and computers must be able to load CDs. Windows XP, Windows Vista, or
Windows 7 is required.
Instructor(s): Melvin I Freeman MD FACS*, William T Driebe MD, Zoraida Fiol-Silva

MD*, Michael H Goldstein MD*, Jeanine Suchecki MD, Bruce Koffler MD*, Peter R
Kastl MD PhD, John S Massare PhD
Senior Instructor(s): John C Morrison MD
Course Director(s): Jeremiah P Tao MD
Instructor(s): Young H Kwon MD PhD*, Paul A Sidoti MD*, Steven D Vold MD*,
Frank J Mares MD, Jason C Swanner MD**, Mansi Parikh MD, Kevin P Pikey DO**
Course: LAB100
Sunday, 8:00 - 11:00 AM
Room: N226
Fee: $165
EduLevel: ADV
Synopsis: In this course we introduce the orbitocentric approach to facial fracture
repair, including anatomy, principals of rigid internal fixation, and preferred surgical
approaches. A series of lectures and a hands-on lab introduce fixation systems and
plating concepts. Model skulls, facial plating hardware, and instrumentation will
be provided.
Objective: At the conclusion of the course, the attendee will understand the benefits of an orbitocentric approach to orbitofacial bone repair. In addition, participants
gain practical experience with facial plating and instrumentation.
Neuro-Ophthalmology
Jointly Sponsored By the Academys Skills Transfer Advisory Committee and the
North American Neuro-Ophthalmology Society (NANOS)
Course Director(s): Christopher C Glisson DO*
Course: LAB105
Sunday, 9:00 - 11:00 AM
Room: N231
Fee: $100
EduLevel: INT
Synopsis: This review of CT and MRI scans of the head and orbit will improve participants knowledge of anatomy and imaging analysis using illustrative cases. The
course will be supervised by experienced neuro-ophthalmologists and will employ
a hands-on format. Through detailed discussion and review of cases and related
films, participants will gain knowledge to enhance skills used when ordering and
interpreting imaging studies.
Objective: Participants will recognize normal structures and pathologic findings
on CT and MRI scans, recognize the indications for ordering various types of imaging, and become proficient at reviewing neuroimaging studies.
Instructor(s): Michael S Vaphiades DO*, Eric Eggenberger DO*, Eric L Berman MD,
Jade Schiffman MD, Larry P Frohman MD*, Jacqueline A Leavitt MD, Michael C
Brodsky MD, Nicholas J Volpe MD, Rosa A Tang MD*, Julie Falardeau MD, Roger E
Turbin MD*, Fiona E Costello MD*

EQUIP Soft Contact Lens Fitting for the Practicing
Ophthalmologist
Jointly Sponsored By the Academys Skills Transfer Advisory Committee and the
Contact Lens Association of Ophthalmologists (CLAO)
Course Director(s): Peter C Donshik MD*, William H Ehlers MD
Course: LAB119
Sunday, 2:30 - 5:00 PM
Room: N227a
Fee: $85
EduLevel: BAS
Synopsis: To appropriately utilize contact lenses in practice, the Eye M.D. needs
to recognize suitable candidates, select the appropriate lens, and know how to fit
and evaluate the lens. This course is for Eye M.D.s who want to add or expand soft
contact lens (SCL) fitting in their practices. The learning format includes PowerPoint
114
Instructor(s): Hui Bae Harold Lee MD, Peter J Timoney MBBCh, Mithra O Gonzalez
MD, Jeffrey M Joseph MD
NEW Periocular Rejuvenation With Fillers and 2-D Videos
and Video-Assisted Teaching
Course Director(s): Shubhra Goel MD
Course: LEC106
Room: E352
Sunday, 9:00 - 10:00 AM

EduLevel: BAS
Synopsis: This course will provide a of the basics of Botulinum toxin and hyaluronic acid filler injections around the periocular region. The course highlights will
include 2-D anatomy videos, clinical case scenarios, and video-assisted teaching
to demonstrate and master the planning of various injection techniques. It will also
highlight how to manage various complications and surprises using simple modification techniques and use of hyalase / vitrase. There will be interactive case-based
discussions and time for audience discussion.
Objective: At the conclusion of this course, each attendee will have clear knowledge of periocular anatomy and principles and techniques of periocular rejuvenation using fillers.
Instructor(s): Sabrina D Shah-Desai MBBS**, Vinod Gauba MD, Cynthia Boxrud MD
FACS**, Nikolaos Trakos MD**
Course Director(s): Shubhra Goel MD
Lab
Synopsis: This course will provide personalized hands-on instruction in the basic
of Botulinum toxin and hyaluronic acid filler injections around the periocular region.
The course highlights will include 2-D anatomy videos, clinical cases, video-assisted teaching and specially designed silicone models to practice proper injection


techniques and learn to manage complications with hyalase / vitrase. There will be
interactive case-based discussions and time for audience discussion.
Objective: At the conclusion of this course, each attendee will have clear knowledge of periocular anatomy and the principles and techniques of periocular rejuvenation using BOTOX and fillers, with real-time simulated injection practice.
Note: Participants are required to bring surgical loupes.
Course: LAB106A
Room: N229
Fee: $120
Sunday, 10:30 AM - 12:30 PM

EduLevel: INT
Instructor(s): Sabrina D Shah-Desai MBBS**, Vinod Gauba MD, Cynthia Boxrud MD

FACS**, Nikolaos Trakos MD**
Cosmetic Botulinum Toxin and Facial Fillers: An

Introductory Course
EQUIP W
Course Director(s): Kathleen M Duerksen MD
Instructor(s): Michael S McCracken MD, Deborah D Sherman MD*, John Joseph

Martin MD*
Lab
Synopsis: Taught by experienced instructors, this lab provides hands-on, personalized instruction in the basics of botulinum toxin and facial filler injections utilizing
cadaver heads.
Objective: At the completion of the lab, the participant will be able to identify
the proper sites, doses, and indications for injection of botulinum toxin and facial
fillers. The participant will demonstrate proper injection technique with the goal of
avoiding technique-related complications.
Note: Participants are required to bring surgical loupes. Participants are also required
to sign an infectious disease transmission waiver / release form.
Course: LAB112A
Room: N229
Fee: $275
Sunday, 1:30 - 3:00 PM

EduLevel: BAS
Instructor(s): Michael S McCracken MD, Deborah D Sherman MD*, John Joseph

Martin MD*, Christopher M DeBacker MD, Morris E Hartstein MD, Cat Burkat
MD, Jose R Montes MD*, Craig Erwin Geist MD, Rona Z Silkiss MD FACS*, Gary
Borodic MD**, Charles B Slonim MD, Dawn C Buckingham MD, Dale R Meyer MD
FACS, Asa Dan Morton III MD, Ronald W Kristan MD, Jeffrey P Edelstein MD*,
Julie A Woodward MD*, Fred S Bodker MD, Kenneth David Steinsapir MD**,
Kristin J Tarbet MD**
Introduction to Aesthetic Facial Surgery by Fractional

Lasers, Intense Pulsed Light, Radiofrequency, and
Ultrasound Devices
Course Director(s): Julie A Woodward MD*
Course: LEC115
Room: S106b
Sunday, 10:15 AM - 12:30 PM
EduLevel: BAS
Instructor(s): Randal Pham MD FACS, Adam J Scheiner MD*, Ioannis P Glavas MD,
John Joseph Martin MD*, Wendy W Lee MD*
Lab
Synopsis: This lab will present a unique opportunity to compare and contrast a
variety of lasers, intense pulsed light, and other energy-based devices in a handson format.
Objective: At the completion of this course, participants will (1) understand safe
application of rejuvenation technology, (2) learn how to manage complications, and
(3) start to choose which devices and procedures to incorporate into their current
practices.
Course: LAB115A
Room: N230
Fee: $220
Sunday, 3:30 - 5:30 PM

EduLevel: BAS
Instructor(s): Julie A Woodward MD*, John Joseph Martin MD*, Randal Pham MD
FACS, Adam J Scheiner MD*, Ioannis P Glavas MD, Wendy W Lee MD*, Usha P
Reddy MD**, Amina Husain MD**, Kristina M Price MD, Amy M Fowler MD
W Surgical Anatomy of the Eyelids: Cadaver
Demonstration
Course Director(s): Edward H Bedrossian MD FACS
Course: LAB117
Sunday, 12:00 - 2:30 PM
Room: N226
Fee: $140
EduLevel: INT
Synopsis: Using slides, video, and cadaver prosections, this course will demonstrate landmarks important in the correction of brow ptosis, blepharoptosis, ectropion, entropion, and retraction. Included will be a precourse quiz and participant
interaction.
Objective: This course is designed to (1) review eyelid anatomy, (2) show structures in prosected cadavers, and (3) improve surgical technique.
release form.
Instructor(s): Edward H Bedrossian MD FACS, Robert C Della Rocca MD**, Bryan

Arthurs MD FRCSC
EQUIP W
Course Director(s): Stuart R Seiff MD
Course: LEC123
Room: N427a
Sunday, 3:15 - 5:30 PM

EduLevel: ADV
Synopsis: In this course the aesthetic evaluation of the patient with eyebrow ptosis, the anatomy of the eyebrow and forehead, and a description of the endoscopic
brow and forehead elevation procedure will be discussed. A course handbook will
be provided, detailing the surgical technique.
Objective: This course is designed to provide an understanding of the preoperative patient evaluation, pertinent surgical anatomy, and technique of endoscopic
brow and forehead elevation.
115
Sunday, 10:15 AM - 12:30 PM
EduLevel: BAS
Synopsis: Principles of aesthetic facial injection of botulinum toxin and facial fillers will be presented in a didactic format.
Objective: At the conclusion of this course, the attendee will better understand
the salient anatomy, clinical techniques (including complication avoidance), and
pharmacological principles pertaining to aesthetic injection of these substances.
Course: LEC112
Room: S106a
Synopsis: This course will focus primarily on ablative laser resurfacing (CO2 and
erbium), laser incisional blepharoplasty, and intense pulsed light. Preoperative,
intraoperative, and postoperative care and management of complications will be
covered. There will also be very brief introductions to the latest in nonablative
fractional resurfacing, radiofrequency, and microfocused ultrasound.
Objective: By the conclusion of this course, attendees will be able to (1) compare and contrast the many different devices on the market, (2) have introductory
knowledge of how to incorporate such new technologies into their practices, and
(3) recognize and manage complications of these devices.

Senior Instructor(s): Susan R Carter MD
Lab
Synopsis: A brief lecture outlining the steps in endoscopic forehead and eyebrow
elevation will be followed by step-by-step cadaver dissections for hands-on experience with the equipment and surgical technique.
Objective: Participants will obtain a familiarity with the surgical anatomy of the
brow and forehead, instrumentation, planes of dissection, and closure techniques
in endoscopic forehead and eyebrow elevation.
Course: LAB123A
Room: N229
Fee: $440
Monday, 7:30 - 10:00 AM

EduLevel: ADV
Instructor(s): Kimberly Cockerham MD FACS*, Kathleen M Duerksen MD, Jill

Annette Foster MD FACS*, Susan R Carter MD, David E Holck MD**, John Bryan
Holds MD*, Asa Dan Morton III MD, Eve E Moscato MD, Harmeet S Gill MD, Morris E Hartstein MD, Craig N Czyz DO, Louis Savar MD**, Rona Z Silkiss MD FACS*,
David J Russell MD
Workshop in Flap Techniques in Oculoplastic Surgery

Course Director(s): Dawn C Buckingham MD
Course: LAB126
Sunday, 3:30 - 5:30 PM
Room: N226
Fee: $120
EduLevel: INT
Synopsis: This course will begin with a discussion of various suturing materials
and techniques. Basic flap techniques will then be discussed, including advancement, rotation, and bilobe and rhomboid flaps. Additionally, Z-plasty, Y-V plasty,
and the management of dog ears will be covered. These techniques are crucial
in achieving the best possible cosmetic result in periorbital reconstruction. The
majority of the course will be a hands-on practicum, during which participants may
perform these procedures under the supervision of experienced course instructors,
utilizing pigs feet.
Objective: At the conclusion of this course, the participant will be more familiar
with various suturing techniques useful in periorbital wound closure and will have
a better understanding of the indications for and techniques utilized in flap reconstruction of periorbital cutaneous defects.
Instructor(s): Morris E Hartstein MD, Suzanne K Freitag MD, George O Stasior MD,
Junhee Lee MD**, Sang H Hong MD, Cat Burkat MD, Nicholas A Ramey MD, Alice
Song MD, Julie A Woodward MD*
EQUIP W
Course Director(s): Arthur Perry MD*
Course: LAB127
Sunday, 4:00 - 5:30 PM
Room: N229
Fee: $275
EduLevel: INT
Synopsis: This course will review indications for silicone intubation and will show
different intubation systems and techniques. Participants will spend most of the
course time actually performing the intubation procedure on cadavers.
Objective: Participants should leave the course feeling confident that they can
successfully intubate the lacrimal system and understand both the indications for
this procedure and possible complications.
Instructor(s): Bruce B Becker MD*, Jeffrey P Edelstein MD*, Arthur Perry MD*,
Melissa L Meldrum-Aaberg MD, Bert Bowden MD, Karim G Punja MD**, Scott M
Goldstein MD, Adam S Hassan MD, Asa Dan Morton III MD
116
EQUIP W Endoscopic Transnasal Lacrimal Surgery:

Principles and Practice
Course Director(s): Francois Codere MD
Course: LEC128
Room: N427bc
Sunday, 4:30 - 5:30 PM

EduLevel: INT
Synopsis: The transnasal diagnosis and treatment of lacrimal outflow disorders
will be presented. Endoscopic nasal anatomy, transnasal dacryocystorhinostomy
surgical techniques, endoscopic Jones tubes placement, and endoscopic diagnosis
and management of lacrimal disorders will be covered.
Objective: At the conclusion of this course, participants will understand transnasal endoscopic diagnosis and treatment of lacrimal outflow disorders.
Instructor(s): Bruce M Massaro MD, Jennifer A Sivak MD
Lab
Synopsis: This course will present the transnasal diagnosis and treatment of
lacrimal outflow disorders. Endoscopic nasal anatomy, transnasal dacryocystorhinostomy surgical techniques, endoscopic placement of Jones tubes, endoscopeassisted intubation, and use of the endoscope for diagnosis and management of
lacrimal disorders will be covered.
Objective: At the conclusion of this course, participants will understand transnasal endoscopic diagnosis and treatment of lacrimal outflow disorders.
Course: LAB128A
Room: N229
Fee: $440
Monday, 11:00 AM - 1:30 PM

EduLevel: ADV
Instructor(s): Francois Codere MD, Bruce M Massaro MD, Jennifer A Sivak MD,
Jorge Corona MD**, Steven C Dresner MD, Angela M Dolmetsch MD, James H
Merritt MD, John T Harvey MD, Liat Attas-Fox MD, Patrick R Boulos MD
Oculoplastic Surgery: Anatomic Foundations, Surgical

Techniques, and Enhanced Results
W
Course Director(s): Cat Burkat MD
Course: LAB129
Monday, 8:00 - 10:00 AM
Room: N226
Fee: $120
EduLevel: INT
Synopsis: Anatomic principles provide the cornerstone of successful oculofacial
surgery. This course will cover the anatomic foundations to be considered when
performing surgical procedures of the eyebrow, forehead, upper and lower eyelids,
midface, and lacrimal system. A series of short lectures will be followed by interactive demonstration and teaching of clinically relevant anatomy on various cadaver
prosections.
Objective: This course is designed to provide knowledge of anatomic foundations
on which participants can build successful oculofacial surgical procedures, and allows close interaction with the instructors.
release form.
Instructor(s): Mark J Lucarelli MD FACS, Sang H Hong MD, Don Kikkawa MD*,
Bobby S Korn MD PhD FACS*, David B Lyon MD FACS, Marcus M Marcet MD, John
J McGetrick MD FACS, Karim G Punja MD**, Nicholas A Ramey MD, Joseph P
Shovlin MD**, Leslie A Wei MD, Katherine M Whipple MD**, Gregory J Griepentrog MD, Courtney Y Kauh MD


EQUIP W
Course Director(s): David Khoramian Isaacs MD
Course: LEC136
Monday, 10:15 - 11:15 AM
Room: S103a
EduLevel: BAS
Synopsis: The purpose of this Recommended Didactic course is to present facial
fat grafting as a technique for volume restoration. Indications for surgery, patient
selection, alternatives to surgery, surgical techniques and instrumentation, and
postoperative details will be reviewed. An interactive case presentation will allow
attendees to participate.
Objective: At the conclusion of this course, the attendee will be acquainted with
facial fat grafting techniques and appropriate patient selection, as well as addressing potential postoperative complications. The course will enable the attendee to
formulate a customized approach to a patients needs and goals.
Instructor(s): Robert M Schwarcz MD**, Brett S Kotlus MD*, Tanuj Nakra MD,
Cynthia Boxrud MD FACS**, Robert A Goldberg MD*, Norman Shorr MD**
Note: Participants are required to bring surgical loupes. Participants are also
required to sign an infectious disease tansmission waiver / release form.
Course: LAB136A
Room: N229
Fee: $275
Tuesday, 8:00 - 9:30 AM

EduLevel: BAS
Instructor(s): Robert M Schwarcz MD**, Brett S Kotlus MD*, Catherine Hwang MD,
Tanuj Nakra MD, Shu-Hong Chang MD, Robert A Goldberg MD*, Norman Shorr MD**
YO
Course Director(s): Eve E Moscato MD
Course: LAB137
Monday, 11:00 AM - 1:30 PM
Room: N226
Fee: $225
EduLevel: BAS
Synopsis: This course is designed to refresh the ophthalmologists basic oculoplastics skills in a laboratory setting (employing porcine specimens), while simultaneously reviewing the fundamentals of ophthalmic plastic and reconstructive
surgery knowledge. The basic principles involved in choosing suture materials
and types of suture needle for various oculoplastics procedures will be reviewed.
Surgical positioning and instrumentation will be touched upon as the course participants perform various surgical techniques employed in ophthalmic plastic and
reconstructive surgery, with instructor assistance.
Objective: The main of the course is to provide participants with an opportunity
to hone surgical skills that are employed in basic oculoplastics procedures such
as eyelid lesion removal, eyelid margin lesion resection and reconstruction, eyelid
laceration repair, ectropion repair, and blepharoplasty. A very basic introduction to
ptosis repair will also be presented.
Instructor(s): Christopher I Zoumalan MD, Raymond I Cho MD, Parag D Gandhi MD,
Alice Song MD, Julia Song MD, Jennifer Trew Scruggs MD**, Edward Wladis
MD*, Harmeet S Gill MD, Keshini C Parbhu MD, Bryan J Winn MD**, Sarit M
Patel MD, Amy M Fowler MD, Louis Savar MD**, Ami Ashvin Shah MD, Michael
Kangwhi Yoon MD, Lyndon B Lee MD**, Jill S Melicher Larson MD, Elizabeth M
Palkovacs MD
Course Director(s): Robert A Goldberg MD*
Monday, 11:30 AM - 12:30 PM
EduLevel: ADV
Synopsis: This course is designed to foster creative thinking in orbital decompression. Staging, planning, and techniques for orbital decompression will be reviewed,
including deep lateral, fat removal, transcaruncular, and endoscopic. Surgical versatility and creative decision making will be stressed.
Objective: This course is designed to acquaint participants with a variety of techniques for orbital decompression and to enable them to design an individualized
approach based on the patients needs and goals.
Course: LEC139
Room: N138
Instructor(s): Norman Shorr MD**, Catherine Hwang MD, Mehryar Taban MD,
Raymond Douglas MD PhD*, Joseph L Lin MD**, Daniel B Rootman MD MSc, Alice
Siew Ching Goh MD, Michael Kazim MD, Chee-Chew Yip MBBS FRCS**, Kenneth
A Feldman MD**, Jonathan W Kim MD, Raman Malhotra MBChB FRCOphth, Tanuj
Nakra MD, Ronald Mancini MD, Shu-Hong Chang MD, Kelvin Kam Lung Chong MD
Lab
Synopsis: Through lectures, video presentations, and laboratory dissection, various techniques for orbital decompression will be reviewed, including deep lateral,
fat removal, transcaruncular, and endoscopic. Surgical versatility and creative decision making will be stressed.
Objective: This course is designed to acquaint participants with a variety of techniques for orbital decompression and to enable them to design an individualized
approach based on the patients needs and goals.
Note: Participants are required to bring surgical loupes and headlamps. Participants
are also required to sign an infectious disease transmission waiver / release form.
Course: LAB139A
Room: N229
Fee: $440
Monday, 2:30 - 5:00 PM

EduLevel: ADV
Instructor(s): Norman Shorr MD**, Catherine Hwang MD, Jonathan W Kim MD,
Joseph L Lin MD**, Daniel B Rootman MD MSc, Aline Pimentel MD**, Shu-Hong
Chang MD, Kelvin Kam Lung Chong MD, David Khoramian Isaacs MD, Payam Vali
Morgan MD**, Jack Rootman MD FRCSC**, Erin B Lessner MD, Shani Golan
Enucleation and Evisceration: Hands-On Practical Pearls

Course Director(s): Parag D Gandhi MD
Course: LAB142
Monday, 2:30 - 5:00 PM
Room: N226
Fee: $225
EduLevel: INT
Synopsis: This skills-oriented course will provide an enriching experience focused
on the pearls of enucleation and evisceration surgery with detailed surgical steps,
hands-on practical training, and video demonstrations. A variety of ocular implants
will be available for attendees to use.
Objective: By the conclusion of this course, participants will be able to (1) understand preoperative evaluation and imaging, (2) develop an instrument set and decide ocular implant options before surgery, (3) anticipate anesthesia requirements,
(4) understand and perform the steps of enucleation and evisceration surgeries, (5)
develop and implement a framework for deciding which procedure to choose and
when, (6) gain facility with ocular implants currently available and identify their advantages, (7) understand the controversies of wrapping and pegging implants, and
(8) enumerate and apply various strategies for management of early postoperative
complications, late complications, and the postenucleation socket syndrome.
Instructor(s): Maria Kirzhner MD, Gary J Lelli MD, Marcus M Marcet MD, Eve E
Moscato MD, Sarit M Patel MD, Erin Shriver MD, Manoj M Thakker MD, M Reza
Vagefi MD
117
Lab
Synopsis: The purpose of this course is to allow attendees to have a hands-on
cadaver learning module in fat grafting. Lectures, video presentations, and laboratory demonstrations on cadavers will teach tumescent anesthesia, fat harvesting,
and fat grafting techniques.
Objective: At the conclusion of this course, the attendee will be familiar with safe
and effective fat grafting techniques and addressing potential postoperative complications. The course will enable the attendee to formulate a customized approach
to a patients needs and goals.
EQUIP W Advanced Techniques in Orbital Decompression

and Expansion

EQUIP W
Jointly Sponsored by the Academys Skill Transfer Advisory Committee and the
American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS)
Course Director(s): Brett S Kotlus MD*
Course: LEC146
Room: N427d
Monday, 3:15 - 5:30 PM

EduLevel: INT
Synopsis: This basic course will consist of a step-by-step slide and video presentation of a preoperative assessment, surgical facial anatomy, fundamental facelifting techniques, postoperative care, and potential complications. A downloadable
course manual will be available to participants.
Objective: Participants will acquire the ability to select appropriate patients, develop hands-on familiarity with facial surgical anatomy, perform safe surgical dissection, provide appropriate postoperative care, and integrate facelifting into their
aesthetic oculofacial practice.
Instructor(s): Tanuj Nakra MD, Robert M Schwarcz MD**, Bobby S Korn MD PhD
FACS*
Lab
Synopsis: Step-by-step cadaver dissection will demonstrate surgical anatomy,
safe surgical planes, and fundamental facelifting techniques, including cervicalmental restoration, superficial musculoaponeurotic system and skin management,
and skin closure.
Objective: Participants will acquire hands-on familiarity with the surgical anatomy and basic facelifting techniques so they will be able to incorporate facelifting
procedures into their aesthetic practices.
Note: Participants are required to bring surgical loupes. Participants are required to
sign an infectious disease transmission waiver / release form.
Course: LAB146A
Room: N229
Fee: $360
Tuesday, 11:00 AM - 1:00 PM

EduLevel: INT
Instructor(s): Bobby S Korn MD PhD FACS*, Robert M Schwarcz MD**, Tanuj Nakra
MD, David E Holck MD**, Stuart R Seiff MD, Allan E Wulc MD FACS*, Kenneth
David Steinsapir MD**, Kathleen M Duerksen MD, William R Nunery MD, Jill
Annette Foster MD FACS*, Mikel W Lo MD, John D Ng MD*, Asa Dan Morton III
MD, Christopher M DeBacker MD, John Joseph Martin MD*, Adam S Hassan MD,
Janet M Neigel MD*, Scott M Goldstein MD, Geva E Mannor MD MPH, Dustin M
Heringer MD**, David Khoramian Isaacs MD, Robert A Goldberg MD*
EQUIP W
Blepharoplasty
Course Director(s): Keith D Carter MD FACS
Tuesday, 10:15 AM - 12:30 PM
EduLevel: INT
Synopsis: This course will cover the latest techniques in upper and lower eyelid
blepharoplasty. Basic and advanced surgical techniques, eyelid anatomy, patient
selection, preoperative evaluation, and avoidance of complications will be discussed. A course handbook with illustrations outlining the surgical techniques will
be provided.
Objective: This course will provide participants with the techniques required to
perform successful upper and lower eyelid blepharoplasties.
Course: LEC149
Room: N140
Objective: Participants will be shown the clinically relevant anatomy as it relates

to performing upper and lower eyelid blepharoplasties.
Course: LAB149A
Room: N229
Fee: $360
Tuesday, 2:00 - 4:00 PM

EduLevel: INT
Instructor(s): Keith D Carter MD FACS, Mark A Alford MD, Richard C Allen MD PhD,
Richard L Anderson MD FACS*, Francesco P Bernardini MD, Carlo de Conciliis MD,
Adam G de la Garza MD, Martin H Devoto MD, Jill S Melicher Larson MD, Robert C
Kersten MD, Jose R Montes MD*, Jeffrey A Nerad MD, Rachel K Sobel MD, Alice
Song MD, Julia Song MD

W
Course Director(s): Kenneth W Wright MD*
Sunday, 10:15 - 11:15 AM
EduLevel: INT
Synopsis: Over the past several years, important surgical innovations have made
strabismus surgery safer and more effective. This course will teach the use of novel
strabismus surgical techniques, including grooved hook for suturing the muscle
insertion, minimally invasive techniques (rectus central tenotomy and plication),
and use of amniotic membrane transplant for restrictive strabismus. Video will be
presented to help teach the techniques. Outcome studies of surgical procedures
will be presented.
Objective: At the conclusion of this course, the attendee will be able to use new strabismus surgical techniques to improve surgical outcomes and reduce complications.
Course: LEC111
Room: S102d
Instructor(s): Yi Ning Strube MD, Luke W Deitz MD
Lab
Synopsis: This hands-on lab will transfer the surgical skills required for the use
of new strabismus techniques. Attendees will actually perform the procedures.
Specific techniques will include use of the grooved hook for safe suturing of tight
muscles and suturing of muscles during topical anesthesia surgery. Techniques for
amniotic membrane transplant useful in the treatment of restrictive strabismus will
be taught. Minimally invasive techniques of partial rectus tenotomy and plication
will be presented. The minimally invasive procedures have utility for the treatment
of small-angle strabismus.
Objective: At the conclusion of the course, the attendee will be able to perform new
strabismus surgical techniques that will improve patient care and clinical outcomes.
release form.
Course: LAB111A
Room: N230
Fee: $165
Sunday, 1:00 - 3:00 PM

EduLevel: INT
Instructor(s): Yi Ning Strube MD, Lisa S Thompson MD, Luke W Deitz MD, Rebecca
S Leenheer MD**
Instructor(s): Mark A Alford MD, Richard C Allen MD PhD, Richard L Anderson MD

FACS*, Robert C Kersten MD, Jill S Melicher Larson MD, Jeffrey A Nerad MD
Lab
Synopsis: This course is designed to provide hands-on laboratory experience with
the techniques used in upper and lower eyelid blepharoplasty. Videos of techniques will be presented, along with personal assistance with cadaver dissection.
118


Refractive Surgery
Phakic IOLs
Course Director(s): Thomas M Harvey MD*
Course: LEC125
Room: N427d
Sunday, 3:15 - 5:30 PM

EduLevel: INT
Synopsis: This course will educate the participant on the use of phakic IOLs in
refractive surgery. Topics of discussion will include patient selection and preoperative testing, IOL power calculations, postoperative care, complication management, surgical technique, and managing residual refractive error. Phakic IOLs currently available in the United States will be emphasized.
Objective: At the course conclusion, the participant will understand indications
for the use of phakic IOLs and key management aspects of phakic IOL candidates.
Instructor(s): Sherman W Reeves MD MPH*, David R Hardten MD*, Jack T Holladay MD MSEE FACS*, Scott D Barnes MD**, Paul J Harton Jr MD*, Gregory
Parkhurst MD*, Elizabeth A Davis MD*
Instructor(s): David R Hardten MD*, D Rex Hamilton MD*, Scott D Barnes MD**,
Thomas M Harvey MD*, Andrew J Velazquez MD**, John P Berdahl MD*, Anthony
J Lombardo MD PhD, William Wiley MD*, Sherman W Reeves MD MPH*, Preeya K
Gupta MD*, George O Waring MD*, Gregory Pamel MD**, Andrew C Shatz MD**,
Asim R Piracha MD*, Michael Vrabec MD, Paul J Dougherty MD*, Lisa Nijm MD**,
Paul J Harton Jr MD*, Gregory Parkhurst MD*, Scott M MacRae MD*, Chirag S
Shah MD
International Society of Refractive Surgery Laser

Refractive Surgery Course
Jointly Sponsored by the Academys Skills Transfer Advisory Committee and the
International Society of Refractive Surgery (ISRS)
Course Director(s): Jason E Stahl MD
Monday, 9:00 - 11:15 AM
EduLevel: BAS
Synopsis: This course will start with the basics of how conventional and laser
microkeratomes work and what one needs to know before performing LASIK and
surface ablation. It will move on to cover tips, step by step, with presentations discussing the newest applications and developments in LASIK and surface ablation.
The prevention and treatment of complications will be covered in detail.
Objective: This course is designed to give participants the information and skills
needed for LASIK and surface ablation, including patient selection, basic principles, postoperative care, and management of complications.
Course: LEC131
Room: N138
Synopsis: This wet lab is designed for those interested in learning techniques in
laser refractive surgery. Mechanical microkeratomes, femtosecond lasers, excimer
lasers, and corneal inlays will be available in the lab, with experienced surgeons
on hand to assist with questions and to demonstrate techniques.
Objective: Participants will become acquainted with a broad array of both mechanical and laser microkeratomes and how they work with excimer lasers.
Course: LAB131A
Room: N227b
Fee: $220

Monday, 3:30 - 5:30 PM
EduLevel: BAS
Instructor(s): Jason E Stahl MD, Daniel S Durrie MD*, Shachar Tauber MD**, Scott
D Barnes MD**, Renato Ambrosio Jr MD*, John A Hovanesian MD*, David A
Goldman MD*, Michael Vrabec MD, Erin D Stahl MD*, James C Loden MD*, Allen
Boghossian DO, Michael J Collins MD FACS*, Ryan T Smith MD, Lisa Nijm MD**,
Erik Letko MD*, Jeremy Z Kieval MD*, Jessica B Ciralsky MD*, Aylin Kilic MD,
Jason P Brinton MD
Course: LAB131B
Room: N227B
Fee: $220
Tuesday, 8:00 - 10:00 AM

EduLevel: BAS
Instructor(s): Jason E Stahl MD, David R Hardten MD*, Vance Michael Thompson
MD*, Wallace Chamon MD*, Minoru Tomita MD PhD*, Parag A Majmudar MD*,
Karolinne M Rocha MD, Sherman W Reeves MD MPH*, Elizabeth Yeu MD*, Duane
A Wiggins MD, Raj K Goyal MD MPH*, Paul C Kang MD*, William Wiley MD*,
John J DeStafeno MD*, Thomas M Harvey MD*, John P Berdahl MD*, Brandon
Ayres MD*, Jodhbir S Mehta MBBS PhD*, Suphi Taneri MD*, Ashvin Agarwal,
Mihai Pop MD**, Calvin G Eshbaugh MD**

Course Director(s): Jean-Luc Febbraro MD*, Hamza N Khan MD FACS*
Monday, 9:00 - 11:15 AM
EduLevel: INT
Synopsis: This course will supply participants with the necessary principles, theories, and practical instruction in the various forms of astigmatic keratotomy (PRI,
limbal relaxing incisions) and nonincisional astigmatism correction (LASIK, toric
IOLs).
Objective: Attendees will gain an understanding of techniques used to evaluate
and manage astigmatism as a primary procedure and as an adjunct to lens surgery.
Course: LEC133
Room: N427bc
Instructor(s): Ronald N Gaster MD FACS*, David H Haight MD, Jack T Holladay MD

MSEE FACS*, Douglas D Koch MD*, R Bruce Wallace MD**
Lab
Synopsis: This practical wet lab course allows participants hands-on skill development to improve their management of astigmatism, identify appropriate surgical candidates for astigmatism correction, and select the best techniques for each
case, either combined with lens surgery or alone.
Objective: Participants will learn to mark appropriately for toric IOLs and perform
corneal incisions (peripheral corneal relaxing incisions or limbal relaxing incisions),
and will learn pearls and common pitfalls of each. The impact of various cataract
Instructor(s): Richard L Lindstrom MD**, Daniel S Durrie MD*, George O Waring

IV MD*
119
Lab
Synopsis: Using pig eyes, the participant will have the opportunity to practice the
insertion of phakic IOLs. Instructors will be available to assist and answer questions. FDA-approved phakic IOLs will be emphasized and available for implantation.
Objective: This wet lab will enable the participant to practice the surgical technique of inserting phakic IOLs.
Course: LAB125A
Monday, 10:30 AM - 12:00 PM
Room: N228
Fee: $255
EduLevel: INT
Labs
Course Director(s): George O Waring IV MD*

incisions on astigmatism (surgically induced astigmatism) and laser vision correction will be discussed.
Course: LAB133A
Monday, 1:30 - 3:00 PM
Room: N227b
Fee: $170
EduLevel: INT
Instructor(s): Ronald N Gaster MD FACS*, Paul Gilwit MD FACS, David H Haight
MD, R Bruce Wallace MD**, Baseer U Khan MD*
Retina, Vitreous
YO
Course Director(s): John S Pollack MD*
Sunday, 10:15 AM - 12:30 PM
EduLevel: BAS
Synopsis: This course provides basic instruction on accurate interpretation of
OCTs of common macular pathologies, as well as instruction on how to identify and
prevent common OCT artifacts. The course also provides a clinically meaningful
review of indications and limitations of OCT in the diagnosis and management of
common macular diseases such as AMD, diabetic maculopathy, epiretinal membrane, macular holes, vitreomacular traction, central serous retinopathy, vascular
occlusions, and postoperative cystoid macular edema.
Objective: Upon completion of this course, participants should be able to (1) accurately interpret OCTs of common macular pathologies, (2) describe the indications
for and limitations of OCT in the diagnosis and management of macular diseases,
and (3) identify, interpret, and correct common OCT artifacts.
Course: LEC114
Room: E351
Instructor(s): John S Pollack MD*, Anat Loewenstein MD*, Dante Pieramici MD*,
Nadia Khalida Waheed MD, Glenn C Yiu MD
thy Study and subsequently reviewing DRCRnet publications that may modify some
of those recommendations. Case presentations made to a panel of experts will
illustrate the role of OCT and pharmacotherapy relative to laser therapy.
Objective: By the conclusion of this course, participants will be able to understand
(1) the clinical indications for laser treatment of diabetic retinopathy and (2) the role
of pharmacotherapy and OCT in current management of diabetic retinopathy.
Instructor(s): Abdhish R Bhavsar MD*, David J Browning MD PhD*, Alexander J
Brucker MD*, Emily Y Chew MD, Harry W Flynn MD, Arthur D Fu MD, Justin L Gottlieb MD, Sam Edward Mansour MD*
Course Director(s): Keye L Wong MD*
Lab
Synopsis: Using case presentations in small groups, the treatment algorithms
guiding management of diabetic macular edema, nonproliferative diabetic retinopathy, and proliferative diabetic retinopathy will be reviewed. Panel discussions
with an extensive faculty will highlight current treatment controversies in which
DRCRnet results may modify Diabetic Retinopathy Study (DRS) and Early Treatment
Diabetic Retinopathy Study (ETDRS) recommendations.
Objective: By the conclusion of this course, participants will be able to understand the clinical indications for pharmacotherapy and laser treatment of diabetic
retinopathy and to know the best treatment techniques based on DRS, ETDRS, and
DRCRnet clinical trial results.
Course: LAB121A
Monday, 8:00 - 10:30 AM
Room: N231
Fee: $120
EduLevel: INT
Instructor(s): Keye L Wong MD*, Justin L Gottlieb MD, Gary W Abrams MD*,
Michael M Altaweel MD*, Neal H Atebara MD, Maria H Berrocal MD*, Robert A
Braunstein MD, David J Browning MD PhD*, Alexander J Brucker MD*, Clement K
Chan MD*, Suresh R Chandra MD, John H Drouilhet MD FACS*, Michael S Ip MD*,
Richard H Johnston MD**, James L Kinyoun MD
Lab
Synopsis: This course will provide attendees with a small-group interactive format (5-6 attendees per instructor) for hands-on experience reviewing and evaluating OCTs covering a wide range of common macular diseases, with emphasis on
sharpening the OCT interpretation skills of the attendees. Attendees will rotate
with all instructors, covering a variety of topics, including but not limited to AMD,
vascular occlusions, epiretinal membrane, vitreomacular traction, macular holes,
diabetic retinopathy, and postoperative cystoid macular edema. Attendees are
invited to bring one challenging case for discussion at the end of the lab, time
permitting.
Objective: Upon completion of this course, participants should be able to (1) identify the OCT features of normal and abnormal macular anatomy, (2) diagnose common macular pathologies based on specific OCT characteristics, and (3) identify,
correct, and prevent common OCT artifacts.
Course: LAB114A
Sunday, 3:00 - 5:00 PM
Room: N231
Fee: $100
EduLevel: BAS
Instructor(s): John S Pollack MD*, Jack A Cohen MD FACS, Dafna Goldenberg,
Sanford Chen MD FACS*, Justis P Ehlers MD*, Brandon G Busbee MD*
Diabetes 2014: Course on Diabetic Retinopathy

Course Director(s): Keye L Wong MD*
Course: LEC121
Room: S102abc
Sunday, 3:15 - 5:30 PM

EduLevel: INT
Synopsis: This course will present a rational approach to the diagnosis and treatment of diabetic retinopathy based on first understanding results and recommendations of the Diabetic Retinopathy Study and Early Treatment Diabetic Retinopa120

Cataract
Retinal
Refractive
Glaucoma
Corneal
Ocular Surface Disease
Oculoplastic
Keeping your vision in sight

with the most trusted brands in your ophthalmic specialty
Visitec Merocel Parasol Wet-Field

Atomic Edge Accu-Temp Osher ThermoDot
Readypak CustomEyes
Beaver
And More!
Come See Whats New!
Visit AAO booth #2321
For more information, call 1.866.906.8080 or visit us at www.beaver-visitec.com
Beaver-Visitec International, Inc. | 411 Waverley Oaks Road Waltham, MA 02452 USA | Merocel trademark is the property of Medtronic Xomed, Inc. BVI, BVI Logo and all other trademarks (unless noted otherwise) are property of a Beaver-Visitec International (BVI) company 2014 BVI
Superior
wound
closure
Safe and
comfortable
for the patient
Visit us at
booth #2770
Effectively
seals clear
corneal incisions
ReSure Sealant is indicated for intraoperative management of clear corneal incisions

(up to 3.5mm) with a demonstrated wound leak for which a temporary dry surface
can be achieved, in order to prevent postoperative fluid egress from such incisions
following cataract surgery with intraocular lens (IOL) placement in adults.
Opening Session
Opening Session
Sunday, Oct. 19
8:30 10:00 AM
North, Hall B
Join your colleagues to launch AAO 2014, the Academys 118th meeting, in conjunction with the European Society of Ophthalmology. Hear from
the Academys President, Executive Vice-President and CEO, as well as the SOE President. Celebrate the leaders in our profession and hear Hans E.
Grossniklaus, MD give this years Jackson Memorial Lecture. Listen to a panel of distinguished colleagues discuss how to prepare residents for the
future practice of ophthalmology.
Time
8:30 AM
Topic
Opening Remarks
Speaker
8:32 AM
SOE Presidents Address
Stefan Seregard MD
8:38 AM
Academy Presidents Address
Gregory L Skuta MD
8:44 AM
Academy Awards
8:56 AM
Laureate Award: Jerry A Shields MD
Carol L Shields MD
8:59 AM
Academys Executive Vice-Presidents Address
David W Parke II MD
9:05 AM
Academys President-Elects Address
9:10 AM
Can We Better Prepare the Residents of 2015 for the Practice of 2020?
9:30 AM
Introduction of the Jackson Memorial Lecture

Moderator: Thomas A Oetting MD
Panelists: Nicholas J Volpe MD, Tara A Uhler MD, Paul Sternberg
Jr MD, Anthony C Arnold MD
9:32 AM
Jackson Memorial Lecture: Retinoblastoma: 50 Years of Progress
Hans E Grossniklaus MD
9:57 AM
Jackson Memorial Lecture Award Presentation
Thomas J Liesegang MD
9:58 AM
Concluding Remarks
10:00 AM
End of Session
You can experience the Opening Session through the Virtual Meeting: www.aao.org/virtual-meeting.
Virtual Moderator: Matthew W Wilson MD
2014 Laureate Award:

Jerry A Shields MD
Jackson Memorial Lecture:

Dr. Shields is director of the Ocular Oncology

Service at Wills Eye Hospital and Professor of
Ophthalmology at Thomas Jefferson University. For
more than 40 years, Dr. Shields has been active
caring for patients with tumors of the eyelids,
conjunctiva, intraocular structures, and orbit.
Through clinical research he has helped pioneer
methods of diagnosis and management of these
conditions.
Dr. Grossniklaus is director of the L.F. Montgomery

Laboratory and the founding director of the Ocular
Oncology and Pathology service of Emory Eye
Center. He is board certified in both ophthalmology
and anatomic pathology. Dr. Grossniklaus is
also Professor of Ophthalmology and Pathology,
Oculo-Pathology, at the Emory University School of
Medicine.
2014 Academy Awards

Guests of Honor
Richard K Parris II MD
M Bruce Shields MD
Richard Zorab MSc
Laura L Wayman MD
European Society of Ophthalmology (SOE)

Richard P Mills MD
Rubens Belfort Jr MD PhD

Cynthia Mattox MD FACS
Kenneth D Tuck MD FACS

Alan S Crandall MD
For a full description of all Academy Awards and award recipients, turn to Tab 1, Awards, page 1.
121
ACADEMY CAF
Saturday - Tuesday, Oct, 18 - 21
Room S404
Engage in the conversation: hear expert panels debate, then use your cell phone,
smartphone or laptop to text message the speakers your questions.
How to submit a question: Point the browser on your laptop or wireless mobile
device to http://ai.acuport.org and log in with your Badge ID and Password or
send SMS text to 41411 with the keyword ACafe followed by a space and your
question (example: ACafe Here is my question).
Free Coffee.
Your Questions.
Expert Panels.
Lively Conversation.
Note: For SMS, standard text messaging fees may apply based on your wireless plan.
Saturday, Oct. 18
SYM50 IRIS Registry
1:15 2:30 PM
SYM51 Cataract
3:15 4:30 PM
Moderator: William L Rich MD

Panel: Michael F Chiang MD*, Cynthia Mattox MD FACS*
Moderator: Terry Kim MD*
Panel: Quentin B Allen MD*, John P Berdahl MD*, Elizabeth Yeu MD*, Lisa
Park MD, Brandon Ayres MD*
Sunday, Oct. 19
SYM52 Glaucoma
10:30 11:45 AM
SYM53 Cornea, External Disease
1:00 2:15 PM
SYM54 Retina
2:30 3:45 PM
Moderator: Thomas W Samuelson MD*

Panel: Anjali M Bhorade MD, Reay H Brown MD*, Marlene R Moster MD*,
Nathan M Radcliffe MD*, Kuldev Singh MD MPH*
Moderator: Edward J Holland MD*
Panel: Clara C Chan MD*, Douglas A Katsev MD*, William Barry Lee MD*,
Neda Shamie MD*
Moderator: Thomas R Friberg MD*
Panel: Carl C Awh MD*, Brian B Berger MD*, Alan F Cruess MD*
Monday, Oct. 20
SYM55 Uveitis
SYM56 Oculoplastics
8:30 9:45 AM
10:30 11:45 AM
Moderator: Justine R Smith MD*

Panel: Russell Read MD PhD*, Howard Tessler MD*, Jennifer E Thorne MD
PhD*, Daniel V Vasconcelos-Santos MD PhD
Moderator: Stuart R Seiff MD
Panel: Malena M Amato MD, Suzanne K Freitag MD, Jeffrey A Nerad MD,
Bryan S Sires MD PhD
Tuesday, Oct. 21
SYM57 Cataract
10:30 11:45 AM
Moderator: Richard S Hoffman MD*

Panel: Lisa B Arbisser MD*, George Beiko MD*, Carlos Buznego MD*
122
SPOTLIGHT SESSIONS
AND SYMPOSIA

Spotlight Sessions and Symposia are free of charge and open to all attendees.
SOE Sponsored by the European Society of Ophthalmology
SA
Designated as self-assessment credit and is pre-approved by the ABO for the Maintenance of Certification (MOC)
Part II CME requirements.
EHR Electronic Health Records
GO Global Ophthalmology
SO Endorsed by Senior Ophthalmologist Committee
YO Endorsed by Young Ophthalmologist Committee
Selection Committee
The Special Projects Committee developed: the Spotlights on Pediatric Ophthalmology, Glaucoma and Neuro-Ophthalmology; the Great
Debates: Retina and Cornea; the Best of Anterior and Posterior Segment Specialty Meetings 2014; Grand Rounds; the Academy Cafs and
Hot Topics 2014.
The Annual Meeting Program Committee selected all other spotlight sessions and symposia.
See page 33 for committee details.
123
Spotlight Sessions & Symposia

Saturday, Oct. 18
GO Global Symposium: Low Vision Rehabilitation and
New Technologies for the Developing World
Spotlight Sessions &

Symposia
Event No: SYM01

Room: S405
2:00 - 3:30 PM
Combined meeting with the Academys Global Education and Outreach

Committee
Chair(s): Mary Lou Jackson MD*, Brad H Feldman MD
This inspiring and forward-looking symposium will address two distinct but
critically important aspects of ophthalmology in the developing world: visual rehabilitation for those with low vision and the potential of new technologies to
improve eye care. The challenges unique to approaching these problems in the
developing world will be discussed by international experts who will share their
personal successes and failures. You will hear their perspectives on how we as
a global community are developing innovative solutions to some of the largest
problems in vision and eye care.
Part 1: Low Vision Rehabilitation
2:00 PM Introduction
Mary Lou Jackson MD*
2:02 PM Resident Education about Vision Loss and Rehabilitation
2:08 PM Vision Rehabilitation in Patients with Multiple Disabilities
Linda M Lawrence MD
2:16 PM Setting Targets and Measuring Outcomes
Karen Wolffe PHD
2:24 PM Integrating Vision Rehabilitation into Comprehensive Eye Care
Muhammad M Rabiu MD
2:32 PM Panel Discussion
2:42 PM Break
Part 2: New Technologies for the Developing World
Brad H Feldman MD
2:49 PM WHO initiatives to Improve Access to Appropriate Medical Devices
Ivo Kocur MD**
2:57 PM Developing Technologies for Global Eye Care: PEEK
3:05 PM Evaluating Technologies in Global Eye Care: Self-adjustable Glasses
Nathan G Congdon MD
3:13 PM Bringing Affordable Technologies and Products to Market
Siriam Ravilla Duraisamy*
3:21 PM Panel Discussion
3:30 PM End of Session
SOE Conference for Ophthalmic Educators: Improving
Teaching Effectiveness
Event No: SYM58

Room: S104ab
2:00 - 5:30 PM
Combined meeting with the International Council of Ophthalmology (ICO) and

the European Society of Ophthalmology (SOE)
Chair(s): Ana Gabriela Palis MD, Eduardo P Mayorga MD*, Karl C Golnik
MD
The Conference for Ophthalmic Educators offers expert instruction, interactive
workshops, and group discussion for ophthalmic educators. Educators of ophthalmology residents, fellows, medical students, CME, and allied health will learn
about the latest tools and practice techniques of modern education. These sessions will help educators at any experience level to improve teaching effective124
ness and provide an opportunity to connect with other educators from around the
world. Past conferences have been held in Argentina, South Korea, India, Brazil,
Denmark, and Australia. Open to all AAO 2014 registered attendees. For more
information: www.icoph.org/ConfEdsChicago2014.
2:00 PM Welcome and Introductions - Goals and Review of the Agenda and
Workshops
Ana Gabriela Palis MD
2:10 PM Plenary Session I
Critical Thinking
Eduardo P Mayorga MD*
Curriculum Adaptation
Ana Gabriela Palis MD
Assessment Principles
Simon J Keightley MBBS
2:25 PM Workshop Session 1
Helping Residents Develop Critical Thinking
Eduardo P Mayorga MD*
Curriculum Adaptation
Ana Gabriela Palis MD, Peter A Quiros MD
Assessment Principles and Tools
Simon J Keightley MBBS, Clare C Davey MD**, Nicola Quilter
3:20 PM Large Group Discussion of Workshops
3:35 PM Break
3:55 PM Plenary Session II
3:55 PM Webinars
Matthew D Gearinger MD
Effective Feedback
Andreas Lauer MD*
Developing Workshops
Karl C Golnik MD
4:10 PM Workshop Session 2
Presenting on the Web: How to Develop Successful Webinars
Prashant Garg MD*, Matthew D Gearinger MD
Effective Structured Feedback and Resident Remediation
Andreas Lauer MD*, Helena Prior Filipe MD
Developing Workshops
Karl C Golnik MD
5:05 PM Large Group Discussion of Workshops
5:20 PM Wrap-up
5:30 PM Adjourn
Sunday, Oct. 19
YO Introduction to Corneal and Lens-Based Refractive
Surgery for Residents
Event No: SYM02

Room: E450
8:00 - 11:00 AM
Sponsored by the International Society of Refractive Surgery (ISRS)

Chair(s): J Bradley Randleman MD, Ronald R Krueger MD*
This course will provide an overview of the most relevant topics on corneal and
lens-based refractive surgery, including patient evaluation, topographic evaluation, a step-by-step surgical explanation of LASIK and surface ablation procedures, discussion of surgical complication recognition and management, and
decision trees for choosing appropriate premium IOL candidates and managing
complications unique to these individuals. This will provide a basis upon which


Free and Easy for Low Vision: Help and Resources for
the Visually Impaired
Event No: SYM03
Room: S102d
9:00 - 10:00 AM
Combined meeting with the Vision Rehabilitation Committee

Chair(s): John Shepherd MD, Richard A Harper MD
Vision loss adversely affects function and quality of life. It has been demonstrated that vision rehabilitation and self management programs improve the
function and quality of life for the visually impaired. Fortunately, information and
support are available from many organizationslocal, national and online. This
symposium will inform the ophthalmologist about the ready availability of support, information, resources, and other help, often either free or at low cost, for
those with vision loss. Emerging technology such as free apps for smart phones
and tablets will be discussed, as well as help from traditional organizations for
the blind and visually impaired. After attending this symposium, ophthalmologists will know of currently available resources and organizations that will help
their visually impaired patients cope with the problems of vision loss and will be
Spotlight on Pediatric Ophthalmology: Front Line and

First Steps Management of Strabismus for the
Comprehensive Ophthalmologist
Event No: SPO1
Room: Grand Ballroom S100ab
10:30 AM - 12:00 PM
Chair(s): Laura B Enyedi MD, Michelle J Cabrera MD

Virtual Moderator: Erin O Schotthoefer MD
This Spotlight symposium will emphasize practical tips that the comprehensive ophthalmologist can use in evaluating and managing strabismus and diplopia in both adults and
children. It will follow a case-based format, including panel discussion. Panelists will
include pediatric ophthalmologists, strabismus surgeons, and neuro-ophthalmologists.
Speakers will highlight clinical pearls for evaluating and managing the following conditions: accommodative esotropia, intermittent exotropia, isolated cranial neuropathies,
diplopia in an elderly patient, thyroid eye disease, and sensory strabismus. Participants
will gain knowledge in the use of prisms for diplopia management, when to image, and
other pearls in systemic workup for diplopia, as well as strategies for examining and
managing uncooperative children.
10:30 AM Accommodative Esotropia

Tammy L Yanovitch MD
10:40 AM Panel Discussion
10:45 AM Intermittent Exotropia
Erin P Herlihy MD
11:00 AM Isolated Cranial Neuropathies
Mitchell B Strominger MD
11:15 AM Elderly Patient With Diplopia
Nandini G Gandhi MD**
11:30 AM Thyroid Eye Disease
Shira L Robbins MD*
11:45 AM Sensory Strabismus
Erick D Bothun MD

125

Symposia
these individuals in training may begin to grow their knowledge base and gain
comfort in practicing independently after graduation. The course will be an interactive didactic session led by recognized experts and international leaders
in the field of refractive surgery, but will be specifically directed at the resident
education level, as opposed to many of the courses at AAO directed towards
specialists already in practice. This focus should allow the resident to gain the
optimal learning experience.
Corneal Laser-Based Refractive Surgery Options
8:00 AM Welcome and Opening Remarks
8:05 AM Basic LASIK Patient Evaluation
Ronald R Krueger MD*
8:30 AM Topographic and Tomography Evaluation
8:50 AM Discussion: Patient Screening
9:00 AM Step-by-Step PRK and LASIK
Sonia H Yoo MD*
9:20 AM Decision Tree: When PRK and LASIK
Marguerite B McDonald MD*
9:30 AM LASIK/PRK Complications and Management
David R Hardten MD*
9:50 AM Discussion: Avoiding Complications
Lens-Based Refractive Surgery Options
10:00 AM Diagnostic Tools for Achieving Refractive Outcomes
George O Waring MD*
10:20 AM Toric, Multifocal, and Accommodating IOLs and Patient Selection
Bonnie A Henderson MD*
10:40 AM Video Cases: Techniques and Complications
10:50 AM Discussion: Lens-based Options
10:58 AM Closing Remarks
10:59 AM Closing Remarks
11:00 AM End of Session
able to prevent the depression and isolation that all too frequently result from
diminished vision.
9:00 AM Introduction
John Shepherd MD
9:02 AM Free or Inexpensive Apps for iPhone, iPad and Other Devices
Donald Calvin Fletcher MD
9:14 AM Education for the Blind and Visually Impaired: Hadley School for the
Blind Online Courses, the Braille Institute, and Others
Paul Homer MD
9:24 AM Help from Others: Support GroupsLocal, National, and Online Help
for the Visually Impaired
Joseph L Fontenot MD
9:34 AM Federal and State Programs and Services: Department of
Rehabilitation, Vocational Rehabilitation, and Other National
Programs
Suzanne B Mitchell**
9:44 AM Organizations Offering Services to the Blind and Visually Impaired:
Who Are They, and How Do They Help Your Patient?
9:54 AM Q&A and Panel Discussion

Update on Molecular Analysis in Ophthalmic Disease

Symposia
Event No: SYM05

Room: E350
10:30 AM - 12:00 PM
Combined meeting with the American Association of Ophthalmic Oncologists

and Pathologists (AAOOP)
Chair(s): Debra J Shetlar MD, R Nick Hogan MD PhD
Over the past few years, there have been significant advances in our knowledge
of the genetics of ocular diseases. Some of these advances are being used to
enhance our ability to diagnose and treat these conditions. This symposium will
serve to update the audience on molecular advances in ocular disease, with an
emphasis on those advances that have translated to diagnostic and therapeutic
advances and have had an impact on clinical practice.
Hans E Grossniklaus MD*
10:32 AM Update on Growth Factors in AMD
Joan W Miller MD*
10:40 AM Update on Pathogenesis and Treatment of Diabetic Eye Disease
Lloyd P Aiello MD PhD*
10:48 AM Use of Molecular Techniques in the Diagnosis and Treatment of
Ocular Infections
Patricia Chevez-Barrios MD
10:56 AM Update on Molecular Pathology of Choroidal Melanoma
Joan M OBrien MD
11:04 AM Update on Molecular Pathology of Retinoblastoma
Matthew W Wilson MD
11:12 AM Q&A
ZIMMERMAN LECTURE
11:19 AM Introduction of the Zimmerman Lecturer
Myron Yanoff MD
11:22 AM Zimmerman Lecture: The Yin and Yang of the Opioid Growth
Regulatory System: Focus of Diabetes
Joseph W Sassani MD*
11:58 AM Presentation of the Zimmerman Medal
Treatment for Wet and Dry AMD: Where We Are and

Where We Are Going
Event No: SYM06
Room: S406a
10:30 AM - 12:00 PM
Combined meeting with American Society of Retina Specialists (ASRS)

Chair(s): G Baker Hubbard MD*
Virtual Moderator: Jorge A Fortun MD**
With the large and growing number of patients affected by AMD, it is becoming increasingly important to balance efficacy of treatment with time and cost
burdens on patients and health-care delivery systems. Presently the mainstay
for treatment of wet AMD is anti-VEGF therapy. Optimal dosing regimens and
the choice of agents in particular circumstances, however, remain uncertain. No
proven treatments exist for dry AMD except nutritional supplements and lifestyle
strategies that may reduce risk of progression. This symposium will review various strategies for optimizing outcomes for patients with AMD. The latest data on
regimens to balance outcomes with treatment burden will be presented. In addition, promising new treatments under investigation for both wet and dry AMD
will be reviewed. Case presentations and discussions by a panel of experts will
126
highlight areas of controversy and consensus. Panel members will offer insights
into the evolution of AMD treatment in the next several years.
G Baker Hubbard MD*
10:32 AM AMD: Overview of AMD Risk Factors, Pathogenesis, and Imaging
R Theodore Smith MD
10:42 AM Role of Nutritional Supplements and Lifestyle Strategies to Reduce
Risk
Emily Y Chew MD
10:52 AM Wet AMD Treatment: Risks and Benefits of the 3 Anti-VEGF
Medicines
Philip J Rosenfeld MD PhD*
11:02 AM Dosing Strategies and Combination Therapy to Optimize Outcomes
(PDT, Focal Laser, Submacular Surgery)
Jeffrey S Heier MD*
11:12 AM Future Treatments for AMD
Timothy W Olsen MD*
11:22 AM Case Presentations and Panel Discussion
11:57 AM Summary and Closing Remarks
G Baker Hubbard MD*
Update 2014: Infectious Keratitis

Event No: SYM07
Room: Grand Ballroom S100c
10:30 AM - 12:00 PM
Combined meeting with the Contact Lens Association of Ophthalmologists

(CLAO)
Chair(s): Deepinder K Dhaliwal MD*, Deborah S Jacobs MD*
This symposium will present current information on the diagnosis and treatment
of infectious keratitis. Speakers will present case examples of the various types
of infectious keratitis, including bacterial, viral, fungal, and parasitic causes, as
well as advances in diagnosis and treatment over the last decade. Therapeutic
outcomes of medical treatment, as well as advances in pharmaceutical therapies, will be presented. The symposium concludes with the Whitney G Sampson
MD lecture.
Deepinder K Dhaliwal MD*
10:32 AM Risk Factors for Infection with Contact Lens Wear: Lessons Learned
in the Last 10 Years
Oliver Douglas Schein MD*
10:40 AM The Role of the FDA in Reducing Cases of Contact Lens-Related
Infectious Keratitis
Malvina Eydelman MD
10:48 AM The Role of Biofilm
Michael E Zegans MD*
10:56 AM Update and Case Studies in the Treatment of Bacterial Keratitis and
the Role of Steroids
Jennifer R Rose-Nussbaumer MD
11:04 AM Update and Case Studies in the Treatment of Herpes Simplex Virus
Keratitis
Rookaya Mather MBBCH*
11:12 AM Update and Case Studies in the Treatment of Varicella Zoster Virus
Keratitis and the Role of Zostavax
Elisabeth J Cohen MD
11:20 AM Update and Case Studies in the Treatment of Fungal Infections
Denise de Freitas MD


WHITNEY G SAMPSON MD LECTURE
Cataract Surgery: The Cutting Edge

Event No: SYM08
Room: North Hall B
11:28 AM Introduction of the Whitney G Sampson MD Lecture

11:31 AM Whitney G Sampson MD Lecture: Little Things Do Matter: Individual
Case Studies and the Complex Role of Risk Factors in Acanthamoeba
Keratitis
Elmer Tu MD
11:56 AM Award Presentation
Deborah S Jacobs MD*
11:58 AM Concluding Remarks
Chair(s): Robert H Osher MD*
Event No: SYM09

Room: S406a
The Food and Drug Administration/National Eye

Institute/Department of Defense LASIK Quality of Life
Project
Event No: SYM59
Room: E450
11:30 AM - 12:30 PM
Panelists: Douglas D Koch MD*, Richard Mackool MD*, Boris Malyugin MD

PhD*, Amar Agarwal MD*, Armando Crema MD**, Thomas Kohnen MD*
To stimulate a panel discussion, this symposium will present short videos of

novel ideas, techniques, and devices from cataract surgeons around the world.
Expect controversy and spirited debate from the expert international panel. Guaranteed to keep you on the edge of your seats!
Michael F Marmor MD Lecture in Ophthalmology and

the Arts
12:45 - 1:45 PM
Chair(s): Michael F Marmor MD*

In this lecture, Mark Foster Gage will illustrate the often uncelebrated, yet significant links between theories of sight and some of the most dramatic innovations
in the history of architecture.
Michael F Marmor MD*
12:50 PM Architecture, Ophthalmology and the Seeing of Space
Mark Foster Gage, Principal, Mark Foster Gage Architects and
Assistant Professor, Yale School of Architecture
1:15 PM Discussion
EHR EHRs: Improve Quality, Cost-Effectiveness and Your
Headaches
Event No: SYM10

Room: S406b
12:45 - 1:45 PM
Combined meeting with the Committee on Medical Information Technology

(CMIT)
Chair(s): Michael F Chiang MD*
Ophthalmology is unique in its clinical workflow. Ophthalmologists need systems
that can be integrated into a busy workflow, that can provide clinical images and
data frequently associated with patient visits, and that can help them meet reporting and information exchange requirements. Payment incentives associated
with federal meaningful use criteria are accelerating the adoption of EHRs, but
it is necessary that these systems actually help ophthalmologists deliver care
efficiently. The purpose of this symposium will be to highlight successful EHR implementation stories for audience members. The session will explore the impact
of EHR systems on point-of-care clinical decision support, new patient-centric
care delivery methods, personalized medicine, data analysis opportunities, integration with imaging and information systems in the office, and ultimately on the
bottom line or economics of the practice.
12:45 PM Setting the Stage: What Do We Know about How EHRs Benefit
Health Care?
Michael F Chiang MD*
12:55 PM How EHRs and Expert Systems Will Change How We Practice
James D Brandt MD*
1:05 PM The Positive Impact of EHRs on Cost-Effectiveness (the Bottom Line)
Robert E Wiggins MD MHA*
1:15 PM The Positive Impact of EHRs on Data Integration and Accessibility
Jeffrey L Marx MD
1:25 PM Panel Discussion and Q&A

127

Symposia
Chair(s): Frederick L Ferris MD*, Malvina Eydelman MD

The LASIK Quality of Life Collaboration Project (LQOLCP), a government partnership among the Food and Drug Administration (FDA), the Department of Defense
(DoD), and the National Eye Institute (NEI), examines patient-reported outcomes
(PROs) following LASIK. Initial work showed that previously developed paperbased ophthalmic questionnaires could be administered using the web and yield
valid measurements. Following this work, the FDA, DoD, and NEI worked collaboratively with patient input and clinical expertise to develop the Patient Reported
Outcomes with LASIK (PROWL) questionnaire, preoperative and postoperative
versions. To assess the validity of the questionnaire, we conducted the PROWL-1
study, where U.S. military personnel electing LASIK completed the questionnaire
before surgery and at 1, 3, and 6 months after surgery. To determine whether the
questionnaire behaved similarly in the general LASIK population, we conducted
PROWL-2, a multicenter national clinical study. The LQOLCP datasets contain
detailed information on clinical characteristics of the patients, their surgical
procedures, and their reported (PROWL questionnaire) and measured clinical
outcomes.
11:30 AM Introduction to the LASIK Quality of Life Collaboration Project
C P Wilkinson MD*
11:35 AM Overcoming the Study Conduct Challenges: Perspectives from
EMMES, the Contract Research Organization
Keri Renee Hammel MS*
11:40 AM Web vs. Paper Ophthalmic PRO Assessments
Susan Vitale PhD MHS
11:47 AM Development and Validation of the PROWL Questionnaire
Ronald Hays PhD*
11:55 AM Findings from the Navy Study: PROWL-1
Elizabeth M Hofmeister MD
12:05 PM Findings from the Multicenter Civilian Study: PROWL-2
Malvina B Eydelman MD
12:15 PM Summary
Frederick L Ferris MD*
12:20 PM Question & Answers
12:15 - 1:45 PM

2:19 PM
Grand Rounds: Cases and Experts From Across the

Nation
Event No: SYM12
2:00 - 3:15 PM
Chair(s): Nicholas J Volpe MD

Symposia
Panelists: Alfredo A Sadun MD PhD*, Alexander J Bruker MD*, Lee M Jampol

MD*, Raymond S Douglas MD PhD*
Virtual Moderator: Andreas K Lauer MD*
Real residents present real cases from real department grand rounds. Residents
chosen from different academic programs will present cases to a panel of experts followed by Q&A and discussion by the panel.
2:00 PM Introduction and Welcome Remarks
Nicholas J Volpe MD
2:02 PM I Cant Close My Eye
Craig W See MD**
2:13 PM 49-year-old With Irritation and Inability to Close My Eyes
Solly Elmann MD**
2:24 PM 13-year-old Girl With Acute Bilateral Vision Loss
Andrew W Stacey MD**
2:35 PM Not This, Nor That
Andrew J McClellan MD
2:46 PM 57-year-old With Pain, Proptosis and Ophthalmoplegia
Avni V Pate, MD**
2:58 PM Another Case of High Pressure
Jiaxi Ding MD
3:10 PM Closing Remarks
Nicholas J Volpe MD
The Great Debate: Retina

Event No: SYM47
Room: E450
2:00 - 3:15 PM
Chair(s): Peter K Kaiser MD*

This symposium will be structured as a lively, old-fashioned debate. Groups of
debaters will argue the pros and cons of controversial topics. Speakers will have
the opportunity to present prepared statements and then will have a chance to
rebut those of their opponents. Audience voting will be used to determine which
speakers were most effective in stating their arguments.
Peter K Kaiser MD*
Anti-VEGF Should Be the Initial Treatment for Macular Edema
2:05 PM Introduction of Question and Audience Voting
2:06 PM Pro
Neil M Bressler MD*
2:09 PM Con
Darius M Moshfeghi MD*
2:12 PM Pro Rebuttal
2:13 PM Con Rebuttal
2:14 PM Audience Voting
There is a Safety Difference Between the Anti-VEGF Agents
2:16 PM Pro
Robert L Avery MD*
128
Con
Jeff S Heier MD*
There is a Difference in Efficacy Between the Anti-VEGF Agents
2:26 PM Pro
Allen C Ho MD*
2:29 PM Con
Daniel F Martin MD
Ocriplasmin is Not Safe to Use in VMT Patients
2:36 PM Pro
Mark W Johnson MD*
2:39 PM Con
Baruch D Kuppermann MD PhD*
Wide Field Imaging is a Necessary Imaging Device for Your Office
2:46 PM Pro
Szialard Kiss MD*
2:49 PM Con
K Bailey Freund MD*
2:55 PM Conclusions
Peter K Kaiser MD*
SOE A View Across the Pond: Current Cataract and IOL
Practices in Europe and the United States
Event No: SYM04

Room: North Hall B
2:00 - 3:30 PM
Joint Session with the European Society of Ophthalmology (SOE)

Chair(s): Bonnie A Henderson MD*, Jan-Tjeerd H N de Faber MD
Cataract surgery with an implantation of an intraocular lens is one of the most
common ophthalmologic procedures performed in the world. However, the surgical technique, choice of IOLs, and management of the eye differ from country to
country. In this symposium, several key differences between surgeries performed
in Europe vs in the United States will be highlighted. Top experts will present the
viewpoints from their respective continents about management of subluxated
lenses, presbyopia correcting IOLs, antibiotic prophylaxis, and governmental approval of new innovations. Dont miss this Ryder Cup for Ophthalmology!
2:02 PM Scleral Fixated IOLs
Roger F Steinert MD*


RUEDEMANN LECTURE

2:10 PM
2:18 PM
2:26 PM
2:34 PM
2:42 PM
2:50 PM
2:58 PM
3:06 PM
3:26 PM
3:30 PM
FDA: Friend or Foe

Stephen S Lane MD*
Antibiotic Prophylaxis in the United States
David F Chang MD*
Multifocal IOLs in the United States
Robert J Cionni MD*
Trifocal IOLs in Europe
Rudy Nuijts MD*
The Netherlands: Missing the Bag? Artisan the Solution With a
Dutch Touch
IOLs in Children
M Edward Wilson Jr MD
Antibiotic Prophylaxis in Europe
Peter James Barry MD*
Panel Discussion
Conclusion
End of Session
Making a Bad Situation Better: Retinoblastoma and the

Anophthalmic Socket
2:00 - 3:30 PM
Combined meeting with the American Society of Ocularists (ASO)

Chair(s): Jonathan W Kim MD, Doss K Tannehill BCO BADO
Enucleation remains the most common treatment for children diagnosed with
retinoblastoma. There are special considerations when managing the anophthalmic socket of a retinoblastoma patient, such as the young age of the patients,
concomitant use of chemotherapy and/or radiation, and increased risk of complications. Ophthalmologists and ocularists will attend this joint symposium to
discuss and review the comprehensive care of the anophthalmic socket in a child
diagnosed with retinoblastoma. The topics include blepharoptosis in the retinoblastoma patient, socket reconstruction in retinoblastoma patients, psychological implications of enucleation in young children, and options for implant pegging
in retinoblastoma patients.
2:00 PM Blepharoptosis in the Retinoblastoma Patient
Donnie R Franklin BCO**
2:08 PM Socket Reconstruction in Retinoblastoma Patients
James H Merritt MD
2:16 PM Psychological Implications of Enucleation in Young Children
William R Trawnik BCO
2:24 PM Tips for Fitting the Pediatric Patient after Enucleation
Pascale Scuflaire BCO
2:32 PM Socket Considerations for Patients Undergoing Chemotherapy and/or
Radiation
Jonathan W Kim MD
2:40 PM Implant Exposure in Retinoblastoma Patients
Jonathan W Kim MD
2:48 PM Ideal Implant Choices for Retinoblastoma Patients
Jesse L Berry MD
2:56 PM Q&A
3:06 PM
3:26 PM
3:30 PM
Introduction of the Ruedemann Lecture

Doss K Tannehill BCO BADO
Ruedemann Lecture: Understanding the Dynamics of Managing the
Anophthalmic Socket When Things Go Wrong
Michael C Webb BCO
Presentation of Award
Doss K Tannehill BCO BADO
End of Session
Hot Topics 2014

Event No: SYM14
Room: S406a
2:00 - 3:30 PM
Chair(s): Maria M Aaron MD

Get a quick take on hot topics for the year. Designed for the comprehensive ophthalmologist, the hot topics symposium is a series of 10-minute
talks on emerging trends, technologies and therapies across ophthalmology.
Maria M Aaron MD
2:01 PM Sun Exposure and the Development of Pseudoexfoliation Syndrome
Louis R Pasquale MD*
2:11 PM Head Trauma and Neuro-Ophthalmology
Laura J Balcer MD MSC**
2:21 PM IgG4 Disease
Elizabeth A Bradley MD
2:31 PM SMILE/ReLEx Laser Surgery
Dan Z Reinstein MD*
2:41 PM Small Aperture Implants to Achieve Depth of Focus
John Allen Vukich MD*
2:51 PM Comparison of CTL and IOL Correction of Monocular Aphakia During
Infancy
Scott R Lambert MD*
3:01 PM Telemedicine Screening for ROP
Graham E Quinn MD*
3:11 PM Aflibercept, Dexamethasone Intravitreous Implant, or Fluocinolone
Acetonide Implants
Neil M Bressler MD*
3:21 PM Emerging Treatments for Dry AMD
Baruch D Kuppermann MD PhD*
Contemporary Management of Orbital Fractures: An

International Perspective
Event No: SYM15
Room: E350
2:00 - 3:30 PM
Combined meeting with the American Society of Ocular Trauma (ASOT)

Chair(s): Michael P Grant MD PhD**, Don Kikkawa MD*
The evaluation and optimal treatment of patients with orbital fractures continues
to inspire great debate. Many of the current treatment paradigms were established prior to modern imaging and still persist today. Absent are clear, agreed
upon criteria for treatment and established outcome measures. In this symposium a panel of international experts will present their current practice pattern
for treatment of orbital fractures. Advanced technology, such as image-guided
surgery, preoperative planning, and STL modeling, will be discussed, and its ap-

129

Symposia
Event No: SYM13

3:04 PM

3:56 PM

plication to orbital fractures will be illustrated. After 4-5 brief presentations, a
case-based interactive learning session will be the focus of the symposium.
Michael P Grant MD PhD**
2:02 PM Workflow in the Evaluation and Treatment of Acute Orbital Injuries
Nicholas R Mahoney MD
2:10 PM Management of Orbital Foreign Bodies
Christopher P Fleming MD**
2:18 PM Diplopia and Extraocular Muscle Dysfunction in Orbital Fractures
Kyung In Woo MD
2:26 PM Special Considerations in the Management of Pediatric Orbital
Trauma
Louise A Mawn MD*
2:34 PM Delayed Reconstruction of Complex Orbital Defect: The Role of
Preoperative Planning, Rapid Prototype Modeling, and Navigation
Xianqun Fan MD PhD
2:42 PM Case-Based Interactive Learning Session
HELEN KELLER LECTURE

3:02 PM

Symposia
3:04 PM
3:29 PM
3:30 PM
Introduction of the Helen Keller Lecturer

Ferenc P Kuhn MD PhD
Helen Keller Lecture: The Concept of the Buttresses of the Orbit in
Treatment
Paul N Manson MD FACS
End of Session
Tumors of the Brain and Orbits: Neuro-Ophthalmic

Considerations
Event No: SYM16
3:30 - 5:30 PM
Combined meeting with the North American Neuro-Ophthalmology Society

(NANOS)
Chair(s): Timothy J McCulley MD, Mays A El-Dairi MD*
Missing malignancy or other neoplasm is one of the most common fears among
comprehensive and neuro-ophthalmologists alike. Neoplastic disease can present with any number of elusive signs and symptoms. Balancing the contemporary pressures to control cost and avoid medico-legal repercussions against
our primary goal of providing the best care possible for our patients has never
been more daunting. This symposium provides an overview of potential neuroophthalmic manifestations of neoplastic disease and discusses recent diagnostic
and therapeutic advances in relevant management. Topics will include signs and
symptoms (eg, periocular pain, visual field defects, abnormal ocular motility),
therapy (eg, glioma and meningioma) and neoplastic mimickers (eg, tumefactive
multiple sclerosis). Attendees will be better informed and able to coordinate care
among the medical and surgical subspecialties.
Timothy J McCulley MD
3:32 PM Periocular Pain: When Should I Worry?
Fiona E Costello MD*
3:40 PM Optic Nerve Gliomas: Surgery, Radiation, Chemotherapyor Leave
Them Alone?
Grant T Liu MD
3:48 PM OCT and an Optic Neuropathy: When Is It Useful?
Y Joyce Liao MD PhD
130
4:04 PM
4:12 PM
4:20 PM
4:28 PM
Fooled by the Chiasm: Do Compressive Lesions Always Produce

Hemianopia?
Jonathan C Horton MD PhD**
Its Not a Tumor: What Is Tumefactive Multiple Sclerosis?
Funny Eye Movements in a Child: Could It Be a Tumor?
Michael X Repka MD MBA*
Cancer-Associated Retinopathy: When and How Do I Test?
Byron L Lam MD*
Closing Remarks
Mays A El-Dairi MD*
WILLIAM F HOYT LECTURE

4:30 PM
4:35 PM
5:00 PM
5:05 PM
Introduction of the William F Hoyt Lecturer

Larry P Frohman MD*
William F Hoyt Lecture: Optical Imaging of the Optic NerveBeyond
Documenting RNFL Loss
Mark J Kupersmith MD*
End of Session
Spotlight on Glaucoma: Medical and Surgical

Management for the Comprehensive Ophthalmologist
Event No: SPO2
Room: North Hall B
3:45 - 5:15 PM
Chair(s): Steven Gedde MD*, Douglas J Rhee MD*

Glaucoma is a common disease, affecting an estimated 60 million individuals worldwide.
Most comprehensive ophthalmologists devote a significant portion of their clinical practice to the care of glaucoma patients. The medical and surgical treatment of glaucoma
patients continues to generate questions that are the topic of discussion and debate. In
this Spotlight symposium glaucoma experts will provide their perspective on some of
these important questions in glaucoma management.
3:45 PM
3:47 PM
3:54 PM
4:01 PM
4:08 PM
4:15 PM
4:22 PM
4:29 PM
4:36 PM
4:43 PM
Introduction
Steven Gedde MD*
How Should I Set A Target IOP?
Philip P Chen MD
How Should I Manage a Patient who is Progressing at Low Levels of
IOP?
Ta Chen Chang MD*
When Should I add or Switch a Glaucoma Medication?
Peter Andreas Netland MD PhD**
Which Glaucoma Medications can be Safely Used During Pregnancy?
In childhood?
Helen L Kornmann MD
Are Any Neuroprotective Agents Currently Available for Treating
Glaucoma?
Louis R Pasquale MD*
What is the Relationship Between Adherence and Glaucoma
Progression?
Kuldev Singh MD MPH*
When Should I Use Selective Laser Trabeculoplasty?
Donald L Budenz MD MPH*
When Should I Perform a Prophylactic Laser Iridotomy?
Douglas J Rhee MD*
When Should I Recommend Incisional Glaucoma Surgery?
Joseph F Panarelli MD*


4:50 PM
4:57 PM
5:04 PM
5:15 PM
What Is the Role of Microinvasive Glaucoma Surgery?

Malik Y Kahook MD*
Which is BetterTube or Trabeculectomy?
Dale K Heuer MD*
Audience Questions and Discussion
End of Session
Adult Strabismus: Techniques to Alleviate Visual

Discomfort
Event No: SYM17
3:45 - 5:15 PM
Event No: SYM18

Room: S406a
3:45 - 5:15 PM
Combined meeting with the Senior Ophthalmologist (SO) and Women in

Ophthalmology (WIO) Committees
Chair(s): Harry Zink MD*, Linda M Tsai MD
Panelists: Ruth D Williams MD*, Linda M Christmann MD
Times are changing, and practicing ophthalmology less than full-time may be
desired or needed for a variety of reasons. Our panel of speakers will share their
experiences and discuss the challenges, opportunities, and benefits they have
experienced in this type of practice. These presentations will help the participants understand the complexities of this model and provide ideas for how to
create their own best practice situations.
Linda M Tsai MD
3:50 PM Demographics and Changing Practice Possibilities
Tamara R Fountain MD*
3:57 PM Economics of a Part-time Practice
4:04 PM Work/Family Balance
Susan H Forster MD
4:11 PM Slowing Down Approaching Retirement
Michael W Brennan MD
4:18 PM Part-time With an Alternate Career
Andrew P Doan MD PhD*
4:25 PM Part-time With a Research Career
Lynn K Gordon MD PhD*
4:32 PM Panel/Audience Discussion and Questions
Ocular Drug and Gene Delivery to the Posterior

Segment
Event No: SYM19
Room: E450
3:45 - 5:15 PM
Combined meeting with the Association for Research in Vision and

Ophthalmology (ARVO)
Chair(s): William F Mieler MD*
Treatment of numerous retina disorders, including neovascular AMD, diabetic
macular edema, and retinal vein occlusion, has become primarily pharmacologic
in nature (i.e., anti-VEGF therapy, and corticosteroids). Treatment is oftentimes
required on a monthly basis for an extended period of time. While a wide array
of new treatments are being investigated, research is also evolving around more
effective means of delivering currently available agents to the posterior segment,
in terms of being potentially less invasive, and in providing a longer duration
of effectiveness. This symposium will review ongoing research in drug delivery,
emphasizing new delivery modalities along with the potential limitations of each
technique. Finally, gene therapy will be discussed as a potential future solution
to the problem of extensive drug therapy.
William F Mieler MD*
3:47 PM Overview of Challenges in Drug Delivery to the Posterior Segment
Henry F Edelhauser PhD**
3:57 PM Topical Drug Delivery
Peter A Campochiaro MD*

131

Symposia
Combined meeting with the American Orthoptic Council (AOC) and A merican
Association of Certified Orthoptists (AACO)
Chair(s): Katherine A Lee MD PhD, Cheryl Lynn McCarus CO COMT
Adults with strabismus challenge the skills of the orthoptist and ophthalmologist.
Adult strabismus is often acquired, is frequently associated with troublesome
diplopia, and can present with concurrent macular or neurologic disease. Successful treatment of adult strabismus can be an extremely rewarding to both
patient and practitioner. In this symposium we share the nonsurgical and surgical
management of several case presentations, addressing some of the most vexing
issues of adult strabismus. Let the orthoptists, pediatric ophthalmologists, and
neuro-ophthalmologists in this symposium share their tricks for alleviation of the
visual discomfort of adult strabismus.
Cheryl Lynn McCarus CO COMT
3:48 PM Small Deviations: Vertical, Horizontal, and Combined
Steven M Archer MD
3:58 PM Skew Deviations: Utility of the Upright-Supine Test
Linda A Colpa CO
4:08 PM Macular Diplopia
Sara Shippman CO
4:18 PM Divergence Insufficiency Esotropia: Prism Management
Terra Haller CO
4:28 PM Divergence Insufficiency Esotropia: Surgical Treatment
Stacy L Pineles MD
4:38 PM Strabismus Associated With Neurodegenerative Disease: Prism
Management
Rikki Gilligan CO
4:48 PM Strabismus Associated With Neurodegenerative Disease: The NeuroOphthalmologists Perspective
Michael S Lee MD*
4:58 PM Torsion With Minimal Strabismus
Aaron M Miller MD*
5:08 PM Conclusion and Q&A
Katherine A Lee MD PhD
SO Structuring a Part-time Practice in the Evolving

Medical Environment: How to Make It Work

4:07 PM
4:17 PM
4:27 PM
4:37 PM
4:47 PM
4:57 PM
5:00 PM
5:15 PM
Suprachoroidal, Trans-scleral, and Microneedle Drug Delivery

Timothy W Olsen MD*
Encapsulated Cell Technology
Jeffrey L Goldberg MD PhD*
Hydrogels and Micro/Nanoparticles
Jennifer J Kang-Mieler PhD*
Implantable Micropump Drug Delivery
Mark S Humayun MD PhD*
Gene Delivery to the Retina
Stephen Richard Russell MD*
Conclusion
Q&A
End of Session
Spotlight on Cataracts: Clinical Decision-making

With Cataract Complications
SA

Symposia
Video Case StudiesYou Make the Call

This case-based video symposium will focus on cataract surgical complications. Twentyone different cataract experts will address prevention and management of complications. Panelists will then comment and recommend management. The audience will
weigh in using response pads. The session will conclude with the 10th annual Kelman
Lecture.
8:17 AM
8:22 AM
8:27 AM
8:32 AM
8:37 AM
8:42 AM
8:49 AM
8:54 AM
8:59 AM
9:04 AM
9:09 AM
9:17 AM
132
9:32 AM
9:39 AM
9:44 AM
9:49 AM
9:54 AM
10:04 AM
10:12 AM
8:15 AM - 12:15 PM
Chair(s): David F Chang MD*, William J Fishkind MD FACS*

Virtual Moderator: Mark Packer MD
8:15 AM
9:27 AM
9:59 AM
Monday, Oct. 20
Event No: SPO3

Room: North Hall B
9:22 AM
Introduction
David F Chang MD*
Case 1: Unhappy Multifocal IOL Patient
Panel
Jorge L Alio MD PhD*, Eric D Donnenfeld MD*
Postop Blur: Is It Astigmatism?
Scott M MacRae MD*
Postop Blur: Is It the Multifocal Optic?
Jack T Holladay MD MSEE FACS*
Multifocal IOL Dissatisfaction: When to Exchange?
Stephen G Slade MD FACS*
Multifocal IOL Exchange: Surgical Pearls
Stephen S Lane MD*
Audience Response and Panel Discussion
Case 2: White Lens
Panel
Douglas D Koch MD*, Carl C Awh MD*
Femtosecond Laser for Complex Cases
Kerry D Solomon MD*
White Cataract Pearls
Brock K Bakewell MD*
Anterior Vitrectomy: Limbal or Pars Plana?
Abhay Raghukant Vasavada MBBS FRCS*
Case 3: Recurrent Microhyphema
Panel
Nick Mamalis MD*, Kenneth J Rosenthal MD FACS**
10:17 AM
10:22 AM
10:27 AM
10:34 AM
10:39 AM
10:44 AM
10:49 AM
10:54 AM
11:02 AM
11:07 AM
11:07 AM
11:12 AM
11:17 AM
11:22 AM
11:32 AM
Sulcus IOLs Dos and Donts

Liliana Werner MD PhD*
Suture Fixation of PC IOLs
Walter J Stark MD*
Case 4: Misaligned Toric IOL
Panel
Edward J Holland MD*, Richard L Lindstrom MD**
Toric IOL Complications
Warren E Hill MD*
Correcting Toric IOL Misalignment
Roger F Steinert MD*
No Capsule Support: Anterior Chamber vs. Posterior Chamber IOL
Richard S Hoffman MD*
Posterior Capsule Rupture With Premium IOLs
Thomas A Oetting MD
Case 5: Diffuse Zonulopathy
Panel
Boris Malyugin MD PhD*, Robert H Osher MD*
Phaco With Zonulopathy
Michael E Snyder MD*
Fixating the Loose Capsular Bag
Robert J Cionni MD*
Case 6: Catarocks and the Crowded Anterior Chamber
Panel
Rosa Braga-Mele MD*, Alan S Crandall MD*
Strategies for Crowded Anterior Chamber
Richard Jonathan Mackool Jr MD**
Pearls for Endothelial Protection
Terry Kim MD*
Strategies for the Catarock
Juan F Batlle MD*
Case 7: Rapid Cataract Post-vitrectomy
Panel
David S Boyer MD*, Bonnie A Henderson MD*
Rapid Post-vitrectomy Cataract Why and What Now?
David F Williams MD*
Phaco With a Compromised Posterior Capsule
Samuel Masket MD*
IOL Scaffold: Technique and Outcomes
Amar Agarwal MD*
Conclusion
David F Chang MD*
CHARLES D KELMAN LECTURE

11:35 AM Introduction of Kelman Lecturer
William J Fishkind MD FACS*
11:42 AM Charles D Kelman Lecture: Entrepreneurship in Clinical Research
Randall J Olson MD


STRAATSMA LECTURE
Best of NANOS 2014: Featuring Best Papers from the

Event No: SYM24
Room: S405
8:30 - 9:30 AM
Leveraging Technology and the Educational Team

Event No: SYM21
8:30 - 10:00 AM
Combined meeting with the Association for University Professors of

Ophthalmology (AUPO)
Chair(s): Tara A Uhler MD
In the Next Accreditation System, training programs are tasked with developing
and documenting an effective curriculum and clinical learning environment designed to produce competent physicians prepared to deliver top-notch care both
safely and efficiently. The Accreditation Council for Graduate Medical Education
(ACGME) is focusing increasingly on safety, quality improvement, use of electronic medical records, and teamwork. Simultaneously, educators must ensure
the transfer of increasingly vast amounts of information and technical skills in a
short period of time. Educators and institutions need efficient, effective, and inexpensive methods to accomplish this. This is possible if we leverage technology
and the skills of all members of the educational health-care system. The topics
presented in this section provide concrete examples and encourage participants
to leverage their talents.
8:30 AM Welcome, Introduction, and Instructions for Table Selection
Tara A Uhler MD
8:35 AM Table One: The Educational Team: Managing Your Coordinator
Shahzad I Mian MD*, Tara A Uhler MD
Table Two: When and How to Introduce New Technology into Training
(Femtosecond Laser)
Bhavna P Sheth MD, Thomas A Oetting MD
Table Three: Leveraging EMR for Quality Improvement Projects
Laura L Wayman MD, R Michael Siatkowski MD*
9:15 AM Summaries
Introduction of Straatsma Lecturer

Bartly J Mondino MD
9:22 AM Straatsma Lecture: The Spectrum of Prostaglandin Orbitopathy
Laura L Wayman MD
9:42 AM Introduction of the Excellence in Medical Student Education Lecturer
Bartly J Mondino MD
9:44 AM Excellence in Medical Student Education Lecture: Educating
Referring Doctors of Tomorrow: Why Medical Student Training in
Ophthalmology is CriticalToday!
Linda S Lippa MD**
The Affordable Care Act: Present and Future Prospects

for Ophthalmology
Event No: SYM22
Room: S406a
8:30 - 10:00 AM
Combined meeting with the American Medical Association Ophthalmology

Section Council (AMA)
Chair(s): Kevin Thomas Flaherty MD, Ravi D Goel MD, Dawn C Buckingham
MD
Virtual Moderator: Ruth D Williams MD*
The Affordable Care Act (ACA) will continue to impact ophthalmology practices
in many ways and at different levels. These include the addition of more patients
now covered by insurance, the expansion of Medicaid, new individual insurance mandates, and new insurance exchanges for comparison shopping. The
ACA also imposes new regulations on medical practices as business entities,
as well as changes in the health insurance environment, with accountable care
organizations that may manage a continuum of a patients care across different
settings. The ACA created the federal center for Medicare and Medicaid Innovation (CMMI), which may result in new payment methodologies such as bundled
payments for services. The speakers will provide insight on how ophthalmologists should respond to these changes.
8:30 AM The Accountable Care Act and Ophthalmology
Michael X Repka MD MBA*
8:40 AM An Insiders View of the ACA from a State Perspective
Mariannette Miller-Meeks MD**
8:50 AM Balancing Social Media in Light of Newly Expanded Patient
Populations Under the ACA
PARKER HEATH LECTURE

9:00 AM
Introduction of the Parker Heath Lecturer

9:02 AM Parker Health Lecture: Views on Health Care
Randal H Paul MD**
9:27 AM Presentation of Parker Heath Award
9:32 AM Q&A

133

Symposia
Chair(s): Jacqueline A Leavitt MD

8:30 AM Leber Hereditary Optic Neuropathy G11778A Gene Therapy Clinical
Trial: Stability of Clinical Parameters of Carriers in Preparatory Phase
Byron L Lam MD*
8:42 AM Small Posterior Fossa Strokes Causing Severe Vertigo: Anatomic
Distribution and Clinical Features of the Lacunar Acute Vestibular
Syndrome
Ali S Saber Tehrani MD
8:54 AM In Vivo and In Vitro Imaging of RGC Axonal Transport and
Degeneration Following Experimental Anterior Ischemic Optic
Neuropathy
Y Joyce Liao MD PhD
9:06 AM Orbital Fibroblasts From Thyroid Eye Disease Patients Differ In
Proliferative And Adipogenic Responses Depending On Disease Subtype
Ajay E Kuriyan MD*
9:18 AM Peripapillary RPE-layer Shape in Idiopathic Intracranial Hypertension:
Before and After Treatment
Patrick A Sibony MD
9:21 AM

8:49 AM
Oculoplastics Oncology Update

Symposia
Event No: SYM23

Room: E350
8:30 - 10:00 AM
Combined meeting with the American Society of Ophthalmic Plastic and

Reconstructive Surgery (ASOPRS)
Chair(s): Eric A Steele MD
This symposium will provide an update on some of the most feared diagnoses
that an ophthalmologist may encounter in clinical practice. A variety of malignant
lesions that affect the eyelids, orbit, and lacrimal system will be quickly reviewed
by experts in the field, providing an overview of the diagnosis, management, and
appropriate referral of these conditions.
Eric A Steele MD
8:32 AM Sebaceous Carcinoma
Bita Esmaeli MD FACS
8:41 AM Extraocular Extension of Choroidal Melanoma
Jerry A Shields MD
8:50 AM Conjunctival Melanoma
Carol L Shields MD
8:59 AM Orbital Lymphoma
Louise A Mawn MD*
9:08 AM Rhabdomyosarcoma
Scott M Goldstein MD
9:17 AM Adenoid Carcinoma of the Lacrimal Gland
David T Tse MD FACS*
WENDELL L HUGHES LECTURE

9:26 AM
Introduction of the Wendell L Hughes Lecturer

James C Fleming MD
9:31 AM Wendell L Hughes Lecture: The Spectrum of Prostaglandin
Orbitopathy
Philip L Custer MD*
9:58 AM Presentation of Award
Eric A Steele MD
SOE A View Across the Pond: Retina
Event No: SYM44

8:30 - 10:00 AM

Chair(s): Susanne Binder MD*, Jay S Duker MD*
Virtual Moderator: Pravin U Dugel MD
The symposium will compare and contrast North American and European approaches to the diagnosis and management of a variety of medical and surgical
disorders of the retina.
Jay S Duker MD*
8:32 AM The North American Approach to Silicone Oil Use in Vitrectomy
8:39 AM The European Approach to Silicone Oil Use in Vitrectomy
Marta Figueroa MD*
8:46 AM Discussion
134
Ocriplasmin for Vitreomacular Traction and Macular Hole: The North

American Perspective
David R Chow MD*
8:56 AM Ocriplasmin for Vitreomacular Traction and Macular Hole: The
European approach
Peter W Stalmans MD PhD*
9:03 AM Discussion
9:06 AM Neovascular (Wet) AMD: Which Drug and Which Maintenance
Program--The North American Approach
Jeffrey S Heier MD*
9:13 AM Neovascular (Wet) AMD: Which Drug and Which Maintenance
Program--The European Approach
Stephan Michels MD MBA*
9:20 AM Discussion
9:23 AM The Role of Laser in Diabetic Macular Edema in 2014: The North
American Approach
Charles C Wykoff MD PhD*
9:30 AM The Role of Laser in Diabetic Macular Edema in 2014: The European
Approach
Francesco M Bandello MD FEBO*
9:37 AM Discussion
9:40 AM New Concepts in Retinal Detachment Surgery: The North American
Approach
Maria H Berrocal MD*
9:47 AM New Concepts in Retinal Detachment Surgery: The European
Approach
Christiane I Falkner-Radler MD
9:54 AM Discussion
9:57 AM Conclusion
Susanne Binder MD*
GO Global Forum: Global Research
Event No: SYM25

Room: S101ab
8:30 - 11:00 AM
Combined meeting with the Academys Global Education and Outreach

Committee
Chair(s): Victoria M Sheffield*, Fernando Pena MD*
A panel of international experts with wide experience in international clinical,
programmatic, and epidemiological research will discuss the current status of
global eye research including a presentation by WHO/Geneva, the history of
epidemiological studies in public eye health, current studies to address the leading causes and economics of blindness, and the logistical, ethical, and financial
considerations of global research. Audience participation in Q&A sessions with
the panelists is planned, as well as a generous tea and cookies break for informal
interaction.
8:30 AM Welcome
Linda M Lawrence MD
Panel I: Current Status of Global Research, History of Epidemiological
Studies in Public Eye Health, and the Importance of Economic Data in
Reducing Blindness
Victoria M Sheffield*
8:35 AM An Overview on WHO Key Resources for Internationally Conducted
Research and Experiences
Ivo Kocur MD**


8:45 AM
8:55 AM
9:05 AM
9:25 AM
9:33 AM
9:41 AM
9:49 AM
9:57 AM
10:30 AM
11:00 AM
Best of Anterior Segment Specialty Meetings 2014

Event No: SYM41
Room: S406a
10:15 - 11:30 AM
Chair(s): Tammy L Yanovitch MD, Florentino E Palmon MD

This symposium will feature 10 of the best papers from the major anterior segment specialty meetings of 2014. These papers will be in the major anterior segment specialty areas and are selected by the program committees of the respective societies from their annual specialty meetings.
10:17 AM Generating an Animal Model of Glaucoma
John Fingert MD PhD
10:24 AM IOP Spikes Represent a Significant Portion of Total IOP Energy During
Waking Hours
J Crawford Downs PhD**
American Association for Pediatric Ophthalmology and Strabismus
10:31 AM Binocular iPad Treatment for Amblyopia in Preschool Children
Eileen E Birch PhD*
American Society of Ophthalmic Plastic and Reconstructive Surgery
10:38 AM Infection Rates Comparing Antibiotic Versus Antibiotic-free Topical
Ointments in Blepharoplasty Surgery
Mark A Alford MD
10:45 AM The Impact at Five Years of an Ocular Surface Prosthetic Device

Joshuan Agranat BS
10:52 AM Diabetes Mellitus Increases Risk of Unsuccessful Graft Preparation in
Descemets Membrane Endothelial Keratoplasty: A Multicenter Study
Mark Greiner MD
American Society of Cataract and Refractive Surgery
10:59 AM Role of Percentage of Tissue Altered as Risk Factor for Ectasia After
LASIK in Eyes With Normal Preoperative Topography
Marcony R Santhiago MD
11:06 AM In-the-Bag IOL Dislocation: Comparison of Presentation
Characteristics and Surgical Outcomes in Eyes With and Without CTR
Betty Lorente MD**
International Society of Refractive Surgery
11:13 AM Advanced Analysis for IOL Power Calculation in Refractive Surgery
Karolinne M Rocha MD
11:20 AM Real Time Dynamic Aberrometry
11:27 AM Conclusion
Clinical Pearls in the Diagnosis of Masquerades in

Infectious and Inflammatory Disease of the Eye
Event No: SYM26
10:15 - 11:45 AM
Combined meeting with the Ocular Microbiology and Immunology Group (OMIG)
Chair(s): Bennie H Jeng MD*, Irmgard Behlau MD
Management of infectious and inflammatory diseases can be challenging, as
even a single diagnosis can have extremely varied presentations. While microbiological and laboratory results can aid in diagnosis, an appropriate suspicion
for the various etiologies must be present to drive an appropriate workup. Some
more unusual disease entities manifest as other, more common ones do, and
thus there is often a delay in diagnosis for these masquerades. This symposium will be comprised of leading experts in the field presenting unknown cases
that represent some of these masquerades. The attendees will learn methods
for developing an appropriate level of suspicion for masquerades, allowing for
earlier diagnosis and initiation of treatment.
Bennie H Jeng MD*
10:16 AM Nongranulomatous Anterior Uveitis
Debra A Goldstein MD*
10:25 AM Q&A
10:27 AM Chronic Ocular Surface Inflammation
Carol L Karp MD
10:36 AM Q&A
10:38 AM Chronic Panuveitis
Arun D Singh MD
10:47 AM Q&A
10:49 AM Peripheral Ulcerative Keratitis
Esen K Akpek MD*
10:58 AM Q&A
11:00 AM Posterior Uveitis
Lucy H Young MD PhD FACS
11:09 AM Q&A

135

Symposia
10:05 AM
10:25 AM
History of Epidemiological Studies Impacting the Reduction of

Blinding Malnutrition, Trachoma, and Onchocerciasis
Hugh R Taylor MD FRACS
Examples of How Economic Research on Blindness Led to Data That
Supported Advocacy That Led to Funding for Specific Prevention of
Blindness Programs
Kevin Frick PHD**
Audience Question & Answer
Panel II: Current Studies to Address the Leading Causes of Blindness,
and the Logistical, Ethical, And Financial Considerations of Global
Research
Fernando Pena MD*
Using Data and Research for Practice and Advocacy - The Difference
Between Clinical and Programmatic Research
Fernando Pena MD*
Current International Research Supported By the US National Eye
Institute
Gyan John Prakash PHD
Rapid Assessment of Avoidable Blindness Studies
Muhammad M Rabiu MD
PRECOG Cataract Outcomes Study
Nathan G Congdon MD
Considerations of Conducting Research in Other Countries
David S Friedman MD MPH PhD*
Audience Question & Answer
Summary
Timothy P Page MD*
Volunteer Fair
End of Session
Cornea Society

11:11 AM Vitritis and Systemic Disease
Prithvi Mruthyunjaya MD*
11:20 AM Q&A
Event No: SYM29

Room: E350
JONES/SMOLIN LECTURE
11:22 AM Introduction of the Jones/Smolin Lecture
Bennie H Jeng MD*
11:25 AM Jones/Smolin Lecture: Changing Times in the Diagnosis and
Management of Ocular Infectious Diseases
Russell N Van Gelder MD PhD*
New Frontiers of the Vitreoretinal Interface: Where

Worlds Collide

Symposia
Event No: SYM28

10:15 - 11:45 AM
Combined meeting with the European Latin America Retina Specialist Society
(Eurolam)
Chair(s): Stanley Chang MD*, Gisbert W Richard MD*
Using intraoperative videotapes and case presentations, a panel of internationally recognized experts will demonstrate their approach to various types of
diseases involving the vitreoretinal interface, including macular hole, macular
pucker, traumatic macular hole, tractional diabetic macular edema, myopic macular hole, and others. Clinical evolution and diagnosis options, as well as different
management options, will also be discussed.
10:15 AM New OCT Technology in Vitreoretinal Interface and Digital Biopsy
David E Pelayes MD*
10:23 AM New OCT-Based Nomenclature Classification for Diseases of the
Vitreoretinal Interface
Jay S Duker MD*
10:31 AM Early Vitreomacular Traction: Do We Know the Natural History?
Alain Gaudric MD*
10:39 AM The Importance of Internal Limiting Membrane and External Limiting
Membrane
Federico A Graue-Wiechers MD
10:47 AM Closure of Macular Holes: Lessons Learned from Experimental Retinal
Wound Healing
Mark S Blumenkranz MD*
10:55 AM Tractional Diabetic Macular Edema Interface
Francesco M Bandello MD*
11:03 AM Myopic Hole Interface
Borja F Corcostegui MD*
11:11 AM Predictors of Visual Outcome in Vitreomacular Surgery
Rene H Cano MD*
11:19 AM Discussion
136
SO Adjusting to the Changing Demographic: Valuing the

Patient in Determining Options for Treatment
10:45 - 11:45 AM
Combined meeting with the Committee on Aging and the Senior

Ophthalmologist (SO) Committee
Chair(s): Gwen K Sterns MD, Andrew G Lee MD*
As the population ages, we are confronted with hard decisions involving the medical and surgical management of our patients. We must help patients and family members make choices that are not always straightforward. How aggressive
should our treatments be for the frail elderly patient with macular degeneration
or glaucoma? Who should decide? How do we know when an elderly patient is
competent to make decisions independently? How do we frame choices between
treatment and no treatment in a manner that a cognitively impaired but legally
competent patient can understand? When should family or others be involved in
these decisions? This symposium will address these questions.
Gwen K Sterns MD
10:47 AM Customizing Macular Degeneration Care for the Elderly: Does Age
Play a Role? Should It?
James E Kempton MD**
10:55 AM Macular Degeneration: The Eye Can Handle the TreatmentCan the
Patient?
Chirag P Shah MD*
11:03 AM Customizing a Glaucoma Treatment Plan in the Elderly Patient: Does
the Treatment Improve the Quality of Life for This Patient?
M Bruce Shields MD*
11:11 AM Considering Comorbidities When Defining a Glaucoma Treatment
Plan: What Defines SuccessA Target Pressure or Stable Outcomes
in a Satisfied Patient?
George A Cioffi MD*
11:19 AM Ethics: How Do We Know if Patients or Their Family Members
Understand What Were Telling Them?
Shellie N Williams MD
11:43 AM Closing
Andrew G Lee MD*
Innovation in Ophthalmology: From Theory to Therapy

Event No: SYM30
12:15 - 1:45 PM
Chair(s): Emmett T Cunningham Jr MD PhD MPH

This course is intended to give clinical ophthalmologists an improved understanding of the factors driving and influencing innovation in ophthalmology. Participants should gain an improved understanding of the innovative process, including
how to protect and advance their own innovations.
12:15 PM Welcome
Emmett T Cunningham Jr MD PhD MPH
12:19 PM Helpful Tips for Aspiring Entrepreneurs
Emmett T Cunningham Jr MD PhD MPH
12:27 PM Funding Innovation
Gilbert H Kliman MD**
12:35 PM An Investors View on Innovating in the Ophthalmic Sector: Winners,
Losers, Lessons Learned
William Link PhD*


12:43 PM Starting a New Company: How to Pick a Winner
Eugene de Juan Jr MD*
12:51 PM The Role of Physician Innovators
Daniel M Schwartz MD*
12:59 PM Innovating From Private Practice
Richard L Lindstrom MD**
1:07 PM Innovating From Academia
Mark S Blumenkranz MD*
1:15 PM Panel Discussion/Q&A
Telehealth is in Your Future

Event No: SYM31
Room: S405
12:15 - 1:45 PM
Beyond Ophthalmology
Event No: SYM32
Room: S406b
12:15 - 1:45 PM
Combined meeting with the Museum of Vision

Chair(s): Michael F Marmor MD*
The Museum of Visions history symposium will look at the lives of ophthalmologists whose passion for medicine is matched or even overshadowed by an
interest in another field. Beyond Ophthalmology features stories of ophthalmologists who left the profession or pursued activities beyond the profession
to achieve notoriety in other disciplines, such as literature, politics, and the arts.
Dr. Allan Jensen and Claire Jensen Lecture in

Professionalism and Ethics
Event No: SYM33
Room: S406a
12:45 - 1:45 PM
Chair(s): Christie L Morse MD*

Failing to address unprofessional behavior may promote similar behavior in other
individuals and tarnishes the image of the profession. Addressing unprofessional
behavior results in higher levels of personal satisfaction, creates better mentors
for younger ophthalmologists, and improves patient safety and risk-management
experiences. Attendees will become knowledgeable about issues relating to
professionalism and unprofessional behavior, i.e., how to identify and address
unprofessional behavior, and what to do about these issues in their own communities. Every physician needs skills for addressing unprofessional / unethical
behavior even if it is as simple as knowing that the Academys Ethics Committee is in place to assist. Dr. Gerald B Hickson will be delivering our inaugural Dr.
Allan Jensen and Claire Jensen Lecture in Professionalism and Ethics with his
presentation, Promoting Ethics and Professionalism.
12:45 PM Promoting Ethics and Professionalism
Gerald B Hickson MD
1:15 PM Q&A
Why Take the Risk? How to Create an Effective Risk

Management Strategy With Patient Education and
Informed Consent Documents
Event No: SYM34
Room: S403b
12:45 - 1:45 PM
Combined meeting with the Patient Education Committee and the Ophthalmic
Mutual Insurance Company (OMIC)
Chair(s): Philip R Rizzuto MD FACS
Through analysis of specific medicolegal cases and a survey of Ophthalmic Mutual Insurance Company (OMIC) defense counsel, attendees will learn how to
minimize their risk against malpractice lawsuits with the effective use of ophthalmic patient education and informed consent tools.
12:45 PM Introductions and Program Overview
Philip R Rizzuto MD FACS
12:50 PM A Medicolegal Case Presentation
Devin A Harrison MD

137

Symposia
Combined meeting with Women in Ophthalmology (WIO)

Chair(s): Kimberly Cockerham MD FACS*, Roberta Gausas MD**
The aging population will need additional medical care over the coming decades.
Driving to a doctors office, checking in, waiting, undergoing examination, and
driving home requires access to transportation and time. These human and financial costs do not necessarily improve quality of care for the patient or make financial sense for the doctor. With advances in widely available technology, virtual
visits between doctors and their patients have become possible with minimal expense. Webportals, smart phones, video calls, and other forms of communication
have opened up new options by which patients and doctors can communicate.
Smart phone applications can now remind patients to take their medications,
measure blood pressure and other parameters, and record postoperative pictures
over time. The goal of this symposium is to provide information to ophthalmologists in a wide range of practice models with the new, fixed (lap or desktop) and
mobile options that they can integrate now to improve their efficiency and job
satisfaction.
Kimberly Cockerham MD FACS*
12:20 PM The Evolution of Telehealth in the United States
Rosa A Tang MD*
12:35 PM Telehealth and the Department of Veterans Affairs
Kimberly Cockerham MD FACS*
12:50 PM Smartphone and Tablet Apps
Suzann Pershing MD
1:05 PM International Telehealth: The Orbis Experience
Joan Brown BSMT MBA
1:40 PM Conclusion
Roberta Gausas MD**
1:20 PM Q&A
Speakers including the doctors themselves will discuss how to pursue a dream
and how those dreams can change over time.
12:15 PM Welcome
12:20 PM Politics: Jose Rizal MD and Other Political Leaders
Tracy B Ravin MD
12:35 PM Literature: Sir Arthur Conan Doyle MD and Others
James G Ravin MD
12:50 PM Classical Music: Samuel Wong MD and a Conductors Life
Samuel T Wong MD
1:05 PM Entertainment: Jules Stein MD: The Movies and Beyond
Bradley R Straatsma MD
1:20 PM Photography: Howard Schatz MD and His Vision
1:35 PM Closing Remarks/Questions

2:02 PM

1:05 PM
1:20 PM
1:35 PM
1:45 PM
Discussion of OMIC Defense Counsel Survey Results and Points

Academy and OMIC Resources for Education and Informed Consent
Philip R Rizzuto MD FACS
Conclusion and Q&A
End of Session
Management of Retinal Breaks and Idiopathic Macular

Holes: Latest Diagnostic and Treatment Strategies from
the New Preferred Practice Pattern Guidelines

Symposia
Event No: SYM35

Room: E350
12:45 - 1:45 PM
Combined meeting with the Preferred Practice Patterns Committee (PPPC)

Chair(s): Timothy W Olsen MD*
Retinal breaks and idiopathic macular holes are the focus of two revised Preferred Practice Pattern guidelines. The authors are the Retina PPP committee
members, who will use the evidence-based recommendations from this PPP to
provide the comprehensive ophthalmologist with a good understanding of how
the latest diagnostic equipment and surgical techniques can provide the best
care for a patient with these conditions. The utility of OCT will be discussed.
The emphasis will be on teaching the comprehensive eye physician about the
basic indications, benefits, and risks of various surgical techniques. Through didactic lecture and case presentation, the goal is to provide the attendees with
pearls and take-home points to be used in their clinical practices. A free CD-ROM
containing all 20 PPP titles and Summary Benchmarks will be distributed to attendees.
12:45 PM What Is the PPP?
Stephen D McLeod MD*
12:48 PM Current Diagnostic Options
Jose S Pulido MD MS
12:58 PM How Does the Retina Specialist Manage Retinal Breaks?
Ron Afshari Adelman MD MPH
1:13 PM How Does the Retina Specialist Manage Idiopathic Macular Hole?
James C Folk MD*
1:28 PM Panel Q&A
Timothy W Olsen MD*
GO SOE
Care?
Ethics and Professionalism: Why Should I
Event No: SYM27

Room: S406a
2:00 - 3:00 PM
Combined meeting with the Academys Ethics Committee and the European
Society of Ophthalmology (SOE)
Chair(s): Christie L Morse MD*, Andrzej Grzybowski MD*
Virtual Moderator: Anthony J Aldave MD*
In this international symposium, actual ethics case studies will be presented illustrating ethical dilemmas common across international borders such as the
learning curve in using new technology, publishing scientific research, the use
of IRBs, off-label use of drugs, informed consent and others ethical concerns.
Resolution of these dilemmas and the difficulties in creating resolutions where
no formal ethics programs exist will be discussed. Potential joint educational
endeavors between national societies represented on the symposium panel will
be discussed.
Christie L Morse MD*
138
2:10 PM
2:18 PM
2:26 PM
2:34 PM
3:00 PM
Relationships with Industry

Anthony J Aldave MD*
Informed Consent
Roberto Pineda II MD*
Off Label Drugs and Patient Needs
Matteo Piovella MD*
Learning Curve with New Technology
Boris Malyugin MD PhD*
Q&A
End of Session
Pediatric Vision Rehabilitation

Event No: SYM40
Room: E350
2:00 - 3:00 PM
Combined meeting with the Vision Rehabilitation Committee

Chair(s): Mary Lou Jackson MD*, Deepthi M Reddy MD
This symposium will highlight services available to provide vision rehabilitation
for children with vision loss and their families. These services are an essential
part of the ocular care of the child with vision loss to ensure healthy development
and full participation of the child in educational and community settings.
2:02 PM Pediatric Vision Rehabilitation Interventions: The Preschooler and
School Aged Child
Gwen K Sterns MD
2:13 PM Vision Rehabilitation Services for Teens and Postsecondary Students
Terry L Schwartz MD
2:25 PM Vision Rehabilitation Services for Children: The Perspective of the
Vocational Rehabilitation Commission
Janet LaBreck
2:38 PM Vision Rehabilitation Services for Children: The Pediatric
Ophthalmologist Perspective
C Gail Summers MD
2:49 PM Vision Rehabilitation Services for Children; The Parent Perspective
Suzanne Kouri
2:59 PM Summary
Deepthi M Reddy MD
Spotlight on Neuro-Ophthalmology: Things You Dont

Want to Miss
Event No: SPO4
2:00 - 3:30 PM
Chair(s): Nicholas J Volpe MD

Virtual Moderator: Michael S Lee MD*
This spotlight session for the comprehensive ophthalmologist will both emphasize highstakes diagnoses that must be made and also discuss the perils of overdiagnosis. A
case-based series of presentations will provide the state-of-the-art approach to common neuro-ophthalmic signs and symptoms. Examples of topics to be presented include
transient monocular vision loss, temporal arteritis, the swollen optic nerve, ptosis, acute
vision loss, and the pediatric patient with neuro-ophthalmic findings. A practical approach will be emphasized to ensure no misses but also to help the comprehensive
ophthalmologist avoid overdiagnosing and overtesting.
2:00 PM
2:13 PM
Introduction
Nicholas J Volpe MD
Vertical Diplopia: Thirds, Thyroid, and More
Dean M Cestari MD


2:24 PM
2:35 PM
2:46 PM
2:57 PM
3:08 PM
3:19 PM
The Pediatric Patient: What Not to Miss

Grant T Liu MD
Temporal Arteritis: What It Does and Doesnt Do
Peter A Quiros MD
Ptosis and Double Vision: Who Has Myasthenia Gravis
Not Everything Is the Optic Nerve and Brain: Retinal Disease in
Neuro-Ophthalmic Differential Diagnosis
Michael S Lee MD*
The Patient Probably Does Not Have Optic Neuritis If
Madhura A Tamhankar MD
Papilledema? Avoiding the Pseudopapilledema Overcall
Alfredo A Sadun MD PhD*
Lessons Learned from Recent Clinical Trials on

Diabetic Retinopathy
Event No: SYM43
2:00 - 3:30 PM
Combined meeting with the Macula Society

Chair(s): Neil M Bressler MD*, Lawrence J Singerman MD*
Panelists: Michael J Elman MD*, Lee M Jampol MD*, Michael S Ip MD*, Barbara Ann Blodi MD**
Event No: SYM39

Room: North Hall B
2:00 - 4:00 PM
Combined meeting with the American Society of Cataract and Refractive

Surgery (ASCRS)
Chair(s): Edward J Holland MD*, Stephen S Lane MD*
Panelists: Eric D Donnenfeld MD*, Thomas W Samuelson MD*, Roger F Steinert
MD*
The ASCRS Symposium with feature a series of expert speakers to discuss the
most significant challenges in cataract surgery. Each talk will be followed by
an interactive panel discussion. Topics to be discussed include: Ocular surface
disease, astigmatism management, post-refractive calculations, corneal dystrophies, glaucoma, iris abnormalities, dense cataracts, zonular weakness and
Retinal pathologies.
2:00 PM Ocular Surface Disease
Neda Shamie MD*
2:07 PM Discussion
2:11 PM Astigmatism Management
2:18 PM Discussion
2:22 PM Dense Cataract
Rosa Braga-Mele MD*
2:29 PM Discussion
2:33 PM Post Refractive
Douglas D Koch MD*
2:40 PM Discussion
2:44 PM Fuchs Dystrophy
Terry Kim MD*
2:51 PM Discussion
2:55 PM Glaucoma
Richard A Lewis MD*
3:02 PM Discussion
3:06 PM Iris Defects
Michael E Snyder MD*
3:13 PM Discussion
3:17 PM Small Pupil
Richard S Hoffman MD*
3:24 PM Discussion
3:28 PM Dislocated IOL
Robert J Cionni MD*
3:35 PM Discussion
3:39 PM Maculopahthy
Stephen Charles MD MBBS
3:46 PM Discussion
3:50 PM Conclusion
Edward J Holland MD*
The Great Debate: Cornea

Event No: SYM11
3:45 - 5:00 PM
Chair(s): Christopher Rapuano MD*

Virtual Moderator: William B Trattler MD*

139

Symposia
The total number of people worldwide with diabetes mellitus is projected to rise
to over 350 million by 2030. In the United States, over 20 million people, or 8
percent of the population, have diabetes mellitus, including 4 million Americans
age 40 and older who have diabetic retinopathy. This includes almost 1 million
with vision-threatening disease, including macular edema or features predicting a high risk of worsening to proliferative diabetic retinopathy. To address the
growing burden of this condition on the ophthalmic community, this symposium
will address lessons learned from clinical trials evaluating the comparative effectiveness of different anti-VEGF agents for diabetic macular edema from government-sponsored trials, along with new approaches to treating proliferative
diabetic retinopathy.
2:00 PM Introduction to the Symposium, Classification and Importance of
Diabetic Retinopathy
Lawrence J Singerman MD*
2:08 PM Recent Results from Randomized Clinical Trials Evaluating Anti-VEGF
Treatments on Management of Diabetic Macular Edema
John A Wells III MD*
2:18 PM Current Treatment and Follow-up Strategies for Managing Diabetic
Macular Edema
Susan B Bressler MD*
2:28 PM Current Approaches to Imaging and Treating Proliferative Diabetic
Retinopathy
Jennifer K Sun MD**
2:38 PM Potential Impacts of Recent Clinical Trial Results on Preferred
Practice Patterns
Paul Sternberg Jr MD
2:48 PM Coordinating New Retina Treatments With Primary Care Providers for
Diabetes
Lloyd P Aiello MD PhD*
2:58 PM Case Studies, Summary, and Future Directions
Neil M Bressler MD*
Challenges in Cataract Surgery: Gems to Take Home

and Treasure

Symposia

This symposium will be structured as a lively, old-fashioned debate. Groups of
debaters will argue the pros and cons of controversial topics. Speakers will have
the opportunity to present prepared statements and then will have a chance to
rebut those of their opponents. Audience voting will be used to determine which
speakers were most effective in stating their arguments.
Christopher Rapuano MD*
Epithelium-off or Epithelium-on
3:51 PM Epithelium-off
Theo Seiler MD PhD
3:56 PM Epithelium-on
Rajesh K Rajpal MD*
4:01 PM Epithelium-off Rebuttal
4:02 PM Epithelium-on Rebuttal
Topical Steroid Use Within the First Few Days
4:06 PM Yes
Stephen D McLeod MD*
4:11 PM No
Sonal S Tuli MD
4:16 PM Yes Rebuttal
4:17 PM No Rebuttal
Separate or Combined Cataract Surgery and EK?
4:21 PM Cataract Surgery First, Then EK
Marian Sue Macsai-Kaplan MD*
4:26 PM Combined Cataract Surgery and EK
Francis W Price Jr MD*
4:31 PM Separate Rebuttal
4:32 PM Combined Rebuttal
Corneal Transplant for Patient with Advanced Keratoconus, Which
Procedure: DALK or PK?
4:36 PM DALK
4:41 PM PK
Yaron S Rabinowitz MD
4:46 PM DALK Rebuttal
4:47 PM PK Rebuttal
4:49 PM Conclusions
140
Best of the Posterior Segment Specialty Meetings 2014

Event No: SYM36
Room: S406a
3:45 - 5:00 PM
Chair(s): Nicholas J Volpe MD, Scott C Oliver MD*

This symposium will feature best papers focusing on the posterior segment from
the major uveitis, neuro-ophthalmology, retina, oculoplastics, and pediatric ophthalmology specialty meetings of 2014.
American Uveitis Society
3:47 PM
Longitudinal Cohort Study of Birdshot Chorioretinopathy: Highlights

From the Analysis of Data at 5 Years of Follow-up
Gary N Holland MD*
3:54 PM
Retinal Ganglion Cell Layer Thinning Within One Month of

Presentation for Non-arteritic Anterior Ischemic Optic Neuropathy
and Optic Neuritis
Macula Society
4:01 PM
Effect of Aspirin Use on Progression of Age-Related Macular

Degeneration
Emily Y Chew MD
4:08 PM The Societal Costs Associated With Neovascular Macular
Degeneration in the United States
Gary C Brown MD*
The Retina Society
4:15 PM
Detection Rate of New CNV in Eyes With AMD and Visits Prompted
by Home Monitoring Device, Symptoms and Standard Care
Susan B Bressler MD*
4:22 PM Intravitreal Ranibizmab for Diabetic Macular Edema With Prompt
Versus Deferred Laser Treatment
Christina J Flaxel MD
American Society of Retina Specialists
4:29 PM
Is A Systemic Effect of Intravitreal Anti-VEGF Agents Observable in

the Fellow Eyes of Patients Treated for Diabetic Macular Edema?
Robert L Avery MD*
4:36 PM Combined CFH and Age-Related Maculopathy Susceptibility 2 (ARMS
2) Risk Predicts Response to AMD Nutritional Prophylaxis: A New
Analysis of AREDS Data
Carl C Awh MD*
American Society of Plastic and Reconstructive Surgery
4:44 PM
Vismodegib in the Treatment of Periocular and Orbital Basal Cell

Carcinoma
Hakan Demirci MD
American Association for Pediatric Ophthalmology and Strabismus
4:51 PM
4:58 PM
5:00 PM
Comparison of the WINROP and CHOP-ROP Growth Models for the

Detection of ROP
Irene Shyu**
Conclusion
End of Session


Pediatric Orbital Disease

Event No: SYM37
3:45 - 5:15 PM
MARSHALL M PARKS LECTURE

4:43 PM
4:48 PM
5:13 PM
5:15 PM
Introduction of the Marshall M Parks Lecturer

Elias I Traboulsi MD*
Marshall M Parks Lecture: Craniofacial Malformations
James A Katowitz MD
Award Presentation
Elias I Traboulsi MD*
End of Session
Funding Our Future: Making Investments in

Ophthalmology
Event No: SYM38
Room: E350
3:45 - 5:15 PM
Combined meeting with the National Medical Association (NMA)

Chair(s): Leslie S Jones MD**, Chasidy D Singleton MD
The future of medicine has become increasingly uncertain due to new government regulations and a sluggish economy, despite an ever-expanding patient
population with more demands for excellent service. The field of ophthalmology,
Tuesday, Oct. 21
Focus on Practice Efficiency: How to Deal Effectively

with Increasing Patient Volume of the Aging Population
Event No: SYM42
8:30 - 10:00 AM
Combined meeting with the Committee on Practice Improvement

Chair(s): Joseph Caprioli MD FACS*, Anne Louise Coleman MD PhD*
In 2020, the workload for ophthalmology is projected to be 47% greater than
in 2001, based on the needs of the aging baby boomer generation. This demographic shift underscores the need to keep up with the growing eye care needs of
the country, and to prevent ourselves from being overwhelmed. Ophthalmology
can seize the opportunity to solidify its role as the leader of eye care by becoming
more efficient and capable of meeting the increased and varied demands of the
population. Ophthalmologists may need to consider changes in workflow and to
focus on specific areas of competency, delegation of duties, redesign of office
space, and use of physician extenders to fill gaps in the delivery of care while
maintaining the quality of care. In this symposium, panelists will address the impending demographic trends and present the ophthalmology-led eye care team,
a calculator for measuring practice efficiency, and additional tools and resources
the Academy has developed to help its members.
Joseph Caprioli MD FACS*

141

Symposia
Combined meeting with the American Association of Pediatric Ophthalmology

and Strabismus (AAPOS)
Chair(s): Stephen P Christiansen MD*, Sherwin Isenberg MD*
Diagnosing and managing the child with orbital and adnexal disease can be
challenging on multiple levels. Congenital malformations, for example, often are
hereditary and may require genetic analysis and multidisciplinary care. Growth of
the orbit and eye, as well as visual development, demand special consideration
and care both in the short and in the long term. The developing brain and facial
skeleton require modifications in imaging techniques. These and many more considerations make management of pediatric orbital disease especially challenging and particularly worth our collective attention. In this symposium, experts
will discuss advances in diagnosis and in medical and surgical management of
pediatric orbital disease.
3:45 PM Welcome and Introduction
Stephen P Christiansen MD*
3:47 PM Orbital Vascular Malformations: Classification and Treatment
Kenneth V Cahill MD FACS
3:54 PM Mini-symposium: Solid Orbital Tumors - Pathology
Ralph Eagle MD*
4:01 PM Clinical Presentation and Treatment
William R Katowitz MD
4:08 PM Optic Nerve Gliomas
Grant T Liu MD
4:15 PM Mini-Symposium: Expansion of the Small Orbit - Socket Expansion in
Congenital Microphthalmos
Jill Annette Foster MD FACS*
4:22 PM Orbital Expansion in Congenital Anophthalmos
David T Tse MD FACS*
4:29 PM Orbital Cellulitis
Rachel K Sobel MD
4:36 PM Congenital Eyelid Malformations
Femida Kherani MD*
however, has the opportunity to thrive in the midst of these challenges by making
lasting investments to maintain productive practices. While some of these investments are financial, they are also related to improving the quality of clinical
care and patient outcomes by developing efficient practices and improving access to care for our diverse patient population. In addition, we must support the
development of our young ophthalmologists as leaders in innovation, research,
clinical care, and public policy. Every ophthalmologist has the responsibility to
capitalize now on making our profession sustainable and successful through
transforming our mindsets to prepare for this exciting future.
3:45 PM Introductions and Welcome
Leslie S Jones MD**
3:47 PM Protecting Our Practice: OPHTHPAC and the Surgical Scope Fund
Robert A Copeland MD
3:55 PM Managing Our Reputation With the Public
Andrew P Doan MD PhD*
4:03 PM Physician Quality Measures: Participation in the IRIS Registration
System
William L Rich MD
4:11 PM The Time Is Now: Incorporating ICD-10 Without Affecting Patient
Flow
Patricia Kennedy COMT CPC COE*
4:19 PM Encouraging Our Youth to Pursue Academic Medicine
Eydie G Miller MD*
4:27 PM Creating Leaders in Our Young Ophthalmologists
4:35 PM The Workforce of the Future
Ruth D Williams MD*
4:43 PM How the Power of Diversity Creates Better Groups
Darrell G Kirch MD
4:51 PM Q&A and Panel Discussion
5:13 PM Closing Remarks
Chasidy D Singleton MD

8:59 AM
Implications of the Changing Demographics of the United States

Paul P Lee MD JD*
8:45 AM Efficiencies of Ophthalmology-Led Eye Care Teams
Ruth D Williams MD*
8:55 AM The Practice Efficiency Calculator and How It Can Help Your Practice
Joseph Caprioli MD FACS*
9:05 AM Academy Aids and Tools to Enhance Practice Efficiency
9:15 AM How Can the EHR Help Improve Practice Quality and Volume?
Michele C Lim MD*
9:25 AM Panel Discussion and Q&A
9:01 AM
The Battle of Glaucoma: How to Diagnose, Assess, and

Manage Glaucoma That is Getting Worse
9:20 AM
8:35 AM

Symposia
Event No: SYM45

Room: S406a
8:30 - 10:00 AM
Combined meeting with Prevent Blindness

Chair(s): David S Friedman MD MPH PhD*, Steven L Mansberger MD*
Virtual Moderator: Savak Teymoorian MD**
This symposium will discuss the practical evaluation, detection, and management of patients whose condition is getting worse from glaucoma. The topics
include structural evaluation of the optic disc with confocal scanning laser ophthalmoscopy and ocular coherence tomography, visual field testing with evaluation of velocity and location of loss, how to treat when patients are getting worse
because of poor adherence to glaucoma therapy, and the best approach for initial
surgery on a patient who is getting worse from glaucoma. Two expert speakers
will address these topics by advocating for different approaches to the same controversial case of glaucomatous progression, with a rebuttal subsequently. The
discussion will be case based and highly clinically relevant for ophthalmologists
evaluating and treating glaucoma patients. After each case, attendees will vote
for the most convincing management approach.
8:30 AM Introduction and Case #1: Glaucoma Getting Worse By Objective
Structural Testing
Steven L Mansberger MD*
8:32 AM Case #1: Confocal Scanning Laser Is The Gold Standard
Mitra Sehi PHD*
8:37 AM Case #1: Ocular Coherence Tomography Is The Gold Standard
Claude F Burgoyne MD*
8:42 AM Rebuttal
Mitra Sehi PHD*
8:43 AM Rebuttal
Claude F Burgoyne MD*
8:44 AM Case #2: Progression By Visual Field
8:47 AM Case #2: Any Change Is Significant and Needs to Be Addressed
Jeffrey M Liebmann MD*
8:52 AM Case #2: Rate of Change Is the Important Aspect
Kouros Nouri-Mahdavi MD*
8:57 AM Rebuttal
Jeffrey M Liebmann MD*
8:58 AM Rebuttal
Kouros Nouri-Mahdavi MD*
142
9:06 AM
9:11 AM
9:12 AM
9:13 AM
9:15 AM
9:25 AM
9:26 AM
9:27 AM
Case #3: Patient Is Getting Worse and Not Taking Drops as Prescribed
Steven L Mansberger MD*
Case #3: We Should Treat the Adherence
Kelly Walton Muir MD*
Case #3: Treating Adherence Is a Wasted Effort: Its Time For Surgery
Rohit Varma MD MPH*
Rebuttal
Kelly Walton Muir MD*
Rebuttal
Rohit Varma MD MPH*
Case #4: Patient Is Worsening on Maximal Medical Therapy: What
Next?
Case #4: A MIGS Is the Next Best Step
Malik Y Kahook MD*
Case #4: Forget MIGS: You Should Use Standard Treatments (Trab
and Tube)
Steven Gedde MD*
Rebuttal
Malik Y Kahook MD*
Rebuttal
Steven Gedde MD*
Summary of Session
ROBERT N SHAFFER LECTURE

9:30 AM
9:34 AM
9:59 AM
Introduction of Robert N Shaffer Lecturer and Presentation of Plaque

Andrew George Iwach MD*
Robert N Shaffer Lecture: Global Collaborations: Improving Glaucoma
Care
Alan L Robin MD*
Conclusion
Ophthalmic Premier League: A Team Video Competition

on Managing Cataract Complications
Event No: SYM60
Room: North Hall B
8:30 - 10:00 AM
Chair(s): Amar Agarwal MD*, Richard L Lindstrom MD**

The Ophthalmic premier league (OPL) symposium is similar to the American football league games, but the OPL is connected to ophthalmology. There will be 4
teams with 4 captains. Each team will sport their team jersey. Each team will
have a total of 4 members. Each team member will be given 4 minutes to show
his/her most challenging cataract/complication cataract case through videos.
Each team will be given a total of 18 minutes. There will be a good discussion on
each case for the remaining time. The audience will vote for their favorite team.
The winning team will be awarded the AAO-OPL trophy.
Moderators: Richard L Abbott MD*, Jonathan B Rubenstein MD*
Judges: William J Fishkind MD FACS*, Nick Mamalis MD*
Match Referee: Ronald R Krueger MD*
Team 1: Chicago Choppers
Captain: Roger F Steinert MD*
Vice Captain: Jorge L Alio MD PhD*
Susan M MacDonald MD*, Samuel Masket MD*
Team 2: LA Accommodators
Captain: Kevin M Miller MD*


9:26 AM
9:35 AM
Vice Captain: Richard S Hoffman MD*

Sonia H Yoo MD*, Boris Malyugin MD PhD*
9:44 AM
Team 3: Frisco Flomaxinators

Captain: David F Chang MD*
Vice Captain: Thomas A Oetting MD
CASTROVIEJO LECTURE
9:57 AM
Athiya Agarwal MD, Thomas Kohnen MD*
Team 4: Vegas Multifocals

Captain: Robert H Osher MD*
Vice Captain: Abhay Raghukant Vasavada MBBS FRCS*
George Beiko MD*, Ehud I Assia MD*
8:30 AM
Advanced Treatment of Ocular Surface Inflammatory

Diseases
8:30 - 10:30 AM
Combined meeting with the Cornea Society

Chair(s): William Barry Lee MD*, Edward J Holland MD*
This symposium will feature a combined effort by the Cornea Society and the
German Ophthalmological Society (DOG) to discuss a number of immune-mediated and inflammatory conditions that can severely affect the anterior segment
of the eye. The various diagnostic strategies and treatment options for some of
the most challenging local and systemic inflammatory conditions of the anterior
segment will be reviewed. The symposium will conclude with a lecture from the
Castroviejo Lecture awardee for 2014, Professor Mark Mannis MD FACS.
8:32 AM The Itchy Eyes Have It: A Case-Based Approach to Allergic Eye
Diseases
Penny Asbell MD FACS*
8:41 AM Atypical Causes of Immune-Mediated Conjunctivitis
8:50 AM Rosacea and the Ocular Surface: How to Get the Red Out?
Gerd Geerling MD PHD*
8:59 AM Cicatricial Ocular Surface Diseases: Advances in Treatment Options
Darren G Gregory MD
9:08 AM Graft-versus-Host Disease: Treatment Strategies, from Mild to Severe
Disease
Claus Cursiefen MD*
9:17 AM Localized Immune-Mediated White Spots of the Cornea
Berthold Seitz MD
Introduction of the Castroviejo Lecturer

Edward J Holland MD*
9:59 AM Castroviejo Lecture: Points of Light in the History of Cornea
Mark J Mannis MD
10:29 AM Conclusion
Decision Making in Contemporary Refractive Surgery

Event No: SYM48
Room: S406a
10:15 - 11:45 AM
Combined meeting with the International Society of Refractive Surgery (ISRS)

Chair(s): George O Waring MD*, Renato Ambrosio Jr MD*
The subspecialty of refractive surgery has evolved significantly in recent years.
From topography-guided excimer treatments to laser lens surgery, refractive
procedures and platforms are emerging rapidly. Biomechanical treatments are
quickly becoming the standard of care for ectatic disorders, and small corneal
lenticule extraction may emerge as one of the most versatile treatment paradigms in corneal refractive surgery. Furthermore, lens-based surgery, historically
the original refractive surgical procedure, has become a primary focus for the
comprehensive refractive surgeon, and the surgical correction of presbyopia is
quickly becoming a recognized sub-subspecialty. This symposium was designed
to aid the lens- and corneal-based refractive surgeon in decision making in contemporary refractive surgery.
George O Waring MD*
10:18 AM Corneal or Lens-Based Refractive Surgery
George O Waring MD*
10:23 AM Defining Refractive and Therapeutic Procedures
Renato Ambrosio Jr MD*
10:28 AM Prevention and Treatment of Infections in Refractive Surgery: What
Do We Need to Know?
Denise de Freitas MD
10:33 AM Correction of Ametropia on the Cornea: Advanced Excimer Ablation
Daniel S Durrie MD*
10:38 AM Correction of Ametropia on the Cornea: Femtosecond Lenticule
Extraction
Dan Z Reinstein MD*
10:43 AM Crosslinking: Show Me the Evidence: Epithelium Off
Theo Seiler MD PhD
10:48 AM Crosslinking: Show Me the Evidence: Epithelium On
William B Trattler MD*
10:53 AM Crosslinking: Show Me the Evidence: Iontophoresis
Paolo Vinciguerra MD*
10:58 AM Surgical Correction of Presbyopia: Lens Based
Jason E Stahl MD
11:03 AM Surgical Correction of Presbyopia: Cornea Excimer Based
Gustavo E Tamayo MD*
11:08 AM Surgical Correction of Presbyopia: Corneal Inlay Based
Minoru Tomita MD PhD*

143

Symposia
Introduction of OPL
Amar Agarwal MD*
8:33 AM Moderator Comments
8:35 AM Judges Comments on the OPL
8:36 AM Match Referee Comments
8:37 AM Team 1: Chicago Choppers
8:55 AM Team 2: LA Accommodators
9:13 AM Team 3: Frisco Flomaxinators
9:31 AM Team 4: Vegas Multifocals
9:49 AM Match Referee Comments
9:50 AM Audience Vote for Best Team and Moderator and Judges Comments
9:55 AM Present OPL-AAO Trophy to the Best Team
Event No: SYM46

Scleritis: Medical Management Strategies for Scleral Disease

TBD
Stage-Related Therapy for Atopic Ulcerative Keratitis
Walter Lisch MD
Q&A

11:13 AM Cataract Surgery: Non-Laser Assisted
James C Loden MD*
11:18 AM Cataract Surgery: Laser Assisted
Burkhard Dick MD*
BARRAQUER LECTURE
11:23 AM Introduction of the Barraquer Lecturer
George O Waring MD*
11:26 AM Barraquer Lecture: Predicting and Treating Corneal Ectasia after
LASIK
R Doyle Stulting MD PhD*
11:41 AM Presentation of the Award
George O Waring MD*
GO YO International Opportunities for Young
Ophthalmologists

Symposia
Event No: SYM49

10:45 - 11:45 AM
Combined meeting with the Young Ophthalmologist International Subcommittee

Chair(s): Grace Sun MD, Brad H Feldman MD
Todays residents and young ophthalmologists (YOs) must become tomorrows
leaders in the global fight against eye disease. This course will address the challenges of treating eye disease in underserved parts of the world and will identify
the organizations working toward this goal and the opportunities available for
resident and YO involvement. The course will also examine the unique challenges
of incorporating volunteer service into ones career by sharing the experiences of
those who have found ways to balance work abroad with family, clinical practice,
and financial concerns at home. There will be ample time for responses to the
audiences questions to the panel. At the conclusion of the course, the attendee
will have an understanding of the global burden of eye disease, the organizations
and strategies employed to address this burden, the role residents and YOs can
play in this work, and the challenges of balancing domestic life with international
service.
Grace Sun MD
10:48 AM Working Abroad During Residency
John D Welling MD**
10:56 AM Incorporating International Work Into Your Life
Linda M Lawrence MD
11:16 AM Bringing World Class Eye Care to Africa
John M Cropsey MD
11:24 AM Global Ophthalmology Fellowship
Michael R Feilmeier MD
144
SOE A View Across the Pond: Cornea Enigmas
Event No: SYM20

10:45 AM - 12:15 PM

Chair(s): Friedrich E Kruse MD*, William Barry Lee MD*
The symposium will highlight the state of the art treatment of corneal and surface
disorders in the United States versus Europe.
10:46 AM Diagnosis and Management of Dry Eye Disease: The U.S. Experience
Steven I Rosenfeld MD FACS*
10:58 AM Discussion
11:01 AM Diagnosis and Management of Dry Eye Disease: The European
Experience
Christophe Baudouin MD PhD**
11:13 AM Discussion
11:16 AM Management of Corneal Ectasia: The U.S. Experience
Kenneth S Himmel MD
11:28 AM Discussion
11:31 AM Management of Corneal Ectasia: The European Experience
Theo Seiler MD PhD
11:43 AM Discussion
11:46 AM Surgical Management of Endothelial Disease: The U.S. Experience
11:58 AM Discussion
12:01 PM Surgical Management of Endothelial Disease: The European
Experience
Friedrich E Kruse MD*
12:13 PM Discussion

TM
Help Your Dry Eyes
Eyes Dry, Dont Cry.

Crocodile Tears Soothes Your Eyes.
They Dont Sting......And They Dont Bite!
To order online,
visit croctears.com
Made
In USA
or call 1-855-880-9538
twitter.com/crocteardrops
facebook.com/crocteardrops
Developed by
an accomplished
eye surgeon with
four decades of
experience.
youtube.com/croctearseyedrops
ORIGINAL PAPERS
Sunday Tuesday, Oct. 19 21
Unless otherwise noted, a panel discussion will follow each paper presentation. At the end of each session, the panel will select the best
paper from that session.
Selection Committee
The Annual Meeting Program Committee selected all Original Papers.
See page 33 for committee details.
145
Original Papers
Cataract
Sunday, Oct. 19
10:30 AM - 12:00 PM
Room: S405
Moderator: R Bruce Wallace MD
Panel: George Beiko MD, James A Davison MD, Boris Malyugin MD PhD
PA001
10:30 AM
Impact of First Eye vs. Second Eye Cataract Surgery on

Quality of Life
Presenting Author: Nakul Shekhawat MD
Co-Author(s): Michael V Stock MD, Elizabeth F Berzin MD, Mary K Daly MD,
David E Vollman MD MBA*, Mary Gilbert Lawrence MD MPH, Amy Chomsky
MD
Purpose: To compare the impact of first eye with second eye cataract
surgery on quality of life (QoL). Methods: 342 patients completed prepost Visual Function Questionnaires for first and second eye surgeries.
Postoperative QoL and QoL improvement of first eye surgery were compared
to those for second surgery. Results: QoL was higher after second eye
surgery than first eye surgery for all subscales and composite score (P < .05
for all). First and second eye surgery showed no significant differences in QoL
improvement for general vision, near activity, mental health, role difficulties,
dependence, or driving ability subscales and composite score (P > .05 for
all). Conclusion: Second eye cataract surgery improves patients quality of
life beyond first eye surgery alone. For many aspects of vision, second eye
surgery is no less beneficial than first eye surgery.
Original Papers
PA002
10:37 AM
SOE Are We Operating Too Many Patients for Cataract? A

Critical Analysis of Indications for Cataract Surgery Using
Data on 7300 Cataract Extractions
Presenting Author: Mats H Lundstrom MD

Co-Author(s): Charlotta Zetterstrom MD**, Ulf Stenevi MD
Purpose: To analyze indications for a cataract extraction. Methods: Clinics
affiliated with the Swedish Cataract Register participated in outcomes studies
during 1 month in 2012 and in 2013. Clinical data and patient-reported visual
function were registered. Results: Poor preoperative visual acuity was the
indication for the majority of patients. For patients with better preoperative
visual acuity, 18% were dissatisfied with their vision and reported visual disabilities. Another 8% reported difficulties performing vision-related daily life
activities. Indications like anisometropia or high IOP were stated by the surgeons in 0.4%. For 2.6% of the surgeries, no obvious indication for a cataract
extraction was found. Conclusion: In 97.4% a reasonable indication for a
cataract was found. The remaining 2.6% will be discussed.
PA003
10:44 AM
Evaluation of Effect of the Amount of Energy on IOP in

Nd:YAG Laser Capsulotomy
Presenting Author: Harshika Chawla MBBS
Co-Author(s): Manav Deep Singh, Vishal Vohra MBBS MS, Mayank Bansal
MD
Purpose: Although studies suggest that using high energy during Nd:YAG
capsulotomy increases the risk of IOP rise, no study has quantified these effects. This study was undertaken to quantify the same. Methods: Nonglaucomatous cases with posterior capsule opacity were recruited. Based on the
146
total energy (mJ) used, cases were grouped into Group A (< 40), Group B (4180), or Group C (> 80). Results: Significant rise of IOP was noted in Groups B
and C from 2 hours to 1 week following laser. The rise was greater in Group
C than in Group B. Overall, 3.2% of patients in Group A, 17.9% in Group B,
and 70% in Group C showed a rise of IOP 5 mmHg. Conclusion: If energy
used during the procedure is 40 mJ, the procedure can be safely carried out
without the need for perioperative antiglaucoma drugs.
10:51 AM Panel discussion of previous papers
PA004
11:01 AM
Evaluation of Sustained-Release Dexamethasone

for Safety and Efficacy After Cataract Surgery in a
Multicenter Study
Presenting Author: Tom R Walters MD*
Purpose: To evaluate a 4-week tapered-release dexamethasone punctum
plug (OTX-DP) for treatment of ocular inflammation and pain in patients undergoing cataract surgery. Methods: Sixty patients across 4 sites were randomized and administered OTX-DP or placebo vehicle punctum plug (PVPP)
immediately following surgery and followed for 30 days. Results: 34.5% of
OTX-DP subjects vs 3.4% of PVPP subjects at Day 14 (P = .0027) and 62.1%
vs. 13.8% at Day 30 (P = .0002) had an absence of anterior chamber (AC) cells.
Significantly more OTX-DP subjects had an absence of pain at Days 1, 4, 8,
11, 14, and 30 (P .0002). No long-term IOP spikes or adverse events related
to OTX-DP were reported. Conclusion: OTX-DP was statistically significantly
superior to PVPP for clearing AC cells at Days 14 and 30 and pain at all followup visits.
PA005
11:08 AM
Comparative Effectiveness of Intracameral Antibiotic

Agents for Preventing Phacoemulsification-Related
Endophthalmitis
Presenting Author: Kevin L Winthrop MD**
Co-Author(s): Neal H Shorstein MD*, Liyan Liu MHSA
Purpose: To compare the effectiveness of intracameral (IC) cefuroxime and
moxifloxacin prophylaxis. Methods: Retrospective cohort study of 150,086
Kaiser Permanente members, 118 with confirmed endophthalmitis, from 2005
to 2012. Key variables were validated. The logistic regression analysis adjusted for age, year of surgery, ocular and systemic comorbidity, posterior capsular
rupture, and topical antibiotic. Results: Risk on IC cefuroxime was 0.43 per
1000. The odds of endophthalmitis with IC moxifloxacin compared with IC cefuroxime was 1.16 (CI, 0.51-2.65). Conclusion: Cefuroxime and moxifloxacin
are effective intracameral agents.
PA006
11:15 AM
Transzonular Steroid/Antibiotic as Cataract Prophylaxis:

Retrospective Analysis of 2300 Patients
Presenting Author: M Stewart Galloway MD
Co-Author(s): Jeffrey Todd Liegner MD*
Purpose: To evaluate transzonular injection of combined triamcinolone,
moxifloxacin with and without vancomycin to reduce postop inflammation,
to serve as prophylaxis against infection, and to reduce use of topical eye
drops. Methods: Cataract patients from 2006 to 2013 received TriMoxi and
TriMoxiVanc intravitreal injections after IOL implantation, and retrospective
outcomes were assessed: CME rates, IOP, rebound inflammation, infection,
and floaters. Results: Average age, 71.8; CME rate, 1.99% (low- and high-risk
patients, n = 2313); postop IOP, 15 (average POW5 ); rebound inflammation,
3.6% (n = 736); infection, none; floaters, 10.9% (POW5, n = 551). Conclusion:
Intravitreal transzonular antibiotic / steroids concurrent with cataract surgery
* The presenter has a financial interest. ** The presenter has not submitted financial interest disclosure information as of press date.
No asterisk indicates that the presenter has no financial interest.
Original Papers
Sunday, Oct.19
provided significant benefit with minimum risk. Patient acceptance and convenience was high.
3:45 PM to 5:20 PM
Room: E350
PA007
11:32 AM
Single-Center Results of Ocular Sealant Evaluation

Compared With Suture in Preventing Wound Leaks After
Cataract Surgery
Presenting Author: Charles D Reilly MD*
Co-Author(s): William Flynn MD*, Edward R Rashid MD, Robert A Rice MD
Purpose: To evaluate the safety and efficacy of the ReSure Sealant compared
to suture at a single site for wound leak prevention in cataract surgery patients. Methods: Forty Seidel positive wounds (spontaneous or provoked with
a force gauge) received either sealant (n = 24) or suture (n = 16) following
cataract surgery. Wounds were challenged after device application for Seidel.
Results: Prior to device application, 65% of wounds leaked spontaneously
and 97.5% leaked with 0.50 ozf. After treatment, no sealant subjects leaked,
but 31% of suture subjects leaked when provoked. Sixty-nine percent of suture subjects vs. only 33% of sealant subjects experienced transient ocular
adverse events. Conclusion: The ReSure Sealant improved wound resistance
to leaks over suture in this case series.
PA008
11:39 AM
Moderator: William J Fishkind MD FACS

Panel: Kenneth J Rosenthal MD FACS, R Bruce Wallace MD,
Liliana Werner MD PhD
PA025
3:45 PM
Improved Algorithm for IOL Power Calculation in Long or

Short Eyes
Presenting Author: Eric D Donnenfeld MD*
Purpose: To determine the efficacy of a new method of calculating IOL power
in long and short eyes using intraoperative aberrometry. Methods: Mean absolute value of the prediction error (MAVPE) was calculated for 119 short and
189 long eyes and compared to MAVPE for 204 short and 227 long eyes after
optimization of the power calculation algorithm. Results: Prior to the change,
MAVPE was 0.47 D 0.36 D in short and 0.40 D 0.32 in long eyes, with 84%
and 93%, respectively, within 0.75 D of the predicted postop refraction. With
the new algorithm, MAVPE was 0.31 D 0.26 D in short and 0.27 D 0.23 D
in long eyes, with 93% and 97% within 0.75 D. Conclusion: A refined intraoperative aberrometry algorithm improves refractive outcomes in eyes with
unusual axial lengths.
PA026
3:52 PM
American Society of Cataract and Refractive Surgery /

European Society of Cataract and Refractive Surgeons
Survey on Foldable IOLs Requiring Explantation or
Secondary Intervention: 2013 Update
SOE Laser Arcuate Incisions: One-Year Safety and

Effectiveness Data
Presenting Author: Nick Mamalis MD*
Co-Author(s): Michaela Netukova MD
Co-Author(s): Scott Cameron Cole MD MS, Joshua Richard Ford MD, Justin
C Kohl MD**
Purpose: To present results of laser astigmatic keratotomy combined with

cataract surgery. Methods: Laser arcuate incisions were performed by Victus (Technolas Bausch + Lomb) femtosecond laser on 50 eyes with 1 year
follow-up. All patients had corneal astigmatism of 0.5 D -3.0 D. The arc was
positioned at a diameter of 8.5 mm, and depth was 80%. Results: Astigmatism decreasing from -1.8 0.7 D preoperatively to -0.5 0.4 D at 3 months.
Seventy percent of eyes had manifest cylinder of 0.50 D, 83% eyes at 0.75
D, and 94% at 1.0 D. Mean postoperative objective cylinder was -0.3 0.6
D. Conclusion: Our 1-year data was comparable with the published data on
the correction of astigmatism using toric IOLs and better than published data
on manual Aks.
PA027
3:59 PM
Residual Astigmatism After IOL Placement

Presenting Author: Brent Kramer
Co-Author(s): David R Hardten MD*, John P Berdahl MD*
Purpose: Analysis of patients with residual astigmatism after toric IOL placement. Methods: Retrospective review of 4572 patients with residual astigmatism after toric IOL placement. Results: Fifty-two percent of patients had IOLs
currently > 15 from their intended location, 23% between 5 and 15, and
25% < 5. If toric IOLs are rotated to their ideal location, the average residual
astigmatism is reduced from 2.05 D to 0.75 D, 1.49 D to 0.96 D, and 1.48 D
to 1.21 D respectively. The intended toric IOL placement was with-the-rule
in 58% of patients, oblique in 13%, and against-the-rule in 29%. Conclusion: Surgically rotating toric IOLs in patients with residual astigmatism can
significantly decrease the amount of astigmatism. Even when the IOL is in
the intended location, significant residual astigmatism can be present, and
improved by proper rotation
4:06 PM Panel discussion of previous papers

147
Original Papers
Purpose: To survey members of the ASCRS/ESCRS regarding explantation

of foldable IOLs. Methods: Preoperative data and information on the type
and material of IOL requiring explantation were collected. Patients signs and
symptoms as well as complications requiring explantation were tabulated.
Postoperative results were also assessed. Results: Dislocation / decentration was the most common complication associated with 1-piece and 3-piece
acrylic IOLs and 3-piece silicone IOLs. The most common reason for explantation of multifocal IOLs was glare / optical aberrations. Incorrect lens power
was the third most common complication. Calcification / opacification of IOLs
was also infrequently noted. Conclusion: The most common complications
with foldable IOLs were dislocation / decentration, glare / optical aberrations,
and incorrect lens power.
Presenting Author: Pavel Stodulka MD PhD*
Original Papers
PA028
4:16 PM
Influence of Ophthalmic Viscosurgical Devices on

4:47 PM
Presenting Author: Samuel Masket MD*
Refractive Outcomes in Post-refractive Eyes Undergoing

Cataract Surgery With Toric IOL Implantation Guided by
Co-Author(s): Nicole R Fram MD*, Jack T Holladay MD MSEE FACS*
Presenting Author: P Dee G Stephenson MD FACS*
Purpose: To determine whether there is a difference in intraoperative aberrometry IOL power calculation when the anterior chamber is filled with ophthalmic viscosurgical device (OVD) instead of BSS. Methods: Calculated IOL
power was compared for 6 groups of 20 eyes, each undergoing aberrometry at
measured physiologic IOP when the aphakic eye was filled with BSS and then
repeated immediately with 1 of 6 OVDs. Results: Aberrometry-calculated IOL
power is insignificantly different between BSS and 3 tested low molecular
weight low concentration hyaluronate based OVDs. There were statistically
significant differences between OVD and BSS with a chondroitin-hyaluronate
combined OVD and higher concentration pure hyaluronate based agents.
Conclusion: Some, but not all, OVDs are equivalent to BSS for aphakic lens
power calculation.
Purpose: To evaluate outcomes in post-refractive eyes undergoing toric IOL

implantation guided by intraoperative aberrometry. Methods: Twenty postrefractive eyes were implanted with toric IOLs with the aid of intraoperative
aberrometry (ORA with VerifEye, WaveTec Vision) to refine IOL spherical and
cylinder power, and cylinder axis. The ORA prediction error (MAVPE) was compared to the preop lens choice MAVPE. Results: Mean postop manifest astigmatism was 0.25 0.39 D. MAVPE was 0.30 0.23 D with ORA vs. 0.64 0.48
for the calculated preop lens choice (P < .05). The prediction error was 0.50
D in 80% of eyes, with ORA vs. 60% of eyes with the preop lens choice. Conclusion: Intraoperative aberrometry can improve toric IOL power accuracy in
challenging post-refractive eyes.
PA029
Analysis of IOL Calculation Prediction Error in Post-Radial

Keratotomy Patients Undergoing Cataract Surgery
4:23 PM
Correlating OCT With Lens Density and Energy Required

During Cataract Extraction
Presenting Author: Leah Kammerdiener MD
Co-Author(s): George N Magrath MD, Lynn Perry MD PHD**, Rupal H Trivedi
MBBS MS*, Jan A Kylstra MD
Original Papers
PA031
Purpose: To evaluate the role of preoperative macular OCT signal strength in

predicting cataract density. Methods: The OCT signal strength and cataract
grade were recorded for patients with otherwise clear media and the effective phacoemulsification (EPT) and cumulative dissipated energy (CDE) were
recorded for surgical patients. Results: Twenty-one (15 operated) nuclear
sclerotic cataracts and 14 (8 operated) combined cataracts were identified.
Nuclear cataract r-squared value was 0.71 and 0.66 when OCT signal strength
was compared to nuclear color and opalescence. R-squared values were 0.72
and 0.75 when combined cataracts were compared with EPT and CDE. Conclusion: OCT signal strength has a correlation with nuclear cataract grading
and energy required for cataract removal in combined cataracts.
PA030
4:30 PM
Comparison of High Resolution Scheimpflug With OCT

Images in Evaluating Anterior Segment Parameters for
Femtosecond Cataract Surgery
Presenting Author: Harvey S Uy MD*
Co-Author(s): Ajay Pillai MD
Purpose: To compare the clinical utility of high-resolution Scheimpflug (HRS)
with OCT images. Methods: Thirty-seven masked surgeons graded anterior
segment images, generated by 4 different laser systems, according to clinical
parameters. Results: The mean grading scores of HRS images were higher
than those of OCT images with regard to overall image resolution, quality
and ability to define lens layers, lens thickness, and nuclear density. One of
the OCT-based machines was ranked best for ability to define the posterior
capsule. Both modalities were equal with regard to corneal image resolution.
Conclusion: FCS laser images differ in image quality and ability to provide
information about anterior segment anatomy. Overall, the HRS images were
ranked higher than OCT images in majority of evaluated parameters.
148
PA032
4:54 PM
Presenting Author: Stephen F Brint MD*

Purpose: To compare refractive outcomes from a new algorithm for intraoperative aberrometry IOL power calculation in post-radial keratotomy (RK)
eyes to those of the previous calculation algorithm. Methods: Results were
compared from 50 consecutive cases, each with the new algorithm designed
for post 4- or 8-incision RK and the previous algorithm for the ORA system.
Results: The mean absolute value of prediction error with the old algorithm
was 0.54 0.51 D vs. 0.45 0.38 D with the new algorithm. Sixty-eight percent were 0.5 D, and 48% were 0.25 D of the predicted postoperative error
with the new algorithm vs. 58% and 40%, respectively, with the old algorithm.
Conclusion: A new algorithm designed specifically for post 4- and 8-incision
RK improved refractive outcomes better than the previous algorithm.
PA033
5:01 PM
Hoffer H-5 Clinical Results Comparing All Formulas on

6000 Eyes
Presenting Author: Kenneth J Hoffer MD FACS*
Purpose: To evaluate the new H-5 formula (dependent upon race and gender)
with all modern formulas on a very large series of eyes from around the world.
Methods: Months of biometric data collection will produce more than 6000
eyes. The eyes will be calculated using the Barrett, Haigis, Hoffer Q, Holladay
1 and 2, and SRK/T formulas and be compared to those with the new Hoffer
H-5. Results: This being one of the largest such series performed, the results
will compare the MedAE, SD, and range of errors, as well as the % 0.25,
0.50 and 1.00 D prediction. Conclusion: With such a large series, the results will show statistically which formulas are more accurate in predicting
IOL power, as well as showing which are more accurate based on AL and
corneal power.
PA034
5:08 PM
Diagnostic Intraoperative OCT for the Prediction of

Postoperative Lens PositionDuring Femtosecond
Refractive Laser-Assisted Cataract Surgery
Presenting Author: Joseph J Ma MD*
Purpose: To predict postoperative lens position (PLP) from algorithm-derived
intraoperative OCT (AD-iOCT) to improve refractive outcomes. Methods: In
a retrospective review of 50 eyes, AD-iOCT was compared to theoretical PLP
Original Papers
(T-PLP) calculated from preop biometry and postop measured, manually validated PLP (MV-PLP). Correlation coefficients, t tests, and Bland Altman plots
were obtained. Results: Average follow-up: 93 days (SD: 30). Average MVPLP: 5.04 mm (SD: 0.30). Average AD-iOCT derived PLP: 5.00 mm (SD: 0.43), r =
0.59 (P < .01). Average 5 variable preop biometry-based T-PLP: 5.62 (SD: 0.56),
r = 0.28 (P = .22). Pachymetry, anterior chamber depth, and lens thickness by
AD-iOCT had r = 0.88, r = 0.91 and r = 0.93, respectively, vs. biometry, with P
< .01 for all metrics. Conclusion: AD-iOCT data can more accurately predict
actual MV-PLP than preop biometry-based T-PLP, which may help improve refractive outcomes.

Sunday, Oct. 19
3:30 - 5:30PM
Room: S405
Moderator: Shahzad I Mian MD
Panel: Sophie X Deng MD PhD, Anat Galor MD, Vincenzo Sarnicola MD
PA015
3:30 PM
Midterm Results of Descemet Membrane Endothelial
Keratoplasty: Six-Year Clinical Outcomes
SOE
Presenting Author: Fook Chang Lam MBChB

Co-Author(s): Maria Satue MD, Lisanne Ham PhD, Gerrit RJ Melles MD PhD*
3:37 PM Panel discussion of previous paper
PA016
3:42 PM
Comparative Study of Long-term Graft Survival Between

Full-Thickness and Partial Thickness Corneal Transplants
Presenting Author: Anshu Arundhati MD
Co-Author(s): Jodhbir S Mehta MBBS PhD*, Stephanie S Lang MS, Donald
Tan MD FRCS FRCOphth*
Purpose: To compare 5-year graft survival between penetrating keratoplasty
(PK), Descemet-stripping automated endothelial keratoplasty (DSAEK), and
deep anterior lamellar keratoplasty (DALK) for optical indications. Methods:
1242 primary grafts were analyzed. Kaplan-Meier survival curve was generated to compare graft survival. Results: Pseudophakic bullous keratopathy was
the most common diagnosis for PK and DSAEK, and keratoconus was the most
common for DALK. The overall graft survival rates for PK, DSAEK, and DALK
were 94.3%, 96.7%, and 96.3%, respectively, at 1 year and 70.7%, 77.3%,
and 93.1%, respectively, at 5 years. Glaucoma and rejection were significantly
lower in the lamellar group. Conclusion: Long-term graft survival is better
in DSAEK and DALK than in PK, with lowered risk of rejection and glaucoma.
3:54 PM
Eye Bank-Prepared Preloaded Grafts Can Be Successfully

Used for Descemet Stripping Endothelial Keratoplasty
Presenting Author: Sotiria Palioura MD
Co-Author(s): Kathryn A Colby MD PhD*
Purpose: To assess the feasibility of Descemet-stripping endothelial keratoplasty (DSEK) using preloaded donor tissue. Methods: Thirty-five eyes had
DSEK with tissue that was precut, trephined, loaded into EndoGlide Ultrathin inserters at the Lions Eye Institute (Tampa, Fla.), and shipped overnight
in storage media. Complications and postoperative endothelial cell density
(ECD) were reviewed. Results: There was 1 primary graft failure (2.8%), 2 rebubblings (5.7%), and 1 graft rejection (2.8%). Mean preoperative donor ECD
was 2859 227 cells/mm2. At 3 months, mean ECD was 2041 505 (cell loss:
28.9% 15.6%). At 6 months, mean ECD was 2148 469 (cell loss: 24.5%
16.6%). Conclusion: Eye bank-prepared preloaded tissue can be successfully used for DSEK without undo surgical complications or endothelial cell loss.
PA018
4:06 PM
Descemet Membrane Endothelial Keratoplasty: Early
Complications and 6-Month Endothelial Cell Loss in a
Comparative Series of Unstamped and Stromal Sided
S-Stamped Tissue in 101 Consecutive Cases
Presenting Author: Peter B Veldman MD
Co-Author(s): Zachary Mayko MS, Michael D Straiko MD*, Mark A Terry MD*
Purpose: To compare outcomes in Descemet membrane endothelial keratoplasty (DMEK) cases performed with and without a stromal sided S-stamp to
aid tissue orientation. Methods: A series of 101 consecutive cases of DMEK
were performed utilizing 32 unstamped and 69 S-stamped grafts. Outcomes
compared included rebubble and iatrogenic primary graft failure (iPGF) rates,
6-month endothelial cell loss (ECL), and visual acuity (BSCVA). Results: Rebubbles were performed in 1/32 unstamped vs. 6/69 S-stamped cases (p =
.43), and iPGF occurred in 3/32 unstamped vs. 0/69 S-stamped cases (p =
.028). Preliminary 6-month ECL was 27% 13% (n = 21) in the unstamped,
vs. 30% 21% (n = 9) in the S-stamped group (p = .67). Conclusion: The
introduction of the S-stamp eliminated iPGF in this series without a statistically significant change in rebubble rate or ECL to date, pending BCVA data.
PA019
4:18 PM
SOE Endothelial Cell Changes as an Indicator for Allograft

Rejection Following Descemet Membrane Endothelial
Keratoplasty
Presenting Author: Maria Satue MD

Co-Author(s): Fook Chang Lam MBChB, Claire Monnereau MS, Gerrit RJ
Melles MD PhD*
Purpose: To report early changes in endothelial cell (EC) morphology as a
predictor for allograft rejection after Descemet membrane endothelial keratoplasty (DMEK). Methods: Out of 500 DMEK eyes, 8 developed an allograft
rejection. Specular microscopy images were analyzed and compared with 49
asymptomatic DMEK eyes. EC morphology was evaluated by subjective scoring and objective comparison. Results: Subjective scores and EC density differed from control eyes before and after rejection, while hexagonality only
differed before rejection. Conclusion: Allograft rejection may not be an acute

149
Original Papers
Purpose: To evaluate the midterm outcomes of Descemet membrane endothelial keratoplasty (DMEK). Methods: In 300 eyes, DMEK was performed for
endothelial dysfunction. BCVA and endothelial cell density (ECD) were documented before and up to 6 years after DMEK, as were postoperative complications. Results: At 6 months postoperative, 97% of eyes reached a BCVA of
20/40, and 79% reached 20/25, which remained stable for up to 6 years.
ECD decreased 35% in the first half-year after surgery, followed by an annual
decrease of 9%. Longer term complications were allograft rejection (2%) and
late-onset graft failures (0.7%). Conclusion: DMEK provides a fast and often
complete visual recovery, with an acceptable ECD remaining stable up to 6
years after surgery. Complications are rare after the first 6 months.
PA017
Original Papers
event, but rather a slow-onset immune response, and early, specific changes
in EC morphology may announce an upcoming allograft rejection.
PA020
4:30 PM
Diagnostic Performance of Descemet Membrane

Thickness vs. Central Corneal Thickness in Active Cornea
Graft Rejection
Presenting Author: Mohamed F Abou Shousha MD*
PA023
Co-Author(s): Ravi Shah, Sean L Edelstein MBChB, Matthew D Council MD,

Rocio Bentivegna, George Harocopos MD, Sonia H Yoo MD*, Victor L Perez
MD*
Transepithelial vs. Epithelium-off Corneal Collagen

Crosslinking for Progressive Keratoconus
Purpose: To evaluate diagnostic performance of Descemet membrane thickness (DMT) in comparison with central corneal thickness (CCT) in active corneal graft rejection. Methods: Forty-two grafts (27 controls and 15 actively
rejecting) were imaged using OCT to measure DMT and CCT. Results: Actively
rejecting grafts had significantly thicker CCT and DMT than controls (570 vs.
520 m, P = .03 and 27 vs. 17 m, P < .0001). DMT receiver operating characteristic curve showed very high predictive accuracy (area under the curve, or
AUC, = 0.97) that was significantly higher (P < .001) than CCT (AUC = 0.65).
DMT was 100% sensitive and 89% specific (optimal cutoff = 20 m), while
CCT was 73% sensitive and 59% specific (optimal cutoff = 550 m). Conclusion: DMT has very high predictive accuracy, sensitivity, and specificity in
diagnosing active corneal graft rejection, which are significantly better than
CCT.
Co-Author(s): Salman Fawaz Alfayez MBBS
PA021
4:42 PM
Prophylactic Povidone-Iodine Rinses and Topical

Amphotericin B Significantly Reduce Postoperative
Infections After Boston Type I Keratoprosthesis
Original Papers
thelial defects (14/32), sterile melt (12/32), and microbial keratitis (11/32).
There was clinical association between the inability to retain bandage contact
lens (BCL) and surface complications. Tarsorrhaphy was the most frequent
procedure done. In spite of the complications, the anatomical retention was
43.8% at mean follow-up of 21.8 14.6 months. Conclusion: Ocular surface
complications are mainly due to the inability to retain the BCL, but the keratoprosthesis is retained if appropriately managed.
Presenting Author: Jeffrey D Welder MD
5:06 PM
Presenting Author: Mashhoor F Al Fayez MD

Purpose: To compare the safety and efficacy of transepithelial corneal crosslinking to that of epithelium-off corneal crosslinking for progressive keratoconus. Methods: In a prospective clinical trial, 70 patients with progressive
keratoconus were randomized to undergo corneal crosslinking with intact
epithelium (n = 34) or after de-epithelialization (n = 36). The main outcome
measure was change in maximum K reading. Results: With a 3-year followup, K-max decreased in the epithelium-off group with a mean of 2.4 D and no
patient showed evidence of progression. In the transepithelial group, K-max
increased by a mean of 1.1 D and 20 patients (55%) showed progression of
keratoconus. Conclusion: In this study, epithelium-off was significantly more
effective than transepithelial corneal crosslinking in halting progression of
keratoconus (P < .0005).
PA024
5:18 PM
Bowman Layer Implantation to Reduce and Stabilize

Advanced Progressive Keratoconus
Presenting Author: John Steven Parker MD
Co-Author(s): Michael D Wagoner MD, Anna S Kitzmann MD, Kenneth M

Goins MD**, Mark Greiner MD
Co-Author(s): Korine van Dijk OD, Maria Satue MD, Gerrit RJ Melles MD
PhD*
Purpose: To compare the incidence of infection in Boston type I keratoprosthesis (Kpro-1) when using vancomycin and fluoroquinolone alone with the
incidence when using additional quarterly povidone-iodine fornix rinses or additional topical amphotericin B. Methods: Seventy-nine eyes were reviewed
in 3 groups: (1) vancomycin and a fluoroquinolone, (2) additional povidoneiodine, (3) additional povidone-iodine and amphotericin B. Results: The incidence of infection was 0.13/year in Group 1 (12 infections: 4 keratitis, 8 endophthalmitis), 0.09/year in Group 2 (4 infections: 3 keratitis, 1 endophthalmitis),
and 0.01/year in Group 3 (1 culture-negative keratitis) (P < .05). Kpro-1 loss
occurred in 35.3% of eyes with postoperative infections (P = .0002). Conclusion: Additional quarterly povidone-iodine and amphotericin B significantly
reduces postoperative infections in KPro-1.
Purpose: To evaluate the efficacy of Bowman layer (BL) implantation in

reducing and stabilizing corneal ectasia in eyes with advanced progressive
keratoconus (KC). Methods: Twenty-two eyes of 19 patients with progressive KC, ineligible for UV-crosslinking, underwent midstromal implantation of
an isolated BL and were followed for a mean of 21 (7) months. Results:
No complications related to BL implantation were observed. Average maximum corneal power decreased from 72.7 (6.4) D to 67.2 (5.2) D (P = .001)
6 months postoperatively and remained stable thereafter (P = .335). Twelve
months postoperatively, mean BSCVA had improved significantly (P < .001).
Conclusion: BL implantation may be safe and effective in treating ectasia
in advanced KC.
PA022
4:54 PM
Ocular Surface Complications after Boston Type I

Keratoprosthesis
Presenting Author: Shraddha Sureka MBBS MS
Co-Author(s): Sayan Basu MBBS**, Virender S Sangwan MBBS
Purpose: To describe ocular surface complications after Boston type I keratoprosthesis. Methods: Retrospective case series of 81 procedures. Results:
Thirty-two of 81 procedures developed surface complications, including epi150
Original Papers
Monday, Oct. 20
18.2% (median survival: 7 months). Conclusion: PK with SLET is a viable option in extensive stromal scarring or perforation.
2:00 - 3:30 PM
Room: S405
Moderator: Bennie H Jeng MD

Panel: Darren G Gregory MD, Charles C Lin MD, Jennifer R Rose-Nussbaumer MD
PA040
2:00 PM
Ocular Graft Versus Host Disease: Ten Years Experience

Presenting Author: Xihui Lin MD
Co-Author(s): H Dwight Cavanagh MD PhD FACS*
Purpose: To evaluate the presentation, treatment, and course of ocular graft
versus host disease (GVHD). Methods: 230 patients with GVHD (2003-2013)
were reviewed. Results: Sixty-one patients (26.5%) had ocular involvement.
Mean age was 51.1 years and latency of 21.3 months. The most common presentations were keratoconjunctivitis sicca (KCS), cataract, blepharitis, ocular
hypertension, and filamentary keratitis. 44.8% of the patients presented with
a visual acuity of 20/50 or worse; 45.0% had visual acuity worse than 20/100
at some point during follow-up. KCS was controlled with tears alone in only
6.3% of the patients; the rest required topical cyclosporine (59.4%), steroids
(31.3%), autologous serum (34.4%), and/or a bandage contact lens (21.9%).
Conclusion: Many patients with GVHD suffered from severe KCS requiring
early aggressive therapy.
2:12 PM
Prosthetic Replacement of the Ocular Surface Ecosystem

(PROSE) for Ocular Graft Versus Host Disease
Presenting Author: Hassan Nasir Tausif
Co-Author(s): Karen DeLoss OD, Taylor Blachley MS, Shahzad I Mian MD*
SOE Aganirsen Antisense Oligonucleotide Eye Drops

Inhibit Keratitis-Induced Corneal Neovascularization and
Reduce Need for Transplantation: The I-CAN Study
Presenting Author: Claus Cursiefen MD*

Objective To investigate the antiangiogenic effect of aganirsen eye drops on
corneal neovascularization. Methods: Multicenter, double-masked, randomized, placebo-controlled Phase 3 study including 69 patients with keratitisrelated progressive corneal neovascularization. Results: Aganirsen significantly reduced the relative corneal neovascularization (P = .014). Conclusion:
This first Phase 3 study on a topical inhibitor of corneal angiogenesis showed
aganirsen eye drops to significantly inhibit corneal neovascularization and to
reduce the need for transplantation in patients with viral keratitis and central
neovascularization.
PA044
2:48 PM
Tacrolimus in Vernal Keratoconjunctivitis
2:24 PM
Penetrating Keratoplasty and Simple Limbal Epithelial

Transplantation: Clinical Outcomes
Co-Author(s): Sayan Basu MBBS**, Virender S Sangwan MBBS
Purpose: To describe outcomes of simple limbal epithelial transplantation
(SLET) with penetrating keratoplasty (PK) for limbal stem cell deficiency
(LSCD). Methods: Retrospective case series. Results: Of 154 SLET procedures from 2010 to 2013, 8 patients underwent simultaneous PK. Two patients
each needed therapeutic PK and repeat SLET. Four of 8 grafts survived, and 5/8
patients had a stable ocular surface at mean follow-up of 11.6 12.0 months
(median: 7.9 months). Kaplan-Meier graft survival rate at 6 months was 60
Co-Author(s): Mahmoud O Jaroudi MD, Khalid F Tabbara MD*

Purpose: To study topical tacrolimus 0.01% eyedrop effects in patients with
vernal keratoconjunctivitis (VKC) not responding to conventional therapy.
Methods: We included 32 consecutive patients with VKC. Each patient underwent complete ophthalmologic examination and scrapings for cytology.
Patients were placed on tacrolimus 0.01% eyedrops. Results: There were 26
males and 6 females, with an age range of 5-36 years (mean age: 16 years).
Twenty six out of 32 patients (81%) had improvements in itching, redness, and
discharge. Thirty out of 32 patients (93%) had improvement in ocular surface
temperature, keratitis, and limbal infiltrates. Conclusion: Tacrolimus 0.01%
eyedrops is effective in severe VKC.
PA045
3:00 PM
The Corneal Ulcer One-Touch Study: A Simplified

Microbiological Specimen Collection Method
Presenting Author: Kaivon Pakzad-Vaezi MD
Co-Author(s): Steve D Levasseur MD, Steven Schendel MD, Richard G
Mathias MD, Diane Roscoe MD, Simon P Holland MD*
Purpose: To determine if a new, single-sample method can simplify infectious keratitis culturing. Methods: Eighty-one consecutive corneal ulcers
received the one-touch ESwab and the traditional multisample method with
randomized order. The laboratory was blinded to the two methods. Results:
Culture positivity rate for the multisample method and ESwab was 70% and
69%, respectively, with a 75% agreement rate. ESwab sensitivity was 84%
(95% CI, 72%-93%), with a specificity of 67% (95% CI, 45%-84%). Positive
and negative predictive values were 86% (95% CI, 74%-94%) and 64% (95%
CI, 43%-82%), respectively. There was no difference between sampling order. Conclusion: The single-sample ESwab is comparable to the traditional
method and is more accessible to community ophthalmologists in the workup
of corneal ulcers.
151
Original Papers
Purpose: To assess the utility of PROSE as adjunct treatment in patients with

ocular graft versus host disease. Methods: Retrospective series measuring
degree of symptoms as predicted by the Ocular Surface Disease Index (OSDI)
prior to undergoing PROSE treatment was conducted. BCVA was measured at
initial consult and compared to BCVA after final fitting. Differences in OSDI
and BCVAs were measured for statistical significance (paired t test; a = 0.01;
N = 18). Results: 100% (N = 18) of patients with complete follow-up history
showed decline in OSDI (P = .003). Mean decline measured at 46.14 (SD =
22.03) (Range: -15.91 to -89.58). BCVA demonstrated mean decrease in logMAR of 0.1721 (p = .001) / 0.1657 (P = .005) O.D./O.S., respectively. Conclusion: Patients who underwent PROSE treatment demonstrated reduction in
dry eye symptoms as demonstrated using a standard measurement (OSDI).
PA042
2:36 PM
Presenting Author: Samir S Shoughy MD
PA041
PA043
Original Papers
PA046
3:12 PM
SOE Deep Anterior Lamellar Keratoplasty in Acanthamoeba

Keratitis
Presenting Author: Caterina Sarnicola

Co-Author(s): Vincenzo Sarnicola MD
Purpose: To report our experience with deep anterior lamellar keratoplasty
(DALK) in Acanthamoeba keratitis (AK). Methods: Two years follow-up cases
series report of 12 patients with AK: 9 eyes with controlled infection and 3
eyes with active infection unresponsive to medical treatment (10 days of therapy with chlorexidine gluconate, propamidine isethionate, neomycin sulfate).
Results: Nine descemetic DALK and 3 predescemetic DALK were obtained.
No Descemet ruptures occurred. Postoperative anti-amoebic therapeutic protocol was prescribed. No episode of rejection or recurrence of the infection
was recorded. BSCVA average was 17/20 (range: 14-20/20). Conclusion:
DALK is a good procedure for restoring vision in cases with significant corneal
scarring. It should also be considered as an early indication for cases with
active infection unresponsive to medical therapy.
Glaucoma
Monday, Oct. 20
2:00 - 5:30 PM
Room: S404
Moderator: Julia Agapov DO
Panel: Steven L Mansberger MD MPH, Paul F Palmberg MD PhD, Jody R PiltzSeymour MD
Original Papers
PA047
2:00 PM
Reading Performance in Glaucoma Patients With 20-20

Visual Acuity
the IOP data of 1 eye per case per month from 1116 POAG patients (29,842
eyes) and 1423 NTG patients (27,837 eyes) from January 1997 to December
2012 and then plotted the data. An IOP regression line of POAG and NTG
was then made, and each reduction slope (RS) was statistically compared.
Results: Yearly POAG and NTG seasonal IOP variation was maintained and
gradually decreased over 16 years. The IOP RS was -0.18 mmHg/year in POAG
and -0.14 mmHg/year in NTG. Conclusion: In both POAG and NTG, IOP gradually decreased over 16 years with seasonal variation, and its RS was significantly steeper in POAG than in NTG.
PA049
2:24 PM
Influence of Lamina Cribrosa Thickness and Depth on the

Rate of Progressive Retinal Nerve Fiber Layer Thinning
Presenting Author: Eun Ji Lee MD
Co-Author(s): Tae-Woo Kim MD PHD*, Hyunjoong Kim PHD, Seung Hyen Lee
MD
Purpose: To investigate whether the lamina cribrosa thickness (LCT) and
depth (LCD) are associated with a faster rate of progressive retinal nerve fiber
layer (RNFL) thinning in open-angle glaucoma (OAG). Methods: Optic nerves
of 110 OAG patients were scanned using enhanced depth imaging spectral domain OCT. The LCT and LCD were measured in the B-scan images in each eye.
The rate of RNFL thinning was determined by linear regression of serial OCT
RNFL thickness measurements against time. Results: Greater RNFL thickness
(P = .008), larger LCD (P = .002), and smaller LCT (P = .047) were associated
with a faster rate of RNFL thinning both in the univariate and multivariate
analysis. Conclusion: Thinner LC and greater LC displacement had a significant influence on the rate of progressive RNFL thinning.
PA050
2:36 PM
Presenting Author: Aron B Guimaraes MD
Lamina Cribrosa Posterior Bowing in Eyes of Primary

Open-Angle Glaucoma: Swept Source OCT Study
Co-Author(s): Vital Paulino Costa MD*, Keila M Monteiro de Carvalho MD
Presenting Author: Yong-Woo Kim MD
Purpose: To investigate the influence of visual field defects on the reading

performance of patients with primary open-angle glaucoma (POAG). Methods: Data were collected from 35 POAG patients and 35 age-matched controls, all with 20/20 visual acuity. The following parameters were measured
during monocular reading using the MNREAD chart: maximum reading speed
(MRS), critical print size (CPS), and reading acuity (RA). Results: Mean MRS
in the POAG group (125.04 38.36 words per minute) was significantly lower
than in the control group (183.95 15.54) (P = .001). MRS correlated significantly with visual field mean deviation (r = 0.954, P = .01) in the POAG group.
Conclusion: Glaucoma patients with normal visual acuity show an impairment in reading performance that correlates with the severity of the visual
field defect.
Co-Author(s): Jin Wook Jeoung MD*, Ki Ho Park MD*, Dong Myung Kim MD
PA048
2:12 PM
Purpose: Quantitative evaluation of the lamina cribrosa (LC) posterior bowing

in primary open-angle glaucoma (POAG) eyes. Methods: Optic discs of 77
POAG eyes and 77 age-matched normal eyes were scanned by swept source
OCT. LC vault, defined by the difference between mean LC depth and mean
anterior laminar insertion depth, was measured at each horizontal and vertical B-scans (reference plane, Bruch membrane openings). Humphrey visual
field (VF) tests were performed. Results: The POAG eyes showed significantly
larger horizontal (78.69 43.80 vs. 59.56 63.04, P = .030) and vertical (45.80
45.24 vs. 26.59 38.78, P = .005) LC vault compared to controls. Only vertical
LC vault was associated with increased mean deviation of VF (Beta = - 0.020,
P = .038). Conclusion: Vertical LC vault was increased in POAG eyes and
reflected functional severity.
Evaluation of IOP and Reduction Slope Over a 16-Year

Time Course in Japanese Glaucoma Patients
Presenting Author: Yoko Ikeda MD
Co-Author(s): Kazuhiko Mori MD*, Morio Ueno MD*, Kojiro Imai MD, Kengo
Yoshii PHD, Masakazu Nakano PHD
Purpose: To evaluate IOP and reduction slope over a 16-year time course
based on accumulated primary open-angle glaucoma (POAG) and normaltension glaucoma (NTG) data in our original database. Methods: We selected
152
Original Papers
PA051
2:48 PM
SOE Validation of a Polymorphism Associated With

Latanoprost Response in White and Japanese Populations
Presenting Author: Fernando Ussa-Herrera MD*

Co-Author(s): Itziar Fernandez, Maria Brion PHD, Angel Carracedo, Ana
Sanchez-Jara MD, Lourdes Juan PHD, Soledad Jimenez-Carmona MD,
Ramon Juberias MD, Jose Maria Martinez de La Casa MD*, Francisco
Blazquez-Arauzo MD MS**, J Carlos Pastor MD PhD
Purpose: External validation of a single nucleotide polymorphism (SNP),
rs3753380, previously associated with reduced latanoprost response in Japanese (JPN) patients, in a white European (wEU) sample of primary open-angle
glaucoma (POAG) patients. Methods: Genotyping (Iplex assay) was performed
in 117 POAG patients treated with latanoprost during > 4 weeks. Statistical
multiple comparison tests were performed and association evaluation was
done with contingency tables analysis and odds ratio (OR) estimation. Results: PTGFR gene SNP rs3753380 increases around 3 times (OR: 3.1938; 95%
CI: 9.4696-1.0756) the possibility of a negative latanoprost response in wEU
POAG patients. Conclusion: SNP rs3753380 may also determine latanoprost
response in wEU POAG patients.
PA052
3:00 PM
A Novel Imaging Device for Monitoring Patient Eye Drop

Installation Technique and Compliance at Home and in
Clinic
Presenting Author: Alexander M Eaton MD*
Co-Author(s): Gabriel Gordon PHD*, Adam Sgarlata, Hussein Wafapoor MD*,
Robert L Avery MD*
PA053
3:12 PM
Predicting Glaucomatous Visual Field Damage With

Fourier Domain OCT in the Advanced Imaging for
Glaucoma Study
Presenting Author: David Huang MD PhD*
Co-Author(s): Xinbo Zhang PHD**, Nils A Loewen MD*, Ou Tan PHD*, Brian
A Francis MD*, Rohit Varma MD MPH*, David S Greenfield MD*, Joel S
Schuman MD*
Purpose: To predict the onset of glaucomatous visual field (VF) damage using
Fourier-domain OCT (FD-OCT). Methods: Glaucoma suspect and pre-perimetric glaucoma (GS-PPG) eyes were assessed every 6 months. Disc, retinal nerve
fiber layer, and ganglion cell complex (GCC) were mapped by FD-OCT. Conversion to perimetric glaucoma (PG) was confirmed when 3 consecutive VF tests
were abnormal. Results: After a mean 52 months of follow-up, 55 of 515
GS-PPG eyes converted to PG. By Cox regression, most OCT variables were
PA054
3:24 PM
Estimated Rates of Retinal Ganglion Cell Loss in

Glaucomatous Eyes With and Without Optic Disc
Hemorrhages
Presenting Author: Carolina P B Gracitelli MD
Co-Author(s): Andrew J Tatham MBChB*, Ting Liu MD PHD, Linda Zangwill
PhD*, Robert N Weinreb MD*, Felipe A Medeiros MD*
Purpose: To evaluate whether disc hemorrhages are associated with faster
rates of estimated retinal ganglion cell (RGC) loss in glaucoma. Methods:
222 eyes of 122 patients were followed for 3.74 0.85 years. Serial OCT,
standard automated perimetry, and stereophotography were performed. RGC
counts were estimated from structural and functional tests using previously
described formulas. Results: Nineteen eyes had at least 1 disc hemorrhage
during follow-up. A random coefficient model found eyes with disc hemorrhages had faster rates of estimated RGC loss (P = .020). Conclusion: Disc
hemorrhages in glaucoma are a risk factor for progression and are associated
with faster rates of estimated RGC loss.
PA055
3:36 PM
Functional Measures as Surrogates for Vision-Related

Quality of Life in Patients With Glaucoma
Presenting Author: Sachin Jain MD
Co-Author(s): Vy Nguyen, Jessica Liloong Liu, Krishna Patel, J Jason
McAnany MA PHD, Jacob Wilensky MD, Ahmad A Aref MD*, David Scott
Hillman MD*, Thasarat S Vajaranant MD*
Purpose: To determine which clinical measures best correlate with visionrelated quality of life measures in glaucoma patients. Methods: We recruited
22 patients with primary open-angle glaucoma and visual acuity (VA) 20/40.
VA, Humphrey 24-2 visual fields, contrast sensitivity, and National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) results were analyzed in
the eye with better mean deviation. Results: Controlling for age and VA, patients with a higher pattern standard deviation (PSD) reported worse distance
vision (r = -0.8, P = .001) and driving (r = -0.8, P = .002), while patients with a
lower visual field index (VFI) reported worse distance vision (r = 0.8, P = .003)
and color vision (r = 0.8, P = .001). Conclusion: This suggests that PSD and VFI
could be used as surrogates for vision-related quality of life.
PA056
3:48 PM
Changes in Glaucoma Procedural Volume Following

Reductions in the Medicare Payment Schedules
Presenting Author: Dan Gong
Co-Author(s): Jun Lin PHD, James C Tsai MD MBA*
Purpose: To calculate Medicare payment-procedural volume elasticities for
laser trabeculoplasty (CPT 65855), trabeculectomy (CPT 66170 and 66172),
aqueous shunt to reservoir (CPT 66180), laser iridotomy (CPT 66761), and
scleral reinforcement with graft (CPT 67255). Methods: Fixed-effects regression model using 2005-09 Medicare Part B Carrier data for all 50 states, controlling for national trends in procedural volume, Medicare beneficiary popula-
153
Original Papers
Purpose: To develop a compact imaging device to allow physicians to personalize therapeutic regimens based on a better understanding of patient compliance and eye drop technique. Methods: A novel imaging system was used to
record video of the drop technique of subjects in the clinic (n = 18) or at home
(n = 6) for 1 week. Video assessment by a reading center was compared to
patient reporting of how many drops were applied and how many landed in
the eye. Results: Reading center assessment of both attempted drops and
drops in was significantly different from the prescribed regimen in the clinical
(pa = 0.03, pi < 0.001) and at-home arms (pa = 0.03, pi = 0.005). Conclusion:
This imaging system is a powerful tool to help physicians tailor therapeutic
decisions more accurately for each patient and can help researchers evaluate
new drop therapies.
significant risk factors, the best of which was the GCC focal loss volume (FLV,
P < .001). Abnormal or borderline GCC FLV increased conversion risk 4-fold at
6 years. Conclusion: FD-OCT may be useful in the prognostic evaluation of
glaucoma suspects.
Original Papers
tion, number of ophthalmologists, and income per capita. Results: Every 1%
decrease in Medicare payment was associated with significant increases in
procedural volume for CPT 65855 (+0.78%, P = .009), CPT 66761 (+1.04%, P
< .001), and CPT 67255 (+4.19%, P = .005). Conclusion: Reductions in Medicare payment may lead to increased procedural volume for certain glaucoma
procedures.

Moderator: Shan C Lin MD
Panel: Husam Ansari MD PhD, Nathan M Radcliffe MD, Mark B Sherwood MD
PA057
4:05 PM
Cataract Surgery Combined With Trabecular Micro

Bypass Stent Implantation in Patients With Open-Angle
Glaucoma, 1 Year Follow-up
Presenting Author: George Beiko MD*
Original Papers
Purpose: To determine IOP control following combined cataract surgery and

trabecular micro bypass stent implantation. Methods: Retrospective analysis
of the first 100 patients with medically controlled open-angle glaucoma (OAG),
following combined trabecular micro bypass stent implantation and cataract
surgery. Results: All patients received 1 stent except for 11, who received 2.
The preop IOP was 16.767 3.837 mm Hg; there was a statically significant
decrease to 15.310 2.776 mmHg (P = .004) at 6 months; the IOP remained at
the same level at 12 months, 15.885 3.307 mm. There was a statistically significant decrease in the number of topical glaucoma meds at 6 and 12 months
(P = .000). Conclusion: Trabecular micro bypass stent implantation combined
with cataract surgery results in a decrease in topical glaucoma medications.
(PACG). Methods: We retrospectively reviewed 103 subjects with PAC or

PACG who underwent cataract surgery. IOL power was calculated with various
formulas. The errors according to biometric factors were evaluated. Measurements included 2 novel parameters: relative lens vault (rLV), ratio of LV to anterior vault (AV), and AV, sum of LV and anterior chamber depth. Results: Eyes
with PAC or PACG showed significant hyperopic result (P < .05). The Hoffer Q
formula had the least prediction error (P = .043). Prediction error was positively
correlated with rLV (P < .01). Conclusion: Preoperative rLV can be a key factor
predicting unstable refractive outcome in patients with PAC or PACG.
PA060
4:41 PM
Glaucoma-Related Adverse Events After Cataract

Removal in Infancy: Outcomes at Age 5 in the Infant
Aphakia Treatment Study (IATS)
Presenting Author: Sharon F Freedman MD
Co-Author(s): Allen Dale Beck MD*, Michael J Lynn MS*, Scott R Lambert
MD*
Purpose: To report prevalence of glaucoma (G) and glaucoma suspect (GS) after unilateral cataract surgery (CE) with/without primary (IOL) vs. contact lens
(CL). Methods: 114 children were randomized (n = 57 each group). G = IOP >
21 mmHg with IOP-related anatomic changes or glaucoma surgery; GS = IOP
> 21 x 2 visits without anatomic changes or glaucoma medication. Results:
Prevalence of G vs. G+GS was 20 (18%) vs. 36 (32%), and similar CL vs. IOL
groups (P > .05) @ mean 4.8 years post-CE. Younger age at surgery (28-48 vs. >
49 days) and smaller corneal diameter (< 10 mm vs. 10 mm) conferred higher
risk of G+GS (P = .005 and P = .002, resp.). Conclusion: Risk of G+GS rises
after cataract removal in infancy, with/without primary IOL. Longer follow-up
will better define this complication.
PA058
SOE
PA061
Presenting Author: Magda Rau*
A Randomized Study of a Schlemm Canal Microstent in

Combination With Phacoemulsification for IOP Reduction
in Open-Angle Glaucoma
4:17 PM
Supraciliary Microstent Implantation in Combination
With Cataract Surgery in a Single Center: The Cham
Experience
Co-Author(s): Tsontcho Ianchulev MD*
Purpose: To evaluate the ab interno supraciliary implant (CyPass Micro-Stent,
Transcend Medical) in patients with open-angle glaucoma undergoing cataract surgery at a single center in Cham, Germany. Methods: The device was
implanted after cataract surgery. Adverse events, IOP, and number of IOP-lowering medications were the main outcomes evaluated through the follow-up
period. Results: Baseline mean IOP (n = 24) was 22.3 6.6 mmHg, and mean
number of IOP-lowering medications was 1.8 1.2. All implants were placed
successfully, with no major sight-threatening adverse events. At Month 12 (n
= 17), mean IOP was 15.0 3.4 mmHg with mean medication usage reduced
to 0.7 1.0. Conclusion: CyPass Micro-Stent implantation with cataract surgery results in minimal complications and reduction of IOP and IOP-lowering
medications at 1 year.
PA059
4:29 PM
Factors Affecting Refractive Outcome After Cataract

Surgery in Primary Angle-Closure Glaucoma
Presenting Author: Thomas W Samuelson MD*

Co-Author(s): Norbert Pfeiffer MD*, Julian Garcia-Feijoo MD PhD**, Hans G
Lemij MD**, Jose M Larrosa MD**, Stefano A Gandolfi MD*, Antonio Fea
MD, Oliver Schwenn MD**
Purpose: To compare the ability of a microstent (Hydrus) to lower IOP in openangle glaucoma (OAG) when combined with phacoemulsification to phacoemulsification alone. Methods: 100 subjects with OAG and cataract were
recruited from 7 centers. Prior to surgery subjects were randomized 1:1 into
phaco + microstent or phaco only treatment groups. Subjects were followed
for 18 months post operatively. Results: At 18 months follow-up, medication use was reduced by 57% (P = 0.015) and a med-free IOP of 21 mmHg
was reached in 80% in the treatment group vs. 48% in the control (P < .05).
There were no significant safety events in either group. Conclusion: An intracanalicular microstent reduces IOP and medication use in combination with
phacoemulsification.
Presenting Author: Sam Seo MD

Co-Author(s): Jin Wook Jeoung MD*, Dong Myung Kim MD, Ki Ho Park MD*
Purpose: To evaluate biometric factors associated with IOL power predictions
in eyes with primary angle closure (PAC) or primary angle-closure glaucoma
154
4:53 PM
Original Papers
PA062
5:05 PM
One-Year Results of Supraciliary Microstent Implantation

in Patients Refractory to Topical Glaucoma Therapy
Presenting Author: Quang H Nguyen MD*
Co-Author(s): Julian Garcia-Feijoo MD PhD**, Gunther Grabner MD*, Herbert
A Reitsamer MD**, Swaantje Grisanti MD*, Salvatore Grisanti*
Purpose: To assess the safety and clinical outcomes of supraciliary (SC) microstent implantation as a treatment for open-angle glaucoma (OAG) in patients refractory to topical glaucoma therapy. Methods: Subjects with IOP
uncontrolled by topical medications (IOP 21 mmHg) underwent SC implantation of the CyPass Micro-Stent. Results: There were no adverse events or
serious complications. Mean medicated IOP at baseline was 24.5 mmHg (n =
65). Mean IOP at 12 months was 16.8 mmHg, a 32% reduction from baseline.
Mean medication use also decreased from 2.2 medications to 1.5 medications. Conclusion: The CyPass Micro-Stent provided safe and sustained IOP
reduction in OAG patients refractory to topical medications.
PA063
5:17 PM
Intraoperative Injection vs. Sponge-Applied Mitomycin C
During Trabeculectomy: One-Year Study
Presenting Author: Grace Huang
Co-Author(s): Linda Y Huang MD, Albert S Khouri MD*

Sunday, Oct. 19
2:00 - 3:15 PM
Room: S405
Moderator: Khalid F Tabbara MD
Panel: Elisabetta Miserocchi MD, Jose S Pulido MD MS
PA009
2:00 PM
PA010
2:12 PM
Diagnostic Findings Identified by Ultrawide-Field

Fluorescein Angiography in Uveitis Patients
Presenting Author: Sunil K Srivastava MD*
Co-Author(s): Kathleen Farhang, Kimberly Marie Baynes COA, Francesco Pichi
MD, Justis P Ehlers MD*, Careen Yen Lowder MD PhD
Purpose: To identify changes in the retinal periphery identified using ultrawide-field fluorescein angiography (UWF-FA) in uveitis patients. Methods:
This is an institutional review board-approved retrospective case series of
uveitis patients who had UWF-FA with the Optos 200Tx system. Imaging
analysis, including comparisons between simulated 50-degree fundus images
and UWF-FA images, was performed. Results: 116 patients with 458 sets of
UWF-FA images were reviewed. 71.2% of UWF-FA images yielded information not seen with standard imaging. Findings included peripheral nonperfusion (23.1%), diffuse leakage (70.9%), and multifocal lesions (7.7%). Seventy
percent of UWF-FA images impacted medical management. Conclusion:
UWF-FA improves the evaluation of the retinal periphery and affects the medical care of uveitis patients.
PA011
2:24 PM
The Use of Anterior Segment Spectral Domain OCT in

Evaluation of Patients With Anterior Scleritis
Presenting Author: Ashleigh Laurin Levison MD
Co-Author(s): Kimberly Marie Baynes COA, Careen Yen Lowder MD PhD,
Sunil K Srivastava MD*
Purpose: To describe the utility of anterior segment spectral domain OCT (SDOCT) in anterior scleritis. Methods: Institutional review board-approved, prospective, observational case series. Patients underwent slitlamp exam, and
scleral inflammation was recorded. Scleral SD-OCT was performed. Results:
To date, 23 patients have been enrolled, with a total of 43 separate imaging
visits. Of patients with active disease, 95.7% had findings on OCT. The common findings included intrascleral hyporeflective spaces (69.6%), vessels in
deep sclera (43.4%), and nodules, some not seen on exam (34.7%). While
exam appeared quiet, 2 patients (8.7%) had an OCT suggesting activity. Treatment response corresponded with improvement on OCT (eg, fewer hyporeflective spaces, resolution of deep vessels, changes in thickness). Conclusion:
SD-OCT provided objective measures to monitor / grade patients with scleritis.
Characterization of Uveitis in Patients With Multiple

Sclerosis
Presenting Author: Wyatt Messenger
SOE Abatacept for Juvenile Idiopathic Arthritis-Related

Uveitis
Co-Author(s): Lena Hildebrandt, Friederike Mackensen MD PhD*, Eric B

Suhler MD*, James T Rosenbaum MD*
Purpose: To characterize uveitis in multiple sclerosis (MS). Methods: Multicenter retrospective review of patients with uveitis and MS. Results: We
identified 113 patients (196 eyes) with uveitis and MS. The majority presented
with intermediate (80%) and anterior uveitis (15%). Uveitis presented before
PA012
2:36 PM
Presenting Author: Ekaterina V Denisova MD

Co-Author(s): Ludmila Katargina
Purpose: To evaluate the efficacy and safety of Abatacept (Aba) in the treatment of juvenile idiopathic arthritis (JIA)-related uveitis. Methods: Twenty-six
children with active JIA-related uveitis received standard Aba treatment over
155
Original Papers
Purpose: To compare outcomes of injection of mitomycin (MMC) against conventional sponge-applied MMC during trabeculectomy. Methods: Patients (N
= 60; 30 injection, 30 sponge) were reviewed and postop variables collected
up to 1 year. Results: The injection group had overall lower IOP and higher
proportions of > 30% IOP reduction at each time point; however, this did not
reach significance. The number of postop visits within 3 months and the proportion of eyes needing 5-FU intervention were significantly lower in the injection group (P = .03 and P = .04 respectively). No patients in the injection group
needed additional surgical revisions, while 3 patients in the sponge group
did. Conclusion: Injection of MMC was as safe and effective as sponge application, with less need for visits within 3 months, 5-FU intervention, and
revisions.
or with MS (69%). Mean visual acuity (VA) was fair (20/39). During follow-up,
VA improved -0.09 logMAR/year. Compared to controls with intermediate uveitis (n = 16), cases with intermediate uveitis and MS were significantly older (P
= .006) and more likely to be female (P = .047), but had no differences in VA (P
= .87) or vision loss (P = .56). Conclusion: Uveitis with MS generally presents
as intermediate or anterior uveitis. Compared to controls, patients with MS
are older and more likely to be female. Visual prognosis is favorable.
Original Papers
3-37 months (mean: 18). All patients received other immunosuppressive drugs;
in 8, Aba was the secondfourth biologic. Results: After initiation of Aba,
remission of uveitis was achieved in 35%, improvement was achieved in 30%
of cases. Efficacy of Aba in patients who received it as the first or as second
fourth biologic was 83% and 25% (P < .05), respectively. No ocular or systemic
adverse effects were observed. Intraocular surgery was uncomplicated in all
20 cases. Conclusion: Aba was effective in 65% of children with JIA-related
uveitis. Aba is more effective when used as the first biologic.
PA013
2:48 PM
Self-reported Experience With Side Effects From

Medications Used to Treat Noninfectious Nonanterior
Uveitis
Presenting Author: Nisha Acharya MD*
Co-Author(s): Suhasini Ramalingam, Michelle L Chernock PHD**, Noah
Goodman**
Purpose: To characterize the burden associated with treatment in patients
with intermediate, posterior, and panuveitis. Methods: 120/141 eligible
patients recruited from uveitis and retinal specialty practices completed an
online survey. Results: Fifty-one percent of patients have received corticosteroid-sparing immunosuppressants; 28%, corticosteroid injections / implants;
24%, biologics; and 17%, systemic corticosteroids. Systemic corticosteroid
side effects were most bothersome, including weight gain/bloating (80%),
trouble sleeping (70%), mood swings / irritability (60%), and increased appetite (55%). Fifty percent of patients on immunosuppressants reported fatigue.
Fewer side effects were reported with biologics, but there was a high financial
burden. Conclusion: Patients experience significant side effects with uveitis
medications.
Original Papers
PA014
Monday, Oct. 20
3:45 - 4:20 PM
Room: S405
Moderator: Tara A McCannel MD
Panel: Hakan Demirci MD, Jeffrey A Nerad MD
PA064
3:45 PM
SOE Eyelid Carcinoma Treated by Interstitial

Brachytherapy
Presenting Author: Anna Maria Comoli MD

Co-Author(s): Vito Belloli MD, Laura Masini**, Letizia Deantonio MD**,
Marco Krengli MD
Purpose: To review local control and outcomes in patients with eyelid tumors
treated by interstitial 192Ir wires. Methods: Sixty patients (52 basal cell carcinoma and 8 squamous cell carcinoma) were treated with Ir wire implantation: 51 cases had no prior treatment, 4 had received previous surgery with
positive or close surgical margins, 5 had local recurrence after surgery. We
evaluated toxicity and functional and cosmetic results. Results: Mean followup: 92 months. Local control was obtained in 58/60 patients; functional and
cosmetic results were satisfactory in 55/60; late effects higher than grade
2 were observed in 3% of cases. Conclusion: Interstitial brachytherapy for
carcinoma of the eyelid can obtain satisfactory results with acceptable late
toxicity.
PA065
3:57 PM
Gamma Knife Radiosurgery for Uveal Melanoma:
Twenty Years of Experience
SOE
3:00 PM
Key Outcomes of SAKURA 1: A Phase 3 Study of

Intravitreal Sirolimus for Noninfectious PosteriorSegment Uveitis
Presenting Author: Quan Dong Nguyen MD*
Co-Author(s): Pauline T Merrill MD*, W Lloyd Clark MD*, Alay S Banker MD,
Marye Ellen Valentine**, Joel Naor MD**, Afsheen Khwaja MD*, Yang Yang
PHD*, Yusuf Ali*, Abu Abraham MD*, Sri Mudumba PhD**, Naveed Shams
MD PhD**
Purpose: To present key results of SAKURA Study 1. Methods: The SAKURA
studies are 2 randomized, double-masked, Phase 3 studies of patients with
active noninfectious posterior-segment uveitis (NI-PSU). SAKURA 1 had 347
subjects with baseline vitreous haze (VH) score 1.5+. Results: At Month 5,
primary endpoint (% with VH of 0) favored 440 g intravitreal sirolimus (44 g,
10.3%; 440 g, 22.8%; 880 g, 16.4%; P = .025, 440 vs. 44 g). Key secondary
endpoints also favored 440 g: % with VH of 0 or 0.5+ (44 g, 35.0%; 440
g, 51.8%; 880 g, 43.1%; P = .012, 440 vs. 44 g). Treatment effect of 440
vs. 44 g was similar across subgroups: age, gender, and race. Safety with
440 g intravitreal sirolimus was favorable. Conclusion: 440 g intravitreal
sirolimus demonstrated a decrease in VH and was well tolerated in subjects
with NI-PSU.
Presenting Author: Giulio Modorati MD

Co-Author(s): Maura DiNicola MD, Elisabetta Miserocchi MD, Francesco M
Bandello MD*
Purpose: To evaluate the results of gamma knife radiosurgery (GKR) in treating 141 patients with uveal melanoma. Methods: Records of 141 consecutive
patients with uveal melanoma treated with GKR (treatment doses: 50 to 30
Gy at 50% isodose) between 1994 and 2014 were retrospectively reviewed.
Results: Mean follow-up was 58.8 months (range: 5.3-209.9). Local tumor
control was achieved in 93.6% of patients. Mean ultrasound thickness before
and after GKR was 6.56 mm and 3.90 mm, respectively, with mean reduction rate of 40.5% (P < .0001). Eye retention rate was 90.1%. Reasons for
enucleation were recurrence in 9 cases, neovascular glaucoma in 3 cases, and
phthisis bulbi in 2 cases. Survival rate was 92.2%. Conclusion: GKR can be
considered a valid conservative treatment in uveal melanomas.
PA066
4:09 PM
Comprehensive Polymerase Chain Reaction

Assay for Detection of Pathogenic DNA in Orbital
Lymphoproliferative Disorders
Presenting Author: Yoshihiko Usui MD
Co-Author(s): Shunichiro Ueda MD**, Hiroki Takahashi DVM, Takeshi Kezuka
MD PhD*, Hiroshi Goto MD
Purpose: In the present study, we utilized this system to conduct an exhaustive search for DNA of pathogens in orbital lymphoproliferative disorders
156
Original Papers
(OLPD). Methods: Forty-nine patients diagnosed with OLPD of the ocular
adnexa were studied. Biopsy specimens were screened for DNA of bacteria,
viruses, fungi, and parasites by multiplex polymerase chain reaction. Results:
Among 31 cases of mucosa-associated lymphoid tissue lymphoma, HHV-6
DNA was detected in 7 cases, parvovirus B19 DNA in 3 cases, and EBV DNA
in 3 cases. Among 18 cases of IgG4-related ocular disease, HHV-6 DNA was
detected in 6 cases, HHV-7 DNA in 11 cases, and HHV-8 DNA in 3 cases.
Conclusion: Chronic stimulation due to these continuous infections may be
involved in the pathogenesis of OLPD.
months. Conclusion: Topical CsA 0.05% showed a satisfactory effect in longstanding prosthetic eye wearers.
Purpose: To document the utility of intraoperative intravenous acetaminophen (IIVA) in orbital surgery. Methods: Postoperative metrics were compared
for patients undergoing orbitotomy with (n = 100) or without (n = 100) IIVA.
Results: As compared with patients who did not receive IIVA, patients who
received IIVA had a statistically significant decrease in the need for postoperative narcotic medications (P < .05) and in the requirement for postoperative antiemetic medications (P < .05). No side effects were related to IIVA. Conclusion: IIVA dramatically reduced the requirement for analgesic and antiemetic
medications after orbitotomy. This study documents the first use of IIVA in
orbital surgery and indicates that IIVA may be a useful, low-risk, inexpensive
adjunct to traditional analgesic regimens for these procedures.

Monday, Oct. 20
4:25 - 5:00 PM
Room: S405
Moderator: Elizabeth A Bradley MD
Panel: Aaron M Fay MD, Michael T Yen MD
PA067
4:25 PM
Are Frozen Section Margin Control and Conjunctival Map

Biopsy Mandated in Sebaceous Gland Carcinoma of the
Eyelid?
PA069
Intravenous Acetaminophen in Orbital Surgery

Presenting Author: Edward Wladis MD*
Co-Author(s): Bryant P Carruth MD

Monday, Oct. 20
Presenting Author: Fairooz Puthiyapurayil Manjandavida MD
11:00 AM - 12:00 PM
Room: S405
Co-Author(s): Santosh G Honavar MD, Geeta K Vemuganti MD
PA068
4:37 PM
Short-term Effects of Topical Cyclosporine A 0.05%

(Restasis) in Long-standing Prosthetic Eye Wearers
Presenting Author: Jung-Woo Han MD
Co-Author(s): Sun Young Jang MD, Jin S Yoon MD
Purpose: Long-standing prosthetic eye wearing induces ocular surface inflammation. We investigated the short-term effects of topical cyclosporin A
(CsA) 0.05% in patients with ocular discomfort. Methods: Twenty patients
who were unilateral prosthetic eye wearers over a period of 5 years were
enrolled. The subjects were instructed to instill topical CsA 0.05% . Measurements were made pretreatment and after 1 and 3 months of treatment. Outcome measures were the ocular symptom score, the lid margin abnormality
score, the Schirmer test, and the tear meniscus amount, using Fourier domain
OCT. Results: Ocular symptoms were improved after treatment for 1 month
in all patients. The Schirmer test results were improved after treatment for 3
Moderator: Terri L Young MD

Panel: Audina M Berrocal MD, Hilda Capo MD, Ta Chen Chang MD, Martha P
Schatz MD
PA035
11:00 AM
Retinal Fluorescein Angiographic Changes Following

Intravitreal Anti-Vascular Endothelial Growth Factor
Therapy for Treatment-Requiring ROP: A Pilot Study
Presenting Author: Andree Henaine-Berra MD
Co-Author(s): Gerardo Garcia-Aguirre MD*, Hugo Quiroz-Mercado MD*,
Maria Ana Martinez-Castellanos MD
Purpose: To describe the retinal vascular morphology in eyes treated with intravitreal bevacizumab (IB) for treatment-requiring ROP. Methods: We included 47 eyes of 26 patients, with stage 3, threshold, or prethreshold ROP. Fundus
photographs and fluorescein angiography (FA) were obtained before and after
IB treatment. Results: Before treatment, FA showed vascular abnormalities.
After IB, FA showed involution of the neovascularization, flattening of the demarcation line, and subsequent growth of vessels to the capillary-free zones.
During the following weeks vascular remodeling and vascular loops were
seen. Conclusion: Patients showed improvement of their abnormal vascular
findings after IB; there was creation of small vessels, establishment of directional flow, and maturation of retinal vessels.
11:07 AM Panel discussion of previous paper
157
Original Papers
Purpose: To assess utility of frozen section (FS) margin control and conjunctival map biopsy in the management of eyelid sebaceous gland carcinoma
(SGC). Methods: Retrospective interventional study of 107 consecutive cases
of SGC that underwent primary surgical excision. Results: Mean age was
56.3 12.8 years. Intraoperative FS was used in 83 (76%) and conjunctival
map biopsy in 81 (75%). Despite 4-mm clinically clear surgical margins, FS
was positive in 16 (19%), necessitating additional excision. Tumor recurrence
occurred in 9 of 24 (37.5%), who did not undergo FS vs. 11 of 83 (13%) who
did (hazards ratio 5.8, P = .018). Conjunctival map biopsy showed pagetoid
invasion in 17 (21%), of whom 16 were clinically suspected. Conclusion: FS
margin control is vital in the management of SGC, while conjunctival map
biopsy may be reserved for cases with clinical suspicion of pagetoid invasion.
4:49 PM
Original Papers
PA036
11:12 AM
Evaluation of an Image-Based Reference Standard for

ROP Diagnosis
children for self-assessment, practice improvement, visual outcome studies,

and possible re-evaluation of guidelines.
Presenting Author: Michael Ryan MS
PA039
Co-Author(s): Karyn Jonas RN, Audina Berrocal MD*, Kimberly A Drenser MD

PhD*, Jason D Horowitz MD*, Thomas Lee MD*, Charles Simmons Jr MD*,
Raghu C Murthy MD, Maria Ana Martinez-Castellanos MD, R V Paul Chan
MD, Michael F Chiang MD*
Gonioscopy-Assisted Transluminal Trabeculotomy:

A Novel Ab Interno Trabeculotomy for the Treatment
of Developmental Glaucoma: Technique Report and
Preliminary Results
Purpose: To measure diagnostic agreement between image-based exam,

ophthalmoscopic exam, and a proposed reference standard. Methods: 714
clinical exams were performed in 289 infants. Retinal images were captured
and independently interpreted by 3 readers. Image-based and clinical diagnoses were compared for zone, stage, and category. A new reference standard that combined image-based and clinical diagnoses was also evaluated.
Results: Absolute agreement between image-based diagnosis and clinical
exam was highest for zone (80%) and lowest for category (68%). Compared to
the new reference standard, agreement on category was 90% for the imagebased diagnosis and 81% for the clinical exam. Conclusion: ROP diagnosis is
subjective and variable, and may be improved by combining impressions from
multiple readers with the clinical exam.
Presenting Author: Davinder S Grover MD*

Co-Author(s): Oluwatosin U Smith MD*, Ronald Leigh Fellman MD OCS*,
David G Godfrey MD**, Michelle R Butler MD, Ildamaris Mercedes
MontesdeOca MD**, William J Feuer MS
IOL Exchange for High Myopia in Pseudophakic Children
Purpose: To introduce gonioscopy-assisted transluminal trabeculotomy

(GATT) for the treatment of developmental glaucoma and to report early results. Methods: Retrospective study of 12 eyes of 8 consecutive patients
who underwent GATT with > 6 months follow-up. Patients were < 27 years
old with trabeculodysgenesis. Results: Twelve eyes of 8 patients (aged 1 to
27 years) underwent GATT with a mean drop in IOP and medications of 13.3
mmHg (range: 1-39) and 1.5 (range: 0-4), respectively. Transient postop hyphema developed in 4 eyes. All eyes were considered a clinical success, with a
substantial decrease in IOP and/or glaucoma medications. Conclusion: Early
results for GATT demonstrate that it is a safe and effective method for treating
developmental glaucoma.
Presenting Author: Courtney L Kraus MD
PA037
11:24 AM
Co-Author(s): Rupal H Trivedi MBBS MS*, M Edward Wilson Jr MD, Brita S

Deacon MD
Original Papers
11:48 AM
Purpose: To report preoperative factors and postoperative outcome of children undergoing IOL exchange due to myopic shift. Methods: Chart review of
pseudophakic children undergoing IOL exchange for correction of high myopia.
Results: Eighteen eyes had IOL exchange, 13 for myopic shift. Nine of 13
had unilateral cataract. Average spherical equivalent before IOL exchange:
-9.88; afterwards: -1.48. Average axial length of operative and nonoperative
eyes: 24/22.1 mm (P-value < .005). Average eye growth in operative and nonoperative eye: 4.4/3.02 mm (P-value < 0.04). Conclusion: Myopic shifts in
refraction may necessitate IOL exchange after infantile cataract surgery with
IOL implantation. IOL exchange should be included during initial preoperative
informed consent process.
8:30 - 10:15 AM
Room: S404
Moderator: Kendall E Donaldson MD
Panel: Damien Gatinel MD, Rajesh K Rajpal MD, Karolinne M Rocha MD
PA070
8:30 AM
Corneal Coupling: Its Importance in Incisional and

Ablative Procedures
Co-Author(s): George Stamatelatos OD*, James Kwan Ong*
11:36 AM
Pediatric Ophthalmologist Glasses Prescribing Patterns

Presenting Author: Lindsay Dawson
Co-Author(s): Jiayan Huang MS**, Gil Binenbaum MD*
Purpose: To describe glasses prescribing patterns among pediatric ophthalmologists and compare them to American Academy of Ophthalmology (Academy) guidelines. Methods: Electronic medical records (EMR) study of 16,011
children refracted by 7 providers. Exclusions: esotropia, cataract, blindness,
wearing glasses. Results: Using 19,372 refractions (7421, age 0-3; 6897, 3-8;
5054, 8-18), proportions glasses prescribed were stratified by age, type, and
amount of refractive error. Prescribing thresholds decreased with age in all
categories. Prescribing matched Academy guidelines in only 15%-50% for age
< 1, but in 65%-100% for age 1-3. Conclusion: EMR and IRIS integration
will enable large-scale assessment of actual glasses prescribing thresholds in
158
Tuesday, Oct. 21
Presenting Author: Noel A Alpins MD FACS*
11:31 AM
Panel discussion of previous paper
PA038
Refractive Surgery
Purpose: To assess the importance of corneal coupling in incisional and ablative procedures. Methods: Retrospective incisional and ablative data are
analyzed to demonstrate the applicability of newly defined coupling terms.
Results: Compound myopic and hyperopic astigmatism excimer laser treatments (3818 eyes) showed a coupling ratio close to zero, a coupling constant
close to 0.5, and a coupling adjustment close to zero. Incisional limbal relaxing
incisions (74 eyes) demonstrated a coupling ratio close to 1.0, and a coupling
constant close to zero. Conclusion: The revised definitions of coupling ratio
and coupling constant can be used with both incisional and ablative surgery.
Coupling adjustment can be used to improve surgical outcomes.
Original Papers
PA071
8:42 AM
Prospective Study of Patient Satisfaction With LASIK and

Contact Lenses: Two-Year Results
PA074
Presenting Author: Francis W Price Jr MD*
Refractive Outcomes of Topography-Guided

Photorefractive Keratectomy With Simultaneous
Crosslinking for Keratoconus
Co-Author(s): Marianne O Price PhD*
Presenting Author: David Lin MD
Purpose: To evaluate satisfaction with 2 popular vision correction choices:

contact lenses and LASIK. Methods: Subjects 18-60 years old who planned
to have LASIK or continue successful contact lens wear were enrolled and
surveyed at baseline (before surgery in the LASIK arm) and 1 and 2 years
later. Results: Response rates were 69% at 1 year and 64% at 2 years. In
the Contacts Group, 1- and 2-year responses were comparable to baseline. In
contrast, ease of night driving was significantly improved both 1 and 2 years
after LASIK. The rate of dry eye symptoms increased 1 year after LASIK but
decreased back to baseline at 2 years. Conclusion: Modern LASIK significantly improves the ease of night driving and temporarily increases the rate
of dry eye symptoms.
Co-Author(s): Simon P Holland MD*
PA072
8:54 AM
9:18 AM
Purpose: To evaluate topography-guided photorefractive keratectomy with

collagen cross-linking (TG PRK/CXL) for keratoconus. Methods: TG PRK/CXL
performed with the Allegretto WaveLight laser and the topography neutralization technique using Dresden protocol safety and efficacy was evaluated at 1
year. Results: 215 eyes met follow-up criteria. Forty-seven percent had UCVA
20/40. Fifty-five percent improved BCVA: 22% gained 2 lines; 6% lost 2
lines. Mean astigmatism decreased 2.52 D. Seven had hyperopic progression;
4 had SE > 1.50 D. Complications included herpetic keratitis, delayed epithelialization, and haze. Conclusion: One-year outcomes of TG PRK/CXL among
215 keratoconus eyes showed satisfactory efficacy and safety, with minimal
hyperopic progression.
Contralateral, Randomized Comparison of LASIK With

Optimized Prolate Ablation, Wavefront, and TopographyGuided Prolate Ablations
9:30 AM
Clinical Outcomes of the Implantable Collamer Lens
With Central Port: One Year of Follow-up
Presenting Author: Alaa M Eldanasoury MD*
Presenting Author: Erik L Mertens MD FRACOPHTH*
Co-Author(s): George O Waring III MD FACS*
Purpose: To assess the refractive outcomes at 1-year follow-up on patients

who received the implantable collamer lens with central port for the correction of myopic astigmatism. Methods: 165 eyes underwent implantation of
a myopic or toric ICL (V4C model, Staar Surgical, Inc.). The design features a
central hole that allows a more natural aqueous flow, eliminating the need to
perform Nd:YAG iridotomy or peripheral iridectomy. Results: At 1 year the
mean spherical equivalent dropped from -5.23 2.80 D (range: -13.75 to 1.25
D) preoperatively to 0.01 0.086 D (range: 0.00 to 0.75 D). 164 eyes (99%)
achieved UDVA of 20/20 or better. No case of pupillary block was detected.
Conclusion: The results of the present study support the good predictability,
efficacy, safety, and stability outcomes of the new implantable collamer lens
V4C model.
PA073
SOE
PA076
9:06 AM
SOE Detecting Keratoconus by Combining Topographic

and Tomographic Intereye Asymmetry Data
9:42 AM
Comparison of Posterior Chamber and Iris-Fixated Phakic

IOLs in 5-Year Outcomes
Presenting Author: Akihiro Yasuda MD
Presenting Author: Alain Saad MD*
Co-Author(s): Yoshihiro Kitazawa
Co-Author(s): Emmanuel Guilbert, Damien Gatinel MD*

Purpose: To discriminate between normal (N) and keratoconus (KC) corneas
by analyzing intereye asymmetry parameters and define a score of similarity
that outlines the normal range. Methods: Prospective, nonrandomized study
that included 102 N corneas and 64 KC corneas. Topographic and tomographic
parameters of the right and left eye were subtracted to determine asymmetry.
A discriminant function was constructed in order to separate between the 2
groups. Results: The mean intereye asymmetry differences were statistically
significant (P < .001) for all variables except the vertical and horizontal decentration of the thinnest point. The discriminant function reached a sensitivity of
94% and a specificity of 100%. Conclusion: Combining intereye differences
may be accurate and useful for the topography-based detection of KC.
Purpose: To evaluate the efficacy and safety of posterior chamber phakic IOLs
(eg, ICL) with that of iris-fixated lenses (eg, Artisan). Methods: 1232 eyes
with ICLs (mean MRSE: -9.14 D) and 1103 eyes with Artisan lenses (-9.85
D) were compared in terms of outcomes and safety. Results: Mean MRSE
of ICL/Artisan eyes were +0.06 D / -0.12 D at 1 month, and -0.35 D / -0.34 D
at 5 years. More eyes achieved UCVA of 20/20 or better with the ICL (97.4%)
than with the Artisan (88.3%) at 1 month, 92.9% vs. 81.9% at 5 years. BCVA
in ICL/Artisan was gained in 56.9%/53.5%, lost in 1.9%/5.9%. During 5 years
after 1 month, 21.9% of Artisan and 16.0% of ICL eyes lost more than 10%
endothelial cell density. Conclusion: Both lenses showed stable outcomes
for 5 years; however, the ICL showed better predictability, UCVA, more gained
/ less lost BCVA, and less stress to the corneal endothelium.
159
Original Papers
Purpose: To compare outcomes of myopic LASIK with those of optimized

prolate ablation (OPA), wavefront-guided (WF-OPA), and topography-guided
(Topo-OPA) ablation. Methods: Fifty-six patients underwent LASIK, with one
eye randomized to receive OPA and the fellow eye to receive WF-OPA or TopoOPA. Results: At 6 months postoperatively, 58% of OPA, 69% of WF-OPA,
and 62% of Topo-OPA eyes, respectively, saw -0.10 logMAR or better without
correction (P < .05 compared to preoperative, all groups ). Ocular spherical
aberration was 0.10 0.09 , and 0.13 in the OPA, WF-OPA, and Topo-OPA
eyes, respectively. Modulation transfer function was similar for all eyes. Patient satisfaction between groups was similar (P > .05, all comparisons). Conclusion: Refractive outcomes, visual quality, and patient satisfaction were
similar between groups.
PA075
Original Papers
PA077
9:54 AM
Comparison of Depth of Focus and Mesopic

Contrast Sensitivity in Small-Aperture Corneal Inlay,
Accommodating IOL, and Multifocal IOL Patients
Presenting Author: Jay Stuart Pepose MD PhD*
Purpose: To compare monocular defocus curves and binocular mesopic contrast sensitivity of a small-aperture intracorneal inlay to those of 3 premium
IOLs. Methods: A retrospective comparison of Crystalens AO, AcrySof ReSTOR 3.0, and Tecnis Multifocal to the Kamra inlay. Monocular defocus curves
were determined. Binocular mesopic contrast was measured with and without
glare at 1.5, 3, 6, and 12 cpd. Results: Crystalens AO (n = 25) and Kamra inlay
(n = 327) patients had continuous functional vision of 20/40 or better over 3
D and 4 D, respectively. ReSTOR 3.0 (n = 25) and Tecnis MF (n = 22) IOLs had
noncontinuous functional vision over a 4.5 D dioptric range. Conclusion: Patients monocularly implanted with a small-aperture inlay achieved a broader
continuous range of vision and better mesopic contrast sensitivity than patients with any of these IOLs.
Retina, Vitreous
Tuesday, Oct. 21
8:30 AM - 12:45 PM
Room: S405
Moderator: David Sarraf MD
Panel: J Fernando Arevalo MD FACS, Neil M Bressler MD, Michael W Stewart
MD
Original Papers
PA078
8:30 AM
High-Dose Ranibizumab for Diabetic Macular Edema:

Month 24 Outcomes of the READ-3 Study (Ranibizumab for
Edema of the Macula in Diabetes, Protocol 3)
PA080
Purpose: To compare 2-mg ranibizumab (RBZ) injections to 0.5-mg RBZ for

eyes with center-involving diabetic macular edema (DME) with central subfield (CSF) of 250 microns or greater on time domain OCT (TD-OCT) to determine if high dose was superior. Methods: Eyes were randomized 1:1 to 2-mg
RBZ or 0.5-mg RBZ. All eyes received 6 monthly injections. Subjects were
followed monthly and received additional injections based on predetermined
criteria. Primary outcome was mean change in BCVA at Month 6. Study duration was 24 months. Results: 152 eyes participated. At Month 6 / Month 24
the change in BCVA was +7.0 / +6.77 in the 2-mg group and +9.4 / +11.0 in the
0.5-mg group. Conclusion: At Month 6 both doses appeared equivalent. At
Month 24, 0.5 mg was superior (P = .02). High dose showed no improvement
over 0.5 mg.
8:42 AM
Open-Label Extension of the RIDE and RISE Trials:

Association of Diabetic Macular Edema Patient
Characteristics With Treatment Frequency
The Fate of Diabetic Macular Edema Patients With Little

or No Initial OCT Response to Ranibizumab in the RISE
and RIDE Trials
Presenting Author: Dante Pieramici MD*
Co-Author(s): Helen Marie Chmiel EdD*, Beiying Ding PHD*, Anne E Fung
MD*
Purpose: To evaluate BCVA improvement in eyes with 10% reduction in
baseline central foveal thickness (CFT) following 1-6 doses of ranibizumab
(RBZ). Methods: Summary statistics and change from baseline BCVA and CFT.
Results: In 0.3-mg RBZ arm, 10% CFT reduction was seen in 23/249 eyes
(9%) following 3 doses and in 14/249 eyes (6%) following 6 doses (82/251
[33%] and 56/251 [22%] in sham, correspondingly). The RBZ 10% CFT reduction eyes had thinner retinas at baseline by ~80 mm compared to eyes with
> 10% CFT reduction. At Month 24, BCVA in eyes with 10% CFT reduction
following 1-6 RBZ doses was comparable to the RBZ full study population.
Conclusion: Fewer than 10% of RBZ eyes showed 10% reduction in CFT
after 3 injections. Significant BCVA gains were realized despite gradual CFT
response.
PA081
9:06 AM
Dexamethasone Intravitreal Implant for Treatment of
Persistent Diabetic Macular Edema
Presenting Author: Soraya Mediero Clemente MD
Co-Author(s): Zurnie Del Barrio Lopez De Ipina MD, Jesus Ramon Garcia
Martinez**, Paula Larranaga-Fragoso MD, Bruno Casco Silva MD, Felix
Armada-Maresca MD
Purpose: To evaluate the effectiveness of a single intravitreal injection of
Ozurdex over 12 months in patients with chronic diabetic macular edema
(CDME). Methods: Retrospective review of the medical records of 52 eyes
with CDME refractory to other treatments. Results: Statistically significant
improvement was seen in the mean BCVA at Month 1 (P = .0002) and at Month
12 (P = .0261), in the mean thickness central subfield at Month 1 (P < .0001)
and at Month 5 (P < .0001), and in the mean thickness average cube at Month
1 (P < .0001), at Month 5 (P < .0001), and at Month 12 (P = .0001) after treatment. Conclusion: The study suggests that dexamethasone implant is a favorable option in patients with CDME refractory to other treatments, producing an improvement that remains over time.
Presenting Author: Charles C Wykoff MD PhD*

Co-Author(s): Beiying Ding PHD*, Na Lu PHD*, Ivo Stoilov MD*
Purpose: To investigate baseline (BL) characteristics of patients with diabetic
macular edema (DME) associated with 0.5-mg ranibizumab (RBZ) treatment
frequency during the RIDE/RISE open-label extension (OLE). Methods: Core
160
8:54 AM
SOE
Presenting Author: David S Boyer MD*
PA079
BL RIDE/RISE patient characteristics were analyzed by RBZ p.r.n. injection

number per year during the OLE (0, > 0 to 3, > 3 to 7 and > 7). Results:
Compared to patients receiving > 7 injections/year (n = 88, 18%), patients
needing no OLE treatment (n = 121, 24%) had a shorter diabetes duration,
shorter time from DME diagnosis, better vision, lower diabetes retinopathy
severity scores, and less DME at RIDE/RISE core study BL. Conclusion: Many
DME patients in the RIDE/RISE OLE remained stable with no or few injections;
in the 24% requiring no injections, RBZ appears to have been initiated earlier
in the course of disease.
Original Papers
PA082
9:18 AM
Dexamethasone Intravitreal Implant in Previously Treated

Patients With Diabetic Macular Edema: Subgroup
Analysis of MEAD
Presenting Author: Baruch D Kuppermann MD PhD*
Co-Author(s): Albert J Augustin MD*, Xiao-Yan Li MD*, Scott M Whitcup
MD*
Purpose: To evaluate outcomes of dexamethasone intravitreal implant (DEX)
treatment in patients with previously treated diabetic macular edema (DME).
Methods: Subgroup analysis of MEAD, a 3-year, randomized, Phase 3 study
evaluating DEX 0.7 mg and 0.35 mg vs. sham in DME. Results: Within the
previously treated subgroup of 757 patients (72.2% of study population),
21.5%, 17.7%, and 11.1% of patients in the DEX 0.7 mg, DEX 0.35 mg, and
sham groups, respectively, had 15-letter BCVA gain from baseline (BL) at
study end (P .036 DEX vs. sham), and mean average central retinal thickness
change from BL by OCT was -126, -117, and -39 m, respectively (P < .001
DEX vs. sham). Conclusion: DEX significantly improved visual and anatomic
outcomes in patients with previously treated DME.
PA083
9:30 AM
Two-Year Outcomes of the VISTA/VIVID Trials of

Intravitreal Aflibercept Injection in Diabetic Macular
Edema
Presenting Author: Quan Dong Nguyen MD*
PA084
9:42 AM
Intravitreal Aflibercept Injection in Patients With Prior

Therapy for Diabetic Macular Edema: Outcomes From
VISTA
Presenting Author: David S Boyer MD*
Purpose: To assess outcomes after intravitreal aflibercept injection (IAI) or
laser in diabetic macular edema (DME) patients with and without prior antivascular endothelial growth factor (VEGF) therapy for diabetic macular edema
(DME). Methods: VISTA randomized 872 patients to IAI 2 mg every 4 weeks
(2q4), IAI 2 mg every 8 weeks following 5 monthly doses (2q8), and laser.
Results: Over 52 weeks, BCVA letter gain with 2q4, 2q8, and laser was 12.5,
10.7, and 0.2 (P < .0001). Of the VISTA patients, 43% had prior anti-VEGF,
of which 71%-82% had only bevacizumab. BCVA letter gain with 2q4, 2q8,
and laser was +10.7, +10.5, and -1.0 (P < .0001) in patients who had prior
anti-VEGF, and +13.8, +10.9, and +1.1 (P < .0001) in patients who had no prior
anti-VEGF. The most frequent ocular serious adverse event was vitreous hem-

Moderator: Sharon D Solomon MD
Panel: Judy E Kim MD, Baruch D Kuppermann MD PhD, Jason S Slakter MD
PA085
9:58 AM
SOE Visual Acuity and Subfoveal Choroidal Thickness:

The Beijing Eye Study
Presenting Author: Jost B Jonas MD*

Co-Author(s): Du Kuifang**
Purpose: To examine the association between BCVA and subfoveal choroidal
thickness (SFCT). Methods: In the population-based Beijing Eye Study, participants underwent spectral domain OCT. Results: In multivariate analysis,
better BCVA was associated with thicker SFCT (P = .002) in general and a
SFCT thicker than 90 m (P = .001) in particular. If eyes with glaucoma, diabetic
retinopathy, late AMD, and myopic retinopathy were excluded, better BCVA
was still significantly associated with thicker SFCT (P = .01) and SFCT thicker
than 90 m (P < .001) in multivariate analysis. Conversely, thicker SFCT was
associated with better BCVA (P < .001) in multivariate analysis. Conclusion:
Better visual acuity is strongly associated with thicker SFCT.
PA086
10:10 AM
No Association of Statin Use and AMD in the Age-Related

Eye Disease Study 2 (AREDS2)
Presenting Author: Shaza Nizar Al-Holou*
Co-Author(s): William R Tucker MBBS, Elvira Agron MS, Traci E Clemons PhD,
Emily Y Chew MD, The AREDS2 Research Group
Purpose: To evaluate the association of statin use with progression to late
AMD. Methods: We assigned propensity scores based on covariates to statin
users and nonusers. Age-adjusted Cox regression models were performed on
paired propensity-score matched statin users and nonusers in AREDS2. Results: Statin use was not statistically significantly associated with progression to late AMD in participants with baseline bilateral large drusen (hazard
ratio [HR]: 0.63; 95% CI, 0.37-1.05) or with baseline unilateral late AMD (HR:
1.22; 95% CI, 0.67-2.20). Conclusion: Statin use was not associated with
progression to late AMD.
PA087
10:22 AM
Lack of Association Between Thiazolidinedione Use and

Incidence of Diabetic Macular Edema at 4 Years Followup in the ACCORD Eye Study
Presenting Author: Craig M Greven MD*
Co-Author(s): Emily West Gower PHD, Letitia H Perdue MS, Ronald Peter
Danis MD*, Matthew D Davis MD, Emily Y Chew MD, Walter T Ambrosius
PhD*
Purpose: To report the association between thiazolidinedione (TZD) and incidence of diabetic macular edema (DME) in the ACCORD Eye Study. Methods:
Stereoscopic fundus photographs at baseline and Year 4 examinations (n =
2856) were centrally graded and analyzed to examine the longitudinal association of TZD use with DME progression. The analyses were adjusted for age,
sex, race, and diabetes duration. Results: DME incidence was 5.2% with and
4.7% without exposure to TZDs (adjusted OR = 1.12; 95% CI, 0.71-1.76, P =
161
Original Papers
Purpose: To compare intravitreal aflibercept injection (IAI) with laser for diabetic macular edema (DME). Methods: Patients (n = 872) were randomized to
IAI 2 mg every 4 weeks (2q4) or 8 weeks (after 5 monthly doses; 2q8) or laser.
Results: Over 52 weeks, BCVA gain with 2q4, 2q8 vs. laser was 12.5, 10.7
vs. 0.2 letters (P < .0001) in VISTA and 10.5, 10.7 vs. 1.2 letters (P < .0001) in
VIVID. Most frequent ocular adverse events were conjunctival hemorrhage,
eye pain, and vitreous floaters. At Week 100, BCVA was 11.5, 11.1 vs. 0.9 letters (P < .0001) in VISTA. Additional 2-year results will be presented, including
diabetic retinopathy severity, where more 2q4, 2q8 vs. laser patients had
2-step improvement at Week 100 in VISTA (37.0%, 37.1% vs. 15.6%; P < .001).
Conclusion: Both IAI regimens significantly improved BCVA in comparison
with laser at Week 52 and sustained BCVA gains through Week 100 (VISTA).
orrhage. Conclusion: BCVA gains over laser with both IAI regimens were
similar in both patient subgroups.
Original Papers
.63). Conclusion: In this longitudinal study of patients with Type II diabetes,
there was no increased risk of macular edema associated with TZD use.
PA088
10:34 AM
Ranibizumab in Diabetic Macular Edema: Review of

Arterial Thromboembolic Events From Controlled Clinical
Trials
PA091
11:10 AM
Intravitreal Aflibercept Injection for Macular Edema Due

to Branch Retinal Vein Occlusion: 52-Week Outcomes
Presenting Author: Marco A Zarbin MD PhD FACS*
Presenting Author: David Brown MD FACS*
Co-Author(s): Vladimir Bezlyak**, Philippe Margaron PHD*
Purpose: To compare intravitreal aflibercept injection (IAI) with grid laser

for macular edema due to branch retinal vein occlusion (BRVO). Methods:
VIBRANT, a Phase 3 trial, randomized eyes with macular edema secondary
to BRVO to receive IAI 2 mg every 4 weeks (n = 91) or grid laser (n = 92) from
baseline to Week 20. Results: The proportion of eyes that gained 15 letters
from baseline to Week 24 was 53% and 27% (P < .001) in the IAI and laser
groups, respectively. The mean improvement in BCVA from baseline to Week
24 was 17.0 and 6.9 letters (P < .0001), respectively. The most common ocular
adverse event in IAI eyes was conjunctival hemorrhage (19.8%). The 52-week
results will be presented. Conclusion: Monthly IAI provided significantly
greater visual benefit at 24 weeks than laser in eyes with macular edema
due to BRVO.
Purpose: To review arterial thromboembolic events (ATEs) from diabetic

macular edema (DME) studies with up to 36 months ranibizumab exposure.
Methods: Retrospective analysis of ATEs from 5 ranibizumab DME studies
(> 1250 patients). Results: Relative risks at 12 months (ranibizumab/control, N = 634) for all ATEs, myocardial, and nonmyocardial ATEs were 0.75
(95% CI, 0.32-1.73), 0.70 (0.24-2.07), and 0.98 (0.30-3.19), respectively. At 12
months, 2.9%, 1.7%, and 1.7% of patients had these events per year. By 24
months these values were 3.2%, 0.6%, and 2.8%. There was no increase at
36 months. Conclusion: No pattern suggestive of a causal relationship with
ranibizumab was evident for cardiovascular or cerebrovascular events. The
favorable systemic safety is consistent with ranibizumabs minimal effect on
systemic VEGF levels.
PA089
10:46 AM
Pharmacodynamic Properties of Emixustat Hydrochloride

in the Treatment of Geographic Atrophy
Presenting Author: Roger L Novack MD PhD*
Original Papers
based on PED thickness, and when analyzed by dose (0.5 mg or 2.0 mg) or by
p.r.n. regimen. Conclusion: BL PED eyes had positive VA gains, similar to
non-PED, with p.r.n. RBZ regardless of PED size.
Purpose: To evaluate the pharmacodynamic effect of emixustat hydrochloride

on rod photoreceptor activity. Methods: Emixustat (2-10 mg) was administered to 54 geographic atrophy subjects for up to 90 days with a 7-14 day
follow-up period. Electroretinography (ERG) was performed, and both A- and
B-wave amplitudes were measured to assess the effect on photoreceptors
and bipolar cells, respectively.Results: A dose-dependent, reversible, and
comparable suppression of A- and B-wave activity was observed. Prebleach
ERG showed a marked suppression of activity with evening dosing. Conclusion: The linear relationship between A- and B-wave amplitudes with treatment is consistent with the proposed mechanism of action. Suppression of
photoreceptor activity during dark adaptation may reduce retinal metabolic
stress.
PA090
10:58 AM
Ranibizumab Treatment in Patients With Wet AMD With

Pigment Epithelial Detachment: A HARBOR Subgroup
Analysis
Presenting Author: Nikolas J London MD*
Co-Author(s): Helen Marie Chmiel EdD*,
Purpose: To evaluate whether the presence / absence of pigment epithelial
detachment (PED) at baseline (BL) affects visual acuity (VA) outcomes in eyes
with wet AMD given ranibizumab monthly or p.r.n. Methods: Exploratory subgroup analysis of 24-month data from the Phase 3 randomized HARBOR study.
Results: At BL, eyes with PED (n = 598; 54.5%) had higher mean BCVA than
those without PED (55.7 vs. 51.9 letters, respectively). BCVA gains from BL at
Month 24 were comparable in eyes with/without PED after adjusting for BL
covariates. In the RBZ 0.5-mg p.r.n. arm, eyes with PED averaged 14 injections
vs. 12.5 for no PED. Median Month 24 VA gains were similar across quartiles
162

Moderator: Jennifer Irene Lim MD
Panel: H Culver Boldt MD, Homayoun Tabandeh MD MS FRCP FRCOphth
PA092
11:26 AM
Dual Antagonism of Platelet Derived Growth Factor
(Fovista 1.5 mg) and Vascular Endothelial Growth Factor
(Lucentis 0.5 mg) Results in Reduced Subretinal Fibrosis
and Neovascular Growth
SOE
Presenting Author: Usha Chakravarthy MBBS PhD*

Co-Author(s): Glenn J Jaffe MD*
Purpose: To assess severity of fibrosis in eyes treated with combination Fovista and Lucentis vs. Lucentis alone. Methods: Masked retrospective analysis of fundus images at baseline and 24 weeks in a subset (70 eyes) of a Phase
2B study of which n = 33 (combined); n = 37 (monotherapy) that experienced >0
ETDRS letter loss. Fibrosis was graded on a 0 to 4 categorical scale. Results:
At 24 weeks, 27% of eyes (combined) vs. 54% (monotherapy) had 2 step
worsening of fibrosis. In eyes with no fibrosis, 10% (combined) vs. 51% (monotherapy) developed fibrosis. Mean change in fibrosis: 0.97 vs. 2.0 (P = .003).
Conclusion: Combined antagonism of VEGF and PDGF was associated with
reduced development and progression of fibrosis, and inhibition of neovascular growth may play a role in improved visual outcomes in neovascular AMD.
PA093
11:38 AM
Comparison of Anatomic and Visual Acuity Outcomes in

Neovascular AMD Patients Treated With ESBA 1008 and
Ranibizumab
Presenting Author: Pravin U Dugel MD*
Purpose: Efficacy comparison of ESBA 1008 (an antibody fragment) with
ranibizumab to treat neovascular AMD. Methods: Prospective, activecontrolled, randomized, double-masked, single-dose ascending, multicenter
study. Subjects were randomized to 1 of 5 arms to receive a single intravitreal
dose of ESBA 1008 or ranibizumab. Efficacy endpoints included change in cen-
Original Papers
tral subfield thickness (CSFT) at Month 1 (primary) and change in BCVA. Results: 194 subjects were randomized. A dose-related reduction of CSFT was
observed for ESBA 1008. At 6 weeks, patients receiving 6 mg of ESBA 1008
gained a mean of 10.4 (9.2) letters in BCVA, compared to 6.2 (9.5) letters for
ranibizumab. Conclusion: ESBA 1008 exhibited a dose-dependent effect on
CSFT reduction and BCVA gain in patients with neovascular AMD.
PA094
11:50 AM
The Prospective Intraoperative and Perioperative

Ophthalmic Imaging With Optical Coherence Tomography
(PIONEER) Study: Two-Year Vitreoretinal Results
Presenting Author: Justis P Ehlers MD*
Co-Author(s): Peter K Kaiser MD*, Rishi P Singh MD*, Daniel F Martin MD,
Alex Yuan MD, Sunil K Srivastava MD*
Purpose: To assess the utility of intraoperative OCT (i-OCT) for vitreoretinal
(VR) surgery. Methods: Prospective multisurgeon study examining i-OCT feasibility, safety, and utility during VR surgery with a microscope-mounted OCT
system. Surgeon feedback questionnaires were completed on utility. Results:
At 24 months, 256 eyes were enrolled in the PIONEER VR surgery arm. The
median time required per scan session was 3.4 minutes. No serious adverse
events occurred. During membrane peeling, i-OCT informed surgical decision
making in 43% of procedures (63/146). Conclusion: i-OCT appears to provide
important surgical feedback in a large percentage of vitreoretinal cases while
resulting in only minimal delay in surgical time.
PA095
12:02 PM
SOE Indications and Results of a New L-Shaped Macular

Buckle to Support a Posterior Staphyloma in High Myopia
Co-Author(s): Ron Afshari Adelman MD MPH

Purpose: The efficacy of a macular buckle in treating myopic traction maculopathy (MTM) was studied. Methods: Fifty-two eyes with MTM, macular
detachment with macular hole (MHMD), or without macular hole (MD) and
macular foveoschisis (MF) were treated with vitrectomy combined with macular buckle or with a macular buckle alone. Results: Combined Group: The
retina was attached in 100% and the hole was closed in 32% of MHMD.
Buckle Groups: The retina was attached in 100% of MHMD, MD, and MF, with
visual improvement. The macular hole was closed in 50% of cases of MHMD.
Limited complications included conjunctiva erosion, diplopia, and pain. MRI
showed flattening of the posterior staphyloma. Conclusion: Macular buckle
alone should be the first treatment of MTM.
PA097
12:26 PM
Clinical Outcomes After Antivascular Endothelial Growth

Factor Therapy for Prethreshold ROP: The Results of the
International Anti-VEGF for ROP Collaborative Study
Group
Presenting Author: Jorge I Calzada MD*
Co-Author(s): Rocio Diaz MD, Maria Ana Martinez-Castellanos MD, Clio A
Harper III MD*, Audina Berrocal MD*, Mehmet Kocak MD, W Lloyd Clark
MD*, Caroline R Baumal MD*
Purpose: To report the clinical outcomes of anti-VEGF therapy in prethreshold ROP. Methods: Retrospective, interventional, multicenter study. Results:
1207 eyes of 109 infants were included; 98 cases where both eyes were treated Mean gestational age at birth was 26.1 2.7 weeks; mean birth weight
was 774 259 grams. Regression of ROP was observed in 93.2% one week
following injection. 0.97% of eyes developed a new vitreous hemorrhage, and
0.5% had a retinal detachment following injection. No systemic complications
were reported. Eleven infants (10.1%) had recurrence of neovascularization
with plus disease. Of these, mean gestational age at birth was 24.6 1.9
weeks for infants with recurrence versus 26.3 2.7 for infants without recurrence (P = .043), and mean birth weight = 608 129 for the infants with
recurrence versus 761 217 grams (P = .061). Re-treatment was performed in
24.7% (21.3% laser/ 2.4% injection/1% PPV). Conclusion: Anti-VEGF injections were demonstrated to be an effective treatment for prethreshold ROP.
PA096
12:14 PM
SOE Subretinal Implantation and Functional Results of

the Alpha IMS Chip to Restore Vision in 26 Blind Retinitis
Pigmentosa Patients
Presenting Author: Helmut Sachs MD*

Co-Author(s): Karl-Ulrich Bartz-Schmidt MD**, Caroline K L Chee MBBS*,
Veit-Peter Gabel MD**, Florian Gekeler MD*, Timothy L Jackson MBChB*,
Robert E MacLaren MBChB**, Janos Nemeth MD, Katarina Stingl MD*,
David Wong FRCOPHTH, Walter G Wrobel MD*, Eberhart Zrenner MD*
Purpose: Twelve-month visual function and safety data after transchoroidal
implantation of a subretinal electronic chip in 26 blind RP patients. Meth* The presenter has a financial interest. ** The presenter has not submitted financial interest disclosure information as of press date.
163
Original Papers
Presenting Author: Barbara Parolini MD
ods: Transchoroidal subfoveal implantation of a chip with 1500 electrodes.

Functional tests with 4 procedures. Monitor-based tests for light perception,
localization, movement detection, grating acuity, and Landolt C. Detection,
localization, and identification of objects. Reading letters. Visual experiences
during daily life. Results: No safety concerns for transchoroidal implantation.
Implant mediated light perception in 85% of patients; light localization, 58%;
movement detection, 23%; grating acuity, 54%; visual acuity, 18%. Reading
letters. Visual experiences during daily life. Conclusion: Improvement of visual function in majority of patients. Transchoroidal surgery is safe. CE mark.
SCIENTIFIC POSTERS
South Hall A
There will be two sessions of scientific posters.
Session One
Saturday, Oct. 18
9:00 AM 5:00 PM
Sunday, Oct. 19
7:00 AM 5:00 PM
Session One Presenters will be at their displays on Sunday, Oct. 19 from

12:30 PM - 2:00 PM.
Session Two
Monday, Oct. 20
7:00 AM 5:00 PM
Tuesday, Oct. 21
7:00 AM 1:00 PM
Session Two Presenters will be at their displays on Monday, Oct. 20 from

12:30 PM - 2:00 PM.
Posters designated by a H received the highest grades by the Annual Meeting Program Committee and selected as Best Posters.
Scientific Posters Online

View scientific posters at your convenience at the Scientific Posters Online computer terminals in McCormick Place.
This service is also available through the Mobile Meeting Guide, www.aao.org/mobile.
After Nov. 1, view Scientific Posters online: www.aao.org/aao-archives.
Onsite Poster Tours

The Meeting Point near Scientific Posters Online/Videos on Demand in Booth 65.
Subject
Tour Leaders
Sunday, Oct. 19 12:30-1:30 PM

Cataract
Steve A Arshinoff MD,
Stephen H Johnson MD
James J Reidy MD
Jayne S Weiss MD
Glaucoma
Robert L Stamper MD
Pediatric Ophthalmology, Strabismus Ta Chen Chang MD
Terri L Young MD
Retina, Vitreous
Keith A Warren MD
Subject
Tour Leaders
Monday, Oct. 20 12:30-1:30 PM

Cataract
Mark H Blecher MD
Luther Fry MD
Penny A Asbell MD FACS
Kenneth R Kenyon MD
Glaucoma
Edward J Rockwood MD,
Leonard K Seibold MD
Pediatric Ophthalmology, Strabismus Hilda Capo MD
Martha P Schatz MD
Retina, Vitreous
Shlomit Schaal MD PhD
Lucia Sobrin MD
164
Scientific Posters
Cataract
SESSION ONE, SATURDAY & SUNDAY
Scientific Poster 1
Residual Astigmatism Discrepancies in FDA Approved Toric
IOLs
Presenting Author: Fatma Dihowm MD
Co-Author(s): David Hjelmstad, Samir Sayegh MD PhD
Purpose: To compare residual astigmatism as computed for equivalent lenses for FDAapproved IOLs by 2 manufacturers. Methods: We used the recommended toric IOL calculators by 2 manufacturers and submitted the same spherical power and corneal astigmatism
information to generate a recommended toric IOL and its residual astigmatism (RA). RA
was compared and graphed for a given amount of astigmatism ranging from 1 to 4 D as a
function of increasing spherical IOL power, from 10 to 30. Results: There were consistent
discrepancies between manufacturers displayed RA. One manufacturer RA was constant
throughout the variation range of the IOL power, while the other varied. Conclusion: Calculation paradigms for toric IOLs need to be critically reviewed.
Scientific Poster 2
SOE Presbyopia Correction With Multifocal Toric IOL
Implantation
Presenting Author: Ewa Mrukwa-Kominek MD PhD*
Purpose: To assess presbyopia correction with a toric multifocal IOL in cataract patients
with corneal astigmatism (CA). Methods: Fifteen patients (30 eyes) with CA > 1.5 D received the M-Flex T IOL (Rayner). Outcomes included uncorrected distance visual acuity
(UDVA), uncorrected near VA (UNVA), refraction, contrast sensitivity, and quality of life
(QoL). Results: Mean preop UDVA and corrected distance VA (CDVA) were 0.33 0.11 and
0.61 0.09, respectively. Mean postop UDVA was 0.99, and 85% of eyes achieved UNVA of
J2. Mean contrast sensitivity improved in all spatial frequencies. There was no significant
difference between preop and postop CA, and no correlation was seen between change in
UDVA and QoL. Conclusion: The M-Flex T IOL reduces spectacle dependence.
Scientific Poster 3
Femtosecond Laser OCT-Guided Intrastromal Arcuate
Keratotomy to Reduce Corneal Astigmatism During Cataract
Surgery
Presenting Author: Dilraj Singh Grewal MD
Co-Author(s): Surendra Basti MBBS*, Satinder Pal Singh Grewal MD MBBS
Scientific Poster 4
SOE The Clinical Outcomes After Bilateral Implantation of
an Apodized Diffractive +2.5 D Multifocal Toric IOL
Presenting Author: Liliana Werner MD PhD*

Co-Author(s): Erica Liu MD**, Scott Cameron Cole MD MS, Thomas Kohnen MD*,
Fritz H Hengerer MD**, Thomas Kohnen MD*, Nick Mamalis MD*
Purpose: To provide complete histopathologic evaluation of explanted IOL capsular bag
complexes that spontaneously dislocated in the late postoperative period. Methods: Capsular bags containing an IOL or an IOL and capsular tension ring (CTR) from 28 consecutive explanted specimens were analyzed histopathologically. Additionally, the explanting
surgeons submitted a clinical course summary with each specimen. Results: Different IOL
materials / designs were represented; 2 specimens contained a CTR. A history of pseudoexfoliation (PEX) was noted in 11 cases. However, PEX material was found in 18 cases
histopathologically. Conclusion: PEX may be implicated in a larger proportion of late inthe-bag IOL subluxation / dislocation than previously thought.
Scientific Poster 6
SOE Risk Factors and Treatment Options in Late
Postoperative IOL Dislocation
Presenting Author: Yaran Koban MD
Co-Author(s): Selim Genc MD**, Gorkem Bilgin MD, Halil Huseyin Cagatay Sr**
Purpose: To evaluate risk factors and treatment options for IOL dislocation in the late
postoperative period. Methods: Retrospective analysis of medical records of 157 patients
who had phacoemulsification with IOL implantation and developed IOL dislocation in the
late postoperative period was performed. Results: Pseudoexfoliation (PEX) syndrome was
found in 74.5% of the eyes. We performed anterior vitrectomy-scleral fixation IOL (70.0%),
pars plana vitrectomy (PPV)-scleral fixation IOL (15.9%), IOL reposition (9.6%), PPV-IOL removal (3.2%), and anterior vitrectomy-iris-fixated IOL (1.3%) for treatment. Conclusion:
PEX syndrome was the most common predisposing risk factor for late postoperative IOL
dislocation. Scleral fixation IOL implantation provides significant increase in postoperative
BCVA.
Scientific Poster 7
H Mortality After Cataract Surgery in the U.S. Medicare
Population
Presenting Author: Victoria L Tseng MD
Co-Author(s): Fei Yu PhD, Flora Lum MD, Anne Louise Coleman MD PhD*
Purpose: To examine the association between cataract surgery and mortality in patients
with cataract. Methods: A 5% random sample of 2011 Medicare files was used to identify
cataract patients and their demographics, systemic and ocular comorbidities, and cataract
severities. Odds ratios (ORs) of 2-year mortality were calculated for cataract patients with
and without surgery, adjusting for all covariates. Results: Of 328,422 cataract patients,
14,616 (4.5%) died within 2 years. Adjusted ORs of cataract surgery on mortality were
0.94 (0.90, 0.99) for all patients, 0.79 (0.74, 0.85) for patients 80 years old, and 0.85
(0.78, 0.93) for patients with severe cataract. Conclusion: In Medicare cataract patients,
cataract surgery is associated with reduced 2-year mortality, especially in patients who are
older or with severe cataract.
Scientific Poster 8
The Expression of Micro-34a in Age-Related Cataract and
Its Molecular Mechanism of Regulating Apoptosis in Human
Lens Epithelial Cells by Targeting Notch2
Presenting Author: Fan Fan
Presenting Author: Yonca A Akova MD*
Co-Author(s): Yi Luo**, Yi Lu MD PhD**, Peng Zhou MD
Co-Author(s): Osman S Arslan MD, Fatma Nilufer Alparslan MD*
Purpose: To investigate the expression changes of miR-34a and the methylation of its
promoter in age-related cataract (ARC). Methods: Quantitative real-time polymerase chain
reaction was used to evaluate the expression of miR-34a in ARC and transparent lens capsules. Pyrosequencing was performed to detect the DNA methylation in miR-34a promoter.
Results: The expression of miR-34a was significantly higher in the cataract group (P <
.05), while there was no significant difference in the methylation of miR-34a between the
2 groups (P = .152). After transfection, apoptosis of HLECs increased significantly (P < .05)
in the miR-34a overexpressed group. The 3UTR reporter activities of Notch2 were significantly inhibited in the miR-34a overexpressed group (P = .01), suggesting miR-34a could
directly inhibit Notch2. Conclusion: miR-34a is upregulated in ARC patients and induces
HLECs apoptosis via targeting Notch2.
Purpose: To assess the outcomes after bilateral implantation of +2.5 D multifocal toric
IOL. Methods:Twelve patients with bilateral cataract and corneal astigmatism from 0.75
to 2.5 D had implantation of the AcrySof IQ ReSTOR +2.5 D toric multifocal IOL. Results: At
6 months, the mean spherical equivalent (SE) was 0.12 D 0.23, and the mean refractive
cylinder decreased from 1.55 0.8 D to 0.42 0.43 D. The mean binocular UCVA was 0.94
0.08 at 4 mt, J4 at 40 cm, J2 at 60 cm. The mean IOL rotation was 0.83 1.7 degrees.
Conclusion: Patients had significantly reduced SE and refractive cylinder, excellent visual
acuity at far and intermediate distances, acceptable near visual acuity, and minimal IOL
rotation.
165
Scientific Posters
Purpose: To determine the efficacy of using the femtosecond cataract laser (FSL) to perform OCT-guided intrastromal astigmatic keratotomy (IAK) to reduce astigmatism during
cataract surgery. Methods: The FSL (Catalys, AMO; Calif.) was employed to create single
or symmetric IAK (5 J energy, 90 side cut angle, 8.5-mm optical zone) at 80% of corneal
depth in eyes with > 0.50 D naturally occurring regular corneal astigmatism, assessed using
Pentacam topography. Results: In 30 eyes, corneal astigmatism was significantly reduced
(P < .0001) from 0.96 0.58 D (range: 0.5 to 3.2 D) to 0.35 0.26 D (range: 0 to 0.8 D) at 1
month following IAK. Average reduction was 0.61 0.51 D (range: 0.1 to 2.4 D). There were
no cases of posterior perforation. Conclusion: OCT-guided FSL IAK is an effective way to
reduce corneal astigmatism during cataract surgery.
Scientific Poster 5
Pathological Evidence of Pseudoexfoliation in Cases of Inthe-Bag IOL Subluxation / Dislocation
Scientific Posters
Scientific Poster 9
SOE Changes in Angle Configuration and Corneal Thickness
After Phacoemulsification by Anterior Segment OCT,
Ultrasound Biomicroscopy, and Pentacam
Scientific Poster 14
Confocal Microscopic Findings in 1-Year Follow-up of
Corneal Inlay Insertion for Presbyopic Correction
Presenting Author: Ahmed Mohamed Ghoneim MD
Co-Author(s): Mauro S Campos MD, Sandra M Beer MD*
Co-Author(s): Tamer E Wasfy MBBS
Purpose: To describe the confocal microscopic images found at 1 year follow-up. Methods: Thirty-one eyes of 31 patients were implanted with Flexivue Microlens for presbyopia
correction. Confocal microscopy was performed at 1 year postop. Results: Small, bright,
round, hyper-reflective images were observed in all eyes over the inlay area. No signs of
active acute inflammation were seen; still, alteration in transparency was observed in all
eyes. Well-demarked, sharp-edged images were observed on the surface and in the inlay
borders in most cases. Conclusion: The inlay does not to seem to be stable in terms of
histological activity and material compatibility over time. Further analysis, such as scanning electronic microscopy and immunohistochemistry, is required to confirm the authors
suspicion of material corrosion.
Purpose: To evaluate results of anterior segment OCT, ultrasound biomicroscopy, (UBM)

and Pentacam in evaluating angle changes and corneal thickness and structure compared
with contact pachymetry. Methods: In 40 patients undergoing phacoemulsification, anterior segment OCT, Pentacam, and UBM were obtained 1 week before and 1 week and 1
month after phaco to evaluate nasal and temporal angle and to measure corneal thickness.
Results: Mean anterior chamber depth increased, from 2.25 mm to 4.06 mm by anterior
segment OCT, from 3.02 mm to 4.41 mm by UBM, and from 3.19 mm to 4.45 mm by Pentacam. Also corneal thickness measurements increased 1 week after phaco as measured
by all means. Conclusion: Anterior segment OCT, UBM, and Pentacam demonstrated increase of angle width after phaco and also demonstrated increased corneal thickness after
phaco, with more or less similar results compared with contact pachymetry.
Digital Management and Education of Cataract Patients:
Analyzing Effects of a Mobile Health Platform
Presenting Author: Richard M Awdeh MD
Purpose: This multisite clinical study researched the use of a mobile health patient management and education software tool. Methods: Researchers used both qualitative and
quantitative research methods to determine the usability and clinical efficacy of the tool in
both private practice and academic settings. Results: Patients scored an average of 35%
higher on information retention questions as compared to the preimplementation phase of
the study. Data also indicated that in the postimplementation phase of the study, patients
were more likely to select a premium intraocular lens implant. Conclusion: The tool was
clinically effective as a point-of-care intervention in improving patient education, information retention, comfort levels about their upcoming surgery, and adherence to physician
after-care instructions.
Femtosecond Laser Cataract Surgery Using the Alcon LenSx
and Abbott Medical Optics (AMO) Catalys
Presenting Author: Zaina N Al-Mohtaseb MD
Scientific Posters
Co-Author(s): Seth M Pantanelli MD, Florence A Cabot MD, William J Feuer MS,
Daniel Waren MS, Sonia H Yoo MD*, Kendall Donaldson MD
Purpose: To evaluate the phaco energy used and endothelial cell loss in patients having
manual cataract surgery and femtosecond laser-assisted cataract surgery using 2 different
laser platforms. Methods: Mean phaco energy and endothelial cell count were measured
in 182 traditional, 56 LenSx, and 33 Catalys cases. Results: There was a significant difference in phacoemulsification energy used between platforms (P = .017, ANOVA). Both LenSx
and Catalys were lower than traditional (P < .040), but they were not different from each
other (P = .89). The mean endothelial cell loss postoperatively was 15.8% (SD = 38.5%) and
not different among the 3 groups (P = .87). Conclusion: The femtosecond laser reduced
the mean phaco energy used during lens fragmentation and did not increase endothelial
cell damage.
SOE The Effect of Femtosecond Laser Capsulotomy on the
Development of Posterior Capsule Opacification
Presenting Author: Zoltan Nagy MD*
Co-Author(s): Illes Kovacs MD PhD, Kinga Krnitz MD**
Purpose: To evaluate effects of femtolaser and manual capsulotomy on posterior capsule
opacification (PCO). Methods: In 40 eyes femtolaser and in 39 eyes manual capsulotomy
was performed. PCO was measured with Open-access Systematic Capsule Assessment
(OSCA) software, IOL position with Pentacam, 18-26 months postoperatively. Results:
Vertical tilt, horizontal and total decentration of IOLs, and PCO were higher in the manual
group (P = .03, .04, .03, and .01). After adjusting for axial length and follow-up time, manual
capsulorrhexis was a significant predictor of higher PCO in the multivariable regression
model (b: 0.33; 95% CI, 0.01 to 0.65; P = .04). Vertical tilt affected PCO after adjusting for
axial length and follow-up time (b: 0.07; 95% CI, 0.01 to 0.12; P = .02). Conclusion: Due
to better IOL position, femtolaser capsulotomy resulted in slightly decreased PCO scores.
166
Presenting Author: Eliane-Mayumi Nakano MD
Visual Effects of Blue Light Filtration
Presenting Author: John P Berdahl MD*
Co-Author(s): Billy R Hammond Jr PhD*
Purpose: To assess visual performance with the addition of blue light filtration. Methods:
Cross-sectional study of 158 pseudophakes with IOL largely transparent to visible light.
Photostress recovery time and disability glare threshold were measured with a blue light
filter (BLF) and placebo (no blue light filtration). The test eye and order of filter used in the
study were randomized. Results: Difference in photostress recovery time (BLF placebo)
was significant (mean difference: -1.37 4.32 seconds, P = .0001), demonstrating faster
recovery with BLF. Disability glare threshold was significantly higher with BLF (1.37 0.88
log unit) than with placebo (1.26 0.92, P = .0001). Conclusion: The addition of blue light
filter to pseudophakes with no BLF IOL allows significantly faster photostress recovery and
greater threshold to disability glare.
SOE Optical Bench Analysis of Different Optical Designs in
IOLs
Presenting Author: Florian T A Kretz MD*
Co-Author(s): Gerd U Auffarth MD*, Ramin Khoramnia MD*, Tamer Tandogan MD**
Purpose: Optical bench analysis of 3 different optic designs. Methods: Optical bench
analysis (OptiSpheric IOL, Trioptics) contained modulation transfer function (MTF), autofocus, through focus scan , and effective focal length of 3 IOL models (monofocal, bifocal,
and trifocal; Carl Zeiss Meditec) based on the same platform. Five lenses (21 D) per group
were analyzed 5 times each. Results: Mean sagittal MTF (100 lp/mm far focus), 0.607
(monofocal), 0.328 (bifocal), and 0.236 (trifocal) showed a statistically significant difference. Conclusion: Monofocal IOLs showed the best image quality and highest MTF values
for a far focal point. Near focal point was significantly better for bifocal and trifocal IOLs.
Intermediate distance was best for trifocal IOLs.
SOE Outcomes Obtained With 2 Models of Trifocal IOLs for
the Correction of Presbyopia
Presenting Author: Ahmed A Abdou MD Phd
Co-Author(s): Jorge L Alio MD PhD*, Esperanza Sala OD, Ana Belen Plaza MS**
Purpose: To compare visual and optical quality outcomes obtained with 2 models of trifocal lenses. Methods:Two groups of eyes: Group A, 20 eyes implanted with AT LISA tri
839MP, and Group B, 20 eyes implanted with Fine Vision. Main outcomes measures were
uncorrected distance (UCVA) and uncorrected near visual acuity (UNVA), defocus curve, and
contrast sensitivity. Results: Postoperatively, significant improvement in UDVA and CDVA
were found in both groups. Statistically significant differences were not found (P = .337)
between groups in UNVA and contrast sensitivity (P .09) postoperatively. The defocus
curves showed significantly better visual acuities in Group A (P < .05). Conclusion: Good
results were obtained in both groups at all the distances but were better with AT LISA tri
in distance and intermediate.
Scientific Posters
Evaluating the Visualization and Repeat Placement of
Hydrogel Punctum Plugs as a Vehicle for Drug Delivery
Antimicrobial Activity of Moxifloxacin-Soaked Acrylic IOLs:
Hydrophobic SA60 vs. the Hydrophilic Afinity CQ 2015
Presenting Author: Thomas R Elmer MD*
Presenting Author: Deep Parikh MD
Co-Author(s): Michael J Endl MD*, Claus M Fichte MD, William Flynn MD*, Edward R
Rashid MD, Robert A Rice MD, Tom R Walters MD*
Co-Author(s): Christopher A Minning MD, Amilia Schrier MD, Edward F Smith MD
Purpose: To assess visualization and replacement of polyethylene glycol hydrogel punctum

plugs in healthy volunteers. Methods: Plugs containing fluorescein as a visual aid were
evaluated in 60 patients. Plugs were replaced bilaterally every 90 days following insertion.
Device presence was monitored via slit lamp and blue light and yellow filter mirror by
the investigators and patients, respectively. Results: Preliminary results through Day 330
showed plugs were well tolerated and easily visualized by patients and investigators. Replacement was rated as easy in 94.2% of the cases. There were no serious or unexpected
adverse events. Conclusion:The replaceability and detectability of the hydrogel punctum
plugs make them a viable means for sustained drug delivery for chronic conditions such
as glaucoma.
Purpose: To compare the potential of acrylic IOLs to deliver an intracameral antibiotic.

Methods: Twenty hydrophobic acrylic AcrySof SA60 (Alcon) and 20 hydrophilic collamer
Afinity CQ2015 (Staar) IOLs were soaked in saline or commercial-strength moxifloxacin (5
mg/ml) for 1 minute. Presoaked lenses were plated on agar with Staphylococcus aureus or
Staphylococcus epidermidis overlay. Bacterial kill zones were measured after 24 hours. Results: The mean S aureus kill zone for the SA60 (33.67 3.19 mm) was larger than for the
CQ2015 (31.89 2.01 mm) (P = .18). The mean S epidermidis kill zone for the SA60 (38.83
3.52 mm) was likewise larger than for the CQ2015 (37.28 5.78 mm) (P = .50). Conclusion:
Presoaked acrylic SA60 lenses have antibiotic properties similar to those of CQ2015 lenses
and may be used to deliver antibiotics intracamerally.
Incremental Effectiveness of Combined Topical and
Intracameral Antibiotic Prophylaxis for Preventing
Phacoemulsification-Related Endophthalmitis
Presenting Author: Maria Karasawa MD
Presenting Author: Neal H Shorstein MD*
Co-Author(s): , Akira Murakami MD
Co-Author(s): Liyan Liu MHSA
Purpose: To evaluate 2-year postoperative outcomes of Y-fixation technique used for intrascleral haptic fixation of posterior chamber IOL. Methods: Eyes operated with Y-fixation
technique from March 2010 to December 2011 were included. All patients were evaluated
for preoperative status, postoperative status, and complications. Results: A total of 85
eyes of 70 patients were analyzed. The median follow-up was 26.5 months. IOL decentration was observed in 3 eyes but was corrected without difficulty. There was no decline in
corrected visual acuity except 1 eye with a postoperative retinal detachment. Conclusion: Results obtained 2 years after Y-fixation technique showed good visual outcomes
with minimal complications.
Purpose: To assess whether topical and intracameral antibiotic (IC) are more effective than
either alone. Methods: Retrospective cohort study of 150,086 Kaiser Permanente members, 2005-2012. Ascertainment of endophthalmitis (N =118), prophylaxis, and posterior
capsular rupture (PCR) were validated. The logistic regression analysis adjusted for age,
year of surgery, ocular and systemic comorbidity, and PCR. Results: Risk on topical agent
alone was 1.28 per 1000 (42% of cohort). Compared to topical alone (excluding aminoglycoside), the following odds ratios were observed: 0.40 for IC alone (CI, 0.10-1.7) and 0.55
for topical plus IC (CI, 0.32-0.95). Conclusion:Although sample size was limited, topical
antibiotic was not evidenced to increased the effectiveness of IC injection.
Clinicopathological Correlation of Posterior Capsule
Plaques in Postvitrectomized Eyes
Presenting Author: Ruchi Mittal MD
H Refractive Outcomes for Tecnis Multifocal IOL Using
Various Lens Power Formulas with Koch Axial Length
Correction
Co-Author(s): Srikant Kumar Sahu**, Geet Mayur Shah MS, Sujata Das MBBS
Presenting Author: Arman S Zaman MD
Purpose: Clinicopathologic correlation of posterior capsule (PC) plaques in post-vitrectomized eyes. Methods: Thirty-three post-vitrectomized eyes underwent cataract surgery
from July 2011 to June 2013. Results: Seventeen out of 33 patients (51%) had PC plaques,
14/17 (82.3%) were males, and 12/17 patients (70.5%) had rhegmatogenous retinal detachment. Duration between two surgeries varied from 1-35 months; the 0-3, 3-9, and >
9 months groups were called Group A, B, and C, respectively. Thickness and cellularity
of plaque was highest in Group B. Group C plaques demonstrated maximum collagen by
cytochemical and immunohistochemical techniques. PC rent was seen in 2/5 patients in
Group C. Conclusion: PC plaque removal is safe in the early evolving or intermediate
cellular to fibrocellular stage.
Co-Author(s): Jamie K Alexander MD, Fei Yu PhD, D Rex Hamilton MD*
SOE Visual Function Without Corrective Lenses After
Cataract Surgery
Presenting Author: Hector Fernandez Sr
Co-Author(s): Carlos Salvador Fernandez Escamez MD**, Nicolas Toledano Fernandez
MD**, Jose Reche-Sainz**
Purpose: To study the relationship between refraction after cataract surgery and the use of
optical correction in patients over 65 years old. Methods: Retrospective case control study.
Forty retired elderly subjects (over 65) were recruited. Patients were asked to complete a
validated questionnaire on visual function (VF14). The difference between VF14 with and
without glasses (difVF14) was studied. Results: There was a significant correlation between difVF14 and postoperative refraction, with lower values of difVF14 associated with
postoperative refraction in the range of -0.50 to -1.00 D (OR 0.479; 95% CI, 0.286-0.804).
Conclusion: Patients with postoperative refraction between -0.50 and -1.00 D showed
better visual function without optical correction.
Purpose: To determine accuracy of formulas (Holladay I and II, SRK/T, Hoffer Q) in predicting refractive outcomes for cataract surgery using the Tecnic Multifocal IOL (TMF) implant.
Methods: Mean absolute errors (MAE) between predicted and actual outcomes were calculated for 101 eyes, stratified by axial length (AL) with Koch correction. Results: Analyzing all eyes, Holladay 1 had the lowest MAE (P < .05). For AL < 22 mm, all formulas were
equivalent. For 22 mm < AL < 24.5 mm, Holladay I and SRK/T were equivalent and outperformed other formulas (P < .05). For 24.5 mm < AL < 26 mm, Holladay I and II and Hoffer Q
outperformed SRK/T (P < .05). For AL > 26 mm, all formulas were equivalent. Conclusion:
Using ALs adjusted according to Koch correction, the Holladay 1 formula provides excellent
accuracy across all ALs when implanting the TMF.
In Vivo Measurement of the Forces of Accommodation With
a Zonular Capture Haptics Dynamometer
Presenting Author: Paul Beer MD*
Co-Author(s): Paul L Kaufman MD*, Mary Ann Croft MS*, Gregg Heatley MD, Jared
McDonald**, Alexander Katz
Purpose: To measure intraocular forces of disaccommodation in vivo with a zonular capture haptic (ZCH)-based dynamometer. Methods: ZCH dynamometers were implanted in
surgically aniridic eyes of rhesus monkeys (Macaca mulatta) and activated. Supramaximal
accommodation was induced with 40% carbachol. The loads on the device were determined using a twin device, parallel geometry method. Results: The ZCH dynamometer captured zonular forces successfully. The geometry of the device was carefully recorded in both
configurations, and the force load was successfully determined. Conclusion: ZCH technology offered an effective method for in vivo dynamometer load determination. The results
obtained with a first-generation ZCH are being refined with a second-generation device.
167
Scientific Posters
Long-term Postoperative Results of Y-Fixation Technique
Used for Intrascleral Posterior Chamber IOL Fixation
Scientific Posters
Analysis of Multifocal IOL Refractive Outcomes With
Intraoperative Aberrometry With and Without Streaming
Refractive Data
Improving Efficiency in Ophthalmology Surgery Using LEAN
Redesign
Presenting Author: Jason P Brinton MD
Co-Author(s): Jean-Luc Febbraro MD*, Sheila Bissonnette, Carla M Service MHA

RN**
Purpose: To compare refractive outcomes after multifocal IOL implantation with intraoperative aberrometry with and without streaming refractive data (ORA with VerifEye and
ORA, respectively). Methods: Data from multiple sites were compared, including 1971
cases with standard intraoperative aberrometry and 1267 cases using aberrometry with
streaming refractive data. Results: The mean absolute value of prediction error was 0.3
0.27 D for standard aberrometry and 0.28 0.24 D for aberrometry with streaming data
(P < .03). The percentage of eyes 0.5 D was 83% in the standard aberrometry group vs.
85% in the streaming data group. Conclusion: Intraoperative aberrometry with streaming
refractive data yielded better refractive results than standard aberrometry.
The Visual Outcomes and Safety Profile of Scleral-Fixated
IOLs Using Gore-Tex Suture
Presenting Author: Omesh P Gupta MD
Co-Author(s): Ryan G Smith, Brandon Ayres MD*, Marc J Spirn MD, Irving M Raber
MD*
Purpose: To evaluate the visual outcomes and intraoperative and postoperative complications of Gore-Tex scleral-fixated IOLs. Methods: A retrospective, consecutive series. Results: The study criteria were met by 114 eyes. The mean follow-up was 1.51 years. The
mean Snellen visual acuity improved from 20/490 to 20/85 (P < .05). There were 2 cases
(1.8%) of ciliary body hemorrhage. Postoperatively, the complications included hypotony
(8.8%), hyphema (3.5%), persistent corneal edema (0.8%), vitreous hemorrhage (4.4%),
choroidal detachment (0.8%), and epiretinal membrane (0.8%). Endophthalmitis, prolonged
inflammation, erosion, or breakage were not observed. Conclusion: Gore-Tex scleral-fixated IOL implantation is a valuable technique in selected cases. The visual outcomes and
safety profile are similar to those of other surgical approaches.
Sutureless Intrascleral Fixation of Posterior Chamber IOL:
Simpler Technique and 1-Year Follow-up
Presenting Author: Takahiro Kawaji
Scientific Posters
Co-Author(s): Mikiko Fukushima MD PhD, Hidenobu Tanihara MD PhD**

Purpose: To report the results of sutureless scleral fixation of posterior chamber IOL using our new, simpler technique. Methods: Forty-three eyes of 42 patients who underwent
sutureless intrascleral fixation of IOL for at least 1-year follow-up periods were included
in this study. A 25-gauge microvitreoretinal knife was used to create a sclerotomy and a
limbus-parallel scleral tunnel in which the haptics were fixed. Results: The median followup was 17 months. The IOLs were fixed and well centered. The postoperative complications
included iris capture in 2 eyes, cystoid macular edema in 3 eyes, and no IOL dislocation.
Conclusion: Our simpler and safe technique for intrascleral fixation of IOLs may improve
the long-term stability without sutures.
A Novel Device and Technique for Scleral Fixation of an IOL
Presenting Author: Michael Erlanger MD
Co-Author(s): Jeffrey L Olson MD*
Purpose: To describe a novel device and technique to achieve scleral fixation of an IOL.
Methods: The device and technique were tested in the laboratory setting. Results: The
device, which consists of a double-armed 10-0 prolene needle with a preformed cow hitch
with a silicone bolster, is injected with a 25-gauge injector through the pars plana. The IOL
haptic is threaded through the preformed cow hitch and the knot is tightened around the
haptic. Each of the 2 needles is used to take a scleral bite while externalizing the needles
through the sclerotomy, achieving a buried knot and sclerotomy closure. Conclusion:This
novel device and technique may simplify the complex process of achieving a secure and
sutured scleral-fixated IOL.
168
Presenting Author: Hamza N Khan MD FACS*
Purpose: To compare the operational efficiency of cataract surgery after process changes
were undertaken to improve patient value and reduce wastes using LEAN redesign methods. Methods: We tracked 2 consecutive series of cataract patients (N = 62) through their
OR journey with a LEAN redesign of the process. A multidisciplinary team developed recommendations to reduce waste and time through delivery of care. Pre- and postimplementation measures included total duration of stay, OR transit time, and patient satisfaction
surveys. Results: Redesign led to a reduction of total patient journey (208 vs. 70 mins; P
< .001) and improved satisfaction scores. Mean surgical room transit was unchanged (29
5 min). Conclusion: Use of LEAN redesign to reduce unnecessary steps and time can
improve efficiency and satisfaction in the cataract OR.
SESSION TWO, MONDAY AND TUESDAY

SOE Agreement Between Verion and Other Keratometers for
Astigmatism Assessment
Presenting Author: Juan Gros-Otero
Co-Author(s): Jorge Luis Garcia-Perez, Francisco J Hurtado Cena MD**, Gema Bolivar
de Miguel MD, Laureano Rementeria PhD
Purpose: Accurate assessment of corneal astigmatism plays a significant role in the refractive outcome of cataract surgery. The aim of this study is to compare the new Verion
keratometer to other well-known older keratometers. Methods: A retrospective study was
performed that includes the first 60 eyes in which Verion was used in our clinic. Keratometric readings were compared to those obtained with IOL Master and Oculyzer or Orbscan.
Results: Intraclass correlation coefficient for the steep meridian was 0.958 (P < 0.0005)
between Verion and IOL Master, 0.950 (P < 0.0005) between Verion and Oculyzer and 0.910
(P < 0.0005) between Verion and Orbscan. Conclusion: The keratometric measurements
showed a very high agreement when measured by Verion and the other keratometers studied.

Topographic Impact of Femtosecond Laser-Assisted Arcuate
Keratotomy Prior to Incision Opening
Presenting Author: Sachin Jain MD
Co-Author(s): Joshua H Hou MD, Maria S Cortina MD, Jose J de la Cruz Napoli MD*
Purpose: To determine the topographic impact of unopened femtosecond laser-assisted
arcuate keratotomy (FLAAK). Methods: Retrospective review of patients who underwent
FLAAK from October 2012 to February 2014 at a single institution. Patients were excluded if
pre- or postoperative topographies were unavailable. Astigmatic calculator and topographic SimK were used to determine arcuate keratomy (AK) position and arc length. Results: In
the 23 patients included, average preop astigmatism was 1.4 D (range, 0.32.6 D). Anterior
and posterior corneal astigmatism decreased by a mean of 0.065 D (standard deviation
[SD], 0.68) and 0.030 D (SD, 0.17), respectively. Conclusion: Corneal astigmatism was
minimally decreased by unopened FLAAK. Placement of AK wounds at the time of cataract
surgery allows for the option of future astigmatism titration while having minimal effect at
the time of placement.

Evaluation of Visual Outcomes Following Artisan Lens
Implantation in Complicated Cataract Surgery
Presenting Author: Hossein Mohammad Rabie MD**
Co-Author(s): Ahmad Shojaei-Baghini MD, Hamid Norouzi**, Kourosh Sheibani
Purpose: To determine the visual outcome in eyes undergoing primary aphakic artisan lens
implantation due to complicated cataract surgery. Methods: Forty eyes were examined
preoperatively and one day, one week, and one, three, and six months following surgery.
Patients were followed up for at least six months. Results: At final follow-up, 81.8% of
eyes experienced an improvement in best spectacle-corrected visual acuity (BSCVA) compared with that measured preoperatively, 9.1% of eyes matched their preoperative BSCVA
and 9.1% of eyes experienced a decline in BSCVA compared with that measured preop-
Scientific Posters
eratively. Conclusion: This study suggests that despite the probable complications after
primary artisan aphakia lens implantation, these lenses are beneficial to improve visual
outcome in aphakic eyes undergoing complicated surgery.

Treatment Outcomes for Pseudophakic Negative
Dysphotopsia
Presenting Author: Jewel L Sandy MD
Purpose: To evaluate the benefit of various treatment modalities to address pseudophakic negative dysphotopsia. Methods: Data of patients with pseudophakic negative dysphotopsia treated with either Nd:YAG laser anterior capsulectomy or IOL exchange were
reviewed retrospectively. Primary outcome was partial or complete resolution of negative
dysphotopsia symptoms six months postoperatively. Results: Fifteen eyes with negative
dysphotopsia were treated. Seven of nine eyes treated with Nd:YAG laser anterior capsulectomy and two of six eyes treated with IOL exchange had partial or complete resolution
of symptoms by six months. Conclusion: Modification of the anterior capsule-IOL relationship is important for the resolution of negative dysphotopsia symptoms. No one treatment
method yielded consistent results, suggesting a multifactorial etiology.

The Effect of OMS302 on Pupil Diameter in Patients With
Diabetes Mellitus During IOL Replacement
Presenting Author: Alan S Crandall MD*
Co-Author(s): David R Hardten MD*, David Schaaf MD*, Eric D Donnenfeld MD*
Purpose: OMS302, a new drug product containing phenylephrine and ketorolac, is added
to irrigation fluid during IOL replacement . This analysis evaluated the effect of OMS302 on
intraoperative pupil diameter in patients with diabetes mellitus (DM) in a high-risk population. Methods: Patients with DM across three clinical trials were included in the analysis.
Pupil diameter was measured every minute during the procedure and analyzed as the mean
area under the curve of the change from baseline. Results: In the 184 patients with DM,
placebo patients experienced more pupil constriction than OMS302 patients (P < 0.0001).
Adverse events were comparable between placebo and OMS302 patients. Conclusion: In
these studies, OMS302 improved intraoperative pupil management and was well tolerated
in a population with DM, a group prone to intraoperative miosis.

Lenticular Changes in Congenital Iridolenticular Choroidal
Coloboma
Presenting Author: Muralidhar Ramappa MBBS
Co-Author(s): Ashik Mohamed MBBS, Sunita Chaurasia MD, Virender S Sangwan
MBBS, Subhadra Jalali MS

Practice Eyes for Wet Lab Training in the Use of Iris Hooks,
Capsule Support Hooks, and Insertion of Capsular Tension
Ring and Pupil Dilating Ring
Presenting Author: Satish C Gupta MBBS MS
Purpose: To present the method of use of the dummy eyes for wet lab training in the use of
iris hooks and capsule hooks and the insertion of a pupil expander and capsular tension ring
(CTR). Methods: The dummy eye consists of a flexible transparent cornea fixed in a plastic
casing and mounted on a stand for stability. Iris module consists of a flexible iris with a
central 3-mm pupil. Capsule module has a capsular bag with a 5-mm capsulorhexis and
subluxation in one quadrant. Results: The trainee gets to practice steps needed for insertion of the hooks pulling the iris/capsule and locking the stopper in place and insertion
and placement of the pupil expander and CTR Conclusion: The dummy eyes give a very
good opportunity for the beginners to practice the use of iris hooks and capsule hooks and
insertion of a pupil expander and CTR in a wet lab setting.

SOE Comparison of Femtosecond Laser Cataract Surgery
With the Manual Procedure in a Contralateral Comparative
Study
Presenting Author: Gerd U Auffarth MD*
Co-Author(s): Ramin Khoramnia MD*, Anna Fitting MS**, Mary Attia MBBCH*,
Florian Niklas Auerbach MD, Mike P Holzer MD*
Purpose: To compare femtosecond laser cataract surgery with conventional surgery.
Methods: In a prospective, contralateral, comparative, randomized, single-center study,
capsulotomy and lens fragmentation is performed with the Victus Femtosecond Laser
(Bausch & Lomb/Technolas) in one eye of each patient. In the fellow eye, the manual technique is used. Main outcome parameter included effective phacoemulsification time (EPT),
absolute phacoemulsification time (APT), and endothelial cell loss. Results: Median EPT
was significantly lower in the laser group (1.06 vs. 2.21 seconds). No statistically significant
difference between both groups was found in terms of APT (7.70 vs. 13.71 seconds). Lower
endothelial cell loss was seen in the laser group. Conclusion: Femtosecond laser cataract
surgery reduces EPT significantly, with more precise and centered capsulotomies and less
endothelial cell loss.

Femtosecond Laser-Assisted Cataract Surgery in the
Presence of Corneal Opacity
Presenting Author: Safaa Ibrahim Beheiri
Co-Author(s): William May MD**
Purpose: In Saudi Arabia, corneal opacity is present in one-half of cataract surgery patients. We evaluated the ability of the femtosecond laser to make incisions through opaque
corneas. Methods: We developed a scale to grade corneal opacities. The corneal opacity
grading scale grades the opacity in terms of the observers ability to recognize iris details
from one to three. After grading opacity, the default settings of the Alcon LensEx were used
in eight consecutive cataract surgery patients with corneal opacity. Results: In all patients
with peripheral corneal opacity, the primary incision was successful. Three of these patients had complete opacity. Four cases had central corneal opacity. All had complete capsulorhexis. Conclusion: Even patients with complete corneal opacity may be candidates
for femtosecond laser-assisted cataract surgery.

SOE Opacification of Hydrophilic Acrylic IOLs After
Vitreoretinal Surgery
Presenting Author: Jose Juan Martinez Toldos MD

Laser Capsulotomy With the LensAR Laser Is as Effective
as Manual Continuous Capsulorrhexis in Supracapsular
Cataract Surgery
Co-Author(s): Aida Navarro-Navarro MBBS, Cristian Fernandez MD, Fernando

Hernandez-Artola MD, Javier Clavel Laria MD
Presenting Author: William J Lahners MD*

Co-Author(s): William L Soscia MD**
Purpose: To describe four cases of secondary optic lens opacification in hydrophilic IOLs
after vitreoretinal surgery. Methods: Decreased vision with central optic lens opacification
was observed in all cases. Surgical extraction of the IOL was performed with implantation
of a new hydrophobic lens. The explanted lens was examined using electron microscopy
and spectrometry. Results: In all cases, central optic lens opacification with calcium deposits was confirmed in patients who underwent several surgeries after IOL implantation due
to vitreoretinal diseases. Conclusion: We describe a rare complication where hydrophilic
lenses can suffer central opacification when the patient is subjected to several complex
interventions with a significant inflammatory process.
Purpose: To determine if laser capsulotomy with the LensAR laser is as effective as manual continuous capsulorrhexis in supracapsular surgery. Methods: We performed 1,195
cases of LensAR-assisted laser cataract surgery and 862 cases of matched controls manually. In all cases, the lens was hydrodissected into the iris plane. Results: There was one
anterior capsular tear without vitreous loss with LensAR and one anterior capsular tear
without vitreous loss with manual. One capsule complication was seen in 1,195 consecutive LensAR capsulotomy cases and one capsule complication in the 862 manual cases (P =
0.320). Conclusion: There was no difference in capsular complications between LensAR
and manual techniques. There was no clinically significant difference in the strength of the
capsulotomy in LensAR-assisted cataract surgery versus manual.
169
Scientific Posters
Purpose: To evaluate lenticular changes in congenital iridolenticular retinochoroidal coloboma. Methods: Medical records of patients (n = 98; median age, 23 years; approximately
1:1 male to female) with this diagnosis (48% bilateral) seen at a tertiary eye care center
in 2011 to 2012 were reviewed retrospectively. Results: Lens showed cataract in 68 eyes
(48.9%), one-half (51%) being nuclear sclerosis. A distinct type named coloboma cataract
(characterized by linear opacity in the region of coloboma) was seen in 29%. Disc and/or
macular involvement in 57 eyes (39.3%) did not influence the type or density of cataract
(P > 0.05). Conclusion: A distinct description with nomenclature coloboma cataract is
suggested to be considered in clinical grading of cataract in such conditions associated
with early cataractous changes.
Scientific Posters
SOE Accommodation Amplitude and Visual Acuity of the
Accommodative IOL, the AkkoLens Lumina

Cataract Surgery Practice and Endophthalmitis Prophylaxis
in Australia
Presenting Author: Jorge L Alio MD PhD*
Presenting Author: Jonathon Q Ng MBBS*
Co-Author(s): Ana Belen Plaza MS**, Alfredo Vega-Estrada MD, Alexander Angelov
Angelov MD, Yavor Petrov Angelov MS
Co-Author(s): Max Bulsara**, Nigel Morlet MBBS
Purpose: To compare the accommodation response and visual acuity of the Akkolens Lumina with a monofocal IOL. Methods: Two groups of eyes are differentiated: group A, 18 eyes
implanted with the accommodative Akkolens Lumina IOL and Group B, eight eyes implanted
with the monofocal Acrysof SA60AT. Main outcomes measures were near visual acuity,
defocus curve, contrast sensitivity, and objective accommodation. Results: Postoperatively
better uncorrected near visual acuity and distance-corrected near visual acuity were found
for group A (P 0.01). In the defocus curve, significant better visual acuities were observed
for group A (P 0.02). No statistical differences were detected between groups in contrast
sensitivity (P 0.28). Conclusion: The Akkolens Lumina restores the visual function with
good near visual acuity due to the accommodation provided.

Pseudophakic Dysphotopsia

Analysis of Higher-Order Aberrations After Intrascleral
Fixation of Posterior IOLs
Presenting Author: Robert Dale Pilkinton Jr MD
Presenting Author: Kenji Yamamoto MD PhD
Purpose: To evaluate the occurrence of negative and positive dysphotopsia between a

larger ovoid monofocal IOL and other monofocal IOLs. Methods: A dysphotopsia questionnaire was given to patients at two to three weeks postop over a two-month period. This
standard questionnaire measures the presence and severity of both positive and negative
dysphotopsia. Results: The most common lenses implanted were the AMO Z9002, a 6-mm
silicone three-piece lens, the Softec HD, a 6-mm hydrophilic acrylic one-piece lens, and the
Softec HDO, a 6.5- by 5.75-mm oval hydrophilic acrylic one-piece lens. The incidence of
negative dysphotopsia was 30.4%, 25%, and 1.9%. The incidence of halo was 13%, 29%,
and 13.4%. The incidence of streaks was 15.9%, 39.5%, and 17.3%. Lastly, the incidence of
unwanted images was 1.4%, 12.5%, and 3.8%. Conclusion: Negative dysphotopsia was
greatly reduced in the Softec HDO.
Co-Author(s): , Akira Murakami MD, Tetsuro Oshika MD

Visual and Optical Performance With a Small-Aperture IOL

H Orthopedic Benefits of Visual Restoration Measured
With Cataract and Simulated Patients
Presenting Author: Robert Edward T Ang MD*
Scientific Posters
Purpose: To determine current cataract surgery practice in Australia. Methods: Australian ophthalmologists were surveyed about their cataract surgery practices and methods of
chemoprophylaxis. Results: The 407 respondents reported 118,170 cataract operations.
Self-reported postoperative endophthalmitis incidence (0.01%) decreased five-fold compared with a 2003 survey. Phacoemulsification was predominant (96%) with femtosecond
laser-assisted cataract surgery comprising 3% of operations. Almost 70% of operations
were under anesthetic block (43.5% peribulbar, 21.3% subtenons, and 5% retrobulbar),
with temporal corneal wounds most popular. Intracameral antibiotic use increased from 5%
of surgeons in 2003 to 78%. Conclusion: The reduction in postoperative endophthalmitis
may be related to the marked uptake in use of intracameral antibiotics.
Purpose: Previous studies have reported a correlation between intraocular coma-like aberrations and the amount of tilt of IOLs. We compared intraocular coma aberrations after
standard cataract surgery (in-the-bag group), intrascleral IOL haptics fixation (intrascleral
fixation group), and conventional transscleral suture fixation of the IOL (suture group).
Methods: Aberration was measured with a wavefront sensor in 25, 26, and 20 eyes, respectively. Results: Mean aberration was 0.11 0.08, 0.13 0.07, and 0.21 0.11 m,
respectively. Values were significantly larger in the suture group than the other groups (P
< 0.01, Scheffes F test). Conclusion: Intrascleral haptic fixation technique allows smaller
IOL tilt, resulting in better optical outcomes after surgery.
Co-Author(s): Gunther Grabner MD*
Presenting Author: Masahiko Ayaki MD
Purpose: To evaluate visual performance of patients implanted monocularly with a small

aperture hydrophobic IOL (HP-SA-IOL). Methods: Prospective, nonrandomized study of
cataract patients who were implanted monocularly with a single-piece hydrophobic acrylic
IOL with a centrally located opaque annular mask measuring 3.23 mm in total diameter
with a 1.36-mm central aperture. Visual acuity was evaluated at six months. Results: At
six months, mean binocular uncorrected distance visual acuity (UCDVA) and uncorrected
intermediate visual acuity (UCIVA) were 20/20. Mean uncorrected near visual acuity (UCNVA) was 20/25. Additionally, 100%, 82%, and 91% of patients achieved 20/25 or better
for UCDVA, UCIVA, and UCNVA, respectively. Conclusion: Early results demonstrate monocular HP-SA-IOL implantation provides a continuous, broad range of vision and excellent
acuity across all focal distances.
Co-Author(s): Kazuno Negishi MD, Kazuo Tsubota MD*

Purpose: To measure and simulate improvement of mobility after cataract surgery. Methods: The participants included 223 cataract patients (mean age, 74 years) and 197 subjects with normal vision. Four-meter gait speed was measured. Three-dimensional motion
analysis with eight-camera capture system was performed for 11 simulated patients with
impaired vision to 20/2000, hand motion, or no light perception. Results: Mean gait speed
was 0.86 0.18 m/s before surgery, 0.96 0.23 m/s two months after surgery, 0.98 0.24
m/s seven months after surgery, and 0.88 0.23 m/sec for controls. Gait speed increased
significantly for seven months after surgery (P < 0.05, t-test). The results of gait speed and
one leg standing of simulated patients were closely correlated with vision. Conclusion:
Visual restoration may be beneficial to maintain postural control.

SOE Results of 6 Years Experience With Plate TorsionHaptic IOLs

Transconjunctival Sutureless Needle-Guided Intrascleral
IOL Fixation
Presenting Author: Sergey Kuznetsov MD*
Presenting Author: Shin Yamane MD
Co-Author(s): Timur Galeev**, Andrey Zolotarev**
Co-Author(s): Maiko Inoue MD, Akira Arakawa MD, Kazuaki Kadonosono MD
Purpose: Clinical study of six-year results of implantation of plate torsion-haptic IOL

(PTHIOL; open-bag device) in patients with age cataract. Methods: PTHIOL by Reper-NN
were used in 207 eyes of 175 patients with age cataract during a routine phaco through
2.2-mm incision. PTHIOL position was monitored by ultrasound biomicroscopy (UBM) in
follow-up from six months to six years (4.14 1.51 years). Results: Visual acuity was at
mean 0.72 0.15. Correct and stable PTHIOL position was proved by UBM. In studied group,
the parameters of the capsular bag with implanted PTHIOL did not significantly differ from
those of the native lens. Refractive error was less than 1.0 D in 95.65% of all cases. Secondary cataract was observed in five cases (2.42%) of follow-up. Conclusion: The study
shows that PTHIOL really can restore eye anatomic parameters and decrease a number of
secondary cataracts.
Purpose: To report clinical and experimental outcomes of a new technique for intrascleral
fixation of an IOL. Methods: Two angled incisions parallel to the limbus were made by 30-G
needles. Haptics of an IOL were externalized with the needles and cauterized. The cauterized haptics were pushed back and fixed into the scleral incisions. Strength of the haptic
fixation was evaluated using porcine eyes. Results: Thirty eyes of 30 patients underwent
this surgery. The mean IOL tilt was 3.2 degrees. The mean best-corrected visual acuity was
improved from 0.38 to 0.70 (P = 0.03). The force to pull out cauterized haptic from porcine
sclera was over 0.8 N . Conclusion: This simple technique provides good functional and
anatomical outcomes and solid IOL fixation.
170
Scientific Posters
H Randomized Controlled Trial of the Efficacy of PovidoneIodine in Reducing Bacterial Load Prior to Cataract Surgery
when Premedicated With Gel vs. Drops

Comparison of Predicted Vault on Ultrasound
Biomicroscopy and Postoperative Vault on Anterior
Segment OCT in Patients with Implantable Collamer Lens
Presenting Author: Joshua C Teichman MD
Presenting Author: Vishal Arora MD
Co-Author(s): Michael Ying Kit Mak, Nina Ahuja MD, Dalia M Eino MD**,Varun
Chaudhary MD**
Co-Author(s): Mathew Kurian MD MBBS, Shama Chandrashekhar Shaligram Sr, Rohit

Shetty MD MBBS
Purpose: Laboratory studies suggest that the antiseptic effect of povidone-iodine may
be inhibited by application of gels to the eye. The purpose of this study is to elucidate if
this is seen clinically. Methods: Randomized controlled trial. Patients were randomized
to medications in gel versus liquid form. The skin and eye were cleansed with povidoneiodine. The conjunctiva was swabbed and plated. Colony forming units (CFU) were read by
masked readers. Results: For this trial, 104 eyes were included. Prerandomization, there
were no differences in CFU between the groups (P = 0.3197). Post-povidone-iodine, mean
CFU was 0.019 in both groups. Linear regression revealed no significant difference between
the groups on blood or chocolate agar (P = 0.989 for both). Conclusion: There were no
significant differences in CFU after gel or liquid premedication.
Purpose: To compare predicted vault with ultrasound biomicroscopy (UBM) and postoperative vault on anterior segment optical coherence tomography (ASOCT) in patients with
implantable collamer lenses (ICLs). Methods: Preoperative ASOCT and UBM were done for
23 patients who underwent ICL implantation. Predicted vault from UBM was calculated and
compared with postoperative vault on ASOCT. Results: Mean age was 25.09 3.46 years,
with mean spherical equivalent of -11.73 5.51 D. Preop anterior chamber depth was
comparable on UBM and ASOCT (P = 0.86). Postop vault (0.57 0.14 mm) on ASOCT was
comparable to predicted vault (0.66 0.21 mm) on UBM (P = 0.06). Two patients needed
resizing of ICL on the basis of preop UBM. Conclusion: UBM can be used to predict postop
vault in patients undergoing ICL implantation.

Risk Factors for Phacoemulsification-Related
Endophthalmitis, Other Than Prophylaxis

Macular Edema Following Intravitreal Triamcinolone as an
Alternative to Postcataract Anti-inflammatory Drops
Presenting Author: Lisa Herrinton PhD*
Presenting Author: James S Lewis MD*
Co-Author(s): William J Chang MD
Purpose: To investigate postcataract macula thickness when intravitreal triamcinolone is

used in lieu of topical steroids and nonsteroidal anti-inflammatory drugs (NSAIDs). Methods: Two hundred consecutive cataract patients were followed with OCT assessment preoperatively and one day, one week, one month, and two months following uncomplicated
surgery. Transzonular injection of 0.2 cc of a compounded medication containing triamcinolone acetonide was performed at the end of each case. Macula scans were performed
at the intervals described. Results: Macula thickness was not statistically different from
those reported in the literature for patients treated with topical steroids and NSAIDS. Conclusion: Transzonular triamcinolone matches topical anti-inflammatory drops in control of
OCT-detectible postcataract macular edema.
Purpose: To examine risk factors for endophthalmitis other than prophylactic antibiotic.
Methods: Retrospective cohort study of 150,086 Kaiser Permanente members, from 2005
to 2012. Endophthalmitis (118) was confirmed with chart review. Logistic regression analysis evaluated age, year of surgery, comorbidity, and posterior capsular rupture (PCR) after
accounting for prophylaxis and surgeon. Results: Risk of endophthalmitis declined 6% with
each calendar year (CI, 5%7%) and increased by a factor of 1.76 (CI, 1.152.70) with
ocular comorbidity and by a factor of 3.9 (CI, 1.59.8) with PCR. Age (OR, 1.0; CI, 0.981.03)
and systemic comorbidity (OR, 1.02; CI, 0.821.13) were not related to endophthalmitis.
Conclusion: PCR remains a target for quality improvement.

SOE Assessing the Imaging Quality of Different Multifocal
IOLs With Different Optics
Presenting Author: Gerd U Auffarth MD*
Co-Author(s): Tamer Tandogan MD**, Ramin Khoramnia MD*, Florian T A Kretz MD*

Systemic Pharmacokinetics of Phenylephrine / Ketorolac
Irrigating Solution During IOL Replacement Procedures
Presenting Author: John A Hovanesian MD*
Co-Author(s): Mitchell Jackson MD*, Johnny L Gayton MD*
Purpose: OMS302, a new combination of phenylephrine (PE) and ketorolac (KE), is added
to irrigation fluid used during an IOL replacement procedure (ILR). This studys purpose was
to assess systemic exposure of KE and PE. Methods: In a Phase 3 trial of subjects undergoing ILR, plasma concentrations of PE and KE were measured prior to surgery and at 15,
30, 60, 120, 240, 480, and 1,440 minutes following the start of study drug administration.
Results: Twenty-six subjects (14 OMS302) entered this PK study; only one had detectable
PE levels, and the highest level preceded OMS302 administration, most likely due to preoperative drops. Ten subjects had detectable levels of KE, the highest of which was lower
than the range reported for topical KE drops. Conclusion: OMS302 administration during
ILR resulted in minimal to no systemic exposure to PE or KE.

Visual Results and Patient Satisfaction: Trifocal Diffractive
vs. Bifocal Diffractive IOLs

SOE A Novel Iridoplasty Suture Technique to Repair Iris
Defects and Traumatic Mydriasis
Presenting Author: Luis Izquierdo Jr MD

Co-Author(s): Maria A Henriquez MD, Mauricio Rodriguez Sr**
Purpose: To evaluate visual outcomes after cataract surgery with trifocal diffractive
IOL and bifocal diffractive IOL. Methods: A prospective, comparative study included 30
patients with bilateral Tecnis ZBM00 and 30 patients with bilateral FineVision (Physiol)
IOL between September 2012 and November 2013. At three months, postoperative near,
intermediate, and distance visual acuities, defocus curve, and patient satisfaction were
compared. Results: There was no statistically significant difference between the groups in
uncorrected distance, intermediate, and near visual acuity (P > 0.05, all). The range of focus
in intermediate vision was larger in the trifocal group (P < 0.001, all). Conclusion: Both
IOLs showed excellent near and distance visual acuity. The trifocal IOL showed larger range
of focus in intermediate vision.
Presenting Author: Levent Veysel Karabas MD

Co-Author(s): Ozlem Sahin MD**, Sengul C Ozdek MD*
Purpose: To describe a new U-shaped iridoplasty suture technique. Methods: Two 0.9mm corneal incisons were created. An Alcon PC-9 needle was used. One of the suture
loops was cut close to its needle insertion. The needle was inserted through the first incision, passed through iris leaflets, and externalized through the other side, and the needle
was reinserted, passed through the iris again to create an U-shaped suture, and taken out
from the initial incision. Modified Siepser technique was performed to secure the suture,
or, alternatively, suture ends were pulled out by a 23-G forceps and tied, and the knot was
inserted and secured by using an IOL manipulator. Results: Satisfactory aesthetic and functional results were achieved in all cases. Conclusion: U-shape suture is an easy-to-use,
effective, and safe iridoplasty technique.
171
Scientific Posters
Purpose: To assess optical quality for different multifocal IOLs (MIOLs). Methods: Optical
bench analysis (OptiSpheric IOL, Trioptics) was performed for Mplus LS-313 MF30, Oculentis; M-Flex 630F, Rayner; AcriLisa 809M, Carl Zeiss Meditech; Restor SN6AD1, Alcon; and
Tecnis ZMB00, AMO. Analyzed parameters included MTF , TFS, EFL, Autofocus, and USAF.
Results: Distance sagittal MTF values were as follows: M-Flex = 0.119; Mplus = 0.161;
Restor = 0.194; AcriLisa = 0.153; and Tecnis = 0.163. Energy loss with a 4-mm apperture
was, respectively, 7% (Mplus), 14% (M-Flex), 19% (AcriLisa), 22% (Restore), and 22% (Tecnis). Conclusion: Energy loss was significantly lower in asymmetric, segmental the MIOL
compared with the other symmetric refractive or diffractive models.
Scientific Posters
Evaluation of Wound Closure Techniques in Large Clear
Corneal Incisions
Presenting Author: Rajesh K Rajpal MD*
Co-Author(s): John A Hovanesian MD*, John F Doane MD*, Farrell Tyson II MD**,
Josef Tamory, Sachin D Rajpal MS
Purpose: To evaluate sutures versus an ocular sealant for wound closure in 3.0- to 3.5-mm
incisions. Methods: Cataract patients with a demonstrated wound leak were randomized
to a 10-0 nylon suture or the ReSure Sealant in a prospective multicenter study. Up to
1-oz force was applied using an ocular force gauge intraoperatively to assess fluid egress
pre- and postrandomization. Results: Sixty-four patients were evaluated at nine U.S. clinical sites. Patients randomized to suture (26) experienced a leak rate of 38.5% versus the
sealant (38) at 2.6%. Device-related adverse event rates were 26.9% for suture and 0.0%
for sealant patients. Conclusion: Incisions may require enlargement during surgery due to
type of IOL, etc. The sealant demonstrated more effective wound closure than sutures with
fewer adverse events.
Scientific Posters

SESSION ONE, SATURDAY & SUNDAY
Confocal Scan Study of Corneal Grafts Following Descemeton vs. Descemet-off Deep Anterior Lamellar Keratoplasty
Presenting Author: Hamidreza Hasani MD
Co-Author(s): Sepehr Feizi, MohamadAli Zare Mehrjerdi MD**, Roghiyeh
Shamsoddinimotlagh MD, Shahin Yazdani MD
Purpose: To compare the confocal features of grafts following big-bubble deep anterior
lamellar keratoplasty using a donor without Descemet membrane (DM) to those of grafts
from a donor with intact DM. Methods: Of 45 keratoconic eyes, 27 received DM-free donor
tissue (Group 1), and 18 received donor tissue with an intact DM (Group 2). A group of
normal eyes (n = 28, Group 3) served as controls. Confocal scan was used to determine
keratocyte density, explore the donor-recipient interface, and evaluate endothelial cell density and morphology. Results: Significantly more severe interface haziness was observed
when donor DM was retained (mean interface reflectivity value of 102.7 2 vs. 161.7 3
light reflectance units in Groups 1 and 2, respectively; P < .001). Conclusion: Graft cellular
profiles and healing response at the donor-recipient interface can be profoundly affected,
depending on DM removal or retention.

Design and Rapid Prototyping of a Novel 3-D Printed
Smartphone Lens Adapter System
Descemet-on vs. Descemet-off Deep Anterior Lamellar
Keratoplasty: Does It Make a Difference?
Presenting Author: David Myung MD*
Co-Author(s): Alexandre Jais MS, Lingmin He MD*, Mark S Blumenkranz MD*, Robert
T Chang MD*
Co-Author(s): MohamadAli Zare Mehrjerdi MD**, Sepehr Feizi, Roghiyeh

Shamsoddinimotlagh MD
Purpose: To develop a modular 3D-printed smartphone lens adapter system for both anterior and posterior segment imaging. Methods: A computer-aided design model of the
adapter system was rendered and initially printed at the Stanford Product Realization
Laboratory using a Multi-Jet Modeling 3D Printer. Subsequent adapters were printed out
of black, laser-sintered polyamide material with higher print quality. Results: The adapter
system captured high-quality anterior and posterior segment photographs. Fundus photographs taken with the adapter provided a wider field of view compared to those taken with
the Welch Allyn iExaminer. Conclusion: A novel 3D-printed lens adapter system has been
developed that enables high quality images of the eye using smartphones and may lower
the barrier to mobile teleophthalmology.
Purpose: To determine the effect of retained donor Descemet membranes on visual outcomes, contrast sensitivity (CS), higher-order aberrations (HOA), and central graft thickness
after deep anterior lamellar keratoplasty (DALK) using the big-bubble technique. Methods:
A donor cornea without DM (Group 1; 48 eyes) or with DM (Group 2; 22 eyes) was sutured to the recipient bed. Results: The postoperative BSCVA was 0.18 logMAR and 0.24
logMAR, respectively(P = .36). The 2 groups had comparable postoperative keratometric
astigmatism, spherical equivalent refraction, and HOAs. In terms of CS, however, Group
1 demonstrated better results at a low spatial frequency. Conclusion: DALK performed
using the big-bubble technique for keratoconus may give better results in terms of CS if a
donor cornea without the DM is transplanted.

Web-Based Patient Referral System
SOE Limbal Stem Cell Transplantation in Congenital Aniridia
Presenting Author: Hussein Wafapoor MD*

Co-Author(s): Alexander M Eaton MD*
Purpose: To develop a Web-based patient referral portal, which would facilitate patient
exchange between diferrent offices independent of the electronic health record system
used. Methods: Initially, a prototype using HTML and static pages was developed. A
Web-based system was created using ASP.NET, CSharp, and SQL servers. A secure Health
Insurance Portability and Accountability Act-compliant testing environment with SSL was
selected for hosting. Testing of 250 offices was performed for quality assurance (QA). Fictitious incoming and outgoing patients were created and referred. Once QA was completed,
seven local ophthalmic/optometric pratices were signed up for live referrals. A warning
email system was set up if a failure in scheduling was detected. Results: A total of 520
patients were referred electronically. Conclusion: We have created a Web-based referring
system that may facilitate patient referral.
Presenting Author: Osman S Arslan MD

Co-Author(s): Yonca A Akova MD*, Olgu Capar MD, Ceyhun Arici Sr MD, Mustafa
Unal MD**
Purpose: To present our outcomes of conjunctival-limbal allograft transplantation in congenital aniridia (CA) patients. Methods: Twelve eyes of 9 patients (5 male, 4 female) with
CA were treated with allogeneic conjunctival-limbal transplantation (7 partial, 5 total).
First-degree relatives with HLA-DRB1 compatibility were chosen as donors. Four eyes of
2 first-degree relatives were used as stem cell donors in 360-degree limbal stem cell deficiency cases. Results: Mean follow-up time was 38.7 17.9 months. Age range was
between 11 and 29 years. Eight (66.6%) achieved a stable ocular surface. Overall, the mean
visual acuity improved from 20/1000 to 20/165. Conclusion: Limbal stem cell transplantation seems to be an effective method to provide sustainable ocular surface, although it
needs long-term follow-up and strict medical attention.
Endothelial Cell Densities in Congenital Hereditary
Endothelial Dystrophy
Presenting Author: Ali A AlRajhi MD
Purpose: To report endothelial cell densities (ECD) in congenital hereditary endothelial
dystrophy (CHED). Methods: Fifteen patients (20 eyes) with a mean age of 7 years (range:
1-20), underwent pachymetry prior to surgery, specular microscopy (SM), and scanning
electron microscopy (SEM) for corneal buttons of CHED eyes during penetrating keratoplasty. Results: Corneal thickness was 1147 m (1060-1200) centrally and 1114 m (987-1080)
peripherally. Mean ECD by SM and SEM was 1690 (550-2650) and 1504 (640-2184) cen-
172
Scientific Posters
trally and 1336 (550-2050) and 1511 (867-2084) peripherally, respectively. The Descemet
membrane was covered by endothelium in 78%-84%. Conclusion: Corneal edema with
adequate ECD could be due to dysfunctional endothelium.
was an increase in the apoptotic markers and a concurrent decrease in the proliferation
markers in LECs exposed to A-CXL. Conclusion: The higher energy dosage delivered in the
A-CXL procedure has a more severe adverse effect on the cultured LECs.
Intracorneal Scleral Patch-Supported Cyanoacrylate
Application for Corneal Perforations Secondary to
Rheumatoid Arthritis
SOE Corneal Collagen Crosslinking With Ionthophoresis
Imbibition: Clinical and Morphological Results
Presenting Author: Ashok Sharma MD**
Co-Author(s): Roberta Calienno MD, Niccolo Salgari**, Mario Nubile MD, Leonardo
Mastropasqua**
Co-Author(s): Verinder S Nirankari MD
Presenting Author: Manuela Lanzini MD PhD
Purpose: To evaluate results of intracorneal scleral patch (ICSP)-supported cyanoacrylate

tissue adhesive (CTA) applications in corneal perforations greater than 3.0 mm secondary
to rheumatoid arthritis (RA). Methods:Prospective, nonrandomized series included 14 eyes
(age range: 34-72 years) with corneal perforations of 3.5-4.5 mm (mean: 3.9 mm) due to
RA treated with ICSP-supported CTA application. Results: All 14 eyes (100%) healed with
corneal opacity. No eyes developed infectious keratitis or wound leak requiring penetrating
keratoplasty. Conclusion: ICSP-supported CTA application is an effective modality in treating corneal perforations (3.5-4.5 mm) with associated RA.
Purpose: To describe clinical and morphological results of collagen crosslinking (CXL)

with iontophoresis. Methods: Thirty-five eyes with progressive keratoconus underwent
CXL with iontophoresis imbibition and irradiation at 10 mW. Clinical, morphological, and
biomechanical evaluation was performed preoperatively and at 1 hour, 1 day, 1 week, and
1, 3, 6, 9, and 12 months. Results: Stability of UCVA, BCVA, K1/2, and K-max was observed (P = ns). Confocal microscopy showed a superficial and transient epithelial damage.
The deformation index improved at 1 month (P = .039) and remained stable. No significant
changes were observed in anterior segment OCT. Conclusion: Iontophoresis in CXL is safe
and effective to stabilize progressive keratoconus with minimal damage on corneal tissue.
Antibodies to Salivary Gland Protein 1 Parotid Secretory
Protein and Carbonic Anhydrase VI in a Cohort of Patients
With Idiopathic Xerophthalmia
Accelerated vs. Conventional Corneal Collagen Crosslinking
in Progressive Keratoconus: Does Faster Work Better?
Presenting Author: Sandra L Everett MD

Co-Author(s): Sahana Vishwanath MBBS, Lakshmanan Suresh MS, Kishore
Malyavantham PhD*
Purpose: Sjgren syndrome (SS) is an autoimmune disease presenting with dry eyes. Antibodies to SP1, PSP, and CA VI have recently been described as markers for early SS. Methods: A group of 64 patients were studied. Dry eyes was confirmed by Schirmer testing. Sera
were evaluated for ANA, RF, Ro, La, anti-SP1, PSP, and CA VI. Results: Of the 64 patients,
12 expressed only antibodies to Ro and/or La, and 18 patients were Ro and La negative. Of
the 18 Ro- and La-negative patients, 13 expressed antibodies to of SP1, PSP, and/or CA VI.
Three expressed ANA and/or RF, and 5 did not express any autoantibodies. Conclusion:
Many patients with idiopathic xerophthalmia have SS and express antibodies to SP1,
PSP, and CA VI but not the commonly recognized autoantibodies including ANA, RF, Ro, and
La, and this allows for early identification of SS.
Keratoconus in Children: Long-term Follow-up
Presenting Author: Enrique Graue MD
Purpose: To determine visual outcomes and risk factors for progression in patients
younger than 18 years old with keratoconus (KC). Methods: Retrospective chart review /
case series in a 6-year period. We evaluated as risk factors for progression: age, allergic
conjunctivitis, refraction, and KC grade. Results: We included 132 eyes of 79 patients;
mean age, 13.6 years; median follow-up, 33.6 months (up to 71 months); 82.1% had allergic
conjunctivitis and 40.2% showed progression. Progression was correlated with less than 13
years of age (RR 1.85) and greater severity of disease (RR 1.99). Conclusion: Progression
occurred in 40.2% of children with KC; younger age and greater severity were associated
with risk of progression.
Comparative Analysis of the Effect of Conventional and
Accelerated Corneal Crosslinking on Ex Vivo Cultured
Limbal Epithelial Cells
Presenting Author: Harsha Nagaraja MS
Co-Author(s): Rohit Shetty MD MBBS, Debashish Das PhD**, Ashwini Ranganath**,
Himanshu P Matalia MBBS**
Purpose: Accelerated corneal crosslinking (A-CXL) is becoming a treatment of choice for
patients with keratoconus. As a procedural safety assessment we have compared the effects of conventional crosslinking (C-CXL) with those of the A-CXL procedure on cultured
limbal epithelial cells (LECs). Methods: Cultured LECs were exposed to both C-CXL and
A-CXL. The outcome was assayed using molecular biological and biochemical tools for
proliferative, apoptotic, and regenerative markers. Results: The results showed that there
Co-Author(s): Mohammad Mehdi Sadoughi MD**, Roghiyeh Shamsoddinimotlagh MD

Purpose: To compare outcomes of accelerated with those of conventional corneal crosslinking (CXL) in progressive keratoconus. Methods: Sixty eyes of 30 patients randomly
received conventional CXL (3 mW/cm2 for 30 min) in one eye or accelerated CXL (18 mW/
cm2, 5 min) in the fellow eye. Results: Decrease in K-min and K-max were statistically
significant in the accelerated CXL group (P = .02) and the conventional CXL group (P = .03).
But there was no statistically significant difference in K-max change (P = .11), K-min change
(P = .43), uncorrected distance visual acuity (P = .61), or corrected distance visual acuity (P
= .52) between the 2 groups. The mean decrease of corneal hysteresis (P = .33), corneal resistance factor (P = .92), central corneal thickness (P = .061), and endothelial cell count (P =
.08) was similar in both groups. Conclusion: Refractive and visual outcome, biomechanical
and central corneal thickness changes, and endothelial cell loss were comparable in both
accelerated and conventional CXL methods.
Collagen Crosslinking in Infectious Keratitis: Does Light
Save the Sight?
Co-Author(s): Mohammad Mehdi Sadoughi MD**, Roghiyeh Shamsoddinimotlagh MD
Purpose: To evaluate the effect of collagen crosslinking (CXL) in the management of infectious keratitis. Methods: Forty eyes (22 male and 18 female) with active bacterial, fungal,
or Acanthamoebal keratitis after medical (20 eyes) or combined medical plus CXL treatment
(20 eyes) were enrolled. Results: The infectious keratitis was associated with bacteria in
26 eyes (65%), with fungus in 9 eyes (22.5%), and with Acanthamoeba in 5 eyes (12.5%).
The mean time of re-epithelialization after CXL was 15.41 1.8 days in the CXL group vs.
17.23 1 days in the control group (P = .04). Small infiltrations ( 3 mm) healed in 10.24
1 days in the CXL group vs. 15.38 1 days in the control group (P = .03). Conclusion:
Compared to conventional medical therapy, combined medical and CXL accelerate corneal
epithelialization. The smaller the lesion, the faster the healing time.
Sleep Position and Obstructive Sleep Apnea in Keratoconus
Presenting Author: Natasha V Nayak MD
Co-Author(s): Tenley N Bower MD, Leela V Raju MD, Amy Catherine Nau OD, Alex
Mammen MD**, Roheena M Kamyar MD**, Deepinder K Dhaliwal MD*
Purpose: To characterize sleep position and prevalence of obstructive sleep apnea (OSA)
in patients with keratoconus (KCN). Methods: Telephone survey (Berlin questionnaire for
OSA, sleep position) and retrospective chart review. Wilcoxon rank-sum test for analysis.
Results: Fifty-six KCN patients (39.9 14.1 years old; 66% males) were included. Six (11%)
had prior OSA diagnosis; another 13 (23%) were at high risk for OSA. Supine/prone (n =17
[30%]) vs. lateral decubitus (n =39 [60%]) sleepers had lower interocular differences in
Scheimpflug parameters: central corneal thickness, pachymetry at thinnest point, astigmatism, max keratometry, corneal toricity (P < .05 for each). Conclusion: Lateral decubitus
sleep positions are associated with more asymmetric KCN.
173
Scientific Posters
Co-Author(s): Arturo J Ramirez-Miranda MD*, Andrew Olivo Payne, Alejandro Navas

MD*, Jazmin Lucero Pedro-Aguilar MD, Aida Jimenez, Enrique O Graue Hernandez
MD
Scientific Posters
The Incidence of Tomographic Features of Keratoconus
in Patients With Sleep Apnea Syndrome: A Prospective
Randomized Double Masked Clinical Study
Pythium Insidiosum Keratitis: A Severe and Under-reported
Fungal Infection
Presenting Author: Brent R Mittelstaedt DO
Co-Author(s): Swapna Reddy Motukupally**, Prashant Garg MD*, Praveen Kumar

Balne, Varsha M Rathi DO
Co-Author(s): Matthew C Caldwell MD, Laura Rubinate MD, Vasudha A Panday MD,
James R Townley MD, Douglas Apsey MS OD
Purpose: To determine if a correlation exists between obstructive sleep apnea (OSA) and
keratoconus (KCN). Methods: 150 patients undergoing routine sleep studies were evaluated by Pentacam. Eyes with a Belin and Ambrsio total deviation value (D) of 1.6 or greater
were categorized as suspicious for KCN; and less than 1.6, as normal. The presence and
severity of OSA was determined by the Apnea Hypopnea Index (AHI) and the Respiratory
Distress Index (RDI). Results: Mean AHI separated by normal and suspicious keratoconus
indices were 9.8 and 23.6 (P = .033). Mean RDI separated by normal and suspicious were
18.3 and 34.5 (P = .034). Conclusion: The presence of Pentacam tomographic features of
KCN has a statistically significant positive correlation with the presence of OSA.
Photorefractive Keratectomy and Corneal Crosslinking in
Keratoconus
Purpose: To describe clinicomicrobiological features of patients with Pythium insidiosum keratitis. Methods: Corneal scrapings were examined by microscopy and culture.
Zoospore-based identification was confirmed by sequencing of ITS1-5.8S-ITS2 of rRNA
gene. Results: Eight patients (7/8, farmers), with clinically fungal keratitis (mean age: 45
6.2 years, M:F = 3:5), were seen between January and March of 2014. Vision was light
perception in 5 with corneal infiltrate > 25 mm2 in 7/8. Characteristic features were seen in
microscopy (7/8) and culture. Treated with natamycin, all patients worsened and required
penetrating keratoplasty. Conclusion: P insidiosum causes severe keratitis that responds
poorly to natamycin. Zoospore demonstration helps make a quick and reliable diagnosis.
Microbial Keratitis in Stevens-Johnson Syndrome:
Clinicomicrobiological Profile and Outcome
Presenting Author: Bhupesh Bagga MD FRCS MBBS
Presenting Author: Khalid F Tabbara MD*
Co-Author(s): Savitri Sharma MD, Virender S Sangwan MBBS
Co-Author(s): Ashraf Said Mahrous**, Samir S Shoughy MD
Purpose: To study clinicomicrobiological profile and outcome of microbial keratitis in Stevens-Johnson syndrome (SJS). Methods: Retrospective data review. Results: Data of 70
eyes were reviewed. Average time of presentation was 3 weeks from onset. Mean size of
ulcer was 3.5 mm. Fifty-five percent of ulcers responded to medical management. Average
time of response was 30 days. Six eyes needed tarsorrhaphy. eyes needed tissue adhesive
application. Two required therapeutic graft, and 1 got eviscerated. Positive culture was
isolated in 45 eyes (64.3%): bacterial, 60%; fungal, 11%; and polymicrobial, 37.8%. All
Gram-positive isolates were susceptible to vancomycin and Gram-negative isolates were
susceptible to gentamicin and amikacin. Conclusion: Corneal infections in SJS need a
systematic approach along with surface protective procedures.
Purpose: To evaluate the safety and efficacy of surface ablation followed by corneal crosslinking (CXL) in patients with keratoconus. Methods: Patients with contact lens intolerance, corneal thickness > 450 m, keratometry < 56 D, and corneal astigmatism < 6 D were
included. Results: Forty-four patients (30 males and 14 females) with mean age of 27 years
underwent PRK and CXL on the same day. There was significant improvement in visual acuity and keratometry. Patients had 20/40 or better vision in 91% of the cases. Conclusion:
Surface ablation with CXL is a safe and effective procedure in mild keratoconus.
Conjunctival Microbial Flora in Stevens-Johnson Syndrome
Ocular Sequelae Patients at a Tertiary Eye Care Center
Presenting Author: Namrata Sharma MD MBBS
Scientific Posters
Presenting Author: Savitri Sharma MD
SOE Cytoarchitecture of Corneal Epithelium Indicates the
Etiology of Infectious Keratitis
Co-Author(s): Renu Venugopal PhD, Sushil Kumari Sangwan PhD**, Geeta Satpathy
MD**, Rasik B Vajpayee MD
Presenting Author: Adrian P Smedowski MD
Purpose: To evaluate and compare conjunctival microbial flora in Stevens-Johnson syndrome (SJS) eyes (n =176) with controls (n = 73) prospectively. Method: Conjunctival
swabs were collected and cultured for bacteria and antibiotic resistance testing. Results:
104 eyes had positive cultures (59%)in SJS vs. 9 eyes (12.08%) in controls. In SJS eyes,
coagulase-negative Staphylococci was the most common (17%), followed by Staphylococcus aureus (10.7%)and Corynebacteriae (19.8%). Analysis of microbial flora between the 2
groups showed a significantly higher rate of positivity in the SJS group (46%) than in the
control group (P = .001). Multiple micro-organisms were found in 7 eyes. Sixteen percent
of isolates in SJS eyes showed resistance to fluoroquinolones. Conclusion: Conjunctival
microbial flora varies widely in SJS eyes, and the pathogenic organism may predispose
them for infection.
Purpose: To analyze histological findings of infectious keratitis in corneal epithelium.

Methods: In vivo corneal confocal microscopy in 190 infectious keratitis (72 viral, 66 bacterial, 34 fungal, 18 amoebal) was performed. Analysis of inflammatory cell infiltration,
superficial nerve plexus and cytology of epithelial cells was compared between groups. Results: Inflammatory cell densities showed no differences between groups; however, there
was various ratios of round / dendritic inflammatory cells: respectively, 0.07, 8.0, 1.0, and
1.2 for viral, bacterial, fungal, and amoebal keratitis (P < .05). Differences were observed
also in nerve fiber numbers (P < .05) and epithelial layer architecture. Conclusion: In vivo
analysis of corneal epithelial histology shows high specificity and sensitivity in infectious
keratitis diagnosis.
H Evaluation of Efficacy of Auro Keratoprosthesis in Endstage Corneal Disease
Presenting Author: Namrata Sharma MD MBBS
Co-Author(s): Rasik B Vajpayee MD
Purpose: To evaluate results of Auro keratoprosthesis (Auro KPro), a low-cost modification
of the Boston Keratoprosthesis in end-stage corneal disease, prospectively. Methods: Ten
eyes underwent Auro Kpro. Parameters analyzed were BCVA, retention, and complications.
Preoperative diagnoses were multiple failed grafts (n = 7), bullous keratopathy (n = 2), and
chemical injury (n = 1). Mean BCVA logMAR before surgery was 2.6 (range: 2-3); and after
surgery, 1.13 (range: 0.3-3). The most frequent complication was formation of retroprosthetic membrane (RPM) (n = 4), followed by glaucoma (n = 2). One eye underwent therapeutic
keratoplasty due to infection. Anatomical retention with ambulatory visual acuity was seen
in 9 eyes at 1 year follow-up. Conclusion: The Auro Kpro is a viable low-cost option in
end-stage corneal disease in developing countries.
174
Co-Author(s): Dorota Tarnawska MD, Edward A Wylegala MD PhD**
Persistence of Ocular Surface Disease After Resolution of
Infectious Keratitis
Presenting Author: Rodrigo Thiesen Muller MD
Co-Author(s): Bernardo Menelau Cavalcanti MD, Andrea C Cruzat MD**, Arsia Jamali
MD, Deborah P Langston MD FACS*, Pedram Hamrah MD*
Purpose: To analyze clinical and in vivo confocal microscopy (IVCM) findings in patients
with infectious keratitis (IK). Methods: Fifty-four patients with IK were evaluated prospectively during the acute phase, at cessation of antimicrobial therapy, and 1 to 6 months
thereafter. Clinical signs, symptoms, and corneal IVCM images were assessed. Results:
One to 6 months after resolution of infection, foreign body sensation (6.6%), tearing (6.6%),
photophobia (20.0%), and superficial punctate keratitis (52.9%) persisted. Despite regeneration, significantly lower corneal sub-basal nerve density (12.1 6.9 mm/mm2) was shown,
as compared to controls (24.1 5.1; P < .0001). Conclusion: Patients with IK demonstrate
persistent signs and symptoms after the resolution of IK, which may be related to persistent
corneal nerve alterations.
Scientific Posters
H Late Acute Graft Rejection After Kerato-Limbal Allograft
Topical Cysteamine Effects in Corneal Cystinosis
Presenting Author: Medi Eslani MD
Presenting Author: Amal I N Alhemidan MBBS
Co-Author(s): Alireza Baradaran-Rafii MD, Asadolah Movahedan, Adam M Moss MD,

Edward J Holland MD*, Ali R Djalilian MD
Co-Author(s): Mahmoud O Jaroudi MD, Khalid F Tabbara MD*
Purpose: To report late acute graft rejection (> 3.5 years) after successful kerato-limbal
allograft (KLAL). Methods: A retrospective review of 5 patients (2 aniridia, 3 chemical burn)
with late KLAL graft rejection who had either been tapered off of the immunosuppression (n
= 3) or were receiving inadequate levels (n = 2). Results: The mean time to acute KLAL graft
rejection was 52.2 7.4 months. The presenting signs in all cases included graft injection
and epithelial rejection line. Despite aggressive treatment, all patients developed sectoral
limbal stem cell deficiency. Conclusion: This study provides evidence for the persistence
of donor cells up to 5 years after KLAL. It suggests that while immunosuppression can be
tapered off successfully in many patients, in some cases long-term therapy may be necessary for graft survival.
Safety, Efficacy, and Ease of On-site Compounded
Autologous Serum in the Treatment of Ocular Surface
Disease
Presenting Author: Mona Sane MD
Co-Author(s): Archana Anil Gupta MBBS, James J Reidy MD**
Purpose: To describe on-site compounding of autologous serum (AS) in an office setting
and evaluate its safety and efficacy for treatment of chronic ocular surface diseases. Methods: Retrospective review of medical records of patients treated with on-site compounded
AS for noninfective nonhealing corneal epithelial defects from 2011 to 2014. Preparation
and storage of serum is described. Results: Seventy-five percent of eyes with neurotrophic
keratopathy, and all eyes with graft versus host disease and keratoconjunctivitis sicca
showed resolution of epithelial defects over an average of 5 months (25 days to 547 days),
with no incidence of microbial keratitis. Conclusion: AS prepared in office is safe, effective, and economically favorable in most patients with chronic ocular surface diseases
resistant to conventional therapies.
SOE The Risk Factors for Pterygium: A Field-Wide Metaanalysis Identifies Chaos and Brings Order
Presenting Author: Stylianos Serghiou
Co-Author(s): YanYu Tan**, Menelaos S Serghiou MD, John Ioannidis MD DSC**,
Peter Y Koay FRCS(ED) FRCOPHTH
SOE Evaluation of Cicatricial Pemphigoid Conjunctiva With
OCT
Presenting Author: Michele Lanza MD
Co-Author(s): Raffaele Ppiscopo PhD, Diego Strianese, Michela Cennamo MD**
Purpose: To evaluate conjunctival changes in patients with ocular cicatricial pemphigoid
(OCP) using anterior segment OCT. Methods: A complete ophthalmic visit, slitlamp imaging, and OCT scans were performed in 16 eyes of 8 patients affected by OCP (at different
stages). OCT and slitlamp data were compared. Results: OCT showed many alterations
in OCP conjunctiva impossible to detect only with slit lamp: subepithelial folds (in 81% of
eyes), increase of subepithelial optical reflectivity (in 88% of eyes), a membrane identified
over the conjunctiva epithelium (in 75% of eyes), and a combination of them (in 31% of
eyes). Conclusion: If these results should be confirmed in further studies, OCT could have
an important role in early diagnosis and management of patients affected by OCP.
H Lifitegrast 5.0% vs. Placebo for Dry Eye Disease:
Symptom Outcomes From the Phase 3 OPUS-2 Study
Presenting Author: Joseph Tauber MD*
Co-Author(s): Charles P Semba MD*, Aparna Raychaudhuri PhD*
Purpose: Lifitegrast (LIF) 5.0% is a novel LFA-1 antagonist targeting chronic inflammation of dry eye disease (DED). Methods: A randomized, double-masked, placebo-controlled
study was conducted comparing LIF (n = 360) with placebo (n = 358) twice daily for 84 days
in subjects with DED. Co-1 endpoints: change from baseline in inferior corneal staining
(ICSS) and eye dryness score (EDS; visual analogue scale [VAS]). 2 symptom endpoints:
eye discomfort (VAS), ocular discomfort. Ocular Surface Disease Index (OSDI) was supporting. Results: LIF did not improve ICSS (P = .6186) or other signs. LIF improved EDS (P
< .0001), 2 parameters (nominal P < .001), all OSDI parameters (total score and all subscales; nominal P < .05). No ocular serious adverse events. Conclusion: LIF 5.0% improved
symptoms of DED.
Effectiveness of Additional LipiFlow Treatment for Chronic
Meibomian Gland Dysfunction and Evaporative Dry Eye
Presenting Author: Parag A Majmudar MD*
Co-Author(s): Chad L Betts MD, Jack Volker Greiner DO PhD*, Edward J Holland MD*,
John A Hovanesian MD*, Mitchell Jackson MD*, Stephen S Lane MD*, William B
Trattler MD*
Purpose: To evaluate effectiveness of second LipiFlow treatment for meibomian gland dysfunction (MGD) and evaporative dry eye. Methods: This prospective, multicenter controlled
study of 200 patients included 18 who reported declining symptom relief 1 year after initial LipiFlow treatment and had a second treatment. Twelve control patients who received
crossover LipiFlow treatment also had a second treatment. Results: Mean improvement in
MG function from 1 year after initial treatment to 1 month after second treatment was 13.7
to 17.7 (P = .0005) and in symptoms was 42.9 to 26.9 (P < .0001). Outcomes were similar
for crossover patients after second treatment. Conclusion: Additional LipiFlow treatment
provides continued benefit for chronic MGD.
Ocular Surface and Tear Function After Allogeneic
Hematopoietic Stem Cell Transplantation
Presenting Author: Soonil Choi
Co-Author(s): Kyung-Sun Na, Choun-ki Joo MD
Purpose: We evaluated the changes of ocular surface and tear function after hematopoietic stem cell transplantation (HSCT) in nonchronic graft versus host disease (GVHD) patients. Methods: In this prospective study, patients without chronic GVHD had undergone
tear breakup time (TBUT), Schirmer test, Ocular Surface Disease Index (OSDI) score, tear
osmolarity, and corneal / conjunctival staining before and after (1, 2, and 3 months) HSCT.
Results: Total of 56 eyes of 28 patients were included. Compared with the baseline, there
were significant differences of TBUT, Schirmer score, OSDI score, and ocular staining score
after HSCT(all P < .01). Conclusion: Regardless of GVHD status, HSCT aggravated instability of the ocular surface and reduced tear function.
175
Scientific Posters
Purpose: To identify heterogeneous data availability and pterygium risk factors. Methods:
Systematic literature search for observational studies on pterygium risk factors and metaanalytic data synthesis. Results: Fifty-one eligible studies with 173,792 participants and
18,715 pterygium cases. Each of 63 risk factors was studied on average 4.3 times (8.4%;
standard error [SE], 7.0). Type of statistical analysis significantly altered the effect size (F2
= 24.1; P-value < .0001). Significant risk factors at a = 0.01 were rural residence, low income, high sunlight exposure, and manual/outdoor occupation. No measures of prevention
were significantly protective. Conclusion: Field-wide meta-analyses can map data availability and heterogeneity. Sunlight and dust exposure are the most likely direct or indirect
causes of pterygium.
Purpose: To study the effects of topical cysteamine 0.5% eyedrops in corneal cystinosis.
Methods: Patients with nephropathic cystinosis were included. Each patient underwent
examination. Patients with cystine crystals in the cornea were given topical cysteamine
0.5% eyedrops. Symptoms and corneal findings were graded before and after treatment.
Results: Thirty-three patients with cystinosis (13 males and 20 females). The age range
was 6 months to 19 years, with a mean age of 8 years. Twenty patients (61%) showed
improvement in symptoms, and 26 patients (79%) had improvement in corneal deposits.
Conclusion: Cysteamine 0.5% eyedrops are safe and effective in cystinosis.
Scientific Posters
Predicting Patient Satisfaction After Thermal Pulsation
Treatment for the Management of Meibomian Gland
Dysfunction
Long-term Follow-up in Boston Type 1 Keratoprosthesis
Implantation
Presenting Author: Allister G Gibbons MD
Co-Author(s): Anthony J Aldave MD*
Co-Author(s): Tayyeba K Ali MD, Daniel Waren MS, Juan Carlos Murillo MD, Kendra
Davis COA**, Samantha P Herretes MD, Carolina Betancurt MD**, Victor L Perez
MD*
Purpose: To evaluate long-term outcomes of the Boston type I keratoprosthesis (KPro).

Methods: Retrospective, interventional case series of KPros performed by a single surgeon
prior to 3/2009. Preoperative characteristics and postoperative outcomes including retention, visual acuity, and complications were determined. Results: Seventy-one KPros were
implanted in 61 eyes with a mean follow-up of 43.5 months. 23 KPros were not retained
(mean time to removal: 26.3 months) with an annual retention rate between 91% (1 year)
and 40% (8 years). In the 84% of eyes that maintain a KPro, current corrected distance
visual acuity is 20/200 in 57% (4% preop) and preop in 80%. Complications included
RPM (56%), PED (41%), and sterile corneal necrosis (21%), but no endophthalmitis. Conclusion: KPro offers significant lasting visual improvement to eyes not eligible for other
forms of visual rehabilitation.
Purpose: To evaluate the dry eye parameters with the highest ability to predict patient
satisfaction after a thermal pulsation treatment (TPT). Methods: A retrospective review
of patients with meibomian gland dysfunction and evaporative dry eye. Patients received
a full dry eye workup. Measured outcome was patient subjective improvement. Results:
Thirty-four patients had bilateral treatment, with 2 follow-ups involving manual expression of the meibomian glands. Twenty patients (58.8%) reported subjective improvement. A
higher corneal staining score was the most significant factor (P = .03) associated with TPT
satisfaction. Conclusion: TPT can be effective in treating dry eye symptoms of patients.
Our data show that patients with more objective findings of dry eye have a higher chance
of satisfaction.
The Effect of Trabeculectomy on the Ocular Surface
Therapeutic and Cosmetic Keratopigmentation Using an
Intrastromal Streaking Technique
Presenting Author: Hamed Mofeez Anwar MD
Presenting Author: Hesam Hashemian MD
Co-Author(s): Alaa M Eldanasoury MD*
Co-Author(s): Mahmoud Jabbarvand Behrooz MD**, Mehdi Khodaparast MD**,

Mohammad Riazi Esfahani MD
Purpose: To demonstrate the surgical technique and therapeutic applications of a novel

method of keratopigmentation by intrastromal streaking with suture material. Methods:
Keratopigmentation was performed on 38 eyes of 38 patients with disorders including corneal leucomata, opacified patch grafts, and traumatic aniridia. Postoperative satisfaction
and complications were noted. Results: At 5 years, all except 2 patients were satisfied
with their postoperative appearance. Three eyes with traumatic aniridia noted a subjective
reduction in glare. Three patients required a tattoo enhancement after 5 years. Conclusion: Keratopigmentation by intrastromal streaking is easy to perform, safe, and effective,
yielding good cosmetic and therapeutic results.
Purpose: To analyze the ocular surface changes after trabeculectomy. Methods: Seventytwo glaucoma patients who were candidates for trabeculectomy entered the study. We
evaluated 9 subjective and objective measures for dry eye preoperatively and during 1
year postoperatively. We compared dry eye scores during the follow-up period with the
preoperative data and normal controls. Results: Preoperatively 5 out 9 parameters were
significantly higher than normal controls. After 1 year, 2 out of 9 parameters had significant
differences compared to preoperative values, but 3 out of 9 parameters were significantly
higher than normal controls. Conclusion: Patients on topical antiglaucoma medication and
post-trabeculectomy patients were more likely to have ocular surface deterioration.
SOE Topical Cyclosporine A Therapy in Children With
Ocular Rosacea
Scientific Posters
Presenting Author: Jamie K Alexander MD
Comparative Evaluation of Harvesting Corneas Through
Hospital Cornea Retrieval Program and Voluntary Eye
Donation at a Tertiary Eye Care Center
Presenting Author: Rasik B Vajpayee MD
Presenting Author: Yonca A Akova MD*
Co-Author(s): Tushar Agarwal MD, Murugesan Vanathi, Namrata Sharma MD MBBS
Co-Author(s): Osman S Arslan MD, Fatma Nilufer Alparslan MD*

Purpose: To assess the efficacy of topical cyclosporine A (CsA) therapy in patients with pediatric ocular rosacea (OR) with steroid-dependent corneal inflammation. Methods: Topical
CsA 0.05% was given 4 times daily, combined with topical loteprednol therapy for 3 weeks.
Results: The study included 10 children (16 eyes) with a mean age of 10 years (range: 5-14
years). The disease was previously resistant to lid hygiene (all patients), oral erythromycin
(9), and intermittent topical steroids (all). Inflammation was diminished in all eyes during
CsA therapy, with a mean follow-up of 12 7 months. The treatment was stopped in 8
patients after a mean of 11 6 months without recurrences. Conclusion: Long-term topical CsA 0.05% therapy is effective in controlling ocular inflammation in children with OR.
Purpose: To compare donor corneas from a hospital cornea retrieval program (HCRP) and
voluntary eye donation (VED), prospectively. Methods: 1014 corneas were retrieved. Demography, death preservation time (DPT), socioeconomic status (SES), lens status, cornea
grade, and endothelial counts were analyzed. Results: 81.4% in HCRP were < 65 years,
and 79% in VED were > 65 years (P = .0001). DPT was < 6 hours in 48% and > 12 hours in
12% in HCRP vs. 85% and 1%, respectively, in VED (P = .0001). SES was above middle class
in 40% and 82% in HCRP and VED (P = .0001). 13.5% were pseudophakic in HCRP vs. 66%
in VED (P = .0002). Forty-five percent had cell counts > 2000 in HCRP , compared to 28%
in VED (P = .0001). Optical and therapeutic grade eyes were 59.3% and 39.4% in HCRP,
respectively, compared to 12.7% and 80.6% in VED (P = .0001). Conclusion: HCRP yields
better quality corneas than does a VED program.
Efficacy of Autologous Serum Tears for Treatment of Severe
Corneal Pain in Patients With Corneal Neuropathy: An In
Vivo Confocal Microscopic Study
SOE Corneal Graft Patch to Repair Baerveldt Valve Silicone
Tube and Scleral Buckling Extrusions
Presenting Author: Shruti Aggarwal MBBS

Co-Author(s): Clara M Colon, Ahmad Kheirkhah MD, Pedram Hamrah MD*
Purpose: To evaluate use of autologous serum tears (AST) in treatment of severe corneal pain in patients with corneal neuropathy using in vivo confocal microscopy (IVCM).
Methods: Sixteen eyes of 16 patients suffering from severe corneal neuropathy-induced
corneal pain and no current ocular surface disease were compared retrospectively to 16
age-matched controls. Changes in pain severity (0-10) and IVCM nerve parameters were
evaluated after AST treatment. Results: Pain severity decreased from 9.4 0.2 at baseline
to 3.4 0.4 (P = .03) following 3.8 0.5 months of AST. IVCM showed significantly improved
nerve density and morphology from baseline, paralleling symptomatic improvement (P =
.01). Conclusion: AST-induced nerve regeneration may lead to improvement in patientreported corneal pain, particularly post-refractive surgery pain.
176
Presenting Author: Caterina Sarnicola

Co-Author(s): Gian Marco Tosi MD, Vincenzo Sarnicola MD
Purpose: To evaluate the efficacy of corneal and sclerocorneal graft to cover Baerveldt
valve (BV) silicone tube or scleral buckling (SB) extrusions. Methods: Retrospective cases
series about 8 patients with BV silicone tube extrusion and 4 patients with SB extrusion.
The movable conjunctiva was opened in flaps, and the graft patch was placed on the device. Interrupted suture and fibrin glue were used. Results: Graft patches were all vital
at last follow-up (6 months). The conjunctival flaps had progressively covered the whole
grafted tissue (7 cases after 3 months and 5 cases after 6 months). No complications were
recorded. Conclusion: Corneal and sclerocorneal graft patches seem to be a good option
for the treatment of SB and BV silicone tube extrusions. However, a larger number of cases
and a longer follow-up are required.
Scientific Posters
H Rho-Associated Kinase (ROCK) Inhibitors in the
Management of Persistent Corneal Graft Edema: Does It
Work?
SOE Repeat Descemet Membrane Endothelial Keratoplasty
(DMEK) for Unsuccessful Previous DMEK
Co-Author(s): Lamis Baydoun MD, Gerrit RJ Melles MD PhD*
Co-Author(s): Alireza Baradaran-Rafii MD, Roghiyeh Shamsoddinimotlagh MD
Purpose: To describe the feasibility, outcomes, and complications of repeat Descemet

membrane endothelial keratoplasty (re-DMEK). Methods: Seventeen eyes received reDMEK for graft detachment and/or endothelial graft failure after initial DMEK. Outcome
measures were BCVA, endothelial cell density (ECD), and complications. Results: ReDMEK was uneventful and BCVA improved in all eyes. Donor ECD decreased from 2580 (
173) cells/mm2 before, to 1390 ( 466) cells/mm2 6 months postoperatively. Complications
included graft failure, graft detachment, secondary glaucoma, and cataract. Conclusion:
Re-DMEK proved feasible, with acceptable BCVA. Complications may be better anticipated
because graft detachment and failure tended to reoccur, suggesting an influence by intrinsic properties of the host eye.
Purpose: To report cases of corneal persistent graft edema that were successfully treated
by Rho-associated kinase (ROCK) inhibitors. Methods: Three eyes unresponsive to medical treatment (BCVA 4/100) underwent subconjunctival Fasudil injection (0.5 mg/1 ml) 2
times with 2 weeks interval time. Results: Corneal clarity recovered and vision improved
4-6 weeks after the second injection. At 3 months, vision improved to 20/160. Average
central corneal thickness was 579 10 m, significantly lower than its pretreatment value
(744 9 m). The average corneal endothelial density in the central cornea increased from
894 64 to 1549.3 98 cells/mm3;. Conclusion: These cases highlight the possibility of
the use of subconjunctival ROCK inhibitors as an alternative to regraft surgery for certain
forms of persistent corneal graft edema.
Crystalline Lens Management in a Case of Boston
Keratoprosthesis 1, and Its Relationship With
Retroprosthetic Membrane Formation
Presenting Author: Samar K Basak MD DNB MBBS*
Co-Author(s): Soham Basak
Purpose: To report the relationship between crystalline lens management during Boston
KPro1 implantation and formation of retroprosthetic membrane (RPM). Methods: Retrospective review of charts of 70 consecutive cases of Boston KPro1 surgery. Crystalline lens
status and case management were noted. In phakic eyes, a plano 3-piece IOL was placed in
some cases. RPM formation in these cases were analyzed separately. Results:Thirty-three
eyes were phakic; 14 were aphakic; and 23 were pseudophakic preoperatively. Posterior
chamber IOL was implanted in 13 phakic eyes (39.4%). Incidence of RPM was significantly
higher in aphakic eyes with capsule than without capsule and then pseudophakia (P < .05).
Conclusion: Incidence of RPM is less in pseudophakic eyes, whether present preoperatively or made pseudophakic during surgery.
Presenting Author: Maria Satue MD
Clinical Outcomes of Repeat Keratoplasty After Failed
Therapeutic Keratoplasty Performed for Fungal or Bacterial
Keratitis
Co-Author(s): Jagadesh C Reddy MD**, Pravin Vaddavalli MD, Shreyas Ramamurthy
MBBS MS
Purpose: To analyze outcomes of repeat optical penetrating keratoplasty (PK) or endothelial keratoplasty (EK) after failed therapeutic keratoplasty (TPK). Methods: Retrospective
study of patients (112 eyes) who underwent optical PK (67 eyes) or EK (45 eyes) after failed
TPK from 2000 to 2012. Results: Improvement in corrected distance visual acuity among
both types of grafts was statistically significant(P < .01). Graft transparency at 1 year was
significantly better in the PK group than in the EK group (P < .05). Significantly better outcomes were obtained in Aspergillus-infected corneas than in corneas infected with other
agents. Cumulative graft survival at 8 years was 50%. Conclusion: Good long-term functional outcomes can be achieved by performing repeat PK or EK in patients after failed TPK.
Randomized Comparison of loteprednol 0.5% Gel vs.
Prednisolone Acetate 1% Solution in the First Year
Following Endothelial Keratoplasty
Presenting Author: Samar K Basak MD DNB MBBS*
Presenting Author: Marianne O Price PhD*
Co-Author(s): Ayan Mohanta
Co-Author(s): Francis W Price Jr MD*
Purpose: To evaluate the clinical outcomes of Descemet-stripping endothelial keratoplasty

(DSEK) to treat corneal edema in iridocorneal endothelial (ICE) syndrome. Methods: Clinical course of 15 consecutive patients who underwent DSEK for corneal edema in ICE syndrome between 2007 and 2013 was reviewed retrospectively for BCVA, graft clarity, and
glaucoma control. Results:Ten patients had glaucoma before DSEK. Cataract surgery was
required in 11 eyes; and additional trabeculectomy, in 6 eyes. Grafts remained clear in 9
eyes (60%) with BCVA of 20/40 in 7 eyes (46.7%) with mean follow-up of 19 months. Poor
outcomes after DSEK included uncontrolled glaucoma and late graft failure. Conclusion:
Outcomes of DSEK in ICE syndrome are not always favorable because of the continuous
nature of the disease.
Purpose: To compare efficacy and side effects of prednisolone 1% to those of a new

loteprednol gel formulation following Descemet membrane endothelial keratoplasty
(DMEK). Methods:Subjects used prednisolone 4x/day for 1 month, then were randomized
to continue it or switch to loteprednol. Dosing was 4x/day for 2 more months, 3x/day for
1 month, 2x/day for 1 month, then 1x daily for 1 year. Results: 232 eyes were enrolled.
Rejection episodes were rare (< 1%). The incidence of IOP elevation was significantly lower
in the loteprednol arm. Conclusion: Compared with prednisolone 1% ophthalmic solution,
loteprednol 0.5% gel had a similarly low rate of rejection episodes and a significantly lower
incidence of IOP elevation in the first year after DMEK.
Femtosecond Laser-Assisted Intrastromal Astigmatic
Keratotomy for the Treatment of Astigmatism Following
Penetrating Keratoplasty
Presenting Author: Season T Yeung MBBS
Co-Author(s): Ronan Conlon MD, Joshua C Teichman MD, Salina Teja MD, George
Minstioulis FRCSC, W Bruce Jackson MD FRCSC*, Kashif Baig MD MBA*
Purpose: To report the outcomes of femtosecond laser-assisted intrastromal astigmatic
keratotomy (FISAK) in post-penetrating keratoplasty (PKP) patients. Methods: A prospective, interventional case series of 10 PKP patients with high corneal astigmatism. Results:
At the 3-month follow-up, the mean manifest cylinder was reduced significantly, from 5.78
1.43 D preoperatively to 2.25 1.09 D postoperatively (P = .001). Similarly, the mean
topographic cylinder was decreased significantly from 5.90 2.37 D to 3.49 0.97 D (P =
.01). No serious adverse effects were reported. Conclusion: FISAK is a precise, effective,
and safe technique in reducing corneal astigmatism in post-PKP patients.
Retrospective Single-Center Evaluation of an Ocular Sealant
for Wound Closure in Descemet-Stripping Endothelial
Keratoplasty
Presenting Author: Terry Kim MD*
Co-Author(s): Gary L Legault MD
Purpose: To evaluate the safety and effectiveness of ReSure Sealant for wound closure in
Descemet-stripping endothelial keratoplasty (DSEK) surgery. Methods: Fourteen patients
were treated with the sealant during DSEK surgery. Patients enrolled included patients who
had DSEK only (n = 5), DSEK with cataract surgery and IOL placement (n = 7), DSEK with
anterior vitrectomy (n = 1), and DSEK with lens exchange (n = 1). The main temporal clear
corneal wounds were 4.1 mm. Results: 100% of patients maintained a complete air bubble
fill after the sealant was placed, and 100% of patients were Seidel negative on postop Day
1. Wound healing was normal, patients were comfortable overall, and no adverse events
occurred in relation to the device. Conclusion: The sealant proved safe and effective for
wound closure in DSEK surgery.
177
Scientific Posters
Descemet-Stripping Endothelial Keratoplasty for Corneal
Edema in Iridocorneal Endothelial Syndrome
Scientific Posters
Evaluation of Endothelial Cell Changes and Pachymetry of
Precut Corneal Tissues Stored in McCarey-Kaufmann Media
SOE Aloe Vera Gel Facilitates Re-epithelialization of the
Cornea in Normal and Diabetic Rats
Presenting Author: Somasheila I Murthy MD
Presenting Author: Tamer E Wasfy MBBS
Co-Author(s): Varsha M Rathi DO, Hemal Vinod Kenia BMBS**, Geeta K Vemuganti
MD
Co-Author(s): Ahmed Mohamed Ghoneim MD, Ayman Atiba**
Purpose: To evaluate the safety-efficacy of McCarey-Kaufman medium for precut corneal

tissues. Methods: 180 precut corneal tissues obtained with automated microkeratomes
300 and 350 targeted cap were evaluated for ultrasound pachymetry, endothelial cell
(EC) changes, and immediate post-endothelial keratoplasty (EK) complications. Results:
300 and 350- blades cut tissues thicker by 15.26% and 17.46%, respectively. Precutting
caused a 2.17% decrease in ED density (P = .0018), a 2.64% decrease in hexagonal cells
(P = .575), and a 5.33% increase in coefficient of variation (P = .001). Post-EK primary graft
failure (1.11%) and corneal infiltrate (1.67%) were noted. Conclusion: Storage in McCarey-Kaufman medium was comparable to published literature with Optisol-GS Medium.
Purpose: To investigate the wound healing effect of aloe vera gel (AV) after a corneal alkali
injury in normal and diabetic rats. Methods: Twenty-eight Wastar male rats were divided
into 4 groups (normal untreated, normal treated, diabetic untreated, and diabetic treated).
The corneal alkali-burn injury model was established by contacting eyes with filter paper
saturated with 0.01 N NaOH for 45 seconds. Treated groups were treated with AV eye
drops 4 times daily for 3 days, and the untreated groups were treated with normal saline.
Results: Corneal wound healing was significantly accelerated in the diabetic treated group
compared with the diabetic untreated group (P < .005). Conclusion: Corneal alkali injuries
heal faster and more completely in AV treated groups than in untreated groups, by means
of rapid re-epithelialization and reduced inflammation.
Descemet Membrane Endothelial Keratoplasty: Enhanced
Results With a Standardized Technique
Trauma in a Large Series of Ehlers-Danlos Syndrome:
Characteristics and Outcome
Presenting Author: Michael D Straiko MD*
Presenting Author: Ali A AlRajhi MD
Co-Author(s): Mark A Terry MD*, Peter B Veldman MD, Zachary Mayko MS
Purpose: To report trauma characteristics and outcome in Ehlers Danlos syndrome. Methods: Forty eyes of 23 patients sustained 1 to 3 episodes of trauma at a mean age of 4.6
years (1-12). Results: Trauma occurred twice in 10 and 3 times in 2 eyes, 83% of eyes
had corneal laceration following minor trauma, and 65% of cases were bilateral. Trauma
resulted in adherent leukoma and glaucoma in 42%, visual loss in 67%, and globe loss in
15% of eyes. Conclusion: Eyes in EDS are easily traumatized and associated with visual
and structural poor outcome. Protective measures against trauma and strengthening procedures such as epikeratoplasty are highly recommended.
Purpose: This report improved Descemet membrane endothelial keratoplasty (DMEK) results with a standardized technique using prestripped tissue, SF6 gas, glass injector, and
avoiding graft overlap with the host Descemet. Methods: Prospective study of our initial
consecutive 101 DMEK surgeries using this standardized technique. Results: Seven cases
received an air bubble injection postoperatively (7%). There were 3 primary graft failures
(PGF); all were upside-down grafts (3%). The 6-month endothelial cell loss was 30% (n
= 31). There were no cases of pupillary block. A technique modification has eliminated
upside-down grafts and PGF in our 68 most recent cases. Conclusion: The use of this
standardized technique at our institution has resulted in low complication rates and acceptable cell density. Further modifications have improved our results by eliminating our
main cause of PGF.
SOE IOL Opacification After Descemet-Stripping Automated
Presenting Author: Peter J Morgan-Warren BMBCH
Scientific Posters
Co-Author(s): Amit K Patel MBBCH

Purpose: To report 5 cases of IOL opacification after Descemet-stripping automated endothelial keratoplasty (DSAEK) surgery. Methods: Retrospective case note review of patients
identified with IOL opacification after DSAEK. Results: Five patients developed IOL opacification 5 to 80 months after DSAEK. All patients had Fuchs endothelial dystrophy and had
received hydrophilic acrylic IOL models previously. Central anterior IOL opacification was
noted in all 5 cases. Four cases (80%) required rebubbling due to dislocated graft tissue,
and 1 had an early postoperative IOP rise. Conclusion: Intracameral air, elevated IOP, and
other factors may be major etiological factors for IOL opacification after DSAEK. We advise
avoiding hydrophilic acrylic IOLs in patients who may require future DSAEK.

SOE Deep Anterior Lamellar Keratoplasty vs. Penetrating
Keratoplasty for Keratoconus: A Systematic Review
Presenting Author: Christin Henein MBBS
Co-Author(s): Mayank A Nanavaty MD
Purpose: A systematic review of comparative studies assessing the outcomes of deep
anterior lamellar keratoplasty (DALK) and penetrating keratoplasty for keratoconus. Methods: Inclusion criteria were sample size of at least 20 eyes in each arm and follow-up of
at least 12 months. Primary outcomes were uncorrected and best-corrected visual acuity.
Secondary outcomes were allograft rejection, endothelial density, and complications. Fixed
and random effects models were applied to results combined for analysis. Results: DALK
had less allograft rejection and more endothelial density (P < 0.05). Secondary outcomes
were not significantly different. There was no evidence to suggest heterogeneity of results (P > 0.05). Conclusion: Studies showed no difference in visual acuity. DALK reduces
the risk of allograft rejection and has significantly increased endothelial cell density at
12-month follow-up.
Characteristics of Patients Undergoing Endothelial vs.
Penetrating Keratoplasty for Corneal Endothelial Disease,
2009 to 2011

Deep Anterior Lamellar Keratoplasty in Children With
Advanced Keratoconus
Presenting Author: Roni M Shtein MD
Co-Author(s): Ritu Arora MD MBBS, Pooja Jain MBBS MS, Parul Jain MD, Aditi
Abhay Manudhane MBBS, Vikas Veerwal MBBS, Vikas Veerwal MBBS
Co-Author(s): Taylor Blachley MS, Maria A Woodward MD*, Shahzad I Mian MD*,
Alan Sugar MD, Joshua D Stein MD MS*
Purpose: To assess differences in characteristics of patients undergoing endothelial (EK)
vs. penetrating keratoplasty (PK) for corneal endothelial disease (CED) from 2009 to 2011.
Methods: Retrospective longitudinal cohort study of 83,918 individuals with CED in a U.S.
managed care network. Multivariable regression modeling was performed to assess factors that affected odds of undergoing EK vs. PK. Results: 1115 keratoplasties were performed for CED (644 EK; 471 PK). Latinos had a 56% reduced odds of undergoing EK (OR =
0.44, P = .02) compared to whites. Women had a 49% increased odds of undergoing EK (OR
= 1.49, P = .01). Conclusion: Further research needs to be done to understand variations
in the demographic characteristics of those who undergo EK vs. PK for CED and its impact
on outcomes.
178
Presenting Author: Jawahar Lal Goyal MD
Purpose: To evaluate the outcomes of deep anterior lamellar keratoplasty (DALK) in

children with advanced keratoconus. Methods: Retrospective analysis of 20 eyes of 16
children (1118 years old) who underwent DALK for advanced keratoconus. The follow-up
ranged from one to nine years. Graft clarity, best-corrected visual acuity (BCVA), average
keratometry, and complications were evaluated. Results: Eighteen eyes had clear grafts.
Mean decimal BCVA changed from 0.12 preoperatively to 0.35. The average keratometric
power changed from 64.86 to 45.70 D . The complications noted were graft rejection (1),
interface infection (2), and shield ulcers (2). They were managed accordingly, and only one
patient needed penetrating keratoplasty. Conclusion: DALK is an excellent therapeutic
modality for management of advanced keratoconus in children.
Scientific Posters
Subconjunctival Injection of Anti-Vascular Endothelial
Growth Factor Agents for Treatment of Superior Limbic
Keratoconjunctivitis

Intrastromal Corneal Rings Segments for the Treatment of
Keratoconus
Presenting Author: Chi Chiau Wu
Purpose: To report the visual, keratometric, and safety outcomes of intrastromal corneal
rings placed in patients with keratoconus. Methods: An observational, retrospective study
was conducted. Patients with keratoconus treated with intrastromal rings between 2007
and 2012 with one year of follow-up were included. Visual acuity, keratometry, pachymetry,
degree of incision, follow-up, and complications were assessed. Results: A total of 197
eyes were included. Uncorrected and best-corrected visual acuity improved by 0.36 0.47
logMAR (P 0.001) and 0.16 0.28 logMAR (P 0.001), respectively. Mean keratometric
values decreased by 2.66 3.62 D (P 0.001). A total of eight patients (4.06%) had complications. Conclusion: Instrastromal corneal ring segments appear to improve visual acuity
and corneal topography.
Co-Author(s): Shihkung Huang MD**, Lu Jyun-Wei MD, Chieh-Chih Tsai MD

Purpose: To evaluate the efficacy of subconjunctival injection of bevacizumab or aflibercept for treatment of superior limbic keratoconjunctivitis (SLK). Methods: Patients with
SLK unresponsive to conventional treatments were included and followed up for six
months. Five cases recieved 0.1 cc subconjunctival bevacizumab, and five recieved 0.05
cc subconjunctival aflibercept every one to four months as clinicaly needed. The subjective symptoms and signs, including slit-lamp examination, external eye photography, and
fluorescein angiography, were recorded and compared before and after treatment. Results:
The fluorescein leakage from abnormal microvasculature was compatible with the severity
of symptoms in each eye. Both the symptoms and signs improved after treatments. Conclusion: Anti-VEGF agents are effective treatments for remission of SLK.
Presenting Author: Erick Hernandez-Bogantes MD

Characteristics of Primary Sjgren Syndrome in Men

SOE Intraoperative OCT Pachymetric Mapping During
Accelerated Pulsed High-Fluence Corneal Collagen
Crosslinking With Dextran-Free Riboflavin
Presenting Author: Priya Mathews MD
Presenting Author: Miguel M Rechichi MD
Co-Author(s): Alan N Baer MD, Esen K Akpek MD*
Co-Author(s): Sheraz M Daya MD*, Cosimo Mazzotta MD PhD, Rita Mencucci MD,
Michele Lanza MD
Purpose: To report the clinical features of primary Sjgren syndrome (pSS) in men. Methods: Retrospective review of a tertiary care-based, longitudinal cohort. Results: Of the
163 patients with pSS, 14 were men. On presentation, men were a decade older (61 vs. 50
years, p < 0.01) and reported less chronic dry eye (5.9 vs. 10.8 years, p = 0.07) than women.
Men were more likely to present with serious ocular complications than women (43% vs.
11%, p = 0.001). Systemic complications were also more common in men (64% vs. 40%, p
= 0.08). Furthermore, men were more likely to be seronegative than women (36% of men
were negative for Sjgren syndrome A, Sjgren syndrome B, and anti-nuclear antibodies vs.
11% of women, p = 0.01). Conclusion: Although pSS is typically a disease of middle-aged
women, clinicians should note that it may be underdiagnosed in men, which may contribute
to the differences in disease severity.
Purpose: To assess in vivo intraoperative corneal pachymetric variations by OCT mapping

during corneal pulsed accelerated collagen crosslinking (PACXL) treatment with the use of
dextran-free riboflavin. Methods: Thirty eyes underwent PACXL. Pachymetric maps within
central 5-mm zone were obtained. Central anf thinnest corneal thickness measurements
were obtained at baseline, after epithelial removal, after 10-minute riboflavin drop instillation, and after eight minutes of pulsed irradiation at 30 Mw/cm2 and 7.2 J/cm2. Results:
There was not a statistically significant decrease after 10 minutes of the corneal soaking
phase and after eight minutes of pulsed irradiation. No complications were observed. Conclusion: PACXL is a safe procedure that does not induce a statistically significant corneal
shrinking.

SOE Corneal Intrastromal MyoRing Implantation in
Keratoconus Treatment

Is Inflammation Driving Keratoconus? A Holistic Study of
Molecular Pathways
Presenting Author: Ahmed M Saeed MD
Presenting Author: Natasha Kishore Pahuja DOMS MBBS
Co-Author(s): Amr Ibrahim Sharawy, Doaa Mohammad Guda MD
Co-Author(s): Rohit Shetty MD MBBS, Arkasubhra Ghosh MS PhD, Himanshu P

Matalia MBBS**, Himabindu Veluri MS**, Bhujang K Shetty MD**

SOE Influence of Pregnancy on Corneal Biomechanics
Presenting Author: David Tabibian MD
Co-Author(s): Begona Martinez-de-Tejada MD PhD**, Farhad Hafezi MD PhD*
Purpose: There is increasing evidence that hormonal changes during pregnancy alter
the biomechanical stability of the human cornea. Methods: Prospective, monocentric
clinical study measuring biomechanical changes during and after pregnancy. Examinations
included slit-lamp examination, blood samples, and Ocular Response Analyzer (Reichert
Technologies) and Pentacam (Oculus) measurements. Results: Results show increases of
the following parameters in the third trimester: corneal hysteresis (P = 0.007), cornealcompensated intraocular pressure (IOP; p < 0.001), and Goldmann-corrected IOP (P = 0.008).
Conclusion: Changes in estradiol levels may lead to biomechanical adaptations in the
cornea during pregnancy, which might explain ectatic decompensation triggered during
pregnancy.
Purpose: Biomarkers that may predict outcome and severity of disease in keratoconus are
unknown. Therefore, we investigated inflammatory and genetic components in tears and
the epithelium. The process was to understand deregulated pathways that may drive the
pathophysiology of disease. Methods: Tears and epithelium of 94 patients and 20 controls
were analyzed using mass spectroscopy for TNFa, MMP9, lysyl oxidase (LOX), and COL4A1
(collagen), and genetic screening was done in eight families for mutation in the VSX1 gene.
Results: Tear cytokine results show high levels of inflammatory markers and low levels of
LOX in the epithelium. Genetic screening revealed mutation in the VSX1 gene. Conclusion: This holistic data argues that etiopathogenesis of keratoconus is possibly linked to an
inflammatory network. These signals resemble chronic autoimmune disease.

SOE H Factors Influencing Outcomes of Corneal Collagen
Crosslinking in Pediatric Keratoconus Patients
Presenting Author: Nurullah Cagil MD
Co-Author(s): Ozge I Sarac MD**, Mehtap Caglayan, Emine Kalkan Akcay**, Hasan
Basri Cakmak MD
Purpose: To assess the preoperative patient characteristics that may predict outcomes
of corneal collagen crosslinking (CXL) in pediatric keratoconus (KC). Methods: Thirty-nine
eyes with one-year follow-up period following CXL were included. Subgroup analyses and
cutoff values included age (14 years), uncorrected visual acuity (UCVA; 0.8 logMAR),
cone location (central, paracentral, and peripheral), Kmax (54 D), and thinnest pachymetry
(t-CCT , 450 m). Results: Kmax in patients under 14 years of age and/or with paracentral
cones showed more progression (age:P = 0.017, OR = 16.5; cone location:P = 0.025, OR =
14.0). UCVA in patients with paracentral cones and/or t-CCT lower than 450 m was more
likely to decrease (cone location:P = 0.012, OR = 7.5; t-CCT:P = 0.04, OR = 20). Conclusion:
In pediatric KC, age, cone location, and baseline t-CCT affect the success of CXL.
179
Scientific Posters
Purpose: To evaluate corneal intrastromal MyoRing in keratoconus (KC) management.

Methods: A MyoRing was inserted into 22 KC eyes. Data included uncorrected (UCVA) and
best-corrected visual acuity (BCVA) and Pentacam imaging. Results: There was statistically significant improvement of UCVA, BCVA, K1, K2, and Km (0.12 0.2, 0.3 0.1, 48.5
3.8, 54.5 4, and 51.3 3.6, respectively), compared with 0.5 0.2, 0.7 0.2, 45.8 3,
42.6 3.2, and 49.1 3.3, respectively, at six postoperative months (P < 0.001). Four cases
underwent position adjustment of the implant. Conclusion: The MyoRing could represent
an efficient, safe, and modifiable therapeutic option for KC treatment.
Scientific Posters
Complication of Corneal Collagen Crosslinking
in Keratoconus in Young Patients With Vernal
Keratoconjunctivitis

Penetrating Keratoplasty in cases of Post-herpetic (HSV)
Vascularized Scars: Indications, Surgical Challenges, and
Outcomes
Presenting Author: Vikas Veerwal MBBS
Presenting Author: Muralidhar Ramappa MBBS
Co-Author(s): Ritu Arora MD MBBS, Jawahar Lal Goyal MD, Pooja Jain MBBS MS,
Trushaa Garg MS**, Parul Jain MD
Co-Author(s): Sunita Chaurasia MD, Ashik Mohamed MBBS
Purpose: To report patterns of sterile corneal infiltrates after corneal collagen crosslinking
(CXL) in keratoconus with vernal keratoconjunctivitis (VKC). Methods: Retrospective case
series of eight eyes of eight patients (age group, 1015 years) in a series of 92 patients
who underwent CXL for progressive keratoconus. Results: The patients presented 24 to 48
hours after CXL with severe pain and redness. All patients had central corneal edema with
pinpoint corneal infiltrates. There was associated moderate to severe VKC in all patients.
There was also severe stromal melt with perforation on the fourth day in one of the patients. All except two patients responded to topical steroids. Conclusion: CXL in younger
patients with VKC is fraught with the possibility of sterile corneal infiltrates.

SOE H Unusually Low Prevalence of Keratoconus in a Very
Large Series of Patients With Vernal Keratoconjunctivitis
Presenting Author: Roberto Caputo MD*
Co-Author(s): Rita Mencucci MD, Francesco Versaci MS*, Neri Pucci**, Salvatore
DeMasi MHSA, Gioia Danti Sr**, Bennie H Jeng MD*
Scientific Posters
Purpose: To evaluate the prevalence of keratoconus (KC) in a large series of patients

affected by vernal keratoconjunctivitis (VKC) treated with topical cyclosporine A (CycA).
Methods: Three hundred ninety-one patients affected by VKC (mean age, 11.15 3.13
years) and a control group of 301 (mean age, 11.21 2.82 years; range, six to 20 years) were
investigated by means of a Scheimpflug camera combined with a corneal topographer. Results: Only three patients out of 391 (0.76%) in the VKC group presented with topographic
signs of KC, and corneal indices were similar in both groups (symmetry indices and corneal
thickness). Conclusion: The prevalence of topographic KC in this study is lower than the
11% to 22% reported in previous studies. Constant control of symptoms using CycA with
less eye rubbing could lead to a lower risk of developing KC.
Purpose: To determine long-term functional success of penetrating keratoplast (PK) in

cases of postherpetic corneal scars. Methods: Retrospectively analysed the data of 87
eyes of 84 patients with postherpetic vascularized corneal scars that underwent PK from
2001 to 2013. Results: Median age, 35 years; male:female = 67:17. Active keratitis was
noted (19), and healed keratitis (65) underwent therapeutic PK and optical PK, respectively.
Mean BCVA improved from 2.32 0.82 preoperatively to 1.08 1.22 at one year postoperatively (P < 0.001). In regards to complications, 34 cases (39%) experienced a herpes simplex
virus recurrence, and 29 (33%) had a graft rejection. In 28 cases (32%), the graft eventually failed. Conclusion: PK in postherpetic scars is associated with higher postoperative
complications. Surgeons should be aware of the long-term consequences and the need for
reintervention.

Comparison of 10 Commercially Available Contact Lens
Solutions in the Complete Kill of Acanthamoeba Cysts
Presenting Author: Salwa Abdel-Aziz MD
Co-Author(s): Regis P Kowalski MS, Amy Catherine Nau OD
Purpose: Acanthamoeba keratitis incidence may be reduced with good hygiene complemented with the use of amoeba cysticidal solutions. Methods: We tested 10 contact lens
solutions against five isolates of Acanthamoeba incubated over 24, 48, and 72 hours. The
Standard of Efficacy was the complete kill of all isolates calculated at each time point.
Results: Only one contact lens solution killed all five isolates at 24 hours. Three solutions produced a complete kill at 48 hours, and five solutions produced a complete kill at
72 hours. Overall, 72-hour incubation was most efficacious in killing Acanthamoeba cysts
(Chi-square, p = 0.032). Conclusion: Contact lens solutions have varied Acanthamoeba
cysticidal actions, which improve with increased incubation time.

Herpetic Eye Disease and Glaucoma

Changes in Corneal Sub-basal Nerves in Different Subtypes
of Dry Eye Disease
Presenting Author: Charles Daniel Earley
Presenting Author: Ahmad Kheirkhah MD
Co-Author(s): Sarkis H Soukiasian MD
Co-Author(s): Bernardo Menelau Cavalcanti MD, Andrea C Cruzat MD**, Pedram

Hamrah MD*
Purpose: To describe the presenting features and long-term consequences of glaucomarelated diagnosis (GRD) in patients with herpetic eye disease (HED). Methods: Ten-year
retrospective medical record review of patients with the diagnosis of HED (herpes simplex
[HS] and herpes zoster [HZ]) and GRD. Results: Of 1,098 patients with HED, 371 (33.8%)
had a GRD (226 with HZ [61%] and 145 [39%] with HS), with 177 (54%) being diagnosed at
the time of (35) or after (142) the onset of HED. The average time to reporting a GDR was
2.2 years, with a significant difference between the HZ (1.9 years) versus the HS (2.7 years)
groups (P < 0.05). There was no difference in age at diagnosis (69.8 years). Conclusion:
GRD is commonly encountered with HED, with the majority of cases reported around two
years after onset of HED and with HZ being more common and with earlier onset.

Clinical Features of Atypical Mycobacterial and Nocardial
Keratitis
Presenting Author: Mahmoud O Jaroudi MD
Co-Author(s): , Khalid F Tabbara MD*
Purpose: To report the clinical features and risk factors of atypical mycobacterial and
nocardial keratitis. Methods: Seventeen patients were included. All patients underwent
complete ophthalmologic examination and corneal scraping for cytology and cultures. Results: There were eight female and nine male patients. Mean age was 39 years. Indolent,
round corneal ulcers with ring infiltrates and mild edema were characteristic features. Eight
patients (47%) were contact lens users, and nine (53%) were after LASIK. Conclusion:
Atypical mycobacteria and nocardia are uncommon exogenous causes of keratitis that are
frequently misdiagnosed. Characteristic clinical features and microbiologic evaluation are
important for diagnosis. Refractive interventions (LASIK and contact lenses) are main risk
factors.
180
Purpose: To evaluate changes in corneal subbasal nerve fibers (SNF) in different subtypes
of dry eye disease (DED). Methods: This study included 75 eyes with aqueous-deficient dry
eye (ADDE), 68 eyes with evaporative dry eye (EDE), and 32 eyes of age-matched controls.
Laser in vivo confocal microscopy was used to quantify SNF in central cornea. Results: SNF
number and density were significantly lower in ADDE (14.2 8.2 nerves/frame and 17.2
7.6 mm/mm2) and EDE (17.59.2 nerves/frame and 19.77.4 mm/mm2) than controls (28.4
6.2 nerves/frame and 24.3 3.6 mm/mm2), all P < 0.05. Eyes with ADDE had significantly
lower SNF number and density compared with those with EDE (P < 0.05). Conclusion: SNF
parameters are significantly lower in ADDE than EDE. This may show the role of corneal
nerves in reduced tear production and pathophysiology of DED.

Effects of Steroid Therapy on Corneal Sub-basal Nerves in
Dry Eye Disease
Presenting Author: Ahmad Kheirkhah MD
Co-Author(s): Thomas Dohlman MD**, Michael Alexander Arnoldner MD, Pedram
Hamrah MD*
Purpose: To evaluate changes in corneal subbasal nerve fibers (SNF) and immune dendritic cells (DC) after treatment with topical steroids in dry eye disease (DED). Methods:
Thirty-four patients with DED were randomized to receive either topical loteprednol (19)
or artificial tear (15) twice daily for four weeks. In vivo confocal microscopy was used to
quantify corneal SNF and DC before and after treatment. Results: In the loteprednol group,
SNF density increased from 18 5 mm/mm2 to 20 5 mm/mm2 after four weeks, and DC
density decreased from 139 129 cell/mm2 to 83 99 cell/mm2 (all P < 0.05). In the artificial tear group, SNF and DC densities did not change significantly at four weeks (SNF, 19 6
mm/mm2 and DC, 160 144 cell/mm2) compared with baseline (SNF, 18 5 mm/mm2 and
DC, 138 135 cell/mm2; all P > 0.05). Conclusion: Reduced ocular surface inflammation in
DED is associated with corneal nerve regeneration.
Scientific Posters
H Dry Eye Symptoms Align More Closely to Systemic
Complaints Than to Tear Parameters

Demodex Infestation as a Potential Cause of Keratitis
Presenting Author: Anat Galor MD*
Co-Author(s): Lixia Lin MD
Co-Author(s): Nabeel M Shalabi MBBS**, Allison Louise McClellan OD, Elizabeth Roy
Felix PhD, William J Feuer MS, Roy Clifford Levitt MD*
Purpose: To report ocular demodicosis in keratitis. Methods: This retrospective study

reviewed 20 eyes of 15 patients with refractory keratitis. Results: The patients included
eight males and seven females aged 17.8 12.1 years. Demodex mites were detected
in all cases, while other pathogen cultures were negative. The corneal changes included
peripheral infiltration in 12 eyes, peripheral ulceration in five eyes, and central infiltration
in three eyes. In vivo confocal microscope revealed Langerhan cell infiltration. After using
tea tree oil lid scrub, all patients showed dramatic resolution of ocular inflammation, while
Demodex counts dropped from 4.3 2.5 to 0.4 0.6 (P < 0.001). All corneal signs resolved
within two weeks, except for residual stromal scar in four eyes. Conclusion: Demodicosis
should be considered as a potential cause of keratitis.
Purpose: To evaluate correlations between dry eye symptoms and systemic complaints
versus tear parameters. Methods: Fifty-three patients completed questionnaires on dry
eye symptoms, systemic pain, depression, and PTSD and underwent tear measurements.
Results: Correlations between dry eye symptoms and all systemic measures were moderate (r = 0.520.65, P < 0.05), while correlations between symptoms and all tear parameters
were weak (r = -0.090.29). Multivariable regression analysis revealed that depression and
systemic pain explained approximately 33% of variability in dry eye questionnaire-5 scores.
PTSD and antidepressant use explained approximately 48% of variability in ocular surface
disease index scores. No tear parameters significantly predicted symptoms. Conclusion:
Dry eye symptoms more closely align to systemic complaints than to tear parameters.

A New, Objective, Automated, Computer-Assisted Method to
Quantify Corneal Fluorescein Staining
Presenting Author: Francisco Amparo MD*
Co-Author(s): Haobing Wang**, Reza Dana MD MSc MPH*
Purpose: To describe a new automated method to objectively quantify corneal fluorescein
staining (CFS) in slit-lamp photographs. Methods: We developed a system that quantifies
CFS as a proportion of the corneal surface and provides the average intensity of the fluorescence, both using a centesimal scale. We clinically assessed CFS in a set of photographs
(n = 50) from patients with dry eye disease. Next, we used the computer-assisted system
to score the same set of photographs. Results: The automated scores were strongly correlated with the scores from the clinical evaluation for both affected area (R = 0.80, P < 0.001)
and fluorescence intensity (R = 0.85, P < 0.001). Conclusion: The new system provides a
reliable, continuous, and objective score to evaluate CFS in patients with dry eye.

SOE Comparing Effects of Plasma Rich in Growth Factors
(Endoret) With Those of Autologous Serum Eye Drops on on
Ocular Surface Wound Healing
Presenting Author: Francisco Muruzabal PhD*
Co-Author(s): Jesus Merayo-Lloves MD**, Gorka Orive PhD*, Gorka Orive PhD*

Classification and Grading of Meibomian Gland Dysfunction:
A Novel Approach
Presenting Author: Juan Carlos Murillo MD
Co-Author(s): Samantha P Herretes MD, Daniel Waren MS, Allister G Gibbons MD,
Hilal E Ozturk MD**, Carolina Betancurt MD**, Victor L Perez MD*
Purpose: To present a new standardized scale for the assessment of meibomian gland
dysfunction (MGD). Methods: Eighty-nine eyes with MGD were included. Lid margin features and meibomian gland morphology were evaluated with both Foulks and Bron (F and
B) scoring system and our novel scale by two independent observers. Results: The new
evaluation scale is shown to effectively evaluate MGD, correlating with tear osmolarity (P
= 0.004), tear breakup time (P < 0.001), Schirmers test (P = 0.027), and meibum expression
expressibility (P = 0.008). Comparison with the F and B scale denoted a positive correlation
(r = 0.53) in the assessment of MGD. Interobserver reproducibility was obtained with a
correlation coefficient of 0.71 for our new scale. Conclusion: MGD is evaluated in an
effective and practical fashion with this novel evaluating system.

Meibomian Gland Dysfunction and Dyslipidemia: A
Systematic Review
Presenting Author: Puneet S Braich MD
Co-Author(s): Amarjot Singh Mann, Vikram S Brar MD, Christopher T Leffler MD**
Purpose: To perform a systematic review examining the relationship between meibomian
gland dysfunction (MGD) and dyslipidemia. Methods: None of the patients had a prior
diagnosis of dyslipidemia. A total of 219 patients with MGD were compared to 216 agematched controls from the local populations in three different studies. Results: Dyslipidemia was found in 58% to 67% of patients with MGD versus 6% to 39% of controls (P <
0.01). Mean LDL was 127 6 versus 90 8 (P 0.01). Logistic regression analysis revealed
that patients with MGD were at 8% to 18% higher odds of having dyslipidemia. The prevalence of increased LDL was not statistically significant in one of three studies. Conclusion:
Patients with MGD with no history of dyslipidemia may have undetected serum cholesterol
abnormalities compared with controls of similar age without MGD.

OCT in the Diagnosis of Scleritis and Episcleritis
Presenting Author: Samir S Shoughy MD
Co-Author(s): Mahmoud O Jaroudi MD, Igor Kozak MD, Khalid F Tabbara MD*
Purpose: To assess the scleral thickness in scleritis by OCT. Methods: OCT of the sclera
was performed on 16 patients with scleritis and 16 control eyes. Results: There were 10
male and six female patients. The mean age was 43 years. Twelve patients had scleritis,
and four had episcleritis. The mean scleral thickness was 836 47 m in patients with
scleritis compared with 722 74 m in normal eyes P = 0.0005. The mean scleral thickness in patients with episcleritis was 766 37 m (P = 0.293). Conclusion: OCT showed
significant increase in scleral thickness in patients with scleritis and no significant increase
in episcleritis.

Outcomes of Cataract Surgery in Patients With Ocular
Surface Disease Secondary to Graft Versus Host Disease
Presenting Author: Tulio Batista Abud MD
Co-Author(s): Ujwala Saboo MD, Francisco Amparo MD*, Reza Dana MD MSc MPH*
Purpose: To evaluate the outcomes of phacoemulsification in patients with chronic ocular
graft-versus-host disease (oGVHD). Methods: Records of 51 eyes with oGVHD undergoing phacoemulsification were reviewed. Preoperative and postoperative visual acuity and
postoperative complications were recorded. Results: The mean preoperative visual acuity
was 0.70 0.60 logMAR and improved to 0.16 0.19 at one month (P < 0.001) and 0.13
0.19 at the final visit (P < 0.001). Postoperative complications included corneal epithelial defect (10%), filamentary keratitis (12%), posterior capsular opacification (20%), and cystoid
macular edema (6%). Conclusion: Phacoemulsification significantly improves visual acuity
and is a safe procedure with complication rates comparable to other reports in patients
with ocular GVHD.
181
Scientific Posters
Purpose: To evaluate and compare the biological outcomes of Endoret eye drops versus
autologous serum (AS). Methods: AS and Endoret eye drops were obtained from 10 donors. Several growth factors were quantified in each sample. The proliferative and migration potential of Endoret and AS was evaluated on keratocytes and conjunctival fibroblasts.
Their capability to prevent and inhibit myofibroblast differentiation was also evaluated.
Results: Endoret showed significant (P < 0.05) higher levels of all growth factors. Furthermore, Endoret enhanced significantly (P < 0.05) the proliferation and migration of both cell
types and reduced myofibroblast differentiation compared with AS. Conclusion: Endoret
may improve the treatment of ocular surface wound healing, minimizing scar formation
compared with AS.
Presenting Author: Lingyi Liang MD
Scientific Posters
Symptom and Imaging Assessment of Topical Steroids in
Meibomian Gland Dysfunction-Associated Inflammation
Presenting Author: Yureeda Qazi MBBS
Co-Author(s): Ahmad Kheirkhah MD, Thomas Dohlman MD, Reza Dana MD MSc
MPH*, Pedram Hamrah MD*
Purpose: To assess changes in symptoms and lid and corneal inflammation in meibomian gland dysfunction (MGD) using in vivo confocal microscopy (IVCM) comparing topical steroid-containing drugs (loteprednol [LE] and loteprednol plus tobramycin [LE/T]) to
artificial tears (AT). Methods: A randomized, double-masked clinical trial was conducted
with 54 subjects with MGD receiving either AT, LE, or LE/T for four weeks with symptom assessment and lid and corneal immune cell quantification on IVCM pre- and posttreatment.
Results: Lid and corneal immune cell densities reduced significantly in both steroid-containing treatment groups (P 0.04) but not AT (P 0.4). Symptomatic improvement (11%)
approached significance only for LE (P = 0.08). Conclusion: Steroid-containing drugs, but
not AT, are effective at reducing lid and corneal immune cell densities in MGD on IVCM.

New Device for Preparation of Donor Corneal Tissue During
Boston Keratoprosthesis (KPro) Surgery
Presenting Author: Ronan Conlon MD
Co-Author(s): Salina Teja MD, Joshua C Teichman MD, Season T Yeung MBBS, Kashif
Baig MD MBA*, Behrooz Azizi MD
Scientific Posters
Purpose: To assess centration accuracy and precision of an adapter used in trephination,

developed for Boston keratoprosthesis (KPro) donor cornea tissue preparation. Methods:
Thirty corneoscleral rims were trephined. Ten donor corneas were prepared by trephining
the 8-mm cut followed by the 3-mm cut (Group 1). Ten corneas were prepared by trephining
the 3-mm cut followed by the 8-mm cut (Group 2). Ten corneas were prepared by using our
adapter, which allows for the cuts to be made almost simultaneously (Group 3). Results:
The simultaneous method of trephination revealed a mean decentration of 0.185 mm.
Group 1 had a mean decentration of 0.388 mm, and Group 2 had a mean decentration of
0.135 mm. Conclusion: Our study demonstrates that a device that cuts the corneal tissue
simultaneously yields more predictable grafts for Boston KPro surgery.

SOE Effect of Scleral Buckling in Retinal Detachment
Surgery on Corneal Biomechanics Using the Ocular
Response Analyzer
Presenting Author: Mohsen A Abou Shousha MD
Purpose: To evaluate effect of scleral buckling on corneal biomechanics. Methods: This
study included 21 patients with bilateral high myopia (-6.00 or more) and unilateral rhegmatogenous retinal detachment (RRD). All patients were subjected to cryotherapy for the
retinal break(s) with encircling buckle in eyes with RRD. Ocular response analyzer (ORA)
was done for both eyes (the operated and the contralateral eye) one month postoperatively.
Statistical analysis of different ORA parameters were evaluated using one-way analysis of
variance. Results: A statistically significant decrease in corneal hysteresis of the buckled
eyes (7.78 1.72) when compared with the nonoperated eyes (9.13 1.90; P = 0.025). Other
ORA parameters also differed. Conclusion: Scleral buckling leads to changes in corneal
biomechanics.

Pediatric Therapeutic Penetrating Keratoplasty: Challenges
and Outcomes in a Tertiary Care Centre
Presenting Author: Meena Lakshmipathy MBBS
Co-Author(s): K Lily Therese PhD**, Sudhir R Rachapalle MBBS DO DNB MPH, Lingam
Gopal MBBS*
Purpose: To study the indications, microbiology, and outcome of therapeutic keratoplasty
in children less than 18 years old in a tertiary care center in South India. Methods: This is a
retrospective case series of 40 children with a mean age group of 6.8 5.06 years. Underlying predisposing factor was trauma in 55%. Central corneal ulcers (27.5%) was the most
common presentation. Positive cultures were noted in 42.5% in corneal buttons. Results:
Range of follow-up was six months to four years. Thirty-seven (92.5%) patients completed
six months follow-up, and failed graft was noted in 33 patients (82.5%). Postoperative
complications were graft infiltrate (7.5%), glaucoma (25%), and persistent epithelial defect
(20%). Moreover, 92.5% had vision less than 20/200 at last follow-up. Conclusion: Poor
outcome was attributed to late presentation and predisposing trauma.

Surgical vs. Medical Treatment of Ocular Surface Squamous
Neoplasia: A Comparison of Costs

Vital Dye Staining Evaluation of Internationally Shipped
Prestripped Donor Tissue for Descemet Membrane
Presenting Author: Christina S Moon MD
Presenting Author: Akira Kobayashi MD
Co-Author(s): Afshan A Nanji MD, Anat Galor MD*, Carol L Karp MD
Co-Author(s): Hideaki Yokogawa, Noriaki Murata**, Kazuhisa Sugiyama MD PhD
Purpose: To compare financial and time costs of surgery versus interferon (IFN) for ocular
surface squamous neoplasia (OSSN). Methods: Retrospective review of 49 patients treated with surgery and 49 treated with IFN. Financial costs were calculated by two methods:
hospital billing records and Medicare-allowable charges. Results: Hospital charges were
higher in the surgical group compared with the IFN group. Overall cost between the two
was comparable using Medicare-allowable charges. The cost to the patient depended on
insurance coverage. The IFN group had an average of two more office visits than the surgical group over one year. Conclusion: Treating OSSN with IFN involves compliance and
often out-of-pocket expenses. The difference in financial cost between the two treatments
is dependent on a patients insurance status and coverage.
Purpose: To evaluate endothelial cell damage of internationally shipped prestripped

Descemet membrane endothelial keratoplasty (DMEK) donor. Methods: Internationally
shipped prestripped DMEK donors (n = 6) and precut Descemet-stripping automated endothelial keratoplasty (DSAEK) donors (n = 7) were stained with trypan blue and quantitatively
analyzed. Results: Mean endothelial cell damage of prestripped DMEK donors (0.32%)
was higher than that of precut DSAEK donors (0.01%, P = 0.029). Conclusion: Although
the endothelial damage of internationally shipped prestripped DMEK donors was higher
than precut DSAEK donors, the damage was relatively low.

SOE Five-Year Follow-up in Patients With
Keratopigmentation
Presenting Author: Jorge L Alio MD PhD*
Co-Author(s): Alejandra Rodriguez MS, Mohamed Elbahrawy MBBCH MS, Ahmed A
Abdou MD Phd
Purpose: Analysis of the five-year follow-up outcomes of keratopigmentation, both cosmetic therapeutic or functional. Methods: Study of 20 keratopigmentation patients, with
an average follow up of 7.15 1.85 years. Surgery was done either by manual intrastromal
dissection (17) or superficial pigmentation (3), using black and brown medical-grade chemical pigments. Results: Eighty-five percent of patients expressed satisfaction with their
results. Only 10% experienced discomfort. Complications were recorded in three patients.
Although pigmentation pattern was excellent in 65% of the patients, repigmentation was
required in 50% of cases. Conclusion: At the five-year follow-up, all patients expressed
significant cosmetic satisfaction, while maintaining excellent pigmentation stability.
182

SOE Hemi-DMEK (Descemet Membrane Endothelial
Keratoplasty) Transplantation: A Novel Method for
Increasing the Pool of Endothelial Graft Tissue
Presenting Author: Fook Chang Lam MBChB
Co-Author(s): Lamis Baydoun MD, Martin Dirisamer MD, Gerrit RJ Melles MD PhD*
Purpose: To evaluate the technical feasibility and clinical outcome of using whole-diameter semicircular grafts for Descemet membrane endothelial keratoplasty (hemi-DMEK).
Methods: A prospective evaluation of three eyes of three patients with Fuchs endothelial dystrophy. Results: At six months, best-corrected visual acuities were 20/28, 20/40
(amblyopic eye), and 20/17. Central corneal thicknesses decreased from 682 to 707 mm
to 489 to 534 mm, and endothelial cell density decreased by 38% to 63%. Conclusion:
Hemi-DMEK proved technically feasible and may give visual outcomes similar to routine
DMEK. Hemi-DMEK potentially allows the use of a single donor cornea for two endothelial
keratoplasty procedures.
Scientific Posters
Wide-Field Analysis of Corneal Endothelial Remodeling
Following Descemet Membrane Endothelial Keratoplasty by
Contact Scanning-Slit Specular Microscopy
Presenting Author: Hiroko Nakagawa MD
Co-Author(s): Tsutomu Inatomi MD PhD, Shigeru Kinoshita MD*
Purpose: To investigate corneal endothelial cell (CEC) remodeling after Descemet membrane endothelial keratoplasty (DMEK) by use of wide-field contact specular microscopy.
Methods: In five patients, endothelial cell density (ECD) of the DMEK graft at the central
and peripheral regions was analyzed (mean follow-up, three months). Results: Throughout
the follow-up period, ECD at the central area was higher than that at the graft edge. ECD
loss from one to three months postoperatively at the central and peripheral regions was
7% and 16%, respectively. Migration of endothelial cells was detected toward the stripped
regions at one month postoperatively. Conclusion: ECD at the center of the DMEK graft
is higher than that at the periphery, and CECs migrate from the donor graft to the stripped
region of the host.

Descemet Membrane Endothelial Keratoplasty and
Descemet-Stripping Automated Endothelial Keratoplasty
Performed on Different Eyes of the Same Patients: A
Comparison of Visual Outcome and Endothelial Cell Survival
Presenting Author: Mahmood J Showail MD
Co-Author(s): Yakov Goldich, David S Rootman MD*
Purpose: To compare visual outcome and endothelial cell survival after Descemet membrane endothelial keratoplasty (DMEK) and Descemet-stripping automated endothelial
keratoplasty (DSAEK) in the fellow eye of the same patients. Methods: A chart review was
completed for 17 patients who underwent DSAEK in one eye and later DMEK in the contralateral eye. Main outcomes included best-corrected visual acuity (BCVA) and endothelial
cell density at six months after surgey. A subjective questionnaire was used to assess
patients satisfaction. Results: The DMEK group showed better BCVA (P = 0.02) and lower
endothelial cell density (P = 0.049) than the DSAEK group at six months. Average level of
satisfaction was higher after DMEK (P = 0.002). Conclusion: Our results support the benefits of DMEK and suggest the need for long-term studies for further evaluation.

Descemet Membrane Endothelial Keratoplasty in Corneas
With Prior Refractive Surgery: Visual Results, Topography
Changes, and Complications
Presenting Author: Mark A Terry MD*
Purpose: Report results and complications of Descemet membrane endothelial keratoplasty (DMEK) in eyes with prior LASIK or radial keratotomy (RK). Methods: Seven LASIK
and two RK eyes with edema from Fuchs received DMEK. Best spectacle-corrected vision
(BSCVA) and Pentacam astigmatic changes (astig) were measured. Rebubble and graft failure events were recorded. Results: Mean BSCVA improved from preop 20/41 to 20/24
postop (P = 0.026). Topographic astig changed from preop between 0.9 D of astig increase
to 3.2 D of astig decrease. Steep axis changes from preop were unpredictable, ranging from
only a 1-degree shift to a 64-degree shift . One eye was rebubbled. Conclusion: DMEK
improves vision in eyes with prior refractive surgery, but correction of corneal edema may
unmask large shifts in corneal topography. Triple procedures and especially toric lenses
may be unpredictable in these eyes.

SOE H Clinical Outcome of the First 500 Consecutive Cases
Undergoing Descemet Membrane Endothelial Keratoplasty
Presenting Author: Martin Dirisamer MD
Co-Author(s): Marina Rodriguez Calvo De Mora MD, Gerrit RJ Melles MD PhD*

Sulfur Hexafluoride for Descemet Membrane Endothelial
Keratoplasty in the Learning Curve: Six-Month
Postoperative Endothelial Cell Loss
Presenting Author: Matthew Raeker MD
Co-Author(s): Jordan J Rixen MD, Anna S Kitzmann MD, Michael D Wagoner MD,
Kenneth M Goins MD**, Mark Greiner MD
Purpose: To report six-month endothelial cell density (ECD) loss after Descemet membrane
endothelial keratoplasy (DMEK) using sulfur hexafluoride (SF6) 20% air-gas tamponade.
Methods: A retrospective review was performed on 22 eyes with Fuchs or posterior polymorphous dystrophy that underwent DMEK using SF6 20% by surgeons in their learning
curve. ECD prior to graft preparation was obtained using specular microscopy. ECD six
months after DMEK was obtained using confocal microscopy. The percentage ECD loss
6 months after DMEK was calculated. Results: Mean ECD prior to graft preparation was
2,684 cells/mm2 (range, 2,1233,067; standard deviation [SD], 177). Mean ECD six months
after DMEK was 1,594 cells/mm2 (range, 7132,399; SD, 461). Mean percentage ECD loss
six months after DMEK was 41% (range, 968; SD, 16). Conclusion: The use of SF6 20%
in DMEK results in acceptable six-month postoperative endothelial cell loss for surgeons
in their learning curve.

SOE H Endothelial Cell Loss Stabilizes as Early as 2
Years After Descemet-Stripping Automated Endothelial
Keratoplasty
Presenting Author: Yoav Nahum MD
Co-Author(s): Cristina Bovone MD, Benedetta Filipovic-Ricci MD, Massimo Busin
MD*, Cataldo Russo MD
Purpose: To evaluate the progression of endothelial cell loss after Descemet-stripping
automated endothelial keratoplasty (DSAEK) performed by an experienced surgeon. Methods: Students t test was used to determine, in 846 eyes, the significance of changes in
endothelial cell count obtained six and 12 months after surgery and then yearly for up to five
years. Results: The average follow-up time was 21.3 18.6 months. The mean endothelial
cell loss at six months was 33.3% and increased significantly only up to two years postoperatively, reaching 39.3%. At later examination times (three, four, and five years), changes
were not statistically significant and varied between 2.1% to 2.4% yearly. Conclusion:
Endothelial cell density stabilizes as early as two years after DSAEK.
Scientific Posters
Co-Author(s): Michael D Straiko MD*, Peter B Veldman MD, Ahmad Mohammad

Alshaarawy MD, Zachary Mayko MS
surgeries declined from 10% to 4%. Conclusion: DMEK may consistently give excellent
clinical results. Technique standardization contributed to less graft detachments and relatively few secondary interventions required.
SESSION ONE, SATURDAY AND SUNDAY

SOE Optimizing EHRs for Ophthalmology and Big Data
Analysis: An Experience Report
Presenting Author: Karsten Ulrich Kortuem MD
Co-Author(s): Paul Foerster, Thomas C Kreutzer MD*, Anselm Kampik MD*
Purpose: To design ophthalmological user interfaces (UIs) in EHR i.s.h.med, linking examination devices and thus creating a base for Big Data analysis. Methods: UIs were
modified to ophthalmological needs using Advanced Business Application Programming
language. Examination devices were linked using HL7 and DICOM standard. For every exam
order, the unique EHR Patient ID was used. Results: Several UIs for in- and outpatients
were created since 2012 based on clinical needs and workflow to acquire structured data.
All clinical data (eg, visual acuity, medication, diagnosis) were saved in a database using
the unique EHR Patient ID. In 2013, 27,599 outpatients were documented. Conclusion:
A powerful base for clinical documentation as well as for future Big Data use was implemented.
Purpose: Clinical evaluation of Descemet membrane endothelial keratoplasty (DMEK).

Methods: In 500 DMEK eyes, clinical outcome was evaluated up to six months postoperatively. Outcome was compared between three groups (I: cases 1125, II: cases 126250,
and III: cases 251500). Results: At six months, 80% of eyes reached a best-corrected
visual acuity of 20/25 and 44% reached 20/20 (n = 394). Mean endothelial cell density was 1,600 490 cells/mm2 (n = 447) and did not differ between groups. (Partial) graft
detachment rate decreased from 24% in group I to 10% in group III. Likewise, secondary
183
Scientific Posters
Identifying Factors Associated With Increased Pediatric
Ophthalmology Visit Times Using EHR Data
Presenting Author: Grant D Aaker MD
Co-Author(s): Sarah Read-Brown, David S Sanders MD*, Leah Greenhill Reznick
MD**, Thomas Yackel MD MPH**, Michael F Chiang MD*
Purpose: To identify factors leading to increased patient visit times in a single-practitioner
pediatric ophthalmology practice using EHR data. Methods: All patient visits from 1 year
were reviewed, and multiple regression was employed comparing the following factors:
age, new versus follow-up visit, and diagnosis type, to total visit time from EHR timestamp
data. Results: Of 2701 visits, 5 visit types resulted in significantly longer visits (P < .001)
with all other variables held constant: new patients (29 minutes longer than follow-up),
adult patients (20 minutes longer than infants), adult strabismus, nystagmus, and new patients with cataract were 18, 19, and 34 minutes longer, respectively, than visits without
these diagnoses. Conclusion: EHRs can identify factors affecting patient visit times.
H Postoperative Eye Drop Documentation Omissions With
EHRs After Resident Cataract Surgery: An Under-recognized
Source of Error
Presenting Author: Julie M Kumata MD
Co-Author(s): , Jayne Weiss MD*
Purpose: To evaluate the accuracy of medication reconciliation (MR) in EHRs after resident-performed cataract surgery. Methods: This is a retrospective EHR review of all patients with resident cataract surgery in 2013 at one hospital. All patients received prednisolone acetate, moxifloxacin, and Tobradex ointment postoperatively. MR was reviewed to
determine if drops were accurately charted by the first postoperative visit (POD1). Results:
Ninety-eight percent of the 302 patients (296/302) returned for POD1. Thirteen percent had
no MR completed, while 87% (258/296) had a completed MR. Of these, 64% (164/258) had
a MR that omitted some or all of the drops. Only 36% (94/258) had a correct MR. Conclusion: Despite perceptions that EHRs facilitate accuracy of documentation, our study shows
that MR errors and omissions still occur.
General Medical Care
Scientific Posters

SOE The Choroid and Lamina Cribrosa Is Affected in
Patients With Parkinson Disease: Enhanced Depth Imaging
OCT Study
Presenting Author: Muhsin Eraslan MD
Co-Author(s): Sevcan Balci, Eren erman, Ozlem Sahin MD**, Devran Suer
Purpose: To compare lamina cribrosa(LC) and choroidal thickness using enhanced depth
imaging OCT (EDI-OCT) in Parkinson patients (PP) and controls. Methods: Complete ophthalmic examinations and OCT assessments of 28 PP and 26 healthy subjects were done.
Severity was evaluated according to United Kingdom Parkinson Disease Society Brain Bank
criteria. Results: There were no significant differences between groups regarding age and
sex (P = .144, P = .569). The mean LC and choroidal thicknesses were significantly less in
PP than control subjects. (P < .001, P < .05, respectively). Results were not correlated with
severity of PP. Conclusion: Parkinson disease causes anatomical changes in the LC and
choroid. Imaging these changes with OCT may help in diagnosis of early stage PP.
Ocular Trauma in the Emergency Department, 20062011
of 20 and 49, and the most common causes of injury were foreign bodies and falls. Conclusion: Policies aimed at protecting working-age males would likely have the greatest effect
on reducing ocular trauma in the United States.
Ocular Manifestation in Severe Familial
Hypercholesterolemia Patients
Presenting Author: Alaa Samih Bou Ghannam MD
Co-Author(s): Rola N Hamam MD, Jean Magdi Chalhoub BSMT MD, Mohamed
Serhan Hamam MD, Robert H Habib PhD
Purpose: To study ocular manifestations of patients with severe familial hypercholesterolemia (FHC). Methods: Twenty-eight patients known to have severe FHC and 24 agematched healthy controls were recruited and underwent full eye exam, including fluorescein angiography and OCT. Results: Patients with FHC had significantly higher percentage
of early corneal arcus (64% vs. 4%) and xanthelasmas (32% vs. 0%) than the control group.
These patients had also a prominent yellow rim around the optic nerve, not found in the
control group (35% vs. 0%). Peripheral retinal vascular plaques and occlusions were more
common among patients with FHC than among controls (21.4% vs. 0%). Conclusion: Severe FHC can have many ocular manifestations and complications that may require regular
eye exam.

Modified Portable Digital Camera (Pictor Plus) Is as
Effective as Traditional Nonmydriatic Fundus Camera for
Teleretinal Screening of Diabetic Retinopathy
Presenting Author: Shailesh K Gupta MD**
Co-Author(s): Sandeep Grover MD, K V Chalam MD PhD
Purpose: To compare the efficacy of a modified portable digital camera (MPDC) to nonmydriatic fundus camera (NMFC) in screening of diabetic retinopathy. Methods: One hundred sixteen patients underwent one-field NMFC photography prior to MPDC photography
followed by ophthalmoscopy by an ophthalmologist . The main outcome measure was
detection of referable diabetic retinopathy (DR). Results: For MPDC, the sensitivity was
98.2%, specificity was 96%, and the technical failure rate was 2.2%. For nonmydriatic photography, the sensitivity was 93.0%, specificity was 89.7%, and the technical failure rate
was 11.7%. Conclusion: Portable digital camera-assisted retinal photography is a cheap,
effective method of screening for DR and superior to nonmydriatic digital photography.

H Effects of Relocating an Academic Ophthalmology
Program From a Regional Level-1 Trauma Center to an
Outpatient Facility
Presenting Author: Surbhi Bansal MD
Co-Author(s): Jorawer Singh MD, Vincent M Imbrogno MD, Mary Howard, Amandip
Singh Cheema, Ausra Selvadurai MD
Purpose: To investigate the effect on consult service of moving an inpatient ophthalmology department to an outpatient office. Method: Consults performed at a level 1 trauma
center for the three years before and after department relocation were reviewed for patient
demographics, diagnoses, and related procedures. Results: Relocation did not affect total
surgical or consult volume, but fewer Medicaid patients and more privately insured patients
were seen. Consults after the move focused more on acute ophthalmic issues and less on
systemic conditions. Twenty-three percent of patients were seen for outpatient follow-up
before the move versus 2% after. Conclusion: Closure of an ophthalmology clinic at a
county hospital resulted in a greater than 90% decrease in patient follow-up but had little
effect on inpatient and emergency department consultations.
Presenting Author: Sterling Haring

Co-Author(s): Joseph Kaiser Canner MS, Rohit R Lakhanpal MD*, Eric B Schneider
PhD*
Purpose: To characterize demographic, causational, and mechanistic attributes of ocular
trauma in the United States. Methods: Data on primary and all-diagnosis ocular trauma
were collected from the Nationwide Emergency Department Sample and stratified by sex,
age, type of injury, external mechanism, and whether ocular trauma was a primary diagnosis. Population-specific rates were calculated. Results: Over a period from 2006 to 2011, a
total of 5,541,434 ocular trauma cases presented to emergency departments nationwide.
64.8% of presenting patients were male. Peak incidence rates occurred between the ages
184
Scientific Posters
Glaucoma
group. The myopic glaucoma eye group showed significantly higher ALD (P = .018), PTT
(P < .001), PTT/line connecting BMO (P < .001), and PTT/ALD (P < .001) than the myopic
eye group. Conclusion: LC parameters may be useful to differentiate normal, myopic, and
myopic glaucoma eyes.
H Female Reproductive Factors and Risk of Glaucoma in
the United States
Analysis of the Effect of Lighting Variation on Anterior
Chamber Angle Measurements using Spectral Domain OCT
Presenting Author: Noelle Layer Pruzan MD
Presenting Author: Vikas Chopra MD*
Co-Author(s): Mary Qiu MD, Sophia Ying Wang MD, Kuldev Singh MD MPH*, Shan C
Lin MD*
Co-Author(s): Kenneth Marion MBA MS,
Purpose: To investigate the relationship between female reproductive factors and glaucoma prevalence. Methods: Cross-sectional study of 2220 women age 40 years, including 1158 postmenopausal women, from the 2005-2008 National Health and Nutrition
Examination Study. Results: In a multivariate analysis adjusted for potential confounders,
a significantly greater risk of self-reported glaucoma was found with later age of menarche
(OR: 4.92; 95% CI, 1.86-13.00). Among postmenopausal women, glaucoma was not significantly associated with the time between menarche and menopause (OR: 0.98; CI, 0.22-4.33)
or with the use of hormone replacement therapy (OR: 0.87; CI, 0.33-2.26). Conclusion: Late
menarche is associated with greater risk of glaucoma, adding support to the potentially
protective role of sex hormones in glaucoma development.
SOE Does Early Glaucoma Affect the Central 10 Degrees of
Visual Field?
Presenting Author: Katia Novak-Laus PhD
Co-Author(s): Freja Barisic**, Zoran Vatavuk MD**, Mia Zoric Geber MD*, Renata
Ivekovic MD PhD**
Purpose: To explore the comparison between the loss in sensitivity measured by standard
automated perimetry (SAP) with local retinal ganglion cell + inner plexiform layer (RGC+IPL)
thickness measured by spectral domain OCT in the macula of patients with an early stage of
glaucoma. Methods: We evaluated the central 10 degrees in the Octopus visual field (VF).
In OCT we analyzed RGC+IPL layer thickness. Results: Seventy-one percent of patients had
loss of retinal sensitivity in the central 10 degrees VF, and 58% had structural changes;
44% of all patients had structural and functional changes. Conclusion: A 10 degree test
pattern in 2/3 of patients showed loss of retinal sensitivity in the central VF. This functional
damage more often appeared in the upper hemifield of VF, which corresponds to the lower
retina, like a mirror picture.
Presenting Author: Mary Qiu MD

Co-Author(s): Noelle Layer Pruzan MD, Ye Elaine Wang MD**, Kuldev Singh MD
MPH*, Shan C Lin MD*
Purpose: To examine the association between gynecologic surgery and glaucoma. Methods: Cross-sectional study of 2262 women age 40 years from the 2005-2008 National
Health and Nutrition Examination Survey. Results: Self-reported history of hysterectomy
and/or bilateral oophorectomy was associated with an increased odds of self-reported
glaucoma (OR: 1.6; 95% CI, 1.0-2.6), adjusting for demographics and systemic diseases.
Additional adjustment for gynecologic history resulted in an OR increase to 2.1 (CI, 1.2-3.9).
Further adjustment for other eye diseases resulted in the OR decreasing to 0.7 (CI, 0.31.9), with diabetic retinopathy diagnosis having the greatest impact. Conclusion: Diabetic
retinopathy may augment or confound the association between gynecologic surgery and
glaucoma.
Comparison of the Lamina Cribrosa Parameters in Myopic
Eyes and Myopic Glaucoma Eyes
Presenting Author: Bo Ram Seol MD
Purpose: To compare the lamina cribrosa (LC) parameters between normal, myopic, and
myopic glaucoma eyes. Methods: This study included 35 normal eyes, 24 myopic eyes, and
64 myopic glaucoma eyes. The LC parameters3/4including anterior lamina depth (ALD), prelamina tissue thickness (PTT), ALD/line connecting Bruch membrane opening (BMO), and
PTT/line connecting BMO, PTT/ALD3/4were obtained using swept source OCT. Results:
The normal eye group showed significantly higher PTT/ALD (P = .006) than the myopic eye
SOE Mapping the Visual Field to the Macular Ganglion Cell
Complex Thickness in Glaucoma
Presenting Author: Antonio Ferreras MD PhD*
Co-Author(s): Ana Belen Pajarin MD PhD, Pilar Calvo MD PhD*, Beatriz Abadia MD
PhD, Michele Figus MD, Blanca Monsalve MD, Michele Iester MD
Purpose: To determine the relationship between standard automated perimetry (SAP)
and ganglion cell complex (GCC) thickness measured with OCT. Methods: Fifty-six healthy
subjects and 52 open-angle glaucoma patients were selected. Factor analysis determined
5 superior and 7 inferior visual field (VF) regions. Pearson correlations were calculated between the GCC thickness and the VF regions. A map relating the GGC to the VF regions was
plotted. Results: Mild to moderate correlations were observed between the VF regions
and the GCC thicknesses. The strongest correlation was found between temporal inferior
GCC and the sector corresponding to the nasal step in the superior hemifield (r = 0.556; P <
.001). Conclusion:There was a moderate association between SAP and the GCC thickness.
SOE Relationship Between the Macular Ganglion Cell
Complex and the Retinal Nerve Fiber Layer in Glaucoma
Presenting Author: Antonio Ferreras MD PhD*
Co-Author(s): Pilar Calvo MD PhD*, Mirian Ara MHSA, Beatriz Abadia MD PhD, Paolo
Frezzotti MD**, Paolo Fogagnolo**, Ana Belen Pajarin MD PhD
Purpose: To evaluate the relationship between the macular ganglion cell complex (GCC)
measured with OCT and the retinal nerve fiber layer evaluated with scanning laser polarimetry (GDx). Methods: Forty-five healthy subjects and 40 open-angle glaucoma subjects
were included. Participants were examined with Cirrus OCT (Macular Cube 512x128) and
GDx with enhanced corneal compensation. Pearson correlations were calculated between
the parameters of both devices. Results: Moderate to strong correlations were observed
between the GCC thicknesses and the GDx parameters. The strongest correlation was
found between the inferior GCC thickness and the nerve fiber indicator (NFI) of GDx (r =
0.704; P < .001). Conclusion: NFI of GDx showed the strongest correlations with the GCC.
Vessel Caliber, Not Retinal Oximetry, Is Affected in
Glaucoma: A Comparison Between Eyes With Asymmetrical
Glaucoma Severity
Presenting Author: Clarissa Cheng MBBS
Co-Author(s): Charles Ong, Zhu Li Yap MD, Shih Hsiang Andrew Tsai MD, Monisha E
Nongpiur MD, Shamira A Perera MBBS
Purpose: To compare and correlate retinal vascular oxygenation (RVO2) and vessel caliber (VC) in glaucoma and normal controls. Methods: Prospective cross-sectional study of
primary angle-closure glaucoma (PACG), primary open-angle glaucoma (POAG), normaltension glaucoma (NTG), and normal control eyes. RVO2, VC, OCT, and visual field were
tested. Results: Forty PACG, 44 POAG, 42 NTG, and 40 normal controls were included.
Venular diameter was thinner in all glaucoma groups than in normal controls (P < .01). In
eyes with asymmetrical severity, arteriolar diameter was thinner in the worse eye in the
185
Scientific Posters
Association Between Gynecologic Surgery and Glaucoma
Prevalence in the United States
Purpose: First study to report the impact of variations in ambient lighting conditions on the
reproducibility of newer anterior chamber angle parameters based on the Schwalbe line
(SL). Methods: The inferior angles of 50 normal eyes were imaged 20 times (total = 500
assessments) with Zeiss Cirrus SD-OCT at 5 different strictly controlled light levels guided
by a light meter and graded independently by 2 experts. Results: Angle parameters are
exquisitely sensitive to changes in ambient illumination. Decreasing the light level from
1.0 to 0.0 ft-candles decreased SL-angle opening distance (AOD) and SL-trabecular iris
space area (TISA) by 10.7% and 13.7%, respectively. Intra- and intergrader results showed
excellent reproducibility at each lighting level (R2 = 0.94-0.98). Conclusion: Strict control
of lighting conditions is needed to obtain reproducible anterior chamber measurements.
Scientific Posters
PACG group (P = .001). Arteriolar RVO2, venular RVO2, and arteriovenous difference was
similar across the groups and between eyes of asymmetrical severity. Conclusion: VC, not
RVO2, is reduced in glaucoma and inversely related to severity.
SOE Comparison of the Results of Heidelberg Retina
Tomograph III and Spectral Domain OCT in Large and Small
Discs
Presenting Author: Belgin Izgi MD
Co-Author(s): Serife Bayraktar, Nevbahar Tamcelik MD
Purpose: To evaluate the correlation between the optic nerve head parameters obtained
by the Heidelberg Retina Tomograph III (HRT III) and the retina nerve fiber layer (RNFL)
measurements obtained by spectral domain OCT (SD-OCT) in large and small discs for the
diagnosis of glaucoma. Methods:The patients who had large (> 2.55 mm2) and small (<
1.60 mm2) discs were evaluated by HRT III and SD-OCT on the same day. Results: We have
evaluated 194 eyes of 133 patients in the large disc group (Group 1) and 115 eyes of 70
patients in the small disc group (Group 2). The mean disc area was 2.9 0.3 mm2 and 1.4
0.13 mm2 in Group 1 and Group 2, respectively. The correlation was poor in all quadrants
in Group 1. It was moderate only in the superior quadrant and poor in the other quadrants in
Group 2. Conclusion: To avoid the misdiagnosis of glaucoma in large and small discs it is
important to obtain the RNFL measurements by SD-OCT after HRT III evaluation.
Factors Affecting Plastic Lamina Cribrosa Displacement in
Glaucoma Patients
Presenting Author: Kyoung In Jung
Co-Author(s): Younhea Jung MD, Hae-ri Yum MD,
Purpose: To investigate factors associated with irreversible components of anterior lamina
cribrosa (LC) depth in glaucoma patients. Methods: A total of 141 glaucoma patients and
51 control subjects were enrolled. The depth of the lamina cribrosa (LC) was measured at
the optic nerve head using Spectralis OCT. Results: In younger patients (age < 60 years),
multivariate analysis revealed that those with a young age, short axial length, and a high
follow-up IOP were at increased risk for having a deeper LC (P = .042, .028, .010). In older
patients (age > 60 years), young age and a high untreated IOP were significantly associated
with a deeper LC (P = .023, .001). Conclusion: Age and axial length as well as IOP were
significantly related to LC depth in glaucoma.
Risk Factors for the Hypertensive Phase
Presenting Author: Kyoung In Jung
Scientific Posters
Co-Author(s): Younhea Jung MD, Hae-ri Yum MD,

Purpose: To investigate risk factors for the development of the hypertensive phase after
implantation of the Ahmed glaucoma valve (AGV). Methods: A total of 130 patients who
had undergone AGV implantation were included in the study. Patients were divided into
hypertensive and nonhypertensive groups. Results: Axial length was significantly longer in
the hypertensive group than that in the nonhypertensive group (P = .011). Only axial length
was significantly associated with development of the hypertensive phase (P = .009). Axial
length was correlated with postoperative IOP postoperatively (P < .05). Axial length was
correlated with bleb wall thickness at 1 month postoperatively (P = .021). Conclusion: Eyes
with a long axial length were at the greatest risk for developing the hypertensive phase.
SOE Effect of Topical Prostaglandin Analogues on the IOP
Measured Using 3 Different Tonometers
SOE Intraocular Pressure After Intravitreal Anti-Vascular
Endothelial Growth Factor Injections
Presenting Author: Vanessa Lemos MD
Co-Author(s): Ana Cabugueira MD, Duarte Moreira Amado**, Maria P Reina MD,
Teresa Gomes MD
Purpose: To determine the effect of intravitreal bevacizumab injections (bIV) on IOP and to
identify possible risk factors. Methods: This prospective study included 106 eyes receiving
bIV as treatment for macular edema or choroidal neovascularization. IOP was measured
immediately before and 5 minutes, 1 hour, and 15 days after injection. Data collected were
age, gender, glaucoma, diabetes mellitus, phakic status, medication, subconjunctival reflux,
and number of injections. Results: Mean preoperative IOP was 15.31 3.90 mmHg and
postoperative IOP at 5 minutes was 27.27 11.87 mmHg; at 1 hour, 17.59 6.24 mmHg;
and at 15 days, 16.86 3.86 mmHg. IOP elevation was statistically significant. Conclusion:
One-third of the eyes achieved IOPs higher than 30 mmHg. Subconjunctival reflux contributes to a lower mean postoperative IOP. IOP management should be performed.

SOE Method Agreement in IOP Measurement With the
Keeler Tonometer, Ocular Response Analyzer, Dynamic
Contour Tonometer, and Goldmann Applanation Tonometer
Presenting Author: Taiwo Christopher Makanjuola MD
Co-Author(s): Gerassimos Lascaratos, Ahmed Elsheikh PhD, Ahmed Abass, Tuan Ho
PhD, David F Garway-Heath MD FRCOphth*
Purpose: The aim of this study was to compare the intermethod agreement in IOP measurements made with the Keeler Non-Contact Tonometer, Ocular Response Analyzer (ORA),
Pascal Dynamic Contour Tonometry (DCT), and Goldmann applanation tonometer (GAT).
Methods: IOP was measured with all 4 devices in the right eye of 89 healthy subjects
and in 58 patients with primary open-angle glaucoma and in 1 with ocular hypertension.
Results: Mean IOP was 16.2 (3.6) mmHg, 18.7 (3.7) mmHg, 15.4 (4.4) mmHg, 16.6(4.3)
mmHg, and 17.4 (4.2) mmHg for GAT, DCT, Keeler, ORA IOPg, and ORA IOPcc, respectively.
The mean difference in IOP measurement (in mmHg) was +2.5, -0.8, +0.4, and +1.2 between
GAT and DCT, Keeler, ORA IOPg, and ORA IOPcc, respectively, with 95% LoA (in mmHg) of
4.0, 4.8, 4.6, and 5.5, respectively. Conclusion: The differences in IOP measurements
between Keeler and ORA may be due to a calibration difference.

Comparison of IOP Readings Following Radial Keratotomy
Using 3 Tonometry Techniques
Presenting Author: Mujtaba A Qazi MD*
Co-Author(s): Jay R Patel MD, Jay Stuart Pepose MD PhD*
Purpose: To compare IOP and corneal biomechanical metrics following radial keratotomy
(RK) using Goldmann (GAT), Ocular Response Analyzer (ORA), and Pascal Dynamic Contour (DCT) Tonometry. Methods: Topography, pachymetry, and ORA corneal biomechanical
markers were recorded in RK eyes (n = 14). IOP measurements using 3 tonometry techniques were statistically analyzed. Results: Hysteresis following RK was 8.5 1.8 mmHg.
Mean GAT (mean: 17.8 mmHg) and DCT (18.1) IOP were significantly lower (P < .05) than
ORA IOPg (20.6) and IOPcc (22.4). Conclusion: IOP measurement in RK presents a unique
challenge given normal pachymetry with altered corneal shape and biomechanics. Clinical
correlation of IOP with visual field and optic nerve imaging should be utilized to screen and
monitor these patients for glaucoma.
Presenting Author: Cristina Sanchez-Barahona MD

Poor Follow-up and Knowledge Retention Despite
Glaucoma Disease Counseling
Co-Author(s): Gema Bolivar de Miguel MD, Consuelo Gutierrez PhD
Presenting Author: Anna Do
Purpose: To evaluate the IOP using the Goldmann applanation tonometer (GAT), Ocular
Response Analyzer (ORA), and Corvis ST after treatment with prostaglandin analogues
(PGAs) in naive eyes. Methods: Prospective, observational study. GAT IOP, ORA cornea
compensated IOP (IOPCC), and Corvis IOP were measured before and after 3 months of
topical PGA treatment. Results: Fifty-nine eyes were analyzed. We did not find any statistically significant difference in drug-induced IOP decrease between GAT-IOP and IOPcc. IOP
decrease measured by Corvis was significantly different (P = .0001). Conclusion: The IOP
decrease induced by PGA treatment is different depending on the tonometer used.
Co-Author(s): Kuldev Singh MD MPH*, Elizabeth Washburn, Bradford William Lee MD

MSC
186
Purpose: To quantify longitudinal loss to follow-up among newly diagnosed glaucoma

patients, and to evaluate learning and retention of glaucoma knowledge through disease
counseling. Methods: 399 glaucoma patients completed a 9-point glaucoma knowledge
questionnaire before and after glaucoma counseling at diagnosis and follow-up visits over
a 12-month period. Results: After 12 months, 86.5% of subjects were lost to follow-up.
Counseling improved knowledge of glaucoma temporarily (35.6% increase in glaucoma
questionnaire score, P < .0001), but with poor retention 1 month later (14.1% decrease
Scientific Posters
in questionnaire score from prior visit, P < .001). Conclusion: Despite diligent counseling
efforts, the majority of newly diagnosed glaucoma patients were lost to follow-up at 12
months and showed poor retention of learned glaucoma knowledge.

SOE An Open, Nonrandomized Study on the Effect of
Preservative-Free Tafluprost on IOP in Patients With Ocular
Hypertension or Primary Open-Angle Glaucoma
Presenting Author: Anton B Hommer MD*
Co-Author(s): Doreen Schmidl MD DOMS, Gerhard Garhofer, Leopold Schmetterer
PhD*
Purpose: To investigate the effect of an 8-week treatment with preservative-free tafluprost on IOP in patients with primary open-angle glaucoma (POAG) or ocular hypertension
(OHT). Methods: Sixteen patients with either POAG or OHT with an uncontrolled IOP 30
mmHg were included in the study. IOP was measured at 8 a.m. and 6 p.m. on each study
day. Results: Eight weeks after treatment start, average IOP had decreased from 35.6
4.5 mmHg to 24.4 4.6 mmHg at 8 a.m. and from 32.9 5.4 mmHg to 21.9 3.9 mmHg at
6 p.m. (P < .01 each). Conclusion: Our data indicate that treatment with preservative-free
tafluprost is a safe and potent therapy to lower IOP in patients with POAG and OHT. Further
studies are warranted to investigate the effect of preservative-free formulations for longterm treatment.

Adherence and Persistence of Topical Bimatoprost 0.01%
vs. Bimatoprost 0.03% in Prior Latanoprost Users
Presenting Author: Gail F Schwartz MD*
Co-Author(s): Vaishali Patel**, Pamela Landsman-Blumberg MS PhD*, William Wong
MS PHARMD*
Purpose: Bimatoprost 0.01% (B01), a new ophthalmic formulation, was hypothesized to
improve adherence and persistence compared with the original bimatoprost 0.03% (B03)
formulation. Methods: Using pharmacy claims, adherence in 6035 B01 and 2705 B03 patients was measured as proportion of days covered (PDC). Persistence, as proportion of
patients on continuous treatment for 12 months, was measured in 7780 B01 and 3454 B03
patients. Results: Adherence to B01 was significantly greater than to B03 (mean PDC:
0.74 vs. 0.68; P < .001). Persistence with B01 (52%) was significantly greater than with
B03 (46%), < .001 . Those < 65 and 65+ had similar results. Conclusion: In clinical practice, B01 demonstrated adherence and persistence superior to that of B03 in latanoprostexperienced patients.
Presenting Author: Hector Fernandez Sr

Co-Author(s): Nicolas Toledano Fernandez MD**, Carlos Salvador Fernandez Escamez
MD**, Esther Corredera MD**, Susana Perucho**
Purpose: To assess the effects on the human cornea of ocular hypotensors with benzalkonium chloride (BAK). Methods: Prospective single-blind cohort study of 50 eyes of 50
patients. One group was exposed to BAK and the other group was not. Mean follow-up
time was 22 weeks. The change in cell density before and after therapy was measured.
The changes in stromal reflectivity and branches of the sub-basal nerve plexus were also
measured. Results: A major increase in the density of the layer of basal cells in the epithelium was observed in the group exposed to BAK (P < .05). No significant density differences
were detected in the endothelium, the limbal cells, stromal reflectivity, or the sub-basal
nerve plexus. Conclusion: Drops without preservatives showed less alteration of the eye
surface, using confocal microscopy analysis.

Trabeculodialysis for Uveitic Glaucoma
Presenting Author: Sunita Radhakrishnan MD*
Co-Author(s): Dmitry Yarovoy MD, Lian Chen MD, Terri-Diann Pickering MD, Andrew
George Iwach MD*
Purpose: To describe outcomes of trabeculodialysis in uveitic glaucoma. Methods: Retrospective review. Success defined as 30% IOP reduction with no further surgery. Results:
Ten eyes (7 patients) were included. Mean age was 33.6 23.3 years. Causes of uveitis
(juvenile rheumatoid arthritis, herpetic disease, and idiopathic: 80%; 8/10) were quiet be-

SOE Segmental Dilation of the Schlemm Canal Using an
Original Canal Expander in Open-Angle Glaucoma Surgery:
One-Year Results
Presenting Author: Vinod Kumar MD PhD
Co-Author(s): Frolov Mikhail**, Elena Bozhok, Galina Dushina**
Purpose: To evaluate effectiveness of segmental dilation of the Schlemm canal (SC) using an original canal expander (CE) in decreasing IOP in patients with open-angle glaucoma (OAG). Methods: Between October 2012 and December 2013, an original CE was
implanted ab externo to dilate a segment of SC in 18 eyes (18 patients) with OAG. Efficacy
measures were IOP changes, complication rate, and additional medication. Results: At 12
months, complete and partial success was achieved in 60% and 40% of cases; mean IOP
decrease was 13.5 mmHg (49.8% decrease from the baseline; P = .000); mean decrease in
medication use was 1.5 (62% decrease; P = .000), respectively. Conclusion: Permanent
dilation of a segment of SC using an original CE significantly decreases IOP in the long term.

H Twelve-Month Results After Stand-alone Implantation of
CyPass Micro-Stent in Patients With Open-Angle Glaucoma
in Bulgaria
Presenting Author: Tsontcho Ianchulev MD*
Co-Author(s): Bissera Petrova Samsonova MD PhD, Pravoslava Ianchuleva MD PhD*
Purpose: To evaluate a supraciliary implant as a stand-alone treatment for patients with
open-angle glaucoma unresponsive to topical therapies in a single site in Bulgaria. Methods: The implant was placed ab interno through a corneal incision under gonioscopic visualization as a stand-alone procedure. Outcomes were adverse events, IOP changes, and
number of IOP-lowering medications at baseline and 1 year. Results: Eyes (n = 17) were
enrolled. There were no major adverse events. Mean (SD) baseline IOP (n = 17) was 24.2
(5.2) mmHg, and medication usage was 2.1 (1.1). At 12 months (n = 15), subjects had a mean
IOP of 17.6 (5.4) mmHg, representing a 23% reduction, with mean medication usage of 1.3
(0.9). Conclusion: The CyPass Micro-Stent is a safe and effective stand-alone treatment
for open-angle glaucoma patients unresponsive to medications.

Effect of Trabectome in Patients With Prior Failed Tube
Shunt Surgery
Presenting Author: Sameh Mosaed MD*
Purpose: To evaluate the safety and efficacy of Trabectome after failed tube shunt surgery. Methods: Twenty-four patients with prior failed tube shunt surgery who underwent
Trabectome procedures were included in this study. All patients had at least 3 months of
follow-up. Outcomes measured included IOP, glaucoma medications, and secondary glaucoma surgeries, if any. Results: IOP was reduced from baseline of 23.0 6.5 mmHg to
16.1 4.9 mmHg (P = .02), while number of medications was reduced from 3.2 1.4 to 2.4
1.5 (P = .34) at 12 months. Three patients required additional glaucoma surgery, with 15
patients reaching 12 months follow-up. Conclusion: The Trabectome was safe and effective in reducing IOP at 1 year follow-up in patients with prior failed tube shunt surgery, but
not effective in reducing medication reliance in these patients.

Trabeculectomy Following Intraocular Bevacizumab
for Neovascular Glaucoma: Long-term Outcomes and
Prognostic Factors
Presenting Author: Tomomi Higashide MD PhD
Co-Author(s): Shinji Ohkubo MD PhD*, Kazuhisa Sugiyama MD PhD
Purpose: To evaluate long-term outcomes and prognostic factors of trabeculectomy (TLE)
following intraocular bevacizumab (IOB) for neovascular glaucoma (NVG). Methods: Retrospective review of consecutive cases (60 eyes of 54 patients). Postoperative follow-up
periods were 42.2 23.0 months. Surgical failure was defined as IOP 21 mmHg, additional medical or surgical treatments to reduce IOP, or loss of light perception. Results:
187
Scientific Posters

SOE Corneal Effects of Ocular Hypotensors That Contain
Benzalkonium Chloride: In Vivo Confocal Microscopy
Analysis
fore surgery. Mean follow-up was 6.0 5.6 years. Eight eyes (80%) were successful; at
last follow-up, IOP reduction was 39%-67% from baseline in these eyes and number of
medications was reduced by 1.8 1.6. Two eyes (20%) failed due to further glaucoma
surgery. There were no major complications; 1 eye had a 2-stage procedure due to bleeding. Conclusion: Trabeculodialysis was successful in 80% of eyes in this series. Since it is
a minimally invasive procedure, it may be considered as first-line surgery in patients with
uveitic glaucoma.
Scientific Posters
Surgical success rates were 89.0%, 78.5%, and 68.2% at 1, 3, and 5 years, respectively.
Multivariate Cox regression analysis showed that vitrectomy before and after TLE were
significant independent risk factors (hazard ratio = 8.35, 8.44; P = .015, .006, respectively).
Conclusion: The long-term outcome of TLE following IOB for NVG was favorable. Vitrectomy may negatively affect it.

H Management and Visual Outcome of Hemorrhagic
Descemet Detachment in Canaloplasty

SOE Subconjunctival Bevacizumab Compared With
Adjunctive Mitomycin C for Trabeculectomy
Co-Author(s): Ibrahim A Aljadaan MD, Saleh Alobeidan MD
Presenting Author: Nitin Anand MD FRCS*

Purpose: To compare medium-term outcomes of primary trabeculectomy with subconjunctival bevacizumab (SCB) to those with intraoperative mitomycin C (MMC) application.
Methods: Sixty-seven eyes of 61 patients, with 36 eyes receiving SCB 2.5 mg and 31 eyes
in with MMC 0.02% for 2-3 minutes and a mean follow-up of 33 months, were included.
Results:The probability of an IOP of < 19, > 5 mmHg with 20% decrease from baseline was
66% and 61% in the first year and 64% and 57% in the second year in the bevacizumab and
MMC groups, respectively (P = .8). No differences were noted in complications, avascular
blebs, or postoperative medications. Conclusion: No differences were found between IOP
outcomes, bleb characteristics, or complications after trabeculectomy was augmented by
either SCB or MMC.

SOE Cataract Extraction After Nonpenetrating Filtering
Surgery
Presenting Author: Nitin Anand MD FRCS*
Purpose: To report the incidence of cataract extraction (CE) after deep sclerectomy (DS)
and its effect on IOP control. Methods: 241 eyes of 241 patients with consecutive DS and
follow-up of 85.4 30.6 months. Results: The probability of avoiding cataract surgery was
97.5%, 83%, and 74.2% at 1, 3, and 5 years after DS. There was a significant association
of age with cataract surgery (HR 1.06, P < .0001) and needle revision prior to cataract (HR
1.9, P = .02). Mean follow-up after CE was 47.6 28.3 months. The mean IOP before CE was
11.6 4.5 mmHg and increased significantly at all measured time intervals up to 3 years
after cataract surgery by 1-2 mmHg, with no change in the number of glaucoma medications. Conclusion: The probability of CE after DS is low and gradually increases with time
and age. IOP increases after CE.

Long-term Outcome of Ahmed Glaucoma Valve Implantation
for Refractory Glaucoma in a Tertiary Hospital in Brazil
Presenting Author: Ricardo Y Abe MD
Scientific Posters
Co-Author(s): Jose Paulo Cabral Vasconcellos MD**, Vital Paulino Costa MD*
Presenting Author: Faisal Almobarak MD

Purpose: To report the management and visual outcome of hemorrhagic Descemet detachment (HDD) in canaloplasty. Methods: Noncomparative case series. Results: Four eyes of
65 (6.15%) developed HDD. The first case was observed for 2 weeks and then intracameral
SF6 15% injection was given. The patient developed dense corneal stain that resolved
slowly over 24 months. The vision dropped from 20/40 to 20/80. Two cases underwent
immediate and 1 day after canaloplasty surgical evacuation and regained vision (20/30 and
20/100) and corneal transparency. The last case had Yag membranotomy 2 weeks later and
regained vision (20/60) and corneal transparency. Conclusion: HDD is a rare but serious
complication of canaloplasty. Early recognition and management are important to prevent
visual impairment.

Second Glaucoma Drainage Device vs. Combined
Phacoemulsification After Primary Tube Shunt Failure
Presenting Author: Yohko Murakami MD
Co-Author(s): Laurie Dustin MS**, James Chee Hian Tan MD*, Vikas Chopra MD*,
Brian A Francis MD*
Purpose: To evaluate the efficacy in controlling IOP with second glaucoma drainage device
(GDD2) implantation vs. phacoemulsification cataract extraction with GDD2 (phaco-GDD2)
in the treatment of glaucoma with a prior aqueous shunt. Methods: A retrospective chart
review was conducted. Treatment success was defined as 5 IOP 21 mmHg and 20%
reduction from baseline. Main outcome measures were reduction in IOP and antiglaucoma
medications. Results: A total of 82 patients matched on preoperative IOP were analyzed.
GDD2 lowered IOP by 34.3% and phaco-GDD2 by 36.4% at 3 years. GDD2 reduced antiglaucoma medications by 1.5 at 1 year. Phaco-GDD2 reduced medications by 2.0 at 1 year and
1.0 at 2 years. Conclusion: Both GDD2 and phaco-GDD2 are effective as a second surgery.
Phaco-GDD2 achieved successful IOP control with fewer medications than GDD2 at 2 years.

Combined Trabectome and Cataract Surgery vs. Combined
Trabeculectomy and Cataract Surgery in Open-Angle
Glaucoma
Presenting Author: Sahar Bedrood MD
Co-Author(s): Brian A Francis MD*
Purpose: To evaluate survival of Ahmed glaucoma valve and risk factors associated with
failure. Methods: Retrospective study with 80 eyes of 77 patients. Failure was defined as
additional glaucoma surgery, loss of light perception, or IOP greater than 18 mmHg and
less than 5 mmHg. Results: The patients had a mean age of 57.16 years ( 18.73) and
mean follow-up time of 35.25 months ( 20.05). Using Kaplan-Meier survival analyses, the
cumulative probability of success was 80% in 1 year, 64.4% in 3 years, and 50.4% in 5
years. Cox proportional hazards model indicated that failure was associated with previous
glaucoma surgery (P = .02) and African-American descendance (P = .002). Conclusion:
African-American descendance and previous glaucoma surgery were associated with increased risk of failure.
Purpose: To compare the IOP-lowering effect of Trabectome combined with phacoemulsification cataract extraction (Trabectome+PCE) and trabeculectomy combined with PCE
(trabeculectomy+PCE). Methods: Eighty-nine eyes were in the Trabectome+PCE group
and 23 eyes were in the trabeculectomy+PCE group with at least 1 year follow-up. The
main outcomes were IOP, complications, and glaucoma medications. Results: IOP was
reduced from 22.1 5.5 mmHg (n =89) to 15.4 + 3.1 mmHg (P < 0.01) in Trabectome+PCE
cases, and 23.0 10.7 mmHg (n = 23) to 11.0 ;5.7 mmHg at 1 year (P < 0.01) in the
trabeculectomy+PCE cases. Four cases (4%) required additional glaucoma surgery in the
Trabectome+PCE group and 3 cases (13%) in the trabeculectomy+PCE group. Conclusion:
Trabectome+PCE may be another option for patients. However, patients requiring low target
IOP may still benefit from trabeculectomy+PCE.

H Effectiveness of Retrobulbar Chlorpromazine Injection in
Controlling Ocular Pain in Patients With Glaucoma

Anterior Chamber Biometrics and IOP Dynamics Following
Cataract Extraction in Glaucoma Patients
Presenting Author: Davinder S Grover MD*
Presenting Author: Ferhina S Ali MD
Co-Author(s): Stephen M Hypes DO, Ronald Leigh Fellman MD OCS*, Ildamaris

Mercedes MontesdeOca MD**, Harry A Quigley MD*, Pradeep Y Ramulu MD PhD*
Co-Author(s): Sasan Moghimi MD, Diego Tebaldi de Queiroz Barbosa MD, Guofu
Huang MD**, Shan C Lin MD*
Purpose: To determine the effectiveness of retrobulbar chlorpromazine injection (RBCI)

in reducing ocular pain. Methods: The charts of glaucomatous eyes undergoing RBCI between 2011 and 2012 were reviewed. Survival analyses were performed to assess ocular
pain. Results: 109 patients received RBCI with 94% simultaneous diode laser cyclophotocoagulation. Fifty-seven percent of eyes had neovascular, 13% had primary open-angle, and
8% had traumatic glaucoma. Kaplan-Meier analyses of 1 injection resolved pain in 89%,
86%, and 81% of patients at 6, 12, and 24 months. With persistent pain, a second injection
was successful in 71% of eyes. Conclusion: RBCI is an effective procedure for painful
eyes with glaucoma and should be considered as an alternative to enucleation.
Purpose: To determine the association of anterior chamber biometrics with IOP lowering
after cataract surgery in primary open-angle glaucoma (POAG) patients. Methods: Preand postoperatively, angle opening distance 500 m anterior to the scleral spur (AOD500),
the trabeculariris space area 500 m from the scleral spur (TISA500), and iris curvature
were obtained by anterior segment OCT (n = 34). Results: The mean AOD500 increased
significantly by 0.180 mm and the mean TISA500 increased with marginal significance by
0.054 mm3. The mean IOP decreased significantly by -2.5 mmHg (P < .01), which correlated
by marginal significance with the increase in the AOD500 (r = 0.30, P = .05) and with the
change in iris curvature (r = 0.032, P = .05). Conclusion: The reduction in IOP was associated with the increase in the angle opening and the change in iris curvature.
188
Scientific Posters
A Retrospective Survey of Childhood Glaucoma Prevalence
According to Childhood Glaucoma Research Network
Classification

Clinical Utility of Short-Duration Transient Visual Evoked
Potential Pathologic Indicators in Chronic Glaucoma
Presenting Author: Ambika Hoguet MD
Co-Author(s): Richard Trevino OD, Sylvia L Groth MD, Joseph J Allen, Kimberly A Thoe
COA
Co-Author(s): Alana Grajewski MD*, Elizabeth A Hodapp MD, Mark A Werner MD**,
Ta Chen Chang MD*
Purpose: To evaluate the Childhood Glaucoma Research Network (CGRN) classification
system and describe the prevalence of each subtype according to this classification. Methods: The medical records of 125 consecutive childhood glaucoma and glaucoma suspect
patients over a 6-month period were retrospectively reviewed. The initial diagnosis and
new diagnosis according to CGRN classification were recorded. Results: All patients fit
1 of the 7 categories of the new classification. Seventy-three percent of diagnoses were
changed upon reclassification. The most common diagnosis was Glaucoma Suspect (38%,
P < .05), followed by Primary Congenital Glaucoma (18%) and Glaucoma Associated With
Acquired Conditions (18%). Conclusion:The CGRN classification provides a useful method
of classifying childhood glaucoma.

SOE Early Clinical Features of Pseudoexfoliation Syndrome
Presenting Author: Atilla Bayer MD
Co-Author(s): Sirel Gur Gungor MD, Ahmet Akman MD
Purpose: To determine the early signs of pseudoexfoliation (PX) in fellow eyes of cases
with unilateral PX. Methods: Fellow eyes of 34 cases with unilateral PX were evaluated by
slit lamp and gonioscopy. Findings associated with PX were recorded. Results were compared with the findings of 25 age-matched healthy eyes. Results: Mean age was 65.8 3.4
years. Thirty-two eyes (94%) had pigmentation in the inferior angle located on or anterior
to the Schwalbe line (P < .05). Other findings were pigmentation of trabecular meshwork in
the inferior angle (71%), loss of peripupillary ruff (43%), and pigment dispersion following
pupil dilation (43%) (P < .05). Conclusion: Pigmentation in the inferior angle seems to be
the earliest finding associated with PX. This finding must be considered in cases with ocular
hypertension for proper management.
Presenting Author: William Eric Sponsel MD*
Purpose: To assess rates of abnormal amplitude and latency findings in adults with chronic
glaucoma using Diopsys Nova-LX P100 / N-75-referenced high contrast (Hc) and low contrast (Lc) stimuli. Methods: 143 eyes of 88 adults with chronic glaucoma staged as mild
(HVF 30-2 MD > -6 dB), moderate (< -6 > -12 dB), or severe (< -12 dB) with Nova-LX were
assessed, with paired t tests of Hc vs. Lc deficits. Results: Age (68.1 13.2) was consistent
across staged subgroups (71 mild, 25 moderate, 47 severe). Amplitudes were normal in >
85% of eyes and nondiscriminatory. Conversely, Lc and Hc latency both showed strong associations with perimetric staging, but Hc latency deficits were far more common (% abnormal [mild / moderate / severe / ] Lc: 8.1:13.3:38.2; Hc: 22.5:43.1:53.9; P = .0002). Conclusion: Latency increased with glaucoma severity, with Hc twice as common as Lc defects.

Exfoliation Syndrome and Human T-Lymphotropic Virus Type
1
Presenting Author: Mineo Ozaki MD
Co-Author(s): Saya Ishii MD, Mitsugu Shimmyo MD, Robert Ritch MD FACS*
Purpose: The onset of exfoliation syndrome (XFS) may be influenced by virus infection.The
epidemiological distribution of human T-lymphotropic virus type 1 (HTLV-1) carriers seems
to correlate with the distribution of XFS in Japan. Our aim was to compare the prevalence
of HTLV-1 carriers between XFS and non-XFS patients. Methods: We studied 165 XFS
patients and 160 controls. Blood samples were analyzed by chemiluminescent immunoassay. Results: HTLV-1 was positive in 21 cases (12.7%) in the XFS group and in 17 cases
(10.6%) in the control. Conclusion: There was no statistically significant difference in the
prevalence of HTLV-1 carriers between the two groups (P = 0.5554).

Comparison of Anterior Chamber Parameters in Patients
With Plateau Iris Configuration and Pupillary Block Using
Anterior Segment OCT

Juvenile Open-Angle Glaucoma: Clinical and Genetic
Characterization in Mexican Patients
Presenting Author: Sasan Moghimi MD
Purpose: To describe the clinical features in patients with juvenile glaucoma and perform
genetic mutation Pro137Leu and Q368X study in a Mexican population. Methods: Complete ophthalmic examination and study in search of the mutation Pro137Leu and Q368X.
Results: Of a total of 22 patients with juvenile glaucoma, 63.63% of patients had a history
of hereditary familial primary open-angle glaucoma and juvenile glaucoma. A change was
found, never before reported in three patients from the same family I432T. The PolyPhen
analysis suggests that this change is probably damaging, with a score of 0.998. Conclusion: A Mexican group of 22 patients with juvenile glaucoma was studied, and a new
mutation was found in the myocilin gene for the Mexican population.
Co-Author(s): Yingjie Li Jr**, Diego Tebaldi de Queiroz Barbosa MD, Mingguang He

MD PhD, Shan C Lin MD*

Natural History of Visual Field Loss in Myopic Eyes
Presenting Author: Paul M Tesser MD PhD*
Co-Author(s): Jeremy Andrew Beatty OD
Purpose: To investigate the natural history of visual field loss in eyes with myopia and myopic discs. Methods: Observational cohort study evaluating 55 patients with myopic discs
who were referred with a previous diagnosis of primary open-angle glaucoma or normaltension glaucoma and established visual field loss in the context of myopia. Patients were
followed for 5 years with serial achromatic perimetry. Patients demonstrating an IOP >
24 mmHg were excluded. Results: The decrease in mean deviation (MD) was -0.5 dB/yr
for 76% of patients this cohort. In 54% of patients no net decrease in MD was observed.
No patient demonstrated a change in MD of > -1.5 dB/yr. The change in pattern standard
deviation was < 1.0 dB/yr for 96% of patients. Conclusion: The majority of patients with
myopic discs demonstrated no progression of visual field loss.

SOE Correlation Between Posterior Pole Asymmetry
Analysis and Peripapillary Retinal Nerve Fiber Layer in
Early Primary Open-Angle Glaucoma
Presenting Author: Ana Cabugueira MD
Co-Author(s): Vanessa Lemos MD, Lus Pinto, Teresa Gomes MD, Rita Maria Flores*,
Maria P Reina MD
Purpose: To investigate the diagnostic ability of spectral-domain OCT posterior pole asymmetry analysis (PPAA) in early primary open-angle glaucoma (POAG). Methods: Peripapillary retinal nerve fiber layer (RNFL) and PPAA were acquired in 48 eyes of early POAG and
in 39 eyes with ocular hypertension. Results: Total, superior, and inferior macular thickness
was lower in the POAG group (P < 0.01). In POAG subjects, we observed a moderate positive
correlation between superior temporal RNFL and macular thickness of a selected region of
the superior hemisphere (R = 0.403; P < 0.01) and a strong positive correlation between inferior temporal RNFL and a selected region of the inferior hemisphere (R = 0.612; P < 0.001).
Conclusion: Used with RNFL measurements, PPAA may be useful for early detection of
POAG. The inferior macular hemisphere may be more vulnerable to early glaucomatous
damage.
189
Scientific Posters
Purpose: To quantitatively analyze the anterior chamber parameters in patients with pupillary block (PB) and plateau iris configuration (PIC) using anterior segment OCT (AS-OCT).
Methods: Nonglaucomatous subjects were consecutively recruited and divided into 3
groups of open angles (121 eyes), PB (60 eyes), and PIC (31 eyes) based on gonioscopic
and ultrasound biomicroscopy findings. AS-OCT parameters were obtained and compared.
Results: There was no significant difference in angle parameters, anterior segment parameters (anterior chamber depth and area), iris thickness, iris curvature, or lens vault between
PB and PIC groups. PIC eyes had borderline greater iris thickness than the PB group eyes
(P = .05). Conclusion: AS-OCT parameters are not significantly different between PB and
PIC eyes.
Presenting Author: Janet M Galicia Del Castillo MD
Scientific Posters
Reduction Rates of Macular Ganglion Cell Complex
Thickness in Preperimetric Glaucoma and Normal Eyes

Changes in the Prelamina and Lamina Cribrosa of
Contralateral Eyes in Unilateral Glaucoma Patients
Presenting Author: Daisuke Shiba MD
Presenting Author: Dai Woo Kim MD
Co-Author(s): Takeshi Ono, Naoki Ozeki**, Kenya Yuki MD PhD, Kazuo Tsubota MD*
Co-Author(s): Jin Wook Jeoung MD*, Young Kook Kim MD, Ki Ho Park MD*, Dong
Myung Kim MD
Purpose: To compare the changes of the macular ganglion cell complex thickness (GCCT)
measured by spectral-domain OCT (SD-OCT) between preperimetric glaucoma (PPG) eyes
and normal eyes. Methods: We retrospectively enrolled 27 PPG and 30 normal eyes with
five or more times of macular SD-OCT examination as routine clinical practice. We compared the velocities of mean GCCT within 10 degrees from the fovea between PPG eyes and
normal eyes by unpaired t-test. Results: The mean ages of PPG eyes and normal eyes were
51.6 11.0 and 54.9 13.3, respectively. The velocities of GCCT were 0.77 0.70 m/
year in PPG eyes and 0.00 0.43 m/year in control eyes (P < 0.001). Conclusion: GCCT
reduction rate in PPG eyes was higher than that in normal eyes.

SOE Noninvasive Intracranial Pressure Measurement
Method in Open-Angle Glaucoma
Presenting Author: Lina Siaudvytyte MD
Co-Author(s): Ingrida Januleviciene MD PhD*, Laimonas Bartusis, Alon Harris PhD*
Purpose: To present a noninvasive absolute intracranial pressure (ICP) measurement
method using a two-depth transcranial Doppler (TCD) device in open-angle glaucoma patients. Methods: We used a novel TCD device (Vittamed 205) to measure ICP in 60 normaltension glaucoma (NTG) and 60 high-tension glaucoma (HTG) patients. Results: Patients
with NTG had lower ICP compared with HTG (P > 0.05). ICP was positively correlated with
neuroretinal rim area in NTG (P < 0.05). Conclusion: The TCD device is the only available
noninvasive ICP measurement method that does not need an individual patient-specific
calibration. Further studies are needed to evaluate ICPs role in the progression and management of glaucoma.

Baseline Structural Risk Factors for Functional Progression
in the Advance Imaging for Glaucoma Study Clinical Trial
Presenting Author: Mitra Sehi PhD*
Scientific Posters
Co-Author(s): Xinbo Zhang PhD**, Ou Tan PhD*, Rohit Varma MD MPH*, David S
Greenfield MD*, Joel S Schuman MD*, Brian A Francis MD*, David Huang MD PhD*
Purpose: To identify baseline structural predictors for the development of glaucomatous
visual field (VF) progression. Methods: Two hundred seventy-seven glaucomatous eyes
underwent Fourier-domain OCT and VF biannually. Event-based progression was defined as
significant deterioration of at least three locations on three pattern deviation plots. Trendbased progression was defined as significant loss of VF index . Multivariate Cox models
were constructed. Results: Forty-eight eyes reached event-based and 64 eyes reached
trend-based progression. The most significant predictors of progression were baseline ganglion cell complex focal loss volume (GCC FLV; HR = 1.08 per 1% higher; P < 0.001) and
central corneal thickness (HR = 1.07 per 10 m thinnerl; P = 0.01). Conclusion: Greater GCC
FLV and a thinner cornea are risk factors for VF progression.

SOE Screening of Glaucoma Using Spectral Domain OCT in
an Elderly Population: The ALIENOR Study
Presenting Author: Cedric Schweitzer MD
Co-Author(s): Olivier Rahimian**, Florence E Malet MD, Melanie Le Goff PhD, MarieBenedicte Rougier MD**, Marie-Noelle Delyfer MD PhD**, Jean-Francois Dartigues
PhD**, Pascale Barberger-Gateau PhD*, Jean-Francois Korobelnik MD*, Cecile
Delcourt PhD*
Purpose: To screen glaucoma patients in an elderly population. Methods: Populationbased study involving 535 patients aged 75 years or older. Retinal nerve fiber layer (RNFL)
thickness was measured using spectral-domain OCT (SD-OCT), and glaucoma diagnosis
was made using retinophotography of the optic nerve head and International Society for
Epidemiologic and Geographical Ophthalmology criteria. Results: RNFL thickness was
significantly lower in the glaucoma group (65.4 14.4 m ) than in the control group (88.2
13.0 m; P < 0.001). Area under the receiving operating curve was higher for the global RNFL
thickness (0.886), followed by the inferotemporal (0.867) and the superotemporal RNFL
sector (0.857). Conclusion: SD-OCT may be a useful, fast, and noncontact tool to screen
glaucoma in an elderly population.
190
Purpose: To investigate the changes of the prelamina (PL) and lamina cribrosa (LC) of contralateral nonglaucomatous eyes in unilateral glaucoma patients. Methods: Optic discs
of 52 glaucomatous eyes (Group 1), 52 contralateral nonglaucomatous eyes (Group 2), and
46 eyes of healthy control subjects (Group 3) were scanned by swept-source OCT. The LC
parameters were measured and compared. Results: In Group 1, anterior PL surface depth
(APLD) and LC depth (LCD) were deeper (P = 0.001 and P = 0.029, respectively), and PL
thickness (PLT) was thinner (P < 0.001) than in Group 3. In Group 2, APLD and LCD showed
no differences compared with Group 3; however, PLT was significantly thinner (P = 0.009).
Conclusion: In the fellow eyes of unilateral glaucoma patients, PLT was decreased compared with that of healthy control eyes.

Three-dimensional Swept Source OCT Accurately
Measures Optic Cup Volume in Primary Open-Angle
Glaucoma
Presenting Author: K V Chalam MD PhD
Co-Author(s): Shailesh K Gupta MD**, Kumar Sambhav MBBS MD, Sandeep Grover
MD
Purpose: To measure optic nerve cup in primary open-angle glaucoma (POAG) using 3D
swept-source OCT (SS-OCT). Methods: In this prospective, observational case series, SSOCT scans of the optic nerve head (12- by 9-mm area; 100,000 B-scans; interval, 100 m
) were obtained in 66 POAG eyes and compared with 66 age-matched controls. Bruchs
membrane opening and anterior LC boundary were automatically delineated. The point with
maximum LC depth and prelaminar neural thickness were averaged. Results: Optic cup
volume in POAG measured 0.414 0.281 (range, 0.0221.5) cu mm and is significantly
larger (P < 0.01) compared with controls with mean of 0.076 0.005 (range, 0.010.23).
Conclusion: SS-OCT objectively and accurately measured cup volume in POAG and is a
useful tool in longitudinal monitoring of disease.

Effect of Myopia and Optic Disc Size on Ganglion Cell Inner
Plexiform Layer and Retinal Nerve Fiber Layer Profiles
Presenting Author: Sam Seo MD
Purpose: To evaluate the effect of myopia and optic disc size on the ganglion cell inner
plexiform layer (GCIPL) and retinal nerve fiber layer (RNFL) profiles. Methods: This study
enrolled 168 eyes of 168 young healthy subjects. All individuals underwent imaging with
the Cirrus OCT. RNFL and GCIPL thickness profiles were determined according to the disc
area and spherical equivalent (SE). Results: Average and nontemporal RNFL thickness decreased as the SE decreased and disc area increased (all, P 0.001). The overall GCIPL
thickness parameters were correlated positively with SE (all, P 0.005). Temporal GCIPL
shows increasing tendency as disc area increased. Conclusion: Myopia and optic disc size
affected the RNFL and GCIPL thickness profiles. GCIPL thickness decreased consistently
depending on the degree of myopia.

Peripheral Lamina Cribrosa Depth in Primary Open-Angle
Glaucoma: A Swept-Source OCT Study of the Lamina
Cribrosa
Presenting Author: Yong-Woo Kim MD
Co-Author(s): Jin Wook Jeoung MD*, Dong Myung Kim MD, Ki Ho Park MD*
Purpose: To investigate anterior laminar insertion depth (ALID) in primary open-angle glaucoma (POAG) eyes. Methods: The optic discs of 90 POAG eyes and 90 age-matched normal eyes were scanned by swept-source OCT. ALID, defined by vertical distance between
anterior laminar insertion and the reference plane connecting Bruchs membrane openings,
was measured at each horizontal and vertical scans and compared between the groups.
Results: The horizontal (382.60 155.26 m vs. 339.53 111.61 m; P = 0.034) and vertical
ALID (429.93 158.95 m vs. 357.05 115.57 m; P = 0.001) was significantly larger in
POAG eyes than normal eyes. Vertical-horizontal ALID difference was significantly larger
in POAG eyes (P = 0.001). Conclusion: POAG eyes showed increased ALID and increased
vertical-horizontal ALID difference compared with normal eyes.
Scientific Posters
SOE Corneal Biomechanical Parameters in Different Types
of Glaucoma

Caffeinated Energy Drink and IOP in a Young Population
Presenting Author: Goktug Seymenoglu MD
Co-Author(s): Sang Soo Kim MD
Co-Author(s): Esin Fatma Baser MD
Purpose: We examined the effect of caffeinated energy drinks on IOP of healthy young
people. Methods: Forty healthy young volunteers consumed two types of drinks, each
taken after four weeks of washout period. IOP and blood pressure (BP) were measured at 0,
30, 60, 90, and 120 minutes and 12 and 24 hours after the ingestion of the drink. Results:
Ingested caffeinated energy drinks increase IOP, and the difference between both groups
was statistically significant at 30, 60, 90, and 120 minutes (P < 0.05). There was also a
corresponding increase in BP of the experimental group, and it was clinically significant
at 30 and 60 minutes after consumption. Conclusion: Consumption of caffeinated energy
drinks, which are popular among young people, induces increase of IOP and BP for a short
duration of time.
Purpose: To compare the corneal biomechanical parameters in different types of glaucoma. Methods: Data from 400 patients were recorded. Corneal biomechanical properties
and central corneal thickness (CCT) were compared between different glaucoma groups.
Results: The mean corneal resistance factor of normal-tension glaucoma (NTG; 8.5) and
pseudoexfoliative glaucoma (PXG; 8.7) groups were significantly lower than those of the
primary open-angle glaucoma (POAG; 10.6) group (P = 0.001). The mean corneal hysteresis
of NTG (7.9) and PXG (8.4) groups were significantly lower than those of POAG (9.6), primary
angle-closure glaucoma (9.8), and ocular hypertension (10.8) groups (P = 0.001). The mean
CCT of NTG (554) and PXG (533) groups were significantly thinner than those of all other
glaucoma groups (P = 0.001). Corneal-compensated IOP measurements of NTG and PXG
groups were significantly lower than all other glaucoma groups (P = 0.001). Conclusion:
Corneal biomechanical parameters vary between different glaucoma types.

Change in Corneal Hysteresis and Optic Nerve Head
Topography After IOP Reduction in Adult Glaucoma Patients
Presenting Author: Surinder Singh Pandav MBBS MS
Co-Author(s): Alka Khera PhD, Savleen Kaur MBBS, Sushmita Kaushik, Srishti Raj
Sr**, Jagat Ram MBBS
Purpose: To study any correlation in the change in corneal hysteresis (CH) and the lamina
compliance after surgical reduction of IOP. Methods: Forty-eight adult patients underwent
measurement of CH by the Ocular Response Analyzer and optic disc imaging on the Heidelberg Retina Tomograph preoperatively and at one week, one month, and three months
posttrabeculectomy. Results: At three months, the CH decreased from a preoperative value
of 8.96 1.92 to 6.52 2.89 (P = 0.00) and showed no correlation to the lamina compliance
(r = 0.26) Conclusion: Changes in corneal biomechanical properties are independent of
change in the lamina position in glaucoma patients.

The Effect of Repeat Selective Laser Trabeculoplasty on IOP
Control
Presenting Author: Georges M Durr MD
Co-Author(s): Paul J Harasymowycz MD*

SOE Trans-scleral Diode Laser Cyclophotocoagulation
for the Management of Refractory Glaucoma Following
Intravitreal Triamcinolone Acetonide
Presenting Author: Mohamed El-Bradey MD

Introducing Generic Latanoprost to the Marketplace: The
Impact on Glaucoma Medication Adherence Rates
Presenting Author: Joshua D Stein MD MS*
Co-Author(s): Nidhi Talwar MS, Rajesh Balkrishnan**
Purpose: To determine whether enrollees with open-angle glaucoma (OAG) who switched
from brand name to generic prostaglandin analogues (PGAs) exhibited a difference in medication adherence compared with those who remained on brand name products. Methods: We calculated the mean PGA adherence rates during the 18 months prior to generic
latanoprost availability (September 2009February 2011) and the mean adherence rates
during the subsequent 18 months after generic latanoprost became available (July 2011
December 2012) for 8,427 patients with OAG. Results: Patients who remained on brand
name PGAs after generics became available had 39% increased odds of experiencing a
25% worsening of adherence (OR = 1.39; CI, 1.041.86). Conclusion: Adherence can be
significantly improved by switching from brand name to generic PGAs.

SOE Temperament and Character Personality Traits of
Glaucoma Patients
Presenting Author: Sema Oruc Dundar MD
Co-Author(s): Gokhan Evren Evlicoglu Sr MD**, Suzan Guvenyilmaz III, Tolga Kocaturk
MD, Alper Yazici MD, Ali Osman Saatci MD**
Purpose: To characterize the temperament and character personality profile of glaucoma
patients. Methods: All participants were given theTemperament and Character Inventory (TCI). The TCI measures four domains of temperament (novelty seeking [NS], harm
avoidance [HA], reward dependence, and persistence [PS]) and three domains of character
(self-directedness [SD], cooperativeness, and self-transcendence [ST]). Results: Patients
have lower scores compared with controls for the NS, PS, and ST dimensions (P < 0.0001).
Patients achieved higher scores for the HA dimensions than controls (P < 0.0001). The SD
scores were higher in the patients than controls (P = 0.008). Conclusion: Glaucoma patients had different personality profiles than healthy individuals. This may affect treatment
compliance and is important for coping with maladaptive patient attitudes.

The Novel Topical Ocular Insert (Helios) for Sustained
Delivery of Bimatoprost in Glaucoma and Ocular
Hypertension
Presenting Author: Ivan Goldberg MBBS FRANZCO*
Co-Author(s): Tarek Ragaey MD**
Co-Author(s): Guna Laganovska MD, Kristine Baumane, Juris Vanags, Stuart L Graham
MBBS MS PhD*, Yair Alster*, Anne Rubin MBA*, Eugene de Juan Jr MD*
Purpose: To evaluate the efficacy and safety of transscleral diode laser cyclophotocoagulation (TDLC) in the management of refractory glaucoma complicating intravitreal triamcinolone acetonide (TAAC). Methods: This study included 21 eyes of 21 patients that developed refractory glaucoma following intravitreal TAAC (IOP 35 mmHg despite maximum
medical treatment). Low energy level of TDLC was used, and the patients were followed up
for at least one year. Results: The mean pretreatment IOP was 42.67 5.61 mmHg, which
reduced significantly (P = 0.0001) to 16.28 5.82 mmHg after one year. The mean number of
medications per eye dropped significantly from 3.52 0.51 to 0.95 1.24 (P = 0.0001). Only
three eyes (14.3%) failed to respond to repeated TDLC. Conclusion: TDLC is a safe and
effective treatment modality for refractory glaucoma following intravitreal TAAC.
Purpose: To assess the safety and effectiveness of the topical ForSight VISION5 Helios
Insert to lower IOP. Methods: In two Phase 1 trials, eye drops were replaced by placebo
ocular inserts during a washout of four weeks. Then, the effects of 4.2-mg bimatoprost
inserts were monitored up to six months. Results: Of 43 subjects, 36 (71 eyes) received active inserts. Mean standard deviation IOP fell from 25.1 2.8 mmHg post washout to 18.4
4.4 mmHG (n = 66 eyes) at three months (D = -6.7 3.4 mmHg; last observation carried
forward if second medication added). Efficacy decreased after four months. Insert awareness/discomfort, increased mucus, and hyperemia were the most common observations.
Conclusion: Bimatoprost inserts controlled IOP through three months with satisfactory
safety. An insert designed to control IOP for six months is also under study.
191
Scientific Posters
Purpose: To evaluate the effect of repeat selective laser trabeculoplasty (SLT) on IOP.
Methods: This study was conducted on 46 eyes with primary open-angle glaucoma (31),
normotensive glaucoma (10), or secondary glaucoma (5). We measured the IOP at baseline
before the first (SLT1) and second (SLT2) 360-degree SLT and at one, six, and 15 months.
Results: Baseline IOP prior to SLT1 was 19.0 3.7 mmHg, which dropped to 16.0 3.7
mmHg, 16.9 3.8 mmHg, and 17.2 3.3 mmHg at one, six, and 15 months (P < 0.01). For
SLT2, baseline IOP was 18.0 4.5 mmHg, which dropped to 15.1 3.8 mmHg, 15.1 4.3
mmHg, and 16.0 3.6 mmHg at one, six, and 15 months (P < 0.01). Conclusion: Repeat
SLT diminishes IOP similarly to the first SLT, with a slightly more important response initially
that seems to diminish similarly to the primary SLT with time.
Presenting Author: Seung Hwan Jo MD
Scientific Posters
SOE Supraciliary Device Implantation With
Phacoemulsification: One-Year Single-Center Experience in
Warsaw, Poland
Presenting Author: Marek Rekas MD*
Co-Author(s): Izabela Nowak-Gospodarowicz, Mariusz Kosatka**, Tsontcho Ianchulev
MD*
Purpose: To evaluate the CyPass Micro-Stent, an ab interno supraciliary device, in patients
with glaucoma undergoing cataract surgery. Methods: Patients were enrolled at the Military Institute of Medicine in Warsaw, Poland. The device was implanted following cataract
surgery through the same corneal incision. Adverse events, IOP changes, and number of
medications at one year were the main outcomes. Results: At baseline (n = 20), subjects
had a mean IOP of 16.1 3.3 mmHg, with 80% of patients taking at least two medications.
There were no major adverse events. At one year, mean IOP reduced to 14.1 3.1 mmHg,
with 82% of subjects taking no medications. Conclusion: CyPass implantation with cataract surgery has an excellent safety profile and can reduce IOP and IOP-lowering medication
usage at one year postoperatively.

Phaco-iStent in the Management of Patients With Cataract
and Open-Angle Glaucoma Using the Modified Edmonton
Surgical Technique
Presenting Author: Michael W Dorey MD**
Co-Author(s): Sourabh Arora MD, Christopher J Rudnisky MD*, Khaliq Kurji MD,
Simrenjeet Sandhu**
Purpose: To study the efficacy and safety of Phaco-iStent in patients with cataract and
open-angle glaucoma (OAG) using a modified surgical technique. Methods: Patients underwent combined phacoemulsification and implantation of two iStents using the Edmonton
technique. Results: One hundred forty-one eyes of 91 patients were included. The sixmonth IOP reduction among all cases was 4.82 mmHg (P < 0.01). Number of medications
was reduced by 0.16 at six months (P = 0.45). For eyes with a preop IOP of at least 21 mmHg
(n = 41), there was a reduction of 9.71 mmHg (P < 0.001). One patient had frank hyphema,
and 12 (8.5%) had an IOP spike greater than 25 mmHg. Conclusion: Phaco-iStent using
the modified Edmonton technique appears to be highly safe and efficacious in patients with
cataract and OAG, especially those with higher baseline IOP.
Scientific Posters

Conjunctival Sparing Surgery in Overfiltration Hypotony:
Transconjunctival Sutures of the Scleral Flap for Hypotony
Maculopathy After Trabeculectomy
there was no significant difference in IOP at each time point between the two groups. The
success rate of TR and LTDS at two years were 51.8% and 54.6%, respectively (P = 0.51).
Conclusion: TR and LTDS were equally effective in lowering IOP in patients with POAG
and EXG.

SOE Subconjunctival Bevacizumab to Augment
Trabeculectomy with Mitomycin-C in Management of Failed
Glaucoma Surgery
Co-Author(s): Tarek Tawfik Aboulnasr V**
Purpose: To evaluate the efficacy and safety of trabeculectomy with intraoperative mitomycin C (MMC) plus subconjunctival bevacizumab injection compared with the effect
of trabeculectomy with only adjunctive MMC. Methods: Twenty-eight eyes with failed
scarred bleb were divided into two equal groups. The main outcome results included cumulative probability of surgical success, IOP values, and number of antiglaucoma drugs
needed. Results: The achieved cumulative probability of complete success was 0.769 at
24 months. It achieved lower mean IOP with less antiglaucoma drugs at all visits (P > 0.05).
No significant adverse effects were reported. Conclusion: Trabeculectomy with adjunctive
MMC and bevacizumab could present an efficient and safe treatment strategy for failed
trabeculectomy.

SOE Modified Trabeculectomy With Extended Subscleral
Tunnel: Could It Be a Secure Way to Successful Glaucoma
Surgery?
Co-Author(s): Sameh Mahmoud Saleh**
Purpose: To evaluate safety and efficacy of an extended subscleral tunnel (ESST) in IOP
control. Methods: Fifty-four glaucomatous eyes were divided into two groups. The main
outcome results included surgical success, IOP values, number of needed antiglaucoma
drugs, and size of aqueous drainage route (ADR). Results: The modified technique group
achieved a cumulative probability of success of 0.96 at 24 months, lower mean IOP values
with less antiglaucoma drugs at all postoperative visits, larger size of ADR (P > 0.05), and
less postoperative complications and additional interventions (P = 0.029). Conclusion:
Modified trabeculectomy with ESST could present an efficient and safe technique for a
favorable long-term outcome of glaucoma surgery.
Presenting Author: Noureen J Khan MD

Safety and Efficacy of Combined TrabeculotomyTrabeculectomy With Intraoperative Mitomycin C for
Developmental Glaucoma
Co-Author(s): Cyrus Golshani MD, Sameer Ahmad MD
Presenting Author: Vera A Essuman MBCHB*
Purpose: To assess transconjunctival resuturing of the scleral flap as a means of surgical

intervention for hypotony maculopathy after glaucoma filtering surgery. Methods: Retrospective case series of transconjunctival resuturing in 11 eyes with hypotony maculopathy
after trabeculectomy. Results: Mean preoperative IOP of 11 eyes was 2 mmHG, and mean
final IOP was 12 mmHG (P < 0.05). Postoperative day 1 IOP spikes were noted (mean IOP,
22 mmHg). Preoperative visual acuity (VA) ranged from hand movements to 20/200. Final
mean VA was 20/60, ranging from 20/25 to counting fingers (P < 0.05). VA improved after
surgery from a mean of 20/200 to a final vision of 20/60. Conclusion: Transconjunctival
scleral flap resuturing is a simple, repeatable, and minimally invasive procedure that can
improve hypotony with quicker postoperative recovery compared with tradition bleb revision. Repeat sutures may be necessary.
Co-Author(s): Tom Akuetteh Ndanu**, Imelda-Odille Dziffa-Bella Ofori-Adjei MBCHB*,

Samuel Owusu Asiedu OD, Christine Ntim-Amponsah MBCHB**

Clinical Results of Trabectome vs. Trabeculotomy Combined
With Deep Sclerectomy for Open-Angle Glaucoma
Presenting Author: Takanori Mizoguchi MD
Co-Author(s): Tomoki Sato MD, Nobuchika Ogino MD PhD
Purpose: To compare the effect of Trabectome (TR) with trabeculotomy combined with
deep sclerectomy without using mitomycin C (LTDS) for primary open-angle glaucoma
(POAG) and exfoliation glaucoma (EXG). Methods: We retrospectively reviewed 82 eyes
(POAG, 43; EXG, 39) for the TR group and 66 eyes (POAG, 38; EXG, 28) for the LTDS group.
Data were analyzed by using Kaplan-Meier survival analysis with an IOP endpoint of at
least 20 mmHg and no more than 20% IOP reduction from baseline. Results: IOPs after
surgery were significantly lower than baseline IOP in both groups (P < 0.000). However,
192
Purpose: To compare safety and efficacy of combined trabeculotomy-trabeculectomy (CTT)

with intraoperative mitomycin C (MMC; 0.4 and 0.2 mg/mL) for developmental glaucoma.
Methods: Randomized controlled trial of children younger than 16 years of age enrolled
from 2009 to 2013. Results: Fifty-seven eyes of 34 patients were analyzed: 37 controls and
20 in treatment groups. Overall success was 84.2%. Probability of success was reduced
from 84% at six months to zero at 48 months. Significant differences found in pre- and
postoperative IOPs ( P < 0.001). No significant differences found between groups regarding
surgical success, pre-and postop visual acuities, bleb characteristics, and complications ( P
> 0.05). Twenty-one eyes (36.8%) had well-functioning blebs. Conclusion: MMC added no
advantage to the surgical success.

Visco-Trab Operation: A Dual Filtration Pathway for
Management of Advanced Glaucoma
Presenting Author: Tarek M Eid MD
Purpose: To study efficacy and safety of visco-trab operation for management of advanced
uncontrolled glaucoma. Methods: Visco-trab (a merge between viscocanalostomy and trabeculectomy operations) was used in 170 eyes. Mean follow-up was 37.3 11.3 months.
Results: Postoperative IOP, glaucoma drops, and visual field mean deviation were 11.6
5.0, 0.7 1.2, and 15.2 5.7, compared with 23.1 9.2, 3.1 1.1, and 17.8 6.8, preoperatively. Early postoperative course was unremarkable, with no devastating complications or
visual loss. Moreover, 83.6% of eyes achieved a target IOP of 14 mmHg. Old age (P = 0.01),
Scientific Posters
previous surgery (P < 0.001), high preoperative IOP (P = 0.004), pseudophakia (P = 0.002),
and needling (P = 0.001) were associated with failure. Conclusion: Visco-trab operation is
safe and effective in achieving a low target pressure for advanced glaucoma.
number of antiglaucoma drugs in PEG eyes was 3.6 0.85 1 versus 3.45 1.28 in POAG
eyes (P = 0.603). The complication rate was comparable (P = 1.000). Conclusion: ExPress
is as effective in PEG as in POAG.

SOE Survival of Central Visual Acuity in Patients With
Advanced Glaucoma Undergoing Trabeculectomy With
Mitomycin C

SOE The Outcomes of Ex-Press Glaucoma Filtration Device
in Secondary Glaucomas
Presenting Author: Dimitrios Tsoukanas MD
Co-Author(s): Shimon Rumelt MD MPA
Co-Author(s): Georgia Kosti**, Konstantina Platari MD, Theodoros Filippopoulos MD*
Purpose: To evaluate the ExPress glaucoma filtration device in eyes with secondary glaucomas. Methods: Forty-two consecutive eyes (n = 37) with secondary glaucomas. Results:
The IOP decreased by 20.7 7.4 mmHG (mean standard deviation) in all the secondary
glaucomas, except in neovascular glaucoma (NVG) and iridocorneal endothelial dystrophy
(ICE; 56 10.4 mmHg, P = 0.007), at a follow-up of six to 40 months (mean, 12.2). Failure
was encountered only in NVG and in ICE (P = 0.048) because of recurrent uveal tissue blockage. Conclusion: ExPress is efficient in secondary glaucomas, except for NVG and ICE.
Purpose:To determine the survival of visual acuity (VA) in advanced glaucoma patients
undergoing surgery. Methods: Retrospective consecutive case series of 28 eyes with mean
deviation <-20dB on automated perimetry (AP). We chose four criteria for failure: loss of 3
dB on AP, loss of three lines in VA, decrease in VA <20/200, and additional glaucoma surgery.
We constructed survival curves for each criterion and all four combined. We also looked
at risk factors for failure, such as age, postop IOP/medications, phakic status, glaucoma
type/stage, and length of follow-up. Results: Mean pre and postop IOP was 28.2 12.2
mmHG and 11.2 3.6 mmHg, respectively (P = 1.4 x 10-7). Median follow-up was 472 days.
Survival satisfying all four criteria was 87.5% at 24 months. Conclusion:Trabeculectomy
salvages central vision in advanced glaucoma patients.

SOE Heterologous Fresh Human Donor Sclera as Patch Graft
Material in Ahmed Glaucoma Drainage Device Surgery
Presenting Author: Dimitrios Tsoukanas MD
Co-Author(s): Paraskevi Xanthopoulou, Georgia Kosti**, Gerasimos Kopsinis MD PhD,
Theodoros Filippopoulos MD*
Purpose: To determine the safety of heterologous human donor scleral patch grafts in
glaucoma drainage device (GDD) surgery. Methods: Retrospective, consecutive case series
of all GDD cases between 2008 and 2013 in which human donor scleral patch grafts were
utilized immediately after the central corneal button was used for keratoplasty (57 patients/
eyes identified). Results: Mean age of the cohort was 65.4 19.5 years, with an average
of 1.6 0.9 previous incisional surgeries. Mean preop IOP was 31.7 10.6 mmHg, and
mean follow-up was 17.7 16.4 months (range 163). There were no cases of blebitis/
endophthalmitis, and there was one case of erosion/plate exposure (1.8%). Conclusion:
Heterologous fresh human donor sclera appears to be a safe and cheaper alternative material for GDD coverage.
Presenting Author: Felix Bernier-Turmel MD

Co-Author(s): Paul J Harasymowycz MD*
Purpose: To determine outcomes of capsule excision for glaucoma drainage device failure.
Methods: Fifteen cases were reviewed on a 12-month period, five cases with Ologen with
mitomycin C (MMC; Group A) and 10 cases with MMC alone (Group B). We defined qualified success as an IOP 21 mmHg and a relative reduction of IOP 20% with or without additional topical medications. Results: The mean preoperative IOP for both groups were not
statistically different. At 12 months, mean IOP was 13 mmHg in Group A, 3.6 mmHg lower
than Group B (P < 0.05). Qualified success rate was 0.6 (95% CI, 0.1700.927) in Group
A and 0.375 (95% CI, 0.1370.726) in Group B. Conclusion: This therapeutic approach
significantly lowers IOP and has a good qualified success rate compared to other surgical
methods in the reported literature.

SOE The Ex-Press Glaucoma Filtration Device: A
Comparison Between Outcomes in Pseudoexfoliative
Glaucoma and in Primary Open-Angle Glaucoma
Presenting Author: Valery Bersudsky MD**
Co-Author(s): Shimon Rumelt MD MPA
Purpose: To compare the outcomes of ExPress glaucoma filtration device in eyes with
pseudoexfoliative glaucoma (PEG) with primary open-angle glaucoma (POAG). Methods:
Thirty-five PEG eyes were compared to 20 POAG eyes. Results: PEG eyes had a 20.6
7.5 mmHg (mean standard deviation) decrease in IOP compared with 19.1 6.7 mmHg
in POAG eyes (P = 0.725) at follow-up of six to 40 months (mean, 12.5). A decrease in the

SOE Differential Corneal Thickness in Pediatric Eyes
Implanted With a Glaucoma Drainage Device
Presenting Author: Yasmine M El Sayed Ibrahim MD
Purpose: To compare corneal thickness in different quadrants of pediatric eyes implanted
with a superotemporal glaucoma drainage device (GDD). Methods: Corneal thickness
measurements were taken in superotemporal, superonasal, inferotemporal, and inferonasal quadrants and centrally and compared with a control group of glaucomatous pediatric
eyes not implanted with a GDD. Results: Corneal thickness was significantly higher in all
areas in the GDD group (13 eyes), with most significant difference superotemporally (P =
0.0009). The superotemporal quadrant was most likely to be the thickest of all quadrants
(69.2%) compared with 16.7% in the control group (24 eyes). The difference between superotemporal and inferonasal thickness was significantly higher in the GDD group (P = 0.004).
Conclusion: Corneal thickness adjacent to tube is significantly increased in children.

Resident-Performed Trabeculectomy and Ahmed Valve
Surgery Outcomes vs. Experienced Glaucoma Surgeon
Outcomes
Presenting Author: Kendall Wannamaker
Co-Author(s): Robert Allan Sharpe, Elizabeth D Sharpe MD
Purpose: To compare outcomes of trabeculectomy (trab) and Ahmed valve surgery (valve)
performed by residents-in-training (RIT) versus experienced glaucoma surgeons (EGS).
Methods: Retrospective study of RIT surgeries by a PGY-4 and literature review including
randomized, prospective trials with EGS with one-year follow-up. Results: One hundred
four RIT surgeries were included. Both procedures produced significant IOP reductions at
one year (P < 0.01). Total complications were similar between RIT and EGS. Overfiltration
(12%), bleb leak (3%), and hyphema (8%) were less in RIT trabs. Hyphema (27%) was higher in RIT valves, but choroidal effusion (13%) was similar to EGS. Conclusion: Residentperformed trabs and valves are effective procedures, with complication rates comparable
to experienced surgeons.

Utility of Operative Glaucoma Tube Shunt Viscoelastic
Bolus Flush
Presenting Author: Sylvia L Groth MD
Co-Author(s): Kelsi Greider, William Eric Sponsel MD*
Purpose: To assess the utility of viscoelastic injection to induce bleb expansion and decrease IOP in eyes with encapsulated blebs. Methods: Forty-three glaucomatous eyes
underwent viscoelastic flush procedure. A 30-G cannula was passed through a 27-G paracentesis and insinuated into the tube shunt lumen, and 0.55 mL of viscoelastic was injected
to hyperinflate the bleb. Paired t-tests of preop IOP and meds used were performed at one,
six, 12, 18, and 24 months. Results: Mean preop IOP 26.0 1.2 mmHg improved to 15.8
1.0 at one month and remained stable at each interval to 15.1 1.1 mmHg at 24 months (P
< 0.0001). Meds were also reduced. Pressure remained 21 mmHg at two years in 85% of
eyes treated no more than one year after implant (n = 23) and in 62% more than one year
postimplant (n = 20). Conclusion: Tube shunt flush can resurrect encapsulated bleb function with sustained IOP decrease.
193
Scientific Posters

Excision of Fibrotic Capsule Over Glaucoma Drainage
Devices and Mitomycin C: One-Year Results With and
Without Ologen
Presenting Author: Valery Bersudsky MD**
Scientific Posters
SOE Phaco / Endoscopic Cyclophotocoagulation for
Glaucoma Management

H Baseline Anterior Segment Parameters Associated With
the Long-term Outcome of Laser Peripheral Iridotomy
Presenting Author: Line A Langsaeter MBBS
Presenting Author: Sophia Kim MD
Co-Author(s): Pieter Gouws MBChB*
Co-Author(s): Kyung Rim Sung MD PhD, Jin Wook Jeoung MD*
Purpose: Phaco-endoscopic cyclophotocoagulation (ECP) is relatively new in the United

Kingdom. Our case study establishes the effect of phaco-ECP in one hospital (20092013).
Methods: A retrospective audit of patient demographics, pre- and postoperative management, and complications. All glaucoma subtypes and previous surgery included. Results:
Three hundred twenty-eight eyes (207 patients) were included with a mean age of 78.7
years (standard deviation [SD], 10). Fifty-two percent were male. The subtypes were primarily primary open-angle glaucoma (76%). Preoperative mean number of agents was 1.7 (SD,
1.1), and IOP was 17 mmHg (SD, 5; range, 1541). At two years, the mean IOP reduction
was 24% (range, 721), with a reduction in number of agents of 38%. Thirty-four eyes had
uveitis, with no hypotony noted. Eleven eyes had further surgery. Conclusion: A sustained
lower IOP and decreased dependence on drops with reduced glaucoma surgery rates and a
low complication rate were noted. We recommend comparison with phaco alone.
Purpose: To investigate the baseline anterior segment (AS) parameters determined by

AS OCT in the prediction of long-term laser peripheral iridotomy (LPI) outcome. Methods:
Ninety-six angle closure eyes were imaged at pre-LPI and at three years post-LPI. Anterior
chamber depth, iris curvature, iris thickness at 750 m from the scleral spur (IT750), and
lens vault were estimated. Change in angle opening distance (AOD750) was used as outcome measures for LPI. Results: Thinner IT750 (P = 0.046) and less AOD750 (P = 0.002) at
baseline were associated with a greater AOD750 change when assessed at three years
post-LPI. Conclusion: Angle closure eyes with thick peripheral iris at baseline showed
persistently narrow angles at long-term follow-up after LPI.

H Phacoemulsification and Goniosynechialysis for the
Management of Chronic Angle Closure Glaucoma With and
Without a History of Acute Attack
Presenting Author: Mostafa Mafi MD
Co-Author(s): Zakieh Vahedian, Sasan Moghimi MD
Purpose: To compare the effectiveness of phacoemulsification with goniosynechialysis
(GSL) in the management of chronic angle closure glaucoma (CACG) patients. Methods:
Fifty-six medically uncontrolled CACG patients with (Group 1) and without (Group 2) a history of AACA and with a patent laser peripheral iridotomy were enrolled and underwent
phacoemulsification and GSL. Results: Mean baseline IOP was 35.7 6.58 mmHg in Group
1 and 34.5 5.35 mmHg in Group 2 (P = 0.465). Last-visit IOP was 17.3 3.05 mmHg and
20.6 3.09 mmHg in Groups 1 and 2, respectively (P < 0.001). Complete success rate in
Group 1 and Group 2 were 75% and 25%, respectively (P < 0.001). Conclusion: Phacoemulsification with GSL seems to be effective in the management of CACG patients.

Outcomes of 360 Trabeculotomy With Deep Sclerectomy for
Open-Angle Glaucoma
Presenting Author: Tomoki Sato MD
Scientific Posters
Co-Author(s): Akira Hirata MD PhD, Takanori Mizoguchi MD

Purpose: To examine the effectiveness of 360 LOT+DS on open-angle glaucoma (OAG)
compared with that of 120 LOT+DS. Methods: Twenty-six eyes of 26 patients treated with
360 LOT+DS and 29 eyes of 29 patients treated with 120 LOT+DS followed for 12 months
or longer were retrospectively enrolled. Results: Postoperative IOP after 360 LOT+DS was
13.1 mmHg at 12 months after surgery. Defining an IOP exceeding 16 or 13 mmHg at 12
months after surgery as failure, the success rate determined employing the Kaplan-Meier
method was significantly higher in the 360 LOT+DS group (96.2% and 57.7% in the 360
LOT+DS group, respectively, and 75.9% and 27.6% in the 120 LOT+DS group, respectively;
P = 0.038 and 0.027 on the log-rank test, respectively). Conclusion: We found that 360
LOT+DS may achieve a lower postoperative IOP than 120 LOT+DS.

Use of an iPad Tablet to Perform Visual Field Screening in
Nepal
Presenting Author: Chris A Johnson PhD*
Co-Author(s): Suman Shumsher Thapa, Alan L Robin MD*
Purpose: To perform visual field screening in Nepal using a free program, Visual Fields
Easy, on the iPad. Methods: The Visual Fields Easy program on the iPad (background
= 10 cd/m2; size V target; 16-dB stimulus) was used to screen more than 300 eyes (about
150 healthy normals, 150 glaucomas, and 20 diabetic retinopathies) in Nepal. Results were
compared to the 24-2 SITA Standard findings on the Humphrey Field Analyzer. A comprehensive eye examination was used to establish the diagnosis. Results: Correlations of
missed targets on the iPad test with SITA Standard 24-2 MD and PSD results were better
than 0.75 and 0.60, respectively. Test time for the visual field screening was about 210
seconds per eye. Conclusion: With the Visual Fields Easy program, the iPad can quickly
and easily identify moderate and advanced glaucoma.

H The Relationship Between Quality of Vision and Visual
Field Loss in Glaucoma Patients
Presenting Author: Kazuyuki Hirooka MD
Co-Author(s): Shino Sato**, Akitaka Tsujikawa MD PhD*
Purpose: To evaluate the relationship between quality of life (QOL) and loss of visual field
in patients with open-angle glaucoma. Methods: We examined 202 eyes of 101 glaucoma
patients. Participants completed the Japanese version of the 11-item short-form Visual
Function Questionnaire (VFQ-J11). Visual field testing was used to determine mean deviation (MD) and visual field index (VFI). Eyes with a better MD or VFI were defined as the
better eye, with the fellow eyes designated as the worse eye. Results: VFI in the worse
eye exhibited the highest correlation with VFQ-J11 (Pearson; r = 0.45, P < 0.001). VFQ-J11
scores significantly decreased at VFI values below 60% (P = 0.02). Conclusion: A good
correlation exists between VFI and QOL in glaucoma patients.

Assessing Driving Capability in Patients With Visual Field
Impairment

SOE Corneal Thickness Measurements of Subjects With
Primary and Secondary Congenital Glaucoma
Presenting Author: Shiho Kunimatsu MD
Presenting Author: Nevbahar Tamcelik MD
Purpose: To assess motor vehicle collision (MVC) risk in patients with visual field impairment using a driving simulator. Methods: Twenty-seven glaucoma patients and 13 retinitis
pigmentosa (RP) patients (total = 40, all with better-eye mean deviation [MD; Humphrey
Field Analyzer 24-2 SITA-S] <-12 dB) underwent driving simulator testing (Honda Motor
Co.) with eye tracking (EMR-9, NAC Image Technology). We assessed MD and binocular
Esterman visual field test (EVFT) scores in the patients. Results: The number of collisions
in the simulator correlated with binocular EVFT score in all patients (RP:r = 0.74, P = 0.004;
glaucoma:r = 0.47, P = 0.02), but with better-eye MD in RP patients only (RP:r = -0.64, P =
0.02; glaucoma:r = -0.16, P = 0.45). Conclusion: Binocular EVFT scores can be used to
assess MVC risk.
Co-Author(s): Ahmet Ozkok MD, Olgu Capar MD

Purpose: To compare central corneal thickness (CCT) and corneal diameter (CD) of patients
with primary (PCG) and secondary congenital glaucoma (SCG). Methods: Charts of patients
diagnosed with congenital glaucoma were retrospectively reviewed. Results: Seventy
single eyes of patients with PCG and 50 single eyes of patients with SCG were included.
Mean CCT measurements of PCG and SCG patients were 561.34 67.10 and 593.92
65.75, respectively (P = 0.009). Mean CD measurements of the same groups were 13.41
1.40 and 12.87 1.36, respectively (P = 0.036). Patients with Haab stria had higher CCT
(551.90 vs. 592.51) and CD values (14.02 vs. 12.54). Conclusion: Patients with SCG had
thicker but smaller corneas, probably due to a more delayed presentation, yet with a more
intractable course of elevated IOP.
194
Co-Author(s): Aiko Iwase MD PhD*, Chota Matsumoto MD, Toru Nakazawa MD PhD,
Hiroshi Ono**, Makoto Araie MD**
Scientific Posters
Mobile Operation Theatre on Wheels in India: A Novel Idea
to Reach the Unreachable
Presenting Author: Rajesh P Sangameswaran MBBS
Co-Author(s): Tarun Sharma MBBS, Sengamedu Srinivasa Badrinath FRCSC MBBS**,
Sheila John DO, Mohanasankar Sivaprakasam PhD**
Purpose: To evaluate the surgical outcome in patients undergoing cataract surgery in
a mobile eye surgical unit. Methods: During the period 2012 and 2014, records of 649
patients were reviewed. Results: At the mean follow-up of one month, visual acuity of
20/40 was achieved in 87%. Perioperative complications included posterior capsule rupture
(0.61%) and postoperative inflammation (0.15%). Conclusion: Surgery in an asepsis environment in a mobile van is a feasible concept and provides eye care at the door step of the
needy community, in far-off villages and tribal areas, in a developing nation.

H Malaria Retinopathy: Practice Patterns of Funduscopy, a
Window to the Brain
Presenting Author: Lakshmi Swamy MD
Co-Author(s): Nicholas Beare MD MBCHB*, Tamer H Mahmoud MD*
Purpose: Assess the knowledge, usage patterns, and barriers to use of fundoscopy in the
diagnosis of cerebral malaria (CM). Methods: Online survey sent to general clinicians in
malaria-endemic areas of Africa and Asia.Results: One-half of clinicians never or almost
never examine the eyes when diagnosing CM. One-quarter did not believe that examining the fundus would help them diagnose CM. More than two-thirds expressed interest in
obtaining a fundoscope and/or dilating drops and training on how to use them. Over 80% of
respondents want in-person training. The most common barriers to fundoscopy were lack of
a fundoscope, dilating drops, and the training to perform the eye exam. Conclusion: There
is a need and desire among clinicians for better education, training, and more practical
technology for eye exams in the diagnosis of CM.
Health Policy
Presenting Author: Adel H Alsuhaibani MD**

Co-Author(s): Mazen S Alsamnan MD, Ahmed Mousa AbdelRahim PhD
Purpose: To introduce an effective and safe ophthalmic triaging system to be used by the
ophthalmic nurse practitioner. Methods: A newly modified scoring triage system from a
previously published Rome Eye Scoring System for Urgency and Emergency (RESCUE) was
evaluated in a prospective study over a 1-month period. Its reliability in differentiating urgent ophthalmic conditions from nonurgent conditions, along with picking up patients who
need immediate intervention was tested. Results: With the new system the sensitivity
improved from 90.7% to 96% and the specificity decreased from 97.2% to 84% compared
with RESCUE. Conclusion: This triage system seems to be safe and effective in categorizing patients presenting to ophthalmic emergency. It may help in reducing unnecessary
ophthalmic emergency load and waiting time.

Quality Measures Within a Group Retina Practice: Cultural
Shift and Clinical Outcomes
Presenting Author: Brian C Joondeph MD FACS*
Purpose: To demonstrate the feasibility of a large retina practice instituting quality measures, clinical and nonclinical, and the cultural shift in the practice, supporting these measures. Methods: Within an 11-physician retina-only practice, the success rate for repair
of retinal detachment (RD) and macular hole (MH) and 2 patient satisfaction scores were
measured along with wrong eye or wrong drug intravitreal injections. Results: The success
rate was RD, 80%, and MH, 88%, with variation between physicians. Patient satisfaction scores were 95%. Injection errors were 0.0125%. Less than half of the physicians

H An Evaluation of International Primary Open-Angle
Glaucoma Clinical Practice Guidelines
Presenting Author: Annie Wu
Co-Author(s): Connie Wu, Benjamin K Young BA MS, Dominic Wu, Paul B Greenberg
MD*
Purpose: To compare the quality of primary open-angle glaucoma (POAG) clinical practice
guidelines (CPGs) of the American Academy of Ophthalmology (AAO), Canadian Ophthalmological Society (COS), and Royal College of Ophthalmologists (RCO). Methods: Four evaluators independently appraised CPGs using the six domains of the Appraisal of Guidelines for
Research and Evaluation (AGREE II) instrument. Results: Scores were 28% to 85% (AAO),
51% to 96% (COS), and 55% to 97% (RCO); interrater reliability was 0.89, 0.86, and 0.74,
respectively. The strongest domains were Scope and Purpose (AAO, COS, and RCO) and
Clarity of Presentation (COS and RCO); the weakest were Stakeholder Involvement (AAO
and COS) and Editorial Independence (AAO, COS, and RCO). Conclusion: Future POAG
CPGs can be improved by ensuring editorial independence and stakeholder involvement.

Bevacizumab vs. Ranibizumab for Neovascular AMD: The
Potential Effect of Who and Where
Presenting Author: Nakul Shekhawat MD
Co-Author(s): Nicholas Matthew Pajewski PhD, Emily West Gower PhD, Shravani
Mikkilineni, Joshua D Stein MD MS*
Purpose: To determine whether use of bevacizumab versus ranibizumab for neovascular AMD varies by demographic and geographic factors. Methods: We identified 202,062
Medicare beneficiaries diagnosed with neovascular AMD from 2006 to 2009. Hierarchical regression models assessed factors associated with receipt of bevacizumab or ranibizumab. Results: Enrollees had 60% lower odds of receiving ranibizumab in 2009 versus
2006. Compared with Caucasians, African Americans had 50% reduced odds of receiving ranibizumab (P < 0.001). Residents of western states had 80% lower odds of getting
ranibizumab compared with those in the Northeast. Older persons and those residing in
urban areas had higher odds of receiving ranibizumab (P < 0.001). Conclusion: Receipt of
bevacizumab or ranibizumab for neovascular AMD is impacted by demographic factors and
location of residence.
Intraocular Inflammation Uveitis

Rebound of Choroidal Thickening in Chronic Phase of VogtKoyanagi-Harada Disease
Presenting Author: Yukinori Sugano MD
Co-Author(s): Ichiro Maruko MD, Masaaki Saito MD, Akira Ojima MD*, Tetsuju
Sekiryu MD
Purpose: To evaluate subfoveal choroidal thickness (SFCT) after high-dose steroid therapy
for Vogt-Koyanagi-Harada disease (VKH). Methods: SFCT was measured using enhanceddepth-imaging OCT for 12 months. Results: SFCT in all 46 eyes of 23 patients rapidly
decreased after treatment. Twenty-eight of 46 eyes (61%) showed rebound of choroidal
thickening. SFCT of these eyes at 7, 14, and 30 days was significantly thicker than that
of the eyes without rebound (P < .05). Furthermore, 6/28 eyes (21%) showed recurrence
of serous retinal detachment. The incidence of sunset glow fundus in the eyes showing
rebound of choroidal thickening was higher than that in the eyes without rebound (P < .01).
Conclusion: Choroidal thickness change within a few weeks at the beginning of steroid
therapy may influence on the prognosis of VKH.
195
Scientific Posters

Triaging Self-referred Patients Presenting to Ophthalmology
Emergency
wanted to know their outcomes upon completion of the project. Conclusion: Quality can
be measured within a group retina practice, but the cultural shift toward systematic quality
measurement remains challenging.
Scientific Posters
Detection of Mycobacterium Tuberculosis in the Vitreous
Fluid of Eyes With Multifocal Serpiginoid Choroiditis

Tuberculous Sclerokeratitis
Presenting Author: Reema Bansal MBBS MD
Co-Author(s): Samir S Shoughy MD, Mahmoud O Jaroudi MD
Co-Author(s): Kusum Sharma MD, Amod K Gupta MBBS, Aman Sharma MD, Shivali
Kamal PhD
Purpose: To describe the clinical findings in cases with tuberculous sclerokeratitis. Methods: A total of 8 patients with tuberculous sclerokeratitis without active pulmonary disease
were included. The diagnosis was confirmed by skin testing, interferon-gamma release
assay, or isolation of mycobacteria. Results: There were 8 patients (1 male and 7 females).
The mean age was 29 years. Six patients had nodular scleritis and 2 patients had diffuse
scleritis. All patients responded to antituberculous medications with complete resolution of
sclerokeratitis without anti-inflammatory agents. Conclusion: Sclerokeratitis is an uncommon ocular manifestation of Mycobacterium tuberculosis. Antituberculous therapy may be
sufficient for treatment.
Purpose: To compare 3 different molecular techniques to detect Mycobacterium tuberculosis (MTB) in multifocal serpiginoid choroiditis (MSC). Methods: Vitrectomy samples from
12 eyes (12 patients) were subjected to multitargeted polymerase chain reaction (MPCR),
Gene Xpert MTB/RIF assay, and MTBDRplus assay. Positive samples from MPCR were sequenced for rpoB gene. Results: MPCR was positive in 11 eyes (3 rifampicin [RIF] resistant),
MTBDRplus assay in 7 eyes (4 RIF resistant), and Gene Xpert MTB/RIF assay in 4 eyes (1 RIF
resistant). Conclusion: MTB was detected in MSC by 3 techniques with variable sensitivities, with RIF resistance detected for first time in MSC.

SOE Risk Factors for the Development of Cataract Among
Children With Uveitis
Presenting Author: Tamar Blum-Hareuveni MD
Co-Author(s): Oren Tomkins-Netzer MD, Sophie Seguin-Greenstein, Guy Hareuveni,
Lazha Talat, Susan L Lightman MBBS
Purpose: To identify risk factors for cataract development in children with uveitis. Methods: Ninety-six children were observed at the pediatric uveitis clinic in Moorefields Eye
Hospital, obtained by chart review. The main measure was the interval between the childs
first presentation and the diagnosis of cataract. This interval was examined in relation to
clinical characteristics, activity, and treatment strategies. Results: Prevalence of cataract
was 33%. The mean time interval for the group that developed cataract was 29 months. A
shorter interval was found for children with intermittent uveitis (22), CMO (23), posterior
synechia (PS) at presentation (21), and use of more than 3 drops of topical steroids per day
(28). Conclusion: Factors that influenced the interval were PS at presentation, cystoid
macular edema, and more than 3 drops per day of topical steroids.

SOE Herpetic Ocular Disease in an Italian Referral Center
Presenting Author: Elisabetta Miserocchi MD
Scientific Posters
Co-Author(s): Giovanni Fogliato MD, Francesco M Bandello MD*, Giulio Modorati MD

Purpose: To describe clinical characteristics of herpes simplex virus (HSV) and varicella
zoster virus (VZV) ocular disease in Italy. Methods: Retrospective study of 234 patients
with clinical / laboratory diagnosis of HSV and VZV. Results: 189 patients with HSV
(80.7%) , 45 with VZV (19.2%); mean follow-up: 3.5 years. Clinical manifestations in HSV
and VZV groups: keratitis (41.3%, 31.1%), anterior uveitis (18.5%, 11.1%), keratouveitis
(33.3%, 28.9%), acute retinal necrosis (2%, 15%). Complications: glaucoma (38.1%, 40%
) cataract (27.5%, 26.7%), corneal opacities (12.2%, 8.9%). Recurrences (65.1%, 51.1%).
Long-term antiviral treatment in 73% of patients (mean time: 24.9 months). Conclusion:
Herpetic ocular disease was represented similarly to other series, although we found a
higher rate of ocular complications and recurrences.

Etiologic Diagnosis of Anterior Uveitis in a Mexican
Population
Presenting Author: Khalid F Tabbara MD*

SOE Dexamethasone-Cyclodextrin Nanoparticle Eye Drops
in the Management of Vitritis and Uveitic Macular Edema
Presenting Author: Shiri Shulman MD*
Co-Author(s): Einar Stefansson MD PhD*, Anat Loewenstein MD*, Zohar HabotWilner MD
Purpose: Dexamethasone-cyclodextrin nanoparticle eye drops (DexNP) were shown to effectively deliver dexamethasone to the retina and vitreous in rabbits and humans. This
study evaluated the effect of DexNP eye drops in eyes with noninfectious uveitis with vitritis and/or macular edema. Methods: A prospective pilot study. DexNP drops were administered for 8 weeks. BCVA, ocular examination, and spectral domain OCT were performed on
baseline and during follow-up. Results: Eight eyes (5 patients) were included in the study:
3 eyes with vitritis and 5 with macular edema. BCVA improved from a mean logMAR of 0.2
to a mean of 0.1. Vitritis improved from a mean haze score of +2 to +0.5. Macular edema
resolved in all eyes. Conclusion: In this pilot study DexNP drops had a favorable effect on
vitritis and macular edema in uveitic eyes.

Cigarette Smoking, Male Sex, and Age Are Independent
Risk Factors for the Development of Ocular Sarcoidosis in a
New Orleans Sarcoidosis Population
Presenting Author: Adam C Janot MD
Co-Author(s): Doerte Huscher, Matthew R Lammi MD, Lesley Ann Saketkoo MD
Purpose: This study sought to examine potential risk factors associated with the development of ocular sarcoidosis (OS). Methods: Charts of patients with sarcoidosis (SA) were
reviewed. Inclusion criteria were biopsy-proven SA and disease duration for greater than
1 year. Multivariate regression analyses were used to determine independent risk factors
associated with the development of OS. Results: 109 patients met the inclusion criteria.
Tobacco exposure (OR = 5.25, P = .007, 95% CI, 1.58-17.41), male sex (OR = 7.48, P = .002,
95% CI, 2.152-26.006), and age (OR = 1.114 per 5 years, P = .002, 95% CI, 1.04-1.19) were
found to be independent risk factors for the development of OS. Conclusion: Tobacco use
should be discouraged and ocular screening should not remit in patients with sarcoidosis.
Further studies examining the pathogenesis of OS are needed.

SOE Clinical Experiences in Endogenous Endophthalmitis
Presenting Author: Lorena Ramirez-Patino MD
Presenting Author: Zafer Cebeci MD
Co-Author(s): Miguel Pedroza-Seres MD PhD
Co-Author(s): Nur Kir MD, Yusuf Cem Yilmaz, Merih Oray MD, Ilknur Tugal-Tutkun
MD*
Purpose: To determine the etiology of anterior uveitis in a Mexican population, as well

as age and gender more commonly affected in each group. Methods: A descriptive and
cross-sectional study that included patients with anterior uveitis between September 2007
and May 2013. Results: We studied 1597 patients; 79.27% were nongranulomatous and
20.72% granulomatous. Females were the most affected, with 62.93%, and the most affected age group was the sixth decade, with 20.6%. Patients were subsequently divided
into 4 etiological subgroups: idiopathic, 50.7%; infectious, 24.23%; in study, 14.27%; and
autoimmune, 10.77%. Herpetic uveitis was the most predominant infectious cause, at
90.95%. Conclusion: Anterior uveitis may be caused by a vast number of highly variable conditions, and it is important for treatment and prognosis to determine the etiologic
diagnostic .
196
Purpose: To evaluate the clinical features and outcomes of endogenous endophthalmitis

in a tertiary center in Turkey. Methods: We retrospectively reviewed clinical records of
23 patients (28 eyes) diagnosed with endogenous endophthalmitis from January 2000 to
December 2013. Results: Mean age was 55 (13-80) years, and 52.1% were male. Diabetes mellitus (43.4%) was the most common detected underlying disease. Candida was
isolated from 11 patients (47.8%). Early vitrectomy has been done as initial procedure in 18
eyes (64.2%) to have vitreous sample and to remove pathogens and inflammatory products.
Conclusion: Diabetes mellitus is the most frequent systemic disease and Candida is the
most common organism. Early identification and rapid management helps to reduce the
damage.
Scientific Posters
H Elevation of Th17 Cell-Related Cytokines in the Vitreous
Fluids of Proliferative Diabetic Retinopathy

H Visual Outcome in Sympathetic Ophthalmia
Presenting Author: Masaru Takeuchi MD PhD
Co-Author(s): Khalid F Tabbara MD*, Samir S Shoughy MD, Mahmoud O Jaroudi MD
Co-Author(s): Tomohito Sato MD, Yoko Karasawa, Yutaka Sakurai**, Masataka Ito
MD PhD
Purpose: To study the visual outcome and complications in sound eyes of patients with
sympathetic ophthalmia (SO) following immunosuppression. Methods: We retrospectively
included 49 patients with SO seen in the period 2004 to 2011 who underwent complete
eye examination and imaging. Results: There were 29 male (59%) and 20 female (41%)
patients. The mean age was 37 years (age range, 490 years). Mean follow-up period
was 19 months. Sixty-one percent had a final visual acuity of 20/40 or better. Major ocular
complications included glaucoma (11%) and cataract (13%). Conclusion: Current immunomodulatory therapy is effective in ameliorating the treatment of patients with SO.
Purpose: To investigate helper T (Th)-related cytokines in proliferative diabetic retinopathy

(PDR). Methods: Vitreous samples were collected from 61 eyes with PDR, 16 eyes with
rhegmatogenous retinal detachment (RD), and 14 eyes with epiretinal membrane (ERM)
during vitrectomy, and Th1-, Th2-, and Th17-related cytokines were measured by Bio-plex
assay. Results: IL-4, IL-6, IL-17A, IL-21, IL-22, IL-31, sCD40L, and TNFa were detected in the
vitreous fluids of PDR, RD, and ERM; however, IL-17A, IL-22, and TNFa were significantly
higher in PDR than in RD or ERM. Although vitreous levels of IL-4, IL-21, and IL-31 were
also higher in PDR more than others, neither IL-10 nor IFN-g was detected in most of these
samples. Conclusion: Th17-related cytokines and TNFa were significantly elevated in the
vitreous of PDR compared with RD or ERM.

SOE Long-term Clinical Outcome and Causes of Vision Loss
in Patients With Uveitis
Presenting Author: Abeir Baltmr FRCS MBCHB MD
Co-Author(s): Oren Tomkins-Netzer MD, Lazha Talat, Asaf Bar MD, Lavnish Joshi,
Susan L Lightman MBBS
Purpose: To evaluate the long-term outcome among patients with uveitis. Methods: Information was gathered of 1,799 eyes of 1,076 patients with uveitis. Results: Average
follow-up was 7.97 0.17 years. Average best-corrected visual acuity remained stable for
patients with anterior uveitis (20/30 at baseline to 20/33 at 10 years) or with nonanterior
uveitis (20/50 at baseline to 20/47 at 10 years). Chronic cystoid macular edema (3.55%)
and macular scarring (4%) were the most common causes of vision loss. Conclusion:
Long-term outcome among uveitis patients is good, with vision remaining stable for over 10
years. Vision loss is mainly related to retinal changes.

Use of QuantiFERON-TB Gold to Establish a Tubercular
Etiology in Serpiginous-Like Choroiditis
Presenting Author: Akshay Gopinathan Nair MD
Co-Author(s): S Sudharshan DOMS MBBS**, Jyotirmay Biswas MBBS**, Sudha
Ganesh, Amala Elizabeth George FRCS(ED) MBBS

Intravitreal Clindamycin vs. Oral Therapy or Combined
Therapy for Active Toxoplasmic Retinochoroiditis
Presenting Author: Andrs Francisco Lasave MD
Co-Author(s): Alberto J Castro MD, Sandra mileth Garcia Ramirez**, Hugo Ocampo*
Purpose:To report and compare results of intravitreal clindamycin (IVC), oral therapy (OT),
and combined therapy (CT) for toxoplasmic retinochoroiditis (TRC). Methods: Retrospective, interventional, comparative case series of 153 patients (153 eyes) at three years of
follow-up. Results: In the IVC group, the mean baseline best-corrected visual acuity (BCVA)
improved from logMAR 1.1 (20/250) to logMAR 0.5 (20/60; P = 0.003). In OT, BCVA improved
from logMAR 0.8 (20/125) to logMAR 0.4 (20/50; P = 0.0007), and the CT group improved
from logMAR 1 (20/200) to logMAR 0.5 (20/60; P < 0.0001). The improvement rate was similar among the three groups (ANOVA; P = 0.46). However, patients with baseline BCVA less
than 20/200 showed higher BCVA improvement with IVC and CT than OT alone (ANOVA; P
< 0.001). Conclusion: OT was associated with a higher probability of visual loss compared
with IVC or CT for severe TRC.

SOE Long-term Outcome of Treating Pediatric Uveitis With
Repeat Dexamethasone Implants
Presenting Author: Susan L Lightman FRCOphth FRCP PhD
Co-Author(s): Lazha Talat, Lavnish Joshi, Oren Tomkins-Netzer MD, Asaf Bar MD
Purpose: To describe the long-term outcomes in eyes of children with uveitis following
repeated treatment with dexamethasone (Ozurdex) implants. Methods: A retrospective
review of 22 eyes of 17 pediatric patients. Results: Average follow-up was 15.5 2.1
months, with nine eyes (40.9%) receiving multiple implantations. Following treatment, the
average best-corrected visual acuity improved from 0.55 0.08 logMAR to 0.37 0.08 logMAR (P = 0.024), and the central retinal thickness decreased by 159 44 m (P = 0.02). The
average duration of therapeutic effect following implantation was 10.7 2.4 months, with
a similar response achieved after repeat implamtations. Conclusion: The use of Ozurdex
in children with uveitis results in improved retinal thickness and in restoration of ocular
function.

Cataract Surgery Outcomes in Uveitis: The Multicenter
Uveitis Steroid Treatment (MUST) Trial
Presenting Author: Hatice N Sen MD
Co-Author(s): Francis Mayela Abreu, Thomas A Louis PhD, Elizabeth Ann Sugar PhD*,
Michael M Altaweel MD*, Susan G Elner MD, Janet Holbrook PhD**, Rosa Y Kim
MD**, Douglas A Jabs MD MBA*, John H Kempen MD*
Purpose: To compare the outcomes of cataract surgery during the Multicenter Uveitis
Steroid Treatment (MUST) Trial in eyes that received flucinolone acetonide implant or systemic therapy. Methods: Prospective cohort study. Results: Among 479 uveitic eyes in
the MUST Trial, 117 eyes that underwent cataract surgery met the criteria for inclusion
(28 in systemic group and 89 in implant group). Visual acuity (VA) improved by 29.9 ETDRS
letters zero to four months after surgery (P < 0.001) and remained stable up to 10 months.
Although the implant group had significantly better VA at baseline (P = 0.046), there was
no significant difference in the change from baseline between groups after accounting for
relevant confounders (P = 0.24). Conclusion: Cataract surgery resulted in significant and
sustained VA improvement among uveitis patients treated with flucinolone acetonide implant or standard systemic therapy.

SOE Sustained-Release Dexamethasone Intravitreal Implant
in Juvenile Idiopathic Arthritis-Related Uveitis
Presenting Author: Francesco Pichi MD
Co-Author(s): Paola Carrai MD**, Paolo Nucci MD*, Kimberly Marie Baynes COA,
Careen Yen Lowder MD PhD, Sunil K Srivastava MD*
Purpose: To report outcomes of juvenile idiopathic arthritis-associated uveitis treated with
intravitreal Ozurdex. Methods: Retrospective chart review. Results: Sixteen eyes of 10
patients with a mean age of 17.5 years. At baseline, mean anterior chamber (AC) cell count
was 2.03, and mean central retinal thickness (CRT) was 437.6 m . Mean best-corrected
visual acuity (BCVA) was 25.2 ETDRS letters. A total of 34 Ozurdex implants were delivered
with a mean of 7.5 months between injections. One month after injection, mean BCVA
had improved to 39.6 letters. Mean AC cell count was 0.79 and 0.75 at three months,and
there was a reduction of CRT to 342.4 m. After the second injection, 11 eyes achieved
remission of the anterior uveitis, and BCVA improved to 44.6 ETDRS letters. Four eyes had
resolution of macular edema with CRT of 250.4 m. Conclusion: In juvenile idiopathic
arthritis-associated uveitis, Ozurdex can achieve resolution of AC inflammation and uveitic
macular edema.
197
Scientific Posters
Purpose: To study a possible tubercular etiology serpiginous-like choroiditis (SLC) in a

region with high tuberculosis prevalence. Methods: Thirty-two cases of SLC in whom
QuantiFERON-TB Gold (QFT-G) and tuberculin sensitivity test (TST) had been done were
reviewed. As controls, we analyzed charts of 32 patients with nontubercular uveitis. Antitubercular treatment was decided by an independent infectious disease specialist. Results:
In the SLC group, QFT-G was positive in 17/32 patients (53.12%), and TST was positive in
nine patients (28.12%). Among controls, QFT-G was positive in 6/32 patients (18.75%), and
7/32 patients (21.8%) had a positive TST. Difference between the positivity rates of QFT-G
was found to be statistically significant (P = 0.0085). Conclusion: The positivity rate of
QFT-G in SLC provides evidence of a possible tuberculous etiology.
Presenting Author: Ali M Alhalafi MBBS
Scientific Posters
Brimonidine-Induced Anterior Uveitis
Presenting Author: Jacqueline E Beltz MBBS

Massive Choroidal Granuloma as the Presenting Feature of
Disseminated (Miliary) Tuberculosis
Co-Author(s): Ehud Zamir
Presenting Author: Supriya Batta MS
Purpose: To present the largest series reported so far of brimonidine-induced granulomatous anterior uveitis. Methods: Retrospective case series. Results: Seventeen eyes of
11 patients with chronic glaucoma developed granulomatous anterior uveitis with mutton
fat keratic precipitates after being treated with brimonidine for periods of two days to
three years (mean, 18.5 months). Six eyes had concurrent granulomatous conjunctivitis, and
three were asymptomatic. Fourteen eyes were pseudophakic. Stopping brimonidine led to
complete, rapid resolution of uveitis in all patients. Conclusion: Ophthalmologists should
be aware of this uveitis syndrome, which is easily curable once considered and recognized.
Unnecessary investigations or interventions may be avoided.
Co-Author(s): Neha Goel MBBS**, Gauri Bhushan MBBS**, Usha K Raina MD,
Basudeb Ghosh**

Epidemiology of Ocular Behet Disease in a Non-endemic
Region
Presenting Author: Katherine J Donnithorne MD
Co-Author(s): Russell W Read MD PhD*
Purpose: To determine the epidemiology of Behet disease (BD) in a nonendemic area.
Methods: Retrospective review of BD patients seen between 2001 and 2013 at a tertiary
care uveitis center in Alabama. Results: Of 33 BD patients, Caucasian was the most common ethnicity (79%). A greater proportion of those with uveitis were African American
compared with Middle Eastern (14% vs. 10%). Males developed ocular disease more than
females. Panuveitis and bilateral disease were most common (62% and 71%, respectively).
Conclusion: African Americans developed ocular disease at a greater frequency than did
Caucasian or patients of Middle Eastern descent.

Comparison of devR Polymerase Chain Reaction
(PCR) Assay With MPB64 PCR for Diagnosis of Ocular
Tuberculosis
Presenting Author: Kusum Sharma MD
Scientific Posters
Co-Author(s): Mangat R Dogra MBBS, Mangat R Dogra MBBS, Pankaj Kataria, Reema
Bansal MBBS MD, Amod K Gupta MBBS
Purpose: To compare devR polymerase chain reaction (PCR) assay and MPB64 PCR for diagnosing intraocular tuberculosis (IOTB). Methods: devR and MPB64 PCR were performed
on vitrectomy fluid samples of 25 patients with presumed IOTB, 25 disease controls, and 25
nonuveitic vitrectomy samples. Results: devR and MPB64 PCR were positive in 16 (64%)
and 18 (72%) patients, respectively. Both tests were negative in all controls. Conclusion:
MPB64 PCR had a higher sensitivity than devR PCR for diagnosing IOTB.

Comparison of Gene Xpert MTB/RIF Assay With Multiplex
Polymerase Chain Reaction for Diagnosis of Ocular
Tuberculosis
Presenting Author: Kusum Sharma MD
Co-Author(s): Reema Bansal MBBS MD, Amod K Gupta MBBS
Purpose: To compare Gene Xpert MTB/RIF (GX) assay and Multiplex polymerase chain
reaction (MPCR) for diagnosing intraocular tuberculosis (IOTB). Methods: GX and MPCR
were performed on vitrectomy fluid samples of 55 patients with presumed IOTB, 40 disease
controls, and 20 nonuveitic vitrectomy samples. rpoB gene sequencing was done for diagnosing Rifampicin resistance in positive cases. Results: GX and MPCR were positive in 17
(30.9%) and 39 (70.9%) patients, respectively. Both tests were negative in all controls. Rifampicin resistance was detected in two of 17 by GX and in five by MPCR positive with rpoB
gene sequencing. Conclusion: MPCR had a higher sensitivity than GX for diagnosing IOTB.
Purpose: To report massive choroidal granuloma and exudative retinal detachment (RD) as
the presenting feature of miliary tuberculosis (TB). Methods: Case series of six patients
presenting with a massive choroidal granuloma and exudative RD. They underwent ocular
ultrasound and detailed systemic work-up. Results: All patients had intracranial tuberculomas, pleural effusion, and/or lung nodules suggestive of disseminated TB. They received
antitubercular therapy with steroids for nine months in conjunction with a physician. The
lesions resolved, and visual acuity improved. No recurrences occurred till the last follow-up
of three years. Conclusion: Patients with miliary TB may present with ocular manifestations without any other systemic symptoms.

SOE H Anti-Tumor Necrosis Factor aTherapy in
Refractory Pediatric Uveitis
Presenting Author: Tania Borges
Co-Author(s): David Dias, Vasco Miranda MD, Ricardo L Parreira MD, Angelina S
Meireles MD, Pedro Meneres MD
Purpose: To evaluate the efficacy and safety of anti-Tumour Necrosis Factor a (TNFa)
therapy in refractory pediatric uveitis. Methods: Retrospective review of case files of nine
children with uveitis refractory to corticosteroids and immunomodulation therapy and under
anti-TNFa therapy (Infliximab and Adalimumab). Results: We found that 66.7% of patients
had juvenile idiopathic arthritis. Infliximab (4.59.8 mg/m2; 6/6 weeks; mean follow-up,
30.9 months) and Adalimumab (25 mg/m2; 2/2 weeks; mean follow-up, 20 months) showed
no serious adverse effects. Morever, 88.9% entered remission within six months, 55,5%
reduced and/or suspended corticosteroid and immunomodulation therapy, and 55,5% maintained remission for more than 12 months. Conclusion: Anti-TNFa therapy has a favorable
response in most refractory pediatric uveitis.
Medical Education
SOE Linear and Nonlinear Interactive Virtual E-patients in
Ophthalmology for Medical Student Teaching
Presenting Author: Lavnish Joshi
Co-Author(s): Rose Gilbert, Oren Tomkins-Netzer MD, Susan L Lightman MBBS
Purpose: To describe our experience in developing and evaluating linear and nonlinear epatient ophthalmology scenarios for medical students. Methods:The MOODLE e-learning
platform was used to create scenarios and gain student feedback. Results: The development time was 55 hours for the linear scenarios and 35 hours for the branching scenario.
The latter allowed several options to be chosen. Both designs had good and similar satisfaction levels among students. The branching scenario was regarded as more authentic
(100% vs. 53% in the linear group) since students felt involved in gathering information.
Conclusion: Branching nonlinear e-patient scenarios were more authentic than linear
scenarios.

SOE Play-Doh Models Are a Very Effective Tool for Teaching
Anatomy of the Eye
Presenting Author: Fiona Jazayeri MBBS
Co-Author(s): Eleanor Rachel MacLeod**, Sally Margaret Webber FRCOPHTH, Philip
Alexander MBBS, Ruth Manners FRCOPHTH MBBS
Purpose: We present a method of constructing an eyeball from Play-Doh. This has been
used as an addition to the teaching armamentarium in allowing visualization of the anatomy of the eye. Methods: The stages of creating a 3-D model of the eye using Play-Doh are
illustrated using sequential photographs. Results: Play-Doh models of eye anatomy are
more efficient and realistic in training than simple drawings or photographs alone. No prior
experience with Play-Doh is required to be able to construct the model. This educational
tool has received excellent feedback from medical students at courses where it has been
198
Scientific Posters
used. Conclusion: Play-Doh modelling is an extremely effective way of teaching ocular
anatomy in 3 dimensions and is readily available at low cost. We recommend the use of
this method of teaching anatomy to others.

H Effect of Manual Dexterity and Fine Motor Skills
Training of the Nondominant Hand on Suturing and Surgical
Simulator Performance
graphics, clinical features, and course were tabulated and analyzed. Results: Nine males
and 12 females presented at a mean age of 24 months. Eight patients (38%) had ophthalmic
presentations: eye movement abnormalities, proptosis, and blindness and 12 (60%) had
diencephalic syndrome; 4 (19%) had both. Fifteen (71%) had optic atrophy. Sixteen tumors
(76%) were supersellar, where the typical sign of heterogeneous enhancement was seen
in 6 (33%). Conclusion:The most common presentations were diencephalic syndrome and
optic atrophy. Typical neuroradiologic signs occurred in a minority.

Topiramate-Induced Palinopsia: Case Series Report and
Review of Literature
Presenting Author: Mary-Magdalene U Dodd MD
Presenting Author: Samuel H Yun MD
Co-Author(s): Danica Kindrachuk, Paul Murphy MD
Co-Author(s): Martha P Schatz MD, Robert L Lesser MD
Purpose: To evaluate the efficacy of manual dexterity and fine motor skills training for
improving surgical skill. Methods: Trainees were randomly assigned to control or intervention, consisting of a week of tasks proposed to improve the manual dexterity of the
nondominant hand. Using the EYESi simulator and silicone globes, 20 subjects underwent
baseline and postintervention testing on single-handed tasks and corneal suturing. Results: There was significant improvement in speed (3.5 vs. 2.1 min; P = 0.08) and in total
score (65 vs. 12; P = 0.02) in the intervention group compared with control. There was no
difference in accuracy (number of times instrument slipped out of the sphere) or tremor.
Conclusion: Manual dexterity and fine motor skills training of the nondominant hand may
be of benefit in improving surgical skill.
Purpose: To report 4 cases of topiramate-induced palinopsia and to compare their features with those cases previously reported. Methods: Retrospective review of case series
and literature review. Results: Four cases of topiramate-induced palinopsia in addition
to previously reported 4 cases are reviewed. All were female (100%) with diagnoses of
migraine (62.5%), idiopathic intracranial hypertension (25%), and bulimia nervosa (12.5%).
The lowest dose that caused palinopsia was 50 mg daily. Six patients symptoms resolved
after stopping the drug, while 1 patients palinopsia ceased despite continuing topiramate
110 mg daily for several years. Fifty percent of patients reported exacerbation of visual
disturbance in early morning or late evening. Conclusion: Palinopsia from topiramate may
not be an uncommon side effect from topiramate.

Congestion in the Ophthalmology Residency Match
Presenting Author: Sarah E Brown MD

SOE The Effect of Fingolimod on Macular Parameters: A
2-Year Longitudinal Study
Co-Author(s): Robert M Fischer MD**
Presenting Author: Michele Lanza MD
Purpose: To identify and analyze trends in the ophthalmology residency match. Methods:
Data from the San Francisco Match for ophthalmology residency between 2004 and 2014
were analyzed using linear regression. Results: From 2004 to 2014, there was a 46% increase in the mean number of submitted applications per applicant, which correlated with
an improved unadjusted match rate (P < 0.05). However, when the match rate was adjusted
for the number of available positions, this relationship no longer existed. Conclusion: The
aggregate match rate did not improve, as more applications were submitted between 2004
and 2014. Further investigation is needed to investigate the efficiency of an application
limit.
Co-Author(s): Vito Romano**, Michele Rinaldi MD**, Alvino Bisecco MD**, Antonio
Gallo MD*, Gioacchino Tedeschi MD**
Neuro-Ophthalmology
Presenting Author: Jaroslaw Kociecki MD

Co-Author(s): Izabela Rogalinska, Robert Juszkat PhD**, Andrzej Dmitriew MD*
Purpose: To evaluate the effect on visual acuity of endovascular treatment in patient with
unruptured internal carotid artery aneurysms located near the origin of the ophthalmic artery. Methods: A prospective study involving 13 patients with aneurysms treated with
stents and coils. All patients were ophthalmologically tested prior to and after embolization. Mean follow-up was 36 weeks. Results: Decreased visual acuity prior to embolization
was found in 1 case(7.7%). Permanent vision loss due to embolization was observed in 2
cases (15.4%). Transient vision loss occurred in 1 case(7.7%). Conclusion: Endovascular
treatment may be associated with the risk of visual deterioration or loss in the eye on the
side of the aneurysm, as well as with a significant improvement in visual acuity.

Pediatric Pilomyxoid Astrocytoma: Ophthalmic and
Neuroradiologic Manifestations
Presenting Author: Joyce N Mbekeani MBBS
Co-Author(s): Maaly Abdelhalim Abdelfattah Sr MD PhD, Anwar Ul Haq III MD**,
Essam Abdulaziz Alshail MBBS, Selwa A F Al-Hazzaa MD FRCS
Purpose: To study the clinical and radiologic features of a new tumor class with a propensity for the chiasmal-hypothalamic axis. Methods: Retrospective chart review of 21
patients with histologically-proven pediatric pilomyxoid astrocytoma (PMA). Patient demo-

Risk of Optic Pathway Glioma Development in
Neurofibromatosis Type 1 Patients With Optic Nerve
Tortuosity or Thickness
Presenting Author: Marc H Levin MD
Co-Author(s): Robert Zimmerman MD, Larissa T Bilaniuk MD, Tamara Feygin MD,
Grant T Liu MD, Michael Fisher MD
Purpose: To determine associations between optic nerve tortuosity (ONT) or thickening
and optic pathway glioma (OPG) development in neurofibromatosis type 1 (NF1). Methods:
132 NF1 subjects without OPG initially and with 1 year visual acuity (VA) follow-up were
included. ONT was defined using validated criteria. ONT/thickening were also established
from MRI reports. Nerve diameters were measured. Results: Baseline MRI report (med
3.6 yo ) noted ONT in 21 subjects, who developed OPG with greater frequency than those
without ONT (33% vs. 12%, P = .02). Validated scale established 7 ONT subjects with even
greater OPG incidence (57% vs. 13%, P = .0003). Tumor-related VA loss (median 7.3 years
after MRI) was not influenced by ONT. Thickening on MRI report and nerve/sheath diameter
did not correlate with OPG evolution. Conclusion: ONT warrants close surveillance but
may not predispose to OPG-related VA loss.

Mutational and Clinical Spectrum of the Mitochondrial
DNA Mutations in Koreans with Leber Hereditary Optic
Neuropathy
Presenting Author: Shin Hae Park MD
Co-Author(s): Sun-Young Shin MD, Myungshin Kim MD PhD**, Hae-ri Yum MD
Purpose: To investigate the mutational and clinical features of Korean patients with Leber
hereditary optic neuropathy (LHON). Methods: We analyzed genetic mutations among
199
Scientific Posters

SOE Visual Complications Following the Endovascular
Treatment of Internal Carotid Artery Aneurysms
Purpose: To study the effect of fingolimod, an oral sphingosine-1-phosphate receptor modulator approved for treatment of multiple sclerosis (MS), on macular parameters. Methods:
After neurological and ophthalmic evaluations, OCT has been performed in 44 eyes of 22
MS patients before fingolimod therapy and at 6, 12, and 24 months follow-up. Central
macular thickness (CMT) and macular volume (MV) measured at 3 mm were obtained and
compared before and after treatment. Results: No significant increases in CMT (+0.24
0.76 m; P = .18) and in MV (+41.5 20.21 mm3 ; P = .82) at 24 months follow-up have
been observed. Conclusion: Also if they have to be confirmed in further studies , our data
show that fingolimod therapy does not cause macular alterations after 2 years of therapy.
Scientific Posters
164 patients who are clinically suspected as having LHON. Mutations were determined by
DNA sequencing using polymerase chain reaction products. Also we performed ophthalmic examinations. Results: The group of patients with secondary mutation had a higher
proportion of women than the group with primary mutation. Visual acuity and color vision
were significantly decreased in the primary mutation group compared with the secondary
mutation group. The retinal nerve fiber layer thickness did not differ significantly between
primary and secondary mutation groups. However, the visual field index was significantly
lower in the secondary mutation group. Conclusion: We report the mutational and clinical
features of mtDNA in Koreans with LHON, which has not been previously reported.

SOE H Bioactive Peptide Nanofibers for Optic Nerve
Regeneration
Presenting Author: Fatma Yulek MD
Co-Author(s): Gozde Uzunalli MS
Purpose: To investigate the effect of bioactive peptide nanofibers on optic nerve regeneration. Methods: In this work, laminin mimetic PA molecules, which increase neurite
outgrowth in in vitro conditions, were used. The PA nanofiber network was characterized
by scanning electron microscopy, rheology, and circular dichroism. For in vivo studies, PA
nanofibers were injected into the damage site of an optic nerve degeneration model, where
they formed hydrogels. Results: Our preliminary results showed that the regeneration process was initiated in PA-injected samples even after 1 week. Moreover, the presence of
PA nanofibers augmented axonal outgrowth. Conclusion: These results showed that PA
nanofibers can be used as an efficient scaffold for optic nerve regeneration.

Retinal Dysfunction in Patients With Congenital Fibrosis of
the Extraocular Muscles Type 2
Presenting Author: Arif O Khan MD
Co-Author(s): Darren Oystreck COMT MS, Elizabeth C Engle MD*, Khaled Abu-Amero
PhD, Thomas M Bosley MD
Scientific Posters
Purpose: Congenital fibrosis of the extraocular muscles type 2 (CFEOM2; recessive

PHOX2A mutations) is characterized by bilateral ptosis, large exotropia, ophthalmoplegia,
and poorly reactive pupils. Nonamblyopic subnormal vision is not considered characteristic,
but we have repeatedly observed this in genetically confirmed cases and herein document
the finding. Methods: Retrospective case series (2002-2012). Results: All 18 patients
(5-63 years old; median, 10 years old; 4 families) had decreased BCVA in both eyes not
explainable by amblyopia alone. Those who had visual fields (5) and electroretinography
(10) showed abnormalities not ascribable to amblyopia. Conclusion: In addition to a distinct form of congenital incomitant strabismus, the phenotype of CFEOM2 includes retinal
dysfunction.

Clustered Volley Stimuli Improve Multifocal Objective
Pupillographic Perimetry
SESSION TWO: MONDAY AND TUESDAY

SOE Correlation of OCT Parameters With Visual Function in
Patients With Optic Pathway Gliomas
Presenting Author: Carlos Perpetua MD
Co-Author(s): Ana Rita Baptista Couceiro Neto MD, Mario Canastro MD, Joana V
Valadares MD**, Joaquim P Canelas MD, Ana Claudia P Fonseca MD, Fatima Campos
MD**, Manuel E Monteiro-Grillo MD
Purpose: To determine the ability of spectral-domain OCT (SD-OCT) to detect visual dysfunction in children with optic pathway Gliomas (OPG). Methods: We evaluated 26 patients
diagnosed with OPG. The correlation between peripapillary retinal nerve fiber layer (RNFL)
thickness with Humphrey field analyzer perimetry parameters was evaluated. Results: In
patients with visual dysfunction, a strong positive correlation was observed between global
RNFL thickness and MD (R = 0.700, P < 0.001) and a moderate to strong positive correlation
between sectoral RNFL thickness and the corresponding MS (R = 0.4250.704, P < 0.001).
The area under the receiver operating characteristic curve for global RNFL thickness was
0.983 (P < 0.001). Conclusion: A normal RNFL thickness is a strong indicator of absence
of visual dysfunction. The strong relationship between visual function and RNFL thickness
may predict visual deterioration.

Congenital Ocular Motor Apraxia With Wheel-Rolling
Ocular Torsion-A Diagnostic Sign of Joubert Syndrome
Presenting Author: Michael C Brodsky MD
Co-Author(s): Paraskevi-Eleni Papanagnu MD, Lindsay D Klaehn, Genie M Bang
MD**, Rafif Ghadban MD, Brian G Mohney MD
Purpose: To describe the association of congenital ocular motor apraxia with wheel-rolling alternating torsional deviations of the eyes as a diagnostic sign of Joubert syndrome.
Methods: Retrospective review of clinical, neuroimaging, video-oculography, and genetic
studies in two children with congenital ocular motor apraxia and Joubert syndrome. Results: In two children, retinal examination showed a tonic alternating cyclodeviation with
a periodicity of 10 to 15 seconds. Magnetic resonance imaging and genetics confirmed
the diagnosis of Joubert syndrome. Conclusion: In patients with congenital ocular motor
apraxia, the unique finding of tonic alternating ocular torsional deviations on retinal examination establishes the diagnosis of Joubert syndrome.

H Longitudinal Evaluation of Circumpapillary Retinal
Nerve Fiber Layer Thickness and Ganglion Cell-Inner
Plexiform Layer Thickness for Prediction of Ethambutol
Optic Neuropathy
Presenting Author: Jinu Han MD
Presenting Author: Ted Maddess PhD*
Co-Author(s): So Young Han MD, Hyoung J Koh MD*, Sueng-Han Han MD**
Co-Author(s): Andrew Charles James PhD*, Rohan W Essex MBBS, Maria Kolic*,
Corinne Francis Carle PhD*
Purpose: To evaluate change of retinal nerve fiber layer (RNFL) and ganglion cell-inner
plexiform layer (GCIPL) thickness in patients with pulmonary tuberculosis who are taking
ethambutol (EMB). Methods: A single-center prospective study was conducted in 98 eyes
of 49 patients with pulmonary tuberculosis who are taking EMB, and serial measurements
of circumpapillary RNFL and GCIPL thickness with Cirrus OCT were done initially and at four
and six months. Results: RNFL and GCIPL thickness had no changes in the normal group (n
= 96), but an increase of RNFL thickness in the temporal sector (68173 m) and reduction
of GCIPL thickness (8032 m) was noted at four months in EMB optic neuropathy group (n
= 2). Conclusion: Evaluation of circumpapillary RNFL and GCIPL thickness by Cirrus OCT
would be a useful screening tool in EMB optic neuropathy.
Purpose: To investigate the improvement in signal-to-noise ratio (SNR) of the new clustered volley stimulus presentation method for multifocal objective pupillographic perimetry. Methods: 398 visual fields were measured in 73 normal subjects (37 males) in 5 studies
in which ages ranged from 21.0 1.0 years to 70.2 4.9 years (mean SD). Light sensitivities at 44 regions/field, expressed as z-score SNRs, were tested with and without the new
clustered volley (CV) method. Results: The mean z-score and SE for CV presentation in the
5 studies was 4.37 0.23, which was 40% 11% (SD) higher than our older method, all
5 studies P < .005. Conclusion: To obtain a 40% improvement in SNR without CV would
require a test duration of 11.7 min. compared to the 6. min to test both eyes used here.

SOE Analysis of Retinal Nerve Fiber Layer Thickness With
OCT in Patients With Parkinson Disease
Presenting Author: Turgay Ucak
Co-Author(s): Gursoy Alagoz MD
Purpose: To investigate retinal nerve fiber layer thickness (RNFLT), macular thickness (MT),
and ganglion cell complex (GCC) of Parkinsons patients (PP) and compare with healthy subjects (HS). Methods: Fifty-eight eyes of 30 PP and 60 eyes of 30 HS were included. RNFLT,
MT, and GCC were examined with OCT. Results: Age, gender, and best-corrected visual
acuity were similar in both groups. Mean IOP of PP was lower than HS. The mean superior
and inferior RNFLT and mean GCC thickness of the PP group were lower than the HS group.
200
Scientific Posters
MT of both groups was statistically similar. Conclusion: RNFLT and GCC measurements
with OCT may be useful for evaluating eurodegeneration of Parkinsons disease. These
measurements may be an additional step to diagnose Parkinsons disease in the future.

SOE Changes of Retinal Nerve Fiber Layer Thickness in
Patients With Parkinson Disease According to Duration and
Severity of the Disease
Presenting Author: Turgay Ucak
Co-Author(s): Gursoy Alagoz MD
Purpose: To test the diagnostic ability of OCT for the detection of Parkinsons patients (PP)
using retinal nerve fiber layer (RNFL) thickness. Methods: Fifty-eight eyes of 30 PP were included in this study. PP were tested with the Unified Parkinsons Disease Rating Scale (UPDRS) and the mini-mental test (MMT) to investigate the severity of the disease. Results:
Duration of Parkinsons disease and RNFL thickness was not correlated statistically. While
there was no correlation between superior and temporal quadrants of RNFL thickness and
the UPDRS, the mean, nasal, and inferior quadrants of RNFL thickness were correlated with
the UPDRS. The mean and nasal quadrants of RNFL thickness were found correlated with
the MMT. Conclusion: RNFL thickness measurements may be a useful sign for evaluating
neurodegeneration of Parkinsons disease.

SOE Evaluation of Patients With Syndrome of Horizontal
Gaze Palsy with Progressive Scoliosis
Presenting Author: Nadine Sousa Marques Sr
Co-Author(s): Ana Filipa Miranda, Ana Melo Cardoso MD**, Joao Cardoso MD**,
Nuno P Campos MD**, Sandra Rodrigues Barros Jr**

A Novel Drug, CE0866w, Decreases Human Primary and
Metastatic Malignant Skin Melanoma Cells by Apoptosis
Presenting Author: Robert Weir MD
Co-Author(s): Souriya Vang**, John David Pemberton DO, LuGuang Luo MD PhD**
Purpose: Effective malignant melanoma therapies are limited by the inability to control
cell growth / differentiation, cell death, and metastasis. We hypothesize that a novel drug
is a potential candidate for therapy by inducing apoptotic cell death in malignant melanoma
cells. Methods: Primary and metastatic cells were exposed to 3 separate drug concentrations: 6, 3, and 1.5 mg/ml. Apoptosis and rates of cell differentiation were quantified
using TUNEL and BrdU immuno-histochemical fluorescence. Results: Apoptosis increased
significantly in direct relation to drug concentration (P < .05, .01, and 0.01 vs. controls). No
effect of drug concentration was observed on cell differentiation. Conclusion: CE0866w is
a potential therapeutic candidate for skin melanoma by inducing cell apoptosis.

Clinical Presentation and Outcome of Retinoblastoma in
Older Patients: A Comparative Study
Presenting Author: Santosh G Honavar MD
Co-Author(s): , Kaustubh Mulay MD**, Geeta K Vemuganti MD, Vijay Anand P Reddy
MD

SOE Ocular Effects of CyberKnife Robotic Radiosurgery in
Patients With Central Nervous System Tumors

SOE Characteristics and Clinical Presentation of
Retinoblastoma in Istanbul Between 1980 and 2013
Presenting Author: Michal Orski MD
Presenting Author: Serife Bayraktar
Co-Author(s): Dorota Tarnawska MD, Edward A Wylegala MD PhD**
Co-Author(s): Samuray Tuncer MD, Selen Cagman**, Nihan Aksu, Rejin Kebudi
Purpose: To radiation-related ocular side effects in patients undergoing radiosurgery for

meningiomas located close to the optic chiasm. Methods: We examined 13 patients who
received 18 Gy in three fractions. Doses delivered to the optic tract were, on average,
5.52 Gy (1.04-14.08 Gy). Best-corrected visual acuity, IOP, endothelial cell count, Pentacam
nucleus staging, central macular thickness, retinal nerve fiber layer, and visual evoked potentials were measured at baseline and 12 months after radiotherapy. Results: No statistically significant changes in measured parameters (P > 0.05, Wilcoxon paired test) were
revealed. Conclusion: CyberKnife radiosurgery for meningiomas located close to the optic
chiasm seems to be a safe and therapeutic option for the eye and eye tract.
Purpose: To report the characteristics and clinical presentations of retinoblastoma from

a referral center in Istanbul, Turkey. Methods: We analyzed the clinical records of 206
children (276 eyes) diagnosed with retinoblastoma and treated between 1980 and 2013,
retrospectively. Results: Of the total of 206 patients, there was no sex predominance: 113
male (54.8%) vs. 93 female (45.2%). A total of 136 cases (66.02%) were unilateral, and
70 cases (33.98%) were bilateral. The mean age overall at the time of diagnosis was 25.3
months. The most common presenting signs were leukocoria (159 cases, 77%), strabismus
(82 cases, 39.8%) and proptosis (5 cases, 2%). Conclusion: Leukocoria is the most presenting sign in our patients, as in developed countries.

Cigarette Smoking and Activities of Daily Living in Ocular
Myasthenia Gravis

SOE Prognostic Indicators of Visual Outcome in Macular
Retinoblastoma: A 10-Year Review
Presenting Author: Sean M Gratton MD

Co-Author(s): Byron L Lam MD*
Purpose: To determine whether cigarette smoking influences disease activity in ocular
myasthenia gravis (OMG). Methods: Smoking status and the Myasthenia Gravis-Specific
Activities of Daily Living (MG-ADL) scale were assessed by a prospective survey administered to patients with OMG from a single institution between 2005 and 2014. Results:
Among 39 patients with OMG, current smokers (5.4 5.5) and former smokers (2.9 3.1)
had significantly higher MG-ADL scores than nonsmokers (1.4 2.5; P = 0.012) after controlling for age and gender. Conclusion: Cigarette smoking may significantly worsen disease
activity in OMG.
Presenting Author: Graeme Kenneth Loh MBBS

Co-Author(s): John Bladen MBBS MRCS**, Maddy A Reddy MBBCH*, Mandeep S
Sagoo MBBChir PhD*
Purpose: To explore whether macular retinoblastoma (mRB) size, scar location, subretinal fluid (SRF), and response to chemotherapy can predict final logMAR visual acuity (VA).
Methods: Thirty-four mRBs in 28 cases (retrospective, 2001-2010) had primary chemotherapy alone; tumor reduction > 50% was termed a good response. Retina Area Analysis
Tool measured RetCam tumor/scar areas. Results: Visual acuity (VA): 18%, 0.3; 35%,
1.0. Subretinal fluid (SRF) was detected in 24%; mean VA of 2.19 vs. 1.32 (P = .059). Adjusting for age, gender, and initial tumor area, a good response: mean VA of 0.74 vs. 2.04 (P =
.0070). Scars covering < 5 ETDRS subfields: mean VA of 0.84 vs. 1.86 (P = .0022). Tumors
201
Scientific Posters
Purpose: To report two cases of horizontal gaze palsy with progressive scoliosis (HGPPS)
with mutations in the ROBO3 gene identified in our hospital. Methods: Clinical records and
spinal and head RMN findings of these patients were reviewed. Results: Patients with
HGPPS showed a medulla abnormally butterfly like, defects in abducens nuclei, abnormal
flattening of the basis pontis, and hypoplasia of the pontine tegmentum in head MNR .
Genetic analysis revealed a mutation in the ROBO 3 gene. Conclusion: HGPPS is a rare
disease and an infrequent cause of horizontal gaze palsy and scoliosis, which requires
surgical intervention early in life.
Purpose: To study the clinical presentation and outcome of Rb in the older age group.
Methods: Comparative case series. Results: Of 1000 consecutive patients with Rb, 320
patients (435 eyes) aged 36 months (range: 36-340, median 49) were compared with 680
patients (820 eyes) aged < 36 months at presentation. Older patients with Rb more often
presented with masquerades / misdiagnosis (30% vs. 11%), advanced tumor, group D/E
(66% vs. 34%), showed poor response to chemoreduction (55% vs. 24%), needed enucleation (72% vs. 30%), had high-risk features on histopathology requiring adjuvant treatment
(54% vs. 12%), and had metastasis (9% vs. 3%). The differences were all statistically significant (P < .05). Conclusion: Rb in the older age group is often misdiagnosed, presents
with more advanced disease, and has relatively poor prognosis for eye and life salvage.
Scientific Posters
below mean size (9962): mean VA of 1.64 vs. 1.44 (P = .5963). Conclusion: Greater tumor
response and non-foveola involving mRBs occupying < 5 ETDRS subfields confer better
visual outcome; tumor size or SRF presence alone did not predict VA.

SOE Silencing of PARK7/DJ-1 Gene by siRNA Inhibits Uveal
Melanoma Cell Proliferation
Presenting Author: Maria Santiago-Varela
Co-Author(s): Manuel Francisco M Bande Rodriguez MD, Manuel Gomez-Torreiro MD
Purpose: DJ-1/PARK7 is an oncoprotein whose aberrant expression has been related
to the proliferation of the tumors. The overexpression of DJ-1 has been described by our
group in uveal melanoma (UM). We detected DJ-1 in UM tumor secretomes and in UM
patients sera. The aim of this work was to investigate the effect of DJ-1 inhibition on the
proliferation of UM cells lines. Methods: Small interfering RNA (siRNA) directed against
DJ-1 or siRNA control was introduced in UM cell lines with Lipofentamine. Dynamic cell
proliferation of silenced DJ-1 vs. nonsilenced cells was assayed by xCelligence System.
Results:Down-regulation of DJ-1 expression in UM cells showed a significant decrease of
cell proliferation compared to control. Conclusion: The expression of DJ-1 oncogene may
play a role in the proliferation of UM cells in vitro.

The Effect of Human Deficiency Virus Status on Ocular
Surface Squamous Neoplasia: A Case-Control Study
Presenting Author: Saurabh Kamal
Co-Author(s): Swathi Kaliki MD, Jyoti Batra MD**, Adit Gupta Jr MBBS, Mohammad
J Ali MBBS MS, Milind N Naik MBBS, Akshay Gopinathan Nair MD
Purpose: To compare the clinical features, treatment outcomes, and histopathological
features of ocular surface squamous neoplasia (OSSN) based on human immunodeficiency
virus (HIV) status. Methods: Case-control study with HIV positive (n = 48) and HIV negative (n = 62) cases. Results: The following features were significant on comparison of HIV
positive vs. negative cases, tumor size (mm) (12 vs. 8, P < .01), T3 tumor category (24% vs.
14%, P = .01), and scleral / deeper invasion (60% vs. 32%, P = .01). The need for lamellar
sclerectomy (20% vs. 10%) and enucleation / exenteration was higher in HIV-positive than
in HIV-negative cases (22% vs. 12%). Conclusion: OSSN in HIV-positive individuals is
aggressive, with a poorer ocular prognosis.

Retinoblastoma in Adults: A Study of 6 Cases
Presenting Author: Adit Gupta Jr MBBS
Scientific Posters
Co-Author(s): Swathi Kaliki MD, VijayAnand Reddy Palkonda MD, Dilip Kumar Mishra,
Milind N Naik MBBS, Akshay Gopinathan Nair MD
Purpose: To describe the clinical and histopathologic features, treatment, and outcome
of retinoblastoma (RB) in adults. Methods: Retrospective clinicopathologic case series of
6 adults (age > 20 years) with RB. Results: The mean age at presentation was 27 years
(range: 22-37). There were 3 males and 3 females. The mean duration of symptoms was 9
months (range: 1-25). All cases had sporadic unilateral RB. Based on International Retinoblastoma Staging System, 4 cases were classified as stage I (intraocular), and 2 as stage
IIIA (orbital). Intraocular RB was treated by enucleation (n = 5). Multimodal treatment was
performed in the 2 cases with orbital RB. Systemic metastasis and death due to metastasis
occurred in 1 case. Conclusion: RB in adults is rare. It usually presents as an advanced
disease necessitating multimodal approach.

SOE Swept-Source OCT Imaging of Choroidal Tumors
Presenting Author: Jose M Caminal MD PhD
Co-Author(s): Jaume Catala MD*, Alejandro Filloy MD, Agnieszka Dyrda MD, Ignacio
Flores-Moreno MD PhD, Estefania Cobos MD, Marcos J Rubio Caso MD*
Purpose: To describe the swept-source OCT (SS-OCT) features of a series of choroidal
tumors and correlate them with clinical findings. Methods: A group of 50 tumors from 50
eyes corresponding to 45 patients with choroidal tumors underwent fundus photography,
ultrasound and fundus autofluorescence imaging, and SS-OCT. Results: We included 22
nevi, 7 melanocytic lesions at risk, 6 choroidal melanomas, and 5 hemangiomas. SS-OCT
allowed an accurate measurement of all tumors. Choroidal nevi displayed a compact and
regular structure with preserved choriocapillaris. Choroidal melanomas showed an irregular inner structure. Choroidal hemangiomas have a regular sponge-like pattern different
from melanomas and nevi. Conclusion: SS-OCT may play a role in differential diagnosis,
follow-up, and monitorization of the choroidal tumors of the posterior pole.
202

Iris Metastasis From Systemic Cancer in 103 Patients
Presenting Author: Carol L Shields MD
Co-Author(s): Swathi Kaliki MD, Gordon Crabtree, Ani Peshtani, Spenser Joel Morton,
Ronan Akshay Anand, Jerry A Shields MD
Purpose: To describe features of iris metastasis. Methods: Analysis of 103 patients. Results: The primary tumor was located in the breast (33%), lung (27%), skin (12%), kidney
(7%), esophagus (3%), prostate (2%), endometrium (2%), urinary bladder (2%), and others
(12%). The tumor was located at the iris root (52%), midzone (34%), or pupillary margin
(15%), with mean diameter of 6 mm, multifocality (21%), and secondary glaucoma (37%).
Ocular treatment included plaque / external radiotherapy (64%), systemic chemotherapy
(22%), iridectomy (5%), or enucleation (4%). Conclusion: Iris metastases arise from breast
or lung carcinomas in 60% of cases and are mostly controlled with chemotherapy or radiotherapy.

Comparison of Impression Cytology and Pathology in 72
Consecutive Conjunctival Tumors
Presenting Author: Maria Cristina Gabela
Co-Author(s): , Maria Teresa Daza**, Pedro F Salazar MD
Purpose: To estimate sensitivity and specificity of impression cytology for suspicious conjunctival neoplasia. Methods: We included 72 patients with clinically suspicious ocular
surface neoplasia. All cases underwent impression cytology, complete resection and histopathology study. Results: Sensitivity for cytology was 84.8% (CI, 68.1%-94.9%), and
specificity 40.7% (CI, 20.4%-61.1%). Bayesian methods showed that sensitivity of cytology
is near 65%, with 0.95 probability to be between 63% and 76%. Conclusion: Impression
cytology is sensitive but has a low specificity. Using Bayesian analysis and combining clinical and cytologic diagnosis, a better specificity can be obtained. Impression cytology may
be helpful in clinical practice for a more accurate diagnosis of ocular surface squamous
neoplasias.

SOE Incidence and Indications for Pars Plana Vitrectomy
Following the Treatment of Posterior Uveal Melanomas in
Scotland, United Kingdom
Presenting Author: Henry Smith MD
Co-Author(s): Seen Chia, Harold M Hammer MBChB**, Ewan G Kemp MD
Purpose: To analyze indications and outcomes from vitrectomy following globe-sparing
treatment of uveal melanoma in the Scottish Ocular Oncology Service. Methods: Review
715 cases from 1993 to 2008. Results: Of 445 eyes treated with Ru-106 plaque brachytherapy, 43 treated with local resection, and 227 treated with proton beam therapy (PBT),
17 (2.4%) required vitrectomy 10 for vitreal hemorrhage (VH), eight for retinal detachment
(RD), and one combined VH/RD. Mean interval from tumor treatment vitrectomy was 2.2
years. RD followed 9.3% of local resection, 0.2% of plaques, and 0.9% of PBT. VH followed
7.0% of local resection and 1.6% of plaques. Conclusion: Most early vitrectomies (less
than six months) were for RD following local resection (P = 0.011), and most late vitrectomies (more than six months) were for VH following plaques (P = 0.007). Rates of late RD
following Ru-106 plaques were low.

H Ocular Toxicity, Systemic Toxicity, and Safety of
Intravitreal Melphalan Injections for Retinoblastoma
Presenting Author: Jasmine H Francis MD
Co-Author(s): Scott Brodie MD PhD, Brian P Marr MD, Yves Pierre Gobin MD**, Ira
Dunkel MD, David Abramson MD FACS
Purpose: To evaluate the toxicity and safety of intravitreal melphalan. Methods: Twentynine eyes received 173 weekly intravitreal melphalan injections (a median of six times).
Electroretinogram (ERG) recordings and complete blood counts were obtained. One hundred
fifty-nine ocular surface and 108 needle-washing samples were cytopathologically evaluated. Results: Linear regression: For every additional injection, the ERG amplitude decreased
by 4.6 V (P = 0.0008). Upon treatment completion, there was no significant change in ERG
(P = 0.63). There were no grade 2 hematologic events nor malignant cells in the ocular/
needle-washing samples. Conclusion: Despite no systemic toxicity, weekly melphalan injections can result in a decreased ERG response, suggesting retinal toxicity. The procedure
appears safe, with no malignant cells recovered in the ocular/needle washings.
Scientific Posters
Blood Flow Velocity in Monocular Retinoblastoma
Presenting Author: Maria Teresa B Bonanomi MD

Renal Cell Carcinoma Metastasis to the Eye and Ocular
Adnexa in 27 Patients
Co-Author(s): Osmar Cassio Saito, Patricia Picciarelli MD, Roberta Chizzotti Bonanomi
FEBO**
Presenting Author: Sanket U Shah MD
Purpose: To compare velocity in central artery (vCRA )and vein (vCRV) between normal
and tumor eyes, correlate them with tumor diameter and volume (TUvol), and evaluate
influence on flow of clinical and high-risk features, including invasion of optic nerve (ONi),
prelaminar (PreONi), postlaminar, surgical margin, anterior uvea, choroid, sclera, and extrascleral space. Methods: Enucleated retinoblastoma, magnetic resonance imaging, and
ultrasonography with color Doppler 16 MHz assessing vCRA, vCRV, resistive index in central
artery, pulse index (PI) in central vein, and HE pathology. Results: Eighteen cases. In terms
of significant findings, vCRA and vCRV were higher in tumor eyes than in normal eyes (P <
0.001 for both). A larger TUvol is associated with a higher vCRA (P = 0.03). Boys had lower PI
than girls (P = 0.02). Lower PI is related to ONi and PreONi (P = 0.008 for both). Conclusion:
Retinoblastoma eyes have faster flow. Lower PI is related to ONi.
Purpose: To describe features and management of ocular metastases from renal cell
carcinoma (RCC). Methods: Retrospective study. Results: RCC diagnosis preceded metastasis in 95% by 41 months. Of 56 tumors, most were unilateral (89%) and in males
(81%). Involvement was intraocular (75% choroidal, 5% ciliochoroidal, 4% iridociliochoroidal, and 4% iris) or extraocular (7% orbit and 5% eyelid). Uveal metastases were orange,
4-mm thick, and echodense. Brachytherapy (25%), teletherapy (22%), intravitreal anti-VEGF
(19%), or systemic chemotherapy (16%) achieved tumor control in 56%. Final visual acuity
was <20/200 in 30%, and mortality was 50% at 11 months. Conclusion: Current therapies
achieve fair local control, but poor visual and systemic outcomes.

Uveal Melanoma: A SEER Review of 7043 Cases
Presenting Author: Michael T Andreoli MD
Co-Author(s): William F Mieler MD*, Yannek I Leiderman MD PhD
Purpose: This study aims to evaluate the epidemiology of uveal melanoma since 1973 by
utilizing the Surveillance, Epidemiology, and End Results (SEER) Program registry. Methods: A total of 7,043 uveal melanoma cases were analyzed. Results: Patient age at diagnosis has increased over the last 37 years. The proportion of tumors demonstrating spindle
cell histology has decreased over the last four decades. The median age at diagnosis of
spindle cell tumors (60 years) was significantly younger than epithelioid tumors (65 years)
and mixed tumors (64 years old; P < 0.0001). The prevalence of cutaneous melanoma was
increased in uveal melanoma patients, but the lifetime prevalence of other primary cancers
was not appreciably increased. Conclusion: These findings have implications for disease
surveillance and prognostic counseling.

SOE Iodine-125 Plaque Radiotherapy for Choroidal
Melanoma Touching the Optic Disc in 83 Consecutive Cases
Presenting Author: Pauline Zoppe MD
Co-Author(s): Patrick V De Potter MD PhD, Laurette Renard MD**, Francoise Marie
Vanneste MS**, Jean-Francois Baurain MD PhD

Peripapillary Uveal Melanoma Treated With I-125 Notched
Episcleral Plaque: Impact of Dose on Disease Control and
Complications
Presenting Author: Prithvi Mruthyunjaya MD*
Co-Author(s): Bradford Alan Perez MD, Pradeep S Mettu MD, Lejla Vajzovic MD, David
G Kirsch MD PhD
Purpose: Peripapillary uveal melanoma (UM) is typically treated by episcleral plaque therapy with 85 Gy delivered to the tumor apex, inducing significant tissue toxicity. Methods:
Forty-three peripapillary UMs were treated with notched plaques. Variable doses to apex
were delivered (interquartile range, 7296 Gy). Disease control and complications were
reviewed. Median follow-up was 4.1 years. Results: Local tumor control (90%) was not
associated with higher apex dose (P = 0.78). Retinopathy and optic neuropathy were associated with higher apex dose (P = 0.03 and P = 0.05, respectively). Visual acuity worse
than 20/200 was associated with higher radiation dose to 5 mm (P < 0.01). Conclusion:
Strategies to safely reduce radiation dosing used to treat peripapillary UM are effective and
may prevent severe complications and vision loss.
Ophthalmic History
SOE Edward Nettleship (18451913): An Important British
Ophthalmologist in 100 Years After His Death?
Presenting Author: Andrzej Grzybowski MD*
Purpose: To analyze the life and work of Edward Nettleship 100 years after his death.
Methods: The analysis of all available biographical materials and original articles by Netteleship. Results: Nettleship traced hundreds of congenital stationary night blindness
cases and prepared with Pearson and Usher the major early monography on albinism in
man. The details of his life and work of will be presented and discussed. Conclusion:
Edward Nettleship, an important contributor both to ophthalmology and to dermatology,
was a pioneer in genetic ophthalmology.

Modern Context and Significance of Adie Syndrome and Its
Pupil
Presenting Author: Aazim A Siddiqui
Co-Author(s): Jonathan C Clarke MBBS**, Andrzej Grzybowski MD*
Purpose: William John Adie was an Australian neuro-ophthalmologist in the early 20th
century who provided extensive descriptions of a syndrome and pupillary finding that now
bear his name. This report provides the modern context, observations, and significance
of Adie syndrome and associated tonic pupil. Methods: These findings are based on a
comprehensive literature review of Adies original publications and subsequent conclusions
and cases reported by other experts in the field. Results:Newly reported cases confirm
the original epidemiologic conclusions of Adie syndrome. These cases also suggest its association with a number of comorbidities but confirm its benign nature. Conclusion: The
modern significance of Adie syndrome lies in differentiating its pupillary finding from the
Argyll Robertson pupil of syphilis.

H Sleep and Myopia in Korean Adolescents
Presenting Author: Shin Hae Park MD
Co-Author(s): Hae-ri Yum MD, Yong-Gyu Park
Purpose: To investigate the relationship between sleep duration and refractive status in
Korean adolescents. Methods: This study was based on data from the National Health and
Nutrition Examination Surveys (KNHANES) IV and V. Results: A total of 1749 Korean adolescents aged 13 to 18 years who had completed the Health Examination Survey and underwent ophthalmological examinations were included. The SE refractive error correlated
significantly with the sleep duration (r = 0.044, P < .0001). As sleep duration decreased, the
risks of myopia < -0.5, - 3.0, and - 6.0 D increased significantly (P for trend 0.0421, .0005,
and .0065, respectively). Conclusion: This population-based study of 13- to 18-year-old
Korean adolescents showed that subjects with shorter sleep durations were more likely
to be myopic.
203
Scientific Posters
Purpose: To evaluate ocular and systemic outcomes after Iodine-125 plaque radiotherapy
(IPR) for choroidal melanoma touching the optic disc. Methods: A clinical case series of 83
patients. Results: Adjuvant transpupillary thermotherapy was used in 77% of eyes. After a
mean follow-up of 46 months and a mean radiation dose to the tumor apex of 80 Gy, local
recurrence was documented in 1% and metastasis in 8% of patients. The most significant
risk factor for neovascular glaucoma (NVG; 17% of eyes) and late enucleation (7%) was the
percentage of disc surface covered by the tumor. Kaplan-Meier estimates at five years were
25% for NVG, 8% for enucleation, and 17% for metastasis. Conclusion: IPR provides a
reasonable chance of globe salvation at five years, despite the risk of NVG.
Co-Author(s): Emil Anthony T Say MD, Chandana Das MA MD, Carol L Shields MD
Scientific Posters
Early Pathologic Myopia Changes in Young Male Singapore
Adults With High Myopia
Presenting Author: Seang-Mei Saw MBBS PhD
Co-Author(s): Victor Koh MBBS, Colin S Tan MBBS*, Tien Yin Wong MBBS*, Gerard
Kwang Ming Nah MD, Ching-Yu Cheng MD**, Paul S Zhao MBBS
Purpose: To determine the early pathologic myopia changes in young male Singaporean
adults with high myopia. Methods: Fundus photography and cycloplegic refraction were
performed in 610 (85% response rate) randomly selected males with spherical equivalent
(SE) more than -6.0 D. A trained optometrist graded myopia-related disc and macular lesions. Results: The average age was 21.1 years and mean SE was -8.21. The main optic
disc findings were peripapillary atrophy (PPA) (97.3%) and optic disc tilt (27.5%). The most
common macular findings were posterior staphyloma (43.8%), chorioretinal atrophy (8.4%),
and lacquer cracks (1.0%). Conclusion: The documentation of early signs of pathologic
myopia, including PPA and tilted discs, will facilitate the screening, detection, and treatment of visually disabling lesions in later life.

Prevalence of Uncorrected Refractive Errors, Presbyopia,
and Spectacle Coverage by Using Novel Rapid Assessment
of Visual Impairment Survey Method in Western India
Presenting Author: Rohankumar A Chariwala MBBS
Scientific Posters
Co-Author(s): Uday R Gajiwala MBBS, Chintan V Dholakia DO
of young controls with no significant difference. Gains were generalized to higher functions,
such as reading. Conclusion: Our training is effective for overcoming the blurred vision in
presbyopic pilots, with real operational benefits.

H Prosthetic Replacement of the Ocular Surface
Ecosystem in Stevens-Johnson Syndrome
Presenting Author: Geeta K Vemuganti MD
Co-Author(s): Varsha M Rathi DO, Somasheila I Murthy MD
Purpose: To study the role of scleral contact lens (prosthetic replacement of the ocular
surface ecosystem [PROSE]) in Stevens-Johnson Syndrome (SJS). Methods: Two hundred
seven patients (350 eyes) with SJS who received PROSE were studied retrospectively; the
primary goal was improved comfort with a secondary goal of improving vision. Results:
116 F, 91 F , Mean age, 28.86 years. Thirty-eight patients, <16 years. Average daily lens
wear, nine hours. The complications noted were infectious keratitis, infiltrative keratitis,
red eyes, and lens breakage. The comfort improved in all patients. Visual acuity improved
in >50% of patients by two lines. Conclusion: Scleral lens helped improve comfort and
vision in SJS patients.

Contact Lenses for Extreme Ectasia: A Comparative Analysis
Presenting Author: Jatin Naresh Ashar MD
Co-Author(s): Anurag Mathur MS
Purpose: To estimate prevalence of uncorrected refractive errors (UREs) and presbyopia

among people 40 years in western India. Methods: A cross-sectional population-based
survey was conducted using 26 randomly selected clusters, each having 60 people selected
by probability proportional to size of sampling. Results: A total 1487 people were examined out of 1560 enumerated (response rate: 95.3%). Prevalence of UREs and presbyopia
were 17.2% (95% CI, 15.1-19.4) and 51.8% (95% CI, 48.8-54.7), respectively. Spectacle
coverage was 38% for UREs and 39% for presbyopia. Use of spectacles was twice as
common in urban area as in rural areas (P -value .000). Conclusion: This baseline data is
the first of its kind in the whole of western India and will be useful in planning refractive
services, as the burden of UREs and presbyopia is significant in the area.
Purpose: To evaluate various contact lenses (CLs): Rose K XL, hybrid CL (H CL), semiscleral
15.2 mm, scleral (S CL) 18.2 mm, Jupiter, Europa universal fit (E CL) 16 mm for extreme
ectasia, mean K > 60 D. Methods: Twenty-four cases of extreme ectasia were fitted with
various CLs. CL fit, visual acuity (VA), comfort, and chair time in 10 keratoconus (KCN),
six pellucid marginal degeneration, four post-LASIK, and four post-radial keratotomy (RK)
cases were analyzed. Results: VA improved to mean 0.9 in all. H CL, Rose K XL, and E CL
fitted equally well in KCN. Peripheral design modification was done in post-LASIK and RK in
Rose K XL, thus needing multiple trials. Reverse geometry S CL and E CL required minimal
design modification. Comfort was maximum with E CL and H CL. Subjective visual improvement was maximum with H CL. Conclusion: CLs are a good option in extreme ectasia and
can avoid need for keratoplasty.

SOE Significantly Aberrated Ocular Condition: Elevated
Higher-Order Aberrations in Patients With Visual Symptoms
in Native Eyes

Contact Lenses in Patients With Boston Keratoprosthesis
Type 1 Implants: Do They Play a Role in Surface
Inflammation?
Presenting Author: Jens Buehren MD
Presenting Author: Sarmad H Jassim MBChB
Co-Author(s): Oliver Klaus Klaproth*, Thomas Kohnen MD*
Co-Author(s): Joshua H Hou MD, Ellen Shorter OD, Maria S Cortina MD
Purpose: To compare higher-order aberrations (HOA) of eyes with visual complaints such
as monocular diplopia to those of a young, normal population. Method: Total, corneal, and
internal aberrations from 44 native symptomatic eyes (30 patients; mean age: 48 11 a )
and 50 asymptomatic control eyes (50 subjects; mean age: 27 4 a) were compared. Results: Symptomatic eyes exhibited significantly higher total coma (0.502 0.291 vs. 0.287
0.122 m, P < .001), spherical aberration (0.301 vs. 0.184 m, P < .001) and residual HOA
RMS (0.497 0.329 vs. 0.088 0.074 m, P < .001); also internal HOAs were elevated significantly. Conclusion:Patients who complained about visual symptoms had significantly
elevated HOA and a lower retinal image quality compared to a control group.
Purpose: To investigate the inflammatory role of biofilm found on contact lenses (CLs)
of patients with Boston type 1 (KPro). Methods: CLs (Kontour, Air Optix, or Hybrid) were
collected from 10 KPro patients and processed for immunofluorescence (IF) or electron microscopy (EM) for the detection of biofilm components. IF for neutrophil elastase (NE) and
cathelicidin (Cath) was performed. 4,6-diamidino-2-phenylindole was used to identify nuclei. Results: Two of two CL analyzed by EM showed bacteria growing in biofilm structures.
Eight of eight CLs revealed some degree of cellular components. IF showed the presence
of neutrophils with neutrophil extracellular traps stained with NE and Cath. Conclusion:
Biofilm formation on the surface of CLs in patients with KPro may induce sustained surface
inflammatory activity that could contribute to complications and corneal melt.

SOE Vision Improvement in Pilots With Presbyopia
Following Perceptual Learning
Presenting Author: Anna Sterkin PhD*
Co-Author(s): Oren Yehezkel PhD*, Maria Lev MS**, Ravid Doron**, Yuval Levy MD
MHA**, Liora Levian II MHA**, Russell Pokroy MD**, Barak Gordon MD MHA, Uri
Polat PhD*, Tova Ma-Naim MD
Purpose: Israeli Air Force pilots continue flying combat missions after the onset age of
presbyopia. Optical corrections limit their flying capabilities. Here, we aimed to improve pilots near visual acuity (VA) using our proven, effective perceptual learning method. Methods: Forty presbyopic pilots were trained (GlassesOff mobile app, Gabor stimuli, three per
week, 15-minute sessions, two to four months). Results: Despite their advantage of 0.26
logMAR (P = 0.001) in VA for brief presentations (120 or 60 ms) compared with 152 agematched controls, pilots improved after training (P = 0.01), most of them reaching the level
204

Should We Perform Levator Resection in Congenital Ptosis
Patients With Poor Levator Function?
Presenting Author: Adit Gupta Jr MBBS
Co-Author(s): Akshay Gopinathan Nair MD, Swathi Kaliki MD, Milind N Naik MBBS,
Mohammad J Ali MBBS MS, Tarjani V Dave MBBS**
Purpose: To report the outcome of levator resection in patients with severe congenital
ptosis. Methods: Single-surgeon, retrospective, interventional case series. Records of patients with severe congenital ptosis (levator palpebrae superioris [LPS] action < 5 mm) were
reviewed. Outcome of the correction was evaluated by objective grading by 2 surgeons us-
Scientific Posters
ing photographs. Results: Twenty-five patients with a mean age of 16.92 years and mean
follow-up duration of 7.2 months. The mean LPS action was 3.84 mm. Functional success
was noted in 21 eyes. Objective grading of the correction reported 11 cases with perfect
symmetry, 10 with mild-moderate undercorrection, and 4 with no benefit. Complications
were noted in 7, which included exposure keratopathy in 4, microbial keratitis in 1, and
contour abnormality in 3. Conclusion: Levator resection is a good alternative in severe
congenital ptosis.

Endonasal Endoscopy-Assisted Lacrimal System Intubation
Presenting Author: Jia-xu Hong MD
Co-Author(s): Jian-jiang Xu MD**
Purpose: To investigate the usefulness and safety of endonasal endoscopy (EES) in aiding
the intubation for lacrimal duct obstruction. Methods: The surgery was performed in 378
eyes of 346 patients. Patients decided to receive or not receive the help of EES for the
intubation. Intraoperative complication, surgery time, and patients pain scores were assessed. Results: With EES, the intubation was performed successfully in all 206 patients
(221 eyes). However, the success rate was only 93% (146/157 eyes) without EES. The nasal
mucosal bleeding rate and the pain scores were higher without the EES. The EES group
took less surgery time. Conclusion: EES proved to be easy to perform, time saving, less
invasive, and better tolerated for lacrimal system intubation.

The Effectiveness of Topical Steroid Instillation in Patients
With Recently Developed Nasolacrimal Drainage Stenosis
Presenting Author: YongDae Kim
Co-Author(s): Namju Kim MD, Ho Kyung Choung MD**, Sang In Khwarg MD
and 95.8%. There was a significant difference in operation duration; C was shortest, then
A, then B. There was no difference in success rate. Conclusion: The double encirclage
technique has many advantages, such as saving time, ease of communication, keeping
canaliculus widely, resistance to avulsion force, and lower possibility of narrowing after
tube removal.

Plasma Surface Modification of Porous Polyethylene
Implants in Orbital Reconstruction
Presenting Author: Seong-Won Yang MD PhD
Co-Author(s): Saemi Park MD
Purpose: To investigate the preosteoblast adhesion and osseointegration on hydrophobic
porous polyethylene (PE). Methods: Surface modified PE was prepared by oxygen or nitrogen plasma. After plasma treatment, adhesion and differentiation of MC3T3-E1 cells were
evaluated using a MTT assay and alkaline phosphatase (ALP) activity, respectively. A total
of 6 white rabbits orbital (medial, inferior, and maxilla) bones were exposed. After that,
the pretreated implant was inserted. Micro-CT and immunostaining were performed before
exposure and at 4 and 8 weeks. Results: In vivo, plasma-treated samples demonstrated a
better bone formation than the control. Conclusion: Plasma-treated porous PE can be used
as a useful material for orbital fracture.

Periocular Changes Associated With Topical Bimatoprost in
the Rabbit
Presenting Author: Tiffany L Kent MD
Co-Author(s): Philip L Custer MD*
Purpose: To evaluate the effectiveness of steroid eye drops in patients with recently developed nasolacrimal drainage stenosis. Methods: The medical records of 108 eyes of 56
patients who recently (within 3 months) developed epiphora and received topical steroid
eye drops were reviewed. Changes in epiphora were assessed, and tear meniscus heights
and fluorescein dye disappearance tests were evaluated at 1, 3, and 6 months. Results:
Epiphora had improved in 45 patients (42.0%) at 1 month and in 55 patients (51.0 %) at 3
months after treatment, and mean time to symptom improvement was 3.8 1.9 weeks.
Fifty-six eyes (51.9 %) of 108 eyes had improved at last follow-up visit. Conclusion: Instillation of topical steroids should be considered in patients who got recent-onset epiphora.
Purpose: To determine the anatomic effects of topical prostaglandin analogs on the eyelids of New Zealand white rabbits. Methods: Animals were divided among 3 groups: untreated controls, 0.03% bimatoprost (PGA), and artificial tears (AT). Eyelid measurements
were obtained at baseline and after 3 months of treatment. Results: Measurements from
controls, Ats-treated lids, and PGA-treated lids, respectively, were as follows: (1) canthuscanthus: 21.5 0.58, 20.25 1.26, and 19.0 0.87; (2) lower lid distraction: 8.125 0.63,
8.75 0.5, and 6.11 0.60; (3) upper lid distraction: 11.25 0.5, 10.0 0.82, and 7.78
1.20. Conclusion: Daily topical PG drops resulted in horizontal shortening of the eyelids
and acquired blepharophimosis in rabbits. This finding is similar to what is observed in
human patients.

Crawford Tube Dislocation Following Endoscopic
Dacryocystorhinostomy: A Retrospective Comparison of 3
Securing Techniques

Slitlamp Laser for Removal of Small Eyelid Nonmelanoma
Skin Cancers
Presenting Author: Mazeyar Saboori MD
Co-Author(s): Victoria Michelle Rice
Purpose: To compare the rate of Crawford tube prolapse in patients who underwent endoscopic dacryocystorhinostomy (DCR) using 3 different techniques for securing the tubes in
the nose. Methods: Retrospective review of patients who underwent primary endoscopic
DCR. All patients underwent surgery by 1 of 3 surgeons who used a similar technique
except for their method for securing the Crawford tubes: (1) tying a knot and securing to the
lateral wall with 6-0 vicryl, (2) using a red rubber catheter at the end of the tube, or (3) tying
the tubes in a square knot. Results: Dislocation rates for the 3 groups were as follows: (1)
7% (n = 57), (2) 11.5% (n = 61), (3) 17.8% (n = 45) P = .243. Conclusion: While there was
a higher rate of tube prolapse in Group 3 than in the other groups, this difference was not
statistically significant.

Comparing the New Bicanalicular Double Silicone
Encirclage and Thick Bicanalicular Mono Silicone
Encirclage in Canalicular Laceration
Presenting Author: Seong-Won Yang MD PhD
Co-Author(s): Saemi Park MD
Purpose: To compare the double silicone encirclage with the thick mono silicone encirclage in canalicular laceration. Methods: Forty-eight patients were reviewed. Twelve were
treated with a mono silicone encirclage (A, diameter = 0.6 mm), 12 with a thick mono
silicone encirclage (B, diameter = 0.9 mm), and 24 with a double encirclage (C, diameter
= 0.6 mm). The outcome was analyzed according to the operation methods, types of tube,
and number of suture knots. Results: The success rates of A, B, and C were 91.6%, 91.6%,
Purpose: To determine the success of an office-based slitlamp 532-nm diode laser for
removal of small eyelid margin nonmelanoma skin cancers that are typically removed in
an outpatient setting. Methods: Twenty-five malignant eyelid lesions along the lid margin
or lash line underwent biopsy and slitlamp laser ablation over a 6-year period. Results:
There was a success rate of 88% (22 of 25 lesions) with a follow-up period ranging from
12 to 71 months (median: 31 months). The 3 recurrences were detected at 9, 12, and 44
months following initial treatment. Conclusion: The slitlamp diode laser is a cost-effective
method for removal of small eyelid nonmelanoma skin cancers. The nearly 90% success
rate supports further research into this minimally invasive and less expensive office-based
treatment.

Hemifacial Spasms: Epidemiological Aspects and
Management Outcome Over a Decade
Presenting Author: Ankita Nema MBBS MS
Co-Author(s): Aditi Pujari, Swathi Kaliki MD, Mohammad J Ali MBBS MS, Milind N
Naik MBBS, Akshay Gopinathan Nair MD
Purpose: To describe the epidemiologic profile and management outcomes of hemifacial
spasm (HFS). Methods: Clinicoepidemiologic profile and management outcomes with
botulinum toxin injection of patients diagnosed with HFS and treated at the Department of
Ophthalmic Plastic Surgery, LV Prasad Eye Institute, Hyderabad, India, between 2003 and
2013 were reviewed. Results: Among the 198 patients studied, mean age at presentation
was 49.7 years. 482 injections with average dose of 18.5U were given, with the effect lasting for 4.6 months with a follow-up of 17.6 months. Side-effects noted were lagophthalmos
and ptosis. Conclusion: HFS patients usually present in the fifth decade. With an average
dose of 18U, control was observed for 4.6 months.
205
Scientific Posters
Co-Author(s): Ryan T Scruggs MD, Evan H Black MD, Geoffrey J Gladstone MD**,
Francesca D Nesi MD, Frank A Nesi MD**
Presenting Author: Charles D Rice MD
Scientific Posters
Sutureless Blepharoptosis Repair
Presenting Author: Christian Swinney

SOE Occurrence and Severity of Upper Eyelid Skin
Contracture in Facial Paralysis
Co-Author(s): Ming Chen MD, Douglas P Dworak MD, Thomas D Patrianakos DO
Presenting Author: Kimia Ziahosseini MD
Purpose: To describe the efficacy and safety of the sutureless Fasanella-Servat operation.
Methods: A sutureless variation of the Fasanella-Servat operation was performed by a
single surgeon at a single surgical location. Results: Of the 61 eyes included in this study,
good lid position was obtained in 58 eyes (95.1%). The remaining 3 eyes showed improvement of lid position but not to the desired extent. No major complications were observed.
Conclusion: The sutureless Fasanella-Servat procedure can be used to effectively treat
mild blepharoptosis. The extended follow-up of this study supports this procedures longterm efficacy. The lack of complications suggests that this operation is a safer alternative
to the traditional Fasanella-Servat operation.
Co-Author(s): Vanessa Venables**, Charles Nduka**, Raman Malhotra MBChB

FRCOphth

Dynamic Analysis of Mllers Muscle Response to
Phenylephrine
Presenting Author: Sathyadeepak Ramesh MD
Co-Author(s): Ronald Mancini MD
Purpose: To characterize the in vivo response of the Mllers muscle to phenylephrine
regarding time response and diurnal variation. Methods: A nonrandomized trial of healthy
adults (n = 20, 40 eyes) measured for response of margin reflex distance-1 (MRD-1) to
topical phenylephrine in the morning (6-9 a.m.) and evening (6-9 p.m.). Mean MRD-1 was
plotted over time, and morning and evening MRD-1 were compared with paired t test. Results: Ninety percent of subjects had maximal response to phenylephrine within 1 minute.
There was no difference between morning and evening response. Conclusion: Maximal
response to phenylephrine occurs within 1 minute of instillation; there was no diurnal variation with the phenylephrine test.

Methicillin-Resistant Staphylococcus Aureus Infection as
a Cause of Chronic Socket Discharge and Orbital Implant
Exposure
Presenting Author: Imtiaz Chaudhry MD PhD
Scientific Posters
Co-Author(s): Yonca O Arat MD**, Ayman Al-Ayoubi MD**, Milton Boniuk MD**
Purpose: To report methicillin-resistant Staphylococcus Aureus (MRSA) infection as the
cause of anophthalmic socket complications. Methods: A noncomparative, interventional,
retrospective case series of 40 patients with MRSA-caused socket infection studied over
a 4.5-year period for their complications. Results: Among the 40 patients (25 male; average age: 45.4 years), all had chronic discharge from their sockets, and despite therapy,
27 showed evidence of orbital implant exposures or extrusions. Presence of MRSA was
confirmed by culture results. All patients required treatment with antibiotics, and 25 required surgical intervention in the form of implant removal, exchange, or dermis fat graft.
Conclusion: MRSA infection should be considered in patients with chronic discharge and
exposed / extruded orbital implants.

Eyelid Complications due to Trachoma in Patients
Presenting to a Tertiary Care Center
Presenting Author: Imtiaz Chaudhry MD PhD
Co-Author(s): Waleed A Al Rashed MBBS**, Osama ALSheikh, Yonca O Arat MD**,
Ayman Al-Ayoubi MD**, Farrukh A Shamsi PhD, Milton Boniuk MD**
Purpose: To report eyelid complications due to trachoma in patients presenting to a tertiary care center (TCC). Methods: A retrospective clinical study of eyelid complications
due to trachoma was conducted in patients presenting to an eye clinic of a TCC over a
2-year period to document types of abnormalities. Results: There were 156 patients (108
females) with average age of 64.3 years (range: 11 to 95 years), all had clinical evidence
of old trachomatous scarring. Evidence of entropion / trichiasis was found in 82 patients
(52.6%), eyelid retraction in 24 patients (15.4%), and eyelid ptosis in 7 patients (4.5%).
Eyelid complications of trachoma were more severe in female patients who presented at
early age than in male patients. Conclusion: Eyelid complications are common in patients
with trachoma presenting to an eye clinic of a TCC.
206
Purpose: To quantify upper eyelid skin contracture in patients with facial paralysis (FP).
Methods: We developed a standardized technique to measure the distance between the
upper eyelid margin and the lower border of brow (LMBD). We prospectively compared
the LMBD on both sides in patients with unilateral FP and without previous eyelid surgery.
Results: Thirty-six patients (mean age: 50.3) with a mean FP duration of 65 months were
identified. Sixty-four percent showed shorter LMBD compared to the normal side. The mean
LMBD on the paralytic side was significantly smaller than on the contralateral side; 30.4
mm (95% CI, 29.2-31.8) vs. 32.6 mm (95% CI, 31.2-34.0), P = .02. Five patients showed
contracture of 5 mm or more. Conclusion: This is the first study that quantifies shortening
of LMBD in FP. This reinforces the principle of avoiding skin excision in FP.

SOE Combined Nasolabial and Glabellar Flaps for
Reconstruction of Large Medial Canthal Defects: Ten Years
Experience
Presenting Author: Joyce N Mbekeani MBBS
Co-Author(s): Frederic Chiambaretta MD**, Selwa A F Al-Hazzaa MD FRCS, Hachemi
Nezzar MD
Purpose: To report the results of combined nasolabial and glabellar flaps for reconstruction
of large medial canthal defects following excision of basal and squamous cell carcinoma.
Methods: Retrospective, observational study of 416 patients over 10 years. Mohs micrographic surgery and nasolabial and glabella flaps were rotated to defects greater than 2
cm. Flaps were anchored to canthal ligaments. Success was defined as no necrosis, functional and cosmetic canthal position, and no recurrence. Results: Mean follow-up was 23
months. The first month, 30% experienced flap edema; 10%, ecchymosis; 3.5%, recurrence.
Flap necrosis, ectropion, or lagophthalmos have not been observed, and canthal positions
are anatomically stable. Conclusion: Combined glabella-nasolabial V-Y flap technique results in good lid position, function, and cosmesis.

Surgical Outcomes of Deep Superior Sulcus Augmentation
Using Acellular Human Dermal Matrix in Asian
Anophthalmic or Phthisis Socket
Presenting Author: Won Kyung Cho MD PhD
Co-Author(s): Hae-ri Yum MD, Won-Mo Lee MD**
Purpose: To evaluate surgical outcomes of deep superior sulcus (DSS) using acellular dermal matrix in Asian patients with anophthalmos. Methods: We retrospectively reviewed
medical records and focused on 3 aspects: the possibility of wearing contact prosthesis,
correction degree, and complications. The correction degree was classified as excellent
(removal of sunken sulcus shadow), fair (shadow remained), or fail (no effect). Results: Ten
eyes of 10 Korean patients could wear contact prosthesis. Correction degree was excellent
in 8 patients and fair in 2. Three of 10 showed complications: entropion, multiple creases,
and spontaneous wound dehiscence followed by inflammation. Conclusion: The overall
surgical outcomes were favorable, showing an excellent degree of correction of DSS and
low surgical complication rates.

Radiological Assessment of the Variation of the Angle of the
Orbital Strut Between Right and Left Orbits Using CT Scans
Presenting Author: Raghuraj S Hegde MBBS
Co-Author(s): Gangadhara J K Sundar MBBS
Purpose: To describe and compare the angle of the orbital strut (AOS) between right and
left orbits using CT scans. Methods: Retrospective review of 50 consecutive CT scan orbits
(max. 3-mm cuts) with intact bilateral orbits measuring angle between orbital floor and
medial wall. AIOS were measured at 3 standard locations: (1) RimRim AOS (RAOS), (2)
9 mm behind the RAOS; Middle AOS (MAOS), (3) 18 mm behind the RAOS; Posterior AOS
(PAOS). Statistical analysis (unpaired t test) was done taking race into account. Results:
100 orbits (50 patients) were studied. Analysis showed significant symmetry of AOS at all
the above locations irrespective of race (P > .05). Average AOS: East Asians: 127.6; South
Asians: 126.7; and whites: 127.3. Conclusion: Variations of AOS between the right and
left orbits are small, indicating real-world applications in repair of orbital fractures.
Scientific Posters
Serum IgG4 Level as a Prognostic Factor for Ocular IgG4Related Disease
Presenting Author: Wei-Kuang Yu
Co-Author(s): Chieh-Chih Tsai MD
Purpose: To investigate factors associated with response to systemic steroid in patients
with ocular IgG4-related disease (IgG4-RD). Methods: We suspected a relationship of clinical factors to steroid treatment response and retrospectively reviewed 10 pathologically
confirmed ocular IgG4-RD patients who underwent steroid treatment to analyze possible
factors associated with outcome. Results: Patients with lower serum IgG4 and IgG4-toIgG ratio at diagnosis were associated with poor response to systemic steroid (P = .037).
Conclusion: Results suggest that lower serum IgG4 level at diagnosis may be a factor for
poor response to steroid treatment in ocular IgG4-RD.

Treatment of Lower Eyelid Retraction With Silicon Sheet
Presenting Author: Wei-Kuang Yu
Co-Author(s): Chieh-Chih Tsai MD
Purpose: To report a new technique for correction of lower eyelid retraction using silicon sheet as a posterior lamellar spacer graft. Methods: Seven Graves ophthalmopathy
patients with symptomatic lower eyelid retraction were treated with surgical correction
using silicon sheet (Perthese) as a spacer graft. Results: Mean improvement in margin
reflex distance-2 was 2.0 0.4 mm. After a mean follow-up of 9 months, all achieved
satisfactory functional and cosmetic outcome. They had improvement of ocular symptoms,
with a decreased dependence on topical lubricants. Conclusion: Silicon sheet can offer an
alternate graft for eyelid reconstruction.

SOE H Prevalence of Ocular Hypertension and Glaucoma
in Graves Orbitopathy
Presenting Author: Susanne Pitz MD*
Co-Author(s): Esther M Hoffmann MD**, Norbert Pfeiffer MD*
Purpose: Graves orbitopathy (GO) is postulated to increase IOP via increased orbital pressure / pressure of extraocular muscles on the eyeball, and reduced venous outflow. However, studies investigating the prevalence of glaucoma in Graves orbitopathy yield conflicting
results. Methods: 294 GO patients and 61 healthy subjects underwent IOP measurement,
white-on-white perimetry, funduscopy, and imaging of the optic nerve head. Results: Seven of 217 (3.2%) GO patients were identified to suffer from glaucoma, and 37/217 (17.1%)
from ocular hypertension (OHT). Conclusion: Prevalences of glaucoma and OHT in GO are
higher than previously reported, and higher than known for the average European/white
population.

Co-Author(s): Roghiyeh Shamsoddinimotlagh MD
Purpose: To describe children with post-traumatic subperiosteal orbital hematoma. Methods: A retrospective analysis of 5 cases plus literature review was performed. Results: A
total of 28 cases (82% boys) with a mean age of 10 (4-17) years; 27 patients (96%) had a
history of blunt trauma. Eighty-nine percent were unilaterally involved. Mean time interval
between trauma and presentation was 10 days. Visual acuity was decreased in 63% of
patients, of which 30% had a compressive traumatic optic neuropathy. Seventeen percent
had a nondisplaced orbital roof fracture. Treatment options were surgical evacuation in 13
patients (46%), needle aspiration in 6 patients (21%), and observation in 8 children (28%).
Conclusion: Pediatric post-traumatic orbital subperiosteal hematoma typically occurs in
the superior orbital wall after blunt trauma. Traumatic optic neuropathy is uncommon. Surgical drainage is a safe option.

SOE Management of Dysfunctional Epiphora:
Comparing the Surgical Outcome of Bicanalicular
Silicone Intubation, Transcanalicular Diode Laser-
Presenting Author: Can Ozturker MD

Co-Author(s): Pelin Kaynak Hekimhan MD, Gamze Ozturk Karabulut**, Korhan Fazil,
Serpil Akar MD, Ahmet Demirok MD, Omer Faruk Yilmaz MD**
Purpose: Comparing the outcomes of bicanalicular intubation (BI), transcanalicular diode
laser-assisted dacryocystorhinostomy (TDL-DCR), and external dacryocystorhinostomy (ExtDCR) as the first choice of treatment of dysfunctional epiphora. Methods: Postsurgical
success rates of the three groups were compared retrospectively. Results: Data of 76 eyes
of 72 patients in demographically similar groups were analyzed. Functional success rates
were 62.5% in BI, 66.7% in TDL-DSR, and 82.1% in Ext-DSR groups at 12.9, 18.8, and 18.4
months, respectively (P = 0.035 and P = 0.045). Conclusion: The Ext-DCR group yielded a
higher success rate compared with BI and TDL-DCR groups for the treatment of dysfunctional epiphora. BI may be the first choice of treatment as a minimally invasive procedure
that eliminated the need for DCR in 62.5% of the cases.

A Novel, Stepwise Diagnostic Protocol for the
Differentiation Between Malignant and Benign Lacrimal
Gland Tumors
Presenting Author: Jiang Qian MD
Purpose: To assess the ability of magnetic resonance imaging in differentiating benign
from malignant lacrimal gland tumors. Methods: Eighteen malignant and 24 benign masses were recruited. Apparent diffusion coefficient (ADC) obtained from diffusion-weighted
imaging and time intensity curve (TIC) type obtained from DCE were compared in the two
groups. ADC threshold for differentiation was determined. The dignostic performances of
TIC and of ADC and TIC in concert were compared. Results: ADC threshold for discriminating pleomorphic adenomas from carcinomas was 1.097 x 10-3 mm2/s. After referring to
ADC, the diagnostic sensitivity (77.78%100%) and accuracy (88.1%92.86%) were enhanced significantly (P = 0.0313). Conclusion: The type A with ADC less than 1.097 x 10-3
mm2/s and type C were regarded as malignant, while type A with ADC greater than that
and type D were regarded as benign.

Randomized Controlled Trials in Endoscopic
Dacryocystorhinostomy: A Systematic Review
Presenting Author: Marcus M Marcet MD
Co-Author(s): Andrew Kin Ting Kuk BSB MBBS MRCS, Paul O Phelps MD, Ebby Elahi
MD FACS, Dinesh Selva MBBS
Purpose: To systematically review all randomized controlled trials (RCTs) for endoscopic
dacryocystorhinostomy (e-DCR). Methods: PubMed database Boolean search on April 7,
2014, without age, date, or language limits of endonasal OR endoscopic AND dacryocystorhinostomy, which yielded 767 studies. Of 25 RCTs, seven were excluded (five, unrelated
topic; one, no abstract; and one, duplicate study). Eighteen articles met inclusion criteria
and were analyzed. Results: The 18 RCTs reported on antimetabolite use (6), stents (4),
lasers (3), and other techniques (5). Conclusion: Antimetabolites reduce scarring but do
not improve outcomes, except possibly in revision e-DCR. Use of silicone stents is not associated with improved outcomes and may lower surgical success. There is limited evidence
laser is beneficial.

Management of Failed External, Transcanalicular Laser, and
Endonasal Dacryocystorhinostomy
Presenting Author: Sabita Katoch MBBS MD
Purpose: To evaluate outcomes after repeat dacryocystorhinostomy (DCR) following failed
lacrimal surgery. Methods: Repeat external DCR done in 131 cases (Group A) and repeat
transcanalicular diode laser (TCL) DCR done in 42 cases (Group B). Follow-up ranged from
four to 36 months. Results: In Group A, success rates were 64.6% (primary surgery external), 86.2% (primary TCL), and 100% (primary endonasal). In Group B, success rate was
70.73%. Repeat external DCR had prolonged surgical time and many minor complications.
Conclusion: TCL DCR may be a good alternative to the external approach in failed external
DCR. The external route is as good as the primary surgery post TCL and endonasal DCR, as
these approaches interfere least with the anatomy.
207
Scientific Posters

Posttraumatic Orbital Subperiosteal Hematoma in Children
Assisted Dacryocystorhinostomy, and External

Dacryocystorhinostomy
Scientific Posters
Extreme Eyelid Lymphedema Associated With Rosacea
(Morbihan Disease): Case Series, Literature Review, and
Therapeutic Considerations

Changes in Spontaneous Blinks After Blepharoptosis Repair
and Blepharoplasty
Presenting Author: Bryant P Carruth MD

Co-Author(s): Dale R Meyer MD FACS, Edward Wladis MD*, Elizabeth A Bradley MD,
Rami N Al-Rohil MBBS, David Michael Jones**, George B Bartley MD
Co-Author(s): Takayuki Hattori MD**, Norihiko Yokoi MD PhD**, Yukito Yamanaka,

Hideki Fukuoka, Noriko Koizumi MD**, Kazutaka Suzuki*, Haruyoshi Toyoda PhD*,
Shigeru Kinoshita MD*
Purpose: To describe Morbihan disease, an infrequently reported and poorly understood

entity consisting of solid midfacial and eyelid lymphedema and rosacea. Methods: Chart
review, pathologic and immunohistochemical analysis, and literature review. Results:
Histopathologic examination of five cases revealed pleomorphic perivascular/lymphatic
inflammation with lymphangiectasis, suggesting elements of both rosacea and localized
lymphedema. Therapeutic interventions included antiinflammatory therapy, surgical debulking, and corticosteroid injection. Conclusion: Extreme eyelid edema associated with characteristic skin changes and histopathologic findings represents Morbihan disease, which is
rare and difficult to treat. Multiple modalities have been employed, and future therapeutic
considerations may include targeted biologic agents.
Purpose: To assess spontaneous blinks post blepharoptosis repair and blepharoplasty

(BLEPH). Methods : Eighty-two eyelids of 50 blepharoptosis cases (mean age, 63.8 years)
underwent blepharoptosis repair, and 18 eyelids of 10 dermatochalasis cases (mean age,
71.5 years) underwent BLEPH. Spontaneous blinks were measured prior to surgery and 1.5,
three, and six months after surgery by an intelligent vision system camera prototype. Results: Mean blepharoptosis group blink up-phase maximum velocity (mm/sec), up/downphase depth, and down-phase duration were statistically greater at all follow-up points,
yet in the BLEPH group, only the mean down-phase blink duration was significantly greater.
Conclusion: Spontaneous blinks are longer and faster after blepharoptosis repair, yet only
slightly change after BLEPH.

Comparison of Orbital Anatomy in Korean and White
Subjects by Computed Tomography

The Effect of Upper Lid Blepharoplasty on Visual Quality in
Patients With Lash Ptosis and Dermatochalasis
Presenting Author: Hee Bae Ahn MD PhD
Presenting Author: An Seounghyun
Co-Author(s): HyunChul Jeong, Jongsoo Kim MD
Co-Author(s): Jongsoo Kim MD, Hee Bae Ahn MD PhD
Purpose: To analyze and compare the anatomy of orbits in Korean and Caucasian subjects
using computed tomographic measurements. Methods: A retrospective analysis of 44 CT
scans of subjects (22 Korean and 20 Caucasian) with no appreciable orbital disease was
performed by two observers. Ten length and three angle measurements of the orbit were
obtained. Results: Anterior medial interorbital length was 24.05 mm in Korean subjects
and 21.85 mm in Caucasian subjects. Anterior vertical orbital length was 34.19 mm in Korean subjects and 34.99 mm in Caucasian subjects. Interorbital angle was 47.7 in Korean
subjects and 45.9 in Caucasian subjects. Significant differences were found in those measurements mentioned above. Conclusion: Compared with Caucasian subjects, the Korean
orbit shows narrower orbital opening and longer interorbital distance.
Purpose: To assess the effect of upper lid blepharoplasty surgery on visual quality. Methods: Seventy-three eyes of 39 patients underwent upper lid blepharoplasty surgery. Preand postoperative contrast sensitivity, visual acuity, vertical palpebral fissure, and degree
of lash ptosis were measured. Results: The mean log contrast sensitivity in photopic (P =
0.017) and mesopic conditions (P = 0.009) was improved after surgery and statistically significant. The degree of lash ptosis also decreased after blepharoplasty (P < 0.001). Conclusion: In our study, significant contrast sensitivity increase was found after surgery. These
results suggest that upper lid blepharoplasty can be helpful to improve visual quality.

Imaging Analysis of Pleomorphic Adenoma of Lacrimal
Gland
Presenting Author: Hyun Jin Shin MD
Scientific Posters
Co-Author(s): Kyung In Woo MD, Yoon-Duck Kim MD

Purpose: To analyze the imaging characteristics of primary lacrimal gland pleomorphic
adenoma (LGPA). Methods: We reviewed computed tomography and magnetic resonance
imaging findings of 41 patients who were histologically diagnosed with primary LGPA.
Results: Most LGPAs showed typical radiologic findings with well-defined margins. Calcification (9.8%), orbital roof defect (9.8%), hemorrhage (4.9%), and bone invasion (2.4%),
which are characteristic findings in malignant lacrimal gland tumors, were also observed
in primary LGPA. Conclusion: Even if malignancy is suspected based on the radiologic
findings, lacrimal fossa tumors with well-defined margin should be removed intact without
prior biopsy to reduce the risk of recurrence and malignant transformation.
Presenting Author: Akihide Watanabe MD

The Role of Prophylactic Antibiotics in Preventing Infection
and Sling Exposure in Patients Undergoing Frontalis Sling
Presenting Author: Justin J Kuiper
Co-Author(s): Meredith S Baker MD, Richard C Allen MD PhD, Keith D Carter MD
FACS, Jeffrey A Nerad MD, Erin Shriver MD
Purpose: To evaluate the role of prophylactic intravenous and postoperative oral antibiotics in preventing infection and exposure in patients undergoing frontalis sling procedures.
Methods: Retrospective review of frontalis sling procedure patients from January 1987
to January 2014. Results: There were 23 cases of infection or exposure in 104 patients.
Infections, exposures, and total complications (percentage rate), respectively, for each of
the antibiotics categories were: IV and oral (n = 29), two, one, and three (10.3%); IV only
(n = 7), zero, one, and one (14.2%); oral only (n = 15), zero, two, and two (13.3%); and none
(n = 53), seven, 10, and 17 (32.0%). Sling materials were: silicone (n = 72), fascia lata (n =
17), and Supramid (n = 15). Conclusion: Prophylactic antibiotics significantly reduced the
postoperative complication rate in frontalis sling patients (P = 0.023).

H Epidemiology, Clinical Features, and Treatment
Outcomes of Orbital Inflammatory Disease: A 10-Year
Review

Mllers Muscle and Conjunctival Resection With or
Without Tarsectomy for the Treatment of Severe Ptosis
Presenting Author: Stephanie M Young
Co-Author(s): Juliana de Filippi Sartori MD, Vinay Aakalu md**, Allen M Putterman
MD, Pete Setabutr MD
Co-Author(s): Anita S Y Chan MD**, Sunny Shen MD, Lay Leng Seah MBBS**,
Stephanie S Lang MS, Audrey Looi MD FRCS(ED)
Purpose: To analyze the clinical profile and treatment outcomes of orbital inflammatory
disease in our local population. Methods: A 10-year (20012011) retrospective review
of patients with biopsy-proven orbital inflammatory disease at a tertiary referral center in
Singapore. Results: Our study was comprised of 70 patients, of which one-half (n = 35)
had nonspecific inflammation of the orbit. Patients with lacrimal gland disease responded
better to treatment (P = 0.002), whereas the vasculitic group had poorer response (P =
0.013). Subtypes with the highest recurrences were the myositic (75%) and vasculitic (75%)
groups. Conclusion: Our study of biopsy-proven orbital inflammatory disease in an Asian
population allows us to better understand the clinical response of various histological subtypes.
208
Presenting Author: Rakesh M Patel MD*
Purpose: Mllers muscle and conjunctival resection (MMCR) has classically been described to treat mild to moderate ptosis. We hypothesize it is an effective modality for treatment of severe ptosis. Methods: We performed a retrospective chart review identifying all
patients with severe involutional ptosis (margin reflex distance 1 [MRD-1] of 0 mm or less)
from January 2008 to December 2012 who had a MMCR. Results: One hundred forty-one
eyelids of 91 patients were defined as severely ptotic. Average preoperative MRD-1 was
-1.08 mm, and postoperative MRD-1 was 2.73 mm. We found that 80.2% achieved symmetry on initial surgery, defined as the difference in MRD-1 being 1 mm or less. Conclusion:
MMCR with or without tarsectomy is an effective procedure in the management of severe
involutional ptosis.
Scientific Posters
H Drill Hole Canthopexy: Our Technique and Experience
Presenting Author: Andrea N Kossler MD*
Co-Author(s): Erin Shriver MD, David T Tse MD FACS*
Purpose: To describe a technique aimed at correcting lateral canthal tendon disinsertion
with drill hole augmentation, review our experience, and determine which patients would
benefit from drill hole canthopexy. Methods: A retrospective, interventional case series
of all patients who underwent drill hole canthopexy between 2006 and 2011. Results:
Fifty-three drill hole canthopexy (DHC) procedures were performed on 42 patients. Risk
factors for failure with conventional treatments include previous lateral canthal surgery,
anophthalmic sockets, and paralytic ectropion. All DHC cases showed an improvement in
eyelid position; however, two cases (3.77%) needed additional surgery. Conclusion: DHC
is effective and simple to perform and should be considered in patients with previous lateral canthal surgery, anophthalmic sockets, or paralytic ectropion.

Lateral Canthal Tendon Disinsertion: The Clinical Clues and
Anatomic Rationale for Surgical Repair
Presenting Author: Erin Shriver MD
Co-Author(s): Andrea N Kossler MD*, David T Tse MD FACS*
Purpose: To provide a diagnostic algorithm for lateral canthal tendon disinsertion (LCTD)
and rationale for superficial lateral canthopexy (SLC). Methods: Retrospective, interventional case series. A thumb test identified LCTD patients who underwent SLC. Results:
Sixty-four eyelids (48 patients) met criteria and underwent SLC. LCTD features included
medial lateral canthal tendon displacement, incomplete blink, temporal eyelid imbrication,
pseudoretraction, and lagophthalmos. We found that 76.5% had resolution of signs and
symptoms postoperatively with 19 months median follow-up. Ninety-two percent did not
require further canthal surgery. Conclusion: LCTD is a seldom-recognized anatomic defect,
identified with a thumb test, that alters eyelid blink mechanics and lacrimal pump function. SLC restores lateral canthal anatomy, thereby improving eyelid function and ocular
symptoms.

H Rapid and Cost-effective Orbital Prosthesis Fabrication
via Automated Noncontact Facial Topography Mapping and
3-D Printing
Presenting Author: Landon Grace PhD
Co-Author(s): Mauro Fittipaldi, David T Tse MD FACS*

Cost-effectiveness of School-Based Eye Examinations in
Preschoolers Who Fail Vision Screening
Presenting Author: Eugene Lowry MD
Co-Author(s): Alejandra G de Alba-Campomanes MD*
Purpose: Cost-effective analysis of community vs. preschool-based eye exams after
screening. Methods:The same 37 preschools were screened over 4 years, first with charts
and community referral then with autorefraction and eye-mobile follow-up. With this data,
we model an auto-refraction screening program with community or eye-mobile follow-up.
Cases met AAPOS 2013 refractive errors or abnormal cover-uncover. Results: Community
follow-up rate was 59% at a cost of $802 per case compared with 55% in preschool-based
follow-up at a cost of $675 per case. Community referral was dominant in cost-effective

SOE Fixation Patterns Evaluation in Anisometropic Children
Without Manifest Strabismus
Presenting Author: Joao Nuno Bicho Beato MD
Co-Author(s): Joao Breda MD, Carla Sofia Ferreira MD, Augusto Magalhaes MD,
Renato Santos-Silva MD, Jorge F R Breda MD**, Fernando M Falcao-Reis MD PhD**
Purpose: To study fixation changes through microperimetry in a population of anisometropic children and compare these with a control group. Methods: We studied 32 eyes of
16 controls and 38 eyes of 19 anisometropic patients. Inclusion criteria were anisometropia
> 2 D (spherical equivalent) and presence of amblyopia at the beginning of follow-up. Results: There was a statistical difference between the anisometropic patients eyes regarding BCVA (P < .001), sensitivity (P = .046), and fixation malpositioning (P = .036). A significant
correlation was found between the patients worst eyes and control eyes regarding fixation stability and position (P = .007 and P = .048, respectively). Conclusion: Anisometropic
children have altered fixation patterns between both eyes and in comparison with controls.

Predictors of Postoperative Visual Acuity After Bilateral
Cataract Surgery in Children
Presenting Author: Rupal H Trivedi MBBS MS*
Co-Author(s): M Edward Wilson Jr MD, Viswanathan Ramakrishnan PhD**
Purpose: To identify predictors of long-term visual acuity (VA) after bilateral cataract surgery in children. Methods: A multivariate model was constructed to predict the odds of
worse logMAR postoperative VA based on perioperative variables. Results: N = 157 (314
eyes). Age at surgery: median = 3.9 years. Target refraction: median 1 D (IQR: 0.1-3.3).
Follow-up: median = 6.4 years. Age at final VA: median = 11.1 years (range: 5-32). For
univariate analysis, age at surgery (P = .048), nystagmus (< .001), strabismus (.03), IOL (.04),
and interocular axial length difference (< .001) were found to be significant. In multivariate
analysis, however, only nystagmus was found to be significant (P < .001). Conclusion: The
presence of preoperative nystagmus was the most important predictor of poor VA after
bilateral cataract surgery in children.

H Cost of IOL vs. Contact Lens Treatment After Unilateral
Congenital Cataract Surgery in the Infant Aphakia Treatment
Study: Retrospective Analysis at Age 5 Years
Presenting Author: Stacey J Kruger MD
Co-Author(s): Lindreth G DuBois CO, Edmund Becker MA PhD, M Edward Wilson Jr
MD, Scott R Lambert MD*
Purpose: To analyze differences in the cost of treating infants randomized to primary
IOL implantation vs. contact lens (CL) after unilateral cataract extraction (CE) in the Infant
Aphakia Treatment Study (IATS). Methods: Retrospective cost analysis of a prospective,
randomized clinical trial based on Georgia Medicaid reimbursement as well as costs of
supplies, adjusted for inflation. Results: The cost of treatment for 5 years of the IATS for
an infant in the IOL arm was $35,293 vs. $33,452 for a patient in the CL arm. The total cost
of supplies was $2,669 in the IOL group vs. $6128 in the CL group. Conclusion: CE coupled
with primary IOL is about 5% more expensive than aphakia and CL correction. Patient costs
are more than double with aphakia and CL vs. IOL.

Genetic Analysis of True Leber Congenital Amaurosis With
(and Without) Neurodevelopmental Delay
Co-Author(s): Saleh A Al-Mesfer MD**, Shahira I Al-Turkmani MD, Hanno Jrn Bolz
MD
Purpose: Leber congenital amaurosis (LCA) is severe nonsyndromic infantile retinal dystrophy. Neurodevelopmental delay has been described in up to 20% of cases in older studies;
however, more recent genetic studies have not replicated this association, raising the possibility that older studies included syndromic retinal dystrophy cases. We investigate this
possibility. Methods: Retrospective review (2012-2014) of children diagnosed with LCA,
all of whom underwent genetic analysis (candidate gene screening). Results: Eighteen
of 19 (22/23 children) families (all consanguineous or endogamous) harbored homozygous
209
Scientific Posters
Purpose: To propose a novel, low-cost technique for orbital prosthesis development.

Methods: A noncontact facial topography mapping technique was used to build a digital
representation of facial anatomy including the orbital defect. Results: A custom prosthesis
seamlessly integrated with surrounding facial structure was fabricated using 3D printing.
Exterior surface details were based on a mirrored version of the contralateral periorbital region and the posterior prosthesis contour based on orbital defect geometry. This technique
was applied to the orbital defect of an exenteration patient with excellent cosmetic match
and prosthesis fit. Conclusion: The method is capable of fabricating quality prostheses
without an ocularist and providing a patient from remote parts of the world an affordable
solution to the facial disfigurement associated with orbital exenteration.
analysis. Preschool-based follow-up may become cost-effective at a follow-up rate of 76%

or if costs were reduced by 50%. Conclusion: Referral to community is likely more costeffective than preschool-based follow-up.
Scientific Posters
mutations in RPGRIP1 (11), GUCY2D (5), and RPE65 (2). Five of /23 children (22%) had delay,
and they harbored homozygous mutations in RPGRIP1 (2) or GUCY2D (3). Conclusion: Neurodevelopmental delay is a recurrent feature of true LCA.

The Use of Irradiated Corneal Patch Grafts in Pediatric
Glaucoma Drainage Implants
Presenting Author: Kaitlyn M Wallace MD
Co-Author(s): Eun Sara Huh MD, Ahmad A Aref MD*, Thasarat S Vajaranant MD*,
Jacob Wilensky MD, Javaneh Abbasian MD
Purpose: To describe the novel use of irradiated cornea for scleral reinforcement in glaucoma drainage implant (GDI) devices in children. Methods: Retrospective case series of
patients under age 18 who underwent GDI surgery with irradiated cornea as scleral reinforcement. Results: Twenty-five procedures on 23 eyes met the inclusion criteria. Mean
follow-up was 9 months (range: 1-782 days). Baerveldt glaucoma implants were used in
5 cases, and Ahmed glaucoma valves were used in 20 cases. One tube (4%) extruded at
postoperative Month 3.5. There was no known transmission of infectious agents and no
cases of endophthalmitis. Conclusion:This is the first report describing the use of corneal
patch grafts in children. Irradiated cornea improves cosmesis and enhances visualization of
the underlying tube. Risk of tube exposure was found to be low.

SOE Spectral Domain OCT Findings in Pediatric Tilted Disc
Syndrome
Presenting Author: Paolo Nucci MD*
Co-Author(s): Francesco Pichi MD, Antonio P Ciardella MD, Kyoko Ohno-Matsui MD*
Purpose: To report a novel OCT finding in children affected by tilted disc syndrome (TDS)
and to correlate it with early visual field defects. Methods: Pediatric patients with a diagnosis of TDS were examined with spectral domain OCT (SD-OCT) and standard automated
perimetry 24-2. Results: Seventy eyes of 35 patients (mean age: 13.1 years, range: 8-17
years) were enrolled. The OCT images of the optic discs showed a protrusion of the upper
edge of the Bruch membrane and choroid at the nasal edge of the optic disc in 81.4% of the
eyes. The retinal nerve fiber tissue appeared to be herniated into this protrusion and bent
superiorly in 57 eyes. This severe bending corresponded to early visual field anomalies in
97.7% of the eyes. Conclusion: SD-OCT provides important evidence on how TDS affects
the optic nerve from early childhood.

iExaminer: A Portable and Inexpensive Option for Fundus
Photography and Videography in the Pediatric Population
Scientific Posters
Presenting Author: Jiaxi Ding MD

Co-Author(s): Matthew S Pihlblad MD
Purpose: Fundus photography is invaluable for documenting and tracking pathology as
well as educational visualization. Standard fundus cameras are not feasible for inpatients
and those unable to position, such as children. We will test the iExaminer, which combines
PanOptic ophthalmoscopy and iPhone technology, as a viable alternative for photography
and videography. Methods: We utilized the iExaminer to image pediatric patients in the
clinic and hospital. Results: We imaged a diverse range of retinal and optic nerve findings:
ROP plus-disease, retinal coloboma, morning glory disc, optic nerve hypoplasia, pallor, cupping, drusen, hemorrhages, and others. Conclusion: The iExaminer is an inexpensive, portable, and effective tool for imaging posterior pole pathology with telemedicine potential.

SOE Pediatric Visual Impairment in Northern Ireland:
19842011
Presenting Author: Sarah Chamney MBBCh
Co-Author(s): Premadeva Satkurunathan MBBS MS, Eibhlin M Mc Loone MBBCh**
Purpose: The aim of this study was to establish the most common causes of pediatric
visual impairment in Northern Ireland. Methods: Data were collected from the Certificate
of Visual Imapirment of every child registered partially sighted or blind in Northern Ireland
over a 28-year period. Results: 227 children were registered as partially sighted, and 353
were registered as blind. The mean age at registration was 7.4 years ( 4.6 years). The
most common causes for registration were coloboma, cerebral visual impairment, and optic
atrophy. Sixty-one percent of cases were neither preventable nor treatable. The prevalence
of visual impairment in those under 16 years was 0.52/1000. Conclusion: This study gives
new insights into the causes of pediatric visual impairment in Northern Ireland.
210

Diamond Knife-Assisted Deep Anterior Lamellar
Keratoplasty for the Treatment of Mucopolysaccharidoses
1H (Hurler Syndrome) in Children
Presenting Author: Michelle R Boyce MD
Co-Author(s): John E Sutphin MD*, Erin D Stahl MD*
Purpose: To describe diamond knife-assisted deep anterior lamellar keratoplasty (DiaDALK) for the treatment of mucopolysaccharidoses 1H (MPS 1H). Methods: A case series
reviewing surgical techniques and outcomes of Dia-DALK in MPS 1H. Results: Four eyes
in 3 patients, ages 8-18, underwent Dia-DALK for treatment of corneal clouding and visual
acuity of 20/200 or worse. All patients showed improvement in corneal clarity and visual
acuity ranging from 20/60 to 20/125 during follow-up of 1-8 months. One patient had improved visual acuity of the untreated eye. Conclusion: Dia-DALK therapy is useful for the
treatment of corneal complications of MPS 1H in children.

Cycloplegic Autorefraction: Does It Have a Role in Children?
Presenting Author: Sujata Guha MBBS
Co-Author(s): Tarun Sharma MBBS, Preeti Megundappa Hurakadli Sr**
Purpose: To determine the accuracy of autorefraction vs. traditional retinoscopy under
cycloplegic conditions. Methods: 294 children (mean age: 8.2 years) were enrolled. Clinically significant difference was defined as > 0.5 D difference in sphere or cylinder or > 20
in axis. Patients were categorized in to 3 groups: 1: myopia and myopic astigmatism; 2:
hyperopia and hyperopic astigmatism; 3: mixed astigmatism. Results: Clinically significant
differences were noted in 13.2% of eyes in Group 1, 15.1% of eyes in Group 2, and 20.9%
of eyes in Group 3. These differences were greater in those with age < 6 years: 25% vs.
9.1%. Conclusion: Cycloplegic autorefraction can be used reliably in children > 6 years of
age; in others it should be corroborated with retinoscopy.

SOE The Utility of Early IGF-1 and Clinical Parameters
to Predict the Development of Severe ROP in a Diverse
Population
Presenting Author: Maddy A Reddy MBBCH*
Co-Author(s): Himanshu Patel FRCS MBBS MS, Shah Karim**, Catey Bunce MBBS
PhD, Steve Kempley MA MBBCHIR MD, Ajay Kumar Sinha MBBS MD
Purpose: To validate risk factors and identify a threshold level for serum insulin-like
growth factor 1 (IGF-1) in the development of severe ROP in an ethnically diverse population. Methods: Data were collected prospectively. Risk factors included IGF-1 at 31, 32,
and 33 weeks, gestational age (GA), birth weight (BWT), absolute weight gain (AWG),
and maternal ethnicity (ME). Outcomes were minimal ROP (stages 0 or 1) and severe ROP
(stages 2 and worse). Results: Thirty-six patients (14 minimal, 22 severe) were collected.
Significant differences between the groups were found in GA, BWT, AWG, ME, and IGF-1
at 32 and 33 weeks. Minimal IGF-1 rise existed for Black babies. No threshold level of IGF-1
could distinguish between the ROP outcomes. Conclusion: About a third of patients could
safely be excluded from screening.

Large Spot Laser for the Treatment of ROP
Presenting Author: Parijat Chandra MD
Co-Author(s): Priti Bhoutekar MBBS MD**, Raj V Azad MD FRCS(ED)**, Yog Raj
Sharma MD MBBS, Anil Babanrao Gangwe MBBS MD**
Purpose: To compare large spot laser with standard spot laser for treatment of ROP. Methods: Eighty eyes of 40 premature babies with bilateral type 1 ROP were randomized to
treatment with standard spot laser in one eye and large spot laser in other eye. Results:
All babies had 100% regression. Total treatment duration was significantly reduced in the
large spot laser group in zone I (P = .005) and zone II (P = .0006) ROP. Total laser duration was
32% and 63.4% less in zone I and zone II, respectively. High Premature Infant Pain Profile
scores indicated moderate to severe pain during laser in both groups. Mean induced myopia
was comparable. Conclusion: Large spot laser can be a better alternative for treatment
of ROP in terms of faster procedure, shorter total duration of pain, and similar regression
profile.
Scientific Posters
H Regression Patterns Following Primary Anti-Vascular
Endothelial Growth Factor Therapy Without Laser for
Aggressive Posterior Retinopathy of Prematurity
Presenting Author: Alay S Banker MD
Purpose: To evaluate efficacy of intravitreal bevacizumab (IB) without laser in aggressive
posterior ROP (APROP). Methods: Prospective study of APROP eyes receiving IB as primary
therapy. Primary outcome was regression of ROP, and secondary outcomes were degree
of vascularization and recurrences. Results: In 37/40 eyes (92.5%), ROP regressed and
had continued vascularization (Responders). Three eyes (7.5%) had minimal regression and
received laser (Resistors). Twenty-two of 37 responder eyes (59.5%) vascularized up to 1
DD of ora (Vascularized). Fifteen of 37 (40.5%) had persistent avascularity (Nondevelopers),
of which 4 (10%) developed recurrence after 14.5 weeks. Conclusion: IB is effective in
treating APROP, alleviates the need to ablate Zone 1 retina, and preserves the macula. The
majority of eyes developed full vascularization; only a few had persistent avascularity and
recurrences.

Role of Strabismus Surgery in the Treatment of Adult-Onset
Esotropia
Presenting Author: Sara Grace MD
Co-Author(s): Kara M Cavuoto MD, Wei Shi MS**, Hilda Capo MD
Purpose:To describe the characteristics, surgical management, and outcomes of adultonset esotropia. Methods: Retrospective chart review of 250 patients with strabismus
surgery for adult-onset ( 18 years) esotropia in the past 15 years at a large academic
center. Results:The most common etiologies were cranial nerve VI palsy (32%), thyroid eye
disease (18%), and divergence insufficiency (DI) (15%). Diplopia was present in over 90%.
All patients had various strabismus surgeries, with adjustable sutures in approximately
80% of cases. Diplopia resolved in three-fourths, and 13% required reoperation within
a year postoperatively. DI patients had the lowest reoperation rate at 8%. Conclusion:
Multiple surgical options, in conjunction with adjustable sutures, yield good results with
low reoperation rates in adult-onset esotropia.

Botulinum Toxin-Augmented Surgery Compared to
Conventional Surgery in the Treatment of Large-Angle
Infantile Esotropia
Presenting Author: Michael J Wan MD
Co-Author(s): Melanie A Kazlas MD, Carolyn S Wu MD, David G Hunter MD PhD*,
Jason S Mantagos MD, Ankoor S Shah MD*

Incidence and Natural History of Traumatic Cataract After
Hyphema in the Pediatric Population
Presenting Author: Ankoor S Shah MD*
Purpose: To understand the sequelae of traumatic cataract after blunt trauma that causes
hyphema. Methods: Retrospective, cohort study of patients at a single tertiary-care pediatric hospital. Results: Seventeen of 128 (13%) developed cataract a median of 14 days
(range: 2-113) after injury. Median follow-up was 29 months (range: 5-97). Median visual
acuity was 20/245 initially and 20/25 at final visit (P = .0001). Seven patients required
surgery at a median of 54 days (range: 20-698). Conclusion: Traumatic cataract after hyphema from blunt ocular trauma is common, presents within 2 weeks, requires surgery in
~40% of cases, and can be associated with good visual outcomes.

The Safety of Difluprednate Ophthalmic Emulsion for
Treatment of Inflammation After Cataract Surgery in 0-3
Year-Olds
Presenting Author: M Edward Wilson Jr MD
Co-Author(s): Pam Kaur**
Purpose: To evaluate the safety of difluprednate ophthalmic emulsion after pediatric
cataract surgery. Methods: Patients up to three years of age were randomized to receive
difluprednate 0.05% (39) or prednisolone acetate 1% (40), one drop four times daily in the
operated eye for 14 days followed by a two-week tapering period. Safety parameters were
assessed at all postoperative visits. Results: The proportion of patients with treatmentrelated adverse events (TRAEs) in the difluprednate and prednisolone group were 7.7%
and 5%, respectively, with the most common TRAEs being increased IOP (5.1% vs. 2.5%),
corneal edema (2.6% vs. 0%), and ocular hypertension (0% vs. 2.5%). Conclusion: In patients up to three years of age, the safety profile of difluprednate 0.05% is similar to that
of prednisolone acetate 1%.

Pharmacokinetic and Safety Study of Travoprost 0.004%
Ophthalmic Solution in Pediatric Glaucoma Patients
Presenting Author: Erin D Stahl MD*
Purpose: To assess steady-state plasma pharmacokinetics (PK) and safety of travoprost
0.004% in pediatric subjects. Methods: Travoprost was administered QD for seven days to
patients aged two months to <18 years diagnosed with glaucoma or ocular hypertension.
PK was assessed on plasma samples collected prior to the final dose and at 0.17, 0.33, 0.67,
and 1.33 hours post dose. Results: Nineteen of 119 samples from 24 patients had quantifiable travoprost-free acid concentrations (0.01 ng/mL). Cmax ranged from undetectable
to 0.0545 ng/mL and was achieved at 10 minutes post dose in eight of 11 patients, with
no correlation between age or body surface area and drug concentration. No new adverse
events were reported. Conclusion: Travoprost exposure in plasma was low, with concentrations below the assay quantitation limit in a majority of patients.

Congenital Glaucoma Surgery Improves Caregivers Quality
of Life
Presenting Author: Anil K Mandal MD
Co-Author(s): Bharani Seelam, Vijaya K Gothwal
Purpose: To evaluate caregivers quality of life (QoL) and to determine if demographic
and clinical variables affect caregivers QoL in regards to children operated on for primary
congenital glaucoma (PCG). Methods: Sixty-three caregivers of PCG children were administered the caregiver CGlauQoL (CarCGlauQoL) and patient health questionnaire-9 (PHQ-9)
before and six weeks after surgery. Results: Surgical success was achieved in 93.6% patients. A significant improvement occurred in CarCGlauQoL and PHQ-9 scores (P < 0.001),
and magnitude was large (Cohen d = 0.76 and 0.80, respectively). Conclusion: Successful
PCG surgery helps reduce IOP and has significant positive impact on caregivers QoL regardless of demographic and clinical variables.

Novel Phenotype With PAX6 Mutation
Presenting Author: Anagha Medsinge MD
Co-Author(s): Eva Gajdosova MD, Hannah Leigh Scanga MS, Bharesh Kumar Chauhan
PhD, Kanwal K Nischal MBBS*
Purpose: To investigate the association between PAX6 mutations to bilateral anterior
pyramidal congenital cataracts (APCCs) with nystagmus. Methods: Multicenter observational and mutational screening study. Results: Three out of four patients were diagnosed
with bilateral APCCs with nystagmus. A fourth patient was found to have unilateral APCC.
Genetic testing identified that the first three patients only had missense mutations in PAX6.
Sequence and protein alignments showed a high degree of sequence conservation of the
mutated amino acids. Conclusion: This study confirms for the first time a genotype-phenotype relationship for missense mutations in PAX6 to bilateral APCCs with nystagmus.
211
Scientific Posters
Purpose: To compare botulinum toxin-augmented surgery to conventional surgery in the

treatment of large-angle infantile esotropia. Methods: Retrospective, nonrandomized,
comparative study of patients with infantile esotropia (55 PD or greater) treated at a
tertiary-care pediatric hospital. Results: Thirteen patients were treated with augmented
surgery, and 27 patients were treated with conventional surgery. The augmented surgery
group had less mean recession of the medial rectus muscles (5.5 vs. 5.9 mm, P = .02) and a
smaller median angle of deviation at 1 year (0 vs. 16 PD, P = .03). Conclusion: Augmented
surgery may improve surgical outcomes in large-angle infantile esotropia.
Scientific Posters
A Case Series of Congenital Primary Aphakia
Presenting Author: Anagha Medsinge MD
Co-Author(s): Hannah Leigh Scanga MS, Asim Ali MD, Alex V Levin MD, Erin D Stahl
MD*, Kanwal K Nischal MBBS*
Purpose: To describe clinical features and outcomes in nine children with congenital primary aphakia (CPA). Methods: Retrospective chart review. Results: Seventeen eyes of
nine patients had clinical and imaging diagnosis of CPA. The mean age at diagnosis was
29.9 months (range, one to 144 months). Male-to-female ratio was 3.5:1. All the patients
had buphthalmos with characteristic silvery appearance of the cornea and peripheral vascularization. Spontaneous corneal perforation was reported in two patients. All patients
had glaucoma at the onset. Two patients underwent penetrating keratoplasty with poor
visual outcome. Consanguinity was reported in five patients, and genetic testing was positive for FOXE3 mutation in six patients. Conclusion: CPA is a rare anomaly with poor visual
outcome secondary to refractory glaucoma.

Feasibility of Retinal Screening in a Pediatric Population
With Type 1 Diabetes Mellitus
Presenting Author: Anton Kolomeyer MD
Co-Author(s): Natasha V Nayak MD, Melissa Ann Simon MD, Albert S Khouri MD*
Purpose: To demonstrate feasibility of nonmydriatic imaging of children with type 1 diabetes mellitus (DM1) to detect diabetic retinopathy. Methods: Prospective, pilot imaging
study of 106 children (two to 17 years). Canon CX-1 nonmydriatic fundus photos were
obtained. Images were assessed, and quality was graded (scale, 15). Kappa coefficient
determined interobserver agreement. Results: One hundred four of 106 children (98%)
underwent imaging (mean age, 11.1 years; 51% male; 88% Caucasian). One (1%) had nonproliferative diabetic retinopathy, and two (1.9%) had incidental findings. Sixty-two percent
had an eye exam within the past year (P = 0.03, DM1 duration >5 years; P = 0.01, mean age
). High-quality images (grades 4/5) were obtained in 178 eyes (86%), and images of clinical
value (grade 2) were obtained in 207 (99.5%). Image quality interobserver agreement was
0.896. Conclusion: Nonmydriatic imaging may supplement standard clinical examination
of a pediatric diabetic population.

SOE ROP Hybrid Form: Fluorescein Angiographic Findings

Is the Childhood Obesity Epidemic Affecting the Prevalence
and Patient Characteristics of Pediatric Idiopathic
Intracranial Hypertension?
Presenting Author: Rebecca A Shields MD
Co-Author(s): Roberto Warman MD, Kara M Cavuoto MD
Purpose: Our multicenter study investigates the characteristics of pediatric idiopathic
intracranial hypertension (IIH). Methods: A retrospective chart review identified children
(four to 17 years of age) diagnosed with IIH. Results: Fifty-four patients were divided into
Group 1 (four to eight years), Group 2 (nine to 12 years), and Group 3 (13 to 17 years). The
overall average age was 11.5 years, differing significantly between males and females
(9.7 vs. 13.3 years, P = 0.001). Females comprised 48% of Group 2 versus 86% of Group 3.
The body mass index (BMI) differed between males and females in Group 3 (23.6 vs. 33.5).
Conclusion: Postpubescent females have similar clinical presentations to adults, whereas
males are younger, with lower BMI.

Serial Fundus Photography and Fluorescein Angiography
After Off-label Intravitreal Bevacizumab Treatment for ROP:
The Importance of Angiography in Off-label BevacizumabTreated Eyes
Presenting Author: Luxme Hariharan MD
Co-Author(s): Aleksandra V Rachitskaya MD, Ditte J Hess CRA FOPS**, Catherin
Negron, Audina Berrocal MD*
Purpose: To analyze and describe a new form of retinopathy of prematurity (ROP) called
Hybrid Form and its features. We try to use such information for indication for laser treatment. Methods: Retrospective review of fundus angiographic images from 2007 to 2013
of all newborns sent to our regional referential center for ROP screening in Turin, Italy.
Results: We included 12 patients (24 eyes) among 200 babies. Conclusion: Fluorescein
angiography is a useful tool to diagnose and treat hybrid forms.
Purpose: To demonstrate the importance of fluorescein angiography (FA) in the management of retinopathy of prematurity (ROP) after an intravitreal bevacizumab treatment.
Methods: This is an institutional review board-approved retrospective, consecutive case
series of 38 eyes of 19 infants with ROP from 2006 to 2013. Eleven patients were treated
solely with intravitreal bevacizumab, while eight received additional laser. Clinical exam,
RetCam fundus photography, and fluorescein angiography were performed prior to and post
treatment. Results: Regression and progression of ROP was difficult to assess solely by
digital fundus photographs and clinical exam. FA showed changes in vasculature more
clearly. Conclusion: Fluorescein angiograms are critical in demonstrating the details in
the vasculature needed to follow bevacizumab-treated eyes.

Measurement of Corneal Thickness and IOP in Preterm
Babies

SOE Optos-Guided Targeted Retinal Laser Photocoagulation
in Premature Infants With ROP
Presenting Author: Sandeep Grover MD
Presenting Author: Timothy Fung MBCHB
Co-Author(s): Shamim A Haji MBBS, Wassia A Khaja MD, K V Chalam MD PhD,

Merrill L Stass-Isern MD
Co-Author(s): Chetan K Patel MD**
Presenting Author: Mario Ravot MD
Scientific Posters
nese school children (n = 98) who were examined annually for four years. Refractions and
axial length were determined by an optical biometer (IOL Master, Carl Zeiss) and wavefront
analyzer (KR-9000PW, Topcon). Results: The mean refraction/axial length at years 1, 2, 3,
and 4 were -0.54 D/23.09 0.81 mm, -0.57 D/23.27 0.85 mm, -0.77 D/23.46 0.4mm , and
-1.12 D/23.64 0.99 mm, respectively. Long axial length during the first year was found to
be the primary risk factor for the progression of myopia (P < 0.01). Conclusion: Measurement of axial length should be included in the yearly medical examinations of elementary
school children.
Purpose: To study the central corneal thickness (CCT) and IOP in preterm babies. Methods: During retinopathy of prematurity screening rounds at the neonatology intensive care
unit, the IOP was measured using the Tono-Pen tonometer, and CCT was measured with a
pachymeter. Results: Fifty eyes of 34 infants were measured. The mean gestational age at
birth was 28.1 weeks (standard deviation [SD], 2.3 weeks) and at the time of measurements
was 33.4 weeks (SD, 2.0 weeks). The mean IOP measured 31 mmHg (SD, 10.7 mmHg),
and the mean corneal thickness was 647 m (SD, 69.7 m). Conclusion: Compared with
the adult population, both the CCT and IOP measurements were higher in preterm infants.
Purpose: To evaluate the clinical effects of targeted retinal laser photocoagulation (TRLP)
in threshold retinopathy of prematurity (ROP). Methods: A retrospective review of six premature infants (12 eyes) with threshold ROP who had laser photocoagulation to zones of
retinal ischemia and capillary nonperfusion guided by noncontact ultra-widefield fluorescein
angiography (Optos). Main outcome measures, determined by repeat Optos ultra-widefield
fluorescein angiography, were regression of neovascularization and decrease in vascular
dilatation and tortuosity. Results: Following TRLP, there was regression of neovascularization and improvement in vascular dilatation and tortuosity in all eyes. Conclusion: Optosguided TRLP demonstrated a favorable outcome in premature infants with threshold ROP.

The Relationship Between the Progression of Myopia and
the Growth of Axial Length in Elementary School Children
Presenting Author: Yoshinori Nakai
Co-Author(s): Osamu Hieda MD, Shigeru Kinoshita MD*
Purpose: To investigate the relationship between myopia progression and axial length
growth in Japanese school children. Methods: This study involved eight-year-old Japa-
212
Scientific Posters
SOE Extreme Prematurity and Its Impact on Visual
Development
Presenting Author: Carla Sofia Ferreira MD
Co-Author(s): Jorge F R Breda MD**, Augusto Magalhaes MD, Renato Santos-Silva
MD, Angela Maria Carneiro MD PhD*, Amandio A Rocha de Sousa MD, Fernando M
Falcao-Reis MD PhD**
Purpose: To assess the overall impact of prematurity on visual development. Methods:
Forty children were included, born <30 weeks premature and <1,000 g . Variables were
obtained in consultation and diagnostic procedures. Results: Maximum visual acuity (VA)
was found in 84%, refractive errors in 45%, strabismus in 15%, and stereopsis 550 in
70%. By spectral-domain OCT (SD-OCT), foveal differentiation was complete in 53%, and
retinal nerve fiber layer was normal in 39%, both related to the decrease of stereopsis (P
= 0.048 and P < 0.001), but not VA. Median subfoveal choroidal thickness was 313 m.
Microperimetry was not associated with VA or OCT. Chromatic contrast sensitivity tests
showed a relation with VA (P < 0.001) and microperimetry (P = 0.0010.036), but not with
OCT. Conclusion: Preterm children are predisposed to a broad spectrum of anatomical and
functional visual sequelae.

SOE The Efficacy of Retroequatorial Myopexy in Esotropias
Presenting Author: Carla Sofia Ferreira MD
Co-Author(s): Jorge F R Breda MD**, Augusto Magalhaes MD, Renato Santos-Silva
MD, Fernando M Falcao-Reis MD PhD**
Purpose: To evaluate the efficacy and safety of retroequatorial myopexy of medial rectus
(MR) in the correction of esotropias (ETs). Methods: Retrospective study with 92 patients
undergoing bilateral retroequatorial myopexy of MR. Success was defined as 5 final deviation. Results: Median age was 5[4,7 ] years. Median deviation prior to surgery was
Krimsky +45[35,50], and the accommodative convergence to accommodation was high for
17.7%. Surgical success was achieved in 72%, and 21.7% required additional surgery;
in 3.3% of surgeries, there were complications. The median follow-up was three years
[1.25,5]. The success of surgery was related to previous deviation value (P = 0.003), age
at the time of surgery (P = 0.011), evolution of ET (P = 0.039), and follow-up (P = 0.001).
Conclusion: Retroequatorial myopexy is a safe technique with high success rates in the
various types of ETs.

The Efficacy of Povidone-Iodine in Reducing Surgical Site
Contamination During Strabismus Surgery: Dual Application
vs. Single Application
Presenting Author: Donny Won Suh MD
Purpose: To investigate contamination rates of strabismic patients who received surgical
prep using single versus dual application of povidone-iodine (PI). Methods: One hundred
four patients undergoing surgery were divided into Groups A and B. Surgical sites for both
Groups A and B were prepped by applying PI directly into the conjunctival fornices, followed
by cleansing the eyelashes and periocular skin. Group B received additional PI immediately prior to surgery. Conjunctiva, sclera, needles/sutures, and lid speculum were cultured.
Gram stain and cultures were obtained. Results: Group A had a 25% contamination rate of
surgical site and sutures, and Group B had a 10% rate. Lid speculum and conjunctiva were
most common areas of contamination. Conclusion: Second applications of PI significantly
decreased the rate of contamination and infection.

New Stereoacuity Test Using a 3-Dimensional Display
System Reducing the Mismatch of Accommodation and
Convergence
Presenting Author: Sang Beom Han
Co-Author(s): Hee Kyung Yang MD, Jeong-Min Hwang MD, Youngmin Kim, Won
Ryang Wee MD
Purpose: To evaluate the efficacy of a new 3D display stereotest that reduces the accommodation-convergence mismatch. Methods: Sixty children were recruited. Randot images
were randomly displayed on a 3D monitor with shutter glasses. The 3D image was located
in front of (conventional) or behind (proposed) the monitor. Results: The new stereotest
was concordant with the Randot stereotest in 83.3% at near and 88.3% at distance. Only

SOE Extraocular Muscle Repositioning for Ophthalmic
Plaque Radiation Therapy for Choroidal Melanoma
Presenting Author: Sonali Nagendran MBBCHIR*
Co-Author(s): Paul Finger MD*, Brian N Campolattaro MD**
Purpose: To evaluate the incidence, type, and complications of extraocular muscle surgery
for plaque brachytherapy for choroidal melanoma. Methods: Retrospective study of 329
eyes of 329 patients treated with plaque brachytherapy. Results: Two hundred fifty-four
patients (77.2%) required muscle surgery. The most common muscles repositioned were
lateral rectus (30.8%) and inferior oblique (18.7%), correlating with tumor location (P <
0.01). The main complication was diplopia. In patients with preoperative visual acuity better than 20/400, the incidence of transient diplopia was 11.2%, and the incidence of persistent diplopia was 1.9%. Three (0.9%) required prisms, and two (0.6%) required surgery.
Conclusion: Extraocular muscle surgery is frequently required for plaque brachytherapy,
but complications are uncommon and treatable.

The Incidence of Torsional Diplopia Following Inferior
Muscle Recession in Thyroid Eye Disease
Presenting Author: Tara Elizabeth Tae
Co-Author(s): Natalie Kerr MD, Chantel Devould COA
Purpose: To investigate the incidence of torsional diplopia following inferior rectus recession in thyroid eye disease (TED). Methods: A retrospective chart review of patients with
TED who had undergone single or bilateral inferior rectus muscle recession (Irc) without
horizontal transposition was performed. Charts were reviewed for clinically significant
torsional diplopia following surgery. Results: Forty-seven patients met inclusion criteria.
Incidence of torsional diplopia was 6.4% (3/47) at two months postoperatively and 4.3%
(2/47) at last exam. All were excyclotropic. Conclusion: The absence of incyclotorsion
following Irc without horizontal transposition in TED implicates nasalward transposition
of the Irc rather than superior oblique restriction as the etiology of clinically significant
postoperative incyclotropia.
Refractive Surgery
Four-Year Outcomes of AcrySof Cachet Phakic IOL in
Patients With Intrastromal Corneal Ring Segments in
Keratoconic Eyes
Presenting Author: Luis Alberto Rodriguez Torres MD
Co-Author(s): Luis A Rodriguez JR
Purpose: To evaluate outcome of AcrySof Cache Phakic IOL (Cache) in patients with intrastromal corneal ring (Intacs) implanted in stable keratoconus eyes. Methods: Study
included 24. All eyes had stable refraction over 48 months of follow-up. Cache IOL was
implanted to correct the sphere. All cases were followed up more than 48 months. Results:
Patients mean age was 28.2 4.4 years (range: 22 to 34 years). Preoperative sphere was
-8.7 D 3.3 D (-6.00 D to -14.50 D), and cylinder was -1.8 D 0.8 D. The BCVA was 0.3 1.1.
Postoperative UCVA was 4.3 1.2. One hundred percent of cases gained 1 line or more. No
single major complication was reported. Conclusion: Cache IOL is a promising solution in
refractive correction of keratoconus after stabilizing the conditions with Intacs.

Clinical Outcomes of Topography-Guided Photorefractive
Keratectomy for Irregular Astigmatism Following
Penetrating Keratoplasty
Presenting Author: Simon P Holland MD*
Co-Author(s): David Lin MD, Choon Hwai Johnson Tan MBBS**
Purpose: To evaluate efficacy and safety of the Vancouver Custom Topographic Neutralization Technique (TNT) in topography-guided photorefractive keratectomy (TG-PRK) for irregular astigmatism following penetrating keratoplasty (PK). Methods: Forty-nine eyes with
213
Scientific Posters
Co-Author(s): Christy E Benson MD**
the proposed 3D stereotest showed significant correlation with near and distance Randot
stereotests. Conclusion: The newly proposed 3D stereotest showed better good concordance with the Randot stereotests compared with the conventional method.
Scientific Posters
post-PK astigmatism underwent TG-PRK with the Allegretto WaveLight laser. Results:
Twenty-three eyes completed 12 months follow-up. Thirty-five percent had UCVA 20/40
or better, while none had preoperatively. Forty-eight percent had improved BSCVA, 35%
gained 2 lines or more, 4% lost 2 lines or more. Refractive cylinder improved from a range
of 1D-8D to 0D-6D. Average spherical equivalent improved from -2 D to -1 D. There was a 3
D mean astigmatic reduction. Conclusion: Early results of TG-PRK for post-PK astigmatism
show satisfactory efficacy and safety, with one-third achieving 20/40 UCVA or better and
almost all with symptomatic improvement.

SOE Novel Keratoconus Diagnosis and Progression Criteria,
Based on Multiple Anterior Segment Imaging Devices
Presenting Author: George Asimellis PhD
Co-Author(s): A John Kanellopoulos MD*, Costas H Karabatsas MD*
Purpose: To evaluate keratoconus (KCN) diagnosis and progression assessment by anterior segment imaging modalities. Methods: 250 KCN eyes were evaluated for keratoconic
grading and anterior surface indexing by Scheimpflug imaging, Placido topography, anterior
segment OCT (AS-OCT) and a novel multispot topographer (MSRT). The correlations between anterior-surface irregularity indices and epithelial thickness (by AS-OCT) and the
MSRT-derived keratoconus indices were investigated. Results: There was excellent agreement among keratoconic grading and anterior-surface irregularity indices with the MSRT.
Increased topographic thickness variability and range correlated with Scheimpflug-imaging
derived irregularity indices. Conclusion: Novel quantitative topographic indices may help
aid in early diagnosis, proper monitoring, and surgical follow-up in KCN.

SOE Epithelial Remodeling Following FemtosecondAssisted High Myopic LASIK: Comparison of Stand-alone
to LASIK Combined With Prophylactic High-Fluence
Crosslinking
Presenting Author: George Asimellis PhD
Co-Author(s): A John Kanellopoulos MD*
Scientific Posters
Purpose: To evaluate topographic epithelial profile thickness changes following high myopic femtosecond-LASIK with prophylactic high-fluence crosslinking (LASIK Xtra) compared
to standard LASIK. Methods: LASIK-Xtra, 67 eyes. Standard LASIK, 72 eyes. Preoperative and 6-month postoperative epithelial thickness distribution maps were investigated
via anterior segment OCT. Results: LASIK-Xtra midperipheral increase was +3.79 m and
+3.95 m for the -8.00 D to -9.00 D and -7.00 D to -8.00 D subgroups. Stand-alone LASIK
was +9.75 m (P = .032) and +7.14 m (P = .041). Conclusion: The comparison of matched
myopic correction subgroups shows lower epithelial thickness in LASIK-Xtra. This difference may correlate with higher regression rates and/or may depict increased biomechanical instability in the stand-alone LASIK.

SOE One-Month Interim Analysis for the FS200 Flap
Accuracy Study
Presenting Author: Vance Michael Thompson MD*
Co-Author(s): A John Kanellopoulos MD*, James A Gow MD*
Purpose: To evaluate the safety, efficacy, and flap thickness accuracy in myopic FSA LASIK.
Methods: Prospective evaluation of 118 LASIK eyes from 2 sites (United States and European Union) with a target flap thickness (FT) of 110 m. FT was measured by anterior
segment OCT in 6 points over a 6-mm flap diameter. Results: 100 of 118 treated eyes at 1
month achieved mean flap corneal thickness of 117.62 (SD 6.15) m. Difference between
average achieved and target flap thickness was 7.86 (SD 4.88) m. Conclusion: FSA
LASIK flaps at 1 month appear < 10 m within target thickness. This does not only represent
central, but overall measurement.
0.039 D (SD 0.35 D). 92.6% achieved MRSE 0.5 D, and 97.5% achieved MRSE 1.0 D.
Preoperative BCVA O.U. was -0.0113 logMAR, and postoperative UCVA O.U. was -0.0259 (P
< .0001). Distance UCVA: 20/20 or better = 83.0%, 20/16 or better = 60.2%. 53.0% gained
1 or more lines of BCVA (P < .0001). Conclusion: Following LASIK with the WaveLight
Refractive Suite, patients had statistically significant improvements from preop BCVA O.U.
to 1 month postop UCVA O.U. (P < .0001).

Randomized, Double Blind, Contralateral Eye Study to
Compare Surgical and Visual Outcomes in 100-micron and
120-micron LASIK Flaps
Presenting Author: Vishal Jhanji MBBS
Co-Author(s): Marco Yu
Purpose: To compare visual outcomes in 100- and 120-micron LASIK flaps using a 150-KHz
femtosecond laser. Methods: 100-micron and 120-micron LASIK flaps were created in contralateral eyes of 100 patients. Patients were evaluated at 1 week and 1, 3, and 6 months
after the surgery. Results: Both groups matched preoperatively and intraoperatively (P >
.05). No statistically significant differences were observed at any time point postoperatively
in terms of central and thinnest corneal thickness, refraction, and, UCVA or BCVA (P > .05).
Flap displacement occurred in 5 eyes in the 100-micron group and in 3 eyes in the 120-micron group (P > .05). Conclusion: LASIK outcomes were comparable between 100- and
120-micron flaps 1 week postoperatively.

Intraoperative Flap Complications in LASIK Surgery
Performed by Ophthalmology Residents in Training
Presenting Author: Arturo J Ramirez-Miranda MD*
Co-Author(s): Lorena Romero-Diaz-de-Leon MD**, Juan Carlos Serna MD, Alejandro
Navas MD*, Enrique O Graue Hernandez MD
Purpose: To determine the incidence of flap-related complications in LASIK surgery performed by in-training ophthalmology residents and the risk factors involved in those complications. Methods: We analyzed 273 flap sections from 145 patients during one year,
performed by 25 residents using a microkeratome. Results: There were 19 flap-related
complications out of the 273 flap sections involved (6.95%). The most common complication was an incomplete flap section (n = 10; 3.66%). No significant differences in right or
left eye, flat or steep keratometries, pachymetries, white-to-white diameter, or spherical
equivalent between complicated and uncomplicated cases were seen. Conclusion: Flaprelated complications are frequent in resident-performed LASIK. They should be considered
as part of the informed consent in training hospitals.

Predictability of Postoperative Day 1 Wavefront
Aberrometry Refraction to Postoperative Year 1 Aberrometry
and Subjective Manifest Refraction
Presenting Author: Charles Q Yu MD
Co-Author(s): Edward E Manche MD*
Purpose: To determine if wavefront refractions 1 day after LASIK are predictive of objective and subjective refractions at 1 year. Methods: Ninety-four eyes underwent LASIK.
Wavefront refractions were recorded on postoperative Day 1 and Year 1. Subjective manifest refractions were collected at Year 1. Results: The mean Day 1 wavefront spherical
equivalent was +0.22 D. The mean Year 1 wavefront refraction was -0.08 D. The mean Year
1 manifest refraction was -0.20 D. There was a correlation of R = 0.66 (P < .0001) when
comparing wavefront refraction at Day 1 and Year 1. There was a correlation of R = 0.53 (P
< .0001) when comparing wavefront refraction at Day 1 with subjective refraction at Year
1. Conclusion: Postoperative Day 1 wavefront aberrometry refractions correlate well with
objective and subjective refractions at 1 year.

SOE Prospective Visual Outcomes in LASIK Myopic
Patients With WaveLight EX500 Excimer Laser and FS200
Femtosecond Laser

Role of Percentage of Tissue Altered as a Risk Factor for
Ectasia after LASIK
Presenting Author: Arthur B Cummings MD*
Co-Author(s): David Smadja MD*, Beatriz De Abreu Fiuza Gomes, Glauco H Reggiani
Mello MD, Mario Luiz R Monteiro MD**, Steven E Wilson MD*, J Bradley Randleman
MD
Purpose: To assess the visual outcomes of patients who had myopic LASIK with the WaveLight Refractive Suite: BCVA preop vs. UCVA postop at 1 month. Methods: 194 eyes were
treated at 4 sites (2 United States / 2 European Union); interim analysis at 1 month postop.
Preop mean manifest spherical equivalent (MRSE) was -3.79 (SD 2.09), with mean cylinder -0.28 (SD 0.84). Results: 166/194 treated eyes at 1 month had mean MRSE of
214
Presenting Author: Marcony R Santhiago MD
Purpose: To investigate the association of percentage of tissue altered (PTA) with ectasia
after LASIK. Methods: PTA is obtained from (flap thickness + ablation depth) / preoperative
Scientific Posters
corneal thickness. We suspected a relationship between PTA 40 and post-LASIK ectasia
in eyes with normal preoperative topography and retrospectively reviewed 30 cases to test
this hypothesis. We selected a control group of 174 eyes with uncomplicated LASIK and 3
years of postoperative follow-up. Results: Prevalence of PTA 40 was significantly higher
in the ectasia group (97%) than in controls (11%; P < .0001). Stepwise logistic regression
revealed the PTA 40 as a significant factor (P < .0001) with a high odds ratio (223). Conclusion: PTA 40 may be a factor in susceptibility to ectasia and may permit identification
of ectasia risk.

SOE Femtosecond-Assisted Myopic LASIK: Long-term
Comparison of LASIK Combined With Prophylactic HighFluence Crosslinking to Stand-alone LASIK

SOE Comparison of Femtosecond Small-Incision Lenticule
Extraction (SMILE) and Wavefront-Optimized LASIK for the
Correction of Myopia and Myopic Astigmatism
Purpose: To evaluate the refractive and keratometric stability of myopic LASIK with prophylactic high-fluence crosslinking (LASIK-Xtra). Methods: LASIK-Xtra, Group A, 65 eyes;
standard LASIK, Group B, 75 eyes. MRSE, visual acuity, and keratometry were investigated
3, 6, and 12 months postoperatively. Results: In Group A MRSE was -0.25 D from -6.75 D.
Flat K was 37.67 D from 43.92, and steep K was 38.37 D from 45.15 D. In Group B MRSE
was -0.27 D from -5.33 D. Flat K was 38.02 D from 43.15, and steep K was 38.66 D from
44.03 D. Refractive predictability was 0.975 in Group A and 0.968 in Group B. Conclusion: LASIK-Xtra offers improved refractive and keratometric stability in comparison to the
stand-alone. The procedure is safe and opens up a new potential for LASIK application in
myopic corrections.
Presenting Author: Moataz Mohamed Sabry MD

Co-Author(s): Osama I Ibrahim MD PhD*,
Purpose: To compare femtosecond small-incision lenticule extraction (SMILE) with wavefront-optimized femtoLASIK in patients with myopic astigmatism up to -6.00 D sphere and
3.00 D cylinder. Methods: Forty eyes were divided into 2 groups: in Group A, SMILE was
performed using the VisuMax 500, and in Group B, wavefront-optimized femtoLASIK using
the Allegretto excimer laser. The WASCA analyzer was used to measure ocular wavefront.
Results: Preoperative mean spherical equivalent refraction was -4.25 1.19 D and - 4.15
1.21 D in Groups A and B, respectively. Three months postoperatively, 18 eyes in Group A
and 17 eyes in Group B had uncorrected distance visual acuity of 20/20. Higher-order aberrations increased in both groups. Conclusion: The 2 techniques achieved similar refractive
outcomes. Higher-order aberrations and contrast sensitivity changes were the same in both
groups.

SOE Comparison of Visual Outcomes After Correcting
Myopia Using the Variable Spot Scanning Refractive
Procedure vs. the Wavefront Optimized Procedure
Presenting Author: Mounir A Khalifa MD
Co-Author(s): Ehab Farouk Mossallam**

SOE Scanning Electron Microscopy of Lenticules at
Variable Corneal Thickness in Small-Incision Lenticule
Extraction (SMILE) cases
Presenting Author: Ihab M Osman MD
Co-Author(s): Osama I Ibrahim MD PhD*
Purpose: To evaluate lenticule surfaces using electron microscopy in deeper corneal layers
and compare them to the superficial ones. Methods: Forty eyes underwent SMILE refractive procedure using femtosecond laser by VisuMax (Zeiss Meditech). Two groups were
used, one with lenticules at 100 m and the other at 160 m. Lenticules were immediately
processed (fixed, dehydrated, dried, and mounted with gold coating). A JSM-5300 scanning electron microscope was used for observations. Results: Deeper lenticules had more
irregular surfaces and were more difficult to dissect. Comparing the central and peripheral
thickness of lenticules to the intended thickness was significantly more accurate in the
superficial group. Conclusion: Energy settings still needs further adjustment to be able to
create deeper predictable lenticules in SMILE cases.
Co-Author(s): George Asimellis PhD

SOE Refractive Corneal Correction With TopographyAssisted Customized High-Fluence Crosslinking (PiXL)
Presenting Author: A John Kanellopoulos MD*
Co-Author(s): Ioanna Kontari MD, George Asimellis PhD
Purpose: Investigation of customizable high-fluence transepithelial crosslinking (PiXL)
to achieve predictable myopic, astigmatic, and hyperopic refractive changes. Methods:
One-year evaluation of 20 cases (10 myopic eyes, 5 hyperopic, and 5 astigmatic) for PiXL
refractive error change and cornea clarity, keratometry, topography, OCT tomography, and
endothelial cell count (ECC). Results: Mean values achieved: -1.8 D in the myopic group,
+0.12 D in the hyperopic group, and -1.3 D in the astigmatic group; there was a 0.3 D regression in Month 1. No change in ECC or corneal clarity. Conclusion: This novel application
of PiXL appears to offer predictable and stable myopic, astigmatic, and hyperopic effect.
Minimal postoperative morbidity and immediate visual rehabilitation were noted.

SOE Combined Femtosecond Laser-Assisted Myopic
Refractive Lens Extraction With Customized Very HighFluence Collagen Crosslinking: A Novel Procedure
Co-Author(s): George Asimellis PhD
Purpose: To evaluate feasibility of a novel technique combining femtosecond laser in
refractive lens extraction and collagen crosslinking (cCXL). Methods: Femtosecond laserassisted myopic refractive lens extraction was pioneered with the WaveLight FS200 laser.
The 50-m lenticule was extracted through a novel 3.5-mm canal. cCXL was applied in
the pocket created. Scheimpflug and anterior segment OCT were employed for imaging
perioperatively. Results: All 10 cases were feasible ex vivo. Corneal thickness and topographic differences were consistent with achieved myopic change. Interlamellar CXL effect
was verified by corneal OCT imaging. Conclusion: This study demonstrated feasibility and
expands FSME with another platform. Additional combination with cCXL introduces a novel
technique.

Evaluation of an OCT-Based Keratoconus Risk Scoring
System
Presenting Author: Edwin W Nunnery III MD
Co-Author(s): J Bradley Randleman MD
Purpose: To investigate the validity of an OCT-based risk scoring system for keratoconus risk stratification in patients with normal and suspicious Placido-based topographic
patterns. Methods: Fourier-domain OCT acquired corneal pachymetric maps. Variables
included minimum, minimum-median, superior-inferior, superonasal-inferotemporal, and
the vertical location of the thinnest cornea. Summation of variables yielded a composite
keratoconus risk score. Low risk was defined as 0 to 3, and high risk as 4 or higher. Results:
Ninety-eight normal eyes were evaluated; 78% were classified as low risk, and 22% as
high risk. 100 suspicious eyes were evaluated; 70% were classified as low risk, and 30%
as high risk. Conclusion: An OCT-based pachymetric keratoconus risk scoring system correctly classifies most normal eyes but not suspicious eyes.
215
Scientific Posters
Purpose: To compare variable spot scanning (VSS) with wavefront-optimized (WFO) ablations for the correction of myopia. Methods: Two groups, each with 50 eyes of myopia.
Both had LASIK using the M2 microkeratome. The VSS group had VSS refractive ablation
using the Star S4IR, and the WFO group had WFO ablation using the Allegretto Eye-Q. Visual outcome was evaluated preoperatively and 3 months postoperatively including contrast
sensitivity and higher-order aberrations. Results: Mean pre- and postoperative spherical
equivalent (SE) in the VSS group: 3.8 and -0.14; in the WFO group: -4.03 and -0.15, with no
significant difference. After 3 months, there was no significant difference in UCVA, BCVA,
or SE. Mean induced +ve spherical aberration (SA): 0.041 m (P = .00) in VSS and 0.195
m (P = .00) in WFO, with significant difference between the 2 groups (P = .000). Conclusion: VSS and WFO ablations are equally effective, safe, predictable, and stable in treating
myopia. Both ablations induced minimal +ve SA, which was significantly higher with WFO.
Scientific Posters
SOE Femtosecond Laser Lenticular Extraction Outcomes
in Correction of Myopia Compared to Sixth-Generation
Excimer Laser

Phakic IOL Sizing Using Manual Caliper and Videoimaging
Modalities
Presenting Author: Ahmed A Abdou MD PhD
Co-Author(s): Jay R Patel MD, Jay Stuart Pepose MD PhD*
Co-Author(s): Jorge L Alio MD PhD*, Mohamed Elbahrawy MBBCH MS
Purpose: To compare predictability of white-to-white (w-w) or sulcus measurements for

horizontal sizing of posterior chamber phakic (Visian ICL) IOLs. Methods: Postoperative
ICL vault and angle dimensions were retrospectively used to predict resizing of ICL (rICL)
diameters, which were then statistically compared to values predicted by manual caliper
and imaging (Orbscan, IOLMaster, Visante) techniques. Results: There was no statistical
difference between caliper w-w (mean 11.9 mm) and Visante sulcus readings (12.0, P > .07).
Correspondingly, planned ICL size differed significantly from rICL for Orbscan or IOLMaster
w-w (P < .02), but not for caliper and Visante measurements (P > .2). Conclusion: Anterior
segment imaging did not offer a significant advantage over manual caliper white-to-white
measurements for ICL sizing.
Purpose: Femtosecond lenticular extraction (FLEx) / small-incision lenticule extraction

(SMILE) efficiency and safety profile assessment. Methods: Comparative retrospective series of cases including 128 eyes, divided into 4 groups of 16 eyes according to gender, each
of which was matched to an identical LASIK case. Results: FLEx showed a slight BCVA
decrease; SMILE showed a slight increase, evident in females; 0.093 0.1 (P = .083), -0.025
0.1 (P = .014), on logMAR. Females had more residual error, highest with FLEx, -0.21 D
(2.16). Horizontal coma changes were most significant in males: SMILE, P = .06); FLEx, P =
.026, with no significant changes in vertical coma in any group. Conclusion: FLEx/SMILE
techniques had satisfyingly stable refractive outcomes.

SOE Presbyopia Reversal: Accommodation Research Using
Femtosecond Lasers
Presenting Author: Sunil Shah MD*
Scientific Posters
Purpose: To determine effect of in vivo femtosecond lenticular treatments on accommodative amplitude. Methods: Prospective evaluation of 80 patients undergoing cataract surgery and 20 undergoing clear lens extraction treated with a range of treatment algorithms.
Follow-up visits at Weeks 1 and 2 and Month 1. Results: At 1 week, 33.3% showed an
improvement in objective accommodation. Fifty-three percent of subjects showed an improvement in subjective accommodation. best distance-corrected near visual acuity (BDCNVA) improved in 37.3% of patients at Week 1, improving to 40.8% at Month 1. Maximum
improvement at Month 1 was 1.5 D and 2.3 D for objective and subjective accommodation,
respectively. Mean improvement in best corrected distance visual acuity was an increase
from baseline of 31 letters at Month 1. Conclusion: In-the-lens treatment can improve
objective and subjective accommodation and DCNVA in many patients.
Presenting Author: Mujtaba A Qazi MD*

Ten-Year Follow-up of Patients With Keratoconus Who
Received a Staar Toric Phakic Lens Implant
Presenting Author: Juan F Batlle MD*
Purpose: Retrospective study of the long-term safety and efficacy of the Staar Toric Phakic
Lens in patients with keratoconus. Methods: Seventy-two patients who were diagnosed
with keratoconus have been followed for at least 3 years, and 12 have reached the 10-year
mark. The implant was studied for refractive and rotational stability, and the patients were
studied for progression of their cone. Results: The average spherical equivalent was -12.0
D, and the average cylinder was 3.5 D. The lens remained within 5 degrees of the predicted
axis in 90% of the cases, and the position remained unchanged. Conclusion: This study
demonstrates that the Staar Toric ICL is safe and effective in the treatment of keratoconus.
The toric ICL remained stable without axis rotation and refractive changes over this period
of follow-up.

SOE Clinical Results and Rotation Stability of Toric IOLs

Treating Emmetropic Presbyopes With a Small Aperture
Inlay: Three-Year Results
Presenting Author: Rita Matos
Presenting Author: John Allan Vukich MD*
Co-Author(s): Joana Pires MD, Mariana S Cardoso MD**, Sergio G Monteiro MD**,
Manuel S Mariano MD**
Purpose: To evaluate the safety and efficacy of a small-aperture corneal inlay for the treatment of presbyopia. Methods: Prospective, nonrandomized clinical trial of 154 emmetropic
presbyopes implanted in the nondominant eye with a small-aperture inlay for the correction
of presbyopia. Inclusion criteria were uncorrected near visual acuity (UCNVA) of worse than
20/40 and better than 20/100 and a best corrected distance VA 20/20 in both eyes, with
a SE between +0.50 D and -0.75 D. VA, refractive stability, and satisfaction were evaluated.
Results: Mean UCNVA improved from J8 at preop to J2 at 3 years postop. Mean uncorrected distance VA was virtually unchanged. Ninety-two percent of patients were 20/25 or
better at 3 years postop; 96% were within 1.00 D of intended target. Conclusion: Near
VA improves with implantation of a small aperture inlay, while good distance vision is
retained over the long term.
Purpose: To compare the clinical results and rotation stability of 3 toric IOLs. Methods:
A total of 60 eyes with corneal astigmatism ranging from 1.03 to 4.13 D underwent phacoemulsification with toric IOL implantation; 20 eyes were implanted with an Alcon AcrySof
Toric IOL, 20 eyes with an Abbott Tecnis Toric IOL, and 20 eyes received a Bausch+Lomb
enVista Toric IOL. Patients were observed at 1 day and 1, 3, and 6 months postoperatively.
Results: At final follow-up, 91.6% of the eyes showed an UCVA of 20/25 or greater; average overall rotation was 3.78 2.26 with a range of rotation between 0-8. Conclusion:
All IOLs showed good rotational stability, with no significant differences being found between the 3 IOLs.

Confocal Observation of Corneal Reinnervation After SmallIncision Lenticule Extraction: Two-Year Results
Presenting Author: Meiyan Li MBCB
Co-Author(s): Xingtao Zhou MD PhD
Purpose: To evaluate corneal reinnervation and the corresponding corneal sensitivity after
small incision lenticule extraction (SMILE). Methods: In this prospective, observational
study, 10 patients (20 eyes) who received SMILE surgery to correct myopia were included.
The corneal sub-basal nerve fibers were evaluated by confocal microscopy prior to surgery
and 2 years after surgery. Corneal sensation was tested with Cochet-Bonnet esthesiometry. A correlation analysis was performed between sub-basal nerve density and corneal
sensation. Results: There was no statistical difference in sub-basal nerve density (P > .05)
or corneal sensation (P > .05) relative to the corresponding preoperative values. Conclusion: The corneal sub-basal nerve density after SMILE can recover to preoperative levels
by postoperative 2 years.
216

Lens-Based Accommodation Restoration Using a
Femtosecond Laser
Presenting Author: Harvey S Uy MD*
Co-Author(s): Sunil Shah MD*, Ajay Pillai MD, Ronald R Krueger MD*
Purpose: To determine the efficacy and safety of accommodation restoration (AR) using a
femtosecond laser (FS). Methods: Interventional case series of 20 presbyopic eyes that underwent FS applied to the crystalline lens. Main outcome measures: proportion of eyes with
distance-corrected near visual acuity (DCNVA) > 20/40 at 40 cm, binocular viewing distance
(BVD) after 1 month. Results: Among emmetropes, the proportion of eyes with DCNVA >
20/40 at pre- and post-treatment was 0% and 100%, while among nonemmetropic eyes it
was 7.9 % and 38.5%, respectively. Among emmetropes, the mean BVD (SD) at pre- and
post-treatment was 50.25 cm and 46.3 cm while among nonemmetropic eyes, 45.8 cm
(11.0) and 37.2 cm (9.2), respectively. Conclusion:These results suggest that lens-based
FS is a promising and safe method for AR.
Scientific Posters
PRK vs. LASEK vs. Epi-LASIK: A Comparison of Corneal Haze
and Visual Recovery in Myopic Patients

Clinical Outcomes of Topography-Guided Photorefractive
Keratectomy With Crosslinking for Ectasia After LASIK
Presenting Author: James R Townley MD
Presenting Author: David Lin MD
Co-Author(s): Gary L Legault MD, Courtney Hintz MD, Matthew C Caldwell MD,
Vasudha A Panday MD
Co-Author(s): Simon P Holland MD*
Purpose: To compare clinical outcomes of visual acuity (VA) and corneal haze following
PRK, LASEK, and epi-LASIK. Methods: A retrospective institutional review board-approved
study assessed advanced surface ablation (ASA)/ PRK performed at the War Fighter Refractive Surgery Center at Lackland, Texas, from January 2002 to 2011. The study compared
postoperative UCVA, BCVA, BCVA at 5% contrast, and corneal haze. Results: 2240 eyes
PRK, 347 eyes LASEK, and 125 eyes epi-LASIK. No statistical difference was found in haze,
UCVA, BCVA, or BCVA; 5% among PRK, LASEK, and epi-LASIK at 6 months. Patient age was
associated with haze at 3 months (P < .001) but not at 6 months. Conclusion: There was no
significant difference in clinical outcomes between PRK, LASEK, and epi-LASIK.

SOE The Influence of New Technologies on the Quality of
Vision in Patients After Refractive Surgery
Presenting Author: Ewa Mrukwa-Kominek MD PhD*
Purpose: To evaluate simultaneous topography-guided photorefractive keratectomy with

collagen crosslinking (TG PRK/CXL) for ectasia after LASIK. Methods: Fifty-five eyes with
post-LASIK ectasia treated by Allegretto Wavelight (AW) laser with TG PRK/CXL. Clinical
outcomes were evaluated. Results: Thirty-one of 55 eyes treated by AW laser with sixmonth follow-up. Fifty-nine percent had uncorrected visual acuity 20/40. Fifty-two percent
gained at least two lines of best-corrected visual acuity, with none losing two or more lines.
Mean reduction in astigmatism was 2.65 D. All but three patients symptomatically improved. Complications included delayed epithelialization beyond one week in two patients
and visually symptomatic haze in one. Conclusion: Early results with TNT TG PRK/CXL
show promise as an effective and safe treatment for post-LASIK ectasia.

Vector Analysis of Compound Myopic Astigmatism
Comparing Wavefront-Guided and Wavefront-Optimized
Excimer LASIK
Co-Author(s): Aanna Orlicka-Mosiej, Monika Sarnat
Presenting Author: Brian C Toy MD
Purpose: To assess the influence of new technologies on tear film stability, corneal epithelium condition, and optical aberrations in patients after PRK. Methods: Twenty eyes,
cationic nanoemulsion, and 20 eyes, preservative-free artificial tears used 4 times daily
after PRK. Changes in UCVA, BCVA, spherical equivalent (SEq), keratometric values, optical
aberrations, fluorescein tear breakup time, and subjective symptoms. Results: No differences in UCVA, BCVA, SEq, or keratometric values. Changes observed in corneal aberration.
We observed significant differences in tear film stability in Group I, 6 weeks after PRK (P
< .05). Epitheliopathy and dryness were not observed in Group I, while 4 eyes in Group
II. Patients subjective symptoms changed significantly in Group I (P < .05). Conclusion:
Cationic nanoemulsion after PRK is efficient in tear film stability and improvement of subjective satisfaction.
Purpose: To compare astigmatic outcomes in eyes undergoing wavefront-guided (WFG)

and wavefront-optimized (WFO) LASIK. Methods: Sixty-six eyes of 33 patients underwent
LASIK for myopia. One eye underwent WFG LASIK, and the fellow eye underwent WFO
LASIK. Eyes were stratified for subgroup analysis based on preop astigmatism, 0.25 to 1
D, 1.25 to 2.25 D, and 2.5 to 3.5 D. Results: Vector analyses for the WFG and WFO groups
were, respectively, surgically induced astigmatism (0.9 0.7 D vs. 1 0.9 D, P = 0.71), error
magnitude (0.2 0.2 D vs. 0.2 0.3 D, P = 0.3), correction index (1 0.4 vs. 1.1 0.3, P =
0.2), success index (0.3 0.6 vs. 0.3 0.4, P = 0.91), and flattening index (1 0.8 vs. 1.1
0.9, P = 0.8). Conclusion: There were no significant differences between eyes undergoing
WFG LASIK and WFO LASIK using Alpins vector analysis of astigmatism.

H Transparent Corneal Hydrogel Inlay in Emmetropic
Presbyopes: Clinical Trial Update
Presenting Author: Gregory Parkhurst MD*
Co-Author(s): Roger F Steinert MD*

Agreement of Aberrometry With Manifest Refraction Before
and After LASIK: Prospective Comparison of HartmannShack and Tscherning Devices
Presenting Author: Christopher S Sales MD
Purpose: To assess agreement of manifest refraction (MR) with Hartmann-Shack and
Tscherning aberrometry. Methods: Measurements were obtained in 100 eyes of 50 subjects preoperatively and 12 months after myopic LASIK with the WaveScan and the WaveLight. Correlation with MR was assessed with intraclass correlation coefficients (ICCs; 1
= perfect agreement, 0 = disagreement). Results: Preoperative agreement was excellent
between the MR and both aberrometers (ICC, WaveScan: sphere = 0.97, cylinder = .95;
WaveLight: sphere = 0.98, cylinder = 0.92) but poor to fair after LASIK (ICC, WaveScan:
sphere = 0.4, cylinder = 0.1; WaveLight: sphere = 0.2, cylinder = 0.02). Conclusion: Variable
effects of LASIK on Hartmann-Shack (WaveScan) and Tscherning (WaveLight) devices may
affect the accuracy of spherocylinder measurements.

SOE Screening for Ectasia Risk Using Corneal Indices
and High-Order Aberrations: Creation and Validation of an
Artificial Intelligence Scoring System

A Prospective Comparison of Wavefront-Guided LASIK and
Wavefront-Guided PRK Following Prior Keratorefractive
Surgery
Presenting Author: Damien Gatinel MD*
Presenting Author: Jennifer S Kung MD
Co-Author(s): Alain Saad MD*
Purpose: Evaluate the accuracy of a new objective method for the detection of ectasia
susceptibility. Methods: Three hundred consecutive Placido topographies were retrospectively classified as normal or at risk for LASIK by a refractive surgeon and then by an objective automated system. The concordance between the objective and the subjective classification was assessed by receiver operating characteristic curve Results: The sensitivity
and specificity of the scoring system were 88% and 89%, respectively. Only 20 cases were
wrongly classified. Conclusion: The combination of high-order aberrations can create an
accurate artificial intelligence for the detection of corneas at risk for refractive surgery.
Purpose: To prospectively evaluate retreatment with LASIK versus photorefractive keratectomy (PRK) after prior keratorefractive surgery. Methods: Twenty-six eyes of 22 participants (mean age, 39.6 years; 77% female) initially treated with LASIK or PRK were
retreated with wavefront-guided LASIK (38%) or PRK (62%) using the AMO VISX S4 CustomVue IR excimer laser. Uncorrected distance visual acuity (UDVA) and manifest refraction
were measured at one, three, six, and 12 months. Results: Mean UDVA was better in
LASIK versus PRK retreatment eyes at postop month 1 (0.08 < 0.04 D ; P = 0.04) but was
equivalent in both groups at three, six, or 12 months. The percentage of eyes with spherical
equivalent within 0.5 D of plano was equal between the two groups at all time points.
Conclusion: Wavefront-guided LASIK or PRK following prior refractive surgery achieves
similar efficacy and predictability.
217
Scientific Posters
Purpose: To evaluate visual outcomes and satisfaction in emmetropic presbyopes unilaterally implanted with a transparent hydrogel corneal inlay in the U.S. Federal Drug Administrations Investigational Device Exemption study. Methods: Visual acuities were collected
at various distances and time points. Visual symptoms and patient satisfaction were evaluated with a National Eye Institute-Refractive Error Quality of Life questionnaire. Results:
Binocularly at 12 m , 93% of patients were 20/25 (0.8) or better at all distances. Ninety-four
percent of patients reported absent or mild visual symptoms (glare and halos) at 12 m.
Patient satisfaction was high at 94%. Conclusion: Raindrop inlay provided patients with
good binocular acuity, low visual symptoms, and high patient satisfaction.
Scientific Posters
SOE Long term Epithelial Ingrowth
Presenting Author: Melania Cigales MD
Co-Author(s): Jairo Hoyos-Chacon MD, Jairo E Hoyos MD
Purpose: We present a myopic patient with a history of LASIK 10 years ago. Methods:
The patient arrived to our clinic complaining of a loss of vision and foreign body sensation
for over a year due to epithelial ingrowth. Uncorrected visual acuity (UCVA) was 20/30,
and best-corrected visual acuity was 20/20 with a refraction of +12 x 120. Topography
showed irregular astigmatism of 4 D. Results: We treated this by lifting the flap and scraping the epithelium on the bed and in the stromal face of the flap. To avoid a recurrence, we
scraped the epithelium on the bed until the corneal limbus, and in this way, the re-epithelialization occurs from both the flap border and the limbus, coinciding halfway and far from
the border of the flap. Conclusion: One month later, UCVA was 20/20, and topography was
regular. Today, two years later, there has been no recurrence.

SOE FemtoLASIK to Correct Low Myopia vs. High Myopia
Presenting Author: Miguel A Teus MD*
Co-Author(s): Pilar Drake MD, Montserrat Garcia-Gonzalez MD, Esther ArranzMarquez MD PhD
Purpose: To compare the refractive results of FemtoLASIK performed to correct low myopia (up to -5.75 D) versus high myopia (higher than 6 D). Methods: Retrospective study.
Visual and refractive outcomes were evaluated at one day, one week, and one and three
months postoperatively. Results: We included 1,177 eyes (900 in the low myopia group vs.
277 in the high myopia group). At three months, 89.8% of the eyes with low myopia versus
73.6% with high myopia (P < 0.01) were within 0.5 D. Conclusion: FemtoLASIK to correct
myopia is an effective and safe procedure. The accuracy obtained in low myopia is slightly,
but significantly, better than in high myopia.

H Patient-Reported Quality of Vision After Refractive
Surgery
Presenting Author: Osamu Hieda MD
Scientific Posters
Co-Author(s): Shigeru Kinoshita MD*

Purpose: To evaluate the short- and long-term efficacy of refractive surgery via a patient
reported quality-of-vision (QOV) questionnaire. Methods: This study involved 1,400 patients who underwent refractive surgery at the Baptist Eye Clinic in Kyoto, Japan. The patients were asked to respond to the Refractive Status and Vision Profile questionnaire prior
to surgery and at six months (n = 1,100) and 5.5 years (n = 230) postoperatively. Results:
The mean preoperative total QOV score was 35.13, yet that score significantly improved six
months after surgery (P < 0.01) and remained the same throughout the 5.5-year postoperative period. Conclusion: After refractive surgery, the patients reported short-term improvement of their QOV, which continued throughout the 5.5-year follow-up period.

SOE Femtosecond-Assisted LASIK With or Without
Intraoperative Mitomycin C to Correct Hyperopia
Presenting Author: Pilar Drake MD
Co-Author(s): Miguel A Teus MD*, Montserrat Garcia-Gonzalez MD, Javier Paz
Moreno-Arrones MD**
Purpose: To compare the refractive results of Intralase laser using mitomycin C (MMC) in
hyperopic patients versus no MMC. Methods: One hundred fifty-two consecutive patients
were divided in two groups: applying MMC (0.02% for five seconds) and without MMC. We
evaluated the uncorrected visual acuity (UCVA) at one day, one week, and one and three
months after surgery and the refractive error. Results: There was no significant difference
in UCVA between groups at any visit, except at three months, when UCVA was better in
the MMC group (P = 0.03) . The residual sphere at the three-month postop was significantly
lower in the MMC group (P = 0.007), and more eyes with MMC were within 0.50 D than
in the non-MMC group (P = 0.006). Conclusion: MMC hyperopic eyes showed less regression three months after surgery and had better UCVA and a smaller residual sphere. The use
of MMC seemed to have a better predictability.
218

SOE Evaluation of the Aberrometric Outcomes After LASIK
Surgery Using iDesign System for Treatment Planning in
Myopic Eyes
Presenting Author: Aylin Kilic MD
Purpose: To evaluate outcomes of wavefront-guided LASIK surgery using iDesign. Methods: Fifty-eight eyes with spherical -2.71 2.23 D and cylinderic 1.26 1.10 D were
enrolled. High-order aberration (HOA) root mean square (RMS) and spherical aberration
were measured for a 5-mm (32 eyes) and 6-mm (26 eyes) pupil size. Results: All eyes had a
spherical refraction between 0.50 D. Postoperatively, in 97% of the eyes, the uncorrected
visual acuity (UCVA) was 1.0 or better (Snellen acuity chart), and 65% achieved an UCVA
of 1.2 or better. There was insignificant change in the HOA RMS and spherical abberation
(P > 0.05) for 5-mm and 6-mm pupil diameters after three months . Conclusion: Use of the
iDesign system to calculate the ablation profile was found effective, safe, and predictable.
There was insignificant induction of HOA and spherical aberrations.

Intra-user, Intrasubject Reliability of a New, Advanced
Aberrometer for Normal Refractive Surgery Candidates
Presenting Author: Gaurav Prakash MBBS
Co-Author(s): Dhruv Srivastava OD, Vishal Jhanji MBBS
Purpose: To evaluate intrauser repeatability of a new aberrometer. Methods: In this
cross-section study, 110 right eyes were assessed on a new aberrometer (iDesign, AMO).
Three readings were taken by a single user five minutes apart. Corneal and wavefront measurements were analyzed. Results: All parameters were similar between three measurements (ANOVA, P < 0.001). Outcomes were (in terms of overall mean standard deviation
and intraclass correlation coefficient), sphere (3.7 2.9 D, 0.99), cylinder (0.99 1.0 D,
0.99), white to white (12.05 0.35 mm, 0.96), scotopic pupil (6.5 0.91 mm, 0.97), topographic K1 (42.4 1.5 D, 0.96) and K2 (43.5 1.6 D, 0.96), high-order abberation (0.36 0.15
m, 0.91), coma (0.18 0.09 m, 0.93), spherical aberration (0.03 0.1 m, 0.97), and trefoil
(0.14 0.07 m, 0.89). Conclusion: The new aberrometer has repeatable measurements
for anatomical parameters and ocular wavefront.

Tissue Glue for the Treatment of Recalcitrant Epithelial
Ingrowth
Presenting Author: Edward E Manche MD*
Co-Author(s): Jennifer S Kung MD
Purpose: To evaluate the efficacy of fibrin tissue glue for the treatment of epithelial ingrowth under LASIK flaps and buttonholes. Methods: A retrospective chart review was
conducted to evaluate outcomes of eyes treated with fibrin glue after removal of epithelial
ingrowth in LASIK flaps and buttonholes. Results: Eight eyes of eight patients were identified. Three had paracentral buttonhole defects, three had prior multiple ingrowth removal
procedures, and one had epithelial ingrowth after a traumatic flap dislocation. All were
treated with a flap lift and scraping of the ingrowth with fibrin tissue glue applied to the flap
edges. No eyes have experienced significant recurrence of the epithelial ingrowth at last
follow-up. Conclusion: Fibrin glue can be a useful adjunct for the treatment of epithelial
ingrowth under LASIK flaps and buttonholes.

H A Prospective Evaluation of Eyes Undergoing PRK Using
a Novel Silicone Corneal Shield for Pain Mitigation
Presenting Author: Edward E Manche MD*
Co-Author(s): Christopher S Sales MD
Purpose: To prospectively evaluate the safety, efficacy, and predictability of photorefractive keratectomy (PRK) in eyes using the Nexis Vision silicone corneal shield. Methods:
Forty-five eyes were fitted with the Nexis corneal shield for three days after undergoing
wavefront-guided myopic PRK. The corneal shield was designed to minimize postop pain
and speed visual recovery. Results: Six months after PRK, the mean preoperative uncorrected distance visual acuity (UDVA) improved from 1.3 to -0.1 logMAR (P = 0.000), 78%
of eyes achieved UDVA of 20/20 or better, 13% of eyes lost one line of corrected distance
visual acuity (CDVA), and no eye lost two lines of CDVA. Conclusion: Preliminary results
suggest that the novel corneal shield provides safe and effective refractive outcomes.
Scientific Posters
SOE Effect of Intraoperative Mitomycin C on Postoperative
Pain after Laser-Assisted Subepithelial Keratomileusis
(LASEK)

SOE Stromal Surface Topography-Guided Ablation as a
Repair Tool for Irregular Stromal Surface
Presenting Author: Gustavo A Fernandez-Baca MD
Co-Author(s): Marine Gobbe PhD**, Timothy J Archer MS, Gerhard Youssefi PhD**,
Hugo F Sutton MD
Co-Author(s): Jaime Garrido Linares MD, Cristina Perez Casaseca**

Purpose: To evaluate the analgesic effect of intraoperative mitomycin C (MMC) 0.02% in
postoperative laser-assisted subepithelial keratomileusis (LASEK) patients. Methods: This
retrospective study included 106 patients who underwent bilateral LASEK. We compared
73 LASEK cases that received MMC 0.02% intraoperatively for 10 seconds (MMC group)
with 33 LASEK cases not receiving MMC (no MMC group). Patients were asked to rate
their experience of pain two days after surgery, and we compared both groups. Results:
Mean patient age was similar in both groups (P = 0.055). Preoperative spherical equivalent
refraction was higher in the MMC group (P = 0.021). The level of pain reported by patients
in the MMC group was 1.51 (standard deviation [SD], 0.7) and 2.45 (SD, 0.9) in the no MMC
group (P = 0.000). Conclusion: MMC 0.02%, used to prevent corneal haze, also reduces
pain in patients after LASEK surgery.

H Infectious Keratitis After Photorefractive Keratectomy in
31,563 Procedures
Presenting Author: Mahmoud Jabbarvand Behrooz MD**
Co-Author(s): Hesam Hashemian MD, Mehdi Khodaparast MD**, Narges Hassanpoor
MD, Mohammad Riazi Esfahani MD
Purpose: To review the recorded data of infectious keratitis cases after photorefractive
keratectomy (PRK) during an eight-year period. Methods: The medical records of postPRK patients (62,312 eyes) were searched for cases of infectious keratitis. Results: Infectious keratitis was diagnosed in 92 eyes of 79 patients. Most of the cases diagnosed were
between the second and tenth day (87%). Cultures were positive in 56 of the 92 eyes.
The most frequent organism was Staphylococcus (27 cases). The final visual acuity was
20/20 or better in 54 eyes. Conclusion: Infectious keratitis is a rare but potentially visionthreatening complication of PRK. Visual outcome is good after treatment in most cases.

SOE Small-Incision Lenticule Extraction Induces
Significantly Less Spherical Aberration With Less Tensile
Strength Change Compared to Wavefront Optimized LASIK
Presenting Author: Dan Z Reinstein MD*
Co-Author(s): Timothy J Archer MS, Marine Gobbe PhD**

SOE Bilateral Surgical Flap Amputation for the Treatment of
Bilateral Central Flap Necrosis After LASIK
Presenting Author: Montserrat Garcia-Gonzalez MD
Co-Author(s): Pilar Drake MD, Juan Gros-Otero, Esther Ciancas MD
Purpose: To report a case of bilateral central flap necrosis syndrome (CFNS) after LASIK
treated with a surgical flap amputation. Methods: Bilateral CFNS was diagnosed after
uneventful FemtoLASIK. One month postop, uncorrected visual acuity (UCVA) was 0.05 with
a hyperopic shift of +3.25 D (best spectacle-corrected visual acuity [BSCVA] was 0.2 in both
eyes). Both flaps were surgically amputated, and mitomycin C 0.02% was applied for one
minute over the stromal bed. Results: One day postop, UCVA was 0.7 in both eyes. At
three months, the residual refraction was +3.00 D in both eyes, and the BSCVA was 1.0.
Conclusion: Surgical flap amputation is a valid option for the treatment of CFNS, at least
for the more severe cases.
Purpose: To present the first report of stromal surface topography-guided ablation for repair after a short nasal LASIK flap and ablation. Methods: To account for epithelial masking
of the stromal irregularity, the ablation profile was calculated using the stromal surface
height obtained by subtracting Artemis VHF digital ultrasound epithelial thickness from
Orbscan II corneal front surface elevation. Results: One month after treatment, the epithelial thickness irregularity was reduced by 54%. Axial power asymmetry was reduced by 4
D. Anterior elevation map showed reduced asymmetry. The patient reported significant improvement in night vision. Conclusion: Stromal surface topography-guided ablation was
effective in reducing stromal surface irregularity and improving visual quality.

SOE IOP Changes Following Lengthy Topical Corticosteroid
Use in Normal vs. Keratoconic Nonglaucoma Patients
Presenting Author: Emerson M Cruz MD
Co-Author(s): Robert Edward T Ang MD*, A John Kanellopoulos MD*, George
Asimellis PhD
Purpose: To investigate steroid-related IOP spikes following topical corticosteroid use for
over a month in normal versus keratoconic (KCN) patients. Methods: Four hundred sixtyone normal and KCN eyes were treated with topical dexamethasone 0.1% following corneal
laser refractive and/or collagen crosslinking for over six weeks and were evaluated for IOP
changes. Results: Six percent of normal eyes had IOP rise over 25 mmHg compared with
the statistically significant (P < 0.001) 21% of KCN cases. All cases returned to normal IOP
within three months (follow-up, one to five years). Conclusion: This study demonstrates
a potentially significant predisposition for KCN eyes to develop steroid-induced glaucoma.

SOE Phototherapeutic Keratectomy for Groenouw Corneal
Dystrophy: Five-Year Results
Presenting Author: Fabrizio I Camesasca MD
Co-Author(s): Paolo Vinciguerra MD*, Silvia Trazza MD, Riccardo Vinciguerra MD*
Purpose: Groenouw type 1 (granular) and 2 (macular) corneal stromal dystrophies (CSDs)
cause progressive visual acuity decrease and recurrent erosions. We present long-term
follow-up of phototherapeutic keratectomy (PTK )for Groenouw CSD. Methods: Twentynine eyes with Groenouw (type 1, 44.8%; type 2, 55.2%) hindering visual acuity underwent
PTK. Results: Preoperative best spectacle-corrected visual acuity (BSCVA) was 0.26 0.24
with +1.06 2.12 D sphere and -1.95 0.37 D cylinder . Mean pupillary K was 45.16 4.38
D. Five years after PTK, BSCVA was 0.65 0.12 with +1.50 1.90 D sphere and -1.71 0.90
D cylinder. Mean pupillary K was 42.72 2.51 D. No patients reported recurrence of corneal
erosions. Conclusion: Five years after PTK, eyes with Groenouw types 1 and 2 showed
BSCVA improvement, stability of refraction, and no recurrent erosion.

Clinical Outcomes of Transepithelial Photorefractive
Keratectomy in the Correction of Astigmatism: A Follow-up
Study
Presenting Author: Soheil Adib Moghaddam MD
Co-Author(s): Fatemeh Adili-aghdam**, Saeed Soleymanjahi
Purpose: To evaluate trans-photorefractive keratectomy (PRK) using a Schwind Amaris
500 laser in astigmatism. Methods: In this prospective study, 95 eyes were enrolled and
followed up till 12 months. Results: Preoperative mean uncorrected distance visual acuity
(UDVA) logMAR of 0.68 0.41 improved to -0.08 0.09 (P < 0.0005). Moreover, 91.5% of
eyes reached UDVA of 20/20 or better. The mean spherical equivalent of eyes was reduced
greatly from -3.66 1.54 D to -0.02 0.17 D (P < 0.0005). Mean reduction in astigmatism
was 91% (1.390.12 D). We also found that 96.7% and 100% of eyes were within 0.5 D
and 1 D of target refraction, respectively. These percentages were 90.3% and 100% for
cylindrical refraction. Only one eye lost more than two lines of preoperative corrected distance visual acuity, and 95.3% of eyes had preserved it or gained one line or more. Conclusion: Trans-PRK is an effective, predictable, and safe method for treatment of astigmatism.
219
Scientific Posters
Purpose: To analyze spherical aberration (SA) induction by small-incision lenticule extraction (SMILE) and LASIK correlated to postop tensile strength (PTS). Methods: SMILE eyes
using a spherical profile (6- to 7-mm optical zone) were matched for sphere, cylinder, and
pachymetry to LASIK eyes using an aspheric profile (6-mm optical zone). Corneal SA change
and PTS were plotted against spherical equivalent . Results: SA induction was 64% lower
in the SMILE group (0.11 vs. 0.31 m), and PTS was 28% greater in the SMILE group (73%
vs. 57%), despite 32% more tissue removal (107 and 81 m) from use of larger optical zones
(6.7 and 6.1 mm). Conclusion: SA induction was lower for spherical SMILE than aspheric
LASIK for same tissue removal. By preserving stronger anterior stroma, SMILE optical zones
can be increased to improve SA control while still leaving higher PTS.
Presenting Author: Dan Z Reinstein MD*
Scientific Posters
SOE AcrySof Cachet Angle-Supported Phakic IOL: Safety,
Stability, and Visual Outcomes
Presenting Author: Joana Pires MD

Novel Ocular Fixation Device Improves Implant Positioning
and Leads to Improved Results in Scleral Implant Surgery
for Presbyopia
Co-Author(s): Mariana S Cardoso MD**, Rita Matos, Manuel S Mariano MD**
Presenting Author: Barrie D Soloway MD*
Purpose: To assess the safety, stability, and visual outcomes of implantation of an anglesupported phakic IOL (pIOL). Methods: Seventy-nine eyes underwent implantation of the
Acrysoft Cachet pIOL. Rotational stability, uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), IOP, and endothelial cell density (ECD) were the main
outcomes recorded at one, six, and 12 months postoperatively. Results: Seventy-nine eyes
of 43 patients, ranging in age from 21 to 51 years old, were evaluated. At final follow-up,
the mean UDVA was 0.8 in 93.7% of the eyes, the CDVA was 1.0 in 87.3%, and the overall mean ECD loss was 0.44% 1.16% (P > 0.05) . Conclusion: The Acrysoft Cachet pIOL
seems to be predictable, effective, and safe, providing satisfactory refractive correction in
patients with moderate to high myopia.
Purpose: To discuss novel advancements in the device, surgical instrumentation, and

technique used in the clinical trial for presbyopia. Methods: An evolution of the device,
instrumentation, and technique has occurred. Changes to a two-piece locking implant and
the Oculock Incisional System have standardized the procedure. Results: Three hundred
thirty subjects (645 eyes) have received the two-piece locking implant. No slipping has been
noted, and efficacy continues to improve (95% 20/40 or better by 24 months). Conclusion:
A greater number of patients treated by a wider variety of surgeons meet or exceed the
primary outcome efficacy of distance-corrected near visual acuity of 20/40 or better.

SOE Five-Year Assessment of Endothelial Cell Density and
Cell Morphology With an Investigational Angle-Supported
Phakic Lens
Presenting Author: Thomas Kohnen MD*
Purpose: To sssess corneal endothelium changes of an angle-supported phakic lens for
the correction of moderate to high myopia. Methods: Five hundred fifteen study eyes (n
= 360 patients) in a prospective, multicenter clinical trial. Corneal images with the Konan
Noncon Robo specular microscope. Assessments at five years included endothelial cell
density (ECD), percentage hexagonality (% hex), and coefficient of variation (CV). Results:
Mean central comparison of preop versus five years, respectively: ECD was 2,856.5 (standard deviation [SD] 299.2; n = 515) and 2,620.4 (SD 343.7; n = 409), % hex was 57.5 (SD
6.3; n = 512) and 58.0 (SD 6.0; n = 417), and CV was 33.4% (SD 4.5%; n = 512) and
31.3% (SD 3.6%; n = 417). Conclusion: Five-year outcomes showed minimal changes
in corneal ECD and stable cell morphology compared with preop. Six-month follow-up is
recommended to monitor possible changes in ECD loss.

SOE Visual Results After Femtosecond Laser-Assisted
Phacoemulsification and Implantation of a Trifocal IOL
Scientific Posters
Presenting Author: Thomas Kohnen MD*

Purpose: To evaluate outcomes after femtosecond laser-assisted phacoemulsification and
implantation of a trifocal IOL. Methods: Thirty patients were enrolled after bilateral femtosecond laser-assisted (LenSx, Alcon) phacoemulsification with implantation of a trifocal IOL
(AT Lisa Zeiss). Assessment three months postop included uncorrected and corrected visual
acuity (VA) at 4 m, 0.8 m, and 0.4 m and a questionnaire. Results: Postop sean spherical
equivalent was 0.34 0.00 D. Uncorrected binocular VA was -0.1 0.1 logMAR at 4 m and
0.0 0.1 logMAR at 0.8 and 0.4 m. Eighty-four percent of patients do not use additional
optical aids. Sixteen percent occasionally use additional near correction. Conclusion: The
trifocal IOL showed good VA at far, intermediate, and near distance and a high rate of
spectacle independence.

SOE Visual Performance and Subjective Experience of
Patients Implanted With a new Bi-aspheric, Segmented,
Multifocal IOL: The SBL-3
Presenting Author: Sunil Shah MD*
Purpose: To assess visual performance of a new biaspheric, segmented multifocal (MIOL),
the SBL-3. Methods: Patients were monocularly (n = 7) or binocularly (n = 10) implanted.
Three months later, assessment was made of manifest refraction, uncorrected (UCDVA) and
best-corrected distance visual acuity, uncorrected (UCNVA) and best-corrected near visual
acuity (BCNVA), defocus curves, contrast sensitivity (CS), and halometry. Results: Mean
residual manifest refraction was +0.06 0.45 D. Mean UCDVA was +0.07 0.14 logMAR.
Mean UCNVA was J3, and BCNVA was J2. Mean CS was 1.66 0.13 log units. Halometry
showed a glare profile of less than one degree of light scatter. Conclusion: The SBL-3
MIOL provides a good visual outcome at distance and near with minimal dysphotopsia.

Visual Outcomes of Pseudophakes When Implanted With a
Transparent Hydrogel Corneal Inlay to Treat Presbyopia
Presenting Author: Jeffrey Whitman MD OCS*
Co-Author(s): Dan B Tran MD**, Arturo S Chayet MD*, Enrique Barragan MD*, Hai
Yen Tran MD**
Purpose: To assess visual function in pseudophakes treated with a hydrogel corneal inlay
(Raindrop) to improve near and intermediate vision. Methods: Uncorrected and distance
corrected visual acuities will be reported based on standard measurement methods, while
patient satisfaction, visual function, and any visual symptoms will be assessed using a
questionnaire. Results: At three months , 35 patients were examined, and on average,
subjects achieved binocularly 0.1 uncorrected near visual acuity, 0.1 uncorrected intermediate visual acuity, and 0.0 uncorrected distance visual acuity logMAR. Eighty-five percent of
subjects were satisfied or very satisfied with this procedure. Conclusion: In this cohort
of pseudophakic patients implanted with monofocal IOLs, the transparent inlay provided
functional binocular vision at all distances.

SOE Femtosecond Laser-Assisted Intracorneal Ring
Segment Implantation, Corneal Collagen Crosslinking,
and Topography-Guided PRK in Combined Keratoconus
Treatment
Presenting Author: Alexander V Doga MD PhD**
Co-Author(s): Ekaterina Branchevskaya
Purpose: To evaluate the efficacy of topography-guided photorefractive keratectomy (PRK)
and intracorneal ring segments (ICRSs) implantation and corneal collagen crosslinking (CXL)
in keratoconus management. Methods: Consecutive patients received femto-assisted
ICRS implantation followed by a sequential CXL procedure. T-guided PRK was performed
12 months after CXL. Outcome measurements included uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), topography, Scheimpflug tomography,
contrast sensitivity, and ocular aberrations (PSF , Strehl ratio). Results: Study included 36
eyes of 22 patients. Preop UDVA and CDVA (logMAR) were 1.24 0.13 and 0.64 0.16
and improved at last follow-up 12 months after PRK to 0.44 0.23 and 0.21 0.12. No
patients lost lines of CDVA. Conclusion: Combined keratoconus treatment was effective
for improving visual functions in select patients.
Retina, Vitreous
SOE Effect of Intraocular Silicone Oil on Subfoveal
Choroidal Thickness
Presenting Author: Gunhal Satirtav MD**
Co-Author(s): Enver Mirza**, Hurkan Kerimoglu MD, Refik Oltulu MD**, Pinar Topcu
Yilmaz MD, Mehmet Okka MD
Purpose: To detect any potential effect of intraocular silicone oil (SiO) endotamponade on
subfoveal choroidal thickness (SFCT). Methods: Seventeen eyes with retinal detachment
were operated with pars plana vitrectomy (PPV) and 1000 cst SiO endotamponade injection.
SFCT was measured with enhanced depth imaging with OCT, 1 month and 3 months after
PPV and 1 month after SiO removal. Contralateral eyes served as controls. Results: Mean
220
Scientific Posters
SFCT was 300.43 74.90 m at post-PPV first month, 285.21 86.92 m at post-PPV third
month, and 253.15 61.01 m after SiO removal. The difference between each measurement was found to be statistically insignificant (P > .01). Conclusion: Results suggest
that intraocular 1000 cst SiO endotamponade does not seem to exert any effect on SFCT.

Central Serous Chorioretinopathy Misdiagnosed as Ocular
Inflammatory Disease
Presenting Author: Salim Ben Yahia MD*
Co-Author(s): Rim Korbaa Kahloun MD, Mbarek Samah MD**, Bechir Jelliti MD,
Moncef Khairallah MD
Purpose: To determine the proportion of central serous chorioretinopathy (CSCR) cases
misdiagnosed as ocular inflammatory condition (OIC). Methods: The charts of 120 patients
with a definitive diagnosis of CSCR were reviewed. Results: CSCR had been initially misdiagnosed as OIC in 17 patients (14.2%). Referring diagnoses included Vogt-Koyanagi-Harada
disease (N = 5), multifocal choroiditis (N = 2), serpiginous choroiditis (N = 1), Birdshot chorioretinopathy (N = 1), Behet uveitis (N = 2), toxoplasmic retinochoroiditis (N = 1), tubulointerstitial nephritis and uveitis syndrome-associated uveitis (N = 1), idiopathic panuveitis (N =
2), and optic neuritis (N = 2). Fifteen patients (88.2%) had received systemic corticosteroids
before referral. Conclusion: It is not uncommon for CSCR to be misdiagnosed as OIC. This
usually leads to inappropriate management with potentially harmful corticosteroid therapy.

Gene Variants Associated With ROP
Presenting Author: Mary Elizabeth Hartnett MD FACS*
Co-Author(s): Margaret M DeAngelis PhD*
Purpose: To determine genetic variants associated with severe ROP in extremely low
birth weight U.S. infants. Methods: Whole genome amplified DNA from blood spots was
genotyped for 145 candidate gene single nucleotide polymorphisms (SNPs) in preterm infants phenotyped for ROP. Results: Ventilation days and seizures were associated with
severe ROP. After controlling for significant factors and multiple comparisons, SNPs in
BDNF (rs7934165, rs2049046; P < 3.1x10-5) were associated with severe ROP in discovery
(n = 817 infants). After meta-analysis with 543 different infant blood samples, rs7934165
increased in associated significance with severe ROP (P = 2.9 x10-7). Conclusion: Variants in BDNF encoding brain-derived neurotrophic factor were associated with severe ROP.

Reassessment of Scleral Depression in the Clinical Setting
Presenting Author: Shripaad Y Shukla MD
Co-Author(s): Nikhil N Batra MD, Ravi D Patel MD, Shaun Ittiara MD*, Seenu M
Hariprasad MD*

Speculum vs. Bimanual Lid Retraction During Intravitreal
Injection: Prospective Comparison of Patient Experiences
Presenting Author: Ehsan Rahimy MD
Co-Author(s): Allen Chiang MD, Marc J Spirn MD, Sunir J Garg MD*, Jason Hsu
MD*, Richard S Kaiser MD*, Mitchell S Fineman MD*
Purpose: Effective lid retraction, a critical step during intravitreal injection, has been associated with patient discomfort. Methods: Thirty-one patients with bilateral retinal disease
requiring intravitreal anti-VEGF therapy were randomized to either bimanual retraction or a
bladed metal speculum in the first eye followed by the opposite method in the fellow eye.
Level of discomfort was assessed with a visual analog 0-10 pain scale. Results: Twenty-six
patients (83.9%) preferred bimanual retraction vs. 0 (0.0%) for a speculum, while 5 (16.1%)
had no preference. Mean pain score was 2.50 (0-7) with a speculum vs. 0.63 (0-5) with
bimanual retraction (P = .0005). Conclusion: A majority of patients preferred bimanual
retraction over a speculum based on discomfort level.

Fundus Autofluorescence in Retinal Angiomatous
Proliferation
Presenting Author: Masaaki Saito MD
Co-Author(s): Kanako Itagaki**, Mariko Kano**, Tetsuju Sekiryu MD
Purpose: To evaluate the characteristics of fundus autofluorescence in retinal angiomatous proliferation (RAP). Methods: We retrospectively studied the fundus characteristics
of 42 patients (mean age: 81.4 years) of 56 eyes with nave RAP. Short-wavelength and
near-infrared autofluorescence (SW-AF and IR-AF) were performed. Results: Abnormalities
corresponding to the RAP lesions on indocyanine green angiography were seen in 23 eyes
with SW-AF and 50 eyes with IR-AF (P < .001). Of 42 patients, 13 eyes developed RAP during the follow-up period. All 13 eyes showed hypoautofluorescence by IR-AF before onset
of RAP. Conclusion: Abnormalities on SW-AF and IR-AF may be related to the dysfunction
of the photoreceptor-retinal pigment epithelium complex. Hypoautofluorescence on IR-AF
may indicate the presence or the onset of RAP lesions.

Subfoveal Choroidal Thickness After Intravitreal Aflibercept
for Neovascular AMD: Twelve-Month Results
Presenting Author: Hideki Koizumi MD
Co-Author(s): Akiko Yamamoto MD, Masaaki Saito MD, Ichiro Maruko MD, Tetsuju
Sekiryu MD, Annabelle A Okada MD*, Tomohiro Iida MD*
Purpose: To investigate subfoveal choroidal thickness (SCT) after intravitreal aflibercept
injections (IAIs) in eyes with neovascular AMD. Methods: SCT was measured in 42 eyes
with neovascular AMD before and after 3 monthly IAIs, followed by injections every 2
months for a 12-month period. Results: The mean SCT decreased significantly, from 264
m at baseline to 230 m at 3 months (change ratio compared with baseline, 87.1%), and
to 217 m (81.8%) at 12 months (P < .0001 for both), independent of AMD subtype. Conclusion: Subfoveal choroidal thickness decreased with aflibercept therapy in eyes with
neovascular AMD.

H Clinical, Functional, and Imaging Characteristics of
Cancer-Associated Retinopathy and Optic Neuropathy

Association Between Reticular Pseudodrusen and
Choroidal Thickness in Early AMD
Presenting Author: Rebecca S Epstein MD
Presenting Author: Celine Saade
Co-Author(s): Eric Sollenberger BBA, Alessandro Iannaccone MD
Co-Author(s): Hao Cheng MD PhD**, Nicole Pumariega MS, Rachel M Cymerman, R

Theodore Smith MD
Purpose: To characterize patients with cancer-associated retinopathy (CAR) and/or cancerassociated optic neuropathy (CAON). Methods: We report 13 cases, 45-76 years old, with
visual loss and a diagnosis of cancer consistent with CAR and/or CAON. Results: Photophobia (87%) and nyctalopia (73%) were most common at onset. Acuity ranged from 20/20
to count fingers. Cone electroretinograms were always abnormal in CAR. Changes at or
around the disc, delayed visual evoked potentials, and perimetry changes consistent with
optic nerve involvement were always seen. Compared to 45 primary autoimmune cases,
patients > 50 years old and with < 3 autoantibodies (AAbs) were 13.5-fold (2: 24.4, P <
.001) and 5.4-fold (2: 6.8, P = .009) more likely to have CAR/CAON, respectively. Conclu-
Purpose: To study the association between reticular pseudodrusen (RPD) and choroidal
thickness (CTh) in early AMD. Methods: Thirty-three eyes (26 subjects) with early AMD/
no RPD and 18 eyes (16 subjects) with early AMD/RPD underwent enhanced depth imaging
OCT. Temporal, foveal and nasal CTh were measured. Results: CTh was significantly reduced in the RPD group vs. the non-RPD group in the nasal and foveal areas (116.9 7.1 vs.
134.3 8.8, P = .002; 155.2 3.4 vs. 172.4 4.2, P < .001) but not in the temporal area (171.6
6.6 vs. 171 7.2, P = .83). Conclusion: RPD eyes have a thinner choroid in the studied
areas than non-RPD eyes, except in the temporal area, the known area of predilection for
RPD; this relative temporal thickness may be due to fibrotic changes.
221
Scientific Posters
Purpose: To examine the use and utility of scleral depression in todays retina practice.
Methods: Prospective comparative trial of 100 eyes of 50 new patients (25 with symptoms,
25 without) with the findings of a single examiner using a 28 D lens compared to findings in
the same eye after 360-degree scleral depression. Patients rated the level of pain associated with each exam on a 0-10 scale. Retina specialists (128) were anonymously surveyed
regarding their use of scleral depression. Results: No additional pathology was detected
by the use of scleral depression (0%, P < .001). Patients reported more pain with scleral depression (4.68 vs. 1.84, P < .001). Survey revealed that use of scleral depression is symptom
driven. Conclusion: Exam with scleral depression provided little benefit over exam without
depression, while increasing pain.
sion: Besides pure CAON, optic neuropathy is seen also in CAR. Cone dysfunction prevails
in CAR. Patients > 50 years old and with < 3 AAbs are far more likely to have a cancerassociated etiology.
Scientific Posters
Serum Auto-Antibody (AAb) Studies in Patients With AMD
Identify the Apoptosis Inhibitor of Macrophage / CD5
Molecule-Like Protein as a Novel Human Retinal Protein
and an AAb Target in AMD
Presenting Author: Alessandro Iannaccone MD
Co-Author(s): David New PhD, Francesco Giorgianni MBA PhD**, Nataliya I Lenchik
MD, Albert Alhatem MD MS, Sarka Beranova-Giorgianni PhD, Ivan Cullen Gerling
PhD, Marko Radic PhD*
Purpose: To characterize the serum autoantibody (AAb) profile in AMD and to show evidence for a novel retinal protein as one of the targets recognized by circulating AAbs in
AMD. Methods: Sera from 131 AMD and 245 controls, all 70 years old, were screened
for AAbs against human macular tissue antigens. A subset underwent immunoprecipitation, 2D gel electrophoresis, mass spectrometry, and ELISA. Tissue antigen expression was
confirmed by immunohistochemistry. Results: Autoreactivity in AMD is more frequent (P
= .02x10-8) and more intense than in controls. AIM/CD5L is a novel 38-kDa retinal protein
with 2.5-fold higher reactivity in AMD (P = .000007) expressed throughout the human retina.
AMD sera stain retinal sections consistently with its expression pattern Conclusion: Autoreactivity is frequent, and AIM/CD5L is a novel retinal protein and autoantigen in AMD.

SOE Visual and Anatomical Outcomes of Intravitreal
Aflibercept for Chronic Refractory AMD

Intraocular Inflammation and Pain Following Intravitreal
Injection of Ranibizumab or Aflibercept: The PLANET Study
Presenting Author: Arshad M Khanani MD*
Purpose: To evaluate intraocular inflammation and pain following ranibizumab (RBZ) or
aflibercept (AFL) injection for wet AMD. Methods: Patients given open-label RBZ 0.5 mg (n
= 35) or AFL 2.0 mg (n = 53) were followed up 24-48 hours (Visit 1) and 5-7 days following
injection (Visit 2) for pain, anterior chamber inflammation (ACI), and vitreous inflammation
(VI). Evaluator was blinded to treatment allocation. Results: One RBZ (2.9%) and 10 AFL
eyes (18.9%) had mild ACI (score = 0.5) at Visit 1 (P = .04), which resolved by Visit 2 in all
but 1 AFL eye. Moderate to severe pain ( 4 on 0-10 scale) immediately following injection
was greater in patients switching from RBZ to AFL (31.9%) than in those switching from
AFL to RBZ (11.8%; P = .04). Conclusion: AFL-treated eyes may be more likely to have
post-injection inflammation.

H Evolution of Reticular Pseudodrusen in Eyes With AMD
Presenting Author: Manju Chandran Jr MRCOPHTH
Presenting Author: Celine Saade
Co-Author(s): Geeta Menon MD*
Co-Author(s): Camellia Nabati MS, Marcela Marsiglia MD PhD, Sucharita Boddu**,

Ana Rita Santos MS, Rufino Silva MD MSC*, Jose G Cunha-Vaz MD PhD*, R
Theodore Smith MD
Purpose: To assess the efficacy of aflibercept in eyes refractory to ranibizumab in AMD.

Methods: Retrospective review of patients who had more than 10 injections of ranibizumab and had persistent fluid on OCT. Visual acuity (VA), central macular thickness (CMT),
macular volume (MV), and OCT features were analyzed. Treatment involved 3 monthly
doses of 2-mg aflibercept followed by 8 weekly dosing. Results: 119 eyes were included.
There was significant improvement in CMT and MV (P < .0001). OCT assessment showed
anatomic normalization in 27% of eyes, improvement in 55%, no change in 8% eyes, and
deterioration in 15% of eyes. Twenty-one percent gained 1 line of vision, while 58% maintained vision and 22% lost 1 line. Conclusion: Converting patients with AMD to aflibercept results in stabilized vision and improved anatomic outcomes.
Scientific Posters
to measure CT and microperimetry to assess Se. Eight patients had bilateral GA (16 eyes)
(B-GA group), 11 patients had GA in one eye and CNV in the fellow eye (11 eyes) (FE-CNV
group). Results: CT was significantly thicker in the B-GA group at baseline and during
follow-up. CT significantly decreased only in the FE-CNV group (P = .0276), whereas Se
significantly decreased only in the B-GA group (P = .0405). Conclusion: Se and CT show
different changes in GA, probably reflecting different GA phenotypes. These results should
be taken into consideration when planning clinical trials to treat GA.

H Treatment Extension and Visual Outcomes of AntiVascular Endothelial Growth Factor Therapy With
Ranibizumab or Aflibercept for 100 Patients With
Neovascular AMD
Presenting Author: Michelle V Carle MD
Co-Author(s): Thomas Gerald Chu MD PhD**, Homayoun Tabandeh MD MS FRCP
FRCOphth*, Firas M Rahhal MD*, Roger L Novack MD PhD*, Richard H Roe MD*,
Pouya N Dayani MD*, David S Liao MD, Alexander C Walsh MD*, David S Boyer MD*
Purpose: To evaluate maximal treat-and-extend (T&E), BCVA, and anatomic outcomes in
neovascular AMD (nvAMD) treated with IV ranibizumab (IVR) or aflibercept (IVA). Methods:
Retrospective case series of nvAMD on therapy with IVR or IVA. BCVA, number of treatments, duration of drug-free phase, OCT characteristics. Results: 100 patients, 50 with
each IV drug. Mean drug-free interval: IVR, 8.8 (SD 2.8); IVA, 7.5 (SD 2.8) weeks. Average
number injections: 7.6. Failed to reach a drug-free phase: IVR, 10; IVA, 13. Improved or
stabilized BCVA: over 85% of IVR and IVA. BCVA improved 2 lines: IVR, 17 (34%); IVA, 24
(48%). BCVA stabilized: IVR, 29 (58%); IVA, 14 (28%). Vision loss of 2 lines: IVR, 4 (8%);
IVA, 7 (14%). Conclusion: T&E with IVR and IVA resulted in improvement or stabilization
in over 85%. Both groups had similar T&E (8.8 and 7.5 weeks).

SOE Different Phenotypes of Progressing Geographic
Atrophy
Presenting Author: Elisabetta Pilotto MD
Co-Author(s): Francesca Guidolin MD, Enrica Convento PhD, Francesco Giuseppe
Stefanon MD, Raffaele Parrozzani MD, Edoardo Midena MD
Purpose: To analyze choroidal thickness (CT) and retinal sensitivity (Se) changes in patients with geographic atrophy (GA). Methods: Nineteen consecutive patients with GA
at least in 1 eye were studied every 6 months by means of enhanced depth imaging OCT
222
Purpose: To quantitatively analyze reticular pseudodrusen (RPD) evolution in eyes with

AMD. Methods: Fifty-two patients with AMD and unilateral CNV were included. The nonCNV eye was prospectively analyzed for the development of CNV and for the presence and
extent of RPD at baseline and 2-year follow-up using indocyanine green angiography, short
wavelength autofluorescence (AF), and near infrared reflectance (NIR) imaging. Results:
In eyes that developed CNV compared to eyes that did not, RPD were less prevalent on
AF (12% vs. 50%, P = .013) and covered smaller areas on NIR (9.69% of total image area
vs. 22.72%, P = .027) and AF (4.31% vs. 14.78%, P = .011). Conclusion: RPD are dynamic
structures demonstrating spatiotemporal changes with a tendency to fade when CNV develops.

Systematic Review of Safety Across the Phase 2 and 3
Clinical Trials of Intravitreal Aflibercept Injection
Presenting Author: Peter K Kaiser MD*
Purpose: Systematic review of selected ocular / systemic adverse events (AEs) from intravitreal aflibercept injection (IAI) trials for neovascular AMD, macular edema due to central /
branch retinal vein occlusion (CRVO/BRVO), and diabetic macular edema (DME). Methods:
Number of events and person-years at risk (PYR) from patients across 9 Phase 2/3 trials
were analyzed. Results: Over 4000 patients contributed > 5400 PYRs. Event rates were
low and similar between controls and IAIs. Intraocular inflammation, hypertension, and
adjudicated Antiplatelet Trialists Collaboration rates were 2.5 and 2.3; 14.5 and 12.7; and
1.9 and 1.9 per 100 PYR for controls vs. IAI. Conclusion: Overall, Phase 2/3 trials data
demonstrate rates of selected ocular / systemic AEs were low, similar to controls, and this
suggests that IAI was generally well tolerated.

Endophthalmitis Is More Common After Intravitreal Injection
of Ranibizumab and Aflibercept Than Bevacizumab
Presenting Author: Christopher D Riemann MD*
Co-Author(s): Martin F Wilkes MD, Robert A Sisk MD, Daniel Matthew Miller MD
PhD*, Robert E Foster MD, Michael R Petersen MD
Purpose: We investigated endophthalmitis rates after injection of bevacizumab (IVA), ranibizumab (IVL), aflibercept (IVE), and triamcinolone (IVT) at our institution. Methods: A
retrospective analysis was performed on all patients who received intravitreal injections
by 6 surgeons from January 2002 to July 2013 at the Cincinnati Eye Institute. Results:
71,988 injections were performed: 49,756 IVA, 11,480 IVL, 7774 IVT, 2590 IVE, and 388
pegaptanib. Fifty-five eyes received vitreous tap and inject for endophthalmitis (14 IVA, 13
Scientific Posters
IVL, 25 IVT, 3 IVE), and 15 of these were culture positive (5 IVA, 7 IVL, 3 IVT). Conclusion:
At the Cincinnati Eye Institute, intravitreal injection of bevacizumab has a much lower rate
of endophthalmitis than intravitreal injection of any other drug.

H Vitreomacular Interface after Anti-Vascular Endothelial
Growth Factor Intravitreal Injections in AMD
Presenting Author: Frederico Braga Pereira MD
Co-Author(s): Carlos Veloso, Tereza Kanadani, Marcio B Nehemy MD*
Purpose: To evaluate the prevalence of posterior vitreous detachment (PVD) induced by
intravitreal injection of anti-VEGF agents. Methods: Vitreomacular interface of 68 eyes
with neovascular AMD and presence of vitreomacular adhesion (VMA) were evaluated by
spectral domain OCT before and after intravitreal injection of anti-VEGF. Results: The mean
number of intravitreal injections was 7.9 (53.5% were ranibizumab injections, 32.0% were
bevacizumab, and 14.5% were aflibercept injections). Four eyes (5.8%) developed PVD following intravitreal drug injection (2 eyes after the first injection, 1 eye after the second,
and 1 eye after the sixth). Sixty-four eyes remained with VMA. Conclusion: Intravitreal
injection of anti-VEGF agents rarely induces PVD.

Retinal Pigment Epithelial Elevation Size/Intraretinal Fluid
Effect on Visual Acuity in VIEW 1 and 2
Presenting Author: Jason S Slakter MD*

Baseline BCVALow Luminance Visual Acuity Gap Predicts
Treatment Response in Patients With Wet AMD
Presenting Author: Ronald Eric P Frenkel MD*
Co-Author(s): Howard Shapiro PhD*, Ivo Stoilov MD*
Purpose: This HARBOR study subanalysis explored the effect of baseline (BL) low luminance visual acuity (LLVA) on mean BCVA gain in patients with wet AMD treated with
ranibizumab (n = 1097). Methods: LLVA was measured using a 2.0-log-unit neutral density
filter while reading a normally illuminated ETDRS chart. LLVA and BCVA were assessed
at BL and over 24 months of treatment. Results:The magnitude of the difference (gap)
between BCVA and LLVA at BL was negatively correlated with BCVA gain at Month 24 (P
< .0001). Patients with a BCVA-LLVA gap 17 letters at BL gained 13.4 letters in BCVA at
Month 24, while those with a 33-letter gap gained only 2.4 letters in BCVA at Month 24.
Conclusion:The BCVA-LLVA gap was prognostic for treatment response, with a wider gap
predicting lower BCVA gains over 24 months of treatment.

SOE The Role of Posterior Vitreous Detachment and
Vitreomacular Adhesion in Patients With AMD
Presenting Author: Cezmi Akkin MD
Co-Author(s): Orhan Ilim, Serhad Nalcaci**, Zafer Oztas MD, Filiz Afrashi MD*, Jale
Mentes MD*
Purpose: To determine baseline (BL) effect of retinal pigment epithelium elevation (RPEE)
size and (intraretinal fluid) IRF status on visual acuity in VIEW 1 and 2 studies in neovascular
AMD (NV-AMD) patients. Methods: Pooled analysis of 1593 patients treated with 2-mg intravitreal aflibercept injection (IAI) or 0.5-mg ranibizumab with known BL RPEE size (sum of
width and height) and IRF status was done. Six groups were determined based on BL RPEE
size (0, < median, > median) and IRF status (absent / present). Differences in methods for
determining RPEE size and IRF within each study were accounted for. Results: Mean BCVA
change from BL to Week 52 decreased as RPEE size increased and was 13.6, 11.2, and 7.6
letters in eyes without BL IRF, and 8.7, 8.8 and 6.5 letters in eyes with BL IRF. Conclusion:
Week 52 visual acuity outcomes were worse with larger RPEE and presence of IRF at BL.
Purpose: To evaluate the state of the posterior vitreous in exudative AMD, nonexudative
AMD, and controls. Methods: Spectral OCT and B-scan ultrasonography were performed
in exudative AMD (86 eyes), nonexudative AMD (44 eyes), and controls (46 eyes). Results:
Total posterior vitreous detachment (PVD) incidence was 37.2% in exudative AMD, 50.0%
in nonexudative AMD, and 28.2% in control eyes. Incomplete PVD incidence was 50.0%
in exudative AMD, 29.5% in nonexudative AMD, and 28.2% in control eyes. Vitreomacular
adhesion (VMA) was present in 33.7%, 18.1%, and 10.8% of exudative AMD, nonexudative
AMD, and control eyes, respectively. Conclusion: Since incomplete PVD and VMA rates
were higher in the exudative form of AMD, tractional forces through the posterior vitreous
face may play a role in AMD pathogenesis.

SOE Treatment Outcomes in Patients Switched From
Ranibizumab to Aflibercept for Resistant Exudative AMD in
Aberdeen, Scotland

Single-Session Pattern Scan Laser (Pascal) Panretinal
Photocoagulation in Proliferative Diabetic Retinopathy: A
Randomized Study
Presenting Author: Lai-Yeung Ngai MBBS PhD*

Co-Author(s): Kay Por Yip, Chee Peng Cheng, Kurt Spiteri Cornish, Cynthia Santiago
FRCS*

Incidence of CNV in Asymptomatic Fellow Eyes of Patients
with Neovascular AMD
Presenting Author: Abdhish R Bhavsar MD*
Purpose: To determine the incidence of asymptomatic CNV in fellow eyes of patients with
neovascular AMD. Methods: Consecutive patients with neovascular AMD who were seen
by the same surgeon between April 18, 2011, and August 31, 2013, who had asymptomatic CNV in the fellow eye were noted. Results: Fifty-six patients developed CNV in their
asymptomatic fellow eye out of 803 patients with exudative AMD over the 16-month study
timeframe. The incidence of CNV in asymptomatic fellow eyes of patients with neovascular
AMD was 7%. Conclusion: The incidence of asymptomatic CNV in fellow eyes warrants
bilateral complete retinal examination of all patients with neovascular AMD during each
visit, even if they are presenting only for an injection in the eye that originally developed
CNV.
Co-Author(s): Janice Jing Chee Cheung MBBS**, Lap Ki Ng, Rita Gangwani**, Derek
K Yu MBBS, Kenneth K W Li MBCHB
Purpose: To assess the safety and efficacy of single-session panretinal photocoagulation
(PRP) using pattern scan laser in proliferative diabetic retinopathy (PDR). Methods: Twentyfour treatment-naive PDR patients were randomized to 1700 or 2500 shots PRP in a single
session. Central foveal thickness (CFT) was measured before and 1 week after laser by
OCT. Regression of PDR was judged using fundus photos and fluorescein angiograms taken
before and 3 months after laser. Results: Between the 2 groups, there was no significant
difference in the change of CFT or final visual acuity at 6 months. Neovascularization regression rate at 3 months was higher in the 2500-shot group than in the 1700-shot group
(33.3% vs. 9.1%). Conclusion: Single-session PRP, with up to 2500 shots, using pattern
scan laser, is safe in PDR, but more aggressive treatment is required to achieve a higher
regression rate.

Contrast Sensitivity Outcome After Panretinal
Photocoagulation and Macular Lasers in Diabetic
Retinopathy
Presenting Author: Nilesh A Kakade MBBS
Co-Author(s): Sheetal D Dharmadhikari MBBS**
Purpose: To determine the changes in contrast sensitivity after panretinal photocoagulation (PRP) and macular lasers done for diabetic retinopathy. Methods: Contrast sensitivity
was measured with a Peli-Robson contrast sensitivity chart before and after PRP and macular lasers done in patients with diabetic retinopathy. Contrast sensitivity was measured at
1 week, 6 weeks, and 6 months after the procedure. Results: Thirty-five eyes underwent
PRP, and 32 eyes underwent macular lasers. At the end of 6 months contrast sensitivity
decreased in 65.71% of cases of PRP (P = .002), whereas after macular lasers 56.25% of
223
Scientific Posters
Purpose: To report functional and anatomical outcomes following switch from ranibizumab
to aflibercept in patients with active exudative AMD. Methods: Patients whose treatment
was changed from ranibizumab to aflibercept from July 2013 to December 2013 were included. Visual and anatomic outcomes were analyzed at 4 months after 3 monthly loading
doses of 2-mg aflibercept. Results: 163 eyes were switched to aflibercept. The number
of prior ranibizumab injections ranged from 3-39. Thirty-five percent of patients showed a
better visual outcome ( 5 ETDRS letter improvement, n = 133), and 84% had an improved
OCT appearance following 3 injections(n = 126). Conclusion: Aflibercept is of therapeutic
benefit in a subgroup of patients with persistent exudative AMD following multiple injections with ranibizumab.
Presenting Author: Chung-yee Chung FRCS(ED) MBBS MRSCED(OPHTH)
Scientific Posters
cases maintained contrast sensitivity to prelaser levels and 43.75% of cases improved(P =
.125). Conclusion: PRP causes a decrease in contrast sensitivity, whereas it was either
maintained to prelaser levels or improved after macular lasers.
with decreased IRL intensity (R = 0.5; P < .001; N = 91). Increased RT was correlated with
decreased IRL intensity (R = -0.4; P < .001; N = 91). Conclusion: ISe intensity and RT were
significantly correlated with IRL intensity in DR subjects.

Comparing Technical Failure Rates in Diabetic Retinopathy
Screening Between RETeval, a Novel ERG Device, and
Dilated Fundus Photography

SOE Diabetic Retinopathy Screening: Is It Effective?
Presenting Author: April Y Maa MD
Purpose: To evaluate the effectiveness of diabetic retinopathy screening (DRS) service in

a defined population. Methods: Retrospective comparative analysis of 4-year DRS data
(2010- 2014). Results: Our region has a population of 320,000. Five percent to 6% of the
population are diabetic and eligible for DRS during this period. An increase of 5%-6 %
in the number of diabetics had been noted over the preceding 12 months. The referable
retinopathy was reduced from 5.6% in 2010/11 to 2.93% in 2013/14, with reduced need
for vitrectomy. Conclusion: DRS service in our region is effective in early detection and
intervention for diabetic retinopathy and thereby reduces preventable blindness. Education
of diabetic patients and providers has helped tremendously.
Co-Author(s): Ensa Pillow MD, William J Feuer MS, Quentin Davis PhD*, Rachel
Caywood, Joel Chasan MD, Stephen Fransen MD*
Purpose: Screening reduces visual impairment from diabetic retinopathy. Better methods
are necessary as current ways have high failure rates. This study compared the failure
rate between fundus photos and RETeval. Methods: 408 patients with varying retinopathy levels (ETDRS scores of 10-53+) were recruited. RETeval was performed followed by
mydriatic 7-field ETDRS stereo fundus photography. Results: The RETeval device failed
(no results generated) 0.7% (3/408 patients), whereas photography failed (ungradeable images) 14.7% (60/408 patients)3/4a highly statistically significant difference (P < .001, exact
McNemar test). Conclusion: Results suggest the RETeval device has promise as a new
screening tool because of low failure rates.

Real-World Outcomes in Diabetic Macular Edema Treated
with Anti-Vascular Endothelial Growth Factors: An Analysis
of EMR Data From a Large Integrated U.S. Health System
Presenting Author: Szilard Kiss MD*
Co-Author(s): Arghavan Almony MD, Herbert J Ingraham MD, Steven J Marks MD**,
Ashley Cole MS*, Hitesh Chandwani MBBS MS*, Nancy M Holekamp MD*
Scientific Posters
Purpose: To examine vision outcomes in diabetic macular edema (DME) patients managed with intravitreal anti-VEGFs in clinical practice. Methods: Electronic medical records
analysis of 94 anti-VEGF treated eyes from January 2007 to May 2013 with baseline BCVA
of 20/40-20/320. Results: At 12 months, mean number of anti-VEGF injections was 2.6;
mean BCVA change was 3.7 letters; the number of eyes gaining 3 lines was 21 (22.3%),
while 10 eyes (10.6%) lost 3 lines, by LOCF. Conclusion: This study links less frequent
injections to less visual acuity gain in clinical practice than reported in randomized clinical
trials like RISE/RIDE. Further research should assess potential factors that may result in
underutilization of anti-VEGF injections for DME patients.

Intravitreal Aflibercept Injection in Diabetic Macular
Edema by Baseline Demographics and Systemic Disease
Characteristics
Presenting Author: Rishi P Singh MD*
Purpose: To compare intravitreal aflibercept injection (IAI) with laser in diabetic macular
edema (DME) patients by race and baseline hemoglobin A1c (BL HbA1c) levels ( 8% vs. >
8%). Methods: VISTA/VIVID randomized 872 patients to IAI 2 mg every 4 weeks (2q4) or
8 weeks (after 5 monthly doses; 2q8) or laser. Results: Of patients, 82% were White, 6%
were Black, and 10% were Asian. Over 52 weeks, BCVA letter gain with 2q4, 2q8 vs. laser
was +11.9, +10.7 vs. +0.6 (P < .0001) in Whites, +10.8, +9.8 vs. +2.9 (P .0206) in Blacks,
and +8.8, +10.6 vs. -0.4 (P < .0001) in Asians. At baseline, 65% and 35% of patients had
HbA1c 8% and > 8%. BCVA letter gain in patients with BL HbA1c 8% was +12.3, +10.9
vs. +1.1 (P < .0001), and in patients with BL HbA1c> 8% was +10.4, +10.3 vs. -0.3 (P < .0001).
Conclusion:BCVA gains with 2q4 and 2q8 were significantly greater than laser and similar
in the subgroups studied.

Enface Imaging of Inner Retinal and Inner Segment Ellipsoid
Layer Integrity in Diabetic Retinopathy
Presenting Author: Andrew W Francis MD
Co-Author(s): Justin Wanek MS, Jennifer Irene Lim MD*, Mahnaz Shahidi PhD**
Purpose: To relate photoreceptor inner segment ellipsoid layer (ISeL) intensity, inner retinal layer (IRL) intensity, and retinal thickness (RT) in diabetic retinopathy (DR) subjects by
spectral domain OCT (SD-OCT) enface imaging. Methods: SD-OCT volume imaging and
image processing were performed in 12 DR and 12 control subjects. Regions of reduced
intensity on ISeL enface image were identified, and indices of IRL and ISeL intensities and
RT were compared to data in control subjects. Results: Ranges of IRL and ISeL intensity
indices were 0.19-1.57 and 0.30-0.85, respectively. Reduced ISeL intensity was correlated
224
Presenting Author: Balakrishna Vineeth Kumar MBBS*

Co-Author(s): Gianluca Carifi MBBS, Farrukh Ali FRCS

SOE MAPKAPK3, the Causal Gene of West Indies Crinkled
Retinal Pigment Epitheliopathy
Presenting Author: Albert P Jean-Charles MD
Co-Author(s): Salomon Y Cohen MD*, Harold R Merle MD, Alain Gaudric MD*,
Christian Hamel, Isabelle A Meunier MD
Purpose: To identify the causal gene of Martinique crinkled retinal pigment epithelium
(RPE) dystrophy. Methods: Whole exome sequencing was performed in 1 nonaffected and
4 affected patients (3 generations). Results: Three genes of chromosome 3 were in line
with familial segregation. ELP6 and USP4 variations were not retained considering frequency or predicted benignity. MAPKAPK3 with a variation predicted to be damaging, not noted
in human databases, is expressed in RPE. The mutant protein has an abnormal localization
in the cytoplasm in transfected HEK cells. Retina of MAPKAPK3 knockout mice disclosed
thickening and disorganization of Bruch membrane. Conclusion: MAPKAPK3, actor of p38
MAPK pathway, is the causal gene of this dystrophy, characterized by an autosomal dominant transmission and a striking crinkled pattern of the RPE.

Familial Pediatric Cone-Rod Dystrophy From Recessive
RPGRIP1 Mutations
Co-Author(s): Carsten Bergmann MD**, Hanno Jrn Bolz MD
Purpose: Recessive RPGRIP1 mutations cause severe Leber congenital amaurosis. Although an alternate phenotype, cone-rod dystrophy, was reported in one study of Pakistani
families, this has not been since replicated. We document RPGRIP1-related cone-rod dystrophy in an affected Saudi Arabian family. Methods: Retrospective case series. Results:
A brother and sister born of first-cousin parents had nystagmus, poor vision, and photophobia noted soon after birth; serial electroretinography over a 4-year period confirmed conerod dystrophy. Candidate gene testing revealed underlying homozygous RPGRIP1 mutations
(c.3565C>T; p.Arg1189*; NM_020366.3) Conclusion: Recessive RPGRIP1 mutations can
cause pediatric cone-rod dystrophy rather than severe Leber congenital amaurosis.

H Global Reported Endophthalmitis Risk Following
Intravitreal Injection of Anti-Vascular Endothelial Growth
Factor
Presenting Author: Douglas K Sigford MD
Co-Author(s): Shivani Reddy MD, Christine Mollineaux MD**, Shlomit Schaal MD*
Purpose: To compare the risk of endophthalmitis with bevacizumab vs. ranibizumab.
Methods: A total of 535 articles on intravitreal use of bevacizumab and/or ranibizumab
were analyzed for total injections, endophthalmitis cases, and perioperative techniques.
Results: The overall risk of endophthalmitis was 0.058% with bevacizumab and 0.029%
with ranibizumab (P = .01). There was a significantly higher culture-negative risk with bevacizumab (0.036% vs. 0.015%, P < .01). Culture-positive risks were not statistically different.
The use of postoperative antibiotics significantly increased the risk of culture-positive endophthalmitis. Conclusion: The risk of reported postinjection endophthalmitis was higher
with bevacizumab than ranibizumab, although the risk of culture-positive disease was not
statistically different.
Scientific Posters
Ultrawide-Field Fundus Abnormalities in Various Uveitic
Disorders

SOE Dexamethasone Intravitreal Implant for Treatment of
Persistent Macular Edema in Irvine-Gass Syndrome
Presenting Author: Min Sagong MD
Presenting Author: Zurnie Del Barrio Lopez De Ipina MD
Co-Author(s): Hossein Nazari Khanamiri**, Narsing A Rao MD, Srinivas R Sadda MD*
Co-Author(s): Soraya Mediero Clemente MD, Pino Cidad MD, Felix Armada-Maresca
MD
Purpose: To evaluate peripheral fundus autofluorescence (FAF) and color photographic

findings in various uveitic disorders. Methods: Eyes of 82 intermediate / posterior uveitis
with ultrawide-field FAF and pseudocolor images were graded for the presence, location,
extent, and type of peripheral FAF abnormalities. Results: Peripheral abnormalities were
observed in 73.2% of FAF images, whereas clinical abnormalities were evident on 75.6%
of pseudocolor images. Although there was significant overlap in the pseudocolor and FAF
findings, discordance was noted in 25.6% of cases. There was no significant difference or
trend in localization of the peripheral abnormalities. Conclusion: Wide-field pseudocolor
and FAF images appear to provide complementary information regarding peripheral abnormalities in uveitis.
Purpose: To evaluate the effectiveness of a single intravitreal injection of Ozurdex over

12 months in patients with chronic cystoid macular edema (CCME) due to Irvine-Gass
syndrome. Methods: Retrospective review of the medical records of 12 eyes with CCME
refractory to other treatments. Results: Statistically significant improvement was seen in
the mean BCVA at Month 1 (P = .0042), at Month 5 (P = .0103), and at Month 12 (P = .0015),
in the mean central subfield thickness at Month 1 (P < .0001), at Month 5 (P = .0008), and at
Month 12 (P = .0083), and in the mean thickness average cube at Month 1 (P = .003) and at
Month 5 (P = .0178) after treatment. Conclusion: The study suggests that dexamethasone
implant is a favorable treatment option to improve visual acuity and reduce CCME.

Intravitreal Aflibercept for Presumed Ocular Histoplasmosis
Syndrome-Related CNV: Six-Month Results From the
HANDLE Study

Real-World Assessment of Efficacy and Safety of 1
Dexamethasone Intravitreal Implant(s) (0.7 mg) in Patients
With Macular Edema
Presenting Author: Brian W Toussaint MD
Presenting Author: Wai-Ching Lam MD*
Co-Author(s): Daniel Matthew Miller MD PhD*, Dennis M Marcus MD*, John W

Kitchens MD*, Harinderjit Singh MD*
Co-Author(s): Amin Kherani MD, John C Chen MD*, Darryl Baptiste*
Purpose: To evaluate the response of presumed ocular histoplasmosis syndrome (POHS)related CNV to aflibercept. Methods: Eyes were randomized to 2 regimens: monthly
aflibercept for 3 months then mandatory aflibercept every 2 months for 12 months (SG) or
1 aflibercept at randomization with monthly p.r.n. dosing for 12 months (PRN). Results:Ten
eyes had 6-month follow-up. At baseline, mean visual acuity was 70 letters (20/40) and
average OCT central subfield thickness (CST) was 388 m. SG and PRN groups received
on average 4.2 and 3.6 injections, respectively, by the 6-month visit. At 6-month follow-up,
mean visual acuity of the SG group was 86.4 letters (20/18). Average visual acuity of the
PRN group at 6 months was 78.6 letters (20/26). At 6 months, mean OCT CST of SG was
356.4 . Average 6-month OCT CST of the PRN group was 248.8 . Conclusion: There was
favorable acuity and anatomic response to aflibercept.

Intraocular Inflammation Following Aflibercept (Eylea)
Injection
Presenting Author: Howard F Fine MD MHS*
Co-Author(s): Daniel B Roth MD*, Sumit P Shah MD**, Matthew Wheatley MD

Medical Management of Live Subretinal Cysticercosis With
Exudative Retinal Detachment
Presenting Author: Kaushick Biswas MBBS
Co-Author(s): Wondwossen T Kabtimer MD**
Purpose: To evaluate the efficacy of combined oral albendazole and prednisolone therapy
in cases of live subretinal cysticercosis presenting with exudative retinal detachment (RD)
and vitritis. Methods: Three patients who presented with live subretinal cysticercosis and
exudative RD with vitritis were treated with oral albendazole 400 mg twice daily for 3
weeks and 1 week after starting albendazole oral prednisolone 1 mg/kg body weight were
started for 3 weeks. Results: Exudative RD and vitritis subsided in all 3 patients with improvement of visual acuity. Conclusion: Medical management with oral albendazole and
prednisolone is effective and an alternative to complicated surgical procedures in cases of
live subretinal cysticercosis.

Analyses of Dome-Shaped Macula in a Large Population of
Patients With Pathologic Myopia
Presenting Author: I-Chia Liang MD
Co-Author(s): Noriaki Shimada MD, Natsuko Nahako MD, Kosei Shinohara MD, Kyoko
Ohno-Matsui MD*
Purpose: To analyze the fundus and OCT features of dome-shaped macula in a large
series of highly myopic patients. Methods: Retrospective review. Results: 225 eyes of
160 patients were divided into bidirectional, horizontally oriented, and vertically oriented
dome. LogMAR BCVA was inversely correlated with dome height (r = -0.245, P < .01). In the
horizontally oriented group, serous retinal detachment, macular pigmentation, and a newly
described horizontal line were significantly more frequently found in eyes with dome height
over 200 m. Conclusion: Some fundus features may suggest the existence of high dome,
which may relate to more complications and lead to worse vision.

SOE Dome-Shaped Macula in Patients With Pathological
Myopia
Presenting Author: Edward Millan Valbuena MD
Co-Author(s): Daniel Lorenzo Parra MD, Netan Choudhry MD*, Luis Arias MD*
Purpose: To describe the clinical features of dome-shaped macula (DSM) due to pathological myopia. Methods: Retrospective cases series of 16 patients with DSM (followup range: 12-40 months). Results: DSM was bilateral in 12 patients and unilateral in 4.
The mean initial visual acuity was 20/50; at the last visit, it was 20/60. In all affected
eyes, spectral-domain OCT exhibited a serous retinal detachment (SRD) and a convexity
of the retinal-choroidal complex in the macula. Seven patients were treated with intravitreal ranibizumab, 4 with photodynamic therapy, and 5 were observed only. SRD remained
unchanged in all patients, and none of the subgroups showed statistically significant differences in the final visual acuity. Conclusion: We could not determine any effective treatment for SRD in DSM.
225
Scientific Posters
Purpose: To report the characteristics and frequency of intraocular inflammation following

intravitreal aflibercept injection. Methods: Retrospective case series of consecutive patients. Results: There were 28 cases of intraocular inflammation following a total of 5905
aflibercept injections among 1660 patients. The mean baseline acuity was 20/57, which
decreased to 20/179 at diagnosis (P < .0001) but recovered to 20/59 at Month 1, 20/57 at
Month 3, and 20/52 at Month 6 (P = NS). Vitreous culture and injection of antibiotics were
performed in 8 cases; all were culture negative. The remainder received only topical corticosteroids. Conclusion: The frequency of inflammation following aflibercept was 0.47%
per injection. Visual acuity and inflammation returned to baseline within 1 month in most
cases with topical corticosteroids.
Purpose: Assessment of real-world efficacy and safety of 1 dexamethasone intravitreal

implant(s) (0.7 mg) in patients with macular edema (DME). Methods: Retrospective chart
review of 101 patients (120 study eyes including DME, n = 34; retinal vein occlusion, n = 30;
and uveitis, n = 23), treated with 1 implants and followed 2-26 weeks after last implant.
Results: Mean peak changes in Snellen equivalent lines, central retinal thickness, and IOP
from baseline was +1.4 ( 0.3) lines, -183.4 ( 17.9) m, and 0.0 ( 0.5) mmHg. Glaucoma
and cataract surgery occurred in 2.5% and 28.3%. Conclusion: DEX implant(s) alone or
in combination with other treatments is safe and effective for improving vision and CRT.
Scientific Posters
H Comparison of Intravitreal Gas (C3F8) Injection vs.
Intravitreal Ocriplasmin for Vitreomacular Traction
Presenting Author: Nathan C Steinle MD*
Co-Author(s): Dilsher S Dhoot MD*, Alessandro A Castellarin MD*, Dante Pieramici
MD*, Robert F See MD, Carlos Quezada Ruiz MD, Melvin D Rabena MD*, Stephen S
Couvillion MD**, Maan A Nasir MD, Robert L Avery MD*
Purpose: To evaluate the efficacy and safety of C3F8 for vitreomacular traction (VMT) vs.
intravitreal ocriplasmin (IVO). Methods: Consecutive VMT patients treated with IVO or
C3F8 injection were retrospectively reviewed. VMT release rates, visual acuity (VA), and
outer retinal band (ORB) changes on spectral domain OCT were compared. Results: Thirtyeight cases were included. Release rate was 48% (11/23) with IVO and 73% (11/15) with
C3F8, P = .22. Three of 4 C3F8 patients without release showed a reduction in retinal traction and edema. Four of 5 patients with past failed IVO released with C3F8. VA improved
slightly in both groups. ORB changes were noted in 10/23 with IVO and 0/15 with C3F8, P
< .01. Conclusion: C3F8 is an inexpensive treatment option for VMT, even after failed IVO.
No ORB changes with C3F8 implies that its presence after IVO may be due to enzymatic
effect rather than release of VMT alone.

Characterization of Epiretinal Membrane Features
Associated With Lamellar Macular Holes
Presenting Author: Ashleigh Laurin Levison MD
Co-Author(s): Yuji Ito MD, Peter K Kaiser MD*, Rishi P Singh MD*, Sunil K Srivastava
MD*, Justis P Ehlers MD*
Purpose: To characterize and compare the OCT features of lamellar macular holes and
pseudoholes. Methods: Institutional review board-approved, retrospective review of eyes
with lamellar macular holes (LMH) and ERM with pseudoholes. Qualitative and quantitative OCT analysis was performed. Results: Eighty-two eyes (53 LMH and 29 pseudoholes)
were included. A preretinal prominent hyporeflective band (eg, between internal limiting
membrane and ERM) was present in 27 eyes (50.9%) with LMH compared to 2 (6.9%)
with pseudohole (P < .001). The hyporeflective band ranged from 16 to 118 microns. Conclusion: Compared to pseudoholes, LMH is characterized by the presence of a preretinal
hyporeflective band. Further research is needed to better characterize the pathophysiologic
nature of this band.

SOE Novel Aqueous Cytokines in Diabetic Macular Edema
and Neovascular AMD
Scientific Posters
Presenting Author: Marten Brelen BMBCH FRCOPHTH PhD

Co-Author(s): Shaheeda Mohamed MBBS MRCSEd MRCOphth, Carmen Chan, Fiona O
Luk MBChB*, Terri Pui Pui YIP**, Chi Wai Tsang MBCHB, Yolanda Yip**, Chi-Pui Pang
PhD**, Timothy Y Lai MBBS*
Purpose: To assess the levels of 9 cytokines in the aqueous of diabetic macular edema
(DME) and neovascular AMD. Methods: The aqueous from 15 eyes with DME and 25 eyes
with AMD were sampled. The cytokines VEGF, Ang2, bFGF, HGF, PDGF, IL8, TNF-alpha,
TIMP1, and TIMP2 were analyzed using multiplex ELISA and correlated with BCVA and
central macular thickness (CMT). Results: In DME, a greater CMT was correlated with
higher bFGF (P = .034) and a worse BCVA was correlated with higher IL8 (P = .044) and HGF
(P = .022). In AMD, both greater CMT and worse BCVA were correlated with higher levels
of Ang2 (P < .001 and P = .028, respectively). Conclusion: Elevated levels of bFGF, Il8, and
Ang2 may have important roles in the pathogenesis of DME and AMD.

H Retinal Alterations After Intravitreal Injection of
Ocriplasmin for Symptomatic Vitreomacular Adhesion
Presenting Author: Yuji Itoh MD
Co-Author(s): Peter K Kaiser MD*, Rishi P Singh MD*, Sunil K Srivastava MD*, Justis
P Ehlers MD*
Purpose: To evaluate the retinal architecture following ocriplasmin injection for symptomatic vitreomacular adhesion (sVMA). Methods: Quantitative spectral domain OCT analysis
of retinal layer changes were assessed in 19 eyes following ocriplasmin treatment. Results: Outer retinal thickness was significantly reduced at 1 week after ocriplasmin injection (P < .001) and recovered by 3 months. The distance between ellipsoid zone and retinal
pigment epithelium was also reduced at 1 week (P < .0001), 1 month (P < .0001), and 3
months (P < .001) after injection. Subretinal fluid (SRF) accumulation and ellipsoid zone
226
loss was found in 10 of 19 eyes (52.6%). Conclusion: Transient outer retinal thickness
change and SRF accumulation after intravitreal ocriplasmin injection appears to be a common finding.

Pediatric Choroidal Neovascular Membranes in the AntiVascular Endothelial Growth Factor Era
Presenting Author: Cindy S Hwang MD
Co-Author(s): Steven Yeh MD*, G Baker Hubbard MD*
Purpose: To review clinical characteristics and outcomes of pediatric patients with choroidal neovascular membrane (CNV) since the advent of intravitreal anti-VEGF therapy. Methods: A retrospective chart review of patients under the age of 18 years between January
2004 and February 2014 with a diagnosis of CNV was conducted. Results: Of 19 eyes, 53%
were treated with intravitreal bevacizumab and 47% were observed. In both groups, there
was no statistically significant difference between presenting and final visual acuity (P = .9
and .8 in observation and treatment groups). Causes of CNV included uveitis (10), tumors
(4), retinal dystrophies (2), disc drusen (1), and idiopathic (1). Conclusion: In this small
retrospective study, treatment with intravitreal bevacizumab was well tolerated and led to
maintenance of visual acuity.

To Study the Effect of Intravitreal Bevacizumab in
Nonresolving Vitreous Hemorrhage in Eales Disease
Presenting Author: Pooja Jain MBBS MS
Co-Author(s): Meenakshi Thakar**, Usha K Raina MD, Basudeb Ghosh**
Purpose: To compare pars plana vitrectomy (PPV) with intravitreal bevacizumab-assisted
treatment in Eales disease. Methods: Group I (14) received IVB. At 4 weeks, resolution of
vitreous hemorrhage (VH) was noted. If the VH resolved, laser was done; otherwise PPV
with endolaser (EL) was done. Group II (15) underwent PPV with EL. BCVA, intraoperative
ooze, and need of hemostatic measures were evaluated. Results: In Group I, VH resolved
in 6 patients. Intraoperative ooze and need of hemostatic measures were noted in 1 patient
in Group I and in 5 patients in Group II. In Group I, a significant change in BCVA at 2 and 4
weeks following laser (P = .027) and following PPV (P = .011) was noted. In Group II, there
was a significant change in BCVA at 2 and 4 weeks (P = .001). Conclusion: The use of IVB
results in resolution of VH and assists surgery.

Ocriplasmin for Vitreomacular Adhesion (VMA) in the
Clinical Setting: Rates of VMA Release and Visual
Outcomes
Presenting Author: Claudia G Hooten MD
Co-Author(s): Amy C Schefler MD, David Brown MD FACS*, Tien Pei Wong MD*
Purpose: To evaluate visual outcomes of symptomatic vitreomacular adhesion (VMA) after intravitreal injection of ocriplasmin. Methods: Consecutive case series of all patients
treated with ocriplasmin immediately after the FDA approval at a multisite retina practice.
Results: Twenty-two of a total of 47 patients demonstrated resolution of VMA by OCT.
The majority of patients with hyaloid release had stable or improved visual acuity with a
mean of 1 line gained. Twelve patients developed a loss of the inner segment/outer segment junction. Conclusion: This large series describes the use of ocriplasmin in a clinical
setting since the MIVI-TRUST trial. We observed a 46.8% rate of anatomic resolution of
VMA. Almost 40% of patients required vitrectomy. While temporary in most, the incidence
of photoreceptor disruption was evident in 25% of patients.

Infrared Reflectance and Spectral Domain OCT Findings
Following Pneumatic Retinopexy
Presenting Author: Steven M Cohen MD
Purpose: To describe the infrared reflectance (IR) and spectral domain OCT (SD-OCT) findings in eyes with retinal detachment repaired by pneumatic retinopexy. Methods: A retrospective chart review was done of 10 consecutive patients. Results: IR showed 0-1000
(average: 285) 200-micron hyporeflective spots in the dependent, inferior area, where the
retina had been detached. The SD-OCT showed the lesions were small subretinal fluid
pockets 10-500 microns high. The subretinal deposits were documented from 25 to 259
days following retinal detachment repair (average: 126 days). Conclusion: IR shows multifocal hyporeflective spots in eyes following retinal detachment repair with pneumatic
retinopexy. The SD-OCT shows that these spots represent small pockets of subretinal fluid.
Scientific Posters
SOE En Face Swept Source OCT Features of Macular Area
in Retinal Detachment Patients
Presenting Author: Marcos J Rubio Caso MD*

Noninvasive Retinal Angiography (OCTA) of AMD and
Diabetic Retinopathy Using Ultrahigh Speed, Swept Source
OCT
Co-Author(s): Ignacio Flores-Moreno MD PhD, Estefania Cobos MD, Luis Arias MD*
Presenting Author: Mehreen Adhi MD
Purpose: To characterize en face anomalies of macular area in eyes operated on for retinal
detachment and relate these to visual acuity. Methods: Swept source OCT (SS-OCT) images were obtained from 17 eyes using 2 patterns: high-definition scan (HD Scan) through
the foveal area and 3-D 9x12-mm macular raster scan (3D Scan) using a Topcon DRI OCT-1
Atlantis (Topcon Corp.; Japan). Segmentation of the retinal pigment epithelium generated
a reference surface, and images from 6 layers were extracted for analysis. Results: Concordance between observers (kappa 1.0 to 0.638). For HD scans: Inner retinal cysts (P =
.032) and inner segment / outer segment (IS/OS) anomalies (P = .003) were associated with
visual acuity. For 3D scans: IS/OS anomalies (P = .048) were associated with visual acuity.
Conclusion: En face SS-OCT can effectively detect these macular anomalies.
Co-Author(s): Nadia Khalida Waheed MD, WooJhon Choi MS, Eric Michael Moult,
Chen David Lu MS, Benjamin Potsaid PhD*, Zhao Wang PhD**, Tarek Alasil MD,
Caroline R Baumal MD*, Andre J Witkin MD, Jay S Duker MD*, James Fujimoto PhD*

Characteristics and Outcomes of Sequential
Rhegmatogenous Retinal Detachments
Presenting Author: Harpreet S Walia MD
Co-Author(s): Gaurav K Shah MD*, Kevin J Blinder MD*
Purpose: To evaluate features and outcomes of patients with subsequent rhegmatogenous
retinal detachment (RRD). Methods: Retrospective review of patients with sequential RRD
repair in each eye over 5 years. Results: Eighty-eight eyes were included. The initial eye
was symptomatic of an average of 21.11 days and the subsequent eye for 3.95 days. 22.7%
of initial eyes had prior treatment; 36.36% of subsequent eyes did. 47.7% of initial eyes
were macula-off; 18.2% of subsequent eyes were. Ten initial eyes presented with proliferative retinopathy (PVR). Twenty-five percent of initial eyes redetached, while 6.81% of subsequent eyes did. Conclusion: Initial eyes had worse initial visual acuity, longer duration
of symptoms, macula-off status, and concurrent PVR. More initial eyes redetached. Initial
eye had worse final visual acuity. Subsequent eyes developed RRD despite retinopexy.

OCT Angiography in Diabetic Retinopathy
Presenting Author: Thomas Hwang MD
Co-Author(s): Yali Jia PhD*, Steven T Bailey MD, Andreas Lauer MD*, Christina J
Flaxel MD, David J Wilson MD*, David Huang MD PhD*

SOE Comparison of Smartphone-Based Ophthalmoscopy
With Dilated Ophthalmic Examination to Detect Ocular
Pathologic Features
Presenting Author: Andrea Russo MD
Co-Author(s): Francesco Morescalchi Sr FICO**, Ciro Costagliola MD, Mario R
Romano MD PhD*, Iari-Gabriel Marino PhD*, Francesco Semeraro Sr MD
Purpose: To evaluate the ability of smartphone-based imaging to detect ocular pathologic
features compared to dilated ophthalmic examination by retinal specialist ophthalmologists. Methods: 160 outpatients underwent dilated examination and smartphone ophthalmoscopy. The smartphone was equipped with a compact add-on that filtered and delivered
the smartphones LED light coaxially to the camera, allowing a clear and convenient view
of the retina. Results: K-values for all lesions (k 0.66) demonstrated substantial agreement between smartphone-based imaging and clinical examination. Conclusion: Smartphone ophthalmoscopy showed considerable agreement with clinical examination in the
detection of ocular diseases, suggesting a potential role in screening environments for
smartphone-based imaging.

SOE H Comparison of Smartphone-Based Ophthalmoscopy
With Dilated Ophthalmic Examination for Diabetic and
Nondiabetic Eye Disease
Presenting Author: Andrea Russo MD
Co-Author(s): Francesco Morescalchi Sr FICO**, Ciro Costagliola MD, Mario R
Romano MD PhD*, Iari-Gabriel Marino PhD*, Francesco Semeraro Sr MD
Purpose: To evaluate the ability of smartphone-based imaging to grade diabetic retinopathy (DR) compared to dilated ophthalmic examination by retinal specialist ophthalmologists. Methods: A subset of 120 diabetic patients underwent dilated examination
and smartphone ophthalmoscopy. The smartphone was equipped with a compact add-on
that filtered and delivered the smartphones LED light coaxially to the camera, allowing a
clear and convenient view of the retina. Results: There was exact agreement in 213 eyes
(88.8%) and agreement within 1 step in 237 (98.8%). Weighted kappa was 0.80 0.04.
Conclusion: Smartphone ophthalmoscopy showed near-perfect agreement with dilated
ophthalmic examination in the detection of DR.

SOE Characterization of Central Serous Chorioretinopathy
Spectrum by Multi-wavelength Retinal Imaging
Presenting Author: Roberto Gallego-Pinazo MD*
Co-Author(s): Rosa Dolz Marco MD*, Sergio Pagliarini MD**, Mariano Cozzi, Maria
Andreu-Fenoll NP**, Diamar Pardo PhD**, Pablo D Hernandez Martinez MD
Purpose: To study the multi-wavelength retinal imaging (MWL) characteristics in cases of
central serous chorioretinopathy (CSC) and its clinical spectrum. Methods: The macular
area of consecutive patients with CSC, pachychoroid pigment epitheliopathy (PPE), and
neovasculopathy (PNV) was simultaneously scanned with MWL, autofluorescence (AF),
and OCT. Results: Leaking points appeared whitish on MWL and hypoautofluorescent on
FA; outer retinal atrophic areas appeared blue-green on MWL and hyperautofluorescent on
FA; drusen-like deposits appeared red on MWL and hyperautofluorescent on FA. Conclusion: MWL imaging may distinguish the different types of retinal changes in cases of CSC,
PPE, and PNV. The potential clinical value of these findings warrants further investigations.

Vitreomacular Adhesion Progression Traits During Normal
Aging of Human Eyes
Presenting Author: Agustina Cecilia Palacio MD
Co-Author(s): Akash Gupta, Puja Jadav, Brooke L W Nesmith MD, Shlomit Schaal
MD*, Lahav Lipson
Purpose: To characterize the normal progression of vitreomacular adhesion (VMA) through
8 decades of life. Methods: Spectral domain OCT (Heidelberg Spectralis) was used to
measure and delineate the area of VMA in 324 normal eyes of asymptomatic patients aged
20-97 years. Results: Patients were grouped by decade (3rd to 10th). As a proportion of
total macular area, VMA declined with age (93 1%, 76 2%, 60 3%, 49 2%, 49
2%, 25 2%, 3 1%, 2 1%). VMA area continuously and significantly decreased (26 2
mm2, 21 7 mm2, 17 8 mm2, 14 7 mm2, 14 5 mm2, 7 7 mm2, 0.9 2 mm2, 0.8 2
227
Scientific Posters
Purpose: To demonstrate OCT angiography findings of diabetic retinopathy. Methods:

Ten patients with proliferative and nonproliferative diabetic retinopathy were imaged with
fluorescein angiography and compared to OCT angiography using split-spectrum amplitude
decorrelation angiography algorithm (SSADA). Results: En face and 3-D OCT angiography
show areas of retinal neovascularization, capillary dilation, and nonperfusion in eyes with
diabetic retinopathy. These areas correlate well with fluorescein angiography. Conclusion: OCT angiography demonstrates clinically relevant features of diabetic retinopathy
and shows promise as a noninvasive alternative to fluorescein angiography in the management of diabetic retinopathy.
Purpose: We investigated microvascular changes using a prototype 400-kHz long wavelength swept source OCT (SS-OCT) and noninvasive retinal angiography (OCTA) in eyes
with macular pathology. Methods: Volumetric scans of 15 patients with drusen, 4 patients
with geographic atrophy (GA), and 32 diabetics with and without diabetic retinopathy (DR)
using an ultrahigh-speed SS-OCT prototype to perform OCTA and generate en face images
at different depths. Results: Choriocapillaris drop-out was seen underlying some drusen
and beyond the margins of GA. Enlargement of the foveal avascular zone and patchy loss of
choroidal vasculature was seen in eyes with DR and in a subset of diabetic eyes with no DR.
Conclusion: The ability to comprehensively image changes in 3-D structural and vascular
features, especially the choriocapillaris, promises to be an important tool for assessing
early disease and progression.
Scientific Posters
mm2) and became significantly more irregular with increasing decades of life. Differences
in gender, race, and refraction were insignificant. Conclusion: VMA progresses throughout life in healthy eyes. VMA progression traits in normal aging are characterized herein.

Retinal Angiography Without Contrast Media: SplitSpectrum Amplitude Decorrelation Algorithm-Based OCTAngiography
Presenting Author: Ching-Jygh Chen MD*
Co-Author(s): Albert L Lin MD, Matthew James Olson
Purpose: To evaluate the retinal vascular imaging potential of a novel, noninvasive splitspectrum amplitude decorrelation algorithm (SSADA)-based OCT-angiography. Methods:
Prospective nonrandomized comparative study of retinal images obtained by standard fluorescein angiography and SSADA OCT-angiography. Results: Quality images were obtained
by this OCT-angiography in 78% of 151 eyes. OCT-angiography identified vascular changes
in major retinal vascular diseases and localized choroidal neovascular membrane in AMD.
Conclusion: SSADA OCT-angiography can produce retinal vascular images without contract media. The en face scan capability allows it to image the vascular changes at different
tissue depths. However, it is more difficult to obtain high-quality images, and the image
size is limited.

H En Face Imaging of the Choroid in Polypoidal Choroidal
Vasculopathy Using Swept-Source OCT
Presenting Author: Tarek Alasil MD
Co-Author(s): Daniela Ferrara MD PhD, Mehreen I Adhi MBBS, Erika M Brewer MD,
Martin F Kraus MS**, Caroline R Baumal MD*, James Fujimoto PhD*, Jay S Duker
MD*, Nadia Khalida Waheed MD
Purpose: To define morphological features of polypoidal choroidal vasculopathy (PCV) using swept source OCT (SS-OCT). Methods: Patients with PCV were scanned with a prototype 1050-nm SS-OCT. Results: Six eyes from 4 patients with unilateral PCV were enrolled.
En face imaging demonstrated pigment epithelial detachments (PEDs). Irregularities in the
outline of the PED were identified as small adjacent PEDs and correlated with the polypoidal lesions seen on indocyanine green angiography in all PCV eyes. The feeder vessels
were visualized in 3 out of 4 PCV eyes. En face SS-OCT demonstrated abnormal dilated choroidal vessels in 4 out of 4 PCV eyes, and in the 2 enrolled contralateral eyes. Conclusion:
En face SS-OCT provides an in vivo tool to visualize the choroidal vascular features in PCV.
Scientific Posters

Paravascular Inner Retinal Defects Associated With the
Deviation of Major Retinal Vessels
Presenting Author: Yuki Muraoka MD
Co-Author(s): Masayuki Hata MD**, Abdallah A Ellabban, Akitaka Tsujikawa MD
PhD*, Kenji Yamashiro MD PhD, Sotaro Ooto MD*, Hideo Nakanishi, Nagahisa
Yoshimura MD PhD*
Purpose: To investigate the clinical characteristics of paravascular inner retinal defect
(PIRD) and its effect on retinal function. Methods: We examined 34 eyes with PIRD by using OCT and Goldmann perimetry (GP). Results: Most PIRDs were detected along the major
retinal vessels in highly myopic eyes. These vessels appeared to be deviated by the axial
length elongation. However, PIRDs had formed along the major retinal vessels deviated by
the traction of the epiretinal membrane (ERM) in 3 eyes with normal axial length. The visual
field defects caused by the PIRDs were revealed by GP. Conclusion: Deviated major retinal
vessels due to axial length elongation or ERM may result in PIRDs, which could cause the
corresponding visual field defects.

SOE Ocular Injuries Related With Empty Bullets During
Military Training: A 10-Year Review
Presenting Author: Soner Guven
Co-Author(s): Ali H Durukan MD, Cuneyt Erdurman MD
Purpose: To raise awareness of potential significant ocular damage secondary to empty
bullets while shooting training. Methods: We reviewed the cases of empty bullet injuries
from 2004 to 2014. Patients demographics, visual acuity (baseline and final), ocular trauma
scores, and surgical approaches have been recorded. Results: Fifteen eyes of 15 patients
with an average age of 21.3 years were included. None had ocular protection at the time of
ocular injury. Nine eyes (60%) of the patients had closed-globe and 6 (40%) had open-globe
228
injury. The baseline and final visual acuities were 20/200 or better in 26.6% and 80% of
patients, respectively. The most common ocular findings were hyphema (60%) and vitreous
hemorrhage (53%). Conclusion: Ocular injuries related to empty bullets are unpredictable.
This is the first report about this topic.

SOE Ocular Injury Characteristics and Surgical Outcomes in
Terrorist Warfare
Presenting Author: Gungor Sobaci MD
Purpose: To describe ocular injury characteristics and surgical outcomes in terrorist warfare. Methods: Retrospective review of injuries by terrorist attack and complete data for
Ocular Trauma Classification System for the last 10 years. Results: 112 patients (130 eyes)
averaging 23 years had open-globe in 80% and closed-globe in 20%. Intraocular foreign
body, in 76.9%, was the most common (type C), as was grade 4, in 55.3%. All in closed
globe and 67.3% in open globe had Zone III injury; 6 eyes (4.61%) had endophthalmitis.
All had no protective eyewear. Improvised explosive devices and mines caused 49.1% and
39.2% of the injuries, enucleation in 23%; VRS in 87%. PVR, comprising 55% and resulting
in anatomical and/or functional failure (< VA 5/200) in 57.7% eyes, was the most common
and dreadful complication. Conclusion: Devastating visual outcomes are common in terrorist warfare. Protective eyewear should be a must.

Comparative Study of Initial Ozurdex vs. Avastin in the
Treatment of Macular Edema following Central Retinal Vein
Occlusion
Presenting Author: Vincent A Deramo MD*
Purpose: To compare visual outcomes in eyes with macular edema following central
retinal vein occlusion after initial treatment with Ozurdex dexamethasone implant (DEX)
or bevacizumab (BEV). Methods: Prospective, randomized, 6-month trial comparing initial
treatment with DEX 0.7 mg (Group I, n = 14 eyes) or BEV 1.25 mg (Group II, n = 13 eyes).
At each monthly visit, eyes with macular edema were treated with BEV 1.25 mg in a p.r.n.
fashion. Results: Visual acuity improved 11.1 letters in Group I and 16.1 letters in Group II
(P = .35). OCT macular thickness decreased 350 m in Group I and 382 m in Group II (P =
.75). On average, eyes in Group I received 2.6 injections and eyes in Group II received 5.1
injections (P = .002). Conclusion: Eyes initially treated with DEX received significantly
fewer injections in a 6-month period. Vision and OCT findings were similar.

SOE Temporal Inverted Flap Technique for Macular Hole
Closure: A Comparative Study
Presenting Author: Jerzy Nawrocki MD PhD
Co-Author(s): Karolina Dulczewska-Cichecka**, Zofia Michalewska MD
Purpose: Comparative study: Classic internal limiting membrane (ILM) flap technique
(Group A) vs. temporal inverted flap technique (Group B) for macular hole. Methods: Fortythree eyes with stage IV macular hole were randomized in Group A and 44 in Group B. In
Group B, ILM between the fovea and optic disc was not peeled. Results: 100% closure
rate. In Group B retina nerve fiber layer (RNFL) defects were less frequent and a U-shape
contour was achieved faster. Conclusion: The temporal inverted ILM flap technique
seems to be equally as effective as the original method, with less damage to the RNFL. It
allows us to achieve good anatomical and functional results.

Vitrectomy and Scleral Shortening in Patients With Macular
Hole Retinal Detachment or Myopic Traction Maculopathy
Presenting Author: Yoshimasa Ando MD
Purpose: The purpose of this study was to assess anatomical and functional outcomes
after vitrectomy with scleral shortening in patients with high myopia. Methods: Fourteen
patients with high myopia, who had progressive visual impairment due to macular hole retinal detachment (MHRD) or traction maculopathy were studied. Myopic macular schisis or
shape of posterior staphyloma were confirmed with OCT. Pars plana vitrectomy with scleral
shortening was performed in all eyes of 14 patients. Results: The macular detachment
resolved completely in all eyes of MHRD (6 eyes) or traction macular detachment (8 eyes).
The curvature of the posterior staphyloma became less steep after the operation according
to OCT findings. Conclusion: Scleral shortening may be effective for changing the shape
of posterior staphyloma.
Scientific Posters
Scleral Imbrication Combined With Pars Plana Vitrectomy
for Myopic Schisis

SOE Perfusion Pressure During Pars Plana Vitrectomy
Presenting Author: Takayuki Baba MD
Purpose: To calculate mean ocular perfusion pressure (MOPP) during pars plana vitrectomy
(PPV) in order to assess if it drops below safe values during surgery. Methods: Real-time
IOP and noninvasive blood pressure (NBP) were continuously monitored throughout surgery and compared to baseline in 18 consecutive patients undergoing PPV for a variety of
reasons. Results: Average IOP increased and NBP decreased during surgery, compared to
baseline. MOPP decreased an average 37.1% compared to baseline. Sixteen of 18 patients
had a significant intraoperative MOPP decrease; 15/18 spent more than 20% and 5/18
more than 50% of the entire surgery below 30 mmHg MOPP. Conclusion: MOPP may drop
well below safe values during surgery for a lengthy time. This could explain visual field
defects after uncomplicated surgery.
Co-Author(s): Sumiyoshi Tanaka MD PhD, Shuichi Yamamoto MD

Purpose: To report the efficacy of scleral imbrication combined with pars plana vitrectomy
(PPV) for myopic schisis (MS). Methods: Thirteen cases with MS have been treated by
scleral imbrication combined with PPV. We retrospectively reviewed BCVA and resolution
of MS determined by spectral domain OCT (SD-OCT). Results: BCVA improved from 0.57
0.39 to 0.41 0.37 logMAR units (P = .011) with a follow-up of 6.7 months. Significant resolution of MS was observed by SD-OCT in 92% of cases. No adverse event, including macular hole formation and chorioretinal atrophy, was observed in the postoperative period.
Conclusion: Scleral imbrication combined with PPV appears to be effective to treat MS.

Cystoid Macular Edema After Cataract Surgery in Eyes With
Previous Vitrectomy for Epiretinal Membrane Removal
Presenting Author: Tanuj Banker MD
Co-Author(s): Michael M Lai MD PhD, James M Osher MD
Presenting Author: Tommaso Rossi MD

A Retrospective Analysis of the Correlation Between
Central Serous Chorioretinopathy and Obstructive Sleep
Apnea
Purpose: To determine the incidence of cystoid macular edema (CME) after cataract extraction / posterior chamber IOL (CE/PC-IOL) in eyes that have previously undergone pars
plana vitrectomy (PPV) with epiretinal membrane peel (MP) with and without internal limiting membrane (ILM) peeling. Methods: A review of 81 cases of ERM removal and subsequent CE/PC-IOL. All PPVs were done using 23-/25-gauge systems. CME was documented
by exam, spectral domain OCT, and fluorescein angiography. Results: The mean visual
acuity was 20/60 pre-MP, 20/80 pre-CE/PC-IOL, and 20/30 (post-CE/PC-IOL (P < .01). The
mean central macular thickness (CMT) was 396.30 pre-MP, decreasing to 334.1 post-MP
(P < .01), and to 341.41 post-CE/PC-IOL (P < .02). Post-CE/PC-IOL, 21.0% of eyes had CME.
The rate of CME with ILM peeling was 31.2%, vs. 7.7% without (P < .02). Conclusion: CME
develops frequently after CE/PC-IOL in eyes with previous MP. Peeling of the ILM may be
associated with higher rates of CME.
Presenting Author: Christopher Joel Rodriguez MD

Cystoid Macular Edema After Cataract Surgery in Eyes With
Previous Macular Hole Surgery

Application of Transpupillary Thermotherapy in the
Treatment of Central Serous Chorioretinopathy
Presenting Author: Tanuj Banker MD
Presenting Author: Durgesh Kumar MBBS
Co-Author(s): James M Osher MD, Michael M Lai MD PhD
Co-Author(s): Pankhuri Johari MBBS**
Purpose: To determine the incidence of cystoid macular edema (CME) after cataract extraction / posterior chamber IOL (CE/PC-IOL) in eyes that have undergone macular hole
(MH) surgery with 23-/25-gauge pars plana vitrectomy (PPV). Methods: A review of eyes
(N = 75) that underwent MH surgery and subsequent CE/PC-IOL. Exam, spectral domain
OCT, and fluorescein angiography documented CME. The primary outcome measure was
the incidence of CME post-CE/PC-IOL. Results: The mean visual acuity was 20/100 preMH surgery, 20/80 prior to CE/PC-IOL, and improving to 20/40 post-CE/PC-IOL (P = .005, P
< .001). Post-CE/PC-IOL, 9.5% of eyes had CME. Neither internal limiting membrane (ILM)
peeling nor time between MH repair and CE/PC-IOL were significantly related to CME (P =
.64, P = .75). Conclusion: Occurrence of CME was not associated with ILM peeling during
MH surgery, or the interval between MH surgery and CE/PC-IOL.
Purpose: To evaluate the role of transpupillary thermotherapy (TTT) in treating leaks of

central serous chorioretinopathy (CSCR). Methods: Sixty-three eyes with CSCR of three
to 18 weeks duration, with fall in visual acuity (VA) of two to five lines on Snellen chart,
were investigated with fundus fluorescein angiography and OCT . All single (64%) or multiple leaks (subfoveal/extrafoveal) were treated with titrated TTT power of 110 to 200 mW
(10- to 30-mW subthreshold, i.e., power to produce mild blanching) and spots size of 0.6
or 1.0 mm for 90 seconds. Results: At one week follow-up, submacular fluid (SMF) was
reduced by 75% to 83% with VA gain of two to four lines on Snellen chart in >75% of eyes.
Overall success rate was 92.2%. Earliest complete SMF reabsorption was seen on tenth
post-TTT day and latest in the eighth week in the chronic case. Both subfoveal/extrafoveal
leaks closed successfully. Conclusion: TTT is a fast, safe, and effective modality in all
forms of CSCR.

Vitrectomy, Perfluorocarbon, and External Subretinal
Drainage for Eyes With Advanced Coats Disease With Total
Retinal Detachment

SOE H A New Surgical Technique to Treat Hypotony
Presenting Author: Shunji Kusaka MD*
Co-Author(s): Gaye Kilic, Ali H Durukan MD, Ali H Durukan MD
Purpose: To determine the efficacy of vitrectomy for severe Coats disease with total retinal
detachment (RD). Methods: The medical records of 10 eyes of 10 patients with Coats
disease (stage 3B, 9 eyes; stage 4, 1 eye) that had undergone surgery for total RD were
reviewed. All patients were boys, with a mean age of 5.9 years. Results: Vitrectomy and
injection of perfluorocarbon liquid (PFCL), followed by external drainage of subretinal fluid
(SRF), were performed on all eyes. The retinas were successfully reattached in 8 eyes, with
a mean follow-up of 18.9 months. In the other 2 eyes, the retinas remained detached due
to reproliferations. Conclusion: These results indicate that vitrectomy, use of PFCL, and
external SRF drainage are effective in reattaching the retina in eyes with advanced Coats
disease.
Purpose: To elucidate an association between central serous chorioretinopathy (CSCR)

and obstructive sleep apnea (OSA). Methods: This is a retrospective study using the Department of Defenses health informatics division database to determine the yearly incidence of CSCR, the prevalence of OSA, and then the prevalence of OSA in CSCR compared
with the general population of active-duty/retired Air Force and/or beneficiaries from 2009
to 2013. Results: A total of 924 patients were diagnosed with CSCR. Of those, 20.5% also
had a diagnosis of OSA at the end of the study period compared with only 7.8% of the total
population (1,369,407). Conclusion: This higher prevalence of OSA in the CSCR population
likely represents an association between these two conditions.
Presenting Author: Gokhan Gurelik MD*

Purpose: To assess the effect of a new surgical method, implantation of a capsular tension
ring to the iridocorneal angle, for the treatment of severe hypotony. Methods: Nine eyes
of nine patients were included in the study. All eyes had severe ocular hypotony (IOP, <4
mmHg). A 13-mm capsular tension ring was placed to the iridocorneal angle through a corneal incision. All patients were followed for at least three months. Results: IOP increased
in all eyes, and this IOP rise remained stable during the follow-up period. Range of IOP rise
was 1 to 10 mmHg. No ocular complication was noted due to surgical procedure. Conclusion: In cases of severe ocular hypotony, as a new method, a 13-mm capsular tension ring
implantation to the iridocorneal angle in order to partially block humor aqueous outflow
may result in an increase of IOP.
229
Scientific Posters
Co-Author(s): Yoshikazu Hatsukawa MD**, Tatsuo Kodama MD, Yoshikazu Shimomura

MD**
Co-Author(s): Darrell E Baskin MD
Scientific Posters
3D-Threshold Amsler Grid Quantification of Distortions in
Macular Pucker and Vitreomacular Traction
Co-Author(s): Kenneth Yee, Christianne Wa, Wolfgang Fink MS PhD*, Alfredo A
Sadun MD PhD*, Jerry Sebag MD*
Purpose: To determine if 3D computer-automated threshold Amsler grid (3D-CTAG) testing
can quantify distortions in macular pucker (MP) and vitreomacular traction (VMT) and to
assess the response to surgery. Methods: 3D-CTAG combines Amsler grid testing at five
different contrast levels into a quantitative index of distortions expressed as a percentage
of the hill of vision. Distortions were quantified in 26 eyes (nine MP, four VMT, and 13
control fellow eyes) before and one month postvitrectomy with membrane peel. Results:
There was 3.9% 5.1% hill-of-vision volume lost preop (controls, 0.24% 0.8%; P < 0.03),
which correlated with macular thickness on OCT (R = 0.67, P < 0.05). On average, patients
had a 56% improvement one month postop (P < 0.03). Conclusion: 3D-CTAG quantifies
distortions induced by MP and VMT, as well as an improvement after surgery.

Prognostic Factors for Visual Outcomes in CNV Secondary
to Pathological Myopia (Myopic CNV)
Presenting Author: Kyoko Ohno-Matsui MD*
Purpose: To identify prognostic factors for improvement in best-corrected visual acuity
(BCVA) in patients with choroidal neovascularization (CNV) secondary to pathological myopia (myopic CNV). Methods: Post hoc analysis of MYRROR study data (Phase 3, double
masked, 48 week) in which 122 myopic CNV patients were randomized 3:1 to intravitreal
aflibercept injection (IAI) 2 mg or sham injection. Results: Stepwise linear regression analysis of patients receiving IAI 2 mg identified age (P = 0.0056), baseline BCVA (P < 0.0001),
spherical equivalent value (P = 0.0059), and baseline central retinal thickness (CRT; P =
0.0394) as statistically significant prognostic factors for improvement in BCVA at week 48.
Conclusion: In patients with myopic CNV, receiving IAI, age, baseline BCVA, spherical
equivalent value, and baseline CRT were prognostic factors for BCVA improvements.

Spectrum of Non-paraneoplastic Autoimmune Retinopathy
Among Asian Patients With Retinal Diseases
Presenting Author: Mayuri Bhargava MBBS MD
Scientific Posters
Co-Author(s): Ranjana Mathur FRCS(ED)**, PengGuan Ong BS, Tien Yin Wong MBBS*
Purpose: To describe demographics of nonparaneoplastic autoimmune retinopathy (npAIR)
in an Asian population with retinal diseases. Methods: Retrospective case series. Results: Serum antiretinal antibodies (ARA) was positive in 46 patients, with mean presenting vision of 6/24. We found that 82.6% patients had retinitis pigmentosa (RP). Remaning patients had Biettes dystrophy, X-linked retinoschisis, myopic degeneration, diabetic
retinopathy, choroidtis, and vasculitis. Moreover, 71.7% had ARA positive against multiple
proteins, 46 kDa (enolase) being the most common. Thirty-two patients (69.5%) underwent
immunosuppresive therapy for three months, among which improvement was noted in 81.2
%, with mean posttreatment visual acuity of 6/15. Conclusion: In our npAIR study, RP
was the most common retinal disease, with visual improvement noted in 81% of patients
with treatment.

Initial Clinical Outcomes of Intravitreal Aflibercept for
Polypoidal Choroidal Vasculopathy
Presenting Author: Akiko Yamamoto MD
Co-Author(s): Hideki Koizumi MD, Masaaki Saito MD, Ichiro Maruko MD, Tetsuju
Sekiryu MD, Tomohiro Iida MD*, Annabelle A Okada MD*
Purpose: To investigate six-month outcomes of aflibercept therapy in treatment-naive polypoidal choroidal vasculopathy (PCV). Methods: Retrospective analysis of 87 eyes treated
at three tertiary centers. After three monthly aflibercept injections, patients were injected
every two months with additional rescue injections performed for worsening. Results:
LogMAR visual acuity improved from 0.32 at baseline to 0.20 at six months (P < 0.001). Polypoidal lesions disappeared in 47% and decreased in 31% of eyes by indocyanine green angiography. Mean central retinal thickness decreased from 318 to 205 m (P < 0.001). Conclusion: Improvement was observed in PCV eyes treated with aflibercept for six months.
230

Treatment Outcomes of Anti-Vascular Endothelial Growth
Factor Monotherapy vs. Pars Plana Vitrectomy With
Subretinal Tissue Plasminogen Activator for Submacular
Hemorrhage due to Exudative Macular Degeneration
Presenting Author: Enchun M Liu MD
Co-Author(s): Rithwick Rajagopal MD, Bradley T Smith MD, M Gilbert Grand MD
Purpose: To compare visual outcomes in patients with submacular hemorrhage (SMH)
who were treated with a nonsurgical versus surgical approach. Methods: We retrospectively reviewed charts of patients with SMH due to wet AMD and found 74 patients who
were treated surgically and 33 patients who were treated with anti-VEGFs only. Results:
In the control group, the average change in logMAR visual acuity (VA) was 0.20, 0.26,
and 0.20 at three, six, and 12 months, respectively (P 0.05 for all three). In the surgical
group, the average change in VA was 0.38, 0.40, and 0.36 at three, six, and 12 months,
respectively (P 0.001 for all three). Conclusion: The average change in VA at the final
visit was 0.34 for the surgical group and 0.15 for the anti-VEGF-only group (P = 0.22).

H Choroidal Thickness Measured Using Enhanced-Depth
Imaging OCT in AMD
Presenting Author: Glenn C Yiu MD
Co-Author(s): , Sandra Stinnett, Neeru Sarin, Sina Farsiu PhD*, Emily Y Chew MD,
Wai T Wong MD PhD**, Cynthia A Toth MD*
Purpose: To compare choroidal thickness (CT) in intermediate or advanced AMD using
enhanced-depth imaging OCT (EDI-OCT). Methods: CT was measured using semiautomated segmentation of EDI-OCT images from 326 eyes of 164 subjects as part of the AREDS2
Ancillary SD-OCT Study. Variables associated with subfoveal CT (SFCT) and average CT
(AvgCT) were determined by multivariate regression. Mean SFCT and AvgCT were compared between controls (n = 154) and intermediate (n = 109) and advanced AMD (n = 62).
Results: SFCT and AvgCT were associated with age and refractive error (P < 0.001). Mean
SFCT and AvgCT were reduced in advanced (P = 0.008) but not intermediate AMD (P =
0.098). When adjusted for age, there was no difference in SFCT (P = 0.675) or AvgCT (P =
0.746) across all groups. Conclusion: CT may not show significant thinning in intermediate
or advanced AMD when adjusted for age.

Factors Associated With Retreatment After Ranibizumab
Loading Treatment for Exudative AMD
Presenting Author: Yoshimasa Kuroda
Co-Author(s): Kenji Yamashiro MD PhD, Akitaka Tsujikawa MD PhD*, Sotaro Ooto
MD*, Hiroshi Tamura MD, Akio Oishi MD PhD*, Hideo Nakanishi MD**, Masahiro
Miyake MBCB DOMS, Munemitsu Yoshikawa, Nagahisa Yoshimura MD PhD*
Purpose: To determine factors associated with retreatment requirement after ranibizumab
loading treatment for AMD or polypoidal choroidal vasculopathy (PCV). Methods: Three
hundred twenty-six patients who received three monthly ranibizumab injections followed
by PRN retreatment were reviewed. Results: Patients who required retreatment within 12
months (n = 262) were significantly older and more male prevalent than those who did not
(n = 81; P = 0.028 and 0.026, respectively). Similar tendency was detected in 199 patients
followed up for 24 months, but there was no significant difference in baseline visual acuity, lesion size, existence of PCV, and genotype of ARMS2 and CFH between patients who
required retreatment (n = 175) and those who did not (n = 35). Conclusion: Sex and age
would be associated with the retreatment requirement.

SOE Subgroups of Anti-Vascular Endothelial Growth Factor
Nonresponders in Neovascular AMD
Presenting Author: Jale Mentes MD*
Co-Author(s): Mine Baris MD, Serhad Nalcaci**, Zafer Oztas MD, Cezmi Akkin MD
Purpose: To identify subgroups of nonresponders (nonRs) to anti-VEGF therapy in eyes with
neovascular AMD (nvAMD). Methods: We prospectively classified anatomical responses
of 235 consecutive eyes with nvAMD treated with monthly intravitreal anti-VEGF injections.
Those classified as nonRs after the sixth monthly injection were seperated into subgroups
based on findings. Results: Overall, 33.2% of eyes were nonRs. Five subgroups of nonRs
were identified as true (27%), partial (37%), anti-VEGF dependent (16.7%), worsening(14%), and nonR over time (5%). Conclusion: Identification of anti-VEGF nonR
subgroups in nvAMD may aid to find the causes of nonresponse.
Scientific Posters
Factors Associated With the Required Interval of
Ranibizumab Treatment for Exudative AMD

SOE Intraocular Pharmacokinetics of Aflibercept and
Vascular Endothelial Growth Factor
Presenting Author: Kenji Yamashiro MD PhD
Presenting Author: Nil Celik*
Co-Author(s): Yoshimasa Kuroda, Masahiro Miyake MBCB DOMS, Munemitsu

Yoshikawa, Akitaka Tsujikawa MD PhD*, Sotaro Ooto MD*, Hiroshi Tamura MD, Akio
Oishi MD PhD*, Hideo Nakanishi, Nagahisa Yoshimura MD PhD*
Co-Author(s): Alexander Scheuerle**, Gerd U Auffarth MD*, Stefan Dithmar MD
Purpose: To determine factors associated with the interval between loading treatment
and retreatment required for AMD. Methods: Three hundred twenty-six patients who received three monthly ranibizumab injections followed by PRN retreatment were reviewed.
Results: The loading treatment completely resolved exudative change in 236 eyes, though
not in 107 eyes. There was no significant difference in age, sex, baseline visual acuity,
lesion size, existence of polypoidal choroidal vasculopathy (PCV), and genotype of ARMS2
and CFH between these two groups. Among 262 eyes that underwent retreatment, lesion
size and PCV lesion showed significant association with the interval to the retreatment.
Conclusion: Larger lesion size and PCV would be associated with shorter interval of retreatment requirement.

Comparison of the Time to Recurrence After Ranibizumab or
Aflibercept Loading for AMD
Presenting Author: Maiko Inoue MD
Co-Author(s): Akira Arakawa MD, Shin Yamane MD, Kazuaki Kadonosono MD
Purpose: To compare the time to recurrence between patients with treatment-naive AMD
who underwent intravitreal ranibizumab (IVR) or aflibercept (IVA) in routine clinical practice.
Methods: We retrospectively studied patients with AMD treated with three consecutive
monthly injections of IVR or IVA followed by pro re nata regimen. The time to recurrence after the third injection in the induction phase to first recurrence was compared with KaplanMeier analysis. Results: One hundred forty-three eyes were treated with IVR, and 49 eyes
were treated with IVA. The mean time to recurrence was three months with IVR and five
months with IVA, with no significant difference (P = 0.189). Conclusion: Results suggest
that the injection burden after ranibizumab or aflibercept loading may be similar.

Comparative Evaluation of Dynamic Change of Aqueous
Concentrations of VEGF Receptors Between Ranibizumab
and Aflibercept in Patients With Wet AMD
Presenting Author: Masahiko Shimura MD PhD
Co-Author(s): Teruumi Minezaki, Hiroshi Goto MD

Home Monitoring With the Preferential Hyperacuity
Perimeter in Patients at High Risk for Neovascular AMD
Presenting Author: Merina Thomas MD
Co-Author(s): Yulia Wolfson MD, Voraporn Chaikitmongkol MD, Susan B Bressler
MD*, Neil M Bressler MD*
Purpose: To determine the ability of patients with intermediate AMD to qualify to use
the home preferential hyperacuity perimeter (PHP). Methods: Patients completed a test to
determine if they qualified to use the device at home successfully. Five stable tests were
subsequently used to determine if a baseline could be established. Results: Ninety-one
of 131 patients (69%; 95% CI, 61%77%) passed the qualification test. Eighty-two of 86
(95%; 95% CI, 88%99%) established a baseline. The mean age of those who qualified and
did not qualify was 73.1 and 80.8, respectively (P < 0.005). Conclusion: Of patients with
intermediate AMD using the home PHP, 61% to 77% likely will pass a qualification test, and
88% to 99% likely will establish a baseline to initiate home monitoring. Younger patients
appear more likely to qualify.

The Association Between Reticular Macular Disease, a
Subphenotype of Early AMD, and Coronary Artery Disease in
Young Patients
Presenting Author: Rachel M Cymerman
Co-Author(s): Adam Skolnick MD**, Camellia Nabati MS, R Theodore Smith MD
Purpose: To screen patients aged 50 to 75 with and without coronary artery disease (CAD)
for reticular macular disease (RMD). The association between CAD and AMD is well established in patients older than 70 years of age but not in younger patients. However, RMD, a
high-risk form of early AMD, also confers decreased longevity, suggesting that RMD and
CAD might coexist at younger ages. Methods: Thirty-one serial patients from one cardiology practice (AHS , WJC; 18 with CAD and 13 without; 42% female; mean age, 64.1) with
no known retinal pathology were imaged with IR /spectral-domain OCT and assessed by
a retina specialist for certain (on IR and OCT) or likely (on IR or OCT) RMD. Results: The
presence of certain or likely RMD was more frequent in patients with CAD versus without
(RR = 2.17, CI = 1.064.44; P = 0.03). Conclusion: A specific relationship between CAD and
RMD would suggest a systemic cause for RMD and warrants further study.

SOE Predictive Value of OCT Morphology on BCVA
Outcomes of Different Ranibizumab Regimens for
Neovascular AMD
Presenting Author: Sebastian M Waldstein MD
Co-Author(s): Jonathan James Wright MS**, James Warburton*, Philippe Margaron
PhD*, Christian Simader, Ursula M Schmidt-Erfurth MD*
Purpose: To establish predictive factors for best-corrected visual acuity (BCVA) outcomes
and retreatment necessity from structure-function correlation. Methods: Standardized
optimized coherence tomography (OCT) analysis of 353 patients receiving either monthly
(frequent) or quarterly (infrequent) ranibizumab treatment in EXCITE. Results: Significant
predictive baseline OCT factors for 12-month BCVA change were vitreomacular interface
status (P < 0.01) and subretinal fluid (SRF; P = 0.05). Mean letter gain differences between
frequent and infrequent treatment were +1 for eyes with SRF and +1 for eyes with posterior
vitreous detachment (PVD) versus +12 for eyes without SRF and >9 for eyes without PVD.
Conclusion: In patients with SRF or PVD at baseline, treatment frequency may be reduced
with similar BCVA outcomes, while patients without SRF/PVD may require continuous
monthly treatment.

Ranibizumab 1 mg as Rescue Therapy for Patients Failing
Traditional Therapy for the Treatment of Neovascular AMD
Presenting Author: Vaidehi S Dedania MD
Co-Author(s): Pawan Bhatnagar MD**, Devang Laxmikant Bhoiwala, Naomi S Falk
MD**, Paul Beer MD*
Purpose: To evaluate the efficacy of high-dose ranibizumab (RZB) for the treatment of
neovascular AMD in patients with persistent fluid on traditional therapy (bevacizumab 1.25
mg or RZB 0.5 mg). Methods: Retrospective review of best-corrected visual acuity (BCVA)
and central foveal thickness (CFT) outcomes of 38 eyes with intractable disease switched
to RZB 1 mg. Results: After switching from monthly traditional dose therapy to monthly
RZB 1 mg, the mean baseline BCVA improved from 20/89 to 20/75 at one year (P = 0.16).
The mean baseline CFT of 323 m decreased to 281 m at one year of follow-up (P = 0.03).
231
Scientific Posters
Purpose: To compare the dynamic change of aqueous concentrations of VEGF receptors

betweeen ranibizumab and aflibercept in patients with wet AMD. Methods: Aqueous
humors were collected at the time of three monthly injections of anti-VEGF drugs (15 ranibizumab, 16 aflibercept). Aqueous concentrations of VEGF and soluble VEGF receptors
(sVEGFRs) in each sample were analyzed by enzyme-linked immunosorbent assay. Results:
Aqueous VEGF was dramatically reduced by both drugs. While aqueous sVEGFRs were
gradually decreased in ranibizumab-treated eyes, they increased in aflibercept-treated
ones. Conclusion: Although both ranibizumab and aflibercept suppressed an intraocular
VEGF activity in AMD, the dynamic changes of intraocular sVEGFRs were dependent upon
the action mechanisim of anti-VEGF drugs.
Purpose: To determine pharmacokinetics of aflibercept (AFB) and VEGF-A in aqueous humor. Methods: We included seven nonvitrectomized patients with wet AMD, who received
an intravitreal injection (IVI) of 2 mg AFB for the first time. Samples were obtained prior to
IVI for six months (three times monthly, then every two months). Thus, of each patient, five
samples were analyzed with a self-developed ELISA for AFB. Results: In all cases, wet
AMD was inactive after IVI. Initial mean concentration of AFB was 300.47 46.97 g/mL
and remained stable with 0.87 0.43 g/mL, with small individual deviations. Initial mean
level of VEGF-A was 190.71 26.92 pg/mL. It significantly decreased after the first IVI to
93.71 26.92 pg/mL (P < 0.05) and remained stable. Conclusion: Levels of AFB and VEGFA remained stable after every month and every second month IVI.
Scientific Posters
Conclusion: RZB 1 mg led to a statistically significant improvement in CFT with a trend
towards improvement in BCVA and may be considered as rescue therapy for the treatment
of neovascular AMD in patients failing traditional therapy.

Long-term Follow-up of Intravitreal Aflibercept Injection for
Neovascular AMD
Presenting Author: W Lloyd Clark MD*
Purpose: To assess long-term safety of intravitreal aflibercept injection (IAI) in neovascular
AMD in an open-label extension study of VIEW1. Methods: In VIEW1, patients (n = 1,217)
received 0.5 mg ranibizumab every four weeks, 2 mg IAI every four weeks, 0.5 mg IAI every
four weeks, or 2 mg IAI every eight weeks after three monthly doses from weeks zero to
48, followed by mandatory quarterly dosing from weeks 52 to 96. After VIEW1, patients
received at least quarterly dosing of 2 mg IAI. Results: Patients in the extension study (n =
323) received a mean of 12.9 injections over a mean of 116.9 weeks. Best-corrected visual
acuity (BCVA) letter gain from the VIEW1 baseline was 10.2 and 6.8 at weeks 96 and 208.
The most common serious ocular adverse event was endophthalmitis (0.9%). Conclusion:
BCVA gains with anti-VEGF therapy in VIEW1 were largely maintained with IAI 2 mg in the
extension study. IAI showed no new safety signals.

Intravitreal Bevacizumab (Avastin) for Choroidal
Neovascularization Secondary to AMD: Five-Year Results of
a Collaborative Retina Study Group
Presenting Author: J Fernando Arevalo MD FACS*
Co-Author(s): Andrs Francisco Lasave MD, Lihteh Wu MD*, Maria H Berrocal MD*,
Manuel Diaz Llopis MD PhD**, Roberto Gallego-Pinazo MD*, Martin A Serrano MD,
Cristian Carpentier Giglio MD**, Arturo A Alezzandrini MD**, Veronica Gabriela
Fortuna MD**, Mauricio Maia MD*, Sergio Rojas*, Silvio M Lujan MD
Scientific Posters
Purpose: To report long-term results of intravitreal bevacizumab (IVB; 1.25 mg) for choroidal neovascularization (CNV) secondary to AMD. Methods: Retrospective, multicenter,
interventional case series of 247 patients (292 eyes). Results: Patients were followed up
for 60 months. Mean number of IVB injections per eye was 10.9 6.4 (range, one to 46).
At five years, best-corrected visual acuity decreased from 20/150 (logMAR, 0.9 0.6) to
20/250 (logMAR, 1.1 0.7; P 0.0001 ). Mean central macular thickness (CMT) decreased
from 343.1 122.3 m at baseline to 314.7 128.8 m (P = 0.009). Complications included
uveitis in six eyes (2.1%) and endophthalmitis in two eyes (0.7%). Conclusion: IVB treatment seems to provide significant decrease of CMT in CNV in AMD at five years. However,
no functional improvement was seen in 80.3% of eyes.

Intravitreal Bevacizumab (Avastin) for Diabetic Macular
Edema: Five-Year Results of a Multicenter Collaborative
Retina Study Group
Presenting Author: J Fernando Arevalo MD FACS*
Co-Author(s): Andrs Francisco Lasave MD, Lihteh Wu MD*, Michel Eid Farah MD,
Manuel Diaz Llopis MD PhD**, Roberto Gallego-Pinazo MD*, Arturo A Alezzandrini
MD**, Veronica Gabriela Fortuna MD**, Hugo Quiroz-Mercado MD*, Guillermo
Salcedo-Villanueva MD, Raul Velez Montoya MD**, Mauricio Maia MD*, Sergio
Rojas*, Martin A Serrano MD
Purpose: To report long-term results of intravitreal bevacizumab (IVB; 1.25 mg) for diffuse diabetic macular edema (DDME). Methods: Retrospective, multicenter, interventional,
comparative case series of 201 patients (296 eyes). Results: All patients were followed up
for 60 months. The mean number of injections per eye was 8.4 7.1 (range, one to 47). At
five years, best-corrected visual acuity (BCVA) remained stable at 20/100 (logMAR, 0.7
0.5; P = 0.387). Mean central macular thickness (CMT) decreased significantly from 403.5
142.2 m at baseline to 313.7 117.7 m (P 0.0001 ) at the end of follow-up. No safety
concerns were noted. Conclusion: IVB treatment seems to provide stability (43.6%) but
no improvement (71%) in BCVA and reduction in CMT for DDME at five years of follow-up.

SOE Multispot Lasers: What Constitutes an Effective
Panretinal Photocoagulation?
Presenting Author: Felicity Allen MBCHB
Co-Author(s): Alex Baneke MBBS*, Tom H Williamson md*, Samantha S Mann
MBBS*
Purpose: To assess the effectiveness of the multispot pattern scan laser (PASCAL) in treating proliferative diabetic retinopathy (PDR). Methods: We performed a retrospective study
of 56 patients (80 eyes) with PDR. The area of the treated retina was correlated with PDR
progression and compared with ETDRS guidelines of a 236 mm2 treatment area. Results:
At 12 months, 65% of eyes had progression of PDR. The mean burn area in this group was
310 mm2, compared with 536 mm2 in eyes that did not progress (P = 0.0091). Seventy percent of eyes with burn area >800 mm2 did not progress. Conclusion: Progression of PDR
occurs with PASCAL panretinal photocoagulation despite using the ETDRS burn area. We
recommend a burn area of 310 to 800 mm2 to reduce the risk of progression and potential
visual loss from PDR.

The Effects of Bariatric Surgery and Intensive Medical
Therapy on Diabetic Retinopathy: Two-Year Data
Presenting Author: Adiel G Smith MD
Co-Author(s): Rumneek Bedi BA, Stacy Alan Brethauer MD*, John P Kirwan, Richard E
Gans MD**, Deepak L Bhatt MD*, Rishi P Singh MD*
Purpose: Glycemic control (GC) improves immediately after bariatric surgery in type 2
diabetes mellitus (T2DM) patients. However, rapid change in GC may cause progression
of diabetic retinopathy (DR). This study examines the effect of bariatric surgery on DR.
Methods: One hundred fifty patients with T2DM had gastric bypass, sleeve gastrectomy,
or intensive medical therapy. Fundoscopic exams were performed at baseline and year 2.
Results: At two years, there was no statistically significant difference in DR among (P >
0.5) or within (P > 0.99) the cohorts. There was a difference in mean change in A1c values
between the medical therapy (-1.1) and surgical (-2.8, -2.7) groups (P < 0.001). Conclusion:
Despite improved GC and A1c, T2DM patients undergoing bariatric surgery or intensive
medical therapy may not be free from DR.

SOE Untargeted Metabolic Screen Identifies Purine
Metabolite With Potential Protective Effects in Diabetic
Retinopathy
Presenting Author: Liliana Paris MD
Co-Author(s): Edith Aguilar MD, Tim U Krohne MD*, Martin Friedlander MD, Yoshihiko
Usui MD
Purpose: To identify circulating factors that may help further understand why some type
1 and type 2 diabetic patients with long-term disease do not develop late-stage retinal
complications. Methods: A retrospective analysis was performed on blood serum samples
collected from well-characterized type 1 and type 2 diabetic patients with at least 20 years
of disease duration and different diabetic retinopathy stages, using a metabolomics mass
spectrometry-based approach. Results: Inosine, a purine metabolite, was significantly upregulated in 33% of the type 1 and type 2 diabetic patients who did not develop proliferative diabetic retinopathy (PDR) despite long-term diabetes. Conclusion: Inosine can be a
protective factor towards PDR development in a subset of diabetic patients and may hold
great potential as a therapeutic agent in diabetic retinopathy.

H Fluocinolone Acetonide for Diabetic Macular Edema: A
Single-Center 5-Year Follow-up Study
Presenting Author: Ramandeep Singh MBBS**
Co-Author(s): Mangat R Dogra MBBS, Vishali Gupta MBBS**, Abiraj Kumar Sr MS**,
Amod K Gupta MBBS
Purpose: To evaluate the efficacy of a fluocinolone acetonide (FA) insert at five years.
Methods: Subjects participating in the Fluocinolone Acetonide for Macular Edema trial
were evaluated prospectively for two more years. Outcome measures included change in
best-corrected visual acuity (BCVA), foveal thickness, and IOP. Results: Of 36 patients enrolled, 30 (83.3%) completed five-year follow-up, including nine in sham, 10 in low dose,
and 11 in high dose. At five-year follow-up, 16 of 21 (76%) patients in two FA insert groups
232
Scientific Posters
versus four of nine (44%) in the sham group improved by 15 BCVA letters. None had an
increase in IOP during the last two years. Conclusion: Both low-dose and high-dose FA
inserts continued to be effective at five years.

SOE Diabetic Retinopathy: The Influence of Antiangiogenic
Therapy in Choroidal Thickness
Presenting Author: Rufino Silva MD MSC*
Co-Author(s): Ines Carvalho Lains MD, Joao P Figueira MD*
Purpose: To analyze the effect of anti-VEGF in the choroidal thickness (CT) of diabetic retinopathy (DR) patients. Methods: Cross-sectional study. Twenty-five DR patients (50 eyes),
two groups: nonproliferative DR (NPDR) and dDME in both eyes, submitted to macular laser
in both eyes and anti-VEGF injection only in one eye (n = 11), and proliferative DR (PDR) in
both eyes, treated with panretinal photocoagulation in both eyes and anti-VEGF injection
only in one eye (n = 14). Results: Eyes treated with anti-VEGF showed a reduction in central CT (CCT; P = 0.002) and subfoveal CT (P = 0.004) versus fellow eyes treated with laser
. The PDR group revealed similar results (CCT, P = 0.02; subfoveal CT, P = 0.03). In NPDR
plus diabetic macular edema group, CCT was also significantly thinner in eyes treated with
anti-VEGF (P = 0.04). Conclusion: Diabetic eyes treated with anti-VEGF have reduced CT.

Four-Year Incidence and Progression of Diabetic
Retinopathy in India
Presenting Author: Tarun Sharma MBBS
Co-Author(s): Vaitheeswaran Kuloyhungan**, Swakshyar Saumya Pal**, Rajiv Raman
MBBS**
Purpose: To determine the four-year incidence and progression of diabetic retinopathy (DR)
in type 2 diabetes. Methods: Between 2003 and 2006, a cohort of 5,999 was enumerated
for estimating prevalence; subsequently eligible ones were re-evaluated for incidence and
progression. Results: The cumulative four-year incidence of any DR was 7.93% and, of
two-step progression, 1.67%. Multivariate models identified risk factors related to incidence, including 10-year increment of duration of diabetes (OR, 1.78) and anemia (OR, 1.85),
and factors related to progression, including duration (OR, 2.08), hemoglobin bA1c (OR,
1.18), total cholesterol (OR, 2.08), insulin use (OR, 4.15), and microalbuminuria (OR, 1.11) .
Conclusion: A low incidence and much lower progression was observed.

TIE2 Pathway in Diabetic Macular Edema: A Phase 1b/2a
Open-Label, Multiple-Ascending Dose Cohort Study to
Assess the Safety, Tolerability, and Pilot Efficacy of Repeat
Subcutaneous Doses of AKB-9778
Co-Author(s): , Peter A Campochiaro MD*
Purpose: To evaluate the safety and efficacy of 28-day BID subcutaneous dosing of AKB9778 in patients with diabetic macular edema (DME). Methods: Twenty-four patients with
central retinal subfield thickness of >325 m and ETDRS acuity of <74 letters participated in
the study. Cohorts of six each were treated with 5, 15, 22.5, and 30 mg of AKB-9778. Exams,
including OCT and best-corrected visual acuity, were obtained. Pharmacokinetic samples
were obtained at multiple time points post dosing. Results: At 15 mg or greater, after one
month of treatment, seven of 18 patients had reduction in central retinal thickness of >50
m, and 13 of 18 patients gained five or more letters of visual acuity. Conclusion: Subcutaneous dosing of AKB-9778 is safe and well tolerated. Reduction of DME and corresponding
increase of visual acuity were observed. The results suggest that TIE2 activation may be
effective in the treatment of DME.

SOE Multimodal Imaging Using Quantitative
Autofluorescence in Achromatopsia: A Case Series
Presenting Author: Alexandre Jacques Matet MD
Co-Author(s): Susanne Kohl PhD, Saddek Mohand Said MD**, Michel Paques*, Jose
A Sahel MD*, Isabelle Audo
Purpose: To correlate quantitative autofluorescence in blue (qBAF) and near infrared (qIRAF) with spectral-domain OCT in achromatopsia (ACHM). Methods: Patients underwent
genetic, clinical, and imaging (Heidelberg Retina Angiograph 2/Spectralis) evaluation. qBAF
and qIRAF charts were generated by pixel averaging along concentric semicircles with an
ImageJ plug-in. Results: Of 12 ACHM patients, six had mutations in CNGA3 and six in

H The Natural History and Genetic Variability of
Choroideremia
Presenting Author: Paul R Freund MD
Co-Author(s): Ian M MacDonald MD*
Purpose: To describe the natural history of choroideremia (CHM) in a quantified and clinically relevant format. Methods: A retrospective review of 128 males with confirmed molecular diagnoses of CHM. Results: Males with missense mutations in the CHM gene do
not have a different natural history compared with males with loss-of-function mutations.
Visual acuity is stable until 40 years of age (P = 0.71) but decreases by 0.05 logMAR units/
year above the age of 40 (P = 0.001). Visual fields decrease at a rate of 0.9 horizontal
degrees/year above the age of 20 (P = 0.006). Visual fields demonstrate higher intereye correlations than visual acuity (r = 0.95 and 0.76, respectively). Conclusion: This natural history data will guide the selection and monitoring of participants in CHM gene therapy trials.

SOE Treatment With Repeat Dexamethasone Implants
Results in Long-term Disease Control in Eyes With
Noninfectious Uveitis
Presenting Author: Oren Tomkins-Netzer MD
Co-Author(s): Susan L Lightman MBBS, Asaf Bar MD, Lazha Talat, Lavnish Joshi,
Ahmed Samy FRCS
Purpose: To describe the long-term outcome of eyes with uveitis following repeated treatment with dexamethasone (Ozurdex ) implants. Methods: A retrospective review of 38
eyes of 27 adult patients. Results: Average follow-up was 17.3 1.8months, with 24 eyes
(63.1%) receiving multiple implantations. Following treatment, the average best-corrected
visual acuity improved from 0.47 0.05 logMAR to 0.27 0.07 logMAR (P < 0.001), and
central retinal thickness decreased by 263 44.22 um (P = 0.003). The median duration
of theraputic effect was six months (range, two to 42months), with a similar response
achieved after each repeat implantation. Conclusion: The accumulated effect of repeat
Ozurdex implantations improves retinal thickness, ocular inflammation, and vision.

Optic Nerve/Retinal Ganglion Cell Involvement in
Autoimmune Retinopathies Resulting in Autoimmune
Neuroretinopathy
Presenting Author: Alessandro Iannaccone MD
Co-Author(s): Eric Sollenberger BBA, Rebecca S Epstein MD, Aleksandr Birg MD,
Purpose: To present evidence for frequent optic nerve/retinal ganglion cell (ON/RGC) involvement in autoimmune retinopathy (AIR) patients (n = 57) confirmed via autoantibody
testing and immunohistochemistry. Methods: Fundus exams, retinal and disc spectral-domain OCT (SD-OCT), and pattern reversal visual-evoked potentials (PVEPs) were analyzed.
Results: Papillary/juxtapapillary changes, disc elevation/hyperemia, temporal atrophy, or
cupping were seen in 53 of 57 patients, and PVEP delays were seen in 50 of 57 patients,
even with 20/20 acuity. Retinal nerve fiber layer (RNFL) changes were common on disc OCT.
Manual segmentation of macular SD-OCT on a subset of patients (n = 22) showed that
macular RNFL was thicker in AIR patients than in healthy patients (P = 0.0186). Conclusion: AIR patients commonly have ON/RGC involvement, hence they actually have AINR
. ON/RGC imaging and functional studies impact diagnosis, treatment, and follow-up and
should be obtained in AIR.

Endophthalmitis Rates After Intravitreal Anti-Vascular
Endothelial Growth Factor Injections for Various Retinal
Diseases
Presenting Author: Jason Hsu MD*
Co-Author(s): Nadim Rayess MD, Ehsan Rahimy MD, Chirag P Shah MD*, Jeremy D
Wolfe MD*, Eric Chen MD*, Francis C DeCroos MD, Sunir J Garg MD*
Purpose: To compare endophthalmitis rates after intravitreal anti-VEGF therapy for diabetic eye disease (DED), wet AMD (wAMD), and retinal vein occlusion (RVO). Methods:
233
Scientific Posters
Presenting Author: Victor H Gonzalez MD*
CNGB3, with three new variants. Two groups were identified: A, perifoveolar hyper-qBAF
ring with continuous or granular ellipsoid line on OCT (n = 4), and B, central hypo-qIRAF
with hyporeflective foveal cavity on OCT (n = 5) . Mean age was higher in Group B (36 vs. 18
years; P = 0.02). Conclusion: qBAF and qIRAF clearly correlate with OCT changes and may
serve as clinical endpoints in forthcoming gene therapy trials.
Scientific Posters
Certain populations may have a higher infection risk due to immune dysfunction. We retrospectively reviewed 499,025 intravitreal anti-VEGF injections given from Jan. 1, 2009 to
July 1, 2013. Results: Endophthalmitis occurred in 159 of 411,823 injections for wAMD
(1/2590), 16 of 40,708 for DED (1/2544), and eight of 46,494 for RVO (1/5812). Endophthalmitis rates for RVO were significantly lower than that for DED (P = 0.0497) and wAMD (P =
0.0219). Conclusion: RVO had the lowest rate of endophthalmitis, possibly due to immune
dysfunction in diabetics and waning immunity in the older wAMD population.

Intravitreal Aflibercept for Diabetic Macular Edema
Refractory to Bevacizumab and/or Ranibizumab
Presenting Author: Brian P Lehpamer MD
Co-Author(s): Jaafar F El Annan MD, Petros Carvounis MD FRCSC, Robert E Coffee
MD
Purpose: To investigate the efficacy of aflibercept for diabetic macular edema (DME)
unresponsive to bevacizumab and/or ranibizumab. Methods: Retrospective review of 33
patients (42 eyes) switched to aflibercept for refractory DME. Mean best-corrected visual
acuity (BCVA) and mean Spectralis OCT central subfield thickness (CSFT) were analyzed.
Results: Forty-two eyes with baseline BCVA of 20/46 and CSFT of 445 m received an
average of 5.5 bevacizumab and/or ranibizumab injections. BCVA and CSFT were stable
at 20/45 (P = 0.67) and 420 (P = 0.24), respectively. After switching to aflibercept, BCVA
improved to 20/37 (P = 0.0005) and CSFT to 349 (P = 0.0007), with an average of 3.3 injections. Conclusion: DME unresponsive to other agents may show favorable response to
aflibercept.

SOE Efficiency and Safety of the Dexamethasone Implant
Ozurdex in Irvine-Gass Syndrome
Presenting Author: David Bellocq MD
Scientific Posters
Co-Author(s): Laurent Kodjikian MD PhD*, Philippe Denis MD**
decrease in $/QALY was seen for longer durations of HCQ use. Conclusion: Testing beyond the Academys guidelines for HCQ retinopathy substantially decreases the cost eficacy
of annual screening.

Factors Associated With Spontaneous Release of
Vitreomacular Traction
Presenting Author: David Almeida MD PhD MBA*
Co-Author(s): Eric Chin MD, Karim J Rahim PhD, James C Folk MD*, Stephen Richard
Russell MD*
Purpose: To analyze the factors that may predict the release of vitreomacular traction
(VMT) and vitreomacular adhesion. Methods: Retrospective case-control study of 61 patients with VMT imaged by OCT over at least three months. Release of VMT (R-VMT) was
defined by resolution of patients symptoms or traction by OCT without surgical intervention
or ocriplasmin injection. Results: Of 61 patients, 21 (35%) developed R-VMT and 40 (65%)
did not. Isolated inner retinal distortion without outer retinal involvement was associated
with R-VMR (P = 0.01). Vitreous injections were also associated with R-VMR (P = 0.02).
Conclusion: Eyes with VMT and isolated inner retinal distortion and those receiving vitreous injections are more likely to develop VMT release without the need for additional
treatment.

Expanded spectral domain OCT Findings to Assist in
Early Detection of Hydroxychloroquine Retinopathy and
Progression Following Drug Cessation
Presenting Author: David R Lally MD
Co-Author(s): Elias Reichel MD*, Andre J Witkin MD, Caroline R Baumal MD*, Adam
H Rogers MD*, Chirag P Shah MD*, Jeffrey S Heier MD*, Jay S Duker MD*
Purpose: To evaluate the efficiency and safety of an implant of dexamethasone, Ozurdex,

in the treatment of Irvine-Gass syndrome. Methods: This is a interventional pilot trial including non-naive patients. An assessment of visual acuity in ETDRS letters and an OCT
spectral domain were made at the baseline visit and then on a monthly basis. The main
objective was to assess changes in visual acuity and macular thickness at M2 and M4
after a first injection of Ozurdex. Results: Fifty patients were included. The initial mean
visual acuity was 55.7 letters . A gain of 15.6 letters was obtained at M2 and a gain of 7.4
letters at M4. The mean macular thickness decreased to 238 m at M2 and 148 m at M4.
Conclusion: Dexamethasone intravitreal implant seems to be effective in the treatment
of Irvine-Gass syndrome.
Purpose: To report large series of eyes with hydroxychloroquine (HCQ) retinopathy after
HCQ cessation and present new spectral-domain OCT (SD-OCT) findings to enable earlier
diagnosis. Methods: Retrospective case review of eyes with HCQ retinpathy followed after
drug cessation. Cohort was divided into three groups (Early, Moderate, and Severe) based
on SD-OCT appearance at diagnosis. Thickness measurements of all nine ETDRS subfields
were recorded. Changes in morphological appearance of SD-OCT appearance were analyzed. Results: Forty-six eyes were included. Eighty-two percent of Early eyes had reduced
reflectivity of parafoveal EZ , broadening of parafoveal Henles fiber layer reflectivity, or loss
of interdigitation zone. Progression of toxicity was detected in 66%. Conclusion: SD-OCT
shows signs of HCQ toxicity before disruption of parafoveal EZ. SD-OCT shows progression
after drug cessation is common.

Clinical Characteristics of Bilateral vs. Unilateral Central
Serous Chorioretinopathy

The Healing Process of Myopic CNV After Anti-Vascular
Endothelial Growth Factor Therapy
Presenting Author: Umesh Chandra Behera MS

Co-Author(s): Rohit Ramesh Modi, Siddharth Shekhar DOMS**, Taraprasad Das MD**
Purpose: To compare clinical characteristics of unilateral (u-CSCR) versus bilateral central
serous choroidoretinopathy (b-CSCR). Methods: Retrospective analysis of 251 u-CSCRs
and 112 b-CSCRs. Results: Between u-CSCR and b-CSCR, age at presentation was 40.98
and 45.129 years (P < 0.0001), duration of symptoms was 370 and 791 days (P = 0.0002),
presenting vision (logMAR) was 0.364 and 0.509 (P = 0.008), and retinal pigment epithelium
atrophy was in 44 and 98 eyes (P < 0.0001), respectively. On follow-up, u-CSCR gained
eight letters and b-CSCR lost five letters (P = 0.0203). There were more males with b-CSCR.
Conclusion: b-CSCR occurs in older age males, with poorer presenting and final vision.

A Cost Analysis of Screening for Hydroxychloroquine
Retinopathy
Presenting Author: Andrew J McClellan MD
Co-Author(s): William E Smiddy MD
Purpose:To evaluate the cost utility of screening for hydroxychloroquine (HCQ) retinopathy
employing current recommendations. Methods: Cost of diagnostic tests and office visits in
hospital and office settings were calculated using Medicare fee schedules. Lines of vision
lost, average age, and incidence per five-year period of HCQ use were abstracted from
published studies to caluclate the cost per quality-adjusted life-year ($/QALY). Results:
$/QALY ranged from 57,000 to 255,000, representing up to a 2-fold increase from previous visual field-only regimens. Each additional test increased the cost as follows: OCT,
30%; fundus autofluorescence, 50%; and multifocal electroretinography, 100%. A slight
234
Presenting Author: Kaori Sayanagi MD

Co-Author(s): Yasushi Ikuno MD, Masahiro Akiba PhD*
Purpose: The hyperreflective line (HRL) on the surface of choroidal neovascularization
(CNV) on OCT image is thought as a CNV encapsulation by retinal pigment epithelium,
which may indicate the stabilization of myopic CNV (mCNV). We observed the extension of
HRL and investigated the healing process of mCNV after anti-VEGF therapy. Methods: The
length of HRL on the surface of CNV was measured in 10 eyes with mCNV using sweptsource OCT preoperatviely and one week and one month after anti-VEGF therapy. The factors associated with the length of HRL and the extension speed of HRL were explored. Results: The length of HRL indicating the CNV encapsulation increased over time significantly
(P < 0.05). The choroidal thickness was significantly correlated with the length of HRL and
the extension speed of HRL (P < 0.05). Conclusion: The choroidal thickness is critical for
stabilizing mCNV.

Stellate Nonhereditary Idiopathic Foveomacular
Retinoschisis
Presenting Author: Michael D Ober MD*
Co-Author(s): K Bailey Freund MD*, Manthan R Shah MD**, Shareef B Ahmed MD**,
Tamer H Mahmoud MD*, Thomas M Aaberg Jr MD*, David N Zacks MD PhD*, Hua
Scientific Posters
Gao MD PhD, Sri Krishna Mukkamala MD, Uday Ravindra Desai MD, Kirk H Packo
MD*, Lawrence A Yannuzzi MD
Purpose: To describe a new disorder, stellate nonhereditary idiopathic foveomacular retinoschisis (SNIFR). Methods: This retrospective case series analyzed history, multimodal
imaging, and genetic testing. Patients with family history, RS1 mutation, myopic degeneration, epiretinal membrane, vitreoretinal traction, optic pit, or advanced glaucomatous optic
nerve were excluded. Results: Twenty-two eyes from 16 female and one male patient were
reviewed from five institutions. Initial visual acuity was 20/50 in all eyes (mean, 20/27).
Follow-up ranged from six months to over five years. Conclusion: In this largest known
series of patients with SNIFR, all patients demonstrated splitting of the outer plexiform
layer, with relatively preserved visual acuity (20/40) except in one case that developed
subfoveal fluid.

SOE Approach of Subretinal and Suprachoroidal Space:
Experimental Study
Presenting Author: Alfredo Insausti Garcia MD
Purpose: To describe a device and an experimental surgical technique for repeated application of therapies in the subretinal and suprachoroidal spaces. Methods: Experimental
study in 25 ex vivo pig eyes. Procedure: subconjunctival device implantation; radial sclerotomy, 4 mm; viscodissection; lighted fiber optic dissection; and microcatheter implantation.
Prototype device: rigid base; methacrylate-cellulose; and diameter, 5 mm. Microcatheter:
polyimide, 36 G. Results: Procedure performed successfully in 18 (72%) out of 25 operated eyes. Major complications included difficulty to localize and guide the lighted optic
fiber, choroidal perforations, retinal perforations, and detachments. Conclusion: Feasible
device and reproducible surgical technique may allow repeated application of intraocular
therapies in subretinal and suprachoroidal spaces.

Intravitreal Vascular Endothelial Growth Factor Levels in
Proliferative Sickle Cell Retinopathy Strongly Correlate
With the Extent of Capillary Nonperfusion Noted on WideAngle Angiography
Presenting Author: Shailesh K Gupta MD**
Co-Author(s): K V Chalam MD PhD

Paraproteinemic Maculopathy
Presenting Author: Ahmad M Mansour MD*
Co-Author(s): J Fernando Arevalo MD FACS*, Josep Badal Lafulla MD, Ramana S
Moorthy MD, Gaurav K Shah MD*, Hernando Zegarra MD, Jose S Pulido MD MS,
Alaa Samih Bou Ghannam MD, Luis Amselem MD, Alejandro Lavaque MD, Antonio
M Casella MD, Baseer U Ahmad MD**, Joshua G Paschall MD, Antonio Caimi MD**,
Giovanni Staurenghi MD*
Purpose: To ascertain the course and therapy of paraproteinemic maculopathy (PM).
Methods: Case series with the following outcome measures: best-corrected visual acuity (VA), area of PM, and rheology. Results: Thirty-three cases were followed for seven
months: diabetes (7); mean immunoglobulin (Ig) of 6,497 mg/dL; viscosity of 5.5 cP ; logMar
VA initlal (final), 0.55 (0.45) in right eye and 0.38 (0.50) left eye; plasmapheresis (18), chemotherapy (30), and intravitreal bevacizumab/triamcilonone (8). PM resolved in 17 cases
(when Ig normalized with medical therapy) and was unchanged or worsened in 14 cases.
PM manifested at lower Ig in diabetics, with positive correlation between PM area and
serum viscosity. Intravitreal therapies failed. Conclusion: Decreasing blood Ig is the primary therapy in PM. Coexisting diabetes facilitates leakage of Ig at lower levels than for
nondiabetics.
Presenting Author: Ahmad M Mansour MD*

Co-Author(s): Rola N Hamam MD, Joanna S Saade MD, Fadi Camille Maalouf MD**,
Mahmoud O Jaroudi MD
Purpose: Scleral windows and sclerotomies often fail due to episcleral scarring in nanophthalmic uveal effusion (NUE). A new surgical technique is presented. Methods: Sclera was
dissected till bluish reflex appeared, and anterior 90% of sclera was excised from muscle
insertion to vortex vein 300 degrees sparing superior temporal quadrant. Results: Seven
patients (11 eyes) were treated, having mean values for age (25 years), hyperopia (14 D),
axial length (15.2 mm), initial visual acuity of 20/200 improving to 20/100 (P = 0.05) at 12
months follow-up. NUE resolved as soon as one day after surgery by OCT, with resolution
of fluorescein leakage, while nondraining techniques require several weeks for subretinal
fluid resolution. Conclusion: This extreme sclera thinning technique rectifies basic defect
of megasclera by transforming pomelo into orange.

Intravitreal Injection of Bevacizumab in Retinal
Detachments at High Risk for Proliferative
Vitreoretinopathy: A Randomized Pilot Clinical Trial
Presenting Author: Masoud Soheilian MD
Co-Author(s): Adib Tousi MD, Alireza Ramezani MD
Purpose: To evaluate the effect of intravitreal bevacizumab (IVB) on proliferative vitreoretinopathy (PVR) development. Methods: In this pilot randomized trial, eyes with primary
rhegmatogenous retinal detachment (RRD) that were high risk for PVR C formation and
underwent encircling band plus pars plana vitrectomy were randomized into two groups.
Eleven received IVB at the end of the procedure, and 12 eyes received no drug. Results:
Anatomical success was 72.7% and 50.0% in the IVB and control groups, respectively (P =
0.40), at month 3. Conclusion: This pilot study suggests a possible efficacy of IVB in the
prevention of PVR formation in high-risk RRD.

Vitrectomy-Scleral Buckle vs. Vitrectomy Alone for Retinal
Detachment at High Risk for Proliferative Vitreoretinopathy
Presenting Author: Philip P Storey MD
Co-Author(s): Rayan A Alshareef MD**, Nikolas J London MD*, Benjamin Leiby PhD,
Francis C DeCroos MD, Richard S Kaiser MD*
Purpose: To compare pars plana vitrectomy (PPV) alone and PPV with scleral buckle (SB)
in patients with rhegmatogenous retinal detachment (RRD) at high risk for proliferative
vitreoretinopathy (PVR). Methods: Six hundred seventy-eight patients with RRD from April
1, 2010 to Aug. 1 2012 were reviewed. High-risk characteristics for PVR were considered
RRD in more than quadrants, retinal tears greater than one clock hour, preoperative PVR,
or vitreous hemorrhage. Results: Sixty-five patients were identified as high risk for PVR.
Thirty-six patients received PPV-SB and 29 patients received PPV alone with 63.1% overall single-surgery anatomical success. PPV-SB was associated with a significantly higher
success rate compared with PPV alone (odds ratio, 3.24; 95% CI, 1.129.17; P = 0.029).
Conclusion: For patients at high risk for PVR, PPV-SB may have superior success compared
with PPV alone.

SOE Treatment Patterns for Patients Starting Anti-Vascular
Endothelial Growth Factor Therapy for Retinal Vein
Occlusion in U.S. Clinical Practice
Presenting Author: Andrew J Lotery MBCHB*
Co-Author(s): Stephane Regnier PhD*
Purpose: To assess real-world usage of anti-VEGF in patients with central (CRVO) or
branch retinal vein occlusion (BRVO). Methods: Analysis of IMS Healths claims database
to calculate frequency of ophthalmologist visits and injections in U.S. patients commencing
anti-VEGF and not switching therapy. Results: In year 1 of ranibizumab therapy, the mean
(standard deviation) number of injections was 4.3 (2.9) for CRVO (n = 1,130) and 4.0 (2.8)
for BRVO (n = 1,394). The mean number of ophthalmologist visits was 7.8 (3.7) for CRVO
and 7.7 (3.8) for BRVO. We also found that 15.4% of CRVO and 13.4% of BRVO patients
had at least eight injections. For CRVO, aflibercept injection frequency was similar to that
of ranibizumab. Conclusion: In U.S. clinical practice, patients with retinal vein occlusion
receive substantially fewer ranibizumab injections in the first year than participants in clinical trials.
235
Scientific Posters
Purpose: To report the correlation between intravitreal VEGF levels in prolferative sickle
cell retinopathy (PSR) and compare them to the degree of capillary nonperfusion (CNP) noted on wide-angle angiogram (WFA). Methods: In this retrospective study, in patients with
SPR (28), WFA was performed and the ratio of CNP was estimated. The cohort consisted of
PSR that required vitrectomy SPR (28). VEGF levels obtarined during surgery were measured
with Luminex assay. Results: VEGF levels ranged from 448 to 1,456. Degree of CNP ranged
from 44% to 89% and correlated strongly (r = 0.69) with VEGF Levels. Conclusion: Degree
of capillary nonperfusion noted on WFA is a good predictor of intravitreal VEGF levels and
may help in modulating anti-VEGF therapy in proliferative sickle cell retinopathy.

Nanophthalmic Uveal Effusion Managed With Maximal
Subtotal Scleral Excision: Pomelo Scleral Peel Technique
Scientific Posters
Patterns of Fundus Autofluorescence Defects in Exudative
AMD Subtypes

SOE Appearance on Adaptive Optics of Foveal Sparing in
Geographic Atrophy Secondary to AMD
Presenting Author: Ahmet Ozkok MD
Presenting Author: Giuseppe Querques MD
Co-Author(s): Douglas K Sigford MD, Tongalp H Tezel MD
Co-Author(s): Anouk Georges, Capuano Vittorio**, Rocio Blanco-Garavito MD*, Eric H

Souied MD PhD*
Purpose: To test whether exudative AMD subtypes can be differentiated from their fundus
autofluorescence (FAF) patterns. Methods: Macular and peripheral FAF patterns of 52 patients with three different exudative AMD (exAMD) subtypes were compared in a masked
fashion. Results: All clinical subtypes had nondistinctive macular FAF patterns; however,
peripapillary FAF defects were common in polypoidal choroidal vasculopathy (PCV; 88.2%)
compared with RAP (12.5%) and non-RAP non-PCV (21.1%) cases (P < 0.0001). Conclusion: Presence of peripapillary FAF defects in exAMD should suggest PCV as the the cause
of choroidal neovascularization.

SOE Choroidal Thickness in Multisystemic Autoimmune
Diseases Under Hydroxychloroquine Treatment Without
Ophthalmologic Manifestations
Presenting Author: Joao Nuno Bicho Beato MD
Scientific Posters
Co-Author(s): Carla Sofia Ferreira MD, Manuel Falcao MD, Angela Maria Carneiro MD
PhD*, Fernando M Falcao-Reis MD PhD**
Purpose: To describe the appearance on adaptive optics (AO) of foveal sparing (FS) in geographic atrophy (GA) secondary to AMD. Methods: AO images were overlaid with near-infrared autofluorescence (NIA). Results: In five eyes of four patients (all female; mean age,
74.2 11.9 years), by direct comparison with adjacent regions of GA, FS areas appeared as
well-demarcated areas of reduced reflectivity with less hyporeflective clumps. AO revealed
cone photoreceptors as hyperreflective dots over the background reflectivity. Microperimetry demonstrated residual function in areas of FS detected by NIA. Conclusion: AO allows appreciating differences in reflectivity between regions of GA and FS. Preservation of
functional cone photoreceptors was demonstrated in areas of FS detected by NIA.

SOE The Natural History of Lamellar Macular Holes: A
Spectral Domain OCT Study
Presenting Author: Goktug Seymenoglu MD
Co-Author(s): Esin Fatma Baser MD
Purpose: To evaluate choroidal thickness in individuals with multisystemic autoimmune

diseases. Methods: One hundred fifty eyes of 75 patients were included, with autoimmune
disease treated with hydroxychloroquine. Choroidal thickness was measured in the center
of the fovea and along a horizontal section, using enhanced depth-imaging spectral-domain
OCT. Results were compared with a control sample. Results: Lupus patients had a thicker
choroid in all measures (P < 0,001). Below the fovea, the choroid was thinner in rheumatoid
arthritis and other autoimmune diseases than controls (P = 0.043). Results were adjusted
for age (P < 0.001), spherical equivalent (P < 0.001), and beginning of therapy (P = 0.032).
Cumulative dose had no influence. Conclusion: Autoimmune diseases may possibly present in the choroid, with differences between diseases.
Purpose: To study the evolution of lamellar macular holes (LMHs) using spectral-domain
OCT (SD-OCT). Methods: Thirty-one consecutive patients (15 males and 16 females; mean
age, 63.9 2.15 years; mean follow-up, 21.95 months) diagnosed with a LMH were examined. LMHs were quantitatively and qualitatively characterized by SD-OCT in terms of base
and apex diameter and residual foveal thickness. Results: The mean best-corrected visual
acuity (logMAR), residual foveal thickness, and apex and base diameters at baseline and
at the final visit were 0.45 0.18 versus 0.42 0.11, 184.25 31.25 m versus 182 22.36
m, 589 82.20 versus 615 93.25 m, and 828 76.14 versus 842 80.65 m, respectively
(P > 0.05 for all). Conclusion: Most lamellar macular holes do not progress anatomically
and do not contribute to a significant decrease in visual acuity during the follow-up period.

Smartphone Photography in ROP Screening: One NICU
Experience From a Community-Based Hospital

Intraoperative OCT During Vitreoretinal Surgery for Dense
Vitreous Hemorrhage in the PIONEER Study
Presenting Author: Fatima Ahmed MD
Presenting Author: Joseph F Griffith MD*
Co-Author(s): Anupa Mandava MD**, Cono M Grasso MD, Ajey Jain**, Julia P
Shulman MD*
Co-Author(s): Sunil K Srivastava MD*, Jamie L Reese RN**, Justis P Ehlers MD*
Purpose: To present our initial experience with fundus photography using a smartphone
and ophthalmic lenses in neonates. Methods: Fundus images were captured with a smartphone and indirect lens. The phone flash provided a coaxial light source for a fundus image.
Results: We were successful in capturing images in neonates with retinopathy of prematurity (ROP). There was a learning curve associated with this technique. It seems inferior
to traditional fundus photography in capturing peripheral findings in ROP at adequate magnification. Conclusion: This technique can be successfully used for photodocumentation,
parent education, and resident training.

Retinal Invasion by Uveal Melanoma With Tumoral-Retinal
Anastomoses and Angiomatous Proliferations
Presenting Author: Gene W Chen MD
Co-Author(s): Jose S Pulido MD MS, Anthony B Daniels MD, Carol L Shields MD
Purpose: To describe multimodal imaging of retinoinvasive uveal melanoma with angiomatous/anastomotic changes on fluorescein angiography (FA)/indocyanine green angiography (ICG). Importantly, invasion may confer poorer prognosis with radiation therapy.
Methods: Case series of 70 tumors with imaging was reviewed. Results: Tumors showed
encroachment/loss of retina in a dome-on-dome configuration on OCT in 17% of patients (35.5% medium). Mean size on ultrasound was greater with invasion compared with
without invasion (thickness, 5.1 vs. 2.2 mm, P > 0.0001; base, 13.3 vs. 8.5 mm, P 0.0004
). Of 12 patients with OCT invasion, all had evidence of tumoral-retinal anastomoses and
angiomatous proliferations (TRAAP) on FA/ICG. Conclusion: OCT may help detect tumoral
invasion, which seems to be accompanied by a vasogenic sequence we propose TRAAP
because of a resemblance to RAP .
236
Purpose: To evaluate intraoperative OCT (iOCT) during vitrectomy surgery (pars plana vitrectomy [PPV]) for dense vitreous hemorrhage (VH). Methods: Eyes were identified within
the PIONEER study, a prospective multisurgeon iOCT study, that underwent PPV for VH, precluding a preoperative OCT, within 60 days of study enrollment. iOCT images were analyzed
for retinal abnormalities that might impact intra- or perioperative management. Results:
Nineteen eyes were identified. iOCT revealed epiretinal membranes (14), macular edema
(10), vitreomacular traction (4), macular holes (2), and retinal detachment (1). Six eyes had
iOCT following membrane peeling to confirm completeness of peel. Conclusion: iOCT during PPV for VH may provide surgeons with clinically relevant information that may impact
management and outcomes.

Swept Source OCT is Superior to Spectralis in Accuracy as
Well as Reproducibility of Choroid Thickness and Volume
Measurements
Presenting Author: K V Chalam MD PhD
Co-Author(s): Sandeep Grover MD
Purpose: To compare coefficient of reproducibility (COR) of choroid measurements between swept-source OCT (SS-OCT) images and Spectralis spectral-domain OCT. Methods:
A prospective observational study of persons (N = 46) with normal macula (CSF thickness,
<315 m). Each study eye underwent two replicate scans. Central subfield choroid thickness (CSCT) and choroid volume (CV) were used in reproducibility analyses. Results: COR
for change in CSCT was lower on SS-OCT versus Spectralis (2% vs. 16%; P < 0.01). Mean
difference in CSCT was 14 m versus 377 m (P < 0.01). COR for change in CV was lower on
SS-OCT versus Spectralis (1% vs. 14%; P < 0.01). Mean difference in CV was 0.18 versus
1.09 cu.mm (P < 0.01). Conclusion: SS-OCT is superior to Spectralis in reproducing CSCT
as well as CV, probably because of better penetration and optical resolution.
Scientific Posters
Comparison of Maximal Basal Dimensions Measured
by Wide-Angle Digital Fundus Camera, Fundus Camera,
Echography, and Clinical Examination in Choroidal Tumors

Rate and Risk Factors of Ocular Neovascularization in Eyes
With a Central Retinal Artery Occlusion
Presenting Author: M Bernadete Ayres MD
Co-Author(s): Frank X Venzara MD**, Shyam Arvind Patel RN, Richard M Feist MD,
Martin Lee Thomley MD, Michael A Albert MD
Co-Author(s): Tanya McClendon**, Hakan Demirci MD

Purpose: To compare the maximal basal dimension measured by clinical examination,
echography, fundus camera (Zeiss FF450), and wide-angle fundus camera (Optos 200Tx)
in choroidal tumors. Methods: Review of 53 choroidal tumors. Results: On average, dimensions were 10% lower on echography, 27% lower on fundus camera, and 47% larger
on wide-angle fundus camera compared with the ones on clinical examination. Measurements by clinical examination correlated most closely by echography (R2 = 0.75), followed
by fundus camera (R2 = 0.56), and wide-angle fundus camera (R2 = 0.26). Color of the lesion
matched in 79% of tumors between fundus camera and wide-angle fundus camera. Conclusion: Measurement of maximal basal dimension in choroidal tumors correlated most
closely between echographic and clinical examinations.
Presenting Author: John O Mason MD
Purpose: To assess the incidence and risk factors that may influence neovascularization
(NV) in eyes with central retinal artery occlusion (CRAO). Methods: Retrospective review
of 82 consecutive charts (83 eyes) with a CRAO diagnosis. Results: Twelve (14.5%) eyes
developed NV. Eleven (91.7%) of these eyes had iris neovasculariztion, 10 (83.3%) had neovascular glaucoma, and two (16.7%) had neovascularization of the disc. The average time
for the development of NV was 30.5 days (range, one day to five months). Diabetes mellitus
type 2 (DM2) was a significant risk factor for NV (odds ratio, 5.1; P = 0.02). Conclusion:
NV is not an uncommon complication of CRAOs, and these patients should be monitored
closely for the first six months, especially if the patient has DM2.

Vitreoretinal Surgery After Ocular Trauma

Safety and efficacy of 25-gauge Sutureless Vitrectomy for
Idiopathic Macular Pucker
Presenting Author: Kristen M Harris MD
Presenting Author: John O Mason MD
Co-Author(s): Jennifer Irene Lim MD*
Co-Author(s): Frank X Venzara MD**, Shawn Agee MD, Richard M Feist MD, Martin
Lee Thomley MD, Michael A Albert MD
Purpose: To evaluate outcomes in vitreoretinal surgery (VRS) after open-globe injury (OGI).
Methods: A retrospective chart review of OGI requiring subsequent VRS from 1998 to
2008. Results: Of 315 OGI repairs, 77 (24.4%) underwent VRS. LogMAR visual acuity (VA)
improved from 2.26 to 1.75 (P < 0.10) following repair, with an increase in the number of
patients with better than light perception (LP) VA (45% vs. 77%, P < 0.0004) . Better final VA
correlated with a higher presenting ocular trauma score (r, -0.406; P < 0.0013 ). Indications
for VRS were retinal detachment (62%), vitreous hemorrhage (48%), and intraocular foreign
body (12%). VRS included pars plana vitrectomy (98.7%), silicone oil (50.6%), scleral buckle
(42.9%), lensectomy (42.9%), and retinectomy (15.6%). Conclusion: Visual outcomes improved beyond LP for over 40% of patients after OGI with subsequent VRS.

Traumatic Maculopathy With Massive Subretinal
Hemorrhage After Close-Globe Injuries
Presenting Author: Kuan-Jen Chen MD
Co-Author(s): Wei-Chi Wu MD, Chi-Chun Lai MD**

Intravitreal Topotecan in the Management of Refractory
Vitreous Seeds in Retinoblastoma
Presenting Author: Vishal Sharma MD
Co-Author(s): Santosh G Honavar MD, Vijay Anand P Reddy MD
Purpose: To evaluate the safety and efficacy of intravitreal topotecan in retinoblastoma
with refractory vitreous seeds. Methods: This prospective, noncomparative case series
included nine consecutive patients who received injections of transconjuctival pars plana
intravitreal topotecan (2030 g in 0.10.15 mL) with injection site triple freeze-thaw cryotherapy. We planned three weekly injections until regression plus an injection of consolidation. Results: Complete regression was achieved in seven eyes with one injection, while
one each needed two and three injections, respectively. There was no recurrence at three
months following the last injection, no complication was observed, and visual acuity remained stable. Conclusion: Intravitreal topotecan appears safe and potent and provides
impressive short-term vitreous seed control with a mean of 1.3 injections.

Intraoperative Spectral-domain OCT Imaging of Glial Tuftlike Lesion After Internal Limiting Membrane Peeling in
Macular Surgery
Presenting Author: Dongheun Nam MD PhD
Co-Author(s): Philip DeSouza, Paul Hahn MD PhD, Du Tran-Viet, David Cunefare Jr,
Sina Farsiu PhD*, Joseph A Izatt PhD**, Cynthia A Toth MD*
Purpose: Although late postoperative findings are known, intraoperative OCT (iOCT) findings of macular nerve fiber layer (NFL) immediately after internal limiting membrane (ILM)
peel in macular surgery remain unknown. Methods: In a prospective study, we compared
NFL qualitative and quantitative iOCT findings after ILM peel in epiretinal membrane (ERM;
n = 15) versus macular hole (MH; n = 14) . Results: In contrast to MH ILM peel, in which we
found minimal NFL changes, macular NFL defects, distortion, and swelling were commonly
noted after ERM/ILM peel. Some of these changes were not seen preoperatively and were
likely due to ERM/ILM peel. Conclusion: The impact of peeling on the NFL differs between
ERM and MH surgery. Using iOCT imaging, these differences can be identified during surgery and may have implications in postoperative recovery.

SOE Causes of Recurrent Retinal Detachment Following
Pars Plana Vitrectomy and Gas Tamponade
Presenting Author: Mostafa A Elgohary MBCHB
Co-Author(s): Philip James Banerjee BMBS FRCOPHTH, Aman Chandra MBBS**, G
William Aylward MD
Purpose: To report the causes of failure of primary pars plana vitrectomy (PPV) and gas
tamponade for rhegmatogenous retinal detachment (RD) and the outcome of secondary
intervention. Methods: We reviewed 223 consecutive case notes of recurrent RD following
primary PPV and sulphur hexafluoride or perfluoropropane tamponade. Cases with history of
trauma, uveitis, or supplementary buckles were excluded. Results: Retinal breaks causing
failure were missed or new in 43%, associated with proliferative vitreoretinopathy (PVR)
in 27.4%, opened (pre-existing) in 16.6%, and laser or cryonecrosis in 13% (P < 0.001) .
Secondary intervention resulted in retinal reattachment in 83.9% of cases, and 9.4% were
attached under silicone oil. Conclusion: Strategies to enhance operative search and reduce the rate of PVR will reduce recurrence of RD following PPV and gas.
237
Scientific Posters
Purpose: To investigate the associated characteristics, management, and visual outcomes

in patients with traumatic maculopathy and massive subretinal hemorrhage (MSH) after
closed-globe injury. Methods: Noncomparative case series. Results: Twenty-five eyes
of 24 patients, 19 males and five females, were analyzed. Mean age was 32 years. The
most common presentation was vitreous hemorrhage. Pars plana vitrectomy was usually
performed in patients with persistent vitreous hemorrhage, retinal detachment, and lens
dislocation. Thirteen eyes with vision of 2/200 or worse showed macular atrophy and/or
scar. OCT showed foveal thinning and loss of inner segment/outer segment junction line in
patients with foveal atrophy. Conclusion: Traumatic maculopathy with MSH after closedglobe injury could cause a poor visual outcome.
Purpose: To assess the safety and efficacy of 25-G vitrectomy (pars plana vitrectomy [PPV])
for idiopathic macular pucker (IMP). Methods: Retrospective review of 217 consecutive
eyes (214 patients) undergoing 25-G PPV for IMP (internal limiting membrane and pucker
were removed in all eyes) from 2010 to 2012. Results: Mean preop best-corrected visual
acuity (BCVA) was 20/82, and postop was 20/39 (P < 0.001). Optimal BCVA was seen at a
mean of three months. Ninety percent of eyes had at least two lines of improvement, while
50% halved their visual angle. Complications occured in nine eyes (4.1%), consisting of two
retinal detachments, six vitreous hemorrhages, and one case of endophthalmitis. Only one
eye had recurrent IMP. Conclusion: In the largest consecutive series to date, 25-G PPV for
IMP resulted in significant vision improvement with few complications.
Scientific Posters
SOE Outcome of Cyclitic Membrane Excision in Children

Vitrectomy for Floaters Normalizes Contrast Sensitivity
Presenting Author: Mostafa A Elgohary MBCHB
Presenting Author: Jerry Sebag MD*
Co-Author(s): Pear Pongsachareonnont MD, Rajeev H Muni MD, Peter J Kertes MD*,
Wai-Ching Lam MD*, William Carroll Halliday MD FRCSC, Asim Ali MD
Co-Author(s): Kenneth Yee, Christianne Wa, Laura Huang BA, Alfredo A Sadun MD
PhD*
Purpose: To report the outcome of surgical excision of cyclitic membranes and their histopathological features in a series of children. Methods: We reviewed the case notes of six
consecutive children who underwent surgical excision of cyclitic membranes. Results: The
median age was 8.7 years. Preoperative median IOP was 7.35 mmHg, and mode visual acuity (VA) was PL . After a median follow-up of 12 months, the median IOP was 16.4 mmHg,
and mode VA was hand movements (perception of light to 20/300). VA was stable in four
patients, improved in one patient, and worsened in one patient. Histopathological examination showed an abundance of fibrous tissue with variable lymphocytic and macrophage
cellular infiltration. Conclusion: Surgical excision cyclitic membrane should be considered
in children, as it appears to help restore IOP and therefore preservation of the eye.
Purpose: To determine the safety and efficacy of limited vitrectomy in 95 eyes with floaters. Methods: Contrast sensitivity (CS) was measured by Freiburg Acuity (92% reproducibility) and patient dissatisfaction by National Eye Institute Visual Function Questionnaire
(VFQ) testing. Morever, 25-G vitrectomy was performed without retrolental surgery and
posterior vitreous detachment (PVD) induction. Results: CS was reduced 71% preop (P
< 0.01) and normalized at one, three, six, more than nine months postop (P < 0.01) . VFQ
improved 32% (P < 0.001). After a mean follow-up of 16 months (three to 52 months), there
were no infections, retinal tears/detachments, or glaucoma. Postop vitreous hemorrhage in
one case cleared. Macular pucker in one case and PVD in two cases were cured by reoperative vitrectomy. Cataract surgery was needed in all but 23% of phakic eyes . Conclusion:
Limited vitrectomy of clinically significant floaters normalizes CS and improves patient satisfaction with a very good safety profile.

SOE Posterior Vitreous Detachment in Highly Myopic Eyes
Undergoing Vitrectomy
Presenting Author: Elise Philippakis MD
Co-Author(s): Aude Couturier MD, Vincent Gualino MD*, David Gaucher MD**, Alain
Gaudric MD*, Pascale Massin*, Ramin Tadayoni MD*
Purpose: To assess complete posterior vitreous detachment (PVD) rate in highly myopic
eyes requiring vitreoretinal surgery. Methods: Retrospective analysis on PVD status using
intraoperative observation in 96 highly myopic eyes requiring surgery. Results: Overall PVD
rate was 52.1% and varied widely among diseases (P < 0.0001): high in rhegmatogenous
retinal detachments (85%) and epiretinal membranes (74.2%) and low in macular hole
retinal detachments (42.9%), foveoschisis (14.3%), and macular holes (10%). Conclusion:
This first study using intraoperative observation to assess PVD found that complete PVD
rate varied among diseases in highly myopic eyes and is very low in foveoschisis and macular holes, supporting specific pathogenesis.

SOE Preoperative Factors Influencing Visual Recovery After
Surgery for Myopic Foveoschisis
Presenting Author: Francois Devin MD
Scientific Posters
Co-Author(s): Mathieu Lehmann MD, David Gaucher MD**, Vincent Gualino MD*,
Alain Gaudric MD*, Bruno Remy Morin MD**, Christopher Morel**, Pascale G
Massin MD**, Ramin Tadayoni MD*
Purpose: Surgery decision for myopic foveoschisis (MFS) needs a better knowledge regarding chances for visual acuity (VA) recovery. Methods: OCT and visual acuity (VA) of 68
consecutive eyes operated on for MFS in three centers were studied preoperatively and at
one, three, and 12-month (M12) postoperative visits. Results: At M12, VA was significantly
higher in eyes with a preoperative VA <0.5 logMAR (Snellen, >20/63) compared with lower
VA: 0.20 0.11 (20/32) versus 0.56 0.35 (20/73; P < 0.001). Only eyes with an associated
macular hole did not present a significant VA improvement. Conclusion: Eyes operated
late at VA 20/63 or with a macular hole did not achieve as favorable results as others.

Small-Incision Vitreoretinal Surgery Without Routine
Scleral Depressed Shaving of Vitreous Base for
Rhegmatogenous Retinal Detachment

IOP Changes in Patients With Gas-Filled Eyes During
Ascending Car Travel
Presenting Author: Alexandre C Assi MD
Co-Author(s): Ali Dirani MD MS, Ali Fadlallah Yahya MD, Georges Cherfan FRCOPHTH
FRCS**
Purpose: To evaluate the effects and safety of mountain travel following pars plana vitrectomy and complete intraocular gas fill. Methods: Twenty-four eyes of 24 patients had
serial IOP measurements taken at sea level and then repeated at regular stations of ascent
until a maximum IOP value of 40 mmHg was reached. Results: There was a significant
positive correlation between the mean IOP and increasing altitude (r = 0.976, P = 0.001).
There was no difference in the mean IOP between phakic and pseudophakic eyes (P > 0.05)
and between eyes containing different types of gases (P > 0.05) at all stations of ascent.
Conclusion: This direct correlation between increasing altitude and IOP rise can guide us
in the postoperative management of patients undergoing ascending car travel.

Direct Intraocular Pressure Measurements During
Vitrectomy with Minimal Incision Valve Surgery
Presenting Author: Kazuhito Yoneda
Co-Author(s): Shigeru Kinoshita MD*
Purpose: To directly measure dynamic IOP during vitrectomy with minimal incision valve
surgery (MIVS). Methods: Dynamic IOP of 44 cases was tested via pars plana trocar with
a sensor to directly measure IOP during 25- and 27-G MIVS vitrectomy. Disposable pressure transducers were placed in the vitreous cavity to directly determine IOP. Results:
IOP varied from 0 to 80 mmHg during surgery. During high-flow infusion cannula, mean
25- and 27-G IOP were 17.0 and 20.6 mmHg, respectively (P < 0.01). During normal-infusion
cannula, mean 25- and 27-G IOP were 6.3 and 7.8 mmHg, respectively (P < 0.01). Within
the same-size incision, high-flow infusion maintained IOP (P < 0.01 for both 25 and 27 G).
Conclusion: IOP was higher during 27 than 25 G. High-flow infusion cannula maintained
IOP during various MIVS vitrectomy steps.
Presenting Author: Homayoun Tabandeh MD MS FRCP FRCOphth*

Bimanual Internal Limiting Membrane Peeling in Repair of
Rhegmatogenous Retinal Detachment With a High Risk of
Proliferative Vitreoretinopathy
Co-Author(s): Nikolas J London MD*, David S Boyer MD*
Presenting Author: Lala Akhundova MD
Purpose: To evaluate outcomes of small-gauge pars plana vitrectomy (PPV) without routine scleral depressed shaving of vitreous base for treatment of retinal detachment (RD).
Methods: Retrospective, consecutive case series including all cases of RD who underwent
PPV. Small-gauge PPV (25 or 23 G) and wide-angle vitrectomy viewing systems were used
in all cases. Results: Two hundred twenty-five eyes (86 pseudophakic, 48 high myopia, 10
giant retinal tear, and three funnel RD). Retina was reattached with one procedure in 212
eyes (94%). Final reattachment was 99% (222 eyes). Conclusion: In the era of wide-angle
viewing systems, small-incision PPV without routine scleral depressed shaving of vitreous
base is associated with good outcomes.
Co-Author(s): Elmar Kasimov MD PhD**, Mushfig Karimov**
238
Purpose:To analyze the effect of internal limiting membrane (ILM) peeling in patients undergoing vitrectomy for the treatment of rhegmatogenous retinal detachment with a highrisk proliferative vitreoretinopathy (PVR). Methods: Thirty-eight eyes of 38 patients were
included in the study. All eyes underwent vitrectomy with ILM peeling with silicone oil/
gas tamponade for retinal detachment with a high-risk PVR. The follow-up was at least
three months. Results: Single-surgery anatomic success was achieved in 86.8%, and final
reattachment was achieved in 97.4% of patients. There was no subsequent development
of epiretinal membranes after ILM peeling. Conclusion: ILM peeling in conjunction with
vitrectomy is an effective technique, with a high anatomic success rate in the challenging
scenario of high-risk PVR-related retinal detachments.
Scientific Posters
SOE Inverted Internal Limiting Membrane Flap Technique
vs. Standard Internal Limiting Membrane Flap Technique for
Large Macular Holes

To Evaluate the Effect of Vitreous Surgery on Corneal
Endothelium
Presenting Author: Ligia M Figueiredo MD

Co-Author(s): Ligia M Ribeiro MD, Miguel Afonso Almeida Pinto Bilhoto
Co-Author(s): Brijesh Takkar**, Amit Jain MBBS MS**, Kumar Vivek Sr, Raj V Azad
MD FRCS(ED)**
Purpose: To compare the functional and anatomic outcomes of a standard internal limiting
membrane (ILM) flap technique with a modified inverted ILM flap technique for large macular holes. Methods: Retrospective, nonrandomized, comparative study. Twenty eyes with
macular holes larger than 400 m were included. In Group 1, 13 eyes underwent ILM peeling. In Group 2, seven eyes underwent the inverted flap technique. Results: Best-corrected
visual acuity three months after surgery improved from 0.067 to 0.223 decimal equivalent
(DE) in Group 1 and from 0.084 to 0.286 DE in Group 2 (P < 0.05). Macular hole closure was
observed in 54% of patients in Group 1 and 100% of patients in Group 2. A flat-open hole
was observed in 38.5% of patients in Group 1 (P < 0.05). Conclusion: The inverted ILM flap
technique seems to be an effective surgical treatment for large macular holes.
Purpose: To evaluate the effect of vitreous surgery on corneal endothelium. Methods:

One hundred thirteen eyes undergoing pars plana vitrectomy for variable indications were
included prospectively. Specular count was noted preoperatively and on postoperative day
1, 30, 90, and 180. Percentage and rate of endothelial loss were measured. Results: We
found that 7.6% of endothelial cells were lost at postoperative day 1. This rate had decreased to 2.5% in the first 30 days, 1.5% between day 30 and 90 and 1.4% between day
90 and 180. Significant difference in endothelial loss was noted on day 1 between phakic,
pseudophakic, and aphakic eyes at 7.2%, 6.4%, and 11.4%, respectively. Conclusion: Precautions should be taken in aphakics and patients requiring anterior segment manipulation.
Endophthalmodonesis in aphakic vitrectomized eyes may be a serious concern.

Macular Hole Surgery Sans Gas Tamponade
Presenting Author: Meena Chakrabarti MBBS

Brilliant Blue Staining Using Whole Blood vs. Conventional
Brilliant Blue Staining in Macular Hole Surgery
Co-Author(s): Arup Chakrabarti MBBS
Presenting Author: Supriya Batta MS
Purpose: To study whether gas tamponade was necessary to improve anatomic and functional outcomes in macular hole surgery (MHS). Methods: Retrospective analysis of 100
patients who underwent MHS with internal limiting membrane (ILM) peeling and with intraoperative gas tamponade (50 eyes) and without gas tamponade (50 eyes) . A comparative analysis of hole closure rate, vision, and complications in both groups was performed.
Results: Hole closure rate was 92% (<400 m) versus 72% (>400 m) in both groups. Complications such as retinal tears (5%), retinal detachment (2%), retinal pigment epithelium
degeneration (16%), and epiretinal membrane (5%) were similar in both groups. A higher
incidence of cataract (40% vs. 8%) was seen in Group 1. Final vision recovery of >6/60
(60%) was achieved in both groups. Conclusion: The anatomic and functional outcomes
in MHS are similar, irrespective of whether intraoperative gas tamponade was used or not.
Co-Author(s): Neha Goel MBBS**, Nalini Saxena MBBS, Richa Pyare MBBS**, Usha
K Raina MD, Meenakshi Thakar**, Basudeb Ghosh**

Structural and Visual Outcomes After Epimacular
Membrane Surgery With Internal Limiting Membrane
Peeling

Tomographic Features of the Fovea After FoveolaNonpeeling Macular Hole Surgery
Presenting Author: Meena Chakrabarti MBBS
Purpose: To study the tomographic features after foveolar internal limiting membrane
(ILM) nonpeeling surgery in stage 2 macular hole. Methods: The patients were divided into
two groups (14 eyes in each group) by the extent of peeling: preservation in Group 1 and
total peeling in Group 2. Results: There was more improvement of logMAR best-corrected
visual acuity in Group 1 than in Group 2. Regain of inner segment/outer segment line in
all eyes in Group 1 (100%) and in seven eyes in Group 2 (50%). Recovered external limiting membrane lines were found in all eyes in Group 1 (100%) and in eight eyes in Group
2 (57%). Group 1 eyes restored umbo reflex and smooth and symmetric foveolar contour
without postoperative inner retinal dimpling. Conclusion: Nonpeeling of the foveolar ILM
restored better foveolar microstructures and achieved more visual acuity improvement.
Co-Author(s): Arup Chakrabarti MBBS

SOE Geometry, Penetration Force and Cutting Profile
of Different 23-Gauge Trocars Systems for Pars Plana
Vitrectomy
Presenting Author: Carsten H Meyer III MD
Co-Author(s): Zengping Liu MD**, Sandeep Saxena MBBS MS, Hakan Kaymak MD**,
Eduardo B Rodrigues MD*
Purpose: To examine 11 23-G trocar systems (spear, back, lancet bevel, and spatula bevel).
Methods: Normative geometrical data were analyzed (ISO 7864 and ISO 9626). A penetrometer measured the piercing, cutting, and sliding and plotted a load displacement
diagram. Results: The mean outer diameter was 0.630 0.009 mm, the point length was
3.11 0.4 mm, the bevel length was 1.46 0.2 mm, the primary angle was 10.75 0.4,
and the secondary angle was 65.9 42.56. The piercing forces of back and spear were
0.087 0.028 Newton (N), and the lancet was 0.41 N (0.350.47), but the spatula was 1.6
N (1.591.73) . The back bevel induced a triangular shape, the spear a linear, the lancet a
straight, and the spatula accurate incisions. Conclusion: Lancet and back systems show
less penetration force than the spatula systems.
Purpose: To compare the outcome of sequential intraoperative use of autologous heparinized whole blood (WB) followed by brilliant blue (BB) versus conventional BB staining
for internal limiting membrane (ILM) peeling in macular hole surgery. Methods: This
randomized, controlled trial included 30 patients in each group. Clinical examination and
spectral-domain OCT were done at three, six, and 16 weeks and six months postoperatively.
Results: Group A (BB staining using WB) had a higher mean best-corrected visual acuity
at all postoperative visits (P < 0.001, 0.001, 0.004, and 0.04, respectively) compared with
Group B (conventional BB staining). Conclusion: Use of WB prior to staining ILM with BB
improves functional outcome of surgery.
Presenting Author: Tzyy-Chang Ho MD

Anatomical and Visual Outcomes of Vitreoretinal Surgery in
Pediatric Retinal Detachments
Presenting Author: Yog Raj Sharma MD MBBS
Co-Author(s): Abdul Shameer MBBS, Raj V Azad MD FRCS(ED)**, Pradeep
Venkatesh**, Parijat Chandra MD, Koushik Tripathy MD MBBS
Purpose: To study outcomes of vitreoretinal surgery (VRSx) in pediatric retinal detachments (RDs). Methods: Prospective case series. Three hundred twenty-two eyes of 308
children (14 years of age) undergoing VRSx with silicone oil injection (23 or 25 G) were
studied, excluding retinopathy of prematurity cases. Results: Mean age was 10.7 2.6
years. Two hundred nineteen patients (71.1%) were boys. Forty-six patients (14.9%) had
bilateral RD. The most common cause was trauma in 135 eyes (41.9%). One hundred
eighty-six eyes (57.7%) had proliferative vitreoretinopathy. At six months, 287 eyes (89.1%)
achieved retinal reattachment. Visual acuity was 20/200 in six eyes preoperatively and
in 96 eyes at six months (P < 0.001) of the 307 eyes in which visual acuity could be measured. Conclusion: The anatomical outcomes of pediatric VRSx are good; however, visual
recovery remains modest.
239
Scientific Posters
Purpose: To study the long-term visual outcome and macular structural changes in 130
consecutive patients who have undergone epimacular membrane surgery with internal limiting membrane peeling. Methods: Retrospective review of the visual outcome and OCT
changes at one, three, six, and 12 months postoperatively. Results: Visual acuity improvement at six months (>6/9) decreased by two lines (<6/18) at 12 months in 80%. Recurrence
(5%), macular hole (3%), and peripapillary retinal nerve fiber layer (RNFL) thinning was
observed. RNFL thinning in superotemporal, inferotemporal, and temporal quadrants (150.6
19 m vs. 165.7 23.4 m [P < 0.001], 125.3 24.8 m vs. 136.22 7.2 m [P < 0.05], and
70.2 17.4 m vs. 98.5 23.7 m [P < 0.001]) was statistically significant. Conclusion: A
statistically significant decrease in RNFL thickness was observed at 12 months follow-up.
Presenting Author: Shorya V Azad MBBS**
Scientific Posters
Another Mans Treasure: Recycling Quality Low Vision Aids
and Devices
Presenting Author: David W Dodds MD
Co-Author(s): Jeffrey T Lynch MD MPH, Ford Thomas Parsons MD MS, Alexander
Dangelo
Scientific Posters
Purpose: To describe a novel sister website for redistributing low vision aids on ReSpectacle, a nonprofit online database where patients can search for quality used glasses at
no cost. Method: Develop an online database for devices donated to ReSpectacle, upload
photos and searchable features, and distribute low vision aids ordered by patients. Results: Many hours of volunteer work has resulted in the development of an easy-to-use
website, the acquisition of devices, and an expected launch of the low vision arm of the
ReSpectacle website in June 2014. Conclusion: Low vision aids can be expensive and
difficult to obtain for many people. ReSpectacle is a website that provides quality glasses
at no cost to patients. Now these devices will also be available to patients anywhere in
the world.
240
VIDEO PROGRAM
Saturday Tuesday, Nov. 16 - 19
Best of Show Videos
Videos designated by a H were selected as Best of Show.
Videos on Demand

View videos at your convenience on the Videos on Demand computer terminals in McCormick Place.
This service is also available through the Mobile Meeting Guide, www.aao.org/mobile.
After Nov. 1, view Videos online: www.aao.org/aao-archives.
Learning Lounge
Booth 107
The Learning Lounge is hosting several At the Movies sessions screening scientific videos from the Video Program with the video producers on hand to lead discussions. A full schedule is available on page 253 or through the Mobile Meeting Guide, www.aao.org/mobile.
Selection Committee
The Annual Meeting Program Committee selected all videos. See page 33 for committee details.
241
Video Program
Video #1
H Video #5
The Quest
Sr. Producer: Liliana Werner MD PhD*

Co-Producer(s): Alan S Crandall MD*, Nick Mamalis MD*
Late spontaneous in-the-bag dislocation of IOLs/capsular tension rings (CTRs)
generally occurs approximately five to eight years after implantation and
involves different types of lenses. The presence of a CTR does not prevent
dislocation, capsular contraction or capsulorhexis phimosis. Methods to recognize zonular weakness, prevent excessive stress to the zonules and provide
additional capsular support shown in this video may help in the prevention
of this complication. If dislocation still occurs, management depends on
surgeon preference and specialty, the type of IOL, the presence or absence
of a CTR, the stage and site of dislocation and the coexisting ocular pathology. Surgical approaches include different methods for repositioning or for
exchange.
Sr. Producer: Robert H Osher MD*

Co-Producer(s): David K Wang
A fascinating biomicroscopic finding ignites an international search for an
explanation. The journey marries nature with ophthalmology and leads to the
discovery of a nanostructural etiology.
Watch Out for the Zonules!
Video #2
Dropped IOL
Sr. Producer: Amar Agarwal MD*
Dislocated IOLs in the posterior chamber have always been a cause of
concern and a known complication following a posterior capsule rupture.
Dislocation of an IOL not only makes the patient aphakic but also can cause
complications related to the dropped IOL. The extrusion cannula has been extensively used for drainage of subretinal fluid by posterior segment surgeons.
The flexible sleeve of the extrusion cannula helps to reach the subretinal
space effectively. In our practice, we use extrusion cannula without sleeves
for levitating dropped IOLs. Removal of the sleeve provides a wider area for
adherence and subsequent creation of effective suction to the IOL.
Video #3
Video Program
New Pupil Expansion Rings: Simple Design and Technique,

Smaller and Lesser Incisions
Sr. Producer: Suven Bhattacharjee MS*
The square and hexagonal designs of the new disposable pupil expansion
rings are made of 5-0 Nylon. They have notches at the corners, flanges at
the sides and a joint and are entirely disposed in a single 0.1-mm-thin plane.
Insertion and removal of the devices through 0.9-mm (20-gauge) incisions
is demonstrated. We also discuss unimanual and bimanual engagement
to pupil margin using 23-gauge forceps and the procedures ease of instrumentation, stability and complications, as well as the postoperative results.
The device is used in standard 2.2-mm coaxial phacoemulsification, 1.4-mm
bimanual microincisional cataract surgery, shallow anterior chambers and
intraoperative miosis. Its use has also demonstrated reduction in the severity
of intraoperative floppy iris syndeome. The design and material superiority
over existing devices is shown, and the advantage of a single-plane device
over one with biplanar scrolls is highlighted.
Video #4
Patchy Trypan Blue Staining/Friable Anterior Capsule/

Capsulorhexis Impossible/Hard Hypermature Cataract
Sr. Producer: Suven Bhattacharjee MS*
Trypan blue staining of the anterior capsule was patchy, with large geographical nonstaining areas for no apparent reason. The anterior capsule was
friable and kept tearing like wet blotting paper wherever it was held with the
forceps. Extensive areas of subcapsular fibrosis and adhesions only made the
job more difficult these were the nonstaining areas too. It was impossible
to shape a continuous curvilinear capsulorhexis. The result was an anterior
capsulorhexis with multiple jagged edges each one having the potential
to run to the periphery. With this threat looming, large phacoemulsification
had to be performed on a large, hard nucleus in a hypermature cataract. The
video demonstrates how these adverse conditions were overcome and an inthe-bag IOL implantation was performed.
242
Video #6
Lens Fiber Orientation During Phacoemulsification:

Intraoperative Global Positioning System for the Surgeon
Sr. Producer: Vishal Arora MD
Co-Producer(s): Mathew Kurian MD MBBS, Somshekar Nagappa, Rohit Shetty
MD MBBS
The video demonstrates the Y sign for trenching endpoint: a clinical sign
that indicates the surgeon should stop trenching and start cracking during
classical divide-and-conquer nucleofractis emulsification using proximal
downslope trenching. The technique exploits the morphological structure
of the lens to precisely gauge the depth of the trench, at which the surgeon
can split even a soft nucleus into small wedges without instrument cheesewiring and perform safer phacoemulsification with less ultrasound energy,
thereby reducing the risk for posterior capsule rupture. This clinical sign can
help in easier nucleus disassembly with reduced chances of complications.
Video #7
Not All Is Lost After a Posterior Capsular Tear

Sr. Producer: Arup Chakrabarti MBBS
Co-Producer(s): Meena Chakrabarti MBBS
This video demonstrates successful management of posterior capsular (PC)
rent in a series of patients undergoing phacoemulsification and establishes
guidelines on how to effectively manage such cases. PC rents were noticed
during various stages of nucleus removal and cortex removal and even during
IOL implantation. Vitreous, when present, was stained with triamcinolone.
Bimanual limbal anterior vitrectomy was performed when indicated. In most
cases, a three-piece hydrophobic acrylic IOL with posterior optic capture
through the rhexis was placed in the sulcus. The intraoperative stability and
centration of the IOL was confirmed at the end of the surgery. All patients
regained normal vision in the postoperative period.
Video #8
Femto-Delineation: Posterior Polar Simplified

Sr. Producer: Abhay Raghukant Vasavada MBBS FRCS*
Co-Producer(s): Shail Vasavada MD*, Samaresh Srivastava BMBS MS*, Shetal M
Raj MS**, Viraj A Vasavada MD
This film describes a novel technique for posterior cataract emulsification. It
highlights the use of femtosecond laser-assisted nuclear delination, which
eliminates the need to perform any hydroprocedures. This allows creation of
multiple customized, concentric layers of nuclear cushioning that protect the
posterior capsule until the final stages of surgery, thus enhancing safety.
H Video #9
Femtosecond Laser Cataract Surgery: Tackling Challenges
and Exploring the Limits
Sr. Producer: Dilraj Singh Grewal MD
Co-Producer(s): Satinder Pal Singh Grewal MD MBBS, Surendra Basti MBBS*
Femtosecond laser-assisted cataract surgery (FLCS) provides real-time
intraoperative imaging and the unique ability to customize identification of
anantomic landmarks, placement of capsulotomy and laser delivery parameters. In this video, we illustrate the utility of these FLCS features to enable
its use in complex cases and demonstrate its ability to offer increased safety
Video Program
in such challenging situations. We highlight the utility of FLCS in eyes with
small pupils, subluxated traumatic cataracts, corneal scars with iridocorneal
adhesions, phacomorphic angle closure and brunescent and white cataracts,
as well as techniques such as secondary capsulotomy for optic capture in
traumatic aphakia.
Video #10
Intraoperative Challenges During Femtosecond LaserAssisted Cataract Surgery and Their Management
Sr. Producer: Dilraj Singh Grewal MD
Co-Producer(s): Surendra Basti MBBS*
Despite its potential for increased safety and precision, femtosecond laserassisted cataract surgery (FLCS) can present unique challenges. This video
presents FLCS cases with complications during corneal wound creation,
capsulotomy, lens fragmentation and hydrodissection. We illustrate cases of
premature gas breakthrough during corneal wound construction through the
main and paracentesis incisions, challenges in limbal relaxing incision placement, situations with incomplete capsulotomy and lens fragmentation and
difficulties with hydrodissection. Strategies for successfully managing such
situations are demonstrated.
H Video #14
Novel Small-Aperture Intraocular Implant
Sr. Producer: Claudio L Trindade MD*
Co-Producer(s): Bruno C Trindade MD
This film presents a new intraocular implant made of black hydrophobic
acrylic with a small central opening, which acts as an intraocular pinhole. It
is used to extend depth of focus and minimize the impact of corneal aberrations on the optical system. Four patients with irregular corneal astigmatism
secondary to previous corneal surgery underwent implantation of this new
device. Ultrasound biomicroscopy examination revealed proper sulcus fixation. Scanning electron microscopy images of the implant showed thin and
exquisitely well-polished haptics. Because the material of the new implant is
100 percent transparent to infrared light, retinal examination is possible after
implantation using infrared equipment such as optical coherence tomography. The new device was also used in a case of pseudophakic presbyopia
and improved near vision by extending the depth of focus.
H Video #15
Ocular Cicatricial Pemphigoid: Not Just Another Red Eye
Sr. Producer: Harmanjit Singh MD

Co-Producer(s): Iqbal K Ahmed MD*
Iris defects and a large, nonreactive pupil may result in severe photophobia
and glare. The purpose of this video is to present different techniques for iris
repair and pupilloplasty. Emphasis is placed on various suturing techniques,
iris cerclage and iridodialysis repair through a case-based approach. A novel
approach using intraocular cautery to reshape the iris will also be presented.
Sr. Producer: Rashmi Omprakash Shukla

Co-Producer(s): Virender S Sangwan MBBS
Ocular cicatricial pemphigoid a rare form of chronic cicatrizing conjunctivitis with or without systemic involvement may be difficult to treat due to
an often delayed diagnosis and referral by the primary ophthalmologist while
the patient is being treated for a milder form of dry eye. This comprehensive
and illustrative video will take the audience through a journey of methods to
diagnose the condition clinically (as well as by biopsy), differentiate it from
other conditions and explore management principles, including systemic immunosuppression.
Video #12
Video #16
Sr. Producer: Yoo YungJu MD

Co-Producer(s): Eitae Kim MD, Baek-Lok Oh MD
The IOL scleral fixation always has the possibility of IOL tilting, decentration and iris capture. This video demonstrates a novel surgical technique
that prevents IOL iris capture, tilting and decentraion. The safety barricade
H technique makes two parallel threads with temporary haptic externalization through corneal incision. The parallel 10-0 prolenes act like a safety
barricade, and these prevent instability of the IOL. This surgical technique
provides minimized lens-induced astigmatism and better visual quality due to
the stable position of the IOL.
Sr. Producer: Samar K Basak MD DNB MBBS*

Descemet stripping endothelial keratoplasty (DSEK) can successfully treat
corneal edema and visual loss in Iridocorneal endothelial (ICE) syndrome;
however, associated glaucoma problems may affect the long-term prognosis.
Trabeculectomy prior to DSEK causes difficulty in air tamponade, and after
DSEK, it is also difficult. This video demonstrates a novel technique of combining quadruple procedures DSEK, phacoemulsification, IOL implantation
and simultaneous trabeculectomy in ICE syndrome. After the conjunctival
flap, the superficial scleral flap is made, and phacoemulsification with and
IOL through a separate limbal incision is performed. After insertion of the
donor lenticule, air tamponade was kept for 30 minutes. Then, the trabeculectomy opening with a peripheral iridotomy was made, a releasable suture
was provided and the conjunctival flap was with an 8-0 vicryl suture. At the
end, 60 percent air was replaced with balanced salt solution.
Video #11
Iris Repair Techniques
Safety Barricade: Anti-Capture H Technique for Scleral

Fixation of IOL
Video #13
Sr. Producer: Mohan Rajan MD MBBS

Co-Producer(s): Sujatha Mohan MBBS
Posterior capsule rupture (PCR) is a dreaded complication of cataract surgery.
Early recognition, combined with advances in instrumentation, has enabled
effective management of a PCR. PCR can occur at any stage in cataract
surgery, including hydrodissection, trenching, segment removal, cortex aspiration and IOL implantation. In this video, we present the 10 commandments
that all phaco surgeons should follow in the management of a PCR so that
we can provide the best possible results to our patients.
Video #17
Pre-Descemet Endothelial Keratoplasty

Sr. Producer: Athiya Agarwal MD
We report a novel method of endothelial keratoplasty in which the endothelium and Descemet membrane, along with the Pre-Descemet layer (PDL), is
transplanted. Pre-Descemet endothelial keratoplasty entails the inclusion of
the PDL in the donor graft, thereby providing the benefits of Descemet membrane endothelial keratoplasty (DMEK), such as speedy visual recovery, and
overcoming the disadvantages posed by DMEK.
243
Video Program
The 10 Commandments of Posterior Capsule Rupture

Recognition and Management
DSEK Quadruple: A Novel Solution for Corneal Edema and

Glaucoma in Iridocorneal Endothelial Syndrome
Video Program
Video #18
Contact Lens-Assisted Cross-Linking for Thin Corneas

Sr. Producer: Soosan Jacob FRCS
Co-Producer(s): Amar Agarwal MD*
In cross-linking, despite a reduction of irradiance from the corneal surface
toward the deeper layers of corneal stroma, irradiation levels still exceed
the endothelial toxic threshold. Contact lens-assisted cross-linking artificially
adds to corneal thickness via a riboflavin-soaked contact lens and a precorneal riboflavin film of known thickness and thereby increases safety. It therefore extends the benefit of safely undergoing cross-linking to a larger number
of patients with thin corneas and provides a greater chance of successfully
completing the procedure.
Video #19
Different Trouble: Different Bubble

Sr. Producer: Bhupesh Bagga MD FRCS MBBS
Co-Producer(s): Varsha M Rathi DO
The big-bubble (BB) technique has been used for decades for deep anterior
lamellar keratoplasty (DALK). There are various types of bubbles, depending
on the indications of DALK. This video will show DALK with a BB in indications such as advanced keratoconus with apical scarring, macular dystrophy,
lipid keratopathy, vascularized corneal scar and Acanthamoeba keratitis. The
type and depth of bubble varies with different grades and levels of scarring.
They can also vary in their texture. This video will demonstrate the various
stages and types of BB formation, with their surgical implication.
Video #20
Relief: Mucous Membrane Graft in Stevens-Johnson

Syndrome
Sr. Producer: Bhupesh Bagga MD FRCS MBBS
Co-Producer(s): Virender S Sangwan MBBS, Milind N Naik MBBS, Sayan Basu
MBBS**
Stevens-Johnson syndrome is a chronic cicatrizing disease primarily involving the lid margin. Corneal complications are more commonly seen with
lid margin keratinization. Oral mucosa provides good surface and lubrication and help in avoiding friction and further related sequelae. This video
demonstrates the technique of oral mucosa harvesting and application on
lid margin. It will also explain preoperative and intraoperative assessment,
along with postoperative care. It also highlights the complications of mucous
membrane graft, such as detachment, necrosis and infection, along with
their management. The demonstrated technique is simplified and animated
for understanding.
Video Program
Video #21
Crescentic Tuck in Lamellar Keratoplasty: A Novel Technique

to Manage Advanced Pellucid Marginal Degeneration
Sr. Producer: Ritu Arora MD MBBS
Co-Producer(s): Aditi Abhay Manudhane MBBS, Jawahar Lal Goyal MD, PARUL
Parul Jain FICO MD, Pooja Jain MBBS MS, Vikas Veerwal MBBS, Trushaa Garg
MS**
We describe crescentic tuck in lamellar keratoplasty in a 58-year-old male
with advanced pellucid marginal degeneration. There was preoperative
astigmatism of 14.7 D, and pachymetry at the inferior thinnest point was
280 m. A 3.5-mm-wide C-shaped area of the host cornea was marked using
7.5- and 11-mm trephines and 3-mm trephines at horizontal edges. Manual
lamellar dissection was done layer by layer to create a host bed with a beveled inner edge. Peripheral groove was dissected along the adjoining corneal
and sclerolimbal borders. A crescent-shaped lamellar graft 3.5 mm wide was
harvested and beveled at the periphery to create a flange to tuck into the
pocket of the host bed, ensuring edge alignment, which was sutured using
10.0 Nylon. Uncorrected and best-corrected visual acuities at 12 weeks were
20/120 and 20/30, respectively, and astigmatism was 4 D.
244
Video #22
Femtosecond LaserAssisted Epidescemetic

Keratoprosthesis
Sr. Producer: Jorge L Alio MD PhD*
Co-Producer(s): Ahmed Abdelhamid Ahmed Abdelghany Sr MBBCH MD PhD,
Alfredo Vega-Estrada MD, Roberto Fernandez Buenaga
We describe the technique of implantation of the new epidescemetic keratoprosthesis. The surgical procedure is performed with the assistance of a
femtosecond laser. We performed a deeper outer diameter cut followed by
a shallower cut in the interior corneal dissection. We set the cut at 100 m
from the Descemet membrane and then dissected the stroma manually with
a crescent knife. Anterior segment optical coherence tomography pachymetry
is used to plan a good depth of the femtosecond cuts. The optical zone of 3.5
mm has to be placed in the visual axis. The implantation of the new keratoprosthesis is an easy technique with minimal complications.
Video #23
Boston Type I Keratoprosthesis Assisted With Intraprosthetic

Amniotic Membrane (AmniotiKPro Sandwich Technique)
Sr. Producer: Alejandro Navas MD*
Co-Producer(s): Arturo J Ramirez-Miranda MD*, Enrique O Graue Hernandez MD,
Juan Carlos Serna MD, Julio Hernandez Camarena MD
We describe a novel technique of Boston type 1 keratoprosthesis (KPro) implantation assisted with intraprosthetic amniotic membrane in patients with
severe ocular surface inflammation. Five eyes of five patients underwent
implantation with amniotic membrane creating a sandwich between the
front plate and the donor cornea. Postoperatively, the KPro remained in place
with the amniotic membrane attached, providing an epithelization scaffold
and an anti-inflammatory and antimicrobial platform. No episodes of melting
epithelial defects or infection were seen. A decreased incidence of tissue
melting and KPro extrusion could be a benefit due to the mechanical closing
of the gap between the optical stem and the donor cornea decreasing the
rate of the keratitis and endophthalmitis.
Video #24
CSI: Heidelberg Searching Under the Surface

Sr. Producer: Ramin Khoramnia MD*
Co-Producer(s): Florian T A Kretz MD*, Anna Fitting MS**, Mary Attia MBBCH*,
Mike P Holzer MD*, Gerd U Auffarth MD*
The calcification of hydrophilic IOLs occurs very rarely. Some cases of IOL
opacification after Descemet stripping automated endothelial keratoplasty
(DSAEK) and Descemet membrane endothelial keratoplasty (DMEK) are currently being analyzed by our research team. This film covers various methods
of IOL analysis (e.g., light microscopy of stained samples, scanning electron
microscopy and x-ray spectroscopy), which detect even the smallest traces
of deposits or opacifications. The IOLs show central opacifications due to deposits of calcium and phosphate below the anterior lens surface. The cause
has been identified as the air or gas bubbles during corneal surgery (DSAEK
or DMEK) to which the IOL surface is exposed. This allows the formation of
crystals made of calcium phosphate within the IOL. Current experiments with
new airgas mixtures are performed to find a solution for this problem.
Video #25
When Big Bubble Fails, Microbubble Helps

Sr. Producer: Sanjib Banerjee MBBS
Co-Producer(s): Samar K Basak MD DNB MBBS*
The big-bubble technique of deep anterior lamellar keratoplasty (DALK) is a
challenging yet rewarding corneal surgery. It is not always easy to achieve
big bubble in all cases. This video demonstrates how to achieve bare Descemets membrane following failed big bubble via the help of microbubbles.
After manual layer dissection, multiple tiny intrastromal air bubbles near
Descemets membrane are noticed during surgery. Puncturing this micro-
Video Program
bubble with a 26-gauge needle and injecting viscoelastic at this site were
successful in achieving cleavage between Descemets membrane and the
remaining corneal stroma. DALK was completed without any complications.
Wet lab experimentation was also done to show the microbubbles in failed
big-bubble cases with anterior segment optical coherence tomography imaging.
Video #26
Scleral Graft in Corneal Perforations: When Less Is More

Sr. Producer: Maria T Iradier MD PhD
Co-Producer(s): Laura Palmero Fernandez MD
This surgical technique is presented as a first intervention in corneal perforations with melting so as to avoid complications and preserve the globe
before an eventual keratoplasty or keratoprosthesis. Three cases of lamellar
scleral graft covered with an amniotic membrane (AM) patch were performed
under subtenonian anesthesia. First, the donor scleral tissue was cut to
fit the perforation and sliced to one-half the thickness in order to improve
coadaptation of its edges. Then, deep lamellar keratectomy was performed
around the stromal margins. Single 10-0 sutures were used for the graft, and
an AM patch was sutured above. This technique helps stabilize and reduce
corneal inflammation prior to the final surgical procedure and may be the
solution for repeated corneal perforations with melting in some cases.
Video #27
Permanent Punctal Closure With the Slit-Lamp 532-nm Diode

Laser
Sr. Producer: Charles D Rice MD
This study describes the effectiveness of permanent punctal closure with
the slit-lamp diode laser. Twenty-four patients who had extrusion or inability
to tolerate punctal plugs underwent permanent closure. The punctum was
marked with gentian violet that served as a target chromophore for the 532nm diode laser. The success rate of closure was 49 of 54 (90 percent) puncta
and defined as complete or pinpoint closure. Silicone plugs have a high rate
of extrusion, and repeated insertions add to the expense of treating dry eye
disease. Thermal cautery is effective but lacks precision. Argon laser treatments are ineffective due to the inability to create a thermal injury. The slitlamp diode laser is a precise, rapid, reproducible and effective method for
permanent punctal closure.
H Video #28
Techniques for ReSure Sealant in Corneal Surgery
Video #29
Stab Incision Glaucoma Surgery

Sr. Producer: Soosan Jacob FRCS
Co-Producer(s): Amar Agarwal MD*
Subconjunctival scarring secondary to subconjunctival dissection can lead to
filtration failure. We describe a new technique for guarded filtration surgery,
stab incision glaucoma surgery, which uses a single instrument (bevel-up
keratome) to create a 2.8-mm conjunctival entry and corneoscleral tunnel
in a single step, while eliminating subconjunctival dissection completely.
The ostium is punched and conjunctiva closed. Bleb is formed by hydrostatic
pressure.
Couched Compression Closure of Conjunctiva in Limbal

Filtration
Sr. Producer: Matthew Starr BA
Co-Producer(s): Steven R Shields MD, Rocio Bentivegna
Fornix-based conjunctival incisions for limbal filtration in glaucoma surgeries have several advantages over limbus-based incisions, including better
exposure of the limbus, less tissue dissection, reduced surgical time and
faster visual recovery. The major disadvantage is a higher incidence of leaks
from the conjuctival closure compared with limbus-based closures. Here, we
present an instructional video of a couching technique that has decreased
the problems with fornix-based conjunctival leaks in our practice. The closure
consists of a single continuous suture secured with a single knot at one
edge of the incision. We also present our review of cases before and after
the adoption of this new closure to demonstrate the reduction in leaks using
couched compression closure.
H Video #31
Gonioscopy-Assisted Transluminal Trabeculotomy: A Novel
Ab Interno Trabeculotomy
Sr. Producer: Davinder S Grover MD*
Co-Producer(s): Ronald Leigh Fellman MD OCS*, Oluwatosin U Smith MD*, David
G Godfrey MD**, Michelle R Butler MD
This video demonstrates the key portions of the gonioscopy-assisted transluminal trabeculotomy (GATT), a novel, minimally invasive blebless ab interno
360 trabeculotomy. In addition, this video demonstrates an episcleral
venous fluid wave (EFW), which the authors feel is intraoperative evidence
for patency of the conventional outflow system. The patient in this video had
uncontrolled pseudoexfoliation glaucoma that was successfully treated with
a GATT. In addition, one can appreciate intraoperative evidence of a diffuse
EFW.
Video #32
Nip/Tuck: A Disturbingly Perfect New Procedure

Sr. Producer: Shamira A Perera MBBS
Here, we showcase the surgical techniques used in post-trabeculectomy bleb
revision and highlight the various pearls and pitfalls of the procedure. This is
a compilation of surgical videos and photographs detailing bleb revision procedures and their comparative outcomes. All footage and images used were
authorized by Dr. Shamira Perera of the Singapore National Eye Centre and
were taken from 2009 to 2013. Our compilation showcases the stepwise process of bleb revision surgery, emphasizes its various pearls and pitfalls and
reviews current literature about the procedure. We found that bleb revision
is a niche procedure that has a high efficacy in managing posttrabeculectomy
complications.
Video #33
The White Abyss

Sr. Producer: Rasik B Vajpayee MD
Co-Producer(s): Tushar Agarwal MD, Vishal Jhanji MBBS
Chuna, which is calcium hydroxide paste, is used as an additive to chewing
tobacco. It is marketed in pouches, which, if burst, cause severe ocular burns,
especially among children who play with them. Despite irrigation with saline,
it is difficult to remove, as it sticks on hydration. Techniques to remove chuna
from fornices, the tarsal plate, the conjunctival and corneal surface and intrastromal and intracameral sites will be shown. Results despite removal are
dismal even after stem cell transplantation and keratoplasty. Doctors must
be made aware that chuna injury cases must have residual particles removed
meticulously. Instruction should be provided to manufacturers so that they
print explicit warnings on packets (to be kept out of reach of children) to
address this preventable cause of blindness.
245
Video Program
Sr. Producer: Karl G Stonecipher MD*

The authors intent is to show the options related to use of ReSure sealant
in various off-label and on-label uses for corneal surgical procedures. The
ReSure sealant will be shown superior to current technologies. Two surgeons
from large corneal practices will show various technological uses of the
ReSure sealant.
Video #30
Video Program
Video #34
Sclerotherapy for Orbital/Periorbital Dermoid Cysts: A Novel

Treatment
Sr. Producer: Akshay Gopinathan Nair MD
Co-Producer(s): Milind N Naik MBBS, Mohammad J Ali MBBS MS, Swathi Kaliki
MD
Angular dermoid cysts are benign, slow-growing tumors that are common in
the periorbital region. They usually present as an internal or external angular
dermoid. The gold standard for their treatment is open surgical excision via
a skin incision that forms a scar over time, which can be unsightly. Sclerotherapy is a treatment modality used in the management of visceral cysts,
varicose veins, cystic lymphangiomas and orbitopalpebral cysts. We have
used sclerotherapy in the management of large periorbital dermoid cysts, and
this video highlights this technique. The sclerosant used is sodium tetradecyl
sulphate, an anionic surfactant. The sclerotherapy technique is a minimally
incasive technique, and it offers a scarless surgery, is aesthetically pleasing
and delivers reproducible results.
Video #35
H Video #38
Sagging Eye Syndrome Presenting as a Form of Strabismus
Fixus
Sr. Producer: Dae Hyun Kim MD PhD
Co-Producer(s): Seong-Won Yang MD PhD, Minho Shin
Sagging eye syndrome manifests as small-angle esotropia and hypotropia
a result of lateral rectus-superior rectus (LR-SR) band degeneration caused
by aging. Heavy eye syndrome, however, generally manifests as large-angle
esotropia and hypotropia, called strabismus fixus a result of LR-SR
band rupture caused by myopic eyeball change. Here, we report a case with
sagging eye syndrome presented with a form of strabismus fixus, which is
usually presented with heavy eye syndrome, and obtained a promising result
of a LR-SR slinging procedure using a silicone band and sleeve.
Intravitreal Chemotherapy for Vitreous Seeds in

Retinoblastoma
Video #39
Sr. Producer: Fairooz Puthiyapurayil Manjandavida MD

Co-Producer(s): Santosh G Honavar MD, Gangadhar Jalli
Retinoblastoma management has undergone a paradigm shift in the recent
past, with improved survival rates. Although the primary goal is to save lives,
the focus is equally on eye salvage and optimization of visual potential. However, vitreous seeds remain one of the major factors that result in treatment
failure. The introduction of intravitreal injection of chemotherapeutic agents
has been a breakthrough in the management of advanced retinoblastoma.
The initial hesitation to inject an eye with retinoblastoma has resulted in
the evolution of a precise and a safe protocol-based technique of intraviteal
injection. This video illustrates the recommended indications and the safe
technique of intravitreal chemotherapy for vitreous seeds in retinoblastoma.
Sr. Producer: Ramesh Kekunnaya MBBS MD

Co-Producer(s): Batriti Shympliang Wallang DO, Virender Sachdeva MS DNB
Duanes retraction syndrome is a relatively common congenital cranial
disinnervation syndrome. The surgical management and successful patient
outcome, however, remain challenging. This video illustrates the surgical
management of various types of esotropic and exotropic Duanes retraction
syndrome. It includes procedures of horizontal muscle resections and recessions, Y split and superior rectus transposition and management of abnormal
head postures.
Surgical Management of Strabismus in Duanes Retraction

Syndrome
Video #40
Video #36
Pediatric Cataract: What Do I Need to Investigate Before I

Operate?
Sr. Producer: Santosh G Honavar MD

Co-Producer(s): , Gangadhar Jalli
Congenital ptosis with Marcus-Gunn synkinesis is a management challenge.
Surgical options include management of ptosis alone or both ptosis and synkinesis, depending upon the severity and patients perception of cosmesis.
Options for the management of severe ptosis coupled with severe synkinesis
include unilateral or bilateral levator excision with fascia lata tarsofrontal
sling. In this video, we demonstrate a simplified surgical technique for unilateral levator excision and 800-m closed-loop silicone tarsofrontal sling with
impressive eyelid height symmetry and complete elimination of synkinesis.
Sr. Producer: Virender Sachdeva MS DNB

Co-Producer(s): Ramesh Kekunnaya MBBS MD, Merle Fernandes MD, Vivek
Warkad, Vaibhev Mittal MS
A wide variety of the etiological considerations come into play while
evaluating children with pediatric cataracts. These considerations differ for
unilateral and bilateral cataracts and could pose a challenge to pediatric and
general ophthalmologists alike. A rational approach to evaluation requires
detailed history taking and ocular and systemic evaluation followed by appropriate laboratory and genetic testing. Family history, specific morphological
indications and associated systemic features provide further clues. This video
attempts to provide a step-wise approach to the evaluation and diagnosis of
the ocular and systemic conditions.
Synkinetic Ptosis Made Simple
Video Program
with a free nasal mucosal graft covering the traumatic nerve sheath defect. A
second patient with radiologically apparent optic canal fracture but no nerve
impingement had no light perception on presentation and opted for compassionate canal decompression. Bone fragments were removed by cold-steel
instruments, and the underlying nerve sheath was intact with no hematoma.
Video #37
Endoscopic Transeptal Transphenoidal Optic Canal

Decompression in Direct and Indirect Traumatic Optic
Neuropathy
Sr. Producer: Kelvin Kam Lung Chong MD
Co-Producer(s): Clement C Y Tham MBBS*
Optic canal decompression was performed using a high-speed diamond drill
to create a bony window and then completed by cold-steel instruments (rongeurs) to minimize heat-related damage. A hairline canal fracture, missed in
the preoperative computerized tomography scan, was noticed, and the nerve
sheath was already torn underneath. The optic nerve was exposed from the
apex towards the sellar floor before chiasmal entry. Surgery was finished
246
Video #41
Key Steps in Repair of Traumatic LASIK Flap Dehiscence

Sr. Producer: Fiona Jazayeri MBBS
Co-Producer(s): Philip Alexander MBBS
LASIK remains an extremely popular refractive procedure, and patients who
suffer a traumatic flap dehiscence may not present to a refractive surgeon.
This video shows the key steps during the repositioning of a folded LASIK
flap following trauma, while minimizing the possible complications of epithelial down growth and LASIK flap folds: 1) Identify the folded edge of the
LASIK flap. 2) Remove the visible epithelium from the flap edge. 3) Remove
the epithelium from the stromal bed interface. 4) Apply 20 percent alcohol to
the stromal bed followed by irrigation with balanced salt solution. 5) Stretch
and reposition the flap, taking care to minimise any folds. This video demonstrates a useful technique that may be difficult to acquire outside of the
private refractive practice setting.
Video Program
Video #42
Video #46
Sr. Producer: Shreyas Ramamurthy MBBS MS

Co-Producer(s): Pravin Vaddavalli MD
Creation of the flap is perhaps the most critical step in LASIK. Although the
femtosecond laser has improved precision and predictability of the flap,
the soft docking techniques used in the newer machines may increase the
chances of suction loss. Suction loss occurring during LASIK flap creation
may lead to incomplete flaps. Retreatment to complete the flap may not
be straightforward, as the repeat flap may not conform to the original flap
dimension. This video succinctly describes a variety of difficult situations
arising due to suction loss during femtosecond and microkeratome LASIK and
small-incision lenticule extraction, intraoperative modifications and postoperative outcomes.
Sr. Producer: Manish Nagpal MD*

Co-Producer(s): Sidharth Satyendrakumar Bhardwaj MS
Relaxing retinectomy is an important step during vitrectomy for proliferative
vitreoretinopathy (PVR), wherein contraction and retinal shortening prevent
contact of the retina with the retinal pigment epithelium. This video demonstrates various situations related to PVR-based retinal contraction in which
retinectomy is carried out to relax the tautness and settle the retina. The
adjunct role of diathermy to prevent bleeding as well as the role of perfluorocarbon liquids and silicon oil are demonstrated in different situations .
Honey, I Lost My Suction!
H Video #43
Small Can Be Beautiful: Upgrading the Inverted ILM Flap
Technique
Sr. Producer: Jerzy Nawrocki MD PhD
Co-Producer(s): Zofia Nawrocka MD**, Zofia Michalewska MD
We developed the Inverted internal limiting membrane (ILM) flap technique
for the treatment of large macular holes and for myopic macular holes. ILM
peeling itself may cause nerve fiber layer defects or full-thickness retinal
defects. To decrease the risk of such complications, we decided to use an
ILM flap peeled only from the temporal side of the macular hole. The video
presents this modification with postoperative spectral-domain optical coherence tomography images and confirms that these defects do not occur in the
space between the macular hole and optic disc. Experience from reoperations confirms that if the flap is only slightly larger than the macular hole,
surgical success depends on precise and secure location of the flap.
Video #44
Surgical Approach to Hemorrhagic Maculopathy Induced by

Blue Laser Pointer
Video #45
Different Surgical Solutions for Optic Pit Maculopathy

Sr. Producer: Sengul C Ozdek MD*
In this video, a step-by-step surgical solution to optic pitrelated macular
detachment will be presented. We will show the following lines of treatment
for recurrent macular detachments: first line vitrectomy with posterior
hyaloid removal, internal limiting membrane (ILM) peeling, laser penetrating
keratoplasty temporal to the optic nerve head and gas; second line ILM
flaps around the optic nerve head to seal over the pit and third line autologous fibrin to seal the pit. We will also present the postop pictures of the
cases.
Video #47
Management of the Traumatized Iris: Save the Iris!

Sr. Producer: Matteo Forlini MD
Co-Producer(s): Adriana Bratu MD**, Paolo Rossini MD, Cesare Forlini MD
We present our strategy on traumatic iris injuries. The iris is often considered
as a boundary area between anterior and posterior segment surgery, and it
is a zone not well defined between the competencies of the vitreoretinal and
anterior segment surgeon. We reviewed eyes with only anterior injuries or
combined anterior and posterior segment injuries. At the end of iris reconstruction, we performed retropupillary implantation of the iris claw IOL. In
all these cases with iris trauma, the retropupillary iris claw IOL was stable
without disenclavation. This middle earth is an area of surgery not well defined. At the time of primary repair, every effort should be made to preserve
as much of the normal iris tissue as possible.
H Video #48
Perfluoro-N-OctaneAssisted Single-Layered Inverted
Internal Limiting Membrane Flap Technique for Macular Hole
Surgery
Sr. Producer: Ji Eun Lee MD
Co-Producer(s): MinKyu Shin MD
It is challenging to achieve surgical closure of a long-lasting large macular
hole. The authors present a modified technique for covering a macular hole
with a single-layered internal limiting membrane (ILM) flap using perfluoron-octane (PFO). An ILM flap of about one disc in diameter was used to cover
the macular hole from its superior margin. The temporal and nasal ILM
was removed separately from inferior to superior in order to remain the
designated area for a flap. PFO was introduced over the macula to keep the
inverted ILM flap in the position during surgery. PFO was removed at the end
of fluid-air exchange.
Video #49
Surgical Treatment for Central Retinal Artery Occlusion

Direct Central Retinal Artery Massage
Sr. Producer: Ning Lu MD**
The common cause of central retinal artery occlusion is an embolus lodging
in the central retinal artery. The actual position of the embolus may be immediately posterior to the lamina cribrosa or more posterior. We have dislodged
the embolus by mechanical movement of the vessels with a probe. Three
cases are presented. In two cases, an embolus at a different position was
shown to be dislodged during the surgery. In the other case, no embolus was
seen. Circulation improved during the operation in all three cases.
247
Video Program
Sr. Producer: David Kohn MD

Co-Producer(s): Paola M Mosqueda MD, Itzhak Hemo MD**, Denise Wajnsztajn
MD
In this case report, a 16-year-old boy complained of decreased OD vision two
hours after three-second eye exposure to a blue laser pointer. Initial visual
acuity was hand motion, and an eye exam revealed a small vitreous hemorrhage, preretinal hemorrhage and a large subinternal limiting membrane
hemorrhage on the macular area, which was confirmed by optical coherence
tomography. During close follow-up for four weeks, poor improvement was
observed. At week 5, a 25-gauge pars plana vitrectomy and peeling of the
ILM were performed. Six weeks after surgery, visual acuity improved to 1.2
D. There was no permanent retinal pigment epithelium damage at three
months follow-up. Accidental exposure to common laser pointers may cause
hemorrhagic maculopathy, which may require surgery.
Relaxing the Retina: The Art of Retinectomy
Video Program
H Video #50
Diving Deeper Into the Eye With Swept Source OCT
Sr. Producer: Zofia Michalewska MD
Co-Producer(s): Janusz Michalewski MD**, Zofia Nawrocka MD**, Jerzy
Nawrocki MD PhD
Swept Source optical coherence tomography enables choroidal imaging and
improves retina imaging in eyes with media opacities. Choroidal thickness is
demonstrated to change with age and axial length and in particular diseases.
The video presents particular choroidal layers, concentrating especially on
the appearance of suprachodoidal layer and suprachoroidal space in different
retinal diseases. The exact delineation of choroidal nevi and differentiation
between nevi and tumors is also shown. The choroid is thicker in epiretinal
membranes, and it normalizes after surgery. It may also contribute to the
etiopathogenesis of vitreomacular interface diseases.
Video #51
Intraoperative OCT With the Haag-Streit iOCT and HI-R

NEO 900 NIR Microscope Provides Robust High-Resolution
Imaging During Pars Plana Vitrectomy
Sr. Producer: Christopher D Riemann MD*
Intraoperative optical coherence tomography (OCT) images are easy to obtain
and clinically useful during all phases of vitrectomy and are of excellent
quality. Par focality and coupled optical and OCT magnification allow for
wide-field OCT during peripheral pars plana vitrectomy using noncontact
wide-angle viewing and high-resolution OCT during macular work visualizing
with a direct contact lens. OCT imaging can be obtained through vitreous,
balanced salt solution, air, gas and silicone oil. Live, continuous line scan and
a variety of cube scan options were used.
Video #52
Volcano-Like Maculopathy From Handheld Green Laser

Pointer
Video Program
Sr. Producer: Javier Sanroman Sr

Co-Producer(s): Nicolas Toledano Fernandez MD**
In this case report, we present a 16-year-old man with an acute loss of visual
acuity in the left eye after accidental exposure to a handheld laser pointer.
The patients best-corrected visual acuity was 0.3. In the fundus exploration,
the patient presents a serius foveal damage with an epiretinal membrane
(ERM) and macular constriction. Within 1 month, his visual acuity was 0.1,
so we decided on surgical treatment of his ERM. After six months, the visual
acuity was 0.7, but the patient retains minimal foveal and retinal pigment
epitelial anormalities. Laser pointers can cause important macular damage.
To our knowladge, this is the first case reporting this type of maculopathy associated with laser pointer damage.
Video #53
My Tryst With Diabetic Vitrectomies

Sr. Producer: Meena Chakrabarti MBBS
Co-Producer(s): Arup Chakrabarti MBBS
This video presentation covers all aspects of the management of diabetic
retinopathy that will assist a vitreoretinal surgeon in evidence-based
decision-making, including indication, timing of surgery, use of pharmacological adjuvants, lens management, choice of vitrectomy gauge, membrane
dissection, bimanual surgery and use of a tamponade. The role of vitrectomy
in diabetic macular edema and the effect of anti-vascular endothelial growth
factor administration before surgery will be discussed. This video will provide
step-by-step guidance in performing diabetic vitrectomy for all indications
and managing postoperative complications and will offer valuable pearls for
optimizing outcomes.
248
Video #54
The Role of Dynamic (Video) Fluorescein and Indocyanine

Green Angiography in Diagnosis of Retinal Diseases
Sr. Producer: Colin S Tan MBBS*
Co-Producer(s): Kelvin Li MBBS, Wei Kiong Ngo MBBS, Tock H Lim MBBS FRCSE*
Dynamic (video) angiography during fluorescein angiography (FA) and indocyanine green angiography (ICGA) provides valuable information on the filling
characteristics of both the retinal and choroidal circulation. The ability to
observe filling of the vaculature during the very early phases of the angiogram in great detail provides valuable additional information to the clinician,
which facilitates the diagnosis and management of both retinal and chorodial
diseases. This video will examine the utility of dynamic FA and ICGA in the
diagnosis of important diseases such as polypoidal choroidal vasculopathy,
retinal angiomatous proliferation and retinal vacular diseases such as retinal
vein occlusion. The characteristic features of these conditions will be illustrated and discussed.
H Video #55
Argus II Implant: A Flavor of the Experience in the Middle East
Sr. Producer: J Fernando Arevalo MD FACS*
Co-Producer(s): Saba Al Rashaed MD
We have performed the implantation of the Argus II in five patients presenting with an advanced form of retinitis pigmentosa. One patient experienced
elevated postoperative IOP, which was controlled medically. Moderate separation of the device from the retina occurred postoperatively in one patient
and did not affect the result significantly. Wound dehiscence, endophthalmitis or retinal detachments were not observed. Performance tests improved
in all patients, and they were able to locate a bright light on the ceiling and
the door of the examination room after surgery. This video will demonstrate
several of our procedures performed in the Middle East.
Video #56
Posttraumatic Suprachoroidal Hemorrhage After Blunt

Trauma in Previous Penetrating Keratoplasty: Overcoming a
Taboo
Sr. Producer: Cesare Forlini MD
Co-Producer(s): Matteo Forlini MD
The cornea transplantation represents, for the eye, a weak point, and in
cases of closed trauma, the opening is always at the level of the corneal
scar. The immediate opening of the cornea provokes the expulsion of the
ocular content. This case shows an approach seven days after the trauma.
After a 23-gauge infusion in the anterior chamber, the suprachoroidal hemorrhage (SCH) is drained through a 23-gauge transconjunctival trocar. Overcoming a taboo of the eye reopening after SCH, the surgeon decided to remove
the cornea, assuming the risk of rebleeding. In this way, it was possible to
free the incarcerated iris with the vitreous from the injury site and clean the
anterior part of the vitreous. After a complete vitrectomy and prior to a new
penetrating keratoplasty and heavy silicone tamponade, a retropupillary IOL
implant in open sky was made thanks to a TKP.
No calibration required.
One button operation.
Large LCD display on
both sides for right
or left handed use.
Long life battery

with on-screen
indicator.
Protect your
investment with
affordable
OCU-FILM +
Tip Covers.
Soft touch grips

ensure stability.
Award-winning,
ergonomic design.
Made in the USA.
Tono-Pen just fits.
The Tono-Pen AVIA Tonometer fits comfortably in your hand. Its ready-to-use, calibration-free operation
fits your busy practice. Over 30 years of trusted accuracy and reliability fits your highest expectations.
Visit us at Booth 3826 or online at tonopen.com
www.reichert.com
Proudly made in the USA.
2014 AMETEK, Inc & Reichert, Inc. (08-2014) All rights reserved.
Alcon In Chicago
ALCON THEATER SCHEDULE
Time
Visit the Alcon Theater (Booth#2908)

to hear from top surgeons discussing
the latest Alcon technologies.
Saturday, October 18, 2014
9:30 am 10:00 am
An NSAID Treatment for Cataract Surgery

Dr. Edward Holland
10:00 am 11:00 am
The Cataract Refractive Suite by Alcon: Designed to Improve Outcomes (Panel Discussion)
Dr. Michael Jones, Dr. Stephen Slade, Dr. Richard Tipperman
11:00 am 11:30 am
Verion Image Guided System: The Image Guided Pursuit of Emmetropia

Dr. John Davidson
11:30 am 12:30 pm
Connect the Dots: Mastering the AcrySof IQ Toric IOL Implantation (Panel Discussion)
Dr. Paul Ernest, Dr. Bonnie Henderson, Dr. Edward Holland
12:30 pm 1:00 pm
LenSx Laser: Leading Innovation in Cataract Surgery

Dr. Harvey Reiser
1:00 pm 2:00 pm
Why We Believe That Centurion Technology Can Make Every Surgeon Better (Panel Discussion)
Dr. Scott Laborwit, Dr. RJ Mackool, Dr. Robert Osher
2:00 pm 2:30 pm
Evolution of Excimer Laser Vision Correction in the US

Dr. Doyle Stulting
Time
Sunday, October 19, 2014
9:30 am 10:00 am
Evolution of Custom Cornea Surgery

Dr. Paul Kang
10:00 am 10:30 am
Delivering More to Your Patients with AcrySof IQ ReSTOR IOL

Dr. Bret Fisher
10:30 am 11:30 am
The Cataract Refractive Suite by Alcon: Improving Confidence with Advanced Technology IOLs
(Panel Discussion) Dr. Bradley Black, Dr. Jonathan Frantz, Dr. Kerry Solomon
11:30 am 12:30 pm
New Vitreoretinal Technology Pearls Video (Panel Discussion)

Dr. Maria Berrocal, Dr. Carl Regillo, Dr. Peter Kaiser
12:30 pm 1:00 pm
Treatment of Inflammation and Pain Associated with Ocular Surgery and Endogenous Anterior Uveitis
Dr. Eric Donnenfeld
1:00 pm 1:30 pm
LenSx Laser: Leading Innovation in Cataract Surgery

Dr. Scott Hartzell
1:30 pm 2:00 pm
Image Guided Technology for Improving Outcomes

Dr. Robin Vann
2:00 pm 2:30 pm
Centurion: The Era, The First Year, The Truth About the Technology
Dr. Brandon Ayers
Time
Monday, October 20, 2014
9:30 am 10:00 am
Image Guided Technology for Improving Outcomes

Dr. Stephen Scoper
10:00 am 10:30 am
LenSx Laser: The Complete Anterior Segment Workstation

Dr. Richard Tipperman
10:30 am 11:00 am
Recommending Advanced Technology IOLs to Your Patients

Dr. Terry Kim
11:00 am 11:30 am
The Cataract Refractive Suite by Alcon: The First and Only Complete Suite
Dr. Jim Davison
11:30 am 12:30 pm
Retinaws: Retinal Adventures in the Operating Room

Dr. Kourous Rezaei (Moderator), Dr. Pravin Dugel, Dr. Carl Claes, Dr. Charles Eifrig
12:30 pm 1:00 pm
Centurion: The Era, The First Year, The Truth About the Technology
Dr. Robert Cionni
1:00 pm 1:30 pm
The Evolution of Custom Cornea Surgery

Dr. Ronald Krueger
1:30 pm 2:00 pm
An NSAID Treatment for Cataract Surgery

Dr. Francis Mah
2:00 pm 2:30 pm
The Cataract Refractive Suite by Alcon: The OR of the Future is Here

Dr. Jack Chapman
Presentations, speakers, and times are subject to change. Please visit the Alcon booth for the most up to date schedule.
These presentations are not affiliated with the official program of AAO 2014.
2014 Novartis
8/14 MEM14025MS
SPECIAL MEETINGS
AND EVENTS
Friday Wednesday, Oct. 17 22
Special Meetings & Events are free of charge, unless otherwise noted. They are not eligible for CME credit.
SO Endorsed by Senior Ophthalmologist Committee
YO Endorsed by Young Ophthalmologist Committee
P.O. Box 7424, San Francisco, CA 94120-7424
| Tel: 415-561-8500 Fax: 415-561-8533

249

Friday, Oct. 17
DICOM Working Group 9 - Eye Care

Event No: SPE01
Fee: FREE
Location: Hyatt Regency McCormick Place
7:30 AM - 3:00 PM
Presenter(s): Mark B Horton MD, Linda L Wedemeyer MD
DICOM is a standard for integrating different imaging data sources so that

they can be readily transferred, stored and exchanged. Working Group 9,
a DICOM committee sponsored by AAO, focuses on digital imaging standards for eye care, e.g, fundus imaging, ophthalmic tomography, biometry,
visual fields macular thickness mapping. This meeting is open to vendors
and ophthalmologists, administrators, ophthalmic photographers and ophthalmic technicians interested in advancing digital imaging.
Saturday, Oct. 18
NEW SO Brain Health and Longevity for SOs in the
Digital Age
Event No: SPE04
Fee: FREE
Room: N427bc
9:00 - 11:00 AM
Presenter(s): Andrew P Doan MD PhD*
Course will cover how the brain stores and retrieves memories. The course
will discuss how technology, digital media, and video games affect the
brain. When used in moderation, technology improves visual acuity, mental
processing time, and memory. On the other hand, if used excessively, may
lead to behavioral dysfunction and health problems. Course will focus on
improving brain health in the digital age.
SO Use Blogging & Social Networking to Super
Charge Your Website & Internet Marketing
Event No: SPE07
Fee: FREE
Room: N227a
1:00 - 4:00 PM
This course will offer an overview of how to blog, publish, and share your
ideas on the Internet. This instruction provides a hands-on, step-by-step
construction of your Internet blog and how to publish articles to use the
power of search engines to attract people to your practice, website, or
business.
Sunday, Oct. 19
Special Meetings
& Events
29th Annual Run for Vision

6:30 - 7:30 AM
YO 2014 YO Program - Its YO World, Jumpstart Your

Career!
Event No: SPE08
Fee: FREE
Room: S101ab
Young ophthalmologists (YOs) face a unique set of challenges in their transition from training to practice. Here, members of the YO Committee along
with leading consultants and experts, present an interactive, panel-based
program addressing topics vital to members-in-training (MITs) and YOs in
their first few years of practice. This year our high-energy and engaging
program will cover key issues such as practice type selection, job searching, contract negotiation, practice building, dealing with medical errors,
management of medical-legal issues, and personal finance.
Annual Business Meeting

Event No: SPE22
Fee: FREE
Room: North Hall B
10:00 - 10:30 AM

Event No: SPE10
Fee: FREE
Location: Fairmont Chicago
11:30 AM - 5:00 PM
Presenter(s): Ann A Warn MD MBA*, Mathew W MacCumber MD PhD*,

Russell N Van Gelder MD PhD*, Gregory L Skuta MD*, David W Parke II MD*,
Cynthia Ann Bradford MD, Daniel J Briceland MD*
Members of the Academys Council, an advisory body to the Board of Trustees, and also leaders of ophthalmic state, subspecialty and specialized
interest societies will meet to discuss the latest advocacy news and provide take home messages and action items during its Council of Advocates
session as part of the Fall Council meeting. In addition, Academy leaders
will provide updates regarding priority activities and strategic issues such
as the ophthalmic registry, compounding pharmaceuticals and health care
reform. The Council will also meet by region to discuss issues common to
certain areas of the country.
2015 Medicare Update
Presenter(s): Andrew P Doan MD PhD*, Randall V Wong MD*
Event No: SPE23

Fee: TBA
MD*, Mark E Kropiewnicki JD LLM*, Andreas Lauer MD*, Diana R Shiba

MD**, Loretta L Stein MD**, Janice C Law MD**, Sidney K Gicheru MD,
Randall V Wong MD*, Anthony J Aldave MD*, Rahul Khurana MD*, Michael J
Parshall*, Debra L Phairas, Justin Nabity**, Ravi D Goel MD, Thomas S Harbin
MD, Robert J Landau JD, John M Cropsey MD, Denise R Chamblee MD
10:00 AM - 2:00 PM
Event No: SPE11

Fee: FREE
Q&A with FDA

Event No: SPE13
Fee: FREE
Room: N427d
12:45 - 1:45 PM
Presenter(s): Wiley Andrew Chambers MD, Malvina Eydelman MD, Suber S

Huang MD*
Have questions about the drug and device approval process? Want to talk
about new FDA initiatives? Need answers about the latest news affecting
ophthalmic products? Join FDA ophthalmic drug and device experts for a
session with a new format driven entirely by you. Submit your questions
to the Academy and FDA experts will give you the information you need
to know!
Presenter(s): Purnima S Patel MD, Jeff H Pettey MD, William Lloyd III MD,
Robert F Melendez MD MBA, Natasha L Herz MD, Vikas Chopra MD*, David E
Vollman MD MBA*, William Barry Lee MD*, Nikolas J London MD*, Donald J
DAmico MD*, Ruth D Williams MD*, Brian T Chan-Kai MD**, Gregory L Skuta
250
12:15 - 1:45 PM

OMIC Annual Members Meeting

Event No: SPE14
1:30 - 2:00 PM
Fee: FREE
Room: S403b
The annual meeting of the members of the Ophthalmic Mutual Insurance
Company (a Risk Retention Group) will be held in order to elect directors
of the company and to transact such other business as may come before
the meeting. OMIC President & CEO, Timothy Padovese, will report on the
companys latest results.
The Bruce E Spivey MD Lecture in Risk Management

and Patient Safety and OMIC Forum
Event No: SPE15
Fee: FREE
Room: S406b
2:00 - 4:00 PM
Presenter(s): Ajit Sachdeva MD FRCSC FACS**, Steven V L Brown MD*,

Michael Carmine Tigani MD**, Timothy J Padovese, Paul Weber JD**, Daniel
B Mills**
The Bruce E. Spivey, MD Lecture in Risk Management and Patient Safety

will be given by Ajit K. Sachdeva, MD, FRSC, FACS. Dr. Sachdeva is the
founding director of the Division of Education at the American College of
Surgeons, responsible for the development and implementation of innovative educational programs for surgeons, surgery residents, medical students and members of surgical teams. Dr. Sachdeva will lecture on education and training programs that enhance patient safety and minimize risk of
adverse outcomes. The lecture will be followed by the OMIC Forum.
The Bruce E Spivey MD Lecture is sponsored jointly by the Ophthalmic
Mutual Insurance Company and the H. Dunbar Hoskins Jr. MD Center for
Quality Eye Care.
Monday, Oct. 20
ophthalmologists had a significantly increased rate of MSD symptoms in

comparison to a family medicine physician control group. Identification
of risk factors and modification of these activities will decrease the risk
MSDs. The symposium will include presentations from ergonomics specialists focusing on practical recommendations to decrease risk of injury
in the office, clinic and operating rooms. In addition, a physical therapist
will demonstrate exercises and stretching routines that can be performed
during the day at work and home.
NEW Visual Impact of Traumatic Brain Injury: Lessons
Learned
Event No: SPE18
12:45 - 1:45 PM
Fee: FREE
Room: S102abc
Featured Speaker: Bob Woodruff
In 2006, journalist Bob Woodruff suffered multiple brain injuries in a nearfatal bomb explosion in Iraq. His experience led him to create the Bob
Woodruff Foundation to help veterans with traumatic brain injuries (TBI)
and posttraumatic stress disorder.
Traumatic Brain Injury (TBI) has become a significant focus in VA, DOD, and
the private sector due to severe blast injuries, vehicular accidents, football and other sports-related injuries. Neurotrauma exhibits diverse clinical
presentations often requiring complex coordination of care. Topics for discussion include ocular and visual outcomes, mechanisms of injury and the
integrated multidisciplinary approach of the TBI patient. Speakers will also
discuss the nature of TBI spectrum including assessment and management.
A question and answer period will follow.
SO SO Special Program and Reception
Event No: SPE19
Fee: FREE
Room: S101ab
Presenter(s): Harry Zink MD*, Andrew P Doan MD PhD*, Tamara R Fountain

MD*, James Ford McDonnell MD**, Julie Doan RN**
YO Welcome to the Real World: Reality 101 for

Residents and Fellows
Event No: SPE17
Fee: FREE
Room: S101ab
12:30 - 1:30 PM
Presenter(s): Alan L Wagner MD FACS**, Jeff H Pettey MD, Purnima S Patel

MD, Eric Fry MD**
Ergonomics/Musculoskeletal Disorders in
Ophthalmologists
Tuesday, Oct. 21
The Resident Hub User Group Session

Event No: SPE20
Fee: FREE
Room: N427a
LE
CANCE
12:45 - 1:45 PM
Presenter(s): Sarah Page
The Resident Hub is an online learning portal for residency programs which
includes high-quality resources such as videos, courses, and self-assessment exams as well as tools for building multimedia courses, assigning
learning plans, and more! This session will include a brief demonstration of
The Resident Hub functions and features, followed by a user group meeting. Users of The Resident Hub are encouraged to attend this meeting to
share ideas for desirable enhancements, to learn about new content, features, and plans for future changes. For more information, go to www.aao.
org/thehub.
12:45 - 1:45 PM
Presenter(s): Jeffrey L Marx MD, Keith Hugh Baratz MD**, Meher Yepremyan
MD**, Renee Ostertag DPT MPT**
Self-reported musculoskeletal disorder (MSD) symptoms in the prior month

have been reported in up to 50% of ophthalmologists. In a recent study,
251
Special Meetings
& Events
Residents and fellows will learn about the non-medical aspects of practicing ophthalmology and get their burning questions answered in this interactive forum. Panelists will discuss their personal experiences & highlight
various practice options, networking & referrals, advantages/disadvantages of fellowship training & resources to assist them. Learn how membership & active involvement within state ophthalmology societies and the
national American Academy of Ophthalmology can benefit you.
Event No: SPE12

Fee: FREE
Room: N427bc
2:30 - 5:00 PM

Wednesday, Oct. 22
28 Lo Mejor de la Academia en Espaol / 28th Best of

the Academy in Spanish
Event No: SPE21
8:00 AM - 5:30 PM
Fee: PAAO/Academy Active Members $40; Non-Members $50;
Residents/Fellows $25 (with letter or appropriate Annual Meeting badge).
Location: Westin Michigan Avenue
Presenter(s): Eduardo Arenas MD**, J Fernando Arevalo MD FACS*, Ivan R
Batlle MD**, Ashley Behrens MD**, Hilda Capo MD, Jose Claros MD**, Jose
Alejandro Claros MD**, Fernando L Colombo MD*, Javier Cordoba Umana
MD**, Zelia M Correa MD, Paulo Elias C Dantas MD PhD**, Valentina Franco
Cardenas MD, Gregorio F Gabela MD, Manuel M Garcia-Marcos MD**,
Fernando Gomez Goyeneche MD**, Victor H Gonzalez MD*, Enrique O Graue
Hernandez MD, Federico A Graue-Wiechers MD, Tomas M Grippo MD**, Luis
Izquierdo Jr MD, Alejandro Lavaque MD, Cristian F Luco MD**, Miguel A
Materin MD, Peter A Quiros MD, Arturo J Ramirez-Miranda MD*, Jose A Roca
MD**, Abelardo Rodriguez-Reyes MD**, Armando G Sandoval MD**, Daniel
H Scorsetti MD, Lihteh Wu MD*
Special Meetings
& Events
The American Academy of Ophthalmology (AAO) and the Pan-American Association of Ophthalmology (PAAO) will sponsor a one-day meeting which
will summarize the important presentations in general ophthalmology and
all subspecialty fields at AAO 2014. New ophthalmic literature and instruments will also be objectively evaluated. The presenting panels will be
composed of Spanish-speaking ophthalmologists. Please note that panel
topics and/or times may change.
La Academia Americana de Oftalmologa (AAO) y la Asociacin Panamericana de Oftalmologa (PAAO) auspiciarn una reunin de un da en la cual
se presentarn y discutirn, por oftalmlogos de habla hispana, los aspectos ms importantes en 2014 ya sean en oftalmologa general o en las diversas subespecialidades. Nueva literatura e instrumentos oftalmolgicos
sern evaluados en forma objectiva.
252
LEARNING LOUNGE
Booth 107
The Learning Lounge is an interactive space for informal, small group discussions facilitated by experts in the field. Float among theaters,
new topics begin every 15 minutes.
Find the most up-to-date schedule through the Mobile Meeting Guide, www.aao.org/mobile.
253
Learning Lounge
Saturday, Oct. 18
12:00
12:15
12:30
Theater 1
Advanced IOL Power Calculations for
Cataract and Refractive Surgeons
Jack T Holladay MD MSEE FACS
12:45
Theater 2
Theater 3
MIGS (Microinvasive Glaucoma Surgery):

Tips for the Cataract Surgeon
Intraocular Lens Exchange
Eric D Donnenfeld MD
1:00
Samuel Masket MD
1:15
1:30
1:45
2:00
2:15
Effective Use of Capsular Tension Devices

Robert J Cionni MD
How I Managed My Worst Case of the Year

Uday Devgan MD
2:30
2:45
Surgical Techniques: Things Im Doing

Differently This Year
Stephen S Lane MD
3:00
3:15
3:30
3:45
4:00
4:15
4:30
4:45
Learning Lounge
5:00
254
Global Ophthalmology Volunteer

Experiences
Heather A Estopinal MD
John M Cropsey MD
Judith T Newman MD
Build Your Brand With Social Media
Global Ophthalmology Invited Guests
Purnima S Patel MD
Timothy P Page MD
Learning Lounge
Sunday, Oct. 19
9:00
Theater 1
Theater 2
Theater 3
9:15
9:30
9:45
10:00
10:30
10:45
11:00
Strategies for Efficient Cataract Surgery

Parag D Parekh MD MPA
Monitoring for Glaucomatous Progression

in the Moderate Era
11:15
11:30
Kaweh Mansouri MD
11:45
12:00
12:15
12:30
Management of Proliferative Diabetic

Retinopathy
Adam S Wenick MD
12:45
1:00
Continue the Conversation
Spotlight on Pediatric Ophthalmology:

Front Line and First Steps Management
of Strabismus for the Comprehensive
Ophthalmologist
Newest Thoughts on Angle Closure

Glaucoma
Christopter Kai-shun Leung MD MBChB
Laura B Enyedi MD
Michelle T Cabrera MD
1:15
1:30
1:45
2:00
2:15
2:30
Patient Selection for Premium Lenses and

Laser Assisted CD
Sonia H Yoo MD
2:45
Treatment for Wet and Dry AMD: Where We

Are and Where We Are Going
Trabeculectomy 2.0
Peter Andreas Netland MD PhD
R Theodore Smith MD
3:00
3:15
3:30
3:45
4:00
4:15
4:30
Managing the Traumatic Cataract

David R Hardten MD
Management of Diabetic Macular Edema

Baruch D Kuppermann MD PhD
Congenital Glaucoma
James D Brandt MD
Alana S Grajewski MD
4:45
5:00
Learning Lounge
255
Learning Lounge
Monday, Oct. 20
9:00
9:15
9:30
9:45
Theater 1
Watch Out for Zonules
Liliana Werner MD PhD (Sr Producer)
Not All Is Lost After a Posterior Capsule

Tear
Intraoperative Challenges During
Femtosecond Laser-Assisted Cataract
Surgery and Their Management
Dilraj Singh Grewal MD (Sr Producer)
at the Movies GlauCoMa
Stab Incision Glaucoma Surgery

Soosan Jacob FRCS (Sr Producer)
Couched Compression Closure of

Conjunctival in Limbal Filtration
Matthew Starr (Sr Producer)
Nip/Tuck: A Disturbingly Perfect New

Procedure
Shamira A Perera MBBS (Sr Producer)
10:45
11:00
at the Movies oCular tuMors

and PatholoGy, and orbit, laCriMal,
PlastiC surGery
Sclerotherapy for Orbital/Periorbital
Dermoid Cysts: A Novel Treatment
Akshay Gopinathan Nair MD (Sr Producer)
Intravitreal Chemotherapy for Vitreous

Seeds in Retinoblastoma
Fairooz Puthiyapurayil Manjandavida MD (Sr Producer)
10:15
10:30
Theater 3
at the Movies CataraCt
Arup Chakrabarti MBBS (Sr Producer)
10:00
Theater 2
Synkinetic Ptosis Made Simple

Santosh G Honavar MD (Sr Producer)
Posterior Capsule Management: How and

Why
Lisa B Arbisser MD
11:15
Ethical Relationships Between Physicians

and Industry
Anthony J Aldave MD
11:30
Ptosis Repair for the Comprehensive

Ophthalmologist
Richard C Allen MD
11:45
12:00
12:30
Endothelial Keratoplasty (DSAEK and

DMEK): Avoid Complications and Enhance
Results
12:45
Mark A Terry MD
12:15
1:00
1:15
1:30
1:45
2:00
2:15
2:30
2:45
3:00
3:15
3:30
3:45
4:00
4:15
4:30
Learning Lounge
4:45
5:00
256
Managing Cataract Post-operative

Inflammation and Pain
Terry Kim MD
Himani Goyal MD
David A Goldman MD
Pitfalls of Blepharoplasty Surgery

Erin M Shriver MD
Certification and Your First MOC Cycle

R Michael Siatkowski MD
Pediatric Refractive Surgery

Lawrence Tychsen MD
Eveltn A Paysse MD
Ocular Surface Diagnostics

Elizabeth Yeu MD
Clinical Pearls in the Diagnosis

of Masquerades in Infectious and
Inflammatory Disease of the Eye
Anat Galor MD
Abusive Head Trauma
Learning Lounge
Tuesday, Oct. 21
9:00
Theater 1
9:15
Different Surgical Solutions for Optic Pit

Maculopathy
9:30
Sengul C Ozdek MD (Sr Producer)
9:45
Relaxing the Retina: The Art of

Retinectomy
Manish Nagpal MD (Sr Producer)
My Tryst With Diabetic Vitrectomies

10:00
Theater 2
Theater 3
at the Movies retina, vitreous
Meena Chakrabarti MBBS (Sr Producer)
at the Movies Cornea, external disease
Relief: Mucous Membrane Graft in StevensJohnson Syndrome

Bhupesh Bagga MD FRCS MBBS (Sr Producer)
Video Program
Best of Show Ceremony
Crescentic Tuck in Lamellar Keratoplasty:

A Novel Technique to Manage Advanced
Pellucid Marginal Degeneration
Ritu Arora MD MBBS (Sr Producer)
Scleral Graft in Corneal Perforations: When

Less Is More
Maria T Iradier MD PhD (Sr Producer)
10:15
10: 30
10:45
Certification and Your First

MOC Cycle
11:00
11:15
11:30
11:45
12:00
Learning Lounge
257
TECHNOLOGY PAVILION
Booth 165
Academy members and independent consultants offer user-friendly instruction on what is available and how to use the latest technology
available for business, clinical and academic applications. Stop by for presentations on:
The latest tech, from mobile and wearable, to cloud computing.
Internet, social networking, productivity and mobile software topics.
Software for medical records, presentations, managing your online reputation and more.
How to make the most of the Mobile Meeting Guide.
258
Technology Pavilion
Presentation Schedule
10:00
Saturday 10/18
9:30-11:00
Maximizing Microsoft Office 365
Sunday 10/19
Monday 10/20
9:30-11:00
Social Media Bootcamp
9:30-10:30
Academys IRIS Registry
10:30
11:00
11:30
12:00
12:30
1:30
2:00
2:30
3:00
3:30
4:00
4:30
11:00-12:00
Advance Technology that You Can
11:30-12:00
11:30-12:00
AAO 2014s Mobile Meeting Guide AAO 2014s Mobile Meeting Guide Wear
12:30-1:30
Google Glass in the Practice of
Ophthalmology
2:00-3:00
Technology Update from the
Academy: Ophthalmic News and
Education (ONE) Network
3:30-4:30
Online Reviews are Driving Me
Crazy!
12:30-2:00
Smartphone and Mobile
Technology Update
Tuesday 10/21
9:30-10:30
Personal Internet Security: Best
Practices
11:00-12:30
Microsoft Windows/Office: Ask
the Expert
12:30-1:30
What if Your current EHR Doesnt
Fit Your Needs?
2:30-3:30
Fully Integrated DICOM Imaging
and EHR
4:00-5:00
Other Technology for Your Practice
2:00-3:00
Protect Your Online Reputation
3:30-4:030
Cloud Computing Forecast: Sunny
With a Chance of Rain
5:00
Indicates IHE session
Saturday, Oct. 18
9:30 11:00 AM
Maximizing Microsoft Office 365

Jude Brown, Senior Instructor, Digital Acumen, Inc.
Microsofts latest version of their Office suite of programs is now is
the cloud-based, Office 365. Available by subscription, the software is
now always up-to-date and packed with new features for collaborating,
storing, and accessing your documents from anywhere and any device
including Apple iPad and other tablets. This session will review each of
the included programs, their newest features, and how the subscription
model compares to disc in terms of benefits and pricing. As always, our
instructor is happy to field your Office-related questions.
11:30 AM 12:00 PM
Get the Most From the Academys Mobile Meeting Guide

This quick session introduces users to the basics and benefits of using
the Academys all new Mobile Meeting Guide to help plan and navigate
the 2014 annual meeting. Learn how to sign in, find sessions, create your
Personal Planner, as well as get an overview of the wealth of content and
features it contains. Did you know you can view Academy posters and
videos, fill out course evaluations, take notes and even ask questions live
during certain sessions through the Mobile Meeting Guide? If not, this
session is for you!
(Repeated on Sunday, 11:30 AM 12:00 PM)
12:30 1:30 PM
Google Glass in the Practice of Ophthalmology

Omar K Ozgur MD, Ophthalmic Plastic and Reconstructive Surgery Fellow,
University of Texas M.D. Anderson Cancer Center
What is Google Glass? It is an eyeglass frame that houses a computer
with a built-in camera and mini-projector screen. It fits just like a regular
pair of glasses. Besides taking pictures, recording video, and serving as a
hands-free wireless communication headset it allows you to run applications much like a smartphone. With an emerging presence of Glass in
medicine, Dr. Ozgur describes his experiences as a Google-selected early
test user and how Glass may help ophthalmologists with patient care.
2:00 3:00 PM
Technology Update From the Academy: Ophthalmic News

and Education (ONE) Network
Robert F Melendez MD MBA, Editor-in-Chief of the ONE Network
Dale Fajard EdD MBA, Director of Online Education and the ONE
Network, American Academy of Ophthalmology
Sarah Page MA, E-Learning Project Manager, American Academy of
Ophthalmology
The Ophthalmic News and Education (ONE) Network is a comprehensive
educational resource which provides members and subscribers the ability
to quickly and effectively access relevant clinical information from an
extensive, up-to-date knowledgebase. In this presentation we will provide
an update on the ONE Network, including a review of new features and
enhancements, and an overview of the latest electronic resources available from the Academy. We will also make time for Q&A.
259
Technology Pavilion
9:30
Technology Pavilion
Technology Pavilion
3:30 4:30 PM
4:00 PM 5:00 PM
Online Reviews are Driving Me Crazy!
Other Technology for Your Practice
Andrew Doan MD PhD, Head, Dept. of Mental Health Addictions &

Resilience Research, Naval Medical Center San Diego
Online reviews about your medical services and practice can be emotionally draining and can also damage your online reputation. Learn how to
bullet-proof your online reputation and use online reviews to attract new
patients and strengthen patient confidence.
H Jay Wisnicki MD, Medical Director, Union Square Eye Care

P Lloyd Hildebrand MD, Department of Ophthalmology, University of
Oklahoma
Rainer Waedlich, President IOTA (International Ophthalmic Technology
Association)
Aside from your EHR and Practice Management systems, where else can
the latest digital technology benefit your ophthalmology practice? From
enhancing communication with your patients inside and outside the exam
room, to keeping the office running during a disaster, to online CME and
telemedicine, our panel will discuss their favorite tips and tricks to make
your practice more efficient and patient-friendly. Bring your questions and
share your own experiences in this interactive session.
Sunday, Oct. 19
9:30 11:00 AM
Social Media Bootcamp

LinkedIn, Facebook, Twitter, Google+, Snapchat, Vinewhere to start?
This basic session for the Social Media novice will introduce the terms
and technologies and have you tweeting in no time. Tips for checking
and protecting your online reputation will also be reviewed.
11:30 AM 12:00 PM
Get the Most From the Academys Mobile Meeting Guide

This quick session introduces users to the basics and benefits of using
the Academys all new Mobile Meeting Guide to help plan and navigate
the 2014 annual meeting. Learn how to sign in, find sessions, create your
Personal Planner, as well as get an overview of the wealth of content and
features it contains. Did you know you can view Academy posters and
videos, fill out course evaluations, take notes and even ask questions live
during certain sessions through the Mobile Meeting Guide? If not, this
session is for you!
Monday, Oct. 20
9:30 10:30 AM
Academys IRIS Registry: How to Meet Regulatory

Requirements for Quality Measures
William L Rich III MD, Medical Director of Health Policy, American
Academy of Ophthalmology
The Academy is launching the IRIS Registry, an EHR-based approach to
collecting data that can be used for quality improvement, qualification for
PQRS incentives or avoidance of penalty, and qualification for one menu
measure in the Meaningful Use incentives for EHR usage. This presentation will explain how the registry works through systems integration with
your EHR, and how it can bring value to participants.
11:00 AM 12:00 PM
12:30 PM 2:00 PM
Advance Technology That You Can Wear
Smartphone and Mobile Technology Update
Andrew Doan MD PhD, Head, Dept. of Mental Health Addictions &

Resilience Research, Naval Medical Center San Diego
Technological advances allow computers to be smaller, faster, and even
wearable. This technology talk will review the latest in wearable technology and how this technology will impact your life and practice.
Vinay A Shah MD, Dean McGee Eye Institute, University of Oklahoma,

Oklahoma City
Rohit Krishna MD, University of Missouri - Kansas City, Kansas City, MO
R Ken Lord MD, Retina Associates of Southern Utah - St. George, UT
What are the latest SmartPhone and Tablet trends and how can you
harness the increasing power of these mobile devices to simplify your
life and maximize productivity in your practice? We will examine current
developments in the mobile computing industry and review the latest
Apps for medical and personal use including clinical reference, education,
increasing efficiency, and practice branding and marketing. Audience
questions are welcome.
2:30 PM 3:30 PM*
Using a Fully Integrated DICOM Imaging and EHR System

Jeffrey Marx MD, Lahey Hospital and Medical Center, Burlington, MA
DICOM is the established medical image formatting standard, allowing
the EHR to talk to the imaging and diagnostic devices in an office network. Tremendous progress has been made in the use of DICOM imaging
in Ophthalmology. Further refinements are being made to assist workflow
in ordering, testing, interpreting and billing. Data extraction from images
can be utilized for graphing and improving patient care. Dr. Marx will describe how his integrated DICOM imaging and EHR system has benefitted
the quality of patient care and the efficiency of his practice.
*Presentation is related to the Electronic Office: Integrating the Healthcare Enterprise (IHE) Booth 3851.
260
12:30 1:30 PM
What if Your Current EHR Doesnt Fit Your Needs?

Amy Hutchinson MD, Emory University
David Gutierrez, Enterprise Project Manager, Modernizing Medicine, Inc.
This case study follows the problem solving and decision making processes involved when a large health systems enterprise EHR did not meet
the ophthalmology sections needs for a specialty specific EHR, mobile
access, or data capture for meaningful use and other purposes. How do
you build administrative and staff support for the change? What criteria
do you look for in a technology partner? Join a physician intrinsically
involved in the implementation and the project manager of the vendor
they teamed with as they review their successes and stumbles during the
process. Questions welcome.
2:00 3:00 PM
Protect Your Online Reputation

Ravi Goel MD, Instructor, Wills Eye Hospital
Patients increasingly rely on Internet rating sites to find medical providers,
but information on these websites is rarely monitored and reviews are often inaccurate. A single negative comment can damage your professional
Technology Pavilion
3:30 4:30 PM
Cloud Computing Forecast: Sunny With a Chance of Rain

H Jay Wisnicki MD, Medical Director, Union Square Eye Care
Thinking of moving your practice to the Cloud? Well review the considerable benefits and occasional pitfalls of moving from the traditional
on-premise and one-time-purchase software/hardware model to the
newer subscription-based Software as a Service (SaaS) and remote
hosting model. Does it even need to be an all or nothing choice? Our
experienced, tech savvy ophthalmologist will help you avoid a potentially
stormy migration.
11:00 AM - 12:30 PM
Microsoft Windows/Office: Ask the Expert

This custom-tailored, interactive session provides an audience-driven
overview of the Windows Operating Systems, Office 365, Office 2013
and Video Editing. Ask our Expert any questions that remain unanswered
after the earlier overview session or about solving a particular problem
you have had using Windows or Office tools in the past.
Tuesday, Oct. 21
9:30 - 10:30 AM
Personal Internet Security Best Practices

Sony, Neiman Marcus, Michaels, Target, Heartbleed, major releases
of stolen personal information such as credit card numbers and pass-
261
Technology Pavilion
reputation and affect practice growth. This session will provide strategies
to effectively monitor your online reputation and use social media to
address negative comments. You will learn common and free tools and
techniques to support promoters, address critics, engage with social
media, and establish and maintain a positive Internet presence.
words are happening regularly. What steps can you take in your online
transactions and daily use of the Internet to protect yourself? Learn how
to identify fraudulent sites and emails, create secure credentials, and limit
your risk of loss as you shop and bank online.
INFORMATIONAL POSTERS
Saturday Tuesday, Oct. 18 - 21
Booth 2480
View Informational Posters during exhibit hall hours presented by organizations that serve allied health and ophthalmological societies as
well as the visually impaired.
| Tel: 415-561-8500 Fax: 415-561-8533

262
Poster 1
Poster 13
Volunteer opportunities at the Mission Eye Hospital in Mombasa,

Kenya.
Presenting various conditions that require prosthetic eyes and

scleral shells. Information available about ASO.
American Society of Ocularists (ASO)
Poster 2
Poster 14
Assisting ophthalmologists to provide free cataract surgery to the

poor and uninsured in their local communities.
Providing refractive, medical and surgical eye care in underserved

areas. Educating people in eye care and preventative measures.
Mission Cataract USA
Lighthouse for Christ Mission and Eye Centre
Global Eye Project
Poster 3
Poster 15
Developing a cure for glaucoma through funding of innovative

research and the Cure Glaucoma Now initiative.
Working across ophthalmology to provide professional and personal

development, as well as opportunities for collaboration.
The Glaucoma Foundation
Ophthalmic Women Leaders (OWL)
Poster 4
Poster 16
Volunteer opportunities for eye surgeons in developing countries to

restore sight surgically, treat severe eye diseases and teach modern
techniques.
Partnership opportunities for ophthalmologists and medical manufacturers to establish clinics/surgery centers.
Volunteer Eye Surgeons International
Poster 5
Pediatric Keratoplasty Association
Addressing the issues associated with the management of corneal

diseases in infants and children.
Poster 6
The Sturge-Weber Foundation
Providing patient support materials, the latest research news

and grant announcements for those interested in Sturge-Weber
syndrome.
Poster 7
Mahatme Eye Bank & Hospital
Offers hands on surgical training courses and International Council

of Ophthalmology fellowships.
Poster 8
Chinese American Ophthalmological Society, Inc.
Advancing medical knowledge, scientific research, and the education and training of ophthalmologists of Chinese descent.
Poster 9
Centro Cristiano De Servicios

Humanitarios De Honduras (CCSHH)
Volunteer opportunities to assist a full service eye clinic established

to serve the indigent in El Progreso, Honduras.
Poster 10
Retinitis Pigmentosa International
Finding and funding the cure, media research, patient services and
public awareness for Retinitis Pigmentosa and related degenerative
eye diseases.
Poster 11
Sightsavers International, Inc.
Providing sight restorative surgery and working to eliminate blinding

diseases, trachoma and river blindness.
Poster 12
Himalayan Cataract Project
Working to eradicate preventable and treatable blindness through

high-quality ophthalmic care, education and the establishment of a
world-class eye care infrastructure.
Deseret International Foundation
Poster 17
Centers For Disease Control and Prevention (CDC)
Learn about the Healthy Contact Lenses Program, including its

purpose, components and partners.
Poster 18
Arunodaya Charitable Trust (ACT)
Volunteer opportunities for ophthalmologists to participate in a

community based eye care project in the field of curable blindness
in India.
Poster 19
LIGA International
The Flying Doctors of Mercy present information about the Eye Clinic
in El Furete, Mexico.
Poster 20
International Eye Clinic
Promotes healthy vision through public education and establishment

of eye care centers in underdeveloped communities.
Poster 21
World Cataract Foundation
CANCELED
Working to eliminate cataract blindness in the developing world

through surgery, training and providing equipment.
Poster 22
Eye Foundation of America, Inc.
Since its inception in 1977, working to improve the accessibility and

affordability of eye care around the world.
Poster 23
New Mexico Eye Injury Registry
Collects data on ocular trauma in New Mexico. This data is then

compared to the rest of the U.S.
Poster 24
Christian Ophthalmology Society
Describes the annual summer CME meeting and Monday prayer

breakfast at AAO 2014 as well the involvement with ophthalmologic
missions worldwide.
263
Notes
264
The
largest public service program in
American medicine
has helped more than
1.8 million people since 1985.

Visit the Foundation desk at the Academy Resource Center (Booth 508) to:
Pick up a special 30th anniversary volunteer gift and recognition certificate.
Enroll as a volunteer! www.eyecareamerica.org
For eye health information you and your patients can trust,
send them to GetEyeSmart.org
Giving your patients the Academys patient
education materials the most trustworthy
on the market wont stop them from
turning to the Internet to do their own
research about eye health. To ensure they
get comprehensive, medically accurate
information you can trust, send them to
GetEyeSmart.org. For information in
Spanish, send them to OjosSanos.org.
See what EyeSmart is all about. Visit the Academy Resource Center, Booth 508.
Like EyeSmart on Facebook
to get the latest eye health news and
vaable eye health tips to share with
your community.
14838.ESad7x4.875.indd 3
YOUR Information Systems

and YOUR Devices
all Working Together
8/8/14 3:59 PM
The Electronic Office

IHE Eye Care, Booth 114
McCormick Place
Exhibition: South Level 3
Visit Academy-sponsored Electronic Office for

Information on Meaningful Use Incentives and
a FREE Demonstration and a FREE USB Drive.
Find out more information

about The Electronic Office
at www.iheeyecare.org
or contact flum@aao.org.
AAOE PROGRAM /
PRACTICE MANAGEMENT
Saturday Tuesday, Oct. 18 - 21
South, Level 5
Network: AAOE Member Lounge
Locations: All rooms are in McCormick Place unless otherwise indicated.

AAOE is the Academys practice management resource, dedicated
to meeting the educational needs of those responsible for managing the business side of ophthalmic practice. The AAOE Program,
the most comprehensive practice management program in the
country, provides over 100 courses for you to choose from.
Not yet a member? Join AAOE at a discounted rate during the
meeting by visiting the Academy Resource Center, Booth 508.
Saturday: 9:00 AM 4:00 PM

Sunday: 9:00 AM 5:00 PM
Monday: 8:00 AM 5:00 PM
Tuesday: 8:00 AM 3:00 PM
Location: South, Level 5
AAOE members can relax between courses; enjoy refreshments and
network with peers and consultants.
AAOE General Session
Sunday, Oct. 19: 12:30 1:30 PM

Monday, Oct. 20: 12:30 1:30 PM
Location: AAOE Member Lounge, South, Level 5
Free informal roundtable discussions on various practice management issues. Share your experiences and learn from other members
during an informal and informative hour moderated by a seasoned
professional.
Powered by Purpose
SPE09, Sunday, Oct. 19
10:00 AM - 12:00 PM
Location: Room S406b
Success ultimately comes down to an individuals ability to articulate their brand values, create a framework or culture built around
those values and lead others to the brand mission or purpose. This
program, based on Scott Demings soon to be released book Powered by Purpose, is devoted to the individuals relationship to his or
her values and purpose, and how better understanding of your own
values and purpose can lead to success.
Sponsored by Alcon, Genentech, Regeneron.
Roundtable Discussions
AAOE Member Reception

Sunday, Oct. 19: 6:00 PM - 8:30 PM
Location: Renaissance Blackstone Chicago Hotel, Crystal
Ballroom, 636 South Michigan Avenue, Chicago, Ill.
The AAOE Member Appreciation Reception is open exclusively to
AAOE members and their guests.
The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
265
AAOE Coding Sessions

Saturday, Oct. 18
AAOE Coding Sessions
Location: S105
A National Board for the Certification of Ophthalmic Executives (NBCOE)
C American Academy of Professional Coders (AAPC)
J Joint Commission on Allied Health Personnel in Ophthalmology (JCAHPO)
The following coding sessions take place concurrently with AAO 2014 as part of the AAOE program. These intensive sessions enhance participants
knowledge of appropriate coding and documentation in order to receive proper reimbursement.
Separate registration is required to attend these events; they are not included in the Academy Plus course pass. Members and nonmembers can
register for the AAOE Coding sessions without registering for AAO 2014.
A C J Introduction to Ophthalmic Coding and ICD-10-CM
Instructor(s): Elizabeth Cottle CPC OCS; Rajiv Rathod MD MBA;
Joy Woodke COE OCS
A C J Coding Camp and Advanced ICD-10-CM

Instructor(s): Elizabeth Cottle CPC OCS; Stephen Kamenetzky MD OCS;
Joy Woodke COE OCS
Moderator: Sue Vicchrilli COT OCS, Academy Coding Executive
Special Presentation: Michael X Repka MD MBA, Medical Director of

Governmental Affairs
Topics will include everything those new to ophthalmic coding need to

know and what experienced coders should know:
Identifying the five categories of payers

Claim submission requirements
Place of service codes
CPT, HCPCS, ABN, introduction to ICD-10-CM, modifiers, CCIs, MUEs,
minor and major surgical procedures
The latest information on testing services
Costly coding errors
Time: 8:00 - 11:00 AM
Fee: $280
Moderator: Sue Vicchrilli COT OCS, Academy Coding Executive

This three-hour comprehensive coding course is designed to sharpen your
coding and documentation skills while boosting your coding confidence.
No matter the subspecialty or the payer, this course helps you receive
proper reimbursement for all the claims you submit.
This course is taught at an intermediate/advanced level.
Time: Time: 12:30 - 3:30 PM
Fee: $280
Co-sponsored by JCAHPO
The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical
education for physicians.
266
AAOE Instruction Courses
Course: 550
Room: S501d
NEW A Practice Mergers and Division or Care Center

Based Mega Groups
Sunday
2:00 - 3:00 PM
Target Audience: ALL
Synopsis: This course will help current and potential owners of ASCs to understand elements for consideration when creating legal documents for an ASC entity
in order to ensure a smooth transition when the time comes. Topics include identifying trigger events, an overview of the buy-in / buyout process and tips for a
successful plan to transition.
Objective: (1) To understand triggering mechanisms. (2) To consider options to use
for buy-ins and buyouts. (3) To create a plan for transitioning. (4) To understand time
frames and resources available.
Senior Instructor(s): Bruce S Maller
Instructor(s): Stephen C Sheppard*, Albert Castillo*, Maureen Waddle MBA*, Jerry
J Sokol**
NEW A ASC Administration, Operations, and Procedures

Course: 303
Room: S504d
Monday
9:00 - 10:00 AM
Synopsis: This course is designed to provide ASCs with the resources to improve
and manage ASC operations and procedures. The course is also designed to look at
all aspects of running an ASC and suggest ways to improve administrative duties,
operations, and procedures.
Objective: (1) To provide key measures to review when looking at your ASC and
identifying what areas to improve. (2) To provide mechanisms for understanding
your business and opportunities for improvement. (3) To provide an overall review
of how to best stay on top of managing your ASC given all the regulatory changes.
Senior Instructor(s): Louis Sheffler
Instructor(s): Maria Tietjen, Glenn Debrueys**
NEW A Flow and Efficiency With the Femtosecond Laser

Course: 401
Room: S504a
Monday
3:15 - 4:15 PM
Synopsis: This course overviews the introduction of the femtosecond laser into
the surgery center and will provide resources and ideas on how to improve efficiency.
Objective: (1) To identify the potential bottlenecks in patient flow associated with
the femtosecond laser. (2) To create solutions to improve efficiency. (3) To create
staffing plans to maximize efficiency. (4) To ensure minimal patient wait time, best
outcomes, and high patient satisfaction.
Senior Instructor(s): Maureen Waddle MBA*
Instructor(s): Jennifer Blanton RN, Louis Sheffler

NEW A Managing Practice Performance
Course: 181
Room: S504a
Sunday
2:00 - 3:00 PM
Synopsis: This course will present the distinctions of assessing your practices
performance and the actions to take to improve performance based on that assessment. Objective: At the completion of this course, the attendees will have tools for
Course: 182
Room: S505ab
Sunday
2:00 - 3:00 PM
Synopsis: Declining reimbursement, increasing expenses, and a changing regulatory environment are pushing practices to get bigger. Many groups arent prepared
for a full-blown merger. Apart from tax issues, other concerns, ranging from governance to valuation, get in the way-the biggest one being fear of loss of autonomy
in one s daily life. One alternative is the creation of a new limited liability entity
in which the physicians from their old practices organize into a division or care
center in the new entity. By retaining autonomy over matters like compensation,
buy-ins, payouts, and the like at the outset, at a divisional level groups can come
together and work out those issues over time, and real progress can be made on reducing overhead and integrating enough to have real force. The care center models are not without their concerns though, and this course addresses those as well.
Objective: By the conclusion of this course, participants will be able to understand
the surge to merge, alternative structures to full-blown mergers, and the issues
involved.
Senior Instructor(s): Robert A Wade JD
NEW A Predictive Analytics: The New Face of Quality

Course: 211
Room: S502ab
Sunday
3:15 - 4:15 PM
Synopsis: Software companies, academics, and health plans are investing millions in predictive analytics(PA), yet few physicians are aware of this very important
development.
Objective: Attendees will learn what PA is and how it is being applied to health
care to establish and measure the quality and value of health-care providers.
Senior Instructor(s): Michael J Parshall*
NEW A Business Strategies for the New Era

Course: 223
Room: S504d
Sunday
4:30 - 5:30 PM
Synopsis: Health-care changes will affect how ophthalmologists do business in

the future. In this course, selected topics will be discussed to help attendees improve efficiency or find new opportunities to grow profits. Topics will include ASCs,
optical shops, growing the practice, satellite offices, and mergers.
Objective: At the conclusion of the course, attendees will be able to look for ways
to make their practices more efficient or consider the possibility of new opportunities. They should be able to do a basic financial analysis to see the financial impact
of their decisions.
Senior Instructor(s): Peter Wasserman MD*
A SO Income Division for Group Practices: Structuring

Appropriate Physician Compensation Arrangements
Course: 300
Room: S501abc
Monday
9:00 - 10:00 AM
Synopsis: This course will explore different models for dividing income in a group
practice, with emphasis on creating incentives, responses to incentives, legal and
regulatory concerns, and modeling different structures. A case study will be employed to illustrate the process.
American Society of Ophthalmic Administrators. C American Academy of Professional Coders. J JCAHPO. EHR Electronic Health Records.
Endorsed by Senior Ophthalmologist Committee. YO Endorsed by Young Ophthalmologists committee. * The presenter has a financial interest.
A
SO
267
NEW A ASC Nuts and Bolts of Transitioning ASC

Ownership
solid financial management as well as the tools and techniques for assessing the
performance of their practice and the interventions appropriate to the results of
that assessment.
Senior Instructor(s): Ron Rosenberg PA MPH*
Instructor(s): Curt Hill BA*

Objective: To provide an understanding of the variety of income division models
available to choose from, the equities of each and their legal and regulatory concerns (Stark fraud and abuse), and the process of developing the right model for
ones group.
Senior Instructor(s): Robert J Landau JD
Instructor(s): Robert A Wade JD
NEW A Our Biller Is Leaving! How Do I Handle This

Situation and Come Out Ahead?
Course: 304
Room: S502ab
Monday
9:00 - 11:15 AM
Synopsis: All too often, practices are not prepared for the inevitable resignation
of a biller. Our biller is leaving! discusses how to prepare and remain prepared
for this resignation event without incurring unnecessary cash flow delays and other
exposures.
Objective: At the conclusion of the course, the attendee should be able to have an
active rather than a reactive approach to losing a biller.
Senior Instructor(s): Jonathan Lohr
NEW A Financial Management of Your Practice

Course: 328
Room: S503ab
Monday
9:00 - 10:00 AM
Target Audience: ADMIN
Synopsis: Financial Management is the foundation for running any practice. This
course will review the basics of financial management. The course will review cash
accounting, accrual accounting, income statements, budgets, cash flow statements,
and balance sheets. The course will also look at capture rate and review profit and
loss statements. We will go over a SWOT analysis. We will look at three key factors
that drive profit and how to audit controls.
Objective: The objective of this course is to help participants to have a better
understanding of financial management. Participants will understand the difference
between cash accounting and accrual accounting. Participants will learn the best
way to utilize specific financial reports and about cost of goods and profit and loss
statements. They will learn the three key factors to drive profit. Participants will
also learn the importance of audit controls.
Senior Instructor(s): Bill Russ*
A Budgeting for the Ophthalmology Practice

Course: 330
Room: S504d
Monday
11:30 AM - 12:30 PM
Synopsis: This course will provide a practical and simple approach for implementing a practice budget. Specific methods will be introduced related to examining
historical and current results, assessing future changes in the practice, forecasting
future results, and integrating the results with financial reporting efforts.
Objective: At the conclusion of this course, the attendee will be able to (1) understand the process of budgeting and how to get started, (2) use current practice
results to accurately predict future performance, (3) perform a thorough review of
practice goals and initiatives for the coming year that will assist in forecasting
results, and (4) integrate budget results into comparative monthly and annual management and benchmarking reports.
Senior Instructor(s): Andrew Maller MBA*
A SO YO Ophthalmology Practice Buy-Ins and Payouts

Course: 340
Room: S504a
Monday
11:30 AM - 12:30 PM
practice buy-ins and payouts. This course will describe and explain appropriate buyins for associates and customary payout arrangements for owners leaving a practice, including the valuation and goodwill of the practice. The extra time allows for a
more detailed explanation of payouts and the limitations and protections necessary
for the ongoing group.
Objective: At the conclusion of this course, attendees will have learned how
to structure buy-in / payout arrangements that are fair and reasonable, both to
practice owners and to joining or departing ophthalmologists. Attendees will also
understand ophthalmology practice goodwill values and learn about the practical
considerations, limitations, and protections needed when establishing buy-in / payout arrangements.
Senior Instructor(s): Mark E Kropiewnicki JD LLM*
Instructor(s): Daniel M Bernick JD*
NEW A Lean Interactive Workshop for Clinic Process

Improvement
Course: 341
Room: S502ab
Monday
11:30 AM - 12:30 PM
Synopsis: Lean is a discipline of process improvement that can enhance value,

increase capacity, improve patient satisfaction, and inform efficient office space
design. This field-tested workshop-directed toward MDs, administrators, and
staff-explains Lean skills specifically tailored to ophthalmology. Lean concepts are
presented with didactics, case studies, and visual demonstrations that will allow
participants to see their processes with a new perspective. These concepts are
augmented by showing real-life examples of clinic process improvement backed
by quantitative data.
Objective: To enable the attendee to apply Lean principles to decrease patient
wait times and increase clinic capacity-without significantly increasing resource
use. (See Suneja A, Suneja C. Lean Doctors. ASQ Quality Press, 2010.)
Senior Instructor(s): Dennis P Han MD*
Instructor(s): Aneesh Suneja*
NEW A Battling Information Overload: What Reports Do

Owners and Administrators Need?
Course: 342
Room: S504bc
Monday
11:30 AM - 12:30 PM
Synopsis: This course will provide guidance on reducing the number of reports
and the length of reports, and setting up meaningful management reports that get
attention. This course will help turn reports into improved practice performance.
Objective: Attendees will be able to (1) prioritize current reporting efforts, (2) develop a plan to change or enhance reports, (3) use resources and tools provided during the course to develop new reports (if necessary), (4) understand the importance
of comparison reporting, and (5) educate others in the practice on analysis of the
practice based on the reports.
A YO Hanging a Shingle in the 21st Century: Is a Start-up

Solo Practice Possible in 2015?
Course: 363
Room: S505ab
Monday
11:30 AM - 12:30 PM
Synopsis: This course will detail the challenges faced by physicians wishing to
open a solo practice in the 21st century and how these challenges can be overcome.
The presenters, who have all opened solo practices in highly competitive markets,
will share their experiences, from strategy to tactical execution of planning, financing, building, credentialing, opening, and growing a practice built from scratch.
Synopsis: Learn how to structure fair, reasonable, and customary financial, legal,
and practical arrangements for ophthalmology practice buy-ins and payouts from
attorneys-consultants with over 50 years of experience, having done thousands of
268

Objective: Attendees will understand the hurdles involved in starting a solo practice from scratch and walk away with a road map of how this can be done today.
Senior Instructor(s): Edwin S Chen MD
Instructor(s): Ajit Nemi MD, Ravi R Patel MD
Course: 365
Room: S501d
Monday
2:00 - 3:00 PM
Synopsis: This course will describe the process of determining and assigning
economic value to ophthalmic practices (and practice-related entities, such as
optical shops and outpatient surgery facilities) for buy-in, buyout, and purchase
/ sale transactions. It will also describe the various considerations that influence
goodwill value, including but not limited to health-care reform, the recession,
and Medicare cuts.
Objective: To provide the attendee with an understanding of (1) the components
of value comprised in an ophthalmology practice, (2) the methods used by qualified
appraisers to determine practice values in the present climate (including the various
factors that influence practice goodwill value), and (3) how practice values translate
to purchase prices in buy-in, buyout, and practice sale scenarios.
Senior Instructor(s): Mark D Abruzzo JD
Instructor(s): Richard C Koval MPA CMPE*
NEW A Physician Provider Cooperatives a New Concept in
Health Care Delivery

Course: 367
Room: S503ab
Monday
2:00 - 3:00 PM
Synopsis: Independent physicians, once the backbone of medical care, are disappearing and being replaced by larger consolidated entities. Regulatory and market
forces are responsible for this quantum change in health-care delivery. The result
is fewer consumer and provider choices and higher costs. A similar transition occurred in agriculture, and today, through the formation of agricultural cooperatives,
the independent farmer and the larger entities coexist in the production of our food
supply.Similarly physicians, forming cooperatives in a similar model, can form joint
ventures that enable independent physicians to deliver health care in a cost-effective and competitive manner.In this course the history, legal structure, hypothetical
structure, antitrust, Stark, and anti-kickback considerations of a physician provider
coop will be discussed.The course will be taught by an MD, JD who has published
on the subject.
Objective: By the conclusion of this course the participant will be able to understand the structure, legal issues, and market rationale for the formation of physician
provider cooperatives.
Senior Instructor(s): Michael Goldstein MD*
NEW A Management and Dashboard Reporting for the

Retina Practice
Course: 369
Room: S504bc
Monday
2:00 - 3:00 PM
Synopsis: This course will introduce the topic of management and dashboard reporting for productivity and efficiency measures as it relates to the retina practice.
During the course, case studies and sample tools will be provided, as well as a
guide on how to interpret results in order to improve practice performance.
Objective: At the conclusion of this course, the attendee will be able to(1) understand the importance of management and dashboard reporting, and (2) develop an
understanding of trends in the retina subspecialty that impact management reporting.
Senior Instructor(s): Andrew Maller MBA*
Course: 400
Room: S501d
Monday
3:15 - 4:15 PM
Synopsis: This course will detail lesser-known ways to make your revenue cycle
management (RCM) processes more efficient, to measure the efficiency of your
current processes, and to continue to measure your progress after implementing
changes. The presenter, the owner of an ophthalmology practice RCM firm, has a
unique perspective-collecting all revenue to which a practice is entitled in the most
efficient manner possible-which course attendees will appreciate.
Objective: Upon completion, course attendees will be able to measure the overall
efficiency of their current RCM processes and implement changes to improve RCM
processes.
Senior Instructor(s): Jeff Grant*
NEW A Space Planning: A Guide to the Effective

Ophthalmic Facility
Course: 402
Room: S505ab
Monday
3:15 - 4:15 PM
Synopsis: Most administrators and doctors who start a new building project have
never been through the process of planning a new facility. They are often left working
with a planner who knows little about the operational aspects of laying out a medical
space, not to mention an ophthalmology space. And the practice staff only know what
works and does not work in their current facility. This course is designed to expand
that knowledge base so the attendees can better guide their design process.
Objective: This course will give the attendees (1) tools to better assess and project their space need, (2) a better understanding of what makes for good and bad
space / site selection, and (3) the knowledge required to make proper planning
decisions based on operational and flow need.
Senior Instructor(s): Larry R Brooks*
A Retina-Specific Panel Discussion: Ask Your Peers

Course: 410
Room: S501abc
Monday
3:15 - 5:30 PM
Synopsis: This course will highlight targeted areas of interest specific to retina
practices. A panel of experienced administrators from retina practices will provide
answers to questions that participants present, as well as questions asked by the
panel to generate discussion and share values.
Objective: At the conclusion of this course, attendees will know retina-specific
data for practice management of retina-specific operational functions.
Senior Instructor(s): Warren E Laurita MBA
Instructor(s): Angela Chambers MBA RN*, Jefferey T Brockette*, Deborah Curran,
Elizabeth Hesford Cifers MBA*
A Financial Decision Making in the Eye Care Practice

Course: 412
Room: S501d
Monday
4:30 - 5:30 PM
Synopsis: This course looks at how accounting affects your bottom dollar in your
practice. We look at the accounting basics, ratio analysis and benchmarking, overhead/expense management, cost analysis and accounts receivable. The financial
statements we will address are Balance Sheet, Income Statement, Cash Flow
Statement. We will look at the difference between ratio analysis and benchmarking. We also will look at your contracts and whether you should participate with
every carrier. Finally we discuss your accounts receivable and how to collect the
monies due you.
Senior Instructor(s): Michael D Brown*
A
SO
269
A SO Practice Valuations: Whats a Practice Worth Today?
NEW A How Do You Know Your Revenue Cycle Really Is

Efficient?

A Practice Problems: Practical Solutions
Course: 501
Room: S504a
Tuesday
9:00 - 10:00 AM
Synopsis: This course will address problems you may be experiencing in your
practice. Items covered will be not enough revenue, not enough patients, being
over-worked, staffing salaries are too high and reimbursement is too low. We will
discuss how other practices are dealing with these same issues. We will also look
at what reports you need for your office to run smoothly and efficiently. We also look
at your accounts receivable and where your buckets should be.
NEW A Top 20 Tips for Optimal Billing

Course: 504
Room: S502ab
Tuesday
9:00 - 10:00 AM
Synopsis: This course will present 20 important tips for optimizing billing performance.
Objective: At the completion of this course the attendees will have 20 actionable
tips for improving the performance of the billing and collections process. They will
be able to implement any of the tips and techniques that are not already in place
in their practices.
Senior Instructor(s): Ron Rosenberg PA MPH*
Instructor(s): Donna Connolly*
A Deciphering Financial Reports

Course: 525
Room: S501abc
Tuesday
9:00 - 10:00 AM
Synopsis: You spend 20 years in training to give sight to the sightless, but your
eyes swim when youre asked to evaluate a practice opportunity such as a buy-in
or an opportunity to invest in an ambulatory surgery center, optical shop, or practice
real estate. You are not alone, and help is on the way. This course will present
and demystify the basic financial reports you will run into when evaluating practice
opportunities-profit and loss statements, balance sheets, accounts receivables reports, and tax returns-and then help you understand how they all relate, and why
they are important.
Objective: This course is designed to get participants grounded in the financial
reports they must be familiar with in practice, without having to get a degree in
accounting!
Instructor(s): Mark D Abruzzo JD
NEW A A Review of Facility Regulatory Requirements for
CMS Accreditation
Course: 526
Room: S501d
Tuesday
9:00 - 10:00 AM
Synopsis: Attendees will explore the Centers for Medicare and Medicaid Services
(CMS) review process as it relates to ambulatory surgery centers. They will hear
about the physical environment regulatory requirements in effect by the CMS, the
Accreditation Association for Ambulatory Health Care (AAAHC), and the National
Fire Protection Association (NFPA). Through illustrations, they will learn about common survey findings and discover how to prevent or fix them. The attendees will
become familiar with the steps of a mock survey and be taught how to utilize a
physical environment checklist.
Objective: By the conclusion of this course, attendees will be able to identify
CMS, AAAHC, and NFPA physical environment requirements. They will know about
270
the most common survey findings and how to handle them. They will know the benefits of a mock survey and how to use a physical environment checklist to prevent
citations.
Senior Instructor(s): Jeffery S Eckert*
NEW A Revenue Cycle Reimbursement Strategies

Course: 502
Room: S501d
Tuesday
10:15 - 11:15 AM
Synopsis: This course will summarize the revenue cycle and collections process
by discussing the following: the patient flow process, revenue cycle management,
best practices in revenue management, and patient collections.
Objective: At the conclusion of this course, the attendee will be able to utilize
strategies that will impact the patient registration and scheduling process; utilize
best practices for the various functions within the revenue cycle process; explain,
decipher, and utilize revenue cycle metrics as discussed; and utilize collection strategies to increase self-pay revenue from patients.
Senior Instructor(s): Lovell Davis CPC MHSA
Instructor(s): Lisa Francine Williams BBA
NEW A SO Divorcing Medicare and Commercial
Insurance
Course: 531
Room: S504a
CANCELED
Tuesday
10:15 - 11:15 AM
Synopsis: In this course the core issues involved in changing participation with
Medicare and commercial insurance will be discussed, including the assessment,
preparation, and experience of terminating private insurance contracts and opting
out of Medicare.
Objective: At the conclusion of this course, the attendee will develop a basic understanding of the following: (1) Making the Decision: reasons to consider changing participation status, (2) Preparing for Action: legal, financial, and contractual
considerations that must be evaluated prior to changing status, (3) The Experience:
a first-person account of what it is like to opt out of commercial insurance and
Medicare.
Instructor(s): Kevin J Corcoran*
NEW A SO How ObamaCare Taxes Affect You: New

Taxes, Hikes, Breaks, Credits, and Other Changes
Course: 545
Room: S504d
Tuesday
10:15 - 11:15 AM
Synopsis: This course will offer insight into the financial landscape of the medical
industry and ObamaCare today. We will examine the tax concerns most physicians
face this fiscal year and offer strategies that can be used to offset the costs, both
professional and personal, that will increase.
Objective: Attendees will be given the information needed to navigate the new
ObamaCare system. We will cover the issues faced by both providers and consumers of medical care, guide attendees through the tax issues, discuss the major questions being asked, and offer alternative avenues for the creation of revenue.
Senior Instructor(s): Donna W Howell JD
NEW A Handling Ancillary Businesses: ASC, Optical, Real

Estate, Equipment, and Management Services
Course: 551
Room: S504a
Tuesday
11:30 AM - 12:30 PM
Synopsis: Should your ASC, optical shop, or real estate (medical office building)
be set up as separate entities? Should there be an equipment leasing entity or management services entity? This course explores the pros, cons, and considerations.
Are there benefits to separate incorporation that outweigh the added accounting

and legal costs involved? Is a separate corporation legally mandated or not? What
type of entity (regular corporation, S corporation, or LLC) should be employed?
Should ownership be limited to the same doctors who are shareholders in the PC,
or should outside investment be permitted? What types of valuation formulae
should be used, for buy-in and buyout? Should buyout from the PC trigger buyout
from the ancillary entity?
NEW A Managing Clinical Trials in Small and Large

Practices
Course: 553
Room: S502ab
Tuesday
11:30 AM - 12:30 PM
Synopsis: This course will discuss the legal and practical aspects of conducting
clinical trials relevant to both small and large practices. The course will include
advice on how to create a clinical trial unit with strategies for both small and large
practices as well as strategies and practical tips for being successful in managing
the clinical trial. In addition, the course will include a discussion of the applicable
laws and regulations as well as how to respond to an audit by the sponsor of the
study.
Objective: Participants will leave the course with ideas and strategies on creating
and maintaining a clinical trial unit relevant to the size of the practice. Participants
will also gain knowledge on the applicable laws and regulations and strategies for
responding to an audit. Lastly, negotiation of the clinical trial agreement will be
discussed.
Senior Instructor(s): Brenda Laigaie JD
Instructor(s): Elise Levine MA CRC OCS
NEW A C J Reimbursement in 2024

Course: 586
Room: S504a
Tuesday
12:45 - 1:45 PM
Synopsis: ObjectivesAt the conclusion of the course, the attendee will be able to
estimate the economic environment for ophthalmic practices in 10 years time, and
to formulate a long-term strategy for coping with the expected changes.
Senior Instructor(s): Bradley Dean Fouraker MD*
Instructor(s): Kevin J Corcoran*
Coding & Reimbursement

A C J YO Audits: Its Not a Matter of If, but When
Course: 176
Room: S501abc
Sunday
2:00 - 4:15 PM
Synopsis: Being the subject of an audit is stressful and time consuming for physicians and staff. Given the way audits are conducted, both by Medicare Part B as
well as all other third-party payers, most physicians will be audited by some payer
at some time during their careers. This course will present real-life audit scenarios
of Focus Medical Review, Comprehensive Error Rate Testing, Recovery Audit Contractors (RACs), Zone Physician Integrity Program (ZPIC), and Office of Inspector
General (OIG) investigations.
Objective: Upon completion of this course, the participant should be able to (1)
recognize that there are numerous types of audits conducted by all payers as well
as government agencies, (2) understand the variety of audits to which physicians
are subject, and (3) learn the steps to take when one receives the request for documentation.
Senior Instructor(s): Sue J Vicchrilli COT OCS
Instructor(s): Stephen A Kamenetzky MD OCS*, Cherie McNett
Course: 209
Room: S505ab
Sunday
3:15 - 5:30 PM
Synopsis: Most of the revenue generated by the ophthalmic practice is from surgery. Accurate surgery coding and an understanding of the various rules are essential.
Objective: Attendees will learn the various aspects of surgical coding and how to
access the right tools for correct reimbursement.
Senior Instructor(s): Elizabeth D Cottle CPC OCS
A C J ICD-10-CM: Simplifying the Complex

Course: 221
Room: S406b
Sunday
4:30 - 5:30 PM
Synopsis: It is here: ICD-10-CM. On October 1, 2014, the diagnostic code set was
overhauled with the largest update in its history, going from ~13,000 codes to over
~68,000 overnight. The result is a significant reorganization and updating of the
codes. There is an entirely new alpha-numeric nomenclature. And while most of
the basic coding principles have remained, there are some significant changes. This
course will explore all you need to know about the new ICD-10-CM coding system.
Objective: Upon completion of this course, attendees will better understand (1)
the background of and need for ICD-10-CM, (2) basic diagnostic coding guidelines,
with specific focus on changes in ICD-10-CM, (3) what is new and different in ICD10-CM, and (4) how they can efficiently and effectively utilize the new coding system in their practices.
Senior Instructor(s): Gordon Johns MD*
A C J Steps for Successful Retina Coding

Course: 301
Room: S504bc
Monday
9:00 - 11:15 AM
Synopsis: The revenue cycle of the retina practice can be quite complex. Multiple
factors impact a successful practice. This course will teach attendees what impacts
their reimbursement the most and how to apply tools in their own practices for
success.
NEW A C J E&M vs. Eye Codes: Who Is the Winner?

Course: 343
Room: S503ab
Monday
11:30 AM - 12:30 PM
Synopsis: End the confusion over when to bill an E&M and when to bill an eye
code. Physicians tend to code far more exams than tests or surgical procedures, so
for the financial success of the practice, its vital to solve the mystery. Medical vs.
wellness and vision coverage will also be addressed.
distinguish between medical and vision and wellness exam documentation, (2) understand Medicare and non-Medicare payer documentation rules, and (3) recognize
the importance of the chief exam and patient expectations.
Senior Instructor(s): Joy Woodke COE OCS*
Instructor(s): Jessica Schroeder
A J CodeFest
Course: 364
Room: S505ab
Monday
2:00 - 3:00 PM
Synopsis: Join your physician, technician, administrator, biller, and coder colleagues in this live coding challenge. In game format, two teams will be selected,
each including a physician, an administrator, a technician, and a biller / coder. The
A
SO
271
Objective: By the end of the course, participants will have an understanding of

the basic issues to consider when separately incorporating an ancillary business.
Senior Instructor(s): Daniel M Bernick JD*
Instructor(s): Mark E Kropiewnicki JD LLM*
A C J Surgery Billing Made Easy for All Specialties
moderator will present the prewritten coding questions with multiple answer options. Through an automated response system, audience members will be able to
play against the two teams.
determine the appropriate level of history, exam, and medical decision making for
exams and (2) identify the correct modifier in exams, tests, and surgical cases that
ophthalmology practices face daily.
A C J Coding for Ophthalmic Testing Services

Course: 413
Room: S504bc
Monday
4:30 - 5:30 PM
Synopsis: Coding and billing for diagnostic testing is a major part of the work
of any ophthalmic practice, but more so for subspecialties such as retina, cornea,
and glaucoma. Many practices are not sufficiently aware of current Medicare regulations that guide the reimbursement of costs for these tests. This presentation
will include information on documentation requirements, unilateral vs. bilateral
payment, multiple testing reimbursement policies, recognition of which tests can
be billed together on the same day, diagnosis coverage, and supervision rules for
ophthalmic testing services.
identify proper code selection for each test performed, (2) recognize documentation
requirements, including what is meant by interpretation and report, (3) understand the impact of the Correct Coding Initiative, (4) learn that what common sense
dictates does not always equal a covered diagnosis, and (5) identify situations
where an Advance Beneficiary Notice should be used.
Instructor(s): Michell Miller-Ballard OCS CPC
A C J Comprehensive Cataract Coding

Course: 500
Room: S503ab
Tuesday
9:00 - 11:15 AM
Synopsis: What are visual acuity requirements (if any)? What makes cataract surgery complex? Is the postop complication separately billable even when performed
in my office? What is the impact of Correct Coding Initiative edits on combined cataract, retina, cornea, and/or glaucoma cases? End the confusion about pre-, intra-,
and postoperative care for the number 1 surgery performed in the United States.
distinguish between Medicare and non-Medicare payer documentation rules prior
to surgery, (2) understand what makes the surgery complex , (3) code correctly for
combined cataract, retina, cornea, and/or glaucoma cases, and (4) recognize which
complications are separately billable and which are considered postop.
Instructor(s): Kristin Carter MD*
A C J Making the Most With Modifiers

Course: 528
Room: S505ab
Tuesday
10:15 - 11:15 AM
Synopsis: Understanding modifiers and their appropriate use impacts reimbursement significantly. This course will walk you through some common everyday scenarios to help you understand the concepts of modifiers and apply this understanding in your practice.
272
J Ophthalmic Coding Specialist Prep Course

Course: 548
Room: S504bc
Tuesday
11:30 AM - 12:30 PM
Synopsis: Demonstrate your coding competency by passing the Ophthalmic Coding Specialist (OSC) Exam. The OCS exam is an open-book, 100-question, multiple
choice online exam. Everyone in the office who is involved in chart documentation
and claim submission should demonstrate their coding competency. This one-hour
course will prepare physicians, technicians, administrators, and billers to test in 18
content areas of ophthalmic coding. This is the best way to learn and subsequently
appropriately code for proper reimbursement.
Objective: Upon completion of this course, participants will be able to (1) identify
and discuss the value of the OCS designation, (2) pass 10 questions with 80% proficiency, (3) identify the appropriate study guides necessary to pass the OCS exam,
and (4) identify appropriate online tools to assist them in passing the OCS exam.
Compliance and Risk Management

A SO YO Social Media Liability in Your Office
Course: 178
Room: S504bc
Sunday
2:00 - 3:00 PM
Synopsis: More than a billion people around the world use social media daily. It is
imperative that providers and business managers learn how to manage and utilize
this communication channel, particularly as it relates to them as employers, healthcare providers, and business owners. This course will discuss the use of social
media in the physician practice and how best to address certain issues, including
HIPAA and confidentiality, reputation control, using social media to conduct informal background checks, and looking at employee use of social media in and out of
the workplace from a legal standpoint.
Objective: At the end of this course, participants will have a basic understanding
of the various social media and social networking sites and the laws involved with
their use in their practices so that they will be able to draft effective policies, monitor the Internet for reputation management, and successfully promote and market
their practices.
Senior Instructor(s): Jill S Garabedian JD
Instructor(s): Caroline Patterson
A Defending the Ophthalmologist in a Medical Malpractice

Lawsuit
Course: 179
Room: S504d
Sunday
2:00 - 3:00 PM
Synopsis: This course will provide an overview of medical malpractice cases

specific to ophthalmology. Topics include malpractice litigation statistics and terms
important to an understanding of malpractice, a review of the malpractice lawsuit process, and common theories of liability against ophthalmologists. Informed
consent, the role of the expert witness, electronically stored information, and the
importance of preparation will be highlighted.
Objective: The current medical malpractice crisis presents ever-increasing challenges to the ophthalmologist. At the conclusion of this course, the physician will
be both educated in and presented with effective approaches to minimize liability
and maximize an effective defense.
Senior Instructor(s): Robert Ritch MD FACS*
Instructor(s): Kenneth R Larywon JD, Thomas A Mobilia JD

NEW A Compliance and Quality of Care
Course: 220
Room: S503ab
Sunday
3:15 - 4:15 PM
Objective: At the conclusion of the course, participants will understand the impact of the focus on quality performance measures as it relates to the provision
of medically necessary care. Participants will have an understanding of key compliance concerns and what to do about them, and will be prepared for increased
enforcement initiatives.
NEW A Better Results from Bad Complications: Risk

Management to Avoid Lawsuits and Licence Investigations
Course: 225
Room: S503ab
Sunday
4:30 - 5:30 PM
Synopsis: What actions can you take to put yourself in the best possible position
when a complication occurs? An experienced trial lawyer uses several examples
derived from cases with records and photographs to advise you on good risk management techniques. What makes your defense easier? What makes it tougher?
What makes your defense easier is often good for the patient as well! Several
office staff practices that make suits less likely will also be discussed. You can not
always predict who will sue, but you can put yourself in a better position to defend
a suit and reduce your exposure. The presentation will outline best practices to
reduce the chance of lawsuits and investigations.
Objective: At the conclusion of this course, attendees will know what actions will
help and what will hurt their positions should litigation take place.
Senior Instructor(s): H Jay Wisnicki MD**
Instructor(s): Neil Harkin Ekblom
NEW A Health Law From the Patient Perspective

Course: 305
Room: S504a
Monday
9:00 - 10:00 AM
Synopsis: This course will discuss the more common patient health-care issues,
starting with the creation of the patients relationship with the physician, moving
through treatment, decision making, and record keeping, and ending with termination.
A Compliance FAQs and NSFAQs (Not So Frequently Asked

Questions)
Course: 399
Room: S502ab
Monday
3:15 - 5:30 PM
Synopsis: Government efforts to get money back from providers (or even avoid
paying it out) are a good way to close budget gaps. Recently loosened rules concerning what constitutes a false claim, who can bring whistleblower actions, and
knowledge requirements for liability, plus even more aggressive data mining before
payments are made, should make compliance a huge concern for all practices. This
course will review the basic areas of concern, highlight recent changes in the law,
and hone in on how to avoid getting caught in the crosshairs of an investigation and
what to do if investigated.
Objective: Participants will leave this course knowing the basic areas of concern
with regard to compliance, how recent changes in the law increase the need for
stepped-up compliance efforts, and strategies to employ to stay out of trouble.
Instructor(s): Brenda Laigaie JD
NEW A SO HIPAA Compliance Now That There is
HITECH
Course: 532
Room: S502ab
Tuesday
10:15 - 11:15 AM
Objective: There are several significant changes to HIPAA and HITECH as a result
of the passage of the Omnibus Rule on January, 25, 2013. Additional changes are
on the horizon, while there is increased enforcement and audit activity. This course
will describe the changes brought by the Omnibus Rule and describe what practices
need to do to be in compliance. The discussion will include: the business associate,
including changes to the business associate agreement and expansion of liability;
changes to the breach notification rule, including requirements for conducting a risk
assessment; marketing and receipt of remuneration rules; compound authorizations
for research activities; changes to the Notice of Privacy Practices; changes in patients rights regarding their health information; changes in permitted fundraising;
and changes in the enforcement rules leading to increased audits and enforcement
activities.
Objective: At the conclusion of the course, participants will have a better understanding of the laws applicable to the patient, including the creation of the
physician-patient relationship, medical decision making, informed consent, medical
records and privacy, and how to terminate the physician-patient relationship.
Objective: Participants will be advised of the specific changes to provisions of the

HIPAA Privacy, Security, Breach Notification and Enforcement Rules, as well as the
HITECH Act, brought about by the Omnibus Rule. Participants will be able to apply
this advice toward bringing their HIPAA and HITECH practices into compliance. Participants will gain knowledge and practical advice on responding to an OCR audit.
Instructor(s): Jill S Garabedian JD
NEW A Negotiating Payer Contracts in Todays Health-care

Environment
A Employment Law Basics for the Small Ophthalmology

Practice
Course: 396
Room: S502ab
Course: 546
Room: S501abc
Monday
2:00 - 3:00 PM
Synopsis: This course will prepare participants to be able to better negotiate

payer contracts in todays environment, with money being tighter and with more
oversight and audits than ever before. Participants will be taught suggestions for
preparation for these negotiations on rates, as well as key issues to look for in the
contract. There will also be a discussion on strategies related to payment delays,
termination, and protecting against payer insolvency and practice risk exposure.
Tuesday
11:30 AM - 12:30 PM
Synopsis: Large practices often have access to expertise on human resources

issues that small practices, with fewer than 30-35 employees, may not. Yet because of fiscal restraints, small practices often simply adopt, without modification,
policies and procedures that dont make sense, given their size. However, being a
small practice or solo practitioner does not exempt you from following the law. This
course will identify the most common legal issues facing small practices today and
A
SO
273
Synopsis: This course will provide information on the intersection between compliance and quality parameters. The course will describe the applicable laws governing quality performance by physicians. It will include a discussion on key compliance concerns and the increased emphasis on enforcement, including repayment
obligations and Zone Program Integrity Contractor fraud investigations.
Objective: At the conclusion of the course, participants will have knowledge of

the preparation needed to negotiate with payers in todays climate. They will also
have a better understanding of the key contractual terms and what they mean, as
well as their impact when there are issues that arise under the contract.
clarify how to minimize exposure in areas like employment discrimination, wage

hour violations (especially overtime), paid time off, drug alcohol use, confidentiality,
privacy, and email, Internet, and social media use.
Objective: By the conclusion of this course, participants will learn about the issues they face as employers, the laws governing those issues, and as a result, what
kinds of provisions they should (or shouldnt) put into their employee manuals.
Instructor(s): Jill S Garabedian JD, Caroline Patterson

NEW A EHR Improving Workflow With EHR
Course: 180
Room: S502ab
Sunday
2:00 - 3:00 PM
Synopsis: Prime concerns of practices implementing EHR systems are the possibilities of slower workflow, loss of productivity, and a negative financial return
on investment. To address these concerns it is important to consider the many
workflows in your practice and how they might change and be optimized after EHR
implementation. In this course the importance of workflow redesign to successful
EHR implementation will be discussed, and examples of ongoing lean redesigns
will be given. In addition, considerations of how workflow may be impacted and
addressed in the event of system downtime will be discussed.
Objective: At the conclusion of this course, attendees will understand the importance of workflow redesign to successful EHR implementation and be able to
improve efficiency in their own practices.
Senior Instructor(s): Robert E Wiggins MD MHA*
Instructor(s): Denise C Fridl COT COE
A EHR Meaningful Use Stage 2, and How to Survive a

Meaningful Use Audit
Course: 244
Room: S504bc
Sunday
4:30 - 5:30 PM
Synopsis: Recently the U.S. Department of Health and Human Services announced the release of the meaningful use Stage 2 and updated certification criteria. Starting as early as 2014, physician practices will be required to achieve more
difficult objectives to demonstrate meaningful use of electronic health records to
earn federal bonuses and prevent future penalties. The final rule mandates that
doctors meet a larger number of core objectives and stricter guidelines for some of
those objectives already in place during the next part of the 3-stage program. Physicians also must adopt and demonstrate meaningful use of EHR systems by Oct. 1,
2014, or be assessed a 1% penalty by Medicare. In addition to the announcement of
new meaningful use rules, Stage 2 also brings audits and additional requirements
for certified EHR vendors. With a ton of cash, up to $44,000 per eligible provider,
scrutiny is sure to follow.
Senior Instructor(s): Jeffery Daigrepont
Instructor(s): Joy Woodke COE OCS*
NEW A EHR Simplifying EHR Security Audits

Course: 332
Room: S503ab
Monday
10:15 - 11:15 AM
Synopsis: A key part of meeting the Meaningful Use compliance requirement is

conducting a risk assessment. There is considerable confusion in the market regarding how complex of an audit is needed / required. At a fundamental level, it
leverages what has been established under the Health Insurance Portability and
Accountability Act regarding security. This session will cover several core areas
of the required security audit and provide a comprehensive understanding of how
and where your electronic health information is used and stored, so members who
attend can develop a stronger risk posture and avoid fines and penalties.
274
Objective: Following this presentation participants will be able to understand (1)

the key components of a risk assessment under the Meaningful Use compliance
requirement, (2) the core areas of a required security audit, and (3) how to develop
and implement a plan to ensure ongoing compliance and reduce potential for fines
and penalties.
NEW A EHR The Urge to Merge: When Two or More EHRs
Collide
Course: 368
Room: S504a
Monday
2:00 - 3:00 PM
Synopsis: Health system consolidation across the country is putting pressure on

executives to deliver clinical integration and back office efficiencies. These objectives often require two or more systems or practices to merge, complicating the
current IT infrastructure. Each merging entity may have its own or occasionally a
competing, EHR or other IT system in place, and the result is chaos, confusion,
and competing forces at play. What further complicates the process is when full
physician adoption is in place. While physician adoption varies and can often be
underestimated, full adoption can create an entirely different set of difficulties.
Objective: At the end of this session, you should be able to navigate the waters
of conversion more soundly and make an informed decision that is based on facts
and not on emotion. Remember, when you get the urge to merge, stay on the right
path to avoid a collision.
NEW A EHR How to Survive the Endless Money Pit of EHR

Course: 403
Room: S504d
Monday
3:15 - 4:15 PM
Synopsis: This course will help with your questions about the costs involved with
the constant requirements of EHR and Meaningful Use. Every time you turn around
there is an upgrade needed, with more costs. The government incentives are no
longer enough to cover all the ongoing bills. Yet the government requires us all to do
things that cant happen without the expense. This course will provide some ideas
on how to get the most bang for your buck. It will provide some ideas for thinking
outside of the box to capitalize on your investment.
Objective: Attendees will(1) learn the tools of negotiation when having to upgrade your EHR, (2) learn that everything is negotiable, (3) discuss how these upgrades can be used to your advantage with patient care and billing, (4) learn how
to look for outside resources to utilize other funds (ie, hospitals that also need to
comply with things for incentives) and (5) learn the difference between needs and
wants to have the ability to sort through the choices.
Senior Instructor(s): Susan M Loen OCS
Instructor(s): Brittney Wachter CPC OCS
NEW A EHR What Happens After an EMR Implementation?

Course: 415
Room: S504d
Monday
4:30 - 5:30 PM
Synopsis: We have all read the research and how-to guides on how to successfully implement an EMR system into a practice. But what happens after an EMR implementation? This course will provide instruction on how to monitor progress, audit
new procedures, and make sure that even though your implementation seemed successful, all of the hard work that was put into place is working.
Objective: At the conclusion of this course, the attendee will be able to(1) monitor
and track the success of an EMR implementation,(2) use key tracking methods to
gauge new processes and procedures implemented during an EMR transition,(3)

implement EMR with more confidence, knowing the audit methods that need to
happen after implementation, and (4) share successful implementation stories
across practices.
Senior Instructor(s): Tracy Pila BA
Instructor(s): Rita S Gallagher
Tuesday
9:00 - 10:00 AM
Synopsis: Understand how and why cloud computing is a growing force in health
care, and the potential benefits it offers. Explore which cloud applications make
sense for your organization, and how to navigate regulatory and security concerns.
Identify the pros and cons of different cloud-based models, and how to leverage the
cloud to expand capabilities without adding IT infrastructure. Learn proven cloud
strategies directly from health-care thought leaders and through real-world case
studies. How to move an on-premise system to the cloud. Critical contracting and
connectivity requirements for cloud services.
A EHR EHR: Great Expectations

Course: 529
Room: S501abc
Tuesday
10:15 - 11:15 AM
Synopsis: Expectation setting can be the difference between a very good EHR
system implementation and a poor implementation. This course will discuss an approach to expectation setting that is critical to stakeholder buy-in and eventual EHR
deployment success.
Objective: After attending EHR: Great Expectations, audience members will
have a game plan for attaining buy-in in their practices through expectation setting.
Senior Instructor(s): Jonathan Lohr
Human Resources
A Human Resources and Your Practice: A Consultants
Guide to Improved Performance
Course: 210
Room: S501d
Sunday
3:15 - 5:30 PM
Synopsis: Nearly everyone agrees that human resources are the most important
asset a practice possesses. Yet many practices do not have a rational human resource plan that can deliver consistent, excellent patient care and financial performance. This course presents a consultants view of an HR program. It focuses on
hiring right, training right, and managing for performance. Practical solutions are
emphasized throughout.
Objective: At the completion of this course, the attendee will be able to (1) outline
Arts HR formula for success, (2) detail the eight major points of the HR process, (3)
set work standards, (4) recruit and hire the right people, (5) train, train, train, (6)
measure and drive for performance, (7) evaluate, (8) compensate, (9) discipline or
replace, and (10) repeat, repeat, repeat.
Senior Instructor(s): Arthur L De Gennaro*
A Managing Generation Y Employees

Course: 222
Room: S502ab
Sunday
4:30 - 5:30 PM
Synopsis: Generation Y employees can be seen as the most frustrating, selfinvolved generation in history, or they can be regarded as the most educated, informed, and plugged-in workers we have ever had the privilege to hire. In either
Objective: At the conclusion of the course, managers should understand that,

with the right management approach, Generation Y employees should be the most
sought-after employees in the workforce.
Senior Instructor(s): Bonnie Callahan Parker
Instructor(s): Gina Mattoon
NEW A Identifying and Developing Trainers

Course: 224
Room: S501abc
Sunday
4:30 - 5:30 PM
Synopsis: Proper training is intrinsically linked to practice success, as it increases

staff efficiency, boosts employee confidence, and results in a higher level of care
for patients. As each new or existing staff member requires proper training, trainers
also need education, tips, and tools on how to best present information to adult
learners. This course provides a step-by-step approach to results-oriented training
that is designed to optimize the training experience so it benefits the trainer, the
trainee, and ultimately, the practice.
Senior Instructor(s): Elizabeth Holloway MA*
A YO Managing Up!
Course: 329
Room: S501abc
Monday
10:15 - 11:15 AM
Synopsis: This course will focus on the challenging role of the middle manager,
who is called upon to manage in both directions: up and down. It will teach middle
managers to successfully supervise staff, or manage down, and to achieve results
by successfully presenting recommendations to their physician bosses by managing up.
Objective: At the conclusion of this course, managers will have a better working
relationship with their physicians based on clear expectations and defined, agreedupon goals and performance measurements.
Senior Instructor(s): Debra L Phairas
A Incorporating the Four Agreements Into Your Practice

Course: 339
Room: S504a
Monday
10:15 - 11:15 AM
Synopsis: The Four Agreements by Don Miguel Ruiz is a book about personal effectiveness that can also be used in the medical practice to develop employees and
increase efficiencies while removing obstacles to success. In this course a panel
will discuss how they have used this tool for their own management abilities and as
a way to develop and lead staff.
Objective: At the conclusion of this course, attendees will have learned what the
Four Agreements are and how to apply them personally and professionally. Examples of how to utilize them in day-to-day practice will be given, and group interaction will focus on problem solving and barriers to implementation.
Senior Instructor(s): Elise Levine MA CRC OCS
Instructor(s): Sandra Dixon Curd MBA COE COA OCS, Susan R Byrd LPN COE OCS**,
Bonnie Callahan Parker
A Employee Discipline for the Smaller Practice: The New

Manager, the Seasoned Manager, and the Doctor
Course: 398
Room: S50ab
Monday
3:15 - 4:15 PM
Synopsis: Small practices may not have the luxury of an in-house human resources representative, and in many cases the task is left to a manager / supervisor or physician who has no experience in this area. Without proper training and
A
SO
275
NEW A EHR Is Cloud Computing the Future of EHR?

Course: 505
Room: S504d
case, managing these employees brings a new set of challenges to the workplace.
In order to hire, train, and retain Generation Y employees, managers must employ
completely different management techniques, which will be the focus of this course.
documentation, human resource / discipline issues can be costly to the practice

and devastating to morale. This course will provide education, tools, and ideas for
how to address discipline / performance issues, from the verbal warning through
termination.
Objective: At the conclusion of this course, attendees will have strategies (and
examples) to implement in their practices, as well as an understanding of the legalities involved in the discipline process. Interactive sharing will allow the group to
discuss and work through potential situations.
Senior Instructor(s): Elise Levine MA CRC OCS
NEW A How to Hire, Train, and Manage your Staff

Course: 416
Room: S504a
Monday
4:30 - 5:30 PM
Synopsis: This course will review how to identify the best fit, write a job description, interview, and select a candidate. The course will also go over how to
document policies, and write an employee manual. We will look at managing vs.
leading, performance management, and evaluating, coaching, and motivating your
employees.
Objective: At the conclusion of this course, the attendee will be able to identify
the best fit for the organization, write a job description, interview properly, select
a candidate, document policies, and write an employee manual. The attendee will
also be able to understand the difference between managing and leading, performance management, how to evaluate employees, how to coach, and how to motivate employees.
NEW A SO X,Y, Boom!: Supercharge Your Management
of Employees and Patients Through Awareness of

Generational Differences
Course: 530
Room: S505ab
Tuesday
9:00 - 10:00 AM
Synopsis: There are four generations in todays workforce, and each has unique
influences, values, beliefs, strengths, weaknesses, and motivations.
Objective: In this course, participants will learn to (1) identify the four generations
in the current workforce, (2) understand the influences that shaped the worldview
of each generationand know their beliefs and values, (3) know how each generation
responds to authority and directions,(4) identify common points of conflict between
the generations, (5) effectively motivate each generation, (6) optimally communicate with each generation in a way they will really understand, and (7) understand
why what works to motivate one generation doesnt work with another.
Senior Instructor(s): Andrea V Gray MD
NEW A Youve Hired a New Employee Now What?

Course: 552
Room: S501d
Tuesday
11:30 AM - 12:30 PM
Synopsis: Half of all senior outside hires fail within 18 months in a new position
and half of all hourly workers leave new jobs within the first 120 days. Hiring new
employees can cost a company over $1,000. With healthcare costs going up and
reimbursement going down, one great way to save money and invest in the future
of the company is to create, implement and maintain a New Employee Onboarding
Program. Hiring, training and being able to keep long-term, successful employees
are all factors of successful practices. For for medium to large practices. So, youve
hired a new employee - now what?
Objective: At the end of this course, the attendee will be able to: 1) define onboarding and what it means to his or her company, 2) site research and statistics
about onboarding, its cost and the cost of employee turnover on a company, 3)
276
define what it costs to hire, train and lose an employee, 4) define The Four Cs of Onboarding, 5) create his/her own Employee Orientation Program based on examples,
references and current programs available
Senior Instructor(s): Tracy Pila BA
Instructor(s): Rita S Gallagher
Marketing & Business Development

NEW A Fundamentals of Creating an Ophthalmic /
Optometric Vision Plan
Course: 212
Room: S504d
Sunday
3:15 - 4:15 PM
Synopsis: This course will provide the fundamentals of creating an ophthalmic /

optometric vision plan.
Objective: Building relationships with optometrists is an important aspect of
many ophthalmic practices. Attendees to this course will be introduced to the fundamentals of establishing an ophthalmic / optometric vision plan. At the conclusion
of this presentation, attendees will have the concepts necessary to contemplate
establishing their own vision plan network.
Senior Instructor(s): David B Dopp
Instructor(s): Ruth D Williams MD*, Charles S Sandor MD**
NEW A Strategies for Patient Access in a Consolidating
World
Course: 344
Room: S501abc
Monday
11:30 AM - 12:30 PM
Synopsis: Ophthalmology groups must collaborate with large health systems, accountable care organizations, and payers to maintain access to patients. Attendees
to this course will hear several strategies for retaining and developing patient access and referral sources and participating in networks. Risks for ophthalmology
groups in an era of powerful, large integrated health systems will be discussed.
Objective: At the conclusion of this course, attendees should be able to assess
their market conditions and utilize strategies to maintain or expand their patient
referral base.
Senior Instructor(s): David B Dopp
Instructor(s): Ruth D Williams MD*, Edward Sung MD
NEW A YO Seven Key Differences Between Thriving

Practices ... and Average Practices
Course: 366
Room: S501abc
Monday
2:00 - 3:00 PM
Synopsis: Todays medical-economic climate makes practicing increasingly more

difficult, yet some entities manage to thrive. They increase reimbursement while
generating more free time and peace of mind for the people that run them. The objective of this course, taught by practicing physicians, is to highlight key differences
between thriving and average practices, including the importance of mindset in
business leaders, practice differentiation through branding and marketing, effecting
innovative change, how market domination can be achieved through the establishment of expert status, the importance of understanding ones own practice and its
position in a local market, effective time management, how to imitate success in
others and not fall prey to inertia, and the role of coaching and accountability for
effecting meaningful differences.
Objective: At the conclusion of this course, the attendees will be poised to analyze, strategize, and execute a plan to catapult their practices to the next level of
productivity.
Senior Instructor(s): Joseph L Sokol MD

A Smile . . . Even If It Kills You: Training for Excellent
Customer Service
Course: 411
Room: S505AB
Monday
4:30 - 5:30 PM
Objective: This course is designed to help participants identify the strengths and
weaknesses in their practices and learn ways to change a problematic work culture.
Attendees will also be able to identify a practices mission statement and learn how
the entire team can improve by changing a few common yet undermining attitudes
and habits.
Senior Instructor(s): Nancy Baker
NEW A YO Managing Your Online Reputation

Course: 414
Room: S503ab
Monday
4:30 - 5:30 PM
Objective: Participants will (1) understand the benefits and pitfalls of social media
marketing, (2) know how to monitor and manage their online reputation, and (3)
understand how to respond to complaints and criticisms online.
Senior Instructor(s): Bonnie Callahan Parker
A Strategic Planning by Fact

Course: 527
Room: S504bc
Tuesday
10:15 - 11:15 AM
Synopsis: Many practices struggle when assessing practice growth opportunities

because they have little upon which to base their decisions, other than their impressions. Todays digital society has amassed information that can inform decisions, for
those who know where to find it.
Objective: Participants will learn what information is available within their practices and from outside sources, and how to use that information to inform practice
development. They will come away with an understanding of data sources, key
demographic characteristics and ratios, and mapping techniques to visualize the
information.
Senior Instructor(s): Michael J Parshall*
NEW A Live Website Analysis: Critique Your Website

Course: 570
Room: S501d
Tuesday
12:45 - 1:45 PM
Synopsis: This course will present a live, interactive walk-through of preselected

websites. Attendees will learn key objectives of website flow, search engine optimization (SEO), and design. Fresh, objective analysis will provide exceptional value
to both the website owners and other participants. NOTE: In order to maximize
value, I will select 5-10 sites for review during the course. Participants are asked to
submit their website for possible inclusion to my email address: Randall.V.Wong@
gmail.com Participants are not required to submit a website for participation in
this course.
Note: In order to maximize value, I will select 5-10 sites for review during the
course. Participants are asked to submit their website for possible inclusion to my
email address: Randall.V.Wong@gmail.com Participants are not required to submit
a website for participation in this course.ObjectivesAttendees will learn the essentials of creating a successful website, key objectives of website flow, SEO evaluations, and design options. Attendees will be able to perform critical evaluations of
medical websites through this practical session.
Senior Instructor(s): Randall V Wong MD*
NEW A What Every Administrator (and Optician) Needs to

Know About the Retail Selling Process
Course: 183
Room: S503ab
Sunday
2:00 - 3:00 PM
Synopsis: To be successful an optician must understand the theory, science, and

art of the retail selling process. The majority of opticians, however, have never been
professionally sales trained. The result is substandard selling performance that
results in fewer captures, fewer satisfied patients, fewer referrals, and mediocre
profits. This course outlines part of the retail selling process and provides practical
solutions for improving performance.
Objective: Upon completion of this course, the attendee will be able to (1) name
the 7 parts of a retail sale, define each step, and explain why each step is important
to the success of the entire process, (2) overcome price objections, (3) sell multiple
pairs, and (4) measure the performance of an opticians sales performance.
NEW A How to Build and Manage a Dispensarys Frame

Inventory
Course: 370
Room: S504d
Monday
2:00 - 3:00 PM
Synopsis: Building and properly managing a frame inventory that will be attractive
to as many customers as possible requires proper market positioning, vendor selection, frame selection, a replenishment strategy, appropriate pricing, and the ability
to manage the inventory over time. This course will discuss the steps necessary to
build and maintain an inventory.
Objective: Upon completion of this course, the attendee will be able to(1) select a
market position, (2) determine how many frames to have in the collection, (3) build
an ideal frame model, negotiate with frame vendors, (4) create a pricing model,
(5) decide on a replenishment strategy, (6) manage the collection using inventory
reports, and (7) decide which frames to replace.
A Optical Shops: Sales Strategies for Todays Economy

Course: 547
Room: S504d
Tuesday
11:30 AM - 12:30 PM
Synopsis: Todays consumers have more information at their disposal than ever
before. The options for prescription eyewear are limitless. Because of ubiquitous
advertising from retail chains, private optical offices frequently must overcome
preconceived opinions about price, quality, and service. Advertisements promoting
deep discounts are intensifying the perception that the private optical is more expensive. The sales training, techniques, and strategies pervasive in the private sector have not been updated in decades, nor have they been modified to meet todays
current economic climate. This course will review sales strategies and techniques
designed to entice and encourage patients to purchase from the private optical
office.
Objective: This course will enable participants to initiate new sales techniques
designed to uncover the patients top priorities, establish low-cost package options
as an added offering, and implement internal marketing strategies to promote the
optical business.
Senior Instructor(s): Carolyn Salvato*
A
SO
277
Synopsis: This course is geared toward training the entire staff for five-star, excellent customer service with a goal of creating a good work environment, a happy
customer base, and a busy, healthy practice.
Optical Dispensing

Professional Growth
YO A A Practical Guide to Understanding and Negotiating

Your First Employment Agreement
Course: 208
Room: S504a
Sunday
3:15 - 5:30 PM
Synopsis: This course will address the various practical, business, and legal
aspects of reviewing and negotiating an initial employment agreement. Issues
covered in the course include understanding the business and legal terms of the
proposed employment arrangement, the fundamentals of a contract, and tips on
how to negotiate the deal with the prospective employer.
Objective: This course will leave attendees with an understanding of the entire
employment and contracting process so that they approach their first contract experience with knowledge and confidence.
Senior Instructor(s): Robert J Landau JD
Instructor(s): Mark D Abruzzo JD
NEW A How to Create a Professional Development
Program for Your Staff

Course: 219
Room: S504bc
Sunday
3:15 - 4:15 PM
Synopsis: This course will review how to develop a professional development program. We will look at how to create a team, define your mission and goal, how to
develop SMART goals, develop monthly meetings, and conduct staff training. We
will review benchmarks to set goals. The course will look at how to evaluate and
coach. We will go over motivation and forms of recognition. We will also look at
performance readiness levels.
Objective: At the conclusion of this course, the attendees will be able to understand how to create a professional development program, create a team, define
their mission and goals, how to develop SMART goals, and how to develop monthly
meetings. The attendees will be able to review benchmarks to set goals, evaluate
staff, and coach. They will be able to understand motivation and recognition and to
know performance readiness levels.
SO A Three Areas of Succession Planning for Senior

Physicians
Course: 302
Room: S501d
Monday
9:00 - 10:00 AM
Synopsis: This course will be a panel presentation by three experts who will
look at succession planning from an attorneys viewpoInt, an optical shop owners
viewpoInt, and a practice management consultants viewpoint. Areas covered will
include the exit strategy from a legal standpoInt, and the impact of the optical shop
on the value of a practice and the sale (an optical shop should represent 30% of
revenue for the practice). We will cover the various methodologies for determining
value. We will look at the various exit strategy scenarios and what key documents
will need to be in place.
Objective: Attendees will have the opportunity to attend a panel presentation by
three professionals who will discuss succession planning from different points of
view. Attendees will learn what steps need to be taken and when. You will learn
what documents will need to be developed. You will learn what the timelines are
for succession.
Instructor(s): Arthur L De Gennaro*, Mark E Kropiewnicki JD LLM*
278
NEW A Do You Know Your Cornea From Your Retina?

Ocular Anatomy and Physiology for Beginners
Course: 331
Room: S501d
Monday
10:15 AM - 12:30 PM
Synopsis: This course will provide the new administrator with a basic knowledge
of ocular anatomy and physiology. Included will be conditions frequently diagnosed
in a general practice and an explanation of commonly performed diagnostic tests
and procedures.
Objective: To (1) list the major considerations for building an ophthalmic schedule,
(2) discuss the relationship between clinical staffing and patient load, (3) discuss
diagnostic testing as it pertains to schedule creation, and (4) explain the impact of
multiple providers, scheduled simultaneously, on patient flow.
Senior Instructor(s): Jane T Shuman COE COT MSM OCS*
Instructor(s): Sergina Maria Flaherty COMT**
NEW A Red 80! Set! Lead! Leadership Lessons From a
Football Coach
Course: 333
Room: S504d
Monday
10:15 - 11:15 AM
Synopsis: My husband has been coaching high school football since 1985. I have
been working in the eye care industry almost as long. Over the years it has amazed
me to see how good football coaches and good leaders employ the same tactics in
order to achieve success. While Ive often used the coachs advice as an administrator or consultant over the years, I thought it would be fun to compile the lessons
Ive learned from a football coach and put them in terms of practical application to
ophthalmic administrators / leaders.
Objective: Upon completion of this course, the participants will understand tactics for setting expectations, have specific tools for better coaching / feedback,
learn some of the secrets of motivating people to perform, learn different communication techniques to create understanding, and incorporate the lessons into
their daily routines.
A American Academy of Ophthalmic Executives Book Club:

Professional Growth and Development
Course: 397
Room: S504bc
Monday
3:15 - 4:15 PM
Synopsis: As a practice administrator or ophthalmologist, it is easy to get caught

up in the day-to-day tasks of running a practice. Often not enough time is given to
personal and professional development. One way to nurture our own development
is through reading, but many busy professionals lack the time to sort through or
read the business literature. Books reviewed in 2013 by a spectrum of leaders in the
field of ophthalmology included Lean In: Women, Work, and the Will to Lead; Brain
Rules: Twelve Principles for Surviving and Thriving at Work, Home, and School;
Thinkertoys: A Handbook of Creative Thinking Techniques; Dont Sweat the Small
Stuff . . . and Its All Small Stuff; and The (Honest) Truth about Dishonesty: How We
Lie to Everyone. . . Especially Ourselves.
Objective: At the conclusion of this course, the participant will have actionable
ideas from top business books that can be applied to his or her professional development.
Senior Instructor(s): Robert E Wiggins MD MHA*
Instructor(s): Nancy Baker, K David Epley MD, Tamara R Fountain MD*, Timothy J
Padovese, Ron W Pelton MD PhD

NEW A SO Work/Life Balance: Unrealistic Expectation or
Achievable Goal?
Course: 503
Room: S504bc
Tuesday
9:00 - 10:00 AM
Synopsis: This course will be presented as a panel discussion by 3 seasoned

administrators on how they have succeeded and failed in achieving a work/life
balance and avoiding burnout. We will share tips, strategies, advice, and cautionary tales to help us all stay focused, motivated, and content, both personally and
professionally.
Objective: The goal of this course is to help administrators identify where their
individual work/life balance goes off the rails and find new and better ways of mitigating stress. We will discuss what has both worked and failed in trying to reach
our own balance in order to come up with new and better ways of maintaining our
equilibrium in a state of constant and often conflicting demands.
Senior Instructor(s): Nancy Baker
NEW A Practice Management Perspectives: A Case Study

Course: 549
Room: S503ab
Tuesday
11:30 AM - 12:30 PM
Synopsis: The purpose of this course is to provide new and experienced administrators with quantifiable recommendations and strategies to make better short- and
long-term decisions in all aspects of practice management.
Objective: At the conclusion of the course, the attendee will be able to implement
opportunities for improvement in the following areas: practice operations, human
resources functions, growth opportunities, organizational culture, increasing patient volume, and training and development.
Senior Instructor(s): Denise C Fridl COT COE
A
SO
279
Practice Management Master Classes
Practice Management
Master Classes
Saturday, Oct. 18
A The Profitable Practice: Managing Your Billing Operations
Learn all of the steps involved in billing and receivables management. Also,
how to monitor collections performance, deploy and manage billing staff,
identify and correct operational problems that cause rejected and/or delayed claims, and obtain benchmarks for staff and cost of billing.
Event No: SPE03
Time: 8:00 AM - 12:00 PM
Room: S502ab
Fee: $345.00
Sr. Instructor(s): Ron Rosenberg PA
Instructor(s): Donna Connolly, Curt Hill
A Keeping Your Practice Out of Legal Hot Water: An HR and
Compliance Workshop
Enhance your knowledge about regulatory compliance and human resource
law at this intensive half-day workshop. The first part of the session will
cover the regulatory landscape and compliance and human resources challenges facing practices. The later part of the session will consist of breakout sessions, allowing participants to select from 4 in-depth discussions on
topics presented earlier in the day.
Event No: SPE05
Time: 9:00 AM - 1:00 PM
Room: S503ab
Fee: $345.00
Instructor(s): Robert J Landau JD, Robert A Wade JD, David Laigaie,
Brenda Laigaie JD, Jill S Garabedian JD, John Duemmel, Caroline Patterson
A NEW The Entrepreneurial ASC: Embracing Policy, People,
Possibilities and Planning
Join OOSS members and industry leaders for this engaging luncheon symposium focusing on contemporary legislative, regulatory, reimbursement,
business and marketing issues that affect the performance of the ophthalmic ASC.
Event No: SPE24
Time: 12:00 - 4:00 PM
Room: S505ab
Fee: FREE
Sr. Instructor(s): Kent L Jackson PhD
Instructor(s): Ralph Chu, Mike Romansky, Regina Boore RN BSN MS,
Kevin J Corcoran, Larry E Patterson MD, Harvey J Reiser MD, Pravin U
Dugel MD, Stephen C Sheppard, Albert Castillo, Rob Grim, Paul S Koch
MD, Maureen Waddle MBA
A NEW Scott Demings Emotional Brand Building Workshop

Scott Deming returns to bring an expanded, in-depth course that will immediately improve your practices success. As an attendee, you will take
part in an engaging, creative, high-energy and interactive seminar that
will positively alter how you do business.
At the end of the workshop, you will be able to:
Understand the true potential of brand building;
Move your staff from knowledge to action;
Execute zero-cost marketing that works!
Expand your leadership skills;
Create your own unique purpose;
Be innovative and dedicated in service;
Create your own ultimate patient experience;
Get to know your patients;
Enjoy teamwork and thrive;
Communicate effectively with patients;
And so much more!
Event No: SPE02
Time: 12:30 - 4:30 PM
Room: S501abc
Fee: $345.00
Presenter: Scott Deming
Note: This workshop is not eligible for CME.
Sponsored by Alcon
A NEW The Optical Dispensing Boot Camp
It is a proven fact that ophthalmologists dispensaries significantly underperform their counterparts in optometry and the commercial optical world.
This interactive Boot Camp explores the factors that contribute to improved
dispensary sales and profits. It is designed for those practices that want to
open a new dispensary or create a plan of action for the growth or improvement of an existing dispensary.
Event No: SPE06
Time: 12:30 - 4:30 PM
Room: S504bc
Fee: $345.00
Presenter: Arthur L De Gennaro
Monday, Oct. 19
NEW PQRS, Value Based Modifier, Meaningful Use and
Sequestration: Bonus and Penalties for 2014 and Beyond
In addition to CMS two percent annual sequestration, physicians in large
and small practices can avoid additional penalties by successfully participating in other government programs no matter the specialty training.
Event No: SPE16
Time: 9:00 - 11:15 AM
Room: S505ab
Fee: FREE
Sr. Instructor(s): Sue J Vicchrilli COT OCS
280
Academy Resource Center
EXPLORE PRODUCTS, MEMBER

BENEFITS AND EVERYTHING ACADEMY
BOOTH
508
Join us for these
special events!
SAVE 10%
Get 10% off all products at the Academy
Resource Centerno minimum purchase required!
iPAD DRAWINGS
Saturday, Sunday and Monday at 4 p.m.
Get a product demo or receive member benefit
information and earn a chance to win an iPad loaded
with digital Academy products.
EXPERIENCE THE IRIS REGISTRY
Saturday, Oct. 18, 3 4:30 p.m.
Come together and learn about the nations first
EHR-based eye disease clinical registry.
CELEBRATE NEW PATIENT EDUCATION TOOLS
Monday, Oct. 20, 2 3:30 p.m.
Sample some sweets and take a look at the newly
redesigned patient education products that also meet
new health literacy guidelines.
OPHTHALMOLOGY MEET AND GREET
Sunday, Oct. 19, 12 3 p.m.
Monday, Oct. 20, 9 11 a.m.
Authors and peer reviewers for Ophthalmology are
invited to stop by and meet members of the journals
editorial board.
Sample more than 100 new

print and digital products
Personalize patient education
DVDs in the Video Production
Services studio
Get a free 20-minute
consultation with a practice
management expert
Renew your Academy, ISRS and
AAOE membershipor join!
Visit the Museum

of Vision Exhibit
Booth #704
MUSEUM
OF VISION
Exhibitors
66 Vision Tech Co., Ltd. .................................... 2104
C.S.O. srl ........................................................... 4220

Caduceus Media, LLC. NEW! .......................... 3176
Calhoun Vision, Inc. .......................................... 4250
Cambrian Medical, Inc. .................................... 1150
Canon U.S.A., Inc.H ......................................... 3803
CareCloud ......................................................... 4556
CareCredit ......................................................... 2350
Ceatus Media Group ........................................ 2802
Centervue.......................................................... 1177
Charmant Inc..................................................... 2873
ChartLogic, Inc. ................................................. 4157
Chenyueqi Biotechnology Co., Ltd. .................. 4356
Chona Surgical Co. ........................................... 4629
Chongqing Kanghua Ruiming Science
Technology Co., Ltd. NEW!......................... 3575
Chongqing Sunkingdom Medical
Instruments Co., Ltd..................................... 4165
Cilita, Ltd. .......................................................... 1903
CIMA Technology, Inc.H .................................. 2945
Clarity Medical Systems, Inc. ........................926
Clearwave Corporation .................................... 3272
Coburn Technologies, Inc. NEW! ...................... 930
Compulink Business Systems, Inc. .................. 1450
Conestoga Equipment Finance Corp. ............... 3178
Covalent Medical, LLC NEW! ......................... 4558
CRC Press NEW!.............................................. 3571
Crestpoint Management .................................. 2900
Crocodile Tears, LLC NEW! ............................. 4269
1144
Croma Pharma GmbH
NCELED
CA.......................................
Daud Jee Mfg. Co. NEW! ............................... 4434

DavLong Business Solutions ............................ 3166
Delta Life Science, Inc...................................... 4550
Demandforce ...................................................... 329
DermaMed Solutions, LLC ................................. 347
Designs For Vision, Inc.H................................. 2800
Device Optical................................................... 4156
Dexta CorporationH ......................................... 1844
DGH Technology, Inc.H .................................... 2500
Diagnosys LLC..................................................... 657
Diamatrix Ltd. ................................................... 1047
DigiSight Technologies, Inc. ............................. 3271
Diopsys, Inc....................................................... 4447
Dioptics Medical Products, Inc. ....................... 3053
Doctors Advantage Products, LLC. .................. 1937
Doctors Allergy Formula ..................................... 353
Doctors Internet .................................................. 429
Doctorsoft ........................................................... 771
DORC International, bv ..................................... 2326
Dove Medical Press, Ltd................................... 3570
Duckworth & Kent Ltd. ..................................... 2900
Dutch Ophthalmic, USA.................................2326
Eagle Labs......................................................... 2044

Eagle Vision, Inc.H ........................................... 2503
Eidolon Optical.................................................. 3104
Einstein Medical ................................................. 550
Electro-Diagnostic Imaging, Inc. ........................ 646
Ellex................................................................... 2617
Ellman InternationalH...................................... 2731
ElsevierH .......................................................... 1500
Emtron ............................................................... 1145
Encore Medical Education NEW! ................... 2476
Endo Optiks, Inc. ............................................... 1703
Enhanced Medical Services NEW! ................. 2401
Enhanced Vision ................................................ 130
Epsilon EyeCare, USA....................................... 1900
Eschenbach Optik ............................................. 2145
Essilor of America .............................................. 357
European Society of Cataract & Refractive
Surgeons (ESCRS) ........................................ 1247
European Society of Ophthalmology (SOE) ..... 1200
European Society of Retina Specialists
(EURETINA) .................................................. 1249
Exhibitor Locator - American Academy
of Ophthalmology .......................................... 3500
Exhibitor Lounge - American Academy
Expeditor Systems, Inc. .................................... 3103
Eye Care and Cure ............................................ 3869
Eye Designs, LLCH ........................................... 3557
Eye Photo Systems, Inc. ..................................... 251
Eyedetec Medical, Inc. ..................................... 4562
EyeKon MedicalH .............................................. 333
Eyekor, LLC ........................................................ 4456
Eyemaginations ................................................ 1700
= Exhibitors celebrating 25 years of participation, H = Exhibitors with more than 25 years of participation, Bold Text = Ophthalmic Business Council Members.
281
Accurate as of Sept. 3, 2014. Review exhibiting companies and their products at www.aao.org/virtualexhibition.
Exhibitors
A Fashion Hayvin, Inc. ...................................... 4067

A Royal Treasure............................................... 3278
A.R.C. Laser GmbH ........................................... 1165
a1 medical GmbH NEW! ................................... 235
AA Vision, Inc. .................................................... 156
Abbott Medical Optics H .............................2308
AccuLens, Inc. ................................................... 2404
Accumold NEW! .............................................. 4564
Accutome .......................................................... 3144
ACIGI Relaxation/FUJIIRYOKI ............................ 950
Action Medical ................................................... 234
AcuFocus, Inc. .................................................4648
Addition Technology, Inc. ................................. 4500
ADP advancedmd ............................................. 4358
Advanced Data Systems .................................... 848
Advanced Tear Diagnostics NEW!.................. 3077
Aeon Astron Europe B.V. .................................. 2776
AIT Industries.................................................... 4153
Ajinomoto Trading, Inc. .................................... 1134
AKAS Medical .................................................. 3274
Akorn Pharmaceuticals..................................... 1439
AL.CHI.MI.A. S.r.l. ............................................. 2701
Alcon Laboratories, Inc. H ...........................2908
Alimera Sciences ...........................................2834
AllerganH.........................................................1408
ALPHAEON Corporation ..................................... 752
Altaire Pharmaceuticals, Inc. ............................. 337
Ambler Surgical ................................................ 2301
Amcon NEW! ................................................... 3102
American Academy of Ophthalmic
Executives (AAOE) .......................................... 508
American Academy of
Ophthalmology (AAO)..................................... 508
American Society of Cataract & Refractive
Surgery (ASCRS) .......................................... 3862
American Society of Ophthalmic
Administrators (ASOA) ................................ 3862
Angies List.......................................................... 150
AngiotechH ...................................................... 3200
Anodyne Surgical ............................................. 2859
AO Lab - American Ophthalmic Lab................. 2300
Appasamy Associates ........................................ 834
Apramed Medical Devices ................................. 762
ARCADOPHTA .................................................. 4405
ArcticDX, Inc ..................................................... 4268
Art Optical Contact Lens, Inc. ............................ 236
Asia-Pacific Academy of
Ophthalmology (APAO) ................................ 1102
ASICO, LLCH ....................................................3400
Association for Research in Vision and
Ophthalmology (ARVO) ................................ 1244
Audio-Digest Foundation ................................. 3270
Aurolab.............................................................. 2371
Aurora Surgical, LLC ......................................... 4402
Avedro, Inc. ....................................................... 2175
Avellino Lab USA, Inc. ...................................... 3049
Bank of America Practice Solutions ................ 2002

Bausch+LombH ..............................................3126
Beaver - Visitec InternationalH ....................... 2321
Beijing Outsmarting Dacone Instrument
Co., Ltd. .......................................................... 967
Belrose Refracting
CompanyH ....... 126
NCELED
CAEquipment
Benign Essential Blepharospasm
Research Foundation ................................... 2969
Best of AAO/Encore Medical
Education NEW! ......................................... 2476
Better (Jiangsu) Device
Medical Co., Ltd. NEW!.............................. 3374
BioD, LLC........................................................... 3376
BIONIKO NEW! ................................................ 2577
Bioptigen, Inc. ................................................... 2757
Biosyntrx ........................................................... 3101
BioTech Vision Care Pvt., Ltd........................... 4133
Bio-Tissue, Inc.................................................3357
Bistro AAO Caf .................................................. 2781
BJB Medical Associates .................................. 2759
Brevium ............................................................. 3469
BrightFocus Foundation ...................................... 448
Bruder Healthcare Company ............................ 3372
Brumaba USA, Inc. ........................................... 2173
Bryn Mawr Communications LLC..................... 1049
BSM Consulting................................................ 1068
BTI Biotechnology Institute NEW! .................. 4259
Exhibitors
EyeMD EMR Healthcare Systems, Inc. ........... 1635
EyeNet - American Academy
EYEOL UK LIMITED ........................................... 1975
EyeSys Vision.................................................... 2368
Exhibitors
Fallon Wellness Pharmacy ............................... 2949

Fashion Optical DisplaysH ................................ 559
FB Eye Equipment ............................................... 256
FCI Ophthalmics .................................................. 726
Feather Safety Razor Co., Ltd........................... 4303
First Insight Corporation ..................................... 149
Fischer Surgical, Inc. .......................................... 457
Florida Eye Equipment ...................................... 4362
Foundation of the American Academy
of Ophthalmology (FAAO) .............................. 508
Freedom Ophthalmic Pvt., Ltd. ......................... 4535
Freedom Scientific .............................................. 249
Fresnel Prism & Lens Co................................... 1904
Fundus Photo .................................................... 3302
GENENTECH .......................................................837
Geuder AG ........................................................ 2900
Gibraltar IT ........................................................ 1978
Glacial Multimedia ........................................... 2003
Glaucoma Research Foundation ...................... 2970
Glaukos Corporation ......................................... 2568
Global Sight Alliance........................................ 2973
Good-Lite ............................................................ 947
Gulden Ophthalmics ........................................... 159
Haag-Streit AG ................................................. 3319

Haag-Streit GroupH .......................................3319
Haag-Streit Surgical GmbH.............................. 3319
Haag-Streit UK.................................................. 3319
HAI Laboratories, Inc. ....................................... 2926
Hangzhou MuleTech Co., Ltd. .......................... 2477
Haohai Biological
Technology Co., Ltd. NEW! ........................... 3275
Harvest Digital NEW! ...................................... 3277
Hausted............................................................... 969
Hawaiian Moon ................................................ 3470
Heidelberg Engineering
........................2344
Heine ................................................................ 4000
Highlights of OphthalmologyH........................ 3672
Howard Instruments, Inc.H ............................. 2405
Hoya Surgical Optics, Inc. ............................2009
Huaian Frimen Co., Ltd. .................................... 4621
Hurricane Medical ............................................ 2921
Huvitz .................................................................. 930
Icare USA .......................................................... 1971

ifa united i-tech, Inc.......................................... 2626
I-Instrument Co., Ltd NEW! ............................. 2575
Images en Ophtalmologie .................................. 970
282
I-MED Pharma .................................................. 2851

iMedicWare, Inc. ................................................ 162
Imprimis Pharmaceuticals, Inc. ........................ 4252
Inami & Co., Ltd. ............................................... 3203
INDO WEBAL SURGICAL.................................... 972
Indo-German Surgical Corporation .................... 451
Infinite Therapeutics........................................... 458
Infinitt North America....................................... 4256
Innova Systems, Inc.......................................... 2853
Insight Instruments, Inc. ................................... 2317
Integrated Orbital Implants, Inc. ...................... 2000
Integrity Digital Solutions, LLC ........................ 1675
International Council of
Ophthalmology (ICO).................................... 1100
International Eye Foundation ........................... 2972
International Sight Restoration Eye Bank.......... 233
IO Practiceware .................................................. 321
IOPH ................................................................. 2135
i-Optics Corporation ......................................... 1671
....................................................... 2621
IRIDEX
iScreen Vision NEW! ....................................... 2673
iSTAR Medical NEW! ...................................... 2857
iViews Imaging System, LLC ............................ 4432
Jaggi Ophthalmic Instrument Co. .................... 2005

JANIX CRO........................................................ 1067
Jaypee-Highlights Medical PublishersH ........ 3672
JCAHPO ............................................................ 1848
JEDMED Instrument Company ........................ 3800
Jingming Science & Technology Co., Ltd. ....... 4433
Jullundur Surgical Works (India) NEW!.......... 4167
K2 Tables........................................................... 3177
KAI Industries, Ltd. ........................................... 1065
Karger Publishers ............................................. 3573
Katalyst Surgical, LLC......................................... 730
Katena Products, Inc.H .................................... 2135
Keeler Instruments, Inc.H................................ 3144
KeyMedical Software, Inc................................ 4300
Khosla Surgical IndustriesH ............................ 2705
....... 2171
King Khaled Eye Specialist Hospital
Kirwan Surgical Products LLCH ...................... 3604
Konan Medical USA ......................................... 3562
Koryo Eyetech Co., Ltd........................................ 157
Kowa Optimed, Inc.H ...................................... 1678
Krebs InstrumentsH ......................................... 1940
Kugler PublicationsH ....................................... 3669
Labtician Ophthalmics, Inc. .............................. 1650

Lacrimedics, Inc. .............................................. 4267
LacriSciences, LLC ............................................ 1066
LACRIVERA NEW! ........................................... 1502
Latham & Phillips Ophthalmic.......................... 1747
LCA Pharmaceutical ......................................... 3262
Learning Lounge - American Academy

of Ophthalmolgy............................................... 107
LeClairRyan NEW! ........................................... 2572
Leica Microsystems.......................................... 2839
Leiters Pharmacy.............................................. 1944
LENSAR............................................................... 533
Lenstec, Inc. ...................................................... 3362
LIGHTMED Corporation .................................... 4130
Lions Clubs International Foundation .............. 3071
Live Eyewear, Inc. ............................................. 1148
Live Oak Bank NEW! ......................................... 358
LKC Technologies, Inc.H .................................. 2922
Lombart InstrumentH ...................................... 2744
Low Vision Works Consulting Group ................. 229
Lumenis VisionH .............................................. 3438
M&S Technologies, Inc. ................................... 1947

MacuHealth NEW! ............................................ 765
Macular Health ....................................... 4152, 4365
MacuLogix, Inc.................................................. 4627
Madhu Instruments ............................................ 231
ManagementPlus ............................................... 144
MANI................................................................. 3100
Marasco & Associates, Healthcare
Architects & Consultants .............................. 135
MarcoH ............................................................ 3820
Market Scope, LLC ........................................... 2650
Mastel Precision Surgical Instruments, Inc. .... 1650
Mayo Clinic ......................................................... 774
MDIntellesys..................................................... 1475
MDoffice, Inc. ................................................... 2916
Meccanottica Mazza S.r.L ................................ 2035
Meda Co., Ltd. .................................................... 237
MedDev Corporation ........................................ 1130
MedEdicus ........................................................ 2852
Medelita Lab Coats and Scrubs NEW!........... 2674
Medennium, Inc................................................ 2550
Medflow, Inc. .................................................... 4340
Medical Ministry International Canada........... 3073
Medicel AG ....................................................... 2531
MEDICEM International ................................... 3173
Medicure Instruments ...................................... 4623
Mediphacos ...................................................... 3375
MediSURG Research & Management Corp. ... 4404
Med-Logics, Inc. ............................................... 2952
MedNet Technologies ...................................... 1938
MedOne Surgical, Inc. ...................................... 2751
MEDVISION ........................................................ 427
Mercoframes Optical
4432
ELED
NC..............................
CACorp.
Mercy Ships ...................................................... 2971
Merge HealthcareH ......................................... 3300
Merrill Lynch ....................................................... 428
Metrovision....................................................... 2858
Micro Medical Devices, Inc. .............................. 449
MID Labs, Inc. ................................................... 4400
Mid-Atlantic Permanente Medical Group ....... 2576
Miracles In Sight .............................................. 2854
Mobius Therapeutics, LLC.................................. 362
Exhibitors
Modernizing Medicine ..................................... 4353
Montefiore Medical Center.............................. 1131
MORIAH ........................................................... 4126
Moss Vision Inc., Ltd. ....................................... 2870
MST (MicroSurgical Technology) ..................... 2245
MTI .................................................................... 2767
Museum of Vision - Foundation of the
American Academy of Ophthalmology...... 704
OASIS Medical, Inc.H ...................................... 4003

Ocular Instruments, Inc.H................................ 3119
Ocular Surgery NewsH...................................... 545
Ocular Systems, Inc. ........................................... 749
Ocular Therapeutix, Inc. ................................... 2770
Oculus, Inc.H .....................................................820
Oculus Surgical, Inc. ........................................... 621
OCuSOFT, Inc. ................................................... 1445
OD-OS GmbH .................................................... 3051
Oertli Instrumente AG ...................................... 3416
Omeros Corporation ......................................... 4350
OMIC - Ophthalmic Mutual Insurance
Company ...................................................... 1004
Omni Lens Pvt., Ltd. .......................................... 4150
OPHMED Co., Ltd................................................ 230
Ophsurin Co., Ltd. ............................................. 2876
OPHTEC ............................................................. 2904
OphthalMed LLC ............................................... 2037
Ophthalmic Instrument Co., Inc........................ 2148
Ophthalmic Instruments, Inc. ........................... 3048
Ophthalmic Photographers Society ................ 1503
Ophthalmology Job Center - American
Academy of Ophthalmology ............................67
Ophthalmology Journal .................................... 3671
Ophthalmology Management .......................... 2947
Ophthalmology TimesH ..................................... 128
OphthalmologyWeb.......................................... 3164
OPTELEC.............................................................. 151
Pacific Ophthalmic Supply.................................. 331

Pan-American Association of
Ophthalmology (PAAO) ................................ 1202
Paragon BioTeck ............................................... 4550
Partners In Vision.............................................. 4162
Patient Education Concepts ............................. 3304
Pelion SurgicalH .............................................. 3105
Penn Medical Informatics Systems ................... 962
Perrigo Specialty Pharmaceuticals NEW! ...... 2403
Peschke Trade GmbH.......................................... 350
PHAKOS ............................................................ 1147
PhysIOL sa........................................................... 977
Pine Pharmaceuticals NEW! ........................... 3174
PinPoint Optics.................................................. 4626
Plusoptix, Inc..................................................... 4154
PM Medical Billing Corp. ................................. 2754
PODIS ................................................................ 4457
Poriferous, LLC NEW! ...................................... 1144
Practice Flow Solutions .................................... 2001
Precision Vision, Inc............................................ 147
Premier Ophthalmic Services, Inc. ............. 126, 133
........................................... 3045
Prescotts, Inc.
Pricon Iscon Surgicals, Ltd. ................................ 431
PRN - Physician Recommended
Nutriceuticals .............................................. 2376
Pro-Paks ............................................................ 2473
PST .................................................................... 1604
Qioptiq............................................................... 2753
QualSight, Inc. .................................................. 2373
Quantel Medical .............................................. 4414
Quest Medical, Inc. .......................................... 1232
R.E.T., Inc........................................................... 2038

Rapid Pathogen Screening, Inc. (RPS) ............. 1602
Ray Vision International Corporation ............... 3369
Rayner Intraocular Lenses Limited .................. 4503
Reckner Healthcare NEW! ................................ 777
Regeneron Pharmaceuticals .......................2762
Reichert TechnologiesH................................... 3826
Reliance InternationalH .................................. 3319
Rest Stop - American Academy of

Ophthalmology ................................................. 780
Review of Ophthalmology .................................. 747
ReVision Optics, Inc. ......................................... 4708
Rexxam Co., Ltd. NEW! ................................... 1134
RGP, Inc. ............................................................ 2046
.................................. 3021
Rhein Medical, Inc.
Rica Surgical Products........................................ 647
Richmond Products, Inc. ................................... 2303
Rose Micro Solutions .....................356, 2004, 4159
Rumex International Co. ................................... 3832
Rysurg, LLC ....................................................... 2772
S4OPTIK ............................................................ 2013

San Diego Eye Bank ......................................... 3366
Santen ...............................................................3453
Scarf King ........................................................... 456
SCHWIND eye-tech-solutions ......................... 3138
SciCan, Inc. ....................................................... 1950
ScienceBased Health ....................................... 2368
Scientific Posters Online / Video on Demand American Academy of Ophthalmology.........65
sea-change, inc................................................. 2801
Second Sight Medical Products, Inc. ............... 1071
SEGAL Instruments Exports ............................... 250
Sensor Medical Technology ............................. 4333
Shamsi Surgical .................................................. 248
Shanghai Canton Optics Equipment
Co., Ltd. NEW! ............................................ 2172
Shanghai EDER Medical Equipment
Co., Ltd. ........................................................ 4459
Shanghai Mediworks ......................................... 965
Shanghai New Eyes Medical, Inc. ..................... 153
Shanghai Xiaolai Science and Trade Co. ......... 4254
Shenyang SINQI Pharmaceutical Co., Ltd. ........ 552
Shire NEW! ........................................................ 768
Si14 SpA NEW! ............................................... 2775
SightLife .............................................................. 648
Sightpath Medical ............................................ 4337
Simply Touch..................................................... 3175
SLACK IncorporatedH........................................ 545
SMR Ophthalmic ................................................ 549
Soderberg InstrumentsH ................................. 2047
Solutionreach...................................................... 259
SOLX, Inc........................................................... 4565
Sonogage, Inc.H .............................................. 2100
Sonomed Escalon .............................................. 526
Sonop Technology Co., Ltd. .............................. 1072
Sony Electronics ................................................. 437
SOOFT iTALiA SpA............................................ 3170
Sophrona Solutions NEW! .............................. 3474
Speedway Surgical Co. .................................... 4332
Springer............................................................... 326
SRSsoft ............................................................. 3873
STAAR Surgical Co.H ...................................... 3844
Stephens InstrumentsH......................... 3135, 3335
Stereo Optical Company, Inc.H ....................... 1945
Sterimedix......................................................... 2400
283
Exhibitors
Nadia International, Inc...................................... 447

National Eye Institute....................................... 3072
NCI Vision Systems NEW! .............................. 2475
Neitz Instruments Co., Ltd. ............................... 1935
NeoMedix Corporation....................................226
Neotech Medical Systems ............................... 3202
Network Technology
Development, Ltd. NEW! ........................... 3373
New Vision, Inc. NEW!.................................... 2975
New World Medical, Inc. ................................... 340
Nextech............................................................. 4326
NextGen Healthcare ......................................... 3856
Nicox, Inc. ........................................................3075
Nidek, Inc.H ..................................................... 3836
Noir Laser ShieldsH......................................... 2700
Notal Vision......................................................1171
NovaBay Pharmaceuticals, Inc. NEW! ........... 2573
Nox India Corporation ...................................... 4435
NUMEDIS, Inc. .................................................. 4359
OptiCall, Inc. ..................................................... 1149

Optikon 2000 SPA ............................................. 2957
Optimed NEW! ................................................ 4640
Optimetrics, Inc................................................. 3503
Optivision 2020, Inc. ......................................... 2856
Optos, Inc. .........................................................3850
OPTOTEK d.o.o. ................................................... 562
Optovue, Inc. ....................................................2353
Optronics........................................................... 4622
Oraya Therapeutics, Inc.................................... 4532
ORBIS International .......................................... 1600
Otto Trading, Inc. NEW! .................................. 1070
Exhibitors
Exhibitors
Super Systems / Fast Grind ............................. 2671

Super-I-Care NEW!............................................ 258
SURGI EDGE...................................................... 1132
Surgical Eye Expeditions (SEE) International... 4302
Surgical Specialties CorporationH.................. 3200
SurgiCube International B.V. NEW! ................ 3371
Surgilum NEW!................................................ 2374
Surgistar, Inc. ...................................................... 944
Suzhou Kangjie Medical, Inc............................ 2676
Synemed, Inc. ................................................... 1744
Synergetics, Inc. ............................................... 4408
Systeem Medical
Information Systems NEW! ....................... 4557
Takagi Seiko Co., Ltd. ....................................... 1162

TBI/Tissue Banks International ........................ 1846
TearLab Corp. .................................................... 1471
TearScience ...................................................... 3153
Tech Bar - American Academy of
Ophthalmology ................................................. 780
Technology Pavilion - American Academy
of Ophthalmology ............................................ 165
Tekia, Inc. .......................................................... 3162
TeleVox .............................................................. 3566
The Allergy Matrix NEW!................................ 3263
The Electronic Office - American Academy
of Ophthalmology ............................................ 114
The Eye Group................................................... 1250
The JAMA Network ........................................... 850
The Lebanon Corporation ................................. 4301
Thea .................................................................... 121
Thieme Medical Publishers.............................. 3569
ThromboGenics ...............................................1174
Tianjin Jingming New Technology
Development Co., Ltd. ................................. 2471
Tianjin Suowei Electronic
Technology Co., Ltd........................................ 847
Titan Surgical ...................................................... 645
Tomey Corporation ........................................... 1435
Topcon Medical SystemsH ..........................2334
Tracey Technologies ......................................... 2431
TransMotion Medical ....................................... 4357
Truevision Systems, Inc. ................................... 1168
TruForm Optics, Inc. ............................................ 349
TSPi ................................................................... 4534
TTI Medical ......................................................... 140
Tulip Surgicals USA, Inc. .................................... 127
Tura, Inc............................................................... 849
Tyoptics Company Limited ............................... 3476
UFSK-International OSYS, GmbH .................... 2150

Ultimate Creations, Inc....................................... 557
UMI ................................................................... 4559
UNICOS Co., Ltd. ................................................ 974
United Sight ...................................................... 3366
284
U.S. Agency for International Development

Child Blindness Program (USAID CBP)........ 2972
University of Tennessee Physician Executive
MBA Program .............................................. 4069
US IOL, Inc.H .......................................... 3135, 3335
US Ophthalmic .................................................. 4257
Valon Lasers Oy .................................................. 344

VaritronicsH ..................................................... 1739
VectorVision, Inc. .............................................. 3603
VersaSuite........................................................... 744
Viewlight, LLC ................................................... 4444
Viewpoint International Corp. .......................... 1946
Viscot Medical, LLC ............................................ 247
Visiometrics, S.L. .............................................. 2950
Vision Assessment Corporation ....................... 2571
Vision Associates ............................................. 2703
Vision Quest Surgical, Inc. ............................... 4335
Vision Share...................................................... 4304
Vision Tiffany, Inc.............................................. 3475
Visionary Medical Supplies.............................. 1746
VisionCare Devices, Inc. ................................... 3264
VisionCare Ophthalmic Technologies .............. 3216
VisionixH .......................................................... 2040
VisionScience Software ................................... 2147
Visoptics NEW!................................................ 1978
Visual Clinic NEW! .......................................... 3273
Vitamin Health, Inc. ......................................... 2672
Vmax Vision, Inc. .............................................. 2271
Volk Optical, Inc.H ........................................... 3144
VRmagic, Inc. .................................................... 3157
Yodle ................................................................. 1936
Zabbys ................................................................ 359

ZeissH ...............................................................3808
Ziemer Ophthalmics AG ................................... 2362
ZyDoc MediSapien ............................................. 426
Walcott RX Products ........................................ 2855

Walman Instrument GroupH ........................... 2047
Wasatch Ophthalmic Instruments ................... 2976
WaveTec Vision .................................................. 538
Welch AllynH ................................................... 1230
Wells Fargo Advisors, LLC NEW! ................... 2774
Wenzhou Raymond Photoelectric
Tech. Co., Ltd. NEW!................................... 2874
Wexler Surgical .................................................. 136
William Blair and Company NEW! ................. 2675
Wills Eye Hospital .............................................. 327
Wilson Ophthalmic Corp./Hilco ....................... 2803
WinFame USA, Inc. ............................................ 158
Wolters Kluwer HealthH ................................. 2331
World Glaucoma Association .......................... 3670
World Ophthalmology Congress 2016 ............. 1101
Wuhan Strong Electronics Co., Ltd. ................. 2756
Wuxi KangMing Medical Device Co., Ltd........ 3473
XOMA (US) LLC ..................................................987
PRODUCT INDEX
Acuity Charts and Devices
AIT Industries........................................................ 4153

Amcon ................................................................... 3102
Coburn Technologies, Inc. ...................................... 930
Jaggi Ophthalmic Instrument Co. ........................ 2005
Krebs Instruments ................................................ 1940
Lombart Instrument .............................................. 2744
M&S Technologies, Inc. ....................................... 1947
OPTELEC.................................................................. 151
Optimetrics, Inc..................................................... 3503
Optos, Inc. ............................................................. 3850
Precision Vision, Inc................................................ 147
Reichert Technologies .......................................... 3826
Richmond Products, Inc. ....................................... 2303
VectorVision, Inc. .................................................. 3603
Visionix.................................................................. 2040
VisionScience Software ....................................... 2147
Walman Instrument Group................................... 2047
Duckworth & Kent ................................................ 2900

Fischer Surgical Inc. ............................................... 457
Geuder AG ............................................................ 2900
JEDMED Instrument Company ............................ 3800
Mastel Precision Surgical Instruments, Inc. ........ 1650
MORIA .................................................................. 4126
NeoMedix Corporation........................................... 226
Numedis, Inc. ........................................................ 4359
Ocular Systems, Inc. ............................................... 749
Oertli Instrumente AG .......................................... 3416
Omeros Corporation ............................................. 4350
Ophthalmic Instruments, Inc. ............................... 3048
Optikon 2000 SPA ................................................. 2957
Quantel Medical ................................................... 4414
SurgiCube International B.V. ................................ 3371
Takagi Seiko Co., Ltd. ........................................... 1162
Thea ........................................................................ 121
VisionCare Ophthalmic Technologies .................. 3216
Adhesive/Bandages
Anterior Segment Imaging
Ocular Therapeutix, Inc. ....................................... 2770
Advertising
Angies List.............................................................. 150

Eyemaginations .................................................... 1700
Glacial Multimedia ............................................... 2003
Ophthalmology Job Center ...................................... 67
Patient Education Concepts ................................. 3304
AMD (Age Related Macular Degeneration)
Biosyntrx ............................................................... 3101

Diopsys, Inc........................................................... 4447
Inami & Co., Ltd. ................................................... 3203
Nicox, Inc. ............................................................. 3075
Notal Vision .......................................................... 1171
Oraya Therapeutics, Inc........................................ 4532
Pine Pharmaceuticals ........................................... 3174
PRN-Physician Recommended Nutriceuticals..... 2376
Thea ........................................................................ 121
Anesthesia
Anodyne Surgical ................................................. 2859

Hurricane Medical ................................................ 2921
Anterior Segment ..........................................................
Alcon Laboratories, Inc......................................... 2908
American Society of Cataract &
Refractive Surgery ........................................... 3862
Avedro, Inc. ........................................................... 2175
285
Ellex....................................................................... 2617
Eye Photo Systems, Inc. ......................................... 251
Fundus Photo ........................................................ 3302
Haag-Streit Group ................................................ 3319
HAI Laboratories, Inc. ........................................... 2926
Leica Microsystems.............................................. 2839
S4OPTIK ................................................................ 2013
Synemed, Inc. ....................................................... 1744
Topcon Medical Systems ..................................... 2334
Visionix.................................................................. 2040
Ziemer Ophthalmics AG ....................................... 2362
Architecture/Facility Design
Practice Flow Solutions ........................................ 2001
A-Scan
Accutome, Inc. ...................................................... 3144

Beijing Outsmarting Dacone
Instrument Co., Ltd. ........................................... 967
Ellex....................................................................... 2617
Florida Eye Equipment .......................................... 4362
Optikon 2000 SPA ................................................. 2957
Optimetrics, Inc..................................................... 3503
Quantel Medical ................................................... 4414
Ray Vision International Corporation ................... 3369
Synemed, Inc. ....................................................... 1744
Auto Refractors


Optimetrics, Inc..................................................... 3503
Optivision 2020, Inc. ............................................. 2856
Premier Ophthalmic Services, Inc. ................. 126, 133
S4OPTIK ................................................................ 2013
Shanghai Canton Optics Equipment Co., Ltd....... 2172
Tracey Technologies ............................................. 2431
Visionix.................................................................. 2040
Billing/Coding
American Academy of Ophthalmology .................. 508

ifa united i-tech, Inc.............................................. 2626
iMedicWare, Inc. .................................................... 162
Integrity Digital Solutions .................................... 1675
MDoffice, Inc. ....................................................... 2916
Merge Healthcare ................................................ 3300
Nextech................................................................. 4326
NextGen Healthcare ............................................. 3856
PM Medical Billing Corp. ..................................... 2754
Billing/Consulting Services

PM Medical Billing Corp. ..................................... 2754
Bimanual Surgical Techniques
Diamatrix Ltd. ....................................................... 1047

Medicel AG ........................................................... 2531
Blades
Beaver - Visitec International............................... 2321

Feather Safety Razor Co., Ltd............................... 4303
Khosla Surgical Industries.................................... 2705
OASIS Medical, Inc. ............................................. 4003
Surgical Specialties Corporation ......................... 3200
Blepharitis
Amcon ................................................................... 3102

Bruder Healthcare Company ................................ 3372
OCuSOFT, Inc. ....................................................... 1445
Paragon BioTeck, Inc. ........................................... 4550
Perrigo Specialty Pharmaceuticals ...................... 2403
Rysurg, LLC ........................................................... 2772
Thea ........................................................................ 121
Information accurate for exhibiting companies who populated their digital booth by Aug. 15, 2014.
Review exhibiting companies and their products at www.aao.org/virtualexhibition or visit the Exhibitor Locator Booth 3500.
Product Index
Books and Publications

Association for Research in Vision
and Ophthalmology ......................................... 1244
JCAHPO ................................................................ 1848
Karger Publishers ................................................. 3573
Springer................................................................... 326
The JAMA Network ............................................... 850
Thieme Medical Publishers.................................. 3569
Product Index
B-Scan
Accutome, Inc. ...................................................... 3144

Ellex....................................................................... 2617
Optikon 2000 SPA ................................................. 2957
Optimetrics, Inc..................................................... 3503
Optos, Inc. ............................................................. 3850
Quantel Medical ................................................... 4414
Synemed, Inc. ....................................................... 1744
Cameras and Accessories
Fundus Photo ........................................................ 3302

Synemed, Inc. ....................................................... 1744
Capsular Dye
ARCADOPHTA....................................................... 4405
Capsular Tension Rings
AA Vision, Inc. ........................................................ 156

FCI Ophthalmics ...................................................... 726
Lenstec, Inc. .......................................................... 3362
Madhu Instruments ................................................ 231
OPHTEC ................................................................. 2904
Capsulorhexis
a1 Medical GmbH................................................... 235

ARCADOPHTA....................................................... 4405
BIONIKO ................................................................ 2577
Cilita Ltd ................................................................ 1903
Crestpoint Management ...................................... 2900
Duckworth & Kent ................................................ 2900
Geuder AG ............................................................ 2900
Huaian Frimen Co., Ltd. ........................................ 4621
MORIA .................................................................. 4126
Zabbys .................................................................... 359
Care and Maintenance of Products
International Eye Foundation ............................... 2972
Cataract/IOL
A.R.C. Laser GmbH ............................................... 1165

a1 Medical GmbH................................................... 235
Abbott Medical Optics ......................................... 2308
Avellino Lab USA, Inc. .......................................... 3049
286

Cilita Ltd ................................................................ 1903
Dioptics Medical Products, Inc. ........................... 3053
Duckworth & Kent ................................................ 2900
Fallon Wellness Pharmacy ................................... 2949
Hoya Surgical Optics, Inc. .................................... 2009
Inami & Co., Ltd. ................................................... 3203
LCA Pharmaceutical ............................................. 3262
Lenstec, Inc. .......................................................... 3362
Medennium, Inc.................................................... 2550
Medicel AG ........................................................... 2531
OPHTEC ................................................................. 2904
Optikon 2000 SPA ................................................. 2957
PhysIOL.................................................................... 977
Sensor Medical Technology ................................. 4333
Sightpath Medical ................................................ 4337
STAAR Surgical Co. .............................................. 3844
Thea ........................................................................ 121
Vision Quest Surgical, Inc. ................................... 4335
VisionCare Devices, Inc. ....................................... 3264
Zabbys .................................................................... 359
Chairs/Instrument Stands
AIT Industries........................................................ 4153

Apramed Medical Devices ..................................... 762
Brumaba USA, Inc. ............................................... 2173
Fashion Optical Displays ........................................ 558
Ophthalmic Instrument Company, Inc. ................. 2148
Optimetrics, Inc..................................................... 3503
Optivision 2020, Inc. ............................................. 2856
Visionix.................................................................. 2040
Charitable Organizations

of Ophthalmology .............................................. 508
Lions Clubs International Foundation.................. 3071
Museum of Vision .................................................. 704
Chart Projectors

Optivision 2020, Inc. ............................................. 2856
S4OPTIK ................................................................ 2013

Cleaning/Sterilization Systems
Rhein Medical, Inc................................................ 3021
Coaxial Surgery
Medicel AG ........................................................... 2531

Collagen Shields
Color Tests

Communications/Electronic, Telephone,
Internet
First Insight Corporation ......................................... 149

Optimed ................................................................ 4640
QualSight, Inc. ...................................................... 2373
Compounding

Mobius Therapeutics, LLC...................................... 362
Computer Systems - Clinical
Compulink Business Systems, Inc. ...................... 1450

DavLong Business Solutions ................................ 3166
EyeMD EMR Healthcare Systems, Inc. ............... 1635
iMedicWare, Inc. .................................................... 162
KeyMedical Software, Inc.................................... 4300
MDoffice, Inc. ....................................................... 2916
Medflow, Inc. ........................................................ 4340
Optimed ................................................................ 4640
Computer Systems - Office Management
Clearwave Corporation......................................... 3272

iMedicWare, Inc. .................................................... 162
ManagementPlus ................................................... 144
MDoffice, Inc. ....................................................... 2916
Medflow, Inc. ........................................................ 4340
Nextech................................................................. 4326
Optimed ................................................................ 4640
QualSight, Inc. ...................................................... 2373
Conjunctival/Lids
Amcon ................................................................... 3102
Conjunctivitis/Lids
Lacrimedics, Inc. ................................................... 4267

Thea ........................................................................ 121
Contact Lens Drops
Crocodile Tears, Inc. ............................................. 4269
Contact Lens Related Irritation
Product Index
Contact Lenses (Diagnostic, Laser,
Surgical)
Corporate Awareness
Insight Instruments, Inc. ....................................... 2317

IRIDEX ................................................................... 2621
Ocular Instruments, Inc. ....................................... 3119
Addition Technology, Inc. ..................................... 4500

Avedro, Inc. ........................................................... 2175
Keeler Intruments, Inc. ......................................... 3144

MDoffice, Inc. ....................................................... 2916
Optivision 2020, Inc. ............................................. 2856
Optos, Inc. ............................................................. 3850
Synemed, Inc. ....................................................... 1744
Volk Optical, Inc. ................................................... 3144
Contact Lenses (Hard, Soft, Disposable)
Cryosurgical Systems
Digital Ophthalmoscope Camera
Shire ........................................................................ 768
Cosmetics/Skin Care
OCuSOFT, Inc. ....................................................... 1445

Cross Linking
Continuing Education
Pelion Surgical ...................................................... 3105

BIONIKO ................................................................ 2577
BSM Consulting.................................................... 1068
JCAHPO ................................................................ 1848
MedEdicus ............................................................ 2852
United Sight .......................................................... 3366
Wills Eye Hospital .................................................. 327
World Glaucoma Association .............................. 3670
Custom Packs
Diagnostic Equipment
Avedro, Inc. ........................................................... 2175

Accutome, Inc. ...................................................... 3144

AcuFocus, Inc. ....................................................... 4648
Advanced Tear Diagnostics.................................. 3077
AIT Industries........................................................ 4153
Diopsys, Inc........................................................... 4447
Electronic Office...................................................... 114
Ellex....................................................................... 2617
Icare USA .............................................................. 1971
Inami & Co., Ltd. ................................................... 3203
Metrovision........................................................... 2858
Neotech Medical Systems ................................... 3202
Nicox, Inc. ............................................................. 3075
Oculus, Inc. ............................................................. 820
Optos, Inc. ............................................................. 3850
Quantel Medical ................................................... 4414
SCHWIND eye-tech-solutions ............................. 3138
Stereo Optical Company, Inc. ............................... 1945
Synemed, Inc. ....................................................... 1744
TearLab Corp. ........................................................ 1471
Visionix.................................................................. 2040
Vmax Vision, Inc. .................................................. 2271
Volk Optical, Inc. ................................................... 3144
Zabbys .................................................................... 359
Corneal Topography
Digital Imaging
Cornea/External Disease

Avedro, Inc. ........................................................... 2175
Cilita Ltd ................................................................ 1903
Eagle Vision, Inc. .................................................. 2503
Lacrimedics, Inc. ................................................... 4267
Miracles in Sight .................................................. 2854
Numedis, Inc. ........................................................ 4359
Rysurg, LLC ........................................................... 2772
SightLife .................................................................. 648
Surgistar, Inc. .......................................................... 944
United Sight .......................................................... 3366
Corneal and InterCorneal Rings

Corneal Cross Linking
Optimetrics, Inc..................................................... 3503

S4OPTIK ................................................................ 2013
Visionix.................................................................. 2040
AIT Industries........................................................ 4153

Ellex....................................................................... 2617
Fundus Photo ........................................................ 3302
iMedicWare, Inc. .................................................... 162
Inami & Co., Ltd. ................................................... 3203

Digital Patient Education

Caduceus Media LLC ............................................ 3176
Eyemaginations .................................................... 1700
Optimed ................................................................ 4640
Digital Video Systems

Eyemaginations .................................................... 1700
Optivision 2020, Inc. ............................................. 2856
Volk Optical, Inc. ................................................... 3144
Direct Fundus
Dispensing Aids/Equipment/Furniture
Fashion Optical Displays ........................................ 558
Disposable Surgical Instruments

Lenstec, Inc. .......................................................... 3362
MANI..................................................................... 3100
MORIA .................................................................. 4126
Pelion Surgical ...................................................... 3105
Sterimedix............................................................. 2400
Surgistar, Inc. .......................................................... 944
Volk Optical, Inc. ................................................... 3144
Wexler Surgical ...................................................... 136
Disposables/Drapes, Gloves, Sponges

Eye Care and Cure ................................................ 3869
Pelion Surgical ...................................................... 3105
SURGI EDGE.......................................................... 1132
Dry Eye

AcuFocus, Inc. ....................................................... 4648
287
Product Index

TruForm Optics, Inc. ................................................ 349
Product Index
Product Index
Allergan................................................................. 1408
Altaire Pharmaceuticals, Inc. ................................. 337
Amcon ................................................................... 3102
DermaMed Solutions, LLC ..................................... 347
Eagle Vision, Inc. .................................................. 2503
FCI Ophthalmics ...................................................... 726
Lacrimedics, Inc. ................................................... 4267
Medennium, Inc.................................................... 2550
Nicox, Inc. ............................................................. 3075
OCuSOFT, Inc. ....................................................... 1445
Rysurg, LLC ........................................................... 2772
TearLab Corp. ........................................................ 1471
Thea ........................................................................ 121

DigiSight Technologies, Inc. ................................. 3271
ManagementPlus ................................................... 144
MDoffice, Inc. ....................................................... 2916
Medflow, Inc. ........................................................ 4340
Nextech................................................................. 4326
Penn Medical Informatics Systems ....................... 962
Dry Eye Disease
Enucleation/Evisceration Implants

Allergan................................................................. 1408
Biosyntrx ............................................................... 3101
BTI - Biotechnology Institute................................ 4259
Eagle Vision, Inc. .................................................. 2503
Lacrimedics, Inc. ................................................... 4267
Medennium, Inc.................................................... 2550
Nicox, Inc. ............................................................. 3075
OCuSOFT, Inc. ....................................................... 1445
Rysurg, LLC ........................................................... 2772
TearLab Corp. ........................................................ 1471
Education

Audio-Digest Foundation ..................................... 3270
BIONIKO ................................................................ 2577
BSM Consulting.................................................... 1068
Eyemaginations .................................................... 1700
JCAHPO ................................................................ 1848
MedEdicus ............................................................ 2852
Museum of Vision .................................................. 704
Nadia International, Inc.......................................... 447
Optimed ................................................................ 4640
SLACK Incorporated ............................................... 545
288
Electronic Medical Records
Endothelial Cell Counter
Surgistar, Inc. .......................................................... 944

United Sight .......................................................... 3366
Eye Channel TV

Optimed ................................................................ 4640
Eye Charts
Eye Drops
Allergan................................................................. 1408
Amcon ................................................................... 3102
Lacrimedics, Inc. ................................................... 4267
OCuSOFT, Inc. ....................................................... 1445
Thea ........................................................................ 121
Eye Drops Lubricating and Rewetting
Allergan................................................................. 1408
OCuSOFT, Inc. ....................................................... 1445
Equipment/Supplies
Eye Handbook
FCI Ophthalmics ...................................................... 726
Equipment Financing/Leasing
AIT Industries........................................................ 4153

Avedro, Inc. ........................................................... 2175
Inami & Co., Ltd. ................................................... 3203
MORIA .................................................................. 4126
MTI ........................................................................ 2767
Nox Medical LLC .................................................. 4435
Super Systems / Fast Grind ................................. 2671
Evoked Potential Systems
Diopsys, Inc........................................................... 4447

Metrovision........................................................... 2858
Exam Chairs

Dexta Corporation ................................................ 1844
MTI ........................................................................ 2767
S4OPTIK ................................................................ 2013
Examining Units

S4OPTIK ................................................................ 2013
Eye Bank Products
AL.CHI.MI.A. S.r.l. ................................................. 2701

BIONIKO ................................................................ 2577
Numedis, Inc. ........................................................ 4359
JCAHPO ................................................................ 1848
Eye Models, Charts, Anatomical Model
BIONIKO ................................................................ 2577

Eye Shields

SURGI EDGE.......................................................... 1132
Surgistar, Inc. .......................................................... 944
Eyelid Cleaner
Amcon ................................................................... 3102

OCuSOFT, Inc. ....................................................... 1445
Rysurg, LLC ........................................................... 2772
Eyelid Closure Products
FCI Ophthalmics ...................................................... 726

MedDev Corporation ............................................ 1130
Eyelid Irritations
OCuSOFT, Inc. ....................................................... 1445

Rysurg, LLC ........................................................... 2772
Facility Design/Furnish/Planning

Femto Lasers and Instruments

Product Index
Femtosecond

Fiberoptics
Designs For Vision, Inc. ........................................ 2800
Filing/Recall Systems

Thea ........................................................................ 121
United Sight .......................................................... 3366
Glaucoma Diagnostics
Bank of America Practice Solutions .................... 2002

CareCredit ............................................................. 2350
Merrill Lynch ........................................................... 428
Finance and Investment
Glaucoma Implants
Bank of America Practice Solutions .................... 2002

Merrill Lynch ........................................................... 428
Fixation Devices

Fluorescein and Staining

Amcon ................................................................... 3102
Fundus Photo ........................................................ 3302
Pelion Surgical ...................................................... 3105
Frames, Glasses, Sunglasses

Inami & Co., Ltd. ................................................... 3203
Fundus Camera

Fundus Photo ........................................................ 3302
Optivision 2020, Inc. ............................................. 2856
Synemed, Inc. ....................................................... 1744
Glasses, Operating Room Goggles
Glaucoma
A.R.C. Laser GmbH ............................................... 1165

Allergan................................................................. 1408
Chenyueqi Biotechnology Co., Ltd. ...................... 4356
Cilita Ltd ................................................................ 1903
Glaukos Corporation ............................................. 2568
Icare USA .............................................................. 1971
Inami & Co., Ltd. ................................................... 3203
IRIDEX ................................................................... 2621
Metrovision........................................................... 2858
Quantel Medical ................................................... 4414

Glaucoma Pressure

Icare USA .............................................................. 1971
Handheld Instruments
a1 Medical GmbH................................................... 235

Cilita Ltd ................................................................ 1903
Diamatrix Ltd. ....................................................... 1047
Duckworth & Kent ................................................ 2900
Geuder AG ............................................................ 2900
Icare USA .............................................................. 1971
MANI..................................................................... 3100
MORIA .................................................................. 4126
Sterimedix............................................................. 2400
Health Care Management

BSM Consulting.................................................... 1068
QualSight, Inc. ...................................................... 2373
Image Management Systems (PACS)

Medflow, Inc. ........................................................ 4340
Imaging

Fundus Photo ........................................................ 3302
Imaging Systems

Fundus Photo ........................................................ 3302
MDoffice, Inc. ....................................................... 2916
Optos, Inc. ............................................................. 3850
Synemed, Inc. ....................................................... 1744
Implants, IOL

Medennium, Inc.................................................... 2550
OPHTEC ................................................................. 2904
PhysIOL.................................................................... 977
Implants, Ocular, Enucleation,

Evisceration

FCI Ophthalmics ...................................................... 726
Zabbys .................................................................... 359
Instrument Maintenance/Repair
a1 Medical GmbH................................................... 235

Accutome, Inc. ...................................................... 3144
Pelion Surgical ...................................................... 3105
Instruments, Disposable
AA Vision, Inc. ........................................................ 156

IRIDEX ................................................................... 2621
MANI..................................................................... 3100
Medicel AG ........................................................... 2531
MORIA .................................................................. 4126
OPHTEC ................................................................. 2904
Pelion Surgical ...................................................... 3105
Sterimedix............................................................. 2400
SURGI EDGE.......................................................... 1132
Volk Optical, Inc. ................................................... 3144
Wexler Surgical ...................................................... 136
289
Product Index
Finance and Credit
Diopsys, Inc........................................................... 4447

Fundus Photo ........................................................ 3302
Icare USA .............................................................. 1971
Quantel Medical ................................................... 4414
Visionix.................................................................. 2040
MDoffice, Inc. ....................................................... 2916

Ophthalmic Photographers Society .................... 1503
Synemed, Inc. ....................................................... 1744
Volk Optical, Inc. ................................................... 3144
Product Index
Instruments, Reusable
a1 Medical GmbH................................................... 235

Cilita Ltd ................................................................ 1903
Duckworth & Kent ................................................ 2900
Eye Care and Cure ................................................ 3869
Lenstec, Inc. .......................................................... 3362
SURGI EDGE.......................................................... 1132
Wexler Surgical ...................................................... 136
Product Index
Insurance

Inter-office Communication Systems
MDoffice, Inc. ....................................................... 2916
Intraocular Lenses
AA Vision, Inc. ........................................................ 156

Lenstec, Inc. .......................................................... 3362
OPHTEC ................................................................. 2904
PhysIOL.................................................................... 977
SURGI EDGE.......................................................... 1132
Intravitreal Injections

IOLs

Medennium, Inc.................................................... 2550
OPHTEC ................................................................. 2904
PhysIOL.................................................................... 977
Tekia, Inc. .............................................................. 3162
IOLs 1 Piece

Lenstec, Inc. .......................................................... 3362
Medennium, Inc.................................................... 2550
PhysIOL.................................................................... 977
IOLs Aspheric

Lenstec, Inc. .......................................................... 3362
Medennium, Inc.................................................... 2550
PhysIOL.................................................................... 977
290
IOLs Multifocal
Lenstec, Inc. .......................................................... 3362

PhysIOL.................................................................... 977
IOLs Preloaded

Lenstec, Inc. .......................................................... 3362
PhysIOL.................................................................... 977
IOLs Toric

PhysIOL.................................................................... 977
Iris Expander
Diamatrix Ltd. ....................................................... 1047

Eagle Vision, Inc. .................................................. 2503
Synergetics, Inc. ................................................... 4408
Irrigation/Aspiration
a1 Medical GmbH................................................... 235

Duckworth & Kent ................................................ 2900
Geuder AG ............................................................ 2900
Sterimedix............................................................. 2400
Wexler Surgical ...................................................... 136
Keratometers/Ophthalmometers

Knives Guarded

Diamatrix Ltd. ....................................................... 1047
MANI..................................................................... 3100
Surgistar, Inc. .......................................................... 944
MANI..................................................................... 3100
Pelion Surgical ...................................................... 3105
SURGI EDGE.......................................................... 1132
Surgistar, Inc. .......................................................... 944
Lacrimal Products
AA Vision, Inc. ........................................................ 156

Amcon ................................................................... 3102
Eagle Vision, Inc. .................................................. 2503
Eye Care and Cure ................................................ 3869
FCI Ophthalmics ...................................................... 726
Lacrimedics, Inc. ................................................... 4267
LACRIVERA ........................................................... 1502
Quest Medical, Inc. .............................................. 1232
Surgistar, Inc. .......................................................... 944
Wexler Surgical ...................................................... 136
Laser Accessories
A.R.C. Laser GmbH ............................................... 1165

Synergetics, Inc. ................................................... 4408
Viewpoint International Corp. .............................. 1946
Laser Phaco
A.R.C. Laser GmbH ............................................... 1165

Lasers
A.R.C. Laser GmbH ............................................... 1165

Ellex....................................................................... 2617
Optimetrics, Inc..................................................... 3503
Quantel Medical ................................................... 4414
Valon Lasers Oy ...................................................... 344
Lasers - Demonstrated
Knives Sapphire
Diamatrix Ltd. ....................................................... 1047

SURGI EDGE.......................................................... 1132
IRIDEX ................................................................... 2621

Quantel Medical ................................................... 4414
Valon Lasers Oy ...................................................... 344
Knives, Diamond
Lasers - Display
a1 Medical GmbH................................................... 235

Accutome, Inc. ...................................................... 3144
Diamatrix Ltd. ....................................................... 1047
Duckworth & Kent ................................................ 2900
Pelion Surgical ...................................................... 3105
Wexler Surgical ...................................................... 136
Knives, Disposable
Accutome, Inc. ...................................................... 3144

Diamatrix Ltd. ....................................................... 1047
Lasers Diode
A.R.C. Laser GmbH ............................................... 1165

Valon Lasers Oy ...................................................... 344
Lasers Excimer

Product Index
Lasers Femto

Lens Manufacturing Equipment
AIT Industries........................................................ 4153

Super Systems / Fast Grind ................................. 2671
Lenses (Aspheric, Filter, Progressive)
AA Vision, Inc. ........................................................ 156

Volk Optical, Inc. ................................................... 3144
Lenses Direct Contact

Oculus Surgical, Inc. ............................................... 621
Lenses for Diagnostic Treatment

Quantel Medical ................................................... 4414
Volk Optical, Inc. ................................................... 3144
Lenses Mirrored

Volk Optical, Inc. ................................................... 3144
Lenses Non Contact Slit Lamp

Quantel Medical ................................................... 4414
Volk Optical, Inc. ................................................... 3144
Lenses Pediatric
Lenses Research
Lenses Vitrectomy

SURGI EDGE.......................................................... 1132
Volk Optical, Inc. ................................................... 3144
Lenses Yag Laser

Oculus, Inc. ............................................................. 820
OPTELEC.................................................................. 151
Low Vision Aids/Screening
Beijing Outsmarting Dacone Instrument Co., Ltd. . 967

Eye Care and Cure ................................................ 3869
Metrovision........................................................... 2858
OPTELEC.................................................................. 151
Low Vision Rehabilitation
Diopsys, Inc........................................................... 4447

Zabbys .................................................................... 359
Manual Refraction

Market Research

QualSight, Inc. ...................................................... 2373
Reckner Healthcare ............................................... 777
Marking Pen

SURGI EDGE.......................................................... 1132
Medical Records, Electronic

iMedicWare, Inc. .................................................... 162
ManagementPlus ................................................... 144
MDoffice, Inc. ....................................................... 2916
Medflow, Inc. ........................................................ 4340
Medical Retina
Fundus Photo ........................................................ 3302

Valon Lasers Oy ...................................................... 344
Medical Society, Association


Quantel Medical ................................................... 4414
Microkeratome
Lensmeters
Microscopes
AA Vision, Inc. ........................................................ 156

S4OPTIK ................................................................ 2013
MORIA .................................................................. 4126

Inami & Co., Ltd. ................................................... 3203
Topcon Medical Systems ........................... 2334, 1187
Microscopes Surgical

Microsurgical Equipment/Instruments
AA Vision, Inc. ........................................................ 156

Diamatrix Ltd. ....................................................... 1047
Medicel AG ........................................................... 2531
MORIA .................................................................. 4126
Synergetics, Inc. ................................................... 4408
Neuro-Ophthalmology
Diopsys, Inc........................................................... 4447

Metrovision........................................................... 2858
New Exhibitors
a1 Medical GmbH................................................... 235

Accumold .............................................................. 4564
Amcon ................................................................... 3102
BIONIKO ................................................................ 2577
QualSight, Inc. ...................................................... 2373
Non-FDA

Duckworth & Kent ................................................ 2900
Geuder AG ............................................................ 2900
MANI..................................................................... 3100
Valon Lasers Oy ...................................................... 344
Nutraceuticals
Biosyntrx ............................................................... 3101

Nutritional Supplements
Biosyntrx ............................................................... 3101

OCuSOFT, Inc. ....................................................... 1445
Thea ........................................................................ 121
Occluders
Ocular Allergies

Lacrimedics, Inc. ................................................... 4267
Ocular Implants
OPHTEC ................................................................. 2904

291
Product Index
Lenses Contact
Loupes Binocular
Product Index
Ocular Prosthetics
Online Services
Product Index
Angies List.............................................................. 150

BSM Consulting.................................................... 1068
JCAHPO ................................................................ 1848
Museum of Vision .................................................. 704
Ophthalmic Pathology
Thea ........................................................................ 121
Ophthalmoscopes

VRmagic, Inc. ........................................................ 3157
Optical Biometry
Optical Management

iMedicWare, Inc. .................................................... 162
ManagementPlus ................................................... 144
Orbital Plates/Implants
FCI Ophthalmics ...................................................... 726
Organizations

Museum of Vision .................................................. 704
Outreach to Patients

Eyemaginations .................................................... 1700
Over the Counter Ophthalmic Products

Eye Care and Cure ................................................ 3869

Eyemaginations .................................................... 1700
IRIDEX ................................................................... 2621
ManagementPlus ................................................... 144
Medflow, Inc. ........................................................ 4340
Nadia International, Inc.......................................... 447
Nicox, Inc. ............................................................. 3075
Optimed ................................................................ 4640
Patient Engagement
CareCloud ............................................................. 4556

Eyemaginations .................................................... 1700
ManagementPlus ................................................... 144
Medflow, Inc. ........................................................ 4340
Optimed ................................................................ 4640
QualSight, Inc. ...................................................... 2373
Televox .................................................................. 3566
Patient Flow

Eyemaginations .................................................... 1700
ManagementPlus ................................................... 144
Optimed ................................................................ 4640
QualSight, Inc. ...................................................... 2373
Patient Follow Up

Eyemaginations .................................................... 1700
QualSight, Inc. ...................................................... 2373
Diopsys, Inc........................................................... 4447

Eye Care and Cure ................................................ 3869
Metrovision........................................................... 2858
Synergetics, Inc. ................................................... 4408
Phacoemulsification

Cilita Ltd ................................................................ 1903
Geuder AG ............................................................ 2900
Medicel AG ........................................................... 2531
Pharmaceuticals
Accutome, Inc. ...................................................... 3144

Allergan................................................................. 1408
Biosyntrx ............................................................... 3101
Eye Care and Cure ................................................ 3869
Numedis, Inc. ........................................................ 4359
Pelion Surgical ...................................................... 3105
Xoma (US) LLC ........................................................ 987
Pharmacy

Phoropters Refractors
AIT Industries........................................................ 4153

Optivision 2020, Inc. ............................................. 2856
S4OPTIK ................................................................ 2013
Photocoagulators
A.R.C. Laser GmbH ............................................... 1165

Ellex....................................................................... 2617
Quantel Medical ................................................... 4414
Valon Lasers Oy ...................................................... 344
Photographic Products
Physician Education Materials
Pediatrics
Accutome, Inc. ...................................................... 3144

Diopsys, Inc........................................................... 4447

OPHTEC ................................................................. 2904

IRIDEX ................................................................... 2621
Nicox, Inc. ............................................................. 3075
Optimed ................................................................ 4640
VRmagic, Inc. ........................................................ 3157
Patient Education Materials
Perimeters/Field Testing
Physician Recruitment
Pachymeters

American Society of Cataract
& Refractive Surgery ....................................... 3862
BIONIKO ................................................................ 2577
292

Metrovision........................................................... 2858
Optimetrics, Inc..................................................... 3503

The Eye Group....................................................... 1250
Product Index
Plastics/Reconstructive
Eagle Vision, Inc. .................................................. 2503

FCI Ophthalmics ...................................................... 726
Posterior Segment
Post-op Treatment

Practice Management/Marketing
Services
American Society of Cataract

& Refractive Surgery ....................................... 3862
Angies List.............................................................. 150
CareCloud ............................................................. 4556
ManagementPlus ................................................... 144
Medflow, Inc. ........................................................ 4340
Nextech................................................................. 4326
QualSight, Inc. ...................................................... 2373
Televox .................................................................. 3566
Preowned Equipment

Punctum Plugs
Amcon ................................................................... 3102

Eagle Vision, Inc. .................................................. 2503
Eye Care and Cure ................................................ 3869
FCI Ophthalmics ...................................................... 726
Lacrimedics, Inc. ................................................... 4267
LACRIVERA ........................................................... 1502
Medennium, Inc.................................................... 2550
OCuSOFT, Inc. ....................................................... 1445
Recruitment
Association for Research in

Vision and Ophthalmology .............................. 1244
BSM Consulting.................................................... 1068
JCAHPO ................................................................ 1848
The Eye Group....................................................... 1250
AIT Industries........................................................ 4153

Nox Medical LLC .................................................. 4435
Visionix.................................................................. 2040
Vmax Vision, Inc. .................................................. 2271
Cilita Ltd ................................................................ 1903

Ellex....................................................................... 2617
FCI Ophthalmics ...................................................... 726
IRIDEX ................................................................... 2621
MedOne Surgical, Inc. .......................................... 2751
Optikon 2000 SPA ................................................. 2957
Quantel Medical ................................................... 4414
Synergetics, Inc. ................................................... 4408
Valon Lasers Oy ...................................................... 344
Volk Optical, Inc. ................................................... 3144
VRmagic, Inc. ........................................................ 3157
Refraction Set
Retinal Specialties
AIT Industries........................................................ 4153

S4OPTIK ................................................................ 2013
Visionix.................................................................. 2040
Vmax Vision, Inc. .................................................. 2271
Refraction Equipment

Zabbys .................................................................... 359
Refractive Surgery

Avedro, Inc. ........................................................... 2175
Cilita Ltd ................................................................ 1903
Medennium, Inc.................................................... 2550
Metrovision........................................................... 2858
OPHTEC ................................................................. 2904
PhysIOL.................................................................... 977
QualSight, Inc. ...................................................... 2373
Zabbys .................................................................... 359
Refractive Surgery Systems
Avedro, Inc. ........................................................... 2175

Research and Development Services

BIONIKO ................................................................ 2577
Optikon 2000 SPA ................................................. 2957
Residents
BIONIKO ................................................................ 2577

Retina/Vitreous Surgery
AL.CHI.MI.A. S.r.l. ................................................. 2701

ARCADOPHTA....................................................... 4405
a1 Medical GmbH................................................... 235

AL.CHI.MI.A. S.r.l. ................................................. 2701
Alimera Sciences.................................................. 2834
Allergan................................................................. 1408
ARCADOPHTA....................................................... 4405
Fundus Photo ........................................................ 3302
Geuder AG ............................................................ 2900
Nicox, Inc. ............................................................. 3075
Valon Lasers Oy ...................................................... 344
Scalpels
Severe Vision Disorders
Slit Lamp Instruments

Volk Optical, Inc. ................................................... 3144
Slit Lamps
A.R.C. Laser GmbH ............................................... 1165

AA Vision, Inc. ........................................................ 156
AIT Industries........................................................ 4153
Inami & Co., Ltd. ................................................... 3203
IRIDEX ................................................................... 2621
Optimetrics, Inc..................................................... 3503
Optivision 2020, Inc. ............................................. 2856
293
Product Index

Alimera Sciences.................................................. 2834
Quantel Medical ................................................... 4414
Synergetics, Inc. ................................................... 4408
Valon Lasers Oy ...................................................... 344
Wexler Surgical ...................................................... 136
Refracting Systems
Product Index
Slit Lamps (cont.)

S4OPTIK ................................................................ 2013
Product Index
Small Incision Surgery

SURGI EDGE.......................................................... 1132
Surgistar, Inc. .......................................................... 944
Smartphone

Optivision 2020, Inc. ............................................. 2856
Software

Diopsys, Inc........................................................... 4447
Eyemaginations .................................................... 1700
iMedicWare, Inc. .................................................... 162
JCAHPO ................................................................ 1848
ManagementPlus ................................................... 144
Medflow, Inc. ........................................................ 4340
Nextech................................................................. 4326
Optimed ................................................................ 4640
Specular Microscopes

Optimetrics, Inc..................................................... 3503
Staff/Assistant Training
BSM Consulting.................................................... 1068

JCAHPO ................................................................ 1848
Optimed ................................................................ 4640
Staining Anterior Capsule
AL.CHI.MI.A. S.r.l. ................................................. 2701
Stereo Vision Tests

Sterilizer
Stools

294
Strabismus
Metrovision........................................................... 2858
Surgery Centers

iMedicWare, Inc. .................................................... 162
Surgery Simulator
Optikon 2000 SPA ................................................. 2957

Pelion Surgical ...................................................... 3105
Synergetics, Inc. ................................................... 4408
The Lebanon Corporation ..................................... 4301
Volk Optical, Inc. ................................................... 3144
Wexler Surgical ...................................................... 136
Zabbys .................................................................... 359
BIONIKO ................................................................ 2577

VRmagic, Inc. ........................................................ 3157
Surgical Lights
Surgical Drapes, Gloves
Surgical Loupes
Zabbys .................................................................... 359
Surgical Instruments, Disposable
Accutome, Inc. ...................................................... 3144

Ellex....................................................................... 2617
IRIDEX ................................................................... 2621
MANI..................................................................... 3100
Medicel AG ........................................................... 2531
MORIA .................................................................. 4126
Optikon 2000 SPA ................................................. 2957
Sterimedix............................................................. 2400
Surgistar, Inc. .......................................................... 944
Synergetics, Inc. ................................................... 4408
The Lebanon Corporation ..................................... 4301
Volk Optical, Inc. ................................................... 3144
Wexler Surgical ...................................................... 136
Zabbys .................................................................... 359
Surgical Instruments, Reusable
a1 Medical GmbH................................................... 235

AA Vision, Inc. ........................................................ 156
Accutome, Inc. ...................................................... 3144
Diamatrix Ltd. ....................................................... 1047
Duckworth & Kent ................................................ 2900
Geuder AG ............................................................ 2900
Inami & Co., Ltd. ................................................... 3203
Medicel AG ........................................................... 2531
MORIA .................................................................. 4126
MTI ........................................................................ 2767

Designs For Vision, Inc. ........................................ 2800
Surgical Tables/Stools/Stretchers
Brumaba USA, Inc. ............................................... 2173

MTI ........................................................................ 2767
Nox Medical LLC .................................................. 4435
TransMotion Medical ........................................... 4357
UFSK-International OSYS, GmbH ........................ 2150
Sutures

Diamatrix Ltd. ....................................................... 1047
MANI..................................................................... 3100
Tonometers
A.R.C. Laser GmbH ............................................... 1165

Optivision 2020, Inc. ............................................. 2856
Tissue Grafts/Biologics
Numedis, Inc. ........................................................ 4359

Tomograph
Topical Anesthetic

Toric

Duckworth & Kent ................................................ 2900
Geuder AG ............................................................ 2900
Treatment Planning Solutions
Optimed ................................................................ 4640
Trephines Punches

Surgistar, Inc. .......................................................... 944
Trial Frames/Trial Lens Sets
AA Vision, Inc. ........................................................ 156

Eye Care and Cure ................................................ 3869
Product Index
Oculus, Inc. ............................................................. 820
Ultrasound
Ellex....................................................................... 2617
Optikon 2000 SPA ................................................. 2957
Quantel Medical ................................................... 4414
Synemed, Inc. ....................................................... 1744
Used Equipment
Uveitis/Immunology
Allergan................................................................. 1408
Video Cameras
Video/Digital Systems

Video Production

Optimed ................................................................ 4640
Viscoelastics
Visual Test Equipment
AcuFocus, Inc. ....................................................... 4648

Diopsys, Inc........................................................... 4447
VectorVision, Inc. .................................................. 3603
Vitrectomy
AL.CHI.MI.A. S.r.l. ................................................. 2701

ARCADOPHTA....................................................... 4405
Geuder AG ............................................................ 2900
IRIDEX ................................................................... 2621
Medicel AG ........................................................... 2531
Optikon 2000 SPA ................................................. 2957
Synergetics, Inc. ................................................... 4408
Wavefront Aberrometers

Visionix.................................................................. 2040
Wavefront Analyzer


Lenstec, Inc. .......................................................... 3362
OPHTEC ................................................................. 2904

Optimed ................................................................ 4640
Televox .................................................................. 3566
Vision Screening/Training
Xenon Light
Website Design/Marketing
Metrovision........................................................... 2858
Synergetics, Inc. ................................................... 4408
Vision Testing

The Eye Group....................................................... 1250

Eye Care and Cure ................................................ 3869
Notal Vision .......................................................... 1171
Product Index


VisionScience Software ....................................... 2147
Young Ophthalmologist
Visual Acuity Testing

295
PARTICIPANT INDEX
A
Aaberg Jr, TM 83, 234
Aakalu, V 208
Aaker, GD 184
Aaron, MM 34, 106, 107, 108
Aasuri, MK 89
Abadia, B 185
Abass, A 186
Abbasian, J 210
Abbott, RL xvii, 142
Abboud, E 97
Abdel-Aziz, S 180
Abdelfattah Sr, MA 199
Abdelghany Sr, AA 244
AbdelRahim, AM 195
Abdou, AA 166, 182, 216
Abdul-Kader Ahmed, A 30
Abe, RY 188
Aboulnasr V, TT 192
Abou Shousha, MA 182
Abou Shousha, MF 150
Abraham, A 156
Abrams, GW 120
Abramson, D 202
Abreu, FM 197
Abruzzo, MD 57, 269, 270, 278
Abualghanam, SA 30
Abu-Amero, K 200
Abud, TB 181
Acharya, N 156
Adelman, RA 34, 94, 106, 107,
138, 163
Adhi, M 227
Adhi, MI 228
Adib Moghaddam, S 219
Adili-aghdam, F 219
Afrashi, F 223
Afshari, NA 20, 54, 68, 106, 107
Agarwal, A , 61, 62, 63, 64, 66,
72, 89, 59, 108, 119, 108, 132,
142, 143, 242, 243, 244, 245
Agarwal, MR 33
Agarwal, T 71, 87, 176, 245
Agee, S 237
Aggarwal, S 176
Agrawal, R 74
Agron, E 161
Aguilar, E 232
Ahmad, BU 235
Ahmad, S 192
Ahmed, F 236
Ahmed, IK 61, 63, 76, 106,
113, 243
Ahmed, SB 234
Ahn, CS 107
Ahn, HB 208
Ahuja, N 171
Aiello, L 126, 139
Akar, S 207
Akcay, E 179
Akhundova, L 238
Akiba, M 234
Akkin, C 223, 230
Akman, A 189
Akova, YA 165, 172, 176
Akpek, EK 20, 68, 69, 135, 179
Aksu, N 201
Alagoz, G 200, 201
Alasil, T 227, 228
Al-Ayoubi, A 206
Albe, E 23
Albert, DM 3
Albert, MA 94, 95, 237
Albini, TA 79
Alcorn, DM 20
Aldave, AJ 20, 52, 67, 69, 70, 71,
73, 66, 107, 63, 138, 176, 250
Alexander, JK 167, 176
Alexander, P 198, 246
Alezzandrini, AA 232
Al Fayez, MF 150
Alfayez, SF 150
Alfonso, EC 66, 108
Alford, MA 118
Alhalafi, AM 197
Alhatem, A 222
Al-Hazzaa, S 199, 206
Alhemidan, AI 175
Al-Holou, SN 161
Ali, A 87, 212, 238
Ali, F 224
Ali, FS 188
Ali, IM 30
Ali, MJ 86, 202, 204, 205, 246
Alio, JL 60, 61, 64, 89, 90, 91,
132, 142, 166, 170, 182,
216, 244
Ali, TK 176
Ali, Y 156
Aljadaan, IA 188
Allen, F 232
Allen, JJ 189
Allen, QB , 60
Allen, RC , 85, 86, 118, 84,
118, 208
Almeida, D 234
Al-Mesfer, SA 209
Almobarak, F 188
Al-Mohtaseb, ZN 166
Almony, A 224
Alobeidan, S 188
Alparslan, FN 165, 176
Alpins, NA 158
AlRajhi, AA 172, 178
Al Rashaed, S 248
Al Rashed, WA 206
Al-Rohil, RN 208
Alsamnan, MS 195
Alshaarawy, AM 183
Alshail, EA 199
Alshareef, RA 235
ALSheikh, O 206
Alster, Y 191
Alsuhaibani, AH 195
Altaweel, MM 120, 197
Al-Turkmani, SI 209
Alvarado, JA 113
Alzaga Fernandez, AG 69
Amado, DM 186
Amato, MM 122
Ambati, BK 107
Ambrosio Jr, R 30, 60, 90, 119,
143
Ambrosius, WT 161
Ament, CS 106
Amescua, G 111
Amirikia, A 23
Amparo, F 181
Amselem, L 235
Anand, N 188
Anand, RA 202
Anbari, AA 23
Anderson, RL 84, 118
Ando, Y 228
Andreoli, MT 203
Andreu-Fenoll, M 227
Ang, AY 111
Angelov, AA 170
Angelov, YP 170
Angrist, RC 20
Ang, RT 170, 219
Ansari, H 33, 78
Antoszyk, AN 93
Anwar, HM 110, 176
Apsey, D 174
Aquavella, J 69
Araie, M 194
Arakawa, A 170, 231
Ara, M 185
Arat, YO 206
Arbisser, LB 20, 59, 106
Archer, SM 131
Archer, TJ 219
Aref, AA 153, 210
Arenas, E 252
Arevalo, J 94, 232, 235, 248, 252
Arevalo, JF 34
Arias, L 30, 225, 227
Arici, C 172
Armada-Maresca, F 160, 225
Arnold, AC 121
Arnoldner, MA 180
Aron Rosa, DS 3
Arora, R , 180, 178, 244
Arora, S 192
Arora, T 61, 87
Arora, V 171, 242
Arranz-Marquez, E 218
Arregui, P 107
Arshinoff, SA , 63, 64, 59
Arslan, OS 165, 172, 176
Arthurs, B 115
Arundhati, A 149
Asbell, P 72, 143
Asbell, PA 164
Ashar, JN 67, 71, 87, 204
Asiedu, SO 192
Asimellis, G 214, 215, 219
Asrani, SG 77, 111
Assi, AC 238
Assia, EI 143
Assil, KK 20
Atebara, NH 120
Atiba, A 178
Attas-Fox, L 116
Attia, M 169, 244
Audo, I 96, 233
Auerbach, FN 169
Auffarth, GU 59, 166, 169, 171,
231, 244
Augsburger, J 82
Augustin, AJ 161
Aung, T 20, 75, 113
Avery, RL 128, 153, 226

Awdeh, RM 166
Awh, CC , 96, 132
Ayaki, M 170
Aylward, G 237
Ayres, B , 65, 96, 62, 119, 110,
168
Ayres, MB 237
Ayyala, RS 76, 78
Azad, RV 210, 239
Azad, SV 239
Azar, DT 90
Azizi, B 182
B
Baba, T 229
Bacal, DA 88
Badala, F 110
Badal Lafulla, J 235
Badrinath, SS 195
Baer, AN 179
Baerveldt, G 112
Bagga, B , 66, 244, 174, 244
Baig, K 177, 182
Baikoff, GD 89
Bailey, RS 107
Bailey, ST 227
Baker, CW 93
Baker, MS 208
Baker, N 34, 277, 278, 279
Bakewell, BK 106, 107, 108, 132
Balcer, LJ 129
Balci, S 184
Balkrishnan, R 191
Balne, PK 174
Baltmr, A 197
Bandello, FM , 136, 156, 196
Bande Rodriguez, MM 202
Baneke, A 232
Banerjee, PJ 237
Banerjee, S 244
Bang, GM 200
Banker, AS 34, 93, 94, 156, 211
Banker, T 229
Bansal, M 146
Bansal, R 196, 198
Bansal, S 184
Banta, JT 23, 107
Baptiste, D 225
| Tel: 415-561-8500 Fax: 415-561-8533

296
Participant Index
Berdahl, JP , 52, 64, 62, 112, 119,
112, 147, 166
Berdy, GJ 90
Berger, BB 122
Bergmann, C 224
Berman, EL 114
Bernardini, FP 84, 85, 86, 118
Bernick, DM 23, 53, 268, 271
Bernier-Turmel, F 193
Bernstein, DW 23
Berrocal, A 88, 158, 163, 212
Berrocal, MH , 91, 120, 232
Berry, JL 129
Bersudsky, V 193
Berzin, EF 146
Betancurt, C 176, 181
Betts, CL 175
Bezlyak, V 162
Bhardwaj, SS 247
Bhargava, M 230
Bhatnagar, P 231
Bhattacharjee, S 61, 242
Bhatt, DL 232
Bhavsar, AR 20, 120, 223
Bhisitkul, RB 23, 106
Bhoiwala, DL 231
Bhorade, AM 122
Bhoutekar, P 210
Bhushan, G 198
Bilaniuk, LT 199
Bilgin, G 165
Bilhoto, MA 239
Binder, S 134
Binenbaum, G 158
Biousse, V 81
Bird, AC 3
Birg, A 233
Bisecco, A 199
Bissonnette, S 168
Biswas, J 197
Biswas, K 225
Bitrian, E 88
Blachley, T 151, 178
Black, BC 52
Black, EH 205
Bladen, J 201
Blanco-Garavito, R 236
Blanton, CL 90
Blanton, J 267
Blazquez-Arauzo, F 153
Blecher, MH 20, 60, 107
Blinder, KJ 227
Blodi, BA 139
Blomquist, PH 107, 108
Bloomer, MM 106
Blumenkranz, MS 136, 137, 172
Blum-Hareuveni, T 196
Bodaghi, B 79, 87
Boddu, S 222
Bodker, FS 115
Boehlke, CS 60
Boghossian, A 119
Boland, MV 73
Bolivar de Miguel, G 168, 186
Bolz, HJ 209, 224
Bonanomi, MB 203
Bonanomi, RC 203
Boniuk, M 206
Boore, R 280
Bordewick, DL 108
Borges, T 198
Borodic, G 115
Boscia, F 106
Bosley, TM 200
Bostrom, JP 107
Bothun, ED 125
Bouchard, CS 107
Bou Ghannam, AS 184, 235
Boulos, PR 116
Bovone, C 183
Bowden, B 116
Bowden III, FW 107
Bower, TN 173
Boxrud, C 114, 115, 117
Boyce, MR 210
Boyer, DS 53, 62, 132, 160, 161,
222, 238
Bozhok, E 187
Brackup, AB 23
Bradfield, Y 87
Bradford, C 250
Bradford, CA xv, xvii, 18
Bradley, EA 129, 208
Braga-Mele, R 106, 132, 139
Braich, PS 181
Branchevskaya, E 220
Brandt, JD , 88, 127
Brantley Jr, MA 95
Brar, VS 93, 181
Bratu, A 247
Braunstein, RA 120
Breda, J 209
Breda, JR 209, 213
Brelen, M 226
Brennan, MW 131
Bressler, NM 129, 128, 139, 93, 231
Bressler, SB 55, 93, 139, 231
Brethauer, SA 232
Brewer, EM 228
Briceland, DJ xvii, 18, 250
Briceno, CA 85, 86
Brigell, M 95
Brinton, JP 119, 168
Brint, SF 148
Brion, M 153
Brockette, JT 269
Brodie, S 202
Brodsky, MC 114, 200
Brooks Jr, JG 18
Brooks, LR 269
Brown, D 97, 162, 226
Brown, DM 20
Browning, DJ 95, 120
Brown, J 137
Brown, MD 57, 269, 270, 278
Brown, R 56
Brown, RH 122
Brown, SE 199
Brown, SL 251
Bruce, BB 56
Brucker, AJ 120
Bruker, AJ 128
Bryan III, JA 106
Buchanan, AG 84
Buckingham, DC 115, 116, 133
Buckley, EG 89
Budenz, DL 10, 77, 112, 130
Buehren, J 23, 204
Bulsara, M 170
Bunce, C 210
Bunya, VY 68, 76
Burgoyne, CF 142
Burkat, C 56, 86, 115, 116
Busbee, BG 120
Busin, M 66, 67, 71, 110, 111, 183
Butler, MR 158, 245
Buznego, C , 106
Byrd, SR 275
C
Cabot, FA 166
Cabrera, MJ 89, 125
Cabrera, MT 255
Cabugueira, A 186, 189
Cagatay Sr, HH 165
Cagil, N 179
Caglayan, M 179
Cagman, S 201
Cahill, KV 87, 141
Caimi, A 235
Cakmak, HB 179
Caldwell, MC 23, 174, 217
Calienno, R 173
Callahan Parker, B 34
Calvo, P 185
Calzada, JI 163
Camesasca, FI 59, 90, 219
Caminal, JM 202
Campochiaro, PA 131, 233
Campolattaro, BN 213
Campos, EC 23
Campos, F 200
Campos, MS 166
Campos, NP 201
Canastro, M 200
Canelas, JP 200
Canner, JK 184
Cano, RH 136
Cantero, MA 91
Cantor, LB xv, xvii, 18
Capar, O 172, 194
Capo, H 33, 164, 211, 252
Capone Jr, A 93, 95, 97
Caprioli, J 141, 142
Caputo, R 180
Carbonara, C 60
Cardoso, A 201
Cardoso, J 201
Cardoso, MS 216, 220
Carifi, G 224
Carle, CF 200
Carle, MV 222
Carlson, AN 107
Carneiro, AM 213, 236
Carpentier Giglio, C 232
Carracedo, A 153
Carrai, P 197
Carr, DB 97
Carruth, BP 157, 208
Carter, K 23, 272
Carter, KD 54, 73, 85, 118, 208
Carter, SR 20, 34, 101, 116
Carvalho, RMLS 30
Carvounis, P 23, 97, 234
Casco Silva, B 160
Casella, AM 235
Cassell, MA 109
Castellarin, AA 226
Castillo, A 34, 57, 53, 267
Castro, AJ 197
Castro-Velilla, J 30
Catala, J 202
Cavalcanti, BM 174, 180
Cavanagh, H 151
Cavuoto, KM 211, 212
Caywood, R 224
Cebeci, Z 196
Celik, N 231
Cennamo, M 175
erman, E 184
Cestari, DM 138
Chaikitmongkol, V 231
Chakrabarti, A , 63, 65, 108, 61, 108,
239, 242, 239, 248
Chakrabarti, M , 65, 63, 239, 242,
239, 248
Chakravarthy, U 23, 162
Chalam, KV 184, 190, 212, 235, 236
Chalhoub, JM 184
Challa, P 52
Chambers, A 269
Chambers, W 250
Chamblee, DR 250
Chamney, S 210
Chamon, W 119
Chan, AS 208
Chan, C 226
Chan, CC , 52, 111, 111
Chan, CK 120
Chandra, A 237
Chandran Jr, M 222
Chandra, P 210, 239
Chandra, SR 120
Chandwani, H 224
Chang, DC 23
Chang, DF , 60, 61, 62, 63, 64, 65,
59, 129, 132, 143
Chang, DH 64, 107
Chang, RT 172
Chang, S 117, 136
Chang, T 130, 189
Chang, TC 164
Chang, TS 20
Chang, WJ 171
Chan-Kai, BT 250
Chan, RP 56, 73, 88, 92, 93, 158
Chan, T 23, 60
Chariwala, RA 204
Charles, M 79
Charles, S 139
Chasan, J 224
Chaudhary, V 171
Chaudhry, I 206
Chauhan, BK 211
Chaurasia, S 23, 169, 180
Chawla, H 146
Chaya, CJ 108
Chayet, AS 91, 220
Chee, CL 163
Cheema, AS 184
Chen, C 228
Chen, E 233
Chen, ES 109, 269
Cheng, C 185, 204
Cheng, CP 223
Cheng, H 221
Chen, GW 236
Chen, JC 81, 225
Chen, K 237
Chen, L 187
Chen, M 206
Chen, PP 130
Chen, S 106, 120
Chen, W 85
Cherfan, G 238
Chernock, ML 156
Cherwek, H 23
Cheung, J 223
Chevez-Barrios, P 126
Chew, EY 53, 120, 126, 161, 230
297
Participant Index
Baqai, JA 107
Bar, A 197, 233
Baradaran-Rafii, A 175, 177
Baratz, K 251
Barberger-Gateau, P 190
Barisic, F 185
Baris, M 230
Barkmeier, AJ 97
Barnebey, H 111, 112, 113
Barnes, SD 119
Barney, NP 67
Barra, C 30
Barragan, E 220
Barraquer Compte, RI 68
Barros Jr, SR 201
Barry, P 129
Bartley, GB xv, xvii, 208
Barton, K 112
Bartusis, L 190
Bartz-Schmidt, K 163
Basak, S 177
Basak, SK 67, 108, 177, 243, 244
Baser, EF 191, 236
Baskin, DE 229
Basti, S 60, 90, 107, 108, 165,
242, 243
Basu, S 150, 151, 244
Bateman, JB 88
Batlle, IR 252
Batlle, JF 132, 216
Batra, J 202
Batra, NN 221
Batta, S 198, 239
Baudouin, C 144
Baumal, CR 91, 163, 227, 228, 234
Baumane, K 191
Baurain, J 203
Baydoun, L 67, 177, 182
Bayer, A 189
Baynes, KM 155, 197
Bayraktar, S 186, 201
Beare, N 195
Beato, JN 209, 236
Beatty, JA 189
Beaudette, PT 23
Beaver, HA 107
Beck, AD 88, 154
Becka, M 34
Becker, B 3
Becker, BB 116
Becker, E 209
Bedi, R 232
Bedrood, S 188
Bedrossian, EH 115
Bedrossian Jr, EH 20
Beer, P 167, 231
Beer, SM 166
Beheiri, SI 169
Behera, UC 234
Behlau, I 135
Behrens, A 252
Beiko, G 33, 64, 107, 143, 154
Belfort Jr, R 79, 94
Bellocq, D 234
Belloli, V 156
Beltz, JE 67, 198
Benator, R 23
Benjamin, JE 23
Benson, CE 213
Bentivegna, R 150, 245
Ben Yahia, S 221
Beranova-Giorgianni, S 222
Participant Index
Participant Index
Chew, PK 75
Chhablani, JK 93
Chiambaretta, F 206
Chiang, A 221
Chiang, MF , 88, 73, 127, 158, 184
Chia, S 202
Chin, E 234
Chiu, CS 106
Chmiel EdD, HM 160, 162
Chodosh, J 69, 111
Choi, S 175
Choi, W 227
Chomsky, A 146
Chomsky, AS 23
Chong, K 86, 117, 246
Chontos, NT 30
Choo, C 86
Choplin, NT 111
Chopra, V 94, 185, 188, 250
Cho, RI 117
Chotiner, B 107
Chotiner, EA 107
Choudhry, N 60, 225
Choung, H 205
Cho, W 206
Chow, DR 134
Christiansen, RM 97
Christiansen, SP 141
Christmann, LM 131
Chung, C 223
Chung, M 33
Chung, S 56
Chu, R 280
Chu, T 222
Chu, Y 108
Ciancas, E 219
Ciardella, AP 210
Cidad, P 225
Cifers, EH 269
Cigales, M 218
Cioffi, GA 114, 136
Cionni, RJ , 61, 132, 139, 129
Ciralsky, JB 33, 60, 65, 66, 69, 119
Cisneros, AL 68
Clarke, JC 203
Clark, WL 156, 163, 232
Claros, J 252
Claros, JA 252
Clavel Laria, J 169
Clemons, TE 161
Clifford, WS 107
Cobos, E 202, 227
Coburn, A 107
Cockerham, K 85, 116, 137
Codere, F 20, 116
Coffee, RE 234
Coffman, T 107
Cohen, AW 84
Cohen, EJ 126
Cohen, JA 34, 101, 106, 120
Cohen, JS 78
Cohen, SM 226
Cohen, SY 224
Colby, KA 33, 68, 69, 87, 149
Cole, A 224
Coleman, A 112, 141, 165
Coleman, AL xvii
Cole, SC 147, 165
Collins, ME 87
Collins, MJ 119
Colombo, FL 252
Colon, CM 176
Colpa, LA 131
298
Colvard, M 65
Comoli, AM 156
Condon, GP 76, 106
Congdon, NG 124, 135
Conlon, R 177, 182
Connolly, D , 270
Convento, E 222
Copeland, RA 141
Corcoran, KJ , 270, 73, 271
Corcoran, KP 70
Corcostegui, BF 136
Cordoba Umana, J 252
Corona, J 116
Coroneo, MT 59
Correa, ZM 82, 252
Corredera, E 187
Cortina, MS 111, 168, 204
Costagliola, C 227
Costarides, AP 75
Costa, V 152, 188
Costa, VP 20
Costello, FE 81, 114, 130
Cottle, E 266
Cottle, ED 271, 272
Couceiro Neto, AB 200
Couch, SM 55, 84
Couch, TD 34
Council, MD 150
Couturier, A 238
Couvillion, SS 226
Cozzi, M 227
Crabtree, G 202
Crandall, AS 11, 60, 61, 65, 132, 59,
113, 106, 169, 242
Craven, E 111, 112
Crema, A 127
Croft, MA 167
Cropsey, JM , 144, 250
Cruess, AF 122
Cruzat, AC 69, 174, 180
Cruz, EM 219
Culbertson, WW 60
Cummings, AB 54, 110, 214
Cunefare Jr, D 237
Cunha-Vaz, JG 80, 222
Cunningham Jr, ET 79, 136
Cuozzo, G 30
Curd, SD 34, 275
Curran, D 269
Cursiefen, C 143, 151
Custer, PL 134, 205
Cymerman, RM 221, 231
Czyz, CN 23, 116
D
Daigrepont, J 274, 275
Dalma, J 93
Daly, MK 146
Damato, BE 82, 83
DAmico, DJ 250
Dana, R 181, 182
Dangelo, A 240
Daniels, AB 236
Danis, RP 161
Dantas, PC 252
Danti Sr, G 180
Dapena, I 67
Dartigues, J 190
Dart, JKG 23
Darvish-Zargar, M 111
Das, C 203
Das, D 173
Das, S 70, 79, 167
Das, T 234
Dave, TV 204
Davey, CC 124
Davidorf, J 108
Davidson, RS 90, 107, 111
Davis, EA 119
Davis, J 80, 87, 92
Davis, JL 33, 34
Davis, K 176
Davis, L 270
Davis, MD 161
Davison, JA 146
Davis, Q 224
Dawson, DG 23, 59
Dawson, L 158
Dayani, PN 222
Daya, SM 71, 91, 110, 179
Daza, MT 202
Deacon, BS 158
de Alba-Campomanes, AG 209
DeAngelis, MM 221
Deantonio, L 156
DeBacker, CM 85, 115, 118
Debrueys, G 267
de Conciliis, C 84, 85, 118
DeCroos, FC 233, 235
Dedania, VS 231
de Faber, JH 128, 129
de Faber, JHN 34
de Freitas, D 68, 107, 126, 143
De Gennaro, AL , 277, 278, 275
Deitz, LW 118
de Juan Jr, E 137, 191
de la Cruz Napoli, JJ 111, 168
de la Garza, AG 118
Del Barrio Lopez De Ipina, Z 160,
225
Delcourt, C 190
Della Rocca, RC 115
Dell, SJ 59, 108
Del Monte, DW 60
DeLoss, K 151
De Luise, VP 54
Delyfer, M 190
DeMasi, S 180
Dementiev, D 61, 89
Deming, S 280
Demirci, H 53, 82, 83, 85, 86, 237
Demirok, A 207
De Moraes, G 52
Denisova, EV 155
Denis, P 234
De Potter, PV 203
de Queiroz Barbosa, D 188, 189
Deramo, VA 228
Desai, U 235
DeSouza, P 237
DeStafeno, JJ 106, 119
Devgan, U 254
Devin, F 238
Devoto, MH 84, 85, 86, 118
Devould, C 213
Dewey, SH 106, 107
Dhaliwal, DK 107, 110, 126, 127,
140, 173
Dharmadhikari, SD 223
Dhindsa, HS 52, 97
Dhingra, N 30
Dholakia, CV 204
Dhoot, DS 226
Dias, D 198
Diaz Llopis, M 232

Diaz, R 163
Diaz-Valle, D 30
Dick, B 59, 60, 144
Dihowm, F 165
Ding, B 160
Ding, J 128, 210
DiNicola, M 156
DiPillo, M 106
Dirani, A 238
Dirisamer, M 67, 182, 183
Dithmar, S 231
Djalilian, AR 106, 107, 111, 175
Dmitriew, A 199
Do, A 186
Doan, AP 65, 131, 141, 250, 251
Doane, JF 172
Doan, J 251
Dodd, MU 199
Dodds, DW 240
Dodds, EM 80
Doga, AV 220
Dogra, MR 24, 198, 232
Dohlman, CH 3, 69
Dohlman, T 180, 182
Dolman, PJ 87
Dolmetsch, AM 86, 116
Dolz Marco, R 227
Donahue, SP 55
Donaldson, K 166
Donaldson, KE 158
Donnenfeld, ED , 66, 90, 59, 132,
139, 147, 169
Donnithorne, KJ 198
Donshik, PC 114
Dopp, DB 276
Dorairaj, S 77, 113
Dorey, MW 192
Doron, R 204
Dougherty, PJ 119
Doughman, DJ 107
Douglas, R 86, 87, 117
Douglas, RS 128
Downs, JC 135
Drack, AV 20, 33, 88
Drake, P 218, 219
Drenser, KA 95, 97, 158
Dresner, SC 116
Driebe, WT 114
Droste, PJ 88
Drouilhet, JH 120
DuBois, LG 209
Dudley, DF 24
Duemmel, J 280
Duerksen, KM 115, 116, 118
Dugel, PU , 134, 91, 162
Duker, JS , 134, 136, 227, 228, 234
Dulczewska-Cichecka, K 228
Duncan, JL 96
Dundar, SO 191
Dunkel, I 202
Dunn Jr, J 80
Dunn, SP 68
Dupps, WJ 90, 91
Durcan, F 114
Durr, GM 191
Durrie, DS 90, 119, 143
Durukan, AH 228, 229
Dushina, G 187
Dustin, L 188
Dutton, JJ 84, 87
Dworak, DP 206
Dyrda, A 202
E
Eagle, R 83, 91, 93, 141
Earley, CD 180
Eaton, AM 153, 172
Eckert, JS 270
Edelhauser, HF 131
Edelstein, JP 115, 116
Edelstein, SL 150
Edmond, JC xv, 18
Edward, D 93
Eggenberger, E 114
Ehlers, JP 24, 120, 155, 163, 226,
236
Ehlers, WH 114
Eid, TM 192
Eino, DM 171
Ekblom, NH 273
Elahi, E 207
El Annan, JF 234
Elbahrawy, M 182, 216
El-Bradey, M 191
El-Dairi, MA 130
ElDanasoury, A xv
Eldanasoury, AM 20, 89, 159, 176
Elgin, J 97
Elgohary, MA 237, 238
Eliott, D 96
Ellabban, AA 228
Elman, MJ 139
Elmann, S 128
Elmer, TR 167
Elner Ph D , VM 85, 86, 87
Elner, SG 197
El Rayes, EN 79
El Sayed Ibrahim, YM 193
El Shafei, MS 30
Elsheikh, A 186
Emerick, G 24
Endl, MJ 167
Engle, EC 200
Enyedi, LB , 89, 87, 125
Epley, K 65, 73, 278
Epstein, RJ 108, 110
Epstein, RS 221, 233
Eraslan, M 184
Erdem, U 24
Erdurman, C 228
Erlanger, M 168
Eshbaugh, CG 119
Eslani, M 175
Esmaeli, B 52, 83, 84, 134
Espinoza, G 84
Essex, RW 200
Essuman, VA 192
Estopinal, HA 254
Estribi, MI 30
Everett, SL 173
Eversgerd, N 34
Evlicoglu Sr, GE 191
Eydelman, M 126, 127, 250
Eydelman, MB 127
F
Fadlallah Yahya, A 238
Fagadau, WR 68
Falardeau, J 114
Falcao, M 236
Falcao-Reis, FM 209, 213, 236
Falkner-Radler, CI 134
Participant Index
Fleming, CP 130
Fleming, JC 134
Fletcher, DC 125
Flores-Moreno, I 202, 227
Flores, RM 189
Flowers, BE 113
Flynn, HW 62, 92, 120
Flynn, W 147, 167
Foerster, P 183
Fogagnolo, P 185
Fogla, R 72, 110
Fogliato, G 196
Folgar, FA 96
Folk, JC 138, 234
Fonseca, AP 200
Fontana, L 24, 110
Fontenot, JL 53, 125
Fontes, BM 24
Ford, JR 147
Forlini, C 247, 248
Forlini, M 247, 248
Forster, SH 131
Forstot, S 68
Fortuna, VG 232
Fortun, JA , 97
Foster, C 54, 66, 79
Foster, GJ 33, 54
Foster, J 85, 116, 118, 141
Foster, RE 222
Fountain, TR xvii, 131, 251, 278
Fouraker, B 90, 271
Fournie, PR 24
Fowler, AM 115, 117
Fram, NR 33, 59, 61, 65, 148
Francis, AW 224
Francis, BA 92, 112, 153, 188, 190
Francis, CE 82
Francis, JH 202
Franco Cardenas, V 252
Frankfort, BJ 74
Franklin, DR 129
Fransen, S 224
Fraunfelder, RW 74
Freedman, SF 55, 88, 154
Freeman, JF 107
Freeman, MI 114
Freitag, SK , 116
Frenkel, RP 223
Freund, K 55, 92, 234
Freund, KB 128
Freund, PR 233
Frezzotti, P 185
Friberg, TR 122
Frick, K 135
Fridl, DC , 274
Friedlander, M 232
Friedman, DS 20, 54, 135, 142
Friedman, SM 93, 97
Fritz, PB 24
Fritz, T 34
Frohman, LP 114, 130
Frucht-Pery, J 24
Fry, E 251
Fry, L , 107
Fu, AD 120
Fujimoto, J 227, 228
Fukuoka, H 208
Fukushima, M 168
Fung, AE 160
Fung, T 212
Furlong, RC , 106
G
Gabela, GF 252
Gabela, MC 202
Gabel, V 163
Gaffar, MA 88
Gage, MF 127
Gagne, S 76
Gajdosova, E 211
Gajiwala, UR 204
Galeev, T 170
Galetta, SL 81
Galicia Del Castillo, JM 189
Gallagher, RS 275, 276
Gallego-Pinazo, R 30, 227, 232
Gallie, BL 83, 91
Gallo, A 199
Galloway, M 146
Galor, A , 149, 107, 182, 181
Gamell, LS 113
Gandhi, NG 125
Gandhi, PD 55, 117
Gandolfi, SA 154
Ganesh, S 197
Gangadhar, D 110
Gangwani, R 223
Gangwe, AB 210
Gans, RE 232
Gao, H 235
Garabedian, JS , 273, 274, 272
Garcia-Aguirre, G 157
Garcia-Delpech, S 24, 68
Garcia-Feijoo, J 154, 155
Garcia-Gonzalez, M 218, 219
Garcia-Marcos, MM 252
Garcia Martinez, J 160
Garcia-Perez, JL 168
Garcia Ramirez, Sm 197
Garg, P 66, 67, 69, 124, 174
Garg, S 52, 106, 107
Garg, SJ 96, 221, 233
Garg, T 180, 244
Garhofer, G 187
Garrido Linares, J 219
Garrigus, B 34
Garway-Heath, DF 186
Gass, JDM 3
Gaster, RN 119, 120
Gatinel, D 20, 53, 90, 159, 217
Gauba, V 114, 115
Gaucher, D 238
Gaudric, A 136, 224, 238
Gausas, R 137
Gayton, JL 171
Gearinger, MD 109, 124
Gedde, S 78, 112, 130, 142
Gedde, SJ 33
Geerling, G 143
Geist, C 115
Gekeler, F 163
Geller, L 55
Genc, S 165
George, AE 197
Georges, A 236
Gerling, IC 222
Ghadban, R 200
Ghoneim, AM 166, 178
Ghosh, A 179
Ghosh, B 198, 226, 239
Giaconi, JA 112
Gibbons, AG 176, 181
Gicheru, SK 250
Gilbert, R 198
Gill, HS 116, 117
Gilligan, R 131
Gilwit, P 120
Ginsburg, PB xv
Giorgianni, F 222
Giuliari, GP 30
Gladstone, GJ 205
Glasser, DB 59, 70, 107, 111
Glavas, IP 24, 115
Glikin, RG 107
Glisson, CC 114
Gobbe, M 219
Gobin, Y 202
Godfrey, DG 158, 245
Goel, N 198, 239
Goel, RD 34, 133, 250
Goel, S 114
Goh, A 117
Goins, KM 106, 109, 150, 183
Golan, S 117
Goldberg, I 75, 191
Goldberg, JL 132
Goldberg, RA 117, 118
Goldenberg, D 120
Goldich, Y 183
Goldman, DA 24, 34, 65, 60, 119
Goldstein, DA 79, 80, 87, 92, 135
Goldstein, M 269
Goldstein, MH 114
Goldstein, SM 24, 85, 116, 118, 134
Golnik, KC 80, 124
Golshani, C 192
Gombos, DS 20, 82
Gomes, BD 214
Gomes, J 110, 111
Gomes, T 186, 189
Gomez Goyeneche, F 252
Gomez-Torreiro, M 202
Gomi, F 94
Gong, D 153
Gonzalez, MO 114
Gonzalez, VH 233, 252
Goodman, DF 34
Goodman, N 156
Good, WV 88
Gopal, L 182
Gordon, B 204
Gordon, G 153
Gordon, LK 18, 20, 81, 131
Gorovoy, MS 109
Goshe, JM 109
Gothwal, VK 211
Goto, H 156, 231
Gottlieb, JL 120
Gouws, P 194
Gower, EW 161, 195
Gow, JA 214
Goyal, H 256
Goyal, JL 178, 180, 244
Goyal, NA 107
Goyal, RK 107, 119
Grabner, G 111, 155, 170
Grace, CC 110
Grace, L 209
Grace, S 211
Gracitelli, CP 153
Graham, SL 191
Grajewski, A 88, 189
Grajewski, AS 255
Grand, M 230
Grant, J 269
Grant, MP 74, 129, 130

Grasso, CM 236
Gratton, SM 201
Graue, E 173
Graue Hernandez, EO 91, 173, 214,
244, 252
Graue-Wiechers, FA 136, 252
Gray, AV 276
Greenberg, PB 195
Greenfield, DS 153, 190
Gregory, DG 24, 33, 66, 111, 143
Greider, K 193
Greiner, J 175
Greiner, M 109, 150, 183
Greven, CM 161
Grewal, DS , 242, 165, 243
Grewal, SP 165, 242
Grewal, SPS 30
Griepentrog, GJ 116
Griffith, JF 236
Grim, R 280
Grippo, TM 252
Grisanti, S 155
Groos, EB 52
Grosinger, L 108
Gros-Otero, J 168, 219
Grosskreutz, CL 77
Grossniklaus, HE 121, 126, 143
Gross, RL 74, 78
Groth, SL 189, 193
Grover, AK 86
Grover, DS 113, 158, 188, 245
Grover, S 93, 96, 184, 190, 212, 236
Grupenmacher, L 24
Grzybowski, A 64, 80, 90, 138, 203
Gualdi, L 89
Gualino, V 238
Guda, DM 179
Guell, JL 91
Guha, S 210
Guidolin, F 222
Guilbert, E 159
Guimaraes, AB 152
Gungor, SG 189
Gupta, A 227
Gupta, AA 175
Gupta, AK 196, 198, 232
Gupta Jr, A 202, 204
Gupta, OP 24, 96, 168
Gupta, PK 60, 65, 119
Gupta, S 85
Gupta, SC 169
Gupta, SK 184, 190, 235
Gupta, V 232
Gurelik, G 229
Gurland, JE 33
Gutierrez, C 186
Gutierrez-Carmona, FJ 108
Guven, S 228
Guvenyilmaz III, S 191
H
Habib, RH 184
Habot-Wilner, Z 196
Hafezi, F 179
Hageman, GS 24
Hagemann, LF 30
Hahn, P 60, 96, 237
Haight, DH 119, 120
Haji, SA 212
299
Participant Index
Falk, NS 231
Fan, F 165
Fan, X 130
Farah, M 96, 232
Farhang, K 155
Farjo, AA 24
Farsiu, S 230, 237
Fawzi, A 24, 57, 79, 92
Fazil, K 207
Fea, A 154
Febbraro, J 119, 168
Fechter, HP 52, 76
Fechtner, RD 114
Feder, RS 68, 107
Feilmeier, MR 108, 144
Feist, RM 94, 95, 237
Feitl, ME 112
Feizi, S 172
Fekrat, S 20, 34, 96
Feldman, BH 106, 124, 144
Feldman, KA 117
Feldman, ST 110
Feldon, SE 87
Felix, ER 181
Fellman, R 78, 112, 158, 188, 245
Fenech, TF 34
Fennell, J 34
Fernandes, M 246
Fernandes, S 34
Fernandez-Baca, GA 219
Fernandez Buenaga, R 244
Fernandez, C 169
Fernandez Escamez, CS 167, 187
Fernandez, I 153
Fernandez Sr, H 167, 187
Ferrara, D 228
Ferrara, P 68
Ferreira, CS 209, 213, 236
Ferreras, A 185
Ferris, FL 127
Ferrone, PJ 95
Feuer, WJ 158, 166, 181, 224
Feygin, T 199
Fichte, CM 167
Fielder, AR 24
Fierson, WM 88
Figueira, JP 233
Figueiredo, LM 239
Figueroa, M 134
Figus, M 185
Filipe, HP 124
Filipovic-Ricci, B 183
Filippopoulos, T 193
Filloy, A 202
Fine, HF 53, 225
Fine, LC 24
Fineman, MS 221
Finger, P 213
Fingert, J 135
Fink, W 230
Finley, TA 95
Fiol-Silva, Z 114
Fischer, RM 199
Fisher, M 199
Fishkind, WJ 33, 106, 132, 142
Fitting, A 169, 244
Fittipaldi, M 209
Flach, AJ 78
Flaherty, K 133
Flaherty, KT 24
Flaherty, SM 278
Flaxel, CJ 34, 227
Participant Index
Participant Index
Halfpenny, CP 33
Haller, JA 96
Haller, T 131
Halliday, WC 238
Hamada, S 110
Hamam, MS 184
Hamam, RN 184, 235
Hambrick Dunn, H 34
Hamel, C 224
Hamill, M 90
Hamilton, DR 119, 167
Ham, L 149
Hammel, KR 127
Hammer, HM 202
Hammond Jr, BR 166
Hamrah, P 111, 174, 176, 180, 182
Handler, SM 88
Han, DP 268
Hangai, M 77
Han, J 157, 200
Hannush, SB , 61, 66, 69, 70, 72, 59
Han, S 200, 213
Haq III, AU 199
Harasymowycz, PJ 24, 191, 193
Harbin, TS 250
Harbour, J 82
Hardten, DR , 72, 89, 90, 63, 119,
107, 125, 147, 169
Hareuveni, G 196
Hariharan, L 212
Haring, S 184
Hariprasad, SM 92, 221
Harocopos, G 150
Harper III, CA 163
Harper, RA 125
Harris, A 190
Harris, KM 237
Harrison, DA 24, 137
Hartnett, M 221
Harton Jr, PJ 119
Hartstein, ME 84, 86, 115, 116
Harvey, JT 116
Harvey, TM 119
Hasani, H 172, 173, 177, 207
Hashemian, H 176, 219
Hassan, AS 25, 116, 118
Hassanpoor, N 219
Hassan, TS 96
Hata, M 228
Hatch, KM 60, 110
Hater, M 107
Hatsukawa, Y 229
Hattori, T 208
Hawlina, M 25
Hays, JC 108
Hays, R 127
Heatley, G 167
Hegde, RS 206
Heier, JS , 126, 128, 57, 234
He, L 172
Helal, J 30
He, M 25, 189
Hemo, I 247
Henaine-Berra, A 157
Hendershot, AJ 80
Henderson, B 54, 65, 80, 106, 108,
125, 128, 132, 139
Henein, C 178
Hengerer, FH 165
Henriquez, MA 171
Henson, RD 86
Heringer, DM 118
Herlihy, EP 125
300
Hernandez-Artola, F 169
Hernandez-Bogantes, E 179
Hernandez Camarena, J 244
Hernandez Martinez, PD 227
Herndon JR, LW 54
Herretes, SP 176, 181
Herrinton, L 171
Hersh, PS 110
Hervas, A 68
Herz, NL 250
Hess, DJ 212
Heuer, DK 78, 131
Hickson, GB 137
Hieda, O 212, 218
Higashide, T 187
Higginbotham, EJ 75, 78
Hildebrandt, L 155
Hill, C , 267
Hillman, D 153
Hill, WE 65, 90, 106, 107, 108, 132
Himmel, KS 144
Hinkle, DM 80
Hintz, C 217
Hirata, A 194
Hirooka, K 194
Hirst, LW 72
Hjelmstad, D 165
Ho, AC , 96, 96
Hoar, KL 110
Ho, C 75
Hodapp, EA 189
Hofbauer, JD 62
Hoffer, KJ 65, 148
Hoffmann, EM 207
Hoffman, RS , 106, 108, 62, 106,
132, 139, 143
Hofmeister, EM 127
Hogan, R 126
Hoguet, A 189
Holbrook, J 197
Holck, DE 116, 118
Holds, JB 116
Holekamp, NM 224
Holladay, JT , 64, 65, 90, 60, 119,
119, 132, 148
Holland, EJ , 111, 72, 110, 132, 139,
143, 175
Holland, SP 110, 151, 159, 213, 217
Holloway, E 275
Holmes, JM 88
Holzer, MP 20, 30, 169, 244
Homer, P 97, 125
Hommer, AB 187
Honavar, SG , 83, 91, 72, 157, 237,
246, 201, 246
Hong, J 205
Hong, SH 116
Hooten, CG 226
Horowitz, JD 158
Horton, JC 130
Horton, MB 92, 250
Ho, T 186, 239
Hou, JH 111, 168, 204
Houri, M 30
Hovanesian, JA 119, 171, 172, 175
Howard, M 184
Howcroft, MJ 59
Howell, DW 53, 270
Hoyos-Chacon, J 218
Hoyos, JE 218
Hsu, J 96, 221, 233
Huang, AW 107, 111
Huang, D 153, 190, 227
Huang, G 155, 188

Huang, J 158
Huang, JJ 52
Huang, L 238
Huang, LY 155
Huang, S 179
Huang, SS 250
Hubbard, G 88, 126, 226
Huerva, V 30
Huh, ES 210
Humayun, MS 132
Hunter, DG 89, 211
Hurakadli Sr, PM 210
Hurtado Cena, FJ 168
Husain, A 115
Huscher, D 196
Hutchinson, AK 89
Hwang, C 117
Hwang, CJ 25
Hwang, CS 226
Hwang, DG 66
Hwang, J 213
Hwang, T 227
Hwessa, NMG 30
Hypes, SM 188
I
Ianchuleva, P 187
Ianchulev, T 65, 154, 187, 192
Iannaccone, A 221, 222, 233
Ibrahim, A 30
Ibrahim, OI 57, 215
Iester, M 185
Iezzi, R 25
Iida, T 25, 221, 230
Ikeda, Y 152
Ikuno, Y 234
Ilim, O 223
Imai, K 152
Imbrogno, VM 184
Inatomi, T 69, 183
Ingraham, HJ 107, 224
Inoue, M 170, 231
Inoue, Y 67
Insausti Garcia, A 235
Ioannidis, J 175
Iovieno, A 110
Ip, MS , 91, 120
Iradier, MT , 68, 245
Isaacs, DK 117, 118
Isenberg, S 141
Ishii, S 189
Itagaki, K 221
Itoh, Y 226
Ito, M 197
Ito, Y 226
Ittiara, S 221
Ivekovic, R 185
Iwach, AG 142, 187
Iwase, A 194
Izatt, JA 237
Izgi, B 186
Izquierdo Jr, L 91, 171, 252
J
Jaafar, MS 20
Jabbarvand Behrooz, M 176, 219
Jabs, DA 54, 197
Jackson, KL 280
Jackson, M 124, 125, 138, 171, 175
Jackson, TL 163
Jackson, W 177
Jacob, S 25, 66, 89, 108, 64, 244,
108, 245
Jacobs, DS 66, 68, 69, 126, 127
Jadav, P 227
Jaffe, GJ 96, 162
Jain, A 236, 239
Jain, P 178, 180, 226, 244
Jain, PP 244
Jain, S 90, 153, 168
Jain, V 71, 87
Jais, A 172
Jalali, S 169
Jalli, G 246
Jamali, A 174
James, AC 200
Jampol, LM , 96, 92, 93
Jang, S 157
Janot, AC 196
Januleviciene, I 190
Jaoude, ESA xxiii
Jara, PO 30
Jaroudi, MO 151, 175, 180, 181,
196, 197, 235
Jassim, SH 30, 204
Javadi, MA 25
Javate, RM 86
Jazayeri, F 198, 246
Jean-Charles, AP 224
Jelliti, B 221
Jeng, BH 33, 69, 70, 135, 136, 180
Jensen, A 137
Jensen, C 137
Jeong, H 208
Jeoung, J 152, 154, 185, 190, 194
Jester, JV 25
Jhanji, V 30, 66, 70, 71, 113, 214,
218, 245
Jia, Y 227
Jick, SL 25
Jimenez, A 173
Jimenez-Carmona, S 153
Johari, P 229
John, S 195
Johns, G 271
Johnson, AJ 107
Johnson, AP 33
Johnson, CA 194
Johnson, DA 25
Johnson, MW , 55, 96
Johnson, SH 33, 164
Johnson, T 86
John, SR 25
Johnstone, MA 76
Johnston, RH 120
John, T 109
Jonas, JB 75, 161
Jonas, K 158
Jones, DM 208
Jones, JJ 107
Jones, JK 107
Jones, LS 141
Joo, C 25, 175
Joondeph, BC 195
Joseph, DP 92
Joseph, JM 114
Jo, SH 191
Joshi, L 197, 198, 233
Joussen, AM 80
Juan, L 153
Juberias, R 153
Jung, K 186
Jung, Y 186
Jurkunas, U 69
Juszkat, R 199
Jyun-Wei, L 179
K
Kabtimer, WT 225
Kadonosono, K 170, 231
Kahana, A 86
Kahook, MY 33, 56, 74, 77, 113,
131, 142
Kaiser, PK 128, 163, 222, 226
Kaiser, RS 221, 235
Kai-shun Leung, C 255
Kakade, NA 223
Kaliki, S 25, 202, 204, 205, 246
Kamal, S 196, 202
Kamenetzky, S 266
Kamenetzky, SA 271
Kammerdiener, L 148
Kampik, A 61, 183
Kamyar, RM 173
Kanadani, T 223
Kanellopoulos, AJ 66, 89, 110, 214,
215, 219
Kang-Mieler, JJ 132
Kang, PC 119
Kanjani, NK 108
Kanjani, NN 108
Kano, M 221
Kapetansky, FM 112
Karabas, LV 171
Karabatsas, CH 214
Karabulut, GO 207
Kara-Jose, A 107
Karasawa, M 167
Karasawa, Y 197
Kardon, RH 81
Karimov, M 238
Karim, S 210
Karp, CL 72, 83, 107, 135, 182
Kasimov, E 238
Kastl, PR 114
Katargina, L 155
Kataria, P 198
Katoch, S 207
Katowitz, JA 141
Katowitz, WR 25, 141
Katsev, D 107
Katsev, DA 122
Katz, A 167
Katz, JA 107
Kaufer, RA 107
Kaufman, PL 167
Kaufman, SC 56
Kauh, CY 116
Kaur, P 211
Kaur, S 191
Kaushik, S 191
Kawaji, T 168
Kay, CN 96
Kaymak, H 239
Kaynak Hekimhan, P 207
Kazim, M 87, 117
Kazlas, MA 211
Kearney, JR 113
Kebudi, R 201
Keenan, JD 70
Keightley, SJ 124
Participant Index
Kitchens, JW 225
Kitzmann, AS 150, 183
Klaehn, LD 200
Klaproth, OK 204
Kliman, GH 136
Kline, LB 52, 82
Koay, PY 175
Koban, Y 165
Kobayashi, A 182
Kocak, M 163
Kocaturk, T 191
Koch, DD , 90, 132, 119, 139
Koch, PS 280
Kociecki, J 199
Kocur, I 124, 134
Kodama, T 229
Kodjikian, L 234
Koffler, B 68, 114
Koh, AH 94
Koh, HJ 200
Kohl, JC 147
Kohl, S 233
Kohn, D 247
Kohnen, T , 90, 143, 80, 165, 204,
220
Koh, V 204
Koizumi, H 221, 230
Koizumi, N 208
Kokame, GT 21, 94
Kolic, M 200
Kolker, RJ 83
Kolomeyer, A 212
Ko, MW 52
Kontari, I 215
Kopsinis , G 193
Korbaa Kahloun, R 221
Koreishi, AF 107
Korn, BS 33, 84, 116, 118
Kornmann, HL 130
Korobelnik, J 190
Korroch, DE 70
Kortuem, KU 183
Kosatka, M 192
Kosmorsky, GS 82
Kossler, AN 209
Kosti, G 193
Kotlus, BS 117, 118
Kouri, S 138
Kovach, JL 95
Kovacs, I 166
Koval, RC 25, 269
Kowalski, RP 180
Kozak, I 25, 181
Kramer, B 147
Krnitz, K 166
Kraus, CL 158
Kraus, MF 228
Krebs, DB 25, 107
Krengli, M 156
Kretz, FT 166, 171, 244
Kreutzer, TC 183
Krishnan, C 75
Krishna, R 109
Kristan, RW 25, 115
Krohne, TU 232
Kronbauer, AL 30
Kropiewnicki, ME 55, 250, 268,
271, 278
Krueger, RR 89, 90, 91, 124, 125,
142, 216
Kruger, SJ 209
Kruse, F 69
Kruse, FE , 111, 144
Krzeszowski, B 34
Kuhn, FP 74, 92, 93, 130
Kuifang, D 161
Kuiper, JJ 208
Kuk, AK 207
Kuloyhungan, V 233
Kumar, D 229
Kumar Sr, A 232
Kumar, V 187
Kumata, JM 184
Kung, JS 217, 218
Kunimatsu, S 194
Kupersmith, MJ 130, 139
Kuppermann, BD 128, 161
Kurian, M 171, 242
Kuriyan, AE 133
Kurji, K 192
Kuroda, Y 230, 231
Kurup, S 70
Kusa, B 60, 64
Kusaka, S 229
Kushner, BJ 89
Kuznetsov, S 170
Kwok, AKH 25
Kwon, YH 114
Kylstra, JA 148
Kymionis, GD 34
L
LaBreck, J 138
Laganovska, G 191
Lahners, WJ 169
Lai, C 237
Laigaie, B , 273, 271
Laigaie, D 280
Lai, MM 229
Lains, IC 233
Lai, TY 94, 226
Lakhanpal, RR 184
Lakshmipathy, M 182
Lally, DR 234
Lambert, SR 33, 129, 55, 154, 209
Lam, BL 133, 96, 130, 95, 201
Lam, F 67, 149, 182
Lammi, MR 196
Lam, W 225, 238
Landau, RJ , 53, 250, 268, 278
Landers, MB 21
Landsman-Blumberg, P 187
Lane, SS , 64, 132, 139, 129, 175
Lang, GE 25
Langsaeter, LA 194
Lang, SS 149, 208
Langston, DP 174
Lanza, M 175, 179, 199
Lanzini, M 173
Larranaga-Fragoso, P 160
Larrosa, JM 154
Larywon, KR 272
Lasave, AF 197, 232
Lascaratos, G 186
Latina, MA 113
Latkany, PA 52
Lauer, A 124, 227, 250
Lauer, AK 128
Laurita, WE 269
Lavaque, A 235, 252
Law, JC 250
Lawrence, LM 21, 124, 134, 144
Lawrence, MG 146
Law, SK 112
Layer Pruzan, N 185

Leavitt, JA 33, 133, 81, 114
Leccisotti, A 110
Lee, AG 80, 81, 82, 89, 136
Lee, BS 74
Lee, BW 186
Lee, D 75
Lee, E 152
Lee, HH 114
Lee, J 34, 73, 109, 116, 247
Lee, JK 65
Lee, KA 131
Lee, LB 117
Lee, MS 33, 82, 131, 139
Leenheer, RS 118
Leen, M 112
Leen, MM 33
Lee, PP 142
Lee, S 152
Lee, T 88, 92, 93, 158
Lee, TC 21
Lee, W 94, 107, 206
Lee, WB 34, 101, 62, 110, 111, 107,
106, 143, 144, 250
Lee, WW 56, 85, 115
Leffler, CT 181
Legault, GL 177, 217
Le Goff, M 190
Lehmann, M 238
Lehpamer, BP 234
Lehrer, RA 76, 113
Leiby, B 235
Leiderman, YI 62, 203
Leiter, C 59
Lelli, GJ 66, 117
Lemij, HG 154
Lemos, V 186, 189
Lenchik, NI 222
Lesser, RL 199
Lessner, CM 90
Lessner, EB 117
Letko, E 119
Leung, CK 113
Levasseur, SD 151
Levian II, L 204
Levin, AV 74, 212
Levine, E 25, 34, 271, 275, 276
Levin, MH 199
Levison, AL 155, 226
Levitt, RC 181
Lev, M 204
Levy, Y 204
Lew, H 26
Lewis, JS 171
Lewis, RA 139
Liang, I 225
Liang, L 181
Liang, SS 75
Liao, DS 222
Liao, Y 130
Liao, YJ 133
Liarakos, VS 67
Li, D 86
Liebmann, JM 114, 142
Liegner, J 59, 146
Liesegang, TJ , 80
Lightman, SL 196, 197, 198, 233
Li Jr, Y 189
Li, JY 26, 107, 110, 111
Li, K 223, 248
Li, M 216
Lim, J 95, 224, 237
Lim, MC 73, 142
Lim, TH 248
Lin, AL 228
Lin, D 55, 159, 213, 217
Lindstrom, RL 59, 60, 64, 119, 132,
137, 142
Lin, J 153
Lin, JL 117
Link, W 136
Lin, L 181
Lin, SC 21, 77, 185, 188, 189
Lin, X 151
Lippa, LS 26, 133
Lipson, L 227
Lisch, W 143
Liss, RP , 107, 113
Little, BC 63
Liu, D 85
Liu, E 165
Liu, EM 230
Liu, GT 130, 139, 141, 199
Liu, JL 153
Liu, L 146, 167
Liu, T 153
Liu, Z 239
Li, X 161
Lloyd III, W 250
Loden, JC 26, 119, 144
Loen, SM 34, 274
Loewen, NA 112, 153
Loewenstein, A 120, 196
Loh, GK 201
Loh, JM 62
Lohr, J 268, 275
Lombardo, AJ 119
Lo, MW 118
London, NJ 162, 235, 238, 250
Looi, A 208
Lord, RK 109
Lorente, R 59
Lorenzo Parra, D 225
Lotery, AJ 80, 235
Louis, TA 197
Lowder, C 80, 94, 155, 197
Lowinger, AE 75
Lowry, E 209
Lubeck, DM 60
Lubniewski, AJ 107, 111
Lucarelli, MJ 87, 116
Lu, CD 227
Luchs, J 60, 110
Luco, CF 252
Lueder, GT 21
Lujan, BJ 91
Lujan, SM 232
Luk, FO 226
Lum, F 165
Lu, N 160, 247
Lundstrom, MH 146
Luo, L 201
Luo, Y 165
Lu, Y 165
Lynch, JT 240
Lynch, MG 21
Lynn, MJ 154
Lyon, DB 116
Participant Index
Kekunnaya, R 30, 88, 89, 246

Kelly, MP 77, 92
Kelman, CD 3
Kemp, EG 202
Kempen, JH 197
Kempley, S 210
Kempton, JE 136
Kenia, HV 178
Kennedy, P 141
Kent, TL 205
Kenyon, KR 164
Kerimoglu, H 220
Kerrison, JB 33
Kerr, N 88, 213
Kerr, NC 33
Kersten, RC 84, 85, 118
Kertes, PJ 238
Kezuka, T 156
Khairallah, M 221
Khaja, WA 212
Khalifa, MA 63, 91, 215
Khalifa, YM 64
Khanani, AM 222
Khan, AO 200, 209, 224
Khan, BU 106, 120
Khandelwal, RR 74
Khan, HN 119, 168
Khan, NJ 192
Kheirkhah, A 25, 111, 176, 180, 182
Khera, A 191
Kherani, A 225
Kherani, F 85, 141
Khodabakhsh, AJ 62
Khodaparast, M 176, 219
Khoramnia, R 166, 169, 171, 244
Khouri, AS 155, 212
Khurana, R 250
Khwaja, A 156
Khwarg, S 205
Kieval, JZ 62, 119
Kikkawa, D 84, 85, 87, 116, 129
Kikkawa, DO 33
Kilic, A 119, 218
Kilic, G 229
Kim, D 152, 154, 185, 190, 246
Kim, E 243
Kim, H 152
Kim, J 208
Kim, JE 53, 95
Kim, JW 33, 117, 129
Kim, JY 106, 107, 108, 111
Kim, M 199
Kim, N 205
Kim, RY 197
Kim, S 194
Kim, SJ 25
Kim, SK 66, 67, 69
Kim, SS 191
Kim, T , 72, 65, 108, 139, 132,
152, 177
Kim, Y 85, 86, 152, 190, 205, 208,
213
Kindrachuk, D 199
Kinoshita, S 69, 183, 208, 212,
218, 238
Kinyoun, JL 120
Kirch, DG 141
Kir, N 196
Kirsch, DG 203
Kirwan, JP 232
Kirzhner, M 117
Kiss, S 25, 92, 224
Kitazawa, Y 159
M
Maa, AY 224
Maalouf, FC 235
MacCumber, MW xv, 250
MacDonald, IM 233
301
Participant Index
Participant Index
MacDonald, SM 107, 142
Machemer, R 3
Mackensen, F 155
Mackool Jr , RJ 132
Mackool, R 127
Mackool, RJ 21
MacLaren, RE 163
MacLeod, ER 198
MacRae, SM 63, 119, 132
Macsai-Kaplan, M 70, 107, 140
Maddess, T 200
Maeda, M 112
Mafi, M 194
Magalhaes, A 209, 213
Magrath, GN 148
Mah, FS 21, 67, 68, 69
Mahmoud, TH 55, 96, 195, 234
Mahoney, NR 130
Mahrous, AS 174
Maia, M 232
Ma, JJ 148
Majmudar, PA 63, 72, 90, 110,
119, 175
Makanjuola, TC 186
Mak, MY 171
Malet, FE 190
Malhotra, R 117, 206
Malik, Z 108
Maller, A 268, 269
Maller, BS 267
Mallipatna, AC 91
Maltzman, JS 106
Malyavantham, K 173
Malyugin, B , 61, 107, 132, 138, 143
Mamalis, N 59, 60, 65, 107, 108,
132, 142, 147, 165, 242
Mammen, A 173
Ma-Naim, T 204
Manche, EE 21, 90, 214, 217, 218
Mancini, R 26, 117, 206
Mandal, AK 78, 211
Mandava, A 236
Manjandavida, FP 256
Mann, AS 181
Manners, R 198
Mannis, MJ 70, 110, 111, 143
Mannor, GE 118
Mann, SS 232
Mansberger, SL 21, 33, 113, 142
Manson, PN 130
Mansour, AM 235
Mansouri, K , 77
Mansour, S 120
Mantagos, JS 211
Mantravadi, AV 112
Manudhane, AA 178, 244
Marcet, MM 116, 117, 207
Marcus, DM 225
Mares, FJ 114
Margaron, P 162, 231
Mariano, MS 216, 220
Marinho, AAP 21
Marino, I 227
Marion, K 185
Marks, SJ 224
Marmor, MF 83, 95, 127, 137
Marques Sr, NS 201
Marr, BP 82, 202
Marshall, J 61
Marsiglia, M 222
Martin, DF , 57, 163
302
Martinez-Castellanos, MA 88, 157,

158, 163
Martinez de La Casa, J 153
Martinez-de-Tejada, B 179
Martinez Toldos, J 169
Martin, FJ xv
Martin, J 53, 115, 118
Martyn, N 73
Maruko, I 195, 221, 230
Marx, JL 127, 251
Mascarenhas, JM 70
Mashayekhi, A 21
Masini, L 156
Masket, S , 59, 61, 54, 62, 63, 65,
59, 106, 142, 132, 148
Mason, JO 94, 95, 237
Massare, JS 114
Massaro, BM 116
Massaro-Giordano, M 68, 72, 76
Massin, P 238
Massin, PG 238
Mastropasqua, L 90, 173
Matalia, HP 173, 179
Mateo, C 94
Materin, MA 82, 83, 252
Matet, AJ 233
Mather, R 126
Mathews, P 179
Mathias, RG 151
Mathur, A 67, 71, 204
Mathur, R 230
Mathys, KC 111
Matos, R 216, 220
Matsumoto, C 194
Mattoon, G 275
Mattox, C 13, 33, 75, 75
Maturi, RK 26, 93
Maul, EJ 112
Mawn, LA 18, 55, 130, 134
Mayko, Z 149, 178, 183
Mayle, MD 26
Mayorga, EP 80, 109, 124
May, W 169
Mazzo, J 26
Mazzotta, C 179
Mbekeani, JN 199, 206
McAnany, JJ 153
McCabe, C 107
McCannel, CA 34
McCannel, TA 83
McCarus, CL 131
McClellan, AJ 128, 234
McClellan, AL 181
McClelland, CM 82
McClellan, T 26
McClendon, T 237
McColgin, A 109
McCoy, AN 85
McCracken, MS 115
McCulley, JP 71
McCulley, TJ 130
McDonald, J 167
McDonald, MB 72, 89, 125
McDonnell, J 251
McGetrick, JJ 116
McKee, YF 66
McLeod, SD 138, 140
Mc Loone, EM 210
McNett, C 271
McPhee, TJ 26
Meddeb-Ouertani, A 26
Medeiros, FA 153
Mediero Clemente, S 160, 225
Medsinge, A 211, 212

Mehta, JS 69, 70, 71, 119, 149
Mehyar, MY 30
Meireles, AS 198
Meldrum-Aaberg, ML 116
Melendez, RF xvii, 34, 133, 141, 250
Melendez,RF 254
Meleth, AD 97
Melicher Larson, JS 33, 34, 85, 86,
117, 118
Melles, GR 67, 149, 150, 177,
182, 183
Mencucci, R 179, 180
Meneres, P 198
Menke, AM 74, 88
Menon, G 222
Mentes, J 223, 230
Merayo-Lloves, J 181
Merle, HR 224
Merrill, PT 156
Merritt, JH 116, 129
Mertens, EL 159
Messenger, W 155
Mettu, PS 203
Meunier, IA 224
Meyer, CH 96
Meyer, DR 84, 115, 208
Meyer III, CH 239
Mian, SI 33, 69, 106, 111, 133,
151, 178
Michaelides, M 96
Michalewska, Z 228, 247, 248
Michalewski, J 248
Michelson, MA 107
Michels, S 134
Midena, E 222
Mieler, WF , 64, 92, 93, 94, 96, 59,
131, 132, 203
Mikhail, F 187
Mikkilineni, S 195
Millan Valbuena, E 225
Miller, AM 131
Miller-Ballard, M 272
Miller, CA 106
Miller, DM 26, 222, 225
Miller, EG 76, 77, 141
Miller, JW 126
Miller, KM 33, 34, 52, 62, 63, 65, 83,
59, 106, 107, 108, 142
Miller-Meeks, M 133
Miller, NR 81
Mills, DB 251
Mills, RP xvii, 9, 112
Minckler, DS 112
Minezaki, T 231
Minning, CA 167
Minstioulis, G 177
Miranda, A 26
Miranda, AF 201
Miranda, V 198
Mirza, E 220
Miserocchi, E 156, 196
Mishra, DK 202
Mitchell, J 26
Mitchell, SB 125
Mitra, S 26, 67
Mittal, R 167
Mittal, V 246
Mittelstaedt, BR 174
Mittra, RA 92
Miyake, M 230, 231
Mizoguchi, T 192, 194
Mobilia, TA 272
Modi, RR 234
Modorati, G 156, 196
Moghimi, S 188, 189, 194
Mogk, LG 97
Mohamed, A 169, 180
Mohamed, S 226
Mohammad Rabie, H 168
Mohand Said, S 233
Mohan, S 62, 243
Mohanta, A 177
Mohney, BG 200
Mollineaux, C 224
Mondino, BJ 133
Monnereau, C 149
Monsalve, B 185
Monteiro de Carvalho, KM 152
Monteiro-Grillo, ME 200
Monteiro, MR 214
Monteiro, SG 216
MontesdeOca, IM 158, 188
Montes, JR 84, 86, 115, 118
Montes, RM 34
Montoya, M 70
Moon, CS 182
Moorthy, RS 21, 235
Morales-Canton, V 79
Morel, C 238
Moreno, JA 30
Morescalchi Sr, F 227
Morgan, PV 117
Morgan-Warren, PJ 178
Mori, K 152
Morin, BR 238
Morlet, N 170
Moroi, SE 69
Morrison, DG 26
Morrison, JC 114
Morse, CL xv, 73, 137, 138
Morton III, A 85, 115, 116, 118
Morton III, AD 21
Morton, SJ 202
Mosaed, S 111, 112, 187
Moscato, EE 116, 117
Moshfeghi, AA 34
Moshfeghi, DM 128
Mosqueda, PM 247
Mossallam, EF 215
Moss, AM 175
Moster, ML 76, 81
Moster, MR , 76, 75
Motley, WW 88
Motukupally, SR 174
Moult, EM 227
Movahedan, A 175
Mrochen, M 110
Mrukwa-Kominek, E 165, 217
Mruthyunjaya, P 82, 83, 92, 96,
136, 203
Muccioli, C 79
Mudumbai, R 77
Mudumba, S 156
Mukkamala, S 235
Mulay, K 201
Muller, RT 174
Muni, RH 238
Munnerlyn, C 26
Murakami, A 167, 170
Murakami, Y 188
Mura, M 91
Muraoka, Y 228
Murata, N 182
Murillo, JC 176, 181
Murphy, P 199
Murthy, RC 158
Murthy, SI 26, 67, 178, 204
Muruzabal, F 181
Muskalski, K 30
Myers, JS 21, 112
Myers, WG 59
Myung, D 172
N
Nabati, C 222, 231
Nabity, J 250
Nagappa, S 242
Nagaraja, H 173
Nagendran, S 213
Nagpal, M , 94, 93, 247
Nagy, Z 64, 166
Nahako, N 225
Nah, GK 204
Nahum, Y 183
Naik, MN 202, 204, 205, 244, 246
Nair, AG , 202, 204, 205, 197, 246
Na, K 175
Nakagawa, H 183
Nakai, Y 212
Nakanishi, H 228, 230, 231
Nakano, E 166
Nakano, M 152
Nakashizuka, H 59
Nakazawa, T 194
Nakra, T 117, 118
Nalcaci, S 223, 230
Nam, D 237
Nanavaty, MA 110, 178
Nanji, AA 182
Naor, J 156
Naoumidi, T 61
Nascimento, H 79
Naseri, A 106
Nasir, MA 226
Natarajan, S 79, 91, 93
Nau, AC 173, 180
Navarro-Navarro, A 169
Navas, A 91, 173, 214, 244
Nawrocka, Z 247, 248
Nawrocki, J 26, 106, 228, 247, 248
Nayak, NV 173, 212
Nazari Khanamiri, H 225
Ndanu, TA 192
Nduka, C 206
Neelakantan, A 26, 78, 111
Neff, KD 70, 107, 111
Negishi, K 170
Negron, C 212
Nehemy, MB 223
Neigel, JM 118
Nelson, CC 85, 86
Nema, A 205
Nemeth, J 163
Nemi, A 269
Nerad, JA xvii, 118, 85, 118, 208
Nesi, FA 205
Nesi, FD 205
Nesmith, BW 227
Netland, P 77, 78, 130
Netland, PA 255
Netukova, M 147
Nevyas, HJ 107
Nevyas-Wallace, A 107
New, D 222
Newman, JT 254
Participant Index
O
Ober, MD 234
OBrien, JM 126
OBrien, TP 67
Ocampo, H 197
Oetting, TA xv, 21, 61, 63, 65, 80, 94,
106, 59, 107, 106, 132, 133, 143
Ofori-Adjei, ID 192
Ogino, N 192
Oh, B 243
Ohkubo, S 187
Ohno-Matsui, K 210, 225, 230
Oishi, A 230, 231
Ojima, A 195
Okada, AA 221, 230
OKeeffe, M 26
Okka, M 220
Oliver, AL 70
Oliver, SC 34, 140
Olivier, MMG xv
Olivo Payne, A 173
Olsen, TW 126, 132, 138
Olson, JL 168
Olson, MJ 228
Olson, RJ 60, 63, 65, 107, 132
Oltulu, R 220
Ong, C 185
Ong, JK 158
Ong, P 230
Ong-Tone, L 107
Ono, H 194
Ono, T 190
Ooto, S 228, 230, 231
Opremcak, E 79
Oray, M 196
Orengo-Nania, SD 78
Orive, G 181
Orlicka-Mosiej, A 217
Orlin, A 60
Orlin, SE 68, 107
Orloff, PN 53
Orr, MG 106
Orski, M 201
Osawa, S 91
Osher, JM 229
Osher, RH 59, 61, 62, 63, 65, 127,
132, 143, 242
Oshika, T 170
Oshima, Y 91, 93
Oslar, S 34
Osman, IM 215
Ostertag, R 251
Othman, IS 26
Owoeye, JFA 30
Owsley, C 26, 97
Oystreck, D 200
Ozaki, M 189
Ozdek, SC , 171, 247
Ozeki, N 190
Ozkok, A 194, 236
Oztas, Z 223, 230
Ozturker, C 207
Ozturk, HE 181
P
Packard, RB 27
Packer, M 64, 65, 90
Packo, KH 56, 79, 235
Padhi, TR 79
Padovese, TJ 251, 278
Page, S 251
Page, TP , 135
Pagliarini, S 227
Pahuja, NK 179
Pajarin, AB 185
Pajewski, NM 195
Pakzad-Vaezi, K 151
Palacio, AC 227
Palavecino, ME 30
Palioura, S 149
Palis, A 80, 109, 124
Palkonda, VR 202
Palkovacs, EM 117
Palmberg, PF 113
Palmero Fernandez, L 245
Palmon, FE 34, 111, 107
Pal, SS 233
Pamel, G 66, 119
Panarelli, JF 130
Pandav, SS 191
Panday, VA 174, 217
Pandit, RT 107
Pandya, HK 109
Pang, C 226
Pantanelli, SM 166
Pantcheva, MB 74
Papanagnu, P 200
Pappuru, RR 94
Paques, M 233
Parbhu, KC 117
Pardo, D 227
Parekh, JG 65
Parekh, PD , 108
Parikh, D 167
Parikh, M 114
Paris, L 232
Parke II, DW xv, xvii, 121, 250
Parker, BC 275, 277
Parker, JS 67, 150
Parkhurst, G 89, 119, 217

Park, K 75, 152, 154, 185, 190
Park, S 199, 203, 205
Parks, MM 3
Park, SS 55
Park, Y 203
Parolini, B 163
Parreira, RL 198
Parrish II, RK 5
Parrozzani, R 222
Parshall, MJ 250, 267, 277
Parsons, FT 240
Partamian, LG 27, 75
Paschall, JG 235
Pasquale, LR 129, 130
Pastor, J 153
Pate, AV 128
Patel, AK 178
Patel, CK 212
Patel, H 210
Patel, JR 186, 216
Patel, K 153
Patel, PS , 94, 251, 107, 250
Patel, RD 221
Patel, RM 208
Patel, RR 269
Patel, SA 237
Patel, SM 117
Patel, V 187
Patel, VR 81
Patrianakos, TD 206
Patterson, C , 274, 272
Patz, A 3
Paul, RH 133
Pautler, SE 95
Paysse, EA , 89
Paz Moreno-Arrones, J 218
Peckar, CO 113
Pedro-Aguilar, JL 173
Pedroza-Seres, M 196
Peer, J 27
Pelayes, DE 136
Pelton, RW 278
Pemberton, JD 201
Pena, F 134, 135
Penha, FM 96
Pennesi, ME 96
Pepin, SM 81
Pepose, JS 160, 186, 216
Perdue, LH 161
Pereira, FB 223
Perera, SA , 75, 185, 245
Perez, BA 203
Perez Casaseca, C 219
Perez, VL 67, 68, 111, 150, 176, 181
Perkins, TW 112
Perpetua, C 200
Perry, A 116
Perry, HD 66, 70
Perry, JD 33
Perry, L 148
Pershing, S 137
Perucho, S 187
Peshtani, A 202
Petersen, MR 222
Pettey, JH 64, 107, 108, 250, 251
Pfeiffer, N 154, 207
Phairas, DL 55, 250, 275
Pham, R 85, 115
Phelps, PO 207
Philippakis, E 238
Phillips, PH 56
Phillips, PM 70, 72, 109
Picciarelli, P 203
Pichi, F 155, 197, 210
Pickering, T 187
Pieramici, D 21, 34, 120, 160, 226
Pihlblad, MS 210
Pikey, KP 114
Pila, T 275, 276
Pilkinton Jr, R 170
Pillai, A 148, 216
Pillow, E 224
Pilotto, E 222
Piltz-Seymour, JR 54, 152
Pimentel, A 117
Pineda II, R 21, 106, 138
Pineles, SL 88, 131
Pinto, L 189
Piovella, M 59, 60, 61, 63, 64,
89, 138
Piracha, AR 107, 119
Pira, TN 107
Pires, J 216, 220
Pitz, S 207
Platari, K 193
Plaza, A 166, 170
Pokroy, R 204
Polat, U 204
Pollack, JS 120
Polonski, L 106
Pomeranz, HD 33
Pomerleau, D 95
Pongsachareonnont, P 238
Pop, M 119
Postel, EA 96
Potsaid, B 227
Ppiscopo, R 175
Prajna, L 70
Prakash, G 218
Prakash, GJ 135
Premchand, SK 27
Prenner, J 62
Prescott, CR 33
Price Jr, FW 110, 111, 140, 159, 177
Price, KM 115
Price, MJ 27
Price, MO 159, 177
Pruett, PB 107
Pucci, N 180
Pujari, A 205
Puliafito, CA 91
Pulido, JS 82, 138, 235, 236
Pumariega, N 221
Punja, KG 84, 116
Puthiyapurayil Manjandavida, F 83,
157, 246
Putterman, AM 208
Pyare, R 239
Q
Qazi, MA 186, 216
Qazi, Y 182
Qian, J 207
Qiu, M 185
Quentel, GG 27
Querques, G 236
Quezada Ruiz, C 226
Quigley, HA 188
Quilter, N 124
Quinn, GE 129, 56
Quiros, PA 80, 81, 82, 124, 139, 252
Quiroz-Mercado, H 157, 232
R
Belfort Jr 14
Rabena, MD 226
Raber, IM 109, 110, 168
Rabinowitz, YS 110, 140
Rabiu, MM 124, 135
Rachapalle, SR 182
Rachitskaya, AV 212
Radcliffe, NM 27, 34, 101, 112, 112
Radhakrishnan, S 27, 187
Radic, M 222
Raeker, M 183
Rafaty, M 34
Ragaey, T 191
Rahhal, FM 222
Rahimian, O 190
Rahim, KJ 234
Rahimy, E 221, 233
Raina, UK 27, 198, 226, 239
Rainey, A 88
Raizman, MB 110
Rajagopal, R 230
Rajaii, F 85
Rajan, M 62, 243
Rajpal, RK 21, 34, 90, 110, 140, 172
Rajpal, SD 172
Raj, SM 242
Raj Sr, S 191
Raju, LV 111, 173
Raju, VK 111
Ramakrishnan, V 209
Ramalingam, S 156
Ramamurthy, S 177, 247
Raman, R 233
Ramappa, M 27, 87, 89, 169, 180
Ramesh, S 206
Ramey, NA 116
Ramezani, A 235
Ramirez-Luquin, T 27
Ramirez, MA 112
Ramirez-Miranda, AJ 27, 91, 173,
214, 244, 252
Ramirez-Patino, L 196
Ram, J 191
Ramulu, PY 188
Randleman, J 60, 89, 90, 91, 124,
125, 214, 215
Randleman, JB 21
Ranganath, A 173
Rao, NA 79, 225
Rapuano, C 72, 90, 139, 140
Rapuano, CJ xvii
Rashid, ER 147, 167
Rathi, VM 174, 178, 204, 244
Rathod, R 266
Rathod, RR 34
Rau, M 154
Ravilla Duraisamy, S 124
Ravin, JG 83, 137
Ravin, TB 137
Raviv, T 61, 107
Ravot, M 212
Raychaudhuri, A 175
Rayess, N 233
Read-Brown, S 184
Read, R 122
Read, RW 21, 198
Reche-Sainz, J 167
Rechichi, MM 179
Reddy, DM 138
Reddy, JC 177
303
Participant Index
Newman, NJ 81
Newman, SA 81
Nezzar, H 206
Ngai, L 223
Ng, JD 118
Ng, JQ 170
Ng, L 223
Ngo, WK 248
Nguyen, J 87
Nguyen, Q 96, 156, 161
Nguyen, QH 77, 112, 155
Nguyen, V 153
Nichamin, LD 54, 63, 106, 108
Nichols, B 106
Nijm, L 119
Nirankari, VS 173
Nischal, KK 87, 89, 211, 212
Noecker, RJ 72, 92, 113
Nongpiur, ME 185
Norouzi, H 168
Nouri-Mahdavi, K 26, 142
Novack, RL 162, 222
Novak-Laus, K 185
Nowak-Gospodarowicz, I 192
Nowilaty, SR 26, 30, 97
Ntim-Amponsah, C 192
Nubile, M 173
Nucci, P 197, 210
Nuijts, R 129
Nunery, WR 118
Nunnery III, EW 215
Nussenblatt, RB 79
Participant Index
Participant Index
Reddy, MA 201, 210
Reddy, S 107, 224
Reddy, UP 115
Reddy, VP 201, 237
Reese, JL 236
Reeves, SW 119
Reggiani Mello, GH 214
Regnier, S 235
Reichel, E 234
Reidy, JJ 164, 175
Reidy, KE 27
Reilly, CD 147
Reina, MP 186, 189
Reinstein, DZ 129, 90, 91, 143,
90, 219
Reiser, HJ 280
Reitsamer, HA 155
Rekas, M 192
Rementeria, L 168
Renard, L 203
Repka, MX xvii, 133, 73, 130
Research Group, T 161
Revathi, R 70
Rezaei, K 27, 62
Reznick, LG 184
Rhea, M 34
Rhee, DJ 34, 112, 130
Riazi Esfahani, M 176, 219
Ribeiro, LM 239
Rice, CD 205, 245
Rice, RA 147, 167
Rice, VM 205
Richard, GW 136
Rich III, WL xvii
Rich, WL 122, 141
Riemann, CD 222, 248
Rifaat, M 30
Rinaldi, M 199
Ringel, DM 27
Ritch, R 77, 189, 272
Ritterband, DC 72
Rivera, RP 106
Rixen, JJ 183
Rizzo, S 91, 94
Rizzuto, PR xvii, 137, 138
Robbins, SL 87, 125
Roberts, C 90
Robin, AL 142, 194
Roca, JA 252
Rocha de Sousa, AA 213
Rocha, KM , 60, 119
Rockwood, EJ 164
Rodrigues, EB 27, 96, 239
Rodriguez, A 182
Rodriguez Calvo De Mora, M 183
Rodriguez, CJ 229
Rodriguez, FJ 94
Rodriguez JR, LA 213
Rodriguez-Reyes, A 252
Rodriguez Sr, M 171
Rodriguez Torres, L 213
Roe, RH 222
Rogalinska, I 199
Rogers, AH 234
Rojanapongpun, P 27, 75
Rojas, S 232
Romano, MR 227
Romano, V 199
Romansky, M 280
Romero-Diaz-de-Leon, L 214
Rootman, DB 117
Rootman, DS 71, 183
Rootman, J 117
304
Roper, G 107, 108

Roscoe, D 151
Rose, GE 84
Rose, L 72
Rosenbaum, JT 155
Rosenberg, ES 108
Rosenberg, PR 108
Rosenberg, R , 270, 55, 267
Rosenblatt, MI 27
Rosencrance, D 34
Rosenfeld, PJ 96, 126
Rosenfeld, SI 144
Rosenthal, KJ 61, 107, 108, 132
Rose-Nussbaumer, JR 126
Rosenwasser, GD 70, 109
Rossini, P 247
Rossi, T 229
Roth, DB 225
Rougier, M 190
Rozenbaum, IM 112
Rozsival, P 30
Rubenstein, JB xv, xvii, 18, 33, 108,
54, 72, 142
Rubin, A 191
Rubinate, L 174
Rubinfeld, R 110
Rubio Caso, MJ 202, 227
Rudnisky, CJ 192
Rumelt, S 21, 193
Russ, B 268, 276, 278
Russell, DJ 116
Russell, S 132, 234
Russo, A 227
Russo, C 183
Ryan, E 92
Ryan, M 158
Ryan, SJ 3
Rychwalski, P 88
Rychwalski, PJ 27
S
Saad, A 159, 217
Saade, C 221, 222
Saade, JS 235
Saatci, AO 191
Saber Tehrani, AS 133
Saboori, M 205
Saboo, U 181
Sabry, MM 215
Sachdeva, A 251
Sachdeva, V 246
Sachs, H 163
Sadda, SR 34, 94, 225
Sadoughi, MM 173
Sadun, AA , 139, 230, 238
Saeed, AM 179, 192
Sagong, M 225
Sagoo, MS 201
Sahel, JA 233
Sahin, O 171, 184
Sahu, SK 167
Saidel, M 80, 107
Saini, A 73
Saito, M 195, 221, 230
Saito, OC 203
Saketkoo, LA 196
Sakurai, Y 197
Sala, E 166
Salazar-Marrugo, FE 30
Salazar, PF 202
Salcedo-Villanueva, G 232
Salchow, DJ 27
Saleh, SM 192
Sales, CS 110, 217, 218
Salgari, N 173
Salim, S 77
Salom, D 27, 68
Salvato, C 277
Samah, M 221
Samaras, K 110
Sambhav, K 190
Samples, JR 76
Samsonova, BP 187
Samuels, BC 33
Samuelson, TW 34, 78, 76, 75,
139, 154
Samy, A 233
Sanchez-Barahona, C 186
Sanchez-Jara, A 153
Sanders, DS 184
Sandhu, S 192
Sandor, CS 276
Sandoval, AG 252
Sandy, JL 169
Sane, M 175
Sangameswaran, RP 195
Sangwan, SK 174
Sangwan, VS 21, 66, 150, 151, 169,
174, 243, 244
Sankar, PS 76, 77
Sanroman Sr, J 248
Santhiago, MR 214
Santiago, C 223
Santiago-Varela, M 202
Santos, AR 222
Santos-Silva, R 209, 213
Sanz, GF 30
Sarac, OI 179
Sarin, N 230
Sarkisian, SR 54, 107, 112
Sarnat, M 217
Sarnicola, C 152, 176
Sarnicola, V 33, 54, 72, 110, 152,
176
Sarraf, D 93
Sartori, Jd 208
Sassani, JW 126
Satirtav, G 220
Satkurunathan, P 210
Sato, S 194
Sato, T 192, 194, 197
Satpathy, G 174
Satue, M 67, 149, 150, 177
Savar, L 116, 117
Saw, S 204
Saxena, N 239
Saxena, S 239
Sayanagi, K 234
Sayegh, S 165
Say, ET 203
Scanga, HL 211, 212
Scawn, RL 84
Schaaf, D 169
Schaal, S 34, 164, 224, 227
Schachat, AP 96
Schallhorn, SC 59
Schatz, MP 33, 164, 199
Schefler, AC 83, 226
Scheiner, AJ 115
Schein, OD 126
Schemmer, GB 27
Schendel, S 151
Schepens, CL 3
Scheuerle, A 231
Schiffman, J 114
Schimel, AM 62
Schmetterer, L 187
Schmidl, D 187
Schmidt-Erfurth, UM 231
Schneider, EB 184
Schotthoefer, EO 125
Schrier, A 167
Schroeder, J 271
Schultze, RL 21, 109
Schultz, JS 112
Schuman, JS 77, 91, 113, 153, 190
Schwab, IR 72, 83
Schwarcz, RM 117, 118
Schwartz, DM 137
Schwartz, GF 187
Schwartz, GS 106
Schwartz, SG 95
Schwartz, TL 138
Schweitzer, C 190
Schwenn, O 154
Scoper, SV 27, 107
Scorcia, V 67
Scorsetti, DH 111, 252
Scott, M 107
Scruggs, J 117
Scruggs, RT 205
Scuflaire, P 129
Seah, L 208
Sebag, J 230, 238
See, CW 128
Seelam, B 211
See, RF 226
Seguin-Greenstein, S 196
Sehi, M 142, 190
Seibel, BS 63
Seibold, LK , 74
Seiff, SR , 118, 115
Seiler, T , 110, 110, 140, 143
Seitz, B 143
Sekiryu, T 195, 221, 230
Self, CA 27
Selva, D 207
Selvadurai, A 184
Semba, CP 175
Semeraro Sr, F 227
Sen, HN 79, 197
Seol, B 185
Seo, S 154, 190
Seounghyun, A 208
Seregard, S 34, 121
Serghiou, MS 175
Serghiou, S 175
Sergott, RC 54
Serna, JC 214, 244
Serrano, MA 232
Service, CM 168
Setabutr, P 33, 208
Seymenoglu, G 191, 236
Sgarlata, A 153
Shah, AA 117
Shah, AK 27, 109
Shah, AS 211
Shah, CP 136, 233, 234
Shah, CS 119
Shah-Desai, SD 114, 115
Shah, GK 227, 235
Shah, GM 167
Shahidi, M 224
Shah, MR 234
Shah, PR 107
Shah, R 150
Shah, S 216, 220
Shah, SP 225
Shah, SU 203
Shah, VA 109
Shah, VC 111
Shaikh, ZA 30
Shalabi, NM 181
Shaligram Sr, SC 171
Shameer, A 239
Shamie, N , 109, 90, 106, 139
Shamsi, FA 206
Shams, N 156
Shamsoddinimotlagh, R 172, 173,
177, 207
Shapiro, H 28, 223
Sharawy, AI 179
Sharma, A 30, 173, 196
Sharma, K 196, 198
Sharma, N 61, 66, 70, 71, 87,
174, 176
Sharma, S 79, 96, 174
Sharma, T 195, 210, 233
Sharma, YR 210, 239
Sharpe, ED 193
Sharpe, RA 193
Shatz, AC 119
Shayegani, A 106
Sheffield, VM 22, 134
Sheffler, L 267
Sheibani, K 168
Shekhar, S 234
Shekhawat, N 146, 195
Shen, S 208
Shepherd, J 125
Sheppard, SC , 267
Sherman, DD 115
Sherwood, MB 56, 78
Sheth, BP 133
Sheth, SJ 30
Shetlar, DJ 126
Shetty, BK 179
Shetty, R 71, 171, 173, 179, 242
Sheybani, A 76
Shiba, D 190
Shiba, DR 250
Shields, CL , 55, 82, 83, 91, 94, 72,
134, 202, 203, 236
Shields, JA 2, 72, 82, 83, 91, 94, 96,
134, 202
Shields, M 136
Shields, MB 6
Shields, RA 212
Shields, SR 245
Shimada, N 225
Shimmura, S 110
Shimmyo, M 189
Shimomura, Y 229
Shimura, M 231
Shindler, KS 28, 33, 82, 130
Shingleton, BJ 78
Shin, H 208
Shin, M 246, 247
Shinohara, K 225
Shin, S 199
Shippman, S 131
Shi, W 211
Shojaei-Baghini, A 168
Shorr, N 117
Shorstein, NH 59, 146, 167
Shorter, E 204
Shoughy, SS 151, 174, 181, 196, 197
Shovlin, JP 116
Participant Index
Sobel, RK 118, 141
Sobrin, L 164
Soheilian, M 235
Sohn, EH 96
Sokol, JJ 267
Sokol, JL 276
Soleymanjahi, S 219
Solish, AM 112
Sollenberger, E 221, 233
Solomon, JD 56
Solomon, KD 132
Solomon, SD 34
Soloway, BD 220
Soltau, JB 112
Sommer, A. 3
Song, A 116, 117, 118
Song, CD 107
Song, J 117, 118
Soni, M 79, 94
Sonty, S 78
Sood, P 69
SooHoo, JR 74
Soscia, WL 169
Souied, EH 236
Soukiasian, SH 79, 180
Sousa, L 107, 110
Spaeth, GL 54, 78
Spaide, RF 96
Spencer, MS 112
Spigelman, A 108
Spirn, MJ 168, 221
Spiteri Cornish, K 223
Sponsel, W 189, 193
Spoor, TC 55
Springs, CL 28, 107
Srinivasan, S 62
Srivastava, D 218
Srivastava, S 242
Srivastava, SK 79, 80, 92, 155, 163,
197, 226, 236
Srur, M 28
Stacey, AW 128
Stahl, ED 89, 119, 210, 211, 212
Stahl, JE 22, 119, 143
Stalmans, PW 134
Stamatelatos, G 158
Stamper, RL 164
Stark, WJ 90, 132
Starr, M , 245
Stasior, GO 116
Stass-Isern, ML 212
Staurenghi, G 235
Stechschulte, JR xv
Steele, EA 134
Stefanon, FG 222
Stefansson, E 196
Stegmann, R 113
Steinemann, TL 68
Steinert, RF 59, 128, 132, 139,
142, 217
Stein, JD 178, 191, 195
Steinle, NC 226
Stein, LL 250
Stein, R 53, 110
Steinsapir, K 115, 118
Stenevi, U 146
Stephenson, PG 65, 107, 148
Sterkin, A 204
Sternberg Jr , P 139
Sternberg Jr, P xv, 121
Sterns, GK 97, 136, 138
Stewart, MW 95
Stiles, MC 112
Stingl, K 163
Stinnett, S 230
Stock, MV 146
Stodulka, P 147
Stoilov, I 160, 223
Stojanovic, A 110
Stonecipher, KG 245
Stone, D 28, 80, 107
Storey, PP 235
Straatsma, BR 3, 137
Straiko, MD 28, 70, 72, 109, 149,
178, 183
Strianese, D 175
Strominger, MB 125
Strube, Y 118
Struck, MC 86
Stulting, R 66, 107, 110, 144
Subramanian, PS 33, 81
Suchecki, J 114
Sudharshan, S 197
Suer, D 184
Sugano, Y 195
Sugar, A 178
Sugar, EA 197
Sugar, J 107
Sugiyama, K 182, 187
Suh, D 213
Suhler, EB 155
Sulewski, M 107
Sullivan, TJ 22, 84
Summers, CG 138
Sundar, GJ 74, 206
Suneja, A 268
Suner, IJ 106
Sun, G 52, 144
Sung, E 276
Sung, K 194
Sun, JK 93, 139
Superstein, R 88
Sureka, S 150, 151, 177
Suresh, L 173
Sutphin, JE 210
Sutton, HF 219
Suzuki, K 208
Swamy, L 195
Swanner, JC 114
Swinney, C 206
T
Tabandeh, H 28, 34, 62, 222, 238
Taban, M 28, 117
Tabbara, KF 79, 151, 174, 175, 180,
181, 196, 197
Tabibian, D 179
Tabin, GC 62, 66, 108
Tadayoni, R 238
Tae, TE 213
Takahashi, H 156
Takeuchi, M 197
Takkar, B 239
Talajic, JC 109
Talamo, JH 90, 110
Talat, L 196, 197, 233
Talley-Rostov, AR 68, 107
Talwar, N 191
Tamayo, GE 90, 91, 143
Tamcelik, N 186, 194
Tam, DY 76
Tamhankar, MA 82, 139
Tamory, J 172
Tamura, H 230, 231
Tanaka, S 229
Tan, C 213
Tan, CS 204, 248
Tan, D 66, 69, 71, 110, 111, 149
Tandogan, T 166, 171
Taneri, S 119
Tang, J 88
Tang, RA 114, 137
Tanihara, H 168
Tan, J 90
Tan, JC 188
Tanji, TM 112
Tanna, AP 112
Tannehill, DK 129
Tan, O 153, 190
Tan, Y 175
Tao, JP 28, 53, 114
Tapia-Ramirez, R 30
Taravella, MJ 111
Tarbet, KJ 115
Tarnawska, D 174, 201
Tatham, AJ 153
Tauber, J 67, 175
Tauber, S 119
Tausif, HN 151
Tavares, IM 30
Taylor, HJF xv
Taylor, HR 135
Tedeschi, G 199
Teichman, JC 171, 177, 182
Teja, S 177, 182
Tejedor, J 108
Telander, DG 95
Tello, C 114
Terry, MA 66, 70, 71, 72, 109, 149,
178, 183
Terry. MA 256
Tesha, PE 30
Tesser, PM 189
Tessler, H 122
Teus, MA 218
Tezel, TH 236
Thakar, M 226, 239
Thakker, MM 28, 117
Tham, CC 75, 77, 113, 246
Thapa, S 194
Therese, K 182
Thoe, KA 189
Thomas, BJ 62
Thomas, M 231
Thomley, M 94, 95, 237
Thomley, ML 28
Thompson, CL 111
Thompson, LS 118
Thompson, V 119, 214
Thorne, JE 122
Tietjen, M 267
Tigani, M 251
Timoney, PJ 114
Tims, JS 111
Tipperman, R 60
Titiyal, JS 61, 63, 65, 87
Tjia, KF 63
Toledano Fernandez, N 167, 187,
248
Tomita, M 28, 119, 143
Tomkins-Netzer, O 196, 197, 198,
233
Topcu Yilmaz, P 220
Torquetti, L 68
Tosi, G 176
Toth, CA 93, 96, 230, 237
Touboul, D 28
Tousi, A 235
Toussaint, BW 225
Townley, JR 174, 217
Toy, BC 217
Toyoda, H 208
Traboulsi, EI 74, 88, 141
Trakos, N 114, 115
Tran, DB 107, 220
Tran, H 220
Tran-Viet, D 237
Trattler, WB 34, 62, 72, 139, 60, 110,
110, 143, 175
Trawnik, WR 129
Trazza, S 219
Trese, MT 95, 97
Trevino, R 189
Trindade, BC 243
Trindade, CL 243
Tripathy, K 239
Trivedi, RH 148, 158, 209
Tsai, C 179, 207
Tsai, JC 153
Tsai, JH 107, 111
Tsai, LM xv, 107, 131
Tsai, S 185
Tsang, C 226
Tse, DT 134, 141, 209
Tseng, SG 111
Tseng, VL 165
Tsoukanas, D 193
Tsubota, K 170, 190
Tsujikawa, A 28, 194, 228, 230, 231
Tucker, NA 84
Tucker, SM 84
Tucker, WR 161
Tuck, KD 12
Tu, E 67, 68, 70, 110, 127
Tugal-Tutkun, I 196
Tuli, SS 33, 68, 71, 140
Tuncer, S 201
Turbin, RE 114
Tychsen, L 256
Tyson II, F 65, 172
U
Ucak, T 200, 201
Udaondo, P 28, 68
Uddin, JM 87
Ueberbacher, K 30
Ueda, S 156
Ueno, M 152
Uhler, TA 121, 133
Unal, M 172
Uram, M 113
Ussa-Herrera, F 153
Usui, Y 156, 232
Uy, HS 148, 216
Uzunalli, G 200
V
Vaddavalli, P 71, 177, 247
Vagefi, M 117
Vahedian, Z 194
Vajaranant, T 153, 210
Vajaranant, TS 33
Vajpayee, RB 70, 71, 174, 176, 245
Vajzovic, L 60, 91, 96, 203
Valadares, JV 200
Valdez-Garcia, JE 30
305
Participant Index
Showail, MJ 183
Shriver, E 84, 86, 117, 208, 209
Shriver, EM 33, 256
Shtein, RM 69, 70, 178
Shukla, RO 243
Shukla, SY 221
Shulman, JP 236
Shulman, S 196
Shuman, JT 278
Siatkowski, R 133
Siatkowski, RM 256, 257
Siaudvytyte, L 190
Sibony, PA 133
Siddiqui, AA 203
Sidoti, PA 112, 114
Siegfried, CJ 54, 77, 112
Sieving, PC 88
Sigford, DK 224, 236
Sikder, S 64, 106
Silkiss, RZ 115, 116
Silva, PS 92
Silva, R 222, 233
Silverstone, DE 73, 112
Simader, C 231
Simmons Jr, C 158
Simmons, ST 78
Simon, MA 212
Singer, MA 28, 97
Singerman, LJ 139
Singh, A 76
Singh, AD 82, 83, 91, 135
Singh, H 225, 243
Singh, J 184
Singh, K 122, 130, 185, 186
Singh, M 146
Singh, R 232
Singh, RP 28, 73, 163, 224, 226, 232
Singleton, CD 141
Sinha, AK 210
Sinha, R 61, 87
Sippel, KC 66, 67, 68, 69
Sires, BS 122
Sisk, RA 222
Siswoy, D 86
Sit, AJ 77, 112
Sivak-Callcott, JA 28
Sivak, JA 87, 116
Sivaprakasam, M 195
Skeens, HM 111
Skolnick, A 231
Skuta, GL xv, 121, 250
Slade, SG 132
Slakter, JS 223
Slomovic, A 66
Slonim, CB 115
Smadja, D 214
Smedowski, AP 174
Smiddy, WE 234
Smith, AG 232
Smith, BT 94, 230
Smith, EF 167
Smith, H 202
Smith, JR 122
Smith, LH 97
Smith, OU 158, 245
Smith, R 126, 221, 222, 231
Smith, RG 168
Smith, RT , 119
Smith, TA 86
Smith, WM 56, 79
Sneed, SR 22, 93
Snyder, ME 62, 132, 139
Sobaci, G 228
Participant Index
Participant Index
Valentine, ME 156
Vanags, J 191
Vanathi, M 176
van Dijk, K 150
Van Gelder, RN xv, 79, 136, 250
Vang, S 201
Van Meter, WS 68, 107, 110
Vanneste, FM 203
Vaphiades, MS 55, 114
Varma, DK 76
Varman, A 63
Varma, R 142, 153, 190
Vasavada, AR 59, 61, 63, 65, 108,
132, 143, 242
Vasavada, S 242
Vasavada, VA 242
Vasconcellos, JC 188
Vasconcelos-Santos, DV 122
Vatavuk, Z 185
Vaughn, P 34
Veerwal, V 178, 180, 244
Vega-Estrada, A 170, 244
Velazquez, AJ 119
Veldman, PB 109, 149, 178, 183
Velez Fernandez, M 91
Velez Montoya, R 232
Veloso, C 223
Veluri, H 179
Vemuganti, G 157, 178, 201, 204
Vemulakonda, GA 74
Venables, V 206
Venkatesh, P 239
Ventura, AA 30
Venugopal, R 174
Venzara, FX 237
Verdier, DD 34, 101, 109, 111
Verity, SM 28
Versaci, F 180
Vicchrilli, S 266
Vicchrilli, SJ , 272, 271
Villasenor Fierro, ET 30
Vinciguerra, P 90, 110, 143, 219
Vinciguerra, R 219
Vineeth Kumar, B 224
Vishwanath, S 173
Vitale, AT 79, 97
Vitale, S 127
Vittorio, C 236
Vivek Sr, K 239
Vivino, FB 68
Vohra, V 146
Vold, SD 54, 61, 107, 112, 114
Vollman, DE 146, 250
Volpe, NJ 34, 121, 128, 114, 138,
81, 82
Vrabec, M 119
Vroman, DT 60, 108, 110, 111
Vukich, J 216
Vukich, JA 34, 129
306
W
Wa, C 230, 238
Wachter, B 274
Waddle, M , 267, 268, 278, 267
Wade, RA , 268, 53, 270, 273,
274, 267
Wade, RJ 57
Wafapoor, H 153, 172
Wagner, AL 251
Wagoner, MD 150, 183
Waheed, NK 120, 227, 228
Wajnsztajn, D 247
Waldstein, SM 231
Walia, HS 227
Wallace, DK 53
Wallace, KM 210
Wallace, R 52, 107, 108, 119, 120
Wallace, RB 146
Wallang, BS 246
Walsh, AC 94, 222
Walsh, M 33
Walsh, MK 106
Walsh, TJ 69
Walter, KA 110, 111
Walters, TR 146, 167
Walton Muir, K 142
Walton, R 56
Waltz, K 106
Wanek, J 224
Wang, A 34
Wang, DK 242
Wang, H 181
Wang, N 75, 107
Wang, NL 28
Wang, SY 185
Wang, YE 185
Wang, Z 227
Wan, MJ 211
Wannamaker, K 193
Wanumkarng, N 84
Warburton, J 231
Waren, D 166, 176, 181
Waring, GO 60, 62, 64, 119, 125,
143, 144
Waring III, GO 159
Warkad, V 246
Warman, R 212
Warn, AA xv, 250
Warren, KA , 106
Wasfy, TE 166, 178
Washburn, E 34, 186
Wasserman, P 267
Watanabe, A 208
Wayman, LL 15, 133
Webber, SM 198
Webb, MC 129
Weber, P 251
Wedemeyer, L 73, 250
Wee, W 213
Weikert, MP 33, 54, 60, 90
Wei, LA 116
Weinreb, RN 77, 153

Weinstock, FJ 57
Weinstock, RJ 106, 107
Weir, R 201
Weisenthal, RW 68, 107
Weiss, J 184
Weiss, JS 164
Welder, JD 150
Welling, JD 144
Wells III, JA 93, 139
Wells, JR 107
Wenick, AS 255
Werblin, TP 22
Werner, L , 132, 165, 242
Werner, MA 189
Wheatley, M 62, 225
Whipple, KM 116
Whitcup, SM 161
Whiteside-de Vos, J 112
Whitman, J 107, 220
Wiedman, MS 28
Wiggins, DA 119
Wiggins Jr, RE xv, xvii, 34
Wiggins, RE 127, 131, 142, 274,
278
Wilensky, J 153, 210
Wiley, W 60, 65, 107, 119
Wilkes, MF 222
Wilkinson, CP 127
Williams, DF 93, 132
Williams, GA xvii, 92, 93, 96
Williams, LF 270
Williamson, TH 232
Williams, RD 131, 141, 142,
250, 276
Williams, SN 136
Wilson, DJ 227
Wilson Jr, ME 129, 158, 209, 211
Wilson, MW 33, 126
Wilson, SE 214
Winn, BJ 117
Winthrop, KL 146
Wisnicki, H 273
Witkin, AJ 227, 234
Wittpenn Jr, J 59
Wladis, E 117, 157, 208
Wolfe, JD 233
Wolffe, K 124
Wolfson, Y 231
Wong, AM 28, 81
Wong, D 163
Wong, KL 95, 120
Wong, RV 250, 277
Wong, SC 92, 93
Wong, ST 137
Wong, T 204, 226, 230
Wong, W 187
Wong, WT 230
Woodke, J 266, 271, 272, 274
Woodward, JA 115, 116
Woodward, MA 69, 70, 107, 178
Woo, K 85, 86, 130, 208
Woo, KI 28
Wright, JJ 231
Wright, KW 88, 118
Wright, MM 112
Wrobel, WG 163
Wu, A 195
Wu, C 195
Wu, CC 179
Wu, CS 211
Wu, D 195
Wu, G 65
Wu, HK 107
Wu, L 94, 232, 252
Wulc, AE 118
Wu, MC 69
Wu, W 237
Wykoff, CC 134, 160
Wylegala, EA 174, 201
X
Xanthopoulou, P 193
Xu, J 205
Y
Yackel, T 184
Yamamoto, A 221, 230
Yamamoto, K 170
Yamamoto, S 229
Yamamoto, T 75
Yamanaka, Y 208
Yamane, S 170, 231
Yamashiro, K 228, 230, 231
Yang, H 213
Yang, S 205, 246
Yang, Y 156
Yannuzzi, LA 96, 235
Yanoff, M 126
Yanovitch, TL 34, 125
Yap, Z 185
Yarovoy, D 187
Yasuda, A 159
Yazdani, KI 28
Yazdani, S 172
Yazici, A 191
Yee, K 230, 238
Yehezkel, O 204
Yeh, S 79, 226
Yen, MT 84, 86
Yepremyan, M 251
Yeu, E 28, 34, 65, 62, 119
Yeung, ST 177, 182
Yilmaz, O 207
Yilmaz, YC 196
Yip, C 117
Yip, KP 223
YIP, TP 226
Yip, Y 226
Yiu, GC 120, 230
Yokogawa, H 182
Yokoi, N 208
Yoneda, K 238
Yoon, JS 29, 157
Yoon, MK 117
Yoo, SH 22, 33, 34, 89, 90, 71, 143,
125, 150, 166
Yoshii, K 152
Yoshikawa, M 230, 231
Yoshimura, N 228, 230, 231
Young, BK 195
Young, LH 135
Young, S 208
Young, TL 33, 88, 74
Youssefi, G 219
Yuan, A 163
Yu, CQ 214
Yu, DK 223
Yuen, H 86
Yu, F 165, 167
Yuki, K 190
Yulek, F 200
Yu, M 214
Yum, H 186, 199, 203, 206
Yung, C 107
YungJu, Y 243
Yunker, J 95
Yun, SH 199
Yu, W 207
Z
Zacks, CM xv
Zacks, DN 234
Zalta, AH 75, 77, 78
Zaman, AS 167
Zamir, E 198
Zangwill, L 153
Zarbin, MA 162
Zare Mehrjerdi, M 172
Zauel, DW 29
Zegans, ME 79, 126
Zegarra, H 235
Zein, WM 88
Zetterstrom, C 146
Zhang, F 56
Zhang, X 153, 190
Zhao, PS 204
Zhou, P 165
Zhou, X 216
Ziahosseini, K 206
Zimmer-Galler, IE 92
Zimmerman, LE 3
Zimmerman, R 199
Zink, H 55, 131, 251
Zloty, P 52
Zobal-Ratner, JL 88
Zolotarev, A 170
Zoppe, P 203
Zorab, RA 7
Zoric Geber, M 185
Zoumalan, CI 117
Zrenner, E 163
PARTICIPANT FINANCIAL
DISCLOSURE
The Academys Board of Trustees has determined that a financial relationship should not restrict expert scientific, clinical, or
non-clinical presentation or publication, provided that appropriate
disclosure of such relationship is made. Similarly, it should not
restrict participation in AAO leadership or governance, so long as
appropriate disclosure is made. As an ACCME accredited provider
of CME, the Academy seeks to ensure balance, independence,
objectivity, and scientific rigor in all individual or jointly sponsored
CME activities.
All contributors to Academy educational and leadership activities
must disclose significant financial relationships (defined below)
to the Academy annually. The ACCME requires the Academy to
disclose the following to participants prior to the activity:
Any known financial relationships a meeting presenter, author,
contributor or reviewer has reported with manufacturers of commercial ophthalmic products or providers of commercial ophthalmic
services within the past 12 months
Meeting presenters, authors, contributors or reviewers who report
they have no known financial relationships to disclose
The Academy will request disclosure information from meeting
presenters, authors, contributors or reviewers, committee members, Board of Trustees, and others involved in Academy leadership
activities (Contributors) annually. Disclosure information will
be kept on file and used during the calendar year in which it was
collected for all Academy activities. Updates to the disclosure information file should be made whenever there is a change. At the time
of submission of a Journal article or materials for an educational
activity or nomination to a leadership position, each Contributor
should specifically review his/her statement on file and notify the
Academy of any changes to his/her financial disclosures. These
requirements apply to relationships that are in place at the time of
or were in place 12 months preceding the presentation, publication
submission, or nomination to a leadership position.
Financial Relationship Disclosure

For purposes of this disclosure, a known financial relationship is
defined as any financial gain or expectancy of financial gain brought
to the Contributor or the Contributors immediate family (defined as
spouse, domestic partner, parent, child or spouse of child, or sibling
or spouse of sibling of the Contributor) by:
Direct or indirect compensation;
Ownership of stock in the producing company;
Stock options and/or warrants in the producing company, even if
they have not been exercised or they are not currently exercisable;
Financial support or funding to the investigator, including research
support from government agencies (e.g., NIH), device manufacturers, and\or pharmaceutical companies; or
Involvement with any for-profit corporation that is likely to become
involved in activities directly impacting the Academy where the
Contributor or the Contributors family is a director or recipient of
a grant from said entity, including consultant fees, honoraria, and
funded travel.
Description of Financial Interests
Category
Code
Description
Consultant /
Advisor
Consultant fee, paid advisory boards or fees for

attending a meeting (for the past 1 year)
Employee
Employed by a commercial entity
Lecture Fees
Lecture fees (honoraria), travel fees or

reimbursements when speaking at the invitation
of a commercial sponsor (for the past 1 year)
Equity Owner
Equity ownership/stock options (publicly or

privately traded firms, excluding mutual funds)
Patents /
Royalty
Patents and/or royalties that might be viewed as

creating a potential conflict of interest
Grant Support
Grant support for the past year (all sources) and

all sources used for this project if this form is an
update for a specific talk or manuscript with no
time limitation
| Tel: 415-561-8500 Fax: 415-561-8533

307
Participant Financial Disclosure Index
Participant Financial
Disclosure Index
A
Thomas M Aaberg Jr MD
Allergan; L
Synergetics, Inc.; C
Richard L Abbott MD
Santen, Inc.; C
Mohamed F Abou Shousha, MD
Provisional Patent (University of
Miami); P
Abu Abraham, MD
Santen, Inc.; E
Gary W Abrams MD
Alcon Laboratories, Inc.; C
Nisha Acharya MD
Santen, Inc.; C
Xoma; C
Filiz Afrashi, MD
Allergan; C,L
Novartis Pharmaceuticals
Corporation; C,L
Natalie A Afshari MD
National Eye Institute; S
Shire; C
Amar Agarwal MD
Abbott Medical Optics; C
Bausch & Lomb Surgical; C
Dr. Agarwals Pharma; O
SLACK Incorporated; P
STAAR Surgical; C
Thieme Medical Publishers; P
Iqbal K Ahmed MD
Abbott Medical Optics; C,L,S
Accelerated Vision; C
ACE Vision Group; C
AdeTherapeutics; C
Alcon Laboratories, Inc.; C,L,S
Allergan, Inc.; C,L,S
Aquesys; C,S
Carl Zeiss Meditec; C,L,S
Clarity; C,S
Evisia; C
Eyelight; C
ForSight Labs; C
Glaukos Corporation; C,S
Iantech; C
InnFocus; C
IRIDEX; C
Ivantis; C,L,S
Liquidia Technologies; C
Mastel; S
MST Surgical; L
Neomedix; L
New World Medical Inc; S
Ono Pharma; C
Sensimed; C
SOLX; C,S
Stroma; C
Transcend Medical; C
TrueVision; C
Lloyd P Aiello MD PhD
Eisai; C
Foreseehome; C
Genzyme; C
Kalvista; C
Optos, Inc.; S
Thrombogenetics; C
Masahiro Akiba PhD
Topcon Medical Systems Inc.; E
Yonca A Akova MD
Alcon Laboratories, Inc.; L
Allergan; L
Bausch Lomb; L
308
Esen K Akpek MD
Allergan, Inc.; S
NiCox; C
Shaza Nizar Al-Holou
NIH Medical Research Scholars
Program; S
Thomas A Albini MD
Allergan, Inc.; C
Clearside; C
ThromboGenics, Inc.; C
Valeant; C
Anthony J Aldave MD
Allergan; C,L
Bausch Lomb; C
Nicox; C
Santen, Inc.; C
Eduardo C Alfonso MD
Bio-Tissue, Inc.; C
InSite Vision, Inc.; C
Yusuf Ali, Ph.D.
Santen, Inc.; E
Jorge L Alio MD PhD
Abbott Medical Optics; S
Akkolens ; C,S
Bausch Lomb Surgical; C,S
Carl Zeiss Meditec; S
CSO; C
Dompe; S
Hanita Lenses; C
Jaypee Bros; P
Mediphacos; C
Novagali; S
Oculentis; C,S
Presbia; C
Santen, Inc.; C
SCHWIND eye-tech-solutions;
L,S
SLACK, Incorporated; C
Springer Verlag; P
Tekia, Inc.; P
Thea; S
Topcon; C
Vissum Corporation ; E, O
Quentin B Allen MD
Allergan; C
Bausch Lomb; L
David Almeida, MD PhD MBA
Allergan; L
GENENTECH; L
Fatma Nilufer Alparslan MD
other; C
Noel A Alpins MD FACS
ASSORT; P
Yair Alster
DES; E,O
ForsightVision4; O
ForsigntVision5; C,O
Notal Vision, Inc.; E,O
Pres-By; E,O
Michael M Altaweel MD
Wallace L M Alward MD
InnFocus Inc.; C
Balamurali K Ambati MD
iVeena; O,P
Renato Ambrosio Jr MD
Allergan; L
Carl Zeiss Inc; L
Mediphacos; L
Oculus, Inc.; C
Pontocomsaude.com.br; C
Walter T Ambrosius PhD
Francisco Amparo MD
Nitin Anand MD FRCS
Allergan; L
Richard L Anderson MD FACS
Allergan, Inc.; O
Sofia N Androudi MD PhD
Corporation; C,L
Robert Edward T Ang MD
AcuFocus, Inc.; C,L,S
Allergan, Inc.; L,S
Bausch Lomb Surgical; C,L,S
Santen, Inc.; L
Husam Ansari MD PhD
Alcon Laboratories, Inc.; C,L
Allergan; C,L,S
Ivantis, Inc.; S
Andrew N Antoszyk MD
Allergan, Inc.; C
GENENTECH; C
ICONIC; C
NotalVision, Ltd.; C
Regeneron; C
Thrombogenics; C
Valeant; C
James V Aquavella MD
Allergan; C,S
Bausch & Lomb Surgical; S
Johnson & Johnson Consumer
& Personal Products Worldwide; S
Merck & Co., Inc.; S
Research to Prevent Blindness; S
Lisa B Arbisser MD
Bausch Lomb; C
Optimedica; C,L,S
Ahmad A Aref MD
Carl Zeiss Meditec; L
New World Medical Inc; C
J Fernando Arevalo MD FACS
Alimera Sciences, Inc.; L
IRIDEX; L
King Khaled Eye Specialist
Hospital; S
Corporation; L
Optos, Inc.; L
Second Sight Medical Products,
Inc.; C,L
Springer SBM LLC; P
Luis Arias MD
Allergan; C
Bayer Healthcare Pharmaceuticals; C
Corporation; C
Pablo Miguel Arregui MD
Glaukos Corporation; L
Steve A Arshinoff MD
Anteis; C
Arctic Dx; C
Bausch Lomb; C
Croma; C
iMed Pharma; C
Pablo Artal MD PhD
Abbott Medical Optics Inc.; C
Calhoun Vision, Inc.; C
Comtateq ; C
London Eye Pharma; C
Visiometrics; O
Voptica ; C, O
Penny A Asbell MD FACS
Alcon Laboratories, Inc.; S
Eleven Biotherapeutics; C
NEI; S
Nicox; C
R-tech; S
Sanjay G Asrani MD
Dose Medical; C
Heidelberg Engineering; L
Merck & Co., Inc.; L
Sucampo Pharma; C
Ehud I Assia MD
APX Ophthalmology; O
Bio Technology General; C
Hanita Lenses; C
IOPtima; O
Visidome; O
Vision Care Inc.; S
Mary Attia MBBCH
Abbott Medical Optics Inc.; C,L,S
Alcon Laboratories, Inc.; L,S
Alimera Sciences, Inc.; S
Allergan; C,S
Bausch Lomb; C,L,S
Bayer Healthcare Pharmaceuticals; S
Contamac; S
Dr. Schmidt Intraocularlinsen;
L,S
Geuder; S
Heidelberg Engineering; S
Hoya; S
Corporation; S
Oculentis; L,S
OPHTEC; S
Physiol; S
Powervision; S
Rayner Intraocular Lenses
Ltd; L,S
The presenters above have a financial interest. See page 299 for Description of Financial Interests key.
Gerd U Auffarth MD
Allergan; C,L
Bausch & Lomb Surgical; C,L,S
Bayer Healthcare Pharmaceuticals; L
Carl Zeiss Meditec; L,S
Contamac; S
Glaukos Corporation; S
Hoya; L
HumanOptics; L,S
Kowa; L
Corporation; C,S
Oculentis; L,S
OPHTEC; L
Physiol; L,S
Power Vision; S
Rayner Intraocular Lenses Ltd;
C,L,S
Technolas; C,L,S
Albert J Augustin MD
Alimera Sciences, Inc.; C,L
Allergan; L,S
Carl Zeiss Meditec; C
Corporation; L
Tin Aung, FRCS PhD
Allergan; C,L,S
Aquesys; S
Ellex; L,S
IVANTIS; S
Merck & Co., Inc.; C
Ocular Therapeutix; S
Pfizer, Inc.; C,L
Quark; C,S
Santen, Inc.; C,L,S
Tomey Corp.; L,S
Robert L Avery MD
Alimera Sciences, Inc.; C
Allergan, Inc.; C
Bausch Lomb; C
GENENTECH; C,L,S
IRIDEX; C
Corporation; C,L,O
Ophthotech; C
QLT Phototherapeutics, Inc; C
Regeneron Pharmaceuticals,
Inc.; C,O,S
Replenish; C,O,P
SKS Ocular; O
Carl C Awh MD
Arctic DX; C,O
GENENTECH; C,S
GlaxoSmithKline; S
Katalyst; C,O
Notal Vision, Ltd.; C
Regeneron; C,S
Synergetics, Inc.; C,O,P
Volk Optical; C
William Ayliffe MBBS
Santen, Inc.; C

Brandon Ayres MD
Allergan, Inc.; C,L
Bausch & Lomb Surgical; C,L
Bio-Tissue, Inc.; C,L
Nicox; C,L
TearLab; L
TearScience; L
Ramesh S Ayyala MD FRCS
ElutiMed; O
MediTred; O
patent on antifibrotic GDD
device ; P
Dimitri T Azar MD
ForSight Labs; C, O
Corporation; C, O
Salim Ben Yahia MD

Bausch Lomb; C,L
John P Berdahl MD
Allergan, Inc.; L
Avedro; C
Bausch Lomb; C
Clarvista; C
Envisia; C
Omega Ophthalmic; C,O
Vittamed; C
Gregg J Berdy MD
Allergan, Inc.; C,L
Bio-Tissue, Inc.; L
Karina Berg, MD
Brian B Berger MD
Allergan; C,S
Ampio Pharmaceuticals; S
Diabetic Retinopathy Clinical
Research N; S
GENENTECH; S
GlaxoSmithKline; S
iCO Therapeutics; S
Lpath Inc.; S
Ophthotech; S
Pfizer, Inc.; S
Santen, Inc.; C
Thrombogenics; S
Xoma; S
Daniel M Bernick JD
Health Care Group; C,E,O
Audina M Berrocal MD
Allergan; C
Clarity; L
thrombogenics; C
Maria H Berrocal MD
Hemera; O
Deepak L Bhatt MD
Amarin; S
AstraZeneca; S
Bristol Myers Squibb; S
Ethicon; S
Medtronic; S
Roche; S
Sanofi Aventis; S
The Medicines Company; S
Suven Bhattacharjee, MS
Abbott Medical Optics Inc.; L
Abdhish R Bhavsar MD
Allergan, Inc.; C,S
DRCR; S
GENENTECH; S
Regeneron; S
Robert B Bhisitkul MD
Aerpio Therapeutics; C
Allergan; C
Bausch Lomb; L
GENENTECH; S, L
Santen, Inc.; L
Susanne Binder MD
Gil Binenbaum MD
Pan-American Association of
Ophthalmol; S
Symposia Medicus; L
Eileen E Birch PhD
Fight for Sight; S
Thrasher Research Fund; S
Elena Bitrian, MD
Vitreoretinal Surgery Foundation; S
Rocio Blanco-Garavito MD
Corporation; C
Christopher L Blanton MD
Allergan; C,L
Mark H Blecher MD
Abbott Medical Optics Inc.;
C,L,S
Kevin J Blinder MD
Allergan; C,L
Bausch Lomb; C,L
GENENTECH; C,L
Inc.; C,L
Synergetics, Inc.; L
Mark S Blumenkranz MD
Avalanche Biotechnology; O,P
Digisight; O
Oculogics; O
Optimedica; O,P
Presby Corp.; O
Vantage Surgical; C,O
Michael V Boland MD PhD
Francesco Boscia MD
Allergan, Inc.; C
Corporation; C
Frank W Bowden III MD FACS
Bausch Lomb; C,L
David S Boyer MD
Allegro; C,O
Allergan; C,L
Bausch Lomb; C
GENENTECH; C,L
Glaukos Corporation; C
GSK; C
Neurotech; C
Pfizer, Inc.; C
Quantel Medical; C
Regeneron; C
Santen, Inc.; C
Rosa Braga-Mele MD
Allergan; L
James D Brandt MD
Allergan; C,L
Apple Computer, Inc.; O
Glaukos Corporation; C,O
Neil M Bressler MD
American Medical Association; S
Genentech, Inc.; S
Novartis Pharma AG; S
Inc.; S
The EMMES Corporation; S
Susan B Bressler MD
Allergan; S
Bausch Lomb; S
Boehringer Ingelheim Pharma;
S
GENENTECH; S
GlaxoSmithKline; C
Lumenis, Inc.; S
Notal Vision; S
Corporation; S
Inc.; S
Sanofi-Aventis Group; S
Thrombogenics; S
Stacy Alan Brethauer MD
Ethicon Endosurgery; L,S
OMIC-Ophthalmic Mutual
Insurance Company; C,L
Mitchell Brigell PhD
Aerpio Therapeutics; E
Stephen F Brint MD
WaveTec Vision ; C
Jefferey T Brockette
Allergan; C,L
GENENTECH; C,L
Inc.; C,L
Larry R Brooks
Practice Flow Solutions; O
David M Brown MD
Acucela; S
Aerpio; S
Alcon Laboratories, Inc.; C,S
Alimera; C,S
Allegro Ophthalmics; S
Allergan, Inc.; C
Ampio; S
Bayer Pharmaceuticals; C
GENENTECH; C,S
Genzyme; C,S
GlaxoSmithKline; S
Heidelberg Engineering; C,L
Corporation; C,L
Paloma; C
Pfizer, Inc.; C,S
Regeneron; C,L,S
Santen, Inc.; S
Steba Biotech; C
Thrombogenics; C,S
Gary C Brown MD
Center for Value-Based
Medicine; O
Michael D Brown
Health Care Economics, Inc.; C
309
Disclosure Index
Darron A Bacal MD
George Baerveldt MD
Advanced Medical Optics; P
NeoMedix Corporation; C,L,P
Kashif Baig MD MBA
Alcon Laboratories, Inc.; C,E,L
Allergan; C,E,L,S
Bausch Lomb; C,E,L,S
MORIA; S
Georges D Baikoff MD
STAAR Surgical; L
Carl W Baker MD
Brock K Bakewell MD
Miltos O Balidis, MD, PhD, DO
Allergan; L
Francesco M Bandello MD,
FEBO
Alimera Sciences Inc; C
Allergan, Inc.; C
Bausch Lomb Surgical; C
Bayer Schering Pharma; C
Farmila-Thea Pharmaceuticals; C
GENENTECH; C
Hoffman La Roche, Ltd.; C
Novagali Pharma; C
Corporation; C
Pfizer, Inc.; C
Sanofi Aventis; C
Thrombogenics; C
Alex Baneke BA MBBS
International Glaucoma Association Grant; S
Darryl Baptiste
Allergan; E
Pascale Barberger-Gateau,
PhD
Danone; S
Nutricia; C,L
THEA; S
Vifor Pharma; C
Howard Barnebey MD
Allergan; C,L
Neal P Barney MD
OSOD; C
Enrique Barragan MD
AcuFocus, Inc.; C
revision optics; C,L,O
Rafael I Barraquer Compte MD
Abbott Medical Optics; L
IMEX (Spain); L,P
Medical Mix (Spain); L
Peter James Barry MD
Thea Laboratories, France ; C
Keith Barton MD
Alimera; C
Allergan, Inc.; L
Amakem; C
Aquesys; C,O
Ivantis; C
Kowa; C
Merck & Co., Inc.; C,L,S
Ophthalmic Implants PTE ; O
Pfizer, Inc.; L
Refocus Group, Inc.; C
Thea Labritories; C
Samar K Basak MD FRCS
MBBS
Allergan; C
Central Book International,
Kolkata; P
Jaypee Brothers Publication; P
Surendra Basti MBBS
Juan F Batlle MD
AqueSys; C,L
Innovia; C
Ivantis; C
Optimedica; C,L
Reflow Biomedical Technologies ; C
Sinopsys Surgical; C
STAAR Surgical; L
Caroline R Baumal MD
Allergan; C
Nicholas Beare, MD, MBCHB
Hilary A Beaver MD
Genzyme; L
Allen Dale Beck MD
Bruce B Becker MD
Armadillo Biomedical LLC; O
Quest Medical, Inc.; P
Paul M Beer MD
Z Lens LLC; O,P
Sandra M Beer MD
Presby Corp.; C
George Beiko MD
Abbott Medical Optics Inc.; C,S
Bausch Lomb; S
Croma; S
Rubens Belfort Jr MD PhD
Bayer; C
Kemin Food L.C.; C,S
Roberto Bellucci MD
Physiol; C
Sifi; C
Disclosure Index

Reay H Brown MD
Allergan, Inc.; C
Ivantis; C
LifeSynch; P
Rhein Medical, Inc.; P
Transcend; C
Steven V L Brown MD
OMIC-Ophthalmic Mutual Insurance Company; C
David J Browning MD PhD
Aerpio; S
Research ; S
GENENTECH; S
Corporation; S
Pfizer, Inc.; S
Regeneron Pharmaceuticals; S
Beau Benjamin Bruce, MD, PhD
MedImmune; C
Corporation; S
Alexander J Brucker MD
Escalon Medical Corp; O
GlaxoSmithKline; S
Neurovision; O
Frank A Bucci, Jr., MD
Allergan, Inc.; C,S
Bausch & Lomb Surgical; C,S
LENSAR; C,S
PRN Physician Recommended
Nutriceuticals; C,O,S
Envisia; C
Ivantis; C
Vatinee Y Bunya MD
Claude F Burgoyne MD
Heidelberg Engineering; L,S
Reichert Instruments; S
Brandon G Busbee MD
Akorn Inc.; P
GENENTECH; C,S
Regeneron; C,S
Massimo Busin MD
MORIA; L,P
Yvonne M Buys MD
Allergan; C,L,S
Carlos Buznego MD
Allergan, Inc.; C,L
Bausch Lomb; C,L
CXL; O
Glaukos Corporation; C,O,S
LENSAR; L
Omeros; C
RPS; O
C
David G Callanan MD
Forsight Vision4; O
310
Pilar Calvo, MD, PhD

Corporation; C,L
Jorge I Calzada MD
GENENTECH; S
Peter A Campochiaro MD
Advanced Cell Technology; C
Aerpio; C,S
Allergan; C
Applied Genetic Technologies; C
Gene Signal; C
GENENTECH; C,S
Genzyme; S
GlaxoSmithKline; S
Kala Pharmaceuticals; C
Norvox; C
Oxford BioMedica; S
Regeneron; C
Rene H Cano MD
Corporation; L
Antonio Capone Jr MD
Acucela; S
Alimera Sciences; C
Allergan, Inc.; C,S
FocusROP, LLC; O,P
GENENTECH; C,S
GlaxoSmithKline; S
Corporation; C
Retinal Solutions, LLC; O,P
Thrombogenics; S
Joseph Caprioli, MD, FACS
Allergan; C,S
NIH-NEI; S
RPB; S
Roberto Caputo, MD
Kedrion; S
Corinne Francis Carle
Australian Research Council; S
Alan N Carlson MD
Tear Science; C,O
Angela Maria Carneiro MD PhD
David B Carr, MD
ADEPT; C
American Medical Association; C
Missouri Department of Transportation; S
National Institute of Health; S
Traffic Injury Research Foundation; C
Kristin Carter MD
VisionCare Ophthalmic Technologies; C
Alessandro A Castellarin MD
Alcon, Inc; O
Allergan, Inc; C
GENENTECH; C, L, S
Albert Castillo
OOSS Consultant; C
Jaume Catala MD
Corporation; C
H Dwight Cavanagh MD PhD
FACS
Menicon Ltd,has not conflict
with paper.; C
Nil Celik
Supported by Gertrud Kusen
Foundation; S
Usha Chakravarthy MBBS PhD
Bayer; C
Corporation; C,L
Oraya Therapeutics; C,L
Roche; C
Pratap Challa MD
AERIE pharmaceutical; O
Angela Chambers, MBA, RN
Allergan; C,L
GENENTECH; C,L
Inc.; C
Wallace Chamon MD
Corneal Biomechanincs; P
Crosslinking; P
Wavefront Systems; P
Clara C Chan MD
Allergan, Inc.; C,L
Bausch Lomb; C
Clement K Chan MD
Acucela; S
Allergan; C
GENENTECH; C,S
National Eye Institute; C,S
Inc; C,S
Sequenom; S
ThromboGenics; C
Tat-Keong Chan MD FRCS
FRCOphth
Hoya Optics; L
Santen, Inc.; L
Hitesh Chandwani MBBS MS
Allergan; E
Daniel H Chang, MD
Allergan; C
David F Chang MD
Allergan, Inc.; L
Calhoun Vision Inc; O
Clarity; C,O
ICON bioscience; O
LensAR; C,O
Minosys; O
PowerVision Inc; O
Revital Vision; O
SLACK, Incorporated; P
Transcend Medical; C,O
Versant Ventures; O
John So-Min Chang, MD
Robert T Chang MD
Allergan; C
EyeGo; P
SuCampo; C
Stanley Chang MD
Ta Chen Chang MD
American Glaucoma Society; S
Retrophin, Inc.; C
Martin Charles MD
Corporation; L
Steven T Charles MD
Alcon Laboratories, Inc.; C, P
Topcon Medical Systems; C, P
Craig J Chaya MD
Abbott Medical Optics Inc.; O
Hydrus; S
Arturo S Chayet MD
Nidek, Inc.; C
Caroline K L Chee MBBS
N.U.S. - Baden-Wuerttemberg
grant; S
Corporation; C
Ching-Jygh Chen MD
Clinico; L
Optovue; S
Eric Chen MD
GENENTECH; S
Inc.; S
John C Chen MD
Allergan; C,L
Bayer Healthcare Pharmaceuticals; C,L,S
Corporation; C,L,S
Sanford Chen MD FACS
Allergan; C
Bausch Lomb; C
GENENTECH; C
Inc.; C,L
Paul T K Chew MD
Nidek, Inc.; C
Michael F Chiang MD
Clarity Medical Systems (unpaid
Board); C
Helen Marie Chmiel EdD
GENENTECH; E
James Chodosh MD MPH
Corporation; C
N H Victor Chong, MD
Allergan; C,S
Bayer Healthcare Pharmaceuticals; C,L
Corporation; C,S
Quantel Medical; C,L,S
Vikas Chopra MD
Allergan; C
Bennett Chotiner MD
Netan Choudhry MD
Allergan; C
Bausch Lomb; C
Corporation; L
David R Chow MD
Allergan; L
Arctic Dx; O
Bausch & Lomb Surgical; L
DORC International, bv/Dutch
Ophthalmic, USA; L
Katalyst; C
Lumenis, Inc.; L
Corporation; L
Stephen P Christiansen MD
David S Chu MD
Allergan; S
Biogen Inc; C
Y Ralph Chu MD
Abbott Medical Optics; C,L
Allergan, Inc.; C,L
Lifeguard Health; C
Ocular Therapeutix; C
Ocusoft; C
Powervision; C
Revision Optics; C
Mina Chung MD
Canon, Inc; S
Lowy Medical Research
Institute; S
thome foundation; S
Sophia Mihe Chung MD
Eli Lilly & Company; S
Elizabeth Hesford Cifers, MBA
GENENTECH; L
George A Cioffi MD
Allergan; C
Robert J Cionni MD
Morcher GmbH; P
WaveTec Vision; C
Jessica B Ciralsky MD
Allergan; C
Checked Up; C
Nicox; C

Minas T Coroneo, MD, MS
Allergan; C,L,S
Australian National Health and
Medical Research Council; S
Ophthalmic, USA; L,P
Eagle Vision; P
Genetic Eye Foundation
Australia; S
Oculeve, Inc; C,S
Transcend Medical; C,O,P
Vital Paulino Costa MD
Merck & Co., Inc.; C,L,S
New World Medical Inc; L,S
Pfizer, Inc.; L
Anastasios P Costarides MD
PhD
Allergan; S
Fiona E Costello MD
Corporation; C
Alan S Crandall MD
Alcon Laboratories, Inc.; C, L
AqueSys; C
ASICO; C
iScience; C
Ivantis, Inc.; C
Mastel Surgical; C
Omeros Corporation; C
E Randy Craven MD
Allergan, Inc.; C,L
Ivantis; C,S
King Khaled Eye Specialist
Hospital; E
Mary Ann Croft
Avedro; L
Z-Lens LLC; L
Karl G Csaky MD
Acucela; C
Allergan; C
GENENTECH; C,L,S
Heidelberg Engineering; C
Isis Pharmaceuticals; C
Corporation; C,L
Ophthotech; C,O
Roche Diagnostics; C
Santen, Inc.; C,S
William W Culbertson MD
OptiMedica; C,L,O,P,S
Arthur B Cummings MD
WaveLight AG; C,L
Jose G Cunha-Vaz MD PhD

Alimera Sciences; C,L
Allergan; C
Carl Zeiss Inc; C
F. Hoffmann - La Roche; C
Fovea Pharmaceuticals; C
GeneSignal; C
Corporation; C,L
OM Pharma; C
Christine Curcio PhD
GENENTECH; S
Claus Cursiefen MD
Allergan, Inc.; L
Bausch Lomb Surgical; L
Gene Signal, France; C
Novaliq; C
Pfizer, Inc.; L
Philip L Custer MD
Johnson & Johnson; E
Pfizer, Inc.; E
D
Donald J. DAmico MD
GENENTECH; C
Neurotech, Inc.; C,O
Ophthotech, Inc.; C,O
Optimedica, Inc.; C,O
Reza Dana MD MSc MPH
Allergan, Inc.; C,S
Eleven Biotherapeutics; C,O
GlaxoSmithKline; S
Google; C
Novabay; C
Novaliq; C
Vision Medicines; C,O
Ronald Peter Danis MD
Allergan; C
EyeKor LLC; O
GlaxoSmithKline; C
Oraya Therapeutics; C
Richard S Davidson MD
Carl Zeiss Meditec; C,L
Queensboro Publishing
Company; O
Elizabeth A Davis MD
Bausch Lomb; C
Refractec; O
Janet Louise Davis MD
Clearside; C
Santen, Inc.; S
XOMA Incorporated; C
Quentin Davis PhD
LKC Technologies, Inc; E,O
Sheraz M Daya MD
Abbott Medical Optics Inc.; S
Bausch Lomb; C,L
Nidek, Inc.; C,L
PRN; O
SARcode Bioscience Inc.; C
STAAR Surgical; C
Tear Science; C
Pouya N Dayani MD
Allergan; C
Alejandra G de Alba Campomanes MD
Bayer; S
Arthur L De Gennaro
Arthur De Gennaro & Associates, LLC; O
Eugene de Juan Jr
Bausch Lomb Surgical; P
ForSight Labs; E,O
GENENTECH; P
IRIDEX; O,P
NexisVision; C,O
Second Sight; C,O,P
Synergetics, Inc.; P
Transcend Medical ; C,O
Vision 4; C,O
Vision 5; C,O
Jose J de la Cruz Napoli MD
Marc Dominique De Smet, MD
PhD FRCSC FRCOPHTH
Bayer Pharmaceuticals; C
Centocor, Inc.; C,S
Johnson & Johnson; C
Corporation; C,L
Preceyes; C,O,S
Regeneron; C
Sanofi; C
Santen, Inc.; C,L
Thrombogenics Inc; C,L,P,S
Margaret M DeAngelis PhD
ArcticDx, Inc.; O
Cecile Delcourt PhD
Bausch Lomb Surgical; C,L
Laboratoires Thea (France);
C,L,S
Corporation; C
Joseph L Demer MD PhD
USHS, National Eye Institute; S
Vincent A Deramo MD
Allergan; S
John J DeStafeno MD
Allergan; L
Uday Devgan MD
Aaren Scientific, Inc.; C
Accutome Inc; P
Gerson Lehrman Group; C
Imprimis Pharma; C
LensGen; C,O
Omeros; C
SLACK, Incorporated; L
Specialty Surgical; O
Steven H Dewey MD
Microsurgical Technolgoy; P
Deepinder K Dhaliwal MD
Avedro; S
Eleven Biotherapeutics; S
Dilsher S Dhoot MD
Inc.; C
Burkhard Dick MD
Aquesys; C
Bausch Lomb; C
Morcher GmbH; P
Ocular Surgery News; C
Oculus, Inc.; P
Beiying Ding PhD
GENENTECH; E,O
Andrzej Dmitriew MD
Allergan; C,L
Ellex; L
Polytech; L
Thea; L
Valeant; L
Diana V Do MD
Allergan; C
GENENTECH; S
Lpath, Inc.; S
Regeneron; S
Santen, Inc.; C
Andrew P Doan MD PhD
Credential Protection, LLC; O
FEP International, Inc.; O
John F Doane MD
Anamed, Inc.; O
Calhoun Vision, Inc.; S
Ocular Therapeutics; S
Presbyopia therapies; O
REATA; S
Claes H Dohlman MD PhD
Massachusetts Eye & Ear
Infirmary; E
Rosa Dolz Marco MD
Corporation; L,S
Sean P Donahue MD PhD
GoCheckKids; C
PediaVision; C
Eric D Donnenfeld MD
AcuFocus, Inc.; C
Aquesys; C
Bausch & Lomb Surgical; C,L,S
CRST; C
Elenza; C
Kala; C
Katena Products, Inc; C
lacripen; C
Lensx; C
Mati Pharmaceuticals; C,O
Mimetogen; C
Novabay; C
ocuhub; O
Odyssey; C
PRN; C
Strathspey Crown; O
Tearlab; C
TLC Laser Eye Centers; L,O
truevision; C,O
Wavetec; C
Peter C Donshik MD
Osuka; C
311
Disclosure Index
Thomas A Ciulla MD
Alimera; S
Ampio; S
Lpath Inc.; S
Ohr; C,O,S
Ophthotec; S
Pfizer, Inc.; S
Stealth; C
Thrombogenics; C
Carl C Claes MD
W Lloyd Clark MD
Allergan; S
GENENTECH; C,L,S
Regeneron Pharmaceuticals;
C,L,S
Santen, Inc.; C,S
William S Clifford MD
Ivantis; S
Transcend Medical; S
Kimberly Cockerham MD
FACS
Department of Defense; S
Lumenis, Inc.; L
John S Cohen MD
Bausch Lomb; S
Salomon Y Cohen MD
Allergan; C
Bausch Lomb; C
Bayer; C
Corporation; C
Thea; C
Kathryn A Colby MD PhD
Corporation; E
Ashley Cole MS
Allergan; E
Anne Louise Coleman MD PhD
AHRQ; S
Michael J Collins MD FACS
Bausch Lomb; C
Fernando L Colombo MD
Allergan; L
D. Michael Colvard MD
Bausch & Lomb; C
OASIS Medical, Inc.; P
Garry P Condon MD
Alcon Laboratories, Inc.; C, L
Allergan; C, L
Donna Connolly
Practice Management
Resource Group; E,O
Kevin J Corcoran
Corcoran Consulting Group;
C,E,L,O
Kevin P Corcoran, CAE
Eye Bank Association of
America; E
Borja F Corcostegui MD
Bayer; L
Corporation; L
Disclosure Index

Paul J Dougherty, MD
Bausch Lomb; L
Lenstec, Inc.; C,L,O
Nidek, Inc.; C,L
Revision Inc.; C
STAAR Surgical; L
Raymond S Douglas MD PhD
Arlene V Drack MD
Foundation Fighting Blindnes; S
Hope for Vision; S
Vision for Tomorrow; S
Kimberly A Drenser MD PhD
Allergan; C
FocusROP; O
Retinal Solutions; O
Thrombogenics; L
John H Drouilhet MD FACS
Pravin U Dugel MD
Acucela; C
Alimera Sciences, Inc.; C,O
Allergan; C
ArticDx; C,O
Digisight; O
GENENTECH; C
LUX; C
Macusight; C,O
Neovista; C,O
Ophthotech; C,O
Ora; C
Regeneron; C
ThromboGenics; C
Jay S Duker MD
Allergan; C
Carl Zeiss Meditec; C,S
EyeNETRA; C,O
Hemera Biosciences; O
Nicox; C
Ophthotech; C,O
Optos, Inc.; C
Thrombogenics; C
William J Dupps, MD PhD
Avedro; C,S
Cleveland Clinic Innovations; P
Ziemer; C
Vikram D Durairaj MD
KLS Martin; L
Stryker Corp/Medical Division; L,
Daniel S Durrie MD
Accelerated Vision; C,L,O
AcuFocus, Inc.; C,L,O,S
Alcon Laboratories, Inc.; C,L,O,S
Allergan; L,S
Alphaeon; C,O
Avedro; L,O,S
NexisVision; O
Revital Vision; O
Strathspey Crown LLC; C,L,O
Wavetec; C,L,O,P
Ziemer; C,L
312
E
Ralph Eagle, MD
Childrens Oncology Group; S
Merck & Co., Inc.; O
Alexander M Eaton MD
Advanced Referral Management
Systems; O
Akorn Inc.; O
Allergan, Inc.; S
EDIT ; O
EyeO2Scan, LLC ; O
GENENTECH; S
I Tech JV Development Company, LLC; O,P
IC Labs, LLC; O
Macusight; S
Neuron Systems; O
Psyvida; O
Regeneron; S
Revitalid, Inc.; O
Claus Eckardt MD
Ophthalmic, USA; P
Jeffery S Eckert
Eckert Wordell Architects; O
Jeffrey P Edelstein MD
American World Clinics; O
Jane C Edmond MD
Eric Eggenberger DO
Acorda; C
Berlex, Inc; C,L
Biogen Inc; C,L,S
Genzyme; C
Corporation; C,S
Serono; C,S
Teva Pharmaceutical Industries,
Ltd.; C,L,S
Justis P Ehlers MD
Bioptigen; P
Ohio Department of Development; S
Inc.; L
Thrombogenics; C,L
Ehab N El Rayes, MD PhD
Ophthalmic, USA; P
Medone surgical; P
Corporation; C,L
Mays A El-Dairi MD
Prana pharmaceuticals; C
Alaa M Eldanasoury, MD
Nidek, Inc.; C
STAAR Surgical; C
Dean Eliott MD
Acucela; C
Advanced Cell Technology; S
Alimera; C
Arctic; C,O
Biogen Inc; C
GENENTECH; C
ReNeuron; C
Thrombogenics; C
Michael J Elman MD
GENENTECH; C,L,S
iCo; S
Ohr Pharmaceuticals; O,S
Xfinity; S
Thomas R Elmer Jr MD
Bausch Lomb; L
Victor M Elner Ph.D. , MD
OcuSciences, Inc.; O,P
Takeda; C
Michael J Endl MD
Bausch Lomb; C
Elizabeth C Engle MD
Baylor U and Texas Childrens
Hospital; L
Boston Childrens Hospital
Ophthalmology; S
Brown University; L
Gordon Research Conference; L
Hood Foundation; C
Howard Hughes Medical
Institute; S
March of Dimes; C
Moebius Syndrome Foundation; L
Mt Sinai School of Medicine; L
National Human Genome
Research Institute; S
National Institutes of Health; S
New England College of
Optometry; L
Project ALS; S
Sheikh Khalifa Medica City; L
Stanford U Medical Center; L
Sultan Qaboos U Hospital; L
U of Jordan; L
U of Maryland; L
U of Texas at Austin; L
Universite De Lausanne; L
Virginia Tech School of
Medicine; L
Walsh Lab, Boston Childrens
Hospital; L
Randy J Epstein MD
Vera A Essuman, MBCHB
UNIVERSITY OF GHANA
RESEARCH FUND; S
F
Warren R Fagadau MD
Sina Farsiu PhD
Duke Eye Center; P
Alan Richard Faulkner MD
Bausch Lomb; C,L
Strathspey Crown/Alphaeon; O
Wavetec; C
Jean-Luc Febbraro MD
Sharon Fekrat MD
Alcon Laboratories, Inc.; P
Prana; C
Inc.; C
Steven E Feldon MD
Ronald Leigh Fellman MD OCS

Endo Optiks, Inc.; C
SOLX; S
Transcend; S
Zeiss-Meditec; S
Antonio Ferreras, MD PhD
Allergan, Inc.; L
Instituto de Salud Carlos III; S
Corporation; L
Oculus, Inc.; S
Frederick L Ferris, MD
Bausch Lomb; P
Philip J Ferrone MD
Allergan; C,L,S
Arctic DX; C,O
Bausch Lomb; C
GENENTECH; C,L,S
Regeneron; C,L,S
Joao P Figueira MD
Allergan; C
Kemin Food L.C.; C
Corporation; C
Marta Figueroa MD
Allergan, Inc.; C
Corporation; C
Theodoros Filippopoulos MD
Allergan; C,L
Corporation; C,L
Howard F Fine MD MHS
Allergan; C
Auris Surgical Robotics; C,O,P
GENENTECH; C,L
Regeneron; C,L
Mitchell S Fineman MD
Nutriceuticals; C
ThromboGenics, Inc.; C,S
Paul T Finger MD
IP Liberty Vision Corporation; P
Wolfgang Fink BS MS PhD
Ceeable Technologies, Inc.;
C,O,P
Zoraida Fiol-Silva MD
CIBA Vision, a Novartis
Company; L
William J Fishkind, MD FACS
Abbott Medical Optics; C,
LensAR; C,
Thieme Medical Publishers; P,
Rita Maria Flores
Allergan; L
Corporation; C
Brian E Flowers MD
Forsight Labs; C
Ivantis; C
Transcend Medical, Inc.; C
William J Flynn MD
Allergan; S
AqueSys; S
Bausch Lomb; S
Omeros Corporation ; S
James C Folk MD
IDx LLC; O
S Lance Forstot MD FACS
Allergan, Inc.; C,L
Nicox; C
TearScience; C
C Stephen Foster MD
Abbott Medical Optics; C,S
Bausch Lomb; C,S
Eyegate Pharmaceuticals,
Inc; O,S
IOP Opthalmics; C,L
Lux Biosciences, Inc; C,L,S
Corporation; S
Santen, Inc.; S
XOMA Ltd.; C,L
Jill Annette Foster MD FACS
Allergan, Inc.; C,L,
Merz; C,L
Tamara R Fountain MD
Bradley Dean Fouraker MD
Addition Technology; C,L
Alcon Laboratories, Inc.; C,L,
KeraVision Inc; C,L,
OMIC-Ophthalmic Mutual Insurance Company; C,L,
Nicole R Fram MD
Accutome, Inc; S
Bausch Lomb; L
WaveTec Vision; S
Brian A Francis MD
Allergan, Inc.; C,S
Aquesys; S
Lumenis, Inc.; L,S
NeoMedix Corporation; C
Benjamin J Frankfort MD PhD
Retina Research Foundation; S
Stephen R Fransen MD
LKC Technologies, Inc.; C
Melvin I Freeman MD FACS
Elsevier, Inc.; P
JaypeeHighlights Medical
Publishers; P
G
Roberto Gallego-Pinazo MD
Allergan; S
Heidelberg Engineering; L,S
Corporation; C,L,S
Sensimed; S
Topcon Medical Systems
Inc.; L,S
Brenda L Gallie MD
IMPACT GENETICS; S
Antonio Gallo
Biogen Inc; C,L
Corporation; L
Serono; L
Teva Pharmaceutical Industries, Ltd.; C,L
Anat Galor MD
Bausch Lomb; C
Veterans Affairs Medical
Center; S
Stefano A Gandolfi MD
Allergan; C
IVANTIS; S
Corporation; L
SENSIMED; C
Gerardo Garcia-Aguirre MD
Bayer Pharmaceuticals; C,L
Laboratorios Sophia; L
Corporation; C,L
Prashant Garg MD
Allergan; L
NovaBay Pharmaceutical Inc; C
Santen, Inc.; C
Sumit Garg MD
Sunir J Garg MD FACS
Allergan, Inc.; C
Xoma; S
David F Garway-Heath MD
FRCOphth
Allergan; C,L,S
Moorfields Motion Detection
Test; P
OptoVue; S
Pfizer, Inc.; L,S
Sensimed; C
Topcon Medical Systems
Inc.; L,S
Ronald N Gaster MD FACS
Abbott Medical Optics; O
Damien Gatinel MD
Bausch Lomb; C,L
Hoya; L
Nidek, Inc.; C,L
Physiol; P
Reichert Ophthalmic Instruments; L
Toreasy; O
Visiometrics; C
WaveLight AG; C,L
Alain Gaudric MD
Corporation; S
Johnny L Gayton MD
Bausch Lomb; C
Omeros; C
OptiMedica; C
Steven J Gedde MD
Allergan; C
Gerd Geerling, MD PhD
Allergan; C,L
Bausch Lomb; C,L
Tearlab; C,L,O
TearScience; C,L
Thea Pharma; C,L
Florian Gekeler MD
Retina Implant AG, Reutlingen,
Germany; C
Lawrence Geller MBA

Medical Management Associates, Inc.; E
JoAnn A Giaconi MD
Allergan; C
Christopher C Glisson, DO
Biogen Inc; C,L
Lundbeck, Inc; C,L
Robert S Gold MD
Insurance Company; C,L
Pediavision; C,O
Ivan Goldberg MBBS
FRANZCO
Allergan, Inc.; C,S
Forsight; C,S
Pfizer, Inc.; C
Jeffrey L Goldberg, MD PhD
Allergan; C
NIH, DOD, GRF; S
Theravance; C
Robert A Goldberg MD
Merz; C
David A Goldman MD
Allergan, Inc.; C
Bausch Lomb; C
Compare Networks; C
Modernizing Medicine; C
Debra A Goldstein MD
Abbott pharmaceuticals; C
Clearside ; C
XOMA; C
Eleven Biotherapeutics; E,O
Michael T Goldstein MD
IOP Ophthalmics; L
Dan S Gombos MD
Childrens Oncology Group ; S
Jose Gomes MD
Allergan, Inc.; C,L
CAPES; S
Fapesp; S
Genon; C,L
Merck & Co., Inc.; C,L
Pfizer, Inc.; C
Fumi Gomi, MD PhD
HOYA Corporation; C
Corporation; L
Santen, Inc.; L
Topcon Medical Systems; C,L,S
Victor H Gonzalez MD
Allergan, Inc.; S
GENENTECH; C,L,S
Iconics; S
panoptica; S
Pfizer, Inc.; L,S
Regeneron; L,S
ThromboGenics, Inc.; C,L,S
Valeant; C,L,S
Lingam Gopal MBBS
Allergan; L
Gabriel Gordon, PhD
Retina Health Center; C

Paganini; O,P
Pieter Gouws MBChB
Allergan; C,L
James A Gow MD
Alcon Laboratories, Inc.; E
Raj K Goyal MD MPH
Gunther Grabner MD
AcuFocus, Inc.; L,S
Polytech; C
Evangelos S Gragoudas MD
Aura Biosciences; C
QLT Phototherapeutics, Inc; P
Stuart L Graham MBBS MS
PhD
Biogen Inc; S
Corporation; S
Alana L Grajewski MD
Jeff Grant
Compulink Business Systems,
Inc.; C
Paul B Greenberg MD
US Veterans health Administration; S
David S Greenfield MD
Allergan; C
Bausch Lomb; C
Biometric Imaging, Inc.; C,O
Merz; C
Optovue; S
Quark; C
Senju; C
SOLX; C,O
Jack Volker Greiner DO PhD
Allergan; S
NovaBay; S
ORB, Inc.; O,P
TearScience; S
Craig M Greven MD
Joseph F Griffith, MD
Cleveland Clinic Foundation; E
Salvatore Grisanti
Alimera; C
Allergan; C
Bayer; C,L,S
Corporation; C,L,S
Pfizer, Inc.; C,L,S
Second Sight Medical Products, Inc.; S
Swaantje Grisanti, MD
Ronald L Gross MD
Cynthia L Grosskreutz MD PhD
Corporation; E
Aura Biosciences; S
Clearside Biomedical; P
Fight for Sight; S
National Cancer Institute; S
Davinder S Grover MD
Allergan; L
Tissue Bank International; L
Andrzej Grzybowski MD
Bausch Lomb; C,L
Corporation; C,L
Thea; L
Vincent Gualino, MD
Allergan; C,L
Corporation; C,L
Jose L Guell MD PhD
Calhoun Vision, Inc.; O
Carl Zeiss Inc; C
OPHTEC, BV; C
Orca Surgical; O
RVO Raindrop; C
Thea; C
Preeya K Gupta MD
Tear Science; C,L
Sunil Gupta MD
Allergan; C
GENENTECH; C
Gokhan Gurelik MD
SCIENTIF TECHNOL RESEARCH COUN TURKEY; S
David L Guyton MD
Hartwell Foundation; S
Patents on fixation detection
technology; P
H
Farhad Hafezi, MD PhD
EMAGine SA; O
PCT /CH2012/000090; P
S
Ziemer Ophthalmics; S
Julia A Haller MD
Allergan, Inc.; C
Lpath, Inc.; C
Regeneron; C
Second Sight Medical Products, Inc.; C
Thrombogenics; C
Lawrence S Halperin MD
Covalent; O
Inc.; C
M Bowes Hamill MD
OPHTEC; S
D Rex Hamilton MD
Keri Renee Hammel MS
The EMMES Corporation; E
Billy R Hammond Jr PhD
313
Disclosure Index
Ronald Eric P Frenkel MD

Allergan, Inc.; S
Bausch Lomb; S
GENENTECH; S
GlaxoSmithKline; S
Independent; P
Lpath, Inc.; S
Pfizer, Inc.; S
Regeneron; S
Rigel; S
K Bailey Freund MD
GENENTECH; C
Regeneron; C
Thomas R Friberg MD
Eyetech, Inc.; C
GENENTECH; C
Optos, Inc.; C
Pfizer, Inc.; C,S
David S Friedman MD MPH
PhD
Allergan; C
Carl Zeiss Inc; S
For Sight Vision 5; C
Merck ; C,L
Nidek, Inc.; C
Quark Bio Tech; C
Valeant, Inc.; C
Scott M Friedman MD
Alimera Sciences; C
Larry P Frohman MD
NORDIC; S
Luther Fry MD
Bausch Lomb; S
James Fujimoto PhD
Carl Zeiss Meditec; P
Optovue; O,P
Anne E Fung MD
Digisight; O
GENENTECH; E,S
Inc.; S
Disclosure Index

Pedram Hamrah MD
Allergan; C,S
Revision Optics; C
Dennis P Han MD
Allergan, Inc.; S
GENENTECH; S
Regeneron; S
Masanori Hangai MD
Nidek, Inc.; C
Otsuka; L
Wakamoto; L
Paul J Harasymowycz MD
Allergan; L
Bausch Lomb; L
Ivantis; C
Pfizer, Inc.; L
SOLX; C
J William Harbour MD
Castle Biosciences; P
David R Hardten MD
Bausch Lomb; C
Calhoun Vision Inc; S
ESI, Inc.; C
Oculus, Inc.; L
TLC Vision; C
Seenu Hariprasad MD
Allergan, Inc.; C,L
Bausch Lomb; C
Bayer; C
Clearside Biomedical; C,O
GENENTECH; C,L
Ocular Therapeutix; C,O
OD-OS; C,O
Optos, Inc.; C
Regeneron; C,L
Clio A Harper III MD
Aerpio; S
Allergan; S
DRCR Network; S
GENENTECH; S
iCo; S
Lpath, Inc.; S
Ophthotech Corporation; S
Inc.; S
Santen, Inc.; S
Alon Harris PhD
Adom; O
Biolight; C
Nanoretina; C
ONO; C
Pharmalight; C
Sucampo; C
Andrew R Harrison MD
Neuro-ophthalmix LLC; O
Mary Elizabeth Hartnett MD
FACS
American Diabetes Association; S
March of Dimes; S
WoltersKluwer Lippincott; P
Paul J Harton Jr MD
STAAR Surgical; L
314
Thomas M Harvey MD
Lenstec, Inc.; C
STAAR Surgical; L
TLC Laser Eye Centers; O
Tarek S Hassan MD
Allergan; C
Artic DX; C,L,O
Genentech, Inc.; C,L
Insight Instruments; C,L
Corporation; C,L
Optimedica; C,O
Regeneron; C,L
Thrombogenics; C
Kathryn Masselam Hatch, MD
Allergan; C,L
IOP ophthalmics; C,L
James C Hays MD
Alimera Sciences, Inc.; E
Ronald Hays, PhD
Amgen; C
Lingmin He, MD
EyeGo; P
Oculeve; O
Gena Heidary MD
Knights Templar Eye Foundation
Grant; S
Jeffrey S Heier, MD
Acucela; C,S
Aerpio Therapeutics; C,S
Alimera; C,S
Allegro; C
Allergan, Inc.; C,S
Bausch Lomb; C
Bayer Healthcare; C,S
Forsight Labs; C
Fovea Pharmaceuticals; S
GENENTECH; C,S
Genzyme; C,S
Kanghong; C
Kato Pharmaceuticals; S
Liquidia; C
Lpath, Inc.; S
Merz; C
Neurotech; C
Nicox; C
Notal Vision; C,S
Corporation; S
Ohr Pharmaceutical; C,S
Ophthotech; S
Oraya; C
QLT Ophthalmics; C,S
Regeneron; C,S
Sanofi Fovea; C
Stealth Peptides; C
Thrombogenics; C
Xcovery; C
Bonnie A Henderson MD
Bausch Lomb; C
Genzyme; C
Massachusetts Eye and Ear
Infirmary; P
Raoul Paolo D. Henson, MD
Emmetrope; L
Leon W Herndon Jr, MD

Sight Sciences; C
Lisa Herrinton PhD
Peter S Hersh MD
Addition Technology; S
AVEDRO, INC.; C
Synergeyes Inc; S
Robert Hess, PhD
Amblylotech; P
Dale K Heuer MD
Aeon Astron (DSMB member); C
Innovia (DSMB member); C
Curt Hill, BA
Practice Management Resource
Group; E,O
Warren E Hill MD
Clarity; C,O
Haag-Streit; C,S
Oculus, Inc.; C
PowerVision; C
David Scott Hillman MD
Allergan; L
Lawrence W Hirst, MD MBBS
MPH DO FRACO FRACS
owner of trademark P.E.R.F.E.C.T.
;P
Pterygium Australia Pty Ltd; O
Allen C Ho MD
Allergan; S
GENENTECH; C,L,S
Janssen; C,L,S
NEI / NIH; S
Ophthotech; C,S
PanOptica; C,S
PRN; C,O,S
Regeneron; C,L,S
Second Sight; C,S
Thrombogenics; C,L,S
Ching Lin Ho, FRCS, MBBS
Allergan; C,L
Santen, Inc.; C,L,S
John D Hofbauer MD
Bausch Lomb; C,L
Kenneth J Hoffer, MD FACS
Haag-Streit ; P
Nidek, Inc.; P
Oculus, Inc.; P
SLACK, Incorporated; P
Tomey Corp.; P
Topcon Medical Systems; P
Ziemer; P
Richard S Hoffman MD
Microsurgical Technology; C
John Bryan Holds MD
Allergan; C
Merz Pharmaceuticals; C
Nancy M Holekamp MD
Allergan; C,S
GENENTECH; C,L
Katalyst; C,O,P
Notal Vision; S
Quantel Medical; C
Inc.; C,L
Sequenom CMM; C,L
Jack T Holladay, MD MSEE
FACS
AcuFocus, Inc.; C,O
ArcScan; C,O
Carl Zeiss Inc; C
Elenza; C,O
Oculus, Inc.; C
Visiometrics; C,O
Wavetec; C
Edward J Holland MD
Kala Corporation; C
Mati Therapuetics; C
Nutriceuticals; C,S
RPS; C
Senju Pharmaceutical Co.,
LTD.; C,L
TearLab; C
TearScience; C,L
Gary N Holland MD
Corporation; C
Santen, Inc.; C
XOMA Corp; C
Simon P Holland MD
Allergan; C
Elizabeth Holloway MA
BSM Consulting; C
Jonathan M Holmes MD
Frank G Holz MD
Acucela; C
Bayer Healthcare; C,L
GENENTECH; C,S
Heidelberg Engineering; C,L,S
Corporation; C,L
Optos, Inc.; S
Pfizer, Inc.; C
Roche; C
Mike P Holzer MD
Bausch Lomb; C
HumanOptics; S
OPHTEC; L,S
Rayner Intraocular Lenses Ltd; S
Technolas Perfect Vision GmbH;
C,L,S
Anton B Hommer MD
Santen, Inc.; S
Jason D Horowitz MD
John A Hovanesian MD
1-800-DOCTORS; C,O
Abbott Medical Optics; C,L,O,P
Allergan, Inc.; C
Bausch & Lomb Surgical; C,L,O
Bausch Lomb; C,L,S
Calhoun Vision, Inc.; C,S
Clarity Medical Systems; C,L
Essex Woodlands Health
Ventures; C,L
Fera Pharmaceuticals; C,S
Halozyme; C
IOP Inc; C,L,S
Ivantis; C
Ocular Therapeutix; C,L,O,S
OrbiMed Advisors; C
ReVision Optics; C
SarCode; C,L,S
Sarentis Ophthalmics; C
Sight Sciences; C,O
SLACK, Incorporated; C,L
Tear Science; C,L,S
TLC Laser Eye Centers; C,L,O
TrueVision3D Systems; C,L,S
Versant Ventures; O
Vindico Medical Education; C,L
Visiogen, Inc.; C,L,S
Vista Research; C
Vistakon Johnson & Johnson
Visioncare, Inc.; C,P,S
Michael J Howcroft MD
GENENTECH; L
Jason Hsu MD
GENENTECH; S
GlaxoSmithKline; S
Johnson & Johnson; S
Notal Vision; S
Ophthotech Inc.; S
Santen, Inc.; S
Xoma Corporation; C
Andrew J W Huang MD MPH
Allergan, Inc.; C
David Huang MD PhD
Optovue, Inc; O,P,S
John J Huang MD
Allergan; L
Suber S Huang MD, MBA
i2i Innovative Ideas, Inc.; O
Second Sight; C
Zeiss; L
G Baker Hubbard MD
VisionQuest Biomedical LLC; C
Mark S Humayun MD PhD
Bausch & Lomb Surgical; C,L,P,S
Clearside; C
IRIDEX; C,P
Liquidia; C
Reflow; C,L,O,P,S
Regenerative Patch Technologies (RPT); C,O,P
REPLENISH; C,L,O,P,S
Second Sight; C,L,O,P,S
David G Hunter MD PhD
Childrens Hospital Boston; P
Johns Hopkins University; P
Lippincott Williams Wilkins; P
REBIScan, Inc; C,O

I
J
Douglas A Jabs MD MBA
Corporation; C
Inc.; C
Santen, Inc.; C
Mary Lou Jackson MD
Corporation; C,L
Readers Digest ; S
Visus Technology; C
Murray A Johnstone MD
Allergan; C, P
Cascade Ophthalmics; E
Healionics; E
Ivantis; C
Sensimed; C
University of Washington
C4C; P
Jost B Jonas MD
Alimera Co; C
Boehringer Ingelheim Co., ; C
CellMed AG, Alzenau,
Germany; P
Sanofi; C
Jason J Jones MD
Abbott Medical Optics Inc.; C,L
OptiMedica; C,L
Michael P Jones MD
Brian C Joondeph MD FACS
Allergan; C
Ophthalmic, USA; C,L
J Michael Jumper MD
Allergan; S
Covalent Medical; O
Ophthalmic, USA; L
GENENTECH; S
Ophthotech; S
Inc.; S
ThromboGenics, Inc.; S
Ula Jurkunas MD
61/482,769; P
Altheos; C
GlaxoSmithKline; S
Tissue Banks International; L
K
Malik Y Kahook MD
Abbott Medical Optics; P,S
Aerie; C
ClarVista Medical; C,P
GENENTECH; C,S
Glaukos Corporation; C,P,S
Innovative Laser Solutions
LLC; O,P
IVANTIS; C
New World Medical Inc; P
OASIS Medical, Inc.; P
Regeneron; S
Shape Ophthalmics LLC; O,P
ShapeTech LLC; O,P
Valeant; C
Peter K Kaiser MD
Allegro; C
Bayer; C
Chengdu Kanghong; C
GENENTECH; C
Corporation; C
Ophthotech; C
Oraya; C
Inc.; C
SKS Ocular LLC; C,O
Richard S Kaiser MD
Ophthotech; C,O,
PanOptica; C
Inc.; C
Stephen A Kamenetzky MD
OCS
ANTHEM BCBS; E
Anselm Kampik MD
Corporation; L
A John Kanellopoulos MD
Allergan; C
Avedro; C
i-Optics; C
Optovue,Inc; C
Paul C Kang MD
Allergan, Inc.; L
Jennifer J Kang-Mieler
patent pending; P
Henry J Kaplan MD
Advanced Ocular Technology; O,P
Caremark; C
RegenaSight; O,P
Santen, Inc.; C
Costas H Karabatsas MD
Allergan; L
Santen, Inc.; L
Randy H Kardon MD PhD
Department of Defense
TATRC; S
Corporation; C
Veterans Administration; S
Zeiss Meditec; C
Douglas A Katsev MD
Allergan; S
Bausch Lomb; C
James A Katz MD
i-Optics; C
iDoc; C
Ocular Therapeutix, Inc; S
Refocus Group, Inc.; C,S
TrueVision Systems, Inc.; C,O
Paul L Kaufman MD
Advanced Genetics Technology
Corp; C,L
Allergan, Inc.; C,L
Amakem Therapeutics; C,L
Johnson & Johnson Consumer
& Personal Products Worldwide; C,L
Lens AR, Inc; S
Refocus Group, Inc.; C,L
Santen, Inc.; C,L,S
Sucampo Pharma; C,L
Valeant Pharmaceuticals; C,L
WARF; P,S
Z lens, LLC; S
Stephen C Kaufman MD PhD
Bio-Tissue, Inc.; C
IOP Ophthalmics; C
Christine Nichols Kay MD
Foundation Fighting Blindness; S
Second Sight Medical Products, Inc.; C
John H Kempen MD
Can-Fite; C
Clearside; C
Eyegate; S
Food and Drug Administration; S
Lions Club International
Foundation; S
Lois Pope Life Foundation; S
Mackall Foundation; S
University of Pennsylvania; E
Xoma; C
Patricia Kennedy, COMT,
CPC, COE
Rose and Associates; C,E
Peter J Kertes MD
Allergan; C,S
ArcticDx; O
Bayer; C,L,S
GENENTECH; S
Corporation; C,L,S
Regeneron; S
Takeshi Kezuka MD PhD
Santen, Inc.; L
Baseer U Khan MD
Abbott Medical Optics; L,S
Solx; S
Hamza N Khan MD FACS
Allergan; L
Arshad M Khanani MD
Allergan; C
GENENTECH; C,L,S
Corporation; C,L,S
315
Disclosure Index
Tsontcho Ianchulev MD
Corinthian Ophthalmics; O
Transcend Medical; E
wavetec; C,O
Pravoslava Ianchuleva MD
PhD
Osama I Ibrahim MD PhD
Raymond Iezzi MD
Tomohiro Iida MD
Nidek, Inc.; S
Yoshitsugu Inoue MD PhD
Hoya Corporation; S
Nihon Tenganyaku Kenkyusyo
Co. Ltd.; S
Corporation; S
Otsuka Pharmaceutical Co.,
Ltd; S
Pfizer, Inc.; S
Santen, Inc.; S
Sun Contact Lens Co. Ltd.; S
Michael S Ip MD
Allergan, Inc.; S
GENENTECH; C
Inc.; C
Valeant; C
Sherwin J Isenberg MD
Foresight Biotherapeutics; C
Shaun Ittiara MD
Inc.; O
Andrew George Iwach, MD
Acumems; C,O
Clarity Medical Systems; C
Ellex Laser Systems; L
Aiko Iwase MD PhD
Kowa; C
Otsuka; L
Pfizer, Inc.; L
Santen, Inc.; L
Senju; L
Topcon Medical Systems; C
Mitchell A Jackson MD
ACE Vision Group; O
Allergan; C
Avellino; C
Bausch Lomb; C
Marco Ophthalmics; C
Nicox; C
Noble Vision Group; O
Omeros; C
Paragon Bioteck; C
Sucampo; C
Tear Lab; C
Tear Science; L
Timothy L Jackson MBChB
Retina AG; S
W. Bruce Jackson, MD, FRCSC
Allergan Inc; C,L
Bio-Tissue, Inc.; C
Labtician Ophthalmics Inc; C
Deborah S Jacobs MD
Boston Foundation for Sight
501(C)3; E
Glenn J Jaffe, MD
Abbott Laboratories; C
Neurotech USA; C
pSivida; S
Sandeep Jain MD
University of Illinois at
Chicago; P
Andrew Charles James PhD
Seeing Machines; P
Henry D Jampel MD MHS
Allergan, Inc.; O
ForSight; C
Ivantis; C
Transcend; C
Lee M Jampol MD
Baxter BioScience; C
Jaeb Center/DRCR; S
Corporation; L
Stem Cell Organization/
Quintiles; C
Ingrida Januleviciene MD PhD
Allergan; C
Pfizer, Inc.; L
Santen, Inc.; C
Bennie H Jeng MD
Jade therapeutics; C
Santen, Inc.; C
Jin Wook Jeoung, MD
Allergan; C
Pfizer, Inc.; L
Yali Jia PhD
Optovue, Inc.; P
Gordon E Johns MD
American Academy of Ophthalmology; C
Chris A Johnson PhD
Haag-Streit; C
JAEB Center; C
Mark W Johnson MD
GlaxoSmithKline; C
Oraya; C
Disclosure Index

Femida Kherani MD
Allergan; C,L
Afshin J Khodabakhsh MD
Bausch Lomb; C,L,S
Ramin Khoramnia, MD
Allergan; S
Bausch Lomb; S
Contamac; S
Dr. Schmidt/HumanOptics; S
Kowa; S
Corporation; S
Oculentis; S
Powervision; S
Albert S Khouri MD
Allergan; L
Rahul Khurana MD
Allergan, Inc.; S
GENENTECH; C,L
Regeneron; L,S
Topcon Medical Systems Inc.; C
Afsheen Khwaja MD
Santen, Inc.; E
Jeremy Z Kieval MD
Allergan; C,L
Don O Kikkawa MD
Bausch Lomb; C
Ivana K Kim MD
ArcticDx; C
GENENTECH; S
Judy E Kim MD
Allergan; C
GENENTECH; L
Stella K Kim MD
Eli Lilly & Company; C
Seattle Genetics; C
Tae-Woo Kim, MD, PhD
Allergan; L
Topcon Medical Systems Inc.; C
Terry Kim MD
Bausch Lomb; C,L
Ocular Systems Inc; C
Omerus; C
Powervision; C
Presbyopia Therapies; C
Shire; C
TearScience; C
Shigeru Kinoshita MD
Acucela; C
HOYA; C,L
Johnson & Johnson; L
Otsuka Pharmaceutical Co.;
C,L,S
Pfizer, Inc.; L
Santen, Inc.; C,L,P,S
Senju Paharmaceutical Co.;
C,L,P,S
316
Szilard Kiss MD
Alimera; C,L
GENENTECH; C,L,S
Optos, Inc.; C,L,S
Regeneron; C,L,S
Thrombogenics; C,L
John W Kitchens MD
Allergan; C
Bayer Healthcare Pharmaceuticals; C, L
GENENTECH; C
Corporation; C, L
Inc.; C
Oliver Klaus Klaproth
Heidelberg Engineering; E
Oculus, Inc.; L
Rayner Intraocular Lenses Ltd; L
RTI Health Solutions; C
Stephen D Klyce PhD
Acufocus; C
Centervue; C
LensAR; C,O
Nidek, Inc.; C
NTK Enterprises; C
Ocularis Pharma; C,O
Oculus, Inc.; C
Douglas D Koch MD
i-optics; S
OptiMedica; O
Revision Optics; C
TrueVision; S
Ziemer; C,S
Laurent Kodjikian, MD, PhD
Allergan; C,L
Bausch Lomb; C,L
bayer; C,L
Corporation; C,L
thea; C,L
Bruce H Koffler MD
Bausch Lomb; L
Paragon Vision Sciences; L
Adrian H Koh MD
Allergan; C
BAYER PHARMACEUTICALS; C,L
Carl Ziess Meditec; C,L
Corporation; C,L,S
Hyoung J Koh MD
Allergan; C
Corporation; S
Santen, Inc.; L
Thomas Kohnen MD, PhD, FEBO
Bausch & Lomb Surgical; L,S
Hoya; L,S
Rayner Intraocular Lenses Ltd;
C,L,S
C,L,S
Gregg T Kokame MD
Allergan; C,S
GENENTECH; S
Regeneron; C,L,S
Santen, Inc.; C
Thrombogenics; C,L
Maria Kolic
Seeingmachines ; E
Aaleya F Koreishi MD
Allergan; L
Bausch Lomb; L
Bobby S Korn, MD PhD FACS
Bausch Lomb; S
Elsevier, Inc.; P
Jean-Francois Korobelnik MD
Allergan, Inc.; C
Lab Bayer; C
Lab THEA; C
Corporation; C
Andrea N Kossler, MD
Oculeve; C,O
Brett S Kotlus MD
Symphonic; O,P
Richard C Koval, MPA, CMPE
The BSM Consulting Group; E,O
Florian T A Kretz MD
Alimera Sciences, Inc.; L,S
Allergan; C,L,S
Bausch Lomb; S
Dr. Schmidt Intraocularlinsen;
L,S
Geuder AG; L,S
HOYA; L
KOWA; L
Mediphacos; S
Corporation; L,S
Oculentis; L,S
OPHTEC; S
PhysIOL; L
Powervision; S
Ltd; L,S
Technolas Perfect Vision; L,S
Thomas C Kreutzer MD
Corporation; C
Rohit Krishna MD
Cloud Nine Development; O
Tim U Krohne MD
Corporation; C,L,S
Mark E Kropiewnicki, JD, LLM
Health Care Group; C,E,O
The Health Care Group; C,E,O
Ronald R Krueger MD
Alcon Laboratories, Inc.; CL
Clarity Medical; C
i-Optics; C
LensAR Laser Systems; C,O
Friedrich E Kruse MD
Santen, Inc.; L
TRB Chemedica; L
Derek Y Kunimoto MD JD
Allergan; C
Mark J Kupersmith MD
ECRIP; S
Baruch D Kuppermann MD PhD
AcuFocus; C
Alimera; C,L
Allegro Ophthalmics LLC; C,L
Ampio; C
AquaTherapeutics; C
GENENTECH; C,S
GlaxoSmithKline; S
Neurotech; C
Novagali; C
Corporation; C
Ophthotech; C
Pfizer, Inc.; C
Regeneron; C,S
Santen; C
Second Sight; C
Staar Surgical; C
Ltd.; C
Ajay E Kuriyan, MD
Shree K Kurup MD
Allergan; C,L,S
Eyetech Ltd; C
Pfizer, Inc.; S
Regeneron; L,S
Shunji Kusaka MD
Santen, Inc.; L
Sergey Kuznetsov, MD
Reper-NN Ltd, Nizhny Novgorod,
Russia; P
Young H Kwon MD PhD
Free Educational Publications
Inc.; O
L
William J Lahners MD
Bausch Lomb; L
IOP; L
LensAR; L
Shui T Lai PhD
Laser Diagnostic Technologies; P
Vmax Vision, Inc; O,P
Timothy Y Lai MD, FRCOphth,

FRCS
Allergan; C,L
Bausch Lomb; L
Bayer Healthcare; C,L,S
Corporation; C,L,S
Rohit R Lakhanpal, MD
Allergan; C
Byron L Lam MD
AGTC; S
CDC; S
Department of Defense; S
Foundation for Fighting Blindness; S
Hope for Vision; S
River Vision; S
Inc.; S
University Space Research
Association; C
Wai-Ching Lam MD
Allergan, Inc.; C,L
Bausch Lomb; C
Bayers; C
Corporation; C,L,S
Scott R Lambert MD
Cystic Fibrosis Foundation
Therapeutics ; C
Retrophin; C
Pamela Landsman-Blumberg
MS PhD
Merck & Co., Inc.; E
Stephen S Lane MD
Bausch Lomb; C,L
ClarVista; C
KALA; C
Life Core; C
NICOX; C
Ocular Therapeutix; C,O
PowerVision; C
PRN; C
Rapid Pathogen Screening
(RPS); C,O
TearScience; C,O
Wave Tec; C,O
Deborah P Langston MD FACS
Bausch Lomb; C
Mark A Latina MD
Allergan, Inc.; L
Diopsys, Inc.; C,L
IOP Inc; L
Lumenis, Inc.; C,L,P,S
Andreas K Lauer MD
Acucela; S
Allergan; S
Oxford BioMedica; S
Simon K Law MD
Allergan, Inc.; L,S
Andrew G Lee MD
CredentialProtection; O

Mark R Lesk MD
Allergan; L
Canadian Health Research
Program; S
Canadian Institutes for Health
Research; S
Canadian National Inst BlindCGCRC; S
Dynamic Laminometer; P
Fonds Recherche Universite de
Montreal; S
Glaucoma Research Council of
Canada; S
Nat Sci and Eng Research
Council Canada; S
Ocular Biometric Instrument; P
Erik Letko MD
CXLOphthalmics; O
Christopher Kai-shun Leung
MD MBChB
Allergan; C,L
Oculus, Inc.; L
Santen, Inc.; C
Tomey Corp.; S
Roy Clifford Levitt BS MD
NIDCR R01DE022903; S
Pain Research Enterprises,
LLC; O
James S Lewis MD
Imprimis; C,L,O
Richard A Lewis MD
Advanced Vision Science; C
Aerie; C
Allergan; C
Aquesys; C
Ivantis; C
Mobius; C
Xiao-Yan (Joanne) Li, MD
Allergan; E
Jeffrey M Liebmann MD
Allergan, Inc.; C,S
Bausch Lomb; C,S
Diopsys Corporation; C,O,S
Heidelberg Engineering; C,S
Merz Pharmaceuticals, Inc.; C
New York Glaucoma Research
Institute; S
Optovue, Inc.; C,S
Quark Pharmaceuticals, Inc.; C
Reichert, Inc.; S
SOLX, Inc.; O,S
Sustained Nano Systems; C,O
Topcon Medical Systems; S
Valeant Pharmaceuticals; C
Jeffrey Todd Liegner MD
Imprimis Pharmaceuticals;
C,O,P
Jennifer Irene Lim MD
GENENTECH; L,S
Inc.; C,L,S
Santen, Inc.; C
Michele C Lim MD
Jobson Publishing; L
Tock H Lim MBBS FRCSE

Bayer; L
Corporation; L
Shan C Lin MD
Allergan; C
William Link, PhD
AcuFocus, Inc.; O
Glaukos Corporation; O
Neurotech, Forsight, Neovista,;
O
Second Sight; O
WaveTec; O
Katharina Linz
Allergan; S
Bausch Lomb; S
Dr. Schmidt/HumanOptics; S
Hoya; S
Corporation; S
Oculentis; S
OPHTEC; S
Physiol; S
Powervision; S
Ltd; S
Brian C Little MD
Bausch Lomb; C,L
Eyemovies Ltd; P
James C Loden MD
ANEW Optics; O
iCataract; O,P
Omerous Corporation; C
TearScience; C
Nils A Loewen MD
NeoMedix Corporation; L
Anat Loewenstein MD
Alimera; C
Allergan, Inc.; C,L
Bayer; C,L
Forsightlabs; C
Lumenis, Inc.; C,L
Notal Vision, Ltd.; C,
Corporation; C,L
Teva Pharmaceutical Industries, Ltd.; C
Nikolas J London MD
GENENTECH; C
Inc.; C
Ron K Lord MD
Cloud Nine Development; O
Retina Associates of Southern
Utah PC; O
Andrew J Lotery, MBCHB
Corporation; C
Na Lu PhD
GENENTECH; E
David M Lubeck MD
Anthony J Lubniewski MD
Mid America Transplant
Services Eye Bank; C
Jodi I Luchs MD
Allergan; C,L
Bausch Lomb; C,L
EyeGate; C
Ista Pharmacuticals; C,L
Nicox; C
Brandon J Lujan MD
Avalanche; C
GENENTECH; C,L
Regeneron; L
University of California,
Berkeley; P
Fiona O Luk MBChB
Allergan; L
Michael J Lynn MS
M
Joseph J Ma MD
Bausch Lomb; C
Mathew W MacCumber MD
PhD
Allergan; C
ArcticDx; C
GENENTECH; C
Optos, Inc.; C,S
Regeneron; C,S
Thrombogenics; C,S
Ian M MacDonald MD
Alberta Innovates - Health
Solutions; S
Canadian Institutes for Health
Research; S
Choroideremia Research
Foundation Canada; S
Foundation Fighting Blindness
Canada; S
Susan M MacDonald MD
Jeffrey J Machat MD
C
Friederike Mackensen MD
PhD
Abbvie; L,S
Allergan; S
Santen, Inc.; S
Serono; C
Servier; S
Richard J Mackool MD
Crestpoint Management; P
Impex, MST; P
Scott M MacRae MD
AcuFocus, Inc.; C
Ziemer ; C
Marian Sue Macsai-Kaplan
MD
Allergan, Inc.; L
Nutriceuticals; C
Ted Maddess PhD

EyeCo Pty Ltd; C,O
Seeing Machines; P,S
Naoyuki Maeda MD
Bausch Lomb; L
Johnson & Johnson; L
Oculus, Inc.; L
Otsuka; L
Santen, Inc.; L
Tomey Corp.; L
Topcon Corp; S
Francis S Mah MD
Alcon Laboratories, Inc.; C, S
Allergan; C,L
Bausch Lomb; C,L
ForeSight; C
Imprimis; C
Nicox; C
Ocular Therapeutix; C,S
Omeros; C
Shire; C
Tamer H Mahmoud MD
Allergan; C
Mauricio Maia MD
Bausch Lomb; C,L
FAPESP; S
Federal University of Sao Paulo
and CNPq; P,S
Kemin Food L.C.; C,L,P,S
Corporation; C,L,S
Parag A Majmudar MD
Allergan, Inc.; C
Bausch Lomb; C
CXL Ophthalmics LLC; O
Rapid Pathogen Screening; O
Tear Science; C,S
Andrew Maller MBA
Allergan; C
Robert K Maloney MD
Calhoun Vision Inc; C,L,O
CosmoMD Surgical Media,
Inc.; C
Presbia Corp.; C
STROMA Medical Corporation; O
kishore malyavantham PhD
Immco Diagnostics Inc.,; E
Boris Malyugin MD PhD
Bausch Lomb; C
Morcher GmbH; P
MST; P
Novamedica; C
Corporation; L
Nick Mamalis MD
A.R.C. Laser Corporation; S
Aaren Scientific, Inc.; S
Alcon Laboratories, Inc; S
Allergan; S
Anew Optics, Inc; C,S
Bausch Lomb; S
Medennium, Inc.; C,S
Nu-Vue Technologies, Inc.; S
317
Disclosure Index
David A Lee MD
Pfizer, Inc.; C
Julia Lee, JD OCS
Michael S Lee MD
Neuro-ophthalmix; E,P
Pfizer, Inc.; S
Paul P Lee MD JD
Duke Eye Center; E
GENENTECH; C
GlaxoSmithKline; O
Medco; O
Merck ; O
Corporation; C
Pfizer, Inc.; C
Quorum Consulting; C
University of Michigan Medical
School; E
Vitaspring Health Technologies; O
Thomas C Lee MD
Wen-Hsiang Lee MD PhD
Wendy W Lee MD
Allergan, Inc.; C
Cutera; C
Elizabeth Arden; C
Lumenis, Inc.; C
Medcompare; C
Medicis Aesthetics; C
William Barry Lee MD
Allergan; L
Bausch Lomb; L
Bio-Tissue, Inc.; L
Won Ki Lee MD
Allergan; C
Bayer; C
Corporation; C
Santen, Inc.; C
Martha Motuz Leen MD
Phuc Lehoang MD PhD
Allergan; C
Corporation; C,S
Richard A Lehrer MD
Bausch Lomb; L
InnFocus; S
Charles Leiter
Leiters Compounding Pharmacy; E
Robert E Leonard II MD
Inc.; C,L
Disclosure Index

Edward E Manche MD
Best Doctors, Inc.; C
Guidepoint; C
Krypton Vision, Inc.; C,O
Oculeve, Inc.; C
Refresh Innovations, Inc.; C,O
Seros Medical, LLC; C,O,P
Veralas, Inc.; C,O
Samantha S Mann MBBS
Corporation; C
Steven L Mansberger MD MPH
Allergan; C,S
Envisia; C
Mobius; S
Santen, Inc.; C
Ahmad M Mansour MD
Sam Edward Mansour MD
IRIDEX; C,L
Kaweh Mansouri MD
Sensimed AG; C
Dennis M Marcus MD
Acucela; S
Research N; C,S
GENENTECH; C,L,S
GlaxoSmithKline; S
Juvenile Diabetes Research
Foundation; S
Lpath Inc.; S
Ophthotech; S
Pfizer, Inc.; S
Quark; S
Inc.; C,L,S
Philippe Margaron PhD
Novartis Pharma AG; E
Iari-Gabriel Marino PhD
Optotesys; C
Michael F Marmor MD
Acucela; C
Basilea; C
Corcept; C
Merck; C
John Marshall PhD
Accelerated Vision; C,P
Avedro; C,L,O
Nexisvision; C,O
Optos, Inc.; C,P
SCHWIND eye-tech-solutions; L
John Joseph Martin, MD
medicis; L
Keith R Martin MD
Allergan; C,L
Jose Maria Martinez de La
Casa MD
Glaukos; C,L,S
Icare; C,L
Ivantis; C,S
Pfizer, Inc.; C,L,S
Transcend; C,S
318
Samuel Masket MD
Accutome, Inc. ; S
Haag-Streit; C,P
Morcher GmbH; P
MST Surgical; L
Ocular Theraputix; C,O
PowerVision; C
WaveTec Vision Systems,
Inc.; C,S
Mina Massaro-Giordano MD
Daylan Sciences; O
Nutriceuticals; O
Pascale Massin
Allergan; C,L
Fovea; C
Corporation; C,L
Guy G Massry MD
Elsevier, Inc.; C
Carlos Mateo MD
Rookaya Mather, MBBCH
Allergan; L
Cynthia Mattox MD FACS
Allergan; S
Transcend; S
Raj K Maturi MD
A-C Tap; C
Alimera; C
Ampal; C
Eli Lilly & Company; C
GlaxoSmithKline; C
Jaeb Center for Health
Research; C
NEXUS; C
Ophthotech; C
QUARK PHARMACEUTICALS; C
Santen, Inc.; C
Louise A Mawn MD
Eduardo P Mayorga MD
Indendent e-learning consultant;
C
Cathleen M McCabe MD
Bausch Lomb; L
Bausch Lomb; C
Tara A McCannel MD
ArrayBiopharma; C
Corporation; C,L
James P McCulley, MD, FACS,
FRCOPHTH
Allergan; C
Bausch Lomb; C
Marguerite B McDonald MD
Allergan, Inc.; C
Bausch and Lomb Pharma; C
FOCUS Laboratories; C
NexisVision; C
Ocularis Pharma; C
Oculus, Inc.; C
OCuSOFT; C
Optical Express; C
SARcode; C
TearLab; C
Yuri McKee MD
Haag-Streit; L
Interactive Medical Publishing; O
Mastel Precision Instruments; C
Stephen D McLeod MD
Auris Robotics; C,O,P
Felipe A Medeiros MD
Allergan; C,S
Merck; S
Reichert, Inc; S
Topcon; S
Jodhbir S Mehta, MBBS, PhD
Endothelial Cell Culture; P
UK Network Medical; P
Ziemer; L
Gerrit RJ Melles MD PhD
Ophthalmic, USA; C
Geeta Menon MD FRCS
Allergan; C
Corporation; C,L
Jale Mentes, MD
Allergan; C,L
Corporation; C,L
Travis A Meredith MD
Pfizer, Inc.; C
Pauline T Merrill MD
Abbvie; C,S
Santen, Inc.; C,S
Erik L Mertens, MD, FRACOPHTH
Bausch Lomb; C
PhysIOL; L
STAAR Surgical; C
Shahzad I Mian, MD
Bausch Lomb; S
Stephan Michels MD MBA
Allergan; C
Clanotech; C,L
Esbatech; C
Corporation; C,L,S
William F Mieler, MD
GENENTECH; C
Aaron M Miller MD
Credential Protection; O
Daniel Matthew Miller MD PhD
GENENTECH; S
Inc.; S
Eydie G Miller-Ellis MD
Allergan, Inc.; C
ONO Pharma USA; C
Joan W Miller MD
Biogen Inc; C
Imagen Biotech, Inc.; C
Isis Pharmaceuticals; C
Kalvista Pharmaceuticals; C
Maculogix, Inc.; C
Mass. Eye & Ear/Valeant
Pharmaceuticals; P
ONL Therapeutics, LLC; C
Inc.; C
Kevin M Miller MD
Neil R Miller MD
Quark Phamaceuticals; C
Allergan; C
Donald S Minckler MD
NeoMedix Corporation; C
Paul Mitchell MD PhD
Allergan; C
Bayer Pharmaceuticals; C,L
Corporation; C,L
Lylas G Mogk MD
Random House; P
Daniel S Mojon MD
Carl Zeiss Inc; L
Jose R Montes MD
Allergan; C,O
Valeant; O
Virgilio Morales-Canton MD
Corporation; L
oraya therapeutics; C,L
Sanofi Fovea; C
Kazuhiko Mori MD
MSD; L
Ocular Instruments Inc; P
Pfizer, Inc.; L
Santen, Inc.; L
Senju Pharmaceutical Co.; L
Sayoko E Moroi MD PhD
Lippincott; P
Christie L Morse MD
AAPOS EVP; S
Sameh Mosaed MD
Allergan; L
Solx; S
Andrew A Moshfeghi MD, MBA
Alimera Sciences; C
Allergan; C
Bausch Lomb; C
GENENTECH; C
OptiSTENT, Inc.; C,O
Regeneron, Inc.; C
Synergetics, Inc.; C,O
Thrombogenics, Inc.; C,L,S
Valeant; C
Darius M Moshfeghi MD
Genentech, Inc.; C
Grand Legend Technology,
LTD; C,O
InSitu Therapeutics, Inc.; C,O,P
Oraya Therapeutics, Inc.; C,O
Visunex Medical Systems, Co.
Ltd.; C,O
Mark L Moster MD
Acorda Therapeutics; S
Biogen Inc; L
Marlene R Moster MD
Aeon Astron; S
Allergan; C,L,S
Bausch Lomb; S
Ista Pharmacuticals; C,L
Solx; L
TissueTech, Inc.; S
Michael Mrochen PhD
IROC, Inc.; E
WaveLight AG; C
Ewa Mrukwa-Kominek MD PhD
Medicem; C
Santen, Inc.; L
Thea; L
Prithvi Mruthyunjaya MD
Allergan; C
Timothy G Murray, MD MBA
Francisco Muruzabal PhD
BTI Biotechnology Institute; E
Jonathan S Myers MD
Diopsys, Inc.; S
Inotek; C,S
Sucampo Pharma Americas
Inc.; C
William G Myers MD
Bausch Lomb; L
Leiters Compounding Pharmacy;
E
David Myung, MD
DigiSight Technologies; C
Medigram, Inc.; C
Patent - smartphone optical
adapters; P

N
O
Michael D Ober MD
Allergan; C,L
Bayer; L
OD-OS; L,O
Hugo Ocampo
Corporation; C,L
Imelda-Odille Dziffa-Bella
Ofori-Adjei MBCHB
University of Ghana Research
Fund; S
Yuichiro Ogura MD PhD
Corporation; C,L
Santen, Inc.; C
Wakamoto, Inc.; C
Masahito Ohji MD
Allergan; C
Corporation; C,L
Otsuka Pharmaceutical; L
Pfizer, Inc.; C,L
Santen, Inc.; C,L
Sanwa Kagaku Kenkyusho; C
Senju Pharmaceutical; L
Shionogi; C
Shinji Ohkubo MD PhD
Kowa; C
Nidek, Inc.; C
Kyoko Ohno-Matsui MD
Corporation; C
Akio Oishi, MD PhD
Pfizer, Inc.; L
Akira Ojima, MD
Corporation; L
Annabelle A Okada MD
Bayer; S
Mitsubishi Tanabe Pharma; S
Novartis Pharma Japan; C,S
Santen, Inc.; S
Armando L Oliver MD
Bristol-Myers-Squibb; O
Timothy W Olsen MD
A Tissue Support Structure; P
Abraham J. and Phyllis Katz
Foundation; S
Scleral Depressor; P
The Fraser Parker Foundation; S
The R. Howard Dobbs Jr.
Foundation; S
Jeffrey L Olson MD
2C Tech; P
Galaxy Ophthalmics; P
Microsurgical Technology; C
James Kwan Ong
ASSORT Pty Ltd; E
Lindsay Ong-Tone MD
Sotaro Ooto MD
Alcon Japan; S
Silvia D Orengo-Nania MD
Allergan, Inc.; S
Gorka Orive PhD
BTI Biotechnology Institute; E
Shunsuke Osawa, MD
HOYA, Inc.; L
MANI, Inc.; C
Corporation; L
Pfizer, Inc.; L
RE medical, Inc.; L
Santen, Inc.; L
Senju, Inc.; L
Robert H Osher MD
Beaver-Visitec International,
Inc.; C
Clarity; C
Haag-Streit; C
Video Journal of Cataract &
Refrac Surg; O
Yusuke Oshima MD
Cynthia Owsley MSPH PhD
Centers for Disease Control
and Preventi; S
GENENTECH; S
National Institute on Aging; S
Union Pacific; C
University of Alabama at
Birmingham; P
Sengul C Ozdek MD
P
Mark Packer MD
Advanced Vision Science; C
Aerie Pharmaceuticals; C
Allergan; C
Bausch Lomb; C
Corinthian Ophthalmic; O
Iantech; O
LensAR; C,O
mTuitive; C,O
NewSee; C,O
Oculeve; C
PowerVison; C
Ltd; C
STAAR Surgical; C
SurgiView; C,O
Transcend Medical; C,O
TrueVision; C,O
VisionCare; C
WaveTec; C,O
Kirk H Packo MD
Allergan; S
GENENTECH; S
Inc.; S
Vision Care Inc.; C,S
Timothy P Page MD
Bausch Lomb; C,L
Ioannis G Pallikaris MD
Presby Corp.; C
Paul F Palmberg MD PhD

Aeron Astron, Europe (DSMB
member); C
AqueSys; C,L
Aurolab (unpaid consultant); C
InnFocus, Inc (new name for
Innovia); C,L
Joseph F Panarelli MD
Michel Paques
ImagineEye; C
MerckSerono; C
Ki Ho Park MD, PhD
Allergan, Inc.; C
Pfizer, Inc.; C
Santen, Inc.; L
David W Parke II MD
Insurance Company; C
Gregory D Parkhurst MD
OASIS Medical, Inc.; C
ReVision Optics; C,L
STAAR Surgical; C,L
Michael J Parshall
Michael J. Parshall HCC, LLC;
C,E,O
Leon G Partamian, MD
IOSensor, LLC; P
Louis R Pasquale MD
Rakesh M Patel MD
David E Pelayes MD
Corporation; S
Fernando Yaacov Pena MD
LCIF - Sight First; C
Mark E Pennesi MD PhD
Imagine Eyes; S
Jay Stuart Pepose MD PhD
1-800-Doctors; C,O
AcuFocus, Inc.; O,S
Allergan; C
Bausch Lomb; C,S
Clarity Medical; C,O
Elenza; C,O
Envisia; C
Mimetogen; C
TearLab; C,O
Victor L Perez MD
Allergan; C
Bausch Lomb; C
Elleven; C
GENENTECH; C
Parion; C
Rigel; C
Todd W Perkins MD
Emmes Corporation; C
Arthur C Perry MD
Integrated Orbital Implants,
Inc. (IOI); O,P
319
Disclosure Index
Sonali Nagendran MBBCHIR

Corporation; S
Manish Nagpal MD
Allergan, Inc.; L
Nidek, Inc.; L
Corporation; L
Topcon Medical Systems Inc.; L
Zoltan Nagy MD
Alejandro Navas MD
STAAR Surgical; L
Arvind Neelakantan MD
Allergan; L
Kristiana D Neff MD
Marcio B Nehemy MD
Bayer Shering Pharma; C,L
Corporation; C,L
Janet M Neigel MD
Allergan; C,L
Medicis; C,L
Valient; C,L
Anita Nevyas-Wallace MD
Bausch Lomb; C
Varitronics, Inc.; O
John D Ng MD
Bio-Logic Aqua; C,O
Jonathon Q Ng MBBS
Australian National Health and
Medical Research Council; S
Lai-Yeung Ngai, MBBS, PhD
Quan Dong Nguyen MD
AbbVie Pharmaceuticals; S
Bausch & Lomb Surgical; C,
GENENTECH; S,
Heidelberg Engineering; S,
Lux Biosciences, Inc.; S
Optos, Inc.; S
Inc.; S,
Sanofi Fovea; S
Santen, Inc.; C,S
Quang H Nguyen MD
Allergan, Inc.; L
Louis D Skip Nichamin, MD
3D Vision Systems; C,O
Allergan, Inc.; C
Eyeonics, Inc.; C,O
Foresight Biotherapeutics; C
Harvest Precision Components;
O
iScience; C,O
LensAR; C,O
Liquidia Technologies, Inc; C
PowerVision; C,O
RevitalVision, LLC; C,O
WaveTec Vision System; C,O
Kanwal K Nischal MBBS

CLARITY; L
Robert J Noecker, MD
Aerie; C
Aquesys; S
Innfocus; S
Inotek; C
Lumenis, Inc.; L
Ocular Therapeutics; C
Paradigm Medical Industries,
Inc.; L
Zeiss; S
Kouros Nouri-Mahdavi MD
Allergan; C
Roger L Novack MD PhD
Clarity medical; C
GENENTECH; L
Paolo Nucci MD
alfa intes; L
Allergan; S
Bausch Lomb; S
Corporation; S
SIFI EYELAB; S
Sooft; S
Thea Lab; S
Visufarma; S
Rudy Nuijts MD
ASICO; P
Bausch Lomb; C
Disclosure Index

Henry D Perry MD
Allergan; C
Nutriceuticals; P
Norbert Pfeiffer MD
Consultant for Ivantis; C
Ivantis; C
Novartis; S
Corporation; L
Stephen C Pflugfelder MD
Allergan; C,S
Bausch Lomb; S
GlaxoSmithKline; C, S
Dante Pieramici MD
Allergan; S
Bausch Lomb; C
GENENTECH; C,S
QLT Phototherapeutics, Inc; S
regeneron; S
Santen, Inc.; C,S
Thrombogenics; C
Jody R Piltz-Seymour MD
Allergan; S
Merck ; S
Roberto Pineda II MD
Amgen; C
Angiotech/Sharpoint; C
Genzyme; C
Matteo Piovella MD
Aaren Scientific; C
Inc.; L
Ocular Therapeutic; L
TearScience; L
Asim R Piracha MD
alphaeon; O
Bausch Lomb; L
Susanne Pitz
Actelion; C
Biomarin; L
Genzyme; L
David A Plager MD
Bausch Lomb; S
Omeros Corp; C
Uri Polat PhD
Glassesoff Inc.; C,O
John S Pollack MD
Clarus Acuity Group; O
Covalent Medical; O
Ophthalmic, USA; C
Vestrum Health; O
Eric A Postel MD
ArcticDx, Inc.; O
Benjamin Potsaid
Thorlabs, Inc.; E
Jonathan L Prenner MD
GENENTECH; C
Ophthotech; C,O
Panoptica; C,O
Regeneron; C
320
Francis W Price Jr MD
Allergan; C
Bausch Lomb; L,S
Lenstec, Inc.; C
Oculus, Inc.; L
OPHTEC, BV; C
ReVital Vision; O
STAAR Surgical; C
TearLab; O
Marianne O Price, PhD
Allergan; C
Bausch Lomb; L,S
Lenstec, Inc.; C
Oculus, Inc.; L
OPHTEC; C
ReVital Vision; O
STAAR Surgical; L
TearLab; O
Carmen A Puliafito MD MBA
Humphrey Zeiss; P
Q
Mujtaba A Qazi MD
Addition Technology, Inc.; L
Harry A Quigley MD
AC Immune; C
Graybug; C,O
Sensimed; C
Graham E Quinn MD
Hugo Quiroz-Mercado MD
Allegro Ophthalmics LLC; O
R
Melvin D Rabena MD
GENENTECH; L,S
Irving M Raber MD
Bausch Lomb; L
Allergan, Inc.; C,L
Glaukos Corporation; C,L
IRIDEX; C,L
Sunita Radhakrishnan MD
Netra Systems Inc.; C,O
Marko Radic PhD
Firas M Rahhal MD
Michael B Raizman MD
Allergan, Inc.; C,S
Avedro; C,O,S
Bausch Lomb; C,S
Boston Eye Surgery & Laser
Center; O
EyeGate; C,O,S
Nicox; C
Ocular Therapeutix; C,O,S
Omeros; C
Ophthalmic ConsultantsBoston; E
RPS; C
Rajesh K Rajpal MD
Alcon Laboratories, Inc.; C,L,
Allergan, Inc.; C,L,S,
Avedro; C,L,O,S
Bausch Lomb; C,L
Mimetogen; C
Nicox; C
RPS; C,O
Santen, Inc.; C
Arturo J Ramirez-Miranda MD
Pradeep Y Ramulu MD PhD
P Kumar Rao, MD
Inc.; S
Christopher J Rapuano MD
Allergan; C,L
Bausch Lomb; C,L
Rapid Pathogen Screening; O
Tear Science; C
TearLab; C
Magda Rau
Transcend Medical; C,S
Siriam Ravilla Duraisamy
Aurolab; E
Tal Raviv MD
Bausch Lomb; C,L
Wavetec; L
Aparna Raychaudhuri PhD
Shire ; E
Russell W Read MD PhD
EyeSight Foundation of
Alabama; S
Matthews Family Foundation; S
Maddy A Reddy, MBBCH
Barts Charity; S
Sherman W Reeves MD MPH
Allergan; C
Carl D Regillo MD FACS
Acucela; C,S
Alimera Sciences, Inc.; C,S
Allergan; C,S
Bausch Lomb; C
GENENTECH; C,S
NotalVision, Ltd.; C,S
Corporation; C
Pfizer, Inc.; C
Inc.; C,S
Santen, Inc.; S
Inc.; S
Stephane Regnier PhD
Novartis Pharma AG; E
Elias Reichel MD
Akorn Inc.; P
GENENTECH; C
GlaxoSmithKline; C
NewGen Biopharma; C,O
Ocular Instruments, Inc.; P
Ophthotech; C,O
Inc.; C,L
Thrombogenics; C,L
Charles D Reilly MD
Allergan; S
Bausch Lomb; S
Dan Z Reinstein MD
Arcscan Inc, Morrison, Colorado;
O,P
Marek Rekas MD
Michael X Repka, MD MBA
American Academy of Ophthalmology; S
Kourous Rezaei MD
BMC; C,L
GENENTECH; L,S
Ophthotec; C,O
Regeneron; L,S
Douglas J Rhee MD
Allergan, Inc.; C
Ivantis; C,S
Merck & Co., Inc.; C,S
Santen, Inc.; C
Gisbert W Richard MD
Bayer Healthcare Pharmaceuticals; L,S
Carl Zeiss Inc; S
Corporation; L,S
Pfizer, Inc.; S
Pixium; S
Christopher D Riemann MD
Allergan; S
Bausch Lomb; L
GENENTECH; S
Haag Streit; C
IRIDEX; L
Kaleidoscope Engineering; C
MaCor Industries; O,P
MedOne; C,P
Northmark Pharmacy; O
Inc.; S
SalutarisMD; C
Wolfgang Riha, MD
AcuFocus, Inc.; C
Robert Ritch MD FACS

Aeon Astron; C
Allergan; L
iSonic Medical; C
Ministry of Health of Kuwait; L
Pfizer, Inc.; L
Sensimed; C
David C Ritterband MD
Bausch Lomb; C,S
Robert P Rivera MD
AcuFocus, Inc.; C
Akorn Inc.; S
Avedro; L
Endo Optiks, Inc.; L
Escalon Medical Corp; L
STAAR Surgical; C,L,O
Shira L Robbins MD
Allergan; C
American Academy of Pediatrics; P
US Dept of Health & Human
Services; C
Cynthia Roberts PhD
Oculus, Inc.; C,L
Ziemer Ophthalmic Systems
AG; C,L,P
Alan L Robin MD
Aerie Pharmaceuticals; C,O
Allergan; C,L
Ohr Pharmaceuticals; C
Sucampo; C
XLVision, LTD; C
Eduardo B Rodrigues MD
Francisco J Rodriguez MD
Allergan; L
Bayer; C,L
Corporation; C,L,S
Richard H Roe MD
Adam H Rogers MD
Hemera Biosciences, Inc. ; O
Prin Rojanapongpun, MD
Allergan, Inc.; L,S
Carl Zeiss Inc; L
Pfizer Ophthalmics; L
Santen, Inc.; L
TRB; L
Sergio Rojas
Allergan; C
IRIDEX; L
Corporation; L
Mario R Romano MD PhD
David S Rootman MD
Gerald J Roper MD

Stephen Richard Russell MD
Acucela; S
IDx; O
Publisher of The Lost Art of
Retinal Dra; O
Spark Therapeutics; S
University of Iowa; P
Edwin Hurlbut Ryan Jr MD
S
Alain Saad MD
AcuFocus, Inc.; C
Bausch Lomb; C
Helmut Sachs MD
Retina Implant AG, Reutlingen
Germany; P,S
Srinivas R Sadda MD
Allergan, Inc.; C,S
Bausch Lomb; C
GENENTECH; C,S
Optos, Inc.; C,S
Alfredo A Sadun MD PhD
Edison Pharmaceutical; S
Stealth Peptides; S
Mandeep S Sagoo MBBChir
PhD
Astra Zeneca; C
Jose A Sahel MD
GENESIGNAL; C
GENSIGHT; C,O
PIXIUM VISION; C,O
Sanofi Fovea; C
Second Sight Medical Products, Inc.; P
Michael Saidel MD
Bausch Lomb; C,L
Taiji Sakamoto MD PhD
Bausch Lomb; C
Corporation; C
Santen, Inc.; L
Senju; L
Wakamoto; C
Sarwat Salim MD
Carolyn Salvato
BSM Consulting; C,O
John R Samples MD
Aquasys; C
Eyegenetix; C
Optic Nerve Regeneration
Technologies; C
Transcend; C,S
AcuMems; C
AqueSys; C
Inotek; C
iScience; O
Ivantis; C
ONO Pharmaceuticals; C
Santen, Inc.; C
SLACK, Incorporated; C
Cynthia Santiago, FRCS
Corporation; C,L
Steven R Sarkisian, MD
Aeon Astron; C,S
InnFocus; C
Ivantis; C
New World Medical Inc; C
SightSciences; O
Transcend; S
David Sarraf MD
Allergan; S
Ophthalmic, USA; S
GENENTECH; S
Regeneron; S
Thrombogenics; S
Joseph W Sassani MD
Penn State University; P
David Schaaf MD
Omeros Corporation; E
Shlomit Schaal MD, PhD
Allergan; C
Andrew P Schachat MD
Allergan; C
Bausch Lomb; C
Steven C Schallhorn MD
Allergan; C
Innovega; C
Optical Express; C
STAAR Surgical; C
Oliver Douglas Schein MD
Bausch Lomb; C
Vision Care Inc.; C
Adam J Scheiner MD
Allergan, Inc.; L
Sciton; L
Valeant; L
Leopold Schmetterer, PhD
Allergan; C,L,S
Croma; C,L,S
Corporation; C,L,S
Santen, Inc.; C,L,S
Thea; C,L,S
Ursula M Schmidt-Erfurth MD
Allergan; C
BayerHealthcare; C,L
Boehringer; C
Corporation; C,L
Eric B Schneider PhD

Bergeim, LLC; O
Karolinska Inst.; C
Pending patents related to
CNS injury; P
World Health Organization; C
Robert L Schultze MD
Joel S Schuman MD
Aerie Pharmaceuticals, Inc.; C
Carl Zeiss Meditec; C,P
Daniel M Schwartz MD
Calhoun Vision, Inc.; C,O,P
Gail F Schwartz MD
Stephen G Schwartz, MD MBA
Bausch Lomb; C
Santen, Inc.; C
ThromboGenics, Inc.; L
Steven D Schwartz MD
Allergan, Inc.; C
Genentech, Inc.; C,L
OptiMedica; C,L,O
Optos, Inc.; C,L
Stephen V Scoper MD
Ingrid U Scott MD MPH
GENENTECH; C,L
Sanofi Fovea; C
Santen, Inc.; C
Thrombogenics; C
Maria Cirone Scott MD
TearScience; L
J Sebag MD, FACS, FRCOphth,
FARVO
ThromboGenics; C
Mitra Sehi, PhD
Leonard K Seibold MD
Charles P Semba MD
Shire Pharmaceuticals; P
Robert C Sergott MD
Biogen Inc; C,S
Corporation; C,S
Serono; C
Ankoor S Shah MD, PhD
Medtronic; O
Pfizer, Inc.; O
Chirag P Shah MD MPH
Alimera; S
Allergan; S
Bayer; L
GENENTECH; S
GlaxoSmithKline; S
Molecular Partners; S
Neovista; S
Paloma; S
Regeneron; S
Gaurav K Shah MD
Allergan, Inc.; C,S
QLT Phototherapeutics, Inc; C,L
Inc.; C,L
Sunil Shah MD
Allergan, Inc.; P
CustomVis; O
Lenstec, Inc.; C
Ltd; S
Vinay A Shah MD
Cloud Nine Development,
LLC; O
Neda Shamie MD
Allergan; C,L
Bausch Lomb; C,L
Howard Shapiro PhD
Genentech, Inc.; E
Victoria M Sheffield
Stephen C Sheppard
Bausch Lomb; C
Deborah D Sherman MD
Allergan; C,L,O
Mark B Sherwood MD
Allergan, Inc.; C
Elsevier, Inc.; P
Sensimed; C
M Bruce Shields MD
PRE 2B; P
Transcend ; C
Shigeto Shimmura MD
Santen, Inc.; L
Bradford J Shingleton MD
InnFocus; C
Ivantis; C
Neal H Shorstein MD
Kaiser Permanente; S
Julia P Shulman MD
Allergan; C
Modernizing Medicine EMA; C
Shiri Shulman, MD
Allergan; L
Jane T Shuman, COE COT
MSM OCS
Eyetechs, inc; C,O
Paul A Sidoti MD
Carla J Siegfried MD
Allergan; C,L
HDI, Inc.; O
Shameema Sikder MD
Allergan; C
Association Accumen; C
Rona Z Silkiss MD FACS
GENENTECH; C
321
Disclosure Index
Linda Rose MD PhD

GENENTECH; S
Richard B Rosen MD
Allergan; S
Clarity; C
GENENTECH; S
OD-OS; L
Optovue; C
James T Rosenbaum MD
Allergan; C
GENENTECH; C, S
Lux; C, S
Corporation; C
Regeneron; C
Sanofi Fovea; C
Santen, Inc.; C
Serono; C
Teva Pharmaceutical Industries, Ltd.; C
UCB; C
Xoma; C
Ron Rosenberg, PA MPH
Practice Management
Resource Group; C,O
Philip J Rosenfeld MD PhD
Acucela; C,S
Boehringer Ingelheim; C
Chengdu Kanghong Biotech; C
Digisight; O
GENENTECH; S
GlaxoSmithKline; S
Oraya; C
Xcovery Vision; C
Steven I Rosenfeld MD FACS
Allergan, Inc.; L
Modernizing Medicine; C
Daniel B Roth MD
Allergan; C,L
Forsight Labs; C,O
GENENTECH; S
Ohr Pharmaceutical; C,O
Regeneron; C,L
Thrombogenics; L,S
Ilya M Rozenbaum MD
Allergan; C,L
Bausch Lomb; C
Anne Rubin MBA
ForSight VISION5; E,O,P
Marcos J Rubio Caso MD
Corporation; C
Christopher J Rudnisky MD
Bausch Lomb; L
Corporation; O
Bill Russ
Essilor of America; E,L,O
Disclosure Index

Rufino Silva, MD, MSC
Allergan; C
Corporation; C
THEA; C
Charles Simmons Jr MD
Amgen; O
Apple Computer, Inc.; O
Biogen Inc; O
Clarity; L
Kellbenx; P
Steven T Simmons MD
Allergan; C
Mati Pharmaceuticals; C
Michael A Singer MD
ACUCELA; C
Bausch Lomb; C,L
EYEGATE; S
GENENTECH; C,L,S
Optos, Inc.; S
REGENERON; C,L,S
Santen, Inc.; C
ThromboGenics, Inc.; L,S
Lawrence J Singerman MD
Allergan, Inc.; S
ArcticDx, Inc.; C,O
GENENTECH; S
MacTel; S
Corporation; S
Ohr Pharmaceuticals; C,O,S
Ophthotech; C,O,S
ThromboGenics; S
Harinderjit Singh MD
Acucela; S
Research; S
GENENTECH; S
GlaxoSmithKline; S
Juvenile Diabetes Research
Foundation; S
Lpath, Inc.; S
Ophthotech; S
Pfizer, Inc.; S
Quark; S
Inc.; S
Kuldev Singh MD MPH
Allergan, Inc.; C
Bausch Lomb; C
ForSight; C
Ivantis; C
Santen, Inc.; C
Sucampo; C
Transcend; C
Rishi P Singh MD
Bausch Lomb; C
Bayer Regeneron; C,L,S
GENENTECH; C,L,S
322
Kimberly C Sippel MD
GENENTECH; C
Neurotech, Inc.; O
Ophthotech, Inc.; O
OptiMedica; O
Arthur J Sit MD
AcuMEMS; C
Allergan; C
BrightFocus Foundation; S
Sensimed AG; C
Sucampo Pharma Americas,
LLC; C
Gregory L Skuta MD
Stephen G Slade MD FACS
Alcon Laboratories, Inc.; C,L,O
Bausch Lomb; C
Corporation; O
RVO; C
Tracey Technologies; O
Jason S Slakter MD
Acucela; C,S
Alimera; S
Bayer HealthCare; S
Centocor, Inc.; S
Fovea/SanofiAventis; S
GENENTECH; S
GlaxoSmithKline; S
Lpath Inc.; C,S
Ohr Pharma; C,S
Oraya Therapeutics; C,S
Regeneron Pharmaceuticals; L,S
Sanofi-Aventis; S
Santen, Inc.; S
SKS Ocular, LLC; O
Xcovery Vision; C,S
Allan R Slomovic MD
Allergan; C
Bausch Lomb; C
David Smadja, MD
Justine R Smith MD
National Health&Medical
Research Council; S
Ophthalmic Research Institute
Australia; S
Ltd.; C
Lois E H Smith MD PhD
Shire; C
Oluwatosin U Smith MD
Allergan; C,L
Santen, Inc.; C
Michael E Snyder MD
Haag Streit; C
Humanoptics; C
Alfred M Solish MD
Kerry D Solomon MD
Advanced Vision Research; C,L,S
Aquesys; C,O
LacriScience; C
Mati Therapeutics; O
Nidek, Inc.; S
Versant; O
Zeiss; S
Barrie D Soloway MD
Refocus Group, Inc.; C,L
Joern B Soltau MD
CVS Caremark; C
Sriram Sonty MD FACS
Eric H Souied, MD PhD
Bausch Lomb; L
Corporation; C
Luciene B Sousa MD
Allergan, Inc.; C
George L Spaeth MD FACS
Allergan; L,S
Merck & Co., Inc.; L,S
Pfizer, Inc.; L,S
Richard F Spaide MD
Ltd.; C
Topcon Medical Systems; P
William Eric Sponsel MD
New World Medical Inc; P
Ono Pharmaceutical; C
Sathish Srinivasan, MBBS
Bausch Lomb; C
Samaresh Srivastava, BMBS,
MS
Sunil K Srivastava MD
Allergan; S
Bioptigen; P
Corporation; S
Sanofi Fovea; C
Santen, Inc.; C,L
Erin D Stahl MD
Abbott Medical Optics Inc.; C,L,S
Accelerated Vision; C,L,O
AcuFocus, Inc.; C,L,O,S
Alcon Laboratories, Inc.; C,L,O,S
Allergan; L,S
Avedro; L,O,S
NexisVision; O
Revital Vision; O
Strathspey Crown LLC; C,L,O
WaveTec; C,L,O,P
Peter W Stalmans MD PhD
Bausch Lomb; C,S
Ophthalmic, USA; L
Thrombogenics; L,S
George Stamatelatos OD
ASSORT PTY LTD; E
Walter J Stark MD
VueCare Media; O
Christopher E Starr MD
Allergan, Inc.; C,L
Bausch Lomb; C,L
Nicox; C
RPS Inc.; S
TearLab; C,S
Giovanni Staurenghi MD
Allergan, Inc.; C
Bayer; C,L
Boehringer; C
GlaxoSmithKline; C
Corporation; C,L,S
OD-OS; C
Optos, Inc.; C
Optovue; S
Roche; C
Zeiss; C,S
Einar Stefansson MD PhD
Icelandic Research Council; S
Oculis ehf; O,P
Oxymap ehf; O,P
Risk ehf; O,P
Joshua D Stein, MD, MS
Glaucoma forecasting tool; P
W.K. Kellogg Foundation; S
Roger F Steinert MD
Avedro; C,O
LensGen; O
ReVision Optics; C
Rhein Medical, Inc.; P
WaveTec; C
Nathan C Steinle MD
Inc.; C,L
P Dee G Stephenson MD FACS
Aaren Scientific; C
WaveTec Vision; C,L
Anna Sterkin PhD
GlassesOff Inc.; E
Julian D Stevens, DO
Abbot Medical Optics Inc.; C
Oculentis AG; C
OptiMedica Inc.; C
Revision Optics Inc.; C
Michael W Stewart MD
Allergan; C
Boehringer-Ingelheim; C
Inc.; C
Michael C Stiles MD
Allergan, Inc.; L
iScience; C
Ista Pharmacuticals; L
Pfizer, Inc.; L
Katarina Stingl, MD
Retina Implant AG; S
Pavel Stodulka MD PhD
Bausch Lomb; C
Ivo Stoilov MD
GENENTECH; E
ROCHE; O
Donald Stone MD
Santen, Inc.; C
Karl G Stonecipher MD
Alcon; C,L,S
Allergan; C,L,S
Bausch & Lomb; C,L
LaserACE; C
Nexis; C,S
Nidek; C,L,S
Oasis Medical Inc; C,L
Refocus Group, Inc.; C,S
STAAR Surgical; L
TLC Laser Eye Centers; E
J. Timothy Stout, MD, PhD, MBA
Centocor, Inc.; C
Clayton Foundation for
Research; P
Oxford Biomedica; P,S
Michael D Straiko MD
Bio-Tissue, Inc.; C
R Doyle Stulting MD PhD
Allergan; L
Calhoun Vision Inc; C
EyeYon; C,O
Hoya Corporation; C
NuLens; C
Optovue; C
TearLab; C,O
Prem S Subramanian MD PhD
Lundbeck, Inc.; S
Corporation; S
Elizabeth Ann Sugar PhD
Joel Sugar MD
US Foood and Drug Administration; C
Eric Suhler MD
Abbvie; C,S
Bristol-Myers Squibb; S
Clearside Biomedical; C
EyeGate; S
GENENTECH; S
Xoma; C,S
Aneesh Suneja
FlowOne Lean Consulting, LLC; C
Ivan J Suner MD
GENENTECH; C,L,S
Regeneron; L
ThromboGenics Ltd; C,L
John E Sutphin MD
Elsevier, Inc.; C
Kazutaka Suzuki
HAMAMATSU Photonics K.K.; E
T
Homayoun Tabandeh MD MS
FRCP FRCOphth
Khalid F Tabbara MD
Laboratoires THEA; L

Joseph Tauber MD
Allergan, Inc.; C,S
Auven; C
Bausch Lomb; C
Biolase; C
Eleven Bio; C
EyeGate Pharmaceuticals
Inc.; S
SARcode Bioscience Inc.; S
Shire; C
Xoma; S
Simon RJ Taylor MA PhD
FHEA FRCOphth
GlaxoSmithKline; S
Corporation; C,L,S
Santen, Inc.; C
David G Telander MD
Allergan; L
GENENTECH; S
OPHTEC; C
Mark A Terry MD
Bausch & Lomb Surgical; P,S
MORIA; S
Paul M Tesser MD PhD
Allergan; L
Howard H Tessler MD
Allergan, Inc.; O
Miguel A Teus MD
Clement C Y Tham MBBS
Aeon Astron Corporation; S
Allergan, Inc.; C
Bausch Lomb; C
Icare Finland; S
Pfizer, Inc.; C,L,S
Santen Pharmaceutical Co.,
Ltd.; C,S
Sensimed; S
Bettina Thomas MD
Allergan; S
Bausch Lomb; S
Contamac; S
Dr. Schmidt Intraocularlinsen; S
Corporation; S
Oculentis; S
Physiol; S
Powervision; S
Ltd; S
Vance Michael Thompson MD
AcuFocus, Inc.; C,L,O
Avedro; C
Bausch Lomb; C
Calhoun Vision Inc; C
Euclid Systems; C
Forsight; C
OPHTEC; C
Wavetec; C
Zeiss; C
Jennifer E Thorne MD PhD

AbbVie; S
Allergan; S
Gilead Sciences; C
Xoma; C,S
Richard Tipperman MD
Alcon Laboratories, Inc.; C,
Marco; C
Khiun F Tjia MD
Alcon Laboratories, Inc.; C,
Minoru Tomita MD PhD
AcuFocus, Inc.; C
C
VSY Biotechnology; C
Zimmer; C
Fotis Topouzis MD
Bausch Lomb; C
Humphrey Zeiss; C
Corporation; C,S
Pfizer, Inc.; S
Paul E Tornambe MD
Bausch Lomb; C
GENENTECH; C
Humphrey Zeiss; C,L
Insight Instruments; C,P
Inspire Pharmaceuticals, Inc.; C
Nidek, Inc.; C
Optos, Inc.; C, L
Poway Retinal Technologies;
O,P
QLT Phototherapeutics, Inc; C,L
Stemedica; C
ThromboGenics, Inc.; C,L
Leonardo Torquetti MD, PhD
Ferrara Ophthalmics; C
Cynthia A Toth MD
Bioptigen, Inc.; S
Genentech, Inc.; S
Haruyoshi Toyoda
Hamamatsu Photonics K.K.; E
Elias I Traboulsi MD
Oxford Biomedica; C
William B Trattler MD
Bausch & Lomb; S
CXLO; C,O
CXLUSA; C
LensAR; C
Oculus, Inc.; L
Rapid Pathogen Screenings; S
Tear Science; C
Michael T Trese MD
Focus ROP; C,O
GENENTECH; C
Nu-Vue Technologies, Inc.; C,O
Retinal Solutions LLC; C,O
ThromboGenics Inc.; C,O
Claudio L Trindade, MD
Morcher GmbH; P
Rupal H Trivedi, MBBS, MS
Lippinicott; P
Springer; P
James C Tsai, MD MBA

Amakem; C
Sucampo; C
David T Tse MD FACS
Innovia; O,P
Scheffer C G Tseng MD PhD
Bio-Tissue, Inc.; C,O,P
TissueTech, Inc.; E,O,P,S
Kazuo Tsubota MD
Allergan; S
CEPT Company; P
Functional visual acuity
meter; P
JINS; P
Kissei; S
Kowa; S
Nidek, Inc.; S
Ophtecs; S
Otsuka Pharmaceuticals; S
Pfizer, Inc.; C
Rainbow Optical; P
Santen, Inc.; C,L,S
Suntory; S
Wakasa Seikatsu Co., Ltd; S
Akitaka Tsujikawa MD PhD
Corporation; L
Pfizer, Inc.; L,S
Santen, Inc.; L
Adnan Tufail, MD
Allergan; C,L
GENENTECH; C
Notal Vision, Inc.; S
Corporation; C,L,S
Ilknur Tugal-Tutkun MD
Institut de Recherches Int
Servier; C
Roger E Turbin MD
U
Morio Ueno MD
Santen Pharmaceutical Co; P
Senju Pharmaceutical Co.; P
Martin Uram MD
Endo Optiks, Inc.; O
Fernando Ussa-Herrera MD
Pfizer, Inc.; S
Harvey S Uy MD
Allergan; L
Inc.; S
LensAR; L,S
Corporation; C,L
Santen, Inc.; L
V
Thasarat S Vajaranant MD
Bausch Lomb; S

Corporation; S
Theravance; S
Jan C Van Meurs MD
Ophthalmic, USA; P
Michael S Vaphiades DO
Questcor; L
Devesh K Varma MD
Allergan, Inc.; C,L
Labtician Ophthalmics Inc; C,L
Rohit Varma MD MPH
Allergan, Inc.; C
Aquesys; C
GENENTECH; C,S
Replenish, Inc.; C,S
Abhay Raghukant Vasavada
MBBS FRCS
Shail Vasavada
Francesco Versaci MS
CSO srl; E
Paolo Vinciguerra MD
Nidek, Inc.; C
Oculus, Inc.; C
C
Riccardo Vinciguerra MD
Optimeyes; C
Balakrishna Vineeth Kumar,
MBBS
Corporation; C,L
Steven D. Vold MD
Aeon; S
Allergan, Inc.; L,S
Alphaeon; C,O
AqueSys; C,S
Forsight Labs; C,S
InnFocus; C,S
IRIDEX; C,L,P
Ivantis; C,S
NeoMedix Corporation; C,L
Ocunetics; C,O
SOLX; S
Transcend Medical; C,S
TrueVision Systems; C,S
Wavetec Vision; C
David E Vollman, MD, MBA
ForSight; C
Vistakon Johnson & Johnson
Visioncare, Inc.; C
David T Vroman MD
Alcon Laboratories, Inc.; O,S
Bausch Lomb; L
John Allan Vukich MD
AcuFocus, Inc.; C
Carl Zeiss Meditec; C,
Optical Express; C
STAAR Surgical; C,
323
Disclosure Index
Ramin Tadayoni MD PhD

Alimera Sciences, Inc.; C,L
Allergan; C,L,S
Bausch Lomb; C,L
FCI Ophthalmics; C
GENENTECH; C
Humphrey Zeiss; S
Corporation; C,L,S
Jonathan H Talamo MD
Allergan, Inc.; C
Bausch Lomb; C,S
CXL Opthalmics; C,O
Ikona; C,P
Nexis Vision; C,O
Ocular Therapeutics; S
Optimedica; C,O
Wavetec ; C,S
Audrey R Talley-Rostov MD
Allergan, Inc.; C,L
NICOX; C
Gustavo E Tamayo MD
Abbott Medical Optics; C,O,P
AVEDRO; L
Cellular Bioengineering; C
Presbia Corp.; C
Colin S Tan MBBS
National Healthcare Group
Research Grant; S
Donald Tan MD FRCS
FRCOphth
Bausch Lomb; S
Network Medical Products; P
Santen, Inc.; S
James Chee Hian Tan
Karl Kirchgessner Foundation; S
Jerry Tan MBBS
C
Ou Tan PhD
Optovue; P,S
Zeiss Meditec; P
Suphi Taneri MD
Bausch Lomb; L
Technolas; L
Rosa A Tang MD MPH MBA
Serono; L
Angelo P Tanna MD
Apotex, Inc.; C
Sandoz; C
Sucampo Pharmaceuticals; C
Watson Laboratories, Inc.; C
Andrew J Tatham MBChB
Disclosure Index
W
Maureen Waddle, MBA
BSM Consulting; C
Hussein Wafapoor MD
ARMS LLC; O
Alexander C Walsh MD
Envision Diagnostics; E,O,P
Keith A Walter MD
Bausch Lomb; C,L
Ocular Systems; C,P,S
Thomas R Walters MD
Bausch Lomb; C
Ocular Trerapeutics; L
Omeros; C
Kelly Walton Muir MD
VA HSR&D; S
Kevin Lee Waltz MD
AcuFocus, Inc.; O,S
Akorn Inc.; S
Revital Vision; O
Tracey Technologies; O
James Warburton
Corporation; E,O
George O Waring III, MD FACS
AcuFocus, Inc.; O
Nidek, Inc.; C
OptiMedica; C
George O Waring IV MD
Accelerated Vision; C
AcuFocus, Inc.; C,L,O
Allergan; C
Avedro; C
Bausch Lomb; C
Focal Point, Asia; C
Gerson Lehrman Group; C
Revitalvision; C
Ann A Warn MD MBA
Keith A Warren MD
Peter Wasserman MD
Insight Healthcare Solutions; O
Mitchell P Weikert MD
Ziemer Ophthalmic, Inc.; C
Robert N Weinreb MD
AcuMEMS; C
Aerie; C
Allergan, Inc.; C,L
Aquesys; C
Bausch & Lomb; C
GENENTECH; S
Humphrey Zeiss; L
Nidek, Inc.; S
Quark; C,S
Sensimed; C
Solx; C
Topcon Medical Systems; C,S
324
Robert J Weinstock MD
Bausch Lomb; C,L
STAAR Surgical; C,L
Truevision; C,O
Wavetec; C,O
Jayne S Weiss MD
John A Wells III MD
Allergan; S
Ampio Pharmaceuticals; S
Emmes; S
GENENTECH; S
Iconic Pharmaceuticals; C
Jaeb Center for Health
Research; S
KalVista; S
LPath Inc; S
Corporation; S
Ophthotech Corporation; S
Panoptica; S
Regeneron ; S
Santen, Inc.; S
Liliana Werner MD PhD
Aaren Scientific; S
AcuFocus, Inc.; S
Advanced Vision Science; S
Anew Optics; S
ClarVista Medical; S
Hoya; S
PhysIOL; S
Powervision; C
Tekia, Inc.; S
Scott M Whitcup MD
Allergan; E,O
Jeffrey Whitman MD OCS
Bausch Lomb; C,L
OASIS Medical, Inc.; C
Revision Optics; C
STAAR Surgical; L
Robert E Wiggins, MD MHA
William F Wiley MD
WaveTec; C,O
C P Wilkinson MD
FDA; C
David F Williams MD
Allergan; C
GENENTECH; C
Vestrum Health; O
George A Williams MD
Allergan, Inc.; C,S
ForSight; C,O
Neurotech; C,S
OMIC-Ophthalmic Mutual Insurance Company; E
OptiMedica; C,O
ThromboGenics; C,O
Ruth D Williams MD
Allergan; C
Tom H Williamson, MD
axsys ltd glasgow uk; C
David J Wilson MD
AGTC; S
Foundation Fighting Blindness; S
Oxford BioMedica; C,S
Steven E Wilson MD
Allergan, Inc.; C,L
John R Wittpenn Jr MD
Bausch Lomb; L
Omerus; C
Edward J Wladis MD
Lions Eye Foundation; S
Ted H Wojno MD
Ethicon; C
Medical Director Solutions; C
Jeremy Wolfe MD
Agnes M Wong MD
Canada Foundation for Innovation; S
Canadian Institutes of Health
Research; S
Keye L Wong, MD
Randall V Wong MD
Medical Marketing Enterprises,
LLC; O
S Chien Wong, MBBS, FRCS
Tien Pei Wong MD
Allergan; C
GENENTECH; C
Tien Yin Wong MBBS
Allergan Singapore Pte Ltd; C
Allergan, Inc.; C
Bayer Healthcare Company
Limited; C
Bayer Healthcare Pharmaceuticals Inc.; C
Novartis Pharma AG; C
William Wong MS PHARMD
Allergan; E
Joy Woodke, COE, OCS
Private Consulting; C
Julie A Woodward MD
Elure/syneron; S
Lutronic; C
Medicis; L
Merz; L
Skin Ceuticals; C
Maria A Woodward MD
Kenneth W Wright MD
Springer Publisher; P
Titan Surgical; P
Walter G Wrobel, MD
Retina Implant AG; E,O
Gloria Wu MD
Gloria Wu, MD PC; P
Helen K Wu MD
Allergan; C
Iop inc; L
Lihteh Wu MD
Bayer Health; L
Allan E Wulc MD FACS
Apogee Aesthetic Technologies; O
Merz; C
Charles C Wykoff, MD, PhD

Allergan; C
GENENTECH; L
Regeneron; L
Y
Tetsuya Yamamoto MD
Kowa; C
MSD; L,S
Otsuka; C,L,S
Pfizer, Inc.; C,L,S
Santen, Inc.; L,S
Senju; C,L,S
Yang Yang PhD
Santen, Inc.; E
Steven Yeh MD
Clearside; C
Oren Yehezkel PhD
Glassesoff; E
Michael T Yen MD
Merz Pharmaceuticals; C
Elizabeth Yeu MD
Abbott Medical Optics Inc.; C,S
Allergan; C,L
Bausch Lomb; C,L
Sonia H Yoo MD
Allergan, Inc.; S
Optimedica; C
SLACK, Incorporated; L
Transcend; C
Young Hee Yoon, MD
Allergan; C,L,S
Bayer; C,L,S
Nagahisa Yoshimura MD PhD
Canon, Inc; C,S
Nidek, Inc.; C
Topcon Medical; S
Terri L Young MD
Z
David N Zacks MD PhD
Massachusetts Eye and Ear
Infirmary; P
ONL Therapeutics, LLC; O
University of Michigan; P
Roger Zaldivar, MD
visionmetrics consultant; C
Linda Zangwill PhD
Nidek, Inc.; S
Marco A Zarbin MD PhD FACS
GENENTECH; C
Helios, KK; C
Imagen Biotech, Inc.; C
IRIDEX; C
Corporation; C
Pfizer, Inc.; C
Roche; C
Rutgers University; P
Michael E Zegans MD
Hitchcock Foundation; S
MedImmune; S
NASA; S
Harry A Zink MD
OMIC-Ophthalmic Mutual Insurance Company; C,L
Mia Zoric Geber, MD
Pfizer, Inc.; L
Eberhart Zrenner MD
Merck & Co., Inc.; C,S
Corporation; C
Pfizer, Inc.; C
QLT Inc; C
Retina Implant AG; C,L,O,P,S
CME & CE CREDIT

AAO 2014 Learning Objectives
CME Mission Statement

The purpose of the American Academy of Ophthalmologys Continuing
Medical Education (CME) program is to present ophthalmologists with
the highest quality lifelong learning opportunities that promote improvement and change in physician practices, performance or competence,
thus enabling such physicians to maintain or improve the competence and
professional performance needed to provide the best possible eye care for
their patients.
The American Medical Association has determined that nonU.S. licensed
physicians who participate in this CME activity are eligible for AMA PRA
Category 1 Credits.
Attendees registered as exhibitors, spouses or guests are not eligible to
receive CME credit.
Upon completion of this activity, participants should be able to:

Identify recent advances in the diagnosis and treatment of eye diseases.
Identify major advances in key areas of cutting-edge research and
technology in ophthalmology.
Incorporate skills and techniques from the hands-on Skills Transfer
courses into their daily practice.
Integrate practice management strategies to address critical business
and operational tasks in the ophthalmologists practice.
Develop strategies to identify and address their own individual professional practice gaps.
AAO 2014 CME Credit
This activity has been designed to meet the educational needs of ophthalmologists, nurses, ophthalmic technicians and other allied health personnel
who are engaged in the diagnosis and treatment of eye diseases, as well
as business managers responsible for managing the business aspects of an
ophthalmic practice.
The American Academy of Ophthalmology designates this live activity for
a maximum of 33 AMA PRA Category 1 Credits. Physicians should claim
only the credit commensurate with the extent of their participation in the
activity.
The American Medical Association has determined that nonU.S. licensed
physicians who participate in this CME activity are eligible for AMA PRA
Category 1 Credits. Attendees registered as exhibitors, spouses or guests
are not eligible to receive CME credit.
Portions of the meeting identified for credit include AAO 2014 scientific
sessions, instruction courses, Skills Transfer courses, Breakfast With the
Experts, Practice Management Master Classes, Scientific Papers and Posters, the Video Program, and the Jackson Memorial Lecture at the Opening
Session.
Portions of the meeting not eligible for credit include, but are not limited
to, committee meetings, viewing exhibits, attending Special Meetings &
Events, the AAOE General Session, social networking and any affiliate
event.
AAO 2014 Target Audience
2014 Subspecialty Day CME Credit

Subspecialty Day Activities for Retina and Refractive Surgery

activity.
Subspecialty Day Activities for Cornea, Glaucoma, Ocular

Oncology and Pathology, Oculofacial Plastic Surgery,
Pediatric Ophthalmology and Uveitis

activity.
| Tel: 415-561-8500 Fax: 415-561-8533

325
CME & CE Credit

CME & CE Credit
Self-Assessment Credit
This years Subspecialty Day meetings, as well as up to 10 credit hours
within AAO 2014, have been pre-approved as self-assessment credit.
These courses and the Cataract Spotlight are designated within the AAO
2014 program with a SA symbol.
Portions of these activities meet the Self-Assessment CME requirements defined by the American Board of Ophthalmology (ABO). The
ABO is not an accrediting body for purposes of any CME program. ABO
does not sponsor this or any outside activity, and ABO does not endorse
any particular CME activity. Complete information regarding the ABO
Self-Assessment CME Maintenance of Certification requirements are
available at: http://abop.org/maintain-certification/part-2-lifelonglearning-self-assessment/cme/.
NOTE: Credit designated as self-assessment is AMA PRA Category
1 Credit and is also pre-approved by the ABO for the Maintenance of
Certification (MOC) Part II CME requirements.
AAOE Coding Session CME Credit

The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing
medical education for physicians.
Half-Day Coding Session

activity.
Teaching at a Live Activity

Teaching instruction courses, or delivering a scientific paper or poster are
not AMA PRA Category 1 Credit activities and should not be included
when calculating your total AMA PRA Category 1 Credits.
Presenters may claim AMA PRA Category 1 Credits through the American Medical Association, www.ama-assn.org.
Scientific Integrity and Disclosure of Financial

Interest
The American Academy of Ophthalmology is committed to ensuring that
all continuing medical education (CME) information is based on the application of research findings and the implementation of evidence-based
medicine. It seeks to promote balance, objectivity and absence of commercial bias in its content. All persons in a position to control the content
of this activity must disclose any and all financial interests. The Academy
has mechanisms in place to resolve all conflicts of interest prior to an
educational activity being delivered to learners.
Attendance Verification for CME Reporting

Before processing your requests for CME credit, the Academy must verify
your attendance at AAO 2014 and/or Subspecialty Day. In order to be verified for CME or auditing purposes, you must either:
Register in advance, receive your materials in the mail before traveling
to the meeting, then turn in the Final Program and/or Subspecialty Day
Syllabus exchange voucher(s) onsite;
Register in advance, pick up your materials onsite if you did not receive
them before traveling to the meeting;
Register onsite; or
Scan the barcode on your badge as you enter an AAO 2014 course or
session room.
326
Badge Scanning What Does It Mean?
Each AAO 2014 meeting badge displays a barcode. Staff stationed at

each course and session room will scan your badge, verifying your attendance.
At the end of each day, an e-mail will be sent confirming the courses
and sessions at which your badge was scanned, with links directly to
the evaluation. Your participation in the evaluation process is critical for
maintaining a high-quality program.
NOTE: You do not need to scan your badge at Subspecialty Day meetings,
AAOE coding sessions or at any ticketed event.
Badge Scanning and CME
Getting your badge scanned does not automatically grant CME. You still
need to record your own educational activities. You can do so either in
Chicago, at designated CME Reporting stations, or online after the meeting. Please note: You should claim only the credit commensurate with the
extent of your participation in the activity.
CME Credit Reporting
Attendees whose attendance has been verified at AAO 2014 can claim
their CME credit online during the meeting. Registrants will receive an
email on Monday, Oct. 20 with a link and instructions on how to claim
credit.
Onsite you may also report credits earned during Subspecialty Day and/or
the AAO 2014 at a CME Credit Reporting booth. After AAO 2014, credits
can be claimed online: www.aao.org/2014.
NOTE: CME credits must be reported by Jan. 14, 2015.
Academy Members
The CME credit reporting receipt is not a CME transcript. CME transcripts
that include AAO 2014 credits entered onsite will be available to Academy members on the Academys website beginning Nov. 13, 2014.
The Academy transcript cannot list individual course attendance. It will
list only the overall credits spent in educational activities at Subspecialty
Day and/or AAO 2014.
Nonmembers
The Academy will provide nonmembers with verification of credits

earned and reported for a single Academy sponsored CME activity, but
it does not provide CME credit transcripts. To obtain a printed record of
your credits, you must report your CME credits onsite at the CME Credit
Reporting booths.
Proof of Attendance
The following types of attendance verification will be available during

the AAO 2014 and Subspecialty Day for those who need it for reimbursement or hospital privileges, or for nonmembers who need it to report CME
credit:
CME credit reporting/proof-of-attendance letters
Instruction course and session verification
Onsite registration receipt
Visit www.aao.org for detailed CME reporting information.
CME & CE Credit

AAPC Continuing Education Credit
CME & CE Credit
The American Academy of Professional Coders (AAPC) reviews and

selects courses towards the maintenance of CPC, CPC-H and CPC-P
certification. Approved courses are identified with a C . Granting of prior
approval in no way constitutes endorsement by the AAPC of the program
content or the program sponsor. A certificate of completion is included in
the AAOE Coding Session workbook for AAPC and JCAHPO attendance
verification. Visit www.aapc.com for more information.
NOTE: AAPC credits cannot be claimed on the Academys online CME
system.
NBCOE Continuing Education Credit

The National Board for the Certification of Ophthalmic Executives (NBCOE) reviews the American Academy of Ophthalmic Executives (AAOE)
program for COE Category A credit hours. Approved courses are identified
with a A . All Category A activities yield a 1:1 credit ratio for hours spent
to hours earned. Visit www.asoa.org for more information.
JCAHPO Continuing Education Credit

The Annual Commission on Allied Health Personnel in Ophthalmology
(JCAHPO) reviews courses for continuing education credit toward certification or recertification in ophthalmic medical assisting for COA, COT and
COMT levels. Approved courses are identified with a J and classified as
either Group A or Group B. Though JCAHPO may award continuing education credit for specified courses, JCAHPO does not sponsor these or any
other review course. A certificate of completion is included in the AAOE
Coding Session workbook for AAPC and JCAHPO attendance verification.
Visit www.jcahpo.org for more information.
NOTE: JCAHPO credits cannot be claimed on the Academys online CME
system. Credit must be claimed directly with JCAHPO when you are ready
to recertify.
327
FUTURE MEETINGS
AAO 2015
Las Vegas
Nov. 14 17
Subspecialty Day
Nov. 13 & 14
AAO 2016
Chicago
Oct. 15 18
Subspecialty Day
Oct. 14 & 15
AAO 2017
New Orleans
Nov. 11 -14
Subspecialty Day
Nov. 10 & 11
WHERE ALL OF OPHTHALMOLOGY MEETS
328
TECNIS Toric IOL
Secure rotational stability.

Deliver precise outcomes.
The TECNIS Toric IOL exceeds the ANSI

(American National Standards Institute) criteria
for toric lens rotational stability* 1 a critical factor
in postoperative visual outcomes.2
The IDE study showed:
94% of eyes had a change of axis
5 between baseline and six months1
Average rotation during the same
time period was 2.741
Experience the proven performance of the TECNIS Toric IOL today.
Visit www.TECNISToricIOL.com or call 1-877-AMO-4-LIFE.
Indications: The TECNIS Toric 1-Piece posterior chamber lenses are indicated for the visual correction of aphakia and pre-existing corneal astigmatism of
one diopter or greater in adult patients with or without presbyopia in whom a cataractous lens has been removed by phacoemulsification and who desire
improved uncorrected distance vision, reduction in residual refractive cylinder, and increased spectacle independence for distance vision. The device is
intended to be placed in the capsular bag. Warnings: Physicians considering lens implantation should weigh the potential risk/benefit ratio for any
circumstances described in the TECNIS Toric 1-Piece IOL Directions for Use that could increase complications or impact patient outcomes. The clinical study
did not show evidence of effectiveness for the treatment of preoperative corneal astigmatism of less than one diopter. The TECNIS Toric 1-Piece IOL should not
be placed in the ciliary sulcus. Rotation of the TECNIS Toric 1-Piece IOL away from its intended axis can reduce its astigmatic correction. Misalignment greater
than 30 may increase postoperative refractive cylinder. Precautions: Accurate keratometry and biometry in addition to the use of the TECNIS Toric Calculator
(www.TECNISToricCalc.com) are recommended to achieve optimal visual outcomes. The safety and effectiveness of the toric intraocular lens have not been
substantiated in patients with certain preexisting ocular conditions and intraoperative complications. Refer to the TECNIS Toric 1-Piece IOL Directions for Use for
a complete description of the preexisting conditions and intraoperative complications. All preoperative surgical parameters are important when choosing a toric
lens for implantation. Variability in any of the preoperative measurements can influence patient outcomes. All corneal incisions were placed temporally in the
clinical study. Do not reuse, resterilize, or autoclave. Adverse Events: The most frequently reported adverse event that occurred with the TECNIS Toric 1-Piece
IOL was surgical reintervention, which occurred at a rate of 3.4% (lens repositioning procedures and retinal repair procedures). Other reported events included
macular edema, which occurred at a rate of 2.9% and retinal detachment, which occurred at a rate of 0.6%. Caution: Federal law restricts this device to sale
by or on the order of a physician. Attention: Reference the Directions for Use labeling for a complete listing of Indications, Warnings and Precautions.
The newest addition to the TECNIS family of IOLs. For your peace of mind.
*ANSI Z80.30-2010 requires that >90% of eyes experience a change in axis of 5 between two consecutive visits
approximately three months apart.
1. TECNIS Toric 1-Piece IOL [package insert]. Santa Ana, Calif: Abbott Medical Optics Inc.
2. Novis C. Astigmatism and toric intraocular lenses. Curr Opin Ophthalmol. 2000; 11:47-50.
TECNIS is a trademark owned by or licensed to Abbott Laboratories, its subsidiaries, or affiliates.
2014 Abbott Medical Optics Inc. www.AbbottMedicalOptics.com 2013.01.31-CT6316
PIONEERED
BY ALCON
POWERED BY YOU
A WHOLE
NEW LEVEL
OF PHACO.
THE CATARACT
REFRACTIVE
Visit the
Alcon booth to experience the
SUITEVision
BY ALCON
CENTURION
System, part of the first and
only complete cataract refractive suite.
THE CATARACT
2014 Novartis 8/14 CNT14067SOV
SUITE BY ALCON

Aao Final Program2014 PDF

Загружено:

Сведения о документе

Исходное описание:

Оригинальное название

Авторское право

Доступные форматы

Поделиться этим документом

Поделиться или встроить документ

Параметры публикации

Этот документ был вам полезен?

Это неприемлемый материал?

Авторское право:

Доступные форматы

Aao Final Program2014 PDF

Загружено:

Авторское право:

Доступные форматы

Where all of ophthalmology meets

The American Academy of Ophthalmology is accredited by the Accreditation Council for

Courses and Breakfasts

Skills Transfer Program

Papers / Posters, Videos

Special Meetings and Events

AAOE Program / Practice Management

Sessions and Symposia

Visit the Alcon

For important product information, please see the back of tab 2.

Her eye disease.

Image is designed to represent nondescript visual impairment and is not

At Santen, our single focus in ophthalmology enables

research of novel therapies in uveitis, glaucoma, and

scan this code with your mobile

dry eye/corneal disorderstherapies determined to

device or visit www.santeninc.com.

challenge eye disease, one patient at a time.

Inspiring ophthalmic medicines

Image Guided System

For important product information, please see the back of tab 2.

Three AAO-SOE Joint Sessions

A View Across the Pond: Current Cataract and

A View Across the Pond: Retina

A View Across the Pond: Cornea Enigmas

NEW! Jones/Smolin Lecture

SYM09; Sunday, Oct. 19, 12:45 to 1:45PM

SYM26; Monday, Oct. 20, 10:15 - 11:45 AM

The Bruce E. Spivey, MD Lecture in Risk

NEW! Dr. Allan Jensen and Claire Jensen

SPE15; Sunday, Oct. 19, 2:00 - 4:00 PM

SYM33; Monday, Oct. 20, 12:45 - 1:45 PM

More Interactive Sessions

Scientific Poster Tours

Saturday - Tuesday, Oct. 18 - 21

Sunday, Oct. 19 and Monday, Oct. 20, 12:30-1:30 PM

Breakfast With the Experts

Ophthalmic Premier League:

Sunday Tuesday, Oct. 19 21, 7:30 - 8:30 AM

SYM60; Tuesday, Oct. 21, 8:30 - 10:00 AM

Important Safety Information

Potential for lens subluxation.

Please see Brief Summary of full Prescribing Information on adjacent page.

BRIEF SUMMARY OF FULL PRESCRIBING

5 WARNINGS AND PRECAUTIONS

5.2 Intravitreal Injection Procedure Associated

6.1 Clinical Trials Experience

3 line Improvement in BCVA

8.1 (2.3, 13.9)

> 3 line Worsening in BCVA

16 HOW SUPPLIED/STORAGE AND HANDLING

U.S. License Number: 1866

The Solution to Every Case.

SEE YOU IN VIENNA!

*Members of the Board of Trustees

International Society of Refractive Surgery

ISRS Chicago Schedule

AAO Final Program

Cover more ground

Leaping over 50 times its own length,

The Integrated WaveLight Refractive Suite

Ask your Alcon Sales Representative for more information.